data_2mc9_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2mc9 _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 5.3 p30 . . . . . 0 N--CA 1.494 1.756 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -72.04 144.43 42.57 Favored 'Trans proline' 0 C--N 1.308 -1.561 0 C-N-CA 122.515 2.143 . . . . 0.0 111.752 179.582 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 92.9 mtt180 -126.26 142.2 51.62 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.304 -0.873 . . . . 0.0 109.643 -179.822 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 10.5 p -134.87 143.84 36.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.359 -0.838 . . . . 0.0 109.345 179.803 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 25.0 p90 -139.49 152.89 47.33 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.208 -0.933 . . . . 0.0 109.602 -179.843 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -124.62 133.09 53.37 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.426 -0.796 . . . . 0.0 109.471 179.529 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.7 t0 -91.06 111.95 23.64 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.144 -0.972 . . . . 0.0 108.611 179.248 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 78.9 mtp -106.39 138.91 41.72 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.239 -0.913 . . . . 0.0 110.437 -179.185 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.427 ' OG ' ' OE2' ' A' ' 172' ' ' GLU . 48.8 m -131.6 155.95 46.63 Favored 'General case' 0 N--CA 1.492 1.632 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 179.416 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 25.1 m -118.99 144.29 27.71 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.149 -0.969 . . . . 0.0 109.62 -179.738 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 57.6 -108.99 1.55 Allowed Glycine 0 N--CA 1.488 2.119 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -135.77 28.33 2.98 Favored Glycine 0 N--CA 1.493 2.479 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 32.6 mt-30 -137.44 153.02 74.19 Favored Pre-proline 0 N--CA 1.493 1.719 0 O-C-N 121.297 -1.119 . . . . 0.0 109.186 179.873 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_endo -63.96 139.16 66.32 Favored 'Trans proline' 0 N--CA 1.495 1.56 0 C-N-CA 122.528 2.152 . . . . 0.0 112.05 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -102.84 -60.59 1.52 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.276 -0.89 . . . . 0.0 109.4 179.874 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 179.89 -170.83 42.2 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 98.2 mtt180 -117.57 143.72 45.83 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.365 -1.079 . . . . 0.0 109.583 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 86.5 mt -121.53 122.37 66.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 179.073 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 39.9 t -116.21 132.3 66.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.437 -0.789 . . . . 0.0 109.024 -179.901 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 71.7 mtm -124.76 152.19 44.15 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.403 -0.81 . . . . 0.0 109.346 -179.694 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -106.15 131.76 53.02 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.394 -0.816 . . . . 0.0 109.894 -179.616 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 17.3 mt -100.27 146.4 26.95 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.423 -0.798 . . . . 0.0 109.311 179.162 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 95.5 m-85 -95.43 124.19 39.34 Favored 'General case' 0 N--CA 1.49 1.567 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 178.804 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -99.17 21.48 11.79 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.206 -0.934 . . . . 0.0 109.694 -179.323 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.3 m-20 -120.76 -73.55 0.64 Allowed 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.289 -0.882 . . . . 0.0 110.21 -179.553 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' THR . . . . . 0.443 ' O ' ' OE1' ' A' ' 99' ' ' GLU . 41.3 m -61.15 -43.43 98.89 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.176 -0.953 . . . . 0.0 110.44 -179.117 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 9.4 m -139.95 78.37 24.74 Favored Pre-proline 0 N--CA 1.494 1.746 0 O-C-N 121.126 -0.984 . . . . 0.0 109.963 -179.543 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 68.3 Cg_endo -79.75 -36.94 0.52 Allowed 'Trans proline' 0 C--N 1.306 -1.689 0 C-N-CA 122.614 2.209 . . . . 0.0 112.461 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.418 ' O ' ' OH ' ' A' ' 92' ' ' TYR . 3.3 mtt-85 -59.63 -38.98 82.81 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.247 -0.908 . . . . 0.0 109.79 -179.761 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 85.0 m -64.26 -41.01 97.13 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.187 -0.946 . . . . 0.0 109.793 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -60.72 -32.78 72.02 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.209 -0.932 . . . . 0.0 108.904 179.762 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -69.23 -34.98 75.67 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.486 -0.759 . . . . 0.0 109.744 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 45.2 t-20 -57.11 -41.0 78.13 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.177 -0.952 . . . . 0.0 109.746 -179.616 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 97.7 m-85 -82.54 -45.73 14.28 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.147 -0.971 . . . . 0.0 109.78 -179.892 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . 0.496 ' NH1' ' OE2' ' A' ' 49' ' ' GLU . 72.1 ttp85 -59.2 -40.9 87.18 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.366 -0.834 . . . . 0.0 110.544 -179.377 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.498 ' O ' ' N ' ' A' ' 48' ' ' GLY . . . -69.55 -52.43 26.38 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.143 -0.973 . . . . 0.0 110.348 -179.117 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.45 ' N ' ' CD2' ' A' ' 45' ' ' LEU . 3.4 mm? -63.93 -39.68 94.71 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.066 -1.021 . . . . 0.0 109.702 -179.739 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' CYS . . . . . . . . . . . . . 95.2 m -63.85 -62.69 1.48 Allowed 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.066 -1.021 . . . . 0.0 109.278 -179.863 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 26.6 m -66.53 -36.24 82.22 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.294 -0.879 . . . . 0.0 109.178 179.586 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . 0.498 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 81.6 38.84 13.19 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 110.064 -1.214 . . . . 0.0 110.064 179.749 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.496 ' OE2' ' NH1' ' A' ' 43' ' ' ARG . 95.3 mt-10 -62.04 -35.79 79.65 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.079 -1.248 . . . . 0.0 109.47 179.883 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 31.2 mmtm -60.43 -34.55 74.14 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.308 -0.87 . . . . 0.0 109.546 -179.838 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 93.58 169.11 38.62 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.236 -1.546 . . . . 0.0 109.236 -179.687 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 68.4 m -79.47 141.12 37.04 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.292 -1.122 . . . . 0.0 109.963 -179.853 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -65.02 140.27 41.71 Favored Glycine 0 N--CA 1.489 2.172 0 N-CA-C 109.302 -1.519 . . . . 0.0 109.302 179.637 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 76.5 mtm180 -59.59 -33.24 71.21 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.229 -1.159 . . . . 0.0 110.046 -179.621 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 86.7 p -60.49 -23.44 64.51 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.204 -0.935 . . . . 0.0 110.122 -179.338 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . 0.427 ' O ' ' CG ' ' A' ' 57' ' ' LYS . . . 108.84 76.94 0.96 Allowed Glycine 0 N--CA 1.495 2.633 0 N-CA-C 108.951 -1.66 . . . . 0.0 108.951 -179.486 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . 0.479 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 54.2 mttm -161.2 76.91 2.41 Favored Pre-proline 0 N--CA 1.488 1.463 0 N-CA-C 107.914 -1.143 . . . . 0.0 107.914 -179.822 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -48.42 129.91 20.48 Favored 'Trans proline' 0 C--N 1.301 -1.936 0 C-N-CA 122.932 2.421 . . . . 0.0 112.578 -178.716 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.479 ' CD1' ' O ' ' A' ' 57' ' ' LYS . 8.1 mp -97.88 70.7 2.16 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.719 -0.613 . . . . 0.0 109.42 -179.434 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 96.3 m-70 -139.2 146.5 40.6 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.284 -0.885 . . . . 0.0 109.609 179.871 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 4.1 m-85 -97.0 16.87 18.29 Favored 'General case' 0 N--CA 1.492 1.644 0 N-CA-C 108.488 -0.93 . . . . 0.0 108.488 179.173 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 8.7 mtpm? -75.78 153.09 37.19 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.511 -0.743 . . . . 0.0 109.594 -179.692 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 83.8 m-20 55.19 46.23 24.24 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.468 -0.77 . . . . 0.0 109.796 179.745 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 92.1 p -112.94 150.8 31.33 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.418 -0.801 . . . . 0.0 109.038 179.595 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 29.1 t -120.71 148.08 44.42 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.369 -0.832 . . . . 0.0 109.594 -179.694 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -68.38 132.56 47.25 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.294 -0.879 . . . . 0.0 109.015 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 83.8 t60 -63.4 -49.25 74.53 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.278 -0.889 . . . . 0.0 110.367 -179.43 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 5.6 ttm180 -151.45 154.45 36.61 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.071 -1.018 . . . . 0.0 109.344 -179.351 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 19.2 m -132.43 149.88 32.74 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 121.277 -0.889 . . . . 0.0 109.982 -179.737 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 13.3 mt -148.05 125.58 5.75 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.158 -0.963 . . . . 0.0 108.629 178.892 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -71.94 144.2 42.52 Favored 'Trans proline' 0 N--CA 1.493 1.463 0 C-N-CA 122.123 1.882 . . . . 0.0 112.588 -179.291 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 75.08 -53.37 2.61 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.94 -1.264 . . . . 0.0 109.94 179.566 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 84.4 m-85 -67.51 -83.28 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.196 -1.179 . . . . 0.0 110.082 -179.533 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' MET . . . . . 0.587 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 11.9 ptt? -179.49 158.45 0.84 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.114 -0.991 . . . . 0.0 109.619 -179.736 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 1.1 m -99.35 125.8 45.1 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.329 -0.857 . . . . 0.0 108.755 179.377 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 63.7 tt0 -97.94 121.16 39.53 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.21 -0.931 . . . . 0.0 109.766 -179.645 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -87.06 -176.59 49.09 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.14 -1.584 . . . . 0.0 109.14 179.571 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -142.74 162.79 27.37 Favored Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.666 -1.374 . . . . 0.0 109.666 179.857 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -75.04 147.53 40.63 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.344 -1.092 . . . . 0.0 109.553 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 44.4 p90 -68.11 -18.93 64.78 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.243 -0.91 . . . . 0.0 109.654 -179.842 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.539 ' OG1' ' N ' ' A' ' 88' ' ' GLY . 59.7 p -66.22 -30.27 70.68 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.213 -0.929 . . . . 0.0 109.438 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -177.42 -56.22 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.247 -0.908 . . . . 0.0 109.44 179.823 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 94.36 -4.31 70.0 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 78.7 m-20 -88.16 5.41 41.49 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.23 -1.159 . . . . 0.0 109.413 179.865 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 95.93 -38.78 3.0 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 -179.842 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 48.5 m -60.34 -39.51 87.36 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.248 -1.148 . . . . 0.0 109.218 179.738 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -86.06 -168.29 44.59 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 179.901 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.539 ' N ' ' OG1' ' A' ' 81' ' ' THR . . . 108.32 73.14 0.79 Allowed Glycine 0 N--CA 1.494 2.534 0 N-CA-C 109.753 -1.339 . . . . 0.0 109.753 179.865 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -94.8 135.82 35.84 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.254 -1.145 . . . . 0.0 109.189 179.732 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 50.2 m -122.41 147.9 45.74 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.39 -0.819 . . . . 0.0 109.569 -179.84 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 26.1 pt -67.48 -26.81 36.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.309 -0.869 . . . . 0.0 109.621 179.877 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . 0.418 ' OH ' ' O ' ' A' ' 37' ' ' ARG . 97.3 m-85 -65.23 -30.16 71.02 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.3 -0.875 . . . . 0.0 109.776 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 68.09 -107.61 2.13 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.284 -1.527 . . . . 0.0 109.284 -179.772 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -55.54 147.87 16.94 Favored 'General case' 0 N--CA 1.487 1.39 0 O-C-N 121.241 -1.152 . . . . 0.0 109.319 179.819 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 41.5 mttm -76.05 156.26 34.11 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.388 -0.82 . . . . 0.0 109.694 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 33.7 p90 -133.01 161.67 33.75 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.407 -0.808 . . . . 0.0 109.208 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -60.15 140.31 57.0 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.152 -0.967 . . . . 0.0 109.809 -179.349 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -76.68 135.28 39.09 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.29 -0.881 . . . . 0.0 109.812 -179.886 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . 0.443 ' OE1' ' O ' ' A' ' 34' ' ' THR . 95.9 mt-10 -64.84 148.44 51.33 Favored 'General case' 0 C--N 1.305 -1.348 0 O-C-N 121.32 -0.862 . . . . 0.0 109.245 179.556 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 21.3 m120 -55.84 145.7 23.85 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 121.362 -0.836 . . . . 0.0 109.365 -179.866 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' PHE . . . . . 0.586 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 25.0 p90 -110.27 69.88 0.71 Allowed 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.448 -0.782 . . . . 0.0 109.47 -179.781 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 86.4 mt -59.04 -34.8 54.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.257 -0.902 . . . . 0.0 109.575 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 27.1 mtmm -84.77 150.14 25.26 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.21 -0.931 . . . . 0.0 109.615 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 56.4 pttt -131.91 -179.64 5.52 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.371 -0.831 . . . . 0.0 109.362 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' HIS . . . . . 0.534 ' O ' ' CG ' ' A' ' 105' ' ' HIS . 50.4 p-80 -88.27 98.45 11.59 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.207 -0.933 . . . . 0.0 109.647 -179.832 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 55.5 p -77.44 -22.02 52.1 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.237 -0.915 . . . . 0.0 109.708 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -150.46 179.34 27.27 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.524 -1.431 . . . . 0.0 109.524 -179.744 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -70.99 160.6 48.85 Favored 'Trans proline' 0 C--N 1.307 -1.617 0 C-N-CA 122.863 2.376 . . . . 0.0 112.183 179.886 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 85.62 36.94 9.94 Favored Glycine 0 N--CA 1.493 2.493 0 N-CA-C 109.95 -1.26 . . . . 0.0 109.95 179.725 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 39.3 mm -114.98 135.32 55.28 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 O-C-N 121.364 -1.08 . . . . 0.0 109.364 179.857 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . 0.609 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 2.4 mm? -91.46 136.23 33.27 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.21 -0.931 . . . . 0.0 109.544 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 112' ' ' SER . . . . . 0.44 ' OG ' ' O ' ' A' ' 140' ' ' VAL . 38.0 t -143.82 139.5 29.36 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.336 -0.852 . . . . 0.0 109.244 179.669 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 82.6 mtp -84.96 130.62 34.6 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.169 -0.957 . . . . 0.0 109.247 179.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . 0.443 ' O ' ' OD1' ' A' ' 115' ' ' ASN . . . -68.79 141.25 55.23 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.222 -0.924 . . . . 0.0 109.565 -179.879 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . 0.443 ' OD1' ' O ' ' A' ' 114' ' ' ALA . 72.9 m-20 -145.83 112.75 6.05 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.247 -0.908 . . . . 0.0 109.054 179.554 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -69.07 -31.11 69.62 Favored 'General case' 0 C--N 1.296 -1.723 0 O-C-N 121.448 -0.783 . . . . 0.0 109.234 179.747 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -141.02 167.65 25.6 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.137 -1.585 . . . . 0.0 109.137 179.826 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_endo -66.46 157.46 60.34 Favored 'Trans proline' 0 C--N 1.304 -1.799 0 C-N-CA 122.737 2.292 . . . . 0.0 111.94 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 22.3 m120 56.08 51.38 12.01 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.447 -0.783 . . . . 0.0 109.716 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 61.3 m -131.36 127.18 37.06 Favored 'General case' 0 N--CA 1.485 1.28 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 179.437 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 49.3 t-20 -53.13 -37.55 61.9 Favored 'General case' 0 C--N 1.296 -1.753 0 O-C-N 121.371 -0.831 . . . . 0.0 109.839 -179.274 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 77.0 63.52 2.27 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 109.766 -1.334 . . . . 0.0 109.766 179.826 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 24.0 m -54.76 -33.38 61.22 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.199 -1.177 . . . . 0.0 109.76 -179.796 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.3 mt-30 -92.07 147.4 22.98 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.113 -0.992 . . . . 0.0 109.511 -179.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 49.1 p90 -138.96 162.48 34.78 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.246 -0.909 . . . . 0.0 109.67 -179.901 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . 0.587 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 48.8 p90 -139.27 160.79 38.98 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.398 -0.814 . . . . 0.0 109.355 179.911 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 69.8 mt -118.51 132.39 68.53 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.378 -0.826 . . . . 0.0 109.428 179.833 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -102.13 105.59 16.32 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.325 -0.859 . . . . 0.0 109.273 179.887 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 129' ' ' THR . . . . . 0.439 ' OG1' ' OE2' ' A' ' 156' ' ' GLU . 44.8 p -89.12 -1.38 58.06 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.283 -0.885 . . . . 0.0 109.642 179.937 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -141.71 153.13 44.44 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.261 -0.9 . . . . 0.0 109.485 -179.816 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 79.7 tttt -78.33 130.64 36.41 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.285 -0.884 . . . . 0.0 109.38 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 33.3 p -124.65 156.11 38.06 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.358 -0.838 . . . . 0.0 109.47 -179.863 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -111.81 -36.3 5.47 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.433 -0.792 . . . . 0.0 109.615 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 134' ' ' TRP . . . . . 0.448 ' CD2' ' N ' ' A' ' 134' ' ' TRP . 0.7 OUTLIER -66.84 -15.2 63.45 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.159 -0.963 . . . . 0.0 109.629 -179.722 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . 0.41 ' O ' ' NE2' ' A' ' 139' ' ' HIS . 7.9 mt -89.29 11.09 19.94 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.195 -0.941 . . . . 0.0 109.436 179.568 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -69.7 118.07 12.09 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.163 -0.961 . . . . 0.0 109.41 -179.617 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -177.68 -154.48 12.35 Favored Glycine 0 N--CA 1.487 2.062 0 N-CA-C 108.883 -1.687 . . . . 0.0 108.883 -179.84 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 32.3 mmtp -81.11 113.7 19.46 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.178 -1.189 . . . . 0.0 109.157 179.769 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 139' ' ' HIS . . . . . 0.41 ' NE2' ' O ' ' A' ' 135' ' ' LEU . 99.2 m-70 -137.17 154.83 50.14 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.367 -0.833 . . . . 0.0 109.348 -179.964 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.44 ' O ' ' OG ' ' A' ' 112' ' ' SER . 44.2 t -122.75 134.41 66.02 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.341 -0.849 . . . . 0.0 109.641 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 61.8 t -110.78 130.48 64.08 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 121.419 -0.801 . . . . 0.0 108.881 179.566 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 38.8 p90 -123.37 -4.88 8.31 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.19 -0.944 . . . . 0.0 110.704 -179.478 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -162.59 174.35 38.96 Favored Glycine 0 N--CA 1.493 2.463 0 C-N-CA 119.152 -1.499 . . . . 0.0 110.498 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 51.7 tt0 -138.96 159.98 40.84 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.604 -0.939 . . . . 0.0 109.169 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 79.7 t -97.31 129.39 47.46 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.188 0 O-C-N 121.105 -0.997 . . . . 0.0 109.521 -179.827 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 19.0 m -106.35 -32.19 2.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.376 -0.828 . . . . 0.0 109.425 179.638 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -145.5 173.15 12.27 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.253 -0.904 . . . . 0.0 109.505 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 98.35 1.93 57.9 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 109.89 -1.284 . . . . 0.0 109.89 179.65 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 149' ' ' MET . . . . . 0.413 ' O ' HG12 ' A' ' 152' ' ' VAL . 65.0 mtt -61.2 -32.35 72.1 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.127 -1.219 . . . . 0.0 109.782 179.979 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . 0.548 ' OD1' ' N ' ' A' ' 151' ' ' VAL . 33.8 p-10 -66.37 -38.73 88.22 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.811 -1.181 . . . . 0.0 110.211 -179.512 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . 0.548 ' N ' ' OD1' ' A' ' 150' ' ' ASP . 6.3 p -85.25 -33.71 8.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.712 0 O-C-N 121.036 -1.04 . . . . 0.0 110.339 -179.545 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 152' ' ' VAL . . . . . 0.442 ' CG1' ' N ' ' A' ' 153' ' ' LYS . 1.1 p -52.77 -41.09 37.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 120.952 -1.092 . . . . 0.0 108.832 -179.488 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 153' ' ' LYS . . . . . 0.442 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 99.4 mttt -64.66 -34.64 78.76 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.252 -0.905 . . . . 0.0 109.144 179.122 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -61.19 -35.38 76.99 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.375 -0.828 . . . . 0.0 109.95 -179.537 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.428 HG23 HD12 ' A' ' 155' ' ' ILE . 87.5 mt -71.33 -35.76 58.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.049 -1.032 . . . . 0.0 109.976 -179.882 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . 0.439 ' OE2' ' OG1' ' A' ' 129' ' ' THR . 97.9 mt-10 -76.97 -40.69 45.98 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.079 -1.013 . . . . 0.0 111.474 -178.937 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 18.4 pttp -60.11 -36.44 77.45 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.592 -1.318 . . . . 0.0 109.208 -179.2 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 30.4 m -80.95 -12.88 12.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.163 -0.961 . . . . 0.0 108.562 178.91 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -78.89 175.8 54.89 Favored Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.707 -1.357 . . . . 0.0 109.707 -179.886 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 25.1 t -157.69 166.79 31.88 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.35 -1.088 . . . . 0.0 109.325 -179.859 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 86.9 p -57.67 -26.05 61.12 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.201 -0.937 . . . . 0.0 108.899 179.745 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 26.7 m -57.44 -30.33 64.92 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.444 -0.785 . . . . 0.0 109.394 179.661 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 95.04 15.62 44.39 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.714 -1.354 . . . . 0.0 109.714 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 77.8 ttt-85 -122.93 141.39 51.96 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.341 -1.093 . . . . 0.0 109.495 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 165' ' ' THR . . . . . . . . . . . . . 42.7 p -80.91 143.53 32.6 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.188 -0.945 . . . . 0.0 109.618 179.903 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -68.72 -38.34 80.13 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.262 -0.899 . . . . 0.0 109.185 179.559 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 67.2 mttm -107.75 159.75 16.25 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.485 -0.759 . . . . 0.0 109.325 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -73.39 131.7 42.15 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.18 -0.95 . . . . 0.0 109.227 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 40.2 t -121.2 125.0 73.3 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.341 -0.849 . . . . 0.0 109.431 179.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 41.6 t -147.06 150.81 14.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.343 -0.848 . . . . 0.0 109.219 179.861 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -88.04 120.37 36.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.233 -0.917 . . . . 0.0 109.625 -179.619 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 172' ' ' GLU . . . . . 0.427 ' OE2' ' OG ' ' A' ' 17' ' ' SER . 97.1 mt-10 -65.28 -26.47 68.09 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.413 -0.804 . . . . 0.0 109.324 179.479 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 173' ' ' ASP . . . . . 0.432 ' OD1' ' N ' ' A' ' 174' ' ' CYS . 47.2 t0 -174.8 169.26 3.53 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.201 -0.937 . . . . 0.0 110.412 -179.532 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 174' ' ' CYS . . . . . 0.432 ' N ' ' OD1' ' A' ' 173' ' ' ASP . 31.4 p -150.38 150.83 31.93 Favored 'General case' 0 N--CA 1.491 1.585 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 179.349 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -175.98 -176.49 44.23 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.823 -1.311 . . . . 0.0 109.823 -179.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 6.7 tt0 -104.43 119.67 39.49 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.415 -1.05 . . . . 0.0 109.713 -179.823 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 30.9 tp -62.71 -37.93 88.46 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.129 -0.982 . . . . 0.0 109.154 179.434 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 8.0 t . . . . . 0 N--CA 1.49 1.55 0 CA-C-O 118.017 -0.992 . . . . 0.0 109.433 -179.958 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 7.7 t-20 . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_endo -71.14 139.0 34.61 Favored 'Trans proline' 0 N--CA 1.494 1.502 0 C-N-CA 122.406 2.071 . . . . 0.0 112.493 -179.778 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . 0.568 ' H ' ' HG ' ' A' ' 178' ' ' SER . 86.6 mtt180 -131.65 134.04 45.56 Favored 'General case' 0 N--CA 1.493 1.697 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 179.119 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 12.6 p -136.4 144.52 32.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.412 -0.805 . . . . 0.0 109.353 -179.783 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 48.8 p90 -135.28 151.89 50.99 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.337 -0.852 . . . . 0.0 109.348 179.877 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 90.4 m-85 -119.39 127.52 53.21 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.451 -0.781 . . . . 0.0 110.122 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.4 t0 -92.54 120.31 32.87 Favored 'General case' 0 N--CA 1.493 1.678 0 N-CA-C 108.347 -0.982 . . . . 0.0 108.347 178.86 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 77.2 mtp -122.09 151.12 41.23 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.991 -1.068 . . . . 0.0 110.698 -179.065 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 93.8 p -145.12 160.63 41.11 Favored 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 108.744 -0.836 . . . . 0.0 108.744 179.671 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.419 ' O ' ' C ' ' A' ' 19' ' ' GLY . 18.9 m -128.71 143.55 40.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.274 -0.891 . . . . 0.0 109.488 179.963 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . 0.419 ' C ' ' O ' ' A' ' 18' ' ' VAL . . . 42.11 -103.86 0.04 OUTLIER Glycine 0 N--CA 1.492 2.423 0 N-CA-C 109.692 -1.363 . . . . 0.0 109.692 179.925 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -135.48 22.56 3.51 Favored Glycine 0 N--CA 1.494 2.526 0 N-CA-C 109.32 -1.512 . . . . 0.0 109.32 179.685 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 62.1 mt-30 -127.41 88.61 53.45 Favored Pre-proline 0 N--CA 1.494 1.741 0 O-C-N 121.448 -1.031 . . . . 0.0 109.264 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_exo -48.63 133.17 26.43 Favored 'Trans proline' 0 C--N 1.309 -1.511 0 C-N-CA 122.505 2.137 . . . . 0.0 112.297 -179.637 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -82.47 -64.06 1.25 Allowed 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.405 -0.81 . . . . 0.0 109.772 -179.89 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 175.15 -167.56 39.7 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 -179.858 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 94.5 mtt-85 -106.27 150.23 26.13 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.447 -1.031 . . . . 0.0 109.186 179.886 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 79.6 mt -119.26 120.73 64.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 179.378 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 34.8 t -112.99 132.38 61.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.446 -0.784 . . . . 0.0 108.911 -179.909 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 70.6 mtm -127.45 156.68 41.74 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.323 -0.86 . . . . 0.0 109.679 -179.361 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -99.62 135.51 40.94 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.284 -0.885 . . . . 0.0 109.795 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -108.89 128.35 54.84 Favored 'General case' 0 N--CA 1.492 1.65 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 179.388 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -95.19 118.23 31.61 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.143 -0.973 . . . . 0.0 108.992 179.778 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -80.43 -42.47 22.64 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 121.473 -0.767 . . . . 0.0 109.839 -179.812 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 56.8 t0 -65.52 -46.26 80.28 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.237 -0.914 . . . . 0.0 110.435 -179.365 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 24.8 m -66.17 -45.73 79.88 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.002 -1.061 . . . . 0.0 109.854 -179.38 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.454 ' O ' ' OG1' ' A' ' 35' ' ' THR . 13.2 p -145.33 81.84 10.08 Favored Pre-proline 0 N--CA 1.493 1.711 0 O-C-N 121.317 -0.864 . . . . 0.0 109.332 -179.72 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -70.33 -47.07 0.82 Allowed 'Trans proline' 0 C--N 1.307 -1.615 0 C-N-CA 122.1 1.867 . . . . 0.0 112.215 -179.48 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 22.9 mmt85 -63.04 -39.75 95.68 Favored 'General case' 0 N--CA 1.487 1.409 0 O-C-N 121.1 -1.0 . . . . 0.0 109.581 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 37.9 m -65.16 -40.92 95.01 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.224 -0.922 . . . . 0.0 110.069 -179.736 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -60.69 -31.8 71.05 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.312 -0.867 . . . . 0.0 109.278 -179.699 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -67.09 -38.44 85.7 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.335 -0.853 . . . . 0.0 109.758 -179.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 49.1 t30 -58.48 -42.52 87.72 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.264 -0.898 . . . . 0.0 109.932 -179.644 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . 0.507 ' O ' ' SG ' ' A' ' 46' ' ' CYS . 97.6 m-85 -82.89 -45.72 13.87 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.061 -1.024 . . . . 0.0 109.859 -179.925 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . 0.742 ' HE ' HE22 ' A' ' 176' ' ' GLN . 74.0 ttt-85 -58.73 -41.1 85.62 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.296 -0.878 . . . . 0.0 110.544 -179.342 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -71.77 -53.81 12.21 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.028 -1.045 . . . . 0.0 110.553 -179.019 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.473 ' N ' ' CD2' ' A' ' 45' ' ' LEU . 3.8 mm? -63.32 -38.9 92.95 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.948 -1.095 . . . . 0.0 109.776 -179.631 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' CYS . . . . . 0.507 ' SG ' ' O ' ' A' ' 42' ' ' PHE . 95.6 m -65.83 -55.65 16.02 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.108 -0.995 . . . . 0.0 109.138 179.864 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 50.7 m -66.13 -36.81 84.13 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.373 -0.83 . . . . 0.0 109.279 179.468 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 85.31 30.02 26.13 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 110.269 -1.133 . . . . 0.0 110.269 179.565 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -62.2 -38.71 90.15 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.05 -1.265 . . . . 0.0 109.359 179.83 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 59.7 mmtt -62.5 -31.27 72.0 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.386 -0.821 . . . . 0.0 109.686 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 74.34 -113.95 4.29 Favored Glycine 0 N--CA 1.488 2.125 0 N-CA-C 108.854 -1.698 . . . . 0.0 108.854 -179.37 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 87.4 m -127.61 143.42 51.17 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.339 -1.094 . . . . 0.0 109.749 179.624 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -64.99 137.2 38.31 Favored Glycine 0 N--CA 1.489 2.168 0 N-CA-C 109.221 -1.551 . . . . 0.0 109.221 179.685 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 81.4 mtm180 -59.1 -34.93 72.59 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.205 -1.173 . . . . 0.0 109.913 -179.7 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 86.1 p -61.95 -24.41 66.98 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.174 -0.954 . . . . 0.0 109.782 -179.746 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 112.45 89.6 1.84 Allowed Glycine 0 N--CA 1.495 2.569 0 N-CA-C 109.102 -1.599 . . . . 0.0 109.102 -179.682 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . 0.529 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 22.8 tttp -174.56 79.56 0.34 Allowed Pre-proline 0 N--CA 1.488 1.465 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 -179.677 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_exo -50.47 131.99 33.92 Favored 'Trans proline' 0 C--N 1.304 -1.793 0 C-N-CA 122.892 2.394 . . . . 0.0 113.197 -178.779 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.529 ' CD1' ' O ' ' A' ' 57' ' ' LYS . 8.9 mp -104.49 122.32 45.3 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 108.782 -0.821 . . . . 0.0 108.782 179.325 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . 0.421 ' CD2' ' N ' ' A' ' 60' ' ' HIS . 5.1 p80 -169.7 93.28 0.25 Allowed 'General case' 0 N--CA 1.486 1.375 0 O-C-N 120.971 -1.081 . . . . 0.0 110.272 -179.684 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 8.0 m-85 -64.29 -29.39 70.48 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.182 -0.949 . . . . 0.0 109.066 179.149 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 8.8 ptmm? -55.3 160.3 2.3 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.351 -0.843 . . . . 0.0 109.627 179.842 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . 0.449 ' N ' ' O ' ' A' ' 171' ' ' VAL . 85.0 m-20 54.62 48.01 21.31 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.498 -0.752 . . . . 0.0 109.416 -179.842 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.525 ' H ' ' CG1' ' A' ' 171' ' ' VAL . 89.6 p -126.46 155.07 42.83 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.277 -0.889 . . . . 0.0 109.134 179.754 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 32.1 t -106.48 141.98 36.9 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.335 -0.853 . . . . 0.0 109.056 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -69.61 143.43 53.28 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.343 -0.848 . . . . 0.0 108.892 -179.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 57.2 t-80 -57.33 -51.13 70.62 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.218 -0.927 . . . . 0.0 110.405 -178.851 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 15.6 ptm180 -171.0 163.68 7.45 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 120.896 -1.127 . . . . 0.0 109.697 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -136.47 129.28 45.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.462 -0.774 . . . . 0.0 109.128 179.696 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 70.3 mt -128.92 109.14 18.35 Favored Pre-proline 0 N--CA 1.493 1.695 0 O-C-N 121.543 -0.723 . . . . 0.0 109.631 179.865 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -52.45 147.53 29.28 Favored 'Trans proline' 0 C--N 1.31 -1.482 0 C-N-CA 122.357 2.038 . . . . 0.0 112.62 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 87.12 -59.53 4.48 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 110.156 -1.177 . . . . 0.0 110.156 179.373 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 67.8 m-85 -70.21 -73.48 0.16 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.239 -1.154 . . . . 0.0 110.061 -179.493 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' MET . . . . . 0.528 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 13.4 ptt? 178.45 -165.66 0.05 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.225 -0.922 . . . . 0.0 109.618 -179.918 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' CYS . . . . . 0.435 ' SG ' ' O ' ' A' ' 127' ' ' ILE . 0.0 OUTLIER -121.22 124.13 43.92 Favored 'General case' 0 N--CA 1.494 1.764 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 179.614 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 63.6 tt0 -102.44 124.49 48.09 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.231 -0.918 . . . . 0.0 109.827 -179.663 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -86.26 -173.88 49.34 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.259 -1.536 . . . . 0.0 109.259 179.457 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -136.83 154.5 22.21 Favored Glycine 0 N--CA 1.493 2.477 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 88.0 m-20 -83.77 143.81 29.73 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.432 -1.04 . . . . 0.0 109.642 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 41.3 p90 -65.43 -23.61 66.98 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.283 -0.886 . . . . 0.0 109.624 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.454 ' OG1' ' N ' ' A' ' 88' ' ' GLY . 52.7 p -64.2 -31.54 72.78 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.145 -0.972 . . . . 0.0 109.481 -179.891 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 178.02 -54.08 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.403 -0.811 . . . . 0.0 109.334 179.855 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 96.58 -11.21 66.77 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 80.3 m-20 -88.66 2.77 52.63 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.186 -1.185 . . . . 0.0 109.315 179.795 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 93.66 -5.16 73.3 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.395 -1.482 . . . . 0.0 109.395 -179.868 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 61.7 p -74.47 -19.02 60.54 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.394 -1.062 . . . . 0.0 109.517 179.87 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -131.86 -132.75 3.38 Favored Glycine 0 N--CA 1.494 2.519 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.454 ' N ' ' OG1' ' A' ' 81' ' ' THR . . . 74.57 47.28 16.25 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.293 -1.523 . . . . 0.0 109.293 -179.915 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -93.3 135.36 34.59 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.295 -1.121 . . . . 0.0 109.753 -179.508 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 50.0 m -70.72 158.08 36.91 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.358 -0.839 . . . . 0.0 109.508 179.84 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 24.9 pt -65.94 -31.15 52.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.24 -0.912 . . . . 0.0 109.834 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 59.9 m-85 -64.0 -36.33 83.63 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.256 -0.902 . . . . 0.0 109.591 -179.746 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 82.79 10.16 83.52 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.321 -1.512 . . . . 0.0 109.321 -179.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -148.28 157.25 43.38 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.282 -1.128 . . . . 0.0 109.372 -179.915 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 62.0 mttp -86.57 153.03 22.12 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.22 -0.925 . . . . 0.0 109.466 179.912 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 36.9 p90 -129.09 157.87 40.53 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.425 -0.797 . . . . 0.0 109.329 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -65.68 143.98 57.21 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.294 -0.879 . . . . 0.0 110.052 -179.337 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . 0.504 ' CG ' ' H ' ' A' ' 119' ' ' ASN . 88.5 m-20 -67.01 148.0 52.51 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.35 -0.844 . . . . 0.0 109.617 179.845 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -100.14 161.91 13.3 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.345 -0.847 . . . . 0.0 109.268 179.844 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 81.4 m-20 -62.6 163.17 9.37 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.369 -0.832 . . . . 0.0 109.405 -179.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' PHE . . . . . 0.582 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 22.0 p90 -130.22 79.43 1.9 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.431 -0.793 . . . . 0.0 109.52 -179.898 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 87.8 mt -58.97 -33.94 51.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.183 -0.948 . . . . 0.0 109.376 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 67.2 mttm -83.51 143.18 30.38 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.187 -0.946 . . . . 0.0 109.386 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' LYS . . . . . 0.541 ' O ' ' N ' ' A' ' 106' ' ' THR . 50.0 tttp -127.35 158.24 37.79 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.406 -0.809 . . . . 0.0 109.331 -179.924 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' HIS . . . . . 0.455 ' CE1' ' O ' ' A' ' 107' ' ' GLY . 78.6 t60 -61.01 76.5 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.341 -0.849 . . . . 0.0 109.252 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' THR . . . . . 0.541 ' N ' ' O ' ' A' ' 104' ' ' LYS . 70.5 p -73.52 -27.15 61.21 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.199 -0.938 . . . . 0.0 109.878 -179.731 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.455 ' O ' ' CE1' ' A' ' 105' ' ' HIS . . . -153.75 177.12 31.43 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.561 -1.415 . . . . 0.0 109.561 -179.763 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -70.4 156.65 61.21 Favored 'Trans proline' 0 C--N 1.305 -1.724 0 C-N-CA 122.774 2.316 . . . . 0.0 112.131 179.881 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 86.07 43.59 6.27 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 110.095 -1.202 . . . . 0.0 110.095 179.728 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 45.4 mm -117.13 136.13 55.27 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 O-C-N 121.263 -1.139 . . . . 0.0 109.386 179.593 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . 0.591 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 2.9 mm? -88.65 137.36 32.39 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.21 -0.931 . . . . 0.0 109.413 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 112' ' ' SER . . . . . 0.457 ' OG ' ' O ' ' A' ' 140' ' ' VAL . 46.2 t -146.22 141.22 27.19 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.246 -0.909 . . . . 0.0 109.582 179.804 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 88.5 mtp -88.51 135.59 33.41 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.259 -0.9 . . . . 0.0 109.416 179.67 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . 0.456 ' O ' ' OD1' ' A' ' 115' ' ' ASN . . . -73.73 137.54 44.07 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.202 -0.936 . . . . 0.0 109.585 -179.946 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . 0.456 ' OD1' ' O ' ' A' ' 114' ' ' ALA . 76.3 m-20 -146.58 114.17 6.39 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.203 -0.936 . . . . 0.0 108.945 179.535 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -69.15 -31.07 69.49 Favored 'General case' 0 C--N 1.297 -1.697 0 O-C-N 121.409 -0.807 . . . . 0.0 109.697 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -139.9 167.55 25.34 Favored Glycine 0 N--CA 1.494 2.543 0 N-CA-C 109.396 -1.482 . . . . 0.0 109.396 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -69.08 154.11 70.97 Favored 'Trans proline' 0 C--N 1.307 -1.653 0 C-N-CA 122.701 2.268 . . . . 0.0 111.849 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 119' ' ' ASN . . . . . 0.504 ' H ' ' CG ' ' A' ' 98' ' ' ASP . 80.3 m-20 53.49 43.22 31.58 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.436 -0.79 . . . . 0.0 109.317 -179.939 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 91.8 m -136.37 128.41 29.59 Favored 'General case' 0 C--N 1.305 -1.34 0 O-C-N 121.445 -0.784 . . . . 0.0 109.041 179.84 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 43.4 p-10 -80.76 168.11 19.19 Favored 'General case' 0 C--N 1.298 -1.668 0 O-C-N 121.377 -0.827 . . . . 0.0 109.311 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -159.79 105.94 0.28 Allowed Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.667 -1.373 . . . . 0.0 109.667 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 23.9 t -59.12 -32.61 69.99 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.252 -1.146 . . . . 0.0 109.389 179.85 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.6 mt-30 -71.23 142.96 50.58 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.214 -0.928 . . . . 0.0 109.575 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 48.5 p90 -140.46 162.27 35.73 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.342 -0.849 . . . . 0.0 109.322 179.866 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . 0.528 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 48.2 p90 -138.43 158.56 44.04 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.295 -0.878 . . . . 0.0 109.608 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.435 ' O ' ' SG ' ' A' ' 75' ' ' CYS . 60.3 mt -120.34 132.29 70.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.411 -0.806 . . . . 0.0 109.208 179.85 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 128' ' ' CYS . . . . . 0.507 ' SG ' ' O ' ' A' ' 130' ' ' ALA . 4.4 t -100.99 116.8 33.69 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.135 -0.978 . . . . 0.0 109.389 179.886 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 129' ' ' THR . . . . . 0.445 ' OG1' ' OE1' ' A' ' 156' ' ' GLU . 51.0 p -91.45 0.78 57.47 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.301 -0.875 . . . . 0.0 109.622 -179.842 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . 0.507 ' O ' ' SG ' ' A' ' 128' ' ' CYS . . . -151.25 155.91 39.77 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.188 -0.945 . . . . 0.0 109.601 -179.811 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 77.8 tttt -69.33 140.56 54.32 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.186 -0.946 . . . . 0.0 109.261 179.832 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 17.0 p -113.19 159.68 19.04 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.349 -0.844 . . . . 0.0 109.506 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -154.57 -50.46 0.09 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.397 -0.814 . . . . 0.0 109.282 -179.876 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 134' ' ' TRP . . . . . 0.631 ' CD1' ' N ' ' A' ' 135' ' ' LEU . 35.3 p90 -56.43 -38.8 72.07 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.259 -0.901 . . . . 0.0 109.385 179.836 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . 0.631 ' N ' ' CD1' ' A' ' 134' ' ' TRP . 44.2 tp -60.01 -36.5 77.35 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.428 -0.795 . . . . 0.0 109.505 -179.782 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 59.4 t0 47.26 78.75 0.07 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.337 -0.852 . . . . 0.0 109.798 179.771 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -144.74 134.92 5.84 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.11 -1.596 . . . . 0.0 109.11 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 67.6 mmtt -82.96 135.06 35.01 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.261 -1.141 . . . . 0.0 109.42 -179.754 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 96.4 m-70 -136.02 175.5 9.54 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.414 -0.804 . . . . 0.0 109.376 -179.878 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.457 ' O ' ' OG ' ' A' ' 112' ' ' SER . 20.1 m -124.0 153.77 30.34 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 121.466 -0.771 . . . . 0.0 108.996 179.702 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 58.5 t -118.39 128.2 75.39 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.292 -0.88 . . . . 0.0 109.961 -179.607 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . 0.455 ' CE2' ' CE2' ' A' ' 42' ' ' PHE . 40.6 p90 -117.59 1.61 12.27 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.474 -0.766 . . . . 0.0 109.561 179.412 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -169.29 177.38 42.97 Favored Glycine 0 N--CA 1.495 2.593 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 179.64 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . 0.432 ' CG ' ' N ' ' A' ' 145' ' ' VAL . 48.0 tt0 -143.76 161.62 38.12 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.349 -1.089 . . . . 0.0 109.798 -179.643 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . 0.432 ' N ' ' CG ' ' A' ' 144' ' ' GLN . 79.9 t -100.03 135.59 35.04 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.112 0 O-C-N 121.283 -0.886 . . . . 0.0 109.653 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 6.8 m -118.8 -33.69 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.275 -0.89 . . . . 0.0 109.573 179.672 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -138.37 166.03 25.27 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.237 -0.915 . . . . 0.0 109.713 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 94.47 9.98 58.49 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.845 -1.302 . . . . 0.0 109.845 179.745 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 149' ' ' MET . . . . . . . . . . . . . 88.7 mtp -59.84 -34.07 72.61 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.192 -1.181 . . . . 0.0 109.765 -179.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 89.0 m-20 -64.61 -39.68 94.15 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.896 -1.127 . . . . 0.0 109.846 -179.74 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 5.5 p -85.59 -33.27 7.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.132 -0.98 . . . . 0.0 110.522 -179.423 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 152' ' ' VAL . . . . . 0.412 ' CG1' ' N ' ' A' ' 153' ' ' LYS . 0.7 OUTLIER -55.29 -38.77 49.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 120.953 -1.092 . . . . 0.0 109.376 -179.366 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 153' ' ' LYS . . . . . 0.412 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 50.7 pttt -81.16 -20.97 40.13 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.136 -0.978 . . . . 0.0 109.385 179.683 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -64.39 -39.82 94.6 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.252 -0.905 . . . . 0.0 109.579 -179.916 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 65.2 mt -72.05 -35.68 54.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.304 -0.873 . . . . 0.0 109.541 179.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . 0.445 ' OE1' ' OG1' ' A' ' 129' ' ' THR . 84.7 tt0 -76.26 -42.27 46.22 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.257 -0.902 . . . . 0.0 111.447 -178.772 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 16.4 pttp -61.59 -33.12 73.34 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 120.639 -1.288 . . . . 0.0 110.241 -178.56 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 35.2 m -77.02 -17.84 14.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.018 -1.051 . . . . 0.0 109.683 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -72.87 172.77 48.77 Favored Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.965 -1.254 . . . . 0.0 109.965 -179.655 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 160' ' ' SER . . . . . 0.605 ' HG ' ' HG ' ' A' ' 162' ' ' SER . 85.0 p -150.09 170.07 19.76 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.476 -1.014 . . . . 0.0 109.381 -179.739 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 23.2 m -55.42 -34.72 64.67 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.177 -0.952 . . . . 0.0 108.965 179.705 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 162' ' ' SER . . . . . 0.605 ' HG ' ' HG ' ' A' ' 160' ' ' SER . 86.5 p -62.57 -26.34 68.54 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.373 -0.83 . . . . 0.0 109.189 179.674 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 97.2 3.17 58.94 Favored Glycine 0 N--CA 1.494 2.529 0 N-CA-C 109.674 -1.37 . . . . 0.0 109.674 179.898 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 77.8 ttt180 -99.99 144.56 28.9 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.306 -1.114 . . . . 0.0 109.205 179.818 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 165' ' ' THR . . . . . . . . . . . . . 65.5 p -104.71 152.1 22.93 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.354 -0.841 . . . . 0.0 109.657 -179.877 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -68.47 -37.0 79.77 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.369 -0.832 . . . . 0.0 109.627 179.923 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 47.8 mtmt -112.41 157.82 20.58 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.53 -0.731 . . . . 0.0 109.628 -179.793 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 91.3 mttt -76.54 146.49 38.34 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.333 -0.854 . . . . 0.0 109.306 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 32.6 m -128.75 125.2 62.86 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 O-C-N 121.326 -0.859 . . . . 0.0 109.596 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 48.5 t -144.88 138.23 22.21 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.387 -0.821 . . . . 0.0 109.302 179.589 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . 0.525 ' CG1' ' H ' ' A' ' 64' ' ' SER . 2.5 p -80.41 119.65 30.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 120.99 -1.069 . . . . 0.0 108.999 179.717 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -71.03 -44.41 65.88 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.133 -0.98 . . . . 0.0 111.177 -178.535 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 173' ' ' ASP . . . . . 0.441 ' OD1' ' N ' ' A' ' 174' ' ' CYS . 47.2 t0 -170.15 164.64 9.2 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.754 -1.216 . . . . 0.0 110.542 -179.325 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 174' ' ' CYS . . . . . 0.441 ' N ' ' OD1' ' A' ' 173' ' ' ASP . 1.4 p -151.63 151.86 32.07 Favored 'General case' 0 N--CA 1.49 1.573 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 179.484 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -160.75 178.37 36.77 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 176' ' ' GLN . . . . . 0.742 HE22 ' HE ' ' A' ' 43' ' ' ARG . 62.6 tt0 -99.05 113.96 26.42 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.326 -1.102 . . . . 0.0 109.713 -179.821 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 29.1 tp -63.37 -36.79 84.89 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.216 -0.928 . . . . 0.0 109.022 179.418 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 178' ' ' SER . . . . . 0.568 ' HG ' ' H ' ' A' ' 11' ' ' ARG . 11.8 p . . . . . 0 N--CA 1.491 1.62 0 CA-C-O 118.001 -0.999 . . . . 0.0 109.495 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 2.5 m-20 . . . . . 0 N--CA 1.492 1.661 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 93.3 Cg_endo -82.23 90.53 1.09 Allowed 'Trans proline' 0 C--N 1.308 -1.575 0 C-N-CA 122.898 2.399 . . . . 0.0 111.845 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 73.1 mtm180 -61.68 137.91 58.28 Favored 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.289 -0.882 . . . . 0.0 109.849 -179.595 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 12.7 p -138.29 143.53 32.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 179.497 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 45.1 p90 -141.54 153.96 45.19 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.179 -0.95 . . . . 0.0 110.107 -179.513 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 86.0 m-85 -123.73 140.25 53.18 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 179.162 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.5 t0 -86.88 116.31 24.87 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.053 -1.029 . . . . 0.0 109.259 179.768 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 80.4 mtp -103.96 147.45 27.34 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.291 -0.881 . . . . 0.0 110.19 -179.856 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 97.1 p -143.94 164.39 30.72 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 108.55 -0.907 . . . . 0.0 108.55 179.414 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 12.9 p -128.3 139.03 53.0 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.238 -0.914 . . . . 0.0 109.676 -179.752 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 57.02 -107.33 0.92 Allowed Glycine 0 N--CA 1.488 2.129 0 N-CA-C 109.364 -1.494 . . . . 0.0 109.364 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -136.04 37.15 1.93 Allowed Glycine 0 N--CA 1.493 2.487 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 6.5 pt20 -147.88 126.99 6.3 Favored Pre-proline 0 N--CA 1.492 1.649 0 O-C-N 121.264 -1.139 . . . . 0.0 109.349 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_exo -47.39 139.88 16.29 Favored 'Trans proline' 0 N--CA 1.493 1.455 0 C-N-CA 122.139 1.893 . . . . 0.0 112.17 179.74 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -101.49 -61.31 1.39 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.311 -0.868 . . . . 0.0 109.483 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -178.19 -170.3 40.16 Favored Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.409 -1.476 . . . . 0.0 109.409 -179.871 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 97.5 mtt180 -118.04 142.33 47.5 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.374 -1.074 . . . . 0.0 109.803 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 70.1 mt -120.39 123.2 70.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 178.609 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 38.7 t -110.05 132.58 57.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.387 -0.82 . . . . 0.0 109.382 -179.535 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 76.2 mtm -114.79 149.32 37.16 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.591 -0.693 . . . . 0.0 109.381 -179.689 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -100.92 129.82 46.83 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.286 -0.884 . . . . 0.0 109.698 -179.668 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.408 ' N ' ' CD2' ' A' ' 30' ' ' LEU . 2.7 mm? -108.34 132.66 53.5 Favored 'General case' 0 N--CA 1.494 1.741 0 N-CA-C 108.909 -0.775 . . . . 0.0 108.909 179.588 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.485 ' O ' ' OG1' ' A' ' 35' ' ' THR . 92.7 m-85 -96.36 114.02 25.66 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.031 -1.043 . . . . 0.0 108.742 178.98 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -75.87 -42.43 49.4 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.155 -0.966 . . . . 0.0 109.869 -179.696 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.3 m-20 -66.63 -57.86 6.34 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.149 -0.97 . . . . 0.0 110.191 -179.356 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 54.9 m -67.03 -40.73 87.28 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.246 -0.909 . . . . 0.0 109.853 -179.759 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.485 ' OG1' ' O ' ' A' ' 31' ' ' PHE . 81.7 p -130.04 77.5 76.42 Favored Pre-proline 0 N--CA 1.493 1.711 0 O-C-N 121.358 -0.839 . . . . 0.0 109.377 -179.64 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -72.84 -73.64 0.01 OUTLIER 'Trans proline' 0 N--CA 1.493 1.489 0 C-N-CA 122.676 2.251 . . . . 0.0 113.259 -179.38 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 80.1 mtt85 -59.37 -39.33 82.93 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.612 -0.68 . . . . 0.0 111.061 -178.624 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 42.8 m -61.66 -42.56 99.07 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.864 -1.148 . . . . 0.0 109.452 -179.848 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -63.9 -30.85 71.89 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.263 -0.898 . . . . 0.0 108.593 179.295 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.448 ' OE1' ' OH ' ' A' ' 92' ' ' TYR . 85.2 tt0 -66.25 -36.81 83.96 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.432 -0.792 . . . . 0.0 109.509 179.927 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 38.7 t30 -58.03 -41.2 82.69 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.229 -0.919 . . . . 0.0 109.514 -179.698 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . 0.498 ' O ' ' SG ' ' A' ' 46' ' ' CYS . 98.0 m-85 -83.18 -44.99 14.43 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.058 -1.026 . . . . 0.0 109.661 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . 0.69 ' NE ' HE22 ' A' ' 176' ' ' GLN . 77.5 ttt180 -59.32 -43.2 92.7 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.38 -0.825 . . . . 0.0 110.62 -179.216 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.448 ' O ' ' N ' ' A' ' 48' ' ' GLY . . . -68.1 -43.97 77.29 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.097 -1.002 . . . . 0.0 110.63 -178.834 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -62.39 -39.05 91.95 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.971 -1.081 . . . . 0.0 109.593 -179.659 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' CYS . . . . . 0.498 ' SG ' ' O ' ' A' ' 42' ' ' PHE . 35.7 m -67.64 -47.89 68.27 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.146 -0.972 . . . . 0.0 109.391 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 48.3 p -74.49 -33.75 62.91 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.361 -0.837 . . . . 0.0 109.709 179.864 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . 0.448 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 74.36 33.53 56.29 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 110.077 -1.209 . . . . 0.0 110.077 179.704 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -62.11 -37.55 85.54 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.07 -1.253 . . . . 0.0 109.61 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 72.2 mmtt -61.27 -35.32 76.96 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.262 -0.899 . . . . 0.0 109.578 -179.845 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 90.9 171.68 43.52 Favored Glycine 0 N--CA 1.488 2.113 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 -179.757 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 65.7 m -75.57 140.27 42.59 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.493 -1.004 . . . . 0.0 109.832 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -63.87 138.44 42.07 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.172 -1.571 . . . . 0.0 109.172 179.702 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 81.0 mmt-85 -59.37 -33.32 71.03 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.305 -1.115 . . . . 0.0 109.922 -179.656 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 86.1 p -60.91 -22.98 64.88 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.129 -0.982 . . . . 0.0 109.966 -179.532 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . 0.428 ' O ' ' CG ' ' A' ' 57' ' ' LYS . . . 110.03 77.55 0.95 Allowed Glycine 0 N--CA 1.496 2.636 0 N-CA-C 108.879 -1.688 . . . . 0.0 108.879 -179.586 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . 0.51 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 8.6 mtmp? -160.41 76.8 2.69 Favored Pre-proline 0 C--N 1.303 -1.455 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 -179.837 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 81.8 Cg_exo -49.0 130.0 22.71 Favored 'Trans proline' 0 C--N 1.301 -1.945 0 C-N-CA 122.913 2.409 . . . . 0.0 112.614 -178.867 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.51 ' CD1' ' O ' ' A' ' 57' ' ' LYS . 8.3 mp -99.33 84.86 3.07 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.753 -0.592 . . . . 0.0 109.52 -179.697 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 99.2 m-70 -145.81 143.06 29.43 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.276 -0.89 . . . . 0.0 109.734 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 2.9 m-85 -102.33 17.03 24.48 Favored 'General case' 0 N--CA 1.493 1.724 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 179.317 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 91.7 mttt -81.01 158.84 25.01 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.303 -0.873 . . . . 0.0 109.885 -179.491 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . 0.426 ' N ' ' CG2' ' A' ' 171' ' ' VAL . 84.3 m-20 55.99 45.84 23.02 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.552 -0.717 . . . . 0.0 110.35 179.562 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.677 ' H ' ' CG2' ' A' ' 171' ' ' VAL . 66.7 p -98.74 153.35 18.8 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.143 -0.973 . . . . 0.0 108.616 179.077 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 28.6 t -122.3 145.06 48.6 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.37 -0.832 . . . . 0.0 109.664 -179.566 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 4.3 m-85 -72.7 129.04 37.31 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.314 -0.866 . . . . 0.0 109.034 179.782 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' HIS . . . . . 0.712 ' HE2' HH21 ' A' ' 68' ' ' ARG . 74.9 t60 -62.2 -49.94 73.79 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.358 -0.839 . . . . 0.0 110.116 -179.376 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.712 HH21 ' HE2' ' A' ' 67' ' ' HIS . 18.4 ptp180 -160.17 161.02 33.54 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.035 -1.041 . . . . 0.0 109.922 -179.982 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 17.7 m -132.73 145.23 34.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.478 -0.764 . . . . 0.0 109.043 179.683 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 14.4 mt -148.17 129.5 7.2 Favored Pre-proline 0 N--CA 1.494 1.745 0 O-C-N 121.091 -1.005 . . . . 0.0 109.331 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -72.3 145.36 43.23 Favored 'Trans proline' 0 N--CA 1.492 1.393 0 C-N-CA 122.242 1.961 . . . . 0.0 112.379 179.849 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 82.25 -56.18 4.97 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.918 -1.273 . . . . 0.0 109.918 179.736 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -72.42 -86.16 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.117 -1.225 . . . . 0.0 109.874 -179.715 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' MET . . . . . 0.602 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 12.4 ptt? -179.52 -168.6 0.12 Allowed 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.236 -0.915 . . . . 0.0 109.759 -179.914 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -126.71 131.85 51.28 Favored 'General case' 0 N--CA 1.494 1.732 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.774 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 63.6 tt0 -103.07 126.4 50.23 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.151 -0.968 . . . . 0.0 109.908 -179.611 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -86.29 -174.03 49.38 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.242 -1.543 . . . . 0.0 109.242 179.548 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -138.35 154.9 23.19 Favored Glycine 0 N--CA 1.495 2.575 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 88.4 m-20 -73.67 149.36 42.0 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.35 -1.088 . . . . 0.0 109.43 179.804 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 48.3 p90 -64.72 -26.33 68.32 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.161 -0.962 . . . . 0.0 109.437 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 54.0 p -69.1 -29.08 67.09 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.165 -0.959 . . . . 0.0 109.462 179.925 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 174.79 -55.11 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.386 -0.821 . . . . 0.0 109.254 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 95.95 -6.5 66.9 Favored Glycine 0 N--CA 1.492 2.395 0 N-CA-C 109.658 -1.377 . . . . 0.0 109.658 179.878 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 78.5 m-20 -88.16 2.71 51.52 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.188 -1.184 . . . . 0.0 109.258 179.812 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 94.18 -6.61 72.32 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.321 -1.511 . . . . 0.0 109.321 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 59.0 p -75.15 -18.54 60.18 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.254 -1.145 . . . . 0.0 109.506 179.896 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -132.38 -128.47 2.92 Favored Glycine 0 N--CA 1.494 2.507 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.857 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 81.87 22.35 59.78 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.287 -1.525 . . . . 0.0 109.287 -179.856 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -57.96 145.43 35.91 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.339 -1.095 . . . . 0.0 109.669 -179.855 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 88.5 p -111.85 153.36 26.75 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.417 -0.802 . . . . 0.0 109.331 179.885 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 5.5 pt -63.56 -39.76 86.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.242 -0.911 . . . . 0.0 109.847 -179.76 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . 0.448 ' OH ' ' OE1' ' A' ' 40' ' ' GLU . 3.1 m-30 -63.45 -38.87 92.8 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.089 -1.007 . . . . 0.0 109.459 179.758 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 76.7 19.03 78.39 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.282 -1.527 . . . . 0.0 109.282 -179.861 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -145.62 158.78 43.8 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.328 -1.101 . . . . 0.0 109.442 -179.853 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 62.9 mttp -85.01 153.62 22.64 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.336 -0.852 . . . . 0.0 109.709 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -100.68 133.12 45.61 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.41 -0.806 . . . . 0.0 109.1 179.775 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -83.47 119.73 25.04 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.162 -0.961 . . . . 0.0 109.684 -179.715 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 88.1 m-20 -75.55 143.09 42.61 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.283 -0.886 . . . . 0.0 109.259 179.638 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -153.29 -31.11 0.13 Allowed 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.174 -0.954 . . . . 0.0 110.05 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 84.6 m-20 -97.73 131.33 44.36 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.073 -1.017 . . . . 0.0 109.954 -179.579 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' PHE . . . . . 0.555 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 70.6 t80 -134.56 22.13 3.65 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 179.745 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.431 HD13 HG22 ' A' ' 102' ' ' ILE . 86.2 mt -56.77 -37.5 53.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.437 -0.79 . . . . 0.0 110.052 -179.512 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 56.6 mttm -83.34 138.27 33.6 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.008 -1.057 . . . . 0.0 109.891 -179.65 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 72.8 tttt -134.89 157.56 46.53 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.462 -0.774 . . . . 0.0 109.24 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' HIS . . . . . 0.542 ' O ' ' CG ' ' A' ' 105' ' ' HIS . 52.2 p-80 -68.02 83.5 0.22 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.12 -0.987 . . . . 0.0 109.271 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 57.0 p -77.04 -19.31 57.33 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.275 -0.891 . . . . 0.0 110.116 -179.54 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -150.55 178.25 28.11 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 109.737 -1.345 . . . . 0.0 109.737 -179.654 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -74.9 156.72 43.46 Favored 'Trans proline' 0 C--N 1.306 -1.674 0 C-N-CA 123.027 2.484 . . . . 0.0 112.14 179.831 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 80.8 46.45 7.19 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 110.03 -1.228 . . . . 0.0 110.03 179.638 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 32.9 mm -113.01 137.24 46.7 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.393 -1.063 . . . . 0.0 109.098 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . 0.594 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 2.3 mm? -89.88 131.81 35.61 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.261 -0.899 . . . . 0.0 109.836 -179.383 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 58.4 m -140.28 148.22 41.1 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.393 -0.817 . . . . 0.0 109.406 179.512 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 113' ' ' MET . . . . . 0.575 ' CE ' HD22 ' A' ' 121' ' ' ASN . 85.7 mtp -96.62 136.3 37.34 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.209 -0.932 . . . . 0.0 109.298 179.834 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . 0.55 ' O ' ' ND2' ' A' ' 115' ' ' ASN . . . -71.03 143.38 50.77 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.321 -0.862 . . . . 0.0 109.813 -179.872 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . 0.688 ' H ' ' CD2' ' A' ' 139' ' ' HIS . 18.8 m120 -148.44 113.26 5.41 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.306 -0.871 . . . . 0.0 108.861 179.506 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -68.24 -31.99 71.86 Favored 'General case' 0 C--N 1.299 -1.623 0 O-C-N 121.333 -0.854 . . . . 0.0 109.655 -179.896 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -137.63 171.47 23.23 Favored Glycine 0 N--CA 1.492 2.414 0 N-CA-C 109.326 -1.51 . . . . 0.0 109.326 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -67.29 151.89 80.12 Favored 'Trans proline' 0 C--N 1.305 -1.728 0 C-N-CA 122.753 2.302 . . . . 0.0 111.732 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 75.2 m-20 52.57 44.09 30.43 Favored 'General case' 0 C--N 1.299 -1.601 0 O-C-N 121.459 -0.776 . . . . 0.0 109.294 -179.811 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 120' ' ' THR . . . . . 0.471 ' O ' ' ND2' ' A' ' 115' ' ' ASN . 79.8 m -134.62 128.34 32.95 Favored 'General case' 0 C--N 1.304 -1.394 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 179.875 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 121' ' ' ASN . . . . . 0.575 HD22 ' CE ' ' A' ' 113' ' ' MET . 21.2 t-20 -96.76 109.22 21.94 Favored 'General case' 0 C--N 1.297 -1.677 0 O-C-N 121.479 -0.763 . . . . 0.0 109.294 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -84.48 123.85 6.43 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.642 -1.383 . . . . 0.0 109.642 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 22.6 m -59.46 -33.29 71.11 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.347 -1.09 . . . . 0.0 109.542 179.806 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.8 mt-30 -75.96 144.12 41.17 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.233 -0.917 . . . . 0.0 109.926 -179.636 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 48.6 p90 -137.8 160.92 37.94 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.429 -0.794 . . . . 0.0 109.109 179.684 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . 0.602 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 52.3 p90 -142.53 159.64 41.83 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.147 -0.971 . . . . 0.0 110.012 -179.759 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 4.6 mp -119.68 138.77 49.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.474 -0.766 . . . . 0.0 109.049 179.695 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 17.1 t -121.04 126.74 50.64 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.236 -0.915 . . . . 0.0 109.599 -179.909 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 129' ' ' THR . . . . . 0.414 ' O ' ' OG1' ' A' ' 129' ' ' THR . 0.0 OUTLIER -106.91 15.76 25.06 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.544 -0.722 . . . . 0.0 109.204 179.864 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -141.08 161.21 38.4 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.315 -0.866 . . . . 0.0 109.316 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 64.0 tttm -64.76 132.22 48.96 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.175 -0.953 . . . . 0.0 109.439 -179.79 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 58.6 p -147.66 69.86 1.15 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.287 -0.883 . . . . 0.0 109.24 -179.898 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -58.39 -37.85 76.14 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.295 -0.878 . . . . 0.0 110.033 -179.581 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 0.8 OUTLIER -61.46 -43.94 97.98 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.024 -1.047 . . . . 0.0 109.443 -179.875 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 28.3 mt -65.47 -30.81 71.63 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.186 -0.946 . . . . 0.0 109.754 179.326 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . 0.502 ' CB ' ' CE1' ' A' ' 105' ' ' HIS . 23.2 t70 -76.05 121.24 22.49 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.231 -0.918 . . . . 0.0 109.659 -179.627 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 178.61 -101.84 0.16 Allowed Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.202 -1.559 . . . . 0.0 109.202 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 33.4 mmtm -58.15 -28.56 64.82 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.327 -1.102 . . . . 0.0 109.058 179.506 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 139' ' ' HIS . . . . . 0.688 ' CD2' ' H ' ' A' ' 115' ' ' ASN . 56.3 m170 -83.78 153.2 24.24 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.348 -0.845 . . . . 0.0 109.479 -179.831 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 20.2 m -127.44 160.76 36.15 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 121.516 -0.74 . . . . 0.0 109.278 -179.858 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 21.5 m -96.69 129.25 47.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.245 -0.91 . . . . 0.0 109.519 -179.732 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 44.0 p90 -113.03 -9.07 13.61 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.189 -0.944 . . . . 0.0 110.271 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -158.45 177.49 35.08 Favored Glycine 0 N--CA 1.492 2.41 0 C-N-CA 119.567 -1.302 . . . . 0.0 109.87 179.703 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 47.8 tt0 -139.63 158.78 43.53 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.303 -1.116 . . . . 0.0 109.633 -179.549 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 13.2 t -94.73 134.07 33.44 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.235 0 O-C-N 121.042 -1.036 . . . . 0.0 109.241 179.666 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 17.4 m -112.03 -26.14 3.22 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.407 -0.808 . . . . 0.0 109.512 179.607 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 94.9 mt-10 -145.78 173.07 12.43 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.238 -0.914 . . . . 0.0 109.541 -179.878 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 98.51 2.35 57.64 Favored Glycine 0 N--CA 1.494 2.511 0 N-CA-C 110.085 -1.206 . . . . 0.0 110.085 179.486 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 149' ' ' MET . . . . . 0.409 ' O ' HG11 ' A' ' 152' ' ' VAL . 65.1 mtt -61.15 -33.07 72.82 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.035 -1.274 . . . . 0.0 109.736 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 89.1 m-20 -64.91 -42.13 94.99 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 120.765 -1.209 . . . . 0.0 110.036 -179.556 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.7 p -82.6 -34.46 11.83 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.078 -1.014 . . . . 0.0 110.485 -179.313 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 152' ' ' VAL . . . . . 0.453 ' CG1' ' N ' ' A' ' 153' ' ' LYS . 0.8 OUTLIER -54.92 -41.82 60.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 120.963 -1.086 . . . . 0.0 109.188 -179.323 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 153' ' ' LYS . . . . . 0.453 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 59.1 mttp -64.25 -34.17 77.49 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.263 -0.898 . . . . 0.0 109.473 179.393 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -62.26 -37.36 85.15 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.308 -0.87 . . . . 0.0 110.217 -179.398 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 79.5 mt -71.96 -36.99 59.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.054 -1.029 . . . . 0.0 110.059 -179.752 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -74.08 -41.75 61.22 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.135 -0.978 . . . . 0.0 111.227 -178.706 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 17.4 pttp -61.69 -33.72 74.51 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 120.749 -1.219 . . . . 0.0 109.734 -179.001 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 27.2 m -86.39 -1.15 7.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.119 -0.988 . . . . 0.0 109.044 179.501 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -74.7 174.22 51.13 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.782 -1.327 . . . . 0.0 109.782 -179.706 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 97.0 p -152.33 162.94 40.44 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.328 -1.101 . . . . 0.0 109.942 -179.64 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 22.8 t -58.9 -31.49 68.66 Favored 'General case' 0 N--CA 1.488 1.441 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 179.297 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 23.1 t -55.96 -30.46 61.76 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.427 -0.796 . . . . 0.0 109.069 179.729 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 100.42 10.12 45.43 Favored Glycine 0 N--CA 1.493 2.489 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 179.784 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 34.5 mmt180 -118.26 147.63 43.24 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.224 -1.162 . . . . 0.0 109.282 179.713 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 165' ' ' THR . . . . . . . . . . . . . 82.1 p -81.64 152.72 27.0 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.364 -0.835 . . . . 0.0 109.384 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -65.98 -34.27 77.71 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.289 -0.882 . . . . 0.0 109.587 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 62.1 mttm -118.22 162.08 18.84 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.467 -0.77 . . . . 0.0 109.656 -179.664 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 62.8 mttp -75.15 142.44 43.56 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.355 -0.841 . . . . 0.0 109.594 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 1.8 m -133.45 124.67 49.0 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.308 -0.87 . . . . 0.0 109.738 179.763 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 88.8 t -139.45 142.26 33.49 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.461 -0.774 . . . . 0.0 109.395 179.769 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . 0.677 ' CG2' ' H ' ' A' ' 64' ' ' SER . 3.0 m -71.69 124.84 29.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.014 -1.054 . . . . 0.0 109.55 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 77.9 mm-40 -70.88 -37.72 73.04 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.09 -1.006 . . . . 0.0 110.251 -179.669 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 173' ' ' ASP . . . . . 0.463 ' OD1' ' N ' ' A' ' 174' ' ' CYS . 49.5 t0 -164.84 166.62 19.54 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.063 -1.023 . . . . 0.0 110.032 -179.668 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 174' ' ' CYS . . . . . 0.463 ' N ' ' OD1' ' A' ' 173' ' ' ASP . 12.3 p -141.59 152.34 43.96 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.395 -0.815 . . . . 0.0 109.366 179.803 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -175.52 178.92 47.0 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.649 -1.38 . . . . 0.0 109.649 179.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 176' ' ' GLN . . . . . 0.69 HE22 ' NE ' ' A' ' 43' ' ' ARG . 63.3 tt0 -108.12 127.89 54.21 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.373 -1.075 . . . . 0.0 109.528 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -61.24 -38.8 87.94 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.22 -0.925 . . . . 0.0 108.718 179.694 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 9.6 t . . . . . 0 N--CA 1.49 1.544 0 CA-C-O 117.979 -1.01 . . . . 0.0 109.47 179.81 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . 0.459 ' ND2' ' O ' ' A' ' 10' ' ' PRO . 1.5 t30 . . . . . 0 N--CA 1.49 1.543 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . 0.459 ' O ' ' ND2' ' A' ' 9' ' ' ASN . 53.1 Cg_endo -68.34 140.22 47.87 Favored 'Trans proline' 0 N--CA 1.496 1.645 0 C-N-CA 122.424 2.082 . . . . 0.0 112.211 179.826 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 58.6 mtm180 -132.26 132.44 43.04 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.436 -0.79 . . . . 0.0 109.018 179.537 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.5 p -135.91 143.95 34.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.316 -0.865 . . . . 0.0 109.311 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 33.2 p90 -139.4 152.69 47.3 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.33 -0.856 . . . . 0.0 109.792 -179.633 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.432 ' CE2' ' SG ' ' A' ' 174' ' ' CYS . 94.3 m-85 -123.26 128.65 50.26 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.595 -0.69 . . . . 0.0 109.546 179.475 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.4 t0 -90.31 119.05 30.28 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.14 -0.975 . . . . 0.0 108.94 179.303 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' MET . . . . . 0.411 ' CE ' ' CE1' ' A' ' 66' ' ' PHE . 67.0 mtp -117.13 143.32 45.95 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.217 -0.927 . . . . 0.0 110.375 -179.315 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.414 ' OG ' ' OE2' ' A' ' 172' ' ' GLU . 50.8 m -132.16 155.14 48.71 Favored 'General case' 0 N--CA 1.491 1.612 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 179.639 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 25.4 m -114.87 132.53 63.81 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.234 -0.917 . . . . 0.0 109.657 -179.765 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 65.86 9.9 48.33 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 179.836 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 93.36 -3.89 72.86 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.302 -1.519 . . . . 0.0 109.302 -179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 33.9 mt-30 -99.11 128.39 32.18 Favored Pre-proline 0 N--CA 1.492 1.634 0 O-C-N 121.371 -1.076 . . . . 0.0 109.071 179.806 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 76.1 Cg_exo -43.69 130.11 7.3 Favored 'Trans proline' 0 C--N 1.312 -1.387 0 C-N-CA 122.12 1.88 . . . . 0.0 112.126 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -104.07 -65.25 1.03 Allowed 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.375 -0.828 . . . . 0.0 109.345 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -169.46 -171.21 34.87 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 92.2 mtm-85 -114.1 143.13 45.29 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.385 -1.068 . . . . 0.0 109.465 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 76.4 mt -120.95 117.84 54.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 179.091 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 41.8 t -116.38 132.8 64.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.552 -0.718 . . . . 0.0 109.327 -179.541 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 73.1 mtm -121.48 149.88 42.41 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.464 -0.772 . . . . 0.0 109.209 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -99.88 129.82 46.0 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.24 -0.912 . . . . 0.0 109.822 -179.636 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.429 ' N ' ' CD2' ' A' ' 30' ' ' LEU . 2.5 mm? -105.84 130.75 53.75 Favored 'General case' 0 N--CA 1.493 1.682 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.376 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -94.91 119.33 33.28 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.111 -0.993 . . . . 0.0 109.205 179.739 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -82.14 -42.67 18.76 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.361 -0.837 . . . . 0.0 109.803 -179.764 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -67.19 -44.74 78.88 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.278 -0.889 . . . . 0.0 110.514 -179.266 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 23.2 m -66.93 -45.35 78.14 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.175 -0.953 . . . . 0.0 109.959 -179.296 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 68.9 p -150.39 83.32 6.0 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 121.285 -0.884 . . . . 0.0 109.468 -179.691 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -70.92 -44.36 1.32 Allowed 'Trans proline' 0 C--N 1.308 -1.595 0 C-N-CA 122.19 1.927 . . . . 0.0 112.087 -179.702 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.448 ' O ' ' OH ' ' A' ' 92' ' ' TYR . 25.4 mtp180 -62.59 -39.63 94.32 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.465 -0.772 . . . . 0.0 110.201 -179.862 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 32.4 m -66.07 -41.76 90.3 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.116 -0.99 . . . . 0.0 110.086 -179.736 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -61.81 -31.04 71.24 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.228 -0.92 . . . . 0.0 109.324 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -68.19 -37.7 81.22 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.219 -0.926 . . . . 0.0 109.85 -179.755 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 51.9 t30 -57.45 -42.16 81.97 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.205 -0.935 . . . . 0.0 109.79 -179.437 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 -86.13 -48.07 8.93 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.151 -0.968 . . . . 0.0 109.754 -179.842 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 40.2 ttp180 -57.87 -39.47 77.88 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.457 -0.777 . . . . 0.0 110.3 -179.482 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.506 ' O ' ' N ' ' A' ' 48' ' ' GLY . . . -64.31 -43.13 95.66 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.04 -1.038 . . . . 0.0 110.451 -179.117 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -65.19 -40.02 93.66 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.008 -1.057 . . . . 0.0 109.655 -179.852 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' CYS . . . . . . . . . . . . . 75.7 m -69.22 -49.54 55.53 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.023 -1.048 . . . . 0.0 109.444 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 73.9 p -74.07 -34.04 63.89 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.18 -0.95 . . . . 0.0 109.554 179.828 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . 0.506 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 75.22 35.22 49.4 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 110.395 -1.082 . . . . 0.0 110.395 179.643 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -61.53 -37.26 83.1 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.005 -1.291 . . . . 0.0 109.235 179.836 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 48.2 mmtm -61.76 -33.59 74.35 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.343 -0.848 . . . . 0.0 109.384 179.783 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 94.35 167.54 36.98 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.295 -1.522 . . . . 0.0 109.295 -179.762 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 99.2 m -80.2 141.05 36.01 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.293 -1.121 . . . . 0.0 109.729 -179.908 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -59.03 137.55 50.35 Favored Glycine 0 N--CA 1.489 2.173 0 N-CA-C 109.305 -1.518 . . . . 0.0 109.305 179.764 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 74.5 mtt85 -58.99 -35.35 73.07 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.294 -1.121 . . . . 0.0 109.913 -179.701 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 22.9 t -57.67 -31.9 66.79 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.25 -0.906 . . . . 0.0 109.887 -179.769 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 117.86 91.22 1.49 Allowed Glycine 0 N--CA 1.495 2.626 0 N-CA-C 108.896 -1.681 . . . . 0.0 108.896 -179.503 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . 0.492 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 78.6 tttt -176.62 80.21 0.27 Allowed Pre-proline 0 N--CA 1.488 1.459 0 O-C-N 121.546 -0.973 . . . . 0.0 108.442 -179.666 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_exo -48.99 134.51 29.2 Favored 'Trans proline' 0 C--N 1.304 -1.794 0 C-N-CA 122.727 2.285 . . . . 0.0 112.457 -179.097 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.492 ' CD1' ' O ' ' A' ' 57' ' ' LYS . 7.7 mp -100.5 71.67 1.54 Allowed 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.621 -0.674 . . . . 0.0 109.4 -179.557 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 79.9 m80 -147.06 130.52 16.73 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.197 -0.939 . . . . 0.0 109.887 179.902 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 58.8 m-85 -72.67 -5.04 34.83 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.119 -0.988 . . . . 0.0 108.402 178.748 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 50.4 tttt -53.54 140.58 28.01 Favored 'General case' 0 N--CA 1.487 1.409 0 O-C-N 121.622 -0.674 . . . . 0.0 109.973 -179.501 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 53.7 t0 56.97 43.5 24.52 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.572 -0.705 . . . . 0.0 110.28 179.646 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.718 ' H ' ' CG1' ' A' ' 171' ' ' VAL . 95.6 p -109.79 150.33 28.52 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.157 -0.965 . . . . 0.0 108.68 179.094 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 38.4 t -102.97 141.42 35.81 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.171 -0.956 . . . . 0.0 109.004 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.411 ' CE1' ' CE ' ' A' ' 16' ' ' MET . 3.2 m-85 -66.66 138.72 57.64 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.291 -0.88 . . . . 0.0 109.021 -179.728 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 81.5 t60 -59.05 -52.19 66.81 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.299 -0.876 . . . . 0.0 110.298 -178.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 15.5 ptm180 -166.68 164.01 16.72 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.083 -1.011 . . . . 0.0 109.952 -179.807 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 33.9 m -131.98 147.86 32.3 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.48 -0.762 . . . . 0.0 109.169 179.678 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 11.6 mt -147.74 108.24 3.77 Favored Pre-proline 0 N--CA 1.492 1.648 0 O-C-N 120.965 -1.084 . . . . 0.0 109.74 179.72 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_exo -54.09 146.04 50.44 Favored 'Trans proline' 0 N--CA 1.493 1.485 0 C-N-CA 122.427 2.085 . . . . 0.0 112.448 179.723 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 77.57 -57.81 3.78 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 110.212 -1.155 . . . . 0.0 110.212 179.273 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 95.5 m-85 -69.67 -83.85 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.166 -1.197 . . . . 0.0 109.819 -179.498 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' MET . . . . . 0.471 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 12.2 ptp -178.93 -172.36 0.25 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.255 -0.903 . . . . 0.0 109.59 -179.764 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -127.76 137.15 52.33 Favored 'General case' 0 N--CA 1.494 1.746 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 179.734 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 93.5 mt-30 -110.63 154.46 23.76 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.256 -0.902 . . . . 0.0 109.603 -179.619 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -160.83 -166.93 20.56 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.426 -1.47 . . . . 0.0 109.426 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 88.74 23.66 35.28 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.439 ' C ' ' OD1' ' A' ' 79' ' ' ASP . 54.6 p30 -84.13 10.54 9.9 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.179 -1.189 . . . . 0.0 109.377 179.922 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 85.2 t80 -53.25 -46.25 69.12 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.36 -0.837 . . . . 0.0 109.804 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.555 ' OG1' ' N ' ' A' ' 88' ' ' GLY . 71.9 p -71.17 -28.71 64.45 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.013 -1.055 . . . . 0.0 109.568 179.906 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . 0.4 ' CB ' ' O ' ' A' ' 81' ' ' THR . . . 171.26 -57.46 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.205 -0.935 . . . . 0.0 109.405 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 93.65 1.51 65.89 Favored Glycine 0 N--CA 1.492 2.402 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 -180.0 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 23.6 m120 -86.61 6.31 31.57 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.244 -1.15 . . . . 0.0 109.446 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 95.79 -39.13 2.91 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.327 -1.509 . . . . 0.0 109.327 -179.781 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 52.2 p -74.14 -16.14 61.01 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.336 -1.096 . . . . 0.0 109.055 179.594 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -82.85 -167.25 40.7 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.671 -1.372 . . . . 0.0 109.671 -179.913 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.555 ' N ' ' OG1' ' A' ' 81' ' ' THR . . . 83.85 38.42 10.47 Favored Glycine 0 N--CA 1.488 2.104 0 N-CA-C 109.154 -1.578 . . . . 0.0 109.154 -179.708 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -57.42 144.87 34.77 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.46 -1.024 . . . . 0.0 109.671 -179.774 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 96.4 p -112.26 150.24 31.23 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.449 -0.782 . . . . 0.0 109.191 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 24.0 pt -70.82 -31.48 45.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.171 -0.956 . . . . 0.0 110.059 -179.684 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . 0.448 ' OH ' ' O ' ' A' ' 37' ' ' ARG . 59.2 m-85 -65.38 -37.99 88.68 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.166 -0.959 . . . . 0.0 109.7 -179.65 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 73.22 15.63 78.75 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -148.16 158.72 44.23 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.301 -1.117 . . . . 0.0 109.455 -179.834 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 63.4 mttp -84.95 150.29 25.03 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.366 -0.834 . . . . 0.0 109.473 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 55.4 p90 -132.25 160.52 35.94 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.279 -0.888 . . . . 0.0 109.538 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -110.52 154.18 24.06 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.496 -0.752 . . . . 0.0 109.723 -179.801 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 60.3 t0 -78.48 124.13 27.8 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.264 -0.897 . . . . 0.0 109.306 179.76 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 78.5 mm-40 -60.88 -37.49 82.35 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.278 -0.889 . . . . 0.0 110.003 -179.457 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 19.1 t-20 -166.51 171.11 12.14 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.95 -1.094 . . . . 0.0 109.943 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -109.81 44.09 1.25 Allowed 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.521 -0.737 . . . . 0.0 109.373 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 89.0 mt -52.32 -41.84 35.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.105 -0.997 . . . . 0.0 109.818 -179.514 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 59.6 mttm -91.72 144.42 25.53 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.144 -0.972 . . . . 0.0 109.756 -179.686 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 80.2 tttt -134.38 159.13 42.01 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.371 -0.831 . . . . 0.0 109.444 -179.788 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' HIS . . . . . 0.526 ' CE1' ' O ' ' A' ' 107' ' ' GLY . 70.7 t60 -89.63 111.29 22.2 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.304 -0.873 . . . . 0.0 109.264 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 48.2 p -125.86 1.22 7.37 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.364 -0.835 . . . . 0.0 109.942 -179.797 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.526 ' O ' ' CE1' ' A' ' 105' ' ' HIS . . . -155.62 170.32 33.53 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.811 -1.316 . . . . 0.0 109.811 -179.771 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -75.07 156.24 42.68 Favored 'Trans proline' 0 C--N 1.308 -1.573 0 C-N-CA 123.026 2.484 . . . . 0.0 112.213 179.614 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 84.15 43.27 7.16 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 110.328 -1.109 . . . . 0.0 110.328 179.51 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.409 HG23 HD13 ' A' ' 110' ' ' ILE . 37.1 mm -115.25 134.41 58.47 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.834 0 O-C-N 121.312 -1.111 . . . . 0.0 109.172 179.592 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . 0.578 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 2.9 mm? -90.36 124.91 35.31 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.237 -0.915 . . . . 0.0 109.22 179.903 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 50.4 m -137.95 144.96 41.46 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.208 -0.933 . . . . 0.0 109.779 179.806 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 87.8 mtp -90.35 131.41 36.15 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.352 -0.842 . . . . 0.0 109.114 179.429 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . 0.409 ' O ' ' OD1' ' A' ' 115' ' ' ASN . . . -65.73 143.76 57.32 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.195 -0.94 . . . . 0.0 109.513 -179.829 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . 0.409 ' OD1' ' O ' ' A' ' 114' ' ' ALA . 72.2 m-20 -144.22 113.31 6.85 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.174 -0.954 . . . . 0.0 108.976 179.601 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -70.22 -30.03 67.01 Favored 'General case' 0 C--N 1.297 -1.691 0 O-C-N 121.465 -0.772 . . . . 0.0 109.581 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -140.33 167.16 25.58 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.486 -1.446 . . . . 0.0 109.486 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . 0.533 ' O ' ' ND2' ' A' ' 119' ' ' ASN . 41.0 Cg_endo -67.26 158.36 57.33 Favored 'Trans proline' 0 C--N 1.305 -1.726 0 C-N-CA 122.875 2.383 . . . . 0.0 111.893 179.952 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 119' ' ' ASN . . . . . 0.533 ' ND2' ' O ' ' A' ' 118' ' ' PRO . 9.5 p30 45.41 45.44 10.18 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.514 -0.741 . . . . 0.0 109.543 -179.898 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 89.4 m -134.61 132.26 38.81 Favored 'General case' 0 C--N 1.305 -1.332 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 179.684 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 43.3 p-10 -64.82 162.86 15.32 Favored 'General case' 0 C--N 1.295 -1.768 0 O-C-N 121.343 -0.848 . . . . 0.0 109.309 -179.807 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -109.74 101.47 1.45 Allowed Glycine 0 N--CA 1.494 2.517 0 N-CA-C 109.83 -1.308 . . . . 0.0 109.83 -179.7 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 86.1 p -63.12 -28.15 69.87 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.215 -1.167 . . . . 0.0 109.059 179.543 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.0 mt-30 -125.98 158.31 35.61 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.545 -0.722 . . . . 0.0 109.204 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 49.0 p90 -134.53 163.05 30.58 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.268 -0.895 . . . . 0.0 109.51 -179.925 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . 0.471 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 48.3 p90 -134.44 157.54 46.18 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.312 -0.867 . . . . 0.0 109.414 179.927 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 61.5 mt -122.97 134.35 66.38 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 O-C-N 121.391 -0.818 . . . . 0.0 109.581 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 2.9 t -108.68 125.2 51.63 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.211 -0.931 . . . . 0.0 109.155 179.65 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 129' ' ' THR . . . . . 0.45 ' OG1' ' OE1' ' A' ' 156' ' ' GLU . 7.3 p -114.22 18.05 17.27 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.388 -0.82 . . . . 0.0 109.61 -179.656 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -145.84 162.32 37.98 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.144 -0.973 . . . . 0.0 109.883 -179.548 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 62.5 tttm -59.87 134.11 56.72 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.365 -0.834 . . . . 0.0 109.093 179.863 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 132' ' ' THR . . . . . 0.44 ' OG1' ' OD1' ' A' ' 136' ' ' ASP . 21.9 p -79.17 105.48 10.53 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.26 -0.9 . . . . 0.0 109.909 -179.485 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -66.21 -38.39 87.85 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.087 -1.008 . . . . 0.0 108.672 179.198 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 20.4 p90 -155.31 6.55 0.24 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.44 -0.787 . . . . 0.0 109.968 179.458 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . 0.526 ' N ' ' CD2' ' A' ' 135' ' ' LEU . 3.5 mm? -68.65 -28.01 66.51 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.027 -1.045 . . . . 0.0 109.328 179.562 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . 0.44 ' OD1' ' OG1' ' A' ' 132' ' ' THR . 93.8 m-20 -52.38 144.85 12.27 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.357 -0.839 . . . . 0.0 110.025 -179.336 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 171.02 -128.38 1.6 Allowed Glycine 0 N--CA 1.489 2.202 0 N-CA-C 108.793 -1.723 . . . . 0.0 108.793 -179.909 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 4.3 mptp? -89.86 123.06 33.49 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.077 -1.249 . . . . 0.0 108.851 179.376 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 32.0 p80 -168.96 159.37 9.33 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.181 -0.95 . . . . 0.0 109.745 -179.787 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 38.9 t -123.46 136.65 59.34 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 O-C-N 121.389 -0.819 . . . . 0.0 109.317 179.896 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 17.6 m -108.58 131.41 59.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.231 -0.918 . . . . 0.0 109.014 179.77 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 39.7 p90 -117.01 -4.08 11.53 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.407 -0.808 . . . . 0.0 109.992 -179.609 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -165.53 179.2 40.04 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.648 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.2 pt20 -144.3 165.28 28.33 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.186 -1.185 . . . . 0.0 109.661 -179.787 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 60.4 t -97.56 130.1 46.73 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.224 0 O-C-N 121.269 -0.894 . . . . 0.0 109.449 -179.92 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 16.3 m -106.06 -32.45 2.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.37 -0.832 . . . . 0.0 109.48 179.612 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -144.6 174.37 11.01 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.174 -0.954 . . . . 0.0 109.526 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 99.12 1.21 57.06 Favored Glycine 0 N--CA 1.494 2.509 0 N-CA-C 109.974 -1.25 . . . . 0.0 109.974 179.569 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 149' ' ' MET . . . . . . . . . . . . . 65.1 mtt -60.93 -34.16 74.28 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.105 -1.232 . . . . 0.0 109.718 179.945 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -64.51 -42.77 95.59 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.89 -1.131 . . . . 0.0 110.138 -179.576 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.7 p -83.08 -34.04 10.87 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.113 -0.992 . . . . 0.0 110.518 -179.486 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 152' ' ' VAL . . . . . 0.459 ' CG1' ' N ' ' A' ' 153' ' ' LYS . 0.6 OUTLIER -55.52 -41.65 64.53 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 120.889 -1.132 . . . . 0.0 109.122 -179.36 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 153' ' ' LYS . . . . . 0.459 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 57.3 mttp -63.23 -33.63 75.91 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.281 -0.887 . . . . 0.0 109.486 179.417 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -62.26 -40.52 96.49 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.327 -0.858 . . . . 0.0 109.873 -179.575 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 78.4 mt -72.92 -34.34 45.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.083 -1.011 . . . . 0.0 109.61 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . 0.45 ' OE1' ' OG1' ' A' ' 129' ' ' THR . 78.9 tt0 -75.95 -42.33 48.93 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.216 -0.928 . . . . 0.0 111.258 -178.796 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 43.2 pttt -61.84 -33.9 74.98 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 120.808 -1.183 . . . . 0.0 109.985 -178.831 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 34.5 m -80.34 -10.29 12.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.136 -0.978 . . . . 0.0 109.249 179.73 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -71.28 165.11 53.59 Favored Glycine 0 N--CA 1.488 2.163 0 N-CA-C 110.074 -1.21 . . . . 0.0 110.074 -179.487 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 22.8 t -155.17 171.39 19.88 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.537 -0.978 . . . . 0.0 109.34 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 24.9 m -54.44 -29.64 50.07 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.199 -0.938 . . . . 0.0 109.346 179.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 87.1 p -57.8 -26.6 62.18 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.282 -0.886 . . . . 0.0 109.663 -179.759 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 89.65 15.52 58.12 Favored Glycine 0 N--CA 1.493 2.437 0 N-CA-C 109.823 -1.311 . . . . 0.0 109.823 179.746 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 61.6 ttt180 -126.72 140.67 52.21 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.226 -1.161 . . . . 0.0 109.489 -179.941 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 165' ' ' THR . . . . . . . . . . . . . 68.7 p -75.08 148.66 39.56 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.157 -0.965 . . . . 0.0 109.279 179.813 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -66.12 -39.3 89.81 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.243 -0.911 . . . . 0.0 109.542 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -103.2 155.68 18.26 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.321 -0.862 . . . . 0.0 109.45 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 64.2 mttp -73.74 130.8 40.71 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.222 -0.924 . . . . 0.0 109.197 179.832 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 13.7 t -128.15 125.02 63.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.142 -0.974 . . . . 0.0 109.515 -179.827 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 62.7 t -142.08 135.01 28.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.267 -0.896 . . . . 0.0 109.343 179.332 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . 0.718 ' CG1' ' H ' ' A' ' 64' ' ' SER . 0.4 OUTLIER -63.58 116.01 2.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.213 -0.929 . . . . 0.0 108.923 179.88 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 172' ' ' GLU . . . . . 0.507 ' O ' ' OD1' ' A' ' 173' ' ' ASP . 96.7 mt-10 -70.64 -40.6 72.99 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.04 -1.037 . . . . 0.0 110.649 -179.531 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 173' ' ' ASP . . . . . 0.507 ' OD1' ' O ' ' A' ' 172' ' ' GLU . 80.5 m-20 -145.13 159.03 43.62 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.08 -1.013 . . . . 0.0 110.377 -179.255 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 174' ' ' CYS . . . . . 0.432 ' SG ' ' CE2' ' A' ' 14' ' ' PHE . 53.3 t -145.04 141.84 29.22 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.507 -0.746 . . . . 0.0 109.286 179.474 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -175.73 179.48 46.87 Favored Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.879 -1.288 . . . . 0.0 109.879 179.839 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 6.9 tt0 -107.87 121.75 45.4 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.32 -1.106 . . . . 0.0 109.608 -179.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 30.8 tp -62.66 -37.81 87.87 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.183 -0.948 . . . . 0.0 109.317 179.675 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 3.0 t . . . . . 0 N--CA 1.49 1.564 0 CA-C-O 117.977 -1.011 . . . . 0.0 109.439 -179.872 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 . . . . . 0 N--CA 1.491 1.592 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 78.2 Cg_endo -74.47 89.0 1.12 Allowed 'Trans proline' 0 C--N 1.311 -1.441 0 C-N-CA 122.48 2.12 . . . . 0.0 112.111 179.896 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 89.7 mtt-85 -72.02 134.61 45.98 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.306 -0.871 . . . . 0.0 109.578 -179.913 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.0 p -137.7 142.43 36.4 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.367 -0.833 . . . . 0.0 108.99 179.717 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 42.2 p90 -145.89 155.45 42.88 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.234 -0.916 . . . . 0.0 109.844 -179.671 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 91.1 m-85 -125.1 137.96 54.18 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.432 -0.793 . . . . 0.0 109.467 179.444 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 61.3 t0 -89.03 117.61 28.16 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.2 -0.938 . . . . 0.0 108.511 178.831 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 78.2 mtp -106.32 150.8 25.61 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.147 -0.97 . . . . 0.0 110.52 -178.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 84.6 p -146.5 168.65 20.69 Favored 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 109.02 -0.734 . . . . 0.0 109.02 179.822 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.437 ' O ' ' N ' ' A' ' 20' ' ' GLY . 27.2 m -126.09 155.85 36.1 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.804 0 O-C-N 121.267 -0.896 . . . . 0.0 109.457 -179.879 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -49.47 96.61 0.01 OUTLIER Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.366 -1.494 . . . . 0.0 109.366 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.437 ' N ' ' O ' ' A' ' 18' ' ' VAL . . . 150.88 -84.82 0.16 Allowed Glycine 0 N--CA 1.493 2.438 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 -179.93 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 12.9 mt-30 -139.36 160.67 60.98 Favored Pre-proline 0 N--CA 1.494 1.741 0 O-C-N 121.357 -1.084 . . . . 0.0 109.037 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_exo -47.74 134.15 22.22 Favored 'Trans proline' 0 C--N 1.312 -1.392 0 C-N-CA 122.251 1.967 . . . . 0.0 112.247 179.739 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -89.58 -60.32 1.97 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.303 -0.873 . . . . 0.0 109.578 -179.86 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 176.05 -166.99 38.46 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.7 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 35.8 ptt-85 -126.01 149.22 48.98 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.466 -1.02 . . . . 0.0 109.143 179.818 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 89.3 mt -122.3 130.32 74.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.287 -0.883 . . . . 0.0 109.346 -179.893 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 44.1 t -109.95 132.61 57.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.444 -0.785 . . . . 0.0 109.427 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 74.8 mtm -119.95 147.13 45.13 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.424 -0.798 . . . . 0.0 109.143 179.875 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -101.03 132.1 46.61 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.23 -0.919 . . . . 0.0 109.987 -179.359 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.414 ' N ' ' CD2' ' A' ' 30' ' ' LEU . 2.6 mm? -108.42 132.13 54.08 Favored 'General case' 0 N--CA 1.492 1.626 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 179.44 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 93.3 m-85 -96.02 116.23 28.64 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 120.966 -1.083 . . . . 0.0 108.775 179.045 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -84.72 -43.7 14.06 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.287 -0.883 . . . . 0.0 109.735 -179.705 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.0 m-20 -63.88 -49.43 72.77 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.217 -0.927 . . . . 0.0 109.879 -179.585 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 28.3 m -71.14 -41.83 69.96 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.207 -0.933 . . . . 0.0 109.417 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.517 ' O ' ' OG1' ' A' ' 35' ' ' THR . 2.3 p -135.16 79.62 49.61 Favored Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 121.531 -0.731 . . . . 0.0 109.495 -179.642 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 29.8 Cg_endo -68.48 -62.83 0.05 OUTLIER 'Trans proline' 0 N--CA 1.494 1.557 0 C-N-CA 122.338 2.025 . . . . 0.0 112.867 -179.339 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 79.2 mtp180 -61.23 -37.0 81.49 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.375 -0.828 . . . . 0.0 110.844 -178.952 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 26.8 m -60.66 -43.39 97.7 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.928 -1.107 . . . . 0.0 109.761 -179.51 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -62.83 -30.85 71.81 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.17 -0.956 . . . . 0.0 108.867 179.698 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -68.44 -38.63 81.32 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.47 -0.768 . . . . 0.0 109.899 -179.881 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 47.5 t30 -57.86 -42.52 84.7 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.318 -0.864 . . . . 0.0 109.95 -179.518 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . 0.557 ' O ' ' SG ' ' A' ' 46' ' ' CYS . 97.8 m-85 -84.67 -46.96 10.96 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.069 -1.019 . . . . 0.0 109.938 -179.869 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . 0.644 ' CZ ' HE22 ' A' ' 176' ' ' GLN . 77.0 ttt180 -54.21 -41.13 68.28 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.338 -0.852 . . . . 0.0 110.361 -179.285 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -66.81 -47.62 71.5 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.108 -0.995 . . . . 0.0 110.319 -178.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.435 ' N ' ' CD2' ' A' ' 45' ' ' LEU . 3.2 mm? -65.28 -39.06 92.08 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.078 -1.014 . . . . 0.0 109.96 -179.515 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' CYS . . . . . 0.557 ' SG ' ' O ' ' A' ' 42' ' ' PHE . 27.6 m -64.41 -62.3 1.69 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.939 -1.101 . . . . 0.0 109.392 -179.766 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 25.3 m -64.86 -36.47 84.46 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.282 -0.886 . . . . 0.0 109.183 179.606 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 83.59 35.62 16.24 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 110.176 -1.17 . . . . 0.0 110.176 179.558 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -61.56 -38.1 86.24 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.051 -1.264 . . . . 0.0 109.266 179.674 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 29.5 mmtm -62.27 -29.75 70.63 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.283 -0.885 . . . . 0.0 109.446 179.747 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 86.06 -115.67 4.24 Favored Glycine 0 N--CA 1.488 2.13 0 N-CA-C 108.778 -1.729 . . . . 0.0 108.778 -179.103 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 61.6 m -129.42 142.01 50.9 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.254 -1.145 . . . . 0.0 109.553 179.455 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -64.66 136.21 38.75 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 61.7 ttp85 -55.32 -37.98 68.11 Favored 'General case' 0 C--N 1.305 -1.328 0 O-C-N 121.254 -1.145 . . . . 0.0 110.056 -179.652 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 22.9 t -57.19 -32.7 66.73 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.288 -0.883 . . . . 0.0 109.797 -179.605 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . 0.409 ' O ' ' CB ' ' A' ' 57' ' ' LYS . . . 118.59 105.1 2.21 Favored Glycine 0 N--CA 1.494 2.508 0 N-CA-C 109.014 -1.635 . . . . 0.0 109.014 -179.726 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . 0.409 ' CB ' ' O ' ' A' ' 56' ' ' GLY . 0.8 OUTLIER 167.86 82.61 0.02 OUTLIER Pre-proline 0 N--CA 1.491 1.584 0 N-CA-C 108.104 -1.073 . . . . 0.0 108.104 -179.625 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 81.4 Cg_exo -45.97 126.15 9.1 Favored 'Trans proline' 0 C--N 1.305 -1.742 0 C-N-CA 122.579 2.186 . . . . 0.0 112.269 -178.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.58 ' O ' ' CG ' ' A' ' 60' ' ' HIS . 53.2 mt -95.94 130.61 42.87 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.554 -0.716 . . . . 0.0 109.711 -179.62 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . 0.58 ' CG ' ' O ' ' A' ' 59' ' ' LEU . 0.4 OUTLIER 166.51 110.03 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.258 -0.901 . . . . 0.0 109.577 179.889 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 3.6 m-85 -68.39 -3.5 11.4 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.181 -0.95 . . . . 0.0 108.603 179.163 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 34.6 ttmt -57.52 149.35 21.36 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.378 -0.827 . . . . 0.0 109.523 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . 0.401 ' N ' ' CG2' ' A' ' 171' ' ' VAL . 83.2 m-20 57.35 47.76 16.04 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.478 -0.764 . . . . 0.0 110.231 179.839 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.673 ' H ' ' CG2' ' A' ' 171' ' ' VAL . 92.3 p -104.33 156.79 17.62 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.293 -0.879 . . . . 0.0 108.907 179.257 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 29.2 t -128.9 146.54 50.92 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.153 -0.967 . . . . 0.0 109.623 -179.609 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.7 m-30 -71.81 133.92 45.81 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.283 -0.885 . . . . 0.0 108.662 179.633 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 80.7 m80 -91.02 -31.58 16.25 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.087 -1.008 . . . . 0.0 110.819 -178.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 80.0 mtp180 -135.36 138.61 43.53 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 120.951 -1.093 . . . . 0.0 110.306 -179.458 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -150.8 80.04 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 179.0 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 59.9 mt -96.99 129.39 32.54 Favored Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.345 -0.847 . . . . 0.0 109.537 -179.627 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -74.61 134.67 18.82 Favored 'Trans proline' 0 N--CA 1.491 1.349 0 C-N-CA 122.114 1.876 . . . . 0.0 112.076 179.788 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 92.96 -1.2 70.4 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.899 -1.28 . . . . 0.0 109.899 179.597 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 77.4 m-85 -132.93 -94.02 0.34 Allowed 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.098 -1.236 . . . . 0.0 109.818 179.921 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 4.5 ptt? -163.39 177.48 8.89 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.946 -1.097 . . . . 0.0 110.031 -179.601 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -129.4 131.49 46.81 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.495 -0.753 . . . . 0.0 109.039 179.94 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 50.8 tt0 -97.16 118.5 33.72 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.138 -0.976 . . . . 0.0 109.322 179.816 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -61.86 -39.31 97.33 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 81.53 167.16 38.18 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.494 -1.442 . . . . 0.0 109.494 -179.916 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -104.25 149.83 24.96 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.42 -1.047 . . . . 0.0 109.456 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 45.2 p90 -65.29 -24.17 67.22 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.18 -0.95 . . . . 0.0 109.347 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.517 ' OG1' ' N ' ' A' ' 88' ' ' GLY . 58.9 p -66.31 -31.51 72.35 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.225 -0.922 . . . . 0.0 109.657 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . 0.407 ' N ' ' HG1' ' A' ' 81' ' ' THR . . . 173.46 -53.28 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.242 -0.911 . . . . 0.0 109.44 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 92.53 3.26 66.89 Favored Glycine 0 N--CA 1.492 2.378 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 40.7 p-10 -88.27 7.53 31.69 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.162 -1.199 . . . . 0.0 109.427 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 95.21 -43.52 2.23 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 109.272 -1.531 . . . . 0.0 109.272 -179.851 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 47.1 m -60.58 -38.41 84.5 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.208 -1.172 . . . . 0.0 109.049 179.759 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -84.38 -164.67 38.1 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.473 -1.451 . . . . 0.0 109.473 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.517 ' N ' ' OG1' ' A' ' 81' ' ' THR . . . 86.98 35.51 9.8 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.511 -1.435 . . . . 0.0 109.511 -179.952 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -56.56 146.04 26.31 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.296 -1.12 . . . . 0.0 109.441 179.878 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 29.7 t -100.35 144.02 29.85 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.284 -0.885 . . . . 0.0 109.461 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 21.9 pt -64.36 -32.44 57.6 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.382 -0.824 . . . . 0.0 109.863 -179.728 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 67.7 m-85 -64.12 -37.46 87.54 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.198 -0.939 . . . . 0.0 109.437 -179.795 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 81.43 7.47 88.24 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -151.82 156.92 41.16 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.204 -1.174 . . . . 0.0 109.537 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 86.9 mttt -88.27 148.29 24.4 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.285 -0.884 . . . . 0.0 109.542 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . 0.554 ' CZ ' ' OD1' ' A' ' 121' ' ' ASN . 40.4 p90 -134.33 161.82 33.91 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.253 -0.905 . . . . 0.0 108.973 179.495 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -54.99 138.36 43.9 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.146 -0.971 . . . . 0.0 109.851 -178.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 88.2 m-20 -74.66 141.15 44.62 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.428 -0.795 . . . . 0.0 109.761 -179.901 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -59.82 146.36 42.1 Favored 'General case' 0 C--N 1.305 -1.37 0 O-C-N 121.322 -0.861 . . . . 0.0 109.218 179.672 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 23.0 t-20 -58.26 159.63 5.87 Favored 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.461 -0.774 . . . . 0.0 109.429 -179.87 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' PHE . . . . . 0.482 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 29.3 p90 -96.43 52.26 1.23 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.303 -0.873 . . . . 0.0 109.72 -179.721 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 88.6 mt -56.77 -39.49 64.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.123 -0.986 . . . . 0.0 109.322 179.781 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -93.03 146.16 23.84 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.154 -0.966 . . . . 0.0 109.627 179.901 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' LYS . . . . . 0.531 ' O ' ' N ' ' A' ' 106' ' ' THR . 81.0 tttt -126.8 157.62 38.74 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.439 -0.788 . . . . 0.0 109.346 -179.924 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' HIS . . . . . 0.53 ' ND1' ' OD1' ' A' ' 136' ' ' ASP . 23.2 m80 -59.06 81.25 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.272 -0.893 . . . . 0.0 109.061 179.937 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' THR . . . . . 0.531 ' N ' ' O ' ' A' ' 104' ' ' LYS . 69.3 p -73.96 -22.79 59.51 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.164 -0.96 . . . . 0.0 110.147 -179.485 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -152.75 177.66 30.33 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.734 -1.346 . . . . 0.0 109.734 -179.626 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -73.2 156.29 51.3 Favored 'Trans proline' 0 C--N 1.307 -1.648 0 C-N-CA 122.891 2.394 . . . . 0.0 112.193 179.793 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 109' ' ' GLY . . . . . 0.495 ' N ' ' O ' ' A' ' 128' ' ' CYS . . . 82.23 47.42 6.12 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.91 -1.276 . . . . 0.0 109.91 179.757 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 40.7 mm -115.0 136.67 50.94 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.378 -1.071 . . . . 0.0 109.479 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . 0.595 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 2.7 mm? -89.32 142.34 27.74 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.349 -0.844 . . . . 0.0 109.762 -179.684 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 10.4 t -144.8 140.71 28.63 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.202 -0.936 . . . . 0.0 109.752 179.787 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 89.0 mtp -88.86 137.49 32.27 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.166 -0.959 . . . . 0.0 109.323 179.483 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -68.9 143.52 54.47 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.202 -0.936 . . . . 0.0 109.811 -179.867 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . 0.433 ' OD1' ' O ' ' A' ' 120' ' ' THR . 47.0 t30 -140.83 151.03 44.03 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.334 -0.854 . . . . 0.0 109.474 179.737 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -132.17 -3.72 3.5 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.404 -0.81 . . . . 0.0 109.241 179.755 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -157.51 169.55 34.45 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.078 -1.609 . . . . 0.0 109.078 -179.925 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -70.66 147.91 58.13 Favored 'Trans proline' 0 C--N 1.306 -1.665 0 C-N-CA 122.603 2.202 . . . . 0.0 111.792 179.857 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 87.7 m-20 51.0 42.2 28.18 Favored 'General case' 0 C--N 1.297 -1.679 0 O-C-N 121.476 -0.765 . . . . 0.0 109.467 -179.801 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 120' ' ' THR . . . . . 0.433 ' O ' ' OD1' ' A' ' 115' ' ' ASN . 84.2 m -135.22 124.91 25.26 Favored 'General case' 0 N--CA 1.488 1.44 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 179.717 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 121' ' ' ASN . . . . . 0.554 ' OD1' ' CZ ' ' A' ' 96' ' ' PHE . 35.8 m120 -106.24 128.3 53.85 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.576 -0.703 . . . . 0.0 109.702 -179.919 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -99.52 130.84 10.35 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 179.921 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 22.9 t -60.19 -33.23 71.94 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.186 -1.185 . . . . 0.0 109.63 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 25.7 mt-30 -68.38 147.9 51.45 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.332 -0.855 . . . . 0.0 109.664 -179.668 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 50.2 p90 -137.31 161.14 37.06 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.334 -0.854 . . . . 0.0 109.209 179.905 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 86.0 m-85 -118.87 151.35 38.27 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.266 -0.897 . . . . 0.0 109.711 -179.898 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 76.3 mt -116.82 134.05 61.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 N-CA-C 108.693 -0.854 . . . . 0.0 108.693 179.313 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 128' ' ' CYS . . . . . 0.495 ' O ' ' N ' ' A' ' 109' ' ' GLY . 1.3 m -121.59 132.45 54.69 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.278 -0.889 . . . . 0.0 109.389 -179.774 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 1.7 t -116.65 8.78 13.91 Favored 'General case' 0 N--CA 1.493 1.698 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 179.652 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -141.58 165.94 26.11 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.544 -0.723 . . . . 0.0 109.109 -179.885 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 69.1 mttm -65.5 134.13 52.75 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.114 -0.991 . . . . 0.0 109.453 -179.829 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 57.3 p -141.97 70.45 1.33 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.319 -0.863 . . . . 0.0 109.295 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -61.3 -36.16 79.33 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.277 -0.889 . . . . 0.0 109.992 -179.56 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 0.8 OUTLIER -62.6 -43.15 99.54 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.014 -1.054 . . . . 0.0 109.51 -179.942 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 25.0 mt -65.49 -33.84 76.88 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.14 -0.975 . . . . 0.0 109.765 179.508 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . 0.53 ' OD1' ' ND1' ' A' ' 105' ' ' HIS . 87.3 m-20 -65.76 141.59 58.27 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.277 -0.889 . . . . 0.0 109.611 -179.754 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 153.79 -92.83 0.13 Allowed Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . 0.409 ' HD2' ' N ' ' A' ' 138' ' ' LYS . 1.1 mptp? -87.7 10.54 17.89 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.333 -1.098 . . . . 0.0 109.523 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 63.3 m170 -96.41 140.74 30.63 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.235 -0.915 . . . . 0.0 109.594 -179.751 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 44.9 t -115.37 138.16 46.6 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 O-C-N 121.442 -0.786 . . . . 0.0 109.473 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 11.2 m -100.72 132.17 46.91 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.332 -0.855 . . . . 0.0 109.224 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 41.4 p90 -110.08 -11.08 14.65 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.222 -0.924 . . . . 0.0 110.219 -179.544 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -157.77 179.75 33.27 Favored Glycine 0 N--CA 1.493 2.458 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 179.738 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.5 pt20 -144.3 165.22 28.51 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.086 -1.244 . . . . 0.0 109.717 -179.749 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 75.6 t -97.12 129.66 46.86 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.19 0 O-C-N 121.318 -0.864 . . . . 0.0 109.299 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 16.1 m -101.86 -35.28 4.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.394 -0.816 . . . . 0.0 109.882 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 90.1 mt-10 -144.95 170.59 15.85 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.149 -0.97 . . . . 0.0 109.745 -179.819 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 97.78 4.14 58.02 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 110.315 -1.114 . . . . 0.0 110.315 179.308 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 149' ' ' MET . . . . . 0.433 ' O ' HG13 ' A' ' 152' ' ' VAL . 65.1 mtt -60.53 -32.37 71.41 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 120.991 -1.299 . . . . 0.0 109.518 179.872 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -64.79 -41.75 95.59 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 120.9 -1.125 . . . . 0.0 110.084 -179.652 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 6.6 p -82.21 -33.59 11.6 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.2 -0.938 . . . . 0.0 110.679 -179.425 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 152' ' ' VAL . . . . . 0.459 ' CG1' ' N ' ' A' ' 153' ' ' LYS . 0.9 OUTLIER -55.82 -42.38 70.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 120.901 -1.124 . . . . 0.0 109.249 -179.304 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 153' ' ' LYS . . . . . 0.459 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 91.1 mttt -65.49 -35.49 81.03 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.043 -1.035 . . . . 0.0 109.409 179.429 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -63.01 -38.15 90.06 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.383 -0.823 . . . . 0.0 109.996 -179.532 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 84.7 mt -71.09 -38.44 71.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.295 -0.878 . . . . 0.0 110.594 -179.555 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -78.1 -39.25 41.99 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.1 -1.0 . . . . 0.0 111.573 -178.395 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 31.6 pttt -61.0 -34.16 74.39 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 120.723 -1.236 . . . . 0.0 110.21 -178.682 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 23.8 m -69.8 -15.65 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 120.96 -1.087 . . . . 0.0 109.047 179.786 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -79.05 177.29 54.31 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 23.2 t -152.02 173.51 14.79 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.321 -1.105 . . . . 0.0 109.239 -179.855 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 23.4 m -53.09 -34.89 58.63 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.073 -1.017 . . . . 0.0 108.992 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 24.6 m -59.11 -30.33 68.04 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.373 -0.829 . . . . 0.0 109.363 179.527 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 96.82 11.14 54.23 Favored Glycine 0 N--CA 1.494 2.507 0 N-CA-C 109.35 -1.5 . . . . 0.0 109.35 -179.701 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 88.8 mtt180 -109.25 158.12 18.16 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.369 -1.077 . . . . 0.0 109.02 179.73 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 165' ' ' THR . . . . . . . . . . . . . 43.1 p -116.38 156.82 26.07 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.203 -0.936 . . . . 0.0 110.366 -179.399 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -68.17 -34.72 76.82 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.55 -0.718 . . . . 0.0 109.476 179.624 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -121.98 156.5 33.31 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.481 -0.762 . . . . 0.0 109.473 -179.73 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 90.5 mttt -80.7 141.16 35.14 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.298 -0.876 . . . . 0.0 109.301 -179.904 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 40.6 t -121.74 126.08 74.2 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.341 -0.849 . . . . 0.0 109.7 -179.88 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 43.5 t -141.57 140.68 30.88 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.275 -0.891 . . . . 0.0 109.202 179.712 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . 0.673 ' CG2' ' H ' ' A' ' 64' ' ' SER . 4.0 m -68.58 123.24 21.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.118 -0.989 . . . . 0.0 109.464 179.935 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -68.65 -36.75 78.99 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.008 -1.057 . . . . 0.0 110.046 -179.802 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -160.04 163.05 34.29 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.073 -1.017 . . . . 0.0 110.07 -179.594 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 16.0 p -146.6 149.78 34.21 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.418 -0.801 . . . . 0.0 109.434 179.759 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . 176.84 -178.83 48.04 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 179.892 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 176' ' ' GLN . . . . . 0.644 HE22 ' CZ ' ' A' ' 43' ' ' ARG . 60.4 tt0 -106.69 120.26 41.52 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.343 -1.092 . . . . 0.0 109.651 -179.952 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 177' ' ' LEU . . . . . 0.437 ' O ' ' C ' ' A' ' 178' ' ' SER . 30.3 tp -61.9 -39.34 91.66 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.138 -0.976 . . . . 0.0 109.153 179.454 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 178' ' ' SER . . . . . 0.437 ' C ' ' O ' ' A' ' 177' ' ' LEU . 5.6 p . . . . . 0 N--CA 1.492 1.673 0 CA-C-O 118.046 -0.978 . . . . 0.0 109.806 179.898 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 6.8 m-20 . . . . . 0 N--CA 1.488 1.47 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -65.75 133.77 35.25 Favored 'Trans proline' 0 C--N 1.309 -1.55 0 C-N-CA 122.448 2.099 . . . . 0.0 112.24 -179.695 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 97.4 mtt180 -131.57 129.74 41.34 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.411 -0.805 . . . . 0.0 108.879 179.203 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.5 p -135.88 142.26 39.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.366 -0.834 . . . . 0.0 109.363 -179.822 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 45.1 p90 -142.31 153.4 43.85 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.418 -0.801 . . . . 0.0 109.573 -179.812 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -121.37 134.88 55.13 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.385 -0.822 . . . . 0.0 109.318 179.54 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -90.6 114.75 27.07 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.182 -0.949 . . . . 0.0 108.945 179.485 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' MET . . . . . 0.405 ' SD ' ' CD1' ' A' ' 26' ' ' ILE . 85.1 mtp -102.56 152.19 21.45 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.311 -0.868 . . . . 0.0 110.452 -179.404 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 96.5 p -143.15 163.15 33.68 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.781 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.53 ' O ' ' N ' ' A' ' 20' ' ' GLY . 29.4 m -123.43 139.8 48.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 121.07 -1.019 . . . . 0.0 109.501 -179.953 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 47.01 13.96 0.11 Allowed Glycine 0 N--CA 1.492 2.406 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 179.928 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.53 ' N ' ' O ' ' A' ' 18' ' ' VAL . . . 98.78 -16.3 59.76 Favored Glycine 0 N--CA 1.493 2.447 0 N-CA-C 109.616 -1.393 . . . . 0.0 109.616 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' GLN . . . . . 0.492 ' N ' ' O ' ' A' ' 18' ' ' VAL . 64.5 mm-40 -81.69 146.12 55.89 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.169 -1.195 . . . . 0.0 109.216 179.812 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_endo -63.48 138.89 67.7 Favored 'Trans proline' 0 N--CA 1.494 1.528 0 C-N-CA 122.366 2.044 . . . . 0.0 112.174 -179.736 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -112.6 -66.2 1.11 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.319 -0.863 . . . . 0.0 109.452 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -175.81 -169.97 38.06 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.315 -1.514 . . . . 0.0 109.315 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 71.3 mtp180 -114.95 144.03 44.22 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.226 -1.161 . . . . 0.0 109.587 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . 0.405 ' CD1' ' SD ' ' A' ' 16' ' ' MET . 84.0 mt -120.72 116.07 48.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 N-CA-C 108.44 -0.948 . . . . 0.0 108.44 178.579 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 37.8 t -112.12 133.91 56.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.439 -0.788 . . . . 0.0 109.218 -179.537 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 76.5 mtm -119.53 155.25 32.51 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.454 -0.779 . . . . 0.0 109.532 -179.577 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -100.31 133.02 45.35 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.369 -0.832 . . . . 0.0 109.939 -179.601 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -110.39 134.65 52.11 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.506 -0.746 . . . . 0.0 109.155 179.619 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 84.1 m-85 -95.1 122.84 38.18 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.2 -0.938 . . . . 0.0 108.999 179.388 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -92.9 -41.81 9.84 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.348 -0.845 . . . . 0.0 109.606 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 87.2 m-20 -69.62 -44.45 70.65 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.327 -0.858 . . . . 0.0 110.659 -179.338 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' THR . . . . . 0.439 ' O ' ' OE1' ' A' ' 99' ' ' GLU . 35.2 m -67.84 -46.82 70.69 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.16 -0.962 . . . . 0.0 110.526 -178.924 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.413 ' OG1' ' OG1' ' A' ' 38' ' ' THR . 0.0 OUTLIER -152.63 83.62 4.82 Favored Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.147 -0.971 . . . . 0.0 109.486 -179.447 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -71.92 -33.19 10.22 Favored 'Trans proline' 0 C--N 1.308 -1.593 0 C-N-CA 122.146 1.897 . . . . 0.0 112.12 -179.63 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 35.2 mmt180 -63.35 -40.28 96.85 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.326 -0.858 . . . . 0.0 109.491 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.413 ' OG1' ' OG1' ' A' ' 35' ' ' THR . 36.5 m -64.87 -41.17 95.88 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.274 -0.891 . . . . 0.0 109.929 -179.806 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -62.43 -30.77 71.46 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.286 -0.884 . . . . 0.0 109.282 179.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -67.11 -36.91 82.94 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.293 -0.879 . . . . 0.0 109.864 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 87.5 m-20 -57.95 -39.76 78.88 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.263 -0.898 . . . . 0.0 110.062 -179.498 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . 0.431 ' O ' ' SG ' ' A' ' 46' ' ' CYS . 98.5 m-85 -90.42 -48.13 7.3 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.072 -1.017 . . . . 0.0 109.665 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 51.3 ttp180 -57.65 -40.71 79.9 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.48 -0.762 . . . . 0.0 110.508 -179.361 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.46 ' O ' ' N ' ' A' ' 48' ' ' GLY . . . -66.05 -46.8 76.51 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.976 -1.077 . . . . 0.0 110.425 -179.095 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.449 ' N ' ' CD2' ' A' ' 45' ' ' LEU . 3.6 mm? -64.98 -39.97 94.27 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 120.956 -1.09 . . . . 0.0 109.618 -179.809 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' CYS . . . . . 0.431 ' SG ' ' O ' ' A' ' 42' ' ' PHE . 34.8 m -70.06 -47.85 60.26 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.084 -1.01 . . . . 0.0 109.347 179.769 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 74.8 p -72.55 -34.62 67.65 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.36 -0.837 . . . . 0.0 109.555 179.742 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . 0.46 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 73.61 31.88 60.13 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.978 -1.249 . . . . 0.0 109.978 179.646 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 78.0 mm-40 -62.03 -38.03 87.16 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.029 -1.277 . . . . 0.0 109.534 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 31.4 mmtp -62.18 -35.86 80.11 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.282 -0.886 . . . . 0.0 109.674 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 89.51 167.9 42.97 Favored Glycine 0 N--CA 1.488 2.154 0 N-CA-C 109.074 -1.611 . . . . 0.0 109.074 -179.653 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 85.2 m -75.1 138.73 42.28 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.119 -1.224 . . . . 0.0 109.559 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -59.5 137.18 50.11 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.393 -1.483 . . . . 0.0 109.393 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 83.5 mtm-85 -59.35 -36.09 75.08 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.19 -1.182 . . . . 0.0 109.846 -179.748 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 85.9 p -63.38 -24.26 67.77 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.113 -0.992 . . . . 0.0 109.779 -179.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 115.87 96.35 2.02 Favored Glycine 0 N--CA 1.494 2.524 0 N-CA-C 109.078 -1.609 . . . . 0.0 109.078 -179.572 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . 0.51 ' NZ ' ' OE1' ' A' ' 89' ' ' GLU . 75.8 tttt -179.5 81.47 0.2 Allowed Pre-proline 0 N--CA 1.489 1.518 0 N-CA-C 108.377 -0.971 . . . . 0.0 108.377 -179.664 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 75.9 Cg_exo -50.31 130.12 27.89 Favored 'Trans proline' 0 C--N 1.303 -1.828 0 C-N-CA 122.769 2.313 . . . . 0.0 112.597 -179.014 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.484 ' CD1' ' O ' ' A' ' 57' ' ' LYS . 9.0 mp -100.04 23.49 9.82 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.641 -0.662 . . . . 0.0 109.436 -179.833 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . 0.51 ' O ' ' CE1' ' A' ' 80' ' ' PHE . 93.2 m-70 -101.66 135.32 43.38 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.227 -0.92 . . . . 0.0 109.628 -179.804 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 2.7 m-85 -94.95 12.67 27.55 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.293 -0.879 . . . . 0.0 108.98 179.575 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . 0.463 ' O ' ' CB ' ' A' ' 63' ' ' ASP . 62.1 tttt -62.73 142.82 57.97 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.416 -0.803 . . . . 0.0 109.674 -179.832 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . 0.463 ' CB ' ' O ' ' A' ' 62' ' ' LYS . 21.4 t0 74.76 33.72 0.77 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.581 -0.7 . . . . 0.0 109.736 179.859 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.77 ' H ' ' CG2' ' A' ' 171' ' ' VAL . 52.6 p -76.66 165.31 24.93 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.225 -0.922 . . . . 0.0 109.005 179.34 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 29.7 t -140.9 149.77 42.33 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.085 -1.01 . . . . 0.0 109.814 -179.783 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 58.3 m-85 -90.93 127.22 36.31 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.296 -0.878 . . . . 0.0 109.209 179.552 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 55.4 t-80 -94.85 -30.74 14.04 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.258 -0.901 . . . . 0.0 110.499 -179.27 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 83.0 mtp180 -126.26 140.87 52.19 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.057 -1.027 . . . . 0.0 110.341 -179.38 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 15.8 m -151.57 49.05 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 179.424 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 19.4 mt -77.56 133.78 66.67 Favored Pre-proline 0 C--N 1.301 -1.507 0 O-C-N 121.361 -0.837 . . . . 0.0 110.156 -178.612 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -68.89 147.89 69.42 Favored 'Trans proline' 0 N--CA 1.492 1.421 0 C-N-CA 122.4 2.067 . . . . 0.0 112.266 179.852 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 80.42 -55.75 4.66 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.849 -1.3 . . . . 0.0 109.849 179.642 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 88.4 m-85 -68.36 -87.27 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.27 -1.135 . . . . 0.0 109.67 -179.75 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 11.3 ptt? -179.59 -175.16 0.32 Allowed 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.141 -0.975 . . . . 0.0 109.667 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 58.2 m -126.92 136.74 52.72 Favored 'General case' 0 N--CA 1.493 1.702 0 N-CA-C 108.763 -0.829 . . . . 0.0 108.763 179.608 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 63.2 tt0 -96.9 134.88 39.65 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.226 -0.921 . . . . 0.0 109.695 -179.527 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -139.75 176.19 21.33 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.06 -1.616 . . . . 0.0 109.06 179.769 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 77.14 36.84 34.03 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.235 -1.546 . . . . 0.0 109.235 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -83.72 13.97 4.29 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.321 -1.105 . . . . 0.0 109.413 -179.826 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.51 ' CE1' ' O ' ' A' ' 60' ' ' HIS . 81.0 t80 -51.67 -45.26 63.37 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.293 -0.88 . . . . 0.0 109.803 -179.874 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.612 ' CB ' ' H ' ' A' ' 88' ' ' GLY . 58.9 p -70.51 -28.17 64.75 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.1 -1.0 . . . . 0.0 109.506 179.857 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . 0.467 ' CB ' ' O ' ' A' ' 81' ' ' THR . . . 165.3 -56.9 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.342 -0.849 . . . . 0.0 109.238 179.898 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 93.39 -1.42 69.52 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . 0.43 ' OD1' ' OG1' ' A' ' 86' ' ' THR . 40.7 p-10 -90.02 5.95 44.39 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.126 -1.22 . . . . 0.0 109.473 179.965 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 96.44 -33.53 5.59 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' THR . . . . . 0.43 ' OG1' ' OD1' ' A' ' 84' ' ' ASN . 51.7 p -72.58 -22.26 61.01 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.14 -1.212 . . . . 0.0 109.217 179.76 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -84.97 -161.64 34.29 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 179.915 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.612 ' H ' ' CB ' ' A' ' 81' ' ' THR . . . 90.95 26.87 20.85 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 -179.869 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . 0.51 ' OE1' ' NZ ' ' A' ' 57' ' ' LYS . 96.0 mt-10 -57.1 145.52 30.69 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.375 -1.073 . . . . 0.0 109.577 -179.799 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 29.3 t -106.15 143.55 34.11 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.323 -0.861 . . . . 0.0 109.328 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 20.4 pt -64.58 -33.44 63.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.332 -0.855 . . . . 0.0 109.828 -179.722 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 73.5 m-85 -65.53 -38.12 88.72 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.23 -0.919 . . . . 0.0 109.604 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 81.64 14.5 77.89 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.449 -1.461 . . . . 0.0 109.449 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -146.46 155.77 42.79 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.14 -1.211 . . . . 0.0 109.655 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 97.1 mttt -94.07 142.24 27.62 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.291 -0.88 . . . . 0.0 109.549 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 99.4 m-85 -120.63 150.16 41.34 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.415 -0.803 . . . . 0.0 109.589 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -70.8 154.51 41.77 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.385 -0.822 . . . . 0.0 109.569 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 88.4 m-20 -59.48 147.66 35.85 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.251 -0.906 . . . . 0.0 109.341 179.901 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . 0.439 ' OE1' ' O ' ' A' ' 34' ' ' THR . 96.2 mt-10 -80.4 -89.35 0.06 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.145 -0.972 . . . . 0.0 110.008 -179.583 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 85.3 m-20 -124.86 145.91 49.55 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.301 -0.875 . . . . 0.0 110.049 -179.473 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -100.74 10.83 40.65 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.439 -0.788 . . . . 0.0 109.294 179.589 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.409 HG23 HD12 ' A' ' 102' ' ' ILE . 96.2 mt -53.49 -36.46 27.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.303 -0.873 . . . . 0.0 110.134 -179.391 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 9.2 mtpm? -80.45 136.12 36.27 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.98 -1.075 . . . . 0.0 109.633 -179.789 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 69.1 tttt -135.15 159.37 41.76 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.449 -0.782 . . . . 0.0 109.331 -179.705 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' HIS . . . . . 0.41 ' HD1' ' CB ' ' A' ' 110' ' ' ILE . 92.9 m-70 -74.19 106.55 5.9 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.092 -1.005 . . . . 0.0 109.477 179.865 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 62.3 p -96.03 -9.97 29.65 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.343 -0.848 . . . . 0.0 109.691 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -165.18 -179.03 38.83 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.76 -1.336 . . . . 0.0 109.76 -179.805 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -78.76 160.28 27.82 Favored 'Trans proline' 0 C--N 1.306 -1.677 0 C-N-CA 123.178 2.585 . . . . 0.0 112.23 179.791 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 82.17 40.9 9.78 Favored Glycine 0 N--CA 1.492 2.395 0 N-CA-C 109.995 -1.242 . . . . 0.0 109.995 179.715 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.416 HG21 HD12 ' A' ' 110' ' ' ILE . 33.7 mm -113.66 139.21 40.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.357 -1.084 . . . . 0.0 109.209 179.923 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . 0.55 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 3.4 mm? -86.88 136.18 33.05 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.156 -0.965 . . . . 0.0 109.737 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 30.8 t -144.69 143.41 30.71 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.348 -0.845 . . . . 0.0 109.098 179.47 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 15.1 ptm -87.4 126.06 34.64 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.231 -0.918 . . . . 0.0 109.532 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -66.27 147.77 52.83 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.263 -0.898 . . . . 0.0 109.715 -179.74 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . 0.525 ' N ' ' OD1' ' A' ' 115' ' ' ASN . 8.0 p-10 -157.76 115.56 3.05 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.272 -0.893 . . . . 0.0 109.169 179.634 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -65.46 -30.72 71.54 Favored 'General case' 0 C--N 1.299 -1.63 0 O-C-N 121.406 -0.809 . . . . 0.0 109.8 -179.761 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -135.57 166.09 24.61 Favored Glycine 0 N--CA 1.494 2.519 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -67.38 156.74 64.91 Favored 'Trans proline' 0 C--N 1.306 -1.659 0 C-N-CA 122.867 2.378 . . . . 0.0 111.816 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 75.8 m-20 54.33 45.4 27.3 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.411 -0.805 . . . . 0.0 109.232 -179.895 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 61.5 m -131.85 127.99 37.73 Favored 'General case' 0 C--N 1.305 -1.349 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 179.916 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 20.1 m120 -102.01 137.03 40.84 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.493 -0.755 . . . . 0.0 109.486 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -145.32 125.78 2.42 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 179.91 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 23.1 t -59.02 -30.86 68.32 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.374 -1.074 . . . . 0.0 109.482 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.6 mt-30 -63.22 143.2 58.0 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.194 -0.941 . . . . 0.0 109.537 -179.675 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 45.6 p90 -141.35 164.93 28.91 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.453 -0.78 . . . . 0.0 109.178 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 48.0 p90 -131.47 157.48 43.39 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.231 -0.918 . . . . 0.0 109.517 179.854 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 71.3 mt -120.25 136.36 57.55 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.492 -0.755 . . . . 0.0 109.593 -179.73 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 128' ' ' CYS . . . . . 0.509 ' SG ' ' O ' ' A' ' 130' ' ' ALA . 11.0 t -116.26 123.56 48.01 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.287 -0.883 . . . . 0.0 108.978 179.581 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 37.6 p -95.51 5.5 51.38 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.275 -0.891 . . . . 0.0 109.86 -179.446 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . 0.509 ' O ' ' SG ' ' A' ' 128' ' ' CYS . . . -148.44 155.58 41.39 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.142 -0.974 . . . . 0.0 109.725 -179.905 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 34.7 ttmt -73.51 135.42 44.02 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.316 -0.865 . . . . 0.0 109.309 179.838 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 132' ' ' THR . . . . . 0.634 ' HG1' ' N ' ' A' ' 136' ' ' ASP . 16.9 p -120.87 159.33 25.74 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.447 -0.783 . . . . 0.0 109.431 -179.808 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . 0.436 ' O ' ' OD1' ' A' ' 136' ' ' ASP . 96.2 mt-10 -97.93 -48.24 5.24 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.286 -0.884 . . . . 0.0 110.011 -179.906 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 134' ' ' TRP . . . . . 0.602 ' CD1' ' N ' ' A' ' 135' ' ' LEU . 40.9 p90 -92.16 -44.06 9.0 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.199 -0.938 . . . . 0.0 110.174 -179.477 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . 0.602 ' N ' ' CD1' ' A' ' 134' ' ' TRP . 34.2 tp -61.66 -29.63 70.2 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.268 -0.895 . . . . 0.0 109.184 -179.646 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . 0.634 ' N ' ' HG1' ' A' ' 132' ' ' THR . 53.4 p30 -70.14 9.06 0.63 Allowed 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.447 -0.783 . . . . 0.0 109.513 -179.747 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 137' ' ' GLY . . . . . 0.498 ' H ' ' C ' ' A' ' 135' ' ' LEU . . . -52.02 -30.31 30.13 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.618 -1.393 . . . . 0.0 109.618 -179.904 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . 0.44 ' CE ' ' OD1' ' A' ' 115' ' ' ASN . 46.4 mmtm -77.56 123.18 26.27 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.098 -1.236 . . . . 0.0 109.168 -179.879 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 71.1 m80 -110.61 15.66 21.91 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.398 -0.814 . . . . 0.0 109.754 -179.641 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 45.0 t -100.08 129.8 50.21 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.13 -0.981 . . . . 0.0 109.88 -179.536 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 84.2 t -130.58 129.83 64.55 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 N-CA-C 109.021 -0.733 . . . . 0.0 109.021 179.651 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 39.5 p90 -110.72 -0.4 17.09 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.074 -1.016 . . . . 0.0 110.052 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -175.43 173.52 46.28 Favored Glycine 0 N--CA 1.493 2.495 0 N-CA-C 109.804 -1.319 . . . . 0.0 109.804 179.443 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 94.0 mt-30 -139.36 165.91 25.95 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.29 -1.123 . . . . 0.0 109.584 -179.83 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 55.1 t -95.56 129.54 45.53 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.222 0 O-C-N 121.175 -0.953 . . . . 0.0 109.162 179.816 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 17.3 m -106.73 -33.65 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.314 -0.866 . . . . 0.0 109.455 179.736 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -143.06 170.78 15.07 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.333 -0.855 . . . . 0.0 109.525 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 98.53 2.39 57.61 Favored Glycine 0 N--CA 1.494 2.558 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.74 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 149' ' ' MET . . . . . 0.404 ' O ' HG13 ' A' ' 152' ' ' VAL . 50.6 ttm -61.02 -32.85 72.44 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.063 -1.257 . . . . 0.0 109.667 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -65.33 -42.29 93.08 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.883 -1.135 . . . . 0.0 110.06 -179.596 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.6 p -81.84 -32.92 11.59 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.141 -0.974 . . . . 0.0 110.611 -179.232 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 152' ' ' VAL . . . . . 0.441 ' CG1' ' N ' ' A' ' 153' ' ' LYS . 0.9 OUTLIER -53.76 -41.0 45.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 120.976 -1.077 . . . . 0.0 109.152 -179.285 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 153' ' ' LYS . . . . . 0.441 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 87.2 mttt -64.03 -34.62 78.42 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.122 -0.986 . . . . 0.0 109.188 179.169 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -62.08 -35.06 77.52 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.381 -0.824 . . . . 0.0 109.687 -179.798 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 95.7 mt -70.79 -36.01 62.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.277 -0.889 . . . . 0.0 109.832 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 85.1 tt0 -75.24 -41.89 56.5 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.266 -0.896 . . . . 0.0 111.419 -178.755 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 55.4 pttt -61.27 -34.46 75.21 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.665 -1.272 . . . . 0.0 109.689 -179.047 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 32.6 m -82.82 -6.62 10.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.146 -0.971 . . . . 0.0 108.926 179.427 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -77.67 176.48 53.68 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 109.797 -1.321 . . . . 0.0 109.797 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 86.9 p -157.48 169.54 24.46 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.431 -1.041 . . . . 0.0 109.706 -179.58 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 22.8 t -57.1 -32.69 66.55 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.281 -0.887 . . . . 0.0 108.647 179.256 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 86.2 p -61.38 -27.25 68.39 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.329 -0.857 . . . . 0.0 109.096 179.654 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 93.24 18.04 40.79 Favored Glycine 0 N--CA 1.493 2.488 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 179.756 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 88.7 mtt180 -115.94 143.06 45.96 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.219 -1.165 . . . . 0.0 109.226 179.825 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 165' ' ' THR . . . . . . . . . . . . . 81.7 p -81.98 150.06 27.85 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.208 -0.933 . . . . 0.0 109.675 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -68.96 -36.77 78.3 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.325 -0.859 . . . . 0.0 109.333 179.8 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -111.58 157.84 19.92 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.5 -0.75 . . . . 0.0 109.435 -179.914 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 92.1 mttt -73.02 135.84 44.96 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.309 -0.869 . . . . 0.0 109.175 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 3.4 m -130.94 123.02 53.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.725 0 O-C-N 121.365 -0.834 . . . . 0.0 109.772 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 39.0 t -143.21 138.0 26.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.386 -0.821 . . . . 0.0 108.804 179.557 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . 0.77 ' CG2' ' H ' ' A' ' 64' ' ' SER . 3.0 m -67.7 119.56 13.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 120.826 -1.171 . . . . 0.0 109.547 -179.737 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -68.52 -35.57 77.66 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.233 -0.917 . . . . 0.0 110.086 -179.836 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -156.34 158.32 37.21 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.202 -0.936 . . . . 0.0 110.047 -179.6 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 19.0 p -147.06 148.58 31.79 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.435 -0.79 . . . . 0.0 109.16 179.688 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -177.93 179.72 48.29 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.704 -1.359 . . . . 0.0 109.704 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 61.3 tt0 -106.03 117.25 33.55 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.392 -1.064 . . . . 0.0 109.667 -179.896 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 31.3 tp -62.86 -38.8 92.29 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.094 -1.004 . . . . 0.0 109.216 179.589 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 2.6 p . . . . . 0 N--CA 1.492 1.651 0 CA-C-O 117.897 -1.049 . . . . 0.0 109.707 179.997 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 12.0 m120 . . . . . 0 N--CA 1.492 1.656 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -68.21 138.08 42.2 Favored 'Trans proline' 0 N--CA 1.496 1.648 0 C-N-CA 122.595 2.197 . . . . 0.0 112.272 179.891 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 95.5 mtt180 -128.72 132.27 47.97 Favored 'General case' 0 N--CA 1.492 1.657 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 179.114 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.5 p -133.24 142.3 42.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.363 -0.836 . . . . 0.0 109.607 -179.564 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 47.1 p90 -140.91 155.26 46.32 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.411 -0.806 . . . . 0.0 109.519 -179.838 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 69.8 m-85 -121.86 135.51 54.9 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.455 -0.778 . . . . 0.0 109.643 179.773 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.0 t0 -88.28 118.83 28.15 Favored 'General case' 0 N--CA 1.493 1.703 0 N-CA-C 108.307 -0.998 . . . . 0.0 108.307 178.864 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 75.2 mtp -116.32 142.86 46.28 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.263 -0.898 . . . . 0.0 110.742 -178.822 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.581 ' HG ' ' CD ' ' A' ' 172' ' ' GLU . 31.6 m -136.4 155.88 49.41 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 179.368 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 33.3 m -119.14 133.69 65.17 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.085 -1.009 . . . . 0.0 109.638 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 57.86 15.57 20.59 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.689 -1.365 . . . . 0.0 109.689 179.844 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 92.08 2.38 68.87 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.386 -1.486 . . . . 0.0 109.386 -179.804 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 41.5 tt0 -105.02 115.15 62.88 Favored Pre-proline 0 N--CA 1.492 1.658 0 O-C-N 121.437 -1.037 . . . . 0.0 109.112 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 77.4 Cg_exo -47.33 133.65 19.91 Favored 'Trans proline' 0 N--CA 1.492 1.412 0 C-N-CA 122.088 1.859 . . . . 0.0 112.106 -179.949 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -101.25 -57.67 2.04 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.292 -0.88 . . . . 0.0 109.568 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -178.02 -169.08 38.46 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.401 -1.48 . . . . 0.0 109.401 -179.775 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 50.9 mtp180 -113.22 144.22 43.07 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.415 -1.05 . . . . 0.0 109.383 179.849 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 76.3 mt -117.85 114.56 45.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 N-CA-C 108.183 -1.043 . . . . 0.0 108.183 178.757 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 38.3 t -109.58 135.21 49.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.437 -0.79 . . . . 0.0 109.628 -179.219 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 75.8 mtm -128.41 156.86 42.49 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.514 -0.741 . . . . 0.0 109.225 -179.588 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -103.83 133.93 48.0 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.283 -0.886 . . . . 0.0 109.706 179.882 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -105.37 128.97 53.78 Favored 'General case' 0 N--CA 1.492 1.638 0 N-CA-C 108.752 -0.832 . . . . 0.0 108.752 179.365 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.401 ' CG ' ' NZ ' ' A' ' 103' ' ' LYS . 94.9 m-85 -92.97 119.41 32.21 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.085 -1.009 . . . . 0.0 109.141 179.981 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -86.33 -42.6 13.57 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.346 -0.846 . . . . 0.0 109.535 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.3 m-20 -65.1 -47.49 76.99 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.368 -0.833 . . . . 0.0 110.298 -179.433 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' THR . . . . . 0.622 ' CB ' ' HZ1' ' A' ' 103' ' ' LYS . 37.4 m -67.62 -44.63 77.56 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.211 -0.931 . . . . 0.0 109.775 -179.777 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.474 ' O ' ' OG1' ' A' ' 35' ' ' THR . 5.7 p -138.15 76.98 37.56 Favored Pre-proline 0 N--CA 1.492 1.658 0 N-CA-C 109.082 -0.71 . . . . 0.0 109.082 -179.912 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 10.7 Cg_endo -59.33 -63.31 0.13 Allowed 'Trans proline' 0 C--N 1.31 -1.489 0 C-N-CA 122.571 2.181 . . . . 0.0 112.801 -179.154 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 86.8 mtt-85 -61.24 -35.19 76.58 Favored 'General case' 0 C--N 1.297 -1.688 0 O-C-N 121.652 -0.655 . . . . 0.0 110.755 -178.77 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 25.3 m -60.27 -42.13 94.76 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 120.984 -1.073 . . . . 0.0 110.094 -179.418 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -59.95 -31.82 70.23 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.128 -0.983 . . . . 0.0 109.153 -179.794 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -67.7 -36.88 81.47 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.401 -0.812 . . . . 0.0 109.915 -179.9 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 37.8 t30 -56.6 -40.81 75.92 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.261 -0.899 . . . . 0.0 109.823 -179.458 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 98.4 m-85 -90.43 -48.6 7.01 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.069 -1.019 . . . . 0.0 109.828 -179.89 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . 0.864 ' HE ' HE22 ' A' ' 176' ' ' GLN . 66.2 ttt-85 -57.41 -41.32 80.14 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.512 -0.742 . . . . 0.0 110.505 -179.375 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -65.55 -47.6 75.3 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.049 -1.032 . . . . 0.0 110.373 -178.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.469 ' N ' ' CD2' ' A' ' 45' ' ' LEU . 3.3 mm? -65.51 -39.87 92.36 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.124 -0.985 . . . . 0.0 109.665 -179.735 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' CYS . . . . . . . . . . . . . 72.3 m -68.24 -46.09 71.44 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.1 -1.0 . . . . 0.0 109.315 179.819 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 72.6 p -74.34 -33.53 63.16 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.313 -0.867 . . . . 0.0 109.721 179.877 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 75.03 30.81 58.6 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 110.037 -1.225 . . . . 0.0 110.037 179.739 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 77.9 mm-40 -61.97 -36.67 82.16 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.137 -1.214 . . . . 0.0 109.441 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 42.0 mmtm -60.66 -33.87 73.45 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.233 -0.917 . . . . 0.0 109.402 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 92.84 171.3 40.45 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.096 -1.602 . . . . 0.0 109.096 -179.692 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 99.2 m -75.88 141.39 42.38 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.317 -1.108 . . . . 0.0 109.76 -179.807 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -60.42 138.15 48.62 Favored Glycine 0 N--CA 1.488 2.164 0 N-CA-C 109.405 -1.478 . . . . 0.0 109.405 179.787 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 87.1 mtt-85 -60.24 -29.22 68.62 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.303 -1.116 . . . . 0.0 110.231 -179.803 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 75.4 m -78.52 11.0 2.7 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.181 -0.95 . . . . 0.0 110.32 -179.154 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 82.16 77.03 1.07 Allowed Glycine 0 N--CA 1.492 2.4 0 N-CA-C 109.217 -1.553 . . . . 0.0 109.217 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . 0.478 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 55.0 mttp -157.47 75.0 4.16 Favored Pre-proline 0 C--N 1.302 -1.463 0 O-C-N 121.449 -1.03 . . . . 0.0 108.3 -179.944 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . 0.411 ' O ' ' CE2' ' A' ' 80' ' ' PHE . 73.1 Cg_exo -50.04 130.28 27.32 Favored 'Trans proline' 0 C--N 1.302 -1.909 0 C-N-CA 122.962 2.441 . . . . 0.0 112.517 -179.085 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.478 ' CD1' ' O ' ' A' ' 57' ' ' LYS . 8.6 mp -100.8 74.22 1.63 Allowed 'General case' 0 N--CA 1.489 1.524 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 -179.638 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 77.5 m80 -139.21 150.68 45.82 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.436 -0.79 . . . . 0.0 109.516 179.865 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 3.8 m-85 -101.95 20.48 16.41 Favored 'General case' 0 N--CA 1.493 1.691 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 179.573 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 85.0 mttt -77.57 157.55 30.26 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.434 -0.791 . . . . 0.0 109.525 -179.663 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 54.8 t0 56.89 48.9 15.04 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.486 -0.759 . . . . 0.0 109.805 179.788 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 87.4 p -111.71 154.25 25.26 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.4 -0.813 . . . . 0.0 109.077 179.69 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 27.8 t -131.03 149.3 52.68 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.227 -0.921 . . . . 0.0 109.74 -179.603 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -72.68 135.84 45.49 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.351 -0.843 . . . . 0.0 109.131 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 32.1 m-70 -77.84 -53.01 7.98 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.259 -0.901 . . . . 0.0 110.71 -179.219 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 98.1 mtt180 -130.27 148.96 52.16 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.043 -1.035 . . . . 0.0 110.541 -179.017 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 8.5 m -143.67 59.6 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.585 -0.697 . . . . 0.0 109.135 179.497 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 18.6 mt -82.14 132.67 52.73 Favored Pre-proline 0 C--N 1.301 -1.543 0 O-C-N 121.164 -0.96 . . . . 0.0 109.771 -179.135 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -70.98 149.67 59.49 Favored 'Trans proline' 0 N--CA 1.492 1.437 0 C-N-CA 122.399 2.066 . . . . 0.0 112.113 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 81.33 -58.28 4.86 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 179.879 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -70.01 -84.83 0.03 OUTLIER 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.269 -1.136 . . . . 0.0 109.637 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' MET . . . . . 0.484 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 14.1 ptt? 178.03 -172.83 0.13 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.334 -0.854 . . . . 0.0 109.544 179.877 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 14.6 p -125.75 137.26 53.8 Favored 'General case' 0 N--CA 1.493 1.721 0 N-CA-C 108.595 -0.891 . . . . 0.0 108.595 179.45 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 93.1 mt-30 -111.53 153.99 25.44 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.167 -0.958 . . . . 0.0 109.771 -179.485 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -134.76 174.43 21.07 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.006 -1.638 . . . . 0.0 109.006 179.7 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -137.24 161.03 25.19 Favored Glycine 0 N--CA 1.493 2.477 0 N-CA-C 109.717 -1.353 . . . . 0.0 109.717 -179.88 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 90.3 m-20 -72.89 156.81 38.49 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.379 -1.071 . . . . 0.0 109.457 179.865 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.411 ' CE2' ' O ' ' A' ' 58' ' ' PRO . 50.7 p90 -61.97 -18.49 60.58 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.327 -0.858 . . . . 0.0 109.744 -179.666 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.583 ' OG1' ' N ' ' A' ' 88' ' ' GLY . 73.1 p -61.71 -34.39 75.69 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.046 -1.034 . . . . 0.0 109.534 -179.902 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 172.24 -50.46 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.329 -0.857 . . . . 0.0 109.434 179.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 92.45 3.14 67.2 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 80.3 m-20 -86.9 5.91 34.6 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.218 -1.166 . . . . 0.0 109.306 179.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 95.13 -42.61 2.34 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 -179.804 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 47.8 m -61.23 -38.91 88.33 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.207 -1.172 . . . . 0.0 109.114 179.601 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -85.35 -166.46 41.92 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.583 ' N ' ' OG1' ' A' ' 81' ' ' THR . . . 83.52 43.69 7.25 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 -179.897 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -64.05 144.14 57.33 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.266 -1.138 . . . . 0.0 109.478 -179.848 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 29.3 t -102.91 142.12 34.55 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.34 -0.85 . . . . 0.0 109.369 -179.884 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 6.4 pt -63.26 -42.68 97.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.339 -0.851 . . . . 0.0 109.915 -179.737 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 3.8 m-30 -69.85 -36.19 75.35 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.976 -1.077 . . . . 0.0 109.558 179.871 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 80.81 14.85 78.95 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.224 -1.55 . . . . 0.0 109.224 -179.728 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -145.3 158.11 43.9 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.372 -1.075 . . . . 0.0 109.451 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -86.43 154.46 21.14 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.182 -0.949 . . . . 0.0 109.56 -179.881 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 89.0 m-85 -100.23 130.64 46.38 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.281 -0.887 . . . . 0.0 109.305 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -76.62 138.75 40.29 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.159 -0.963 . . . . 0.0 109.496 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . 0.712 ' H ' HD21 ' A' ' 119' ' ' ASN . 88.5 m-20 -75.54 131.25 39.92 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.267 -0.896 . . . . 0.0 109.266 179.836 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -104.28 -55.46 2.36 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.239 -0.913 . . . . 0.0 110.061 -179.797 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 84.9 m-20 -106.35 128.82 54.3 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.233 -0.917 . . . . 0.0 110.24 -179.149 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 90.2 m-85 -108.38 10.52 27.5 Favored 'General case' 0 N--CA 1.493 1.686 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 179.352 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.428 HD13 HG22 ' A' ' 102' ' ' ILE . 92.0 mt -54.9 -37.0 39.88 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.397 -0.814 . . . . 0.0 110.568 -178.974 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' LYS . . . . . 0.622 ' HZ1' ' CB ' ' A' ' 34' ' ' THR . 87.2 mttt -77.2 127.99 33.59 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.871 -1.143 . . . . 0.0 109.909 -179.427 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' LYS . . . . . 0.593 ' O ' ' N ' ' A' ' 106' ' ' THR . 34.4 ttmt -139.08 149.96 45.18 Favored 'General case' 0 N--CA 1.492 1.636 0 N-CA-C 109.012 -0.736 . . . . 0.0 109.012 179.862 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' HIS . . . . . . . . . . . . . 85.5 m-70 -53.69 82.34 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.094 -1.004 . . . . 0.0 109.66 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' THR . . . . . 0.593 ' N ' ' O ' ' A' ' 104' ' ' LYS . 54.9 p -73.45 -28.0 61.72 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.235 -0.915 . . . . 0.0 109.525 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -150.21 -177.51 24.25 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.882 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 69.6 Cg_endo -76.14 156.33 37.96 Favored 'Trans proline' 0 C--N 1.306 -1.666 0 C-N-CA 123.025 2.483 . . . . 0.0 112.198 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 81.86 45.75 7.05 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 110.098 -1.201 . . . . 0.0 110.098 179.706 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 41.6 mm -115.98 136.91 51.39 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 121.287 -1.125 . . . . 0.0 109.459 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . 0.543 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 2.4 mm? -87.54 128.28 35.25 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.199 -0.938 . . . . 0.0 109.263 179.716 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 87.7 p -143.16 150.84 39.96 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.332 -0.855 . . . . 0.0 109.547 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 113' ' ' MET . . . . . 0.458 ' CE ' ' OD1' ' A' ' 121' ' ' ASN . 86.5 mtp -95.35 139.47 31.6 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.343 -0.848 . . . . 0.0 109.329 179.621 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -64.38 145.35 56.2 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.237 -0.914 . . . . 0.0 109.54 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . 0.512 ' N ' ' OD1' ' A' ' 115' ' ' ASN . 2.7 p30 -165.77 114.98 1.0 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.184 -0.948 . . . . 0.0 109.613 179.863 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -66.19 -31.31 72.06 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.383 -0.823 . . . . 0.0 109.356 179.721 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -136.84 169.81 23.72 Favored Glycine 0 N--CA 1.493 2.474 0 N-CA-C 109.351 -1.5 . . . . 0.0 109.351 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -65.84 157.67 57.82 Favored 'Trans proline' 0 C--N 1.305 -1.757 0 C-N-CA 122.819 2.346 . . . . 0.0 111.969 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 119' ' ' ASN . . . . . 0.712 HD21 ' H ' ' A' ' 98' ' ' ASP . 16.4 m120 55.89 44.3 26.06 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.425 -0.797 . . . . 0.0 109.325 -179.857 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 61.2 m -135.96 127.83 29.37 Favored 'General case' 0 C--N 1.304 -1.383 0 N-CA-C 108.804 -0.814 . . . . 0.0 108.804 179.851 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 121' ' ' ASN . . . . . 0.458 ' OD1' ' CE ' ' A' ' 113' ' ' MET . 31.9 t30 -100.5 109.9 22.05 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.423 -0.798 . . . . 0.0 109.374 -179.954 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -85.8 135.33 13.29 Favored Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.644 -1.383 . . . . 0.0 109.644 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 85.3 p -65.1 -23.38 67.14 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.248 -1.148 . . . . 0.0 109.408 179.871 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.0 mt-30 -101.89 154.2 19.15 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.378 -0.826 . . . . 0.0 109.606 -179.728 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 49.3 p90 -133.6 160.95 35.96 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.471 -0.768 . . . . 0.0 109.461 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . 0.484 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 45.6 p90 -140.0 159.71 41.58 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.324 -0.86 . . . . 0.0 109.504 -179.91 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 72.5 mt -119.77 134.24 63.95 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.407 -0.808 . . . . 0.0 109.444 179.845 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 1.8 m -92.2 105.55 17.74 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.104 -0.998 . . . . 0.0 109.268 179.827 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 54.2 p -74.72 -9.12 58.26 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.271 -0.893 . . . . 0.0 109.463 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -150.44 156.15 40.91 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.362 -0.836 . . . . 0.0 109.277 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 82.5 tttt -68.01 135.16 51.88 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.216 -0.928 . . . . 0.0 109.23 179.855 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 6.5 p -122.11 158.0 30.24 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.409 -0.807 . . . . 0.0 109.558 -179.74 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -138.69 -35.66 0.58 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.317 -0.865 . . . . 0.0 109.081 179.812 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 134' ' ' TRP . . . . . 0.422 ' CD2' ' N ' ' A' ' 134' ' ' TRP . 0.7 OUTLIER -58.7 -29.43 66.64 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.447 -0.783 . . . . 0.0 109.219 179.713 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 18.2 mt -59.49 -35.77 74.77 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.32 -0.863 . . . . 0.0 109.628 179.638 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 57.5 t0 49.45 50.94 17.31 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.286 -0.884 . . . . 0.0 109.518 179.801 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -130.2 127.63 5.37 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.166 -1.574 . . . . 0.0 109.166 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . 0.515 ' O ' ' O ' ' A' ' 139' ' ' HIS . 88.2 mttt -56.58 -38.19 71.65 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.36 -1.083 . . . . 0.0 109.652 -179.846 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 139' ' ' HIS . . . . . 0.515 ' O ' ' O ' ' A' ' 138' ' ' LYS . 54.6 m170 56.86 147.88 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.644 -0.66 . . . . 0.0 109.824 179.936 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 41.0 t -116.05 133.6 62.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.413 -0.804 . . . . 0.0 109.296 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 60.1 t -107.27 127.51 62.99 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 121.272 -0.893 . . . . 0.0 109.52 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 39.1 p90 -116.16 3.06 13.45 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.403 -0.81 . . . . 0.0 109.682 179.773 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -173.08 179.13 44.7 Favored Glycine 0 N--CA 1.494 2.528 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 179.612 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.3 pt20 -145.82 166.29 26.35 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.114 -1.227 . . . . 0.0 109.865 -179.855 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 74.6 t -100.63 132.11 46.92 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.122 0 O-C-N 121.278 -0.888 . . . . 0.0 109.581 -179.855 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 12.9 m -113.85 -31.52 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.308 -0.87 . . . . 0.0 109.422 179.563 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -139.62 167.25 22.52 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.356 -0.84 . . . . 0.0 109.469 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 97.67 4.0 58.18 Favored Glycine 0 N--CA 1.494 2.527 0 N-CA-C 109.941 -1.264 . . . . 0.0 109.941 179.765 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 149' ' ' MET . . . . . . . . . . . . . 65.0 mtt -60.71 -33.44 72.89 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.098 -1.236 . . . . 0.0 109.479 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 89.3 m-20 -64.02 -41.64 97.38 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.913 -1.117 . . . . 0.0 109.852 -179.761 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.5 p -83.24 -34.37 10.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.199 -0.938 . . . . 0.0 110.402 -179.446 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 152' ' ' VAL . . . . . 0.464 ' CG1' ' N ' ' A' ' 153' ' ' LYS . 0.6 OUTLIER -57.02 -42.77 79.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 120.872 -1.142 . . . . 0.0 109.382 -179.219 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 153' ' ' LYS . . . . . 0.464 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 66.6 mttm -63.84 -34.41 77.87 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.242 -0.911 . . . . 0.0 109.517 179.503 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -61.48 -37.9 85.33 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.24 -0.913 . . . . 0.0 109.962 -179.492 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 88.3 mt -72.51 -35.14 50.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.189 -0.945 . . . . 0.0 110.047 -179.717 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -76.29 -41.64 48.04 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.202 -0.936 . . . . 0.0 111.191 -178.865 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 39.1 pttt -61.8 -33.92 74.98 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 120.852 -1.155 . . . . 0.0 109.89 -178.819 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 35.3 m -77.8 -13.99 14.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.011 -1.056 . . . . 0.0 109.26 179.714 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -74.3 168.27 54.44 Favored Glycine 0 N--CA 1.489 2.2 0 N-CA-C 109.789 -1.324 . . . . 0.0 109.789 -179.718 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 160' ' ' SER . . . . . 0.682 ' HG ' ' H ' ' A' ' 161' ' ' SER . 22.8 t -157.67 176.36 12.71 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.418 -1.048 . . . . 0.0 109.361 -179.758 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 161' ' ' SER . . . . . 0.682 ' H ' ' HG ' ' A' ' 160' ' ' SER . 23.6 m -54.01 -31.78 52.16 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.282 -0.886 . . . . 0.0 109.182 179.817 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 23.9 m -55.56 -33.07 63.53 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.28 -0.888 . . . . 0.0 109.462 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 95.38 10.97 56.54 Favored Glycine 0 N--CA 1.493 2.482 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 179.828 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 81.7 mtm180 -121.44 146.57 46.76 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.303 -1.116 . . . . 0.0 109.474 179.874 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 165' ' ' THR . . . . . . . . . . . . . 80.5 p -80.49 151.42 29.24 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.224 -0.923 . . . . 0.0 109.646 -179.884 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -66.66 -37.06 84.02 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.322 -0.862 . . . . 0.0 109.077 179.592 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -108.71 158.69 17.39 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.555 -0.716 . . . . 0.0 109.096 179.721 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -71.4 130.78 42.2 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.14 -0.975 . . . . 0.0 109.394 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 43.6 t -122.15 124.24 70.67 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 121.38 -0.825 . . . . 0.0 109.435 179.795 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 48.8 t -149.1 154.61 9.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.48 -0.763 . . . . 0.0 109.141 179.865 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 2.1 t -90.15 124.87 43.0 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 O-C-N 121.258 -0.901 . . . . 0.0 109.932 -179.312 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 172' ' ' GLU . . . . . 0.581 ' CD ' ' HG ' ' A' ' 17' ' ' SER . 97.1 mt-10 -64.96 -28.87 69.81 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.449 -0.782 . . . . 0.0 109.192 179.46 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 173' ' ' ASP . . . . . 0.425 ' C ' ' OD1' ' A' ' 173' ' ' ASP . 53.1 p30 -175.14 179.58 1.53 Allowed 'General case' 0 N--CA 1.492 1.639 0 C-N-CA 119.449 -0.9 . . . . 0.0 110.352 -179.665 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 26.7 p -151.48 151.38 31.56 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.45 -0.781 . . . . 0.0 109.265 179.711 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -178.18 176.83 48.22 Favored Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.792 -1.323 . . . . 0.0 109.792 179.812 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 176' ' ' GLN . . . . . 0.864 HE22 ' HE ' ' A' ' 43' ' ' ARG . 59.3 tt0 -107.11 127.21 53.29 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.375 -1.073 . . . . 0.0 109.61 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 29.0 tp -60.98 -37.78 83.66 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.187 -0.945 . . . . 0.0 109.194 179.641 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 9.5 t . . . . . 0 N--CA 1.49 1.563 0 CA-C-O 117.945 -1.026 . . . . 0.0 109.483 -179.942 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 3.2 m-80 . . . . . 0 N--CA 1.489 1.485 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -70.65 140.24 38.9 Favored 'Trans proline' 0 N--CA 1.494 1.558 0 C-N-CA 122.777 2.318 . . . . 0.0 112.409 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 97.8 mtt180 -128.96 132.09 47.56 Favored 'General case' 0 N--CA 1.491 1.592 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 179.127 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.6 p -136.51 142.62 37.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.248 -0.907 . . . . 0.0 109.633 -179.441 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 38.5 p90 -144.19 154.79 43.5 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.344 -0.847 . . . . 0.0 109.589 -179.866 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 67.1 m-85 -126.66 138.14 53.38 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.332 -0.855 . . . . 0.0 109.597 179.648 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.468 ' CG ' ' NH1' ' A' ' 25' ' ' ARG . 90.2 m-20 -87.02 129.94 34.68 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.168 -0.957 . . . . 0.0 108.616 178.983 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 83.8 mtp -117.35 153.85 32.31 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.164 -0.96 . . . . 0.0 110.37 -179.441 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 76.9 p -148.14 167.33 25.32 Favored 'General case' 0 N--CA 1.487 1.42 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 179.629 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 7.9 p -127.4 134.24 66.19 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.244 -0.91 . . . . 0.0 109.717 -179.815 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 54.79 17.13 8.55 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.626 -1.389 . . . . 0.0 109.626 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 92.24 4.56 66.39 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 63.9 mt-30 -105.49 113.43 64.24 Favored Pre-proline 0 N--CA 1.494 1.728 0 O-C-N 121.345 -1.091 . . . . 0.0 109.241 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_exo -48.81 137.24 27.6 Favored 'Trans proline' 0 N--CA 1.492 1.406 0 C-N-CA 122.123 1.882 . . . . 0.0 112.086 179.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -111.22 -59.4 1.98 Allowed 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.411 -0.806 . . . . 0.0 109.498 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -170.44 -169.8 33.99 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.376 -1.49 . . . . 0.0 109.376 -179.859 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . 0.468 ' NH1' ' CG ' ' A' ' 15' ' ' ASP . 88.2 mtt-85 -116.46 145.8 43.03 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.308 -1.113 . . . . 0.0 109.784 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 73.5 mt -119.8 122.45 68.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 178.863 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 46.1 t -111.02 133.3 57.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.3 -0.875 . . . . 0.0 109.3 -179.562 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 75.2 mtm -116.22 150.88 36.8 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.447 -0.783 . . . . 0.0 109.412 -179.767 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -101.47 130.92 47.81 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.277 -0.889 . . . . 0.0 109.926 -179.594 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -109.86 127.74 54.9 Favored 'General case' 0 N--CA 1.493 1.683 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 179.277 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 96.3 m-85 -98.96 118.53 35.93 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.167 -0.958 . . . . 0.0 109.049 179.525 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -79.66 -41.94 25.86 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.379 -0.826 . . . . 0.0 109.776 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -64.35 -46.6 82.72 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.286 -0.884 . . . . 0.0 110.246 -179.333 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 33.1 m -67.38 -44.42 78.97 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.136 -0.978 . . . . 0.0 109.815 -179.72 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.479 ' O ' ' OG1' ' A' ' 35' ' ' THR . 6.8 p -141.61 79.65 16.85 Favored Pre-proline 0 N--CA 1.492 1.649 0 O-C-N 121.429 -0.794 . . . . 0.0 109.291 -179.859 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -64.25 -54.63 0.78 Allowed 'Trans proline' 0 C--N 1.308 -1.564 0 C-N-CA 122.286 1.991 . . . . 0.0 112.508 -179.404 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 70.9 mtp180 -62.43 -38.75 90.93 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.52 -0.737 . . . . 0.0 110.636 -179.196 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 28.6 m -65.16 -43.82 90.55 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.948 -1.095 . . . . 0.0 110.236 -179.474 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -63.14 -30.61 71.73 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.18 -0.95 . . . . 0.0 109.21 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -71.2 -43.78 66.72 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.345 -0.847 . . . . 0.0 109.837 -179.733 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 45.8 t30 -62.76 -47.82 81.86 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.248 -0.907 . . . . 0.0 109.992 -179.512 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . 0.499 ' O ' ' SG ' ' A' ' 46' ' ' CYS . 61.1 t80 -63.79 -47.75 79.64 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.208 -0.932 . . . . 0.0 109.567 -179.667 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . 0.626 ' CZ ' HE22 ' A' ' 176' ' ' GLN . 74.4 ttt180 -57.83 -38.17 75.12 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.365 -0.835 . . . . 0.0 109.854 -179.849 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.512 ' O ' ' N ' ' A' ' 48' ' ' GLY . . . -62.32 -42.9 99.76 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.118 -0.989 . . . . 0.0 110.088 -179.247 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -66.28 -38.02 86.79 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.02 -1.05 . . . . 0.0 109.582 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' CYS . . . . . 0.499 ' SG ' ' O ' ' A' ' 42' ' ' PHE . 3.8 m -65.9 -53.56 37.88 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.104 -0.997 . . . . 0.0 109.357 -179.973 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 64.4 p -75.02 -31.46 61.37 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.336 -0.852 . . . . 0.0 109.451 179.674 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . 0.512 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 75.7 37.34 40.12 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 110.314 -1.114 . . . . 0.0 110.314 179.51 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -61.61 -37.66 84.77 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.858 -1.377 . . . . 0.0 109.418 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . 0.448 ' HZ1' ' CD1' ' A' ' 91' ' ' ILE . 27.0 mmtp -61.38 -34.0 74.6 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.28 -0.887 . . . . 0.0 109.279 179.819 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 82.13 -86.63 1.43 Allowed Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.654 -1.378 . . . . 0.0 109.654 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 48.8 m -123.77 140.37 53.05 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.448 -1.03 . . . . 0.0 109.637 -179.779 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -56.58 -35.63 67.69 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.44 -1.464 . . . . 0.0 109.44 179.817 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 74.3 mtp85 -140.22 -110.2 0.15 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.35 -1.088 . . . . 0.0 109.207 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 24.9 p -134.13 0.71 3.16 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.366 -0.833 . . . . 0.0 109.746 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -151.09 49.3 0.55 Allowed Glycine 0 N--CA 1.492 2.417 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 59.7 tttm -172.8 74.29 0.42 Allowed Pre-proline 0 N--CA 1.488 1.474 0 O-C-N 121.364 -1.08 . . . . 0.0 108.855 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_exo -47.77 131.93 20.85 Favored 'Trans proline' 0 C--N 1.305 -1.757 0 C-N-CA 122.702 2.268 . . . . 0.0 112.128 -179.417 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.573 ' O ' ' CG ' ' A' ' 60' ' ' HIS . 14.6 tp -109.31 118.39 36.56 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.616 -0.678 . . . . 0.0 109.437 -179.413 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . 0.577 ' O ' ' CZ ' ' A' ' 80' ' ' PHE . 92.4 m-70 -160.62 135.31 7.51 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.244 -0.91 . . . . 0.0 109.944 179.889 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 2.9 m-30 -87.39 3.38 47.26 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.163 -0.96 . . . . 0.0 108.882 179.104 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 62.2 tttt -68.07 146.31 53.61 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.383 -0.823 . . . . 0.0 109.7 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 46.7 t0 61.67 50.8 4.23 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.427 -0.795 . . . . 0.0 110.07 179.784 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.716 ' H ' ' CG2' ' A' ' 171' ' ' VAL . 96.7 p -97.69 157.24 16.16 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.187 -0.946 . . . . 0.0 109.146 179.531 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 29.0 t -128.84 150.09 50.48 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.438 -0.789 . . . . 0.0 109.378 -179.792 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 4.4 m-85 -75.55 125.77 29.69 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.227 -0.92 . . . . 0.0 109.144 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 79.0 t60 -62.76 -48.57 78.61 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.326 -0.859 . . . . 0.0 110.044 -179.354 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.66 HH21 ' NE2' ' A' ' 76' ' ' GLN . 36.8 ptt180 -163.64 162.38 24.18 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.223 -0.923 . . . . 0.0 109.378 -179.925 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -141.75 112.61 3.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.315 -0.866 . . . . 0.0 109.142 179.738 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 43.8 mt -107.56 124.33 35.33 Favored Pre-proline 0 N--CA 1.492 1.645 0 O-C-N 121.45 -0.781 . . . . 0.0 109.073 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_endo -71.75 137.46 29.91 Favored 'Trans proline' 0 N--CA 1.491 1.363 0 C-N-CA 122.031 1.82 . . . . 0.0 112.338 -179.729 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 94.46 -28.25 11.57 Favored Glycine 0 N--CA 1.493 2.466 0 N-CA-C 109.723 -1.351 . . . . 0.0 109.723 179.739 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 94.3 m-85 -100.87 -80.74 0.48 Allowed 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.271 -1.135 . . . . 0.0 109.789 -179.94 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 13.2 ptp -177.87 -168.95 0.19 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.283 -0.886 . . . . 0.0 109.873 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -124.55 130.44 52.45 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.486 -0.759 . . . . 0.0 109.03 179.822 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' GLN . . . . . 0.66 ' NE2' HH21 ' A' ' 68' ' ' ARG . 93.5 mt-30 -108.03 151.65 25.56 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.379 -0.826 . . . . 0.0 109.818 -179.633 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -169.18 -170.49 33.82 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.32 -1.512 . . . . 0.0 109.32 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 88.67 21.25 44.29 Favored Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.766 -1.334 . . . . 0.0 109.766 179.912 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 83.9 m-20 -84.38 12.64 6.43 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.233 -1.157 . . . . 0.0 109.433 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.577 ' CZ ' ' O ' ' A' ' 60' ' ' HIS . 83.1 t80 -50.08 -40.98 47.23 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.313 -0.867 . . . . 0.0 110.134 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.573 ' CB ' ' H ' ' A' ' 88' ' ' GLY . 60.6 p -65.35 -31.26 72.29 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.957 -1.089 . . . . 0.0 109.499 -179.956 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . 0.491 ' CB ' ' O ' ' A' ' 81' ' ' THR . . . 165.3 -53.37 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.415 -0.803 . . . . 0.0 109.32 179.898 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 88.51 2.36 79.53 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 78.5 m-20 -87.85 6.93 33.06 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.254 -1.145 . . . . 0.0 109.478 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 97.2 -39.31 2.82 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.26 -1.536 . . . . 0.0 109.26 -179.788 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 57.1 p -72.63 -21.35 61.12 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.335 -1.097 . . . . 0.0 109.008 179.49 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -84.65 -167.21 42.57 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.573 ' H ' ' CB ' ' A' ' 81' ' ' THR . . . 81.76 44.6 7.69 Favored Glycine 0 N--CA 1.488 2.134 0 N-CA-C 109.016 -1.634 . . . . 0.0 109.016 -179.871 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -94.36 142.49 27.36 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.377 -1.072 . . . . 0.0 109.708 -179.55 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 90.7 p -112.85 158.26 20.38 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.442 -0.786 . . . . 0.0 109.197 179.844 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . 0.448 ' CD1' ' HZ1' ' A' ' 50' ' ' LYS . 29.1 pt -59.08 -32.02 47.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.142 -0.974 . . . . 0.0 109.634 -179.718 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . 0.53 ' O ' ' N ' ' A' ' 94' ' ' ALA . 56.8 m-85 -66.46 -30.12 70.39 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.223 -0.923 . . . . 0.0 109.631 179.636 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 64.07 -72.27 0.05 OUTLIER Glycine 0 N--CA 1.489 2.206 0 N-CA-C 109.336 -1.506 . . . . 0.0 109.336 -179.889 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . 0.53 ' N ' ' O ' ' A' ' 92' ' ' TYR . . . -63.55 143.96 57.39 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.376 -1.073 . . . . 0.0 109.119 179.719 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 59.0 mttp -88.58 149.33 23.63 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.379 -0.826 . . . . 0.0 109.71 -179.849 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 52.0 p90 -130.86 158.52 39.97 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.425 -0.797 . . . . 0.0 109.252 179.705 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -84.79 146.94 27.11 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.28 -0.887 . . . . 0.0 109.893 -179.577 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 60.4 t0 -78.88 124.8 28.59 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.336 -0.852 . . . . 0.0 109.113 179.747 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -54.42 -39.15 67.06 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.146 -0.972 . . . . 0.0 109.729 -179.518 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . 0.499 ' CG ' ' H ' ' A' ' 101' ' ' PHE . 15.1 t-20 -172.32 -177.45 1.81 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.097 -1.002 . . . . 0.0 109.808 179.855 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' PHE . . . . . 0.499 ' H ' ' CG ' ' A' ' 100' ' ' ASN . 15.7 p90 -147.42 62.57 1.16 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.487 -0.758 . . . . 0.0 109.067 179.861 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 80.6 mt -59.66 -37.34 70.42 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.268 -0.895 . . . . 0.0 110.216 -179.447 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 67.6 mttm -86.15 139.41 31.11 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.017 -1.052 . . . . 0.0 109.982 -179.436 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 59.2 mttp -129.12 -176.02 3.74 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.483 -0.761 . . . . 0.0 109.457 179.737 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' HIS . . . . . 0.53 ' O ' ' CG ' ' A' ' 105' ' ' HIS . 49.1 p-80 -109.57 100.36 9.42 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.519 -0.738 . . . . 0.0 109.276 179.704 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 63.7 p -106.96 -0.8 22.85 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.406 -0.809 . . . . 0.0 109.599 -179.831 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -146.62 171.29 27.45 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.336 -1.505 . . . . 0.0 109.336 -179.89 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -74.39 155.44 45.91 Favored 'Trans proline' 0 C--N 1.306 -1.672 0 C-N-CA 122.888 2.392 . . . . 0.0 112.17 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 83.22 44.9 6.8 Favored Glycine 0 N--CA 1.493 2.493 0 N-CA-C 110.234 -1.146 . . . . 0.0 110.234 179.488 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 44.0 mm -116.31 134.21 60.43 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 121.251 -1.146 . . . . 0.0 109.342 179.723 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . 0.511 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 3.4 mm? -91.44 130.91 37.21 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.251 -0.906 . . . . 0.0 109.385 179.709 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 112' ' ' SER . . . . . 0.454 ' OG ' ' O ' ' A' ' 140' ' ' VAL . 47.2 t -143.68 142.24 30.9 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.238 -0.914 . . . . 0.0 109.439 179.826 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 72.1 mtm -82.87 131.21 35.2 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.193 -0.942 . . . . 0.0 109.205 179.769 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . 0.539 ' O ' ' ND2' ' A' ' 115' ' ' ASN . . . -65.87 141.71 58.17 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.192 -0.943 . . . . 0.0 109.587 -179.911 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . 0.539 ' ND2' ' O ' ' A' ' 114' ' ' ALA . 18.3 m120 -146.27 113.03 6.03 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.322 -0.862 . . . . 0.0 109.027 179.664 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -68.51 -29.96 68.67 Favored 'General case' 0 C--N 1.297 -1.682 0 O-C-N 121.46 -0.775 . . . . 0.0 109.488 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -136.51 167.31 24.54 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 109.256 -1.538 . . . . 0.0 109.256 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -67.39 156.22 67.07 Favored 'Trans proline' 0 C--N 1.306 -1.696 0 C-N-CA 122.805 2.336 . . . . 0.0 111.889 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 119' ' ' ASN . . . . . 0.448 ' N ' HD21 ' A' ' 119' ' ' ASN . 2.5 m120 54.35 45.26 27.55 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.422 -0.799 . . . . 0.0 109.35 -179.886 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 120' ' ' THR . . . . . 0.436 ' O ' ' ND2' ' A' ' 115' ' ' ASN . 57.9 m -133.73 126.58 31.0 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 108.792 -0.818 . . . . 0.0 108.792 179.85 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 39.6 t30 -100.77 107.42 18.99 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.504 -0.748 . . . . 0.0 109.355 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -98.44 126.32 8.85 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 86.1 p -62.96 -25.96 68.6 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.268 -1.137 . . . . 0.0 109.385 179.795 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.3 mt-30 -73.86 148.18 42.58 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.283 -0.886 . . . . 0.0 109.399 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 48.8 p90 -136.3 162.75 32.14 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.326 -0.859 . . . . 0.0 109.446 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 49.0 p90 -136.48 160.8 37.67 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.371 -0.831 . . . . 0.0 109.445 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 69.2 mt -115.99 130.16 71.16 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.446 -0.784 . . . . 0.0 109.352 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -101.17 104.2 15.27 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.273 -0.892 . . . . 0.0 109.241 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 59.2 p -84.59 0.67 49.24 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.281 -0.887 . . . . 0.0 109.37 179.878 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -144.42 161.99 37.64 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.3 -0.875 . . . . 0.0 109.466 -179.768 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 92.4 mttt -76.0 150.65 37.37 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.254 -0.904 . . . . 0.0 109.486 -179.91 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 16.0 p -120.0 161.01 21.65 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.39 -0.819 . . . . 0.0 109.374 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -159.61 -44.12 0.05 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.19 -0.944 . . . . 0.0 109.758 -179.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 134' ' ' TRP . . . . . 0.4 ' CE2' ' CD2' ' A' ' 135' ' ' LEU . 33.3 p90 -73.71 -9.64 58.87 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.284 -0.885 . . . . 0.0 109.39 -179.802 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . 0.51 ' N ' ' CD2' ' A' ' 135' ' ' LEU . 2.8 mm? -61.59 -33.8 74.53 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.238 -0.914 . . . . 0.0 108.771 179.239 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 59.1 t0 49.16 49.91 18.83 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.44 -0.788 . . . . 0.0 109.754 179.648 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -143.83 163.79 27.59 Favored Glycine 0 N--CA 1.485 1.932 0 N-CA-C 108.915 -1.674 . . . . 0.0 108.915 179.847 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 13.6 mptt -97.21 142.73 28.77 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.472 -1.016 . . . . 0.0 109.465 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 99.3 m-70 -128.97 146.75 50.88 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.46 -0.775 . . . . 0.0 109.428 179.853 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.454 ' O ' ' OG ' ' A' ' 112' ' ' SER . 42.3 t -112.94 135.0 53.78 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.402 -0.811 . . . . 0.0 109.277 179.955 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 56.3 t -108.38 128.07 64.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 121.33 -0.856 . . . . 0.0 109.507 -179.757 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 45.9 p90 -112.88 -0.59 14.83 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.342 -0.849 . . . . 0.0 109.401 179.547 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -171.28 174.45 44.92 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 179.619 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 92.1 mt-30 -139.6 165.28 27.67 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.176 -1.19 . . . . 0.0 109.663 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 69.9 t -97.12 129.8 46.66 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.225 0 O-C-N 121.126 -0.984 . . . . 0.0 109.435 -179.952 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 16.0 m -106.99 -29.35 2.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.372 -0.83 . . . . 0.0 109.536 179.657 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -143.52 171.17 14.53 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.265 -0.897 . . . . 0.0 109.512 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 97.99 4.22 57.77 Favored Glycine 0 N--CA 1.493 2.46 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 179.64 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 149' ' ' MET . . . . . . . . . . . . . 88.8 mtp -60.6 -33.95 73.51 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.13 -1.218 . . . . 0.0 109.672 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -64.98 -42.62 94.37 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.843 -1.161 . . . . 0.0 110.124 -179.624 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.1 p -82.79 -33.5 10.76 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.079 -1.013 . . . . 0.0 110.499 -179.429 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 152' ' ' VAL . . . . . 0.45 ' CG1' ' N ' ' A' ' 153' ' ' LYS . 0.7 OUTLIER -55.17 -41.82 62.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 120.882 -1.136 . . . . 0.0 109.251 -179.335 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 153' ' ' LYS . . . . . 0.45 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 93.8 mttt -63.56 -34.8 78.6 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.171 -0.956 . . . . 0.0 109.298 179.356 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -63.0 -36.6 84.09 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.405 -0.809 . . . . 0.0 109.792 -179.599 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 69.9 mt -70.4 -38.6 74.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.211 -0.931 . . . . 0.0 110.036 -179.606 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -76.83 -41.14 45.37 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.067 -1.021 . . . . 0.0 111.63 -178.35 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 36.4 pttt -61.18 -34.19 74.65 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 120.729 -1.232 . . . . 0.0 110.261 -178.553 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 35.6 m -76.12 -20.09 15.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 120.917 -1.115 . . . . 0.0 109.469 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -72.91 165.24 54.81 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.652 -1.379 . . . . 0.0 109.652 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 22.9 t -151.42 171.71 17.09 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.376 -1.073 . . . . 0.0 109.382 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 22.6 t -53.7 -32.11 50.61 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.2 -0.938 . . . . 0.0 109.074 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 22.7 t -56.79 -30.94 64.16 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.251 -0.906 . . . . 0.0 109.34 179.722 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 96.41 8.04 57.75 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.678 -1.369 . . . . 0.0 109.678 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 98.6 mtt180 -120.71 144.14 48.39 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.244 -1.15 . . . . 0.0 109.29 179.831 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 165' ' ' THR . . . . . 0.401 ' OG1' ' O ' ' A' ' 167' ' ' LYS . 59.6 p -91.23 157.29 17.25 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.197 -0.939 . . . . 0.0 109.728 -179.853 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -65.94 -33.79 76.63 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.367 -0.833 . . . . 0.0 109.613 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 167' ' ' LYS . . . . . 0.401 ' O ' ' OG1' ' A' ' 165' ' ' THR . 60.8 mttp -119.41 161.03 21.19 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.406 -0.809 . . . . 0.0 109.905 -179.498 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 67.1 mttm -82.53 145.85 29.53 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.437 -0.789 . . . . 0.0 109.725 -179.918 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 1.9 m -133.75 127.08 52.1 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 O-C-N 121.277 -0.89 . . . . 0.0 109.575 179.783 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 44.3 t -137.99 139.05 43.15 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 O-C-N 121.392 -0.817 . . . . 0.0 109.407 179.837 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . 0.716 ' CG2' ' H ' ' A' ' 64' ' ' SER . 9.5 m -67.06 124.51 22.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.0 -1.062 . . . . 0.0 109.208 179.819 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -69.29 -38.38 78.29 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.158 -0.964 . . . . 0.0 110.356 -179.63 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 173' ' ' ASP . . . . . 0.438 ' OD1' ' N ' ' A' ' 174' ' ' CYS . 48.0 t0 -168.7 168.82 10.48 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.958 -1.089 . . . . 0.0 110.209 -179.502 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 174' ' ' CYS . . . . . 0.438 ' N ' ' OD1' ' A' ' 173' ' ' ASP . 14.4 p -138.81 149.84 45.4 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.513 -0.742 . . . . 0.0 109.095 179.785 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -165.27 176.99 40.83 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.737 -1.345 . . . . 0.0 109.737 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 176' ' ' GLN . . . . . 0.626 HE22 ' CZ ' ' A' ' 43' ' ' ARG . 61.1 tt0 -109.83 113.9 27.03 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.331 -1.1 . . . . 0.0 109.614 -179.906 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 177' ' ' LEU . . . . . 0.407 ' O ' ' C ' ' A' ' 178' ' ' SER . 33.9 tp -64.4 -38.41 90.95 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.299 -0.876 . . . . 0.0 109.187 179.526 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 178' ' ' SER . . . . . 0.407 ' C ' ' O ' ' A' ' 177' ' ' LEU . 1.9 t . . . . . 0 N--CA 1.49 1.565 0 CA-C-O 118.04 -0.981 . . . . 0.0 109.621 179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 75.1 m-20 . . . . . 0 N--CA 1.49 1.551 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -66.88 140.17 54.33 Favored 'Trans proline' 0 N--CA 1.496 1.632 0 C-N-CA 122.593 2.196 . . . . 0.0 112.237 179.966 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 98.0 mtt180 -132.49 131.12 41.33 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.33 -0.857 . . . . 0.0 109.187 179.494 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.8 p -138.47 142.63 34.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.306 -0.871 . . . . 0.0 109.39 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 49.3 p90 -142.46 153.85 44.04 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.298 -0.876 . . . . 0.0 109.624 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 77.0 m-85 -126.19 140.83 52.25 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.409 -0.807 . . . . 0.0 109.538 179.654 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 88.4 m-20 -86.85 129.75 34.75 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.156 -0.965 . . . . 0.0 108.925 179.31 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 84.7 mtp -115.03 153.33 30.86 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.331 -0.855 . . . . 0.0 110.079 -179.683 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 83.8 p -149.0 164.16 35.38 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.442 -0.787 . . . . 0.0 109.129 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.541 ' O ' ' N ' ' A' ' 20' ' ' GLY . 20.4 m -127.25 144.46 37.25 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 121.233 -0.917 . . . . 0.0 109.604 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 47.61 11.43 0.1 OUTLIER Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.822 -1.311 . . . . 0.0 109.822 179.812 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.541 ' N ' ' O ' ' A' ' 18' ' ' VAL . . . 96.49 -14.93 63.64 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.895 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' GLN . . . . . 0.448 ' N ' ' CD ' ' A' ' 21' ' ' GLN . 8.1 mp0 -82.95 149.31 59.13 Favored Pre-proline 0 N--CA 1.492 1.632 0 O-C-N 121.268 -1.137 . . . . 0.0 109.029 179.778 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -62.42 135.35 53.11 Favored 'Trans proline' 0 C--N 1.308 -1.557 0 C-N-CA 122.353 2.035 . . . . 0.0 112.036 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -113.49 -68.11 0.95 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.398 -0.814 . . . . 0.0 109.554 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -176.0 -171.64 40.02 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 -179.865 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 40.0 ttm180 -123.45 142.65 50.78 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.446 -1.032 . . . . 0.0 109.327 -179.931 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 75.5 mt -119.99 132.06 70.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.372 -0.83 . . . . 0.0 109.03 179.641 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 44.5 t -113.3 133.22 59.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.306 -0.872 . . . . 0.0 109.086 179.765 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 72.8 mtm -118.52 148.95 42.09 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.369 -0.832 . . . . 0.0 109.299 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -102.05 131.68 48.35 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.308 -0.87 . . . . 0.0 109.575 -179.752 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -104.9 128.75 53.25 Favored 'General case' 0 N--CA 1.492 1.655 0 N-CA-C 109.044 -0.725 . . . . 0.0 109.044 179.615 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 90.2 m-85 -97.25 120.98 38.61 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.309 -0.869 . . . . 0.0 109.307 179.731 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -82.53 -41.51 19.58 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.321 -0.862 . . . . 0.0 109.875 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 56.8 t0 -69.02 -44.36 72.89 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.228 -0.92 . . . . 0.0 110.828 -179.22 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 32.9 m -67.22 -45.71 75.98 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.047 -1.033 . . . . 0.0 110.491 -178.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 4.3 m -156.4 84.36 3.21 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.127 -0.983 . . . . 0.0 109.484 -179.524 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -75.24 -37.04 2.08 Favored 'Trans proline' 0 C--N 1.307 -1.639 0 C-N-CA 122.334 2.023 . . . . 0.0 112.497 -179.518 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.423 ' O ' ' OH ' ' A' ' 92' ' ' TYR . 37.7 mmt180 -61.76 -41.02 97.14 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.21 -0.931 . . . . 0.0 109.644 -179.803 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 86.5 m -66.21 -39.95 89.98 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.253 -0.904 . . . . 0.0 110.106 -179.71 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -60.11 -32.3 70.86 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.077 -1.014 . . . . 0.0 109.521 -179.818 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -69.82 -36.26 75.47 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.268 -0.895 . . . . 0.0 110.077 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 48.3 t30 -57.9 -42.7 85.23 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.101 -0.999 . . . . 0.0 109.767 -179.629 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -85.79 -48.12 9.09 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.206 -0.934 . . . . 0.0 109.681 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 34.9 ttm180 -57.4 -42.63 82.63 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.407 -0.808 . . . . 0.0 109.842 -179.508 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.451 ' O ' ' N ' ' A' ' 48' ' ' GLY . . . -69.82 -44.89 69.05 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.306 -0.872 . . . . 0.0 110.182 -179.411 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 36.7 tp -61.92 -36.42 81.3 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.078 -1.014 . . . . 0.0 109.446 -179.652 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' CYS . . . . . . . . . . . . . 46.9 m -79.51 -49.93 11.51 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.09 -1.006 . . . . 0.0 109.757 179.589 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 71.2 p -68.75 -34.72 76.06 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.149 -0.97 . . . . 0.0 109.575 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . 0.451 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 75.16 28.92 61.26 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.972 -1.251 . . . . 0.0 109.972 179.6 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 78.0 mm-40 -60.98 -38.35 85.68 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.088 -1.243 . . . . 0.0 109.246 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 29.1 mmtm -62.48 -31.35 72.07 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 121.308 -0.87 . . . . 0.0 109.152 179.484 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 97.75 -119.64 6.49 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 108.87 -1.692 . . . . 0.0 108.87 -179.49 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 95.1 m -126.55 142.09 51.65 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.419 -1.048 . . . . 0.0 109.751 179.739 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -55.48 135.72 47.77 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.093 -1.603 . . . . 0.0 109.093 179.615 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 94.5 mtt180 -59.11 -37.66 77.71 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.18 -1.188 . . . . 0.0 110.079 -179.484 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 22.9 t -59.47 -31.4 69.3 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.179 -0.95 . . . . 0.0 109.834 -179.615 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 119.77 95.54 1.57 Allowed Glycine 0 N--CA 1.495 2.592 0 N-CA-C 108.648 -1.781 . . . . 0.0 108.648 -179.379 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 32.6 tptt -178.56 80.5 0.22 Allowed Pre-proline 0 N--CA 1.489 1.497 0 N-CA-C 108.07 -1.085 . . . . 0.0 108.07 -179.501 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_exo -45.26 127.96 9.45 Favored 'Trans proline' 0 C--N 1.301 -1.922 0 C-N-CA 122.667 2.245 . . . . 0.0 112.203 -178.9 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.564 ' O ' ' CG ' ' A' ' 60' ' ' HIS . 84.0 mt -91.52 124.65 35.84 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.718 -0.614 . . . . 0.0 109.92 -179.285 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . 0.564 ' CG ' ' O ' ' A' ' 59' ' ' LEU . 86.5 m-70 -162.25 96.35 0.97 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.443 -0.785 . . . . 0.0 109.258 179.833 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 18.5 t80 -57.32 -34.39 68.68 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.174 -0.954 . . . . 0.0 108.708 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 3.1 ttmp? -46.79 161.06 0.07 Allowed 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.612 -0.68 . . . . 0.0 109.706 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 80.5 m-20 62.34 48.82 4.51 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.686 -0.634 . . . . 0.0 110.494 179.8 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.69 ' H ' ' CG2' ' A' ' 171' ' ' VAL . 33.7 t -103.48 144.63 31.15 Favored 'General case' 0 N--CA 1.492 1.642 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 178.76 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 28.6 t -124.05 148.63 46.91 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.096 -1.002 . . . . 0.0 110.309 -179.003 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 32.8 m-85 -87.75 129.99 34.99 Favored 'General case' 0 N--CA 1.491 1.614 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 179.494 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 94.7 m-70 -90.97 -28.58 17.94 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.103 -0.998 . . . . 0.0 110.901 -178.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 48.9 mtp180 -134.34 147.97 50.64 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 120.957 -1.089 . . . . 0.0 110.245 -179.367 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 10.2 m -153.98 64.7 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.503 -0.748 . . . . 0.0 109.205 179.825 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 21.7 mt -86.82 131.79 44.11 Favored Pre-proline 0 C--N 1.301 -1.502 0 O-C-N 121.009 -1.057 . . . . 0.0 109.788 -179.277 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_endo -71.27 147.16 52.75 Favored 'Trans proline' 0 N--CA 1.492 1.401 0 C-N-CA 122.354 2.036 . . . . 0.0 112.288 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 83.62 -58.7 5.01 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.763 -1.335 . . . . 0.0 109.763 179.808 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 95.6 m-85 -69.74 -83.83 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.177 -1.19 . . . . 0.0 109.622 -179.796 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' MET . . . . . 0.403 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 12.6 ptt? 179.05 -173.29 0.17 Allowed 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.278 -0.889 . . . . 0.0 109.68 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 1.2 p -126.34 137.57 53.49 Favored 'General case' 0 N--CA 1.491 1.622 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 179.443 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 91.9 mt-30 -116.73 153.92 31.54 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.256 -0.902 . . . . 0.0 109.735 -179.573 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -163.29 -173.65 32.24 Favored Glycine 0 N--CA 1.488 2.151 0 N-CA-C 109.177 -1.569 . . . . 0.0 109.177 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -160.39 -177.4 33.45 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.717 -1.353 . . . . 0.0 109.717 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.546 ' C ' ' H ' ' A' ' 81' ' ' THR . 83.1 m-20 -66.95 154.93 39.87 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.379 -1.071 . . . . 0.0 109.507 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.558 ' CE1' ' O ' ' A' ' 60' ' ' HIS . 36.5 p90 -58.89 0.24 0.09 Allowed 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.413 -0.804 . . . . 0.0 109.762 -179.856 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.546 ' H ' ' C ' ' A' ' 79' ' ' ASP . 72.4 p -63.85 -32.31 73.78 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.991 -1.068 . . . . 0.0 109.538 -179.706 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . 0.423 ' CB ' ' O ' ' A' ' 81' ' ' THR . . . 169.48 -53.12 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.335 -0.853 . . . . 0.0 109.37 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 86.04 2.8 85.78 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.556 -1.417 . . . . 0.0 109.556 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 39.9 t-20 -85.94 5.91 30.94 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.263 -1.14 . . . . 0.0 109.497 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 100.96 -40.19 2.5 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 -179.776 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 58.9 p -70.75 -27.22 63.79 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.273 -1.134 . . . . 0.0 108.837 179.392 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -86.47 -167.66 43.89 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.184 -1.566 . . . . 0.0 109.184 179.657 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.485 ' N ' ' OG1' ' A' ' 81' ' ' THR . . . 82.25 42.38 8.69 Favored Glycine 0 N--CA 1.489 2.179 0 N-CA-C 109.359 -1.496 . . . . 0.0 109.359 -179.919 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -57.03 143.81 36.79 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.303 -1.116 . . . . 0.0 109.391 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 99.3 p -113.44 147.87 36.98 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.348 -0.845 . . . . 0.0 109.268 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 20.0 pt -74.01 -33.64 36.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.297 -0.877 . . . . 0.0 109.993 -179.837 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . 0.423 ' OH ' ' O ' ' A' ' 37' ' ' ARG . 81.8 m-85 -66.46 -41.14 89.48 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.173 -0.954 . . . . 0.0 109.795 -179.668 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 71.3 9.57 68.14 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.278 -1.529 . . . . 0.0 109.278 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -152.34 160.76 43.27 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.294 -1.121 . . . . 0.0 109.389 -179.758 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 63.7 mttp -83.4 145.85 28.77 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.22 -0.925 . . . . 0.0 109.665 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 52.4 p90 -137.05 160.5 38.78 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.402 -0.811 . . . . 0.0 109.312 179.674 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -104.49 144.23 31.96 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.31 -0.869 . . . . 0.0 109.513 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . 0.523 ' O ' ' OD1' ' A' ' 98' ' ' ASP . 41.9 p30 -79.05 128.98 33.96 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.191 -0.943 . . . . 0.0 109.528 179.873 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -60.65 -37.73 82.49 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.159 -0.963 . . . . 0.0 109.693 -179.643 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 84.4 m-20 -124.42 144.18 50.21 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.251 -0.906 . . . . 0.0 109.849 -179.747 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 48.6 p90 -142.69 19.75 2.01 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.333 -0.854 . . . . 0.0 108.838 179.607 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 84.1 mt -59.47 -34.88 56.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.567 -0.708 . . . . 0.0 110.112 -179.649 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 93.0 mttt -79.65 135.65 36.61 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.069 -1.02 . . . . 0.0 109.768 -179.57 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 25.6 pttm -139.11 -178.69 5.46 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.412 -0.805 . . . . 0.0 109.439 -180.0 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' HIS . . . . . 0.535 ' O ' ' ND1' ' A' ' 105' ' ' HIS . 15.1 t-80 -74.27 88.02 2.0 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.174 -0.954 . . . . 0.0 109.256 179.825 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 58.8 p -75.05 -25.48 58.71 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.312 -0.867 . . . . 0.0 109.774 -179.781 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.533 ' O ' ' CE1' ' A' ' 105' ' ' HIS . . . -164.21 -166.95 23.97 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.397 -1.481 . . . . 0.0 109.397 -179.708 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -76.29 155.82 37.18 Favored 'Trans proline' 0 C--N 1.308 -1.574 0 C-N-CA 122.644 2.229 . . . . 0.0 112.117 179.901 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 88.32 24.29 34.51 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.869 -1.292 . . . . 0.0 109.869 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 36.6 mm -112.27 136.79 47.37 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.267 -1.137 . . . . 0.0 109.379 179.854 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . 0.601 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 2.7 mm? -88.2 132.57 34.3 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.283 -0.886 . . . . 0.0 109.152 179.77 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 112' ' ' SER . . . . . 0.445 ' OG ' ' O ' ' A' ' 140' ' ' VAL . 47.0 t -145.8 139.36 26.34 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.189 -0.944 . . . . 0.0 109.609 179.957 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 113' ' ' MET . . . . . 0.413 ' SD ' ' OD1' ' A' ' 121' ' ' ASN . 71.9 mtm -89.23 139.03 30.9 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.243 -0.91 . . . . 0.0 109.267 179.651 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . 0.572 ' O ' ' ND2' ' A' ' 115' ' ' ASN . . . -60.74 138.31 58.11 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.242 -0.911 . . . . 0.0 109.152 179.983 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . 0.572 ' ND2' ' O ' ' A' ' 114' ' ' ALA . 15.0 m120 -148.81 112.95 5.2 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.173 -0.954 . . . . 0.0 109.19 179.93 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -68.31 -30.12 69.04 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 121.338 -0.851 . . . . 0.0 109.134 179.559 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -138.18 168.98 24.42 Favored Glycine 0 N--CA 1.493 2.451 0 N-CA-C 109.049 -1.621 . . . . 0.0 109.049 179.813 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -67.11 155.06 72.41 Favored 'Trans proline' 0 C--N 1.305 -1.739 0 C-N-CA 122.722 2.281 . . . . 0.0 112.027 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 75.6 m-20 53.99 44.34 29.48 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.448 -0.782 . . . . 0.0 109.432 -179.865 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 120' ' ' THR . . . . . 0.546 ' O ' ' ND2' ' A' ' 115' ' ' ASN . 93.3 m -134.64 127.59 31.45 Favored 'General case' 0 N--CA 1.485 1.322 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 179.832 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 121' ' ' ASN . . . . . 0.413 ' OD1' ' SD ' ' A' ' 113' ' ' MET . 52.2 t30 -98.22 106.43 18.72 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.421 -0.8 . . . . 0.0 109.318 179.794 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -80.96 136.61 16.6 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 83.4 p -64.38 -23.73 67.39 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.268 -1.136 . . . . 0.0 109.442 179.853 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.2 mt-30 -103.73 150.89 23.63 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.267 -0.896 . . . . 0.0 109.675 -179.825 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 51.5 p90 -136.23 162.4 33.08 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.431 -0.793 . . . . 0.0 109.292 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . 0.403 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 48.5 p90 -136.34 156.64 48.35 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.193 -0.942 . . . . 0.0 109.636 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 64.9 mt -122.53 133.1 69.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.449 -0.782 . . . . 0.0 109.189 179.812 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 128' ' ' CYS . . . . . 0.506 ' SG ' ' O ' ' A' ' 130' ' ' ALA . 5.7 t -99.82 118.46 36.33 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.154 -0.966 . . . . 0.0 109.499 179.938 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 64.9 p -95.05 4.12 54.1 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.294 -0.879 . . . . 0.0 109.489 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . 0.506 ' O ' ' SG ' ' A' ' 128' ' ' CYS . . . -147.41 155.82 42.31 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.271 -0.893 . . . . 0.0 109.684 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 51.4 tttp -72.9 137.17 45.45 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.204 -0.935 . . . . 0.0 109.423 179.918 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 7.2 p -122.46 161.49 23.45 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.47 -0.769 . . . . 0.0 109.542 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -104.88 -74.98 0.63 Allowed 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.336 -0.853 . . . . 0.0 109.666 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 134' ' ' TRP . . . . . 0.672 ' CD1' ' N ' ' A' ' 135' ' ' LEU . 45.9 p90 -61.65 -45.8 92.48 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.333 -0.854 . . . . 0.0 110.198 -179.56 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . 0.672 ' N ' ' CD1' ' A' ' 134' ' ' TRP . 13.5 tp -61.28 -32.3 72.13 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.336 -0.852 . . . . 0.0 109.72 -179.348 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 60.4 t0 -56.5 136.61 54.1 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.231 -0.918 . . . . 0.0 109.924 -179.38 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 137' ' ' GLY . . . . . 0.669 ' H ' ' CD2' ' A' ' 139' ' ' HIS . . . -162.65 -161.15 11.84 Favored Glycine 0 N--CA 1.486 2.009 0 N-CA-C 108.664 -1.774 . . . . 0.0 108.664 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . 0.464 ' O ' ' O ' ' A' ' 139' ' ' HIS . 92.1 mttt -57.21 -41.14 78.86 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.055 -1.262 . . . . 0.0 109.582 179.887 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 139' ' ' HIS . . . . . 0.669 ' CD2' ' H ' ' A' ' 137' ' ' GLY . 66.2 m-70 37.4 94.66 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.58 -0.7 . . . . 0.0 110.428 179.738 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.445 ' O ' ' OG ' ' A' ' 112' ' ' SER . 39.0 t -61.61 132.43 27.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 120.99 -1.069 . . . . 0.0 108.791 179.579 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 82.3 t -111.38 129.0 67.51 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 O-C-N 121.376 -0.828 . . . . 0.0 109.824 -179.45 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 41.9 p90 -116.19 -1.55 12.37 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.511 -0.743 . . . . 0.0 109.505 179.449 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -168.47 172.73 43.08 Favored Glycine 0 N--CA 1.493 2.479 0 N-CA-C 109.861 -1.296 . . . . 0.0 109.861 179.447 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 55.2 tt0 -139.99 160.33 40.18 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.31 -1.112 . . . . 0.0 109.347 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 54.4 t -96.75 131.22 44.04 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.182 0 O-C-N 121.047 -1.033 . . . . 0.0 109.56 -179.759 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 16.4 m -111.0 -28.75 2.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.444 -0.785 . . . . 0.0 109.32 179.472 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -144.42 169.35 18.11 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.326 -0.859 . . . . 0.0 109.448 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 96.2 6.36 58.94 Favored Glycine 0 N--CA 1.494 2.511 0 N-CA-C 109.946 -1.262 . . . . 0.0 109.946 179.519 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 149' ' ' MET . . . . . 0.439 ' O ' HG13 ' A' ' 152' ' ' VAL . 89.0 mtp -59.89 -32.24 70.55 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.165 -1.197 . . . . 0.0 109.8 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -66.67 -42.66 86.2 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.868 -1.145 . . . . 0.0 109.994 -179.542 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 6.2 p -81.36 -34.86 13.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.167 -0.958 . . . . 0.0 110.555 -179.479 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 152' ' ' VAL . . . . . 0.556 ' O ' ' OE1' ' A' ' 156' ' ' GLU . 1.2 p -50.85 -42.39 23.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 120.843 -1.161 . . . . 0.0 108.772 -179.078 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 153' ' ' LYS . . . . . 0.445 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 61.5 mttp -67.39 -32.91 74.14 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.28 -0.887 . . . . 0.0 109.274 179.094 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -61.03 -30.89 70.58 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.469 -0.769 . . . . 0.0 110.396 -179.244 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 89.8 mt -68.54 -37.31 77.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.035 -1.041 . . . . 0.0 110.616 -179.384 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . 0.556 ' OE1' ' O ' ' A' ' 152' ' ' VAL . 42.0 mp0 -80.35 -39.13 29.13 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 120.815 -1.178 . . . . 0.0 111.743 -178.849 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 19.2 pttp -58.3 -37.4 74.97 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 120.455 -1.403 . . . . 0.0 109.161 -178.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 32.1 m -77.99 -15.05 14.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.273 -0.892 . . . . 0.0 108.82 179.163 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -78.9 176.52 54.6 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.719 -1.353 . . . . 0.0 109.719 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 22.7 t -156.46 171.75 19.73 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.31 -1.112 . . . . 0.0 109.288 -179.769 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 22.6 t -54.71 -30.78 56.88 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.13 -0.981 . . . . 0.0 109.224 179.84 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 86.8 p -59.98 -26.56 66.12 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.175 -0.953 . . . . 0.0 109.56 179.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 90.21 17.07 54.5 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 109.828 -1.309 . . . . 0.0 109.828 179.804 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 28.4 ttm180 -119.12 142.56 47.81 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.311 -1.111 . . . . 0.0 109.221 -180.0 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 165' ' ' THR . . . . . . . . . . . . . 82.2 p -79.36 149.14 31.78 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.165 -0.959 . . . . 0.0 109.761 -179.911 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -67.25 -35.62 79.93 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.314 -0.866 . . . . 0.0 109.153 179.686 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 96.6 mttt -117.27 156.93 26.92 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.515 -0.74 . . . . 0.0 109.138 179.918 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 63.9 mttp -68.69 130.74 43.71 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.096 -1.003 . . . . 0.0 109.333 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 34.4 t -122.42 123.36 68.45 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 121.409 -0.807 . . . . 0.0 109.392 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 42.1 t -144.41 141.03 24.27 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.34 -0.85 . . . . 0.0 109.23 179.762 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . 0.69 ' CG2' ' H ' ' A' ' 64' ' ' SER . 4.8 m -65.65 119.29 10.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.103 -0.998 . . . . 0.0 109.296 179.912 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 -70.92 -36.94 72.87 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.033 -1.042 . . . . 0.0 110.621 -179.638 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 173' ' ' ASP . . . . . 0.482 ' OD1' ' N ' ' A' ' 174' ' ' CYS . 52.1 t0 -155.09 161.72 41.21 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.952 -1.092 . . . . 0.0 110.276 -179.184 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 174' ' ' CYS . . . . . 0.482 ' N ' ' OD1' ' A' ' 173' ' ' ASP . 14.8 p -147.36 152.56 38.4 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.398 -0.814 . . . . 0.0 109.224 179.788 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . 178.41 170.81 41.01 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 179.702 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 64.1 tt0 -105.17 119.35 38.82 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.365 -1.08 . . . . 0.0 109.474 179.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 30.8 tp -61.68 -37.97 86.07 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.213 -0.929 . . . . 0.0 109.422 179.87 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 38.7 m . . . . . 0 N--CA 1.489 1.513 0 CA-C-O 118.027 -0.987 . . . . 0.0 109.498 179.988 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 16.3 m-80 . . . . . 0 N--CA 1.49 1.567 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -68.1 140.76 50.54 Favored 'Trans proline' 0 N--CA 1.496 1.627 0 C-N-CA 122.787 2.325 . . . . 0.0 112.501 -179.802 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 55.2 ttt85 -133.0 129.91 38.78 Favored 'General case' 0 N--CA 1.489 1.524 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 179.027 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.7 p -135.22 144.75 33.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.18 -0.95 . . . . 0.0 110.133 -179.006 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 48.6 p90 -136.79 154.47 50.54 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.447 -0.783 . . . . 0.0 109.1 179.752 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.611 ' CE2' ' SG ' ' A' ' 174' ' ' CYS . 86.9 m-85 -121.42 137.49 54.69 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.437 -0.79 . . . . 0.0 109.934 -179.848 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.2 t0 -94.71 115.06 27.06 Favored 'General case' 0 N--CA 1.494 1.748 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 178.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 77.7 mtp -108.35 146.58 32.77 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.198 -0.939 . . . . 0.0 110.826 -178.824 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.472 ' OG ' ' O ' ' A' ' 21' ' ' GLN . 46.8 t -134.25 149.58 50.96 Favored 'General case' 0 N--CA 1.491 1.605 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 179.61 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.418 ' C ' ' N ' ' A' ' 20' ' ' GLY . 35.5 m -112.2 133.96 56.23 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 121.178 -0.951 . . . . 0.0 109.721 -179.664 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 52.95 12.88 1.94 Allowed Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.418 ' N ' ' C ' ' A' ' 18' ' ' VAL . . . 97.11 -10.22 65.62 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.45 -1.46 . . . . 0.0 109.45 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' GLN . . . . . 0.472 ' O ' ' OG ' ' A' ' 17' ' ' SER . 81.4 mt-30 -88.99 149.37 43.19 Favored Pre-proline 0 N--CA 1.49 1.53 0 O-C-N 121.243 -1.151 . . . . 0.0 109.084 179.733 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -62.38 133.89 45.51 Favored 'Trans proline' 0 C--N 1.309 -1.527 0 C-N-CA 122.288 1.992 . . . . 0.0 112.014 -179.772 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -112.33 -65.21 1.2 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.438 -0.789 . . . . 0.0 109.339 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 179.92 -172.28 43.84 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 61.0 ttp180 -119.1 143.08 47.35 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.422 -1.046 . . . . 0.0 109.198 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 82.7 mt -119.8 128.9 75.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.384 -0.823 . . . . 0.0 109.03 179.779 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 39.0 t -116.59 133.78 62.15 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.406 -0.809 . . . . 0.0 109.272 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 72.6 mtm -122.5 152.07 40.7 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.422 -0.798 . . . . 0.0 109.277 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -100.58 131.58 46.41 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.271 -0.893 . . . . 0.0 109.825 -179.626 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.41 ' N ' ' CD2' ' A' ' 30' ' ' LEU . 2.6 mm? -106.12 133.16 51.26 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 179.487 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -96.57 120.81 37.57 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.025 -1.047 . . . . 0.0 109.054 179.459 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -88.02 -41.51 13.06 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.269 -0.895 . . . . 0.0 109.657 -179.809 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -65.28 -42.42 93.2 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.347 -0.846 . . . . 0.0 110.519 -179.214 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 54.6 m -66.32 -44.61 82.88 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.031 -1.043 . . . . 0.0 110.208 -179.324 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.491 ' OG1' ' OG1' ' A' ' 38' ' ' THR . 0.1 OUTLIER -155.67 84.48 3.45 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.261 -0.899 . . . . 0.0 109.301 -179.72 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 1.7 Cg_endo -62.14 -42.07 31.61 Favored 'Trans proline' 0 C--N 1.307 -1.638 0 C-N-CA 122.078 1.852 . . . . 0.0 112.412 -179.245 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 50.1 mtt180 -63.21 -39.54 94.94 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.426 -0.796 . . . . 0.0 110.81 -179.028 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.491 ' OG1' ' OG1' ' A' ' 35' ' ' THR . 75.6 m -63.27 -40.14 96.55 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 120.834 -1.167 . . . . 0.0 109.947 -179.666 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -61.33 -31.56 71.43 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.137 -0.977 . . . . 0.0 109.216 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -67.55 -36.53 81.14 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.303 -0.873 . . . . 0.0 109.885 -179.898 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 45.2 t-20 -57.88 -41.79 83.26 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.219 -0.926 . . . . 0.0 109.85 -179.622 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 98.8 m-85 -87.0 -46.98 9.33 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.106 -0.996 . . . . 0.0 109.804 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . 0.62 ' CZ ' HE22 ' A' ' 176' ' ' GLN . 78.5 ttt180 -57.07 -39.27 74.6 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.363 -0.836 . . . . 0.0 110.147 -179.623 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.437 ' O ' ' N ' ' A' ' 48' ' ' GLY . . . -63.96 -48.24 77.25 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.02 -1.05 . . . . 0.0 110.214 -179.292 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.411 ' N ' ' CD2' ' A' ' 45' ' ' LEU . 4.3 mm? -65.78 -38.93 90.35 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.092 -1.005 . . . . 0.0 109.663 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' CYS . . . . . 0.56 ' SG ' ' SG ' ' A' ' 174' ' ' CYS . 77.7 m -66.01 -47.97 72.73 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.12 -0.988 . . . . 0.0 109.469 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 63.9 p -76.78 -30.78 56.62 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.259 -0.901 . . . . 0.0 109.697 179.733 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . 0.437 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 76.25 31.64 54.32 Favored Glycine 0 N--CA 1.492 2.379 0 N-CA-C 110.214 -1.154 . . . . 0.0 110.214 179.521 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 77.8 mm-40 -62.25 -36.07 80.91 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.944 -1.327 . . . . 0.0 109.573 179.798 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 61.1 mmtt -60.43 -34.03 73.38 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.17 -0.956 . . . . 0.0 109.494 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 76.4 -94.54 1.04 Allowed Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.475 -1.45 . . . . 0.0 109.475 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 31.8 m -118.01 142.46 47.35 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.372 -1.075 . . . . 0.0 109.296 -179.798 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -54.53 -42.43 76.15 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.838 -1.305 . . . . 0.0 109.838 -179.828 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 82.0 mtp180 -147.05 -113.06 0.08 Allowed 'General case' 0 N--CA 1.486 1.364 0 O-C-N 121.172 -1.193 . . . . 0.0 109.265 179.871 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 3.4 m -107.08 -24.72 11.86 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.401 -0.812 . . . . 0.0 109.521 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -144.31 73.23 0.34 Allowed Glycine 0 N--CA 1.493 2.461 0 N-CA-C 109.471 -1.452 . . . . 0.0 109.471 -179.722 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 46.6 tttm -171.46 74.21 0.51 Allowed Pre-proline 0 N--CA 1.489 1.496 0 O-C-N 121.383 -1.069 . . . . 0.0 108.833 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_exo -50.06 128.75 23.08 Favored 'Trans proline' 0 C--N 1.305 -1.76 0 C-N-CA 122.646 2.231 . . . . 0.0 111.977 -179.4 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.525 ' O ' ' CG ' ' A' ' 60' ' ' HIS . 11.5 tp -112.24 118.38 35.14 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.531 -0.731 . . . . 0.0 109.186 -179.593 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . 0.533 ' O ' ' CE1' ' A' ' 80' ' ' PHE . 95.6 m-70 -158.52 140.73 14.07 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.128 -0.983 . . . . 0.0 109.904 -179.952 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 2.4 m-85 -102.17 12.26 37.01 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.254 -0.904 . . . . 0.0 108.851 179.211 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 83.7 mttt -86.73 156.64 19.86 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.383 -0.823 . . . . 0.0 109.619 -179.709 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 54.6 t0 55.8 46.78 21.65 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.401 -0.812 . . . . 0.0 109.454 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 99.4 p -116.85 155.3 29.25 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.411 -0.806 . . . . 0.0 109.301 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 28.6 t -113.16 147.43 37.4 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.362 -0.836 . . . . 0.0 109.323 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.7 m-30 -61.11 142.43 56.7 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.213 -0.929 . . . . 0.0 108.864 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 80.5 t60 -57.29 -50.72 72.03 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.127 -0.983 . . . . 0.0 109.934 -179.206 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.676 HH21 ' NE2' ' A' ' 76' ' ' GLN . 30.1 ptt180 -169.42 160.95 9.61 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.115 -0.99 . . . . 0.0 109.843 179.834 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -136.1 135.37 50.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 179.548 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 75.1 mt -136.61 128.25 16.92 Favored Pre-proline 0 N--CA 1.492 1.667 0 O-C-N 121.309 -0.87 . . . . 0.0 109.349 -179.699 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -75.41 136.74 19.97 Favored 'Trans proline' 0 C--N 1.312 -1.39 0 C-N-CA 122.091 1.86 . . . . 0.0 111.888 179.672 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 94.5 -5.23 70.34 Favored Glycine 0 N--CA 1.492 2.432 0 N-CA-C 109.821 -1.312 . . . . 0.0 109.821 179.705 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 77.6 m-85 -135.13 -94.96 0.27 Allowed 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.211 -1.17 . . . . 0.0 109.677 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' MET . . . . . 0.506 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 6.9 ptt? -170.81 -165.88 0.46 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.172 -0.955 . . . . 0.0 109.464 -179.653 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 15.4 p -132.7 151.61 51.93 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.423 -0.798 . . . . 0.0 109.054 179.741 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' GLN . . . . . 0.676 ' NE2' HH21 ' A' ' 68' ' ' ARG . 94.1 mt-30 -115.72 158.71 22.39 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.372 -0.83 . . . . 0.0 109.63 -179.703 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -140.28 -172.68 12.97 Favored Glycine 0 N--CA 1.494 2.516 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 -179.898 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 95.59 6.33 59.69 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.475 -1.45 . . . . 0.0 109.475 -179.771 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 56.0 t0 -57.44 -25.75 60.13 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.278 -1.131 . . . . 0.0 109.444 179.912 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.533 ' CE1' ' O ' ' A' ' 60' ' ' HIS . 91.3 t80 -49.19 -44.81 43.38 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.378 -0.826 . . . . 0.0 110.151 -179.483 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.658 ' CB ' ' H ' ' A' ' 88' ' ' GLY . 65.0 p -69.85 -29.52 66.78 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 120.989 -1.069 . . . . 0.0 109.487 179.874 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . 0.492 ' CB ' ' O ' ' A' ' 81' ' ' THR . . . 163.3 -55.53 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.344 -0.847 . . . . 0.0 109.244 179.724 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 91.02 1.46 72.84 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 179.884 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . 0.478 ' ND2' ' OG1' ' A' ' 86' ' ' THR . 39.9 p-10 -89.8 7.64 35.96 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.21 -1.171 . . . . 0.0 109.482 -179.931 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 95.8 -38.45 3.11 Favored Glycine 0 N--CA 1.492 2.389 0 N-CA-C 109.246 -1.541 . . . . 0.0 109.246 -179.793 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' THR . . . . . 0.478 ' OG1' ' ND2' ' A' ' 84' ' ' ASN . 56.7 p -73.16 -17.54 61.37 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.235 -1.156 . . . . 0.0 109.027 179.529 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -82.75 -164.82 36.02 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.589 -1.405 . . . . 0.0 109.589 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.658 ' H ' ' CB ' ' A' ' 81' ' ' THR . . . 81.94 47.76 6.07 Favored Glycine 0 N--CA 1.488 2.16 0 N-CA-C 109.264 -1.534 . . . . 0.0 109.264 -179.808 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -83.45 147.0 28.09 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.421 -1.046 . . . . 0.0 109.521 -179.722 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' SER . . . . . 0.432 ' OG ' ' OG ' ' A' ' 123' ' ' SER . 50.5 m -107.84 150.12 27.41 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.485 -0.759 . . . . 0.0 109.275 -179.937 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 5.1 pt -59.6 -40.69 82.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.196 -0.94 . . . . 0.0 109.898 -179.759 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 3.4 m-30 -63.71 -41.42 98.09 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.013 -1.054 . . . . 0.0 109.321 179.733 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 72.58 24.53 76.04 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.719 -1.352 . . . . 0.0 109.719 179.725 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -147.28 153.82 40.22 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.135 -1.214 . . . . 0.0 109.698 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 94.6 mttt -96.73 142.08 29.19 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.361 -0.837 . . . . 0.0 109.552 179.88 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . 0.533 ' CZ ' ' OD1' ' A' ' 121' ' ' ASN . 38.1 p90 -141.07 156.25 46.03 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.322 -0.861 . . . . 0.0 109.42 179.705 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -70.91 145.44 50.16 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.29 -0.881 . . . . 0.0 109.748 -179.699 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 87.8 m-20 -64.16 139.02 58.72 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.17 -0.957 . . . . 0.0 109.153 179.92 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . 0.482 ' O ' ' OD1' ' A' ' 100' ' ' ASN . 97.2 mt-10 -66.06 -41.13 91.21 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.178 -0.951 . . . . 0.0 110.56 -179.093 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . 0.482 ' OD1' ' O ' ' A' ' 99' ' ' GLU . 83.2 m-20 -149.96 149.16 29.99 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 120.948 -1.095 . . . . 0.0 110.466 -179.582 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -110.75 9.93 22.67 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.849 -0.797 . . . . 0.0 108.849 179.152 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 91.2 mt -54.97 -37.5 42.16 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.408 -0.807 . . . . 0.0 110.583 -179.069 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 57.0 mttm -76.52 134.46 39.46 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 120.899 -1.125 . . . . 0.0 109.63 -179.495 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 39.8 tttp -138.43 159.14 42.82 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.471 -0.768 . . . . 0.0 109.308 -179.735 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' HIS . . . . . 0.491 ' C ' ' ND1' ' A' ' 105' ' ' HIS . 6.8 t-80 -85.46 108.94 18.13 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.195 -0.941 . . . . 0.0 109.282 179.936 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 68.2 p -123.49 2.42 9.01 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.22 -0.925 . . . . 0.0 109.91 -179.888 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -155.05 175.06 33.19 Favored Glycine 0 N--CA 1.492 2.416 0 N-CA-C 109.818 -1.313 . . . . 0.0 109.818 -179.834 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -79.78 157.62 24.48 Favored 'Trans proline' 0 C--N 1.307 -1.617 0 C-N-CA 123.112 2.541 . . . . 0.0 112.142 179.714 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 78.11 45.17 10.5 Favored Glycine 0 N--CA 1.493 2.47 0 N-CA-C 109.678 -1.369 . . . . 0.0 109.678 179.604 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.72 137.33 50.92 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.378 -1.072 . . . . 0.0 109.754 -179.825 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . 0.541 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 2.8 mm? -91.11 129.76 37.07 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.283 -0.886 . . . . 0.0 109.097 179.439 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 29.1 t -142.43 143.6 32.71 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.188 -0.945 . . . . 0.0 109.486 179.954 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 72.2 mtm -89.33 133.31 34.54 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.161 -0.962 . . . . 0.0 109.334 179.839 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -64.98 142.35 58.47 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.18 -0.95 . . . . 0.0 109.311 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . 0.525 ' ND2' ' O ' ' A' ' 117' ' ' GLY . 53.2 t-20 -143.04 153.16 42.67 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.204 -0.935 . . . . 0.0 109.85 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . 0.471 ' N ' ' OD1' ' A' ' 115' ' ' ASN . . . -123.91 -12.31 7.54 Favored 'General case' 0 N--CA 1.493 1.688 0 N-CA-C 108.836 -0.802 . . . . 0.0 108.836 179.624 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . 0.525 ' O ' ' ND2' ' A' ' 115' ' ' ASN . . . -145.52 166.34 27.75 Favored Glycine 0 N--CA 1.493 2.472 0 N-CA-C 109.236 -1.545 . . . . 0.0 109.236 179.934 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -70.74 152.28 64.1 Favored 'Trans proline' 0 C--N 1.306 -1.696 0 C-N-CA 122.72 2.28 . . . . 0.0 112.108 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 76.2 m-20 52.98 41.62 32.14 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.473 -0.767 . . . . 0.0 109.502 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 120' ' ' THR . . . . . 0.52 ' O ' ' ND2' ' A' ' 115' ' ' ASN . 62.2 m -138.75 125.79 21.27 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.339 -0.851 . . . . 0.0 109.223 179.771 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 121' ' ' ASN . . . . . 0.533 ' OD1' ' CZ ' ' A' ' 96' ' ' PHE . 28.7 m120 -106.32 121.89 45.13 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.532 -0.73 . . . . 0.0 109.383 179.844 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -93.6 132.85 11.4 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.669 -1.372 . . . . 0.0 109.669 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 123' ' ' SER . . . . . 0.432 ' OG ' ' OG ' ' A' ' 90' ' ' SER . 18.8 m -58.83 -33.66 70.65 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.29 -1.123 . . . . 0.0 109.399 179.773 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.3 mt-30 -68.97 145.29 53.73 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.372 -0.83 . . . . 0.0 109.636 -179.793 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 48.8 p90 -135.66 162.54 32.45 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.408 -0.808 . . . . 0.0 109.133 179.83 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . 0.506 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 48.9 p90 -136.51 157.1 47.57 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.176 -0.953 . . . . 0.0 109.775 -179.927 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 68.3 mt -120.9 136.54 57.56 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.506 -0.746 . . . . 0.0 109.288 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 23.0 t -115.95 126.74 54.27 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.269 -0.894 . . . . 0.0 109.416 179.881 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 129' ' ' THR . . . . . 0.436 ' OG1' ' OE1' ' A' ' 156' ' ' GLU . 28.0 p -102.51 11.17 38.27 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.353 -0.842 . . . . 0.0 109.511 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -140.39 163.29 33.2 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.306 -0.871 . . . . 0.0 109.431 -179.775 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 71.9 mmtt -67.51 138.29 56.44 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.252 -0.905 . . . . 0.0 109.205 -179.946 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 61.6 p -150.18 85.29 1.4 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.295 -0.878 . . . . 0.0 109.534 -179.868 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -62.82 -36.09 82.05 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.278 -0.889 . . . . 0.0 109.85 -179.895 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 0.9 OUTLIER -64.76 -46.3 82.74 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.125 -0.984 . . . . 0.0 109.515 -179.892 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 18.1 mt -65.83 -32.4 73.9 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.232 -0.918 . . . . 0.0 109.611 179.266 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . 0.445 ' OD2' ' O ' ' A' ' 105' ' ' HIS . 60.9 t0 -79.71 119.65 22.93 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.308 -0.87 . . . . 0.0 109.71 -179.816 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 165.57 -100.54 0.17 Allowed Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 62.5 mttp -57.45 -36.16 71.05 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.294 -1.121 . . . . 0.0 109.825 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 78.0 m80 -65.04 150.22 48.48 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.338 -0.851 . . . . 0.0 109.705 -179.501 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 49.8 t -123.33 144.7 32.02 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 121.542 -0.724 . . . . 0.0 109.423 -179.739 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 61.7 t -92.45 130.58 41.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.293 -0.879 . . . . 0.0 109.857 -179.548 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 40.2 p90 -112.98 -3.11 14.1 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.445 -0.784 . . . . 0.0 109.328 179.624 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -168.19 177.35 42.37 Favored Glycine 0 N--CA 1.492 2.402 0 N-CA-C 109.169 -1.572 . . . . 0.0 109.169 179.796 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.2 pt20 -146.61 166.94 25.0 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.075 -1.25 . . . . 0.0 109.741 -179.744 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 75.0 t -96.45 129.7 46.14 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.283 0 O-C-N 121.266 -0.896 . . . . 0.0 109.389 -179.843 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 15.8 m -105.65 -33.92 2.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.339 -0.851 . . . . 0.0 109.723 179.756 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -142.45 169.17 18.08 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.274 -0.891 . . . . 0.0 109.689 -179.75 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 95.89 7.97 58.36 Favored Glycine 0 N--CA 1.493 2.47 0 N-CA-C 109.929 -1.269 . . . . 0.0 109.929 179.612 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 149' ' ' MET . . . . . 0.408 ' O ' HG13 ' A' ' 152' ' ' VAL . 64.9 mtt -60.34 -34.05 73.29 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.155 -1.203 . . . . 0.0 109.776 179.989 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 89.1 m-20 -65.03 -42.33 94.46 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 120.865 -1.147 . . . . 0.0 110.03 -179.553 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.6 p -82.44 -32.09 10.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.21 -0.932 . . . . 0.0 110.653 -179.263 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 152' ' ' VAL . . . . . 0.43 ' CG1' ' N ' ' A' ' 153' ' ' LYS . 0.8 OUTLIER -55.58 -40.67 60.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 120.833 -1.167 . . . . 0.0 109.008 -179.332 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 153' ' ' LYS . . . . . 0.43 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 67.0 mttm -62.92 -36.46 83.46 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.132 -0.98 . . . . 0.0 108.999 179.396 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -62.45 -35.08 78.16 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.305 -0.872 . . . . 0.0 109.414 179.825 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 93.6 mt -67.35 -12.79 15.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.513 -0.742 . . . . 0.0 109.808 179.9 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . 0.436 ' OE1' ' OG1' ' A' ' 129' ' ' THR . 86.2 tt0 -118.55 -19.48 8.76 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 -179.617 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 157' ' ' LYS . . . . . 0.403 ' N ' ' O ' ' A' ' 153' ' ' LYS . 38.9 tttm -58.83 -42.18 88.63 Favored 'General case' 0 C--N 1.299 -1.597 0 CA-C-O 121.376 0.608 . . . . 0.0 109.743 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 16.5 m -83.75 -12.56 11.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.533 -0.729 . . . . 0.0 109.25 179.449 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -59.97 151.98 37.0 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.941 -1.264 . . . . 0.0 109.941 -179.729 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 27.0 t -143.27 158.31 43.73 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.505 -0.997 . . . . 0.0 109.255 179.917 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 22.9 t -54.1 -33.85 58.73 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.151 -0.968 . . . . 0.0 109.307 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 24.5 m -57.75 -29.47 64.82 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.321 -0.862 . . . . 0.0 109.401 179.682 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 100.52 1.05 55.48 Favored Glycine 0 N--CA 1.493 2.45 0 N-CA-C 109.263 -1.535 . . . . 0.0 109.263 -179.656 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 72.2 ttt-85 -108.16 149.98 27.83 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.477 -1.013 . . . . 0.0 108.933 179.666 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 165' ' ' THR . . . . . . . . . . . . . 69.8 p -117.05 155.51 29.12 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.272 -0.892 . . . . 0.0 110.104 -179.582 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -70.14 -37.29 75.23 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.578 -0.702 . . . . 0.0 109.694 179.776 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 53.9 mttm -109.56 152.6 25.28 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.359 -0.838 . . . . 0.0 109.928 -179.392 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 63.7 mttm -87.95 151.33 22.88 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.404 -0.81 . . . . 0.0 109.43 179.911 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 34.5 m -125.7 127.61 71.59 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 121.247 -0.908 . . . . 0.0 109.744 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 43.4 t -146.63 145.91 19.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.245 -0.909 . . . . 0.0 109.196 179.722 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -88.15 120.95 37.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.111 -0.993 . . . . 0.0 109.479 -179.727 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -62.69 -28.59 70.04 Favored 'General case' 0 C--N 1.3 -1.586 0 N-CA-C 108.901 -0.777 . . . . 0.0 108.901 179.489 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 52.0 p30 -178.67 170.15 1.62 Allowed 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.383 -0.823 . . . . 0.0 110.202 -179.881 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 174' ' ' CYS . . . . . 0.611 ' SG ' ' CE2' ' A' ' 14' ' ' PHE . 54.1 t -139.43 134.98 33.12 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.529 -0.732 . . . . 0.0 109.062 179.356 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -150.67 169.25 30.52 Favored Glycine 0 N--CA 1.493 2.496 0 N-CA-C 109.738 -1.345 . . . . 0.0 109.738 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 176' ' ' GLN . . . . . 0.62 HE22 ' CZ ' ' A' ' 43' ' ' ARG . 63.9 tt0 -108.52 122.75 47.71 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.453 -1.028 . . . . 0.0 109.497 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -63.72 -38.59 91.67 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.23 -0.919 . . . . 0.0 108.908 179.714 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 27.0 t . . . . . 0 N--CA 1.49 1.526 0 O-C-N 121.027 -1.046 . . . . 0.0 109.455 179.872 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 . . . . . 0 N--CA 1.492 1.632 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -68.1 139.69 47.35 Favored 'Trans proline' 0 N--CA 1.497 1.706 0 C-N-CA 122.713 2.276 . . . . 0.0 112.464 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 82.3 mtp180 -132.28 134.47 45.31 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.419 -0.8 . . . . 0.0 108.869 179.071 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.8 p -135.29 143.49 36.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 O-C-N 121.256 -0.903 . . . . 0.0 109.539 -179.652 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 42.8 p90 -138.95 155.61 47.9 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.321 -0.862 . . . . 0.0 109.459 179.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.61 ' CE2' ' SG ' ' A' ' 174' ' ' CYS . 76.4 m-85 -122.13 137.87 54.67 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.451 -0.781 . . . . 0.0 109.697 179.883 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 22.8 t70 -88.04 117.02 26.63 Favored 'General case' 0 N--CA 1.493 1.719 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 179.123 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 83.3 mtp -104.63 143.87 32.48 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.342 -0.849 . . . . 0.0 110.713 -179.044 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.463 ' OG ' ' OE2' ' A' ' 172' ' ' GLU . 61.9 m -141.43 159.3 42.51 Favored 'General case' 0 N--CA 1.49 1.551 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 179.383 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 33.1 m -123.58 147.95 27.77 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.179 -0.95 . . . . 0.0 109.756 -179.759 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 49.09 -107.75 0.33 Allowed Glycine 0 N--CA 1.488 2.113 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.925 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -128.83 25.83 4.62 Favored Glycine 0 N--CA 1.494 2.53 0 N-CA-C 109.631 -1.387 . . . . 0.0 109.631 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 10.7 pt20 -141.58 149.5 54.15 Favored Pre-proline 0 N--CA 1.493 1.714 0 O-C-N 121.3 -1.118 . . . . 0.0 109.29 179.846 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -67.57 138.43 45.64 Favored 'Trans proline' 0 N--CA 1.494 1.544 0 C-N-CA 122.504 2.136 . . . . 0.0 112.108 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -101.72 -54.29 2.77 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.411 -0.806 . . . . 0.0 109.216 179.713 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -176.02 -171.25 39.67 Favored Glycine 0 N--CA 1.488 2.156 0 N-CA-C 109.317 -1.513 . . . . 0.0 109.317 -179.916 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 33.0 ptt180 -131.1 148.57 52.75 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.482 -1.011 . . . . 0.0 109.138 179.73 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 82.8 mt -122.91 130.11 74.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.318 -0.864 . . . . 0.0 109.248 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 42.0 t -111.0 132.63 58.97 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.491 -0.756 . . . . 0.0 109.222 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 74.1 mtm -120.88 146.93 46.08 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.439 -0.788 . . . . 0.0 109.18 -179.894 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -101.13 131.12 47.23 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.294 -0.879 . . . . 0.0 109.794 -179.718 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.418 ' N ' ' CD2' ' A' ' 30' ' ' LEU . 2.5 mm? -106.2 131.67 53.17 Favored 'General case' 0 N--CA 1.493 1.693 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 179.512 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 95.4 m-85 -98.4 118.29 34.74 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.215 -0.928 . . . . 0.0 109.024 179.572 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -80.68 -42.82 21.38 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.341 -0.85 . . . . 0.0 109.771 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -64.7 -45.89 84.67 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.293 -0.879 . . . . 0.0 110.311 -179.328 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 26.4 m -67.8 -45.13 75.67 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.121 -0.987 . . . . 0.0 109.835 -179.57 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.496 ' O ' ' OG1' ' A' ' 35' ' ' THR . 4.6 p -142.67 81.4 13.37 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 121.282 -0.886 . . . . 0.0 109.325 -179.75 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -64.27 -58.29 0.26 Allowed 'Trans proline' 0 N--CA 1.494 1.537 0 C-N-CA 122.283 1.989 . . . . 0.0 112.582 -179.347 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 78.4 mtp180 -62.03 -37.11 83.68 Favored 'General case' 0 C--N 1.299 -1.602 0 O-C-N 121.428 -0.795 . . . . 0.0 110.647 -179.132 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 28.1 m -61.91 -41.34 97.81 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.87 -1.144 . . . . 0.0 109.981 -179.542 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -61.3 -31.23 71.07 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.11 -0.994 . . . . 0.0 109.311 -179.739 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.406 ' O ' ' CB ' ' A' ' 44' ' ' ALA . 97.0 mt-10 -66.69 -35.34 79.91 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.351 -0.843 . . . . 0.0 109.885 -179.862 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 88.6 m-20 -55.98 -37.29 68.87 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.256 -0.903 . . . . 0.0 109.85 -179.688 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -97.67 -53.29 3.47 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.221 -0.925 . . . . 0.0 110.024 -179.852 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 59.7 ttp180 -57.94 -42.74 85.54 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.329 -0.857 . . . . 0.0 110.605 -179.179 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.508 ' O ' ' N ' ' A' ' 48' ' ' GLY . . . -67.73 -44.67 77.05 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.904 -1.123 . . . . 0.0 110.305 -179.181 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.5 ' N ' ' CD2' ' A' ' 45' ' ' LEU . 2.5 mm? -65.74 -40.51 92.19 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.004 -1.06 . . . . 0.0 109.7 -179.801 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' CYS . . . . . 0.405 ' SG ' ' SG ' ' A' ' 174' ' ' CYS . 72.0 m -67.63 -49.54 62.47 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.067 -1.02 . . . . 0.0 109.334 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 57.5 p -74.46 -32.0 62.43 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.397 -0.814 . . . . 0.0 109.38 179.755 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . 0.508 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 75.85 33.63 50.46 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 110.217 -1.153 . . . . 0.0 110.217 179.457 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -62.23 -37.66 86.22 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.99 -1.3 . . . . 0.0 109.423 179.78 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 54.6 mmtt -61.94 -34.12 75.52 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.275 -0.89 . . . . 0.0 109.349 179.934 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 92.53 172.48 41.27 Favored Glycine 0 N--CA 1.486 2.012 0 N-CA-C 109.239 -1.544 . . . . 0.0 109.239 -179.677 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 89.3 m -73.85 140.73 45.95 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.322 -1.105 . . . . 0.0 109.833 179.966 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -57.62 136.17 50.99 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.284 -1.527 . . . . 0.0 109.284 179.829 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 75.6 mtm180 -59.25 -34.11 71.85 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.243 -1.151 . . . . 0.0 110.017 -179.647 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 86.6 p -61.0 -24.82 66.44 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.102 -0.999 . . . . 0.0 109.942 -179.699 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 112.74 90.45 1.89 Allowed Glycine 0 N--CA 1.494 2.507 0 N-CA-C 109.109 -1.596 . . . . 0.0 109.109 -179.696 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . 0.583 ' HZ3' ' CB ' ' A' ' 57' ' ' LYS . 3.0 ttmp? -175.25 80.73 0.31 Allowed Pre-proline 0 N--CA 1.489 1.502 0 O-C-N 121.479 -1.012 . . . . 0.0 108.448 -179.708 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 69.7 Cg_exo -51.18 132.33 38.5 Favored 'Trans proline' 0 C--N 1.303 -1.847 0 C-N-CA 122.942 2.428 . . . . 0.0 112.848 -179.05 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.531 ' CD1' ' O ' ' A' ' 57' ' ' LYS . 7.6 mp -101.09 127.39 47.64 Favored 'General case' 0 N--CA 1.493 1.7 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 179.811 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 6.1 p80 -176.14 132.4 0.24 Allowed 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.094 -1.004 . . . . 0.0 109.86 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 4.4 m-85 -96.95 13.34 29.23 Favored 'General case' 0 N--CA 1.492 1.65 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 179.091 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 85.8 mttt -77.46 149.77 35.01 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.416 -0.802 . . . . 0.0 109.639 -179.765 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 46.4 t0 61.4 35.03 17.99 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.581 -0.699 . . . . 0.0 109.618 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.799 ' H ' ' CG2' ' A' ' 171' ' ' VAL . 55.3 p -83.94 160.08 21.15 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.278 -0.889 . . . . 0.0 108.808 179.094 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 31.3 t -128.58 147.96 50.75 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.168 -0.957 . . . . 0.0 109.57 -179.776 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 22.3 m-85 -72.25 130.12 40.06 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.258 -0.901 . . . . 0.0 109.296 179.86 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 79.4 t60 -61.79 -48.99 78.12 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.16 -0.962 . . . . 0.0 109.481 -179.88 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 37.1 ptt180 -164.71 159.74 19.08 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.27 -0.894 . . . . 0.0 109.678 179.671 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 23.0 m -132.51 148.46 31.8 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 179.539 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 11.5 mt -146.79 125.07 6.17 Favored Pre-proline 0 N--CA 1.494 1.735 0 O-C-N 120.956 -1.09 . . . . 0.0 109.576 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -75.34 135.36 18.37 Favored 'Trans proline' 0 N--CA 1.491 1.34 0 C-N-CA 122.264 1.976 . . . . 0.0 112.117 179.667 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 89.67 1.56 77.19 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.686 -1.365 . . . . 0.0 109.686 179.795 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 95.3 m-85 -134.25 -96.09 0.28 Allowed 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.359 -1.083 . . . . 0.0 109.558 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' MET . . . . . 0.6 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 5.9 ptt? -166.67 158.85 13.5 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.047 -1.033 . . . . 0.0 109.686 -179.659 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 1.7 m -98.45 123.35 42.54 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.417 -0.802 . . . . 0.0 109.008 179.402 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 63.6 tt0 -98.87 125.91 44.39 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.276 -0.89 . . . . 0.0 109.811 -179.584 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -84.85 -174.06 50.16 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 179.599 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -137.59 155.52 23.1 Favored Glycine 0 N--CA 1.494 2.513 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.435 ' OD2' ' OG ' ' A' ' 123' ' ' SER . 87.7 m-20 -77.02 150.5 35.8 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.226 -1.161 . . . . 0.0 109.502 179.93 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 40.8 p90 -64.85 -22.87 67.07 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.142 -0.974 . . . . 0.0 109.443 -179.856 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 58.9 p -67.11 -30.98 71.15 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.294 -0.879 . . . . 0.0 109.52 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 176.77 -56.44 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.314 -0.866 . . . . 0.0 109.328 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 96.12 -10.69 67.76 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 78.7 m-20 -89.15 3.22 52.61 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.177 -1.19 . . . . 0.0 109.323 179.813 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 95.19 -5.54 68.26 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.404 -1.479 . . . . 0.0 109.404 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 64.5 p -72.79 -21.98 60.9 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.245 -1.15 . . . . 0.0 109.41 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -125.32 -123.5 2.71 Favored Glycine 0 N--CA 1.494 2.53 0 N-CA-C 109.384 -1.486 . . . . 0.0 109.384 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 75.6 42.01 27.9 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 179.896 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -79.7 146.55 32.36 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.369 -1.077 . . . . 0.0 109.439 -179.883 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 50.8 m -108.86 148.61 30.35 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.384 -0.822 . . . . 0.0 109.265 -179.83 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 15.8 pt -62.6 -39.42 84.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.295 -0.878 . . . . 0.0 109.948 -179.62 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 73.6 m-85 -68.0 -37.26 81.24 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.112 -0.993 . . . . 0.0 109.578 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 78.14 14.66 82.03 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 -179.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -148.87 158.48 44.2 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.238 -1.154 . . . . 0.0 109.588 -179.825 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 42.7 mttm -85.3 149.51 25.41 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.238 -0.914 . . . . 0.0 109.596 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . 0.538 ' CE1' ' OD1' ' A' ' 121' ' ' ASN . 55.1 p90 -137.12 161.21 36.76 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.268 -0.895 . . . . 0.0 109.453 179.696 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -102.78 148.33 25.75 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.295 -0.878 . . . . 0.0 109.394 -179.785 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 89.3 m-20 -68.41 133.13 48.19 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.264 -0.897 . . . . 0.0 109.352 -179.897 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -66.26 -37.49 85.59 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.235 -0.916 . . . . 0.0 110.134 -179.731 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 86.9 m-20 -126.68 125.15 41.37 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.224 -0.922 . . . . 0.0 110.098 -179.477 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' PHE . . . . . 0.536 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 69.3 t80 -103.11 5.3 37.84 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.318 -0.864 . . . . 0.0 108.886 179.351 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 91.0 mt -57.19 -34.69 46.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.397 -0.814 . . . . 0.0 110.545 -179.187 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 91.7 mttt -72.55 135.08 45.52 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.808 -1.182 . . . . 0.0 109.951 -179.358 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 10.4 ptpp? -139.89 -179.05 5.72 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.435 -0.791 . . . . 0.0 109.382 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 105' ' ' HIS . . . . . 0.523 ' CE1' ' O ' ' A' ' 107' ' ' GLY . 82.3 t60 -84.33 77.6 9.96 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.149 -0.969 . . . . 0.0 109.165 179.872 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 54.6 p -75.5 -27.83 58.94 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.324 -0.86 . . . . 0.0 110.154 -179.581 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.523 ' O ' ' CE1' ' A' ' 105' ' ' HIS . . . -149.14 177.78 27.12 Favored Glycine 0 N--CA 1.494 2.517 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 -179.581 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -72.74 155.18 54.17 Favored 'Trans proline' 0 C--N 1.307 -1.65 0 C-N-CA 122.991 2.461 . . . . 0.0 112.314 179.792 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 82.6 47.0 6.15 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 110.138 -1.185 . . . . 0.0 110.138 179.588 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 41.8 mm -115.7 138.09 47.24 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.819 0 O-C-N 121.302 -1.116 . . . . 0.0 109.628 179.857 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . 0.418 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 3.7 mm? -89.15 126.72 35.59 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.267 -0.895 . . . . 0.0 109.216 179.627 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 112' ' ' SER . . . . . 0.435 ' OG ' ' O ' ' A' ' 140' ' ' VAL . 38.9 t -142.72 142.15 31.91 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.334 -0.854 . . . . 0.0 109.509 179.863 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER -91.55 141.27 28.9 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.319 -0.863 . . . . 0.0 109.174 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . 0.521 ' O ' ' N ' ' A' ' 122' ' ' GLY . . . -63.49 147.31 51.7 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.267 -0.896 . . . . 0.0 109.594 179.986 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . 0.42 ' OD1' ' O ' ' A' ' 114' ' ' ALA . 65.6 m-20 -137.23 112.72 9.35 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.332 -0.855 . . . . 0.0 109.002 179.612 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -72.23 -32.03 66.37 Favored 'General case' 0 C--N 1.294 -1.811 0 O-C-N 121.466 -0.771 . . . . 0.0 109.432 179.807 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -148.49 176.08 27.46 Favored Glycine 0 N--CA 1.492 2.393 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 179.848 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . 0.43 ' O ' ' CG ' ' A' ' 119' ' ' ASN . 71.6 Cg_exo -50.31 148.03 15.17 Favored 'Trans proline' 0 C--N 1.304 -1.786 0 C-N-CA 122.604 2.203 . . . . 0.0 112.903 179.855 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 119' ' ' ASN . . . . . 0.43 ' CG ' ' O ' ' A' ' 118' ' ' PRO . 7.0 p-10 41.83 49.04 3.9 Favored 'General case' 0 N--CA 1.494 1.751 0 CA-C-O 121.135 0.493 . . . . 0.0 110.11 179.451 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 87.9 m -131.38 124.9 31.31 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.308 -0.87 . . . . 0.0 109.004 179.55 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 121' ' ' ASN . . . . . 0.538 ' OD1' ' CE1' ' A' ' 96' ' ' PHE . 25.4 m120 -101.93 119.1 38.25 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.535 -0.728 . . . . 0.0 109.237 179.768 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . 0.521 ' N ' ' O ' ' A' ' 114' ' ' ALA . . . -84.41 142.2 20.21 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.719 -1.352 . . . . 0.0 109.719 -179.751 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 123' ' ' SER . . . . . 0.435 ' OG ' ' OD2' ' A' ' 79' ' ' ASP . 88.1 p -64.26 -22.83 67.09 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.367 -1.078 . . . . 0.0 109.337 179.739 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 92.9 mt-30 -95.12 151.61 19.06 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.296 -0.878 . . . . 0.0 109.511 -179.873 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 49.3 p90 -134.79 161.57 34.83 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.364 -0.835 . . . . 0.0 109.428 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . 0.6 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 54.1 p90 -138.94 158.88 43.41 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.33 -0.856 . . . . 0.0 109.547 -179.955 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 72.6 mt -121.31 130.75 74.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.435 -0.791 . . . . 0.0 109.486 179.758 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 1.6 m -93.25 105.74 17.78 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.273 -0.892 . . . . 0.0 108.89 179.663 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 60.0 p -75.49 -7.05 53.14 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.379 -0.826 . . . . 0.0 109.711 -179.713 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -149.21 156.28 41.9 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.158 -0.964 . . . . 0.0 109.741 -179.769 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 55.7 tttp -69.38 141.27 54.18 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.212 -0.93 . . . . 0.0 109.236 179.808 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 20.7 p -114.66 153.95 29.28 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.397 -0.814 . . . . 0.0 109.604 -179.858 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . 0.423 ' O ' ' CG ' ' A' ' 136' ' ' ASP . 92.6 mt-10 -106.23 -73.49 0.68 Allowed 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.385 -0.822 . . . . 0.0 109.925 -179.925 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 134' ' ' TRP . . . . . 0.524 ' CD1' ' N ' ' A' ' 135' ' ' LEU . 42.8 p90 -56.03 -36.74 68.32 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.265 -0.897 . . . . 0.0 110.109 -179.535 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . 0.524 ' N ' ' CD1' ' A' ' 134' ' ' TRP . 6.9 tp -74.6 4.04 6.79 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.251 -0.906 . . . . 0.0 109.559 -179.327 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . 0.452 ' C ' ' OD1' ' A' ' 136' ' ' ASP . 53.5 p30 -67.36 167.29 12.77 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.99 -1.069 . . . . 0.0 109.569 -179.941 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 148.96 -134.0 4.77 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.17 -1.572 . . . . 0.0 109.17 -179.909 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 13.7 mptt -91.76 128.84 37.75 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.208 -1.172 . . . . 0.0 109.018 179.647 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 139' ' ' HIS . . . . . 0.459 ' O ' ' CE1' ' A' ' 101' ' ' PHE . 98.4 m-70 -135.72 152.61 51.32 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.287 -0.883 . . . . 0.0 109.647 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.435 ' O ' ' OG ' ' A' ' 112' ' ' SER . 24.5 m -127.73 149.82 33.02 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 121.351 -0.843 . . . . 0.0 109.022 179.573 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 46.1 t -132.08 125.81 55.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.272 -0.892 . . . . 0.0 109.763 -180.0 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 47.1 p90 -109.64 3.01 20.61 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.446 -0.784 . . . . 0.0 108.932 178.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -178.11 178.6 48.55 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.024 -1.63 . . . . 0.0 109.024 179.562 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.3 pt20 -145.95 166.68 25.3 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.09 -1.241 . . . . 0.0 109.614 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 69.7 t -97.04 128.37 48.33 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.245 0 O-C-N 121.21 -0.931 . . . . 0.0 109.4 -179.719 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 15.9 m -103.83 -32.01 2.91 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 O-C-N 121.421 -0.799 . . . . 0.0 109.395 179.588 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -143.45 170.07 16.49 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.329 -0.857 . . . . 0.0 109.407 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 96.55 5.13 59.08 Favored Glycine 0 N--CA 1.493 2.475 0 N-CA-C 109.909 -1.276 . . . . 0.0 109.909 179.61 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 149' ' ' MET . . . . . 0.419 ' O ' HG12 ' A' ' 152' ' ' VAL . 97.0 mmm -60.18 -32.22 70.86 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.144 -1.209 . . . . 0.0 109.458 179.778 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -65.36 -41.71 93.52 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.899 -1.125 . . . . 0.0 110.106 -179.548 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 6.7 p -80.96 -33.26 13.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 120.987 -1.07 . . . . 0.0 110.707 -179.279 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 152' ' ' VAL . . . . . 0.439 ' CG1' ' N ' ' A' ' 153' ' ' LYS . 1.0 OUTLIER -51.92 -41.08 29.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 120.84 -1.162 . . . . 0.0 108.998 -179.264 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 153' ' ' LYS . . . . . 0.439 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 66.8 mttm -65.68 -33.38 75.75 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.214 -0.929 . . . . 0.0 109.214 179.213 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -60.63 -37.23 80.79 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.489 -0.757 . . . . 0.0 109.942 -179.42 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 88.4 mt -70.52 -37.63 70.75 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.524 0 O-C-N 121.156 -0.965 . . . . 0.0 110.066 -179.687 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -77.06 -41.16 43.53 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.196 -0.94 . . . . 0.0 111.556 -178.39 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 157' ' ' LYS . . . . . 0.425 ' HG2' ' HZ2' ' A' ' 157' ' ' LYS . 16.7 pttm -59.91 -35.4 74.8 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 120.57 -1.331 . . . . 0.0 109.735 -178.763 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 31.5 m -81.1 -10.39 12.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.041 -1.037 . . . . 0.0 109.017 179.395 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -71.95 165.61 53.84 Favored Glycine 0 N--CA 1.488 2.16 0 N-CA-C 110.056 -1.217 . . . . 0.0 110.056 -179.623 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 24.1 t -154.52 167.87 28.63 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.506 -0.996 . . . . 0.0 109.482 -179.858 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 24.8 m -54.46 -29.89 51.17 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.292 -0.88 . . . . 0.0 109.194 179.827 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 22.8 t -54.26 -30.79 51.8 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.307 -0.871 . . . . 0.0 109.506 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 95.41 12.22 54.5 Favored Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.817 -1.313 . . . . 0.0 109.817 179.916 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 42.1 ttp180 -125.78 143.67 50.96 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.298 -1.119 . . . . 0.0 109.467 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 165' ' ' THR . . . . . . . . . . . . . 71.5 p -74.63 151.28 39.35 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.094 -1.004 . . . . 0.0 109.326 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -66.31 -37.93 86.53 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.154 -0.967 . . . . 0.0 109.52 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 67.1 mttm -108.94 156.96 19.1 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.432 -0.792 . . . . 0.0 109.4 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 48.1 mtmt -72.53 130.61 41.04 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.205 -0.934 . . . . 0.0 109.268 179.816 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 25.0 t -124.75 124.14 67.35 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 O-C-N 121.434 -0.791 . . . . 0.0 109.427 -179.888 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 57.5 t -144.33 137.05 22.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.271 -0.893 . . . . 0.0 109.499 179.668 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . 0.799 ' CG2' ' H ' ' A' ' 64' ' ' SER . 27.0 m -71.31 126.32 31.44 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.251 -0.905 . . . . 0.0 109.487 179.746 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 172' ' ' GLU . . . . . 0.49 ' O ' ' OD1' ' A' ' 173' ' ' ASP . 96.3 mt-10 -69.84 -40.72 75.65 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.077 -1.014 . . . . 0.0 109.901 179.855 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 173' ' ' ASP . . . . . 0.49 ' OD1' ' O ' ' A' ' 172' ' ' GLU . 49.7 m-20 -163.91 167.67 20.36 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.219 -0.925 . . . . 0.0 110.218 -179.641 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 174' ' ' CYS . . . . . 0.61 ' SG ' ' CE2' ' A' ' 14' ' ' PHE . 43.7 t -136.51 140.82 43.29 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.581 -0.7 . . . . 0.0 109.306 179.597 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -154.94 173.34 33.29 Favored Glycine 0 N--CA 1.493 2.491 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 179.907 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 63.8 tt0 -104.48 119.25 38.56 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.343 -1.092 . . . . 0.0 109.526 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 34.5 tp -61.83 -38.24 87.45 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.203 -0.936 . . . . 0.0 109.575 179.897 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 8.7 t . . . . . 0 N--CA 1.488 1.454 0 O-C-N 121.094 -1.004 . . . . 0.0 109.454 -179.964 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 16.4 m120 . . . . . 0 N--CA 1.49 1.562 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -70.21 141.68 44.03 Favored 'Trans proline' 0 N--CA 1.496 1.634 0 C-N-CA 122.769 2.313 . . . . 0.0 112.244 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 59.2 mtm180 -127.89 134.52 49.38 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.376 -0.827 . . . . 0.0 108.902 179.294 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 9.6 p -136.21 144.36 33.31 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.389 -0.819 . . . . 0.0 109.309 -179.701 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 48.3 p90 -138.1 153.89 49.26 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.342 -0.849 . . . . 0.0 109.477 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 88.7 m-85 -121.28 136.36 54.98 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.568 -0.707 . . . . 0.0 109.735 179.755 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -93.62 131.4 38.94 Favored 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 179.228 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' MET . . . . . 0.424 ' SD ' ' CD1' ' A' ' 26' ' ' ILE . 74.2 mtp -125.45 153.24 43.79 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.118 -0.989 . . . . 0.0 110.282 -179.386 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 85.2 p -143.78 161.05 39.62 Favored 'General case' 0 N--CA 1.488 1.463 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 179.718 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.431 ' C ' ' H ' ' A' ' 20' ' ' GLY . 33.0 m -126.32 137.49 57.62 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.105 -0.997 . . . . 0.0 109.534 -179.925 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 53.43 11.62 1.84 Allowed Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 179.848 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.431 ' H ' ' C ' ' A' ' 18' ' ' VAL . . . 95.6 -1.39 63.89 Favored Glycine 0 N--CA 1.493 2.465 0 N-CA-C 109.779 -1.328 . . . . 0.0 109.779 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 2.6 mp0 -99.93 152.09 37.7 Favored Pre-proline 0 N--CA 1.495 1.806 0 O-C-N 121.229 -1.159 . . . . 0.0 109.149 179.876 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -61.66 138.52 75.58 Favored 'Trans proline' 0 C--N 1.308 -1.558 0 C-N-CA 122.581 2.187 . . . . 0.0 112.15 -179.83 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -111.69 -64.18 1.32 Allowed 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.441 -0.787 . . . . 0.0 109.471 179.893 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -179.9 -168.75 39.12 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.414 -1.475 . . . . 0.0 109.414 -179.882 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 79.7 mtm180 -114.37 142.18 46.67 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.381 -1.07 . . . . 0.0 109.759 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . 0.424 ' CD1' ' SD ' ' A' ' 16' ' ' MET . 80.2 mt -122.93 121.1 62.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 179.11 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 40.2 t -120.85 134.6 63.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.469 -0.769 . . . . 0.0 109.27 -179.808 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 72.6 mtm -122.44 154.81 37.28 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.405 -0.809 . . . . 0.0 109.349 -179.845 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -100.85 132.0 46.47 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.347 -0.845 . . . . 0.0 109.968 -179.611 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -107.48 128.93 54.93 Favored 'General case' 0 N--CA 1.493 1.717 0 N-CA-C 108.914 -0.772 . . . . 0.0 108.914 179.318 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -98.04 119.66 37.08 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.189 -0.944 . . . . 0.0 109.058 179.661 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -78.84 -40.16 33.47 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.318 -0.864 . . . . 0.0 110.047 -179.623 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.531 ' OD1' ' N ' ' A' ' 34' ' ' THR . 31.6 p-10 -68.72 -40.79 79.75 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.258 -0.902 . . . . 0.0 110.859 -179.093 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' THR . . . . . 0.531 ' N ' ' OD1' ' A' ' 33' ' ' ASP . 17.4 m -67.51 -44.56 78.15 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.018 -1.051 . . . . 0.0 109.834 -179.4 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 38.2 p -154.03 83.99 4.16 Favored Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.385 -0.822 . . . . 0.0 109.018 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -70.53 -40.84 3.75 Favored 'Trans proline' 0 C--N 1.309 -1.544 0 C-N-CA 122.085 1.856 . . . . 0.0 112.333 -179.212 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 1.5 mpt_? -63.71 -40.95 98.04 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.168 -0.958 . . . . 0.0 109.667 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 38.3 m -66.16 -41.52 90.24 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.19 -0.944 . . . . 0.0 110.004 -179.755 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -60.66 -32.39 71.58 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.174 -0.953 . . . . 0.0 109.032 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -68.05 -38.23 82.24 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.433 -0.792 . . . . 0.0 109.735 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 46.4 t30 -58.23 -41.41 84.07 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.248 -0.908 . . . . 0.0 109.935 -179.436 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . 0.494 ' O ' ' SG ' ' A' ' 46' ' ' CYS . 97.4 m-85 -86.15 -41.08 15.02 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.047 -1.033 . . . . 0.0 110.108 -179.664 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 61.3 ttp180 -59.14 -44.42 92.05 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.229 -0.919 . . . . 0.0 110.937 -178.925 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -71.17 -46.09 62.11 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 120.945 -1.097 . . . . 0.0 110.259 -179.271 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.498 ' N ' ' CD2' ' A' ' 45' ' ' LEU . 2.3 mm? -65.3 -38.13 89.26 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.164 -0.96 . . . . 0.0 109.69 -179.711 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' CYS . . . . . 0.494 ' SG ' ' O ' ' A' ' 42' ' ' PHE . 73.8 m -71.12 -50.5 32.82 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.098 -1.001 . . . . 0.0 109.576 -179.895 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 30.9 m -63.92 -36.72 84.89 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.329 -0.857 . . . . 0.0 109.589 -179.933 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 95.59 8.24 58.52 Favored Glycine 0 N--CA 1.493 2.46 0 N-CA-C 109.838 -1.305 . . . . 0.0 109.838 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 78.1 mm-40 -61.25 -32.24 72.04 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.238 -1.154 . . . . 0.0 109.526 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 20.9 tptp -58.25 -38.97 77.94 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.255 -0.903 . . . . 0.0 109.482 -179.11 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 90.65 171.45 43.75 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 110.018 -1.233 . . . . 0.0 110.018 179.558 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.555 ' O ' ' O ' ' A' ' 53' ' ' GLY . 81.7 m -79.08 148.44 32.42 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.585 -0.95 . . . . 0.0 109.479 179.925 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.555 ' O ' ' O ' ' A' ' 52' ' ' THR . . . -54.93 -122.36 0.01 OUTLIER Glycine 0 N--CA 1.492 2.389 0 N-CA-C 110.036 -1.226 . . . . 0.0 110.036 -179.839 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . 0.537 ' O ' ' CB ' ' A' ' 55' ' ' SER . 93.0 mtt180 -57.5 -41.15 80.2 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 120.971 -1.311 . . . . 0.0 109.766 -179.498 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' SER . . . . . 0.537 ' CB ' ' O ' ' A' ' 54' ' ' ARG . 1.1 t 157.72 -26.86 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.724 0 N-CA-C 108.574 -0.898 . . . . 0.0 108.574 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -119.06 59.94 0.51 Allowed Glycine 0 N--CA 1.493 2.442 0 N-CA-C 109.169 -1.572 . . . . 0.0 109.169 179.926 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 36.4 tptt -172.05 70.97 0.45 Allowed Pre-proline 0 C--N 1.302 -1.474 0 O-C-N 121.447 -1.031 . . . . 0.0 108.56 -179.768 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 92.1 Cg_exo -42.9 94.8 0.02 OUTLIER 'Trans proline' 0 C--N 1.304 -1.766 0 C-N-CA 122.743 2.295 . . . . 0.0 112.202 -179.405 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.484 ' O ' ' CD1' ' A' ' 45' ' ' LEU . 8.2 tp -73.65 54.61 0.48 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.581 -0.699 . . . . 0.0 109.276 -179.731 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 40.5 m80 -138.39 150.63 46.72 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.252 -0.905 . . . . 0.0 109.603 -179.753 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 -67.28 -9.1 37.4 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.233 -0.917 . . . . 0.0 109.26 179.369 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 64.0 tttt -49.18 151.3 1.41 Allowed 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.319 -0.863 . . . . 0.0 109.841 -179.881 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 59.67 47.76 10.18 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.616 -0.677 . . . . 0.0 110.03 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 62.2 p -115.78 151.06 35.91 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.353 -0.842 . . . . 0.0 109.01 179.202 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 29.4 t -126.46 148.61 49.64 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.346 -0.846 . . . . 0.0 109.594 -179.694 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.8 m-85 -70.99 135.34 47.79 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.252 -0.905 . . . . 0.0 109.084 179.958 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' HIS . . . . . 0.501 ' HE2' ' CG ' ' A' ' 79' ' ' ASP . 95.8 m-70 -97.02 -29.99 13.33 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.243 -0.911 . . . . 0.0 110.425 -179.58 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 98.6 mtt180 -134.35 139.95 46.0 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.092 -1.005 . . . . 0.0 110.254 -179.457 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 14.5 m -148.4 42.35 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.497 -0.752 . . . . 0.0 108.973 179.401 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 25.7 mt -76.94 132.84 70.38 Favored Pre-proline 0 C--N 1.301 -1.53 0 O-C-N 121.227 -0.921 . . . . 0.0 109.692 -178.926 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -69.93 145.6 56.66 Favored 'Trans proline' 0 N--CA 1.491 1.363 0 C-N-CA 122.213 1.942 . . . . 0.0 112.154 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 84.63 -54.44 4.92 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.636 -1.386 . . . . 0.0 109.636 179.905 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 83.7 m-85 -69.67 -80.6 0.05 OUTLIER 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.201 -1.176 . . . . 0.0 109.763 -179.905 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 12.9 ptt? 179.37 -179.04 0.38 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.092 -1.005 . . . . 0.0 109.741 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' CYS . . . . . 0.455 ' SG ' ' O ' ' A' ' 127' ' ' ILE . 0.8 OUTLIER -131.8 126.79 35.24 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.499 -0.751 . . . . 0.0 109.068 179.689 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 49.5 tt0 -98.14 137.57 36.71 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.342 -0.849 . . . . 0.0 109.331 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -151.94 -177.72 25.94 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.726 -1.35 . . . . 0.0 109.726 -179.887 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 78.6 56.92 3.46 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.639 -1.384 . . . . 0.0 109.639 -179.925 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.501 ' CG ' ' HE2' ' A' ' 67' ' ' HIS . 59.2 t0 -69.46 90.63 0.54 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.147 -1.208 . . . . 0.0 108.983 -179.96 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 68.3 t80 -61.19 -49.4 77.33 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.371 -0.83 . . . . 0.0 109.803 -179.623 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.533 ' HG1' ' H ' ' A' ' 82' ' ' ALA . 6.6 p -153.2 -98.78 0.05 OUTLIER 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.164 -0.96 . . . . 0.0 109.418 179.828 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . 0.533 ' H ' ' HG1' ' A' ' 81' ' ' THR . . . -86.37 -64.08 1.21 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.326 -0.859 . . . . 0.0 109.664 -179.899 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 98.48 -15.11 61.54 Favored Glycine 0 N--CA 1.493 2.438 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 -179.857 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 86.5 m-20 -63.5 -31.82 73.1 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.27 -1.135 . . . . 0.0 108.858 179.477 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 152.61 -33.3 0.83 Allowed Glycine 0 N--CA 1.489 2.216 0 N-CA-C 108.7 -1.76 . . . . 0.0 108.7 -179.691 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 55.0 p -78.1 -28.75 48.73 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.393 -1.063 . . . . 0.0 109.102 179.532 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -88.18 -171.07 46.33 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 179.854 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.449 ' CA ' ' OG ' ' A' ' 123' ' ' SER . . . 78.77 46.3 8.67 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 179.905 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -88.73 141.1 28.79 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.205 -1.173 . . . . 0.0 109.451 -179.82 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 92.9 p -107.13 159.32 16.41 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.471 -0.768 . . . . 0.0 109.395 -179.931 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 19.5 pt -59.55 -32.11 48.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.268 -0.895 . . . . 0.0 109.51 -179.805 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 76.5 m-85 -66.33 -24.08 66.47 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.165 -0.959 . . . . 0.0 109.436 179.903 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 76.05 -97.79 1.17 Allowed Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.089 -1.604 . . . . 0.0 109.089 -179.614 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -59.74 147.85 36.37 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.319 -1.106 . . . . 0.0 109.019 179.643 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 9.2 mtmp? -72.27 156.33 39.24 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.417 -0.802 . . . . 0.0 109.418 -179.744 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 36.2 p90 -128.6 160.7 31.57 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.437 -0.789 . . . . 0.0 109.484 -179.818 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -61.52 142.59 56.96 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.292 -0.88 . . . . 0.0 110.123 -179.23 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 88.5 m-20 -70.24 151.42 45.36 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.226 -0.921 . . . . 0.0 109.615 179.772 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -94.93 164.73 12.78 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.324 -0.86 . . . . 0.0 109.185 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 81.5 m-20 -58.26 153.23 15.65 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.226 -0.922 . . . . 0.0 109.444 -179.765 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' PHE . . . . . 0.584 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 21.9 p90 -132.43 80.79 1.92 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.293 -0.879 . . . . 0.0 109.451 -179.853 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 87.4 mt -59.47 -34.38 54.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.248 -0.908 . . . . 0.0 109.378 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 63.3 mttp -85.77 145.21 27.34 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.232 -0.917 . . . . 0.0 109.385 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 104' ' ' LYS . . . . . 0.482 ' O ' ' N ' ' A' ' 106' ' ' THR . 19.8 pttm -134.66 -178.91 5.28 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.374 -0.829 . . . . 0.0 109.501 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 105' ' ' HIS . . . . . 0.445 ' HE2' ' CB ' ' A' ' 139' ' ' HIS . 96.5 m-70 -65.02 72.45 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.25 -0.906 . . . . 0.0 109.667 -179.971 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 106' ' ' THR . . . . . 0.545 ' O ' ' NZ ' ' A' ' 131' ' ' LYS . 68.7 p -70.82 -27.45 63.89 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.141 -0.974 . . . . 0.0 109.682 179.946 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -152.97 176.56 31.04 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 109.342 -1.503 . . . . 0.0 109.342 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -72.64 153.97 54.49 Favored 'Trans proline' 0 C--N 1.307 -1.638 0 C-N-CA 122.889 2.393 . . . . 0.0 112.095 179.821 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 82.28 49.27 5.31 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 179.632 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 39.1 mm -115.2 138.4 45.63 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 121.333 -1.098 . . . . 0.0 109.498 179.938 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . 0.508 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 2.9 mm? -89.57 126.93 35.8 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.297 -0.877 . . . . 0.0 109.595 179.84 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 112' ' ' SER . . . . . 0.441 ' OG ' ' O ' ' A' ' 140' ' ' VAL . 37.4 t -143.61 139.0 29.42 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.365 -0.835 . . . . 0.0 109.098 179.624 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 88.5 mtp -81.13 137.13 35.96 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.117 -0.989 . . . . 0.0 109.499 -179.821 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . 0.459 ' O ' ' OD1' ' A' ' 115' ' ' ASN . . . -64.14 142.44 58.41 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.281 -0.887 . . . . 0.0 109.604 -179.865 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . 0.459 ' OD1' ' O ' ' A' ' 114' ' ' ALA . 73.6 m-20 -146.84 114.0 6.22 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.313 -0.867 . . . . 0.0 108.854 179.569 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -68.2 -35.6 78.25 Favored 'General case' 0 C--N 1.298 -1.641 0 O-C-N 121.312 -0.867 . . . . 0.0 109.559 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -150.89 165.59 30.22 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.263 -1.535 . . . . 0.0 109.263 179.823 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_exo -47.14 153.13 1.72 Allowed 'Trans proline' 0 C--N 1.308 -1.585 0 C-N-CA 122.611 2.207 . . . . 0.0 112.826 179.831 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 18.9 m120 54.89 46.46 24.37 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.73 -0.606 . . . . 0.0 109.635 179.695 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 120' ' ' THR . . . . . 0.43 ' O ' ' OD1' ' A' ' 115' ' ' ASN . 58.5 m -135.39 124.45 24.32 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.316 -0.865 . . . . 0.0 109.099 179.857 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 23.1 t-20 -104.38 107.94 19.11 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.511 -0.743 . . . . 0.0 109.123 179.646 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -87.84 128.39 9.01 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.772 -1.331 . . . . 0.0 109.772 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 123' ' ' SER . . . . . 0.449 ' OG ' ' CA ' ' A' ' 88' ' ' GLY . 87.3 p -64.32 -23.43 67.29 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.366 -1.079 . . . . 0.0 109.343 179.719 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.4 mt-30 -92.65 153.25 19.09 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.302 -0.874 . . . . 0.0 109.562 -179.869 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 54.4 p90 -134.3 161.62 34.45 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.368 -0.832 . . . . 0.0 109.185 179.881 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 49.0 p90 -134.45 156.41 48.62 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.335 -0.853 . . . . 0.0 109.649 -179.854 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.455 ' O ' ' SG ' ' A' ' 75' ' ' CYS . 77.1 mt -122.2 134.11 66.46 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.453 -0.779 . . . . 0.0 109.556 179.928 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 128' ' ' CYS . . . . . 0.515 ' SG ' ' O ' ' A' ' 130' ' ' ALA . 3.9 t -97.92 112.92 24.66 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.177 -0.952 . . . . 0.0 109.087 179.346 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 41.3 p -80.36 -5.1 55.85 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.308 -0.87 . . . . 0.0 109.856 -179.469 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . 0.515 ' O ' ' SG ' ' A' ' 128' ' ' CYS . . . -147.5 161.64 40.67 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.19 -0.944 . . . . 0.0 109.669 -179.626 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . 0.545 ' NZ ' ' O ' ' A' ' 106' ' ' THR . 63.6 mttm -76.56 140.8 41.23 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.194 -0.941 . . . . 0.0 109.299 179.898 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 6.3 p -125.11 158.93 32.64 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.437 -0.789 . . . . 0.0 109.258 -179.918 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -101.98 -74.92 0.61 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.204 -0.935 . . . . 0.0 109.956 -179.81 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 134' ' ' TRP . . . . . 0.581 ' CD1' ' N ' ' A' ' 135' ' ' LEU . 41.7 p90 -61.13 -46.93 88.57 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.21 -0.931 . . . . 0.0 109.999 -179.452 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . 0.581 ' N ' ' CD1' ' A' ' 134' ' ' TRP . 32.9 tp -61.63 -33.83 74.61 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.252 -0.905 . . . . 0.0 109.446 -179.819 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 23.5 t70 -76.5 119.03 19.78 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.258 -0.901 . . . . 0.0 109.645 -179.812 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -153.18 -129.87 1.44 Allowed Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.075 -1.61 . . . . 0.0 109.075 179.879 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 47.3 mmtm -86.99 114.43 23.59 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.212 -1.17 . . . . 0.0 108.966 179.659 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 139' ' ' HIS . . . . . 0.445 ' CB ' ' HE2' ' A' ' 105' ' ' HIS . 98.0 m-70 -138.25 165.69 26.07 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.427 -0.795 . . . . 0.0 109.474 -179.858 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.441 ' O ' ' OG ' ' A' ' 112' ' ' SER . 48.1 t -113.58 132.6 62.04 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 121.356 -0.84 . . . . 0.0 109.274 179.845 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 61.4 t -112.69 129.07 68.95 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 121.272 -0.893 . . . . 0.0 109.308 179.826 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 40.0 p90 -115.76 2.2 13.6 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.334 -0.854 . . . . 0.0 109.725 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -176.26 179.69 47.2 Favored Glycine 0 N--CA 1.493 2.447 0 N-CA-C 109.771 -1.332 . . . . 0.0 109.771 179.64 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 2.6 pt20 -145.21 167.83 21.85 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.309 -1.112 . . . . 0.0 109.449 -179.89 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 55.4 t -96.34 130.16 45.39 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 O-C-N 121.157 -0.964 . . . . 0.0 109.576 -179.866 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 15.6 m -109.29 -33.25 2.43 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 121.323 -0.861 . . . . 0.0 109.409 179.558 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -142.14 171.1 14.52 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.324 -0.86 . . . . 0.0 109.483 179.914 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 98.71 1.96 57.46 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 109.858 -1.297 . . . . 0.0 109.858 179.674 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 149' ' ' MET . . . . . . . . . . . . . 72.0 mtm -61.09 -33.76 73.85 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.049 -1.265 . . . . 0.0 109.539 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 56.2 t0 -63.85 -42.6 97.54 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 120.945 -1.097 . . . . 0.0 109.993 -179.713 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.4 p -82.98 -34.49 11.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.152 -0.968 . . . . 0.0 110.547 -179.532 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 152' ' ' VAL . . . . . 0.459 ' CG1' ' N ' ' A' ' 153' ' ' LYS . 0.6 OUTLIER -56.83 -41.93 76.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 120.896 -1.127 . . . . 0.0 109.289 -179.301 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 153' ' ' LYS . . . . . 0.459 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 46.6 mtpt -63.02 -34.28 77.23 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.186 -0.946 . . . . 0.0 109.424 179.459 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -62.13 -39.47 92.66 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.345 -0.847 . . . . 0.0 109.935 -179.559 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 89.2 mt -72.5 -34.86 49.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.162 -0.962 . . . . 0.0 110.042 -179.824 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -76.71 -41.44 45.24 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.153 -0.967 . . . . 0.0 111.182 -178.881 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 16.9 pttp -62.31 -33.59 74.97 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 120.824 -1.173 . . . . 0.0 109.931 -178.846 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 35.1 m -78.3 -10.41 12.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.023 -1.048 . . . . 0.0 109.262 179.662 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -75.52 174.46 52.36 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.743 -1.343 . . . . 0.0 109.743 -179.772 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 22.6 t -161.7 174.54 13.11 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.328 -1.101 . . . . 0.0 109.448 -179.802 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 23.6 m -54.83 -32.03 60.04 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.205 -0.934 . . . . 0.0 109.233 179.813 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 23.5 m -55.72 -33.18 64.0 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.263 -0.898 . . . . 0.0 109.577 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 94.61 10.09 58.23 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.726 -1.35 . . . . 0.0 109.726 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 16.3 tpt180 -116.98 142.69 46.63 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.426 -1.043 . . . . 0.0 109.058 179.833 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 165' ' ' THR . . . . . . . . . . . . . 68.0 p -80.21 151.52 29.63 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.229 -0.92 . . . . 0.0 109.579 -179.808 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -68.39 -35.69 78.05 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.337 -0.852 . . . . 0.0 109.104 179.476 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 93.6 mttt -112.0 159.31 18.56 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.531 -0.731 . . . . 0.0 109.283 179.925 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -72.7 132.74 44.06 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.31 -0.869 . . . . 0.0 109.411 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 42.7 t -121.35 126.14 74.58 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.233 -0.917 . . . . 0.0 109.634 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 43.2 t -147.56 151.22 13.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.334 -0.854 . . . . 0.0 109.302 179.769 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 2.7 t -87.93 125.57 41.43 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 C-N-CA 119.708 -0.797 . . . . 0.0 109.854 -179.271 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 172' ' ' GLU . . . . . 0.423 ' O ' ' HB3' ' A' ' 173' ' ' ASP . 97.3 mt-10 -65.62 -30.82 71.58 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.379 -0.826 . . . . 0.0 109.097 179.509 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 173' ' ' ASP . . . . . 0.425 ' C ' ' OD1' ' A' ' 173' ' ' ASP . 53.0 p30 177.73 -177.78 0.21 Allowed 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.335 -0.853 . . . . 0.0 110.093 -179.864 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 28.5 p -154.04 150.4 28.19 Favored 'General case' 0 N--CA 1.49 1.571 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 179.476 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -172.17 178.46 44.33 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 176' ' ' GLN . . . . . 0.436 ' OE1' ' OG ' ' A' ' 178' ' ' SER . 7.0 tt0 -106.04 124.17 49.15 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.463 -1.022 . . . . 0.0 109.75 -179.954 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 28.9 tp -62.29 -37.97 87.57 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.202 -0.936 . . . . 0.0 109.382 179.604 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 178' ' ' SER . . . . . 0.436 ' OG ' ' OE1' ' A' ' 176' ' ' GLN . 4.5 p . . . . . 0 N--CA 1.491 1.596 0 CA-C-O 117.994 -1.003 . . . . 0.0 109.497 -179.91 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 11.1 m120 . . . . . 0 N--CA 1.492 1.671 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -65.93 141.85 66.4 Favored 'Trans proline' 0 N--CA 1.496 1.663 0 C-N-CA 122.822 2.348 . . . . 0.0 112.206 179.828 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 98.5 mtt180 -128.73 133.22 48.06 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.373 -0.829 . . . . 0.0 108.887 179.237 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.0 p -136.52 142.97 36.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.725 0 O-C-N 121.333 -0.854 . . . . 0.0 109.626 -179.783 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' PHE . . . . . 0.462 ' CZ ' ' NH2' ' A' ' 25' ' ' ARG . 43.0 p90 -140.41 154.28 46.63 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.285 -0.884 . . . . 0.0 109.468 -179.998 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -127.83 140.06 52.26 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.424 -0.797 . . . . 0.0 109.584 179.836 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 87.9 m-20 -91.44 132.94 35.89 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.263 -0.898 . . . . 0.0 108.91 179.368 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 65.6 mtp -124.72 153.53 42.25 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.198 -0.939 . . . . 0.0 110.259 -179.459 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 63.2 p -149.4 165.99 30.42 Favored 'General case' 0 N--CA 1.49 1.538 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 179.741 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 24.0 m -125.54 133.88 68.11 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 121.25 -0.906 . . . . 0.0 109.544 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 54.75 17.08 8.37 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 179.797 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 92.33 4.55 66.22 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 33.7 mt-30 -105.58 111.57 64.77 Favored Pre-proline 0 N--CA 1.493 1.711 0 O-C-N 121.349 -1.089 . . . . 0.0 109.255 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 65.8 Cg_exo -48.35 135.23 25.84 Favored 'Trans proline' 0 N--CA 1.493 1.47 0 C-N-CA 122.171 1.914 . . . . 0.0 112.173 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -104.82 -57.73 1.99 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.42 -0.8 . . . . 0.0 109.417 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -171.55 -171.68 36.89 Favored Glycine 0 N--CA 1.488 2.118 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 -179.856 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . 0.462 ' NH2' ' CZ ' ' A' ' 13' ' ' PHE . 77.6 ttt180 -114.35 143.93 44.09 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.377 -1.072 . . . . 0.0 109.367 179.947 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 83.2 mt -119.62 127.95 75.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.4 -0.812 . . . . 0.0 109.029 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 43.5 t -117.44 133.45 64.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.444 -0.785 . . . . 0.0 109.571 -179.773 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 73.2 mtm -121.35 150.49 41.38 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.423 -0.798 . . . . 0.0 109.03 179.699 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -101.89 131.15 48.42 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.253 -0.904 . . . . 0.0 109.997 -179.512 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.404 ' N ' ' CD2' ' A' ' 30' ' ' LEU . 2.8 mm? -109.59 130.15 55.53 Favored 'General case' 0 N--CA 1.493 1.701 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 179.357 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -97.77 118.26 33.91 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.039 -1.038 . . . . 0.0 108.981 179.427 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -79.6 -43.18 23.4 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.403 -0.811 . . . . 0.0 109.844 -179.739 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 57.6 t0 -65.25 -51.6 59.8 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.196 -0.94 . . . . 0.0 110.037 -179.301 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 49.4 m -67.86 -42.1 81.86 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.196 -0.94 . . . . 0.0 109.712 -179.871 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -137.34 80.37 33.84 Favored Pre-proline 0 N--CA 1.492 1.666 0 O-C-N 121.437 -0.789 . . . . 0.0 109.19 -179.73 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -70.83 -65.82 0.03 OUTLIER 'Trans proline' 0 C--N 1.308 -1.577 0 C-N-CA 122.579 2.186 . . . . 0.0 112.93 -179.601 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 62.7 mtp180 -61.5 -38.39 87.17 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.393 -0.817 . . . . 0.0 110.708 -179.036 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 36.9 m -62.49 -42.41 99.48 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 120.972 -1.08 . . . . 0.0 109.881 -179.691 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -62.65 -30.9 71.71 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.198 -0.939 . . . . 0.0 108.771 179.566 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.429 ' OE1' ' OH ' ' A' ' 92' ' ' TYR . 84.6 tt0 -65.65 -36.23 83.07 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.461 -0.774 . . . . 0.0 109.492 179.784 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 48.7 t-20 -58.59 -42.98 89.33 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.317 -0.864 . . . . 0.0 109.414 -179.794 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . 0.42 ' CE2' ' CE2' ' A' ' 142' ' ' PHE . 90.6 m-85 -80.63 -45.34 17.41 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.31 -0.869 . . . . 0.0 109.625 179.886 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 61.9 ttp180 -57.31 -42.37 81.68 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.261 -0.899 . . . . 0.0 109.533 -179.769 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.505 ' O ' ' N ' ' A' ' 48' ' ' GLY . . . -68.41 -36.35 78.98 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.262 -0.899 . . . . 0.0 109.528 179.975 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 51.7 tp -60.36 -36.18 77.43 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.176 -0.953 . . . . 0.0 109.529 -179.702 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' CYS . . . . . . . . . . . . . 96.8 m -65.83 -59.73 3.58 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.212 -0.93 . . . . 0.0 110.068 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 57.3 p -74.97 -38.71 61.61 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.12 -0.988 . . . . 0.0 109.987 -179.761 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . 0.505 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 71.98 7.3 66.14 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.183 -1.567 . . . . 0.0 109.183 -179.842 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 22.4 pt-20 -72.63 -16.91 61.71 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.451 -1.029 . . . . 0.0 110.033 -179.726 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 44.7 tptt -56.22 -38.61 71.26 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.166 -0.959 . . . . 0.0 109.739 -179.393 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 173.23 -173.23 45.62 Favored Glycine 0 N--CA 1.49 2.245 0 C-N-CA 119.664 -1.255 . . . . 0.0 110.03 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.53 ' O ' ' C ' ' A' ' 53' ' ' GLY . 82.5 m -120.57 145.89 46.88 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.673 -0.899 . . . . 0.0 109.266 179.946 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.53 ' C ' ' O ' ' A' ' 52' ' ' THR . . . -30.74 -73.9 0.05 OUTLIER Glycine 0 N--CA 1.495 2.608 0 N-CA-C 110.513 -1.035 . . . . 0.0 110.513 -179.827 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 93.7 mtt180 -139.86 -112.69 0.15 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.061 -1.258 . . . . 0.0 109.606 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 80.0 p -86.03 -23.64 26.7 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.313 -0.867 . . . . 0.0 110.112 -179.485 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -164.36 93.58 0.11 Allowed Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.377 -1.489 . . . . 0.0 109.377 -179.838 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 11.4 ttmm -174.4 75.31 0.34 Allowed Pre-proline 0 C--N 1.301 -1.506 0 O-C-N 121.484 -1.009 . . . . 0.0 108.629 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_exo -47.89 129.18 17.44 Favored 'Trans proline' 0 C--N 1.303 -1.832 0 C-N-CA 122.539 2.159 . . . . 0.0 111.897 -179.422 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 12.6 tp -106.48 119.96 40.67 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.522 -0.736 . . . . 0.0 109.333 -179.371 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -150.43 140.57 22.13 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.169 -0.957 . . . . 0.0 109.719 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 2.9 t80 -62.25 -35.75 79.9 Favored 'General case' 0 N--CA 1.492 1.657 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 179.431 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 42.6 tttm -50.47 152.66 1.82 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.501 -0.75 . . . . 0.0 109.868 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 34.8 t0 71.24 43.07 0.66 Allowed 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.645 -0.659 . . . . 0.0 109.501 -179.835 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 90.8 p -119.23 152.67 36.24 Favored 'General case' 0 N--CA 1.492 1.659 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 179.503 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 30.3 t -145.85 154.6 42.16 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.198 -0.938 . . . . 0.0 109.778 -179.611 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 47.3 m-85 -89.99 127.58 36.07 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.335 -0.853 . . . . 0.0 109.253 179.651 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' HIS . . . . . 0.403 ' O ' ' O ' ' A' ' 163' ' ' GLY . 97.3 m-70 -99.04 -18.47 17.74 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.319 -0.863 . . . . 0.0 110.291 -179.279 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 58.5 mtp85 -127.31 137.07 52.73 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.11 -0.994 . . . . 0.0 110.126 -179.693 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 3.1 m -153.34 81.33 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 121.428 -0.795 . . . . 0.0 108.98 179.474 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 22.0 mt -95.96 126.04 46.24 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.097 -1.002 . . . . 0.0 109.452 -179.501 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -71.64 138.25 31.72 Favored 'Trans proline' 0 N--CA 1.493 1.491 0 C-N-CA 122.157 1.905 . . . . 0.0 112.332 -179.664 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 92.67 -30.04 7.32 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.684 -1.366 . . . . 0.0 109.684 179.623 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -102.7 -89.73 0.37 Allowed 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.301 -1.117 . . . . 0.0 109.741 -179.884 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' MET . . . . . 0.452 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 7.6 ptt? -171.86 -175.42 1.51 Allowed 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.22 -0.925 . . . . 0.0 109.716 -179.678 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -127.27 141.94 51.59 Favored 'General case' 0 N--CA 1.494 1.748 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 179.699 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 48.1 tt0 -105.85 143.53 33.86 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.209 -0.932 . . . . 0.0 109.843 -179.589 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -156.11 -173.55 24.84 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 96.32 2.34 60.49 Favored Glycine 0 N--CA 1.494 2.516 0 N-CA-C 109.676 -1.37 . . . . 0.0 109.676 -179.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.574 ' O ' ' N ' ' A' ' 83' ' ' GLY . 89.9 m-20 -92.42 14.72 15.77 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.339 -1.095 . . . . 0.0 109.203 179.848 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.541 ' CD1' ' N ' ' A' ' 81' ' ' THR . 42.4 p90 -44.27 -31.56 1.05 Allowed 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.351 -0.843 . . . . 0.0 110.292 -179.815 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.541 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 18.5 m -58.0 -37.46 74.31 Favored 'General case' 0 C--N 1.303 -1.445 0 O-C-N 121.169 -0.957 . . . . 0.0 109.666 -178.993 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -145.48 -32.89 0.37 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.191 -0.943 . . . . 0.0 110.048 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . 0.574 ' N ' ' O ' ' A' ' 79' ' ' ASP . . . 100.16 -37.14 3.69 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.424 -1.471 . . . . 0.0 109.424 -180.0 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 78.4 m-20 -89.7 1.51 55.97 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.316 -1.108 . . . . 0.0 109.376 179.873 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 88.67 2.33 79.13 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.446 -1.462 . . . . 0.0 109.446 -179.934 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 49.5 m -59.71 -38.72 82.4 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.366 -1.079 . . . . 0.0 109.633 -179.919 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -96.31 -115.21 3.09 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.859 -1.296 . . . . 0.0 109.859 -179.706 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.446 ' O ' ' CB ' ' A' ' 123' ' ' SER . . . 81.97 27.71 44.52 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.193 -1.563 . . . . 0.0 109.193 -179.636 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -59.51 142.84 51.69 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.329 -1.1 . . . . 0.0 109.869 -179.83 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 32.9 t -141.93 146.81 36.12 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.353 -0.842 . . . . 0.0 109.278 179.738 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 14.1 pt -69.53 -11.34 14.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.136 -0.977 . . . . 0.0 109.468 -179.887 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . 0.429 ' OH ' ' OE1' ' A' ' 40' ' ' GLU . 80.9 m-85 -107.47 29.51 7.1 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.393 -0.817 . . . . 0.0 109.778 -179.988 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -46.98 -31.26 5.57 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.382 -1.487 . . . . 0.0 109.382 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -63.26 145.16 56.11 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.139 -1.212 . . . . 0.0 108.992 179.625 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 93.8 mttt -87.77 135.51 33.35 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.368 -0.832 . . . . 0.0 109.631 -179.637 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . 0.531 ' CE1' ' ND2' ' A' ' 121' ' ' ASN . 54.4 p90 -144.49 163.26 34.37 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.351 -0.843 . . . . 0.0 109.361 179.672 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -97.6 144.82 26.89 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.281 -0.887 . . . . 0.0 109.324 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 -67.93 135.34 52.27 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.213 -0.929 . . . . 0.0 109.345 -179.883 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . 0.525 ' O ' ' ND2' ' A' ' 100' ' ' ASN . 84.4 tt0 -63.55 -38.21 90.27 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.275 -0.89 . . . . 0.0 110.117 -179.653 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . 0.525 ' ND2' ' O ' ' A' ' 99' ' ' GLU . 24.0 m120 -144.18 171.04 14.84 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.996 -1.065 . . . . 0.0 110.041 -179.539 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' PHE . . . . . 0.43 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 38.3 p90 -151.17 37.85 0.63 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.471 -0.768 . . . . 0.0 109.094 179.772 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 90.3 mt -57.86 -34.13 47.51 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.318 -0.864 . . . . 0.0 109.936 -179.792 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 44.1 mtmt -75.63 144.27 41.8 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.992 -1.068 . . . . 0.0 109.511 -179.895 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 45.2 tttp -130.16 157.77 41.53 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.421 -0.799 . . . . 0.0 109.411 -179.872 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 105' ' ' HIS . . . . . 0.402 ' O ' ' OD2' ' A' ' 136' ' ' ASP . 85.5 t60 -98.93 127.09 44.77 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.328 -0.857 . . . . 0.0 109.39 -179.92 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -160.7 -6.66 0.05 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.229 -0.919 . . . . 0.0 109.698 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -127.72 171.48 19.07 Favored Glycine 0 N--CA 1.494 2.513 0 N-CA-C 109.456 -1.458 . . . . 0.0 109.456 -179.878 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 97.0 Cg_endo -80.61 154.72 20.84 Favored 'Trans proline' 0 C--N 1.306 -1.677 0 C-N-CA 123.023 2.482 . . . . 0.0 112.287 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 77.75 47.55 8.6 Favored Glycine 0 N--CA 1.494 2.536 0 N-CA-C 109.967 -1.253 . . . . 0.0 109.967 179.49 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 40.9 mm -115.29 134.74 57.49 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 O-C-N 121.437 -1.037 . . . . 0.0 109.511 -179.903 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . 0.454 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 3.5 mm? -93.45 112.74 24.72 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.203 -0.936 . . . . 0.0 109.317 179.681 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 47.2 m -131.01 147.95 52.69 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.265 -0.897 . . . . 0.0 109.494 179.737 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 88.5 mtp -94.33 141.2 28.84 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.177 -0.952 . . . . 0.0 109.391 179.892 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . 0.55 ' O ' ' ND2' ' A' ' 115' ' ' ASN . . . -63.3 142.77 58.26 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.295 -0.878 . . . . 0.0 109.338 179.916 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . 0.55 ' ND2' ' O ' ' A' ' 114' ' ' ALA . 16.0 m120 -144.7 113.26 6.65 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.21 -0.931 . . . . 0.0 109.057 179.885 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -68.22 -27.8 66.68 Favored 'General case' 0 C--N 1.297 -1.712 0 O-C-N 121.35 -0.844 . . . . 0.0 109.169 179.795 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -132.55 167.7 23.01 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.254 -1.539 . . . . 0.0 109.254 179.86 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 14.3 Cg_endo -58.44 -25.51 73.95 Favored 'Trans proline' 0 C--N 1.305 -1.76 0 C-N-CA 122.809 2.339 . . . . 0.0 111.929 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 42.5 p-10 -128.38 42.5 3.31 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.354 -0.841 . . . . 0.0 109.489 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 89.1 m -128.87 124.47 35.34 Favored 'General case' 0 N--CA 1.486 1.329 0 O-C-N 121.445 -0.785 . . . . 0.0 108.896 179.77 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 121' ' ' ASN . . . . . 0.531 ' ND2' ' CE1' ' A' ' 96' ' ' PHE . 83.0 m-20 -108.9 149.57 28.96 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.59 -0.694 . . . . 0.0 109.438 -179.842 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -133.78 166.93 23.81 Favored Glycine 0 N--CA 1.494 2.518 0 N-CA-C 109.544 -1.422 . . . . 0.0 109.544 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 123' ' ' SER . . . . . 0.446 ' CB ' ' O ' ' A' ' 88' ' ' GLY . 46.4 p -82.41 -2.08 52.02 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.248 -1.148 . . . . 0.0 109.674 -179.907 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.4 mt-30 -100.5 144.91 28.93 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.253 -0.904 . . . . 0.0 109.752 -179.836 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 50.9 p90 -139.12 163.6 31.98 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.504 -0.747 . . . . 0.0 109.171 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . 0.452 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 50.8 p90 -135.86 154.46 51.16 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.214 -0.928 . . . . 0.0 109.76 -179.89 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 64.5 mt -124.16 134.02 67.72 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.754 0 O-C-N 121.509 -0.745 . . . . 0.0 109.422 179.781 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 3.3 m -114.23 113.07 24.13 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.274 -0.891 . . . . 0.0 109.342 179.855 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 129' ' ' THR . . . . . 0.495 ' OG1' ' OE1' ' A' ' 156' ' ' GLU . 7.3 p -94.39 -0.9 54.52 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.257 -0.902 . . . . 0.0 109.406 -179.905 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -109.97 152.74 25.49 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.383 -0.823 . . . . 0.0 109.338 -179.746 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 49.3 mtpt -77.39 115.29 17.04 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.18 -0.95 . . . . 0.0 109.228 179.84 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 50.0 p -129.23 158.18 39.76 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.445 -0.784 . . . . 0.0 109.366 -179.938 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -110.39 -40.83 4.53 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.368 -0.833 . . . . 0.0 109.683 179.857 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 0.6 OUTLIER -62.58 -34.21 76.52 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.195 -0.941 . . . . 0.0 109.748 -179.602 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 12.5 mt -62.22 -33.09 73.9 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.984 -1.072 . . . . 0.0 109.668 179.648 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . 0.402 ' OD2' ' O ' ' A' ' 105' ' ' HIS . 61.7 t0 -79.33 119.12 21.92 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.2 -0.938 . . . . 0.0 109.517 -179.731 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -165.05 -117.4 0.4 Allowed Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 3.3 mppt? -86.53 7.39 26.3 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.403 -1.057 . . . . 0.0 109.769 -179.853 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 77.3 m80 -70.52 151.24 45.29 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.149 -0.97 . . . . 0.0 109.571 -179.667 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 41.2 t -118.69 140.78 41.18 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.489 -0.757 . . . . 0.0 109.459 -179.776 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . 0.406 HG13 ' H ' ' A' ' 143' ' ' GLY . 50.6 t -100.2 133.32 43.63 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.416 -0.802 . . . . 0.0 109.565 -179.844 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . 0.42 ' CE2' ' CE2' ' A' ' 42' ' ' PHE . 38.0 p90 -109.12 1.09 20.17 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.277 -0.889 . . . . 0.0 109.823 179.873 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . 0.406 ' H ' HG13 ' A' ' 141' ' ' VAL . . . -174.4 -179.42 45.0 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 179.663 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.3 pt20 -146.22 167.39 23.61 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.26 -1.141 . . . . 0.0 109.561 -179.644 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 54.0 t -97.84 131.39 44.91 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.187 0 O-C-N 121.178 -0.952 . . . . 0.0 109.473 -179.885 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 16.6 m -107.76 -34.81 2.81 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.357 -0.839 . . . . 0.0 109.664 179.685 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 94.4 mt-10 -144.32 166.92 23.72 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.212 -0.93 . . . . 0.0 109.705 -179.827 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 96.79 4.15 59.12 Favored Glycine 0 N--CA 1.495 2.583 0 N-CA-C 110.194 -1.162 . . . . 0.0 110.194 179.395 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 149' ' ' MET . . . . . 0.424 ' O ' HG12 ' A' ' 152' ' ' VAL . 71.8 mtm -60.79 -33.22 72.65 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.002 -1.293 . . . . 0.0 109.722 179.923 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 89.3 m-20 -65.11 -41.96 94.4 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.833 -1.167 . . . . 0.0 110.07 -179.541 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.2 p -82.04 -34.29 12.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.216 -0.928 . . . . 0.0 110.696 -179.406 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 152' ' ' VAL . . . . . 0.454 ' CG1' ' N ' ' A' ' 153' ' ' LYS . 0.8 OUTLIER -55.63 -42.49 69.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 120.873 -1.142 . . . . 0.0 109.399 -179.248 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 153' ' ' LYS . . . . . 0.454 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 99.2 mttt -65.53 -33.3 75.6 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.137 -0.977 . . . . 0.0 109.757 179.5 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -60.25 -40.15 89.3 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.312 -0.867 . . . . 0.0 110.284 -179.154 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.446 HD12 HG21 ' A' ' 155' ' ' ILE . 91.9 mt -71.56 -36.21 59.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.029 -1.044 . . . . 0.0 110.466 -179.508 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . 0.495 ' OE1' ' OG1' ' A' ' 129' ' ' THR . 84.4 tt0 -78.49 -40.35 35.58 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.929 -1.107 . . . . 0.0 111.36 -178.587 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 39.8 pttt -61.05 -34.42 74.86 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 120.793 -1.192 . . . . 0.0 110.005 -178.806 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 28.3 m -73.36 -12.65 15.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.101 -0.999 . . . . 0.0 109.377 179.884 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -77.82 173.4 55.08 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.757 -1.337 . . . . 0.0 109.757 -179.891 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 160' ' ' SER . . . . . 0.701 ' HG ' ' H ' ' A' ' 161' ' ' SER . 21.4 t -154.62 178.72 9.79 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.41 -1.053 . . . . 0.0 109.395 -179.741 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 161' ' ' SER . . . . . 0.701 ' H ' ' HG ' ' A' ' 160' ' ' SER . 23.7 t -54.3 -30.45 51.08 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.233 -0.917 . . . . 0.0 109.262 179.819 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 86.6 p -59.3 -26.61 65.13 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.255 -0.903 . . . . 0.0 109.4 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 163' ' ' GLY . . . . . 0.403 ' O ' ' O ' ' A' ' 67' ' ' HIS . . . 87.16 20.31 53.13 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.713 -1.355 . . . . 0.0 109.713 179.794 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 87.7 mtt180 -122.38 145.39 48.32 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.195 -1.18 . . . . 0.0 109.364 179.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 165' ' ' THR . . . . . . . . . . . . . 72.6 p -82.19 151.52 26.85 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.153 -0.967 . . . . 0.0 109.647 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -67.06 -36.44 82.05 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.287 -0.883 . . . . 0.0 109.302 179.692 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 62.4 mttp -117.6 156.57 27.89 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.576 -0.702 . . . . 0.0 109.248 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 94.2 mttt -69.22 131.62 45.2 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.11 -0.994 . . . . 0.0 109.225 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 41.1 t -122.14 125.08 72.49 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.725 0 O-C-N 121.325 -0.859 . . . . 0.0 109.644 -179.896 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 43.7 t -144.94 144.88 21.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.386 -0.821 . . . . 0.0 109.17 179.63 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 2.7 t -74.54 124.17 31.57 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.677 0 C-N-CA 119.722 -0.791 . . . . 0.0 109.787 -179.284 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -67.85 -27.91 67.1 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.363 -0.836 . . . . 0.0 109.593 179.471 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 44.3 t0 -174.38 174.76 2.73 Favored 'General case' 0 N--CA 1.494 1.754 0 C-N-CA 119.29 -0.964 . . . . 0.0 110.321 -179.286 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 26.4 p -146.42 150.25 35.28 Favored 'General case' 0 N--CA 1.491 1.622 0 N-CA-C 109.063 -0.718 . . . . 0.0 109.063 179.638 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -172.64 173.16 45.38 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.804 -1.318 . . . . 0.0 109.804 179.913 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 176' ' ' GLN . . . . . 0.513 ' NE2' ' OXT' ' A' ' 178' ' ' SER . 62.6 tt0 -114.23 118.89 35.24 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.413 -1.051 . . . . 0.0 109.637 -179.985 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 37.1 tp -63.39 -37.42 87.2 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.124 -0.985 . . . . 0.0 109.217 179.403 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 178' ' ' SER . . . . . 0.513 ' OXT' ' NE2' ' A' ' 176' ' ' GLN . 61.2 m . . . . . 0 N--CA 1.491 1.582 0 CA-C-O 118.0 -1.0 . . . . 0.0 109.441 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 2.3 m-80 . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 38.7 Cg_endo -64.85 141.65 72.36 Favored 'Trans proline' 0 N--CA 1.496 1.663 0 C-N-CA 122.616 2.211 . . . . 0.0 112.07 179.775 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 96.4 mtt180 -126.79 131.62 51.24 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.459 -0.776 . . . . 0.0 109.061 179.497 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.4 p -136.09 142.38 38.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.314 -0.866 . . . . 0.0 109.243 -179.905 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 41.2 p90 -142.3 154.01 44.36 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.297 -0.877 . . . . 0.0 109.572 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.6 ' CE2' ' SG ' ' A' ' 174' ' ' CYS . 44.3 m-85 -120.07 135.78 54.82 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.468 -0.77 . . . . 0.0 109.091 179.643 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.1 t0 -88.55 114.47 25.2 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.078 -1.013 . . . . 0.0 108.509 179.489 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 83.7 mtp -104.53 136.17 44.58 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.453 -0.779 . . . . 0.0 110.532 -179.08 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 44.5 m -135.1 154.23 51.74 Favored 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 179.195 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.405 ' O ' ' C ' ' A' ' 19' ' ' GLY . 34.3 m -125.98 141.45 45.61 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.148 -0.97 . . . . 0.0 109.891 -179.886 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . 0.405 ' C ' ' O ' ' A' ' 18' ' ' VAL . . . 41.05 -114.7 0.61 Allowed Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.936 -1.266 . . . . 0.0 109.936 179.77 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -120.94 15.46 9.52 Favored Glycine 0 N--CA 1.496 2.644 0 N-CA-C 109.416 -1.474 . . . . 0.0 109.416 179.858 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 39.6 tt0 -124.12 88.03 53.0 Favored Pre-proline 0 N--CA 1.494 1.756 0 O-C-N 121.459 -1.024 . . . . 0.0 109.078 -179.826 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 75.7 Cg_exo -47.05 132.86 18.24 Favored 'Trans proline' 0 C--N 1.309 -1.548 0 C-N-CA 122.336 2.024 . . . . 0.0 112.294 -179.561 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -85.07 -63.25 1.36 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.313 -0.867 . . . . 0.0 109.834 -179.688 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 172.62 -167.08 39.91 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 -179.756 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 28.7 ptt180 -116.53 151.18 36.67 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.534 -0.98 . . . . 0.0 108.952 179.735 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 83.4 mt -120.1 129.11 75.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.377 -0.827 . . . . 0.0 109.06 -179.854 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 39.5 t -107.7 134.6 48.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.4 -0.813 . . . . 0.0 109.436 -179.599 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 76.3 mtm -120.86 148.9 43.4 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.557 -0.714 . . . . 0.0 109.215 179.932 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -95.77 133.7 39.58 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.277 -0.889 . . . . 0.0 109.731 -179.593 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -108.35 133.42 52.57 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.572 -0.705 . . . . 0.0 109.357 179.895 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -96.37 119.56 35.08 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.23 -0.919 . . . . 0.0 108.656 179.187 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -89.61 -42.48 11.37 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.295 -0.878 . . . . 0.0 109.835 -179.65 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.2 m-20 -64.58 -48.63 74.27 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.218 -0.926 . . . . 0.0 110.24 -179.263 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 33.3 m -70.91 -43.47 68.21 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.075 -1.016 . . . . 0.0 109.966 -179.652 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.486 ' O ' ' OG1' ' A' ' 35' ' ' THR . 5.1 p -136.38 79.85 41.21 Favored Pre-proline 0 N--CA 1.493 1.678 0 O-C-N 121.351 -0.843 . . . . 0.0 109.404 -179.604 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 27.2 Cg_endo -67.05 -60.88 0.09 OUTLIER 'Trans proline' 0 C--N 1.309 -1.525 0 C-N-CA 122.479 2.12 . . . . 0.0 112.849 -179.401 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.476 ' NH2' ' CG ' ' A' ' 92' ' ' TYR . 17.2 mtp-105 -60.8 -37.78 83.12 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.405 -0.809 . . . . 0.0 110.811 -178.878 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 26.3 m -61.8 -43.16 99.4 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.883 -1.136 . . . . 0.0 109.835 -179.764 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -64.81 -28.48 69.59 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.175 -0.953 . . . . 0.0 109.307 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.407 ' OE1' ' OH ' ' A' ' 92' ' ' TYR . 84.6 tt0 -65.18 -37.72 88.22 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.341 -0.849 . . . . 0.0 109.687 -179.833 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 86.7 m-20 -59.59 -41.63 90.7 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.244 -0.91 . . . . 0.0 109.745 -179.652 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . 0.494 ' O ' ' SG ' ' A' ' 46' ' ' CYS . 95.5 m-85 -81.37 -46.68 14.3 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.239 -0.913 . . . . 0.0 109.705 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . 0.677 ' HE ' ' NE2' ' A' ' 176' ' ' GLN . 76.1 ttt180 -58.15 -43.09 87.21 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.346 -0.846 . . . . 0.0 110.019 -179.522 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -78.11 -47.9 17.2 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.141 -0.975 . . . . 0.0 110.165 -179.578 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 58.4 tp -60.59 -38.83 85.93 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.254 -0.904 . . . . 0.0 109.838 -179.518 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' CYS . . . . . 0.494 ' SG ' ' O ' ' A' ' 42' ' ' PHE . 71.2 m -68.56 -58.74 3.84 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.032 -1.042 . . . . 0.0 109.417 -179.908 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 31.6 m -64.11 -37.45 87.5 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.135 -0.978 . . . . 0.0 109.278 179.703 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 81.53 34.27 25.9 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 179.648 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -61.1 -34.36 74.83 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.018 -1.283 . . . . 0.0 109.338 179.61 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 69.4 mmtt -59.57 -33.58 71.61 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.317 -0.864 . . . . 0.0 109.331 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 94.3 168.87 37.44 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.329 -1.508 . . . . 0.0 109.329 -179.771 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 91.7 m -77.79 139.18 39.31 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.413 -1.051 . . . . 0.0 109.737 -179.933 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -60.78 141.19 48.09 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.521 -1.432 . . . . 0.0 109.521 179.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 67.4 mtm180 -59.19 -37.12 76.65 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.277 -1.131 . . . . 0.0 109.765 -179.799 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 23.6 m -58.7 -33.75 70.53 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.273 -0.892 . . . . 0.0 109.709 -179.784 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . 0.427 ' O ' ' CB ' ' A' ' 57' ' ' LYS . . . 120.58 109.53 2.2 Favored Glycine 0 N--CA 1.495 2.577 0 N-CA-C 108.996 -1.642 . . . . 0.0 108.996 -179.645 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . 0.455 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 3.2 mmtp 166.14 85.93 0.02 OUTLIER Pre-proline 0 N--CA 1.492 1.628 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 -179.669 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 71.3 Cg_exo -50.96 133.73 40.98 Favored 'Trans proline' 0 C--N 1.304 -1.773 0 C-N-CA 122.559 2.173 . . . . 0.0 112.383 -179.308 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.455 ' CD1' ' O ' ' A' ' 57' ' ' LYS . 8.9 mp -99.65 44.77 1.01 Allowed 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.558 -0.714 . . . . 0.0 109.378 -179.793 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 88.4 m-70 -123.82 133.31 53.82 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.413 -0.804 . . . . 0.0 109.672 -179.828 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 20.8 m-85 -69.12 -12.11 61.39 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.158 -0.964 . . . . 0.0 108.907 178.789 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 61.2 tttt -49.93 138.62 14.97 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.345 -0.847 . . . . 0.0 109.898 -179.703 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 41.0 t0 67.77 42.53 1.96 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.782 -0.574 . . . . 0.0 110.141 179.67 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.764 ' H ' ' CG2' ' A' ' 171' ' ' VAL . 83.2 p -110.47 149.76 29.84 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.233 -0.917 . . . . 0.0 108.595 178.807 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 28.7 t -117.45 144.23 45.22 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.172 -0.955 . . . . 0.0 109.697 -179.353 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -69.61 138.87 53.47 Favored 'General case' 0 N--CA 1.491 1.595 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 179.66 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' HIS . . . . . 0.693 ' CD2' ' HE ' ' A' ' 68' ' ' ARG . 77.8 t60 -59.59 -50.95 71.91 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.108 -0.995 . . . . 0.0 109.932 -179.416 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.693 ' HE ' ' CD2' ' A' ' 67' ' ' HIS . 20.2 ptp180 -172.81 163.05 4.98 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.213 -0.929 . . . . 0.0 109.684 179.669 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -134.05 127.0 50.97 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.418 -0.802 . . . . 0.0 109.035 179.53 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 39.5 mt -121.9 118.38 29.36 Favored Pre-proline 0 N--CA 1.493 1.719 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 179.86 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -71.58 136.13 27.67 Favored 'Trans proline' 0 C--N 1.31 -1.473 0 C-N-CA 121.853 1.702 . . . . 0.0 111.894 -179.803 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 94.25 -1.07 66.79 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.731 -1.348 . . . . 0.0 109.731 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 85.7 m-85 -137.1 -96.13 0.21 Allowed 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.22 -1.164 . . . . 0.0 109.81 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' MET . . . . . 0.595 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 5.6 ptt? -163.95 160.86 22.46 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.157 -0.964 . . . . 0.0 109.896 -179.491 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' CYS . . . . . 0.492 ' O ' ' SG ' ' A' ' 75' ' ' CYS . 12.1 p -97.38 130.59 44.51 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.417 -0.802 . . . . 0.0 108.966 179.241 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 93.8 mt-30 -105.79 149.82 26.12 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.27 -0.894 . . . . 0.0 109.648 -179.712 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -143.91 126.24 2.69 Favored Glycine 0 N--CA 1.492 2.425 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 179.85 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -86.05 178.48 49.58 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.77 -1.332 . . . . 0.0 109.77 -179.76 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 88.1 m-20 -72.13 149.38 44.79 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.357 -1.084 . . . . 0.0 109.554 179.842 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 43.6 p90 -61.53 -22.97 65.62 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.201 -0.937 . . . . 0.0 109.571 -179.907 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 61.6 p -65.98 -30.17 70.68 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.133 -0.979 . . . . 0.0 109.424 -179.926 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 171.4 -55.7 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.339 -0.851 . . . . 0.0 109.284 179.809 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 94.79 -10.3 70.53 Favored Glycine 0 N--CA 1.493 2.462 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 179.889 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 50.4 t30 -86.18 1.71 49.66 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.176 -1.191 . . . . 0.0 109.345 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 97.21 -8.83 65.02 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.311 -1.516 . . . . 0.0 109.311 -179.865 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 68.0 p -73.34 -20.0 60.89 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.311 -1.111 . . . . 0.0 109.273 179.675 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -127.68 -130.51 3.35 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 109.334 -1.507 . . . . 0.0 109.334 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 72.48 55.02 7.06 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.175 -1.57 . . . . 0.0 109.175 -179.948 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -84.77 140.73 31.03 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.368 -1.077 . . . . 0.0 109.808 -179.506 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 27.8 t -111.65 143.07 43.14 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.453 -0.779 . . . . 0.0 109.111 179.773 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 15.4 pt -65.12 -38.64 83.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.18 -0.95 . . . . 0.0 110.061 -179.529 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . 0.476 ' CG ' ' NH2' ' A' ' 37' ' ' ARG . 50.7 m-85 -67.83 -38.5 83.3 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.09 -1.006 . . . . 0.0 109.677 -179.906 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 76.09 22.05 74.7 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.342 -1.503 . . . . 0.0 109.342 -179.8 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -147.28 162.69 38.42 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.283 -1.128 . . . . 0.0 109.592 -179.708 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 61.0 mttp -77.19 154.16 33.38 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.269 -0.895 . . . . 0.0 109.527 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . 0.463 ' CD1' ' N ' ' A' ' 96' ' ' PHE . 2.1 m-85 -100.37 133.19 45.16 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.303 -0.873 . . . . 0.0 109.059 179.969 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -91.44 130.45 37.27 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.092 -1.005 . . . . 0.0 109.582 -179.874 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 88.2 m-20 -72.05 143.4 49.11 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.269 -0.894 . . . . 0.0 109.362 179.76 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -141.0 -47.44 0.4 Allowed 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.242 -0.911 . . . . 0.0 109.734 -179.848 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 86.0 m-20 -105.0 122.08 45.11 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.242 -0.911 . . . . 0.0 109.905 -179.585 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' PHE . . . . . 0.553 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 71.7 t80 -120.43 14.48 11.98 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.461 -0.774 . . . . 0.0 108.965 179.549 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 89.7 mt -55.11 -38.31 46.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.417 -0.802 . . . . 0.0 110.237 -179.434 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 67.4 mttm -84.54 136.98 33.58 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.991 -1.068 . . . . 0.0 109.782 -179.528 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 104' ' ' LYS . . . . . 0.618 ' HZ3' ' CG2' ' A' ' 106' ' ' THR . 21.3 pttm -139.58 -177.12 4.81 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.457 -0.777 . . . . 0.0 109.274 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 105' ' ' HIS . . . . . 0.533 ' CE1' ' O ' ' A' ' 107' ' ' GLY . 8.5 t-80 -86.52 107.01 17.92 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.121 -0.987 . . . . 0.0 109.491 -179.881 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 106' ' ' THR . . . . . 0.618 ' CG2' ' HZ3' ' A' ' 104' ' ' LYS . 46.6 p -114.43 -1.31 13.51 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.348 -0.845 . . . . 0.0 109.779 179.955 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.533 ' O ' ' CE1' ' A' ' 105' ' ' HIS . . . -154.31 170.54 32.8 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 -179.756 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -77.01 153.7 32.68 Favored 'Trans proline' 0 C--N 1.307 -1.656 0 C-N-CA 122.909 2.406 . . . . 0.0 112.264 179.804 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 78.53 52.4 5.13 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 110.032 -1.227 . . . . 0.0 110.032 179.491 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 35.3 mm -114.27 137.31 47.99 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 O-C-N 121.27 -1.135 . . . . 0.0 109.825 -179.86 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . 0.535 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 2.5 mm? -89.42 125.61 35.23 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.308 -0.87 . . . . 0.0 109.021 179.564 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 112' ' ' SER . . . . . 0.434 ' OG ' ' O ' ' A' ' 140' ' ' VAL . 36.8 t -147.74 142.83 27.07 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.027 -1.046 . . . . 0.0 109.794 -179.896 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 64.9 mtt -88.45 135.96 33.22 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.185 -0.947 . . . . 0.0 109.411 179.606 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . 0.535 ' O ' ' ND2' ' A' ' 115' ' ' ASN . . . -72.22 135.59 46.12 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.137 -0.977 . . . . 0.0 109.34 179.808 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . 0.535 ' ND2' ' O ' ' A' ' 114' ' ' ALA . 17.6 m120 -145.37 113.32 6.45 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.162 -0.962 . . . . 0.0 109.336 179.77 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -70.15 -28.7 65.56 Favored 'General case' 0 C--N 1.297 -1.68 0 O-C-N 121.457 -0.777 . . . . 0.0 109.362 179.796 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -134.46 165.25 24.5 Favored Glycine 0 N--CA 1.493 2.484 0 N-CA-C 109.279 -1.528 . . . . 0.0 109.279 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -70.17 154.91 65.67 Favored 'Trans proline' 0 C--N 1.306 -1.667 0 C-N-CA 122.776 2.317 . . . . 0.0 112.199 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 77.5 m-20 54.72 46.9 23.67 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.467 -0.77 . . . . 0.0 109.559 179.841 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 87.3 m -132.27 129.75 40.0 Favored 'General case' 0 C--N 1.306 -1.312 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 179.709 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 121' ' ' ASN . . . . . 0.402 ' OD1' ' CE2' ' A' ' 96' ' ' PHE . 50.8 t30 -74.69 123.15 24.38 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 121.442 -0.786 . . . . 0.0 109.329 -179.855 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -90.74 103.64 3.06 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.839 -1.304 . . . . 0.0 109.839 -179.84 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 85.5 p -65.03 -23.63 67.25 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.248 -1.148 . . . . 0.0 109.245 179.596 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.0 mt-30 -109.19 151.83 25.96 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.434 -0.791 . . . . 0.0 109.622 -179.805 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 49.2 p90 -136.63 160.85 37.56 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.377 -0.827 . . . . 0.0 109.108 179.75 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . 0.595 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 50.2 p90 -140.58 158.5 43.9 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.224 -0.923 . . . . 0.0 109.724 -179.895 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 65.1 mt -120.98 133.6 67.1 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 O-C-N 121.593 -0.692 . . . . 0.0 109.325 179.674 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 128' ' ' CYS . . . . . 0.462 ' HG ' ' HG1' ' A' ' 132' ' ' THR . 6.7 m -97.48 108.64 21.4 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.169 -0.957 . . . . 0.0 109.305 179.779 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 60.2 p -76.39 -10.07 59.12 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.182 -0.949 . . . . 0.0 109.528 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -137.89 161.55 36.34 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.309 -0.87 . . . . 0.0 109.302 -179.818 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 49.0 tttp -62.22 133.21 54.87 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.226 -0.921 . . . . 0.0 109.433 -179.806 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 132' ' ' THR . . . . . 0.462 ' HG1' ' HG ' ' A' ' 128' ' ' CYS . 29.4 p -140.37 91.93 2.48 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.313 -0.867 . . . . 0.0 109.281 -179.898 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -63.57 -34.9 78.84 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.255 -0.903 . . . . 0.0 109.73 -179.813 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 0.9 OUTLIER -67.76 -47.9 67.93 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.068 -1.02 . . . . 0.0 109.646 -179.876 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 15.3 mt -66.79 -31.73 72.55 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.111 -0.993 . . . . 0.0 109.701 179.511 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 60.0 t0 -78.18 121.48 24.4 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.109 -0.994 . . . . 0.0 109.767 -179.566 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 179.88 -114.94 0.46 Allowed Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . 0.437 ' O ' ' C ' ' A' ' 139' ' ' HIS . 66.4 mttm -57.64 -36.24 71.57 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.297 -1.12 . . . . 0.0 109.748 179.886 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 139' ' ' HIS . . . . . 0.437 ' C ' ' O ' ' A' ' 138' ' ' LYS . 53.7 m170 -40.94 144.69 0.25 Allowed 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.543 -0.723 . . . . 0.0 109.816 -179.683 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.434 ' O ' ' OG ' ' A' ' 112' ' ' SER . 42.4 t -115.11 138.84 44.11 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 121.359 -0.838 . . . . 0.0 109.601 -179.678 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 91.8 t -97.97 129.06 48.72 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.341 -0.85 . . . . 0.0 109.441 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 39.1 p90 -115.15 0.54 13.61 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.348 -0.845 . . . . 0.0 109.492 179.844 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -176.19 175.6 47.48 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.349 -1.5 . . . . 0.0 109.349 179.558 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.4 pt20 -147.86 168.21 22.78 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.125 -1.221 . . . . 0.0 110.045 -179.837 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 82.1 t -94.61 131.28 41.9 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.245 0 O-C-N 121.333 -0.854 . . . . 0.0 109.363 -179.814 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 10.9 m -112.43 -30.71 2.2 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.325 -0.859 . . . . 0.0 109.853 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 92.9 mt-10 -141.91 169.45 17.56 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.152 -0.968 . . . . 0.0 109.611 -179.881 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 95.57 6.85 59.43 Favored Glycine 0 N--CA 1.493 2.452 0 N-CA-C 109.984 -1.246 . . . . 0.0 109.984 179.597 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 149' ' ' MET . . . . . . . . . . . . . 65.0 mtt -60.14 -31.92 70.53 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.058 -1.26 . . . . 0.0 109.543 -179.978 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . 0.54 ' OD1' ' N ' ' A' ' 151' ' ' VAL . 31.8 p-10 -65.0 -36.96 86.08 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.812 -1.18 . . . . 0.0 109.821 -179.64 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . 0.54 ' N ' ' OD1' ' A' ' 150' ' ' ASP . 3.5 p -87.08 -34.19 7.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.148 -0.97 . . . . 0.0 110.385 -179.64 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 152' ' ' VAL . . . . . 0.46 ' CG1' ' N ' ' A' ' 153' ' ' LYS . 0.9 OUTLIER -56.67 -41.87 75.32 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 120.991 -1.068 . . . . 0.0 109.188 -179.478 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 153' ' ' LYS . . . . . 0.46 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 66.8 mttm -63.99 -34.72 78.65 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.274 -0.891 . . . . 0.0 109.406 179.583 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -62.17 -36.81 83.01 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.29 -0.881 . . . . 0.0 109.934 -179.477 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 62.5 mt -74.36 -37.56 45.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.136 -0.977 . . . . 0.0 109.84 -179.786 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -73.73 -40.61 63.43 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.129 -0.982 . . . . 0.0 111.399 -178.493 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 18.1 pttp -59.86 -35.61 75.16 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.679 -1.263 . . . . 0.0 109.696 -178.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 27.1 m -77.04 -17.52 14.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.08 -1.012 . . . . 0.0 108.952 179.389 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -64.43 150.21 50.93 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 49.7 m -136.28 161.23 36.35 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.454 -1.027 . . . . 0.0 109.175 179.914 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 23.8 m -51.35 -33.12 28.17 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.187 -0.946 . . . . 0.0 108.966 179.875 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 22.6 t -57.89 -29.02 64.73 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.36 -0.837 . . . . 0.0 109.334 179.643 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.22 10.14 52.08 Favored Glycine 0 N--CA 1.493 2.465 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 -179.806 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 83.7 mtp180 -117.04 155.28 29.49 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.384 -1.068 . . . . 0.0 109.175 179.909 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 165' ' ' THR . . . . . 0.434 ' OG1' ' O ' ' A' ' 167' ' ' LYS . 44.8 p -110.71 156.43 21.04 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.243 -0.911 . . . . 0.0 109.62 -179.759 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -68.19 -37.28 80.76 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.414 -0.804 . . . . 0.0 109.435 179.676 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 167' ' ' LYS . . . . . 0.434 ' O ' ' OG1' ' A' ' 165' ' ' THR . 3.7 mptp? -105.18 158.67 16.43 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.405 -0.809 . . . . 0.0 109.597 -179.834 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 61.3 mttp -81.34 151.99 27.73 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.346 -0.846 . . . . 0.0 109.475 179.83 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 30.9 m -131.14 124.37 55.45 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.301 -0.874 . . . . 0.0 109.649 179.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 46.3 t -148.59 147.08 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.296 -0.877 . . . . 0.0 108.988 179.602 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . 0.764 ' CG2' ' H ' ' A' ' 64' ' ' SER . 2.8 m -87.81 123.16 40.25 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.838 0 O-C-N 120.952 -1.093 . . . . 0.0 109.944 -179.9 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -74.29 -36.72 63.78 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.327 -0.858 . . . . 0.0 110.367 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 173' ' ' ASP . . . . . 0.465 ' OD1' ' N ' ' A' ' 174' ' ' CYS . 54.3 t0 -155.08 153.65 31.22 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 120.914 -1.116 . . . . 0.0 110.662 -179.1 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 174' ' ' CYS . . . . . 0.6 ' SG ' ' CE2' ' A' ' 14' ' ' PHE . 45.4 t -142.15 141.49 32.64 Favored 'General case' 0 N--CA 1.492 1.63 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.48 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -169.52 -178.86 40.99 Favored Glycine 0 N--CA 1.493 2.441 0 N-CA-C 109.806 -1.318 . . . . 0.0 109.806 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 176' ' ' GLN . . . . . 0.677 ' NE2' ' HE ' ' A' ' 43' ' ' ARG . 6.8 tt0 -105.22 120.49 41.67 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.406 -1.055 . . . . 0.0 109.66 -179.875 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 32.1 tp -63.59 -37.81 88.75 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.156 -0.965 . . . . 0.0 109.321 179.414 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 10.9 t . . . . . 0 N--CA 1.49 1.533 0 CA-C-O 118.001 -0.999 . . . . 0.0 109.432 -179.952 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 14.9 m-80 . . . . . 0 N--CA 1.494 1.73 0 N-CA-C 109.675 -0.491 . . . . 0.0 109.675 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -68.22 141.67 52.9 Favored 'Trans proline' 0 N--CA 1.496 1.67 0 C-N-CA 122.62 2.213 . . . . 0.0 112.144 179.877 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 78.4 mtm180 -128.08 133.43 49.04 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.463 -0.773 . . . . 0.0 108.981 179.428 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.2 p -135.57 143.38 36.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.329 -0.857 . . . . 0.0 109.576 -179.822 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 39.2 p90 -137.22 152.83 50.3 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.418 -0.801 . . . . 0.0 109.34 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.459 ' CE1' ' CE1' ' A' ' 61' ' ' TYR . 98.1 m-85 -124.08 132.84 53.71 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.563 -0.711 . . . . 0.0 109.399 179.8 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.6 t0 -91.29 114.56 27.12 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.224 -0.923 . . . . 0.0 108.776 179.485 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 79.7 mtp -107.26 137.33 45.52 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.255 -0.903 . . . . 0.0 110.031 -179.392 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 19.8 m -130.41 152.93 49.28 Favored 'General case' 0 N--CA 1.492 1.639 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 179.636 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.411 ' O ' ' N ' ' A' ' 21' ' ' GLN . 29.8 m -119.05 134.85 61.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.227 -0.921 . . . . 0.0 109.442 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 49.26 25.03 5.47 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 84.24 20.67 58.52 Favored Glycine 0 N--CA 1.492 2.398 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 -179.914 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' GLN . . . . . 0.411 ' N ' ' O ' ' A' ' 18' ' ' VAL . 40.6 mt-30 -120.11 99.19 48.79 Favored Pre-proline 0 N--CA 1.495 1.778 0 O-C-N 121.377 -1.072 . . . . 0.0 109.414 -179.904 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 75.2 Cg_exo -46.53 99.1 0.03 OUTLIER 'Trans proline' 0 N--CA 1.491 1.382 0 C-N-CA 122.353 2.035 . . . . 0.0 112.237 -179.883 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -65.27 -39.85 93.14 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.355 -0.841 . . . . 0.0 109.806 -179.799 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 167.36 -169.11 40.89 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.677 -1.369 . . . . 0.0 109.677 -179.798 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 97.1 mtt180 -115.26 147.05 40.86 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.5 -1.0 . . . . 0.0 109.45 179.812 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 77.2 mt -119.71 123.29 70.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 N-CA-C 108.463 -0.94 . . . . 0.0 108.463 179.118 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 24.8 t -114.26 132.95 61.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.373 -0.829 . . . . 0.0 109.423 -179.488 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' MET . . . . . 0.521 ' SD ' ' CD1' ' A' ' 111' ' ' LEU . 73.2 mtm -125.66 152.71 44.86 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.382 -0.824 . . . . 0.0 109.196 -179.84 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -99.01 133.26 43.53 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.259 -0.901 . . . . 0.0 109.761 179.877 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -108.85 131.16 55.27 Favored 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 179.794 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 98.2 m-85 -96.36 120.3 36.41 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.095 -1.003 . . . . 0.0 109.063 179.764 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -84.06 -41.1 17.54 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.338 -0.851 . . . . 0.0 109.865 -179.729 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -65.81 -44.71 84.83 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.275 -0.891 . . . . 0.0 110.624 -179.185 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 52.9 m -67.05 -44.87 79.06 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.09 -1.006 . . . . 0.0 110.241 -179.291 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 2.0 m -150.68 82.89 5.98 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.155 -0.966 . . . . 0.0 109.269 -179.666 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 39.9 Cg_endo -71.37 -38.32 4.79 Favored 'Trans proline' 0 C--N 1.308 -1.592 0 C-N-CA 122.19 1.927 . . . . 0.0 112.361 -179.361 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 35.2 mmt180 -64.5 -41.81 96.22 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.126 -0.983 . . . . 0.0 109.691 -179.858 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 80.8 m -67.55 -42.66 82.32 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.194 -0.941 . . . . 0.0 110.034 -179.715 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -61.31 -31.81 71.66 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.11 -0.994 . . . . 0.0 108.962 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.429 ' OE1' ' OH ' ' A' ' 92' ' ' TYR . 85.0 tt0 -70.33 -38.07 74.8 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.422 -0.799 . . . . 0.0 109.999 -179.895 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 20.4 t-20 -57.91 -43.92 86.49 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.265 -0.897 . . . . 0.0 109.865 -179.534 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -85.3 -46.71 10.74 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.247 -0.908 . . . . 0.0 109.606 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 71.2 ttp85 -57.24 -42.88 82.32 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.312 -0.867 . . . . 0.0 109.663 -179.894 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.5 ' O ' ' N ' ' A' ' 48' ' ' GLY . . . -72.13 -46.27 57.22 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.288 -0.883 . . . . 0.0 109.899 -179.691 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 38.2 tp -61.97 -37.68 85.69 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.095 -1.003 . . . . 0.0 109.438 -179.817 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' CYS . . . . . . . . . . . . . 98.7 m -67.19 -65.93 0.62 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.305 -0.872 . . . . 0.0 109.579 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 31.0 m -64.6 -37.17 86.65 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.374 -0.829 . . . . 0.0 109.404 179.656 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . 0.5 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 80.94 37.8 17.86 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 110.037 -1.225 . . . . 0.0 110.037 179.831 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -61.72 -37.85 85.72 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.089 -1.242 . . . . 0.0 109.51 179.913 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 70.4 mmtt -61.37 -35.49 77.62 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.295 -0.878 . . . . 0.0 109.42 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 88.16 -174.89 44.25 Favored Glycine 0 N--CA 1.484 1.875 0 N-CA-C 108.979 -1.648 . . . . 0.0 108.979 -179.574 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 89.6 m -71.36 139.19 49.73 Favored 'General case' 0 C--N 1.295 -1.78 0 O-C-N 121.537 -0.978 . . . . 0.0 109.603 179.893 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -56.8 136.37 50.09 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.176 -1.57 . . . . 0.0 109.176 179.795 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 86.4 mtt-85 -58.77 -36.94 75.22 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.222 -1.164 . . . . 0.0 109.857 -179.617 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 24.8 m -59.59 -33.94 72.11 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.21 -0.931 . . . . 0.0 109.802 -179.825 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 124.96 91.92 0.91 Allowed Glycine 0 N--CA 1.494 2.514 0 N-CA-C 108.953 -1.659 . . . . 0.0 108.953 -179.658 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . 0.494 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 28.0 tttp -175.69 79.76 0.3 Allowed Pre-proline 0 N--CA 1.489 1.478 0 O-C-N 121.447 -1.031 . . . . 0.0 108.406 -179.709 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_exo -49.65 131.8 29.38 Favored 'Trans proline' 0 C--N 1.303 -1.848 0 C-N-CA 122.923 2.415 . . . . 0.0 112.845 -178.927 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.494 ' CD1' ' O ' ' A' ' 57' ' ' LYS . 8.7 mp -103.35 113.09 26.3 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.591 -0.693 . . . . 0.0 109.365 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . 0.507 ' O ' ' CE1' ' A' ' 80' ' ' PHE . 70.8 m80 -141.1 126.25 18.43 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.203 -0.936 . . . . 0.0 109.544 179.473 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . 0.459 ' CE1' ' CE1' ' A' ' 14' ' ' PHE . 13.7 t80 -94.42 -11.67 29.36 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.359 -0.838 . . . . 0.0 108.936 179.743 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -78.68 160.52 27.46 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.451 -0.78 . . . . 0.0 109.775 -179.485 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 50.1 t0 60.44 45.8 10.48 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.513 -0.742 . . . . 0.0 109.932 179.647 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 92.5 p -116.25 150.9 36.82 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.328 -0.858 . . . . 0.0 108.841 179.291 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' SER . . . . . 0.408 ' O ' ' OD2' ' A' ' 79' ' ' ASP . 29.4 t -121.17 147.33 45.73 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.257 -0.902 . . . . 0.0 109.716 -179.514 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.3 m-30 -68.18 138.34 55.56 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.351 -0.843 . . . . 0.0 108.907 179.825 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 80.0 t60 -60.51 -51.2 70.48 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.218 -0.926 . . . . 0.0 110.138 -179.327 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.672 HH21 ' NE2' ' A' ' 76' ' ' GLN . 38.5 ptt180 -162.85 162.78 26.58 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.073 -1.017 . . . . 0.0 109.873 179.946 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 18.4 m -131.52 150.01 33.68 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.725 0 O-C-N 121.445 -0.785 . . . . 0.0 109.052 179.761 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 14.3 mt -147.29 119.43 4.71 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.024 -1.047 . . . . 0.0 109.433 179.714 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -73.95 134.48 19.79 Favored 'Trans proline' 0 C--N 1.313 -1.316 0 C-N-CA 122.022 1.815 . . . . 0.0 111.868 179.948 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 89.54 2.58 76.04 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.456 ' C ' ' SD ' ' A' ' 74' ' ' MET . 80.2 m-85 -137.22 -94.32 0.22 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.312 -1.11 . . . . 0.0 109.711 179.9 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' MET . . . . . 0.456 ' SD ' ' C ' ' A' ' 73' ' ' PHE . 0.0 OUTLIER -162.98 172.71 14.62 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.161 -0.962 . . . . 0.0 109.81 -179.688 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 1.9 m -119.49 135.16 54.89 Favored 'General case' 0 N--CA 1.494 1.728 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 179.543 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' GLN . . . . . 0.672 ' NE2' HH21 ' A' ' 68' ' ' ARG . 93.8 mt-30 -104.06 153.75 20.51 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.286 -0.884 . . . . 0.0 109.816 -179.638 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -158.99 -170.89 24.08 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.329 -1.509 . . . . 0.0 109.329 -179.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 80.02 37.94 20.61 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.504 -1.439 . . . . 0.0 109.504 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.437 ' C ' ' OD1' ' A' ' 79' ' ' ASP . 54.2 p30 -85.24 12.16 8.6 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.291 -1.123 . . . . 0.0 109.46 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.507 ' CE1' ' O ' ' A' ' 60' ' ' HIS . 76.3 t80 -52.88 -44.9 67.2 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.348 -0.845 . . . . 0.0 109.937 -179.902 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.619 ' CB ' ' H ' ' A' ' 88' ' ' GLY . 69.0 p -69.45 -29.25 66.9 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.149 -0.969 . . . . 0.0 109.513 -179.928 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . 0.486 ' CB ' ' O ' ' A' ' 81' ' ' THR . . . 165.76 -55.88 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.229 -0.919 . . . . 0.0 109.365 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 92.28 0.29 70.76 Favored Glycine 0 N--CA 1.492 2.389 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 -179.928 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 77.7 m-20 -87.57 5.51 38.98 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.213 -1.169 . . . . 0.0 109.474 179.931 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 96.04 -36.81 3.67 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.329 -1.508 . . . . 0.0 109.329 -179.903 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 56.2 p -73.53 -18.9 61.03 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.271 -1.134 . . . . 0.0 109.164 179.638 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -83.34 -164.04 35.62 Favored Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.611 -1.395 . . . . 0.0 109.611 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.619 ' H ' ' CB ' ' A' ' 81' ' ' THR . . . 92.28 24.09 25.24 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.314 -1.514 . . . . 0.0 109.314 -179.785 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -57.3 145.59 31.6 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.432 -1.04 . . . . 0.0 109.687 -179.864 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 28.8 t -107.03 146.14 31.49 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.328 -0.858 . . . . 0.0 109.263 179.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 20.3 pt -61.26 -33.24 55.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.131 -0.98 . . . . 0.0 109.746 -179.812 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . 0.429 ' OH ' ' OE1' ' A' ' 40' ' ' GLU . 91.7 m-85 -65.51 -36.15 82.98 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.285 -0.884 . . . . 0.0 109.653 179.959 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.09 15.24 70.12 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.319 -1.513 . . . . 0.0 109.319 -179.654 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -143.64 155.92 44.4 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.309 -1.113 . . . . 0.0 109.545 -179.859 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 63.1 mttp -94.03 137.89 32.72 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.287 -0.883 . . . . 0.0 109.586 -179.846 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -123.9 154.23 40.0 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.309 -0.869 . . . . 0.0 109.768 179.901 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -107.1 154.65 20.85 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.469 -0.769 . . . . 0.0 109.06 179.536 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 60.0 t0 -76.68 105.48 7.77 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.032 -1.042 . . . . 0.0 109.378 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -67.22 -34.15 76.88 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.284 -0.885 . . . . 0.0 110.062 -179.809 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 86.5 m-20 -105.0 124.71 50.0 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.251 -0.906 . . . . 0.0 110.052 -179.35 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 99.2 m-85 -108.13 12.78 26.46 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.462 -0.774 . . . . 0.0 109.067 179.556 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 92.6 mt -53.36 -39.25 34.86 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.326 -0.859 . . . . 0.0 110.048 -179.319 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 58.0 mttm -82.25 132.9 35.23 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.983 -1.073 . . . . 0.0 109.592 -179.849 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 80.7 tttt -138.65 158.85 43.46 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.41 -0.806 . . . . 0.0 109.335 -179.891 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 105' ' ' HIS . . . . . 0.611 ' CE1' ' HG ' ' A' ' 128' ' ' CYS . 85.2 t60 -86.07 99.17 11.29 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.233 -0.917 . . . . 0.0 109.431 179.886 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 65.9 p -115.78 -1.62 12.59 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.352 -0.842 . . . . 0.0 109.607 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.539 ' O ' ' CE1' ' A' ' 105' ' ' HIS . . . -153.84 169.92 32.47 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -73.88 158.86 45.92 Favored 'Trans proline' 0 C--N 1.306 -1.671 0 C-N-CA 122.935 2.424 . . . . 0.0 112.25 179.811 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 81.9 43.21 8.38 Favored Glycine 0 N--CA 1.493 2.459 0 N-CA-C 109.885 -1.286 . . . . 0.0 109.885 179.694 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.418 ' CG1' ' HD1' ' A' ' 105' ' ' HIS . 44.3 mm -117.0 132.7 66.0 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.725 0 O-C-N 121.287 -1.125 . . . . 0.0 109.598 179.981 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . 0.554 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 1.7 mm? -89.23 133.63 34.36 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.214 -0.929 . . . . 0.0 108.756 179.452 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 112' ' ' SER . . . . . 0.561 ' OG ' ' CZ ' ' A' ' 126' ' ' PHE . 99.0 p -143.38 154.26 43.54 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.109 -0.994 . . . . 0.0 109.628 -179.907 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 72.1 mtm -93.64 136.66 33.7 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.305 -0.872 . . . . 0.0 109.213 179.556 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -65.09 138.09 58.08 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.215 -0.928 . . . . 0.0 109.185 179.815 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 70.6 m-20 -135.19 115.29 13.2 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.257 -0.902 . . . . 0.0 109.441 179.88 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -85.1 -9.89 57.43 Favored 'General case' 0 C--N 1.297 -1.675 0 O-C-N 121.501 -0.749 . . . . 0.0 109.096 179.501 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . 0.43 ' H ' HG23 ' A' ' 120' ' ' THR . . . -136.12 173.76 21.76 Favored Glycine 0 N--CA 1.492 2.367 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 -179.746 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -57.09 -25.4 63.41 Favored 'Trans proline' 0 C--N 1.307 -1.648 0 C-N-CA 122.747 2.298 . . . . 0.0 112.196 -179.905 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 119' ' ' ASN . . . . . 0.441 ' O ' ' OD1' ' A' ' 119' ' ' ASN . 42.4 p-10 -153.19 96.18 2.03 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.17 -0.956 . . . . 0.0 109.908 179.836 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 120' ' ' THR . . . . . 0.43 HG23 ' H ' ' A' ' 117' ' ' GLY . 0.5 OUTLIER -148.74 123.81 10.09 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 121.327 -0.858 . . . . 0.0 109.338 179.774 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 51.3 t-20 -100.38 121.84 42.18 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.355 -0.84 . . . . 0.0 109.449 -179.861 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -137.08 158.99 24.52 Favored Glycine 0 N--CA 1.493 2.473 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 78.5 p -69.06 -19.08 64.08 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.345 -1.091 . . . . 0.0 109.645 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.9 mt-30 -66.5 137.44 56.8 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.134 -0.978 . . . . 0.0 109.613 -179.593 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 44.5 p90 -146.49 161.68 39.91 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.33 -0.857 . . . . 0.0 109.323 179.892 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . 0.561 ' CZ ' ' OG ' ' A' ' 112' ' ' SER . 51.9 p90 -141.16 159.05 43.04 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.166 -0.959 . . . . 0.0 109.577 179.716 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 77.7 mt -116.43 135.1 57.77 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.354 -0.841 . . . . 0.0 109.425 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 128' ' ' CYS . . . . . 0.611 ' HG ' ' CE1' ' A' ' 105' ' ' HIS . 0.2 OUTLIER -99.23 99.79 10.81 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.388 -0.82 . . . . 0.0 109.423 -179.871 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 61.9 p -76.3 -6.86 53.37 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.322 -0.861 . . . . 0.0 109.321 179.812 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -139.91 162.76 34.41 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.369 -0.832 . . . . 0.0 109.316 -179.897 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . 0.525 ' O ' ' CZ3' ' A' ' 134' ' ' TRP . 99.2 mttt -71.56 131.99 44.04 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.19 -0.944 . . . . 0.0 109.563 -179.654 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 74.0 p -122.97 37.99 4.29 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.538 -0.726 . . . . 0.0 109.318 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 78.3 mm-40 -57.65 -31.12 65.99 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.272 -0.893 . . . . 0.0 109.733 -179.504 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 134' ' ' TRP . . . . . 0.525 ' CZ3' ' O ' ' A' ' 131' ' ' LYS . 12.7 p90 -55.24 -28.44 53.26 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.047 -1.033 . . . . 0.0 109.64 -179.805 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . 0.503 ' N ' ' CD1' ' A' ' 134' ' ' TRP . 69.0 mt -58.11 -35.93 72.18 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.055 -1.028 . . . . 0.0 109.473 179.3 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 57.2 t0 53.81 69.92 0.66 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.436 -0.79 . . . . 0.0 109.705 179.569 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -138.4 176.36 20.83 Favored Glycine 0 N--CA 1.484 1.857 0 N-CA-C 108.915 -1.674 . . . . 0.0 108.915 179.712 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . 0.427 ' O ' ' O ' ' A' ' 139' ' ' HIS . 63.0 mttp -59.21 -40.12 84.8 Favored 'General case' 0 C--N 1.296 -1.727 0 O-C-N 121.39 -1.065 . . . . 0.0 109.968 -179.768 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 139' ' ' HIS . . . . . 0.427 ' O ' ' O ' ' A' ' 138' ' ' LYS . 61.3 m170 51.75 98.89 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.414 -0.804 . . . . 0.0 109.542 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 52.1 t -105.49 135.18 44.69 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.751 0 O-C-N 121.461 -0.774 . . . . 0.0 109.395 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 48.5 t -117.04 128.71 74.38 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.485 -0.76 . . . . 0.0 109.691 -179.726 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 37.5 p90 -113.31 -1.21 14.32 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.376 -0.828 . . . . 0.0 109.539 179.458 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -173.84 -177.36 42.98 Favored Glycine 0 N--CA 1.493 2.438 0 N-CA-C 109.818 -1.313 . . . . 0.0 109.818 179.842 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.4 pt20 -144.22 171.39 14.37 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.311 -1.111 . . . . 0.0 109.475 -179.763 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 8.3 p -111.08 138.29 40.0 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.902 0 O-C-N 121.268 -0.895 . . . . 0.0 109.281 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 10.5 m -119.32 -28.16 2.05 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.483 -0.761 . . . . 0.0 109.679 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -138.06 167.16 22.37 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.249 -0.907 . . . . 0.0 109.567 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 97.49 3.23 58.6 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.779 -1.329 . . . . 0.0 109.779 179.652 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 149' ' ' MET . . . . . . . . . . . . . 89.2 mtp -60.65 -32.56 71.73 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.183 -1.186 . . . . 0.0 109.771 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . 0.549 ' OD1' ' N ' ' A' ' 151' ' ' VAL . 32.9 p-10 -65.46 -37.44 86.86 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 120.85 -1.156 . . . . 0.0 109.902 -179.565 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . 0.549 ' N ' ' OD1' ' A' ' 150' ' ' ASP . 5.2 p -87.31 -34.31 7.39 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.711 0 O-C-N 121.101 -0.999 . . . . 0.0 110.243 -179.672 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 152' ' ' VAL . . . . . 0.461 ' CG1' ' N ' ' A' ' 153' ' ' LYS . 0.9 OUTLIER -56.04 -42.35 71.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 120.996 -1.065 . . . . 0.0 109.101 -179.513 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 153' ' ' LYS . . . . . 0.461 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 98.7 mttt -64.42 -33.77 76.64 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.172 -0.955 . . . . 0.0 109.433 179.471 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -61.24 -38.8 87.95 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.351 -0.843 . . . . 0.0 110.132 -179.4 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.431 HG21 HD11 ' A' ' 155' ' ' ILE . 86.8 mt -72.3 -36.64 56.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.045 -1.034 . . . . 0.0 110.159 -179.728 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -76.29 -41.69 47.89 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.178 -0.951 . . . . 0.0 111.402 -178.784 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 16.8 pttp -60.45 -35.23 75.36 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 120.744 -1.223 . . . . 0.0 109.734 -178.845 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 32.7 m -82.46 -10.9 12.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.166 -0.958 . . . . 0.0 109.061 179.581 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -70.97 165.1 53.31 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.981 -1.248 . . . . 0.0 109.981 -179.565 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 24.1 t -154.08 168.55 26.1 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.421 -1.046 . . . . 0.0 109.439 -179.82 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 25.1 m -54.32 -29.6 48.33 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.279 -0.888 . . . . 0.0 109.341 179.808 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 24.7 m -53.31 -31.27 43.25 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.287 -0.883 . . . . 0.0 109.589 -179.882 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 96.05 8.98 57.55 Favored Glycine 0 N--CA 1.493 2.472 0 N-CA-C 109.766 -1.333 . . . . 0.0 109.766 179.896 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 82.3 mtm180 -122.93 145.56 48.36 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.209 -1.171 . . . . 0.0 109.471 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 165' ' ' THR . . . . . 0.434 ' OG1' ' O ' ' A' ' 167' ' ' LYS . 80.9 p -80.57 153.52 28.01 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.189 -0.945 . . . . 0.0 109.36 179.79 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -66.0 -34.6 78.46 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.293 -0.879 . . . . 0.0 109.158 179.714 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 167' ' ' LYS . . . . . 0.434 ' O ' ' OG1' ' A' ' 165' ' ' THR . 62.9 mttp -112.38 157.49 20.96 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.466 -0.771 . . . . 0.0 109.262 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 63.0 mttp -69.87 141.69 53.16 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.245 -0.91 . . . . 0.0 109.144 179.912 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 18.2 m -128.05 125.33 64.39 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 121.315 -0.866 . . . . 0.0 109.683 -179.819 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 46.5 t -148.33 152.13 12.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.43 -0.794 . . . . 0.0 109.114 179.766 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -91.15 114.94 29.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.23 -0.919 . . . . 0.0 109.374 -179.753 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -75.68 -11.47 60.01 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.521 -0.737 . . . . 0.0 110.072 -179.882 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 173' ' ' ASP . . . . . 0.475 ' OD1' ' N ' ' A' ' 174' ' ' CYS . 51.8 t0 -164.85 157.79 16.69 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 120.76 -1.212 . . . . 0.0 110.848 -179.31 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 174' ' ' CYS . . . . . 0.475 ' N ' ' OD1' ' A' ' 173' ' ' ASP . 16.7 t -154.85 141.64 19.05 Favored 'General case' 0 N--CA 1.492 1.657 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 179.372 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -178.05 178.08 48.46 Favored Glycine 0 N--CA 1.493 2.48 0 N-CA-C 109.749 -1.34 . . . . 0.0 109.749 179.776 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 60.9 tt0 -106.93 124.06 49.07 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.367 -1.078 . . . . 0.0 109.732 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 30.6 tp -62.92 -37.99 89.22 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.132 -0.98 . . . . 0.0 109.264 179.509 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 33.1 m . . . . . 0 N--CA 1.49 1.549 0 CA-C-O 118.066 -0.969 . . . . 0.0 109.501 -179.967 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 13.4 m-20 . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_endo -67.73 140.81 52.43 Favored 'Trans proline' 0 N--CA 1.494 1.556 0 C-N-CA 122.492 2.128 . . . . 0.0 112.07 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 80.9 mtm180 -126.58 139.18 53.39 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.316 -0.865 . . . . 0.0 109.166 179.614 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 15.0 p -133.71 142.81 40.47 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 121.327 -0.858 . . . . 0.0 109.519 -179.878 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' PHE . . . . . 0.483 ' CE2' ' NH2' ' A' ' 25' ' ' ARG . 28.6 p90 -141.85 155.94 45.54 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.304 -0.872 . . . . 0.0 109.683 -179.598 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -130.46 139.27 50.55 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.484 -0.76 . . . . 0.0 109.777 179.628 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -95.35 117.24 29.97 Favored 'General case' 0 N--CA 1.491 1.601 0 N-CA-C 108.188 -1.041 . . . . 0.0 108.188 178.788 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 76.9 mtp -107.74 147.44 30.79 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.121 -0.987 . . . . 0.0 110.443 -178.816 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 88.4 p -143.3 163.25 33.51 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 179.574 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.401 ' O ' ' C ' ' A' ' 19' ' ' GLY . 29.1 m -122.97 140.55 46.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.218 -0.927 . . . . 0.0 109.476 179.921 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . 0.401 ' C ' ' O ' ' A' ' 18' ' ' VAL . . . 44.46 -102.68 0.04 OUTLIER Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.636 -1.386 . . . . 0.0 109.636 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -130.38 38.15 2.01 Favored Glycine 0 N--CA 1.493 2.475 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 8.4 tt0 -147.18 133.49 9.68 Favored Pre-proline 0 N--CA 1.492 1.656 0 O-C-N 121.125 -1.221 . . . . 0.0 109.181 179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 43.0 Cg_endo -69.9 126.7 13.52 Favored 'Trans proline' 0 N--CA 1.493 1.494 0 C-N-CA 122.193 1.929 . . . . 0.0 112.218 -179.788 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -80.39 -48.21 13.26 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.288 -0.883 . . . . 0.0 109.432 179.849 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 170.94 -169.41 42.42 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.37 -1.492 . . . . 0.0 109.37 -179.788 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . 0.483 ' NH2' ' CE2' ' A' ' 13' ' ' PHE . 66.4 ttt180 -116.93 142.47 46.9 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.413 -1.051 . . . . 0.0 109.291 179.942 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 86.9 mt -120.68 128.03 75.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.424 -0.797 . . . . 0.0 108.998 179.804 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 46.1 t -116.99 133.81 62.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.508 -0.745 . . . . 0.0 109.311 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 71.3 mtm -125.38 147.37 49.19 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.343 -0.848 . . . . 0.0 109.251 179.91 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -112.56 132.6 55.03 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.267 -0.896 . . . . 0.0 109.84 -179.686 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 11.8 mt -103.09 139.66 38.33 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.416 -0.802 . . . . 0.0 109.36 179.262 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -95.6 113.32 24.95 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 108.342 -0.985 . . . . 0.0 108.342 178.795 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -73.96 -42.8 59.97 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 121.232 -0.917 . . . . 0.0 109.94 -179.376 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 56.6 t0 -61.33 -46.58 89.66 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.191 -0.943 . . . . 0.0 110.163 -179.36 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' THR . . . . . 0.432 ' O ' ' OE1' ' A' ' 99' ' ' GLU . 24.0 m -72.41 -45.77 58.18 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.16 -0.962 . . . . 0.0 110.215 -179.596 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 6.4 p -137.87 80.66 29.95 Favored Pre-proline 0 N--CA 1.494 1.774 0 O-C-N 121.162 -0.962 . . . . 0.0 110.069 -179.224 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -77.24 -6.18 16.29 Favored 'Trans proline' 0 C--N 1.307 -1.645 0 C-N-CA 122.507 2.138 . . . . 0.0 111.642 179.546 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 4.5 tpt180 -94.29 -67.03 0.88 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.375 -0.828 . . . . 0.0 110.151 -178.797 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 46.4 m -56.46 -43.32 79.43 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.191 -0.943 . . . . 0.0 110.231 -179.058 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -61.77 -31.71 71.93 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.146 -0.971 . . . . 0.0 108.968 179.747 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -75.51 -51.18 13.55 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.272 -0.893 . . . . 0.0 109.9 -179.898 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 54.2 t-20 -60.39 -46.71 88.99 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.177 -0.952 . . . . 0.0 109.605 -179.707 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . 0.51 ' CE2' ' SG ' ' A' ' 46' ' ' CYS . 71.8 t80 -61.28 -43.23 99.22 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.3 -0.875 . . . . 0.0 109.215 179.637 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 60.1 ttp180 -56.63 -38.37 72.02 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.466 -0.771 . . . . 0.0 109.844 179.825 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.474 ' O ' ' N ' ' A' ' 48' ' ' GLY . . . -62.85 -44.21 96.74 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.137 -0.977 . . . . 0.0 109.915 -179.507 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.434 ' N ' ' CD2' ' A' ' 45' ' ' LEU . 3.7 mm? -62.96 -39.06 93.52 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.097 -1.002 . . . . 0.0 109.131 179.729 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' CYS . . . . . 0.51 ' SG ' ' CE2' ' A' ' 42' ' ' PHE . 3.4 m -69.52 -62.4 1.4 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.259 -0.901 . . . . 0.0 109.473 -179.875 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 35.5 m -63.13 -38.57 91.71 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.398 -0.814 . . . . 0.0 109.272 179.889 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . 0.474 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 80.83 35.33 25.18 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 110.197 -1.161 . . . . 0.0 110.197 179.555 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -62.52 -38.13 88.75 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.046 -1.267 . . . . 0.0 109.544 179.89 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 69.3 mmtt -62.56 -37.18 85.14 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.178 -0.951 . . . . 0.0 109.777 -179.83 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 89.34 170.01 44.58 Favored Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.297 -1.521 . . . . 0.0 109.297 -179.646 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 91.3 m -77.66 139.52 39.47 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.355 -1.085 . . . . 0.0 109.706 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -63.25 139.41 44.18 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 31.6 mmt180 -59.68 -34.37 72.78 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.33 -1.1 . . . . 0.0 109.767 -179.72 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 85.9 p -61.55 -25.58 67.39 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.222 -0.924 . . . . 0.0 109.902 -179.667 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 113.78 93.1 1.99 Allowed Glycine 0 N--CA 1.495 2.596 0 N-CA-C 109.063 -1.615 . . . . 0.0 109.063 -179.64 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . 0.477 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 30.3 ttmt -177.64 80.43 0.24 Allowed Pre-proline 0 N--CA 1.49 1.543 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 -179.769 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . 0.523 ' O ' ' CE2' ' A' ' 80' ' ' PHE . 74.6 Cg_exo -49.64 127.23 18.07 Favored 'Trans proline' 0 C--N 1.304 -1.812 0 C-N-CA 122.847 2.365 . . . . 0.0 112.768 -178.898 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.477 ' CD1' ' O ' ' A' ' 57' ' ' LYS . 8.7 mp -96.97 19.68 12.39 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.57 -0.707 . . . . 0.0 109.263 179.808 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 27.2 m170 -112.44 132.01 55.27 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.354 -0.841 . . . . 0.0 109.759 -179.441 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 46.4 m-85 -71.93 -1.92 16.18 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.217 -0.927 . . . . 0.0 108.838 178.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 43.6 tttm -54.85 144.23 23.34 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.411 -0.805 . . . . 0.0 109.712 -179.88 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 51.1 t0 58.99 45.57 14.72 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.549 -0.719 . . . . 0.0 109.623 179.853 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 87.7 p -116.52 152.12 34.74 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.394 -0.817 . . . . 0.0 109.131 179.547 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 29.4 t -120.95 146.73 46.35 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.395 -0.816 . . . . 0.0 109.506 -179.725 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.428 ' CD2' ' SG ' ' A' ' 75' ' ' CYS . 3.8 m-30 -65.7 134.02 52.31 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.247 -0.908 . . . . 0.0 108.992 179.763 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 78.5 t60 -62.1 -50.73 70.74 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.265 -0.897 . . . . 0.0 110.1 -179.36 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 29.1 ptt180 -164.61 160.41 20.09 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.062 -1.024 . . . . 0.0 109.471 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -141.05 130.08 24.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.217 -0.927 . . . . 0.0 109.585 179.588 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 21.9 mt -121.93 110.11 33.39 Favored Pre-proline 0 N--CA 1.491 1.6 0 N-CA-C 108.874 -0.788 . . . . 0.0 108.874 179.443 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_exo -50.39 140.69 34.29 Favored 'Trans proline' 0 C--N 1.311 -1.438 0 C-N-CA 122.341 2.028 . . . . 0.0 112.758 -179.478 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 86.09 -56.29 4.8 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 110.407 -1.077 . . . . 0.0 110.407 179.038 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 81.2 m-85 -66.51 -75.18 0.1 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.005 -1.291 . . . . 0.0 110.178 -179.303 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 12.9 ptt? 179.63 -168.07 0.09 Allowed 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.01 -1.056 . . . . 0.0 109.912 -179.788 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' CYS . . . . . 0.428 ' SG ' ' CD2' ' A' ' 66' ' ' PHE . 7.7 t -128.76 129.34 45.57 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.544 -0.723 . . . . 0.0 109.276 179.743 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 63.7 tt0 -100.12 112.96 25.27 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.148 -0.97 . . . . 0.0 109.321 179.816 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -63.17 -37.32 94.71 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.772 -1.331 . . . . 0.0 109.772 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 82.23 -164.88 44.4 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.22 -1.552 . . . . 0.0 109.22 -179.671 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.466 ' OD2' ' OG1' ' A' ' 81' ' ' THR . 18.0 t70 -143.82 147.5 34.2 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.203 -1.175 . . . . 0.0 109.385 179.938 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.523 ' CE2' ' O ' ' A' ' 58' ' ' PRO . 50.5 p90 -70.89 -20.58 62.49 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.228 -0.92 . . . . 0.0 109.943 -179.79 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.466 ' OG1' ' OD2' ' A' ' 79' ' ' ASP . 59.0 p -69.26 -28.42 66.3 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.129 -0.982 . . . . 0.0 109.703 -179.817 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 176.57 -58.13 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.277 -0.89 . . . . 0.0 109.47 179.904 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 90.7 2.54 72.32 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 109.413 -1.475 . . . . 0.0 109.413 -179.854 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . 0.597 ' ND2' ' H ' ' A' ' 86' ' ' THR . 0.0 OUTLIER -88.55 7.26 34.03 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.279 -1.13 . . . . 0.0 109.589 179.919 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . 0.507 ' N ' HD21 ' A' ' 84' ' ' ASN . . . 98.29 -37.87 3.31 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 -179.88 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' THR . . . . . 0.597 ' H ' ' ND2' ' A' ' 84' ' ' ASN . 49.4 p -71.38 -25.24 62.28 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.196 -1.179 . . . . 0.0 109.047 179.661 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -86.52 -165.92 41.69 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 179.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 85.44 37.08 9.97 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -60.17 148.4 36.33 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.249 -1.148 . . . . 0.0 109.421 179.925 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 50.3 m -108.01 149.13 28.79 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.402 -0.811 . . . . 0.0 109.391 -179.886 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 21.6 pt -66.24 -32.24 57.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.211 -0.931 . . . . 0.0 110.047 -179.534 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 49.1 m-85 -64.3 -37.4 87.35 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.012 -1.055 . . . . 0.0 109.448 -179.912 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 81.51 8.27 87.22 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.157 -1.577 . . . . 0.0 109.157 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -150.35 155.69 40.09 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.272 -1.134 . . . . 0.0 109.525 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 62.6 mttt -92.95 154.84 17.93 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.241 -0.912 . . . . 0.0 109.641 179.927 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . 0.621 ' CG ' ' ND2' ' A' ' 121' ' ' ASN . 38.6 p90 -128.65 156.17 43.85 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.387 -0.82 . . . . 0.0 109.281 179.563 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -65.0 147.31 53.7 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.216 -0.927 . . . . 0.0 110.358 -179.139 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -62.48 154.33 28.86 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.315 -0.866 . . . . 0.0 109.609 179.912 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . 0.432 ' OE1' ' O ' ' A' ' 34' ' ' THR . 94.6 mt-10 -85.35 -175.41 5.68 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.283 -0.886 . . . . 0.0 109.755 -179.833 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 18.5 m120 -60.3 162.78 5.67 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.416 -0.803 . . . . 0.0 109.94 -179.422 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 -98.67 23.63 8.46 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.43 -0.794 . . . . 0.0 109.585 -179.817 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 97.0 mt -48.38 -42.94 12.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.138 -0.977 . . . . 0.0 109.937 -179.327 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 103' ' ' LYS . . . . . 0.425 ' CE ' ' HG1' ' A' ' 34' ' ' THR . 59.0 mttm -89.47 139.29 30.67 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 120.931 -1.106 . . . . 0.0 109.689 179.972 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 87.5 mttt -127.28 -172.35 2.64 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.492 -0.755 . . . . 0.0 109.489 -179.898 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 105' ' ' HIS . . . . . 0.428 ' C ' ' ND1' ' A' ' 105' ' ' HIS . 12.3 t-80 -113.77 111.67 22.16 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.531 -0.73 . . . . 0.0 109.189 179.752 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 60.6 p -131.16 4.82 4.43 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.276 -0.89 . . . . 0.0 109.922 -179.862 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -149.37 169.46 29.66 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.825 -1.31 . . . . 0.0 109.825 -179.824 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 76.6 Cg_endo -79.54 155.39 24.48 Favored 'Trans proline' 0 C--N 1.309 -1.543 0 C-N-CA 122.942 2.428 . . . . 0.0 112.083 179.783 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 76.89 52.61 5.72 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.894 -1.282 . . . . 0.0 109.894 179.628 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 38.1 mm -115.21 136.38 52.14 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.403 -1.057 . . . . 0.0 109.51 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . 0.561 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 3.3 mm? -88.27 134.37 33.82 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.227 -0.921 . . . . 0.0 109.537 179.786 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 28.9 t -146.3 142.79 28.65 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.255 -0.903 . . . . 0.0 109.374 179.729 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 87.6 mmm -87.64 132.06 34.22 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.231 -0.918 . . . . 0.0 109.284 179.902 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . 0.463 ' O ' ' OD1' ' A' ' 115' ' ' ASN . . . -68.23 139.69 56.04 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.123 -0.986 . . . . 0.0 109.405 -179.948 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . 0.463 ' OD1' ' O ' ' A' ' 114' ' ' ALA . 70.3 m-20 -145.94 113.44 6.31 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.247 -0.908 . . . . 0.0 109.01 179.642 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -69.15 -30.04 68.19 Favored 'General case' 0 C--N 1.297 -1.687 0 O-C-N 121.393 -0.817 . . . . 0.0 109.442 179.816 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -136.11 170.28 23.29 Favored Glycine 0 N--CA 1.494 2.525 0 N-CA-C 109.146 -1.582 . . . . 0.0 109.146 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -67.61 151.99 78.73 Favored 'Trans proline' 0 C--N 1.305 -1.719 0 C-N-CA 122.77 2.314 . . . . 0.0 111.847 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 16.9 m120 53.34 44.26 30.32 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.33 -0.856 . . . . 0.0 109.143 -179.769 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 120' ' ' THR . . . . . 0.451 ' O ' ' OD1' ' A' ' 115' ' ' ASN . 58.3 m -132.26 123.83 27.69 Favored 'General case' 0 N--CA 1.486 1.373 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 179.924 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 121' ' ' ASN . . . . . 0.621 ' ND2' ' CG ' ' A' ' 96' ' ' PHE . 81.0 m-20 -113.39 138.62 49.8 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.506 -0.746 . . . . 0.0 109.537 -179.832 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -138.54 148.09 19.69 Favored Glycine 0 N--CA 1.493 2.489 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 23.3 m -61.23 -32.55 72.34 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.227 -1.16 . . . . 0.0 109.822 179.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.5 mt-30 -64.24 143.26 58.02 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.207 -0.933 . . . . 0.0 109.879 -179.481 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 48.7 p90 -141.42 163.9 31.68 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.346 -0.846 . . . . 0.0 109.028 179.858 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 45.3 p90 -136.91 158.14 45.14 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.299 -0.876 . . . . 0.0 109.696 -179.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 68.5 mt -120.39 136.53 57.13 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.519 -0.738 . . . . 0.0 109.273 179.799 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -108.5 120.82 43.54 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.457 -0.777 . . . . 0.0 109.358 -179.796 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 1.4 t -88.72 0.98 55.94 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.199 -0.938 . . . . 0.0 109.236 179.816 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -148.19 155.48 41.44 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.271 -0.893 . . . . 0.0 109.176 179.937 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 7.7 ttpm? -75.64 127.91 34.09 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.184 -0.947 . . . . 0.0 109.516 179.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 22.6 p -126.98 126.69 43.62 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.37 -0.831 . . . . 0.0 109.247 179.882 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -72.23 -36.56 69.16 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.28 -0.887 . . . . 0.0 110.366 -179.582 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 0.4 OUTLIER -65.03 -41.76 94.99 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.135 -0.978 . . . . 0.0 110.043 -179.157 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . 0.44 ' O ' ' CD2' ' A' ' 139' ' ' HIS . 12.9 mt -66.59 -33.83 76.53 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.985 -1.072 . . . . 0.0 109.8 179.701 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -68.46 140.85 55.75 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.15 -0.969 . . . . 0.0 109.522 -179.824 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 134.59 -86.19 0.26 Allowed Glycine 0 N--CA 1.492 2.417 0 N-CA-C 109.684 -1.366 . . . . 0.0 109.684 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 31.6 mmtp -85.97 5.32 33.79 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.132 -1.216 . . . . 0.0 109.507 -179.835 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 139' ' ' HIS . . . . . 0.44 ' CD2' ' O ' ' A' ' 135' ' ' LEU . 54.4 m-70 -103.26 138.19 40.38 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.286 -0.884 . . . . 0.0 109.477 -179.955 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 43.2 t -120.48 141.54 40.38 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 O-C-N 121.415 -0.803 . . . . 0.0 109.684 -179.565 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 96.1 t -94.8 128.96 45.61 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.361 -0.837 . . . . 0.0 109.245 179.821 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 38.0 p90 -116.18 0.42 12.92 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.429 -0.794 . . . . 0.0 109.757 -179.77 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -169.42 178.04 42.71 Favored Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.676 -1.37 . . . . 0.0 109.676 179.684 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.2 pt20 -145.13 165.8 27.25 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.21 -1.171 . . . . 0.0 109.479 -179.865 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 77.7 t -96.54 127.28 48.82 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.265 0 O-C-N 121.193 -0.942 . . . . 0.0 109.274 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 22.2 m -94.7 -33.77 5.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.134 -0.979 . . . . 0.0 109.746 179.916 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -144.94 171.92 13.77 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.248 -0.907 . . . . 0.0 109.663 -179.797 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 96.68 4.93 58.99 Favored Glycine 0 N--CA 1.493 2.435 0 N-CA-C 109.915 -1.274 . . . . 0.0 109.915 179.642 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 149' ' ' MET . . . . . 0.418 ' O ' HG11 ' A' ' 152' ' ' VAL . 71.9 mtm -60.31 -33.05 71.82 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.071 -1.252 . . . . 0.0 109.809 179.888 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -65.63 -42.49 91.44 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 120.87 -1.144 . . . . 0.0 110.085 -179.586 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 6.5 p -81.73 -34.33 12.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.149 -0.969 . . . . 0.0 110.522 -179.484 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 152' ' ' VAL . . . . . 0.596 ' O ' ' OE1' ' A' ' 156' ' ' GLU . 0.8 OUTLIER -52.55 -43.07 41.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 120.816 -1.178 . . . . 0.0 109.0 -179.13 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 153' ' ' LYS . . . . . 0.454 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 48.5 mttp -63.12 -34.41 77.54 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.192 -0.942 . . . . 0.0 109.317 179.251 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -63.27 -32.11 73.43 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.429 -0.795 . . . . 0.0 110.176 -179.558 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 69.1 mt -68.79 -43.14 82.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.124 -0.985 . . . . 0.0 110.836 -179.179 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . 0.596 ' OE1' ' O ' ' A' ' 152' ' ' VAL . 32.4 mp0 -77.21 -37.98 52.32 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 120.768 -1.207 . . . . 0.0 112.025 -178.683 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 12.1 pttm -57.48 -35.55 70.33 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 120.523 -1.36 . . . . 0.0 109.731 -178.516 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 26.9 m -75.11 -19.8 16.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 120.969 -1.082 . . . . 0.0 109.013 179.042 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -67.33 167.46 40.04 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 -179.911 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 89.4 p -148.74 168.22 23.48 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.316 -1.108 . . . . 0.0 109.42 -179.798 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 22.9 m -54.55 -34.21 61.45 Favored 'General case' 0 N--CA 1.487 1.406 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 179.425 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 23.9 m -58.39 -30.77 67.07 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.472 -0.767 . . . . 0.0 109.063 179.438 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.69 7.49 55.52 Favored Glycine 0 N--CA 1.492 2.431 0 N-CA-C 109.814 -1.315 . . . . 0.0 109.814 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 75.3 ttt-85 -114.74 139.5 49.65 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.31 -1.112 . . . . 0.0 109.084 179.781 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 165' ' ' THR . . . . . 0.422 ' OG1' ' O ' ' A' ' 167' ' ' LYS . 51.1 p -87.47 156.24 19.64 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.214 -0.929 . . . . 0.0 109.879 -179.768 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -66.8 -37.22 84.13 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.531 -0.731 . . . . 0.0 109.433 179.765 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 167' ' ' LYS . . . . . 0.422 ' O ' ' OG1' ' A' ' 165' ' ' THR . 67.2 mttm -111.25 156.82 20.89 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.411 -0.805 . . . . 0.0 109.606 -179.835 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 94.3 mttt -76.24 139.77 41.31 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.287 -0.883 . . . . 0.0 109.331 179.871 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 43.1 t -118.02 126.35 74.84 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.265 -0.897 . . . . 0.0 109.636 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 42.6 t -146.0 150.3 15.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.345 -0.847 . . . . 0.0 109.294 179.608 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -88.54 122.12 39.62 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 O-C-N 121.288 -0.882 . . . . 0.0 109.691 -179.446 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -67.0 -25.61 66.39 Favored 'General case' 0 C--N 1.3 -1.565 0 O-C-N 121.438 -0.789 . . . . 0.0 109.536 179.56 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 173' ' ' ASP . . . . . 0.413 ' OD1' ' N ' ' A' ' 174' ' ' CYS . 44.9 t0 -173.06 169.96 4.52 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.01 -1.056 . . . . 0.0 110.542 -179.383 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 174' ' ' CYS . . . . . 0.413 ' N ' ' OD1' ' A' ' 173' ' ' ASP . 30.4 p -152.61 150.35 29.42 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.501 -0.749 . . . . 0.0 109.014 179.416 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . 179.71 -177.07 47.99 Favored Glycine 0 N--CA 1.494 2.528 0 N-CA-C 110.044 -1.222 . . . . 0.0 110.044 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 58.9 tt0 -105.33 122.39 45.86 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.529 -0.983 . . . . 0.0 109.632 -179.868 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 177' ' ' LEU . . . . . 0.464 ' O ' ' C ' ' A' ' 178' ' ' SER . 0.2 OUTLIER -65.2 -40.82 94.71 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.171 -0.956 . . . . 0.0 108.566 179.485 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 178' ' ' SER . . . . . 0.464 ' C ' ' O ' ' A' ' 177' ' ' LEU . 1.2 t . . . . . 0 N--CA 1.493 1.702 0 CA-C-O 118.022 -0.99 . . . . 0.0 109.935 179.859 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.494 1.738 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -69.18 138.53 39.92 Favored 'Trans proline' 0 N--CA 1.496 1.627 0 C-N-CA 122.744 2.296 . . . . 0.0 112.306 179.913 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . 0.469 HH21 ' CD2' ' A' ' 177' ' ' LEU . 50.8 ttp180 -133.69 126.53 30.96 Favored 'General case' 0 N--CA 1.49 1.568 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 179.143 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.5 p -131.88 141.83 44.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.29 -0.881 . . . . 0.0 109.521 -179.139 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 40.5 p90 -140.28 157.87 44.9 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.379 -0.826 . . . . 0.0 109.524 -179.602 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 95.2 m-85 -126.93 142.58 51.51 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.472 -0.768 . . . . 0.0 109.808 179.902 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 19.1 t70 -93.74 113.51 25.59 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.412 -0.958 . . . . 0.0 108.412 178.931 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 96.8 mmm -97.13 146.54 24.95 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.452 -0.78 . . . . 0.0 110.112 -179.164 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.516 ' HG ' ' N ' ' A' ' 18' ' ' VAL . 41.8 t -149.58 162.07 40.91 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.457 -0.777 . . . . 0.0 109.036 179.628 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.516 ' N ' ' HG ' ' A' ' 17' ' ' SER . 25.6 m -124.27 159.9 29.36 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.314 -0.867 . . . . 0.0 109.562 179.894 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -49.18 -30.45 10.64 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.822 -1.311 . . . . 0.0 109.822 -179.475 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -73.93 -79.65 0.52 Allowed Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.674 -1.37 . . . . 0.0 109.674 -179.837 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 4.2 pt20 -146.35 157.15 49.43 Favored Pre-proline 0 N--CA 1.494 1.727 0 O-C-N 121.177 -1.19 . . . . 0.0 109.129 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 75.6 Cg_exo -45.78 130.31 12.51 Favored 'Trans proline' 0 C--N 1.31 -1.455 0 C-N-CA 122.25 1.967 . . . . 0.0 112.138 179.792 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -80.05 -56.42 4.25 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.28 -0.888 . . . . 0.0 109.703 -179.891 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 168.82 -170.74 42.54 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 -179.898 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 56.9 ttp180 -114.48 142.01 46.95 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.392 -1.063 . . . . 0.0 109.338 179.818 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . 0.436 HG22 HD12 ' A' ' 26' ' ' ILE . 81.5 mt -120.04 130.5 74.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.429 -0.795 . . . . 0.0 109.012 179.877 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 43.6 t -110.56 134.63 52.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.386 -0.821 . . . . 0.0 109.717 -179.792 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 72.1 mtm -121.71 151.89 40.0 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.447 -0.783 . . . . 0.0 109.082 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -105.54 132.86 51.17 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.265 -0.897 . . . . 0.0 110.053 -179.517 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -105.18 129.52 53.55 Favored 'General case' 0 N--CA 1.494 1.767 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 179.143 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -97.7 119.0 35.5 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.207 -0.933 . . . . 0.0 109.131 179.716 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -81.39 -42.21 20.78 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.383 -0.823 . . . . 0.0 109.638 179.847 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -64.8 -46.11 83.42 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.281 -0.887 . . . . 0.0 110.215 -179.388 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 28.4 m -65.99 -45.4 81.74 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.163 -0.961 . . . . 0.0 109.589 -179.766 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.509 ' O ' ' OG1' ' A' ' 35' ' ' THR . 4.1 p -141.38 80.58 16.33 Favored Pre-proline 0 N--CA 1.492 1.668 0 N-CA-C 108.798 -0.816 . . . . 0.0 108.798 179.912 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_endo -59.49 -65.1 0.09 OUTLIER 'Trans proline' 0 N--CA 1.496 1.622 0 C-N-CA 122.419 2.079 . . . . 0.0 113.018 -178.843 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 94.8 mtt180 -60.62 -36.88 79.7 Favored 'General case' 0 C--N 1.298 -1.668 0 O-C-N 121.596 -0.69 . . . . 0.0 110.965 -178.769 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 23.0 m -60.85 -43.32 98.48 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 120.928 -1.107 . . . . 0.0 109.954 -179.423 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -61.94 -31.58 71.91 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.176 -0.952 . . . . 0.0 108.87 179.769 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -70.52 -41.73 72.21 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.352 -0.842 . . . . 0.0 109.937 -179.862 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 81.5 m-20 -60.71 -45.31 94.69 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.137 -0.977 . . . . 0.0 109.75 -179.585 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 56.3 t80 -71.76 -48.24 48.2 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.202 -0.936 . . . . 0.0 109.225 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . 0.509 ' CD ' ' NE2' ' A' ' 176' ' ' GLN . 61.8 ttp180 -58.24 -38.92 77.82 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.47 -0.768 . . . . 0.0 109.887 179.917 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.489 ' O ' ' N ' ' A' ' 48' ' ' GLY . . . -60.99 -40.59 94.09 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.289 -0.882 . . . . 0.0 110.22 -178.925 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -61.61 -39.38 91.03 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.056 -1.027 . . . . 0.0 109.473 179.946 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' CYS . . . . . . . . . . . . . 20.1 m -80.87 -53.13 6.74 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.015 -1.053 . . . . 0.0 109.71 -179.832 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 68.8 p -69.17 -36.74 77.67 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.336 -0.853 . . . . 0.0 109.855 -179.821 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . 0.489 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 73.6 32.79 59.09 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.815 -1.314 . . . . 0.0 109.815 179.636 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 78.1 mm-40 -60.91 -37.43 82.21 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.081 -1.246 . . . . 0.0 109.262 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 32.5 mmtm -61.39 -31.38 71.29 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.311 -0.868 . . . . 0.0 109.303 179.649 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 97.59 169.2 32.7 Favored Glycine 0 N--CA 1.489 2.168 0 N-CA-C 109.323 -1.511 . . . . 0.0 109.323 -179.773 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 98.1 m -75.32 141.68 43.33 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.289 -1.124 . . . . 0.0 109.749 -179.84 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -56.78 140.3 44.25 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.254 -1.538 . . . . 0.0 109.254 179.87 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 93.5 mtt-85 -59.04 -33.39 70.71 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.189 -1.183 . . . . 0.0 109.998 -179.787 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 86.6 p -60.55 -25.46 66.18 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.161 -0.962 . . . . 0.0 109.902 -179.397 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 108.8 90.45 2.11 Favored Glycine 0 N--CA 1.495 2.578 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 -179.756 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . 0.431 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 17.7 tttm -176.26 78.62 0.28 Allowed Pre-proline 0 N--CA 1.489 1.493 0 O-C-N 121.397 -1.06 . . . . 0.0 108.46 -179.683 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 87.0 Cg_exo -47.31 128.9 15.26 Favored 'Trans proline' 0 C--N 1.304 -1.793 0 C-N-CA 122.66 2.24 . . . . 0.0 112.174 -179.046 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.537 ' O ' ' CG ' ' A' ' 60' ' ' HIS . 7.2 mp -91.62 94.78 9.57 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.684 -0.635 . . . . 0.0 109.753 -179.348 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . 0.537 ' CG ' ' O ' ' A' ' 59' ' ' LEU . 93.7 m-70 -159.75 125.39 4.17 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.358 -0.839 . . . . 0.0 109.531 179.685 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . 0.428 ' O ' ' OG ' ' A' ' 64' ' ' SER . 55.5 m-85 -68.59 -5.05 17.7 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.104 -0.997 . . . . 0.0 108.986 179.269 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 35.2 ttmt -54.74 144.9 20.8 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.463 -0.773 . . . . 0.0 109.743 -179.866 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 84.1 m-20 56.25 45.41 23.17 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.612 -0.68 . . . . 0.0 109.793 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.428 ' OG ' ' O ' ' A' ' 61' ' ' TYR . 39.3 m -120.23 147.91 44.35 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.413 -0.804 . . . . 0.0 108.996 179.528 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 30.0 t -113.12 147.04 38.15 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.424 -0.798 . . . . 0.0 109.554 -179.699 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 4.2 m-30 -64.79 136.31 56.77 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.279 -0.888 . . . . 0.0 108.959 179.951 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 53.3 t-80 -61.5 -50.53 72.34 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.274 -0.891 . . . . 0.0 110.285 -179.193 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.677 HH21 ' NE2' ' A' ' 76' ' ' GLN . 36.8 ptt180 -161.47 160.71 29.56 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.117 -0.989 . . . . 0.0 110.136 -179.757 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 24.0 m -132.91 151.34 34.14 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.509 -0.744 . . . . 0.0 108.993 179.716 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 11.6 mt -146.92 119.83 4.91 Favored Pre-proline 0 N--CA 1.492 1.657 0 O-C-N 121.038 -1.039 . . . . 0.0 109.436 179.78 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -74.68 135.35 19.59 Favored 'Trans proline' 0 C--N 1.312 -1.368 0 C-N-CA 122.161 1.907 . . . . 0.0 111.997 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 90.39 1.1 75.47 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 93.1 m-85 -135.81 -90.76 0.29 Allowed 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.376 -1.073 . . . . 0.0 109.632 179.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 9.6 ptp -170.28 172.62 6.13 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.109 -0.994 . . . . 0.0 109.618 -179.946 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 1.7 m -116.14 138.9 50.86 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.403 -0.811 . . . . 0.0 108.877 179.748 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' GLN . . . . . 0.677 ' NE2' HH21 ' A' ' 68' ' ' ARG . 94.6 mt-30 -108.54 154.87 21.32 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.269 -0.894 . . . . 0.0 109.707 -179.683 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -147.04 -165.79 11.96 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 -179.816 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.47 ' O ' ' N ' ' A' ' 80' ' ' PHE . . . 94.37 11.59 57.03 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 109.459 -1.457 . . . . 0.0 109.459 -179.737 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -48.15 -15.4 0.07 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.391 -1.064 . . . . 0.0 109.594 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.47 ' N ' ' O ' ' A' ' 78' ' ' GLY . 81.2 t80 -48.21 -47.96 35.21 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.229 -0.919 . . . . 0.0 110.2 -179.535 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.761 ' CB ' ' H ' ' A' ' 88' ' ' GLY . 54.4 p -71.15 -32.18 68.62 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.916 -1.115 . . . . 0.0 109.49 -179.929 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . 0.484 ' CB ' ' O ' ' A' ' 81' ' ' THR . . . 163.21 -54.64 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.426 -0.796 . . . . 0.0 109.14 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 91.77 1.04 71.23 Favored Glycine 0 N--CA 1.492 2.42 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 179.947 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 78.6 m-20 -87.63 5.91 37.18 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.225 -1.162 . . . . 0.0 109.474 179.923 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 95.53 -39.82 2.78 Favored Glycine 0 N--CA 1.493 2.45 0 N-CA-C 109.263 -1.535 . . . . 0.0 109.263 -179.79 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 56.3 p -73.85 -14.2 61.05 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.418 -1.048 . . . . 0.0 108.944 179.665 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -80.66 -160.76 24.0 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 -179.881 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.761 ' H ' ' CB ' ' A' ' 81' ' ' THR . . . 89.54 23.18 34.54 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.426 -1.47 . . . . 0.0 109.426 -179.819 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -55.69 148.89 15.27 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.293 -1.122 . . . . 0.0 109.529 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 49.8 m -105.14 151.12 24.43 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.394 -0.816 . . . . 0.0 109.384 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 27.6 pt -62.78 -32.48 55.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.247 -0.908 . . . . 0.0 109.974 -179.549 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 89.6 m-85 -65.08 -35.19 80.36 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.155 -0.965 . . . . 0.0 109.606 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 87.1 7.43 77.23 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.391 -1.483 . . . . 0.0 109.391 -179.862 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -147.53 155.89 42.3 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.32 -1.106 . . . . 0.0 109.376 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 64.1 mttp -89.89 143.65 26.61 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.255 -0.903 . . . . 0.0 109.82 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 41.4 p90 -138.15 160.38 39.55 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.543 -0.723 . . . . 0.0 109.067 179.779 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -67.35 132.79 48.38 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.04 -1.037 . . . . 0.0 109.596 -179.599 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -75.27 140.02 42.91 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.4 -0.813 . . . . 0.0 109.799 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -59.83 149.06 32.41 Favored 'General case' 0 C--N 1.305 -1.35 0 O-C-N 121.309 -0.87 . . . . 0.0 109.093 179.581 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . 0.41 ' N ' HD21 ' A' ' 100' ' ' ASN . 2.8 m120 -53.36 162.56 0.73 Allowed 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.409 -0.807 . . . . 0.0 109.309 -179.942 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 101' ' ' PHE . . . . . 0.584 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 22.3 p90 -130.63 82.15 2.04 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.462 -0.774 . . . . 0.0 109.372 -179.787 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 87.8 mt -60.31 -33.97 55.79 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.18 -0.95 . . . . 0.0 109.478 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 91.6 mttt -84.45 136.29 33.9 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.311 -0.868 . . . . 0.0 109.342 179.932 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 61.9 mttp -116.31 -178.62 3.46 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.485 -0.759 . . . . 0.0 109.986 -179.877 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 105' ' ' HIS . . . . . 0.526 ' O ' ' CG ' ' A' ' 105' ' ' HIS . 49.9 p-80 -99.79 101.39 12.53 Favored 'General case' 0 N--CA 1.493 1.694 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 179.692 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 66.5 p -101.19 -2.16 32.01 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.273 -0.892 . . . . 0.0 109.768 -179.743 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -149.8 171.91 29.79 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -74.24 157.81 45.61 Favored 'Trans proline' 0 C--N 1.304 -1.785 0 C-N-CA 122.899 2.399 . . . . 0.0 112.027 179.784 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 84.91 40.47 8.1 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 110.158 -1.177 . . . . 0.0 110.158 179.663 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 43.0 mm -113.66 133.55 59.26 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.382 -1.07 . . . . 0.0 109.183 179.677 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . 0.53 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 3.4 mm? -90.61 133.15 35.31 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.145 -0.972 . . . . 0.0 109.825 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 112' ' ' SER . . . . . 0.459 ' OG ' ' O ' ' A' ' 140' ' ' VAL . 42.9 t -144.8 142.6 30.1 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.353 -0.842 . . . . 0.0 109.197 179.744 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 113' ' ' MET . . . . . 0.586 ' SD ' ' CE1' ' A' ' 142' ' ' PHE . 83.8 mmm -83.97 129.79 34.91 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.12 -0.988 . . . . 0.0 109.288 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . 0.531 ' O ' ' ND2' ' A' ' 115' ' ' ASN . . . -69.6 143.94 53.16 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.283 -0.886 . . . . 0.0 109.462 -179.951 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . 0.531 ' ND2' ' O ' ' A' ' 114' ' ' ALA . 14.6 m120 -142.94 112.72 6.96 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.363 -0.836 . . . . 0.0 108.961 179.463 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -69.45 -29.51 67.22 Favored 'General case' 0 C--N 1.298 -1.66 0 O-C-N 121.471 -0.768 . . . . 0.0 109.657 -179.872 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -134.43 166.73 24.09 Favored Glycine 0 N--CA 1.493 2.477 0 N-CA-C 109.406 -1.477 . . . . 0.0 109.406 179.888 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -68.88 153.82 72.08 Favored 'Trans proline' 0 C--N 1.305 -1.721 0 C-N-CA 122.81 2.34 . . . . 0.0 111.94 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 17.9 m120 54.19 43.17 31.01 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.483 -0.761 . . . . 0.0 109.441 -179.925 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 92.8 m -134.91 125.07 25.98 Favored 'General case' 0 N--CA 1.485 1.324 0 O-C-N 121.42 -0.8 . . . . 0.0 108.929 179.928 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 22.6 t-20 -103.05 102.6 12.63 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.469 -0.77 . . . . 0.0 109.391 179.828 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -92.93 133.93 11.95 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.414 -1.474 . . . . 0.0 109.414 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 83.3 p -63.77 -23.46 67.37 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.191 -1.182 . . . . 0.0 109.296 179.83 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 92.6 mt-30 -68.66 144.57 54.41 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.335 -0.853 . . . . 0.0 109.505 -179.882 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 49.7 p90 -137.53 163.07 32.06 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.396 -0.815 . . . . 0.0 109.166 179.773 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 48.9 p90 -135.81 160.93 37.05 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.271 -0.893 . . . . 0.0 109.776 -179.937 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 70.2 mt -117.61 132.68 66.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.444 -0.785 . . . . 0.0 109.568 -179.918 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 1.9 p -100.72 106.6 18.05 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.325 -0.859 . . . . 0.0 109.255 179.555 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 129' ' ' THR . . . . . 0.438 ' OG1' ' OE1' ' A' ' 156' ' ' GLU . 68.5 p -90.93 3.03 55.68 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.189 -0.945 . . . . 0.0 109.809 -179.765 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -146.0 154.63 42.1 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.12 -0.987 . . . . 0.0 109.674 -179.726 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 78.9 tttt -81.16 131.06 35.28 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.336 -0.853 . . . . 0.0 109.362 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 9.4 p -125.29 161.65 26.49 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.358 -0.839 . . . . 0.0 109.418 179.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -127.52 -28.79 2.73 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.236 -0.915 . . . . 0.0 109.642 -179.891 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 134' ' ' TRP . . . . . 0.413 ' CD2' ' N ' ' A' ' 134' ' ' TRP . 2.0 p90 -75.8 -6.53 51.11 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.159 -0.963 . . . . 0.0 109.777 -179.841 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 8.2 mt -90.78 7.69 38.47 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.242 -0.911 . . . . 0.0 109.548 179.486 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . 0.472 ' O ' ' OD1' ' A' ' 136' ' ' ASP . 52.2 p30 -53.63 153.34 4.43 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.301 -0.874 . . . . 0.0 109.724 -179.755 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 144.48 -129.6 3.64 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.012 -1.635 . . . . 0.0 109.012 -179.685 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 2.0 mptp? -90.4 127.55 36.23 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.214 -1.168 . . . . 0.0 108.91 179.643 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 139' ' ' HIS . . . . . 0.491 ' CD2' ' HD1' ' A' ' 105' ' ' HIS . 85.6 t60 -140.57 127.58 20.75 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.375 -0.828 . . . . 0.0 109.694 -179.85 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.459 ' O ' ' OG ' ' A' ' 112' ' ' SER . 44.7 t -123.11 132.76 70.81 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 121.458 -0.776 . . . . 0.0 109.048 179.595 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 38.8 t -116.5 129.36 73.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.321 -0.862 . . . . 0.0 109.211 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . 0.586 ' CE1' ' SD ' ' A' ' 113' ' ' MET . 38.3 p90 -119.93 5.89 10.89 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.323 -0.861 . . . . 0.0 109.734 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -179.43 177.66 48.37 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 179.655 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.2 pt20 -146.17 167.13 24.2 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.265 -1.138 . . . . 0.0 109.453 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 55.2 t -95.33 130.24 44.36 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 O-C-N 121.232 -0.918 . . . . 0.0 109.326 -179.886 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 13.3 m -108.51 -36.63 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.308 -0.87 . . . . 0.0 109.653 179.812 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 94.4 mt-10 -139.75 161.89 36.46 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.26 -0.9 . . . . 0.0 109.575 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 95.02 5.64 60.78 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 110.102 -1.199 . . . . 0.0 110.102 179.578 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 149' ' ' MET . . . . . 0.446 ' O ' HG12 ' A' ' 152' ' ' VAL . 65.0 mtt -60.0 -32.58 71.0 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.049 -1.266 . . . . 0.0 109.319 179.859 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 56.1 t0 -64.85 -41.89 95.33 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.954 -1.091 . . . . 0.0 110.291 -179.563 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.6 p -78.15 -32.32 17.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.06 -1.025 . . . . 0.0 110.911 -179.266 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 152' ' ' VAL . . . . . 0.446 HG12 ' O ' ' A' ' 149' ' ' MET . 0.9 OUTLIER -51.62 -40.57 26.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 120.962 -1.087 . . . . 0.0 109.011 -179.18 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 153' ' ' LYS . . . . . 0.439 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 59.1 mttp -65.69 -32.63 74.3 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.242 -0.911 . . . . 0.0 109.441 179.09 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -60.11 -39.37 85.97 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.341 -0.849 . . . . 0.0 110.113 -179.28 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.44 HD12 HG21 ' A' ' 155' ' ' ILE . 90.0 mt -72.31 -33.95 47.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.048 -1.033 . . . . 0.0 109.757 -179.919 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . 0.438 ' OE1' ' OG1' ' A' ' 129' ' ' THR . 84.5 tt0 -77.63 -41.72 37.43 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.231 -0.918 . . . . 0.0 111.34 -178.859 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 157' ' ' LYS . . . . . 0.402 ' HG2' ' HZ3' ' A' ' 157' ' ' LYS . 17.5 pttm -59.65 -35.57 74.66 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 120.682 -1.261 . . . . 0.0 109.579 -178.838 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 35.3 m -77.15 -10.34 13.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.155 -0.966 . . . . 0.0 108.798 179.228 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -73.89 163.45 54.63 Favored Glycine 0 N--CA 1.488 2.124 0 N-CA-C 110.178 -1.169 . . . . 0.0 110.178 -179.596 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 54.2 m -148.07 165.77 29.8 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.598 -0.942 . . . . 0.0 109.276 -179.895 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 23.9 t -55.08 -26.56 38.71 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.217 -0.927 . . . . 0.0 109.293 179.849 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 86.8 p -57.64 -25.65 60.48 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.243 -0.911 . . . . 0.0 109.639 -179.749 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 92.48 12.98 57.77 Favored Glycine 0 N--CA 1.492 2.414 0 N-CA-C 109.941 -1.264 . . . . 0.0 109.941 179.87 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 24.2 ttm180 -127.14 143.09 51.35 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.204 -1.174 . . . . 0.0 109.491 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 165' ' ' THR . . . . . 0.444 ' OG1' ' O ' ' A' ' 167' ' ' LYS . 79.1 p -76.9 154.81 33.35 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.255 -0.903 . . . . 0.0 109.344 179.851 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -63.93 -35.88 82.13 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.24 -0.912 . . . . 0.0 109.231 179.813 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 167' ' ' LYS . . . . . 0.444 ' O ' ' OG1' ' A' ' 165' ' ' THR . 68.9 mttm -116.78 154.69 30.23 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.571 -0.706 . . . . 0.0 109.151 179.794 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -66.44 142.43 57.57 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.121 -0.987 . . . . 0.0 109.095 -179.949 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 33.0 m -123.99 128.38 74.09 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.363 -0.836 . . . . 0.0 109.707 -179.716 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 40.7 t -144.16 147.76 19.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.395 -0.816 . . . . 0.0 109.011 179.649 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -83.86 115.53 26.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 120.935 -1.103 . . . . 0.0 109.464 -179.787 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -66.08 -22.39 66.41 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.364 -0.835 . . . . 0.0 109.213 179.469 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 173' ' ' ASP . . . . . 0.454 ' OD1' ' N ' ' A' ' 174' ' ' CYS . 48.0 t0 -167.38 163.39 15.07 Favored 'General case' 0 N--CA 1.492 1.654 0 C-N-CA 119.035 -1.066 . . . . 0.0 110.564 -179.493 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 174' ' ' CYS . . . . . 0.454 ' N ' ' OD1' ' A' ' 173' ' ' ASP . 18.5 p -161.78 146.62 13.06 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.592 -0.693 . . . . 0.0 109.325 179.535 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . 170.45 175.08 38.97 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 179.829 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 176' ' ' GLN . . . . . 0.509 ' NE2' ' CD ' ' A' ' 43' ' ' ARG . 47.9 tt0 -102.58 121.02 41.55 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.228 -1.16 . . . . 0.0 109.779 179.925 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 177' ' ' LEU . . . . . 0.469 ' CD2' HH21 ' A' ' 11' ' ' ARG . 46.2 tp -64.74 -36.58 84.75 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.33 -0.856 . . . . 0.0 109.371 179.408 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 7.9 t . . . . . 0 N--CA 1.49 1.565 0 CA-C-O 118.025 -0.988 . . . . 0.0 109.368 179.999 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 2.4 m120 . . . . . 0 N--CA 1.493 1.686 0 N-CA-C 109.322 -0.621 . . . . 0.0 109.322 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -69.42 139.67 41.97 Favored 'Trans proline' 0 N--CA 1.496 1.65 0 C-N-CA 122.686 2.257 . . . . 0.0 112.152 179.887 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 75.1 mtt85 -128.93 132.87 47.69 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.387 -0.82 . . . . 0.0 109.077 179.092 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.7 p -135.06 142.68 39.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.488 -0.757 . . . . 0.0 109.223 -179.859 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 41.6 p90 -139.55 153.81 47.51 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.296 -0.878 . . . . 0.0 109.505 -179.786 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 93.4 m-85 -122.15 135.23 54.76 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.516 -0.74 . . . . 0.0 109.446 179.699 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.6 t0 -90.3 113.4 25.25 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.111 -0.993 . . . . 0.0 108.374 179.212 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 71.6 mtp -105.24 147.38 28.11 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.072 -1.017 . . . . 0.0 110.389 -179.168 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 84.2 p -144.9 165.2 28.81 Favored 'General case' 0 N--CA 1.489 1.501 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 179.724 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 33.5 m -125.37 151.16 31.01 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.28 -0.888 . . . . 0.0 109.43 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -51.17 102.49 0.07 OUTLIER Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 140.43 -75.13 0.35 Allowed Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.714 -1.354 . . . . 0.0 109.714 179.873 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -138.41 158.78 70.0 Favored Pre-proline 0 N--CA 1.492 1.663 0 O-C-N 121.337 -1.096 . . . . 0.0 109.264 -179.763 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -58.63 138.77 87.64 Favored 'Trans proline' 0 N--CA 1.494 1.524 0 C-N-CA 122.581 2.187 . . . . 0.0 111.887 179.78 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -84.27 -62.47 1.55 Allowed 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.223 -0.923 . . . . 0.0 109.568 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 168.9 -169.69 41.96 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 -179.836 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 58.9 ttp180 -115.72 141.81 47.59 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.338 -1.095 . . . . 0.0 109.265 179.936 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 82.8 mt -121.24 128.96 76.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.331 -0.855 . . . . 0.0 109.237 179.831 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 46.5 t -114.18 134.09 58.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.335 -0.853 . . . . 0.0 109.26 179.908 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 73.9 mtm -119.93 151.74 38.47 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.384 -0.822 . . . . 0.0 109.318 -179.928 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -98.68 131.98 44.43 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.339 -0.851 . . . . 0.0 109.763 -179.57 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -107.34 132.62 52.93 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.494 -0.754 . . . . 0.0 109.143 179.681 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 95.7 m-85 -98.6 125.41 43.85 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.223 -0.923 . . . . 0.0 109.176 179.66 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -94.47 1.25 55.76 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.255 -0.903 . . . . 0.0 109.997 -179.692 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -95.45 -75.17 0.53 Allowed 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.046 -1.034 . . . . 0.0 110.581 -179.342 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 47.0 m -64.67 -40.65 95.79 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.354 -0.841 . . . . 0.0 111.017 -178.646 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 43.3 p -126.46 76.18 73.7 Favored Pre-proline 0 N--CA 1.496 1.829 0 O-C-N 121.089 -1.007 . . . . 0.0 110.149 -178.982 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 63.7 Cg_endo -78.21 -57.42 0.04 OUTLIER 'Trans proline' 0 C--N 1.308 -1.601 0 C-N-CA 122.764 2.31 . . . . 0.0 112.729 179.724 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 24.1 mmt85 -57.39 -38.47 74.32 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.247 -0.908 . . . . 0.0 110.151 -179.249 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 41.5 m -61.41 -40.85 95.9 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.039 -1.038 . . . . 0.0 109.915 -179.581 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -61.89 -31.1 71.36 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.203 -0.936 . . . . 0.0 109.216 179.842 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -67.57 -37.19 82.29 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.389 -0.819 . . . . 0.0 109.766 -179.846 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 49.6 t-20 -58.64 -43.05 89.62 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.24 -0.912 . . . . 0.0 109.841 -179.678 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . 0.495 ' O ' ' SG ' ' A' ' 46' ' ' CYS . 96.9 m-85 -83.31 -46.63 12.38 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.165 -0.96 . . . . 0.0 109.756 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . 0.63 ' NE ' HE22 ' A' ' 176' ' ' GLN . 76.5 ttt180 -57.19 -42.06 80.53 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.295 -0.878 . . . . 0.0 109.901 -179.697 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.523 ' O ' ' N ' ' A' ' 48' ' ' GLY . . . -76.63 -48.54 18.76 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.132 -0.98 . . . . 0.0 110.29 -179.612 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 40.8 tp -58.1 -37.92 75.45 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.112 -0.993 . . . . 0.0 109.795 -179.4 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' CYS . . . . . 0.495 ' SG ' ' O ' ' A' ' 42' ' ' PHE . 39.8 m -77.32 -63.97 1.25 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.113 -0.992 . . . . 0.0 109.929 -179.795 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 26.0 m -63.17 -38.39 91.0 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.117 -0.989 . . . . 0.0 109.678 -179.813 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . 0.523 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 80.58 37.16 21.1 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 110.043 -1.223 . . . . 0.0 110.043 179.744 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -61.4 -37.57 83.94 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.058 -1.26 . . . . 0.0 109.367 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 42.2 mmtm -61.52 -32.56 72.61 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.287 -0.883 . . . . 0.0 109.458 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 95.71 172.4 36.21 Favored Glycine 0 N--CA 1.487 2.097 0 N-CA-C 109.173 -1.571 . . . . 0.0 109.173 -179.62 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 94.1 m -72.36 141.19 48.77 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.315 -1.109 . . . . 0.0 109.871 -179.824 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -58.5 137.84 49.75 Favored Glycine 0 N--CA 1.489 2.169 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 179.804 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 94.1 mtt180 -59.72 -34.14 72.53 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.397 -1.061 . . . . 0.0 109.983 -179.68 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 86.2 p -61.32 -24.95 66.8 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.312 -0.867 . . . . 0.0 109.952 -179.564 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 112.58 89.83 1.85 Allowed Glycine 0 N--CA 1.495 2.572 0 N-CA-C 109.094 -1.603 . . . . 0.0 109.094 -179.595 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . 0.51 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 15.4 tptp -175.98 81.0 0.29 Allowed Pre-proline 0 N--CA 1.488 1.461 0 O-C-N 121.438 -1.036 . . . . 0.0 108.444 -179.659 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 75.2 Cg_exo -51.01 131.48 35.04 Favored 'Trans proline' 0 C--N 1.304 -1.808 0 C-N-CA 122.799 2.333 . . . . 0.0 112.728 -179.168 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.51 ' CD1' ' O ' ' A' ' 57' ' ' LYS . 8.8 mp -101.13 89.13 3.7 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.487 -0.758 . . . . 0.0 109.224 -179.919 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . 0.515 ' O ' ' CE1' ' A' ' 80' ' ' PHE . 77.2 m80 -138.78 136.25 35.49 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.362 -0.836 . . . . 0.0 109.531 179.778 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -87.31 -7.95 57.25 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.289 -0.882 . . . . 0.0 108.771 179.529 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 34.2 ttmt -64.15 151.33 43.6 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.524 -0.735 . . . . 0.0 109.958 -179.729 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 59.93 46.61 10.89 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.628 -0.67 . . . . 0.0 109.965 179.896 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 20.8 t -115.83 141.61 47.87 Favored 'General case' 0 N--CA 1.494 1.728 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.323 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 28.7 t -114.97 145.73 41.95 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.386 -0.821 . . . . 0.0 109.682 -179.64 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.5 m-30 -69.41 137.76 53.02 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.243 -0.91 . . . . 0.0 108.996 179.791 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 58.5 t-80 -60.76 -50.75 72.21 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.242 -0.912 . . . . 0.0 110.249 -179.378 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 37.7 ptt180 -163.72 162.21 23.87 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.061 -1.024 . . . . 0.0 109.939 -179.677 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 15.1 m -131.65 142.81 42.19 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.424 -0.798 . . . . 0.0 108.946 179.615 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 10.3 mt -148.03 109.85 3.75 Favored Pre-proline 0 N--CA 1.494 1.739 0 O-C-N 120.907 -1.121 . . . . 0.0 109.83 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -53.36 145.89 43.4 Favored 'Trans proline' 0 N--CA 1.494 1.524 0 C-N-CA 122.347 2.031 . . . . 0.0 112.489 179.524 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 82.01 -57.52 4.96 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 110.161 -1.175 . . . . 0.0 110.161 179.428 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -70.46 -88.68 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.137 -1.214 . . . . 0.0 109.828 -179.544 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 11.3 ptt? -178.31 176.4 1.08 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.221 -0.925 . . . . 0.0 109.57 -179.753 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -111.1 131.58 54.96 Favored 'General case' 0 N--CA 1.493 1.69 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 179.54 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 63.5 tt0 -98.26 150.14 21.85 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.239 -0.913 . . . . 0.0 109.958 -179.439 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -140.66 -170.1 11.97 Favored Glycine 0 N--CA 1.493 2.487 0 N-CA-C 109.287 -1.525 . . . . 0.0 109.287 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 96.52 6.33 58.57 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.861 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 54.8 t0 -58.33 -24.98 61.37 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.35 -1.088 . . . . 0.0 109.728 179.906 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.515 ' CE1' ' O ' ' A' ' 60' ' ' HIS . 76.4 t80 -48.21 -46.37 35.07 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.359 -0.838 . . . . 0.0 110.068 -179.38 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.698 ' CB ' ' H ' ' A' ' 88' ' ' GLY . 69.1 p -70.95 -29.93 66.09 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 120.96 -1.088 . . . . 0.0 109.493 179.896 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . 0.483 ' CB ' ' O ' ' A' ' 81' ' ' THR . . . 163.85 -55.84 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.412 -0.805 . . . . 0.0 109.225 179.822 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 92.37 0.41 70.33 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.529 -1.429 . . . . 0.0 109.529 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 78.7 m-20 -87.81 5.88 38.0 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.27 -1.135 . . . . 0.0 109.459 -179.962 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 96.12 -38.55 3.07 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 109.253 -1.539 . . . . 0.0 109.253 -179.895 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 61.7 p -73.82 -15.7 61.16 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.242 -1.152 . . . . 0.0 109.092 179.526 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -81.39 -163.9 31.83 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 -179.919 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.698 ' H ' ' CB ' ' A' ' 81' ' ' THR . . . 81.86 50.82 4.76 Favored Glycine 0 N--CA 1.487 2.099 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 -179.896 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -90.31 147.32 23.57 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.342 -1.093 . . . . 0.0 109.665 -179.728 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 50.5 m -112.17 149.71 31.84 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.461 -0.774 . . . . 0.0 109.403 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 5.1 pt -60.8 -42.13 91.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.277 -0.89 . . . . 0.0 110.106 -179.584 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 3.9 m-30 -66.65 -38.82 87.66 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.113 -0.992 . . . . 0.0 109.582 179.915 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 74.29 26.04 69.23 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.118 -1.593 . . . . 0.0 109.118 -179.742 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -143.64 161.29 38.9 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.421 -1.046 . . . . 0.0 109.569 -179.708 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 83.6 mttt -83.24 148.32 27.48 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.405 -0.81 . . . . 0.0 109.74 -179.736 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 88.6 m-85 -104.1 131.85 50.95 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.376 -0.828 . . . . 0.0 108.865 179.618 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -77.27 136.12 38.48 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.139 -0.976 . . . . 0.0 109.573 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . 0.53 ' OD2' ' CE1' ' A' ' 101' ' ' PHE . 32.3 p-10 -87.86 128.22 35.35 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.215 -0.928 . . . . 0.0 109.279 179.714 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . 0.491 ' O ' ' OD1' ' A' ' 100' ' ' ASN . 84.6 tt0 -61.41 -43.15 99.36 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.155 -0.966 . . . . 0.0 109.989 -179.481 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . 0.491 ' OD1' ' O ' ' A' ' 99' ' ' GLU . 84.0 m-20 -155.24 165.4 36.77 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.145 -0.972 . . . . 0.0 110.071 -179.829 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 101' ' ' PHE . . . . . 0.53 ' CE1' ' OD2' ' A' ' 98' ' ' ASP . 98.6 m-85 -102.62 8.17 39.77 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.429 -0.794 . . . . 0.0 109.156 179.358 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 97.4 mt -53.79 -36.47 29.89 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.344 -0.847 . . . . 0.0 110.404 -179.404 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 33.3 mmtp -73.68 124.91 26.89 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.022 -1.049 . . . . 0.0 109.661 -179.512 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 12.9 pttm -142.77 -177.6 5.39 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.321 -0.862 . . . . 0.0 109.246 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 105' ' ' HIS . . . . . . . . . . . . . 93.6 m-70 -74.99 88.33 2.37 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.144 -0.973 . . . . 0.0 109.209 179.723 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 54.9 p -71.06 -26.81 63.24 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.188 -0.945 . . . . 0.0 109.572 -179.79 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -162.08 -168.45 24.0 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.305 -1.518 . . . . 0.0 109.305 -179.855 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -80.58 154.83 20.99 Favored 'Trans proline' 0 C--N 1.306 -1.705 0 C-N-CA 122.935 2.423 . . . . 0.0 112.175 179.783 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 80.33 43.45 9.49 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.944 -1.262 . . . . 0.0 109.944 179.667 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 41.7 mm -115.55 135.5 55.41 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.863 0 O-C-N 121.364 -1.08 . . . . 0.0 109.628 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . 0.408 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 4.3 mm? -91.25 124.4 35.42 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.25 -0.906 . . . . 0.0 109.272 179.654 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 112' ' ' SER . . . . . 0.4 ' OG ' ' O ' ' A' ' 140' ' ' VAL . 30.9 t -140.72 141.07 34.95 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.176 -0.952 . . . . 0.0 109.501 179.867 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 88.9 mtp -89.92 137.89 31.96 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.264 -0.897 . . . . 0.0 109.215 179.75 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . 0.531 ' O ' ' ND2' ' A' ' 115' ' ' ASN . . . -60.9 144.57 52.7 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.121 -0.987 . . . . 0.0 109.381 -179.955 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . 0.531 ' ND2' ' O ' ' A' ' 114' ' ' ALA . 5.0 m120 -137.05 110.78 8.1 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.216 -0.928 . . . . 0.0 109.275 179.848 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -73.57 -29.46 62.44 Favored 'General case' 0 C--N 1.297 -1.677 0 O-C-N 121.406 -0.809 . . . . 0.0 109.4 179.684 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -140.6 175.39 22.08 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 179.926 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -68.17 151.89 76.63 Favored 'Trans proline' 0 C--N 1.305 -1.717 0 C-N-CA 122.746 2.297 . . . . 0.0 111.822 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 119' ' ' ASN . . . . . 0.429 ' OD1' ' OD1' ' A' ' 98' ' ' ASP . 71.8 m-20 52.84 40.52 30.87 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.453 -0.779 . . . . 0.0 109.278 -179.781 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 94.6 m -140.78 124.17 16.76 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.406 -0.809 . . . . 0.0 109.248 179.904 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 87.9 m-20 -109.86 114.81 28.67 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.568 -0.708 . . . . 0.0 109.16 179.503 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -78.05 135.52 16.26 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 179.947 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 22.8 t -55.83 -32.72 63.84 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.212 -1.169 . . . . 0.0 109.195 179.793 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 94.2 mt-30 -72.47 146.6 46.78 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.348 -0.845 . . . . 0.0 109.28 179.729 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 41.2 p90 -133.16 163.3 29.57 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.351 -0.843 . . . . 0.0 109.088 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 49.2 p90 -135.65 156.33 49.02 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.222 -0.923 . . . . 0.0 109.699 -179.931 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 76.2 mt -121.62 134.61 64.41 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 179.804 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 128' ' ' CYS . . . . . 0.517 ' SG ' ' O ' ' A' ' 130' ' ' ALA . 5.5 t -116.22 124.66 50.8 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.288 -0.883 . . . . 0.0 109.368 179.968 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 44.1 p -89.26 -2.1 58.34 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.448 -0.782 . . . . 0.0 109.766 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . 0.517 ' O ' ' SG ' ' A' ' 128' ' ' CYS . . . -149.0 156.96 43.02 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.18 -0.95 . . . . 0.0 109.691 -179.857 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 63.6 tttm -72.84 136.78 45.4 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.31 -0.869 . . . . 0.0 109.34 179.813 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 17.1 p -121.48 158.8 27.63 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.43 -0.794 . . . . 0.0 109.537 -179.846 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -103.05 -74.65 0.63 Allowed 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.246 -0.909 . . . . 0.0 109.915 -179.829 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 134' ' ' TRP . . . . . 0.605 ' CD1' ' N ' ' A' ' 135' ' ' LEU . 42.0 p90 -58.73 -47.76 83.52 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.291 -0.881 . . . . 0.0 110.08 -179.419 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . 0.605 ' N ' ' CD1' ' A' ' 134' ' ' TRP . 31.5 tp -60.98 -35.08 75.87 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.203 -0.936 . . . . 0.0 109.332 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 62.1 t0 -80.05 118.16 21.52 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.202 -0.936 . . . . 0.0 109.541 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 137' ' ' GLY . . . . . 0.489 ' H ' ' CE1' ' A' ' 139' ' ' HIS . . . -144.24 -126.58 1.95 Allowed Glycine 0 N--CA 1.492 2.4 0 N-CA-C 109.096 -1.602 . . . . 0.0 109.096 179.844 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 2.0 mptm? -84.71 105.5 15.55 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.112 -1.228 . . . . 0.0 108.959 179.629 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 139' ' ' HIS . . . . . 0.489 ' CE1' ' H ' ' A' ' 137' ' ' GLY . 76.9 m80 -138.16 161.07 37.76 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.353 -0.842 . . . . 0.0 109.483 -179.862 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.4 ' O ' ' OG ' ' A' ' 112' ' ' SER . 45.0 t -119.58 136.04 58.0 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 O-C-N 121.399 -0.813 . . . . 0.0 109.404 179.932 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 59.2 t -105.31 130.25 56.85 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 O-C-N 121.395 -0.816 . . . . 0.0 109.144 179.82 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 39.9 p90 -114.33 -0.81 13.72 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.306 -0.871 . . . . 0.0 109.766 -179.865 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -174.71 174.79 46.8 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.589 -1.405 . . . . 0.0 109.589 179.546 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 2.6 pt20 -146.72 167.23 24.34 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.213 -1.169 . . . . 0.0 109.665 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 9.5 t -96.73 132.63 40.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 O-C-N 121.218 -0.926 . . . . 0.0 109.529 -179.95 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 15.9 m -111.43 -30.19 2.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.541 -0.724 . . . . 0.0 109.145 179.577 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 78.6 mm-40 -140.02 166.0 25.83 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.342 -0.849 . . . . 0.0 109.344 179.876 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 96.69 4.9 58.98 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.889 -1.285 . . . . 0.0 109.889 179.649 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 149' ' ' MET . . . . . 0.418 ' O ' HG13 ' A' ' 152' ' ' VAL . 65.1 mtt -60.2 -32.24 70.91 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 121.056 -1.261 . . . . 0.0 109.467 179.932 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 89.0 m-20 -64.38 -40.35 95.65 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 120.894 -1.129 . . . . 0.0 109.805 -179.807 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 4.4 p -83.69 -35.09 11.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.251 -0.906 . . . . 0.0 110.502 -179.504 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 152' ' ' VAL . . . . . 0.455 ' CG1' ' N ' ' A' ' 153' ' ' LYS . 0.9 OUTLIER -53.9 -42.0 51.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 120.835 -1.166 . . . . 0.0 108.871 -179.336 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 153' ' ' LYS . . . . . 0.455 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 60.0 mttm -65.68 -32.94 74.77 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.12 -0.987 . . . . 0.0 109.123 179.064 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -60.08 -36.96 78.55 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.423 -0.798 . . . . 0.0 109.751 -179.512 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 98.5 mt -71.2 -34.74 55.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.092 -1.005 . . . . 0.0 109.945 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 83.0 tt0 -76.63 -42.17 43.19 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.246 -0.908 . . . . 0.0 111.324 -178.823 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 33.3 pttt -62.13 -33.38 74.38 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 120.798 -1.189 . . . . 0.0 109.822 -178.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 33.0 m -83.5 -0.59 5.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.036 -1.04 . . . . 0.0 108.828 179.523 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -75.32 173.01 53.34 Favored Glycine 0 N--CA 1.488 2.115 0 N-CA-C 110.048 -1.221 . . . . 0.0 110.048 -179.53 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 89.7 p -153.22 164.02 38.84 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.462 -1.022 . . . . 0.0 109.764 -179.711 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 23.3 m -58.69 -32.82 69.49 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.309 -0.869 . . . . 0.0 108.834 179.31 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 25.4 m -55.84 -31.57 62.84 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.386 -0.821 . . . . 0.0 109.172 179.86 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 101.08 9.08 46.18 Favored Glycine 0 N--CA 1.495 2.574 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 179.893 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 35.8 ttp180 -116.48 141.12 48.59 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.238 -1.154 . . . . 0.0 109.293 179.898 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 165' ' ' THR . . . . . 0.446 ' OG1' ' O ' ' A' ' 167' ' ' LYS . 80.6 p -76.5 155.87 33.44 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.292 -0.88 . . . . 0.0 109.304 179.932 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -62.37 -35.83 80.37 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.231 -0.918 . . . . 0.0 109.298 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 167' ' ' LYS . . . . . 0.446 ' O ' ' OG1' ' A' ' 165' ' ' THR . 62.5 mttp -118.93 152.98 35.34 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.475 -0.766 . . . . 0.0 109.157 179.764 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -64.67 141.55 58.74 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.021 -1.049 . . . . 0.0 108.957 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 33.9 m -121.66 126.63 74.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.226 -0.921 . . . . 0.0 109.8 -179.748 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 44.5 t -145.03 148.81 17.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 N-CA-C 108.839 -0.801 . . . . 0.0 108.839 179.704 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -80.91 115.7 23.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.119 -0.988 . . . . 0.0 109.463 -179.798 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 78.4 mm-40 -67.9 -20.31 65.09 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.396 -0.815 . . . . 0.0 109.505 179.629 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 20.2 t70 -167.66 162.18 13.93 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.015 -1.053 . . . . 0.0 110.364 -179.456 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 30.6 p -155.89 144.52 20.26 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.459 -0.776 . . . . 0.0 109.294 179.604 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . 177.25 179.98 47.8 Favored Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 176' ' ' GLN . . . . . 0.63 HE22 ' NE ' ' A' ' 43' ' ' ARG . 63.6 tt0 -105.62 124.0 48.83 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.41 -1.053 . . . . 0.0 109.77 -179.905 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 35.5 tp -61.23 -37.8 84.34 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.187 -0.946 . . . . 0.0 109.395 179.658 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 7.9 t . . . . . 0 N--CA 1.489 1.522 0 CA-C-O 117.994 -1.003 . . . . 0.0 109.475 -179.967 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . 0.446 ' ND2' ' O ' ' A' ' 10' ' ' PRO . 0.5 OUTLIER . . . . . 0 N--CA 1.491 1.615 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 . . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . 0.446 ' O ' ' ND2' ' A' ' 9' ' ' ASN . 82.8 Cg_endo -75.29 140.15 24.37 Favored 'Trans proline' 0 N--CA 1.495 1.612 0 C-N-CA 122.473 2.116 . . . . 0.0 112.599 -179.833 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 71.0 mtt85 -132.74 132.58 42.45 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.35 -0.844 . . . . 0.0 108.834 178.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.0 p -135.62 143.21 37.22 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.327 -0.858 . . . . 0.0 109.707 -179.764 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 42.7 p90 -138.21 154.21 49.12 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.523 -0.736 . . . . 0.0 109.183 179.941 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.415 ' CE1' ' CE1' ' A' ' 61' ' ' TYR . 97.5 m-85 -124.18 137.54 54.52 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.481 -0.762 . . . . 0.0 109.788 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.4 t0 -93.39 117.94 30.7 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.359 -0.838 . . . . 0.0 108.801 179.425 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 77.1 mtp -112.12 151.21 29.71 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.151 -0.968 . . . . 0.0 110.457 -179.174 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 84.5 p -142.91 163.09 33.73 Favored 'General case' 0 N--CA 1.489 1.519 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 179.804 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.534 ' O ' ' N ' ' A' ' 20' ' ' GLY . 26.2 m -125.96 143.01 40.94 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.201 -0.937 . . . . 0.0 109.706 -179.87 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 47.89 11.5 0.11 Allowed Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.817 -1.313 . . . . 0.0 109.817 179.833 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.534 ' N ' ' O ' ' A' ' 18' ' ' VAL . . . 97.43 -13.98 63.82 Favored Glycine 0 N--CA 1.493 2.499 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 -179.927 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' GLN . . . . . 0.608 ' NE2' ' N ' ' A' ' 21' ' ' GLN . 2.1 mp0 -84.62 150.85 57.54 Favored Pre-proline 0 N--CA 1.492 1.675 0 O-C-N 121.26 -1.141 . . . . 0.0 109.112 179.757 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_endo -62.15 136.93 63.33 Favored 'Trans proline' 0 C--N 1.308 -1.584 0 C-N-CA 122.453 2.102 . . . . 0.0 112.012 -179.893 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -111.72 -65.59 1.16 Allowed 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.439 -0.788 . . . . 0.0 109.359 179.886 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 178.98 -170.1 41.75 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.348 -1.501 . . . . 0.0 109.348 -179.924 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 92.2 mtt180 -116.72 143.72 45.31 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.358 -1.083 . . . . 0.0 109.526 179.792 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 84.7 mt -121.06 122.77 68.49 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 179.304 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 38.8 t -118.47 132.75 67.43 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.434 0 O-C-N 121.376 -0.828 . . . . 0.0 109.154 -179.984 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 73.6 mtm -122.32 151.54 41.03 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.408 -0.807 . . . . 0.0 109.122 -179.886 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -99.32 130.79 45.63 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.298 -0.877 . . . . 0.0 109.847 -179.629 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.404 ' N ' ' CD2' ' A' ' 30' ' ' LEU . 2.7 mm? -107.07 129.12 54.86 Favored 'General case' 0 N--CA 1.491 1.575 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 179.535 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -99.63 120.23 39.36 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.244 -0.91 . . . . 0.0 109.082 179.572 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -78.95 -40.52 31.63 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.337 -0.852 . . . . 0.0 110.01 -179.753 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.537 ' OD1' ' N ' ' A' ' 34' ' ' THR . 31.9 p-10 -68.23 -41.22 81.54 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.228 -0.92 . . . . 0.0 110.72 -179.082 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' THR . . . . . 0.537 ' N ' ' OD1' ' A' ' 33' ' ' ASP . 17.1 m -67.66 -44.52 77.66 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.005 -1.06 . . . . 0.0 109.997 -179.375 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 28.5 p -155.23 83.62 3.73 Favored Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.226 -0.921 . . . . 0.0 109.217 -179.903 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 13.4 Cg_endo -70.55 -35.77 9.79 Favored 'Trans proline' 0 C--N 1.307 -1.654 0 C-N-CA 121.987 1.791 . . . . 0.0 112.088 -179.537 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 1.6 mpt_? -66.51 -41.93 88.07 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.077 -1.014 . . . . 0.0 109.702 179.771 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 56.1 m -65.16 -42.06 94.11 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.203 -0.936 . . . . 0.0 110.008 -179.519 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -61.88 -31.37 71.65 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.135 -0.978 . . . . 0.0 109.083 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -69.84 -37.99 76.37 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.397 -0.814 . . . . 0.0 110.052 -179.742 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 3.3 m120 -58.42 -41.99 86.25 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.026 -1.046 . . . . 0.0 109.965 -179.345 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 -87.13 -48.41 8.08 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.114 -0.991 . . . . 0.0 109.554 179.878 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 66.8 ttp85 -57.63 -42.27 83.01 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.208 -0.933 . . . . 0.0 109.563 -179.853 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -69.74 -46.4 65.98 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.267 -0.896 . . . . 0.0 109.829 -179.674 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 44.9 tp -63.64 -37.78 88.65 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.29 -0.881 . . . . 0.0 109.701 -179.594 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' CYS . . . . . . . . . . . . . 81.7 m -72.99 -48.76 33.69 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.171 -0.956 . . . . 0.0 109.782 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 69.8 p -70.93 -35.58 72.28 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.164 -0.96 . . . . 0.0 109.687 -179.93 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 73.46 25.26 73.13 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 179.906 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 22.7 pt-20 -64.77 -33.1 75.18 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.225 -1.162 . . . . 0.0 109.622 -179.768 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 47.2 mmtm -60.14 -33.81 72.68 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.305 -0.872 . . . . 0.0 109.362 179.771 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 92.24 174.84 42.12 Favored Glycine 0 N--CA 1.486 2.032 0 N-CA-C 109.283 -1.527 . . . . 0.0 109.283 -179.753 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 65.5 m -70.57 139.22 51.44 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.387 -1.067 . . . . 0.0 109.705 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -57.72 135.35 51.82 Favored Glycine 0 N--CA 1.488 2.137 0 N-CA-C 109.219 -1.552 . . . . 0.0 109.219 179.766 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 73.4 mtp180 -59.0 -33.88 71.22 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.178 -1.19 . . . . 0.0 109.958 -179.678 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 87.0 p -60.55 -24.46 65.41 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.18 -0.95 . . . . 0.0 109.684 -179.621 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 112.66 90.92 1.93 Allowed Glycine 0 N--CA 1.494 2.562 0 N-CA-C 109.049 -1.621 . . . . 0.0 109.049 -179.714 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . 0.509 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 33.0 tttm -174.72 78.61 0.33 Allowed Pre-proline 0 N--CA 1.488 1.437 0 O-C-N 121.425 -1.044 . . . . 0.0 108.365 -179.73 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 75.8 Cg_exo -49.47 130.75 26.3 Favored 'Trans proline' 0 C--N 1.304 -1.783 0 C-N-CA 122.787 2.325 . . . . 0.0 112.77 -179.087 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.509 ' CD1' ' O ' ' A' ' 57' ' ' LYS . 7.1 mp -97.48 120.38 37.74 Favored 'General case' 0 N--CA 1.49 1.572 0 N-CA-C 109.195 -0.669 . . . . 0.0 109.195 179.854 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 58.7 m80 -149.79 93.84 2.09 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.273 -0.892 . . . . 0.0 109.448 179.679 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . 0.415 ' CE1' ' CE1' ' A' ' 14' ' ' PHE . 24.3 t80 -60.65 -34.38 74.21 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 179.831 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 92.8 mttt -54.77 167.9 0.33 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.495 -0.753 . . . . 0.0 109.794 -179.686 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 83.0 m-20 57.24 47.16 17.44 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.5 -0.75 . . . . 0.0 110.02 179.609 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 96.3 p -114.12 154.03 28.49 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.383 -0.823 . . . . 0.0 108.918 179.366 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 28.2 t -131.66 149.04 52.63 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.255 -0.903 . . . . 0.0 109.668 -179.552 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 28.6 m-85 -77.51 125.0 28.65 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.306 -0.871 . . . . 0.0 109.369 179.852 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 62.0 t60 -67.93 -46.4 71.6 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.598 -0.689 . . . . 0.0 110.782 -179.176 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 94.5 mtt180 -132.39 150.05 52.23 Favored 'General case' 0 N--CA 1.498 1.925 0 O-C-N 121.041 -1.037 . . . . 0.0 110.739 -178.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.7 m -144.19 52.26 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 N-CA-C 108.744 -0.836 . . . . 0.0 108.744 179.471 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 14.4 mt -76.69 133.44 70.31 Favored Pre-proline 0 C--N 1.301 -1.537 0 O-C-N 121.193 -0.942 . . . . 0.0 110.07 -178.702 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_endo -70.09 149.95 65.53 Favored 'Trans proline' 0 N--CA 1.492 1.405 0 C-N-CA 122.408 2.072 . . . . 0.0 112.283 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 79.42 -55.19 4.38 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 179.864 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 90.9 m-85 -71.35 -87.7 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.249 -1.147 . . . . 0.0 109.702 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' MET . . . . . 0.602 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 12.1 ptt? 179.15 -178.83 0.35 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.184 -0.948 . . . . 0.0 109.763 -179.926 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 1.1 m -117.46 131.9 56.65 Favored 'General case' 0 N--CA 1.492 1.67 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 179.255 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 63.5 tt0 -95.04 146.16 24.46 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.161 -0.962 . . . . 0.0 110.222 -179.013 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -143.55 -175.07 16.31 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.186 -1.566 . . . . 0.0 109.186 179.841 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 93.24 10.55 59.43 Favored Glycine 0 N--CA 1.494 2.528 0 N-CA-C 109.426 -1.47 . . . . 0.0 109.426 -179.905 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.438 ' OD1' ' O ' ' A' ' 82' ' ' ALA . 62.4 t0 -56.18 -15.52 3.91 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.341 -1.094 . . . . 0.0 109.681 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 73.5 t80 -50.07 -47.86 53.37 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.174 -0.954 . . . . 0.0 110.17 -179.291 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.724 ' CB ' ' H ' ' A' ' 88' ' ' GLY . 65.6 p -71.53 -31.96 67.63 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.892 -1.13 . . . . 0.0 109.606 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . 0.503 ' CB ' ' O ' ' A' ' 81' ' ' THR . . . 164.51 -54.63 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.302 -0.874 . . . . 0.0 109.334 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 92.46 1.09 69.2 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.629 -1.388 . . . . 0.0 109.629 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 22.1 m120 -87.3 5.4 38.61 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.256 -1.144 . . . . 0.0 109.511 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 95.41 -39.61 2.82 Favored Glycine 0 N--CA 1.494 2.503 0 N-CA-C 109.243 -1.543 . . . . 0.0 109.243 -179.866 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 60.8 p -73.12 -16.92 61.44 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.24 -1.153 . . . . 0.0 109.085 179.634 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -81.77 -162.37 29.77 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.724 ' H ' ' CB ' ' A' ' 81' ' ' THR . . . 84.19 37.97 10.59 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 -179.951 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 78.1 mm-40 -58.02 149.7 22.65 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.266 -1.137 . . . . 0.0 109.808 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 50.8 m -115.57 147.08 41.15 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.666 -0.646 . . . . 0.0 109.273 179.925 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 18.1 pt -67.82 -35.53 72.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.264 -0.897 . . . . 0.0 110.037 -179.624 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 49.2 m-85 -67.43 -38.67 84.92 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.03 -1.044 . . . . 0.0 109.64 -179.809 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 77.87 13.74 83.09 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.342 -1.503 . . . . 0.0 109.342 -179.701 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -147.0 155.9 42.62 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.275 -1.132 . . . . 0.0 109.429 -179.838 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 53.5 mttp -95.08 148.65 22.13 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.339 -0.851 . . . . 0.0 109.807 -179.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 54.9 p90 -134.33 160.23 38.58 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.403 -0.811 . . . . 0.0 109.141 179.453 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -104.53 150.88 24.23 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.302 -0.874 . . . . 0.0 109.788 -179.633 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 60.1 t0 -137.77 81.58 1.87 Allowed 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.314 -0.866 . . . . 0.0 109.246 179.763 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -63.78 -29.03 70.28 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.429 -0.794 . . . . 0.0 109.956 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . 0.405 HD21 ' N ' ' A' ' 100' ' ' ASN . 2.7 m120 -56.58 141.34 43.52 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.134 -0.979 . . . . 0.0 110.075 -179.244 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 101' ' ' PHE . . . . . 0.537 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 74.4 t80 -150.33 46.51 0.89 Allowed 'General case' 0 N--CA 1.491 1.615 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.824 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 90.9 mt -59.03 -34.82 54.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.416 -0.803 . . . . 0.0 110.228 -179.492 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 71.8 mmtt -80.78 139.85 35.82 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.112 -0.993 . . . . 0.0 109.765 -179.393 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 35.5 tttm -93.32 156.0 17.07 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.394 -0.816 . . . . 0.0 109.571 -179.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 105' ' ' HIS . . . . . . . . . . . . . 85.2 t60 -96.36 78.48 3.05 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.334 -0.854 . . . . 0.0 108.77 179.356 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 14.9 m -56.56 -40.03 74.49 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.3 -0.875 . . . . 0.0 109.436 -179.42 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 130.09 -95.74 0.35 Allowed Glycine 0 N--CA 1.493 2.498 0 N-CA-C 110.044 -1.223 . . . . 0.0 110.044 179.575 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -68.81 141.24 48.65 Favored 'Trans proline' 0 N--CA 1.496 1.621 0 C-N-CA 122.694 2.263 . . . . 0.0 113.131 -179.233 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 75.95 22.65 73.85 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 110.241 -1.143 . . . . 0.0 110.241 179.033 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 33.5 mm -115.54 134.41 58.83 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 121.315 -1.109 . . . . 0.0 110.076 -179.782 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . 0.56 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 3.1 mm? -93.78 137.03 33.46 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.289 -0.882 . . . . 0.0 108.894 179.148 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 112' ' ' SER . . . . . 0.429 ' OG ' ' O ' ' A' ' 140' ' ' VAL . 34.0 t -146.05 141.17 27.35 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.226 -0.921 . . . . 0.0 109.691 179.781 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 72.0 mtm -85.53 137.04 33.15 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.245 -0.91 . . . . 0.0 109.181 179.715 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . 0.452 ' O ' ' OD1' ' A' ' 115' ' ' ASN . . . -61.83 138.32 58.33 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.148 -0.97 . . . . 0.0 109.333 -179.879 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . 0.452 ' OD1' ' O ' ' A' ' 114' ' ' ALA . 77.2 m-20 -148.51 114.01 5.62 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.328 -0.858 . . . . 0.0 109.206 179.828 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -69.21 -29.77 67.8 Favored 'General case' 0 C--N 1.297 -1.713 0 O-C-N 121.43 -0.794 . . . . 0.0 109.179 179.613 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -137.84 168.42 24.52 Favored Glycine 0 N--CA 1.494 2.503 0 N-CA-C 109.085 -1.606 . . . . 0.0 109.085 179.783 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -67.4 155.6 69.68 Favored 'Trans proline' 0 C--N 1.306 -1.666 0 C-N-CA 122.758 2.305 . . . . 0.0 111.946 -179.858 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 75.9 m-20 54.92 45.3 26.78 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.425 -0.797 . . . . 0.0 109.498 -179.907 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 94.1 m -130.27 125.93 36.02 Favored 'General case' 0 N--CA 1.485 1.314 0 O-C-N 121.386 -0.821 . . . . 0.0 108.79 179.725 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 25.1 t-20 -99.09 110.62 23.18 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.449 -0.782 . . . . 0.0 109.621 -179.838 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -106.61 121.27 6.55 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.271 -1.532 . . . . 0.0 109.271 179.646 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 20.1 m -56.84 -34.43 67.76 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.209 -1.171 . . . . 0.0 109.187 179.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.6 mt-30 -71.62 144.94 49.27 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.263 -0.898 . . . . 0.0 109.148 179.81 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 44.9 p90 -135.59 163.53 29.91 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.317 -0.865 . . . . 0.0 109.297 -179.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . 0.602 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 52.8 p90 -132.15 157.38 44.41 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.405 -0.81 . . . . 0.0 109.503 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 67.1 mt -119.08 133.25 66.54 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.49 -0.756 . . . . 0.0 109.338 179.849 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 128' ' ' CYS . . . . . 0.53 ' SG ' ' O ' ' A' ' 130' ' ' ALA . 7.1 t -115.84 126.35 53.86 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.355 -0.841 . . . . 0.0 109.15 179.847 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 30.1 p -97.18 0.53 48.5 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.276 -0.89 . . . . 0.0 109.702 -179.708 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . 0.53 ' O ' ' SG ' ' A' ' 128' ' ' CYS . . . -148.86 164.26 35.0 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.235 -0.915 . . . . 0.0 109.429 -179.8 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -70.07 137.48 51.26 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.118 -0.989 . . . . 0.0 109.177 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 3.6 p -113.53 101.12 9.05 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.495 -0.753 . . . . 0.0 109.45 -179.737 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -64.35 -36.52 84.4 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.296 -0.878 . . . . 0.0 109.596 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 1.2 p90 -67.55 -33.29 74.74 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.15 -0.969 . . . . 0.0 109.59 -179.835 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . 0.546 ' O ' ' NE2' ' A' ' 139' ' ' HIS . 8.6 mt -93.11 12.15 25.23 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.102 -0.998 . . . . 0.0 109.322 179.358 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . 0.406 ' HA ' ' HE2' ' A' ' 139' ' ' HIS . 60.1 t0 -57.05 124.18 17.82 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.137 -0.977 . . . . 0.0 109.616 -179.577 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -176.11 -159.29 21.56 Favored Glycine 0 N--CA 1.486 1.987 0 N-CA-C 109.009 -1.636 . . . . 0.0 109.009 -179.852 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 87.6 mttt -57.24 -38.51 73.92 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.317 -1.107 . . . . 0.0 109.646 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 139' ' ' HIS . . . . . 0.546 ' NE2' ' O ' ' A' ' 135' ' ' LEU . 63.3 m-70 53.57 71.51 0.5 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.318 -0.864 . . . . 0.0 109.957 179.766 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.429 ' O ' ' OG ' ' A' ' 112' ' ' SER . 39.3 t -69.0 135.44 28.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.14 -0.975 . . . . 0.0 108.879 179.295 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 17.4 m -126.94 148.23 31.78 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 121.222 -0.924 . . . . 0.0 109.74 -179.489 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 43.3 p90 -120.06 -6.01 9.99 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.382 -0.824 . . . . 0.0 110.019 179.831 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -164.74 -179.77 38.97 Favored Glycine 0 N--CA 1.495 2.618 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 179.692 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.4 pt20 -143.85 166.53 24.65 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.23 -1.159 . . . . 0.0 109.566 -179.769 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 44.7 t -97.21 132.18 42.36 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.13 0 O-C-N 121.096 -1.002 . . . . 0.0 109.54 -179.742 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 17.2 m -110.45 -32.74 2.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 O-C-N 121.413 -0.805 . . . . 0.0 109.3 179.321 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -145.35 170.25 16.68 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.308 -0.87 . . . . 0.0 109.46 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 97.35 2.47 58.96 Favored Glycine 0 N--CA 1.494 2.539 0 N-CA-C 109.977 -1.249 . . . . 0.0 109.977 179.531 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 149' ' ' MET . . . . . 0.407 ' O ' HG13 ' A' ' 152' ' ' VAL . 88.3 mtp -61.06 -33.07 72.74 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.189 -1.183 . . . . 0.0 109.685 179.925 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -64.78 -42.43 95.1 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 120.876 -1.14 . . . . 0.0 109.987 -179.547 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.4 p -82.53 -34.01 11.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.128 -0.983 . . . . 0.0 110.591 -179.341 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 152' ' ' VAL . . . . . 0.445 ' CG1' ' N ' ' A' ' 153' ' ' LYS . 0.8 OUTLIER -53.74 -40.88 45.21 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 120.957 -1.09 . . . . 0.0 109.067 -179.408 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 153' ' ' LYS . . . . . 0.445 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 99.0 mttt -63.53 -34.12 77.08 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.113 -0.992 . . . . 0.0 109.292 179.201 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -61.51 -37.11 82.49 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.322 -0.861 . . . . 0.0 109.937 -179.638 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 97.9 mt -71.99 -35.05 52.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.173 -0.955 . . . . 0.0 109.981 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -75.93 -42.0 50.05 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.177 -0.952 . . . . 0.0 111.209 -178.894 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 157' ' ' LYS . . . . . 0.428 ' HG2' ' HZ3' ' A' ' 157' ' ' LYS . 15.4 pttm -61.81 -34.2 75.49 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 120.769 -1.207 . . . . 0.0 109.719 -178.924 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 34.0 m -79.91 -13.79 13.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.152 -0.968 . . . . 0.0 109.082 179.562 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -76.88 170.43 55.09 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.836 -1.306 . . . . 0.0 109.836 -179.826 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 23.1 t -159.02 173.95 15.69 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.409 -1.054 . . . . 0.0 109.315 -179.841 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 23.6 m -53.84 -32.47 53.01 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.236 -0.915 . . . . 0.0 109.121 179.663 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 24.0 m -56.45 -32.57 65.05 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.393 -0.817 . . . . 0.0 109.412 179.842 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 95.1 13.23 53.38 Favored Glycine 0 N--CA 1.493 2.465 0 N-CA-C 109.791 -1.323 . . . . 0.0 109.791 179.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 98.0 mtt180 -119.24 144.82 46.54 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.283 -1.128 . . . . 0.0 109.379 179.862 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 165' ' ' THR . . . . . . . . . . . . . 80.1 p -82.39 150.46 27.11 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.25 -0.906 . . . . 0.0 109.563 179.867 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -65.95 -35.5 80.78 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.339 -0.851 . . . . 0.0 108.896 179.523 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 66.6 mttm -112.58 157.68 20.89 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.524 -0.735 . . . . 0.0 109.07 179.731 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -69.7 130.75 43.21 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.134 -0.979 . . . . 0.0 109.324 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 43.0 t -123.2 125.32 71.77 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 121.201 -0.937 . . . . 0.0 109.575 -179.949 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 60.7 t -150.33 157.17 6.15 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 O-C-N 121.486 -0.758 . . . . 0.0 108.972 179.582 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -87.98 119.41 35.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.104 -0.998 . . . . 0.0 109.529 -179.727 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -65.91 -24.62 66.88 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.361 -0.837 . . . . 0.0 109.414 179.407 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 19.9 t70 -173.81 171.16 3.8 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.127 -0.983 . . . . 0.0 110.301 -179.51 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 11.0 p -151.84 153.15 33.65 Favored 'General case' 0 N--CA 1.492 1.66 0 N-CA-C 109.052 -0.721 . . . . 0.0 109.052 179.499 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -175.75 174.55 46.94 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 109.702 -1.359 . . . . 0.0 109.702 179.784 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 62.2 tt0 -107.89 120.67 42.94 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.3 -1.118 . . . . 0.0 109.652 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 32.4 tp -61.71 -37.03 82.66 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.135 -0.978 . . . . 0.0 109.032 179.434 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 25.0 t . . . . . 0 N--CA 1.49 1.559 0 CA-C-O 118.087 -0.959 . . . . 0.0 109.466 179.972 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 8.2 p-10 . . . . . 0 N--CA 1.489 1.489 0 N-CA-C 109.555 -0.535 . . . . 0.0 109.555 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -73.76 145.87 37.32 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 122.803 2.335 . . . . 0.0 112.047 179.763 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . 0.482 ' NH2' ' CB ' ' A' ' 178' ' ' SER . 95.5 mtm-85 -119.16 132.49 55.97 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.271 -0.893 . . . . 0.0 108.783 179.222 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.6 p -135.04 142.39 40.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.269 -0.895 . . . . 0.0 109.772 -179.192 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 42.8 p90 -141.12 155.61 46.09 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.434 -0.791 . . . . 0.0 109.506 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -128.18 142.32 51.21 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.421 -0.799 . . . . 0.0 109.887 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 59.4 t0 -94.6 124.26 38.52 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.227 -0.92 . . . . 0.0 108.734 179.151 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 39.1 mtp -119.66 147.51 44.47 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.136 -0.978 . . . . 0.0 110.279 -179.312 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.43 ' OG ' ' CD ' ' A' ' 172' ' ' GLU . 59.7 m -128.57 153.67 46.98 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.604 -0.685 . . . . 0.0 109.355 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 34.7 m -114.93 131.93 65.66 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.835 0 O-C-N 121.388 -0.82 . . . . 0.0 109.426 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 63.59 9.65 32.99 Favored Glycine 0 N--CA 1.492 2.398 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 179.858 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 94.67 -1.67 66.31 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 -179.895 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 75.0 mt-30 -103.69 151.2 38.74 Favored Pre-proline 0 N--CA 1.493 1.717 0 O-C-N 121.295 -1.121 . . . . 0.0 109.073 179.756 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 14.3 Cg_endo -58.36 134.23 60.08 Favored 'Trans proline' 0 C--N 1.309 -1.507 0 C-N-CA 122.412 2.074 . . . . 0.0 112.266 -179.532 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -114.23 -65.06 1.23 Allowed 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.514 -0.741 . . . . 0.0 109.274 179.775 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -176.77 -170.48 39.34 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.456 -1.457 . . . . 0.0 109.456 179.943 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 46.6 ptt85 -120.06 148.55 43.45 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.318 -1.107 . . . . 0.0 109.11 179.851 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 83.3 mt -122.57 129.15 75.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.496 -0.753 . . . . 0.0 109.32 -179.863 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 46.3 t -113.14 133.26 59.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.539 -0.725 . . . . 0.0 109.062 179.673 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 74.5 mtm -121.12 149.69 42.38 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.391 -0.818 . . . . 0.0 109.52 -179.753 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -97.57 132.51 43.17 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.388 -0.82 . . . . 0.0 109.542 -179.858 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -109.36 130.57 55.49 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.533 -0.729 . . . . 0.0 109.425 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 86.5 m-85 -94.55 118.41 31.63 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.126 -0.984 . . . . 0.0 108.483 178.89 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -93.38 -42.06 9.49 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.299 -0.875 . . . . 0.0 109.68 -179.683 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.6 m-20 -62.26 -49.23 76.53 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.09 -1.006 . . . . 0.0 109.764 -179.498 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' THR . . . . . 0.442 ' O ' ' OE1' ' A' ' 99' ' ' GLU . 61.9 m -73.52 -42.03 62.28 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.069 -1.02 . . . . 0.0 109.72 179.8 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.529 ' O ' ' OG1' ' A' ' 35' ' ' THR . 1.8 p -132.24 79.02 67.21 Favored Pre-proline 0 N--CA 1.492 1.657 0 O-C-N 121.3 -0.875 . . . . 0.0 109.439 -179.69 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 21.2 Cg_endo -66.77 -61.79 0.08 OUTLIER 'Trans proline' 0 C--N 1.31 -1.468 0 C-N-CA 122.376 2.051 . . . . 0.0 112.603 -179.48 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.623 ' NH2' ' CE1' ' A' ' 92' ' ' TYR . 68.7 mtp85 -60.9 -34.98 75.49 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.415 -0.803 . . . . 0.0 110.4 -179.308 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 25.7 m -59.98 -41.47 92.07 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.953 -1.092 . . . . 0.0 109.859 -179.559 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -62.62 -30.18 71.17 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.089 -1.007 . . . . 0.0 109.35 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.435 ' OE1' ' OH ' ' A' ' 92' ' ' TYR . 96.6 mt-10 -67.59 -34.91 77.98 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.284 -0.885 . . . . 0.0 109.761 -179.983 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 26.2 m120 -56.82 -39.08 73.54 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.149 -0.97 . . . . 0.0 109.768 -179.767 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . 0.443 ' O ' ' SG ' ' A' ' 46' ' ' CYS . 98.8 m-85 -94.16 -50.45 5.28 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.121 -0.987 . . . . 0.0 109.512 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . 0.858 ' HE ' HE22 ' A' ' 176' ' ' GLN . 75.8 ttt-85 -57.19 -42.01 80.43 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.41 -0.806 . . . . 0.0 110.491 -179.392 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -63.72 -44.87 92.29 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.999 -1.063 . . . . 0.0 110.077 -179.121 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.515 ' N ' ' CD2' ' A' ' 45' ' ' LEU . 2.7 mm? -67.64 -37.2 82.1 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.19 -0.944 . . . . 0.0 109.637 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' CYS . . . . . 0.443 ' SG ' ' O ' ' A' ' 42' ' ' PHE . 64.1 m -66.69 -48.99 67.57 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.136 -0.977 . . . . 0.0 110.108 -179.533 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 60.6 p -72.65 -30.71 64.52 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.192 -0.943 . . . . 0.0 109.694 -179.844 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 74.03 27.34 66.68 Favored Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 179.778 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 23.0 pt-20 -62.25 -35.59 79.41 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.212 -1.169 . . . . 0.0 109.381 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 43.6 mmtm -61.19 -33.2 73.07 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.289 -0.882 . . . . 0.0 109.128 179.588 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 93.64 168.4 38.29 Favored Glycine 0 N--CA 1.488 2.136 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 -179.793 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 68.4 m -76.45 139.9 41.05 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.306 -1.114 . . . . 0.0 109.686 -179.947 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -53.9 135.15 43.27 Favored Glycine 0 N--CA 1.488 2.165 0 N-CA-C 109.224 -1.551 . . . . 0.0 109.224 179.753 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 91.9 mtm-85 -58.92 -35.99 74.0 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.192 -1.181 . . . . 0.0 109.917 -179.551 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 22.7 t -59.14 -31.21 68.75 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.18 -0.95 . . . . 0.0 109.919 -179.587 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . 0.449 ' O ' ' CG ' ' A' ' 57' ' ' LYS . . . 117.91 81.05 0.77 Allowed Glycine 0 N--CA 1.495 2.614 0 N-CA-C 108.749 -1.74 . . . . 0.0 108.749 -179.381 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . 0.547 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 57.4 mttm -161.69 79.87 2.03 Favored Pre-proline 0 C--N 1.303 -1.434 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 -179.576 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 71.3 Cg_exo -50.9 133.02 39.19 Favored 'Trans proline' 0 C--N 1.301 -1.964 0 C-N-CA 122.894 2.396 . . . . 0.0 112.809 -178.734 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.571 ' O ' ' CG ' ' A' ' 60' ' ' HIS . 7.0 mp -100.19 98.32 9.03 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.613 -0.679 . . . . 0.0 109.524 -179.47 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . 0.571 ' CG ' ' O ' ' A' ' 59' ' ' LEU . 93.5 m-70 -160.45 125.91 3.93 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.167 -0.958 . . . . 0.0 109.948 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 9.5 m-85 -71.95 -5.98 38.73 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.136 -0.978 . . . . 0.0 108.811 178.889 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . 0.561 ' O ' ' O ' ' A' ' 171' ' ' VAL . 48.7 tttt -53.39 -25.88 17.34 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.527 -0.733 . . . . 0.0 109.57 179.891 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 89.3 m-20 -103.6 4.85 36.1 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.467 -0.771 . . . . 0.0 110.071 -179.402 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 63.8 p -82.04 162.35 22.62 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.069 -1.019 . . . . 0.0 109.856 -179.754 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 29.2 t -147.31 159.34 43.78 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.473 -0.767 . . . . 0.0 109.083 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.5 m-85 -64.18 123.5 19.26 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.079 -1.013 . . . . 0.0 108.929 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 61.7 t60 -66.62 -50.26 63.6 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.304 -0.872 . . . . 0.0 110.548 -179.112 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 93.2 mtt180 -141.47 150.47 42.29 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 120.951 -1.093 . . . . 0.0 110.287 -179.658 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 4.9 m -137.09 130.92 45.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 179.096 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 19.1 mt -149.33 128.39 6.2 Favored Pre-proline 0 N--CA 1.492 1.646 0 O-C-N 120.94 -1.1 . . . . 0.0 109.41 -179.785 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 65.3 Cg_endo -76.0 133.44 15.13 Favored 'Trans proline' 0 C--N 1.311 -1.429 0 C-N-CA 122.148 1.899 . . . . 0.0 112.014 179.707 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 90.49 3.88 71.27 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.793 -1.323 . . . . 0.0 109.793 179.662 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 82.6 m-85 -138.77 -94.37 0.18 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.129 -1.218 . . . . 0.0 109.811 179.845 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 7.3 ptt? -171.45 175.79 4.01 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.168 -0.957 . . . . 0.0 109.839 -179.655 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -122.28 136.28 54.88 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 108.231 -1.026 . . . . 0.0 108.231 179.363 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 92.4 mt-30 -94.56 136.0 35.37 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.88 -1.138 . . . . 0.0 110.198 -179.262 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -90.03 -173.52 45.15 Favored Glycine 0 N--CA 1.492 2.379 0 N-CA-C 108.941 -1.664 . . . . 0.0 108.941 179.395 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -155.63 174.3 33.67 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.779 -1.329 . . . . 0.0 109.779 179.84 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.547 ' OD1' ' N ' ' A' ' 83' ' ' GLY . 48.5 p30 -106.37 165.59 11.15 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.415 -1.05 . . . . 0.0 109.56 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 46.4 p90 -75.2 -19.95 59.54 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.309 -0.87 . . . . 0.0 109.66 -179.884 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.557 ' OG1' ' N ' ' A' ' 88' ' ' GLY . 71.2 p -65.93 -37.06 85.06 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.281 -0.887 . . . . 0.0 109.989 -179.629 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -174.46 -51.32 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.267 -0.896 . . . . 0.0 109.539 -179.934 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . 0.547 ' N ' ' OD1' ' A' ' 79' ' ' ASP . . . 94.71 2.2 63.23 Favored Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 78.7 m-20 -86.02 4.15 39.17 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.189 -1.183 . . . . 0.0 109.448 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 93.71 -37.47 3.39 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 51.6 p -69.99 -29.11 66.11 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.185 -1.185 . . . . 0.0 109.231 179.842 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -87.85 -168.23 44.24 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.983 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.557 ' N ' ' OG1' ' A' ' 81' ' ' THR . . . 84.03 45.07 6.43 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.571 -1.412 . . . . 0.0 109.571 179.879 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -56.37 144.37 30.94 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.344 -1.092 . . . . 0.0 109.43 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 27.4 t -78.24 144.57 36.1 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.159 -0.963 . . . . 0.0 109.552 -179.913 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 17.0 pt -66.34 -36.29 77.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.291 -0.881 . . . . 0.0 109.849 -179.871 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . 0.623 ' CE1' ' NH2' ' A' ' 37' ' ' ARG . 96.4 m-85 -66.21 -36.44 83.04 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.175 -0.953 . . . . 0.0 109.566 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.21 5.74 87.03 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.202 -1.559 . . . . 0.0 109.202 -179.752 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -150.97 158.0 43.6 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.348 -1.09 . . . . 0.0 109.381 -179.911 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -85.17 148.29 26.18 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.178 -0.951 . . . . 0.0 109.484 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 45.6 p90 -135.39 159.13 42.56 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.327 -0.858 . . . . 0.0 109.392 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -73.25 135.68 44.51 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.262 -0.899 . . . . 0.0 109.932 -179.678 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . 0.438 ' C ' ' OD1' ' A' ' 98' ' ' ASP . 54.4 p30 -99.84 -163.87 1.07 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.313 -0.867 . . . . 0.0 109.549 179.774 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . 0.442 ' OE1' ' O ' ' A' ' 34' ' ' THR . 94.5 mt-10 -108.02 163.01 13.52 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.371 -0.831 . . . . 0.0 109.455 179.77 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 82.9 m-20 -64.76 165.95 9.66 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.257 -0.902 . . . . 0.0 109.566 -179.809 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 101' ' ' PHE . . . . . 0.489 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 33.3 p90 -80.7 51.43 1.5 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.27 -0.894 . . . . 0.0 109.718 -179.811 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 90.7 mt -56.22 -41.08 68.96 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.101 -0.999 . . . . 0.0 109.547 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 43.6 mtpt -89.33 146.14 24.9 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.178 -0.951 . . . . 0.0 109.693 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 49.3 pttt -134.85 179.98 5.97 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.42 -0.8 . . . . 0.0 109.356 179.804 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 105' ' ' HIS . . . . . 0.532 ' O ' ' CG ' ' A' ' 105' ' ' HIS . 48.4 p-80 -92.64 100.75 13.2 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.292 -0.88 . . . . 0.0 109.407 -179.872 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 51.2 p -76.54 -22.46 54.34 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.331 -0.856 . . . . 0.0 109.628 -179.903 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -151.15 -179.46 26.89 Favored Glycine 0 N--CA 1.492 2.406 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 -179.688 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -72.65 158.87 49.94 Favored 'Trans proline' 0 C--N 1.307 -1.626 0 C-N-CA 122.951 2.434 . . . . 0.0 112.178 179.83 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 84.95 38.25 9.47 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 110.233 -1.147 . . . . 0.0 110.233 179.532 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.405 HD13 HG21 ' A' ' 110' ' ' ILE . 34.4 mm -113.38 138.39 43.13 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.29 -1.123 . . . . 0.0 108.979 179.598 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . 0.604 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 2.4 mm? -87.58 139.75 30.22 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.246 -0.909 . . . . 0.0 109.658 -179.754 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 112' ' ' SER . . . . . 0.427 ' OG ' ' O ' ' A' ' 140' ' ' VAL . 23.1 t -128.16 143.54 51.06 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.54 -0.725 . . . . 0.0 109.27 179.85 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 58.3 ttp -96.71 127.08 42.35 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.305 -0.872 . . . . 0.0 109.533 -179.9 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -66.16 146.5 54.58 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.236 -0.915 . . . . 0.0 109.633 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . 0.502 ' N ' ' OD1' ' A' ' 115' ' ' ASN . 9.1 p-10 -168.25 115.73 0.7 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.272 -0.893 . . . . 0.0 109.668 179.818 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -66.18 -33.95 76.92 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.379 -0.825 . . . . 0.0 109.347 179.806 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -145.52 166.92 27.65 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.352 -1.499 . . . . 0.0 109.352 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -66.59 158.58 55.04 Favored 'Trans proline' 0 C--N 1.306 -1.678 0 C-N-CA 122.822 2.348 . . . . 0.0 111.963 179.919 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 73.7 m-20 55.03 44.07 28.74 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.467 -0.771 . . . . 0.0 109.392 -179.886 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 87.2 m -137.28 129.33 29.22 Favored 'General case' 0 C--N 1.305 -1.359 0 O-C-N 121.405 -0.81 . . . . 0.0 109.113 179.943 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 22.4 t-20 -79.94 116.24 19.97 Favored 'General case' 0 C--N 1.298 -1.65 0 O-C-N 121.489 -0.757 . . . . 0.0 109.33 179.859 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -85.32 -179.54 50.69 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.736 -1.346 . . . . 0.0 109.736 -179.82 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -130.64 -14.25 3.66 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.367 -1.079 . . . . 0.0 109.749 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 94.3 mt-30 -121.89 159.42 26.89 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.299 -0.876 . . . . 0.0 109.622 -179.876 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 43.6 p90 -130.83 158.74 39.35 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.489 -0.757 . . . . 0.0 109.474 -179.898 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -117.47 143.84 45.63 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.49 -0.757 . . . . 0.0 110.02 -179.766 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.41 HD13 HG23 ' A' ' 127' ' ' ILE . 84.2 mt -120.77 134.27 64.75 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 121.613 -0.679 . . . . 0.0 109.224 179.246 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -125.27 126.36 45.01 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.293 -0.879 . . . . 0.0 109.376 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 30.3 p -98.32 3.39 48.64 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.348 -0.845 . . . . 0.0 109.301 179.868 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -153.62 159.63 42.16 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.243 -0.911 . . . . 0.0 109.428 -179.795 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 7.9 ttpm? -66.44 130.05 41.89 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.165 -0.959 . . . . 0.0 109.081 179.8 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 16.6 p -109.09 95.86 5.92 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.395 -0.816 . . . . 0.0 109.633 -179.658 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -65.74 -35.72 81.55 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.213 -0.929 . . . . 0.0 109.581 179.844 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 1.0 OUTLIER -66.47 -33.86 76.64 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.245 -0.91 . . . . 0.0 109.55 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 9.7 mt -90.06 7.17 39.09 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.166 -0.959 . . . . 0.0 109.201 179.295 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . 0.533 ' O ' ' OD1' ' A' ' 136' ' ' ASP . 47.2 p30 -46.79 138.45 6.22 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.184 -0.948 . . . . 0.0 109.783 -179.617 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 174.21 -161.88 32.12 Favored Glycine 0 N--CA 1.484 1.885 0 N-CA-C 108.873 -1.691 . . . . 0.0 108.873 -179.708 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . 0.477 ' O ' ' O ' ' A' ' 139' ' ' HIS . 88.8 mttt -57.36 -39.55 76.21 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 121.276 -1.132 . . . . 0.0 109.432 179.86 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 139' ' ' HIS . . . . . 0.477 ' O ' ' O ' ' A' ' 138' ' ' LYS . 66.3 m-70 53.18 109.22 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.51 -0.744 . . . . 0.0 110.049 179.63 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.427 ' O ' ' OG ' ' A' ' 112' ' ' SER . 40.6 t -107.42 136.54 42.27 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.36 -0.837 . . . . 0.0 108.825 179.435 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 23.5 m -125.09 142.47 41.87 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.307 -0.871 . . . . 0.0 109.587 -179.464 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 42.8 p90 -126.46 -9.89 6.29 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.5 -0.75 . . . . 0.0 109.751 179.73 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -156.52 175.72 34.07 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 179.631 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 58.6 tt0 -141.43 159.44 42.22 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.238 -1.154 . . . . 0.0 109.675 -179.614 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 9.8 t -97.83 134.39 36.24 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.22 0 O-C-N 121.124 -0.985 . . . . 0.0 109.126 179.904 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 11.6 m -113.62 -35.45 2.26 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.493 -0.754 . . . . 0.0 109.535 179.653 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 91.9 mt-10 -142.83 167.86 21.08 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.227 -0.92 . . . . 0.0 109.627 -179.849 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 97.78 4.36 57.95 Favored Glycine 0 N--CA 1.494 2.553 0 N-CA-C 110.079 -1.209 . . . . 0.0 110.079 179.534 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 149' ' ' MET . . . . . 0.414 ' O ' HG11 ' A' ' 152' ' ' VAL . 88.0 mtp -60.84 -33.22 72.72 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.062 -1.258 . . . . 0.0 109.741 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . 0.54 ' OD1' ' N ' ' A' ' 151' ' ' VAL . 30.9 p-10 -65.67 -38.26 88.8 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.9 -1.125 . . . . 0.0 110.107 -179.441 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . 0.54 ' N ' ' OD1' ' A' ' 150' ' ' ASP . 7.6 p -86.52 -33.9 7.51 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.066 -1.021 . . . . 0.0 110.262 -179.593 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 152' ' ' VAL . . . . . 0.469 ' CG1' ' N ' ' A' ' 153' ' ' LYS . 1.0 OUTLIER -56.1 -42.65 73.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 120.943 -1.098 . . . . 0.0 109.175 -179.503 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 153' ' ' LYS . . . . . 0.469 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 98.7 mttt -64.87 -33.88 77.06 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.189 -0.944 . . . . 0.0 109.537 179.431 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -62.33 -40.4 96.22 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.287 -0.883 . . . . 0.0 110.11 -179.321 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 75.4 mt -71.19 -36.79 63.81 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.228 -0.92 . . . . 0.0 110.394 -179.481 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -79.57 -41.45 27.15 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.085 -1.009 . . . . 0.0 111.406 -178.725 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 23.5 pttt -61.02 -34.0 74.15 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.705 -1.247 . . . . 0.0 110.193 -178.591 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 35.1 m -73.37 -10.44 13.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.027 -1.046 . . . . 0.0 109.2 179.906 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -76.38 176.36 52.11 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 -179.822 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 83.2 p -155.31 176.07 13.05 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.425 -1.044 . . . . 0.0 109.039 -179.641 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 22.7 m -52.28 -36.01 51.77 Favored 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 179.429 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 23.8 m -60.71 -33.19 72.52 Favored 'General case' 0 N--CA 1.487 1.387 0 O-C-N 121.377 -0.827 . . . . 0.0 108.93 179.164 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 96.31 8.94 57.29 Favored Glycine 0 N--CA 1.493 2.437 0 N-CA-C 109.805 -1.318 . . . . 0.0 109.805 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 69.6 ttp85 -101.74 138.69 38.39 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.348 -1.089 . . . . 0.0 109.521 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 165' ' ' THR . . . . . . . . . . . . . 65.2 p -84.12 151.85 24.67 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.175 -0.953 . . . . 0.0 109.544 179.81 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -67.28 -34.8 78.15 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.245 -0.909 . . . . 0.0 109.063 179.557 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 63.2 mttp -114.52 158.43 21.65 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.563 -0.711 . . . . 0.0 109.34 -179.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 63.1 mttp -73.79 137.81 44.12 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.148 -0.97 . . . . 0.0 109.353 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 2.7 m -132.65 119.71 39.23 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.35 -0.844 . . . . 0.0 109.843 -179.758 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 39.2 t -145.67 141.58 22.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 CA-C-O 121.898 0.856 . . . . 0.0 109.424 179.41 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . 0.561 ' O ' ' O ' ' A' ' 62' ' ' LYS . 22.1 t -61.36 132.36 26.89 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.783 0 C-N-CA 120.333 -0.547 . . . . 0.0 109.762 -179.608 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 172' ' ' GLU . . . . . 0.452 ' O ' ' OD1' ' A' ' 173' ' ' ASP . 95.6 mt-10 -105.87 -7.08 18.44 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.335 -0.853 . . . . 0.0 109.808 179.61 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 173' ' ' ASP . . . . . 0.452 ' OD1' ' O ' ' A' ' 172' ' ' GLU . 30.5 m-20 -158.44 168.22 27.55 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.082 -1.011 . . . . 0.0 110.007 -179.734 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 20.4 p -170.32 126.25 0.78 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.474 -0.766 . . . . 0.0 109.539 179.565 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -173.55 173.86 45.92 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 179.8 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 176' ' ' GLN . . . . . 0.858 HE22 ' HE ' ' A' ' 43' ' ' ARG . 58.7 tt0 -105.2 121.35 43.66 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.383 -1.069 . . . . 0.0 109.853 -179.787 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 36.8 tp -62.41 -36.57 82.77 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.239 -0.913 . . . . 0.0 108.95 179.125 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 178' ' ' SER . . . . . 0.513 ' OXT' ' NE2' ' A' ' 176' ' ' GLN . 7.2 t . . . . . 0 N--CA 1.491 1.589 0 CA-C-O 117.977 -1.011 . . . . 0.0 109.428 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.529 4.856 0 N-CA-C 119.398 2.519 . . . . 0.0 119.398 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' SER . . . . . 0.404 ' OG ' ' CD2' ' A' ' 3' ' ' PHE . 86.4 p -61.6 -27.6 68.75 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.186 -1.185 . . . . 0.0 109.441 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.404 ' CD2' ' OG ' ' A' ' 2' ' ' SER . 99.2 m-85 -111.03 124.37 52.03 Favored 'General case' 0 N--CA 1.485 1.291 0 N-CA-C 108.82 -0.808 . . . . 0.0 108.82 179.727 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 53.5 p -66.71 -26.86 67.22 Favored 'General case' 0 C--N 1.296 -1.723 0 O-C-N 121.491 -0.756 . . . . 0.0 109.494 -179.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 82.17 18.76 66.29 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 -179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 28.5 t -117.91 146.75 43.72 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.43 -1.041 . . . . 0.0 109.502 -179.919 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' MET . . . . . 0.593 ' N ' ' SD ' ' A' ' 7' ' ' MET . 1.7 mpt? -123.31 69.35 40.8 Favored Pre-proline 0 N--CA 1.494 1.73 0 O-C-N 121.415 -0.803 . . . . 0.0 109.427 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 39.9 Cg_endo -69.16 -9.62 26.8 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 122.657 2.238 . . . . 0.0 112.364 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 5.3 p30 -123.73 70.09 46.96 Favored Pre-proline 0 N--CA 1.494 1.756 0 O-C-N 121.261 -0.899 . . . . 0.0 109.832 -179.65 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -72.04 144.43 42.57 Favored 'Trans proline' 0 C--N 1.308 -1.561 0 C-N-CA 122.515 2.143 . . . . 0.0 111.752 179.582 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 92.9 mtt180 -126.26 142.2 51.62 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.304 -0.873 . . . . 0.0 109.643 -179.822 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 10.5 p -134.87 143.84 36.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.359 -0.838 . . . . 0.0 109.345 179.803 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 25.0 p90 -139.49 152.89 47.33 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.208 -0.933 . . . . 0.0 109.602 -179.843 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -124.62 133.09 53.37 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.426 -0.796 . . . . 0.0 109.471 179.529 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.7 t0 -91.06 111.95 23.64 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.144 -0.972 . . . . 0.0 108.611 179.248 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 78.9 mtp -106.39 138.91 41.72 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.239 -0.913 . . . . 0.0 110.437 -179.185 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.427 ' OG ' ' OE2' ' A' ' 172' ' ' GLU . 48.8 m -131.6 155.95 46.63 Favored 'General case' 0 N--CA 1.492 1.632 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 179.416 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 25.1 m -118.99 144.29 27.71 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.149 -0.969 . . . . 0.0 109.62 -179.738 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 57.6 -108.99 1.55 Allowed Glycine 0 N--CA 1.488 2.119 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -135.77 28.33 2.98 Favored Glycine 0 N--CA 1.493 2.479 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 32.6 mt-30 -137.44 153.02 74.19 Favored Pre-proline 0 N--CA 1.493 1.719 0 O-C-N 121.297 -1.119 . . . . 0.0 109.186 179.873 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_endo -63.96 139.16 66.32 Favored 'Trans proline' 0 N--CA 1.495 1.56 0 C-N-CA 122.528 2.152 . . . . 0.0 112.05 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -102.84 -60.59 1.52 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.276 -0.89 . . . . 0.0 109.4 179.874 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 179.89 -170.83 42.2 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 98.2 mtt180 -117.57 143.72 45.83 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.365 -1.079 . . . . 0.0 109.583 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 86.5 mt -121.53 122.37 66.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 179.073 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 39.9 t -116.21 132.3 66.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.437 -0.789 . . . . 0.0 109.024 -179.901 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 71.7 mtm -124.76 152.19 44.15 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.403 -0.81 . . . . 0.0 109.346 -179.694 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -106.15 131.76 53.02 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.394 -0.816 . . . . 0.0 109.894 -179.616 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 17.3 mt -100.27 146.4 26.95 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.423 -0.798 . . . . 0.0 109.311 179.162 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 95.5 m-85 -95.43 124.19 39.34 Favored 'General case' 0 N--CA 1.49 1.567 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 178.804 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -99.17 21.48 11.79 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.206 -0.934 . . . . 0.0 109.694 -179.323 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.3 m-20 -120.76 -73.55 0.64 Allowed 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.289 -0.882 . . . . 0.0 110.21 -179.553 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' THR . . . . . 0.443 ' O ' ' OE1' ' A' ' 99' ' ' GLU . 41.3 m -61.15 -43.43 98.89 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.176 -0.953 . . . . 0.0 110.44 -179.117 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 9.4 m -139.95 78.37 24.74 Favored Pre-proline 0 N--CA 1.494 1.746 0 O-C-N 121.126 -0.984 . . . . 0.0 109.963 -179.543 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 68.3 Cg_endo -79.75 -36.94 0.52 Allowed 'Trans proline' 0 C--N 1.306 -1.689 0 C-N-CA 122.614 2.209 . . . . 0.0 112.461 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.418 ' O ' ' OH ' ' A' ' 92' ' ' TYR . 3.3 mtt-85 -59.63 -38.98 82.81 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.247 -0.908 . . . . 0.0 109.79 -179.761 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 85.0 m -64.26 -41.01 97.13 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.187 -0.946 . . . . 0.0 109.793 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -60.72 -32.78 72.02 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.209 -0.932 . . . . 0.0 108.904 179.762 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -69.23 -34.98 75.67 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.486 -0.759 . . . . 0.0 109.744 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 45.2 t-20 -57.11 -41.0 78.13 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.177 -0.952 . . . . 0.0 109.746 -179.616 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 97.7 m-85 -82.54 -45.73 14.28 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.147 -0.971 . . . . 0.0 109.78 -179.892 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . 0.496 ' NH1' ' OE2' ' A' ' 49' ' ' GLU . 72.1 ttp85 -59.2 -40.9 87.18 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.366 -0.834 . . . . 0.0 110.544 -179.377 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.498 ' O ' ' N ' ' A' ' 48' ' ' GLY . . . -69.55 -52.43 26.38 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.143 -0.973 . . . . 0.0 110.348 -179.117 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.45 ' N ' ' CD2' ' A' ' 45' ' ' LEU . 3.4 mm? -63.93 -39.68 94.71 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.066 -1.021 . . . . 0.0 109.702 -179.739 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' CYS . . . . . . . . . . . . . 95.2 m -63.85 -62.69 1.48 Allowed 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.066 -1.021 . . . . 0.0 109.278 -179.863 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 26.6 m -66.53 -36.24 82.22 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.294 -0.879 . . . . 0.0 109.178 179.586 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . 0.498 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 81.6 38.84 13.19 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 110.064 -1.214 . . . . 0.0 110.064 179.749 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.496 ' OE2' ' NH1' ' A' ' 43' ' ' ARG . 95.3 mt-10 -62.04 -35.79 79.65 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.079 -1.248 . . . . 0.0 109.47 179.883 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 31.2 mmtm -60.43 -34.55 74.14 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.308 -0.87 . . . . 0.0 109.546 -179.838 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 93.58 169.11 38.62 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.236 -1.546 . . . . 0.0 109.236 -179.687 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 68.4 m -79.47 141.12 37.04 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.292 -1.122 . . . . 0.0 109.963 -179.853 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -65.02 140.27 41.71 Favored Glycine 0 N--CA 1.489 2.172 0 N-CA-C 109.302 -1.519 . . . . 0.0 109.302 179.637 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 76.5 mtm180 -59.59 -33.24 71.21 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.229 -1.159 . . . . 0.0 110.046 -179.621 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 86.7 p -60.49 -23.44 64.51 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.204 -0.935 . . . . 0.0 110.122 -179.338 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . 0.427 ' O ' ' CG ' ' A' ' 57' ' ' LYS . . . 108.84 76.94 0.96 Allowed Glycine 0 N--CA 1.495 2.633 0 N-CA-C 108.951 -1.66 . . . . 0.0 108.951 -179.486 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . 0.479 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 54.2 mttm -161.2 76.91 2.41 Favored Pre-proline 0 N--CA 1.488 1.463 0 N-CA-C 107.914 -1.143 . . . . 0.0 107.914 -179.822 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -48.42 129.91 20.48 Favored 'Trans proline' 0 C--N 1.301 -1.936 0 C-N-CA 122.932 2.421 . . . . 0.0 112.578 -178.716 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.479 ' CD1' ' O ' ' A' ' 57' ' ' LYS . 8.1 mp -97.88 70.7 2.16 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.719 -0.613 . . . . 0.0 109.42 -179.434 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 96.3 m-70 -139.2 146.5 40.6 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.284 -0.885 . . . . 0.0 109.609 179.871 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 4.1 m-85 -97.0 16.87 18.29 Favored 'General case' 0 N--CA 1.492 1.644 0 N-CA-C 108.488 -0.93 . . . . 0.0 108.488 179.173 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 8.7 mtpm? -75.78 153.09 37.19 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.511 -0.743 . . . . 0.0 109.594 -179.692 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 83.8 m-20 55.19 46.23 24.24 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.468 -0.77 . . . . 0.0 109.796 179.745 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 92.1 p -112.94 150.8 31.33 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.418 -0.801 . . . . 0.0 109.038 179.595 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 29.1 t -120.71 148.08 44.42 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.369 -0.832 . . . . 0.0 109.594 -179.694 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -68.38 132.56 47.25 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.294 -0.879 . . . . 0.0 109.015 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 83.8 t60 -63.4 -49.25 74.53 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.278 -0.889 . . . . 0.0 110.367 -179.43 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 5.6 ttm180 -151.45 154.45 36.61 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.071 -1.018 . . . . 0.0 109.344 -179.351 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 19.2 m -132.43 149.88 32.74 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 121.277 -0.889 . . . . 0.0 109.982 -179.737 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 13.3 mt -148.05 125.58 5.75 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.158 -0.963 . . . . 0.0 108.629 178.892 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -71.94 144.2 42.52 Favored 'Trans proline' 0 N--CA 1.493 1.463 0 C-N-CA 122.123 1.882 . . . . 0.0 112.588 -179.291 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 75.08 -53.37 2.61 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.94 -1.264 . . . . 0.0 109.94 179.566 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 84.4 m-85 -67.51 -83.28 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.196 -1.179 . . . . 0.0 110.082 -179.533 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' MET . . . . . 0.587 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 11.9 ptt? -179.49 158.45 0.84 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.114 -0.991 . . . . 0.0 109.619 -179.736 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 1.1 m -99.35 125.8 45.1 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.329 -0.857 . . . . 0.0 108.755 179.377 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 63.7 tt0 -97.94 121.16 39.53 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.21 -0.931 . . . . 0.0 109.766 -179.645 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -87.06 -176.59 49.09 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.14 -1.584 . . . . 0.0 109.14 179.571 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -142.74 162.79 27.37 Favored Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.666 -1.374 . . . . 0.0 109.666 179.857 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -75.04 147.53 40.63 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.344 -1.092 . . . . 0.0 109.553 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 44.4 p90 -68.11 -18.93 64.78 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.243 -0.91 . . . . 0.0 109.654 -179.842 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.539 ' OG1' ' N ' ' A' ' 88' ' ' GLY . 59.7 p -66.22 -30.27 70.68 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.213 -0.929 . . . . 0.0 109.438 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -177.42 -56.22 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.247 -0.908 . . . . 0.0 109.44 179.823 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 94.36 -4.31 70.0 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 78.7 m-20 -88.16 5.41 41.49 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.23 -1.159 . . . . 0.0 109.413 179.865 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 95.93 -38.78 3.0 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 -179.842 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 48.5 m -60.34 -39.51 87.36 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.248 -1.148 . . . . 0.0 109.218 179.738 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -86.06 -168.29 44.59 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 179.901 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.539 ' N ' ' OG1' ' A' ' 81' ' ' THR . . . 108.32 73.14 0.79 Allowed Glycine 0 N--CA 1.494 2.534 0 N-CA-C 109.753 -1.339 . . . . 0.0 109.753 179.865 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -94.8 135.82 35.84 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.254 -1.145 . . . . 0.0 109.189 179.732 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 50.2 m -122.41 147.9 45.74 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.39 -0.819 . . . . 0.0 109.569 -179.84 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 26.1 pt -67.48 -26.81 36.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.309 -0.869 . . . . 0.0 109.621 179.877 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . 0.418 ' OH ' ' O ' ' A' ' 37' ' ' ARG . 97.3 m-85 -65.23 -30.16 71.02 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.3 -0.875 . . . . 0.0 109.776 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 68.09 -107.61 2.13 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.284 -1.527 . . . . 0.0 109.284 -179.772 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -55.54 147.87 16.94 Favored 'General case' 0 N--CA 1.487 1.39 0 O-C-N 121.241 -1.152 . . . . 0.0 109.319 179.819 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 41.5 mttm -76.05 156.26 34.11 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.388 -0.82 . . . . 0.0 109.694 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 33.7 p90 -133.01 161.67 33.75 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.407 -0.808 . . . . 0.0 109.208 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -60.15 140.31 57.0 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.152 -0.967 . . . . 0.0 109.809 -179.349 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -76.68 135.28 39.09 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.29 -0.881 . . . . 0.0 109.812 -179.886 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . 0.443 ' OE1' ' O ' ' A' ' 34' ' ' THR . 95.9 mt-10 -64.84 148.44 51.33 Favored 'General case' 0 C--N 1.305 -1.348 0 O-C-N 121.32 -0.862 . . . . 0.0 109.245 179.556 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 21.3 m120 -55.84 145.7 23.85 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 121.362 -0.836 . . . . 0.0 109.365 -179.866 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' PHE . . . . . 0.586 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 25.0 p90 -110.27 69.88 0.71 Allowed 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.448 -0.782 . . . . 0.0 109.47 -179.781 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 86.4 mt -59.04 -34.8 54.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.257 -0.902 . . . . 0.0 109.575 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 27.1 mtmm -84.77 150.14 25.26 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.21 -0.931 . . . . 0.0 109.615 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 56.4 pttt -131.91 -179.64 5.52 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.371 -0.831 . . . . 0.0 109.362 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' HIS . . . . . 0.534 ' O ' ' CG ' ' A' ' 105' ' ' HIS . 50.4 p-80 -88.27 98.45 11.59 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.207 -0.933 . . . . 0.0 109.647 -179.832 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 55.5 p -77.44 -22.02 52.1 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.237 -0.915 . . . . 0.0 109.708 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -150.46 179.34 27.27 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.524 -1.431 . . . . 0.0 109.524 -179.744 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -70.99 160.6 48.85 Favored 'Trans proline' 0 C--N 1.307 -1.617 0 C-N-CA 122.863 2.376 . . . . 0.0 112.183 179.886 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 85.62 36.94 9.94 Favored Glycine 0 N--CA 1.493 2.493 0 N-CA-C 109.95 -1.26 . . . . 0.0 109.95 179.725 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 39.3 mm -114.98 135.32 55.28 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 O-C-N 121.364 -1.08 . . . . 0.0 109.364 179.857 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . 0.609 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 2.4 mm? -91.46 136.23 33.27 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.21 -0.931 . . . . 0.0 109.544 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' SER . . . . . 0.44 ' OG ' ' O ' ' A' ' 140' ' ' VAL . 38.0 t -143.82 139.5 29.36 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.336 -0.852 . . . . 0.0 109.244 179.669 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 82.6 mtp -84.96 130.62 34.6 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.169 -0.957 . . . . 0.0 109.247 179.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . 0.443 ' O ' ' OD1' ' A' ' 115' ' ' ASN . . . -68.79 141.25 55.23 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.222 -0.924 . . . . 0.0 109.565 -179.879 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . 0.443 ' OD1' ' O ' ' A' ' 114' ' ' ALA . 72.9 m-20 -145.83 112.75 6.05 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.247 -0.908 . . . . 0.0 109.054 179.554 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -69.07 -31.11 69.62 Favored 'General case' 0 C--N 1.296 -1.723 0 O-C-N 121.448 -0.783 . . . . 0.0 109.234 179.747 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -141.02 167.65 25.6 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.137 -1.585 . . . . 0.0 109.137 179.826 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_endo -66.46 157.46 60.34 Favored 'Trans proline' 0 C--N 1.304 -1.799 0 C-N-CA 122.737 2.292 . . . . 0.0 111.94 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 22.3 m120 56.08 51.38 12.01 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.447 -0.783 . . . . 0.0 109.716 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 61.3 m -131.36 127.18 37.06 Favored 'General case' 0 N--CA 1.485 1.28 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 179.437 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 49.3 t-20 -53.13 -37.55 61.9 Favored 'General case' 0 C--N 1.296 -1.753 0 O-C-N 121.371 -0.831 . . . . 0.0 109.839 -179.274 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 77.0 63.52 2.27 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 109.766 -1.334 . . . . 0.0 109.766 179.826 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 24.0 m -54.76 -33.38 61.22 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.199 -1.177 . . . . 0.0 109.76 -179.796 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.3 mt-30 -92.07 147.4 22.98 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.113 -0.992 . . . . 0.0 109.511 -179.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 49.1 p90 -138.96 162.48 34.78 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.246 -0.909 . . . . 0.0 109.67 -179.901 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.587 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 48.8 p90 -139.27 160.79 38.98 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.398 -0.814 . . . . 0.0 109.355 179.911 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 69.8 mt -118.51 132.39 68.53 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.378 -0.826 . . . . 0.0 109.428 179.833 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -102.13 105.59 16.32 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.325 -0.859 . . . . 0.0 109.273 179.887 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' THR . . . . . 0.439 ' OG1' ' OE2' ' A' ' 156' ' ' GLU . 44.8 p -89.12 -1.38 58.06 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.283 -0.885 . . . . 0.0 109.642 179.937 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -141.71 153.13 44.44 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.261 -0.9 . . . . 0.0 109.485 -179.816 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 79.7 tttt -78.33 130.64 36.41 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.285 -0.884 . . . . 0.0 109.38 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 33.3 p -124.65 156.11 38.06 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.358 -0.838 . . . . 0.0 109.47 -179.863 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -111.81 -36.3 5.47 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.433 -0.792 . . . . 0.0 109.615 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 134' ' ' TRP . . . . . 0.448 ' CD2' ' N ' ' A' ' 134' ' ' TRP . 0.7 OUTLIER -66.84 -15.2 63.45 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.159 -0.963 . . . . 0.0 109.629 -179.722 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . 0.41 ' O ' ' NE2' ' A' ' 139' ' ' HIS . 7.9 mt -89.29 11.09 19.94 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.195 -0.941 . . . . 0.0 109.436 179.568 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -69.7 118.07 12.09 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.163 -0.961 . . . . 0.0 109.41 -179.617 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -177.68 -154.48 12.35 Favored Glycine 0 N--CA 1.487 2.062 0 N-CA-C 108.883 -1.687 . . . . 0.0 108.883 -179.84 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 32.3 mmtp -81.11 113.7 19.46 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.178 -1.189 . . . . 0.0 109.157 179.769 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 139' ' ' HIS . . . . . 0.41 ' NE2' ' O ' ' A' ' 135' ' ' LEU . 99.2 m-70 -137.17 154.83 50.14 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.367 -0.833 . . . . 0.0 109.348 -179.964 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.44 ' O ' ' OG ' ' A' ' 112' ' ' SER . 44.2 t -122.75 134.41 66.02 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.341 -0.849 . . . . 0.0 109.641 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 61.8 t -110.78 130.48 64.08 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 121.419 -0.801 . . . . 0.0 108.881 179.566 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 38.8 p90 -123.37 -4.88 8.31 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.19 -0.944 . . . . 0.0 110.704 -179.478 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -162.59 174.35 38.96 Favored Glycine 0 N--CA 1.493 2.463 0 C-N-CA 119.152 -1.499 . . . . 0.0 110.498 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 51.7 tt0 -138.96 159.98 40.84 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.604 -0.939 . . . . 0.0 109.169 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 79.7 t -97.31 129.39 47.46 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.188 0 O-C-N 121.105 -0.997 . . . . 0.0 109.521 -179.827 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 19.0 m -106.35 -32.19 2.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.376 -0.828 . . . . 0.0 109.425 179.638 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -145.5 173.15 12.27 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.253 -0.904 . . . . 0.0 109.505 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 98.35 1.93 57.9 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 109.89 -1.284 . . . . 0.0 109.89 179.65 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 149' ' ' MET . . . . . 0.413 ' O ' HG12 ' A' ' 152' ' ' VAL . 65.0 mtt -61.2 -32.35 72.1 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.127 -1.219 . . . . 0.0 109.782 179.979 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . 0.548 ' OD1' ' N ' ' A' ' 151' ' ' VAL . 33.8 p-10 -66.37 -38.73 88.22 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.811 -1.181 . . . . 0.0 110.211 -179.512 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . 0.548 ' N ' ' OD1' ' A' ' 150' ' ' ASP . 6.3 p -85.25 -33.71 8.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.712 0 O-C-N 121.036 -1.04 . . . . 0.0 110.339 -179.545 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 152' ' ' VAL . . . . . 0.442 ' CG1' ' N ' ' A' ' 153' ' ' LYS . 1.1 p -52.77 -41.09 37.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 120.952 -1.092 . . . . 0.0 108.832 -179.488 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 153' ' ' LYS . . . . . 0.442 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 99.4 mttt -64.66 -34.64 78.76 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.252 -0.905 . . . . 0.0 109.144 179.122 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -61.19 -35.38 76.99 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.375 -0.828 . . . . 0.0 109.95 -179.537 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.428 HG23 HD12 ' A' ' 155' ' ' ILE . 87.5 mt -71.33 -35.76 58.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.049 -1.032 . . . . 0.0 109.976 -179.882 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . 0.439 ' OE2' ' OG1' ' A' ' 129' ' ' THR . 97.9 mt-10 -76.97 -40.69 45.98 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.079 -1.013 . . . . 0.0 111.474 -178.937 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 18.4 pttp -60.11 -36.44 77.45 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.592 -1.318 . . . . 0.0 109.208 -179.2 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 30.4 m -80.95 -12.88 12.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.163 -0.961 . . . . 0.0 108.562 178.91 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -78.89 175.8 54.89 Favored Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.707 -1.357 . . . . 0.0 109.707 -179.886 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 25.1 t -157.69 166.79 31.88 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.35 -1.088 . . . . 0.0 109.325 -179.859 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 86.9 p -57.67 -26.05 61.12 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.201 -0.937 . . . . 0.0 108.899 179.745 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 26.7 m -57.44 -30.33 64.92 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.444 -0.785 . . . . 0.0 109.394 179.661 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 95.04 15.62 44.39 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.714 -1.354 . . . . 0.0 109.714 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 77.8 ttt-85 -122.93 141.39 51.96 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.341 -1.093 . . . . 0.0 109.495 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 165' ' ' THR . . . . . . . . . . . . . 42.7 p -80.91 143.53 32.6 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.188 -0.945 . . . . 0.0 109.618 179.903 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -68.72 -38.34 80.13 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.262 -0.899 . . . . 0.0 109.185 179.559 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 67.2 mttm -107.75 159.75 16.25 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.485 -0.759 . . . . 0.0 109.325 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -73.39 131.7 42.15 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.18 -0.95 . . . . 0.0 109.227 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 40.2 t -121.2 125.0 73.3 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.341 -0.849 . . . . 0.0 109.431 179.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 41.6 t -147.06 150.81 14.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.343 -0.848 . . . . 0.0 109.219 179.861 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -88.04 120.37 36.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.233 -0.917 . . . . 0.0 109.625 -179.619 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 172' ' ' GLU . . . . . 0.427 ' OE2' ' OG ' ' A' ' 17' ' ' SER . 97.1 mt-10 -65.28 -26.47 68.09 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.413 -0.804 . . . . 0.0 109.324 179.479 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 173' ' ' ASP . . . . . 0.432 ' OD1' ' N ' ' A' ' 174' ' ' CYS . 47.2 t0 -174.8 169.26 3.53 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.201 -0.937 . . . . 0.0 110.412 -179.532 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 174' ' ' CYS . . . . . 0.432 ' N ' ' OD1' ' A' ' 173' ' ' ASP . 31.4 p -150.38 150.83 31.93 Favored 'General case' 0 N--CA 1.491 1.585 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 179.349 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -175.98 -176.49 44.23 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.823 -1.311 . . . . 0.0 109.823 -179.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 6.7 tt0 -104.43 119.67 39.49 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.415 -1.05 . . . . 0.0 109.713 -179.823 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 30.9 tp -62.71 -37.93 88.46 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.129 -0.982 . . . . 0.0 109.154 179.434 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 8.0 t . . . . . 0 N--CA 1.49 1.55 0 CA-C-O 118.017 -0.992 . . . . 0.0 109.433 -179.958 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.528 4.774 0 N-CA-C 119.35 2.5 . . . . 0.0 119.35 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 91.5 p -62.84 -23.11 67.12 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.275 -1.133 . . . . 0.0 109.452 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 55.6 p90 -134.25 136.34 43.55 Favored 'General case' 0 N--CA 1.486 1.332 0 O-C-N 121.263 -0.898 . . . . 0.0 108.973 179.569 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 43.4 m -61.84 -40.5 95.53 Favored 'General case' 0 C--N 1.297 -1.689 0 O-C-N 121.563 -0.711 . . . . 0.0 109.928 -179.832 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 90.51 8.04 66.36 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.514 -1.435 . . . . 0.0 109.514 -179.841 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 47.1 m -62.49 155.3 26.03 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.194 -1.18 . . . . 0.0 109.333 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' MET . . . . . 0.606 ' N ' ' SD ' ' A' ' 7' ' ' MET . 0.1 OUTLIER -64.62 150.31 94.17 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.231 -0.918 . . . . 0.0 109.273 -179.914 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -70.52 169.18 20.51 Favored 'Trans proline' 0 C--N 1.309 -1.547 0 C-N-CA 122.742 2.295 . . . . 0.0 112.1 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 7.7 t-20 -63.89 139.01 97.56 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.331 -0.856 . . . . 0.0 109.027 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_endo -71.14 139.0 34.61 Favored 'Trans proline' 0 N--CA 1.494 1.502 0 C-N-CA 122.406 2.071 . . . . 0.0 112.493 -179.778 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.568 ' H ' ' HG ' ' A' ' 178' ' ' SER . 86.6 mtt180 -131.65 134.04 45.56 Favored 'General case' 0 N--CA 1.493 1.697 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 179.119 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 12.6 p -136.4 144.52 32.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.412 -0.805 . . . . 0.0 109.353 -179.783 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 48.8 p90 -135.28 151.89 50.99 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.337 -0.852 . . . . 0.0 109.348 179.877 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 90.4 m-85 -119.39 127.52 53.21 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.451 -0.781 . . . . 0.0 110.122 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.4 t0 -92.54 120.31 32.87 Favored 'General case' 0 N--CA 1.493 1.678 0 N-CA-C 108.347 -0.982 . . . . 0.0 108.347 178.86 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 77.2 mtp -122.09 151.12 41.23 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.991 -1.068 . . . . 0.0 110.698 -179.065 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 93.8 p -145.12 160.63 41.11 Favored 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 108.744 -0.836 . . . . 0.0 108.744 179.671 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.419 ' O ' ' C ' ' A' ' 19' ' ' GLY . 18.9 m -128.71 143.55 40.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.274 -0.891 . . . . 0.0 109.488 179.963 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.419 ' C ' ' O ' ' A' ' 18' ' ' VAL . . . 42.11 -103.86 0.04 OUTLIER Glycine 0 N--CA 1.492 2.423 0 N-CA-C 109.692 -1.363 . . . . 0.0 109.692 179.925 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -135.48 22.56 3.51 Favored Glycine 0 N--CA 1.494 2.526 0 N-CA-C 109.32 -1.512 . . . . 0.0 109.32 179.685 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 62.1 mt-30 -127.41 88.61 53.45 Favored Pre-proline 0 N--CA 1.494 1.741 0 O-C-N 121.448 -1.031 . . . . 0.0 109.264 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_exo -48.63 133.17 26.43 Favored 'Trans proline' 0 C--N 1.309 -1.511 0 C-N-CA 122.505 2.137 . . . . 0.0 112.297 -179.637 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -82.47 -64.06 1.25 Allowed 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.405 -0.81 . . . . 0.0 109.772 -179.89 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 175.15 -167.56 39.7 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 -179.858 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 94.5 mtt-85 -106.27 150.23 26.13 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.447 -1.031 . . . . 0.0 109.186 179.886 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 79.6 mt -119.26 120.73 64.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 179.378 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 34.8 t -112.99 132.38 61.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.446 -0.784 . . . . 0.0 108.911 -179.909 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 70.6 mtm -127.45 156.68 41.74 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.323 -0.86 . . . . 0.0 109.679 -179.361 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -99.62 135.51 40.94 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.284 -0.885 . . . . 0.0 109.795 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -108.89 128.35 54.84 Favored 'General case' 0 N--CA 1.492 1.65 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 179.388 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -95.19 118.23 31.61 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.143 -0.973 . . . . 0.0 108.992 179.778 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -80.43 -42.47 22.64 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 121.473 -0.767 . . . . 0.0 109.839 -179.812 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 56.8 t0 -65.52 -46.26 80.28 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.237 -0.914 . . . . 0.0 110.435 -179.365 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 24.8 m -66.17 -45.73 79.88 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.002 -1.061 . . . . 0.0 109.854 -179.38 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.454 ' O ' ' OG1' ' A' ' 35' ' ' THR . 13.2 p -145.33 81.84 10.08 Favored Pre-proline 0 N--CA 1.493 1.711 0 O-C-N 121.317 -0.864 . . . . 0.0 109.332 -179.72 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -70.33 -47.07 0.82 Allowed 'Trans proline' 0 C--N 1.307 -1.615 0 C-N-CA 122.1 1.867 . . . . 0.0 112.215 -179.48 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 22.9 mmt85 -63.04 -39.75 95.68 Favored 'General case' 0 N--CA 1.487 1.409 0 O-C-N 121.1 -1.0 . . . . 0.0 109.581 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 37.9 m -65.16 -40.92 95.01 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.224 -0.922 . . . . 0.0 110.069 -179.736 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -60.69 -31.8 71.05 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.312 -0.867 . . . . 0.0 109.278 -179.699 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -67.09 -38.44 85.7 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.335 -0.853 . . . . 0.0 109.758 -179.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 49.1 t30 -58.48 -42.52 87.72 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.264 -0.898 . . . . 0.0 109.932 -179.644 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . 0.507 ' O ' ' SG ' ' A' ' 46' ' ' CYS . 97.6 m-85 -82.89 -45.72 13.87 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.061 -1.024 . . . . 0.0 109.859 -179.925 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . 0.742 ' HE ' HE22 ' A' ' 176' ' ' GLN . 74.0 ttt-85 -58.73 -41.1 85.62 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.296 -0.878 . . . . 0.0 110.544 -179.342 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -71.77 -53.81 12.21 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.028 -1.045 . . . . 0.0 110.553 -179.019 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.473 ' N ' ' CD2' ' A' ' 45' ' ' LEU . 3.8 mm? -63.32 -38.9 92.95 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.948 -1.095 . . . . 0.0 109.776 -179.631 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' CYS . . . . . 0.507 ' SG ' ' O ' ' A' ' 42' ' ' PHE . 95.6 m -65.83 -55.65 16.02 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.108 -0.995 . . . . 0.0 109.138 179.864 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 50.7 m -66.13 -36.81 84.13 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.373 -0.83 . . . . 0.0 109.279 179.468 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 85.31 30.02 26.13 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 110.269 -1.133 . . . . 0.0 110.269 179.565 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -62.2 -38.71 90.15 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.05 -1.265 . . . . 0.0 109.359 179.83 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 59.7 mmtt -62.5 -31.27 72.0 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.386 -0.821 . . . . 0.0 109.686 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 74.34 -113.95 4.29 Favored Glycine 0 N--CA 1.488 2.125 0 N-CA-C 108.854 -1.698 . . . . 0.0 108.854 -179.37 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 87.4 m -127.61 143.42 51.17 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.339 -1.094 . . . . 0.0 109.749 179.624 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -64.99 137.2 38.31 Favored Glycine 0 N--CA 1.489 2.168 0 N-CA-C 109.221 -1.551 . . . . 0.0 109.221 179.685 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 81.4 mtm180 -59.1 -34.93 72.59 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.205 -1.173 . . . . 0.0 109.913 -179.7 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 86.1 p -61.95 -24.41 66.98 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.174 -0.954 . . . . 0.0 109.782 -179.746 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 112.45 89.6 1.84 Allowed Glycine 0 N--CA 1.495 2.569 0 N-CA-C 109.102 -1.599 . . . . 0.0 109.102 -179.682 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . 0.529 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 22.8 tttp -174.56 79.56 0.34 Allowed Pre-proline 0 N--CA 1.488 1.465 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 -179.677 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_exo -50.47 131.99 33.92 Favored 'Trans proline' 0 C--N 1.304 -1.793 0 C-N-CA 122.892 2.394 . . . . 0.0 113.197 -178.779 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.529 ' CD1' ' O ' ' A' ' 57' ' ' LYS . 8.9 mp -104.49 122.32 45.3 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 108.782 -0.821 . . . . 0.0 108.782 179.325 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . 0.421 ' CD2' ' N ' ' A' ' 60' ' ' HIS . 5.1 p80 -169.7 93.28 0.25 Allowed 'General case' 0 N--CA 1.486 1.375 0 O-C-N 120.971 -1.081 . . . . 0.0 110.272 -179.684 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 8.0 m-85 -64.29 -29.39 70.48 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.182 -0.949 . . . . 0.0 109.066 179.149 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 8.8 ptmm? -55.3 160.3 2.3 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.351 -0.843 . . . . 0.0 109.627 179.842 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . 0.449 ' N ' ' O ' ' A' ' 171' ' ' VAL . 85.0 m-20 54.62 48.01 21.31 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.498 -0.752 . . . . 0.0 109.416 -179.842 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.525 ' H ' ' CG1' ' A' ' 171' ' ' VAL . 89.6 p -126.46 155.07 42.83 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.277 -0.889 . . . . 0.0 109.134 179.754 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 32.1 t -106.48 141.98 36.9 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.335 -0.853 . . . . 0.0 109.056 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -69.61 143.43 53.28 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.343 -0.848 . . . . 0.0 108.892 -179.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 57.2 t-80 -57.33 -51.13 70.62 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.218 -0.927 . . . . 0.0 110.405 -178.851 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 15.6 ptm180 -171.0 163.68 7.45 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 120.896 -1.127 . . . . 0.0 109.697 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -136.47 129.28 45.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.462 -0.774 . . . . 0.0 109.128 179.696 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 70.3 mt -128.92 109.14 18.35 Favored Pre-proline 0 N--CA 1.493 1.695 0 O-C-N 121.543 -0.723 . . . . 0.0 109.631 179.865 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -52.45 147.53 29.28 Favored 'Trans proline' 0 C--N 1.31 -1.482 0 C-N-CA 122.357 2.038 . . . . 0.0 112.62 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 87.12 -59.53 4.48 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 110.156 -1.177 . . . . 0.0 110.156 179.373 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 67.8 m-85 -70.21 -73.48 0.16 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.239 -1.154 . . . . 0.0 110.061 -179.493 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' MET . . . . . 0.528 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 13.4 ptt? 178.45 -165.66 0.05 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.225 -0.922 . . . . 0.0 109.618 -179.918 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' CYS . . . . . 0.435 ' SG ' ' O ' ' A' ' 127' ' ' ILE . 0.0 OUTLIER -121.22 124.13 43.92 Favored 'General case' 0 N--CA 1.494 1.764 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 179.614 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 63.6 tt0 -102.44 124.49 48.09 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.231 -0.918 . . . . 0.0 109.827 -179.663 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -86.26 -173.88 49.34 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.259 -1.536 . . . . 0.0 109.259 179.457 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -136.83 154.5 22.21 Favored Glycine 0 N--CA 1.493 2.477 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 88.0 m-20 -83.77 143.81 29.73 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.432 -1.04 . . . . 0.0 109.642 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 41.3 p90 -65.43 -23.61 66.98 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.283 -0.886 . . . . 0.0 109.624 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.454 ' OG1' ' N ' ' A' ' 88' ' ' GLY . 52.7 p -64.2 -31.54 72.78 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.145 -0.972 . . . . 0.0 109.481 -179.891 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 178.02 -54.08 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.403 -0.811 . . . . 0.0 109.334 179.855 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 96.58 -11.21 66.77 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 80.3 m-20 -88.66 2.77 52.63 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.186 -1.185 . . . . 0.0 109.315 179.795 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 93.66 -5.16 73.3 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.395 -1.482 . . . . 0.0 109.395 -179.868 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 61.7 p -74.47 -19.02 60.54 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.394 -1.062 . . . . 0.0 109.517 179.87 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -131.86 -132.75 3.38 Favored Glycine 0 N--CA 1.494 2.519 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.454 ' N ' ' OG1' ' A' ' 81' ' ' THR . . . 74.57 47.28 16.25 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.293 -1.523 . . . . 0.0 109.293 -179.915 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -93.3 135.36 34.59 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.295 -1.121 . . . . 0.0 109.753 -179.508 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 50.0 m -70.72 158.08 36.91 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.358 -0.839 . . . . 0.0 109.508 179.84 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 24.9 pt -65.94 -31.15 52.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.24 -0.912 . . . . 0.0 109.834 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 59.9 m-85 -64.0 -36.33 83.63 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.256 -0.902 . . . . 0.0 109.591 -179.746 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 82.79 10.16 83.52 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.321 -1.512 . . . . 0.0 109.321 -179.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -148.28 157.25 43.38 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.282 -1.128 . . . . 0.0 109.372 -179.915 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 62.0 mttp -86.57 153.03 22.12 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.22 -0.925 . . . . 0.0 109.466 179.912 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 36.9 p90 -129.09 157.87 40.53 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.425 -0.797 . . . . 0.0 109.329 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -65.68 143.98 57.21 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.294 -0.879 . . . . 0.0 110.052 -179.337 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . 0.504 ' CG ' ' H ' ' A' ' 119' ' ' ASN . 88.5 m-20 -67.01 148.0 52.51 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.35 -0.844 . . . . 0.0 109.617 179.845 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -100.14 161.91 13.3 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.345 -0.847 . . . . 0.0 109.268 179.844 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 81.4 m-20 -62.6 163.17 9.37 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.369 -0.832 . . . . 0.0 109.405 -179.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' PHE . . . . . 0.582 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 22.0 p90 -130.22 79.43 1.9 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.431 -0.793 . . . . 0.0 109.52 -179.898 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 87.8 mt -58.97 -33.94 51.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.183 -0.948 . . . . 0.0 109.376 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 67.2 mttm -83.51 143.18 30.38 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.187 -0.946 . . . . 0.0 109.386 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . 0.541 ' O ' ' N ' ' A' ' 106' ' ' THR . 50.0 tttp -127.35 158.24 37.79 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.406 -0.809 . . . . 0.0 109.331 -179.924 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' HIS . . . . . 0.455 ' CE1' ' O ' ' A' ' 107' ' ' GLY . 78.6 t60 -61.01 76.5 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.341 -0.849 . . . . 0.0 109.252 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' THR . . . . . 0.541 ' N ' ' O ' ' A' ' 104' ' ' LYS . 70.5 p -73.52 -27.15 61.21 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.199 -0.938 . . . . 0.0 109.878 -179.731 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.455 ' O ' ' CE1' ' A' ' 105' ' ' HIS . . . -153.75 177.12 31.43 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.561 -1.415 . . . . 0.0 109.561 -179.763 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -70.4 156.65 61.21 Favored 'Trans proline' 0 C--N 1.305 -1.724 0 C-N-CA 122.774 2.316 . . . . 0.0 112.131 179.881 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 86.07 43.59 6.27 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 110.095 -1.202 . . . . 0.0 110.095 179.728 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 45.4 mm -117.13 136.13 55.27 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 O-C-N 121.263 -1.139 . . . . 0.0 109.386 179.593 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . 0.591 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 2.9 mm? -88.65 137.36 32.39 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.21 -0.931 . . . . 0.0 109.413 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' SER . . . . . 0.457 ' OG ' ' O ' ' A' ' 140' ' ' VAL . 46.2 t -146.22 141.22 27.19 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.246 -0.909 . . . . 0.0 109.582 179.804 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 88.5 mtp -88.51 135.59 33.41 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.259 -0.9 . . . . 0.0 109.416 179.67 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . 0.456 ' O ' ' OD1' ' A' ' 115' ' ' ASN . . . -73.73 137.54 44.07 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.202 -0.936 . . . . 0.0 109.585 -179.946 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . 0.456 ' OD1' ' O ' ' A' ' 114' ' ' ALA . 76.3 m-20 -146.58 114.17 6.39 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.203 -0.936 . . . . 0.0 108.945 179.535 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -69.15 -31.07 69.49 Favored 'General case' 0 C--N 1.297 -1.697 0 O-C-N 121.409 -0.807 . . . . 0.0 109.697 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -139.9 167.55 25.34 Favored Glycine 0 N--CA 1.494 2.543 0 N-CA-C 109.396 -1.482 . . . . 0.0 109.396 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -69.08 154.11 70.97 Favored 'Trans proline' 0 C--N 1.307 -1.653 0 C-N-CA 122.701 2.268 . . . . 0.0 111.849 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' ASN . . . . . 0.504 ' H ' ' CG ' ' A' ' 98' ' ' ASP . 80.3 m-20 53.49 43.22 31.58 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.436 -0.79 . . . . 0.0 109.317 -179.939 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 91.8 m -136.37 128.41 29.59 Favored 'General case' 0 C--N 1.305 -1.34 0 O-C-N 121.445 -0.784 . . . . 0.0 109.041 179.84 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 43.4 p-10 -80.76 168.11 19.19 Favored 'General case' 0 C--N 1.298 -1.668 0 O-C-N 121.377 -0.827 . . . . 0.0 109.311 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -159.79 105.94 0.28 Allowed Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.667 -1.373 . . . . 0.0 109.667 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 23.9 t -59.12 -32.61 69.99 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.252 -1.146 . . . . 0.0 109.389 179.85 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.6 mt-30 -71.23 142.96 50.58 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.214 -0.928 . . . . 0.0 109.575 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 48.5 p90 -140.46 162.27 35.73 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.342 -0.849 . . . . 0.0 109.322 179.866 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.528 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 48.2 p90 -138.43 158.56 44.04 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.295 -0.878 . . . . 0.0 109.608 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.435 ' O ' ' SG ' ' A' ' 75' ' ' CYS . 60.3 mt -120.34 132.29 70.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.411 -0.806 . . . . 0.0 109.208 179.85 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' CYS . . . . . 0.507 ' SG ' ' O ' ' A' ' 130' ' ' ALA . 4.4 t -100.99 116.8 33.69 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.135 -0.978 . . . . 0.0 109.389 179.886 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 129' ' ' THR . . . . . 0.445 ' OG1' ' OE1' ' A' ' 156' ' ' GLU . 51.0 p -91.45 0.78 57.47 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.301 -0.875 . . . . 0.0 109.622 -179.842 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . 0.507 ' O ' ' SG ' ' A' ' 128' ' ' CYS . . . -151.25 155.91 39.77 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.188 -0.945 . . . . 0.0 109.601 -179.811 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 77.8 tttt -69.33 140.56 54.32 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.186 -0.946 . . . . 0.0 109.261 179.832 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 17.0 p -113.19 159.68 19.04 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.349 -0.844 . . . . 0.0 109.506 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -154.57 -50.46 0.09 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.397 -0.814 . . . . 0.0 109.282 -179.876 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 134' ' ' TRP . . . . . 0.631 ' CD1' ' N ' ' A' ' 135' ' ' LEU . 35.3 p90 -56.43 -38.8 72.07 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.259 -0.901 . . . . 0.0 109.385 179.836 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . 0.631 ' N ' ' CD1' ' A' ' 134' ' ' TRP . 44.2 tp -60.01 -36.5 77.35 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.428 -0.795 . . . . 0.0 109.505 -179.782 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 59.4 t0 47.26 78.75 0.07 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.337 -0.852 . . . . 0.0 109.798 179.771 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -144.74 134.92 5.84 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.11 -1.596 . . . . 0.0 109.11 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 67.6 mmtt -82.96 135.06 35.01 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.261 -1.141 . . . . 0.0 109.42 -179.754 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 96.4 m-70 -136.02 175.5 9.54 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.414 -0.804 . . . . 0.0 109.376 -179.878 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.457 ' O ' ' OG ' ' A' ' 112' ' ' SER . 20.1 m -124.0 153.77 30.34 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 121.466 -0.771 . . . . 0.0 108.996 179.702 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 58.5 t -118.39 128.2 75.39 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.292 -0.88 . . . . 0.0 109.961 -179.607 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . 0.455 ' CE2' ' CE2' ' A' ' 42' ' ' PHE . 40.6 p90 -117.59 1.61 12.27 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.474 -0.766 . . . . 0.0 109.561 179.412 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -169.29 177.38 42.97 Favored Glycine 0 N--CA 1.495 2.593 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 179.64 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . 0.432 ' CG ' ' N ' ' A' ' 145' ' ' VAL . 48.0 tt0 -143.76 161.62 38.12 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.349 -1.089 . . . . 0.0 109.798 -179.643 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . 0.432 ' N ' ' CG ' ' A' ' 144' ' ' GLN . 79.9 t -100.03 135.59 35.04 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.112 0 O-C-N 121.283 -0.886 . . . . 0.0 109.653 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 6.8 m -118.8 -33.69 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.275 -0.89 . . . . 0.0 109.573 179.672 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -138.37 166.03 25.27 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.237 -0.915 . . . . 0.0 109.713 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 94.47 9.98 58.49 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.845 -1.302 . . . . 0.0 109.845 179.745 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 149' ' ' MET . . . . . . . . . . . . . 88.7 mtp -59.84 -34.07 72.61 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.192 -1.181 . . . . 0.0 109.765 -179.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 89.0 m-20 -64.61 -39.68 94.15 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.896 -1.127 . . . . 0.0 109.846 -179.74 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 5.5 p -85.59 -33.27 7.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.132 -0.98 . . . . 0.0 110.522 -179.423 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 152' ' ' VAL . . . . . 0.412 ' CG1' ' N ' ' A' ' 153' ' ' LYS . 0.7 OUTLIER -55.29 -38.77 49.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 120.953 -1.092 . . . . 0.0 109.376 -179.366 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 153' ' ' LYS . . . . . 0.412 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 50.7 pttt -81.16 -20.97 40.13 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.136 -0.978 . . . . 0.0 109.385 179.683 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -64.39 -39.82 94.6 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.252 -0.905 . . . . 0.0 109.579 -179.916 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 65.2 mt -72.05 -35.68 54.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.304 -0.873 . . . . 0.0 109.541 179.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . 0.445 ' OE1' ' OG1' ' A' ' 129' ' ' THR . 84.7 tt0 -76.26 -42.27 46.22 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.257 -0.902 . . . . 0.0 111.447 -178.772 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 16.4 pttp -61.59 -33.12 73.34 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 120.639 -1.288 . . . . 0.0 110.241 -178.56 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 35.2 m -77.02 -17.84 14.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.018 -1.051 . . . . 0.0 109.683 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -72.87 172.77 48.77 Favored Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.965 -1.254 . . . . 0.0 109.965 -179.655 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 160' ' ' SER . . . . . 0.605 ' HG ' ' HG ' ' A' ' 162' ' ' SER . 85.0 p -150.09 170.07 19.76 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.476 -1.014 . . . . 0.0 109.381 -179.739 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 23.2 m -55.42 -34.72 64.67 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.177 -0.952 . . . . 0.0 108.965 179.705 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 162' ' ' SER . . . . . 0.605 ' HG ' ' HG ' ' A' ' 160' ' ' SER . 86.5 p -62.57 -26.34 68.54 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.373 -0.83 . . . . 0.0 109.189 179.674 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 97.2 3.17 58.94 Favored Glycine 0 N--CA 1.494 2.529 0 N-CA-C 109.674 -1.37 . . . . 0.0 109.674 179.898 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 77.8 ttt180 -99.99 144.56 28.9 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.306 -1.114 . . . . 0.0 109.205 179.818 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 165' ' ' THR . . . . . . . . . . . . . 65.5 p -104.71 152.1 22.93 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.354 -0.841 . . . . 0.0 109.657 -179.877 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -68.47 -37.0 79.77 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.369 -0.832 . . . . 0.0 109.627 179.923 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 47.8 mtmt -112.41 157.82 20.58 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.53 -0.731 . . . . 0.0 109.628 -179.793 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 91.3 mttt -76.54 146.49 38.34 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.333 -0.854 . . . . 0.0 109.306 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 32.6 m -128.75 125.2 62.86 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 O-C-N 121.326 -0.859 . . . . 0.0 109.596 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 48.5 t -144.88 138.23 22.21 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.387 -0.821 . . . . 0.0 109.302 179.589 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . 0.525 ' CG1' ' H ' ' A' ' 64' ' ' SER . 2.5 p -80.41 119.65 30.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 120.99 -1.069 . . . . 0.0 108.999 179.717 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -71.03 -44.41 65.88 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.133 -0.98 . . . . 0.0 111.177 -178.535 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 173' ' ' ASP . . . . . 0.441 ' OD1' ' N ' ' A' ' 174' ' ' CYS . 47.2 t0 -170.15 164.64 9.2 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.754 -1.216 . . . . 0.0 110.542 -179.325 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 174' ' ' CYS . . . . . 0.441 ' N ' ' OD1' ' A' ' 173' ' ' ASP . 1.4 p -151.63 151.86 32.07 Favored 'General case' 0 N--CA 1.49 1.573 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 179.484 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -160.75 178.37 36.77 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 176' ' ' GLN . . . . . 0.742 HE22 ' HE ' ' A' ' 43' ' ' ARG . 62.6 tt0 -99.05 113.96 26.42 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.326 -1.102 . . . . 0.0 109.713 -179.821 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 29.1 tp -63.37 -36.79 84.89 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.216 -0.928 . . . . 0.0 109.022 179.418 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 178' ' ' SER . . . . . 0.568 ' HG ' ' H ' ' A' ' 11' ' ' ARG . 11.8 p . . . . . 0 N--CA 1.491 1.62 0 CA-C-O 118.001 -0.999 . . . . 0.0 109.495 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.528 4.812 0 N-CA-C 119.429 2.532 . . . . 0.0 119.429 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 86.6 p -61.87 -27.12 68.57 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.203 -1.175 . . . . 0.0 109.445 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 68.1 t80 -107.53 120.5 42.36 Favored 'General case' 0 N--CA 1.484 1.268 0 O-C-N 121.399 -0.813 . . . . 0.0 108.958 179.689 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 18.1 p -124.23 162.41 23.74 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.663 -0.648 . . . . 0.0 109.343 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -176.84 -175.23 43.99 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 54.4 p -69.22 159.56 32.8 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.207 -1.172 . . . . 0.0 109.369 179.895 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 37.4 mtt -148.16 153.15 40.97 Favored Pre-proline 0 N--CA 1.492 1.641 0 O-C-N 121.241 -0.912 . . . . 0.0 109.463 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.44 ' O ' ' CB ' ' A' ' 9' ' ' ASN . 36.1 Cg_endo -66.83 -179.17 1.55 Allowed 'Trans proline' 0 C--N 1.309 -1.52 0 C-N-CA 122.715 2.277 . . . . 0.0 111.903 179.679 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.44 ' CB ' ' O ' ' A' ' 8' ' ' PRO . 2.5 m-20 73.99 78.23 0.19 Allowed Pre-proline 0 N--CA 1.492 1.661 0 O-C-N 121.408 -0.807 . . . . 0.0 109.624 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 93.3 Cg_endo -82.23 90.53 1.09 Allowed 'Trans proline' 0 C--N 1.308 -1.575 0 C-N-CA 122.898 2.399 . . . . 0.0 111.845 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 73.1 mtm180 -61.68 137.91 58.28 Favored 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.289 -0.882 . . . . 0.0 109.849 -179.595 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 12.7 p -138.29 143.53 32.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 179.497 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 45.1 p90 -141.54 153.96 45.19 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.179 -0.95 . . . . 0.0 110.107 -179.513 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 86.0 m-85 -123.73 140.25 53.18 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 179.162 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.5 t0 -86.88 116.31 24.87 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.053 -1.029 . . . . 0.0 109.259 179.768 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 80.4 mtp -103.96 147.45 27.34 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.291 -0.881 . . . . 0.0 110.19 -179.856 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 97.1 p -143.94 164.39 30.72 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 108.55 -0.907 . . . . 0.0 108.55 179.414 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 12.9 p -128.3 139.03 53.0 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.238 -0.914 . . . . 0.0 109.676 -179.752 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 57.02 -107.33 0.92 Allowed Glycine 0 N--CA 1.488 2.129 0 N-CA-C 109.364 -1.494 . . . . 0.0 109.364 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -136.04 37.15 1.93 Allowed Glycine 0 N--CA 1.493 2.487 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 6.5 pt20 -147.88 126.99 6.3 Favored Pre-proline 0 N--CA 1.492 1.649 0 O-C-N 121.264 -1.139 . . . . 0.0 109.349 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_exo -47.39 139.88 16.29 Favored 'Trans proline' 0 N--CA 1.493 1.455 0 C-N-CA 122.139 1.893 . . . . 0.0 112.17 179.74 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -101.49 -61.31 1.39 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.311 -0.868 . . . . 0.0 109.483 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -178.19 -170.3 40.16 Favored Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.409 -1.476 . . . . 0.0 109.409 -179.871 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 97.5 mtt180 -118.04 142.33 47.5 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.374 -1.074 . . . . 0.0 109.803 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 70.1 mt -120.39 123.2 70.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 178.609 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 38.7 t -110.05 132.58 57.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.387 -0.82 . . . . 0.0 109.382 -179.535 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 76.2 mtm -114.79 149.32 37.16 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.591 -0.693 . . . . 0.0 109.381 -179.689 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -100.92 129.82 46.83 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.286 -0.884 . . . . 0.0 109.698 -179.668 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.408 ' N ' ' CD2' ' A' ' 30' ' ' LEU . 2.7 mm? -108.34 132.66 53.5 Favored 'General case' 0 N--CA 1.494 1.741 0 N-CA-C 108.909 -0.775 . . . . 0.0 108.909 179.588 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.485 ' O ' ' OG1' ' A' ' 35' ' ' THR . 92.7 m-85 -96.36 114.02 25.66 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.031 -1.043 . . . . 0.0 108.742 178.98 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -75.87 -42.43 49.4 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.155 -0.966 . . . . 0.0 109.869 -179.696 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.3 m-20 -66.63 -57.86 6.34 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.149 -0.97 . . . . 0.0 110.191 -179.356 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 54.9 m -67.03 -40.73 87.28 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.246 -0.909 . . . . 0.0 109.853 -179.759 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.485 ' OG1' ' O ' ' A' ' 31' ' ' PHE . 81.7 p -130.04 77.5 76.42 Favored Pre-proline 0 N--CA 1.493 1.711 0 O-C-N 121.358 -0.839 . . . . 0.0 109.377 -179.64 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -72.84 -73.64 0.01 OUTLIER 'Trans proline' 0 N--CA 1.493 1.489 0 C-N-CA 122.676 2.251 . . . . 0.0 113.259 -179.38 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 80.1 mtt85 -59.37 -39.33 82.93 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.612 -0.68 . . . . 0.0 111.061 -178.624 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 42.8 m -61.66 -42.56 99.07 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.864 -1.148 . . . . 0.0 109.452 -179.848 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -63.9 -30.85 71.89 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.263 -0.898 . . . . 0.0 108.593 179.295 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.448 ' OE1' ' OH ' ' A' ' 92' ' ' TYR . 85.2 tt0 -66.25 -36.81 83.96 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.432 -0.792 . . . . 0.0 109.509 179.927 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 38.7 t30 -58.03 -41.2 82.69 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.229 -0.919 . . . . 0.0 109.514 -179.698 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . 0.498 ' O ' ' SG ' ' A' ' 46' ' ' CYS . 98.0 m-85 -83.18 -44.99 14.43 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.058 -1.026 . . . . 0.0 109.661 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . 0.69 ' NE ' HE22 ' A' ' 176' ' ' GLN . 77.5 ttt180 -59.32 -43.2 92.7 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.38 -0.825 . . . . 0.0 110.62 -179.216 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.448 ' O ' ' N ' ' A' ' 48' ' ' GLY . . . -68.1 -43.97 77.29 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.097 -1.002 . . . . 0.0 110.63 -178.834 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -62.39 -39.05 91.95 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.971 -1.081 . . . . 0.0 109.593 -179.659 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' CYS . . . . . 0.498 ' SG ' ' O ' ' A' ' 42' ' ' PHE . 35.7 m -67.64 -47.89 68.27 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.146 -0.972 . . . . 0.0 109.391 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 48.3 p -74.49 -33.75 62.91 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.361 -0.837 . . . . 0.0 109.709 179.864 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . 0.448 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 74.36 33.53 56.29 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 110.077 -1.209 . . . . 0.0 110.077 179.704 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -62.11 -37.55 85.54 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.07 -1.253 . . . . 0.0 109.61 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 72.2 mmtt -61.27 -35.32 76.96 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.262 -0.899 . . . . 0.0 109.578 -179.845 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 90.9 171.68 43.52 Favored Glycine 0 N--CA 1.488 2.113 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 -179.757 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 65.7 m -75.57 140.27 42.59 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.493 -1.004 . . . . 0.0 109.832 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -63.87 138.44 42.07 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.172 -1.571 . . . . 0.0 109.172 179.702 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 81.0 mmt-85 -59.37 -33.32 71.03 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.305 -1.115 . . . . 0.0 109.922 -179.656 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 86.1 p -60.91 -22.98 64.88 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.129 -0.982 . . . . 0.0 109.966 -179.532 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . 0.428 ' O ' ' CG ' ' A' ' 57' ' ' LYS . . . 110.03 77.55 0.95 Allowed Glycine 0 N--CA 1.496 2.636 0 N-CA-C 108.879 -1.688 . . . . 0.0 108.879 -179.586 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . 0.51 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 8.6 mtmp? -160.41 76.8 2.69 Favored Pre-proline 0 C--N 1.303 -1.455 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 -179.837 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 81.8 Cg_exo -49.0 130.0 22.71 Favored 'Trans proline' 0 C--N 1.301 -1.945 0 C-N-CA 122.913 2.409 . . . . 0.0 112.614 -178.867 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.51 ' CD1' ' O ' ' A' ' 57' ' ' LYS . 8.3 mp -99.33 84.86 3.07 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.753 -0.592 . . . . 0.0 109.52 -179.697 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 99.2 m-70 -145.81 143.06 29.43 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.276 -0.89 . . . . 0.0 109.734 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 2.9 m-85 -102.33 17.03 24.48 Favored 'General case' 0 N--CA 1.493 1.724 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 179.317 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 91.7 mttt -81.01 158.84 25.01 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.303 -0.873 . . . . 0.0 109.885 -179.491 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . 0.426 ' N ' ' CG2' ' A' ' 171' ' ' VAL . 84.3 m-20 55.99 45.84 23.02 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.552 -0.717 . . . . 0.0 110.35 179.562 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.677 ' H ' ' CG2' ' A' ' 171' ' ' VAL . 66.7 p -98.74 153.35 18.8 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.143 -0.973 . . . . 0.0 108.616 179.077 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 28.6 t -122.3 145.06 48.6 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.37 -0.832 . . . . 0.0 109.664 -179.566 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 4.3 m-85 -72.7 129.04 37.31 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.314 -0.866 . . . . 0.0 109.034 179.782 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' HIS . . . . . 0.712 ' HE2' HH21 ' A' ' 68' ' ' ARG . 74.9 t60 -62.2 -49.94 73.79 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.358 -0.839 . . . . 0.0 110.116 -179.376 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.712 HH21 ' HE2' ' A' ' 67' ' ' HIS . 18.4 ptp180 -160.17 161.02 33.54 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.035 -1.041 . . . . 0.0 109.922 -179.982 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 17.7 m -132.73 145.23 34.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.478 -0.764 . . . . 0.0 109.043 179.683 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 14.4 mt -148.17 129.5 7.2 Favored Pre-proline 0 N--CA 1.494 1.745 0 O-C-N 121.091 -1.005 . . . . 0.0 109.331 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -72.3 145.36 43.23 Favored 'Trans proline' 0 N--CA 1.492 1.393 0 C-N-CA 122.242 1.961 . . . . 0.0 112.379 179.849 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 82.25 -56.18 4.97 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.918 -1.273 . . . . 0.0 109.918 179.736 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -72.42 -86.16 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.117 -1.225 . . . . 0.0 109.874 -179.715 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' MET . . . . . 0.602 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 12.4 ptt? -179.52 -168.6 0.12 Allowed 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.236 -0.915 . . . . 0.0 109.759 -179.914 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -126.71 131.85 51.28 Favored 'General case' 0 N--CA 1.494 1.732 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.774 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 63.6 tt0 -103.07 126.4 50.23 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.151 -0.968 . . . . 0.0 109.908 -179.611 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -86.29 -174.03 49.38 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.242 -1.543 . . . . 0.0 109.242 179.548 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -138.35 154.9 23.19 Favored Glycine 0 N--CA 1.495 2.575 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 88.4 m-20 -73.67 149.36 42.0 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.35 -1.088 . . . . 0.0 109.43 179.804 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 48.3 p90 -64.72 -26.33 68.32 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.161 -0.962 . . . . 0.0 109.437 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 54.0 p -69.1 -29.08 67.09 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.165 -0.959 . . . . 0.0 109.462 179.925 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 174.79 -55.11 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.386 -0.821 . . . . 0.0 109.254 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 95.95 -6.5 66.9 Favored Glycine 0 N--CA 1.492 2.395 0 N-CA-C 109.658 -1.377 . . . . 0.0 109.658 179.878 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 78.5 m-20 -88.16 2.71 51.52 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.188 -1.184 . . . . 0.0 109.258 179.812 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 94.18 -6.61 72.32 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.321 -1.511 . . . . 0.0 109.321 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 59.0 p -75.15 -18.54 60.18 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.254 -1.145 . . . . 0.0 109.506 179.896 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -132.38 -128.47 2.92 Favored Glycine 0 N--CA 1.494 2.507 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.857 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 81.87 22.35 59.78 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.287 -1.525 . . . . 0.0 109.287 -179.856 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -57.96 145.43 35.91 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.339 -1.095 . . . . 0.0 109.669 -179.855 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 88.5 p -111.85 153.36 26.75 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.417 -0.802 . . . . 0.0 109.331 179.885 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 5.5 pt -63.56 -39.76 86.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.242 -0.911 . . . . 0.0 109.847 -179.76 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . 0.448 ' OH ' ' OE1' ' A' ' 40' ' ' GLU . 3.1 m-30 -63.45 -38.87 92.8 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.089 -1.007 . . . . 0.0 109.459 179.758 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 76.7 19.03 78.39 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.282 -1.527 . . . . 0.0 109.282 -179.861 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -145.62 158.78 43.8 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.328 -1.101 . . . . 0.0 109.442 -179.853 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 62.9 mttp -85.01 153.62 22.64 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.336 -0.852 . . . . 0.0 109.709 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -100.68 133.12 45.61 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.41 -0.806 . . . . 0.0 109.1 179.775 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -83.47 119.73 25.04 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.162 -0.961 . . . . 0.0 109.684 -179.715 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 88.1 m-20 -75.55 143.09 42.61 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.283 -0.886 . . . . 0.0 109.259 179.638 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -153.29 -31.11 0.13 Allowed 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.174 -0.954 . . . . 0.0 110.05 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 84.6 m-20 -97.73 131.33 44.36 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.073 -1.017 . . . . 0.0 109.954 -179.579 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' PHE . . . . . 0.555 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 70.6 t80 -134.56 22.13 3.65 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 179.745 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.431 HD13 HG22 ' A' ' 102' ' ' ILE . 86.2 mt -56.77 -37.5 53.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.437 -0.79 . . . . 0.0 110.052 -179.512 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 56.6 mttm -83.34 138.27 33.6 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.008 -1.057 . . . . 0.0 109.891 -179.65 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 72.8 tttt -134.89 157.56 46.53 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.462 -0.774 . . . . 0.0 109.24 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' HIS . . . . . 0.542 ' O ' ' CG ' ' A' ' 105' ' ' HIS . 52.2 p-80 -68.02 83.5 0.22 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.12 -0.987 . . . . 0.0 109.271 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 57.0 p -77.04 -19.31 57.33 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.275 -0.891 . . . . 0.0 110.116 -179.54 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -150.55 178.25 28.11 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 109.737 -1.345 . . . . 0.0 109.737 -179.654 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -74.9 156.72 43.46 Favored 'Trans proline' 0 C--N 1.306 -1.674 0 C-N-CA 123.027 2.484 . . . . 0.0 112.14 179.831 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 80.8 46.45 7.19 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 110.03 -1.228 . . . . 0.0 110.03 179.638 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 32.9 mm -113.01 137.24 46.7 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.393 -1.063 . . . . 0.0 109.098 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . 0.594 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 2.3 mm? -89.88 131.81 35.61 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.261 -0.899 . . . . 0.0 109.836 -179.383 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 58.4 m -140.28 148.22 41.1 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.393 -0.817 . . . . 0.0 109.406 179.512 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' MET . . . . . 0.575 ' CE ' HD22 ' A' ' 121' ' ' ASN . 85.7 mtp -96.62 136.3 37.34 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.209 -0.932 . . . . 0.0 109.298 179.834 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . 0.55 ' O ' ' ND2' ' A' ' 115' ' ' ASN . . . -71.03 143.38 50.77 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.321 -0.862 . . . . 0.0 109.813 -179.872 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . 0.688 ' H ' ' CD2' ' A' ' 139' ' ' HIS . 18.8 m120 -148.44 113.26 5.41 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.306 -0.871 . . . . 0.0 108.861 179.506 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -68.24 -31.99 71.86 Favored 'General case' 0 C--N 1.299 -1.623 0 O-C-N 121.333 -0.854 . . . . 0.0 109.655 -179.896 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -137.63 171.47 23.23 Favored Glycine 0 N--CA 1.492 2.414 0 N-CA-C 109.326 -1.51 . . . . 0.0 109.326 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -67.29 151.89 80.12 Favored 'Trans proline' 0 C--N 1.305 -1.728 0 C-N-CA 122.753 2.302 . . . . 0.0 111.732 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 75.2 m-20 52.57 44.09 30.43 Favored 'General case' 0 C--N 1.299 -1.601 0 O-C-N 121.459 -0.776 . . . . 0.0 109.294 -179.811 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' THR . . . . . 0.471 ' O ' ' ND2' ' A' ' 115' ' ' ASN . 79.8 m -134.62 128.34 32.95 Favored 'General case' 0 C--N 1.304 -1.394 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 179.875 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' ASN . . . . . 0.575 HD22 ' CE ' ' A' ' 113' ' ' MET . 21.2 t-20 -96.76 109.22 21.94 Favored 'General case' 0 C--N 1.297 -1.677 0 O-C-N 121.479 -0.763 . . . . 0.0 109.294 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -84.48 123.85 6.43 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.642 -1.383 . . . . 0.0 109.642 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 22.6 m -59.46 -33.29 71.11 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.347 -1.09 . . . . 0.0 109.542 179.806 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.8 mt-30 -75.96 144.12 41.17 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.233 -0.917 . . . . 0.0 109.926 -179.636 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 48.6 p90 -137.8 160.92 37.94 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.429 -0.794 . . . . 0.0 109.109 179.684 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.602 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 52.3 p90 -142.53 159.64 41.83 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.147 -0.971 . . . . 0.0 110.012 -179.759 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 4.6 mp -119.68 138.77 49.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.474 -0.766 . . . . 0.0 109.049 179.695 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 17.1 t -121.04 126.74 50.64 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.236 -0.915 . . . . 0.0 109.599 -179.909 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 129' ' ' THR . . . . . 0.414 ' O ' ' OG1' ' A' ' 129' ' ' THR . 0.0 OUTLIER -106.91 15.76 25.06 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.544 -0.722 . . . . 0.0 109.204 179.864 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -141.08 161.21 38.4 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.315 -0.866 . . . . 0.0 109.316 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 64.0 tttm -64.76 132.22 48.96 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.175 -0.953 . . . . 0.0 109.439 -179.79 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 58.6 p -147.66 69.86 1.15 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.287 -0.883 . . . . 0.0 109.24 -179.898 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -58.39 -37.85 76.14 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.295 -0.878 . . . . 0.0 110.033 -179.581 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 0.8 OUTLIER -61.46 -43.94 97.98 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.024 -1.047 . . . . 0.0 109.443 -179.875 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 28.3 mt -65.47 -30.81 71.63 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.186 -0.946 . . . . 0.0 109.754 179.326 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . 0.502 ' CB ' ' CE1' ' A' ' 105' ' ' HIS . 23.2 t70 -76.05 121.24 22.49 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.231 -0.918 . . . . 0.0 109.659 -179.627 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 178.61 -101.84 0.16 Allowed Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.202 -1.559 . . . . 0.0 109.202 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 33.4 mmtm -58.15 -28.56 64.82 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.327 -1.102 . . . . 0.0 109.058 179.506 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 139' ' ' HIS . . . . . 0.688 ' CD2' ' H ' ' A' ' 115' ' ' ASN . 56.3 m170 -83.78 153.2 24.24 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.348 -0.845 . . . . 0.0 109.479 -179.831 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 20.2 m -127.44 160.76 36.15 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 121.516 -0.74 . . . . 0.0 109.278 -179.858 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 21.5 m -96.69 129.25 47.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.245 -0.91 . . . . 0.0 109.519 -179.732 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 44.0 p90 -113.03 -9.07 13.61 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.189 -0.944 . . . . 0.0 110.271 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -158.45 177.49 35.08 Favored Glycine 0 N--CA 1.492 2.41 0 C-N-CA 119.567 -1.302 . . . . 0.0 109.87 179.703 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 47.8 tt0 -139.63 158.78 43.53 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.303 -1.116 . . . . 0.0 109.633 -179.549 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 13.2 t -94.73 134.07 33.44 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.235 0 O-C-N 121.042 -1.036 . . . . 0.0 109.241 179.666 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 17.4 m -112.03 -26.14 3.22 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.407 -0.808 . . . . 0.0 109.512 179.607 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 94.9 mt-10 -145.78 173.07 12.43 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.238 -0.914 . . . . 0.0 109.541 -179.878 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 98.51 2.35 57.64 Favored Glycine 0 N--CA 1.494 2.511 0 N-CA-C 110.085 -1.206 . . . . 0.0 110.085 179.486 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 149' ' ' MET . . . . . 0.409 ' O ' HG11 ' A' ' 152' ' ' VAL . 65.1 mtt -61.15 -33.07 72.82 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.035 -1.274 . . . . 0.0 109.736 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 89.1 m-20 -64.91 -42.13 94.99 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 120.765 -1.209 . . . . 0.0 110.036 -179.556 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.7 p -82.6 -34.46 11.83 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.078 -1.014 . . . . 0.0 110.485 -179.313 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 152' ' ' VAL . . . . . 0.453 ' CG1' ' N ' ' A' ' 153' ' ' LYS . 0.8 OUTLIER -54.92 -41.82 60.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 120.963 -1.086 . . . . 0.0 109.188 -179.323 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 153' ' ' LYS . . . . . 0.453 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 59.1 mttp -64.25 -34.17 77.49 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.263 -0.898 . . . . 0.0 109.473 179.393 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -62.26 -37.36 85.15 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.308 -0.87 . . . . 0.0 110.217 -179.398 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 79.5 mt -71.96 -36.99 59.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.054 -1.029 . . . . 0.0 110.059 -179.752 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -74.08 -41.75 61.22 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.135 -0.978 . . . . 0.0 111.227 -178.706 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 17.4 pttp -61.69 -33.72 74.51 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 120.749 -1.219 . . . . 0.0 109.734 -179.001 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 27.2 m -86.39 -1.15 7.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.119 -0.988 . . . . 0.0 109.044 179.501 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -74.7 174.22 51.13 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.782 -1.327 . . . . 0.0 109.782 -179.706 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 97.0 p -152.33 162.94 40.44 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.328 -1.101 . . . . 0.0 109.942 -179.64 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 22.8 t -58.9 -31.49 68.66 Favored 'General case' 0 N--CA 1.488 1.441 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 179.297 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 23.1 t -55.96 -30.46 61.76 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.427 -0.796 . . . . 0.0 109.069 179.729 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 100.42 10.12 45.43 Favored Glycine 0 N--CA 1.493 2.489 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 179.784 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 34.5 mmt180 -118.26 147.63 43.24 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.224 -1.162 . . . . 0.0 109.282 179.713 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 165' ' ' THR . . . . . . . . . . . . . 82.1 p -81.64 152.72 27.0 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.364 -0.835 . . . . 0.0 109.384 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -65.98 -34.27 77.71 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.289 -0.882 . . . . 0.0 109.587 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 62.1 mttm -118.22 162.08 18.84 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.467 -0.77 . . . . 0.0 109.656 -179.664 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 62.8 mttp -75.15 142.44 43.56 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.355 -0.841 . . . . 0.0 109.594 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 1.8 m -133.45 124.67 49.0 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.308 -0.87 . . . . 0.0 109.738 179.763 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 88.8 t -139.45 142.26 33.49 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.461 -0.774 . . . . 0.0 109.395 179.769 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . 0.677 ' CG2' ' H ' ' A' ' 64' ' ' SER . 3.0 m -71.69 124.84 29.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.014 -1.054 . . . . 0.0 109.55 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 77.9 mm-40 -70.88 -37.72 73.04 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.09 -1.006 . . . . 0.0 110.251 -179.669 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 173' ' ' ASP . . . . . 0.463 ' OD1' ' N ' ' A' ' 174' ' ' CYS . 49.5 t0 -164.84 166.62 19.54 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.063 -1.023 . . . . 0.0 110.032 -179.668 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 174' ' ' CYS . . . . . 0.463 ' N ' ' OD1' ' A' ' 173' ' ' ASP . 12.3 p -141.59 152.34 43.96 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.395 -0.815 . . . . 0.0 109.366 179.803 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -175.52 178.92 47.0 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.649 -1.38 . . . . 0.0 109.649 179.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 176' ' ' GLN . . . . . 0.69 HE22 ' NE ' ' A' ' 43' ' ' ARG . 63.3 tt0 -108.12 127.89 54.21 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.373 -1.075 . . . . 0.0 109.528 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -61.24 -38.8 87.94 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.22 -0.925 . . . . 0.0 108.718 179.694 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 9.6 t . . . . . 0 N--CA 1.49 1.544 0 CA-C-O 117.979 -1.01 . . . . 0.0 109.47 179.81 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.529 4.867 0 N-CA-C 119.425 2.53 . . . . 0.0 119.425 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 23.2 m -57.6 -35.04 69.91 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.257 -1.143 . . . . 0.0 109.495 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 67.4 t80 -108.3 120.84 43.54 Favored 'General case' 0 N--CA 1.484 1.271 0 O-C-N 121.372 -0.83 . . . . 0.0 108.969 179.646 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 8.5 t -137.07 158.26 44.86 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.674 -0.641 . . . . 0.0 109.468 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 165.42 -108.91 0.34 Allowed Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 -179.879 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 57.3 p -67.45 164.65 18.29 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.219 -1.165 . . . . 0.0 109.4 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' MET . . . . . 0.502 ' SD ' ' OG ' ' A' ' 178' ' ' SER . 25.5 mtm -57.21 149.7 45.72 Favored Pre-proline 0 N--CA 1.489 1.486 0 O-C-N 121.251 -0.905 . . . . 0.0 109.358 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -62.02 -31.38 83.87 Favored 'Trans proline' 0 N--CA 1.493 1.498 0 C-N-CA 122.413 2.076 . . . . 0.0 112.316 -179.558 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.459 ' ND2' ' O ' ' A' ' 10' ' ' PRO . 1.5 t30 -169.41 139.36 1.74 Allowed Pre-proline 0 N--CA 1.49 1.543 0 O-C-N 121.151 -0.968 . . . . 0.0 109.362 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . 0.459 ' O ' ' ND2' ' A' ' 9' ' ' ASN . 53.1 Cg_endo -68.34 140.22 47.87 Favored 'Trans proline' 0 N--CA 1.496 1.645 0 C-N-CA 122.424 2.082 . . . . 0.0 112.211 179.826 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 58.6 mtm180 -132.26 132.44 43.04 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.436 -0.79 . . . . 0.0 109.018 179.537 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.5 p -135.91 143.95 34.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.316 -0.865 . . . . 0.0 109.311 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 33.2 p90 -139.4 152.69 47.3 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.33 -0.856 . . . . 0.0 109.792 -179.633 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.432 ' CE2' ' SG ' ' A' ' 174' ' ' CYS . 94.3 m-85 -123.26 128.65 50.26 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.595 -0.69 . . . . 0.0 109.546 179.475 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.4 t0 -90.31 119.05 30.28 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.14 -0.975 . . . . 0.0 108.94 179.303 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' MET . . . . . 0.411 ' CE ' ' CE1' ' A' ' 66' ' ' PHE . 67.0 mtp -117.13 143.32 45.95 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.217 -0.927 . . . . 0.0 110.375 -179.315 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.414 ' OG ' ' OE2' ' A' ' 172' ' ' GLU . 50.8 m -132.16 155.14 48.71 Favored 'General case' 0 N--CA 1.491 1.612 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 179.639 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 25.4 m -114.87 132.53 63.81 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.234 -0.917 . . . . 0.0 109.657 -179.765 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 65.86 9.9 48.33 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 179.836 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 93.36 -3.89 72.86 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.302 -1.519 . . . . 0.0 109.302 -179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 33.9 mt-30 -99.11 128.39 32.18 Favored Pre-proline 0 N--CA 1.492 1.634 0 O-C-N 121.371 -1.076 . . . . 0.0 109.071 179.806 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 76.1 Cg_exo -43.69 130.11 7.3 Favored 'Trans proline' 0 C--N 1.312 -1.387 0 C-N-CA 122.12 1.88 . . . . 0.0 112.126 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -104.07 -65.25 1.03 Allowed 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.375 -0.828 . . . . 0.0 109.345 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -169.46 -171.21 34.87 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 92.2 mtm-85 -114.1 143.13 45.29 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.385 -1.068 . . . . 0.0 109.465 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 76.4 mt -120.95 117.84 54.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 179.091 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 41.8 t -116.38 132.8 64.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.552 -0.718 . . . . 0.0 109.327 -179.541 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 73.1 mtm -121.48 149.88 42.41 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.464 -0.772 . . . . 0.0 109.209 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -99.88 129.82 46.0 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.24 -0.912 . . . . 0.0 109.822 -179.636 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.429 ' N ' ' CD2' ' A' ' 30' ' ' LEU . 2.5 mm? -105.84 130.75 53.75 Favored 'General case' 0 N--CA 1.493 1.682 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.376 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -94.91 119.33 33.28 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.111 -0.993 . . . . 0.0 109.205 179.739 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -82.14 -42.67 18.76 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.361 -0.837 . . . . 0.0 109.803 -179.764 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -67.19 -44.74 78.88 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.278 -0.889 . . . . 0.0 110.514 -179.266 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 23.2 m -66.93 -45.35 78.14 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.175 -0.953 . . . . 0.0 109.959 -179.296 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 68.9 p -150.39 83.32 6.0 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 121.285 -0.884 . . . . 0.0 109.468 -179.691 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -70.92 -44.36 1.32 Allowed 'Trans proline' 0 C--N 1.308 -1.595 0 C-N-CA 122.19 1.927 . . . . 0.0 112.087 -179.702 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.448 ' O ' ' OH ' ' A' ' 92' ' ' TYR . 25.4 mtp180 -62.59 -39.63 94.32 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.465 -0.772 . . . . 0.0 110.201 -179.862 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 32.4 m -66.07 -41.76 90.3 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.116 -0.99 . . . . 0.0 110.086 -179.736 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -61.81 -31.04 71.24 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.228 -0.92 . . . . 0.0 109.324 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -68.19 -37.7 81.22 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.219 -0.926 . . . . 0.0 109.85 -179.755 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 51.9 t30 -57.45 -42.16 81.97 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.205 -0.935 . . . . 0.0 109.79 -179.437 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 -86.13 -48.07 8.93 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.151 -0.968 . . . . 0.0 109.754 -179.842 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 40.2 ttp180 -57.87 -39.47 77.88 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.457 -0.777 . . . . 0.0 110.3 -179.482 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.506 ' O ' ' N ' ' A' ' 48' ' ' GLY . . . -64.31 -43.13 95.66 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.04 -1.038 . . . . 0.0 110.451 -179.117 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -65.19 -40.02 93.66 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.008 -1.057 . . . . 0.0 109.655 -179.852 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' CYS . . . . . . . . . . . . . 75.7 m -69.22 -49.54 55.53 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.023 -1.048 . . . . 0.0 109.444 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 73.9 p -74.07 -34.04 63.89 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.18 -0.95 . . . . 0.0 109.554 179.828 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . 0.506 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 75.22 35.22 49.4 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 110.395 -1.082 . . . . 0.0 110.395 179.643 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -61.53 -37.26 83.1 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.005 -1.291 . . . . 0.0 109.235 179.836 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 48.2 mmtm -61.76 -33.59 74.35 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.343 -0.848 . . . . 0.0 109.384 179.783 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 94.35 167.54 36.98 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.295 -1.522 . . . . 0.0 109.295 -179.762 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 99.2 m -80.2 141.05 36.01 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.293 -1.121 . . . . 0.0 109.729 -179.908 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -59.03 137.55 50.35 Favored Glycine 0 N--CA 1.489 2.173 0 N-CA-C 109.305 -1.518 . . . . 0.0 109.305 179.764 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 74.5 mtt85 -58.99 -35.35 73.07 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.294 -1.121 . . . . 0.0 109.913 -179.701 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 22.9 t -57.67 -31.9 66.79 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.25 -0.906 . . . . 0.0 109.887 -179.769 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 117.86 91.22 1.49 Allowed Glycine 0 N--CA 1.495 2.626 0 N-CA-C 108.896 -1.681 . . . . 0.0 108.896 -179.503 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . 0.492 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 78.6 tttt -176.62 80.21 0.27 Allowed Pre-proline 0 N--CA 1.488 1.459 0 O-C-N 121.546 -0.973 . . . . 0.0 108.442 -179.666 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_exo -48.99 134.51 29.2 Favored 'Trans proline' 0 C--N 1.304 -1.794 0 C-N-CA 122.727 2.285 . . . . 0.0 112.457 -179.097 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.492 ' CD1' ' O ' ' A' ' 57' ' ' LYS . 7.7 mp -100.5 71.67 1.54 Allowed 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.621 -0.674 . . . . 0.0 109.4 -179.557 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 79.9 m80 -147.06 130.52 16.73 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.197 -0.939 . . . . 0.0 109.887 179.902 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 58.8 m-85 -72.67 -5.04 34.83 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.119 -0.988 . . . . 0.0 108.402 178.748 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 50.4 tttt -53.54 140.58 28.01 Favored 'General case' 0 N--CA 1.487 1.409 0 O-C-N 121.622 -0.674 . . . . 0.0 109.973 -179.501 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 53.7 t0 56.97 43.5 24.52 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.572 -0.705 . . . . 0.0 110.28 179.646 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.718 ' H ' ' CG1' ' A' ' 171' ' ' VAL . 95.6 p -109.79 150.33 28.52 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.157 -0.965 . . . . 0.0 108.68 179.094 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 38.4 t -102.97 141.42 35.81 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.171 -0.956 . . . . 0.0 109.004 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.411 ' CE1' ' CE ' ' A' ' 16' ' ' MET . 3.2 m-85 -66.66 138.72 57.64 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.291 -0.88 . . . . 0.0 109.021 -179.728 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 81.5 t60 -59.05 -52.19 66.81 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.299 -0.876 . . . . 0.0 110.298 -178.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 15.5 ptm180 -166.68 164.01 16.72 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.083 -1.011 . . . . 0.0 109.952 -179.807 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 33.9 m -131.98 147.86 32.3 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.48 -0.762 . . . . 0.0 109.169 179.678 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 11.6 mt -147.74 108.24 3.77 Favored Pre-proline 0 N--CA 1.492 1.648 0 O-C-N 120.965 -1.084 . . . . 0.0 109.74 179.72 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_exo -54.09 146.04 50.44 Favored 'Trans proline' 0 N--CA 1.493 1.485 0 C-N-CA 122.427 2.085 . . . . 0.0 112.448 179.723 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 77.57 -57.81 3.78 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 110.212 -1.155 . . . . 0.0 110.212 179.273 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 95.5 m-85 -69.67 -83.85 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.166 -1.197 . . . . 0.0 109.819 -179.498 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' MET . . . . . 0.471 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 12.2 ptp -178.93 -172.36 0.25 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.255 -0.903 . . . . 0.0 109.59 -179.764 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -127.76 137.15 52.33 Favored 'General case' 0 N--CA 1.494 1.746 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 179.734 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 93.5 mt-30 -110.63 154.46 23.76 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.256 -0.902 . . . . 0.0 109.603 -179.619 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -160.83 -166.93 20.56 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.426 -1.47 . . . . 0.0 109.426 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 88.74 23.66 35.28 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.439 ' C ' ' OD1' ' A' ' 79' ' ' ASP . 54.6 p30 -84.13 10.54 9.9 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.179 -1.189 . . . . 0.0 109.377 179.922 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 85.2 t80 -53.25 -46.25 69.12 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.36 -0.837 . . . . 0.0 109.804 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.555 ' OG1' ' N ' ' A' ' 88' ' ' GLY . 71.9 p -71.17 -28.71 64.45 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.013 -1.055 . . . . 0.0 109.568 179.906 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . 0.4 ' CB ' ' O ' ' A' ' 81' ' ' THR . . . 171.26 -57.46 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.205 -0.935 . . . . 0.0 109.405 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 93.65 1.51 65.89 Favored Glycine 0 N--CA 1.492 2.402 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 -180.0 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 23.6 m120 -86.61 6.31 31.57 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.244 -1.15 . . . . 0.0 109.446 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 95.79 -39.13 2.91 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.327 -1.509 . . . . 0.0 109.327 -179.781 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 52.2 p -74.14 -16.14 61.01 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.336 -1.096 . . . . 0.0 109.055 179.594 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -82.85 -167.25 40.7 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.671 -1.372 . . . . 0.0 109.671 -179.913 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.555 ' N ' ' OG1' ' A' ' 81' ' ' THR . . . 83.85 38.42 10.47 Favored Glycine 0 N--CA 1.488 2.104 0 N-CA-C 109.154 -1.578 . . . . 0.0 109.154 -179.708 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -57.42 144.87 34.77 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.46 -1.024 . . . . 0.0 109.671 -179.774 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 96.4 p -112.26 150.24 31.23 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.449 -0.782 . . . . 0.0 109.191 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 24.0 pt -70.82 -31.48 45.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.171 -0.956 . . . . 0.0 110.059 -179.684 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . 0.448 ' OH ' ' O ' ' A' ' 37' ' ' ARG . 59.2 m-85 -65.38 -37.99 88.68 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.166 -0.959 . . . . 0.0 109.7 -179.65 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 73.22 15.63 78.75 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -148.16 158.72 44.23 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.301 -1.117 . . . . 0.0 109.455 -179.834 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 63.4 mttp -84.95 150.29 25.03 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.366 -0.834 . . . . 0.0 109.473 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 55.4 p90 -132.25 160.52 35.94 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.279 -0.888 . . . . 0.0 109.538 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -110.52 154.18 24.06 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.496 -0.752 . . . . 0.0 109.723 -179.801 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 60.3 t0 -78.48 124.13 27.8 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.264 -0.897 . . . . 0.0 109.306 179.76 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 78.5 mm-40 -60.88 -37.49 82.35 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.278 -0.889 . . . . 0.0 110.003 -179.457 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 19.1 t-20 -166.51 171.11 12.14 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.95 -1.094 . . . . 0.0 109.943 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -109.81 44.09 1.25 Allowed 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.521 -0.737 . . . . 0.0 109.373 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 89.0 mt -52.32 -41.84 35.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.105 -0.997 . . . . 0.0 109.818 -179.514 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 59.6 mttm -91.72 144.42 25.53 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.144 -0.972 . . . . 0.0 109.756 -179.686 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 80.2 tttt -134.38 159.13 42.01 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.371 -0.831 . . . . 0.0 109.444 -179.788 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' HIS . . . . . 0.526 ' CE1' ' O ' ' A' ' 107' ' ' GLY . 70.7 t60 -89.63 111.29 22.2 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.304 -0.873 . . . . 0.0 109.264 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 48.2 p -125.86 1.22 7.37 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.364 -0.835 . . . . 0.0 109.942 -179.797 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.526 ' O ' ' CE1' ' A' ' 105' ' ' HIS . . . -155.62 170.32 33.53 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.811 -1.316 . . . . 0.0 109.811 -179.771 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -75.07 156.24 42.68 Favored 'Trans proline' 0 C--N 1.308 -1.573 0 C-N-CA 123.026 2.484 . . . . 0.0 112.213 179.614 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 84.15 43.27 7.16 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 110.328 -1.109 . . . . 0.0 110.328 179.51 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.409 HG23 HD13 ' A' ' 110' ' ' ILE . 37.1 mm -115.25 134.41 58.47 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.834 0 O-C-N 121.312 -1.111 . . . . 0.0 109.172 179.592 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . 0.578 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 2.9 mm? -90.36 124.91 35.31 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.237 -0.915 . . . . 0.0 109.22 179.903 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 50.4 m -137.95 144.96 41.46 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.208 -0.933 . . . . 0.0 109.779 179.806 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 87.8 mtp -90.35 131.41 36.15 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.352 -0.842 . . . . 0.0 109.114 179.429 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . 0.409 ' O ' ' OD1' ' A' ' 115' ' ' ASN . . . -65.73 143.76 57.32 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.195 -0.94 . . . . 0.0 109.513 -179.829 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . 0.409 ' OD1' ' O ' ' A' ' 114' ' ' ALA . 72.2 m-20 -144.22 113.31 6.85 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.174 -0.954 . . . . 0.0 108.976 179.601 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -70.22 -30.03 67.01 Favored 'General case' 0 C--N 1.297 -1.691 0 O-C-N 121.465 -0.772 . . . . 0.0 109.581 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -140.33 167.16 25.58 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.486 -1.446 . . . . 0.0 109.486 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . 0.533 ' O ' ' ND2' ' A' ' 119' ' ' ASN . 41.0 Cg_endo -67.26 158.36 57.33 Favored 'Trans proline' 0 C--N 1.305 -1.726 0 C-N-CA 122.875 2.383 . . . . 0.0 111.893 179.952 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' ASN . . . . . 0.533 ' ND2' ' O ' ' A' ' 118' ' ' PRO . 9.5 p30 45.41 45.44 10.18 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.514 -0.741 . . . . 0.0 109.543 -179.898 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 89.4 m -134.61 132.26 38.81 Favored 'General case' 0 C--N 1.305 -1.332 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 179.684 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 43.3 p-10 -64.82 162.86 15.32 Favored 'General case' 0 C--N 1.295 -1.768 0 O-C-N 121.343 -0.848 . . . . 0.0 109.309 -179.807 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -109.74 101.47 1.45 Allowed Glycine 0 N--CA 1.494 2.517 0 N-CA-C 109.83 -1.308 . . . . 0.0 109.83 -179.7 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 86.1 p -63.12 -28.15 69.87 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.215 -1.167 . . . . 0.0 109.059 179.543 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.0 mt-30 -125.98 158.31 35.61 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.545 -0.722 . . . . 0.0 109.204 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 49.0 p90 -134.53 163.05 30.58 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.268 -0.895 . . . . 0.0 109.51 -179.925 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.471 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 48.3 p90 -134.44 157.54 46.18 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.312 -0.867 . . . . 0.0 109.414 179.927 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 61.5 mt -122.97 134.35 66.38 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 O-C-N 121.391 -0.818 . . . . 0.0 109.581 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 2.9 t -108.68 125.2 51.63 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.211 -0.931 . . . . 0.0 109.155 179.65 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 129' ' ' THR . . . . . 0.45 ' OG1' ' OE1' ' A' ' 156' ' ' GLU . 7.3 p -114.22 18.05 17.27 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.388 -0.82 . . . . 0.0 109.61 -179.656 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -145.84 162.32 37.98 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.144 -0.973 . . . . 0.0 109.883 -179.548 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 62.5 tttm -59.87 134.11 56.72 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.365 -0.834 . . . . 0.0 109.093 179.863 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 132' ' ' THR . . . . . 0.44 ' OG1' ' OD1' ' A' ' 136' ' ' ASP . 21.9 p -79.17 105.48 10.53 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.26 -0.9 . . . . 0.0 109.909 -179.485 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -66.21 -38.39 87.85 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.087 -1.008 . . . . 0.0 108.672 179.198 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 20.4 p90 -155.31 6.55 0.24 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.44 -0.787 . . . . 0.0 109.968 179.458 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . 0.526 ' N ' ' CD2' ' A' ' 135' ' ' LEU . 3.5 mm? -68.65 -28.01 66.51 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.027 -1.045 . . . . 0.0 109.328 179.562 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . 0.44 ' OD1' ' OG1' ' A' ' 132' ' ' THR . 93.8 m-20 -52.38 144.85 12.27 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.357 -0.839 . . . . 0.0 110.025 -179.336 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 171.02 -128.38 1.6 Allowed Glycine 0 N--CA 1.489 2.202 0 N-CA-C 108.793 -1.723 . . . . 0.0 108.793 -179.909 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 4.3 mptp? -89.86 123.06 33.49 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.077 -1.249 . . . . 0.0 108.851 179.376 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 32.0 p80 -168.96 159.37 9.33 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.181 -0.95 . . . . 0.0 109.745 -179.787 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 38.9 t -123.46 136.65 59.34 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 O-C-N 121.389 -0.819 . . . . 0.0 109.317 179.896 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 17.6 m -108.58 131.41 59.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.231 -0.918 . . . . 0.0 109.014 179.77 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 39.7 p90 -117.01 -4.08 11.53 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.407 -0.808 . . . . 0.0 109.992 -179.609 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -165.53 179.2 40.04 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.648 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.2 pt20 -144.3 165.28 28.33 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.186 -1.185 . . . . 0.0 109.661 -179.787 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 60.4 t -97.56 130.1 46.73 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.224 0 O-C-N 121.269 -0.894 . . . . 0.0 109.449 -179.92 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 16.3 m -106.06 -32.45 2.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.37 -0.832 . . . . 0.0 109.48 179.612 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -144.6 174.37 11.01 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.174 -0.954 . . . . 0.0 109.526 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 99.12 1.21 57.06 Favored Glycine 0 N--CA 1.494 2.509 0 N-CA-C 109.974 -1.25 . . . . 0.0 109.974 179.569 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 149' ' ' MET . . . . . . . . . . . . . 65.1 mtt -60.93 -34.16 74.28 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.105 -1.232 . . . . 0.0 109.718 179.945 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -64.51 -42.77 95.59 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.89 -1.131 . . . . 0.0 110.138 -179.576 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.7 p -83.08 -34.04 10.87 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.113 -0.992 . . . . 0.0 110.518 -179.486 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 152' ' ' VAL . . . . . 0.459 ' CG1' ' N ' ' A' ' 153' ' ' LYS . 0.6 OUTLIER -55.52 -41.65 64.53 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 120.889 -1.132 . . . . 0.0 109.122 -179.36 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 153' ' ' LYS . . . . . 0.459 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 57.3 mttp -63.23 -33.63 75.91 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.281 -0.887 . . . . 0.0 109.486 179.417 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -62.26 -40.52 96.49 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.327 -0.858 . . . . 0.0 109.873 -179.575 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 78.4 mt -72.92 -34.34 45.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.083 -1.011 . . . . 0.0 109.61 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . 0.45 ' OE1' ' OG1' ' A' ' 129' ' ' THR . 78.9 tt0 -75.95 -42.33 48.93 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.216 -0.928 . . . . 0.0 111.258 -178.796 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 43.2 pttt -61.84 -33.9 74.98 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 120.808 -1.183 . . . . 0.0 109.985 -178.831 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 34.5 m -80.34 -10.29 12.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.136 -0.978 . . . . 0.0 109.249 179.73 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -71.28 165.11 53.59 Favored Glycine 0 N--CA 1.488 2.163 0 N-CA-C 110.074 -1.21 . . . . 0.0 110.074 -179.487 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 22.8 t -155.17 171.39 19.88 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.537 -0.978 . . . . 0.0 109.34 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 24.9 m -54.44 -29.64 50.07 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.199 -0.938 . . . . 0.0 109.346 179.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 87.1 p -57.8 -26.6 62.18 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.282 -0.886 . . . . 0.0 109.663 -179.759 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 89.65 15.52 58.12 Favored Glycine 0 N--CA 1.493 2.437 0 N-CA-C 109.823 -1.311 . . . . 0.0 109.823 179.746 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 61.6 ttt180 -126.72 140.67 52.21 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.226 -1.161 . . . . 0.0 109.489 -179.941 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 165' ' ' THR . . . . . . . . . . . . . 68.7 p -75.08 148.66 39.56 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.157 -0.965 . . . . 0.0 109.279 179.813 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -66.12 -39.3 89.81 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.243 -0.911 . . . . 0.0 109.542 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -103.2 155.68 18.26 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.321 -0.862 . . . . 0.0 109.45 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 64.2 mttp -73.74 130.8 40.71 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.222 -0.924 . . . . 0.0 109.197 179.832 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 13.7 t -128.15 125.02 63.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.142 -0.974 . . . . 0.0 109.515 -179.827 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 62.7 t -142.08 135.01 28.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.267 -0.896 . . . . 0.0 109.343 179.332 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . 0.718 ' CG1' ' H ' ' A' ' 64' ' ' SER . 0.4 OUTLIER -63.58 116.01 2.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.213 -0.929 . . . . 0.0 108.923 179.88 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 172' ' ' GLU . . . . . 0.507 ' O ' ' OD1' ' A' ' 173' ' ' ASP . 96.7 mt-10 -70.64 -40.6 72.99 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.04 -1.037 . . . . 0.0 110.649 -179.531 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 173' ' ' ASP . . . . . 0.507 ' OD1' ' O ' ' A' ' 172' ' ' GLU . 80.5 m-20 -145.13 159.03 43.62 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.08 -1.013 . . . . 0.0 110.377 -179.255 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 174' ' ' CYS . . . . . 0.432 ' SG ' ' CE2' ' A' ' 14' ' ' PHE . 53.3 t -145.04 141.84 29.22 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.507 -0.746 . . . . 0.0 109.286 179.474 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -175.73 179.48 46.87 Favored Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.879 -1.288 . . . . 0.0 109.879 179.839 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 6.9 tt0 -107.87 121.75 45.4 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.32 -1.106 . . . . 0.0 109.608 -179.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 30.8 tp -62.66 -37.81 87.87 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.183 -0.948 . . . . 0.0 109.317 179.675 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 178' ' ' SER . . . . . 0.502 ' OG ' ' SD ' ' A' ' 7' ' ' MET . 3.0 t . . . . . 0 N--CA 1.49 1.564 0 CA-C-O 117.977 -1.011 . . . . 0.0 109.439 -179.872 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.529 4.851 0 N-CA-C 119.347 2.499 . . . . 0.0 119.347 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 35.4 m -57.74 -34.01 69.07 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.17 -1.194 . . . . 0.0 109.472 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 50.6 p90 -143.27 162.24 36.19 Favored 'General case' 0 C--N 1.307 -1.253 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 179.663 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 18.7 p -121.65 162.5 20.59 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.645 -0.66 . . . . 0.0 109.505 -179.895 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 88.4 176.86 47.26 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 -179.947 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 28.7 t -146.27 146.87 30.9 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.293 -1.122 . . . . 0.0 109.505 -179.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 13.9 mmt -129.44 71.31 82.08 Favored Pre-proline 0 N--CA 1.493 1.721 0 O-C-N 121.482 -0.761 . . . . 0.0 109.432 179.846 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 87.6 Cg_endo -81.11 166.19 18.78 Favored 'Trans proline' 0 C--N 1.307 -1.646 0 C-N-CA 122.889 2.393 . . . . 0.0 112.277 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 -69.9 150.56 96.41 Favored Pre-proline 0 N--CA 1.491 1.592 0 O-C-N 121.355 -0.841 . . . . 0.0 109.06 179.85 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 78.2 Cg_endo -74.47 89.0 1.12 Allowed 'Trans proline' 0 C--N 1.311 -1.441 0 C-N-CA 122.48 2.12 . . . . 0.0 112.111 179.896 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 89.7 mtt-85 -72.02 134.61 45.98 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.306 -0.871 . . . . 0.0 109.578 -179.913 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.0 p -137.7 142.43 36.4 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.367 -0.833 . . . . 0.0 108.99 179.717 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 42.2 p90 -145.89 155.45 42.88 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.234 -0.916 . . . . 0.0 109.844 -179.671 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 91.1 m-85 -125.1 137.96 54.18 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.432 -0.793 . . . . 0.0 109.467 179.444 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 61.3 t0 -89.03 117.61 28.16 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.2 -0.938 . . . . 0.0 108.511 178.831 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 78.2 mtp -106.32 150.8 25.61 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.147 -0.97 . . . . 0.0 110.52 -178.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 84.6 p -146.5 168.65 20.69 Favored 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 109.02 -0.734 . . . . 0.0 109.02 179.822 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.437 ' O ' ' N ' ' A' ' 20' ' ' GLY . 27.2 m -126.09 155.85 36.1 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.804 0 O-C-N 121.267 -0.896 . . . . 0.0 109.457 -179.879 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -49.47 96.61 0.01 OUTLIER Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.366 -1.494 . . . . 0.0 109.366 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.437 ' N ' ' O ' ' A' ' 18' ' ' VAL . . . 150.88 -84.82 0.16 Allowed Glycine 0 N--CA 1.493 2.438 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 -179.93 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 12.9 mt-30 -139.36 160.67 60.98 Favored Pre-proline 0 N--CA 1.494 1.741 0 O-C-N 121.357 -1.084 . . . . 0.0 109.037 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_exo -47.74 134.15 22.22 Favored 'Trans proline' 0 C--N 1.312 -1.392 0 C-N-CA 122.251 1.967 . . . . 0.0 112.247 179.739 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -89.58 -60.32 1.97 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.303 -0.873 . . . . 0.0 109.578 -179.86 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 176.05 -166.99 38.46 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.7 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 35.8 ptt-85 -126.01 149.22 48.98 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.466 -1.02 . . . . 0.0 109.143 179.818 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 89.3 mt -122.3 130.32 74.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.287 -0.883 . . . . 0.0 109.346 -179.893 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 44.1 t -109.95 132.61 57.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.444 -0.785 . . . . 0.0 109.427 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 74.8 mtm -119.95 147.13 45.13 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.424 -0.798 . . . . 0.0 109.143 179.875 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -101.03 132.1 46.61 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.23 -0.919 . . . . 0.0 109.987 -179.359 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.414 ' N ' ' CD2' ' A' ' 30' ' ' LEU . 2.6 mm? -108.42 132.13 54.08 Favored 'General case' 0 N--CA 1.492 1.626 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 179.44 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 93.3 m-85 -96.02 116.23 28.64 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 120.966 -1.083 . . . . 0.0 108.775 179.045 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -84.72 -43.7 14.06 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.287 -0.883 . . . . 0.0 109.735 -179.705 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.0 m-20 -63.88 -49.43 72.77 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.217 -0.927 . . . . 0.0 109.879 -179.585 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 28.3 m -71.14 -41.83 69.96 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.207 -0.933 . . . . 0.0 109.417 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.517 ' O ' ' OG1' ' A' ' 35' ' ' THR . 2.3 p -135.16 79.62 49.61 Favored Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 121.531 -0.731 . . . . 0.0 109.495 -179.642 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 29.8 Cg_endo -68.48 -62.83 0.05 OUTLIER 'Trans proline' 0 N--CA 1.494 1.557 0 C-N-CA 122.338 2.025 . . . . 0.0 112.867 -179.339 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 79.2 mtp180 -61.23 -37.0 81.49 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.375 -0.828 . . . . 0.0 110.844 -178.952 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 26.8 m -60.66 -43.39 97.7 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.928 -1.107 . . . . 0.0 109.761 -179.51 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -62.83 -30.85 71.81 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.17 -0.956 . . . . 0.0 108.867 179.698 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -68.44 -38.63 81.32 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.47 -0.768 . . . . 0.0 109.899 -179.881 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 47.5 t30 -57.86 -42.52 84.7 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.318 -0.864 . . . . 0.0 109.95 -179.518 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . 0.557 ' O ' ' SG ' ' A' ' 46' ' ' CYS . 97.8 m-85 -84.67 -46.96 10.96 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.069 -1.019 . . . . 0.0 109.938 -179.869 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . 0.644 ' CZ ' HE22 ' A' ' 176' ' ' GLN . 77.0 ttt180 -54.21 -41.13 68.28 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.338 -0.852 . . . . 0.0 110.361 -179.285 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -66.81 -47.62 71.5 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.108 -0.995 . . . . 0.0 110.319 -178.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.435 ' N ' ' CD2' ' A' ' 45' ' ' LEU . 3.2 mm? -65.28 -39.06 92.08 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.078 -1.014 . . . . 0.0 109.96 -179.515 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' CYS . . . . . 0.557 ' SG ' ' O ' ' A' ' 42' ' ' PHE . 27.6 m -64.41 -62.3 1.69 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.939 -1.101 . . . . 0.0 109.392 -179.766 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 25.3 m -64.86 -36.47 84.46 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.282 -0.886 . . . . 0.0 109.183 179.606 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 83.59 35.62 16.24 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 110.176 -1.17 . . . . 0.0 110.176 179.558 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -61.56 -38.1 86.24 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.051 -1.264 . . . . 0.0 109.266 179.674 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 29.5 mmtm -62.27 -29.75 70.63 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.283 -0.885 . . . . 0.0 109.446 179.747 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 86.06 -115.67 4.24 Favored Glycine 0 N--CA 1.488 2.13 0 N-CA-C 108.778 -1.729 . . . . 0.0 108.778 -179.103 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 61.6 m -129.42 142.01 50.9 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.254 -1.145 . . . . 0.0 109.553 179.455 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -64.66 136.21 38.75 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 61.7 ttp85 -55.32 -37.98 68.11 Favored 'General case' 0 C--N 1.305 -1.328 0 O-C-N 121.254 -1.145 . . . . 0.0 110.056 -179.652 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 22.9 t -57.19 -32.7 66.73 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.288 -0.883 . . . . 0.0 109.797 -179.605 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . 0.409 ' O ' ' CB ' ' A' ' 57' ' ' LYS . . . 118.59 105.1 2.21 Favored Glycine 0 N--CA 1.494 2.508 0 N-CA-C 109.014 -1.635 . . . . 0.0 109.014 -179.726 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . 0.409 ' CB ' ' O ' ' A' ' 56' ' ' GLY . 0.8 OUTLIER 167.86 82.61 0.02 OUTLIER Pre-proline 0 N--CA 1.491 1.584 0 N-CA-C 108.104 -1.073 . . . . 0.0 108.104 -179.625 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 81.4 Cg_exo -45.97 126.15 9.1 Favored 'Trans proline' 0 C--N 1.305 -1.742 0 C-N-CA 122.579 2.186 . . . . 0.0 112.269 -178.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.58 ' O ' ' CG ' ' A' ' 60' ' ' HIS . 53.2 mt -95.94 130.61 42.87 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.554 -0.716 . . . . 0.0 109.711 -179.62 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . 0.58 ' CG ' ' O ' ' A' ' 59' ' ' LEU . 0.4 OUTLIER 166.51 110.03 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.258 -0.901 . . . . 0.0 109.577 179.889 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 3.6 m-85 -68.39 -3.5 11.4 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.181 -0.95 . . . . 0.0 108.603 179.163 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 34.6 ttmt -57.52 149.35 21.36 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.378 -0.827 . . . . 0.0 109.523 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . 0.401 ' N ' ' CG2' ' A' ' 171' ' ' VAL . 83.2 m-20 57.35 47.76 16.04 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.478 -0.764 . . . . 0.0 110.231 179.839 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.673 ' H ' ' CG2' ' A' ' 171' ' ' VAL . 92.3 p -104.33 156.79 17.62 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.293 -0.879 . . . . 0.0 108.907 179.257 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 29.2 t -128.9 146.54 50.92 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.153 -0.967 . . . . 0.0 109.623 -179.609 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.7 m-30 -71.81 133.92 45.81 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.283 -0.885 . . . . 0.0 108.662 179.633 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 80.7 m80 -91.02 -31.58 16.25 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.087 -1.008 . . . . 0.0 110.819 -178.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 80.0 mtp180 -135.36 138.61 43.53 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 120.951 -1.093 . . . . 0.0 110.306 -179.458 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -150.8 80.04 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 179.0 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 59.9 mt -96.99 129.39 32.54 Favored Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.345 -0.847 . . . . 0.0 109.537 -179.627 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -74.61 134.67 18.82 Favored 'Trans proline' 0 N--CA 1.491 1.349 0 C-N-CA 122.114 1.876 . . . . 0.0 112.076 179.788 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 92.96 -1.2 70.4 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.899 -1.28 . . . . 0.0 109.899 179.597 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 77.4 m-85 -132.93 -94.02 0.34 Allowed 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.098 -1.236 . . . . 0.0 109.818 179.921 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 4.5 ptt? -163.39 177.48 8.89 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.946 -1.097 . . . . 0.0 110.031 -179.601 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -129.4 131.49 46.81 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.495 -0.753 . . . . 0.0 109.039 179.94 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 50.8 tt0 -97.16 118.5 33.72 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.138 -0.976 . . . . 0.0 109.322 179.816 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -61.86 -39.31 97.33 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 81.53 167.16 38.18 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.494 -1.442 . . . . 0.0 109.494 -179.916 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -104.25 149.83 24.96 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.42 -1.047 . . . . 0.0 109.456 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 45.2 p90 -65.29 -24.17 67.22 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.18 -0.95 . . . . 0.0 109.347 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.517 ' OG1' ' N ' ' A' ' 88' ' ' GLY . 58.9 p -66.31 -31.51 72.35 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.225 -0.922 . . . . 0.0 109.657 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . 0.407 ' N ' ' HG1' ' A' ' 81' ' ' THR . . . 173.46 -53.28 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.242 -0.911 . . . . 0.0 109.44 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 92.53 3.26 66.89 Favored Glycine 0 N--CA 1.492 2.378 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 40.7 p-10 -88.27 7.53 31.69 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.162 -1.199 . . . . 0.0 109.427 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 95.21 -43.52 2.23 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 109.272 -1.531 . . . . 0.0 109.272 -179.851 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 47.1 m -60.58 -38.41 84.5 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.208 -1.172 . . . . 0.0 109.049 179.759 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -84.38 -164.67 38.1 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.473 -1.451 . . . . 0.0 109.473 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.517 ' N ' ' OG1' ' A' ' 81' ' ' THR . . . 86.98 35.51 9.8 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.511 -1.435 . . . . 0.0 109.511 -179.952 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -56.56 146.04 26.31 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.296 -1.12 . . . . 0.0 109.441 179.878 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 29.7 t -100.35 144.02 29.85 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.284 -0.885 . . . . 0.0 109.461 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 21.9 pt -64.36 -32.44 57.6 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.382 -0.824 . . . . 0.0 109.863 -179.728 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 67.7 m-85 -64.12 -37.46 87.54 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.198 -0.939 . . . . 0.0 109.437 -179.795 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 81.43 7.47 88.24 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -151.82 156.92 41.16 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.204 -1.174 . . . . 0.0 109.537 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 86.9 mttt -88.27 148.29 24.4 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.285 -0.884 . . . . 0.0 109.542 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.554 ' CZ ' ' OD1' ' A' ' 121' ' ' ASN . 40.4 p90 -134.33 161.82 33.91 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.253 -0.905 . . . . 0.0 108.973 179.495 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -54.99 138.36 43.9 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.146 -0.971 . . . . 0.0 109.851 -178.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 88.2 m-20 -74.66 141.15 44.62 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.428 -0.795 . . . . 0.0 109.761 -179.901 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -59.82 146.36 42.1 Favored 'General case' 0 C--N 1.305 -1.37 0 O-C-N 121.322 -0.861 . . . . 0.0 109.218 179.672 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 23.0 t-20 -58.26 159.63 5.87 Favored 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.461 -0.774 . . . . 0.0 109.429 -179.87 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' PHE . . . . . 0.482 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 29.3 p90 -96.43 52.26 1.23 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.303 -0.873 . . . . 0.0 109.72 -179.721 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 88.6 mt -56.77 -39.49 64.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.123 -0.986 . . . . 0.0 109.322 179.781 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -93.03 146.16 23.84 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.154 -0.966 . . . . 0.0 109.627 179.901 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . 0.531 ' O ' ' N ' ' A' ' 106' ' ' THR . 81.0 tttt -126.8 157.62 38.74 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.439 -0.788 . . . . 0.0 109.346 -179.924 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' HIS . . . . . 0.53 ' ND1' ' OD1' ' A' ' 136' ' ' ASP . 23.2 m80 -59.06 81.25 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.272 -0.893 . . . . 0.0 109.061 179.937 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' THR . . . . . 0.531 ' N ' ' O ' ' A' ' 104' ' ' LYS . 69.3 p -73.96 -22.79 59.51 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.164 -0.96 . . . . 0.0 110.147 -179.485 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -152.75 177.66 30.33 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.734 -1.346 . . . . 0.0 109.734 -179.626 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -73.2 156.29 51.3 Favored 'Trans proline' 0 C--N 1.307 -1.648 0 C-N-CA 122.891 2.394 . . . . 0.0 112.193 179.793 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . 0.495 ' N ' ' O ' ' A' ' 128' ' ' CYS . . . 82.23 47.42 6.12 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.91 -1.276 . . . . 0.0 109.91 179.757 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 40.7 mm -115.0 136.67 50.94 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.378 -1.071 . . . . 0.0 109.479 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . 0.595 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 2.7 mm? -89.32 142.34 27.74 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.349 -0.844 . . . . 0.0 109.762 -179.684 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 10.4 t -144.8 140.71 28.63 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.202 -0.936 . . . . 0.0 109.752 179.787 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 89.0 mtp -88.86 137.49 32.27 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.166 -0.959 . . . . 0.0 109.323 179.483 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -68.9 143.52 54.47 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.202 -0.936 . . . . 0.0 109.811 -179.867 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . 0.433 ' OD1' ' O ' ' A' ' 120' ' ' THR . 47.0 t30 -140.83 151.03 44.03 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.334 -0.854 . . . . 0.0 109.474 179.737 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -132.17 -3.72 3.5 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.404 -0.81 . . . . 0.0 109.241 179.755 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -157.51 169.55 34.45 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.078 -1.609 . . . . 0.0 109.078 -179.925 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -70.66 147.91 58.13 Favored 'Trans proline' 0 C--N 1.306 -1.665 0 C-N-CA 122.603 2.202 . . . . 0.0 111.792 179.857 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 87.7 m-20 51.0 42.2 28.18 Favored 'General case' 0 C--N 1.297 -1.679 0 O-C-N 121.476 -0.765 . . . . 0.0 109.467 -179.801 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' THR . . . . . 0.433 ' O ' ' OD1' ' A' ' 115' ' ' ASN . 84.2 m -135.22 124.91 25.26 Favored 'General case' 0 N--CA 1.488 1.44 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 179.717 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' ASN . . . . . 0.554 ' OD1' ' CZ ' ' A' ' 96' ' ' PHE . 35.8 m120 -106.24 128.3 53.85 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.576 -0.703 . . . . 0.0 109.702 -179.919 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -99.52 130.84 10.35 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 179.921 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 22.9 t -60.19 -33.23 71.94 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.186 -1.185 . . . . 0.0 109.63 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 25.7 mt-30 -68.38 147.9 51.45 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.332 -0.855 . . . . 0.0 109.664 -179.668 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 50.2 p90 -137.31 161.14 37.06 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.334 -0.854 . . . . 0.0 109.209 179.905 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 86.0 m-85 -118.87 151.35 38.27 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.266 -0.897 . . . . 0.0 109.711 -179.898 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 76.3 mt -116.82 134.05 61.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 N-CA-C 108.693 -0.854 . . . . 0.0 108.693 179.313 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 128' ' ' CYS . . . . . 0.495 ' O ' ' N ' ' A' ' 109' ' ' GLY . 1.3 m -121.59 132.45 54.69 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.278 -0.889 . . . . 0.0 109.389 -179.774 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 1.7 t -116.65 8.78 13.91 Favored 'General case' 0 N--CA 1.493 1.698 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 179.652 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -141.58 165.94 26.11 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.544 -0.723 . . . . 0.0 109.109 -179.885 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 69.1 mttm -65.5 134.13 52.75 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.114 -0.991 . . . . 0.0 109.453 -179.829 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 57.3 p -141.97 70.45 1.33 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.319 -0.863 . . . . 0.0 109.295 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -61.3 -36.16 79.33 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.277 -0.889 . . . . 0.0 109.992 -179.56 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 0.8 OUTLIER -62.6 -43.15 99.54 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.014 -1.054 . . . . 0.0 109.51 -179.942 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 25.0 mt -65.49 -33.84 76.88 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.14 -0.975 . . . . 0.0 109.765 179.508 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . 0.53 ' OD1' ' ND1' ' A' ' 105' ' ' HIS . 87.3 m-20 -65.76 141.59 58.27 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.277 -0.889 . . . . 0.0 109.611 -179.754 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 153.79 -92.83 0.13 Allowed Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . 0.409 ' HD2' ' N ' ' A' ' 138' ' ' LYS . 1.1 mptp? -87.7 10.54 17.89 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.333 -1.098 . . . . 0.0 109.523 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 63.3 m170 -96.41 140.74 30.63 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.235 -0.915 . . . . 0.0 109.594 -179.751 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 44.9 t -115.37 138.16 46.6 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 O-C-N 121.442 -0.786 . . . . 0.0 109.473 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 11.2 m -100.72 132.17 46.91 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.332 -0.855 . . . . 0.0 109.224 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 41.4 p90 -110.08 -11.08 14.65 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.222 -0.924 . . . . 0.0 110.219 -179.544 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -157.77 179.75 33.27 Favored Glycine 0 N--CA 1.493 2.458 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 179.738 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.5 pt20 -144.3 165.22 28.51 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.086 -1.244 . . . . 0.0 109.717 -179.749 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 75.6 t -97.12 129.66 46.86 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.19 0 O-C-N 121.318 -0.864 . . . . 0.0 109.299 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 16.1 m -101.86 -35.28 4.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.394 -0.816 . . . . 0.0 109.882 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 90.1 mt-10 -144.95 170.59 15.85 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.149 -0.97 . . . . 0.0 109.745 -179.819 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 97.78 4.14 58.02 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 110.315 -1.114 . . . . 0.0 110.315 179.308 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 149' ' ' MET . . . . . 0.433 ' O ' HG13 ' A' ' 152' ' ' VAL . 65.1 mtt -60.53 -32.37 71.41 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 120.991 -1.299 . . . . 0.0 109.518 179.872 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -64.79 -41.75 95.59 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 120.9 -1.125 . . . . 0.0 110.084 -179.652 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 6.6 p -82.21 -33.59 11.6 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.2 -0.938 . . . . 0.0 110.679 -179.425 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 152' ' ' VAL . . . . . 0.459 ' CG1' ' N ' ' A' ' 153' ' ' LYS . 0.9 OUTLIER -55.82 -42.38 70.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 120.901 -1.124 . . . . 0.0 109.249 -179.304 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 153' ' ' LYS . . . . . 0.459 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 91.1 mttt -65.49 -35.49 81.03 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.043 -1.035 . . . . 0.0 109.409 179.429 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -63.01 -38.15 90.06 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.383 -0.823 . . . . 0.0 109.996 -179.532 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 84.7 mt -71.09 -38.44 71.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.295 -0.878 . . . . 0.0 110.594 -179.555 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -78.1 -39.25 41.99 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.1 -1.0 . . . . 0.0 111.573 -178.395 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 31.6 pttt -61.0 -34.16 74.39 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 120.723 -1.236 . . . . 0.0 110.21 -178.682 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 23.8 m -69.8 -15.65 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 120.96 -1.087 . . . . 0.0 109.047 179.786 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -79.05 177.29 54.31 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 23.2 t -152.02 173.51 14.79 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.321 -1.105 . . . . 0.0 109.239 -179.855 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 23.4 m -53.09 -34.89 58.63 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.073 -1.017 . . . . 0.0 108.992 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 24.6 m -59.11 -30.33 68.04 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.373 -0.829 . . . . 0.0 109.363 179.527 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 96.82 11.14 54.23 Favored Glycine 0 N--CA 1.494 2.507 0 N-CA-C 109.35 -1.5 . . . . 0.0 109.35 -179.701 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 88.8 mtt180 -109.25 158.12 18.16 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.369 -1.077 . . . . 0.0 109.02 179.73 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 165' ' ' THR . . . . . . . . . . . . . 43.1 p -116.38 156.82 26.07 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.203 -0.936 . . . . 0.0 110.366 -179.399 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -68.17 -34.72 76.82 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.55 -0.718 . . . . 0.0 109.476 179.624 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -121.98 156.5 33.31 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.481 -0.762 . . . . 0.0 109.473 -179.73 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 90.5 mttt -80.7 141.16 35.14 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.298 -0.876 . . . . 0.0 109.301 -179.904 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 40.6 t -121.74 126.08 74.2 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.341 -0.849 . . . . 0.0 109.7 -179.88 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 43.5 t -141.57 140.68 30.88 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.275 -0.891 . . . . 0.0 109.202 179.712 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . 0.673 ' CG2' ' H ' ' A' ' 64' ' ' SER . 4.0 m -68.58 123.24 21.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.118 -0.989 . . . . 0.0 109.464 179.935 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -68.65 -36.75 78.99 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.008 -1.057 . . . . 0.0 110.046 -179.802 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -160.04 163.05 34.29 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.073 -1.017 . . . . 0.0 110.07 -179.594 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 16.0 p -146.6 149.78 34.21 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.418 -0.801 . . . . 0.0 109.434 179.759 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . 176.84 -178.83 48.04 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 179.892 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 176' ' ' GLN . . . . . 0.644 HE22 ' CZ ' ' A' ' 43' ' ' ARG . 60.4 tt0 -106.69 120.26 41.52 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.343 -1.092 . . . . 0.0 109.651 -179.952 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 177' ' ' LEU . . . . . 0.437 ' O ' ' C ' ' A' ' 178' ' ' SER . 30.3 tp -61.9 -39.34 91.66 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.138 -0.976 . . . . 0.0 109.153 179.454 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 178' ' ' SER . . . . . 0.437 ' C ' ' O ' ' A' ' 177' ' ' LEU . 5.6 p . . . . . 0 N--CA 1.492 1.673 0 CA-C-O 118.046 -0.978 . . . . 0.0 109.806 179.898 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.529 4.835 0 N-CA-C 119.401 2.52 . . . . 0.0 119.401 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 55.0 p -70.21 161.39 30.37 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.196 -1.179 . . . . 0.0 109.512 -179.941 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 99.3 m-85 -112.18 125.37 54.06 Favored 'General case' 0 N--CA 1.484 1.247 0 O-C-N 121.377 -0.827 . . . . 0.0 108.813 179.678 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 44.6 m -56.79 -37.75 71.58 Favored 'General case' 0 C--N 1.296 -1.759 0 O-C-N 121.441 -0.787 . . . . 0.0 109.477 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -78.18 8.16 40.57 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.798 -1.321 . . . . 0.0 109.798 -179.809 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 37.8 t -58.97 -32.88 70.05 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.136 -1.214 . . . . 0.0 109.748 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 13.5 mtt -124.79 79.18 64.07 Favored Pre-proline 0 N--CA 1.495 1.784 0 O-C-N 121.273 -0.892 . . . . 0.0 109.717 -179.781 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo -85.53 168.43 9.89 Favored 'Trans proline' 0 C--N 1.308 -1.562 0 C-N-CA 122.978 2.452 . . . . 0.0 112.125 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 6.8 m-20 -60.6 150.46 74.81 Favored Pre-proline 0 N--CA 1.488 1.47 0 O-C-N 121.22 -0.925 . . . . 0.0 109.0 179.711 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -65.75 133.77 35.25 Favored 'Trans proline' 0 C--N 1.309 -1.55 0 C-N-CA 122.448 2.099 . . . . 0.0 112.24 -179.695 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 97.4 mtt180 -131.57 129.74 41.34 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.411 -0.805 . . . . 0.0 108.879 179.203 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.5 p -135.88 142.26 39.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.366 -0.834 . . . . 0.0 109.363 -179.822 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 45.1 p90 -142.31 153.4 43.85 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.418 -0.801 . . . . 0.0 109.573 -179.812 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -121.37 134.88 55.13 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.385 -0.822 . . . . 0.0 109.318 179.54 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -90.6 114.75 27.07 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.182 -0.949 . . . . 0.0 108.945 179.485 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' MET . . . . . 0.405 ' SD ' ' CD1' ' A' ' 26' ' ' ILE . 85.1 mtp -102.56 152.19 21.45 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.311 -0.868 . . . . 0.0 110.452 -179.404 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 96.5 p -143.15 163.15 33.68 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.781 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.53 ' O ' ' N ' ' A' ' 20' ' ' GLY . 29.4 m -123.43 139.8 48.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 121.07 -1.019 . . . . 0.0 109.501 -179.953 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 47.01 13.96 0.11 Allowed Glycine 0 N--CA 1.492 2.406 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 179.928 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.53 ' N ' ' O ' ' A' ' 18' ' ' VAL . . . 98.78 -16.3 59.76 Favored Glycine 0 N--CA 1.493 2.447 0 N-CA-C 109.616 -1.393 . . . . 0.0 109.616 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' GLN . . . . . 0.492 ' N ' ' O ' ' A' ' 18' ' ' VAL . 64.5 mm-40 -81.69 146.12 55.89 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.169 -1.195 . . . . 0.0 109.216 179.812 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_endo -63.48 138.89 67.7 Favored 'Trans proline' 0 N--CA 1.494 1.528 0 C-N-CA 122.366 2.044 . . . . 0.0 112.174 -179.736 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -112.6 -66.2 1.11 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.319 -0.863 . . . . 0.0 109.452 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -175.81 -169.97 38.06 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.315 -1.514 . . . . 0.0 109.315 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 71.3 mtp180 -114.95 144.03 44.22 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.226 -1.161 . . . . 0.0 109.587 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.405 ' CD1' ' SD ' ' A' ' 16' ' ' MET . 84.0 mt -120.72 116.07 48.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 N-CA-C 108.44 -0.948 . . . . 0.0 108.44 178.579 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 37.8 t -112.12 133.91 56.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.439 -0.788 . . . . 0.0 109.218 -179.537 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 76.5 mtm -119.53 155.25 32.51 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.454 -0.779 . . . . 0.0 109.532 -179.577 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -100.31 133.02 45.35 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.369 -0.832 . . . . 0.0 109.939 -179.601 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -110.39 134.65 52.11 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.506 -0.746 . . . . 0.0 109.155 179.619 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 84.1 m-85 -95.1 122.84 38.18 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.2 -0.938 . . . . 0.0 108.999 179.388 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -92.9 -41.81 9.84 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.348 -0.845 . . . . 0.0 109.606 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 87.2 m-20 -69.62 -44.45 70.65 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.327 -0.858 . . . . 0.0 110.659 -179.338 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' THR . . . . . 0.439 ' O ' ' OE1' ' A' ' 99' ' ' GLU . 35.2 m -67.84 -46.82 70.69 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.16 -0.962 . . . . 0.0 110.526 -178.924 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.413 ' OG1' ' OG1' ' A' ' 38' ' ' THR . 0.0 OUTLIER -152.63 83.62 4.82 Favored Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.147 -0.971 . . . . 0.0 109.486 -179.447 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -71.92 -33.19 10.22 Favored 'Trans proline' 0 C--N 1.308 -1.593 0 C-N-CA 122.146 1.897 . . . . 0.0 112.12 -179.63 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 35.2 mmt180 -63.35 -40.28 96.85 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.326 -0.858 . . . . 0.0 109.491 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.413 ' OG1' ' OG1' ' A' ' 35' ' ' THR . 36.5 m -64.87 -41.17 95.88 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.274 -0.891 . . . . 0.0 109.929 -179.806 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -62.43 -30.77 71.46 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.286 -0.884 . . . . 0.0 109.282 179.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -67.11 -36.91 82.94 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.293 -0.879 . . . . 0.0 109.864 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 87.5 m-20 -57.95 -39.76 78.88 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.263 -0.898 . . . . 0.0 110.062 -179.498 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . 0.431 ' O ' ' SG ' ' A' ' 46' ' ' CYS . 98.5 m-85 -90.42 -48.13 7.3 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.072 -1.017 . . . . 0.0 109.665 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 51.3 ttp180 -57.65 -40.71 79.9 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.48 -0.762 . . . . 0.0 110.508 -179.361 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.46 ' O ' ' N ' ' A' ' 48' ' ' GLY . . . -66.05 -46.8 76.51 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.976 -1.077 . . . . 0.0 110.425 -179.095 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.449 ' N ' ' CD2' ' A' ' 45' ' ' LEU . 3.6 mm? -64.98 -39.97 94.27 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 120.956 -1.09 . . . . 0.0 109.618 -179.809 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' CYS . . . . . 0.431 ' SG ' ' O ' ' A' ' 42' ' ' PHE . 34.8 m -70.06 -47.85 60.26 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.084 -1.01 . . . . 0.0 109.347 179.769 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 74.8 p -72.55 -34.62 67.65 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.36 -0.837 . . . . 0.0 109.555 179.742 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . 0.46 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 73.61 31.88 60.13 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.978 -1.249 . . . . 0.0 109.978 179.646 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 78.0 mm-40 -62.03 -38.03 87.16 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.029 -1.277 . . . . 0.0 109.534 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 31.4 mmtp -62.18 -35.86 80.11 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.282 -0.886 . . . . 0.0 109.674 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 89.51 167.9 42.97 Favored Glycine 0 N--CA 1.488 2.154 0 N-CA-C 109.074 -1.611 . . . . 0.0 109.074 -179.653 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 85.2 m -75.1 138.73 42.28 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.119 -1.224 . . . . 0.0 109.559 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -59.5 137.18 50.11 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.393 -1.483 . . . . 0.0 109.393 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 83.5 mtm-85 -59.35 -36.09 75.08 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.19 -1.182 . . . . 0.0 109.846 -179.748 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 85.9 p -63.38 -24.26 67.77 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.113 -0.992 . . . . 0.0 109.779 -179.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 115.87 96.35 2.02 Favored Glycine 0 N--CA 1.494 2.524 0 N-CA-C 109.078 -1.609 . . . . 0.0 109.078 -179.572 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . 0.51 ' NZ ' ' OE1' ' A' ' 89' ' ' GLU . 75.8 tttt -179.5 81.47 0.2 Allowed Pre-proline 0 N--CA 1.489 1.518 0 N-CA-C 108.377 -0.971 . . . . 0.0 108.377 -179.664 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 75.9 Cg_exo -50.31 130.12 27.89 Favored 'Trans proline' 0 C--N 1.303 -1.828 0 C-N-CA 122.769 2.313 . . . . 0.0 112.597 -179.014 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.484 ' CD1' ' O ' ' A' ' 57' ' ' LYS . 9.0 mp -100.04 23.49 9.82 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.641 -0.662 . . . . 0.0 109.436 -179.833 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . 0.51 ' O ' ' CE1' ' A' ' 80' ' ' PHE . 93.2 m-70 -101.66 135.32 43.38 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.227 -0.92 . . . . 0.0 109.628 -179.804 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 2.7 m-85 -94.95 12.67 27.55 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.293 -0.879 . . . . 0.0 108.98 179.575 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . 0.463 ' O ' ' CB ' ' A' ' 63' ' ' ASP . 62.1 tttt -62.73 142.82 57.97 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.416 -0.803 . . . . 0.0 109.674 -179.832 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . 0.463 ' CB ' ' O ' ' A' ' 62' ' ' LYS . 21.4 t0 74.76 33.72 0.77 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.581 -0.7 . . . . 0.0 109.736 179.859 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.77 ' H ' ' CG2' ' A' ' 171' ' ' VAL . 52.6 p -76.66 165.31 24.93 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.225 -0.922 . . . . 0.0 109.005 179.34 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 29.7 t -140.9 149.77 42.33 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.085 -1.01 . . . . 0.0 109.814 -179.783 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 58.3 m-85 -90.93 127.22 36.31 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.296 -0.878 . . . . 0.0 109.209 179.552 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 55.4 t-80 -94.85 -30.74 14.04 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.258 -0.901 . . . . 0.0 110.499 -179.27 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 83.0 mtp180 -126.26 140.87 52.19 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.057 -1.027 . . . . 0.0 110.341 -179.38 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 15.8 m -151.57 49.05 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 179.424 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 19.4 mt -77.56 133.78 66.67 Favored Pre-proline 0 C--N 1.301 -1.507 0 O-C-N 121.361 -0.837 . . . . 0.0 110.156 -178.612 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -68.89 147.89 69.42 Favored 'Trans proline' 0 N--CA 1.492 1.421 0 C-N-CA 122.4 2.067 . . . . 0.0 112.266 179.852 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 80.42 -55.75 4.66 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.849 -1.3 . . . . 0.0 109.849 179.642 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 88.4 m-85 -68.36 -87.27 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.27 -1.135 . . . . 0.0 109.67 -179.75 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 11.3 ptt? -179.59 -175.16 0.32 Allowed 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.141 -0.975 . . . . 0.0 109.667 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 58.2 m -126.92 136.74 52.72 Favored 'General case' 0 N--CA 1.493 1.702 0 N-CA-C 108.763 -0.829 . . . . 0.0 108.763 179.608 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 63.2 tt0 -96.9 134.88 39.65 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.226 -0.921 . . . . 0.0 109.695 -179.527 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -139.75 176.19 21.33 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.06 -1.616 . . . . 0.0 109.06 179.769 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 77.14 36.84 34.03 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.235 -1.546 . . . . 0.0 109.235 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -83.72 13.97 4.29 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.321 -1.105 . . . . 0.0 109.413 -179.826 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.51 ' CE1' ' O ' ' A' ' 60' ' ' HIS . 81.0 t80 -51.67 -45.26 63.37 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.293 -0.88 . . . . 0.0 109.803 -179.874 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.612 ' CB ' ' H ' ' A' ' 88' ' ' GLY . 58.9 p -70.51 -28.17 64.75 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.1 -1.0 . . . . 0.0 109.506 179.857 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . 0.467 ' CB ' ' O ' ' A' ' 81' ' ' THR . . . 165.3 -56.9 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.342 -0.849 . . . . 0.0 109.238 179.898 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 93.39 -1.42 69.52 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . 0.43 ' OD1' ' OG1' ' A' ' 86' ' ' THR . 40.7 p-10 -90.02 5.95 44.39 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.126 -1.22 . . . . 0.0 109.473 179.965 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 96.44 -33.53 5.59 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' THR . . . . . 0.43 ' OG1' ' OD1' ' A' ' 84' ' ' ASN . 51.7 p -72.58 -22.26 61.01 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.14 -1.212 . . . . 0.0 109.217 179.76 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -84.97 -161.64 34.29 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 179.915 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.612 ' H ' ' CB ' ' A' ' 81' ' ' THR . . . 90.95 26.87 20.85 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 -179.869 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . 0.51 ' OE1' ' NZ ' ' A' ' 57' ' ' LYS . 96.0 mt-10 -57.1 145.52 30.69 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.375 -1.073 . . . . 0.0 109.577 -179.799 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 29.3 t -106.15 143.55 34.11 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.323 -0.861 . . . . 0.0 109.328 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 20.4 pt -64.58 -33.44 63.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.332 -0.855 . . . . 0.0 109.828 -179.722 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 73.5 m-85 -65.53 -38.12 88.72 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.23 -0.919 . . . . 0.0 109.604 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 81.64 14.5 77.89 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.449 -1.461 . . . . 0.0 109.449 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -146.46 155.77 42.79 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.14 -1.211 . . . . 0.0 109.655 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 97.1 mttt -94.07 142.24 27.62 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.291 -0.88 . . . . 0.0 109.549 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 99.4 m-85 -120.63 150.16 41.34 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.415 -0.803 . . . . 0.0 109.589 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -70.8 154.51 41.77 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.385 -0.822 . . . . 0.0 109.569 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 88.4 m-20 -59.48 147.66 35.85 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.251 -0.906 . . . . 0.0 109.341 179.901 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . 0.439 ' OE1' ' O ' ' A' ' 34' ' ' THR . 96.2 mt-10 -80.4 -89.35 0.06 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.145 -0.972 . . . . 0.0 110.008 -179.583 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 85.3 m-20 -124.86 145.91 49.55 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.301 -0.875 . . . . 0.0 110.049 -179.473 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -100.74 10.83 40.65 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.439 -0.788 . . . . 0.0 109.294 179.589 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.409 HG23 HD12 ' A' ' 102' ' ' ILE . 96.2 mt -53.49 -36.46 27.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.303 -0.873 . . . . 0.0 110.134 -179.391 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 9.2 mtpm? -80.45 136.12 36.27 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.98 -1.075 . . . . 0.0 109.633 -179.789 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 69.1 tttt -135.15 159.37 41.76 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.449 -0.782 . . . . 0.0 109.331 -179.705 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' HIS . . . . . 0.41 ' HD1' ' CB ' ' A' ' 110' ' ' ILE . 92.9 m-70 -74.19 106.55 5.9 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.092 -1.005 . . . . 0.0 109.477 179.865 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 62.3 p -96.03 -9.97 29.65 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.343 -0.848 . . . . 0.0 109.691 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -165.18 -179.03 38.83 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.76 -1.336 . . . . 0.0 109.76 -179.805 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -78.76 160.28 27.82 Favored 'Trans proline' 0 C--N 1.306 -1.677 0 C-N-CA 123.178 2.585 . . . . 0.0 112.23 179.791 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 82.17 40.9 9.78 Favored Glycine 0 N--CA 1.492 2.395 0 N-CA-C 109.995 -1.242 . . . . 0.0 109.995 179.715 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.416 HG21 HD12 ' A' ' 110' ' ' ILE . 33.7 mm -113.66 139.21 40.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.357 -1.084 . . . . 0.0 109.209 179.923 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . 0.55 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 3.4 mm? -86.88 136.18 33.05 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.156 -0.965 . . . . 0.0 109.737 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 30.8 t -144.69 143.41 30.71 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.348 -0.845 . . . . 0.0 109.098 179.47 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 15.1 ptm -87.4 126.06 34.64 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.231 -0.918 . . . . 0.0 109.532 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -66.27 147.77 52.83 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.263 -0.898 . . . . 0.0 109.715 -179.74 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . 0.525 ' N ' ' OD1' ' A' ' 115' ' ' ASN . 8.0 p-10 -157.76 115.56 3.05 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.272 -0.893 . . . . 0.0 109.169 179.634 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -65.46 -30.72 71.54 Favored 'General case' 0 C--N 1.299 -1.63 0 O-C-N 121.406 -0.809 . . . . 0.0 109.8 -179.761 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -135.57 166.09 24.61 Favored Glycine 0 N--CA 1.494 2.519 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -67.38 156.74 64.91 Favored 'Trans proline' 0 C--N 1.306 -1.659 0 C-N-CA 122.867 2.378 . . . . 0.0 111.816 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 75.8 m-20 54.33 45.4 27.3 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.411 -0.805 . . . . 0.0 109.232 -179.895 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 61.5 m -131.85 127.99 37.73 Favored 'General case' 0 C--N 1.305 -1.349 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 179.916 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 20.1 m120 -102.01 137.03 40.84 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.493 -0.755 . . . . 0.0 109.486 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -145.32 125.78 2.42 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 179.91 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 23.1 t -59.02 -30.86 68.32 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.374 -1.074 . . . . 0.0 109.482 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.6 mt-30 -63.22 143.2 58.0 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.194 -0.941 . . . . 0.0 109.537 -179.675 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 45.6 p90 -141.35 164.93 28.91 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.453 -0.78 . . . . 0.0 109.178 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 48.0 p90 -131.47 157.48 43.39 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.231 -0.918 . . . . 0.0 109.517 179.854 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 71.3 mt -120.25 136.36 57.55 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.492 -0.755 . . . . 0.0 109.593 -179.73 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 128' ' ' CYS . . . . . 0.509 ' SG ' ' O ' ' A' ' 130' ' ' ALA . 11.0 t -116.26 123.56 48.01 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.287 -0.883 . . . . 0.0 108.978 179.581 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 37.6 p -95.51 5.5 51.38 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.275 -0.891 . . . . 0.0 109.86 -179.446 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . 0.509 ' O ' ' SG ' ' A' ' 128' ' ' CYS . . . -148.44 155.58 41.39 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.142 -0.974 . . . . 0.0 109.725 -179.905 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 34.7 ttmt -73.51 135.42 44.02 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.316 -0.865 . . . . 0.0 109.309 179.838 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 132' ' ' THR . . . . . 0.634 ' HG1' ' N ' ' A' ' 136' ' ' ASP . 16.9 p -120.87 159.33 25.74 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.447 -0.783 . . . . 0.0 109.431 -179.808 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . 0.436 ' O ' ' OD1' ' A' ' 136' ' ' ASP . 96.2 mt-10 -97.93 -48.24 5.24 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.286 -0.884 . . . . 0.0 110.011 -179.906 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 134' ' ' TRP . . . . . 0.602 ' CD1' ' N ' ' A' ' 135' ' ' LEU . 40.9 p90 -92.16 -44.06 9.0 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.199 -0.938 . . . . 0.0 110.174 -179.477 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . 0.602 ' N ' ' CD1' ' A' ' 134' ' ' TRP . 34.2 tp -61.66 -29.63 70.2 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.268 -0.895 . . . . 0.0 109.184 -179.646 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . 0.634 ' N ' ' HG1' ' A' ' 132' ' ' THR . 53.4 p30 -70.14 9.06 0.63 Allowed 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.447 -0.783 . . . . 0.0 109.513 -179.747 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . 0.498 ' H ' ' C ' ' A' ' 135' ' ' LEU . . . -52.02 -30.31 30.13 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.618 -1.393 . . . . 0.0 109.618 -179.904 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . 0.44 ' CE ' ' OD1' ' A' ' 115' ' ' ASN . 46.4 mmtm -77.56 123.18 26.27 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.098 -1.236 . . . . 0.0 109.168 -179.879 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 71.1 m80 -110.61 15.66 21.91 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.398 -0.814 . . . . 0.0 109.754 -179.641 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 45.0 t -100.08 129.8 50.21 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.13 -0.981 . . . . 0.0 109.88 -179.536 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 84.2 t -130.58 129.83 64.55 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 N-CA-C 109.021 -0.733 . . . . 0.0 109.021 179.651 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 39.5 p90 -110.72 -0.4 17.09 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.074 -1.016 . . . . 0.0 110.052 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -175.43 173.52 46.28 Favored Glycine 0 N--CA 1.493 2.495 0 N-CA-C 109.804 -1.319 . . . . 0.0 109.804 179.443 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 94.0 mt-30 -139.36 165.91 25.95 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.29 -1.123 . . . . 0.0 109.584 -179.83 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 55.1 t -95.56 129.54 45.53 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.222 0 O-C-N 121.175 -0.953 . . . . 0.0 109.162 179.816 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 17.3 m -106.73 -33.65 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.314 -0.866 . . . . 0.0 109.455 179.736 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -143.06 170.78 15.07 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.333 -0.855 . . . . 0.0 109.525 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 98.53 2.39 57.61 Favored Glycine 0 N--CA 1.494 2.558 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.74 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 149' ' ' MET . . . . . 0.404 ' O ' HG13 ' A' ' 152' ' ' VAL . 50.6 ttm -61.02 -32.85 72.44 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.063 -1.257 . . . . 0.0 109.667 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -65.33 -42.29 93.08 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.883 -1.135 . . . . 0.0 110.06 -179.596 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.6 p -81.84 -32.92 11.59 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.141 -0.974 . . . . 0.0 110.611 -179.232 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 152' ' ' VAL . . . . . 0.441 ' CG1' ' N ' ' A' ' 153' ' ' LYS . 0.9 OUTLIER -53.76 -41.0 45.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 120.976 -1.077 . . . . 0.0 109.152 -179.285 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 153' ' ' LYS . . . . . 0.441 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 87.2 mttt -64.03 -34.62 78.42 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.122 -0.986 . . . . 0.0 109.188 179.169 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -62.08 -35.06 77.52 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.381 -0.824 . . . . 0.0 109.687 -179.798 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 95.7 mt -70.79 -36.01 62.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.277 -0.889 . . . . 0.0 109.832 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 85.1 tt0 -75.24 -41.89 56.5 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.266 -0.896 . . . . 0.0 111.419 -178.755 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 55.4 pttt -61.27 -34.46 75.21 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.665 -1.272 . . . . 0.0 109.689 -179.047 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 32.6 m -82.82 -6.62 10.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.146 -0.971 . . . . 0.0 108.926 179.427 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -77.67 176.48 53.68 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 109.797 -1.321 . . . . 0.0 109.797 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 86.9 p -157.48 169.54 24.46 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.431 -1.041 . . . . 0.0 109.706 -179.58 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 22.8 t -57.1 -32.69 66.55 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.281 -0.887 . . . . 0.0 108.647 179.256 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 86.2 p -61.38 -27.25 68.39 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.329 -0.857 . . . . 0.0 109.096 179.654 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 93.24 18.04 40.79 Favored Glycine 0 N--CA 1.493 2.488 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 179.756 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 88.7 mtt180 -115.94 143.06 45.96 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.219 -1.165 . . . . 0.0 109.226 179.825 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 165' ' ' THR . . . . . . . . . . . . . 81.7 p -81.98 150.06 27.85 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.208 -0.933 . . . . 0.0 109.675 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -68.96 -36.77 78.3 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.325 -0.859 . . . . 0.0 109.333 179.8 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -111.58 157.84 19.92 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.5 -0.75 . . . . 0.0 109.435 -179.914 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 92.1 mttt -73.02 135.84 44.96 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.309 -0.869 . . . . 0.0 109.175 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 3.4 m -130.94 123.02 53.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.725 0 O-C-N 121.365 -0.834 . . . . 0.0 109.772 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 39.0 t -143.21 138.0 26.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.386 -0.821 . . . . 0.0 108.804 179.557 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . 0.77 ' CG2' ' H ' ' A' ' 64' ' ' SER . 3.0 m -67.7 119.56 13.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 120.826 -1.171 . . . . 0.0 109.547 -179.737 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -68.52 -35.57 77.66 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.233 -0.917 . . . . 0.0 110.086 -179.836 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -156.34 158.32 37.21 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.202 -0.936 . . . . 0.0 110.047 -179.6 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 19.0 p -147.06 148.58 31.79 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.435 -0.79 . . . . 0.0 109.16 179.688 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -177.93 179.72 48.29 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.704 -1.359 . . . . 0.0 109.704 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 61.3 tt0 -106.03 117.25 33.55 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.392 -1.064 . . . . 0.0 109.667 -179.896 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 31.3 tp -62.86 -38.8 92.29 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.094 -1.004 . . . . 0.0 109.216 179.589 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 2.6 p . . . . . 0 N--CA 1.492 1.651 0 CA-C-O 117.897 -1.049 . . . . 0.0 109.707 179.997 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.528 4.829 0 N-CA-C 119.389 2.515 . . . . 0.0 119.389 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 23.2 m -57.66 -35.28 70.34 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.325 -1.103 . . . . 0.0 109.489 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 99.3 m-85 -111.32 123.02 49.36 Favored 'General case' 0 N--CA 1.485 1.309 0 O-C-N 121.329 -0.857 . . . . 0.0 108.873 179.654 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 43.8 m -57.55 -39.74 77.33 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.515 -0.741 . . . . 0.0 109.42 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 83.58 16.82 67.54 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.617 -1.393 . . . . 0.0 109.617 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 86.3 p -138.58 160.22 40.13 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.232 -1.158 . . . . 0.0 109.447 -179.941 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 7.2 ttt -128.56 76.71 78.27 Favored Pre-proline 0 N--CA 1.493 1.695 0 O-C-N 121.388 -0.82 . . . . 0.0 109.517 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_exo -49.12 -175.97 0.0 OUTLIER 'Trans proline' 0 C--N 1.307 -1.628 0 C-N-CA 122.868 2.379 . . . . 0.0 112.614 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 12.0 m120 -98.86 151.3 37.35 Favored Pre-proline 0 N--CA 1.492 1.656 0 O-C-N 121.582 -0.699 . . . . 0.0 109.261 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -68.21 138.08 42.2 Favored 'Trans proline' 0 N--CA 1.496 1.648 0 C-N-CA 122.595 2.197 . . . . 0.0 112.272 179.891 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 95.5 mtt180 -128.72 132.27 47.97 Favored 'General case' 0 N--CA 1.492 1.657 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 179.114 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.5 p -133.24 142.3 42.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.363 -0.836 . . . . 0.0 109.607 -179.564 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 47.1 p90 -140.91 155.26 46.32 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.411 -0.806 . . . . 0.0 109.519 -179.838 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 69.8 m-85 -121.86 135.51 54.9 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.455 -0.778 . . . . 0.0 109.643 179.773 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.0 t0 -88.28 118.83 28.15 Favored 'General case' 0 N--CA 1.493 1.703 0 N-CA-C 108.307 -0.998 . . . . 0.0 108.307 178.864 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 75.2 mtp -116.32 142.86 46.28 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.263 -0.898 . . . . 0.0 110.742 -178.822 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.581 ' HG ' ' CD ' ' A' ' 172' ' ' GLU . 31.6 m -136.4 155.88 49.41 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 179.368 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 33.3 m -119.14 133.69 65.17 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.085 -1.009 . . . . 0.0 109.638 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 57.86 15.57 20.59 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.689 -1.365 . . . . 0.0 109.689 179.844 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 92.08 2.38 68.87 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.386 -1.486 . . . . 0.0 109.386 -179.804 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 41.5 tt0 -105.02 115.15 62.88 Favored Pre-proline 0 N--CA 1.492 1.658 0 O-C-N 121.437 -1.037 . . . . 0.0 109.112 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 77.4 Cg_exo -47.33 133.65 19.91 Favored 'Trans proline' 0 N--CA 1.492 1.412 0 C-N-CA 122.088 1.859 . . . . 0.0 112.106 -179.949 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -101.25 -57.67 2.04 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.292 -0.88 . . . . 0.0 109.568 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -178.02 -169.08 38.46 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.401 -1.48 . . . . 0.0 109.401 -179.775 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 50.9 mtp180 -113.22 144.22 43.07 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.415 -1.05 . . . . 0.0 109.383 179.849 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 76.3 mt -117.85 114.56 45.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 N-CA-C 108.183 -1.043 . . . . 0.0 108.183 178.757 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 38.3 t -109.58 135.21 49.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.437 -0.79 . . . . 0.0 109.628 -179.219 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 75.8 mtm -128.41 156.86 42.49 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.514 -0.741 . . . . 0.0 109.225 -179.588 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -103.83 133.93 48.0 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.283 -0.886 . . . . 0.0 109.706 179.882 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -105.37 128.97 53.78 Favored 'General case' 0 N--CA 1.492 1.638 0 N-CA-C 108.752 -0.832 . . . . 0.0 108.752 179.365 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.401 ' CG ' ' NZ ' ' A' ' 103' ' ' LYS . 94.9 m-85 -92.97 119.41 32.21 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.085 -1.009 . . . . 0.0 109.141 179.981 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -86.33 -42.6 13.57 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.346 -0.846 . . . . 0.0 109.535 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.3 m-20 -65.1 -47.49 76.99 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.368 -0.833 . . . . 0.0 110.298 -179.433 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' THR . . . . . 0.622 ' CB ' ' HZ1' ' A' ' 103' ' ' LYS . 37.4 m -67.62 -44.63 77.56 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.211 -0.931 . . . . 0.0 109.775 -179.777 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.474 ' O ' ' OG1' ' A' ' 35' ' ' THR . 5.7 p -138.15 76.98 37.56 Favored Pre-proline 0 N--CA 1.492 1.658 0 N-CA-C 109.082 -0.71 . . . . 0.0 109.082 -179.912 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 10.7 Cg_endo -59.33 -63.31 0.13 Allowed 'Trans proline' 0 C--N 1.31 -1.489 0 C-N-CA 122.571 2.181 . . . . 0.0 112.801 -179.154 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 86.8 mtt-85 -61.24 -35.19 76.58 Favored 'General case' 0 C--N 1.297 -1.688 0 O-C-N 121.652 -0.655 . . . . 0.0 110.755 -178.77 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 25.3 m -60.27 -42.13 94.76 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 120.984 -1.073 . . . . 0.0 110.094 -179.418 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -59.95 -31.82 70.23 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.128 -0.983 . . . . 0.0 109.153 -179.794 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -67.7 -36.88 81.47 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.401 -0.812 . . . . 0.0 109.915 -179.9 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 37.8 t30 -56.6 -40.81 75.92 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.261 -0.899 . . . . 0.0 109.823 -179.458 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 98.4 m-85 -90.43 -48.6 7.01 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.069 -1.019 . . . . 0.0 109.828 -179.89 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . 0.864 ' HE ' HE22 ' A' ' 176' ' ' GLN . 66.2 ttt-85 -57.41 -41.32 80.14 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.512 -0.742 . . . . 0.0 110.505 -179.375 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -65.55 -47.6 75.3 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.049 -1.032 . . . . 0.0 110.373 -178.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.469 ' N ' ' CD2' ' A' ' 45' ' ' LEU . 3.3 mm? -65.51 -39.87 92.36 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.124 -0.985 . . . . 0.0 109.665 -179.735 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' CYS . . . . . . . . . . . . . 72.3 m -68.24 -46.09 71.44 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.1 -1.0 . . . . 0.0 109.315 179.819 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 72.6 p -74.34 -33.53 63.16 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.313 -0.867 . . . . 0.0 109.721 179.877 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 75.03 30.81 58.6 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 110.037 -1.225 . . . . 0.0 110.037 179.739 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 77.9 mm-40 -61.97 -36.67 82.16 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.137 -1.214 . . . . 0.0 109.441 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 42.0 mmtm -60.66 -33.87 73.45 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.233 -0.917 . . . . 0.0 109.402 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 92.84 171.3 40.45 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.096 -1.602 . . . . 0.0 109.096 -179.692 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 99.2 m -75.88 141.39 42.38 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.317 -1.108 . . . . 0.0 109.76 -179.807 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -60.42 138.15 48.62 Favored Glycine 0 N--CA 1.488 2.164 0 N-CA-C 109.405 -1.478 . . . . 0.0 109.405 179.787 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 87.1 mtt-85 -60.24 -29.22 68.62 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.303 -1.116 . . . . 0.0 110.231 -179.803 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 75.4 m -78.52 11.0 2.7 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.181 -0.95 . . . . 0.0 110.32 -179.154 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 82.16 77.03 1.07 Allowed Glycine 0 N--CA 1.492 2.4 0 N-CA-C 109.217 -1.553 . . . . 0.0 109.217 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . 0.478 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 55.0 mttp -157.47 75.0 4.16 Favored Pre-proline 0 C--N 1.302 -1.463 0 O-C-N 121.449 -1.03 . . . . 0.0 108.3 -179.944 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . 0.411 ' O ' ' CE2' ' A' ' 80' ' ' PHE . 73.1 Cg_exo -50.04 130.28 27.32 Favored 'Trans proline' 0 C--N 1.302 -1.909 0 C-N-CA 122.962 2.441 . . . . 0.0 112.517 -179.085 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.478 ' CD1' ' O ' ' A' ' 57' ' ' LYS . 8.6 mp -100.8 74.22 1.63 Allowed 'General case' 0 N--CA 1.489 1.524 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 -179.638 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 77.5 m80 -139.21 150.68 45.82 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.436 -0.79 . . . . 0.0 109.516 179.865 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 3.8 m-85 -101.95 20.48 16.41 Favored 'General case' 0 N--CA 1.493 1.691 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 179.573 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 85.0 mttt -77.57 157.55 30.26 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.434 -0.791 . . . . 0.0 109.525 -179.663 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 54.8 t0 56.89 48.9 15.04 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.486 -0.759 . . . . 0.0 109.805 179.788 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 87.4 p -111.71 154.25 25.26 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.4 -0.813 . . . . 0.0 109.077 179.69 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 27.8 t -131.03 149.3 52.68 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.227 -0.921 . . . . 0.0 109.74 -179.603 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -72.68 135.84 45.49 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.351 -0.843 . . . . 0.0 109.131 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 32.1 m-70 -77.84 -53.01 7.98 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.259 -0.901 . . . . 0.0 110.71 -179.219 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 98.1 mtt180 -130.27 148.96 52.16 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.043 -1.035 . . . . 0.0 110.541 -179.017 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 8.5 m -143.67 59.6 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.585 -0.697 . . . . 0.0 109.135 179.497 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 18.6 mt -82.14 132.67 52.73 Favored Pre-proline 0 C--N 1.301 -1.543 0 O-C-N 121.164 -0.96 . . . . 0.0 109.771 -179.135 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -70.98 149.67 59.49 Favored 'Trans proline' 0 N--CA 1.492 1.437 0 C-N-CA 122.399 2.066 . . . . 0.0 112.113 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 81.33 -58.28 4.86 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 179.879 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -70.01 -84.83 0.03 OUTLIER 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.269 -1.136 . . . . 0.0 109.637 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' MET . . . . . 0.484 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 14.1 ptt? 178.03 -172.83 0.13 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.334 -0.854 . . . . 0.0 109.544 179.877 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 14.6 p -125.75 137.26 53.8 Favored 'General case' 0 N--CA 1.493 1.721 0 N-CA-C 108.595 -0.891 . . . . 0.0 108.595 179.45 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 93.1 mt-30 -111.53 153.99 25.44 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.167 -0.958 . . . . 0.0 109.771 -179.485 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -134.76 174.43 21.07 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.006 -1.638 . . . . 0.0 109.006 179.7 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -137.24 161.03 25.19 Favored Glycine 0 N--CA 1.493 2.477 0 N-CA-C 109.717 -1.353 . . . . 0.0 109.717 -179.88 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 90.3 m-20 -72.89 156.81 38.49 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.379 -1.071 . . . . 0.0 109.457 179.865 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.411 ' CE2' ' O ' ' A' ' 58' ' ' PRO . 50.7 p90 -61.97 -18.49 60.58 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.327 -0.858 . . . . 0.0 109.744 -179.666 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.583 ' OG1' ' N ' ' A' ' 88' ' ' GLY . 73.1 p -61.71 -34.39 75.69 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.046 -1.034 . . . . 0.0 109.534 -179.902 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 172.24 -50.46 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.329 -0.857 . . . . 0.0 109.434 179.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 92.45 3.14 67.2 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 80.3 m-20 -86.9 5.91 34.6 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.218 -1.166 . . . . 0.0 109.306 179.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 95.13 -42.61 2.34 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 -179.804 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 47.8 m -61.23 -38.91 88.33 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.207 -1.172 . . . . 0.0 109.114 179.601 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -85.35 -166.46 41.92 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.583 ' N ' ' OG1' ' A' ' 81' ' ' THR . . . 83.52 43.69 7.25 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 -179.897 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -64.05 144.14 57.33 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.266 -1.138 . . . . 0.0 109.478 -179.848 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 29.3 t -102.91 142.12 34.55 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.34 -0.85 . . . . 0.0 109.369 -179.884 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 6.4 pt -63.26 -42.68 97.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.339 -0.851 . . . . 0.0 109.915 -179.737 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 3.8 m-30 -69.85 -36.19 75.35 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.976 -1.077 . . . . 0.0 109.558 179.871 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 80.81 14.85 78.95 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.224 -1.55 . . . . 0.0 109.224 -179.728 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -145.3 158.11 43.9 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.372 -1.075 . . . . 0.0 109.451 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -86.43 154.46 21.14 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.182 -0.949 . . . . 0.0 109.56 -179.881 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 89.0 m-85 -100.23 130.64 46.38 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.281 -0.887 . . . . 0.0 109.305 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -76.62 138.75 40.29 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.159 -0.963 . . . . 0.0 109.496 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . 0.712 ' H ' HD21 ' A' ' 119' ' ' ASN . 88.5 m-20 -75.54 131.25 39.92 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.267 -0.896 . . . . 0.0 109.266 179.836 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -104.28 -55.46 2.36 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.239 -0.913 . . . . 0.0 110.061 -179.797 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 84.9 m-20 -106.35 128.82 54.3 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.233 -0.917 . . . . 0.0 110.24 -179.149 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 90.2 m-85 -108.38 10.52 27.5 Favored 'General case' 0 N--CA 1.493 1.686 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 179.352 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.428 HD13 HG22 ' A' ' 102' ' ' ILE . 92.0 mt -54.9 -37.0 39.88 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.397 -0.814 . . . . 0.0 110.568 -178.974 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . 0.622 ' HZ1' ' CB ' ' A' ' 34' ' ' THR . 87.2 mttt -77.2 127.99 33.59 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.871 -1.143 . . . . 0.0 109.909 -179.427 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . 0.593 ' O ' ' N ' ' A' ' 106' ' ' THR . 34.4 ttmt -139.08 149.96 45.18 Favored 'General case' 0 N--CA 1.492 1.636 0 N-CA-C 109.012 -0.736 . . . . 0.0 109.012 179.862 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' HIS . . . . . . . . . . . . . 85.5 m-70 -53.69 82.34 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.094 -1.004 . . . . 0.0 109.66 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' THR . . . . . 0.593 ' N ' ' O ' ' A' ' 104' ' ' LYS . 54.9 p -73.45 -28.0 61.72 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.235 -0.915 . . . . 0.0 109.525 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -150.21 -177.51 24.25 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.882 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 69.6 Cg_endo -76.14 156.33 37.96 Favored 'Trans proline' 0 C--N 1.306 -1.666 0 C-N-CA 123.025 2.483 . . . . 0.0 112.198 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 81.86 45.75 7.05 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 110.098 -1.201 . . . . 0.0 110.098 179.706 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 41.6 mm -115.98 136.91 51.39 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 121.287 -1.125 . . . . 0.0 109.459 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . 0.543 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 2.4 mm? -87.54 128.28 35.25 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.199 -0.938 . . . . 0.0 109.263 179.716 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 87.7 p -143.16 150.84 39.96 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.332 -0.855 . . . . 0.0 109.547 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' MET . . . . . 0.458 ' CE ' ' OD1' ' A' ' 121' ' ' ASN . 86.5 mtp -95.35 139.47 31.6 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.343 -0.848 . . . . 0.0 109.329 179.621 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -64.38 145.35 56.2 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.237 -0.914 . . . . 0.0 109.54 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . 0.512 ' N ' ' OD1' ' A' ' 115' ' ' ASN . 2.7 p30 -165.77 114.98 1.0 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.184 -0.948 . . . . 0.0 109.613 179.863 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -66.19 -31.31 72.06 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.383 -0.823 . . . . 0.0 109.356 179.721 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -136.84 169.81 23.72 Favored Glycine 0 N--CA 1.493 2.474 0 N-CA-C 109.351 -1.5 . . . . 0.0 109.351 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -65.84 157.67 57.82 Favored 'Trans proline' 0 C--N 1.305 -1.757 0 C-N-CA 122.819 2.346 . . . . 0.0 111.969 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' ASN . . . . . 0.712 HD21 ' H ' ' A' ' 98' ' ' ASP . 16.4 m120 55.89 44.3 26.06 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.425 -0.797 . . . . 0.0 109.325 -179.857 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 61.2 m -135.96 127.83 29.37 Favored 'General case' 0 C--N 1.304 -1.383 0 N-CA-C 108.804 -0.814 . . . . 0.0 108.804 179.851 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 121' ' ' ASN . . . . . 0.458 ' OD1' ' CE ' ' A' ' 113' ' ' MET . 31.9 t30 -100.5 109.9 22.05 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.423 -0.798 . . . . 0.0 109.374 -179.954 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -85.8 135.33 13.29 Favored Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.644 -1.383 . . . . 0.0 109.644 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 85.3 p -65.1 -23.38 67.14 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.248 -1.148 . . . . 0.0 109.408 179.871 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.0 mt-30 -101.89 154.2 19.15 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.378 -0.826 . . . . 0.0 109.606 -179.728 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 49.3 p90 -133.6 160.95 35.96 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.471 -0.768 . . . . 0.0 109.461 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.484 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 45.6 p90 -140.0 159.71 41.58 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.324 -0.86 . . . . 0.0 109.504 -179.91 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 72.5 mt -119.77 134.24 63.95 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.407 -0.808 . . . . 0.0 109.444 179.845 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 1.8 m -92.2 105.55 17.74 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.104 -0.998 . . . . 0.0 109.268 179.827 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 54.2 p -74.72 -9.12 58.26 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.271 -0.893 . . . . 0.0 109.463 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -150.44 156.15 40.91 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.362 -0.836 . . . . 0.0 109.277 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 82.5 tttt -68.01 135.16 51.88 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.216 -0.928 . . . . 0.0 109.23 179.855 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 6.5 p -122.11 158.0 30.24 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.409 -0.807 . . . . 0.0 109.558 -179.74 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -138.69 -35.66 0.58 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.317 -0.865 . . . . 0.0 109.081 179.812 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 134' ' ' TRP . . . . . 0.422 ' CD2' ' N ' ' A' ' 134' ' ' TRP . 0.7 OUTLIER -58.7 -29.43 66.64 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.447 -0.783 . . . . 0.0 109.219 179.713 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 18.2 mt -59.49 -35.77 74.77 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.32 -0.863 . . . . 0.0 109.628 179.638 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 57.5 t0 49.45 50.94 17.31 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.286 -0.884 . . . . 0.0 109.518 179.801 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -130.2 127.63 5.37 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.166 -1.574 . . . . 0.0 109.166 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . 0.515 ' O ' ' O ' ' A' ' 139' ' ' HIS . 88.2 mttt -56.58 -38.19 71.65 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.36 -1.083 . . . . 0.0 109.652 -179.846 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 139' ' ' HIS . . . . . 0.515 ' O ' ' O ' ' A' ' 138' ' ' LYS . 54.6 m170 56.86 147.88 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.644 -0.66 . . . . 0.0 109.824 179.936 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 41.0 t -116.05 133.6 62.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.413 -0.804 . . . . 0.0 109.296 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 60.1 t -107.27 127.51 62.99 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 121.272 -0.893 . . . . 0.0 109.52 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 39.1 p90 -116.16 3.06 13.45 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.403 -0.81 . . . . 0.0 109.682 179.773 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -173.08 179.13 44.7 Favored Glycine 0 N--CA 1.494 2.528 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 179.612 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.3 pt20 -145.82 166.29 26.35 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.114 -1.227 . . . . 0.0 109.865 -179.855 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 74.6 t -100.63 132.11 46.92 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.122 0 O-C-N 121.278 -0.888 . . . . 0.0 109.581 -179.855 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 12.9 m -113.85 -31.52 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.308 -0.87 . . . . 0.0 109.422 179.563 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -139.62 167.25 22.52 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.356 -0.84 . . . . 0.0 109.469 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 97.67 4.0 58.18 Favored Glycine 0 N--CA 1.494 2.527 0 N-CA-C 109.941 -1.264 . . . . 0.0 109.941 179.765 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 149' ' ' MET . . . . . . . . . . . . . 65.0 mtt -60.71 -33.44 72.89 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.098 -1.236 . . . . 0.0 109.479 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 89.3 m-20 -64.02 -41.64 97.38 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.913 -1.117 . . . . 0.0 109.852 -179.761 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.5 p -83.24 -34.37 10.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.199 -0.938 . . . . 0.0 110.402 -179.446 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 152' ' ' VAL . . . . . 0.464 ' CG1' ' N ' ' A' ' 153' ' ' LYS . 0.6 OUTLIER -57.02 -42.77 79.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 120.872 -1.142 . . . . 0.0 109.382 -179.219 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 153' ' ' LYS . . . . . 0.464 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 66.6 mttm -63.84 -34.41 77.87 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.242 -0.911 . . . . 0.0 109.517 179.503 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -61.48 -37.9 85.33 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.24 -0.913 . . . . 0.0 109.962 -179.492 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 88.3 mt -72.51 -35.14 50.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.189 -0.945 . . . . 0.0 110.047 -179.717 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -76.29 -41.64 48.04 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.202 -0.936 . . . . 0.0 111.191 -178.865 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 39.1 pttt -61.8 -33.92 74.98 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 120.852 -1.155 . . . . 0.0 109.89 -178.819 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 35.3 m -77.8 -13.99 14.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.011 -1.056 . . . . 0.0 109.26 179.714 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -74.3 168.27 54.44 Favored Glycine 0 N--CA 1.489 2.2 0 N-CA-C 109.789 -1.324 . . . . 0.0 109.789 -179.718 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 160' ' ' SER . . . . . 0.682 ' HG ' ' H ' ' A' ' 161' ' ' SER . 22.8 t -157.67 176.36 12.71 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.418 -1.048 . . . . 0.0 109.361 -179.758 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 161' ' ' SER . . . . . 0.682 ' H ' ' HG ' ' A' ' 160' ' ' SER . 23.6 m -54.01 -31.78 52.16 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.282 -0.886 . . . . 0.0 109.182 179.817 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 23.9 m -55.56 -33.07 63.53 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.28 -0.888 . . . . 0.0 109.462 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 95.38 10.97 56.54 Favored Glycine 0 N--CA 1.493 2.482 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 179.828 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 81.7 mtm180 -121.44 146.57 46.76 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.303 -1.116 . . . . 0.0 109.474 179.874 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 165' ' ' THR . . . . . . . . . . . . . 80.5 p -80.49 151.42 29.24 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.224 -0.923 . . . . 0.0 109.646 -179.884 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -66.66 -37.06 84.02 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.322 -0.862 . . . . 0.0 109.077 179.592 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -108.71 158.69 17.39 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.555 -0.716 . . . . 0.0 109.096 179.721 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -71.4 130.78 42.2 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.14 -0.975 . . . . 0.0 109.394 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 43.6 t -122.15 124.24 70.67 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 121.38 -0.825 . . . . 0.0 109.435 179.795 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 48.8 t -149.1 154.61 9.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.48 -0.763 . . . . 0.0 109.141 179.865 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 2.1 t -90.15 124.87 43.0 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 O-C-N 121.258 -0.901 . . . . 0.0 109.932 -179.312 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 172' ' ' GLU . . . . . 0.581 ' CD ' ' HG ' ' A' ' 17' ' ' SER . 97.1 mt-10 -64.96 -28.87 69.81 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.449 -0.782 . . . . 0.0 109.192 179.46 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 173' ' ' ASP . . . . . 0.425 ' C ' ' OD1' ' A' ' 173' ' ' ASP . 53.1 p30 -175.14 179.58 1.53 Allowed 'General case' 0 N--CA 1.492 1.639 0 C-N-CA 119.449 -0.9 . . . . 0.0 110.352 -179.665 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 26.7 p -151.48 151.38 31.56 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.45 -0.781 . . . . 0.0 109.265 179.711 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -178.18 176.83 48.22 Favored Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.792 -1.323 . . . . 0.0 109.792 179.812 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 176' ' ' GLN . . . . . 0.864 HE22 ' HE ' ' A' ' 43' ' ' ARG . 59.3 tt0 -107.11 127.21 53.29 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.375 -1.073 . . . . 0.0 109.61 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 29.0 tp -60.98 -37.78 83.66 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.187 -0.945 . . . . 0.0 109.194 179.641 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 9.5 t . . . . . 0 N--CA 1.49 1.563 0 CA-C-O 117.945 -1.026 . . . . 0.0 109.483 -179.942 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.528 4.816 0 N-CA-C 119.357 2.503 . . . . 0.0 119.357 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 55.3 p -70.47 160.59 32.13 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.213 -1.169 . . . . 0.0 109.479 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 99.4 m-85 -114.11 126.23 54.85 Favored 'General case' 0 N--CA 1.486 1.363 0 N-CA-C 108.822 -0.807 . . . . 0.0 108.822 179.563 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 56.2 p -64.04 -31.71 73.0 Favored 'General case' 0 C--N 1.297 -1.711 0 O-C-N 121.554 -0.716 . . . . 0.0 109.41 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 83.04 -170.19 49.18 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.716 -1.354 . . . . 0.0 109.716 179.841 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 49.9 m -66.65 158.02 31.08 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.32 -1.106 . . . . 0.0 109.624 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 57.3 mtp -62.86 150.55 87.3 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.25 -0.906 . . . . 0.0 109.232 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_endo -69.01 169.48 17.87 Favored 'Trans proline' 0 N--CA 1.493 1.462 0 C-N-CA 122.7 2.267 . . . . 0.0 112.108 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 3.2 m-80 -66.91 148.34 98.87 Favored Pre-proline 0 N--CA 1.489 1.485 0 O-C-N 121.38 -0.825 . . . . 0.0 109.486 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -70.65 140.24 38.9 Favored 'Trans proline' 0 N--CA 1.494 1.558 0 C-N-CA 122.777 2.318 . . . . 0.0 112.409 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 97.8 mtt180 -128.96 132.09 47.56 Favored 'General case' 0 N--CA 1.491 1.592 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 179.127 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.6 p -136.51 142.62 37.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.248 -0.907 . . . . 0.0 109.633 -179.441 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 38.5 p90 -144.19 154.79 43.5 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.344 -0.847 . . . . 0.0 109.589 -179.866 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 67.1 m-85 -126.66 138.14 53.38 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.332 -0.855 . . . . 0.0 109.597 179.648 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.468 ' CG ' ' NH1' ' A' ' 25' ' ' ARG . 90.2 m-20 -87.02 129.94 34.68 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.168 -0.957 . . . . 0.0 108.616 178.983 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 83.8 mtp -117.35 153.85 32.31 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.164 -0.96 . . . . 0.0 110.37 -179.441 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 76.9 p -148.14 167.33 25.32 Favored 'General case' 0 N--CA 1.487 1.42 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 179.629 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 7.9 p -127.4 134.24 66.19 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.244 -0.91 . . . . 0.0 109.717 -179.815 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 54.79 17.13 8.55 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.626 -1.389 . . . . 0.0 109.626 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 92.24 4.56 66.39 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 63.9 mt-30 -105.49 113.43 64.24 Favored Pre-proline 0 N--CA 1.494 1.728 0 O-C-N 121.345 -1.091 . . . . 0.0 109.241 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_exo -48.81 137.24 27.6 Favored 'Trans proline' 0 N--CA 1.492 1.406 0 C-N-CA 122.123 1.882 . . . . 0.0 112.086 179.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -111.22 -59.4 1.98 Allowed 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.411 -0.806 . . . . 0.0 109.498 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -170.44 -169.8 33.99 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.376 -1.49 . . . . 0.0 109.376 -179.859 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . 0.468 ' NH1' ' CG ' ' A' ' 15' ' ' ASP . 88.2 mtt-85 -116.46 145.8 43.03 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.308 -1.113 . . . . 0.0 109.784 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 73.5 mt -119.8 122.45 68.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 178.863 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 46.1 t -111.02 133.3 57.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.3 -0.875 . . . . 0.0 109.3 -179.562 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 75.2 mtm -116.22 150.88 36.8 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.447 -0.783 . . . . 0.0 109.412 -179.767 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -101.47 130.92 47.81 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.277 -0.889 . . . . 0.0 109.926 -179.594 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -109.86 127.74 54.9 Favored 'General case' 0 N--CA 1.493 1.683 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 179.277 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 96.3 m-85 -98.96 118.53 35.93 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.167 -0.958 . . . . 0.0 109.049 179.525 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -79.66 -41.94 25.86 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.379 -0.826 . . . . 0.0 109.776 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -64.35 -46.6 82.72 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.286 -0.884 . . . . 0.0 110.246 -179.333 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 33.1 m -67.38 -44.42 78.97 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.136 -0.978 . . . . 0.0 109.815 -179.72 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.479 ' O ' ' OG1' ' A' ' 35' ' ' THR . 6.8 p -141.61 79.65 16.85 Favored Pre-proline 0 N--CA 1.492 1.649 0 O-C-N 121.429 -0.794 . . . . 0.0 109.291 -179.859 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -64.25 -54.63 0.78 Allowed 'Trans proline' 0 C--N 1.308 -1.564 0 C-N-CA 122.286 1.991 . . . . 0.0 112.508 -179.404 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 70.9 mtp180 -62.43 -38.75 90.93 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.52 -0.737 . . . . 0.0 110.636 -179.196 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 28.6 m -65.16 -43.82 90.55 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.948 -1.095 . . . . 0.0 110.236 -179.474 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -63.14 -30.61 71.73 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.18 -0.95 . . . . 0.0 109.21 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -71.2 -43.78 66.72 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.345 -0.847 . . . . 0.0 109.837 -179.733 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 45.8 t30 -62.76 -47.82 81.86 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.248 -0.907 . . . . 0.0 109.992 -179.512 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . 0.499 ' O ' ' SG ' ' A' ' 46' ' ' CYS . 61.1 t80 -63.79 -47.75 79.64 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.208 -0.932 . . . . 0.0 109.567 -179.667 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . 0.626 ' CZ ' HE22 ' A' ' 176' ' ' GLN . 74.4 ttt180 -57.83 -38.17 75.12 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.365 -0.835 . . . . 0.0 109.854 -179.849 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.512 ' O ' ' N ' ' A' ' 48' ' ' GLY . . . -62.32 -42.9 99.76 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.118 -0.989 . . . . 0.0 110.088 -179.247 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -66.28 -38.02 86.79 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.02 -1.05 . . . . 0.0 109.582 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' CYS . . . . . 0.499 ' SG ' ' O ' ' A' ' 42' ' ' PHE . 3.8 m -65.9 -53.56 37.88 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.104 -0.997 . . . . 0.0 109.357 -179.973 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 64.4 p -75.02 -31.46 61.37 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.336 -0.852 . . . . 0.0 109.451 179.674 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . 0.512 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 75.7 37.34 40.12 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 110.314 -1.114 . . . . 0.0 110.314 179.51 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -61.61 -37.66 84.77 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.858 -1.377 . . . . 0.0 109.418 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.448 ' HZ1' ' CD1' ' A' ' 91' ' ' ILE . 27.0 mmtp -61.38 -34.0 74.6 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.28 -0.887 . . . . 0.0 109.279 179.819 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 82.13 -86.63 1.43 Allowed Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.654 -1.378 . . . . 0.0 109.654 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 48.8 m -123.77 140.37 53.05 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.448 -1.03 . . . . 0.0 109.637 -179.779 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -56.58 -35.63 67.69 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.44 -1.464 . . . . 0.0 109.44 179.817 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 74.3 mtp85 -140.22 -110.2 0.15 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.35 -1.088 . . . . 0.0 109.207 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 24.9 p -134.13 0.71 3.16 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.366 -0.833 . . . . 0.0 109.746 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -151.09 49.3 0.55 Allowed Glycine 0 N--CA 1.492 2.417 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 59.7 tttm -172.8 74.29 0.42 Allowed Pre-proline 0 N--CA 1.488 1.474 0 O-C-N 121.364 -1.08 . . . . 0.0 108.855 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_exo -47.77 131.93 20.85 Favored 'Trans proline' 0 C--N 1.305 -1.757 0 C-N-CA 122.702 2.268 . . . . 0.0 112.128 -179.417 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.573 ' O ' ' CG ' ' A' ' 60' ' ' HIS . 14.6 tp -109.31 118.39 36.56 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.616 -0.678 . . . . 0.0 109.437 -179.413 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . 0.577 ' O ' ' CZ ' ' A' ' 80' ' ' PHE . 92.4 m-70 -160.62 135.31 7.51 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.244 -0.91 . . . . 0.0 109.944 179.889 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 2.9 m-30 -87.39 3.38 47.26 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.163 -0.96 . . . . 0.0 108.882 179.104 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 62.2 tttt -68.07 146.31 53.61 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.383 -0.823 . . . . 0.0 109.7 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 46.7 t0 61.67 50.8 4.23 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.427 -0.795 . . . . 0.0 110.07 179.784 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.716 ' H ' ' CG2' ' A' ' 171' ' ' VAL . 96.7 p -97.69 157.24 16.16 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.187 -0.946 . . . . 0.0 109.146 179.531 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 29.0 t -128.84 150.09 50.48 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.438 -0.789 . . . . 0.0 109.378 -179.792 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 4.4 m-85 -75.55 125.77 29.69 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.227 -0.92 . . . . 0.0 109.144 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 79.0 t60 -62.76 -48.57 78.61 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.326 -0.859 . . . . 0.0 110.044 -179.354 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.66 HH21 ' NE2' ' A' ' 76' ' ' GLN . 36.8 ptt180 -163.64 162.38 24.18 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.223 -0.923 . . . . 0.0 109.378 -179.925 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -141.75 112.61 3.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.315 -0.866 . . . . 0.0 109.142 179.738 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 43.8 mt -107.56 124.33 35.33 Favored Pre-proline 0 N--CA 1.492 1.645 0 O-C-N 121.45 -0.781 . . . . 0.0 109.073 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_endo -71.75 137.46 29.91 Favored 'Trans proline' 0 N--CA 1.491 1.363 0 C-N-CA 122.031 1.82 . . . . 0.0 112.338 -179.729 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 94.46 -28.25 11.57 Favored Glycine 0 N--CA 1.493 2.466 0 N-CA-C 109.723 -1.351 . . . . 0.0 109.723 179.739 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 94.3 m-85 -100.87 -80.74 0.48 Allowed 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.271 -1.135 . . . . 0.0 109.789 -179.94 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 13.2 ptp -177.87 -168.95 0.19 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.283 -0.886 . . . . 0.0 109.873 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -124.55 130.44 52.45 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.486 -0.759 . . . . 0.0 109.03 179.822 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' GLN . . . . . 0.66 ' NE2' HH21 ' A' ' 68' ' ' ARG . 93.5 mt-30 -108.03 151.65 25.56 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.379 -0.826 . . . . 0.0 109.818 -179.633 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -169.18 -170.49 33.82 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.32 -1.512 . . . . 0.0 109.32 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 88.67 21.25 44.29 Favored Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.766 -1.334 . . . . 0.0 109.766 179.912 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 83.9 m-20 -84.38 12.64 6.43 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.233 -1.157 . . . . 0.0 109.433 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.577 ' CZ ' ' O ' ' A' ' 60' ' ' HIS . 83.1 t80 -50.08 -40.98 47.23 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.313 -0.867 . . . . 0.0 110.134 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.573 ' CB ' ' H ' ' A' ' 88' ' ' GLY . 60.6 p -65.35 -31.26 72.29 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.957 -1.089 . . . . 0.0 109.499 -179.956 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . 0.491 ' CB ' ' O ' ' A' ' 81' ' ' THR . . . 165.3 -53.37 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.415 -0.803 . . . . 0.0 109.32 179.898 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 88.51 2.36 79.53 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 78.5 m-20 -87.85 6.93 33.06 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.254 -1.145 . . . . 0.0 109.478 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 97.2 -39.31 2.82 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.26 -1.536 . . . . 0.0 109.26 -179.788 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 57.1 p -72.63 -21.35 61.12 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.335 -1.097 . . . . 0.0 109.008 179.49 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -84.65 -167.21 42.57 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.573 ' H ' ' CB ' ' A' ' 81' ' ' THR . . . 81.76 44.6 7.69 Favored Glycine 0 N--CA 1.488 2.134 0 N-CA-C 109.016 -1.634 . . . . 0.0 109.016 -179.871 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -94.36 142.49 27.36 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.377 -1.072 . . . . 0.0 109.708 -179.55 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 90.7 p -112.85 158.26 20.38 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.442 -0.786 . . . . 0.0 109.197 179.844 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . 0.448 ' CD1' ' HZ1' ' A' ' 50' ' ' LYS . 29.1 pt -59.08 -32.02 47.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.142 -0.974 . . . . 0.0 109.634 -179.718 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . 0.53 ' O ' ' N ' ' A' ' 94' ' ' ALA . 56.8 m-85 -66.46 -30.12 70.39 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.223 -0.923 . . . . 0.0 109.631 179.636 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 64.07 -72.27 0.05 OUTLIER Glycine 0 N--CA 1.489 2.206 0 N-CA-C 109.336 -1.506 . . . . 0.0 109.336 -179.889 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . 0.53 ' N ' ' O ' ' A' ' 92' ' ' TYR . . . -63.55 143.96 57.39 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.376 -1.073 . . . . 0.0 109.119 179.719 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 59.0 mttp -88.58 149.33 23.63 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.379 -0.826 . . . . 0.0 109.71 -179.849 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 52.0 p90 -130.86 158.52 39.97 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.425 -0.797 . . . . 0.0 109.252 179.705 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -84.79 146.94 27.11 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.28 -0.887 . . . . 0.0 109.893 -179.577 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 60.4 t0 -78.88 124.8 28.59 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.336 -0.852 . . . . 0.0 109.113 179.747 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -54.42 -39.15 67.06 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.146 -0.972 . . . . 0.0 109.729 -179.518 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . 0.499 ' CG ' ' H ' ' A' ' 101' ' ' PHE . 15.1 t-20 -172.32 -177.45 1.81 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.097 -1.002 . . . . 0.0 109.808 179.855 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' PHE . . . . . 0.499 ' H ' ' CG ' ' A' ' 100' ' ' ASN . 15.7 p90 -147.42 62.57 1.16 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.487 -0.758 . . . . 0.0 109.067 179.861 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 80.6 mt -59.66 -37.34 70.42 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.268 -0.895 . . . . 0.0 110.216 -179.447 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 67.6 mttm -86.15 139.41 31.11 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.017 -1.052 . . . . 0.0 109.982 -179.436 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 59.2 mttp -129.12 -176.02 3.74 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.483 -0.761 . . . . 0.0 109.457 179.737 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' HIS . . . . . 0.53 ' O ' ' CG ' ' A' ' 105' ' ' HIS . 49.1 p-80 -109.57 100.36 9.42 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.519 -0.738 . . . . 0.0 109.276 179.704 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 63.7 p -106.96 -0.8 22.85 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.406 -0.809 . . . . 0.0 109.599 -179.831 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -146.62 171.29 27.45 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.336 -1.505 . . . . 0.0 109.336 -179.89 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -74.39 155.44 45.91 Favored 'Trans proline' 0 C--N 1.306 -1.672 0 C-N-CA 122.888 2.392 . . . . 0.0 112.17 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 83.22 44.9 6.8 Favored Glycine 0 N--CA 1.493 2.493 0 N-CA-C 110.234 -1.146 . . . . 0.0 110.234 179.488 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 44.0 mm -116.31 134.21 60.43 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 121.251 -1.146 . . . . 0.0 109.342 179.723 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . 0.511 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 3.4 mm? -91.44 130.91 37.21 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.251 -0.906 . . . . 0.0 109.385 179.709 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' SER . . . . . 0.454 ' OG ' ' O ' ' A' ' 140' ' ' VAL . 47.2 t -143.68 142.24 30.9 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.238 -0.914 . . . . 0.0 109.439 179.826 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 72.1 mtm -82.87 131.21 35.2 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.193 -0.942 . . . . 0.0 109.205 179.769 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . 0.539 ' O ' ' ND2' ' A' ' 115' ' ' ASN . . . -65.87 141.71 58.17 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.192 -0.943 . . . . 0.0 109.587 -179.911 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . 0.539 ' ND2' ' O ' ' A' ' 114' ' ' ALA . 18.3 m120 -146.27 113.03 6.03 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.322 -0.862 . . . . 0.0 109.027 179.664 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -68.51 -29.96 68.67 Favored 'General case' 0 C--N 1.297 -1.682 0 O-C-N 121.46 -0.775 . . . . 0.0 109.488 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -136.51 167.31 24.54 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 109.256 -1.538 . . . . 0.0 109.256 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -67.39 156.22 67.07 Favored 'Trans proline' 0 C--N 1.306 -1.696 0 C-N-CA 122.805 2.336 . . . . 0.0 111.889 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' ASN . . . . . 0.448 ' N ' HD21 ' A' ' 119' ' ' ASN . 2.5 m120 54.35 45.26 27.55 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.422 -0.799 . . . . 0.0 109.35 -179.886 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' THR . . . . . 0.436 ' O ' ' ND2' ' A' ' 115' ' ' ASN . 57.9 m -133.73 126.58 31.0 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 108.792 -0.818 . . . . 0.0 108.792 179.85 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 39.6 t30 -100.77 107.42 18.99 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.504 -0.748 . . . . 0.0 109.355 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -98.44 126.32 8.85 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 86.1 p -62.96 -25.96 68.6 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.268 -1.137 . . . . 0.0 109.385 179.795 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.3 mt-30 -73.86 148.18 42.58 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.283 -0.886 . . . . 0.0 109.399 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 48.8 p90 -136.3 162.75 32.14 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.326 -0.859 . . . . 0.0 109.446 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 49.0 p90 -136.48 160.8 37.67 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.371 -0.831 . . . . 0.0 109.445 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 69.2 mt -115.99 130.16 71.16 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.446 -0.784 . . . . 0.0 109.352 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -101.17 104.2 15.27 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.273 -0.892 . . . . 0.0 109.241 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 59.2 p -84.59 0.67 49.24 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.281 -0.887 . . . . 0.0 109.37 179.878 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -144.42 161.99 37.64 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.3 -0.875 . . . . 0.0 109.466 -179.768 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 92.4 mttt -76.0 150.65 37.37 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.254 -0.904 . . . . 0.0 109.486 -179.91 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 16.0 p -120.0 161.01 21.65 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.39 -0.819 . . . . 0.0 109.374 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -159.61 -44.12 0.05 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.19 -0.944 . . . . 0.0 109.758 -179.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 134' ' ' TRP . . . . . 0.4 ' CE2' ' CD2' ' A' ' 135' ' ' LEU . 33.3 p90 -73.71 -9.64 58.87 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.284 -0.885 . . . . 0.0 109.39 -179.802 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . 0.51 ' N ' ' CD2' ' A' ' 135' ' ' LEU . 2.8 mm? -61.59 -33.8 74.53 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.238 -0.914 . . . . 0.0 108.771 179.239 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 59.1 t0 49.16 49.91 18.83 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.44 -0.788 . . . . 0.0 109.754 179.648 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -143.83 163.79 27.59 Favored Glycine 0 N--CA 1.485 1.932 0 N-CA-C 108.915 -1.674 . . . . 0.0 108.915 179.847 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 13.6 mptt -97.21 142.73 28.77 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.472 -1.016 . . . . 0.0 109.465 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 99.3 m-70 -128.97 146.75 50.88 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.46 -0.775 . . . . 0.0 109.428 179.853 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.454 ' O ' ' OG ' ' A' ' 112' ' ' SER . 42.3 t -112.94 135.0 53.78 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.402 -0.811 . . . . 0.0 109.277 179.955 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 56.3 t -108.38 128.07 64.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 121.33 -0.856 . . . . 0.0 109.507 -179.757 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 45.9 p90 -112.88 -0.59 14.83 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.342 -0.849 . . . . 0.0 109.401 179.547 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -171.28 174.45 44.92 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 179.619 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 92.1 mt-30 -139.6 165.28 27.67 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.176 -1.19 . . . . 0.0 109.663 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 69.9 t -97.12 129.8 46.66 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.225 0 O-C-N 121.126 -0.984 . . . . 0.0 109.435 -179.952 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 16.0 m -106.99 -29.35 2.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.372 -0.83 . . . . 0.0 109.536 179.657 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -143.52 171.17 14.53 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.265 -0.897 . . . . 0.0 109.512 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 97.99 4.22 57.77 Favored Glycine 0 N--CA 1.493 2.46 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 179.64 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 149' ' ' MET . . . . . . . . . . . . . 88.8 mtp -60.6 -33.95 73.51 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.13 -1.218 . . . . 0.0 109.672 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -64.98 -42.62 94.37 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.843 -1.161 . . . . 0.0 110.124 -179.624 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.1 p -82.79 -33.5 10.76 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.079 -1.013 . . . . 0.0 110.499 -179.429 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 152' ' ' VAL . . . . . 0.45 ' CG1' ' N ' ' A' ' 153' ' ' LYS . 0.7 OUTLIER -55.17 -41.82 62.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 120.882 -1.136 . . . . 0.0 109.251 -179.335 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 153' ' ' LYS . . . . . 0.45 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 93.8 mttt -63.56 -34.8 78.6 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.171 -0.956 . . . . 0.0 109.298 179.356 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -63.0 -36.6 84.09 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.405 -0.809 . . . . 0.0 109.792 -179.599 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 69.9 mt -70.4 -38.6 74.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.211 -0.931 . . . . 0.0 110.036 -179.606 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -76.83 -41.14 45.37 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.067 -1.021 . . . . 0.0 111.63 -178.35 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 36.4 pttt -61.18 -34.19 74.65 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 120.729 -1.232 . . . . 0.0 110.261 -178.553 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 35.6 m -76.12 -20.09 15.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 120.917 -1.115 . . . . 0.0 109.469 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -72.91 165.24 54.81 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.652 -1.379 . . . . 0.0 109.652 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 22.9 t -151.42 171.71 17.09 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.376 -1.073 . . . . 0.0 109.382 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 22.6 t -53.7 -32.11 50.61 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.2 -0.938 . . . . 0.0 109.074 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 22.7 t -56.79 -30.94 64.16 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.251 -0.906 . . . . 0.0 109.34 179.722 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 96.41 8.04 57.75 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.678 -1.369 . . . . 0.0 109.678 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 98.6 mtt180 -120.71 144.14 48.39 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.244 -1.15 . . . . 0.0 109.29 179.831 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 165' ' ' THR . . . . . 0.401 ' OG1' ' O ' ' A' ' 167' ' ' LYS . 59.6 p -91.23 157.29 17.25 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.197 -0.939 . . . . 0.0 109.728 -179.853 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -65.94 -33.79 76.63 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.367 -0.833 . . . . 0.0 109.613 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 167' ' ' LYS . . . . . 0.401 ' O ' ' OG1' ' A' ' 165' ' ' THR . 60.8 mttp -119.41 161.03 21.19 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.406 -0.809 . . . . 0.0 109.905 -179.498 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 67.1 mttm -82.53 145.85 29.53 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.437 -0.789 . . . . 0.0 109.725 -179.918 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 1.9 m -133.75 127.08 52.1 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 O-C-N 121.277 -0.89 . . . . 0.0 109.575 179.783 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 44.3 t -137.99 139.05 43.15 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 O-C-N 121.392 -0.817 . . . . 0.0 109.407 179.837 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . 0.716 ' CG2' ' H ' ' A' ' 64' ' ' SER . 9.5 m -67.06 124.51 22.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.0 -1.062 . . . . 0.0 109.208 179.819 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -69.29 -38.38 78.29 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.158 -0.964 . . . . 0.0 110.356 -179.63 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 173' ' ' ASP . . . . . 0.438 ' OD1' ' N ' ' A' ' 174' ' ' CYS . 48.0 t0 -168.7 168.82 10.48 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.958 -1.089 . . . . 0.0 110.209 -179.502 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 174' ' ' CYS . . . . . 0.438 ' N ' ' OD1' ' A' ' 173' ' ' ASP . 14.4 p -138.81 149.84 45.4 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.513 -0.742 . . . . 0.0 109.095 179.785 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -165.27 176.99 40.83 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.737 -1.345 . . . . 0.0 109.737 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 176' ' ' GLN . . . . . 0.626 HE22 ' CZ ' ' A' ' 43' ' ' ARG . 61.1 tt0 -109.83 113.9 27.03 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.331 -1.1 . . . . 0.0 109.614 -179.906 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 177' ' ' LEU . . . . . 0.407 ' O ' ' C ' ' A' ' 178' ' ' SER . 33.9 tp -64.4 -38.41 90.95 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.299 -0.876 . . . . 0.0 109.187 179.526 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 178' ' ' SER . . . . . 0.407 ' C ' ' O ' ' A' ' 177' ' ' LEU . 1.9 t . . . . . 0 N--CA 1.49 1.565 0 CA-C-O 118.04 -0.981 . . . . 0.0 109.621 179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.529 4.835 0 N-CA-C 119.383 2.513 . . . . 0.0 119.383 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 28.2 t -116.32 143.02 46.07 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.445 -1.033 . . . . 0.0 109.42 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 74.6 t80 -99.3 102.57 14.22 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.292 -0.88 . . . . 0.0 109.233 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 48.8 m -66.53 -41.98 87.92 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.254 -0.903 . . . . 0.0 109.94 -179.781 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 82.61 -171.01 50.91 Favored Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.479 -1.449 . . . . 0.0 109.479 -179.741 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 56.2 p -75.76 159.24 31.27 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.305 -1.114 . . . . 0.0 109.594 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 18.5 ptt? -78.1 148.18 74.46 Favored Pre-proline 0 N--CA 1.489 1.515 0 O-C-N 121.224 -0.923 . . . . 0.0 109.371 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -72.04 167.38 26.9 Favored 'Trans proline' 0 C--N 1.31 -1.46 0 C-N-CA 122.627 2.218 . . . . 0.0 112.039 179.947 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 75.1 m-20 -73.64 148.94 88.06 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.297 -0.877 . . . . 0.0 109.506 179.891 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -66.88 140.17 54.33 Favored 'Trans proline' 0 N--CA 1.496 1.632 0 C-N-CA 122.593 2.196 . . . . 0.0 112.237 179.966 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 98.0 mtt180 -132.49 131.12 41.33 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.33 -0.857 . . . . 0.0 109.187 179.494 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.8 p -138.47 142.63 34.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.306 -0.871 . . . . 0.0 109.39 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 49.3 p90 -142.46 153.85 44.04 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.298 -0.876 . . . . 0.0 109.624 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 77.0 m-85 -126.19 140.83 52.25 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.409 -0.807 . . . . 0.0 109.538 179.654 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 88.4 m-20 -86.85 129.75 34.75 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.156 -0.965 . . . . 0.0 108.925 179.31 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 84.7 mtp -115.03 153.33 30.86 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.331 -0.855 . . . . 0.0 110.079 -179.683 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 83.8 p -149.0 164.16 35.38 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.442 -0.787 . . . . 0.0 109.129 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.541 ' O ' ' N ' ' A' ' 20' ' ' GLY . 20.4 m -127.25 144.46 37.25 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 121.233 -0.917 . . . . 0.0 109.604 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 47.61 11.43 0.1 OUTLIER Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.822 -1.311 . . . . 0.0 109.822 179.812 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.541 ' N ' ' O ' ' A' ' 18' ' ' VAL . . . 96.49 -14.93 63.64 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.895 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' GLN . . . . . 0.448 ' N ' ' CD ' ' A' ' 21' ' ' GLN . 8.1 mp0 -82.95 149.31 59.13 Favored Pre-proline 0 N--CA 1.492 1.632 0 O-C-N 121.268 -1.137 . . . . 0.0 109.029 179.778 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -62.42 135.35 53.11 Favored 'Trans proline' 0 C--N 1.308 -1.557 0 C-N-CA 122.353 2.035 . . . . 0.0 112.036 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -113.49 -68.11 0.95 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.398 -0.814 . . . . 0.0 109.554 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -176.0 -171.64 40.02 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 -179.865 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 40.0 ttm180 -123.45 142.65 50.78 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.446 -1.032 . . . . 0.0 109.327 -179.931 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 75.5 mt -119.99 132.06 70.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.372 -0.83 . . . . 0.0 109.03 179.641 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 44.5 t -113.3 133.22 59.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.306 -0.872 . . . . 0.0 109.086 179.765 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 72.8 mtm -118.52 148.95 42.09 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.369 -0.832 . . . . 0.0 109.299 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -102.05 131.68 48.35 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.308 -0.87 . . . . 0.0 109.575 -179.752 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -104.9 128.75 53.25 Favored 'General case' 0 N--CA 1.492 1.655 0 N-CA-C 109.044 -0.725 . . . . 0.0 109.044 179.615 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 90.2 m-85 -97.25 120.98 38.61 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.309 -0.869 . . . . 0.0 109.307 179.731 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -82.53 -41.51 19.58 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.321 -0.862 . . . . 0.0 109.875 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 56.8 t0 -69.02 -44.36 72.89 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.228 -0.92 . . . . 0.0 110.828 -179.22 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 32.9 m -67.22 -45.71 75.98 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.047 -1.033 . . . . 0.0 110.491 -178.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 4.3 m -156.4 84.36 3.21 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.127 -0.983 . . . . 0.0 109.484 -179.524 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -75.24 -37.04 2.08 Favored 'Trans proline' 0 C--N 1.307 -1.639 0 C-N-CA 122.334 2.023 . . . . 0.0 112.497 -179.518 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.423 ' O ' ' OH ' ' A' ' 92' ' ' TYR . 37.7 mmt180 -61.76 -41.02 97.14 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.21 -0.931 . . . . 0.0 109.644 -179.803 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 86.5 m -66.21 -39.95 89.98 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.253 -0.904 . . . . 0.0 110.106 -179.71 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -60.11 -32.3 70.86 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.077 -1.014 . . . . 0.0 109.521 -179.818 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -69.82 -36.26 75.47 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.268 -0.895 . . . . 0.0 110.077 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 48.3 t30 -57.9 -42.7 85.23 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.101 -0.999 . . . . 0.0 109.767 -179.629 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -85.79 -48.12 9.09 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.206 -0.934 . . . . 0.0 109.681 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 34.9 ttm180 -57.4 -42.63 82.63 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.407 -0.808 . . . . 0.0 109.842 -179.508 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.451 ' O ' ' N ' ' A' ' 48' ' ' GLY . . . -69.82 -44.89 69.05 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.306 -0.872 . . . . 0.0 110.182 -179.411 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 36.7 tp -61.92 -36.42 81.3 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.078 -1.014 . . . . 0.0 109.446 -179.652 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' CYS . . . . . . . . . . . . . 46.9 m -79.51 -49.93 11.51 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.09 -1.006 . . . . 0.0 109.757 179.589 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 71.2 p -68.75 -34.72 76.06 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.149 -0.97 . . . . 0.0 109.575 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . 0.451 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 75.16 28.92 61.26 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.972 -1.251 . . . . 0.0 109.972 179.6 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 78.0 mm-40 -60.98 -38.35 85.68 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.088 -1.243 . . . . 0.0 109.246 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 29.1 mmtm -62.48 -31.35 72.07 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 121.308 -0.87 . . . . 0.0 109.152 179.484 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 97.75 -119.64 6.49 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 108.87 -1.692 . . . . 0.0 108.87 -179.49 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 95.1 m -126.55 142.09 51.65 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.419 -1.048 . . . . 0.0 109.751 179.739 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -55.48 135.72 47.77 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.093 -1.603 . . . . 0.0 109.093 179.615 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 94.5 mtt180 -59.11 -37.66 77.71 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.18 -1.188 . . . . 0.0 110.079 -179.484 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 22.9 t -59.47 -31.4 69.3 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.179 -0.95 . . . . 0.0 109.834 -179.615 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 119.77 95.54 1.57 Allowed Glycine 0 N--CA 1.495 2.592 0 N-CA-C 108.648 -1.781 . . . . 0.0 108.648 -179.379 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 32.6 tptt -178.56 80.5 0.22 Allowed Pre-proline 0 N--CA 1.489 1.497 0 N-CA-C 108.07 -1.085 . . . . 0.0 108.07 -179.501 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_exo -45.26 127.96 9.45 Favored 'Trans proline' 0 C--N 1.301 -1.922 0 C-N-CA 122.667 2.245 . . . . 0.0 112.203 -178.9 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.564 ' O ' ' CG ' ' A' ' 60' ' ' HIS . 84.0 mt -91.52 124.65 35.84 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.718 -0.614 . . . . 0.0 109.92 -179.285 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . 0.564 ' CG ' ' O ' ' A' ' 59' ' ' LEU . 86.5 m-70 -162.25 96.35 0.97 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.443 -0.785 . . . . 0.0 109.258 179.833 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 18.5 t80 -57.32 -34.39 68.68 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.174 -0.954 . . . . 0.0 108.708 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 3.1 ttmp? -46.79 161.06 0.07 Allowed 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.612 -0.68 . . . . 0.0 109.706 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 80.5 m-20 62.34 48.82 4.51 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.686 -0.634 . . . . 0.0 110.494 179.8 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.69 ' H ' ' CG2' ' A' ' 171' ' ' VAL . 33.7 t -103.48 144.63 31.15 Favored 'General case' 0 N--CA 1.492 1.642 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 178.76 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 28.6 t -124.05 148.63 46.91 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.096 -1.002 . . . . 0.0 110.309 -179.003 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 32.8 m-85 -87.75 129.99 34.99 Favored 'General case' 0 N--CA 1.491 1.614 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 179.494 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 94.7 m-70 -90.97 -28.58 17.94 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.103 -0.998 . . . . 0.0 110.901 -178.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 48.9 mtp180 -134.34 147.97 50.64 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 120.957 -1.089 . . . . 0.0 110.245 -179.367 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 10.2 m -153.98 64.7 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.503 -0.748 . . . . 0.0 109.205 179.825 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 21.7 mt -86.82 131.79 44.11 Favored Pre-proline 0 C--N 1.301 -1.502 0 O-C-N 121.009 -1.057 . . . . 0.0 109.788 -179.277 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_endo -71.27 147.16 52.75 Favored 'Trans proline' 0 N--CA 1.492 1.401 0 C-N-CA 122.354 2.036 . . . . 0.0 112.288 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 83.62 -58.7 5.01 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.763 -1.335 . . . . 0.0 109.763 179.808 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 95.6 m-85 -69.74 -83.83 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.177 -1.19 . . . . 0.0 109.622 -179.796 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' MET . . . . . 0.403 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 12.6 ptt? 179.05 -173.29 0.17 Allowed 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.278 -0.889 . . . . 0.0 109.68 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 1.2 p -126.34 137.57 53.49 Favored 'General case' 0 N--CA 1.491 1.622 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 179.443 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 91.9 mt-30 -116.73 153.92 31.54 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.256 -0.902 . . . . 0.0 109.735 -179.573 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -163.29 -173.65 32.24 Favored Glycine 0 N--CA 1.488 2.151 0 N-CA-C 109.177 -1.569 . . . . 0.0 109.177 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -160.39 -177.4 33.45 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.717 -1.353 . . . . 0.0 109.717 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.546 ' C ' ' H ' ' A' ' 81' ' ' THR . 83.1 m-20 -66.95 154.93 39.87 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.379 -1.071 . . . . 0.0 109.507 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.558 ' CE1' ' O ' ' A' ' 60' ' ' HIS . 36.5 p90 -58.89 0.24 0.09 Allowed 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.413 -0.804 . . . . 0.0 109.762 -179.856 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.546 ' H ' ' C ' ' A' ' 79' ' ' ASP . 72.4 p -63.85 -32.31 73.78 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.991 -1.068 . . . . 0.0 109.538 -179.706 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . 0.423 ' CB ' ' O ' ' A' ' 81' ' ' THR . . . 169.48 -53.12 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.335 -0.853 . . . . 0.0 109.37 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 86.04 2.8 85.78 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.556 -1.417 . . . . 0.0 109.556 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 39.9 t-20 -85.94 5.91 30.94 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.263 -1.14 . . . . 0.0 109.497 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 100.96 -40.19 2.5 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 -179.776 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 58.9 p -70.75 -27.22 63.79 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.273 -1.134 . . . . 0.0 108.837 179.392 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -86.47 -167.66 43.89 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.184 -1.566 . . . . 0.0 109.184 179.657 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.485 ' N ' ' OG1' ' A' ' 81' ' ' THR . . . 82.25 42.38 8.69 Favored Glycine 0 N--CA 1.489 2.179 0 N-CA-C 109.359 -1.496 . . . . 0.0 109.359 -179.919 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -57.03 143.81 36.79 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.303 -1.116 . . . . 0.0 109.391 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 99.3 p -113.44 147.87 36.98 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.348 -0.845 . . . . 0.0 109.268 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 20.0 pt -74.01 -33.64 36.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.297 -0.877 . . . . 0.0 109.993 -179.837 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . 0.423 ' OH ' ' O ' ' A' ' 37' ' ' ARG . 81.8 m-85 -66.46 -41.14 89.48 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.173 -0.954 . . . . 0.0 109.795 -179.668 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 71.3 9.57 68.14 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.278 -1.529 . . . . 0.0 109.278 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -152.34 160.76 43.27 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.294 -1.121 . . . . 0.0 109.389 -179.758 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 63.7 mttp -83.4 145.85 28.77 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.22 -0.925 . . . . 0.0 109.665 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 52.4 p90 -137.05 160.5 38.78 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.402 -0.811 . . . . 0.0 109.312 179.674 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -104.49 144.23 31.96 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.31 -0.869 . . . . 0.0 109.513 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . 0.523 ' O ' ' OD1' ' A' ' 98' ' ' ASP . 41.9 p30 -79.05 128.98 33.96 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.191 -0.943 . . . . 0.0 109.528 179.873 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -60.65 -37.73 82.49 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.159 -0.963 . . . . 0.0 109.693 -179.643 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 84.4 m-20 -124.42 144.18 50.21 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.251 -0.906 . . . . 0.0 109.849 -179.747 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 48.6 p90 -142.69 19.75 2.01 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.333 -0.854 . . . . 0.0 108.838 179.607 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 84.1 mt -59.47 -34.88 56.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.567 -0.708 . . . . 0.0 110.112 -179.649 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 93.0 mttt -79.65 135.65 36.61 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.069 -1.02 . . . . 0.0 109.768 -179.57 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 25.6 pttm -139.11 -178.69 5.46 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.412 -0.805 . . . . 0.0 109.439 -180.0 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' HIS . . . . . 0.535 ' O ' ' ND1' ' A' ' 105' ' ' HIS . 15.1 t-80 -74.27 88.02 2.0 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.174 -0.954 . . . . 0.0 109.256 179.825 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 58.8 p -75.05 -25.48 58.71 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.312 -0.867 . . . . 0.0 109.774 -179.781 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.533 ' O ' ' CE1' ' A' ' 105' ' ' HIS . . . -164.21 -166.95 23.97 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.397 -1.481 . . . . 0.0 109.397 -179.708 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -76.29 155.82 37.18 Favored 'Trans proline' 0 C--N 1.308 -1.574 0 C-N-CA 122.644 2.229 . . . . 0.0 112.117 179.901 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 88.32 24.29 34.51 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.869 -1.292 . . . . 0.0 109.869 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 36.6 mm -112.27 136.79 47.37 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.267 -1.137 . . . . 0.0 109.379 179.854 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . 0.601 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 2.7 mm? -88.2 132.57 34.3 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.283 -0.886 . . . . 0.0 109.152 179.77 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' SER . . . . . 0.445 ' OG ' ' O ' ' A' ' 140' ' ' VAL . 47.0 t -145.8 139.36 26.34 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.189 -0.944 . . . . 0.0 109.609 179.957 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' MET . . . . . 0.413 ' SD ' ' OD1' ' A' ' 121' ' ' ASN . 71.9 mtm -89.23 139.03 30.9 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.243 -0.91 . . . . 0.0 109.267 179.651 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . 0.572 ' O ' ' ND2' ' A' ' 115' ' ' ASN . . . -60.74 138.31 58.11 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.242 -0.911 . . . . 0.0 109.152 179.983 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . 0.572 ' ND2' ' O ' ' A' ' 114' ' ' ALA . 15.0 m120 -148.81 112.95 5.2 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.173 -0.954 . . . . 0.0 109.19 179.93 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -68.31 -30.12 69.04 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 121.338 -0.851 . . . . 0.0 109.134 179.559 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -138.18 168.98 24.42 Favored Glycine 0 N--CA 1.493 2.451 0 N-CA-C 109.049 -1.621 . . . . 0.0 109.049 179.813 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -67.11 155.06 72.41 Favored 'Trans proline' 0 C--N 1.305 -1.739 0 C-N-CA 122.722 2.281 . . . . 0.0 112.027 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 75.6 m-20 53.99 44.34 29.48 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.448 -0.782 . . . . 0.0 109.432 -179.865 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' THR . . . . . 0.546 ' O ' ' ND2' ' A' ' 115' ' ' ASN . 93.3 m -134.64 127.59 31.45 Favored 'General case' 0 N--CA 1.485 1.322 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 179.832 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 121' ' ' ASN . . . . . 0.413 ' OD1' ' SD ' ' A' ' 113' ' ' MET . 52.2 t30 -98.22 106.43 18.72 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.421 -0.8 . . . . 0.0 109.318 179.794 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -80.96 136.61 16.6 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 83.4 p -64.38 -23.73 67.39 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.268 -1.136 . . . . 0.0 109.442 179.853 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.2 mt-30 -103.73 150.89 23.63 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.267 -0.896 . . . . 0.0 109.675 -179.825 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 51.5 p90 -136.23 162.4 33.08 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.431 -0.793 . . . . 0.0 109.292 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.403 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 48.5 p90 -136.34 156.64 48.35 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.193 -0.942 . . . . 0.0 109.636 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 64.9 mt -122.53 133.1 69.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.449 -0.782 . . . . 0.0 109.189 179.812 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 128' ' ' CYS . . . . . 0.506 ' SG ' ' O ' ' A' ' 130' ' ' ALA . 5.7 t -99.82 118.46 36.33 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.154 -0.966 . . . . 0.0 109.499 179.938 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 64.9 p -95.05 4.12 54.1 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.294 -0.879 . . . . 0.0 109.489 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . 0.506 ' O ' ' SG ' ' A' ' 128' ' ' CYS . . . -147.41 155.82 42.31 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.271 -0.893 . . . . 0.0 109.684 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 51.4 tttp -72.9 137.17 45.45 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.204 -0.935 . . . . 0.0 109.423 179.918 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 7.2 p -122.46 161.49 23.45 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.47 -0.769 . . . . 0.0 109.542 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -104.88 -74.98 0.63 Allowed 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.336 -0.853 . . . . 0.0 109.666 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 134' ' ' TRP . . . . . 0.672 ' CD1' ' N ' ' A' ' 135' ' ' LEU . 45.9 p90 -61.65 -45.8 92.48 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.333 -0.854 . . . . 0.0 110.198 -179.56 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . 0.672 ' N ' ' CD1' ' A' ' 134' ' ' TRP . 13.5 tp -61.28 -32.3 72.13 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.336 -0.852 . . . . 0.0 109.72 -179.348 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 60.4 t0 -56.5 136.61 54.1 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.231 -0.918 . . . . 0.0 109.924 -179.38 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . 0.669 ' H ' ' CD2' ' A' ' 139' ' ' HIS . . . -162.65 -161.15 11.84 Favored Glycine 0 N--CA 1.486 2.009 0 N-CA-C 108.664 -1.774 . . . . 0.0 108.664 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . 0.464 ' O ' ' O ' ' A' ' 139' ' ' HIS . 92.1 mttt -57.21 -41.14 78.86 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.055 -1.262 . . . . 0.0 109.582 179.887 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 139' ' ' HIS . . . . . 0.669 ' CD2' ' H ' ' A' ' 137' ' ' GLY . 66.2 m-70 37.4 94.66 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.58 -0.7 . . . . 0.0 110.428 179.738 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.445 ' O ' ' OG ' ' A' ' 112' ' ' SER . 39.0 t -61.61 132.43 27.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 120.99 -1.069 . . . . 0.0 108.791 179.579 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 82.3 t -111.38 129.0 67.51 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 O-C-N 121.376 -0.828 . . . . 0.0 109.824 -179.45 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 41.9 p90 -116.19 -1.55 12.37 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.511 -0.743 . . . . 0.0 109.505 179.449 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -168.47 172.73 43.08 Favored Glycine 0 N--CA 1.493 2.479 0 N-CA-C 109.861 -1.296 . . . . 0.0 109.861 179.447 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 55.2 tt0 -139.99 160.33 40.18 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.31 -1.112 . . . . 0.0 109.347 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 54.4 t -96.75 131.22 44.04 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.182 0 O-C-N 121.047 -1.033 . . . . 0.0 109.56 -179.759 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 16.4 m -111.0 -28.75 2.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.444 -0.785 . . . . 0.0 109.32 179.472 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -144.42 169.35 18.11 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.326 -0.859 . . . . 0.0 109.448 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 96.2 6.36 58.94 Favored Glycine 0 N--CA 1.494 2.511 0 N-CA-C 109.946 -1.262 . . . . 0.0 109.946 179.519 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 149' ' ' MET . . . . . 0.439 ' O ' HG13 ' A' ' 152' ' ' VAL . 89.0 mtp -59.89 -32.24 70.55 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.165 -1.197 . . . . 0.0 109.8 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -66.67 -42.66 86.2 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.868 -1.145 . . . . 0.0 109.994 -179.542 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 6.2 p -81.36 -34.86 13.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.167 -0.958 . . . . 0.0 110.555 -179.479 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 152' ' ' VAL . . . . . 0.556 ' O ' ' OE1' ' A' ' 156' ' ' GLU . 1.2 p -50.85 -42.39 23.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 120.843 -1.161 . . . . 0.0 108.772 -179.078 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 153' ' ' LYS . . . . . 0.445 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 61.5 mttp -67.39 -32.91 74.14 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.28 -0.887 . . . . 0.0 109.274 179.094 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -61.03 -30.89 70.58 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.469 -0.769 . . . . 0.0 110.396 -179.244 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 89.8 mt -68.54 -37.31 77.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.035 -1.041 . . . . 0.0 110.616 -179.384 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . 0.556 ' OE1' ' O ' ' A' ' 152' ' ' VAL . 42.0 mp0 -80.35 -39.13 29.13 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 120.815 -1.178 . . . . 0.0 111.743 -178.849 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 19.2 pttp -58.3 -37.4 74.97 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 120.455 -1.403 . . . . 0.0 109.161 -178.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 32.1 m -77.99 -15.05 14.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.273 -0.892 . . . . 0.0 108.82 179.163 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -78.9 176.52 54.6 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.719 -1.353 . . . . 0.0 109.719 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 22.7 t -156.46 171.75 19.73 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.31 -1.112 . . . . 0.0 109.288 -179.769 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 22.6 t -54.71 -30.78 56.88 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.13 -0.981 . . . . 0.0 109.224 179.84 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 86.8 p -59.98 -26.56 66.12 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.175 -0.953 . . . . 0.0 109.56 179.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 90.21 17.07 54.5 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 109.828 -1.309 . . . . 0.0 109.828 179.804 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 28.4 ttm180 -119.12 142.56 47.81 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.311 -1.111 . . . . 0.0 109.221 -180.0 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 165' ' ' THR . . . . . . . . . . . . . 82.2 p -79.36 149.14 31.78 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.165 -0.959 . . . . 0.0 109.761 -179.911 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -67.25 -35.62 79.93 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.314 -0.866 . . . . 0.0 109.153 179.686 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 96.6 mttt -117.27 156.93 26.92 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.515 -0.74 . . . . 0.0 109.138 179.918 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 63.9 mttp -68.69 130.74 43.71 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.096 -1.003 . . . . 0.0 109.333 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 34.4 t -122.42 123.36 68.45 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 121.409 -0.807 . . . . 0.0 109.392 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 42.1 t -144.41 141.03 24.27 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.34 -0.85 . . . . 0.0 109.23 179.762 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . 0.69 ' CG2' ' H ' ' A' ' 64' ' ' SER . 4.8 m -65.65 119.29 10.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.103 -0.998 . . . . 0.0 109.296 179.912 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 -70.92 -36.94 72.87 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.033 -1.042 . . . . 0.0 110.621 -179.638 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 173' ' ' ASP . . . . . 0.482 ' OD1' ' N ' ' A' ' 174' ' ' CYS . 52.1 t0 -155.09 161.72 41.21 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.952 -1.092 . . . . 0.0 110.276 -179.184 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 174' ' ' CYS . . . . . 0.482 ' N ' ' OD1' ' A' ' 173' ' ' ASP . 14.8 p -147.36 152.56 38.4 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.398 -0.814 . . . . 0.0 109.224 179.788 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . 178.41 170.81 41.01 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 179.702 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 64.1 tt0 -105.17 119.35 38.82 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.365 -1.08 . . . . 0.0 109.474 179.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 30.8 tp -61.68 -37.97 86.07 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.213 -0.929 . . . . 0.0 109.422 179.87 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 38.7 m . . . . . 0 N--CA 1.489 1.513 0 CA-C-O 118.027 -0.987 . . . . 0.0 109.498 179.988 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.528 4.812 0 N-CA-C 119.393 2.517 . . . . 0.0 119.393 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 45.5 m -62.7 153.92 31.04 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.266 -1.138 . . . . 0.0 109.529 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 99.2 m-85 -112.89 125.24 54.16 Favored 'General case' 0 C--N 1.308 -1.198 0 O-C-N 121.357 -0.839 . . . . 0.0 108.911 179.72 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 11.2 t -135.12 153.3 52.05 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.502 -0.749 . . . . 0.0 109.538 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -61.12 -38.81 96.19 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.838 -1.305 . . . . 0.0 109.838 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 28.4 t -147.45 149.94 33.66 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.178 -1.189 . . . . 0.0 109.58 -179.816 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' MET . . . . . 0.44 ' N ' ' SD ' ' A' ' 7' ' ' MET . 0.2 OUTLIER -60.64 153.48 61.96 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.345 -0.847 . . . . 0.0 109.235 179.841 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -65.02 172.34 7.45 Favored 'Trans proline' 0 C--N 1.308 -1.575 0 C-N-CA 122.686 2.257 . . . . 0.0 112.054 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 16.3 m-80 -63.61 149.01 93.26 Favored Pre-proline 0 N--CA 1.49 1.567 0 O-C-N 121.353 -0.842 . . . . 0.0 109.437 -179.707 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -68.1 140.76 50.54 Favored 'Trans proline' 0 N--CA 1.496 1.627 0 C-N-CA 122.787 2.325 . . . . 0.0 112.501 -179.802 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 55.2 ttt85 -133.0 129.91 38.78 Favored 'General case' 0 N--CA 1.489 1.524 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 179.027 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.7 p -135.22 144.75 33.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.18 -0.95 . . . . 0.0 110.133 -179.006 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 48.6 p90 -136.79 154.47 50.54 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.447 -0.783 . . . . 0.0 109.1 179.752 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.611 ' CE2' ' SG ' ' A' ' 174' ' ' CYS . 86.9 m-85 -121.42 137.49 54.69 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.437 -0.79 . . . . 0.0 109.934 -179.848 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.2 t0 -94.71 115.06 27.06 Favored 'General case' 0 N--CA 1.494 1.748 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 178.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 77.7 mtp -108.35 146.58 32.77 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.198 -0.939 . . . . 0.0 110.826 -178.824 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.472 ' OG ' ' O ' ' A' ' 21' ' ' GLN . 46.8 t -134.25 149.58 50.96 Favored 'General case' 0 N--CA 1.491 1.605 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 179.61 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.418 ' C ' ' N ' ' A' ' 20' ' ' GLY . 35.5 m -112.2 133.96 56.23 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 121.178 -0.951 . . . . 0.0 109.721 -179.664 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 52.95 12.88 1.94 Allowed Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.418 ' N ' ' C ' ' A' ' 18' ' ' VAL . . . 97.11 -10.22 65.62 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.45 -1.46 . . . . 0.0 109.45 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' GLN . . . . . 0.472 ' O ' ' OG ' ' A' ' 17' ' ' SER . 81.4 mt-30 -88.99 149.37 43.19 Favored Pre-proline 0 N--CA 1.49 1.53 0 O-C-N 121.243 -1.151 . . . . 0.0 109.084 179.733 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -62.38 133.89 45.51 Favored 'Trans proline' 0 C--N 1.309 -1.527 0 C-N-CA 122.288 1.992 . . . . 0.0 112.014 -179.772 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -112.33 -65.21 1.2 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.438 -0.789 . . . . 0.0 109.339 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 179.92 -172.28 43.84 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 61.0 ttp180 -119.1 143.08 47.35 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.422 -1.046 . . . . 0.0 109.198 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 82.7 mt -119.8 128.9 75.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.384 -0.823 . . . . 0.0 109.03 179.779 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 39.0 t -116.59 133.78 62.15 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.406 -0.809 . . . . 0.0 109.272 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 72.6 mtm -122.5 152.07 40.7 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.422 -0.798 . . . . 0.0 109.277 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -100.58 131.58 46.41 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.271 -0.893 . . . . 0.0 109.825 -179.626 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.41 ' N ' ' CD2' ' A' ' 30' ' ' LEU . 2.6 mm? -106.12 133.16 51.26 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 179.487 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -96.57 120.81 37.57 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.025 -1.047 . . . . 0.0 109.054 179.459 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -88.02 -41.51 13.06 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.269 -0.895 . . . . 0.0 109.657 -179.809 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -65.28 -42.42 93.2 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.347 -0.846 . . . . 0.0 110.519 -179.214 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 54.6 m -66.32 -44.61 82.88 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.031 -1.043 . . . . 0.0 110.208 -179.324 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.491 ' OG1' ' OG1' ' A' ' 38' ' ' THR . 0.1 OUTLIER -155.67 84.48 3.45 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.261 -0.899 . . . . 0.0 109.301 -179.72 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 1.7 Cg_endo -62.14 -42.07 31.61 Favored 'Trans proline' 0 C--N 1.307 -1.638 0 C-N-CA 122.078 1.852 . . . . 0.0 112.412 -179.245 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 50.1 mtt180 -63.21 -39.54 94.94 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.426 -0.796 . . . . 0.0 110.81 -179.028 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.491 ' OG1' ' OG1' ' A' ' 35' ' ' THR . 75.6 m -63.27 -40.14 96.55 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 120.834 -1.167 . . . . 0.0 109.947 -179.666 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -61.33 -31.56 71.43 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.137 -0.977 . . . . 0.0 109.216 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -67.55 -36.53 81.14 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.303 -0.873 . . . . 0.0 109.885 -179.898 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 45.2 t-20 -57.88 -41.79 83.26 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.219 -0.926 . . . . 0.0 109.85 -179.622 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 98.8 m-85 -87.0 -46.98 9.33 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.106 -0.996 . . . . 0.0 109.804 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . 0.62 ' CZ ' HE22 ' A' ' 176' ' ' GLN . 78.5 ttt180 -57.07 -39.27 74.6 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.363 -0.836 . . . . 0.0 110.147 -179.623 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.437 ' O ' ' N ' ' A' ' 48' ' ' GLY . . . -63.96 -48.24 77.25 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.02 -1.05 . . . . 0.0 110.214 -179.292 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.411 ' N ' ' CD2' ' A' ' 45' ' ' LEU . 4.3 mm? -65.78 -38.93 90.35 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.092 -1.005 . . . . 0.0 109.663 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' CYS . . . . . 0.56 ' SG ' ' SG ' ' A' ' 174' ' ' CYS . 77.7 m -66.01 -47.97 72.73 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.12 -0.988 . . . . 0.0 109.469 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 63.9 p -76.78 -30.78 56.62 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.259 -0.901 . . . . 0.0 109.697 179.733 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . 0.437 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 76.25 31.64 54.32 Favored Glycine 0 N--CA 1.492 2.379 0 N-CA-C 110.214 -1.154 . . . . 0.0 110.214 179.521 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 77.8 mm-40 -62.25 -36.07 80.91 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.944 -1.327 . . . . 0.0 109.573 179.798 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 61.1 mmtt -60.43 -34.03 73.38 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.17 -0.956 . . . . 0.0 109.494 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 76.4 -94.54 1.04 Allowed Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.475 -1.45 . . . . 0.0 109.475 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 31.8 m -118.01 142.46 47.35 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.372 -1.075 . . . . 0.0 109.296 -179.798 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -54.53 -42.43 76.15 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.838 -1.305 . . . . 0.0 109.838 -179.828 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 82.0 mtp180 -147.05 -113.06 0.08 Allowed 'General case' 0 N--CA 1.486 1.364 0 O-C-N 121.172 -1.193 . . . . 0.0 109.265 179.871 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 3.4 m -107.08 -24.72 11.86 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.401 -0.812 . . . . 0.0 109.521 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -144.31 73.23 0.34 Allowed Glycine 0 N--CA 1.493 2.461 0 N-CA-C 109.471 -1.452 . . . . 0.0 109.471 -179.722 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 46.6 tttm -171.46 74.21 0.51 Allowed Pre-proline 0 N--CA 1.489 1.496 0 O-C-N 121.383 -1.069 . . . . 0.0 108.833 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_exo -50.06 128.75 23.08 Favored 'Trans proline' 0 C--N 1.305 -1.76 0 C-N-CA 122.646 2.231 . . . . 0.0 111.977 -179.4 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.525 ' O ' ' CG ' ' A' ' 60' ' ' HIS . 11.5 tp -112.24 118.38 35.14 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.531 -0.731 . . . . 0.0 109.186 -179.593 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . 0.533 ' O ' ' CE1' ' A' ' 80' ' ' PHE . 95.6 m-70 -158.52 140.73 14.07 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.128 -0.983 . . . . 0.0 109.904 -179.952 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 2.4 m-85 -102.17 12.26 37.01 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.254 -0.904 . . . . 0.0 108.851 179.211 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 83.7 mttt -86.73 156.64 19.86 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.383 -0.823 . . . . 0.0 109.619 -179.709 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 54.6 t0 55.8 46.78 21.65 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.401 -0.812 . . . . 0.0 109.454 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 99.4 p -116.85 155.3 29.25 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.411 -0.806 . . . . 0.0 109.301 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 28.6 t -113.16 147.43 37.4 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.362 -0.836 . . . . 0.0 109.323 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.7 m-30 -61.11 142.43 56.7 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.213 -0.929 . . . . 0.0 108.864 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 80.5 t60 -57.29 -50.72 72.03 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.127 -0.983 . . . . 0.0 109.934 -179.206 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.676 HH21 ' NE2' ' A' ' 76' ' ' GLN . 30.1 ptt180 -169.42 160.95 9.61 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.115 -0.99 . . . . 0.0 109.843 179.834 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -136.1 135.37 50.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 179.548 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 75.1 mt -136.61 128.25 16.92 Favored Pre-proline 0 N--CA 1.492 1.667 0 O-C-N 121.309 -0.87 . . . . 0.0 109.349 -179.699 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -75.41 136.74 19.97 Favored 'Trans proline' 0 C--N 1.312 -1.39 0 C-N-CA 122.091 1.86 . . . . 0.0 111.888 179.672 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 94.5 -5.23 70.34 Favored Glycine 0 N--CA 1.492 2.432 0 N-CA-C 109.821 -1.312 . . . . 0.0 109.821 179.705 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 77.6 m-85 -135.13 -94.96 0.27 Allowed 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.211 -1.17 . . . . 0.0 109.677 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' MET . . . . . 0.506 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 6.9 ptt? -170.81 -165.88 0.46 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.172 -0.955 . . . . 0.0 109.464 -179.653 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 15.4 p -132.7 151.61 51.93 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.423 -0.798 . . . . 0.0 109.054 179.741 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' GLN . . . . . 0.676 ' NE2' HH21 ' A' ' 68' ' ' ARG . 94.1 mt-30 -115.72 158.71 22.39 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.372 -0.83 . . . . 0.0 109.63 -179.703 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -140.28 -172.68 12.97 Favored Glycine 0 N--CA 1.494 2.516 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 -179.898 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 95.59 6.33 59.69 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.475 -1.45 . . . . 0.0 109.475 -179.771 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 56.0 t0 -57.44 -25.75 60.13 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.278 -1.131 . . . . 0.0 109.444 179.912 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.533 ' CE1' ' O ' ' A' ' 60' ' ' HIS . 91.3 t80 -49.19 -44.81 43.38 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.378 -0.826 . . . . 0.0 110.151 -179.483 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.658 ' CB ' ' H ' ' A' ' 88' ' ' GLY . 65.0 p -69.85 -29.52 66.78 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 120.989 -1.069 . . . . 0.0 109.487 179.874 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . 0.492 ' CB ' ' O ' ' A' ' 81' ' ' THR . . . 163.3 -55.53 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.344 -0.847 . . . . 0.0 109.244 179.724 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 91.02 1.46 72.84 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 179.884 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . 0.478 ' ND2' ' OG1' ' A' ' 86' ' ' THR . 39.9 p-10 -89.8 7.64 35.96 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.21 -1.171 . . . . 0.0 109.482 -179.931 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 95.8 -38.45 3.11 Favored Glycine 0 N--CA 1.492 2.389 0 N-CA-C 109.246 -1.541 . . . . 0.0 109.246 -179.793 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' THR . . . . . 0.478 ' OG1' ' ND2' ' A' ' 84' ' ' ASN . 56.7 p -73.16 -17.54 61.37 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.235 -1.156 . . . . 0.0 109.027 179.529 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -82.75 -164.82 36.02 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.589 -1.405 . . . . 0.0 109.589 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.658 ' H ' ' CB ' ' A' ' 81' ' ' THR . . . 81.94 47.76 6.07 Favored Glycine 0 N--CA 1.488 2.16 0 N-CA-C 109.264 -1.534 . . . . 0.0 109.264 -179.808 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -83.45 147.0 28.09 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.421 -1.046 . . . . 0.0 109.521 -179.722 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' SER . . . . . 0.432 ' OG ' ' OG ' ' A' ' 123' ' ' SER . 50.5 m -107.84 150.12 27.41 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.485 -0.759 . . . . 0.0 109.275 -179.937 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 5.1 pt -59.6 -40.69 82.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.196 -0.94 . . . . 0.0 109.898 -179.759 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 3.4 m-30 -63.71 -41.42 98.09 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.013 -1.054 . . . . 0.0 109.321 179.733 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 72.58 24.53 76.04 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.719 -1.352 . . . . 0.0 109.719 179.725 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -147.28 153.82 40.22 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.135 -1.214 . . . . 0.0 109.698 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 94.6 mttt -96.73 142.08 29.19 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.361 -0.837 . . . . 0.0 109.552 179.88 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.533 ' CZ ' ' OD1' ' A' ' 121' ' ' ASN . 38.1 p90 -141.07 156.25 46.03 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.322 -0.861 . . . . 0.0 109.42 179.705 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -70.91 145.44 50.16 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.29 -0.881 . . . . 0.0 109.748 -179.699 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 87.8 m-20 -64.16 139.02 58.72 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.17 -0.957 . . . . 0.0 109.153 179.92 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . 0.482 ' O ' ' OD1' ' A' ' 100' ' ' ASN . 97.2 mt-10 -66.06 -41.13 91.21 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.178 -0.951 . . . . 0.0 110.56 -179.093 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . 0.482 ' OD1' ' O ' ' A' ' 99' ' ' GLU . 83.2 m-20 -149.96 149.16 29.99 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 120.948 -1.095 . . . . 0.0 110.466 -179.582 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -110.75 9.93 22.67 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.849 -0.797 . . . . 0.0 108.849 179.152 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 91.2 mt -54.97 -37.5 42.16 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.408 -0.807 . . . . 0.0 110.583 -179.069 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 57.0 mttm -76.52 134.46 39.46 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 120.899 -1.125 . . . . 0.0 109.63 -179.495 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 39.8 tttp -138.43 159.14 42.82 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.471 -0.768 . . . . 0.0 109.308 -179.735 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' HIS . . . . . 0.491 ' C ' ' ND1' ' A' ' 105' ' ' HIS . 6.8 t-80 -85.46 108.94 18.13 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.195 -0.941 . . . . 0.0 109.282 179.936 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 68.2 p -123.49 2.42 9.01 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.22 -0.925 . . . . 0.0 109.91 -179.888 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -155.05 175.06 33.19 Favored Glycine 0 N--CA 1.492 2.416 0 N-CA-C 109.818 -1.313 . . . . 0.0 109.818 -179.834 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -79.78 157.62 24.48 Favored 'Trans proline' 0 C--N 1.307 -1.617 0 C-N-CA 123.112 2.541 . . . . 0.0 112.142 179.714 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 78.11 45.17 10.5 Favored Glycine 0 N--CA 1.493 2.47 0 N-CA-C 109.678 -1.369 . . . . 0.0 109.678 179.604 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.72 137.33 50.92 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.378 -1.072 . . . . 0.0 109.754 -179.825 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . 0.541 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 2.8 mm? -91.11 129.76 37.07 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.283 -0.886 . . . . 0.0 109.097 179.439 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 29.1 t -142.43 143.6 32.71 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.188 -0.945 . . . . 0.0 109.486 179.954 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 72.2 mtm -89.33 133.31 34.54 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.161 -0.962 . . . . 0.0 109.334 179.839 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -64.98 142.35 58.47 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.18 -0.95 . . . . 0.0 109.311 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . 0.525 ' ND2' ' O ' ' A' ' 117' ' ' GLY . 53.2 t-20 -143.04 153.16 42.67 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.204 -0.935 . . . . 0.0 109.85 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . 0.471 ' N ' ' OD1' ' A' ' 115' ' ' ASN . . . -123.91 -12.31 7.54 Favored 'General case' 0 N--CA 1.493 1.688 0 N-CA-C 108.836 -0.802 . . . . 0.0 108.836 179.624 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . 0.525 ' O ' ' ND2' ' A' ' 115' ' ' ASN . . . -145.52 166.34 27.75 Favored Glycine 0 N--CA 1.493 2.472 0 N-CA-C 109.236 -1.545 . . . . 0.0 109.236 179.934 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -70.74 152.28 64.1 Favored 'Trans proline' 0 C--N 1.306 -1.696 0 C-N-CA 122.72 2.28 . . . . 0.0 112.108 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 76.2 m-20 52.98 41.62 32.14 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.473 -0.767 . . . . 0.0 109.502 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' THR . . . . . 0.52 ' O ' ' ND2' ' A' ' 115' ' ' ASN . 62.2 m -138.75 125.79 21.27 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.339 -0.851 . . . . 0.0 109.223 179.771 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 121' ' ' ASN . . . . . 0.533 ' OD1' ' CZ ' ' A' ' 96' ' ' PHE . 28.7 m120 -106.32 121.89 45.13 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.532 -0.73 . . . . 0.0 109.383 179.844 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -93.6 132.85 11.4 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.669 -1.372 . . . . 0.0 109.669 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' SER . . . . . 0.432 ' OG ' ' OG ' ' A' ' 90' ' ' SER . 18.8 m -58.83 -33.66 70.65 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.29 -1.123 . . . . 0.0 109.399 179.773 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.3 mt-30 -68.97 145.29 53.73 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.372 -0.83 . . . . 0.0 109.636 -179.793 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 48.8 p90 -135.66 162.54 32.45 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.408 -0.808 . . . . 0.0 109.133 179.83 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.506 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 48.9 p90 -136.51 157.1 47.57 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.176 -0.953 . . . . 0.0 109.775 -179.927 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 68.3 mt -120.9 136.54 57.56 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.506 -0.746 . . . . 0.0 109.288 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 23.0 t -115.95 126.74 54.27 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.269 -0.894 . . . . 0.0 109.416 179.881 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 129' ' ' THR . . . . . 0.436 ' OG1' ' OE1' ' A' ' 156' ' ' GLU . 28.0 p -102.51 11.17 38.27 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.353 -0.842 . . . . 0.0 109.511 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -140.39 163.29 33.2 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.306 -0.871 . . . . 0.0 109.431 -179.775 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 71.9 mmtt -67.51 138.29 56.44 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.252 -0.905 . . . . 0.0 109.205 -179.946 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 61.6 p -150.18 85.29 1.4 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.295 -0.878 . . . . 0.0 109.534 -179.868 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -62.82 -36.09 82.05 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.278 -0.889 . . . . 0.0 109.85 -179.895 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 0.9 OUTLIER -64.76 -46.3 82.74 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.125 -0.984 . . . . 0.0 109.515 -179.892 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 18.1 mt -65.83 -32.4 73.9 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.232 -0.918 . . . . 0.0 109.611 179.266 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . 0.445 ' OD2' ' O ' ' A' ' 105' ' ' HIS . 60.9 t0 -79.71 119.65 22.93 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.308 -0.87 . . . . 0.0 109.71 -179.816 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 165.57 -100.54 0.17 Allowed Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 62.5 mttp -57.45 -36.16 71.05 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.294 -1.121 . . . . 0.0 109.825 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 78.0 m80 -65.04 150.22 48.48 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.338 -0.851 . . . . 0.0 109.705 -179.501 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 49.8 t -123.33 144.7 32.02 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 121.542 -0.724 . . . . 0.0 109.423 -179.739 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 61.7 t -92.45 130.58 41.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.293 -0.879 . . . . 0.0 109.857 -179.548 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 40.2 p90 -112.98 -3.11 14.1 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.445 -0.784 . . . . 0.0 109.328 179.624 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -168.19 177.35 42.37 Favored Glycine 0 N--CA 1.492 2.402 0 N-CA-C 109.169 -1.572 . . . . 0.0 109.169 179.796 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.2 pt20 -146.61 166.94 25.0 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.075 -1.25 . . . . 0.0 109.741 -179.744 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 75.0 t -96.45 129.7 46.14 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.283 0 O-C-N 121.266 -0.896 . . . . 0.0 109.389 -179.843 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 15.8 m -105.65 -33.92 2.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.339 -0.851 . . . . 0.0 109.723 179.756 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -142.45 169.17 18.08 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.274 -0.891 . . . . 0.0 109.689 -179.75 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 95.89 7.97 58.36 Favored Glycine 0 N--CA 1.493 2.47 0 N-CA-C 109.929 -1.269 . . . . 0.0 109.929 179.612 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 149' ' ' MET . . . . . 0.408 ' O ' HG13 ' A' ' 152' ' ' VAL . 64.9 mtt -60.34 -34.05 73.29 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.155 -1.203 . . . . 0.0 109.776 179.989 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 89.1 m-20 -65.03 -42.33 94.46 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 120.865 -1.147 . . . . 0.0 110.03 -179.553 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.6 p -82.44 -32.09 10.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.21 -0.932 . . . . 0.0 110.653 -179.263 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 152' ' ' VAL . . . . . 0.43 ' CG1' ' N ' ' A' ' 153' ' ' LYS . 0.8 OUTLIER -55.58 -40.67 60.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 120.833 -1.167 . . . . 0.0 109.008 -179.332 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 153' ' ' LYS . . . . . 0.43 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 67.0 mttm -62.92 -36.46 83.46 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.132 -0.98 . . . . 0.0 108.999 179.396 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -62.45 -35.08 78.16 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.305 -0.872 . . . . 0.0 109.414 179.825 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 93.6 mt -67.35 -12.79 15.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.513 -0.742 . . . . 0.0 109.808 179.9 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . 0.436 ' OE1' ' OG1' ' A' ' 129' ' ' THR . 86.2 tt0 -118.55 -19.48 8.76 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 -179.617 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . 0.403 ' N ' ' O ' ' A' ' 153' ' ' LYS . 38.9 tttm -58.83 -42.18 88.63 Favored 'General case' 0 C--N 1.299 -1.597 0 CA-C-O 121.376 0.608 . . . . 0.0 109.743 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 16.5 m -83.75 -12.56 11.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.533 -0.729 . . . . 0.0 109.25 179.449 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -59.97 151.98 37.0 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.941 -1.264 . . . . 0.0 109.941 -179.729 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 27.0 t -143.27 158.31 43.73 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.505 -0.997 . . . . 0.0 109.255 179.917 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 22.9 t -54.1 -33.85 58.73 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.151 -0.968 . . . . 0.0 109.307 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 24.5 m -57.75 -29.47 64.82 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.321 -0.862 . . . . 0.0 109.401 179.682 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 100.52 1.05 55.48 Favored Glycine 0 N--CA 1.493 2.45 0 N-CA-C 109.263 -1.535 . . . . 0.0 109.263 -179.656 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 72.2 ttt-85 -108.16 149.98 27.83 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.477 -1.013 . . . . 0.0 108.933 179.666 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 165' ' ' THR . . . . . . . . . . . . . 69.8 p -117.05 155.51 29.12 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.272 -0.892 . . . . 0.0 110.104 -179.582 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -70.14 -37.29 75.23 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.578 -0.702 . . . . 0.0 109.694 179.776 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 53.9 mttm -109.56 152.6 25.28 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.359 -0.838 . . . . 0.0 109.928 -179.392 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 63.7 mttm -87.95 151.33 22.88 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.404 -0.81 . . . . 0.0 109.43 179.911 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 34.5 m -125.7 127.61 71.59 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 121.247 -0.908 . . . . 0.0 109.744 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 43.4 t -146.63 145.91 19.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.245 -0.909 . . . . 0.0 109.196 179.722 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -88.15 120.95 37.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.111 -0.993 . . . . 0.0 109.479 -179.727 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -62.69 -28.59 70.04 Favored 'General case' 0 C--N 1.3 -1.586 0 N-CA-C 108.901 -0.777 . . . . 0.0 108.901 179.489 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 52.0 p30 -178.67 170.15 1.62 Allowed 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.383 -0.823 . . . . 0.0 110.202 -179.881 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 174' ' ' CYS . . . . . 0.611 ' SG ' ' CE2' ' A' ' 14' ' ' PHE . 54.1 t -139.43 134.98 33.12 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.529 -0.732 . . . . 0.0 109.062 179.356 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -150.67 169.25 30.52 Favored Glycine 0 N--CA 1.493 2.496 0 N-CA-C 109.738 -1.345 . . . . 0.0 109.738 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 176' ' ' GLN . . . . . 0.62 HE22 ' CZ ' ' A' ' 43' ' ' ARG . 63.9 tt0 -108.52 122.75 47.71 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.453 -1.028 . . . . 0.0 109.497 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -63.72 -38.59 91.67 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.23 -0.919 . . . . 0.0 108.908 179.714 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 27.0 t . . . . . 0 N--CA 1.49 1.526 0 O-C-N 121.027 -1.046 . . . . 0.0 109.455 179.872 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.529 4.837 0 N-CA-C 119.426 2.53 . . . . 0.0 119.426 . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 29.5 t -118.91 142.41 47.78 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.351 -1.088 . . . . 0.0 109.414 179.966 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 73.2 t80 -107.86 116.52 32.1 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.444 -0.785 . . . . 0.0 109.018 179.634 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 66.1 p -112.18 10.71 20.22 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.674 -0.641 . . . . 0.0 109.769 -179.801 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.55 12.36 62.85 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 -179.779 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 24.2 m -58.18 -32.98 68.75 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.337 -1.096 . . . . 0.0 109.642 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 12.5 mmt -122.07 79.83 42.99 Favored Pre-proline 0 N--CA 1.493 1.702 0 O-C-N 121.316 -0.865 . . . . 0.0 109.619 -179.732 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 89.6 Cg_endo -80.79 168.28 17.74 Favored 'Trans proline' 0 C--N 1.308 -1.557 0 C-N-CA 122.837 2.358 . . . . 0.0 112.115 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -66.9 149.39 98.46 Favored Pre-proline 0 N--CA 1.492 1.632 0 O-C-N 121.254 -0.904 . . . . 0.0 109.332 -179.843 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -68.1 139.69 47.35 Favored 'Trans proline' 0 N--CA 1.497 1.706 0 C-N-CA 122.713 2.276 . . . . 0.0 112.464 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 82.3 mtp180 -132.28 134.47 45.31 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.419 -0.8 . . . . 0.0 108.869 179.071 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.8 p -135.29 143.49 36.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 O-C-N 121.256 -0.903 . . . . 0.0 109.539 -179.652 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 42.8 p90 -138.95 155.61 47.9 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.321 -0.862 . . . . 0.0 109.459 179.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.61 ' CE2' ' SG ' ' A' ' 174' ' ' CYS . 76.4 m-85 -122.13 137.87 54.67 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.451 -0.781 . . . . 0.0 109.697 179.883 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 22.8 t70 -88.04 117.02 26.63 Favored 'General case' 0 N--CA 1.493 1.719 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 179.123 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 83.3 mtp -104.63 143.87 32.48 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.342 -0.849 . . . . 0.0 110.713 -179.044 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.463 ' OG ' ' OE2' ' A' ' 172' ' ' GLU . 61.9 m -141.43 159.3 42.51 Favored 'General case' 0 N--CA 1.49 1.551 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 179.383 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 33.1 m -123.58 147.95 27.77 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.179 -0.95 . . . . 0.0 109.756 -179.759 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 49.09 -107.75 0.33 Allowed Glycine 0 N--CA 1.488 2.113 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.925 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -128.83 25.83 4.62 Favored Glycine 0 N--CA 1.494 2.53 0 N-CA-C 109.631 -1.387 . . . . 0.0 109.631 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 10.7 pt20 -141.58 149.5 54.15 Favored Pre-proline 0 N--CA 1.493 1.714 0 O-C-N 121.3 -1.118 . . . . 0.0 109.29 179.846 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -67.57 138.43 45.64 Favored 'Trans proline' 0 N--CA 1.494 1.544 0 C-N-CA 122.504 2.136 . . . . 0.0 112.108 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -101.72 -54.29 2.77 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.411 -0.806 . . . . 0.0 109.216 179.713 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -176.02 -171.25 39.67 Favored Glycine 0 N--CA 1.488 2.156 0 N-CA-C 109.317 -1.513 . . . . 0.0 109.317 -179.916 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 33.0 ptt180 -131.1 148.57 52.75 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.482 -1.011 . . . . 0.0 109.138 179.73 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 82.8 mt -122.91 130.11 74.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.318 -0.864 . . . . 0.0 109.248 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 42.0 t -111.0 132.63 58.97 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.491 -0.756 . . . . 0.0 109.222 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 74.1 mtm -120.88 146.93 46.08 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.439 -0.788 . . . . 0.0 109.18 -179.894 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -101.13 131.12 47.23 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.294 -0.879 . . . . 0.0 109.794 -179.718 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.418 ' N ' ' CD2' ' A' ' 30' ' ' LEU . 2.5 mm? -106.2 131.67 53.17 Favored 'General case' 0 N--CA 1.493 1.693 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 179.512 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 95.4 m-85 -98.4 118.29 34.74 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.215 -0.928 . . . . 0.0 109.024 179.572 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -80.68 -42.82 21.38 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.341 -0.85 . . . . 0.0 109.771 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -64.7 -45.89 84.67 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.293 -0.879 . . . . 0.0 110.311 -179.328 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 26.4 m -67.8 -45.13 75.67 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.121 -0.987 . . . . 0.0 109.835 -179.57 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.496 ' O ' ' OG1' ' A' ' 35' ' ' THR . 4.6 p -142.67 81.4 13.37 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 121.282 -0.886 . . . . 0.0 109.325 -179.75 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -64.27 -58.29 0.26 Allowed 'Trans proline' 0 N--CA 1.494 1.537 0 C-N-CA 122.283 1.989 . . . . 0.0 112.582 -179.347 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 78.4 mtp180 -62.03 -37.11 83.68 Favored 'General case' 0 C--N 1.299 -1.602 0 O-C-N 121.428 -0.795 . . . . 0.0 110.647 -179.132 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 28.1 m -61.91 -41.34 97.81 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.87 -1.144 . . . . 0.0 109.981 -179.542 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -61.3 -31.23 71.07 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.11 -0.994 . . . . 0.0 109.311 -179.739 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.406 ' O ' ' CB ' ' A' ' 44' ' ' ALA . 97.0 mt-10 -66.69 -35.34 79.91 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.351 -0.843 . . . . 0.0 109.885 -179.862 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 88.6 m-20 -55.98 -37.29 68.87 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.256 -0.903 . . . . 0.0 109.85 -179.688 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -97.67 -53.29 3.47 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.221 -0.925 . . . . 0.0 110.024 -179.852 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 59.7 ttp180 -57.94 -42.74 85.54 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.329 -0.857 . . . . 0.0 110.605 -179.179 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.508 ' O ' ' N ' ' A' ' 48' ' ' GLY . . . -67.73 -44.67 77.05 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.904 -1.123 . . . . 0.0 110.305 -179.181 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.5 ' N ' ' CD2' ' A' ' 45' ' ' LEU . 2.5 mm? -65.74 -40.51 92.19 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.004 -1.06 . . . . 0.0 109.7 -179.801 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' CYS . . . . . 0.405 ' SG ' ' SG ' ' A' ' 174' ' ' CYS . 72.0 m -67.63 -49.54 62.47 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.067 -1.02 . . . . 0.0 109.334 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 57.5 p -74.46 -32.0 62.43 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.397 -0.814 . . . . 0.0 109.38 179.755 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . 0.508 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 75.85 33.63 50.46 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 110.217 -1.153 . . . . 0.0 110.217 179.457 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -62.23 -37.66 86.22 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.99 -1.3 . . . . 0.0 109.423 179.78 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 54.6 mmtt -61.94 -34.12 75.52 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.275 -0.89 . . . . 0.0 109.349 179.934 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 92.53 172.48 41.27 Favored Glycine 0 N--CA 1.486 2.012 0 N-CA-C 109.239 -1.544 . . . . 0.0 109.239 -179.677 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 89.3 m -73.85 140.73 45.95 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.322 -1.105 . . . . 0.0 109.833 179.966 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -57.62 136.17 50.99 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.284 -1.527 . . . . 0.0 109.284 179.829 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 75.6 mtm180 -59.25 -34.11 71.85 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.243 -1.151 . . . . 0.0 110.017 -179.647 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 86.6 p -61.0 -24.82 66.44 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.102 -0.999 . . . . 0.0 109.942 -179.699 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 112.74 90.45 1.89 Allowed Glycine 0 N--CA 1.494 2.507 0 N-CA-C 109.109 -1.596 . . . . 0.0 109.109 -179.696 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . 0.583 ' HZ3' ' CB ' ' A' ' 57' ' ' LYS . 3.0 ttmp? -175.25 80.73 0.31 Allowed Pre-proline 0 N--CA 1.489 1.502 0 O-C-N 121.479 -1.012 . . . . 0.0 108.448 -179.708 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 69.7 Cg_exo -51.18 132.33 38.5 Favored 'Trans proline' 0 C--N 1.303 -1.847 0 C-N-CA 122.942 2.428 . . . . 0.0 112.848 -179.05 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.531 ' CD1' ' O ' ' A' ' 57' ' ' LYS . 7.6 mp -101.09 127.39 47.64 Favored 'General case' 0 N--CA 1.493 1.7 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 179.811 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 6.1 p80 -176.14 132.4 0.24 Allowed 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.094 -1.004 . . . . 0.0 109.86 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 4.4 m-85 -96.95 13.34 29.23 Favored 'General case' 0 N--CA 1.492 1.65 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 179.091 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 85.8 mttt -77.46 149.77 35.01 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.416 -0.802 . . . . 0.0 109.639 -179.765 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 46.4 t0 61.4 35.03 17.99 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.581 -0.699 . . . . 0.0 109.618 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.799 ' H ' ' CG2' ' A' ' 171' ' ' VAL . 55.3 p -83.94 160.08 21.15 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.278 -0.889 . . . . 0.0 108.808 179.094 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 31.3 t -128.58 147.96 50.75 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.168 -0.957 . . . . 0.0 109.57 -179.776 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 22.3 m-85 -72.25 130.12 40.06 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.258 -0.901 . . . . 0.0 109.296 179.86 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 79.4 t60 -61.79 -48.99 78.12 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.16 -0.962 . . . . 0.0 109.481 -179.88 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 37.1 ptt180 -164.71 159.74 19.08 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.27 -0.894 . . . . 0.0 109.678 179.671 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 23.0 m -132.51 148.46 31.8 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 179.539 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 11.5 mt -146.79 125.07 6.17 Favored Pre-proline 0 N--CA 1.494 1.735 0 O-C-N 120.956 -1.09 . . . . 0.0 109.576 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -75.34 135.36 18.37 Favored 'Trans proline' 0 N--CA 1.491 1.34 0 C-N-CA 122.264 1.976 . . . . 0.0 112.117 179.667 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 89.67 1.56 77.19 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.686 -1.365 . . . . 0.0 109.686 179.795 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 95.3 m-85 -134.25 -96.09 0.28 Allowed 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.359 -1.083 . . . . 0.0 109.558 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' MET . . . . . 0.6 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 5.9 ptt? -166.67 158.85 13.5 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.047 -1.033 . . . . 0.0 109.686 -179.659 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 1.7 m -98.45 123.35 42.54 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.417 -0.802 . . . . 0.0 109.008 179.402 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 63.6 tt0 -98.87 125.91 44.39 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.276 -0.89 . . . . 0.0 109.811 -179.584 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -84.85 -174.06 50.16 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 179.599 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -137.59 155.52 23.1 Favored Glycine 0 N--CA 1.494 2.513 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.435 ' OD2' ' OG ' ' A' ' 123' ' ' SER . 87.7 m-20 -77.02 150.5 35.8 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.226 -1.161 . . . . 0.0 109.502 179.93 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 40.8 p90 -64.85 -22.87 67.07 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.142 -0.974 . . . . 0.0 109.443 -179.856 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 58.9 p -67.11 -30.98 71.15 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.294 -0.879 . . . . 0.0 109.52 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 176.77 -56.44 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.314 -0.866 . . . . 0.0 109.328 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 96.12 -10.69 67.76 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 78.7 m-20 -89.15 3.22 52.61 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.177 -1.19 . . . . 0.0 109.323 179.813 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 95.19 -5.54 68.26 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.404 -1.479 . . . . 0.0 109.404 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 64.5 p -72.79 -21.98 60.9 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.245 -1.15 . . . . 0.0 109.41 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -125.32 -123.5 2.71 Favored Glycine 0 N--CA 1.494 2.53 0 N-CA-C 109.384 -1.486 . . . . 0.0 109.384 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 75.6 42.01 27.9 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 179.896 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -79.7 146.55 32.36 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.369 -1.077 . . . . 0.0 109.439 -179.883 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 50.8 m -108.86 148.61 30.35 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.384 -0.822 . . . . 0.0 109.265 -179.83 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 15.8 pt -62.6 -39.42 84.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.295 -0.878 . . . . 0.0 109.948 -179.62 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 73.6 m-85 -68.0 -37.26 81.24 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.112 -0.993 . . . . 0.0 109.578 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 78.14 14.66 82.03 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 -179.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -148.87 158.48 44.2 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.238 -1.154 . . . . 0.0 109.588 -179.825 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 42.7 mttm -85.3 149.51 25.41 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.238 -0.914 . . . . 0.0 109.596 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.538 ' CE1' ' OD1' ' A' ' 121' ' ' ASN . 55.1 p90 -137.12 161.21 36.76 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.268 -0.895 . . . . 0.0 109.453 179.696 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -102.78 148.33 25.75 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.295 -0.878 . . . . 0.0 109.394 -179.785 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 89.3 m-20 -68.41 133.13 48.19 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.264 -0.897 . . . . 0.0 109.352 -179.897 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -66.26 -37.49 85.59 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.235 -0.916 . . . . 0.0 110.134 -179.731 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 86.9 m-20 -126.68 125.15 41.37 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.224 -0.922 . . . . 0.0 110.098 -179.477 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' PHE . . . . . 0.536 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 69.3 t80 -103.11 5.3 37.84 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.318 -0.864 . . . . 0.0 108.886 179.351 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 91.0 mt -57.19 -34.69 46.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.397 -0.814 . . . . 0.0 110.545 -179.187 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 91.7 mttt -72.55 135.08 45.52 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.808 -1.182 . . . . 0.0 109.951 -179.358 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 10.4 ptpp? -139.89 -179.05 5.72 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.435 -0.791 . . . . 0.0 109.382 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' HIS . . . . . 0.523 ' CE1' ' O ' ' A' ' 107' ' ' GLY . 82.3 t60 -84.33 77.6 9.96 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.149 -0.969 . . . . 0.0 109.165 179.872 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 54.6 p -75.5 -27.83 58.94 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.324 -0.86 . . . . 0.0 110.154 -179.581 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.523 ' O ' ' CE1' ' A' ' 105' ' ' HIS . . . -149.14 177.78 27.12 Favored Glycine 0 N--CA 1.494 2.517 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 -179.581 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -72.74 155.18 54.17 Favored 'Trans proline' 0 C--N 1.307 -1.65 0 C-N-CA 122.991 2.461 . . . . 0.0 112.314 179.792 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 82.6 47.0 6.15 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 110.138 -1.185 . . . . 0.0 110.138 179.588 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 41.8 mm -115.7 138.09 47.24 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.819 0 O-C-N 121.302 -1.116 . . . . 0.0 109.628 179.857 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . 0.418 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 3.7 mm? -89.15 126.72 35.59 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.267 -0.895 . . . . 0.0 109.216 179.627 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' SER . . . . . 0.435 ' OG ' ' O ' ' A' ' 140' ' ' VAL . 38.9 t -142.72 142.15 31.91 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.334 -0.854 . . . . 0.0 109.509 179.863 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER -91.55 141.27 28.9 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.319 -0.863 . . . . 0.0 109.174 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . 0.521 ' O ' ' N ' ' A' ' 122' ' ' GLY . . . -63.49 147.31 51.7 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.267 -0.896 . . . . 0.0 109.594 179.986 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . 0.42 ' OD1' ' O ' ' A' ' 114' ' ' ALA . 65.6 m-20 -137.23 112.72 9.35 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.332 -0.855 . . . . 0.0 109.002 179.612 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -72.23 -32.03 66.37 Favored 'General case' 0 C--N 1.294 -1.811 0 O-C-N 121.466 -0.771 . . . . 0.0 109.432 179.807 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -148.49 176.08 27.46 Favored Glycine 0 N--CA 1.492 2.393 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 179.848 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . 0.43 ' O ' ' CG ' ' A' ' 119' ' ' ASN . 71.6 Cg_exo -50.31 148.03 15.17 Favored 'Trans proline' 0 C--N 1.304 -1.786 0 C-N-CA 122.604 2.203 . . . . 0.0 112.903 179.855 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 119' ' ' ASN . . . . . 0.43 ' CG ' ' O ' ' A' ' 118' ' ' PRO . 7.0 p-10 41.83 49.04 3.9 Favored 'General case' 0 N--CA 1.494 1.751 0 CA-C-O 121.135 0.493 . . . . 0.0 110.11 179.451 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 87.9 m -131.38 124.9 31.31 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.308 -0.87 . . . . 0.0 109.004 179.55 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 121' ' ' ASN . . . . . 0.538 ' OD1' ' CE1' ' A' ' 96' ' ' PHE . 25.4 m120 -101.93 119.1 38.25 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.535 -0.728 . . . . 0.0 109.237 179.768 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . 0.521 ' N ' ' O ' ' A' ' 114' ' ' ALA . . . -84.41 142.2 20.21 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.719 -1.352 . . . . 0.0 109.719 -179.751 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 123' ' ' SER . . . . . 0.435 ' OG ' ' OD2' ' A' ' 79' ' ' ASP . 88.1 p -64.26 -22.83 67.09 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.367 -1.078 . . . . 0.0 109.337 179.739 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 92.9 mt-30 -95.12 151.61 19.06 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.296 -0.878 . . . . 0.0 109.511 -179.873 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 49.3 p90 -134.79 161.57 34.83 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.364 -0.835 . . . . 0.0 109.428 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.6 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 54.1 p90 -138.94 158.88 43.41 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.33 -0.856 . . . . 0.0 109.547 -179.955 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 72.6 mt -121.31 130.75 74.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.435 -0.791 . . . . 0.0 109.486 179.758 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 1.6 m -93.25 105.74 17.78 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.273 -0.892 . . . . 0.0 108.89 179.663 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 60.0 p -75.49 -7.05 53.14 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.379 -0.826 . . . . 0.0 109.711 -179.713 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -149.21 156.28 41.9 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.158 -0.964 . . . . 0.0 109.741 -179.769 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 55.7 tttp -69.38 141.27 54.18 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.212 -0.93 . . . . 0.0 109.236 179.808 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 20.7 p -114.66 153.95 29.28 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.397 -0.814 . . . . 0.0 109.604 -179.858 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . 0.423 ' O ' ' CG ' ' A' ' 136' ' ' ASP . 92.6 mt-10 -106.23 -73.49 0.68 Allowed 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.385 -0.822 . . . . 0.0 109.925 -179.925 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 134' ' ' TRP . . . . . 0.524 ' CD1' ' N ' ' A' ' 135' ' ' LEU . 42.8 p90 -56.03 -36.74 68.32 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.265 -0.897 . . . . 0.0 110.109 -179.535 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . 0.524 ' N ' ' CD1' ' A' ' 134' ' ' TRP . 6.9 tp -74.6 4.04 6.79 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.251 -0.906 . . . . 0.0 109.559 -179.327 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . 0.452 ' C ' ' OD1' ' A' ' 136' ' ' ASP . 53.5 p30 -67.36 167.29 12.77 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.99 -1.069 . . . . 0.0 109.569 -179.941 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 148.96 -134.0 4.77 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.17 -1.572 . . . . 0.0 109.17 -179.909 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 13.7 mptt -91.76 128.84 37.75 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.208 -1.172 . . . . 0.0 109.018 179.647 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 139' ' ' HIS . . . . . 0.459 ' O ' ' CE1' ' A' ' 101' ' ' PHE . 98.4 m-70 -135.72 152.61 51.32 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.287 -0.883 . . . . 0.0 109.647 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.435 ' O ' ' OG ' ' A' ' 112' ' ' SER . 24.5 m -127.73 149.82 33.02 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 121.351 -0.843 . . . . 0.0 109.022 179.573 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 46.1 t -132.08 125.81 55.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.272 -0.892 . . . . 0.0 109.763 -180.0 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 47.1 p90 -109.64 3.01 20.61 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.446 -0.784 . . . . 0.0 108.932 178.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -178.11 178.6 48.55 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.024 -1.63 . . . . 0.0 109.024 179.562 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.3 pt20 -145.95 166.68 25.3 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.09 -1.241 . . . . 0.0 109.614 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 69.7 t -97.04 128.37 48.33 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.245 0 O-C-N 121.21 -0.931 . . . . 0.0 109.4 -179.719 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 15.9 m -103.83 -32.01 2.91 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 O-C-N 121.421 -0.799 . . . . 0.0 109.395 179.588 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -143.45 170.07 16.49 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.329 -0.857 . . . . 0.0 109.407 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 96.55 5.13 59.08 Favored Glycine 0 N--CA 1.493 2.475 0 N-CA-C 109.909 -1.276 . . . . 0.0 109.909 179.61 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 149' ' ' MET . . . . . 0.419 ' O ' HG12 ' A' ' 152' ' ' VAL . 97.0 mmm -60.18 -32.22 70.86 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.144 -1.209 . . . . 0.0 109.458 179.778 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -65.36 -41.71 93.52 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.899 -1.125 . . . . 0.0 110.106 -179.548 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 6.7 p -80.96 -33.26 13.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 120.987 -1.07 . . . . 0.0 110.707 -179.279 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 152' ' ' VAL . . . . . 0.439 ' CG1' ' N ' ' A' ' 153' ' ' LYS . 1.0 OUTLIER -51.92 -41.08 29.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 120.84 -1.162 . . . . 0.0 108.998 -179.264 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 153' ' ' LYS . . . . . 0.439 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 66.8 mttm -65.68 -33.38 75.75 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.214 -0.929 . . . . 0.0 109.214 179.213 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -60.63 -37.23 80.79 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.489 -0.757 . . . . 0.0 109.942 -179.42 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 88.4 mt -70.52 -37.63 70.75 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.524 0 O-C-N 121.156 -0.965 . . . . 0.0 110.066 -179.687 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -77.06 -41.16 43.53 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.196 -0.94 . . . . 0.0 111.556 -178.39 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . 0.425 ' HG2' ' HZ2' ' A' ' 157' ' ' LYS . 16.7 pttm -59.91 -35.4 74.8 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 120.57 -1.331 . . . . 0.0 109.735 -178.763 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 31.5 m -81.1 -10.39 12.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.041 -1.037 . . . . 0.0 109.017 179.395 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -71.95 165.61 53.84 Favored Glycine 0 N--CA 1.488 2.16 0 N-CA-C 110.056 -1.217 . . . . 0.0 110.056 -179.623 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 24.1 t -154.52 167.87 28.63 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.506 -0.996 . . . . 0.0 109.482 -179.858 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 24.8 m -54.46 -29.89 51.17 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.292 -0.88 . . . . 0.0 109.194 179.827 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 22.8 t -54.26 -30.79 51.8 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.307 -0.871 . . . . 0.0 109.506 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 95.41 12.22 54.5 Favored Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.817 -1.313 . . . . 0.0 109.817 179.916 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 42.1 ttp180 -125.78 143.67 50.96 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.298 -1.119 . . . . 0.0 109.467 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 165' ' ' THR . . . . . . . . . . . . . 71.5 p -74.63 151.28 39.35 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.094 -1.004 . . . . 0.0 109.326 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -66.31 -37.93 86.53 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.154 -0.967 . . . . 0.0 109.52 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 67.1 mttm -108.94 156.96 19.1 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.432 -0.792 . . . . 0.0 109.4 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 48.1 mtmt -72.53 130.61 41.04 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.205 -0.934 . . . . 0.0 109.268 179.816 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 25.0 t -124.75 124.14 67.35 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 O-C-N 121.434 -0.791 . . . . 0.0 109.427 -179.888 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 57.5 t -144.33 137.05 22.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.271 -0.893 . . . . 0.0 109.499 179.668 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . 0.799 ' CG2' ' H ' ' A' ' 64' ' ' SER . 27.0 m -71.31 126.32 31.44 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.251 -0.905 . . . . 0.0 109.487 179.746 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 172' ' ' GLU . . . . . 0.49 ' O ' ' OD1' ' A' ' 173' ' ' ASP . 96.3 mt-10 -69.84 -40.72 75.65 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.077 -1.014 . . . . 0.0 109.901 179.855 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 173' ' ' ASP . . . . . 0.49 ' OD1' ' O ' ' A' ' 172' ' ' GLU . 49.7 m-20 -163.91 167.67 20.36 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.219 -0.925 . . . . 0.0 110.218 -179.641 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 174' ' ' CYS . . . . . 0.61 ' SG ' ' CE2' ' A' ' 14' ' ' PHE . 43.7 t -136.51 140.82 43.29 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.581 -0.7 . . . . 0.0 109.306 179.597 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -154.94 173.34 33.29 Favored Glycine 0 N--CA 1.493 2.491 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 179.907 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 63.8 tt0 -104.48 119.25 38.56 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.343 -1.092 . . . . 0.0 109.526 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 34.5 tp -61.83 -38.24 87.45 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.203 -0.936 . . . . 0.0 109.575 179.897 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 8.7 t . . . . . 0 N--CA 1.488 1.454 0 O-C-N 121.094 -1.004 . . . . 0.0 109.454 -179.964 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.528 4.785 0 N-CA-C 119.379 2.512 . . . . 0.0 119.379 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 89.5 p -62.53 -23.5 67.0 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.236 -1.155 . . . . 0.0 109.537 179.91 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 46.7 p90 -140.27 164.43 30.1 Favored 'General case' 0 C--N 1.308 -1.23 0 N-CA-C 108.515 -0.92 . . . . 0.0 108.515 179.683 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 49.5 m -110.65 138.15 47.41 Favored 'General case' 0 C--N 1.295 -1.77 0 O-C-N 121.689 -0.632 . . . . 0.0 109.444 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 179.69 -174.04 45.72 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.413 -1.475 . . . . 0.0 109.413 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 29.8 t -117.66 139.09 51.48 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.337 -1.096 . . . . 0.0 109.395 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' MET . . . . . 0.586 ' N ' ' SD ' ' A' ' 7' ' ' MET . 2.4 mpp? -75.4 152.13 85.6 Favored Pre-proline 0 N--CA 1.491 1.604 0 O-C-N 121.361 -0.837 . . . . 0.0 109.191 179.908 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -69.49 168.64 20.62 Favored 'Trans proline' 0 C--N 1.311 -1.446 0 C-N-CA 122.636 2.224 . . . . 0.0 111.961 179.816 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 16.4 m120 -69.78 148.05 96.44 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.274 -0.891 . . . . 0.0 109.443 -179.873 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -70.21 141.68 44.03 Favored 'Trans proline' 0 N--CA 1.496 1.634 0 C-N-CA 122.769 2.313 . . . . 0.0 112.244 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 59.2 mtm180 -127.89 134.52 49.38 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.376 -0.827 . . . . 0.0 108.902 179.294 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 9.6 p -136.21 144.36 33.31 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.389 -0.819 . . . . 0.0 109.309 -179.701 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 48.3 p90 -138.1 153.89 49.26 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.342 -0.849 . . . . 0.0 109.477 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 88.7 m-85 -121.28 136.36 54.98 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.568 -0.707 . . . . 0.0 109.735 179.755 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -93.62 131.4 38.94 Favored 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 179.228 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' MET . . . . . 0.424 ' SD ' ' CD1' ' A' ' 26' ' ' ILE . 74.2 mtp -125.45 153.24 43.79 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.118 -0.989 . . . . 0.0 110.282 -179.386 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 85.2 p -143.78 161.05 39.62 Favored 'General case' 0 N--CA 1.488 1.463 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 179.718 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.431 ' C ' ' H ' ' A' ' 20' ' ' GLY . 33.0 m -126.32 137.49 57.62 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.105 -0.997 . . . . 0.0 109.534 -179.925 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 53.43 11.62 1.84 Allowed Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 179.848 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.431 ' H ' ' C ' ' A' ' 18' ' ' VAL . . . 95.6 -1.39 63.89 Favored Glycine 0 N--CA 1.493 2.465 0 N-CA-C 109.779 -1.328 . . . . 0.0 109.779 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 2.6 mp0 -99.93 152.09 37.7 Favored Pre-proline 0 N--CA 1.495 1.806 0 O-C-N 121.229 -1.159 . . . . 0.0 109.149 179.876 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -61.66 138.52 75.58 Favored 'Trans proline' 0 C--N 1.308 -1.558 0 C-N-CA 122.581 2.187 . . . . 0.0 112.15 -179.83 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -111.69 -64.18 1.32 Allowed 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.441 -0.787 . . . . 0.0 109.471 179.893 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -179.9 -168.75 39.12 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.414 -1.475 . . . . 0.0 109.414 -179.882 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 79.7 mtm180 -114.37 142.18 46.67 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.381 -1.07 . . . . 0.0 109.759 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.424 ' CD1' ' SD ' ' A' ' 16' ' ' MET . 80.2 mt -122.93 121.1 62.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 179.11 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 40.2 t -120.85 134.6 63.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.469 -0.769 . . . . 0.0 109.27 -179.808 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 72.6 mtm -122.44 154.81 37.28 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.405 -0.809 . . . . 0.0 109.349 -179.845 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -100.85 132.0 46.47 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.347 -0.845 . . . . 0.0 109.968 -179.611 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -107.48 128.93 54.93 Favored 'General case' 0 N--CA 1.493 1.717 0 N-CA-C 108.914 -0.772 . . . . 0.0 108.914 179.318 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -98.04 119.66 37.08 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.189 -0.944 . . . . 0.0 109.058 179.661 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -78.84 -40.16 33.47 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.318 -0.864 . . . . 0.0 110.047 -179.623 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.531 ' OD1' ' N ' ' A' ' 34' ' ' THR . 31.6 p-10 -68.72 -40.79 79.75 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.258 -0.902 . . . . 0.0 110.859 -179.093 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' THR . . . . . 0.531 ' N ' ' OD1' ' A' ' 33' ' ' ASP . 17.4 m -67.51 -44.56 78.15 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.018 -1.051 . . . . 0.0 109.834 -179.4 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 38.2 p -154.03 83.99 4.16 Favored Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.385 -0.822 . . . . 0.0 109.018 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -70.53 -40.84 3.75 Favored 'Trans proline' 0 C--N 1.309 -1.544 0 C-N-CA 122.085 1.856 . . . . 0.0 112.333 -179.212 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 1.5 mpt_? -63.71 -40.95 98.04 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.168 -0.958 . . . . 0.0 109.667 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 38.3 m -66.16 -41.52 90.24 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.19 -0.944 . . . . 0.0 110.004 -179.755 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -60.66 -32.39 71.58 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.174 -0.953 . . . . 0.0 109.032 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -68.05 -38.23 82.24 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.433 -0.792 . . . . 0.0 109.735 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 46.4 t30 -58.23 -41.41 84.07 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.248 -0.908 . . . . 0.0 109.935 -179.436 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . 0.494 ' O ' ' SG ' ' A' ' 46' ' ' CYS . 97.4 m-85 -86.15 -41.08 15.02 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.047 -1.033 . . . . 0.0 110.108 -179.664 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 61.3 ttp180 -59.14 -44.42 92.05 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.229 -0.919 . . . . 0.0 110.937 -178.925 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -71.17 -46.09 62.11 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 120.945 -1.097 . . . . 0.0 110.259 -179.271 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.498 ' N ' ' CD2' ' A' ' 45' ' ' LEU . 2.3 mm? -65.3 -38.13 89.26 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.164 -0.96 . . . . 0.0 109.69 -179.711 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' CYS . . . . . 0.494 ' SG ' ' O ' ' A' ' 42' ' ' PHE . 73.8 m -71.12 -50.5 32.82 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.098 -1.001 . . . . 0.0 109.576 -179.895 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 30.9 m -63.92 -36.72 84.89 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.329 -0.857 . . . . 0.0 109.589 -179.933 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 95.59 8.24 58.52 Favored Glycine 0 N--CA 1.493 2.46 0 N-CA-C 109.838 -1.305 . . . . 0.0 109.838 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 78.1 mm-40 -61.25 -32.24 72.04 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.238 -1.154 . . . . 0.0 109.526 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 20.9 tptp -58.25 -38.97 77.94 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.255 -0.903 . . . . 0.0 109.482 -179.11 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 90.65 171.45 43.75 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 110.018 -1.233 . . . . 0.0 110.018 179.558 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.555 ' O ' ' O ' ' A' ' 53' ' ' GLY . 81.7 m -79.08 148.44 32.42 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.585 -0.95 . . . . 0.0 109.479 179.925 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.555 ' O ' ' O ' ' A' ' 52' ' ' THR . . . -54.93 -122.36 0.01 OUTLIER Glycine 0 N--CA 1.492 2.389 0 N-CA-C 110.036 -1.226 . . . . 0.0 110.036 -179.839 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . 0.537 ' O ' ' CB ' ' A' ' 55' ' ' SER . 93.0 mtt180 -57.5 -41.15 80.2 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 120.971 -1.311 . . . . 0.0 109.766 -179.498 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' SER . . . . . 0.537 ' CB ' ' O ' ' A' ' 54' ' ' ARG . 1.1 t 157.72 -26.86 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.724 0 N-CA-C 108.574 -0.898 . . . . 0.0 108.574 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -119.06 59.94 0.51 Allowed Glycine 0 N--CA 1.493 2.442 0 N-CA-C 109.169 -1.572 . . . . 0.0 109.169 179.926 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 36.4 tptt -172.05 70.97 0.45 Allowed Pre-proline 0 C--N 1.302 -1.474 0 O-C-N 121.447 -1.031 . . . . 0.0 108.56 -179.768 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 92.1 Cg_exo -42.9 94.8 0.02 OUTLIER 'Trans proline' 0 C--N 1.304 -1.766 0 C-N-CA 122.743 2.295 . . . . 0.0 112.202 -179.405 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.484 ' O ' ' CD1' ' A' ' 45' ' ' LEU . 8.2 tp -73.65 54.61 0.48 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.581 -0.699 . . . . 0.0 109.276 -179.731 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 40.5 m80 -138.39 150.63 46.72 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.252 -0.905 . . . . 0.0 109.603 -179.753 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 -67.28 -9.1 37.4 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.233 -0.917 . . . . 0.0 109.26 179.369 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 64.0 tttt -49.18 151.3 1.41 Allowed 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.319 -0.863 . . . . 0.0 109.841 -179.881 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 59.67 47.76 10.18 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.616 -0.677 . . . . 0.0 110.03 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 62.2 p -115.78 151.06 35.91 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.353 -0.842 . . . . 0.0 109.01 179.202 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 29.4 t -126.46 148.61 49.64 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.346 -0.846 . . . . 0.0 109.594 -179.694 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.8 m-85 -70.99 135.34 47.79 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.252 -0.905 . . . . 0.0 109.084 179.958 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' HIS . . . . . 0.501 ' HE2' ' CG ' ' A' ' 79' ' ' ASP . 95.8 m-70 -97.02 -29.99 13.33 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.243 -0.911 . . . . 0.0 110.425 -179.58 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 98.6 mtt180 -134.35 139.95 46.0 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.092 -1.005 . . . . 0.0 110.254 -179.457 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 14.5 m -148.4 42.35 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.497 -0.752 . . . . 0.0 108.973 179.401 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 25.7 mt -76.94 132.84 70.38 Favored Pre-proline 0 C--N 1.301 -1.53 0 O-C-N 121.227 -0.921 . . . . 0.0 109.692 -178.926 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -69.93 145.6 56.66 Favored 'Trans proline' 0 N--CA 1.491 1.363 0 C-N-CA 122.213 1.942 . . . . 0.0 112.154 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 84.63 -54.44 4.92 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.636 -1.386 . . . . 0.0 109.636 179.905 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 83.7 m-85 -69.67 -80.6 0.05 OUTLIER 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.201 -1.176 . . . . 0.0 109.763 -179.905 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 12.9 ptt? 179.37 -179.04 0.38 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.092 -1.005 . . . . 0.0 109.741 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' CYS . . . . . 0.455 ' SG ' ' O ' ' A' ' 127' ' ' ILE . 0.8 OUTLIER -131.8 126.79 35.24 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.499 -0.751 . . . . 0.0 109.068 179.689 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 49.5 tt0 -98.14 137.57 36.71 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.342 -0.849 . . . . 0.0 109.331 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -151.94 -177.72 25.94 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.726 -1.35 . . . . 0.0 109.726 -179.887 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 78.6 56.92 3.46 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.639 -1.384 . . . . 0.0 109.639 -179.925 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.501 ' CG ' ' HE2' ' A' ' 67' ' ' HIS . 59.2 t0 -69.46 90.63 0.54 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.147 -1.208 . . . . 0.0 108.983 -179.96 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 68.3 t80 -61.19 -49.4 77.33 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.371 -0.83 . . . . 0.0 109.803 -179.623 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.533 ' HG1' ' H ' ' A' ' 82' ' ' ALA . 6.6 p -153.2 -98.78 0.05 OUTLIER 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.164 -0.96 . . . . 0.0 109.418 179.828 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . 0.533 ' H ' ' HG1' ' A' ' 81' ' ' THR . . . -86.37 -64.08 1.21 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.326 -0.859 . . . . 0.0 109.664 -179.899 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 98.48 -15.11 61.54 Favored Glycine 0 N--CA 1.493 2.438 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 -179.857 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 86.5 m-20 -63.5 -31.82 73.1 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.27 -1.135 . . . . 0.0 108.858 179.477 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 152.61 -33.3 0.83 Allowed Glycine 0 N--CA 1.489 2.216 0 N-CA-C 108.7 -1.76 . . . . 0.0 108.7 -179.691 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 55.0 p -78.1 -28.75 48.73 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.393 -1.063 . . . . 0.0 109.102 179.532 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -88.18 -171.07 46.33 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 179.854 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.449 ' CA ' ' OG ' ' A' ' 123' ' ' SER . . . 78.77 46.3 8.67 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 179.905 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -88.73 141.1 28.79 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.205 -1.173 . . . . 0.0 109.451 -179.82 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 92.9 p -107.13 159.32 16.41 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.471 -0.768 . . . . 0.0 109.395 -179.931 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 19.5 pt -59.55 -32.11 48.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.268 -0.895 . . . . 0.0 109.51 -179.805 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 76.5 m-85 -66.33 -24.08 66.47 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.165 -0.959 . . . . 0.0 109.436 179.903 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 76.05 -97.79 1.17 Allowed Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.089 -1.604 . . . . 0.0 109.089 -179.614 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -59.74 147.85 36.37 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.319 -1.106 . . . . 0.0 109.019 179.643 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 9.2 mtmp? -72.27 156.33 39.24 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.417 -0.802 . . . . 0.0 109.418 -179.744 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 36.2 p90 -128.6 160.7 31.57 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.437 -0.789 . . . . 0.0 109.484 -179.818 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -61.52 142.59 56.96 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.292 -0.88 . . . . 0.0 110.123 -179.23 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 88.5 m-20 -70.24 151.42 45.36 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.226 -0.921 . . . . 0.0 109.615 179.772 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -94.93 164.73 12.78 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.324 -0.86 . . . . 0.0 109.185 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 81.5 m-20 -58.26 153.23 15.65 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.226 -0.922 . . . . 0.0 109.444 -179.765 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' PHE . . . . . 0.584 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 21.9 p90 -132.43 80.79 1.92 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.293 -0.879 . . . . 0.0 109.451 -179.853 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 87.4 mt -59.47 -34.38 54.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.248 -0.908 . . . . 0.0 109.378 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 63.3 mttp -85.77 145.21 27.34 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.232 -0.917 . . . . 0.0 109.385 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . 0.482 ' O ' ' N ' ' A' ' 106' ' ' THR . 19.8 pttm -134.66 -178.91 5.28 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.374 -0.829 . . . . 0.0 109.501 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' HIS . . . . . 0.445 ' HE2' ' CB ' ' A' ' 139' ' ' HIS . 96.5 m-70 -65.02 72.45 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.25 -0.906 . . . . 0.0 109.667 -179.971 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' THR . . . . . 0.545 ' O ' ' NZ ' ' A' ' 131' ' ' LYS . 68.7 p -70.82 -27.45 63.89 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.141 -0.974 . . . . 0.0 109.682 179.946 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -152.97 176.56 31.04 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 109.342 -1.503 . . . . 0.0 109.342 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -72.64 153.97 54.49 Favored 'Trans proline' 0 C--N 1.307 -1.638 0 C-N-CA 122.889 2.393 . . . . 0.0 112.095 179.821 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 82.28 49.27 5.31 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 179.632 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 39.1 mm -115.2 138.4 45.63 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 121.333 -1.098 . . . . 0.0 109.498 179.938 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . 0.508 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 2.9 mm? -89.57 126.93 35.8 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.297 -0.877 . . . . 0.0 109.595 179.84 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' SER . . . . . 0.441 ' OG ' ' O ' ' A' ' 140' ' ' VAL . 37.4 t -143.61 139.0 29.42 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.365 -0.835 . . . . 0.0 109.098 179.624 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 88.5 mtp -81.13 137.13 35.96 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.117 -0.989 . . . . 0.0 109.499 -179.821 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . 0.459 ' O ' ' OD1' ' A' ' 115' ' ' ASN . . . -64.14 142.44 58.41 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.281 -0.887 . . . . 0.0 109.604 -179.865 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . 0.459 ' OD1' ' O ' ' A' ' 114' ' ' ALA . 73.6 m-20 -146.84 114.0 6.22 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.313 -0.867 . . . . 0.0 108.854 179.569 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -68.2 -35.6 78.25 Favored 'General case' 0 C--N 1.298 -1.641 0 O-C-N 121.312 -0.867 . . . . 0.0 109.559 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -150.89 165.59 30.22 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.263 -1.535 . . . . 0.0 109.263 179.823 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_exo -47.14 153.13 1.72 Allowed 'Trans proline' 0 C--N 1.308 -1.585 0 C-N-CA 122.611 2.207 . . . . 0.0 112.826 179.831 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 18.9 m120 54.89 46.46 24.37 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.73 -0.606 . . . . 0.0 109.635 179.695 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 120' ' ' THR . . . . . 0.43 ' O ' ' OD1' ' A' ' 115' ' ' ASN . 58.5 m -135.39 124.45 24.32 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.316 -0.865 . . . . 0.0 109.099 179.857 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 23.1 t-20 -104.38 107.94 19.11 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.511 -0.743 . . . . 0.0 109.123 179.646 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -87.84 128.39 9.01 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.772 -1.331 . . . . 0.0 109.772 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 123' ' ' SER . . . . . 0.449 ' OG ' ' CA ' ' A' ' 88' ' ' GLY . 87.3 p -64.32 -23.43 67.29 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.366 -1.079 . . . . 0.0 109.343 179.719 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.4 mt-30 -92.65 153.25 19.09 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.302 -0.874 . . . . 0.0 109.562 -179.869 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 54.4 p90 -134.3 161.62 34.45 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.368 -0.832 . . . . 0.0 109.185 179.881 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 49.0 p90 -134.45 156.41 48.62 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.335 -0.853 . . . . 0.0 109.649 -179.854 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.455 ' O ' ' SG ' ' A' ' 75' ' ' CYS . 77.1 mt -122.2 134.11 66.46 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.453 -0.779 . . . . 0.0 109.556 179.928 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 128' ' ' CYS . . . . . 0.515 ' SG ' ' O ' ' A' ' 130' ' ' ALA . 3.9 t -97.92 112.92 24.66 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.177 -0.952 . . . . 0.0 109.087 179.346 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 41.3 p -80.36 -5.1 55.85 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.308 -0.87 . . . . 0.0 109.856 -179.469 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . 0.515 ' O ' ' SG ' ' A' ' 128' ' ' CYS . . . -147.5 161.64 40.67 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.19 -0.944 . . . . 0.0 109.669 -179.626 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . 0.545 ' NZ ' ' O ' ' A' ' 106' ' ' THR . 63.6 mttm -76.56 140.8 41.23 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.194 -0.941 . . . . 0.0 109.299 179.898 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 6.3 p -125.11 158.93 32.64 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.437 -0.789 . . . . 0.0 109.258 -179.918 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -101.98 -74.92 0.61 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.204 -0.935 . . . . 0.0 109.956 -179.81 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 134' ' ' TRP . . . . . 0.581 ' CD1' ' N ' ' A' ' 135' ' ' LEU . 41.7 p90 -61.13 -46.93 88.57 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.21 -0.931 . . . . 0.0 109.999 -179.452 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . 0.581 ' N ' ' CD1' ' A' ' 134' ' ' TRP . 32.9 tp -61.63 -33.83 74.61 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.252 -0.905 . . . . 0.0 109.446 -179.819 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 23.5 t70 -76.5 119.03 19.78 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.258 -0.901 . . . . 0.0 109.645 -179.812 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -153.18 -129.87 1.44 Allowed Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.075 -1.61 . . . . 0.0 109.075 179.879 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 47.3 mmtm -86.99 114.43 23.59 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.212 -1.17 . . . . 0.0 108.966 179.659 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 139' ' ' HIS . . . . . 0.445 ' CB ' ' HE2' ' A' ' 105' ' ' HIS . 98.0 m-70 -138.25 165.69 26.07 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.427 -0.795 . . . . 0.0 109.474 -179.858 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.441 ' O ' ' OG ' ' A' ' 112' ' ' SER . 48.1 t -113.58 132.6 62.04 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 121.356 -0.84 . . . . 0.0 109.274 179.845 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 61.4 t -112.69 129.07 68.95 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 121.272 -0.893 . . . . 0.0 109.308 179.826 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 40.0 p90 -115.76 2.2 13.6 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.334 -0.854 . . . . 0.0 109.725 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -176.26 179.69 47.2 Favored Glycine 0 N--CA 1.493 2.447 0 N-CA-C 109.771 -1.332 . . . . 0.0 109.771 179.64 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 2.6 pt20 -145.21 167.83 21.85 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.309 -1.112 . . . . 0.0 109.449 -179.89 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 55.4 t -96.34 130.16 45.39 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 O-C-N 121.157 -0.964 . . . . 0.0 109.576 -179.866 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 15.6 m -109.29 -33.25 2.43 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 121.323 -0.861 . . . . 0.0 109.409 179.558 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -142.14 171.1 14.52 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.324 -0.86 . . . . 0.0 109.483 179.914 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 98.71 1.96 57.46 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 109.858 -1.297 . . . . 0.0 109.858 179.674 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 149' ' ' MET . . . . . . . . . . . . . 72.0 mtm -61.09 -33.76 73.85 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.049 -1.265 . . . . 0.0 109.539 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 56.2 t0 -63.85 -42.6 97.54 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 120.945 -1.097 . . . . 0.0 109.993 -179.713 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.4 p -82.98 -34.49 11.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.152 -0.968 . . . . 0.0 110.547 -179.532 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 152' ' ' VAL . . . . . 0.459 ' CG1' ' N ' ' A' ' 153' ' ' LYS . 0.6 OUTLIER -56.83 -41.93 76.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 120.896 -1.127 . . . . 0.0 109.289 -179.301 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 153' ' ' LYS . . . . . 0.459 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 46.6 mtpt -63.02 -34.28 77.23 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.186 -0.946 . . . . 0.0 109.424 179.459 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -62.13 -39.47 92.66 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.345 -0.847 . . . . 0.0 109.935 -179.559 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 89.2 mt -72.5 -34.86 49.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.162 -0.962 . . . . 0.0 110.042 -179.824 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -76.71 -41.44 45.24 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.153 -0.967 . . . . 0.0 111.182 -178.881 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 16.9 pttp -62.31 -33.59 74.97 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 120.824 -1.173 . . . . 0.0 109.931 -178.846 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 35.1 m -78.3 -10.41 12.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.023 -1.048 . . . . 0.0 109.262 179.662 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -75.52 174.46 52.36 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.743 -1.343 . . . . 0.0 109.743 -179.772 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 22.6 t -161.7 174.54 13.11 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.328 -1.101 . . . . 0.0 109.448 -179.802 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 23.6 m -54.83 -32.03 60.04 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.205 -0.934 . . . . 0.0 109.233 179.813 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 23.5 m -55.72 -33.18 64.0 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.263 -0.898 . . . . 0.0 109.577 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 94.61 10.09 58.23 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.726 -1.35 . . . . 0.0 109.726 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 16.3 tpt180 -116.98 142.69 46.63 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.426 -1.043 . . . . 0.0 109.058 179.833 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 165' ' ' THR . . . . . . . . . . . . . 68.0 p -80.21 151.52 29.63 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.229 -0.92 . . . . 0.0 109.579 -179.808 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -68.39 -35.69 78.05 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.337 -0.852 . . . . 0.0 109.104 179.476 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 93.6 mttt -112.0 159.31 18.56 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.531 -0.731 . . . . 0.0 109.283 179.925 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -72.7 132.74 44.06 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.31 -0.869 . . . . 0.0 109.411 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 42.7 t -121.35 126.14 74.58 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.233 -0.917 . . . . 0.0 109.634 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 43.2 t -147.56 151.22 13.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.334 -0.854 . . . . 0.0 109.302 179.769 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 2.7 t -87.93 125.57 41.43 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 C-N-CA 119.708 -0.797 . . . . 0.0 109.854 -179.271 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 172' ' ' GLU . . . . . 0.423 ' O ' ' HB3' ' A' ' 173' ' ' ASP . 97.3 mt-10 -65.62 -30.82 71.58 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.379 -0.826 . . . . 0.0 109.097 179.509 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 173' ' ' ASP . . . . . 0.425 ' C ' ' OD1' ' A' ' 173' ' ' ASP . 53.0 p30 177.73 -177.78 0.21 Allowed 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.335 -0.853 . . . . 0.0 110.093 -179.864 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 28.5 p -154.04 150.4 28.19 Favored 'General case' 0 N--CA 1.49 1.571 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 179.476 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -172.17 178.46 44.33 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 176' ' ' GLN . . . . . 0.436 ' OE1' ' OG ' ' A' ' 178' ' ' SER . 7.0 tt0 -106.04 124.17 49.15 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.463 -1.022 . . . . 0.0 109.75 -179.954 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 28.9 tp -62.29 -37.97 87.57 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.202 -0.936 . . . . 0.0 109.382 179.604 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 178' ' ' SER . . . . . 0.436 ' OG ' ' OE1' ' A' ' 176' ' ' GLN . 4.5 p . . . . . 0 N--CA 1.491 1.596 0 CA-C-O 117.994 -1.003 . . . . 0.0 109.497 -179.91 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.527 4.751 0 N-CA-C 119.449 2.539 . . . . 0.0 119.449 . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' SER . . . . . 0.482 ' OG ' ' CD2' ' A' ' 3' ' ' PHE . 87.3 p -62.18 -25.82 67.99 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.255 -1.144 . . . . 0.0 109.453 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.482 ' CD2' ' OG ' ' A' ' 2' ' ' SER . 99.5 m-85 -124.62 154.29 40.94 Favored 'General case' 0 C--N 1.308 -1.23 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 179.712 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 57.6 p -66.66 -16.82 64.48 Favored 'General case' 0 C--N 1.291 -1.939 0 O-C-N 121.605 -0.684 . . . . 0.0 109.525 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 68.19 -122.09 14.89 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.611 -1.396 . . . . 0.0 109.611 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 54.7 p -66.24 162.14 20.64 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.233 -1.157 . . . . 0.0 109.573 -179.916 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' MET . . . . . 0.518 ' N ' ' SD ' ' A' ' 7' ' ' MET . 1.3 mpt? -63.85 154.37 81.28 Favored Pre-proline 0 N--CA 1.489 1.517 0 O-C-N 121.37 -0.831 . . . . 0.0 109.275 -179.933 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -49.36 -26.15 11.29 Favored 'Trans proline' 0 C--N 1.311 -1.427 0 C-N-CA 122.237 1.958 . . . . 0.0 112.205 179.841 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 11.1 m120 -142.32 152.38 60.64 Favored Pre-proline 0 N--CA 1.492 1.671 0 O-C-N 121.312 -0.867 . . . . 0.0 109.389 -179.948 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -65.93 141.85 66.4 Favored 'Trans proline' 0 N--CA 1.496 1.663 0 C-N-CA 122.822 2.348 . . . . 0.0 112.206 179.828 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 98.5 mtt180 -128.73 133.22 48.06 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.373 -0.829 . . . . 0.0 108.887 179.237 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.0 p -136.52 142.97 36.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.725 0 O-C-N 121.333 -0.854 . . . . 0.0 109.626 -179.783 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' PHE . . . . . 0.462 ' CZ ' ' NH2' ' A' ' 25' ' ' ARG . 43.0 p90 -140.41 154.28 46.63 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.285 -0.884 . . . . 0.0 109.468 -179.998 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -127.83 140.06 52.26 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.424 -0.797 . . . . 0.0 109.584 179.836 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 87.9 m-20 -91.44 132.94 35.89 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.263 -0.898 . . . . 0.0 108.91 179.368 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 65.6 mtp -124.72 153.53 42.25 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.198 -0.939 . . . . 0.0 110.259 -179.459 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 63.2 p -149.4 165.99 30.42 Favored 'General case' 0 N--CA 1.49 1.538 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 179.741 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 24.0 m -125.54 133.88 68.11 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 121.25 -0.906 . . . . 0.0 109.544 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 54.75 17.08 8.37 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 179.797 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 92.33 4.55 66.22 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 33.7 mt-30 -105.58 111.57 64.77 Favored Pre-proline 0 N--CA 1.493 1.711 0 O-C-N 121.349 -1.089 . . . . 0.0 109.255 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 65.8 Cg_exo -48.35 135.23 25.84 Favored 'Trans proline' 0 N--CA 1.493 1.47 0 C-N-CA 122.171 1.914 . . . . 0.0 112.173 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -104.82 -57.73 1.99 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.42 -0.8 . . . . 0.0 109.417 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -171.55 -171.68 36.89 Favored Glycine 0 N--CA 1.488 2.118 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 -179.856 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . 0.462 ' NH2' ' CZ ' ' A' ' 13' ' ' PHE . 77.6 ttt180 -114.35 143.93 44.09 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.377 -1.072 . . . . 0.0 109.367 179.947 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 83.2 mt -119.62 127.95 75.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.4 -0.812 . . . . 0.0 109.029 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 43.5 t -117.44 133.45 64.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.444 -0.785 . . . . 0.0 109.571 -179.773 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 73.2 mtm -121.35 150.49 41.38 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.423 -0.798 . . . . 0.0 109.03 179.699 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -101.89 131.15 48.42 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.253 -0.904 . . . . 0.0 109.997 -179.512 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.404 ' N ' ' CD2' ' A' ' 30' ' ' LEU . 2.8 mm? -109.59 130.15 55.53 Favored 'General case' 0 N--CA 1.493 1.701 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 179.357 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -97.77 118.26 33.91 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.039 -1.038 . . . . 0.0 108.981 179.427 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -79.6 -43.18 23.4 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.403 -0.811 . . . . 0.0 109.844 -179.739 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 57.6 t0 -65.25 -51.6 59.8 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.196 -0.94 . . . . 0.0 110.037 -179.301 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 49.4 m -67.86 -42.1 81.86 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.196 -0.94 . . . . 0.0 109.712 -179.871 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -137.34 80.37 33.84 Favored Pre-proline 0 N--CA 1.492 1.666 0 O-C-N 121.437 -0.789 . . . . 0.0 109.19 -179.73 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -70.83 -65.82 0.03 OUTLIER 'Trans proline' 0 C--N 1.308 -1.577 0 C-N-CA 122.579 2.186 . . . . 0.0 112.93 -179.601 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 62.7 mtp180 -61.5 -38.39 87.17 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.393 -0.817 . . . . 0.0 110.708 -179.036 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 36.9 m -62.49 -42.41 99.48 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 120.972 -1.08 . . . . 0.0 109.881 -179.691 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -62.65 -30.9 71.71 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.198 -0.939 . . . . 0.0 108.771 179.566 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.429 ' OE1' ' OH ' ' A' ' 92' ' ' TYR . 84.6 tt0 -65.65 -36.23 83.07 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.461 -0.774 . . . . 0.0 109.492 179.784 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 48.7 t-20 -58.59 -42.98 89.33 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.317 -0.864 . . . . 0.0 109.414 -179.794 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . 0.42 ' CE2' ' CE2' ' A' ' 142' ' ' PHE . 90.6 m-85 -80.63 -45.34 17.41 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.31 -0.869 . . . . 0.0 109.625 179.886 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 61.9 ttp180 -57.31 -42.37 81.68 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.261 -0.899 . . . . 0.0 109.533 -179.769 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.505 ' O ' ' N ' ' A' ' 48' ' ' GLY . . . -68.41 -36.35 78.98 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.262 -0.899 . . . . 0.0 109.528 179.975 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 51.7 tp -60.36 -36.18 77.43 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.176 -0.953 . . . . 0.0 109.529 -179.702 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' CYS . . . . . . . . . . . . . 96.8 m -65.83 -59.73 3.58 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.212 -0.93 . . . . 0.0 110.068 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 57.3 p -74.97 -38.71 61.61 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.12 -0.988 . . . . 0.0 109.987 -179.761 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . 0.505 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 71.98 7.3 66.14 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.183 -1.567 . . . . 0.0 109.183 -179.842 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 22.4 pt-20 -72.63 -16.91 61.71 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.451 -1.029 . . . . 0.0 110.033 -179.726 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 44.7 tptt -56.22 -38.61 71.26 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.166 -0.959 . . . . 0.0 109.739 -179.393 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 173.23 -173.23 45.62 Favored Glycine 0 N--CA 1.49 2.245 0 C-N-CA 119.664 -1.255 . . . . 0.0 110.03 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.53 ' O ' ' C ' ' A' ' 53' ' ' GLY . 82.5 m -120.57 145.89 46.88 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.673 -0.899 . . . . 0.0 109.266 179.946 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.53 ' C ' ' O ' ' A' ' 52' ' ' THR . . . -30.74 -73.9 0.05 OUTLIER Glycine 0 N--CA 1.495 2.608 0 N-CA-C 110.513 -1.035 . . . . 0.0 110.513 -179.827 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 93.7 mtt180 -139.86 -112.69 0.15 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.061 -1.258 . . . . 0.0 109.606 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 80.0 p -86.03 -23.64 26.7 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.313 -0.867 . . . . 0.0 110.112 -179.485 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -164.36 93.58 0.11 Allowed Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.377 -1.489 . . . . 0.0 109.377 -179.838 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 11.4 ttmm -174.4 75.31 0.34 Allowed Pre-proline 0 C--N 1.301 -1.506 0 O-C-N 121.484 -1.009 . . . . 0.0 108.629 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_exo -47.89 129.18 17.44 Favored 'Trans proline' 0 C--N 1.303 -1.832 0 C-N-CA 122.539 2.159 . . . . 0.0 111.897 -179.422 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 12.6 tp -106.48 119.96 40.67 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.522 -0.736 . . . . 0.0 109.333 -179.371 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -150.43 140.57 22.13 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.169 -0.957 . . . . 0.0 109.719 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 2.9 t80 -62.25 -35.75 79.9 Favored 'General case' 0 N--CA 1.492 1.657 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 179.431 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 42.6 tttm -50.47 152.66 1.82 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.501 -0.75 . . . . 0.0 109.868 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 34.8 t0 71.24 43.07 0.66 Allowed 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.645 -0.659 . . . . 0.0 109.501 -179.835 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 90.8 p -119.23 152.67 36.24 Favored 'General case' 0 N--CA 1.492 1.659 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 179.503 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 30.3 t -145.85 154.6 42.16 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.198 -0.938 . . . . 0.0 109.778 -179.611 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 47.3 m-85 -89.99 127.58 36.07 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.335 -0.853 . . . . 0.0 109.253 179.651 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' HIS . . . . . 0.403 ' O ' ' O ' ' A' ' 163' ' ' GLY . 97.3 m-70 -99.04 -18.47 17.74 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.319 -0.863 . . . . 0.0 110.291 -179.279 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 58.5 mtp85 -127.31 137.07 52.73 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.11 -0.994 . . . . 0.0 110.126 -179.693 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 3.1 m -153.34 81.33 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 121.428 -0.795 . . . . 0.0 108.98 179.474 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 22.0 mt -95.96 126.04 46.24 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.097 -1.002 . . . . 0.0 109.452 -179.501 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -71.64 138.25 31.72 Favored 'Trans proline' 0 N--CA 1.493 1.491 0 C-N-CA 122.157 1.905 . . . . 0.0 112.332 -179.664 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 92.67 -30.04 7.32 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.684 -1.366 . . . . 0.0 109.684 179.623 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -102.7 -89.73 0.37 Allowed 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.301 -1.117 . . . . 0.0 109.741 -179.884 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' MET . . . . . 0.452 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 7.6 ptt? -171.86 -175.42 1.51 Allowed 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.22 -0.925 . . . . 0.0 109.716 -179.678 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -127.27 141.94 51.59 Favored 'General case' 0 N--CA 1.494 1.748 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 179.699 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 48.1 tt0 -105.85 143.53 33.86 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.209 -0.932 . . . . 0.0 109.843 -179.589 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -156.11 -173.55 24.84 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 96.32 2.34 60.49 Favored Glycine 0 N--CA 1.494 2.516 0 N-CA-C 109.676 -1.37 . . . . 0.0 109.676 -179.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.574 ' O ' ' N ' ' A' ' 83' ' ' GLY . 89.9 m-20 -92.42 14.72 15.77 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.339 -1.095 . . . . 0.0 109.203 179.848 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.541 ' CD1' ' N ' ' A' ' 81' ' ' THR . 42.4 p90 -44.27 -31.56 1.05 Allowed 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.351 -0.843 . . . . 0.0 110.292 -179.815 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.541 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 18.5 m -58.0 -37.46 74.31 Favored 'General case' 0 C--N 1.303 -1.445 0 O-C-N 121.169 -0.957 . . . . 0.0 109.666 -178.993 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -145.48 -32.89 0.37 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.191 -0.943 . . . . 0.0 110.048 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . 0.574 ' N ' ' O ' ' A' ' 79' ' ' ASP . . . 100.16 -37.14 3.69 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.424 -1.471 . . . . 0.0 109.424 -180.0 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 78.4 m-20 -89.7 1.51 55.97 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.316 -1.108 . . . . 0.0 109.376 179.873 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 88.67 2.33 79.13 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.446 -1.462 . . . . 0.0 109.446 -179.934 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 49.5 m -59.71 -38.72 82.4 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.366 -1.079 . . . . 0.0 109.633 -179.919 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -96.31 -115.21 3.09 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.859 -1.296 . . . . 0.0 109.859 -179.706 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.446 ' O ' ' CB ' ' A' ' 123' ' ' SER . . . 81.97 27.71 44.52 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.193 -1.563 . . . . 0.0 109.193 -179.636 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -59.51 142.84 51.69 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.329 -1.1 . . . . 0.0 109.869 -179.83 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 32.9 t -141.93 146.81 36.12 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.353 -0.842 . . . . 0.0 109.278 179.738 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 14.1 pt -69.53 -11.34 14.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.136 -0.977 . . . . 0.0 109.468 -179.887 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . 0.429 ' OH ' ' OE1' ' A' ' 40' ' ' GLU . 80.9 m-85 -107.47 29.51 7.1 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.393 -0.817 . . . . 0.0 109.778 -179.988 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -46.98 -31.26 5.57 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.382 -1.487 . . . . 0.0 109.382 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -63.26 145.16 56.11 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.139 -1.212 . . . . 0.0 108.992 179.625 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 93.8 mttt -87.77 135.51 33.35 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.368 -0.832 . . . . 0.0 109.631 -179.637 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.531 ' CE1' ' ND2' ' A' ' 121' ' ' ASN . 54.4 p90 -144.49 163.26 34.37 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.351 -0.843 . . . . 0.0 109.361 179.672 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -97.6 144.82 26.89 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.281 -0.887 . . . . 0.0 109.324 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 -67.93 135.34 52.27 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.213 -0.929 . . . . 0.0 109.345 -179.883 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . 0.525 ' O ' ' ND2' ' A' ' 100' ' ' ASN . 84.4 tt0 -63.55 -38.21 90.27 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.275 -0.89 . . . . 0.0 110.117 -179.653 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . 0.525 ' ND2' ' O ' ' A' ' 99' ' ' GLU . 24.0 m120 -144.18 171.04 14.84 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.996 -1.065 . . . . 0.0 110.041 -179.539 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' PHE . . . . . 0.43 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 38.3 p90 -151.17 37.85 0.63 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.471 -0.768 . . . . 0.0 109.094 179.772 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 90.3 mt -57.86 -34.13 47.51 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.318 -0.864 . . . . 0.0 109.936 -179.792 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 44.1 mtmt -75.63 144.27 41.8 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.992 -1.068 . . . . 0.0 109.511 -179.895 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 45.2 tttp -130.16 157.77 41.53 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.421 -0.799 . . . . 0.0 109.411 -179.872 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' HIS . . . . . 0.402 ' O ' ' OD2' ' A' ' 136' ' ' ASP . 85.5 t60 -98.93 127.09 44.77 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.328 -0.857 . . . . 0.0 109.39 -179.92 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -160.7 -6.66 0.05 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.229 -0.919 . . . . 0.0 109.698 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -127.72 171.48 19.07 Favored Glycine 0 N--CA 1.494 2.513 0 N-CA-C 109.456 -1.458 . . . . 0.0 109.456 -179.878 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 97.0 Cg_endo -80.61 154.72 20.84 Favored 'Trans proline' 0 C--N 1.306 -1.677 0 C-N-CA 123.023 2.482 . . . . 0.0 112.287 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 77.75 47.55 8.6 Favored Glycine 0 N--CA 1.494 2.536 0 N-CA-C 109.967 -1.253 . . . . 0.0 109.967 179.49 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 40.9 mm -115.29 134.74 57.49 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 O-C-N 121.437 -1.037 . . . . 0.0 109.511 -179.903 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . 0.454 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 3.5 mm? -93.45 112.74 24.72 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.203 -0.936 . . . . 0.0 109.317 179.681 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 47.2 m -131.01 147.95 52.69 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.265 -0.897 . . . . 0.0 109.494 179.737 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 88.5 mtp -94.33 141.2 28.84 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.177 -0.952 . . . . 0.0 109.391 179.892 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . 0.55 ' O ' ' ND2' ' A' ' 115' ' ' ASN . . . -63.3 142.77 58.26 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.295 -0.878 . . . . 0.0 109.338 179.916 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . 0.55 ' ND2' ' O ' ' A' ' 114' ' ' ALA . 16.0 m120 -144.7 113.26 6.65 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.21 -0.931 . . . . 0.0 109.057 179.885 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -68.22 -27.8 66.68 Favored 'General case' 0 C--N 1.297 -1.712 0 O-C-N 121.35 -0.844 . . . . 0.0 109.169 179.795 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -132.55 167.7 23.01 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.254 -1.539 . . . . 0.0 109.254 179.86 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 14.3 Cg_endo -58.44 -25.51 73.95 Favored 'Trans proline' 0 C--N 1.305 -1.76 0 C-N-CA 122.809 2.339 . . . . 0.0 111.929 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 42.5 p-10 -128.38 42.5 3.31 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.354 -0.841 . . . . 0.0 109.489 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 89.1 m -128.87 124.47 35.34 Favored 'General case' 0 N--CA 1.486 1.329 0 O-C-N 121.445 -0.785 . . . . 0.0 108.896 179.77 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 121' ' ' ASN . . . . . 0.531 ' ND2' ' CE1' ' A' ' 96' ' ' PHE . 83.0 m-20 -108.9 149.57 28.96 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.59 -0.694 . . . . 0.0 109.438 -179.842 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -133.78 166.93 23.81 Favored Glycine 0 N--CA 1.494 2.518 0 N-CA-C 109.544 -1.422 . . . . 0.0 109.544 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 123' ' ' SER . . . . . 0.446 ' CB ' ' O ' ' A' ' 88' ' ' GLY . 46.4 p -82.41 -2.08 52.02 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.248 -1.148 . . . . 0.0 109.674 -179.907 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.4 mt-30 -100.5 144.91 28.93 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.253 -0.904 . . . . 0.0 109.752 -179.836 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 50.9 p90 -139.12 163.6 31.98 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.504 -0.747 . . . . 0.0 109.171 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.452 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 50.8 p90 -135.86 154.46 51.16 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.214 -0.928 . . . . 0.0 109.76 -179.89 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 64.5 mt -124.16 134.02 67.72 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.754 0 O-C-N 121.509 -0.745 . . . . 0.0 109.422 179.781 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 3.3 m -114.23 113.07 24.13 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.274 -0.891 . . . . 0.0 109.342 179.855 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 129' ' ' THR . . . . . 0.495 ' OG1' ' OE1' ' A' ' 156' ' ' GLU . 7.3 p -94.39 -0.9 54.52 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.257 -0.902 . . . . 0.0 109.406 -179.905 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -109.97 152.74 25.49 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.383 -0.823 . . . . 0.0 109.338 -179.746 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 49.3 mtpt -77.39 115.29 17.04 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.18 -0.95 . . . . 0.0 109.228 179.84 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 50.0 p -129.23 158.18 39.76 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.445 -0.784 . . . . 0.0 109.366 -179.938 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -110.39 -40.83 4.53 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.368 -0.833 . . . . 0.0 109.683 179.857 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 0.6 OUTLIER -62.58 -34.21 76.52 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.195 -0.941 . . . . 0.0 109.748 -179.602 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 12.5 mt -62.22 -33.09 73.9 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.984 -1.072 . . . . 0.0 109.668 179.648 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . 0.402 ' OD2' ' O ' ' A' ' 105' ' ' HIS . 61.7 t0 -79.33 119.12 21.92 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.2 -0.938 . . . . 0.0 109.517 -179.731 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -165.05 -117.4 0.4 Allowed Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 3.3 mppt? -86.53 7.39 26.3 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.403 -1.057 . . . . 0.0 109.769 -179.853 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 77.3 m80 -70.52 151.24 45.29 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.149 -0.97 . . . . 0.0 109.571 -179.667 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 41.2 t -118.69 140.78 41.18 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.489 -0.757 . . . . 0.0 109.459 -179.776 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . 0.406 HG13 ' H ' ' A' ' 143' ' ' GLY . 50.6 t -100.2 133.32 43.63 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.416 -0.802 . . . . 0.0 109.565 -179.844 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . 0.42 ' CE2' ' CE2' ' A' ' 42' ' ' PHE . 38.0 p90 -109.12 1.09 20.17 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.277 -0.889 . . . . 0.0 109.823 179.873 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . 0.406 ' H ' HG13 ' A' ' 141' ' ' VAL . . . -174.4 -179.42 45.0 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 179.663 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.3 pt20 -146.22 167.39 23.61 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.26 -1.141 . . . . 0.0 109.561 -179.644 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 54.0 t -97.84 131.39 44.91 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.187 0 O-C-N 121.178 -0.952 . . . . 0.0 109.473 -179.885 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 16.6 m -107.76 -34.81 2.81 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.357 -0.839 . . . . 0.0 109.664 179.685 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 94.4 mt-10 -144.32 166.92 23.72 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.212 -0.93 . . . . 0.0 109.705 -179.827 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 96.79 4.15 59.12 Favored Glycine 0 N--CA 1.495 2.583 0 N-CA-C 110.194 -1.162 . . . . 0.0 110.194 179.395 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 149' ' ' MET . . . . . 0.424 ' O ' HG12 ' A' ' 152' ' ' VAL . 71.8 mtm -60.79 -33.22 72.65 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.002 -1.293 . . . . 0.0 109.722 179.923 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 89.3 m-20 -65.11 -41.96 94.4 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.833 -1.167 . . . . 0.0 110.07 -179.541 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.2 p -82.04 -34.29 12.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.216 -0.928 . . . . 0.0 110.696 -179.406 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 152' ' ' VAL . . . . . 0.454 ' CG1' ' N ' ' A' ' 153' ' ' LYS . 0.8 OUTLIER -55.63 -42.49 69.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 120.873 -1.142 . . . . 0.0 109.399 -179.248 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 153' ' ' LYS . . . . . 0.454 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 99.2 mttt -65.53 -33.3 75.6 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.137 -0.977 . . . . 0.0 109.757 179.5 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -60.25 -40.15 89.3 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.312 -0.867 . . . . 0.0 110.284 -179.154 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.446 HD12 HG21 ' A' ' 155' ' ' ILE . 91.9 mt -71.56 -36.21 59.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.029 -1.044 . . . . 0.0 110.466 -179.508 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . 0.495 ' OE1' ' OG1' ' A' ' 129' ' ' THR . 84.4 tt0 -78.49 -40.35 35.58 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.929 -1.107 . . . . 0.0 111.36 -178.587 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 39.8 pttt -61.05 -34.42 74.86 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 120.793 -1.192 . . . . 0.0 110.005 -178.806 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 28.3 m -73.36 -12.65 15.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.101 -0.999 . . . . 0.0 109.377 179.884 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -77.82 173.4 55.08 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.757 -1.337 . . . . 0.0 109.757 -179.891 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 160' ' ' SER . . . . . 0.701 ' HG ' ' H ' ' A' ' 161' ' ' SER . 21.4 t -154.62 178.72 9.79 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.41 -1.053 . . . . 0.0 109.395 -179.741 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 161' ' ' SER . . . . . 0.701 ' H ' ' HG ' ' A' ' 160' ' ' SER . 23.7 t -54.3 -30.45 51.08 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.233 -0.917 . . . . 0.0 109.262 179.819 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 86.6 p -59.3 -26.61 65.13 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.255 -0.903 . . . . 0.0 109.4 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 163' ' ' GLY . . . . . 0.403 ' O ' ' O ' ' A' ' 67' ' ' HIS . . . 87.16 20.31 53.13 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.713 -1.355 . . . . 0.0 109.713 179.794 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 87.7 mtt180 -122.38 145.39 48.32 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.195 -1.18 . . . . 0.0 109.364 179.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 165' ' ' THR . . . . . . . . . . . . . 72.6 p -82.19 151.52 26.85 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.153 -0.967 . . . . 0.0 109.647 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -67.06 -36.44 82.05 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.287 -0.883 . . . . 0.0 109.302 179.692 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 62.4 mttp -117.6 156.57 27.89 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.576 -0.702 . . . . 0.0 109.248 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 94.2 mttt -69.22 131.62 45.2 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.11 -0.994 . . . . 0.0 109.225 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 41.1 t -122.14 125.08 72.49 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.725 0 O-C-N 121.325 -0.859 . . . . 0.0 109.644 -179.896 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 43.7 t -144.94 144.88 21.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.386 -0.821 . . . . 0.0 109.17 179.63 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 2.7 t -74.54 124.17 31.57 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.677 0 C-N-CA 119.722 -0.791 . . . . 0.0 109.787 -179.284 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -67.85 -27.91 67.1 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.363 -0.836 . . . . 0.0 109.593 179.471 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 44.3 t0 -174.38 174.76 2.73 Favored 'General case' 0 N--CA 1.494 1.754 0 C-N-CA 119.29 -0.964 . . . . 0.0 110.321 -179.286 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 26.4 p -146.42 150.25 35.28 Favored 'General case' 0 N--CA 1.491 1.622 0 N-CA-C 109.063 -0.718 . . . . 0.0 109.063 179.638 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -172.64 173.16 45.38 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.804 -1.318 . . . . 0.0 109.804 179.913 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 176' ' ' GLN . . . . . 0.513 ' NE2' ' OXT' ' A' ' 178' ' ' SER . 62.6 tt0 -114.23 118.89 35.24 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.413 -1.051 . . . . 0.0 109.637 -179.985 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 37.1 tp -63.39 -37.42 87.2 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.124 -0.985 . . . . 0.0 109.217 179.403 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 178' ' ' SER . . . . . 0.513 ' OXT' ' NE2' ' A' ' 176' ' ' GLN . 61.2 m . . . . . 0 N--CA 1.491 1.582 0 CA-C-O 118.0 -1.0 . . . . 0.0 109.441 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.53 4.925 0 N-CA-C 119.364 2.506 . . . . 0.0 119.364 . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 23.0 m -57.69 -35.26 70.37 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.194 -1.18 . . . . 0.0 109.502 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 99.2 m-85 -111.07 122.57 48.24 Favored 'General case' 0 N--CA 1.485 1.298 0 O-C-N 121.399 -0.813 . . . . 0.0 108.93 179.702 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 51.2 m -81.95 136.34 35.3 Favored 'General case' 0 C--N 1.296 -1.724 0 O-C-N 121.483 -0.76 . . . . 0.0 109.547 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 144.93 154.77 6.23 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 179.905 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 49.9 m -122.88 147.64 46.34 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.42 -1.047 . . . . 0.0 109.356 179.949 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 10.2 mmt -67.18 150.21 98.03 Favored Pre-proline 0 N--CA 1.489 1.48 0 O-C-N 121.23 -0.919 . . . . 0.0 109.28 179.882 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -71.7 166.75 28.5 Favored 'Trans proline' 0 C--N 1.309 -1.531 0 C-N-CA 122.606 2.204 . . . . 0.0 112.149 -179.881 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 2.3 m-80 -73.55 152.6 89.66 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.343 -0.848 . . . . 0.0 109.231 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 38.7 Cg_endo -64.85 141.65 72.36 Favored 'Trans proline' 0 N--CA 1.496 1.663 0 C-N-CA 122.616 2.211 . . . . 0.0 112.07 179.775 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 96.4 mtt180 -126.79 131.62 51.24 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.459 -0.776 . . . . 0.0 109.061 179.497 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.4 p -136.09 142.38 38.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.314 -0.866 . . . . 0.0 109.243 -179.905 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 41.2 p90 -142.3 154.01 44.36 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.297 -0.877 . . . . 0.0 109.572 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.6 ' CE2' ' SG ' ' A' ' 174' ' ' CYS . 44.3 m-85 -120.07 135.78 54.82 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.468 -0.77 . . . . 0.0 109.091 179.643 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.1 t0 -88.55 114.47 25.2 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.078 -1.013 . . . . 0.0 108.509 179.489 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 83.7 mtp -104.53 136.17 44.58 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.453 -0.779 . . . . 0.0 110.532 -179.08 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 44.5 m -135.1 154.23 51.74 Favored 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 179.195 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.405 ' O ' ' C ' ' A' ' 19' ' ' GLY . 34.3 m -125.98 141.45 45.61 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.148 -0.97 . . . . 0.0 109.891 -179.886 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.405 ' C ' ' O ' ' A' ' 18' ' ' VAL . . . 41.05 -114.7 0.61 Allowed Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.936 -1.266 . . . . 0.0 109.936 179.77 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -120.94 15.46 9.52 Favored Glycine 0 N--CA 1.496 2.644 0 N-CA-C 109.416 -1.474 . . . . 0.0 109.416 179.858 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 39.6 tt0 -124.12 88.03 53.0 Favored Pre-proline 0 N--CA 1.494 1.756 0 O-C-N 121.459 -1.024 . . . . 0.0 109.078 -179.826 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 75.7 Cg_exo -47.05 132.86 18.24 Favored 'Trans proline' 0 C--N 1.309 -1.548 0 C-N-CA 122.336 2.024 . . . . 0.0 112.294 -179.561 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -85.07 -63.25 1.36 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.313 -0.867 . . . . 0.0 109.834 -179.688 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 172.62 -167.08 39.91 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 -179.756 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 28.7 ptt180 -116.53 151.18 36.67 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.534 -0.98 . . . . 0.0 108.952 179.735 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 83.4 mt -120.1 129.11 75.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.377 -0.827 . . . . 0.0 109.06 -179.854 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 39.5 t -107.7 134.6 48.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.4 -0.813 . . . . 0.0 109.436 -179.599 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 76.3 mtm -120.86 148.9 43.4 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.557 -0.714 . . . . 0.0 109.215 179.932 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -95.77 133.7 39.58 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.277 -0.889 . . . . 0.0 109.731 -179.593 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -108.35 133.42 52.57 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.572 -0.705 . . . . 0.0 109.357 179.895 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -96.37 119.56 35.08 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.23 -0.919 . . . . 0.0 108.656 179.187 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -89.61 -42.48 11.37 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.295 -0.878 . . . . 0.0 109.835 -179.65 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.2 m-20 -64.58 -48.63 74.27 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.218 -0.926 . . . . 0.0 110.24 -179.263 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 33.3 m -70.91 -43.47 68.21 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.075 -1.016 . . . . 0.0 109.966 -179.652 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.486 ' O ' ' OG1' ' A' ' 35' ' ' THR . 5.1 p -136.38 79.85 41.21 Favored Pre-proline 0 N--CA 1.493 1.678 0 O-C-N 121.351 -0.843 . . . . 0.0 109.404 -179.604 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 27.2 Cg_endo -67.05 -60.88 0.09 OUTLIER 'Trans proline' 0 C--N 1.309 -1.525 0 C-N-CA 122.479 2.12 . . . . 0.0 112.849 -179.401 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.476 ' NH2' ' CG ' ' A' ' 92' ' ' TYR . 17.2 mtp-105 -60.8 -37.78 83.12 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.405 -0.809 . . . . 0.0 110.811 -178.878 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 26.3 m -61.8 -43.16 99.4 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.883 -1.136 . . . . 0.0 109.835 -179.764 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -64.81 -28.48 69.59 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.175 -0.953 . . . . 0.0 109.307 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.407 ' OE1' ' OH ' ' A' ' 92' ' ' TYR . 84.6 tt0 -65.18 -37.72 88.22 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.341 -0.849 . . . . 0.0 109.687 -179.833 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 86.7 m-20 -59.59 -41.63 90.7 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.244 -0.91 . . . . 0.0 109.745 -179.652 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . 0.494 ' O ' ' SG ' ' A' ' 46' ' ' CYS . 95.5 m-85 -81.37 -46.68 14.3 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.239 -0.913 . . . . 0.0 109.705 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . 0.677 ' HE ' ' NE2' ' A' ' 176' ' ' GLN . 76.1 ttt180 -58.15 -43.09 87.21 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.346 -0.846 . . . . 0.0 110.019 -179.522 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -78.11 -47.9 17.2 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.141 -0.975 . . . . 0.0 110.165 -179.578 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 58.4 tp -60.59 -38.83 85.93 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.254 -0.904 . . . . 0.0 109.838 -179.518 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' CYS . . . . . 0.494 ' SG ' ' O ' ' A' ' 42' ' ' PHE . 71.2 m -68.56 -58.74 3.84 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.032 -1.042 . . . . 0.0 109.417 -179.908 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 31.6 m -64.11 -37.45 87.5 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.135 -0.978 . . . . 0.0 109.278 179.703 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 81.53 34.27 25.9 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 179.648 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -61.1 -34.36 74.83 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.018 -1.283 . . . . 0.0 109.338 179.61 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 69.4 mmtt -59.57 -33.58 71.61 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.317 -0.864 . . . . 0.0 109.331 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 94.3 168.87 37.44 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.329 -1.508 . . . . 0.0 109.329 -179.771 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 91.7 m -77.79 139.18 39.31 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.413 -1.051 . . . . 0.0 109.737 -179.933 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -60.78 141.19 48.09 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.521 -1.432 . . . . 0.0 109.521 179.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 67.4 mtm180 -59.19 -37.12 76.65 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.277 -1.131 . . . . 0.0 109.765 -179.799 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 23.6 m -58.7 -33.75 70.53 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.273 -0.892 . . . . 0.0 109.709 -179.784 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . 0.427 ' O ' ' CB ' ' A' ' 57' ' ' LYS . . . 120.58 109.53 2.2 Favored Glycine 0 N--CA 1.495 2.577 0 N-CA-C 108.996 -1.642 . . . . 0.0 108.996 -179.645 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . 0.455 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 3.2 mmtp 166.14 85.93 0.02 OUTLIER Pre-proline 0 N--CA 1.492 1.628 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 -179.669 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 71.3 Cg_exo -50.96 133.73 40.98 Favored 'Trans proline' 0 C--N 1.304 -1.773 0 C-N-CA 122.559 2.173 . . . . 0.0 112.383 -179.308 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.455 ' CD1' ' O ' ' A' ' 57' ' ' LYS . 8.9 mp -99.65 44.77 1.01 Allowed 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.558 -0.714 . . . . 0.0 109.378 -179.793 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 88.4 m-70 -123.82 133.31 53.82 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.413 -0.804 . . . . 0.0 109.672 -179.828 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 20.8 m-85 -69.12 -12.11 61.39 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.158 -0.964 . . . . 0.0 108.907 178.789 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 61.2 tttt -49.93 138.62 14.97 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.345 -0.847 . . . . 0.0 109.898 -179.703 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 41.0 t0 67.77 42.53 1.96 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.782 -0.574 . . . . 0.0 110.141 179.67 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.764 ' H ' ' CG2' ' A' ' 171' ' ' VAL . 83.2 p -110.47 149.76 29.84 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.233 -0.917 . . . . 0.0 108.595 178.807 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 28.7 t -117.45 144.23 45.22 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.172 -0.955 . . . . 0.0 109.697 -179.353 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -69.61 138.87 53.47 Favored 'General case' 0 N--CA 1.491 1.595 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 179.66 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' HIS . . . . . 0.693 ' CD2' ' HE ' ' A' ' 68' ' ' ARG . 77.8 t60 -59.59 -50.95 71.91 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.108 -0.995 . . . . 0.0 109.932 -179.416 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.693 ' HE ' ' CD2' ' A' ' 67' ' ' HIS . 20.2 ptp180 -172.81 163.05 4.98 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.213 -0.929 . . . . 0.0 109.684 179.669 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -134.05 127.0 50.97 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.418 -0.802 . . . . 0.0 109.035 179.53 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 39.5 mt -121.9 118.38 29.36 Favored Pre-proline 0 N--CA 1.493 1.719 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 179.86 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -71.58 136.13 27.67 Favored 'Trans proline' 0 C--N 1.31 -1.473 0 C-N-CA 121.853 1.702 . . . . 0.0 111.894 -179.803 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 94.25 -1.07 66.79 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.731 -1.348 . . . . 0.0 109.731 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 85.7 m-85 -137.1 -96.13 0.21 Allowed 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.22 -1.164 . . . . 0.0 109.81 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' MET . . . . . 0.595 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 5.6 ptt? -163.95 160.86 22.46 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.157 -0.964 . . . . 0.0 109.896 -179.491 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' CYS . . . . . 0.492 ' O ' ' SG ' ' A' ' 75' ' ' CYS . 12.1 p -97.38 130.59 44.51 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.417 -0.802 . . . . 0.0 108.966 179.241 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 93.8 mt-30 -105.79 149.82 26.12 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.27 -0.894 . . . . 0.0 109.648 -179.712 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -143.91 126.24 2.69 Favored Glycine 0 N--CA 1.492 2.425 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 179.85 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -86.05 178.48 49.58 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.77 -1.332 . . . . 0.0 109.77 -179.76 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 88.1 m-20 -72.13 149.38 44.79 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.357 -1.084 . . . . 0.0 109.554 179.842 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 43.6 p90 -61.53 -22.97 65.62 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.201 -0.937 . . . . 0.0 109.571 -179.907 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 61.6 p -65.98 -30.17 70.68 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.133 -0.979 . . . . 0.0 109.424 -179.926 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 171.4 -55.7 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.339 -0.851 . . . . 0.0 109.284 179.809 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 94.79 -10.3 70.53 Favored Glycine 0 N--CA 1.493 2.462 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 179.889 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 50.4 t30 -86.18 1.71 49.66 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.176 -1.191 . . . . 0.0 109.345 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 97.21 -8.83 65.02 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.311 -1.516 . . . . 0.0 109.311 -179.865 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 68.0 p -73.34 -20.0 60.89 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.311 -1.111 . . . . 0.0 109.273 179.675 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -127.68 -130.51 3.35 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 109.334 -1.507 . . . . 0.0 109.334 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 72.48 55.02 7.06 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.175 -1.57 . . . . 0.0 109.175 -179.948 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -84.77 140.73 31.03 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.368 -1.077 . . . . 0.0 109.808 -179.506 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 27.8 t -111.65 143.07 43.14 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.453 -0.779 . . . . 0.0 109.111 179.773 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 15.4 pt -65.12 -38.64 83.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.18 -0.95 . . . . 0.0 110.061 -179.529 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . 0.476 ' CG ' ' NH2' ' A' ' 37' ' ' ARG . 50.7 m-85 -67.83 -38.5 83.3 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.09 -1.006 . . . . 0.0 109.677 -179.906 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 76.09 22.05 74.7 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.342 -1.503 . . . . 0.0 109.342 -179.8 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -147.28 162.69 38.42 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.283 -1.128 . . . . 0.0 109.592 -179.708 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 61.0 mttp -77.19 154.16 33.38 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.269 -0.895 . . . . 0.0 109.527 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.463 ' CD1' ' N ' ' A' ' 96' ' ' PHE . 2.1 m-85 -100.37 133.19 45.16 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.303 -0.873 . . . . 0.0 109.059 179.969 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -91.44 130.45 37.27 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.092 -1.005 . . . . 0.0 109.582 -179.874 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 88.2 m-20 -72.05 143.4 49.11 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.269 -0.894 . . . . 0.0 109.362 179.76 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -141.0 -47.44 0.4 Allowed 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.242 -0.911 . . . . 0.0 109.734 -179.848 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 86.0 m-20 -105.0 122.08 45.11 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.242 -0.911 . . . . 0.0 109.905 -179.585 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' PHE . . . . . 0.553 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 71.7 t80 -120.43 14.48 11.98 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.461 -0.774 . . . . 0.0 108.965 179.549 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 89.7 mt -55.11 -38.31 46.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.417 -0.802 . . . . 0.0 110.237 -179.434 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 67.4 mttm -84.54 136.98 33.58 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.991 -1.068 . . . . 0.0 109.782 -179.528 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . 0.618 ' HZ3' ' CG2' ' A' ' 106' ' ' THR . 21.3 pttm -139.58 -177.12 4.81 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.457 -0.777 . . . . 0.0 109.274 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' HIS . . . . . 0.533 ' CE1' ' O ' ' A' ' 107' ' ' GLY . 8.5 t-80 -86.52 107.01 17.92 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.121 -0.987 . . . . 0.0 109.491 -179.881 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' THR . . . . . 0.618 ' CG2' ' HZ3' ' A' ' 104' ' ' LYS . 46.6 p -114.43 -1.31 13.51 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.348 -0.845 . . . . 0.0 109.779 179.955 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.533 ' O ' ' CE1' ' A' ' 105' ' ' HIS . . . -154.31 170.54 32.8 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 -179.756 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -77.01 153.7 32.68 Favored 'Trans proline' 0 C--N 1.307 -1.656 0 C-N-CA 122.909 2.406 . . . . 0.0 112.264 179.804 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 78.53 52.4 5.13 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 110.032 -1.227 . . . . 0.0 110.032 179.491 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 35.3 mm -114.27 137.31 47.99 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 O-C-N 121.27 -1.135 . . . . 0.0 109.825 -179.86 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . 0.535 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 2.5 mm? -89.42 125.61 35.23 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.308 -0.87 . . . . 0.0 109.021 179.564 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' SER . . . . . 0.434 ' OG ' ' O ' ' A' ' 140' ' ' VAL . 36.8 t -147.74 142.83 27.07 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.027 -1.046 . . . . 0.0 109.794 -179.896 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 64.9 mtt -88.45 135.96 33.22 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.185 -0.947 . . . . 0.0 109.411 179.606 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . 0.535 ' O ' ' ND2' ' A' ' 115' ' ' ASN . . . -72.22 135.59 46.12 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.137 -0.977 . . . . 0.0 109.34 179.808 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . 0.535 ' ND2' ' O ' ' A' ' 114' ' ' ALA . 17.6 m120 -145.37 113.32 6.45 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.162 -0.962 . . . . 0.0 109.336 179.77 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -70.15 -28.7 65.56 Favored 'General case' 0 C--N 1.297 -1.68 0 O-C-N 121.457 -0.777 . . . . 0.0 109.362 179.796 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -134.46 165.25 24.5 Favored Glycine 0 N--CA 1.493 2.484 0 N-CA-C 109.279 -1.528 . . . . 0.0 109.279 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -70.17 154.91 65.67 Favored 'Trans proline' 0 C--N 1.306 -1.667 0 C-N-CA 122.776 2.317 . . . . 0.0 112.199 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 77.5 m-20 54.72 46.9 23.67 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.467 -0.77 . . . . 0.0 109.559 179.841 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 87.3 m -132.27 129.75 40.0 Favored 'General case' 0 C--N 1.306 -1.312 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 179.709 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 121' ' ' ASN . . . . . 0.402 ' OD1' ' CE2' ' A' ' 96' ' ' PHE . 50.8 t30 -74.69 123.15 24.38 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 121.442 -0.786 . . . . 0.0 109.329 -179.855 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -90.74 103.64 3.06 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.839 -1.304 . . . . 0.0 109.839 -179.84 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 85.5 p -65.03 -23.63 67.25 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.248 -1.148 . . . . 0.0 109.245 179.596 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.0 mt-30 -109.19 151.83 25.96 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.434 -0.791 . . . . 0.0 109.622 -179.805 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 49.2 p90 -136.63 160.85 37.56 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.377 -0.827 . . . . 0.0 109.108 179.75 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.595 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 50.2 p90 -140.58 158.5 43.9 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.224 -0.923 . . . . 0.0 109.724 -179.895 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 65.1 mt -120.98 133.6 67.1 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 O-C-N 121.593 -0.692 . . . . 0.0 109.325 179.674 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 128' ' ' CYS . . . . . 0.462 ' HG ' ' HG1' ' A' ' 132' ' ' THR . 6.7 m -97.48 108.64 21.4 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.169 -0.957 . . . . 0.0 109.305 179.779 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 60.2 p -76.39 -10.07 59.12 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.182 -0.949 . . . . 0.0 109.528 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -137.89 161.55 36.34 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.309 -0.87 . . . . 0.0 109.302 -179.818 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 49.0 tttp -62.22 133.21 54.87 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.226 -0.921 . . . . 0.0 109.433 -179.806 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 132' ' ' THR . . . . . 0.462 ' HG1' ' HG ' ' A' ' 128' ' ' CYS . 29.4 p -140.37 91.93 2.48 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.313 -0.867 . . . . 0.0 109.281 -179.898 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -63.57 -34.9 78.84 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.255 -0.903 . . . . 0.0 109.73 -179.813 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 0.9 OUTLIER -67.76 -47.9 67.93 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.068 -1.02 . . . . 0.0 109.646 -179.876 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 15.3 mt -66.79 -31.73 72.55 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.111 -0.993 . . . . 0.0 109.701 179.511 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 60.0 t0 -78.18 121.48 24.4 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.109 -0.994 . . . . 0.0 109.767 -179.566 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 179.88 -114.94 0.46 Allowed Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . 0.437 ' O ' ' C ' ' A' ' 139' ' ' HIS . 66.4 mttm -57.64 -36.24 71.57 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.297 -1.12 . . . . 0.0 109.748 179.886 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 139' ' ' HIS . . . . . 0.437 ' C ' ' O ' ' A' ' 138' ' ' LYS . 53.7 m170 -40.94 144.69 0.25 Allowed 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.543 -0.723 . . . . 0.0 109.816 -179.683 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.434 ' O ' ' OG ' ' A' ' 112' ' ' SER . 42.4 t -115.11 138.84 44.11 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 121.359 -0.838 . . . . 0.0 109.601 -179.678 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 91.8 t -97.97 129.06 48.72 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.341 -0.85 . . . . 0.0 109.441 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 39.1 p90 -115.15 0.54 13.61 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.348 -0.845 . . . . 0.0 109.492 179.844 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -176.19 175.6 47.48 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.349 -1.5 . . . . 0.0 109.349 179.558 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.4 pt20 -147.86 168.21 22.78 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.125 -1.221 . . . . 0.0 110.045 -179.837 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 82.1 t -94.61 131.28 41.9 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.245 0 O-C-N 121.333 -0.854 . . . . 0.0 109.363 -179.814 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 10.9 m -112.43 -30.71 2.2 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.325 -0.859 . . . . 0.0 109.853 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 92.9 mt-10 -141.91 169.45 17.56 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.152 -0.968 . . . . 0.0 109.611 -179.881 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 95.57 6.85 59.43 Favored Glycine 0 N--CA 1.493 2.452 0 N-CA-C 109.984 -1.246 . . . . 0.0 109.984 179.597 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 149' ' ' MET . . . . . . . . . . . . . 65.0 mtt -60.14 -31.92 70.53 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.058 -1.26 . . . . 0.0 109.543 -179.978 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . 0.54 ' OD1' ' N ' ' A' ' 151' ' ' VAL . 31.8 p-10 -65.0 -36.96 86.08 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.812 -1.18 . . . . 0.0 109.821 -179.64 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . 0.54 ' N ' ' OD1' ' A' ' 150' ' ' ASP . 3.5 p -87.08 -34.19 7.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.148 -0.97 . . . . 0.0 110.385 -179.64 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 152' ' ' VAL . . . . . 0.46 ' CG1' ' N ' ' A' ' 153' ' ' LYS . 0.9 OUTLIER -56.67 -41.87 75.32 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 120.991 -1.068 . . . . 0.0 109.188 -179.478 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 153' ' ' LYS . . . . . 0.46 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 66.8 mttm -63.99 -34.72 78.65 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.274 -0.891 . . . . 0.0 109.406 179.583 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -62.17 -36.81 83.01 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.29 -0.881 . . . . 0.0 109.934 -179.477 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 62.5 mt -74.36 -37.56 45.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.136 -0.977 . . . . 0.0 109.84 -179.786 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -73.73 -40.61 63.43 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.129 -0.982 . . . . 0.0 111.399 -178.493 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 18.1 pttp -59.86 -35.61 75.16 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.679 -1.263 . . . . 0.0 109.696 -178.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 27.1 m -77.04 -17.52 14.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.08 -1.012 . . . . 0.0 108.952 179.389 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -64.43 150.21 50.93 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 49.7 m -136.28 161.23 36.35 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.454 -1.027 . . . . 0.0 109.175 179.914 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 23.8 m -51.35 -33.12 28.17 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.187 -0.946 . . . . 0.0 108.966 179.875 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 22.6 t -57.89 -29.02 64.73 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.36 -0.837 . . . . 0.0 109.334 179.643 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.22 10.14 52.08 Favored Glycine 0 N--CA 1.493 2.465 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 -179.806 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 83.7 mtp180 -117.04 155.28 29.49 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.384 -1.068 . . . . 0.0 109.175 179.909 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 165' ' ' THR . . . . . 0.434 ' OG1' ' O ' ' A' ' 167' ' ' LYS . 44.8 p -110.71 156.43 21.04 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.243 -0.911 . . . . 0.0 109.62 -179.759 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -68.19 -37.28 80.76 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.414 -0.804 . . . . 0.0 109.435 179.676 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 167' ' ' LYS . . . . . 0.434 ' O ' ' OG1' ' A' ' 165' ' ' THR . 3.7 mptp? -105.18 158.67 16.43 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.405 -0.809 . . . . 0.0 109.597 -179.834 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 61.3 mttp -81.34 151.99 27.73 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.346 -0.846 . . . . 0.0 109.475 179.83 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 30.9 m -131.14 124.37 55.45 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.301 -0.874 . . . . 0.0 109.649 179.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 46.3 t -148.59 147.08 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.296 -0.877 . . . . 0.0 108.988 179.602 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . 0.764 ' CG2' ' H ' ' A' ' 64' ' ' SER . 2.8 m -87.81 123.16 40.25 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.838 0 O-C-N 120.952 -1.093 . . . . 0.0 109.944 -179.9 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -74.29 -36.72 63.78 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.327 -0.858 . . . . 0.0 110.367 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 173' ' ' ASP . . . . . 0.465 ' OD1' ' N ' ' A' ' 174' ' ' CYS . 54.3 t0 -155.08 153.65 31.22 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 120.914 -1.116 . . . . 0.0 110.662 -179.1 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 174' ' ' CYS . . . . . 0.6 ' SG ' ' CE2' ' A' ' 14' ' ' PHE . 45.4 t -142.15 141.49 32.64 Favored 'General case' 0 N--CA 1.492 1.63 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.48 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -169.52 -178.86 40.99 Favored Glycine 0 N--CA 1.493 2.441 0 N-CA-C 109.806 -1.318 . . . . 0.0 109.806 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 176' ' ' GLN . . . . . 0.677 ' NE2' ' HE ' ' A' ' 43' ' ' ARG . 6.8 tt0 -105.22 120.49 41.67 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.406 -1.055 . . . . 0.0 109.66 -179.875 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 32.1 tp -63.59 -37.81 88.75 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.156 -0.965 . . . . 0.0 109.321 179.414 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 10.9 t . . . . . 0 N--CA 1.49 1.533 0 CA-C-O 118.001 -0.999 . . . . 0.0 109.432 -179.952 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.529 4.859 0 N-CA-C 119.357 2.503 . . . . 0.0 119.357 . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 55.1 p -69.89 161.73 29.36 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.273 -1.133 . . . . 0.0 109.518 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 99.1 m-85 -111.39 122.89 49.04 Favored 'General case' 0 N--CA 1.487 1.379 0 O-C-N 121.479 -0.763 . . . . 0.0 108.956 179.766 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 75.4 m -81.01 139.38 35.8 Favored 'General case' 0 C--N 1.299 -1.625 0 O-C-N 121.565 -0.709 . . . . 0.0 109.507 179.824 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 165.91 40.06 0.02 OUTLIER Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.631 -1.387 . . . . 0.0 109.631 -179.92 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 28.6 t -113.75 142.98 45.38 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.412 -1.052 . . . . 0.0 109.308 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 63.0 mtt -125.48 67.14 56.7 Favored Pre-proline 0 N--CA 1.493 1.714 0 O-C-N 121.371 -0.831 . . . . 0.0 109.521 -179.951 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_endo -66.79 -15.46 47.33 Favored 'Trans proline' 0 C--N 1.308 -1.6 0 C-N-CA 122.587 2.191 . . . . 0.0 112.138 179.926 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 14.9 m-80 -124.19 72.23 55.94 Favored Pre-proline 0 N--CA 1.494 1.73 0 O-C-N 121.342 -0.849 . . . . 0.0 109.675 -179.768 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -68.22 141.67 52.9 Favored 'Trans proline' 0 N--CA 1.496 1.67 0 C-N-CA 122.62 2.213 . . . . 0.0 112.144 179.877 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 78.4 mtm180 -128.08 133.43 49.04 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.463 -0.773 . . . . 0.0 108.981 179.428 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.2 p -135.57 143.38 36.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.329 -0.857 . . . . 0.0 109.576 -179.822 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 39.2 p90 -137.22 152.83 50.3 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.418 -0.801 . . . . 0.0 109.34 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.459 ' CE1' ' CE1' ' A' ' 61' ' ' TYR . 98.1 m-85 -124.08 132.84 53.71 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.563 -0.711 . . . . 0.0 109.399 179.8 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.6 t0 -91.29 114.56 27.12 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.224 -0.923 . . . . 0.0 108.776 179.485 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 79.7 mtp -107.26 137.33 45.52 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.255 -0.903 . . . . 0.0 110.031 -179.392 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 19.8 m -130.41 152.93 49.28 Favored 'General case' 0 N--CA 1.492 1.639 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 179.636 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.411 ' O ' ' N ' ' A' ' 21' ' ' GLN . 29.8 m -119.05 134.85 61.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.227 -0.921 . . . . 0.0 109.442 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 49.26 25.03 5.47 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 84.24 20.67 58.52 Favored Glycine 0 N--CA 1.492 2.398 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 -179.914 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' GLN . . . . . 0.411 ' N ' ' O ' ' A' ' 18' ' ' VAL . 40.6 mt-30 -120.11 99.19 48.79 Favored Pre-proline 0 N--CA 1.495 1.778 0 O-C-N 121.377 -1.072 . . . . 0.0 109.414 -179.904 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 75.2 Cg_exo -46.53 99.1 0.03 OUTLIER 'Trans proline' 0 N--CA 1.491 1.382 0 C-N-CA 122.353 2.035 . . . . 0.0 112.237 -179.883 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -65.27 -39.85 93.14 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.355 -0.841 . . . . 0.0 109.806 -179.799 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 167.36 -169.11 40.89 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.677 -1.369 . . . . 0.0 109.677 -179.798 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 97.1 mtt180 -115.26 147.05 40.86 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.5 -1.0 . . . . 0.0 109.45 179.812 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 77.2 mt -119.71 123.29 70.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 N-CA-C 108.463 -0.94 . . . . 0.0 108.463 179.118 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 24.8 t -114.26 132.95 61.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.373 -0.829 . . . . 0.0 109.423 -179.488 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' MET . . . . . 0.521 ' SD ' ' CD1' ' A' ' 111' ' ' LEU . 73.2 mtm -125.66 152.71 44.86 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.382 -0.824 . . . . 0.0 109.196 -179.84 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -99.01 133.26 43.53 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.259 -0.901 . . . . 0.0 109.761 179.877 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -108.85 131.16 55.27 Favored 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 179.794 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 98.2 m-85 -96.36 120.3 36.41 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.095 -1.003 . . . . 0.0 109.063 179.764 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -84.06 -41.1 17.54 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.338 -0.851 . . . . 0.0 109.865 -179.729 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -65.81 -44.71 84.83 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.275 -0.891 . . . . 0.0 110.624 -179.185 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 52.9 m -67.05 -44.87 79.06 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.09 -1.006 . . . . 0.0 110.241 -179.291 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 2.0 m -150.68 82.89 5.98 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.155 -0.966 . . . . 0.0 109.269 -179.666 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 39.9 Cg_endo -71.37 -38.32 4.79 Favored 'Trans proline' 0 C--N 1.308 -1.592 0 C-N-CA 122.19 1.927 . . . . 0.0 112.361 -179.361 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 35.2 mmt180 -64.5 -41.81 96.22 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.126 -0.983 . . . . 0.0 109.691 -179.858 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 80.8 m -67.55 -42.66 82.32 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.194 -0.941 . . . . 0.0 110.034 -179.715 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -61.31 -31.81 71.66 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.11 -0.994 . . . . 0.0 108.962 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.429 ' OE1' ' OH ' ' A' ' 92' ' ' TYR . 85.0 tt0 -70.33 -38.07 74.8 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.422 -0.799 . . . . 0.0 109.999 -179.895 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 20.4 t-20 -57.91 -43.92 86.49 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.265 -0.897 . . . . 0.0 109.865 -179.534 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -85.3 -46.71 10.74 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.247 -0.908 . . . . 0.0 109.606 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 71.2 ttp85 -57.24 -42.88 82.32 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.312 -0.867 . . . . 0.0 109.663 -179.894 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.5 ' O ' ' N ' ' A' ' 48' ' ' GLY . . . -72.13 -46.27 57.22 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.288 -0.883 . . . . 0.0 109.899 -179.691 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 38.2 tp -61.97 -37.68 85.69 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.095 -1.003 . . . . 0.0 109.438 -179.817 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' CYS . . . . . . . . . . . . . 98.7 m -67.19 -65.93 0.62 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.305 -0.872 . . . . 0.0 109.579 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 31.0 m -64.6 -37.17 86.65 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.374 -0.829 . . . . 0.0 109.404 179.656 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . 0.5 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 80.94 37.8 17.86 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 110.037 -1.225 . . . . 0.0 110.037 179.831 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -61.72 -37.85 85.72 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.089 -1.242 . . . . 0.0 109.51 179.913 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 70.4 mmtt -61.37 -35.49 77.62 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.295 -0.878 . . . . 0.0 109.42 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 88.16 -174.89 44.25 Favored Glycine 0 N--CA 1.484 1.875 0 N-CA-C 108.979 -1.648 . . . . 0.0 108.979 -179.574 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 89.6 m -71.36 139.19 49.73 Favored 'General case' 0 C--N 1.295 -1.78 0 O-C-N 121.537 -0.978 . . . . 0.0 109.603 179.893 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -56.8 136.37 50.09 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.176 -1.57 . . . . 0.0 109.176 179.795 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 86.4 mtt-85 -58.77 -36.94 75.22 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.222 -1.164 . . . . 0.0 109.857 -179.617 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 24.8 m -59.59 -33.94 72.11 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.21 -0.931 . . . . 0.0 109.802 -179.825 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 124.96 91.92 0.91 Allowed Glycine 0 N--CA 1.494 2.514 0 N-CA-C 108.953 -1.659 . . . . 0.0 108.953 -179.658 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . 0.494 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 28.0 tttp -175.69 79.76 0.3 Allowed Pre-proline 0 N--CA 1.489 1.478 0 O-C-N 121.447 -1.031 . . . . 0.0 108.406 -179.709 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_exo -49.65 131.8 29.38 Favored 'Trans proline' 0 C--N 1.303 -1.848 0 C-N-CA 122.923 2.415 . . . . 0.0 112.845 -178.927 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.494 ' CD1' ' O ' ' A' ' 57' ' ' LYS . 8.7 mp -103.35 113.09 26.3 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.591 -0.693 . . . . 0.0 109.365 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . 0.507 ' O ' ' CE1' ' A' ' 80' ' ' PHE . 70.8 m80 -141.1 126.25 18.43 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.203 -0.936 . . . . 0.0 109.544 179.473 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . 0.459 ' CE1' ' CE1' ' A' ' 14' ' ' PHE . 13.7 t80 -94.42 -11.67 29.36 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.359 -0.838 . . . . 0.0 108.936 179.743 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -78.68 160.52 27.46 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.451 -0.78 . . . . 0.0 109.775 -179.485 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 50.1 t0 60.44 45.8 10.48 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.513 -0.742 . . . . 0.0 109.932 179.647 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 92.5 p -116.25 150.9 36.82 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.328 -0.858 . . . . 0.0 108.841 179.291 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' SER . . . . . 0.408 ' O ' ' OD2' ' A' ' 79' ' ' ASP . 29.4 t -121.17 147.33 45.73 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.257 -0.902 . . . . 0.0 109.716 -179.514 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.3 m-30 -68.18 138.34 55.56 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.351 -0.843 . . . . 0.0 108.907 179.825 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 80.0 t60 -60.51 -51.2 70.48 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.218 -0.926 . . . . 0.0 110.138 -179.327 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.672 HH21 ' NE2' ' A' ' 76' ' ' GLN . 38.5 ptt180 -162.85 162.78 26.58 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.073 -1.017 . . . . 0.0 109.873 179.946 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 18.4 m -131.52 150.01 33.68 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.725 0 O-C-N 121.445 -0.785 . . . . 0.0 109.052 179.761 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 14.3 mt -147.29 119.43 4.71 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.024 -1.047 . . . . 0.0 109.433 179.714 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -73.95 134.48 19.79 Favored 'Trans proline' 0 C--N 1.313 -1.316 0 C-N-CA 122.022 1.815 . . . . 0.0 111.868 179.948 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 89.54 2.58 76.04 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.456 ' C ' ' SD ' ' A' ' 74' ' ' MET . 80.2 m-85 -137.22 -94.32 0.22 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.312 -1.11 . . . . 0.0 109.711 179.9 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' MET . . . . . 0.456 ' SD ' ' C ' ' A' ' 73' ' ' PHE . 0.0 OUTLIER -162.98 172.71 14.62 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.161 -0.962 . . . . 0.0 109.81 -179.688 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 1.9 m -119.49 135.16 54.89 Favored 'General case' 0 N--CA 1.494 1.728 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 179.543 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' GLN . . . . . 0.672 ' NE2' HH21 ' A' ' 68' ' ' ARG . 93.8 mt-30 -104.06 153.75 20.51 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.286 -0.884 . . . . 0.0 109.816 -179.638 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -158.99 -170.89 24.08 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.329 -1.509 . . . . 0.0 109.329 -179.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 80.02 37.94 20.61 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.504 -1.439 . . . . 0.0 109.504 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.437 ' C ' ' OD1' ' A' ' 79' ' ' ASP . 54.2 p30 -85.24 12.16 8.6 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.291 -1.123 . . . . 0.0 109.46 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.507 ' CE1' ' O ' ' A' ' 60' ' ' HIS . 76.3 t80 -52.88 -44.9 67.2 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.348 -0.845 . . . . 0.0 109.937 -179.902 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.619 ' CB ' ' H ' ' A' ' 88' ' ' GLY . 69.0 p -69.45 -29.25 66.9 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.149 -0.969 . . . . 0.0 109.513 -179.928 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . 0.486 ' CB ' ' O ' ' A' ' 81' ' ' THR . . . 165.76 -55.88 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.229 -0.919 . . . . 0.0 109.365 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 92.28 0.29 70.76 Favored Glycine 0 N--CA 1.492 2.389 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 -179.928 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 77.7 m-20 -87.57 5.51 38.98 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.213 -1.169 . . . . 0.0 109.474 179.931 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 96.04 -36.81 3.67 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.329 -1.508 . . . . 0.0 109.329 -179.903 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 56.2 p -73.53 -18.9 61.03 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.271 -1.134 . . . . 0.0 109.164 179.638 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -83.34 -164.04 35.62 Favored Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.611 -1.395 . . . . 0.0 109.611 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.619 ' H ' ' CB ' ' A' ' 81' ' ' THR . . . 92.28 24.09 25.24 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.314 -1.514 . . . . 0.0 109.314 -179.785 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -57.3 145.59 31.6 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.432 -1.04 . . . . 0.0 109.687 -179.864 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 28.8 t -107.03 146.14 31.49 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.328 -0.858 . . . . 0.0 109.263 179.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 20.3 pt -61.26 -33.24 55.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.131 -0.98 . . . . 0.0 109.746 -179.812 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . 0.429 ' OH ' ' OE1' ' A' ' 40' ' ' GLU . 91.7 m-85 -65.51 -36.15 82.98 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.285 -0.884 . . . . 0.0 109.653 179.959 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.09 15.24 70.12 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.319 -1.513 . . . . 0.0 109.319 -179.654 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -143.64 155.92 44.4 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.309 -1.113 . . . . 0.0 109.545 -179.859 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 63.1 mttp -94.03 137.89 32.72 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.287 -0.883 . . . . 0.0 109.586 -179.846 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -123.9 154.23 40.0 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.309 -0.869 . . . . 0.0 109.768 179.901 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -107.1 154.65 20.85 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.469 -0.769 . . . . 0.0 109.06 179.536 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 60.0 t0 -76.68 105.48 7.77 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.032 -1.042 . . . . 0.0 109.378 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -67.22 -34.15 76.88 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.284 -0.885 . . . . 0.0 110.062 -179.809 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 86.5 m-20 -105.0 124.71 50.0 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.251 -0.906 . . . . 0.0 110.052 -179.35 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 99.2 m-85 -108.13 12.78 26.46 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.462 -0.774 . . . . 0.0 109.067 179.556 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 92.6 mt -53.36 -39.25 34.86 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.326 -0.859 . . . . 0.0 110.048 -179.319 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 58.0 mttm -82.25 132.9 35.23 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.983 -1.073 . . . . 0.0 109.592 -179.849 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 80.7 tttt -138.65 158.85 43.46 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.41 -0.806 . . . . 0.0 109.335 -179.891 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' HIS . . . . . 0.611 ' CE1' ' HG ' ' A' ' 128' ' ' CYS . 85.2 t60 -86.07 99.17 11.29 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.233 -0.917 . . . . 0.0 109.431 179.886 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 65.9 p -115.78 -1.62 12.59 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.352 -0.842 . . . . 0.0 109.607 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.539 ' O ' ' CE1' ' A' ' 105' ' ' HIS . . . -153.84 169.92 32.47 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -73.88 158.86 45.92 Favored 'Trans proline' 0 C--N 1.306 -1.671 0 C-N-CA 122.935 2.424 . . . . 0.0 112.25 179.811 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 81.9 43.21 8.38 Favored Glycine 0 N--CA 1.493 2.459 0 N-CA-C 109.885 -1.286 . . . . 0.0 109.885 179.694 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.418 ' CG1' ' HD1' ' A' ' 105' ' ' HIS . 44.3 mm -117.0 132.7 66.0 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.725 0 O-C-N 121.287 -1.125 . . . . 0.0 109.598 179.981 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . 0.554 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 1.7 mm? -89.23 133.63 34.36 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.214 -0.929 . . . . 0.0 108.756 179.452 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' SER . . . . . 0.561 ' OG ' ' CZ ' ' A' ' 126' ' ' PHE . 99.0 p -143.38 154.26 43.54 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.109 -0.994 . . . . 0.0 109.628 -179.907 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 72.1 mtm -93.64 136.66 33.7 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.305 -0.872 . . . . 0.0 109.213 179.556 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -65.09 138.09 58.08 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.215 -0.928 . . . . 0.0 109.185 179.815 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 70.6 m-20 -135.19 115.29 13.2 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.257 -0.902 . . . . 0.0 109.441 179.88 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -85.1 -9.89 57.43 Favored 'General case' 0 C--N 1.297 -1.675 0 O-C-N 121.501 -0.749 . . . . 0.0 109.096 179.501 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . 0.43 ' H ' HG23 ' A' ' 120' ' ' THR . . . -136.12 173.76 21.76 Favored Glycine 0 N--CA 1.492 2.367 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 -179.746 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -57.09 -25.4 63.41 Favored 'Trans proline' 0 C--N 1.307 -1.648 0 C-N-CA 122.747 2.298 . . . . 0.0 112.196 -179.905 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 119' ' ' ASN . . . . . 0.441 ' O ' ' OD1' ' A' ' 119' ' ' ASN . 42.4 p-10 -153.19 96.18 2.03 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.17 -0.956 . . . . 0.0 109.908 179.836 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 120' ' ' THR . . . . . 0.43 HG23 ' H ' ' A' ' 117' ' ' GLY . 0.5 OUTLIER -148.74 123.81 10.09 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 121.327 -0.858 . . . . 0.0 109.338 179.774 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 51.3 t-20 -100.38 121.84 42.18 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.355 -0.84 . . . . 0.0 109.449 -179.861 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -137.08 158.99 24.52 Favored Glycine 0 N--CA 1.493 2.473 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 78.5 p -69.06 -19.08 64.08 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.345 -1.091 . . . . 0.0 109.645 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.9 mt-30 -66.5 137.44 56.8 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.134 -0.978 . . . . 0.0 109.613 -179.593 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 44.5 p90 -146.49 161.68 39.91 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.33 -0.857 . . . . 0.0 109.323 179.892 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.561 ' CZ ' ' OG ' ' A' ' 112' ' ' SER . 51.9 p90 -141.16 159.05 43.04 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.166 -0.959 . . . . 0.0 109.577 179.716 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 77.7 mt -116.43 135.1 57.77 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.354 -0.841 . . . . 0.0 109.425 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 128' ' ' CYS . . . . . 0.611 ' HG ' ' CE1' ' A' ' 105' ' ' HIS . 0.2 OUTLIER -99.23 99.79 10.81 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.388 -0.82 . . . . 0.0 109.423 -179.871 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 61.9 p -76.3 -6.86 53.37 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.322 -0.861 . . . . 0.0 109.321 179.812 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -139.91 162.76 34.41 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.369 -0.832 . . . . 0.0 109.316 -179.897 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . 0.525 ' O ' ' CZ3' ' A' ' 134' ' ' TRP . 99.2 mttt -71.56 131.99 44.04 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.19 -0.944 . . . . 0.0 109.563 -179.654 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 74.0 p -122.97 37.99 4.29 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.538 -0.726 . . . . 0.0 109.318 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 78.3 mm-40 -57.65 -31.12 65.99 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.272 -0.893 . . . . 0.0 109.733 -179.504 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 134' ' ' TRP . . . . . 0.525 ' CZ3' ' O ' ' A' ' 131' ' ' LYS . 12.7 p90 -55.24 -28.44 53.26 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.047 -1.033 . . . . 0.0 109.64 -179.805 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . 0.503 ' N ' ' CD1' ' A' ' 134' ' ' TRP . 69.0 mt -58.11 -35.93 72.18 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.055 -1.028 . . . . 0.0 109.473 179.3 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 57.2 t0 53.81 69.92 0.66 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.436 -0.79 . . . . 0.0 109.705 179.569 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -138.4 176.36 20.83 Favored Glycine 0 N--CA 1.484 1.857 0 N-CA-C 108.915 -1.674 . . . . 0.0 108.915 179.712 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . 0.427 ' O ' ' O ' ' A' ' 139' ' ' HIS . 63.0 mttp -59.21 -40.12 84.8 Favored 'General case' 0 C--N 1.296 -1.727 0 O-C-N 121.39 -1.065 . . . . 0.0 109.968 -179.768 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 139' ' ' HIS . . . . . 0.427 ' O ' ' O ' ' A' ' 138' ' ' LYS . 61.3 m170 51.75 98.89 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.414 -0.804 . . . . 0.0 109.542 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 52.1 t -105.49 135.18 44.69 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.751 0 O-C-N 121.461 -0.774 . . . . 0.0 109.395 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 48.5 t -117.04 128.71 74.38 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.485 -0.76 . . . . 0.0 109.691 -179.726 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 37.5 p90 -113.31 -1.21 14.32 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.376 -0.828 . . . . 0.0 109.539 179.458 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -173.84 -177.36 42.98 Favored Glycine 0 N--CA 1.493 2.438 0 N-CA-C 109.818 -1.313 . . . . 0.0 109.818 179.842 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.4 pt20 -144.22 171.39 14.37 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.311 -1.111 . . . . 0.0 109.475 -179.763 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 8.3 p -111.08 138.29 40.0 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.902 0 O-C-N 121.268 -0.895 . . . . 0.0 109.281 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 10.5 m -119.32 -28.16 2.05 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.483 -0.761 . . . . 0.0 109.679 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -138.06 167.16 22.37 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.249 -0.907 . . . . 0.0 109.567 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 97.49 3.23 58.6 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.779 -1.329 . . . . 0.0 109.779 179.652 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 149' ' ' MET . . . . . . . . . . . . . 89.2 mtp -60.65 -32.56 71.73 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.183 -1.186 . . . . 0.0 109.771 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . 0.549 ' OD1' ' N ' ' A' ' 151' ' ' VAL . 32.9 p-10 -65.46 -37.44 86.86 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 120.85 -1.156 . . . . 0.0 109.902 -179.565 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . 0.549 ' N ' ' OD1' ' A' ' 150' ' ' ASP . 5.2 p -87.31 -34.31 7.39 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.711 0 O-C-N 121.101 -0.999 . . . . 0.0 110.243 -179.672 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 152' ' ' VAL . . . . . 0.461 ' CG1' ' N ' ' A' ' 153' ' ' LYS . 0.9 OUTLIER -56.04 -42.35 71.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 120.996 -1.065 . . . . 0.0 109.101 -179.513 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 153' ' ' LYS . . . . . 0.461 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 98.7 mttt -64.42 -33.77 76.64 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.172 -0.955 . . . . 0.0 109.433 179.471 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -61.24 -38.8 87.95 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.351 -0.843 . . . . 0.0 110.132 -179.4 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.431 HG21 HD11 ' A' ' 155' ' ' ILE . 86.8 mt -72.3 -36.64 56.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.045 -1.034 . . . . 0.0 110.159 -179.728 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -76.29 -41.69 47.89 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.178 -0.951 . . . . 0.0 111.402 -178.784 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 16.8 pttp -60.45 -35.23 75.36 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 120.744 -1.223 . . . . 0.0 109.734 -178.845 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 32.7 m -82.46 -10.9 12.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.166 -0.958 . . . . 0.0 109.061 179.581 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -70.97 165.1 53.31 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.981 -1.248 . . . . 0.0 109.981 -179.565 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 24.1 t -154.08 168.55 26.1 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.421 -1.046 . . . . 0.0 109.439 -179.82 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 25.1 m -54.32 -29.6 48.33 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.279 -0.888 . . . . 0.0 109.341 179.808 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 24.7 m -53.31 -31.27 43.25 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.287 -0.883 . . . . 0.0 109.589 -179.882 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 96.05 8.98 57.55 Favored Glycine 0 N--CA 1.493 2.472 0 N-CA-C 109.766 -1.333 . . . . 0.0 109.766 179.896 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 82.3 mtm180 -122.93 145.56 48.36 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.209 -1.171 . . . . 0.0 109.471 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 165' ' ' THR . . . . . 0.434 ' OG1' ' O ' ' A' ' 167' ' ' LYS . 80.9 p -80.57 153.52 28.01 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.189 -0.945 . . . . 0.0 109.36 179.79 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -66.0 -34.6 78.46 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.293 -0.879 . . . . 0.0 109.158 179.714 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 167' ' ' LYS . . . . . 0.434 ' O ' ' OG1' ' A' ' 165' ' ' THR . 62.9 mttp -112.38 157.49 20.96 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.466 -0.771 . . . . 0.0 109.262 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 63.0 mttp -69.87 141.69 53.16 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.245 -0.91 . . . . 0.0 109.144 179.912 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 18.2 m -128.05 125.33 64.39 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 121.315 -0.866 . . . . 0.0 109.683 -179.819 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 46.5 t -148.33 152.13 12.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.43 -0.794 . . . . 0.0 109.114 179.766 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -91.15 114.94 29.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.23 -0.919 . . . . 0.0 109.374 -179.753 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -75.68 -11.47 60.01 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.521 -0.737 . . . . 0.0 110.072 -179.882 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 173' ' ' ASP . . . . . 0.475 ' OD1' ' N ' ' A' ' 174' ' ' CYS . 51.8 t0 -164.85 157.79 16.69 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 120.76 -1.212 . . . . 0.0 110.848 -179.31 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 174' ' ' CYS . . . . . 0.475 ' N ' ' OD1' ' A' ' 173' ' ' ASP . 16.7 t -154.85 141.64 19.05 Favored 'General case' 0 N--CA 1.492 1.657 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 179.372 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -178.05 178.08 48.46 Favored Glycine 0 N--CA 1.493 2.48 0 N-CA-C 109.749 -1.34 . . . . 0.0 109.749 179.776 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 60.9 tt0 -106.93 124.06 49.07 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.367 -1.078 . . . . 0.0 109.732 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 30.6 tp -62.92 -37.99 89.22 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.132 -0.98 . . . . 0.0 109.264 179.509 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 33.1 m . . . . . 0 N--CA 1.49 1.549 0 CA-C-O 118.066 -0.969 . . . . 0.0 109.501 -179.967 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.529 4.881 0 N-CA-C 119.318 2.487 . . . . 0.0 119.318 . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 28.8 t -115.9 141.7 47.76 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.295 -1.121 . . . . 0.0 109.35 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 49.0 p90 -148.12 164.34 34.17 Favored 'General case' 0 C--N 1.306 -1.309 0 O-C-N 121.291 -0.88 . . . . 0.0 108.75 179.837 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 18.8 p -118.53 162.36 18.49 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.593 -0.692 . . . . 0.0 109.285 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -139.13 56.15 0.65 Allowed Glycine 0 N--CA 1.493 2.449 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 -179.761 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 54.5 p -67.2 159.36 29.2 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.089 -1.242 . . . . 0.0 109.257 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 55.1 mtt -74.67 149.78 86.17 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.194 -0.941 . . . . 0.0 109.518 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -71.53 169.67 20.38 Favored 'Trans proline' 0 C--N 1.31 -1.491 0 C-N-CA 122.648 2.232 . . . . 0.0 111.921 179.881 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 13.4 m-20 -64.18 146.62 97.5 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.254 -0.904 . . . . 0.0 109.088 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_endo -67.73 140.81 52.43 Favored 'Trans proline' 0 N--CA 1.494 1.556 0 C-N-CA 122.492 2.128 . . . . 0.0 112.07 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 80.9 mtm180 -126.58 139.18 53.39 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.316 -0.865 . . . . 0.0 109.166 179.614 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 15.0 p -133.71 142.81 40.47 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 121.327 -0.858 . . . . 0.0 109.519 -179.878 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' PHE . . . . . 0.483 ' CE2' ' NH2' ' A' ' 25' ' ' ARG . 28.6 p90 -141.85 155.94 45.54 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.304 -0.872 . . . . 0.0 109.683 -179.598 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -130.46 139.27 50.55 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.484 -0.76 . . . . 0.0 109.777 179.628 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -95.35 117.24 29.97 Favored 'General case' 0 N--CA 1.491 1.601 0 N-CA-C 108.188 -1.041 . . . . 0.0 108.188 178.788 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 76.9 mtp -107.74 147.44 30.79 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.121 -0.987 . . . . 0.0 110.443 -178.816 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 88.4 p -143.3 163.25 33.51 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 179.574 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.401 ' O ' ' C ' ' A' ' 19' ' ' GLY . 29.1 m -122.97 140.55 46.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.218 -0.927 . . . . 0.0 109.476 179.921 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.401 ' C ' ' O ' ' A' ' 18' ' ' VAL . . . 44.46 -102.68 0.04 OUTLIER Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.636 -1.386 . . . . 0.0 109.636 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -130.38 38.15 2.01 Favored Glycine 0 N--CA 1.493 2.475 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 8.4 tt0 -147.18 133.49 9.68 Favored Pre-proline 0 N--CA 1.492 1.656 0 O-C-N 121.125 -1.221 . . . . 0.0 109.181 179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 43.0 Cg_endo -69.9 126.7 13.52 Favored 'Trans proline' 0 N--CA 1.493 1.494 0 C-N-CA 122.193 1.929 . . . . 0.0 112.218 -179.788 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -80.39 -48.21 13.26 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.288 -0.883 . . . . 0.0 109.432 179.849 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 170.94 -169.41 42.42 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.37 -1.492 . . . . 0.0 109.37 -179.788 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . 0.483 ' NH2' ' CE2' ' A' ' 13' ' ' PHE . 66.4 ttt180 -116.93 142.47 46.9 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.413 -1.051 . . . . 0.0 109.291 179.942 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 86.9 mt -120.68 128.03 75.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.424 -0.797 . . . . 0.0 108.998 179.804 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 46.1 t -116.99 133.81 62.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.508 -0.745 . . . . 0.0 109.311 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 71.3 mtm -125.38 147.37 49.19 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.343 -0.848 . . . . 0.0 109.251 179.91 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -112.56 132.6 55.03 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.267 -0.896 . . . . 0.0 109.84 -179.686 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 11.8 mt -103.09 139.66 38.33 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.416 -0.802 . . . . 0.0 109.36 179.262 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -95.6 113.32 24.95 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 108.342 -0.985 . . . . 0.0 108.342 178.795 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -73.96 -42.8 59.97 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 121.232 -0.917 . . . . 0.0 109.94 -179.376 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 56.6 t0 -61.33 -46.58 89.66 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.191 -0.943 . . . . 0.0 110.163 -179.36 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' THR . . . . . 0.432 ' O ' ' OE1' ' A' ' 99' ' ' GLU . 24.0 m -72.41 -45.77 58.18 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.16 -0.962 . . . . 0.0 110.215 -179.596 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 6.4 p -137.87 80.66 29.95 Favored Pre-proline 0 N--CA 1.494 1.774 0 O-C-N 121.162 -0.962 . . . . 0.0 110.069 -179.224 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -77.24 -6.18 16.29 Favored 'Trans proline' 0 C--N 1.307 -1.645 0 C-N-CA 122.507 2.138 . . . . 0.0 111.642 179.546 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 4.5 tpt180 -94.29 -67.03 0.88 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.375 -0.828 . . . . 0.0 110.151 -178.797 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 46.4 m -56.46 -43.32 79.43 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.191 -0.943 . . . . 0.0 110.231 -179.058 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -61.77 -31.71 71.93 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.146 -0.971 . . . . 0.0 108.968 179.747 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -75.51 -51.18 13.55 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.272 -0.893 . . . . 0.0 109.9 -179.898 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 54.2 t-20 -60.39 -46.71 88.99 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.177 -0.952 . . . . 0.0 109.605 -179.707 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . 0.51 ' CE2' ' SG ' ' A' ' 46' ' ' CYS . 71.8 t80 -61.28 -43.23 99.22 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.3 -0.875 . . . . 0.0 109.215 179.637 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 60.1 ttp180 -56.63 -38.37 72.02 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.466 -0.771 . . . . 0.0 109.844 179.825 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.474 ' O ' ' N ' ' A' ' 48' ' ' GLY . . . -62.85 -44.21 96.74 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.137 -0.977 . . . . 0.0 109.915 -179.507 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.434 ' N ' ' CD2' ' A' ' 45' ' ' LEU . 3.7 mm? -62.96 -39.06 93.52 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.097 -1.002 . . . . 0.0 109.131 179.729 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' CYS . . . . . 0.51 ' SG ' ' CE2' ' A' ' 42' ' ' PHE . 3.4 m -69.52 -62.4 1.4 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.259 -0.901 . . . . 0.0 109.473 -179.875 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 35.5 m -63.13 -38.57 91.71 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.398 -0.814 . . . . 0.0 109.272 179.889 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . 0.474 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 80.83 35.33 25.18 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 110.197 -1.161 . . . . 0.0 110.197 179.555 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -62.52 -38.13 88.75 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.046 -1.267 . . . . 0.0 109.544 179.89 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 69.3 mmtt -62.56 -37.18 85.14 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.178 -0.951 . . . . 0.0 109.777 -179.83 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 89.34 170.01 44.58 Favored Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.297 -1.521 . . . . 0.0 109.297 -179.646 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 91.3 m -77.66 139.52 39.47 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.355 -1.085 . . . . 0.0 109.706 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -63.25 139.41 44.18 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 31.6 mmt180 -59.68 -34.37 72.78 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.33 -1.1 . . . . 0.0 109.767 -179.72 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 85.9 p -61.55 -25.58 67.39 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.222 -0.924 . . . . 0.0 109.902 -179.667 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 113.78 93.1 1.99 Allowed Glycine 0 N--CA 1.495 2.596 0 N-CA-C 109.063 -1.615 . . . . 0.0 109.063 -179.64 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . 0.477 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 30.3 ttmt -177.64 80.43 0.24 Allowed Pre-proline 0 N--CA 1.49 1.543 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 -179.769 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . 0.523 ' O ' ' CE2' ' A' ' 80' ' ' PHE . 74.6 Cg_exo -49.64 127.23 18.07 Favored 'Trans proline' 0 C--N 1.304 -1.812 0 C-N-CA 122.847 2.365 . . . . 0.0 112.768 -178.898 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.477 ' CD1' ' O ' ' A' ' 57' ' ' LYS . 8.7 mp -96.97 19.68 12.39 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.57 -0.707 . . . . 0.0 109.263 179.808 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 27.2 m170 -112.44 132.01 55.27 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.354 -0.841 . . . . 0.0 109.759 -179.441 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 46.4 m-85 -71.93 -1.92 16.18 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.217 -0.927 . . . . 0.0 108.838 178.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 43.6 tttm -54.85 144.23 23.34 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.411 -0.805 . . . . 0.0 109.712 -179.88 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 51.1 t0 58.99 45.57 14.72 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.549 -0.719 . . . . 0.0 109.623 179.853 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 87.7 p -116.52 152.12 34.74 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.394 -0.817 . . . . 0.0 109.131 179.547 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 29.4 t -120.95 146.73 46.35 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.395 -0.816 . . . . 0.0 109.506 -179.725 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.428 ' CD2' ' SG ' ' A' ' 75' ' ' CYS . 3.8 m-30 -65.7 134.02 52.31 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.247 -0.908 . . . . 0.0 108.992 179.763 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 78.5 t60 -62.1 -50.73 70.74 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.265 -0.897 . . . . 0.0 110.1 -179.36 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 29.1 ptt180 -164.61 160.41 20.09 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.062 -1.024 . . . . 0.0 109.471 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -141.05 130.08 24.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.217 -0.927 . . . . 0.0 109.585 179.588 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 21.9 mt -121.93 110.11 33.39 Favored Pre-proline 0 N--CA 1.491 1.6 0 N-CA-C 108.874 -0.788 . . . . 0.0 108.874 179.443 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_exo -50.39 140.69 34.29 Favored 'Trans proline' 0 C--N 1.311 -1.438 0 C-N-CA 122.341 2.028 . . . . 0.0 112.758 -179.478 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 86.09 -56.29 4.8 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 110.407 -1.077 . . . . 0.0 110.407 179.038 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 81.2 m-85 -66.51 -75.18 0.1 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.005 -1.291 . . . . 0.0 110.178 -179.303 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 12.9 ptt? 179.63 -168.07 0.09 Allowed 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.01 -1.056 . . . . 0.0 109.912 -179.788 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' CYS . . . . . 0.428 ' SG ' ' CD2' ' A' ' 66' ' ' PHE . 7.7 t -128.76 129.34 45.57 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.544 -0.723 . . . . 0.0 109.276 179.743 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 63.7 tt0 -100.12 112.96 25.27 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.148 -0.97 . . . . 0.0 109.321 179.816 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -63.17 -37.32 94.71 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.772 -1.331 . . . . 0.0 109.772 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 82.23 -164.88 44.4 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.22 -1.552 . . . . 0.0 109.22 -179.671 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.466 ' OD2' ' OG1' ' A' ' 81' ' ' THR . 18.0 t70 -143.82 147.5 34.2 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.203 -1.175 . . . . 0.0 109.385 179.938 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.523 ' CE2' ' O ' ' A' ' 58' ' ' PRO . 50.5 p90 -70.89 -20.58 62.49 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.228 -0.92 . . . . 0.0 109.943 -179.79 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.466 ' OG1' ' OD2' ' A' ' 79' ' ' ASP . 59.0 p -69.26 -28.42 66.3 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.129 -0.982 . . . . 0.0 109.703 -179.817 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 176.57 -58.13 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.277 -0.89 . . . . 0.0 109.47 179.904 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 90.7 2.54 72.32 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 109.413 -1.475 . . . . 0.0 109.413 -179.854 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . 0.597 ' ND2' ' H ' ' A' ' 86' ' ' THR . 0.0 OUTLIER -88.55 7.26 34.03 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.279 -1.13 . . . . 0.0 109.589 179.919 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . 0.507 ' N ' HD21 ' A' ' 84' ' ' ASN . . . 98.29 -37.87 3.31 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 -179.88 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' THR . . . . . 0.597 ' H ' ' ND2' ' A' ' 84' ' ' ASN . 49.4 p -71.38 -25.24 62.28 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.196 -1.179 . . . . 0.0 109.047 179.661 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -86.52 -165.92 41.69 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 179.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 85.44 37.08 9.97 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -60.17 148.4 36.33 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.249 -1.148 . . . . 0.0 109.421 179.925 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 50.3 m -108.01 149.13 28.79 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.402 -0.811 . . . . 0.0 109.391 -179.886 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 21.6 pt -66.24 -32.24 57.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.211 -0.931 . . . . 0.0 110.047 -179.534 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 49.1 m-85 -64.3 -37.4 87.35 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.012 -1.055 . . . . 0.0 109.448 -179.912 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 81.51 8.27 87.22 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.157 -1.577 . . . . 0.0 109.157 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -150.35 155.69 40.09 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.272 -1.134 . . . . 0.0 109.525 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 62.6 mttt -92.95 154.84 17.93 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.241 -0.912 . . . . 0.0 109.641 179.927 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.621 ' CG ' ' ND2' ' A' ' 121' ' ' ASN . 38.6 p90 -128.65 156.17 43.85 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.387 -0.82 . . . . 0.0 109.281 179.563 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -65.0 147.31 53.7 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.216 -0.927 . . . . 0.0 110.358 -179.139 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -62.48 154.33 28.86 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.315 -0.866 . . . . 0.0 109.609 179.912 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . 0.432 ' OE1' ' O ' ' A' ' 34' ' ' THR . 94.6 mt-10 -85.35 -175.41 5.68 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.283 -0.886 . . . . 0.0 109.755 -179.833 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 18.5 m120 -60.3 162.78 5.67 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.416 -0.803 . . . . 0.0 109.94 -179.422 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 -98.67 23.63 8.46 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.43 -0.794 . . . . 0.0 109.585 -179.817 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 97.0 mt -48.38 -42.94 12.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.138 -0.977 . . . . 0.0 109.937 -179.327 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . 0.425 ' CE ' ' HG1' ' A' ' 34' ' ' THR . 59.0 mttm -89.47 139.29 30.67 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 120.931 -1.106 . . . . 0.0 109.689 179.972 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 87.5 mttt -127.28 -172.35 2.64 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.492 -0.755 . . . . 0.0 109.489 -179.898 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' HIS . . . . . 0.428 ' C ' ' ND1' ' A' ' 105' ' ' HIS . 12.3 t-80 -113.77 111.67 22.16 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.531 -0.73 . . . . 0.0 109.189 179.752 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 60.6 p -131.16 4.82 4.43 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.276 -0.89 . . . . 0.0 109.922 -179.862 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -149.37 169.46 29.66 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.825 -1.31 . . . . 0.0 109.825 -179.824 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 76.6 Cg_endo -79.54 155.39 24.48 Favored 'Trans proline' 0 C--N 1.309 -1.543 0 C-N-CA 122.942 2.428 . . . . 0.0 112.083 179.783 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 76.89 52.61 5.72 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.894 -1.282 . . . . 0.0 109.894 179.628 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 38.1 mm -115.21 136.38 52.14 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.403 -1.057 . . . . 0.0 109.51 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . 0.561 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 3.3 mm? -88.27 134.37 33.82 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.227 -0.921 . . . . 0.0 109.537 179.786 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 28.9 t -146.3 142.79 28.65 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.255 -0.903 . . . . 0.0 109.374 179.729 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 87.6 mmm -87.64 132.06 34.22 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.231 -0.918 . . . . 0.0 109.284 179.902 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . 0.463 ' O ' ' OD1' ' A' ' 115' ' ' ASN . . . -68.23 139.69 56.04 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.123 -0.986 . . . . 0.0 109.405 -179.948 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . 0.463 ' OD1' ' O ' ' A' ' 114' ' ' ALA . 70.3 m-20 -145.94 113.44 6.31 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.247 -0.908 . . . . 0.0 109.01 179.642 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -69.15 -30.04 68.19 Favored 'General case' 0 C--N 1.297 -1.687 0 O-C-N 121.393 -0.817 . . . . 0.0 109.442 179.816 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -136.11 170.28 23.29 Favored Glycine 0 N--CA 1.494 2.525 0 N-CA-C 109.146 -1.582 . . . . 0.0 109.146 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -67.61 151.99 78.73 Favored 'Trans proline' 0 C--N 1.305 -1.719 0 C-N-CA 122.77 2.314 . . . . 0.0 111.847 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 16.9 m120 53.34 44.26 30.32 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.33 -0.856 . . . . 0.0 109.143 -179.769 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 120' ' ' THR . . . . . 0.451 ' O ' ' OD1' ' A' ' 115' ' ' ASN . 58.3 m -132.26 123.83 27.69 Favored 'General case' 0 N--CA 1.486 1.373 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 179.924 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 121' ' ' ASN . . . . . 0.621 ' ND2' ' CG ' ' A' ' 96' ' ' PHE . 81.0 m-20 -113.39 138.62 49.8 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.506 -0.746 . . . . 0.0 109.537 -179.832 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -138.54 148.09 19.69 Favored Glycine 0 N--CA 1.493 2.489 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 23.3 m -61.23 -32.55 72.34 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.227 -1.16 . . . . 0.0 109.822 179.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.5 mt-30 -64.24 143.26 58.02 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.207 -0.933 . . . . 0.0 109.879 -179.481 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 48.7 p90 -141.42 163.9 31.68 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.346 -0.846 . . . . 0.0 109.028 179.858 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 45.3 p90 -136.91 158.14 45.14 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.299 -0.876 . . . . 0.0 109.696 -179.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 68.5 mt -120.39 136.53 57.13 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.519 -0.738 . . . . 0.0 109.273 179.799 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -108.5 120.82 43.54 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.457 -0.777 . . . . 0.0 109.358 -179.796 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 1.4 t -88.72 0.98 55.94 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.199 -0.938 . . . . 0.0 109.236 179.816 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -148.19 155.48 41.44 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.271 -0.893 . . . . 0.0 109.176 179.937 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 7.7 ttpm? -75.64 127.91 34.09 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.184 -0.947 . . . . 0.0 109.516 179.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 22.6 p -126.98 126.69 43.62 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.37 -0.831 . . . . 0.0 109.247 179.882 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -72.23 -36.56 69.16 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.28 -0.887 . . . . 0.0 110.366 -179.582 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 0.4 OUTLIER -65.03 -41.76 94.99 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.135 -0.978 . . . . 0.0 110.043 -179.157 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . 0.44 ' O ' ' CD2' ' A' ' 139' ' ' HIS . 12.9 mt -66.59 -33.83 76.53 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.985 -1.072 . . . . 0.0 109.8 179.701 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -68.46 140.85 55.75 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.15 -0.969 . . . . 0.0 109.522 -179.824 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 134.59 -86.19 0.26 Allowed Glycine 0 N--CA 1.492 2.417 0 N-CA-C 109.684 -1.366 . . . . 0.0 109.684 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 31.6 mmtp -85.97 5.32 33.79 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.132 -1.216 . . . . 0.0 109.507 -179.835 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 139' ' ' HIS . . . . . 0.44 ' CD2' ' O ' ' A' ' 135' ' ' LEU . 54.4 m-70 -103.26 138.19 40.38 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.286 -0.884 . . . . 0.0 109.477 -179.955 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 43.2 t -120.48 141.54 40.38 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 O-C-N 121.415 -0.803 . . . . 0.0 109.684 -179.565 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 96.1 t -94.8 128.96 45.61 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.361 -0.837 . . . . 0.0 109.245 179.821 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 38.0 p90 -116.18 0.42 12.92 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.429 -0.794 . . . . 0.0 109.757 -179.77 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -169.42 178.04 42.71 Favored Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.676 -1.37 . . . . 0.0 109.676 179.684 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.2 pt20 -145.13 165.8 27.25 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.21 -1.171 . . . . 0.0 109.479 -179.865 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 77.7 t -96.54 127.28 48.82 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.265 0 O-C-N 121.193 -0.942 . . . . 0.0 109.274 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 22.2 m -94.7 -33.77 5.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.134 -0.979 . . . . 0.0 109.746 179.916 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -144.94 171.92 13.77 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.248 -0.907 . . . . 0.0 109.663 -179.797 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 96.68 4.93 58.99 Favored Glycine 0 N--CA 1.493 2.435 0 N-CA-C 109.915 -1.274 . . . . 0.0 109.915 179.642 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 149' ' ' MET . . . . . 0.418 ' O ' HG11 ' A' ' 152' ' ' VAL . 71.9 mtm -60.31 -33.05 71.82 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.071 -1.252 . . . . 0.0 109.809 179.888 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -65.63 -42.49 91.44 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 120.87 -1.144 . . . . 0.0 110.085 -179.586 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 6.5 p -81.73 -34.33 12.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.149 -0.969 . . . . 0.0 110.522 -179.484 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 152' ' ' VAL . . . . . 0.596 ' O ' ' OE1' ' A' ' 156' ' ' GLU . 0.8 OUTLIER -52.55 -43.07 41.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 120.816 -1.178 . . . . 0.0 109.0 -179.13 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 153' ' ' LYS . . . . . 0.454 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 48.5 mttp -63.12 -34.41 77.54 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.192 -0.942 . . . . 0.0 109.317 179.251 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -63.27 -32.11 73.43 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.429 -0.795 . . . . 0.0 110.176 -179.558 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 69.1 mt -68.79 -43.14 82.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.124 -0.985 . . . . 0.0 110.836 -179.179 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . 0.596 ' OE1' ' O ' ' A' ' 152' ' ' VAL . 32.4 mp0 -77.21 -37.98 52.32 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 120.768 -1.207 . . . . 0.0 112.025 -178.683 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 12.1 pttm -57.48 -35.55 70.33 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 120.523 -1.36 . . . . 0.0 109.731 -178.516 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 26.9 m -75.11 -19.8 16.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 120.969 -1.082 . . . . 0.0 109.013 179.042 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -67.33 167.46 40.04 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 -179.911 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 89.4 p -148.74 168.22 23.48 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.316 -1.108 . . . . 0.0 109.42 -179.798 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 22.9 m -54.55 -34.21 61.45 Favored 'General case' 0 N--CA 1.487 1.406 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 179.425 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 23.9 m -58.39 -30.77 67.07 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.472 -0.767 . . . . 0.0 109.063 179.438 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.69 7.49 55.52 Favored Glycine 0 N--CA 1.492 2.431 0 N-CA-C 109.814 -1.315 . . . . 0.0 109.814 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 75.3 ttt-85 -114.74 139.5 49.65 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.31 -1.112 . . . . 0.0 109.084 179.781 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 165' ' ' THR . . . . . 0.422 ' OG1' ' O ' ' A' ' 167' ' ' LYS . 51.1 p -87.47 156.24 19.64 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.214 -0.929 . . . . 0.0 109.879 -179.768 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -66.8 -37.22 84.13 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.531 -0.731 . . . . 0.0 109.433 179.765 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 167' ' ' LYS . . . . . 0.422 ' O ' ' OG1' ' A' ' 165' ' ' THR . 67.2 mttm -111.25 156.82 20.89 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.411 -0.805 . . . . 0.0 109.606 -179.835 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 94.3 mttt -76.24 139.77 41.31 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.287 -0.883 . . . . 0.0 109.331 179.871 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 43.1 t -118.02 126.35 74.84 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.265 -0.897 . . . . 0.0 109.636 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 42.6 t -146.0 150.3 15.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.345 -0.847 . . . . 0.0 109.294 179.608 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -88.54 122.12 39.62 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 O-C-N 121.288 -0.882 . . . . 0.0 109.691 -179.446 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -67.0 -25.61 66.39 Favored 'General case' 0 C--N 1.3 -1.565 0 O-C-N 121.438 -0.789 . . . . 0.0 109.536 179.56 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 173' ' ' ASP . . . . . 0.413 ' OD1' ' N ' ' A' ' 174' ' ' CYS . 44.9 t0 -173.06 169.96 4.52 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.01 -1.056 . . . . 0.0 110.542 -179.383 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 174' ' ' CYS . . . . . 0.413 ' N ' ' OD1' ' A' ' 173' ' ' ASP . 30.4 p -152.61 150.35 29.42 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.501 -0.749 . . . . 0.0 109.014 179.416 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . 179.71 -177.07 47.99 Favored Glycine 0 N--CA 1.494 2.528 0 N-CA-C 110.044 -1.222 . . . . 0.0 110.044 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 58.9 tt0 -105.33 122.39 45.86 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.529 -0.983 . . . . 0.0 109.632 -179.868 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 177' ' ' LEU . . . . . 0.464 ' O ' ' C ' ' A' ' 178' ' ' SER . 0.2 OUTLIER -65.2 -40.82 94.71 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.171 -0.956 . . . . 0.0 108.566 179.485 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 178' ' ' SER . . . . . 0.464 ' C ' ' O ' ' A' ' 177' ' ' LEU . 1.2 t . . . . . 0 N--CA 1.493 1.702 0 CA-C-O 118.022 -0.99 . . . . 0.0 109.935 179.859 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.528 4.781 0 N-CA-C 119.433 2.533 . . . . 0.0 119.433 . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 44.0 m -62.68 154.13 30.27 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.187 -1.184 . . . . 0.0 109.445 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 99.2 m-85 -111.42 121.88 46.37 Favored 'General case' 0 N--CA 1.486 1.34 0 O-C-N 121.43 -0.794 . . . . 0.0 108.957 179.722 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -135.05 -6.65 2.35 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.515 -0.741 . . . . 0.0 109.489 179.856 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 86.97 9.64 73.57 Favored Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 85.9 p -63.19 -23.94 67.66 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.21 -1.171 . . . . 0.0 109.651 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 30.7 ttm -124.44 77.42 62.31 Favored Pre-proline 0 N--CA 1.494 1.746 0 O-C-N 121.323 -0.861 . . . . 0.0 109.587 -179.784 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -79.9 -61.14 0.03 OUTLIER 'Trans proline' 0 C--N 1.308 -1.555 0 C-N-CA 122.643 2.229 . . . . 0.0 112.239 179.897 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -123.26 153.91 65.23 Favored Pre-proline 0 N--CA 1.494 1.738 0 O-C-N 121.529 -0.732 . . . . 0.0 109.243 179.877 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -69.18 138.53 39.92 Favored 'Trans proline' 0 N--CA 1.496 1.627 0 C-N-CA 122.744 2.296 . . . . 0.0 112.306 179.913 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.469 HH21 ' CD2' ' A' ' 177' ' ' LEU . 50.8 ttp180 -133.69 126.53 30.96 Favored 'General case' 0 N--CA 1.49 1.568 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 179.143 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.5 p -131.88 141.83 44.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.29 -0.881 . . . . 0.0 109.521 -179.139 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 40.5 p90 -140.28 157.87 44.9 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.379 -0.826 . . . . 0.0 109.524 -179.602 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 95.2 m-85 -126.93 142.58 51.51 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.472 -0.768 . . . . 0.0 109.808 179.902 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 19.1 t70 -93.74 113.51 25.59 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.412 -0.958 . . . . 0.0 108.412 178.931 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 96.8 mmm -97.13 146.54 24.95 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.452 -0.78 . . . . 0.0 110.112 -179.164 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.516 ' HG ' ' N ' ' A' ' 18' ' ' VAL . 41.8 t -149.58 162.07 40.91 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.457 -0.777 . . . . 0.0 109.036 179.628 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.516 ' N ' ' HG ' ' A' ' 17' ' ' SER . 25.6 m -124.27 159.9 29.36 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.314 -0.867 . . . . 0.0 109.562 179.894 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -49.18 -30.45 10.64 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.822 -1.311 . . . . 0.0 109.822 -179.475 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -73.93 -79.65 0.52 Allowed Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.674 -1.37 . . . . 0.0 109.674 -179.837 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 4.2 pt20 -146.35 157.15 49.43 Favored Pre-proline 0 N--CA 1.494 1.727 0 O-C-N 121.177 -1.19 . . . . 0.0 109.129 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 75.6 Cg_exo -45.78 130.31 12.51 Favored 'Trans proline' 0 C--N 1.31 -1.455 0 C-N-CA 122.25 1.967 . . . . 0.0 112.138 179.792 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -80.05 -56.42 4.25 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.28 -0.888 . . . . 0.0 109.703 -179.891 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 168.82 -170.74 42.54 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 -179.898 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 56.9 ttp180 -114.48 142.01 46.95 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.392 -1.063 . . . . 0.0 109.338 179.818 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.436 HG22 HD12 ' A' ' 26' ' ' ILE . 81.5 mt -120.04 130.5 74.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.429 -0.795 . . . . 0.0 109.012 179.877 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 43.6 t -110.56 134.63 52.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.386 -0.821 . . . . 0.0 109.717 -179.792 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 72.1 mtm -121.71 151.89 40.0 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.447 -0.783 . . . . 0.0 109.082 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -105.54 132.86 51.17 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.265 -0.897 . . . . 0.0 110.053 -179.517 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -105.18 129.52 53.55 Favored 'General case' 0 N--CA 1.494 1.767 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 179.143 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -97.7 119.0 35.5 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.207 -0.933 . . . . 0.0 109.131 179.716 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -81.39 -42.21 20.78 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.383 -0.823 . . . . 0.0 109.638 179.847 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -64.8 -46.11 83.42 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.281 -0.887 . . . . 0.0 110.215 -179.388 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 28.4 m -65.99 -45.4 81.74 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.163 -0.961 . . . . 0.0 109.589 -179.766 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.509 ' O ' ' OG1' ' A' ' 35' ' ' THR . 4.1 p -141.38 80.58 16.33 Favored Pre-proline 0 N--CA 1.492 1.668 0 N-CA-C 108.798 -0.816 . . . . 0.0 108.798 179.912 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_endo -59.49 -65.1 0.09 OUTLIER 'Trans proline' 0 N--CA 1.496 1.622 0 C-N-CA 122.419 2.079 . . . . 0.0 113.018 -178.843 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 94.8 mtt180 -60.62 -36.88 79.7 Favored 'General case' 0 C--N 1.298 -1.668 0 O-C-N 121.596 -0.69 . . . . 0.0 110.965 -178.769 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 23.0 m -60.85 -43.32 98.48 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 120.928 -1.107 . . . . 0.0 109.954 -179.423 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -61.94 -31.58 71.91 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.176 -0.952 . . . . 0.0 108.87 179.769 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -70.52 -41.73 72.21 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.352 -0.842 . . . . 0.0 109.937 -179.862 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 81.5 m-20 -60.71 -45.31 94.69 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.137 -0.977 . . . . 0.0 109.75 -179.585 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 56.3 t80 -71.76 -48.24 48.2 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.202 -0.936 . . . . 0.0 109.225 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . 0.509 ' CD ' ' NE2' ' A' ' 176' ' ' GLN . 61.8 ttp180 -58.24 -38.92 77.82 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.47 -0.768 . . . . 0.0 109.887 179.917 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.489 ' O ' ' N ' ' A' ' 48' ' ' GLY . . . -60.99 -40.59 94.09 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.289 -0.882 . . . . 0.0 110.22 -178.925 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -61.61 -39.38 91.03 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.056 -1.027 . . . . 0.0 109.473 179.946 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' CYS . . . . . . . . . . . . . 20.1 m -80.87 -53.13 6.74 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.015 -1.053 . . . . 0.0 109.71 -179.832 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 68.8 p -69.17 -36.74 77.67 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.336 -0.853 . . . . 0.0 109.855 -179.821 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . 0.489 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 73.6 32.79 59.09 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.815 -1.314 . . . . 0.0 109.815 179.636 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 78.1 mm-40 -60.91 -37.43 82.21 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.081 -1.246 . . . . 0.0 109.262 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 32.5 mmtm -61.39 -31.38 71.29 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.311 -0.868 . . . . 0.0 109.303 179.649 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 97.59 169.2 32.7 Favored Glycine 0 N--CA 1.489 2.168 0 N-CA-C 109.323 -1.511 . . . . 0.0 109.323 -179.773 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 98.1 m -75.32 141.68 43.33 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.289 -1.124 . . . . 0.0 109.749 -179.84 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -56.78 140.3 44.25 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.254 -1.538 . . . . 0.0 109.254 179.87 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 93.5 mtt-85 -59.04 -33.39 70.71 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.189 -1.183 . . . . 0.0 109.998 -179.787 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 86.6 p -60.55 -25.46 66.18 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.161 -0.962 . . . . 0.0 109.902 -179.397 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 108.8 90.45 2.11 Favored Glycine 0 N--CA 1.495 2.578 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 -179.756 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . 0.431 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 17.7 tttm -176.26 78.62 0.28 Allowed Pre-proline 0 N--CA 1.489 1.493 0 O-C-N 121.397 -1.06 . . . . 0.0 108.46 -179.683 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 87.0 Cg_exo -47.31 128.9 15.26 Favored 'Trans proline' 0 C--N 1.304 -1.793 0 C-N-CA 122.66 2.24 . . . . 0.0 112.174 -179.046 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.537 ' O ' ' CG ' ' A' ' 60' ' ' HIS . 7.2 mp -91.62 94.78 9.57 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.684 -0.635 . . . . 0.0 109.753 -179.348 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . 0.537 ' CG ' ' O ' ' A' ' 59' ' ' LEU . 93.7 m-70 -159.75 125.39 4.17 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.358 -0.839 . . . . 0.0 109.531 179.685 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . 0.428 ' O ' ' OG ' ' A' ' 64' ' ' SER . 55.5 m-85 -68.59 -5.05 17.7 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.104 -0.997 . . . . 0.0 108.986 179.269 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 35.2 ttmt -54.74 144.9 20.8 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.463 -0.773 . . . . 0.0 109.743 -179.866 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 84.1 m-20 56.25 45.41 23.17 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.612 -0.68 . . . . 0.0 109.793 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.428 ' OG ' ' O ' ' A' ' 61' ' ' TYR . 39.3 m -120.23 147.91 44.35 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.413 -0.804 . . . . 0.0 108.996 179.528 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 30.0 t -113.12 147.04 38.15 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.424 -0.798 . . . . 0.0 109.554 -179.699 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 4.2 m-30 -64.79 136.31 56.77 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.279 -0.888 . . . . 0.0 108.959 179.951 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 53.3 t-80 -61.5 -50.53 72.34 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.274 -0.891 . . . . 0.0 110.285 -179.193 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.677 HH21 ' NE2' ' A' ' 76' ' ' GLN . 36.8 ptt180 -161.47 160.71 29.56 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.117 -0.989 . . . . 0.0 110.136 -179.757 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 24.0 m -132.91 151.34 34.14 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.509 -0.744 . . . . 0.0 108.993 179.716 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 11.6 mt -146.92 119.83 4.91 Favored Pre-proline 0 N--CA 1.492 1.657 0 O-C-N 121.038 -1.039 . . . . 0.0 109.436 179.78 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -74.68 135.35 19.59 Favored 'Trans proline' 0 C--N 1.312 -1.368 0 C-N-CA 122.161 1.907 . . . . 0.0 111.997 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 90.39 1.1 75.47 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 93.1 m-85 -135.81 -90.76 0.29 Allowed 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.376 -1.073 . . . . 0.0 109.632 179.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 9.6 ptp -170.28 172.62 6.13 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.109 -0.994 . . . . 0.0 109.618 -179.946 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 1.7 m -116.14 138.9 50.86 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.403 -0.811 . . . . 0.0 108.877 179.748 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' GLN . . . . . 0.677 ' NE2' HH21 ' A' ' 68' ' ' ARG . 94.6 mt-30 -108.54 154.87 21.32 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.269 -0.894 . . . . 0.0 109.707 -179.683 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -147.04 -165.79 11.96 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 -179.816 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.47 ' O ' ' N ' ' A' ' 80' ' ' PHE . . . 94.37 11.59 57.03 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 109.459 -1.457 . . . . 0.0 109.459 -179.737 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -48.15 -15.4 0.07 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.391 -1.064 . . . . 0.0 109.594 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.47 ' N ' ' O ' ' A' ' 78' ' ' GLY . 81.2 t80 -48.21 -47.96 35.21 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.229 -0.919 . . . . 0.0 110.2 -179.535 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.761 ' CB ' ' H ' ' A' ' 88' ' ' GLY . 54.4 p -71.15 -32.18 68.62 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.916 -1.115 . . . . 0.0 109.49 -179.929 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . 0.484 ' CB ' ' O ' ' A' ' 81' ' ' THR . . . 163.21 -54.64 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.426 -0.796 . . . . 0.0 109.14 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 91.77 1.04 71.23 Favored Glycine 0 N--CA 1.492 2.42 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 179.947 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 78.6 m-20 -87.63 5.91 37.18 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.225 -1.162 . . . . 0.0 109.474 179.923 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 95.53 -39.82 2.78 Favored Glycine 0 N--CA 1.493 2.45 0 N-CA-C 109.263 -1.535 . . . . 0.0 109.263 -179.79 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 56.3 p -73.85 -14.2 61.05 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.418 -1.048 . . . . 0.0 108.944 179.665 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -80.66 -160.76 24.0 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 -179.881 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.761 ' H ' ' CB ' ' A' ' 81' ' ' THR . . . 89.54 23.18 34.54 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.426 -1.47 . . . . 0.0 109.426 -179.819 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -55.69 148.89 15.27 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.293 -1.122 . . . . 0.0 109.529 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 49.8 m -105.14 151.12 24.43 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.394 -0.816 . . . . 0.0 109.384 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 27.6 pt -62.78 -32.48 55.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.247 -0.908 . . . . 0.0 109.974 -179.549 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 89.6 m-85 -65.08 -35.19 80.36 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.155 -0.965 . . . . 0.0 109.606 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 87.1 7.43 77.23 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.391 -1.483 . . . . 0.0 109.391 -179.862 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -147.53 155.89 42.3 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.32 -1.106 . . . . 0.0 109.376 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 64.1 mttp -89.89 143.65 26.61 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.255 -0.903 . . . . 0.0 109.82 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 41.4 p90 -138.15 160.38 39.55 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.543 -0.723 . . . . 0.0 109.067 179.779 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -67.35 132.79 48.38 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.04 -1.037 . . . . 0.0 109.596 -179.599 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -75.27 140.02 42.91 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.4 -0.813 . . . . 0.0 109.799 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -59.83 149.06 32.41 Favored 'General case' 0 C--N 1.305 -1.35 0 O-C-N 121.309 -0.87 . . . . 0.0 109.093 179.581 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . 0.41 ' N ' HD21 ' A' ' 100' ' ' ASN . 2.8 m120 -53.36 162.56 0.73 Allowed 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.409 -0.807 . . . . 0.0 109.309 -179.942 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' PHE . . . . . 0.584 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 22.3 p90 -130.63 82.15 2.04 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.462 -0.774 . . . . 0.0 109.372 -179.787 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 87.8 mt -60.31 -33.97 55.79 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.18 -0.95 . . . . 0.0 109.478 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 91.6 mttt -84.45 136.29 33.9 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.311 -0.868 . . . . 0.0 109.342 179.932 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 61.9 mttp -116.31 -178.62 3.46 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.485 -0.759 . . . . 0.0 109.986 -179.877 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' HIS . . . . . 0.526 ' O ' ' CG ' ' A' ' 105' ' ' HIS . 49.9 p-80 -99.79 101.39 12.53 Favored 'General case' 0 N--CA 1.493 1.694 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 179.692 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 66.5 p -101.19 -2.16 32.01 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.273 -0.892 . . . . 0.0 109.768 -179.743 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -149.8 171.91 29.79 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -74.24 157.81 45.61 Favored 'Trans proline' 0 C--N 1.304 -1.785 0 C-N-CA 122.899 2.399 . . . . 0.0 112.027 179.784 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 84.91 40.47 8.1 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 110.158 -1.177 . . . . 0.0 110.158 179.663 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 43.0 mm -113.66 133.55 59.26 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.382 -1.07 . . . . 0.0 109.183 179.677 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . 0.53 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 3.4 mm? -90.61 133.15 35.31 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.145 -0.972 . . . . 0.0 109.825 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 112' ' ' SER . . . . . 0.459 ' OG ' ' O ' ' A' ' 140' ' ' VAL . 42.9 t -144.8 142.6 30.1 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.353 -0.842 . . . . 0.0 109.197 179.744 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 113' ' ' MET . . . . . 0.586 ' SD ' ' CE1' ' A' ' 142' ' ' PHE . 83.8 mmm -83.97 129.79 34.91 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.12 -0.988 . . . . 0.0 109.288 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . 0.531 ' O ' ' ND2' ' A' ' 115' ' ' ASN . . . -69.6 143.94 53.16 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.283 -0.886 . . . . 0.0 109.462 -179.951 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . 0.531 ' ND2' ' O ' ' A' ' 114' ' ' ALA . 14.6 m120 -142.94 112.72 6.96 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.363 -0.836 . . . . 0.0 108.961 179.463 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -69.45 -29.51 67.22 Favored 'General case' 0 C--N 1.298 -1.66 0 O-C-N 121.471 -0.768 . . . . 0.0 109.657 -179.872 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -134.43 166.73 24.09 Favored Glycine 0 N--CA 1.493 2.477 0 N-CA-C 109.406 -1.477 . . . . 0.0 109.406 179.888 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -68.88 153.82 72.08 Favored 'Trans proline' 0 C--N 1.305 -1.721 0 C-N-CA 122.81 2.34 . . . . 0.0 111.94 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 17.9 m120 54.19 43.17 31.01 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.483 -0.761 . . . . 0.0 109.441 -179.925 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 92.8 m -134.91 125.07 25.98 Favored 'General case' 0 N--CA 1.485 1.324 0 O-C-N 121.42 -0.8 . . . . 0.0 108.929 179.928 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 22.6 t-20 -103.05 102.6 12.63 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.469 -0.77 . . . . 0.0 109.391 179.828 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -92.93 133.93 11.95 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.414 -1.474 . . . . 0.0 109.414 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 83.3 p -63.77 -23.46 67.37 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.191 -1.182 . . . . 0.0 109.296 179.83 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 92.6 mt-30 -68.66 144.57 54.41 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.335 -0.853 . . . . 0.0 109.505 -179.882 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 49.7 p90 -137.53 163.07 32.06 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.396 -0.815 . . . . 0.0 109.166 179.773 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 48.9 p90 -135.81 160.93 37.05 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.271 -0.893 . . . . 0.0 109.776 -179.937 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 70.2 mt -117.61 132.68 66.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.444 -0.785 . . . . 0.0 109.568 -179.918 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 1.9 p -100.72 106.6 18.05 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.325 -0.859 . . . . 0.0 109.255 179.555 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 129' ' ' THR . . . . . 0.438 ' OG1' ' OE1' ' A' ' 156' ' ' GLU . 68.5 p -90.93 3.03 55.68 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.189 -0.945 . . . . 0.0 109.809 -179.765 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -146.0 154.63 42.1 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.12 -0.987 . . . . 0.0 109.674 -179.726 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 78.9 tttt -81.16 131.06 35.28 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.336 -0.853 . . . . 0.0 109.362 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 9.4 p -125.29 161.65 26.49 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.358 -0.839 . . . . 0.0 109.418 179.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -127.52 -28.79 2.73 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.236 -0.915 . . . . 0.0 109.642 -179.891 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 134' ' ' TRP . . . . . 0.413 ' CD2' ' N ' ' A' ' 134' ' ' TRP . 2.0 p90 -75.8 -6.53 51.11 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.159 -0.963 . . . . 0.0 109.777 -179.841 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 8.2 mt -90.78 7.69 38.47 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.242 -0.911 . . . . 0.0 109.548 179.486 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . 0.472 ' O ' ' OD1' ' A' ' 136' ' ' ASP . 52.2 p30 -53.63 153.34 4.43 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.301 -0.874 . . . . 0.0 109.724 -179.755 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 144.48 -129.6 3.64 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.012 -1.635 . . . . 0.0 109.012 -179.685 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 2.0 mptp? -90.4 127.55 36.23 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.214 -1.168 . . . . 0.0 108.91 179.643 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 139' ' ' HIS . . . . . 0.491 ' CD2' ' HD1' ' A' ' 105' ' ' HIS . 85.6 t60 -140.57 127.58 20.75 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.375 -0.828 . . . . 0.0 109.694 -179.85 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.459 ' O ' ' OG ' ' A' ' 112' ' ' SER . 44.7 t -123.11 132.76 70.81 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 121.458 -0.776 . . . . 0.0 109.048 179.595 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 38.8 t -116.5 129.36 73.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.321 -0.862 . . . . 0.0 109.211 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . 0.586 ' CE1' ' SD ' ' A' ' 113' ' ' MET . 38.3 p90 -119.93 5.89 10.89 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.323 -0.861 . . . . 0.0 109.734 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -179.43 177.66 48.37 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 179.655 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.2 pt20 -146.17 167.13 24.2 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.265 -1.138 . . . . 0.0 109.453 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 55.2 t -95.33 130.24 44.36 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 O-C-N 121.232 -0.918 . . . . 0.0 109.326 -179.886 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 13.3 m -108.51 -36.63 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.308 -0.87 . . . . 0.0 109.653 179.812 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 94.4 mt-10 -139.75 161.89 36.46 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.26 -0.9 . . . . 0.0 109.575 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 95.02 5.64 60.78 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 110.102 -1.199 . . . . 0.0 110.102 179.578 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 149' ' ' MET . . . . . 0.446 ' O ' HG12 ' A' ' 152' ' ' VAL . 65.0 mtt -60.0 -32.58 71.0 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.049 -1.266 . . . . 0.0 109.319 179.859 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 56.1 t0 -64.85 -41.89 95.33 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.954 -1.091 . . . . 0.0 110.291 -179.563 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.6 p -78.15 -32.32 17.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.06 -1.025 . . . . 0.0 110.911 -179.266 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 152' ' ' VAL . . . . . 0.446 HG12 ' O ' ' A' ' 149' ' ' MET . 0.9 OUTLIER -51.62 -40.57 26.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 120.962 -1.087 . . . . 0.0 109.011 -179.18 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 153' ' ' LYS . . . . . 0.439 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 59.1 mttp -65.69 -32.63 74.3 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.242 -0.911 . . . . 0.0 109.441 179.09 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -60.11 -39.37 85.97 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.341 -0.849 . . . . 0.0 110.113 -179.28 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.44 HD12 HG21 ' A' ' 155' ' ' ILE . 90.0 mt -72.31 -33.95 47.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.048 -1.033 . . . . 0.0 109.757 -179.919 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . 0.438 ' OE1' ' OG1' ' A' ' 129' ' ' THR . 84.5 tt0 -77.63 -41.72 37.43 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.231 -0.918 . . . . 0.0 111.34 -178.859 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . 0.402 ' HG2' ' HZ3' ' A' ' 157' ' ' LYS . 17.5 pttm -59.65 -35.57 74.66 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 120.682 -1.261 . . . . 0.0 109.579 -178.838 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 35.3 m -77.15 -10.34 13.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.155 -0.966 . . . . 0.0 108.798 179.228 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -73.89 163.45 54.63 Favored Glycine 0 N--CA 1.488 2.124 0 N-CA-C 110.178 -1.169 . . . . 0.0 110.178 -179.596 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 54.2 m -148.07 165.77 29.8 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.598 -0.942 . . . . 0.0 109.276 -179.895 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 23.9 t -55.08 -26.56 38.71 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.217 -0.927 . . . . 0.0 109.293 179.849 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 86.8 p -57.64 -25.65 60.48 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.243 -0.911 . . . . 0.0 109.639 -179.749 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 92.48 12.98 57.77 Favored Glycine 0 N--CA 1.492 2.414 0 N-CA-C 109.941 -1.264 . . . . 0.0 109.941 179.87 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 24.2 ttm180 -127.14 143.09 51.35 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.204 -1.174 . . . . 0.0 109.491 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 165' ' ' THR . . . . . 0.444 ' OG1' ' O ' ' A' ' 167' ' ' LYS . 79.1 p -76.9 154.81 33.35 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.255 -0.903 . . . . 0.0 109.344 179.851 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -63.93 -35.88 82.13 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.24 -0.912 . . . . 0.0 109.231 179.813 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 167' ' ' LYS . . . . . 0.444 ' O ' ' OG1' ' A' ' 165' ' ' THR . 68.9 mttm -116.78 154.69 30.23 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.571 -0.706 . . . . 0.0 109.151 179.794 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -66.44 142.43 57.57 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.121 -0.987 . . . . 0.0 109.095 -179.949 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 33.0 m -123.99 128.38 74.09 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.363 -0.836 . . . . 0.0 109.707 -179.716 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 40.7 t -144.16 147.76 19.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.395 -0.816 . . . . 0.0 109.011 179.649 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -83.86 115.53 26.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 120.935 -1.103 . . . . 0.0 109.464 -179.787 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -66.08 -22.39 66.41 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.364 -0.835 . . . . 0.0 109.213 179.469 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 173' ' ' ASP . . . . . 0.454 ' OD1' ' N ' ' A' ' 174' ' ' CYS . 48.0 t0 -167.38 163.39 15.07 Favored 'General case' 0 N--CA 1.492 1.654 0 C-N-CA 119.035 -1.066 . . . . 0.0 110.564 -179.493 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 174' ' ' CYS . . . . . 0.454 ' N ' ' OD1' ' A' ' 173' ' ' ASP . 18.5 p -161.78 146.62 13.06 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.592 -0.693 . . . . 0.0 109.325 179.535 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . 170.45 175.08 38.97 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 179.829 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 176' ' ' GLN . . . . . 0.509 ' NE2' ' CD ' ' A' ' 43' ' ' ARG . 47.9 tt0 -102.58 121.02 41.55 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.228 -1.16 . . . . 0.0 109.779 179.925 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 177' ' ' LEU . . . . . 0.469 ' CD2' HH21 ' A' ' 11' ' ' ARG . 46.2 tp -64.74 -36.58 84.75 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.33 -0.856 . . . . 0.0 109.371 179.408 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 7.9 t . . . . . 0 N--CA 1.49 1.565 0 CA-C-O 118.025 -0.988 . . . . 0.0 109.368 179.999 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.417 ' O ' ' CG2' ' A' ' 4' ' ' THR . . . . . . . . 1 N--CA 1.528 4.821 0 N-CA-C 119.397 2.519 . . . . 0.0 119.397 . . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 85.1 p -64.64 -23.5 67.28 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.179 -1.189 . . . . 0.0 109.958 -179.806 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 98.8 m-85 -95.34 18.74 11.92 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.175 -0.953 . . . . 0.0 110.229 -179.323 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.417 ' CG2' ' O ' ' A' ' 1' ' ' GLY . 60.2 p -68.58 -30.61 69.4 Favored 'General case' 0 C--N 1.297 -1.68 0 O-C-N 121.37 -0.831 . . . . 0.0 109.459 179.644 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 75.67 31.67 55.8 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.73 -1.348 . . . . 0.0 109.73 179.682 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 23.2 t -60.71 -37.97 83.49 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.2 -1.177 . . . . 0.0 109.709 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 1.4 ptm -132.36 80.12 63.96 Favored Pre-proline 0 N--CA 1.496 1.855 0 O-C-N 121.329 -0.857 . . . . 0.0 109.303 -179.884 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -80.82 -24.18 5.11 Favored 'Trans proline' 0 C--N 1.308 -1.596 0 C-N-CA 122.77 2.313 . . . . 0.0 112.488 -179.486 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -141.74 157.55 64.61 Favored Pre-proline 0 N--CA 1.493 1.686 0 O-C-N 121.263 -0.898 . . . . 0.0 109.322 -179.922 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -69.42 139.67 41.97 Favored 'Trans proline' 0 N--CA 1.496 1.65 0 C-N-CA 122.686 2.257 . . . . 0.0 112.152 179.887 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 75.1 mtt85 -128.93 132.87 47.69 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.387 -0.82 . . . . 0.0 109.077 179.092 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.7 p -135.06 142.68 39.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.488 -0.757 . . . . 0.0 109.223 -179.859 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 41.6 p90 -139.55 153.81 47.51 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.296 -0.878 . . . . 0.0 109.505 -179.786 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 93.4 m-85 -122.15 135.23 54.76 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.516 -0.74 . . . . 0.0 109.446 179.699 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.6 t0 -90.3 113.4 25.25 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.111 -0.993 . . . . 0.0 108.374 179.212 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 71.6 mtp -105.24 147.38 28.11 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.072 -1.017 . . . . 0.0 110.389 -179.168 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 84.2 p -144.9 165.2 28.81 Favored 'General case' 0 N--CA 1.489 1.501 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 179.724 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 33.5 m -125.37 151.16 31.01 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.28 -0.888 . . . . 0.0 109.43 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -51.17 102.49 0.07 OUTLIER Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 140.43 -75.13 0.35 Allowed Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.714 -1.354 . . . . 0.0 109.714 179.873 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -138.41 158.78 70.0 Favored Pre-proline 0 N--CA 1.492 1.663 0 O-C-N 121.337 -1.096 . . . . 0.0 109.264 -179.763 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -58.63 138.77 87.64 Favored 'Trans proline' 0 N--CA 1.494 1.524 0 C-N-CA 122.581 2.187 . . . . 0.0 111.887 179.78 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -84.27 -62.47 1.55 Allowed 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.223 -0.923 . . . . 0.0 109.568 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 168.9 -169.69 41.96 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 -179.836 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 58.9 ttp180 -115.72 141.81 47.59 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.338 -1.095 . . . . 0.0 109.265 179.936 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 82.8 mt -121.24 128.96 76.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.331 -0.855 . . . . 0.0 109.237 179.831 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 46.5 t -114.18 134.09 58.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.335 -0.853 . . . . 0.0 109.26 179.908 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 73.9 mtm -119.93 151.74 38.47 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.384 -0.822 . . . . 0.0 109.318 -179.928 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -98.68 131.98 44.43 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.339 -0.851 . . . . 0.0 109.763 -179.57 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -107.34 132.62 52.93 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.494 -0.754 . . . . 0.0 109.143 179.681 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 95.7 m-85 -98.6 125.41 43.85 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.223 -0.923 . . . . 0.0 109.176 179.66 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -94.47 1.25 55.76 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.255 -0.903 . . . . 0.0 109.997 -179.692 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -95.45 -75.17 0.53 Allowed 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.046 -1.034 . . . . 0.0 110.581 -179.342 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 47.0 m -64.67 -40.65 95.79 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.354 -0.841 . . . . 0.0 111.017 -178.646 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 43.3 p -126.46 76.18 73.7 Favored Pre-proline 0 N--CA 1.496 1.829 0 O-C-N 121.089 -1.007 . . . . 0.0 110.149 -178.982 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 63.7 Cg_endo -78.21 -57.42 0.04 OUTLIER 'Trans proline' 0 C--N 1.308 -1.601 0 C-N-CA 122.764 2.31 . . . . 0.0 112.729 179.724 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 24.1 mmt85 -57.39 -38.47 74.32 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.247 -0.908 . . . . 0.0 110.151 -179.249 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 41.5 m -61.41 -40.85 95.9 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.039 -1.038 . . . . 0.0 109.915 -179.581 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -61.89 -31.1 71.36 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.203 -0.936 . . . . 0.0 109.216 179.842 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -67.57 -37.19 82.29 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.389 -0.819 . . . . 0.0 109.766 -179.846 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 49.6 t-20 -58.64 -43.05 89.62 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.24 -0.912 . . . . 0.0 109.841 -179.678 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . 0.495 ' O ' ' SG ' ' A' ' 46' ' ' CYS . 96.9 m-85 -83.31 -46.63 12.38 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.165 -0.96 . . . . 0.0 109.756 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . 0.63 ' NE ' HE22 ' A' ' 176' ' ' GLN . 76.5 ttt180 -57.19 -42.06 80.53 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.295 -0.878 . . . . 0.0 109.901 -179.697 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.523 ' O ' ' N ' ' A' ' 48' ' ' GLY . . . -76.63 -48.54 18.76 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.132 -0.98 . . . . 0.0 110.29 -179.612 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 40.8 tp -58.1 -37.92 75.45 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.112 -0.993 . . . . 0.0 109.795 -179.4 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' CYS . . . . . 0.495 ' SG ' ' O ' ' A' ' 42' ' ' PHE . 39.8 m -77.32 -63.97 1.25 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.113 -0.992 . . . . 0.0 109.929 -179.795 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 26.0 m -63.17 -38.39 91.0 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.117 -0.989 . . . . 0.0 109.678 -179.813 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . 0.523 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 80.58 37.16 21.1 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 110.043 -1.223 . . . . 0.0 110.043 179.744 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -61.4 -37.57 83.94 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.058 -1.26 . . . . 0.0 109.367 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 42.2 mmtm -61.52 -32.56 72.61 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.287 -0.883 . . . . 0.0 109.458 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 95.71 172.4 36.21 Favored Glycine 0 N--CA 1.487 2.097 0 N-CA-C 109.173 -1.571 . . . . 0.0 109.173 -179.62 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 94.1 m -72.36 141.19 48.77 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.315 -1.109 . . . . 0.0 109.871 -179.824 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -58.5 137.84 49.75 Favored Glycine 0 N--CA 1.489 2.169 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 179.804 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 94.1 mtt180 -59.72 -34.14 72.53 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.397 -1.061 . . . . 0.0 109.983 -179.68 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 86.2 p -61.32 -24.95 66.8 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.312 -0.867 . . . . 0.0 109.952 -179.564 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 112.58 89.83 1.85 Allowed Glycine 0 N--CA 1.495 2.572 0 N-CA-C 109.094 -1.603 . . . . 0.0 109.094 -179.595 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . 0.51 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 15.4 tptp -175.98 81.0 0.29 Allowed Pre-proline 0 N--CA 1.488 1.461 0 O-C-N 121.438 -1.036 . . . . 0.0 108.444 -179.659 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 75.2 Cg_exo -51.01 131.48 35.04 Favored 'Trans proline' 0 C--N 1.304 -1.808 0 C-N-CA 122.799 2.333 . . . . 0.0 112.728 -179.168 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.51 ' CD1' ' O ' ' A' ' 57' ' ' LYS . 8.8 mp -101.13 89.13 3.7 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.487 -0.758 . . . . 0.0 109.224 -179.919 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . 0.515 ' O ' ' CE1' ' A' ' 80' ' ' PHE . 77.2 m80 -138.78 136.25 35.49 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.362 -0.836 . . . . 0.0 109.531 179.778 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -87.31 -7.95 57.25 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.289 -0.882 . . . . 0.0 108.771 179.529 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 34.2 ttmt -64.15 151.33 43.6 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.524 -0.735 . . . . 0.0 109.958 -179.729 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 59.93 46.61 10.89 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.628 -0.67 . . . . 0.0 109.965 179.896 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 20.8 t -115.83 141.61 47.87 Favored 'General case' 0 N--CA 1.494 1.728 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.323 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 28.7 t -114.97 145.73 41.95 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.386 -0.821 . . . . 0.0 109.682 -179.64 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.5 m-30 -69.41 137.76 53.02 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.243 -0.91 . . . . 0.0 108.996 179.791 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 58.5 t-80 -60.76 -50.75 72.21 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.242 -0.912 . . . . 0.0 110.249 -179.378 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 37.7 ptt180 -163.72 162.21 23.87 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.061 -1.024 . . . . 0.0 109.939 -179.677 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 15.1 m -131.65 142.81 42.19 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.424 -0.798 . . . . 0.0 108.946 179.615 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 10.3 mt -148.03 109.85 3.75 Favored Pre-proline 0 N--CA 1.494 1.739 0 O-C-N 120.907 -1.121 . . . . 0.0 109.83 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -53.36 145.89 43.4 Favored 'Trans proline' 0 N--CA 1.494 1.524 0 C-N-CA 122.347 2.031 . . . . 0.0 112.489 179.524 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 82.01 -57.52 4.96 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 110.161 -1.175 . . . . 0.0 110.161 179.428 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -70.46 -88.68 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.137 -1.214 . . . . 0.0 109.828 -179.544 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 11.3 ptt? -178.31 176.4 1.08 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.221 -0.925 . . . . 0.0 109.57 -179.753 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -111.1 131.58 54.96 Favored 'General case' 0 N--CA 1.493 1.69 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 179.54 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 63.5 tt0 -98.26 150.14 21.85 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.239 -0.913 . . . . 0.0 109.958 -179.439 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -140.66 -170.1 11.97 Favored Glycine 0 N--CA 1.493 2.487 0 N-CA-C 109.287 -1.525 . . . . 0.0 109.287 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 96.52 6.33 58.57 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.861 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 54.8 t0 -58.33 -24.98 61.37 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.35 -1.088 . . . . 0.0 109.728 179.906 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.515 ' CE1' ' O ' ' A' ' 60' ' ' HIS . 76.4 t80 -48.21 -46.37 35.07 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.359 -0.838 . . . . 0.0 110.068 -179.38 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.698 ' CB ' ' H ' ' A' ' 88' ' ' GLY . 69.1 p -70.95 -29.93 66.09 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 120.96 -1.088 . . . . 0.0 109.493 179.896 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . 0.483 ' CB ' ' O ' ' A' ' 81' ' ' THR . . . 163.85 -55.84 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.412 -0.805 . . . . 0.0 109.225 179.822 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 92.37 0.41 70.33 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.529 -1.429 . . . . 0.0 109.529 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 78.7 m-20 -87.81 5.88 38.0 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.27 -1.135 . . . . 0.0 109.459 -179.962 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 96.12 -38.55 3.07 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 109.253 -1.539 . . . . 0.0 109.253 -179.895 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 61.7 p -73.82 -15.7 61.16 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.242 -1.152 . . . . 0.0 109.092 179.526 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -81.39 -163.9 31.83 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 -179.919 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.698 ' H ' ' CB ' ' A' ' 81' ' ' THR . . . 81.86 50.82 4.76 Favored Glycine 0 N--CA 1.487 2.099 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 -179.896 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -90.31 147.32 23.57 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.342 -1.093 . . . . 0.0 109.665 -179.728 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 50.5 m -112.17 149.71 31.84 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.461 -0.774 . . . . 0.0 109.403 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 5.1 pt -60.8 -42.13 91.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.277 -0.89 . . . . 0.0 110.106 -179.584 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 3.9 m-30 -66.65 -38.82 87.66 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.113 -0.992 . . . . 0.0 109.582 179.915 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 74.29 26.04 69.23 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.118 -1.593 . . . . 0.0 109.118 -179.742 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -143.64 161.29 38.9 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.421 -1.046 . . . . 0.0 109.569 -179.708 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 83.6 mttt -83.24 148.32 27.48 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.405 -0.81 . . . . 0.0 109.74 -179.736 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 88.6 m-85 -104.1 131.85 50.95 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.376 -0.828 . . . . 0.0 108.865 179.618 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -77.27 136.12 38.48 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.139 -0.976 . . . . 0.0 109.573 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . 0.53 ' OD2' ' CE1' ' A' ' 101' ' ' PHE . 32.3 p-10 -87.86 128.22 35.35 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.215 -0.928 . . . . 0.0 109.279 179.714 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . 0.491 ' O ' ' OD1' ' A' ' 100' ' ' ASN . 84.6 tt0 -61.41 -43.15 99.36 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.155 -0.966 . . . . 0.0 109.989 -179.481 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . 0.491 ' OD1' ' O ' ' A' ' 99' ' ' GLU . 84.0 m-20 -155.24 165.4 36.77 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.145 -0.972 . . . . 0.0 110.071 -179.829 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' PHE . . . . . 0.53 ' CE1' ' OD2' ' A' ' 98' ' ' ASP . 98.6 m-85 -102.62 8.17 39.77 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.429 -0.794 . . . . 0.0 109.156 179.358 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 97.4 mt -53.79 -36.47 29.89 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.344 -0.847 . . . . 0.0 110.404 -179.404 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 33.3 mmtp -73.68 124.91 26.89 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.022 -1.049 . . . . 0.0 109.661 -179.512 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 12.9 pttm -142.77 -177.6 5.39 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.321 -0.862 . . . . 0.0 109.246 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' HIS . . . . . . . . . . . . . 93.6 m-70 -74.99 88.33 2.37 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.144 -0.973 . . . . 0.0 109.209 179.723 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 54.9 p -71.06 -26.81 63.24 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.188 -0.945 . . . . 0.0 109.572 -179.79 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -162.08 -168.45 24.0 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.305 -1.518 . . . . 0.0 109.305 -179.855 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -80.58 154.83 20.99 Favored 'Trans proline' 0 C--N 1.306 -1.705 0 C-N-CA 122.935 2.423 . . . . 0.0 112.175 179.783 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 80.33 43.45 9.49 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.944 -1.262 . . . . 0.0 109.944 179.667 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 41.7 mm -115.55 135.5 55.41 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.863 0 O-C-N 121.364 -1.08 . . . . 0.0 109.628 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . 0.408 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 4.3 mm? -91.25 124.4 35.42 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.25 -0.906 . . . . 0.0 109.272 179.654 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 112' ' ' SER . . . . . 0.4 ' OG ' ' O ' ' A' ' 140' ' ' VAL . 30.9 t -140.72 141.07 34.95 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.176 -0.952 . . . . 0.0 109.501 179.867 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 88.9 mtp -89.92 137.89 31.96 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.264 -0.897 . . . . 0.0 109.215 179.75 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . 0.531 ' O ' ' ND2' ' A' ' 115' ' ' ASN . . . -60.9 144.57 52.7 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.121 -0.987 . . . . 0.0 109.381 -179.955 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . 0.531 ' ND2' ' O ' ' A' ' 114' ' ' ALA . 5.0 m120 -137.05 110.78 8.1 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.216 -0.928 . . . . 0.0 109.275 179.848 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -73.57 -29.46 62.44 Favored 'General case' 0 C--N 1.297 -1.677 0 O-C-N 121.406 -0.809 . . . . 0.0 109.4 179.684 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -140.6 175.39 22.08 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 179.926 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -68.17 151.89 76.63 Favored 'Trans proline' 0 C--N 1.305 -1.717 0 C-N-CA 122.746 2.297 . . . . 0.0 111.822 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 119' ' ' ASN . . . . . 0.429 ' OD1' ' OD1' ' A' ' 98' ' ' ASP . 71.8 m-20 52.84 40.52 30.87 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.453 -0.779 . . . . 0.0 109.278 -179.781 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 94.6 m -140.78 124.17 16.76 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.406 -0.809 . . . . 0.0 109.248 179.904 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 87.9 m-20 -109.86 114.81 28.67 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.568 -0.708 . . . . 0.0 109.16 179.503 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -78.05 135.52 16.26 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 179.947 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 22.8 t -55.83 -32.72 63.84 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.212 -1.169 . . . . 0.0 109.195 179.793 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 94.2 mt-30 -72.47 146.6 46.78 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.348 -0.845 . . . . 0.0 109.28 179.729 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 41.2 p90 -133.16 163.3 29.57 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.351 -0.843 . . . . 0.0 109.088 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 49.2 p90 -135.65 156.33 49.02 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.222 -0.923 . . . . 0.0 109.699 -179.931 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 76.2 mt -121.62 134.61 64.41 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 179.804 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 128' ' ' CYS . . . . . 0.517 ' SG ' ' O ' ' A' ' 130' ' ' ALA . 5.5 t -116.22 124.66 50.8 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.288 -0.883 . . . . 0.0 109.368 179.968 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 44.1 p -89.26 -2.1 58.34 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.448 -0.782 . . . . 0.0 109.766 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . 0.517 ' O ' ' SG ' ' A' ' 128' ' ' CYS . . . -149.0 156.96 43.02 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.18 -0.95 . . . . 0.0 109.691 -179.857 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 63.6 tttm -72.84 136.78 45.4 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.31 -0.869 . . . . 0.0 109.34 179.813 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 17.1 p -121.48 158.8 27.63 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.43 -0.794 . . . . 0.0 109.537 -179.846 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -103.05 -74.65 0.63 Allowed 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.246 -0.909 . . . . 0.0 109.915 -179.829 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 134' ' ' TRP . . . . . 0.605 ' CD1' ' N ' ' A' ' 135' ' ' LEU . 42.0 p90 -58.73 -47.76 83.52 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.291 -0.881 . . . . 0.0 110.08 -179.419 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . 0.605 ' N ' ' CD1' ' A' ' 134' ' ' TRP . 31.5 tp -60.98 -35.08 75.87 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.203 -0.936 . . . . 0.0 109.332 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 62.1 t0 -80.05 118.16 21.52 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.202 -0.936 . . . . 0.0 109.541 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . 0.489 ' H ' ' CE1' ' A' ' 139' ' ' HIS . . . -144.24 -126.58 1.95 Allowed Glycine 0 N--CA 1.492 2.4 0 N-CA-C 109.096 -1.602 . . . . 0.0 109.096 179.844 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 2.0 mptm? -84.71 105.5 15.55 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.112 -1.228 . . . . 0.0 108.959 179.629 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 139' ' ' HIS . . . . . 0.489 ' CE1' ' H ' ' A' ' 137' ' ' GLY . 76.9 m80 -138.16 161.07 37.76 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.353 -0.842 . . . . 0.0 109.483 -179.862 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.4 ' O ' ' OG ' ' A' ' 112' ' ' SER . 45.0 t -119.58 136.04 58.0 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 O-C-N 121.399 -0.813 . . . . 0.0 109.404 179.932 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 59.2 t -105.31 130.25 56.85 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 O-C-N 121.395 -0.816 . . . . 0.0 109.144 179.82 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 39.9 p90 -114.33 -0.81 13.72 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.306 -0.871 . . . . 0.0 109.766 -179.865 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -174.71 174.79 46.8 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.589 -1.405 . . . . 0.0 109.589 179.546 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 2.6 pt20 -146.72 167.23 24.34 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.213 -1.169 . . . . 0.0 109.665 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 9.5 t -96.73 132.63 40.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 O-C-N 121.218 -0.926 . . . . 0.0 109.529 -179.95 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 15.9 m -111.43 -30.19 2.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.541 -0.724 . . . . 0.0 109.145 179.577 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 78.6 mm-40 -140.02 166.0 25.83 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.342 -0.849 . . . . 0.0 109.344 179.876 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 96.69 4.9 58.98 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.889 -1.285 . . . . 0.0 109.889 179.649 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 149' ' ' MET . . . . . 0.418 ' O ' HG13 ' A' ' 152' ' ' VAL . 65.1 mtt -60.2 -32.24 70.91 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 121.056 -1.261 . . . . 0.0 109.467 179.932 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 89.0 m-20 -64.38 -40.35 95.65 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 120.894 -1.129 . . . . 0.0 109.805 -179.807 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 4.4 p -83.69 -35.09 11.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.251 -0.906 . . . . 0.0 110.502 -179.504 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 152' ' ' VAL . . . . . 0.455 ' CG1' ' N ' ' A' ' 153' ' ' LYS . 0.9 OUTLIER -53.9 -42.0 51.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 120.835 -1.166 . . . . 0.0 108.871 -179.336 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 153' ' ' LYS . . . . . 0.455 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 60.0 mttm -65.68 -32.94 74.77 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.12 -0.987 . . . . 0.0 109.123 179.064 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -60.08 -36.96 78.55 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.423 -0.798 . . . . 0.0 109.751 -179.512 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 98.5 mt -71.2 -34.74 55.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.092 -1.005 . . . . 0.0 109.945 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 83.0 tt0 -76.63 -42.17 43.19 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.246 -0.908 . . . . 0.0 111.324 -178.823 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 33.3 pttt -62.13 -33.38 74.38 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 120.798 -1.189 . . . . 0.0 109.822 -178.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 33.0 m -83.5 -0.59 5.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.036 -1.04 . . . . 0.0 108.828 179.523 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -75.32 173.01 53.34 Favored Glycine 0 N--CA 1.488 2.115 0 N-CA-C 110.048 -1.221 . . . . 0.0 110.048 -179.53 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 89.7 p -153.22 164.02 38.84 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.462 -1.022 . . . . 0.0 109.764 -179.711 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 23.3 m -58.69 -32.82 69.49 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.309 -0.869 . . . . 0.0 108.834 179.31 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 25.4 m -55.84 -31.57 62.84 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.386 -0.821 . . . . 0.0 109.172 179.86 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 101.08 9.08 46.18 Favored Glycine 0 N--CA 1.495 2.574 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 179.893 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 35.8 ttp180 -116.48 141.12 48.59 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.238 -1.154 . . . . 0.0 109.293 179.898 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 165' ' ' THR . . . . . 0.446 ' OG1' ' O ' ' A' ' 167' ' ' LYS . 80.6 p -76.5 155.87 33.44 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.292 -0.88 . . . . 0.0 109.304 179.932 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -62.37 -35.83 80.37 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.231 -0.918 . . . . 0.0 109.298 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 167' ' ' LYS . . . . . 0.446 ' O ' ' OG1' ' A' ' 165' ' ' THR . 62.5 mttp -118.93 152.98 35.34 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.475 -0.766 . . . . 0.0 109.157 179.764 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -64.67 141.55 58.74 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.021 -1.049 . . . . 0.0 108.957 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 33.9 m -121.66 126.63 74.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.226 -0.921 . . . . 0.0 109.8 -179.748 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 44.5 t -145.03 148.81 17.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 N-CA-C 108.839 -0.801 . . . . 0.0 108.839 179.704 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -80.91 115.7 23.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.119 -0.988 . . . . 0.0 109.463 -179.798 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 78.4 mm-40 -67.9 -20.31 65.09 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.396 -0.815 . . . . 0.0 109.505 179.629 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 20.2 t70 -167.66 162.18 13.93 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.015 -1.053 . . . . 0.0 110.364 -179.456 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 30.6 p -155.89 144.52 20.26 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.459 -0.776 . . . . 0.0 109.294 179.604 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . 177.25 179.98 47.8 Favored Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 176' ' ' GLN . . . . . 0.63 HE22 ' NE ' ' A' ' 43' ' ' ARG . 63.6 tt0 -105.62 124.0 48.83 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.41 -1.053 . . . . 0.0 109.77 -179.905 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 35.5 tp -61.23 -37.8 84.34 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.187 -0.946 . . . . 0.0 109.395 179.658 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 7.9 t . . . . . 0 N--CA 1.489 1.522 0 CA-C-O 117.994 -1.003 . . . . 0.0 109.475 -179.967 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.529 4.839 0 N-CA-C 119.402 2.521 . . . . 0.0 119.402 . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 29.8 t -119.66 143.62 47.61 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.295 -1.12 . . . . 0.0 109.455 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 49.6 p90 -145.52 158.28 43.86 Favored 'General case' 0 C--N 1.306 -1.29 0 O-C-N 121.183 -0.948 . . . . 0.0 108.647 179.721 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 45.1 m -86.23 132.36 34.02 Favored 'General case' 0 C--N 1.297 -1.694 0 O-C-N 121.398 -0.814 . . . . 0.0 109.596 -179.819 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -60.79 -31.92 77.4 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.774 -1.33 . . . . 0.0 109.774 179.88 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 29.5 t -89.44 146.09 24.88 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.304 -1.115 . . . . 0.0 109.701 -179.536 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 44.3 mtt -66.88 151.67 96.63 Favored Pre-proline 0 N--CA 1.489 1.517 0 O-C-N 121.265 -0.897 . . . . 0.0 109.318 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 26.0 Cg_endo -63.32 -20.17 69.82 Favored 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 122.723 2.282 . . . . 0.0 112.377 -179.878 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.446 ' ND2' ' O ' ' A' ' 10' ' ' PRO . 0.5 OUTLIER -62.13 136.67 95.47 Favored Pre-proline 0 N--CA 1.491 1.615 0 O-C-N 121.102 -0.999 . . . . 0.0 109.342 -179.736 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . 0.446 ' O ' ' ND2' ' A' ' 9' ' ' ASN . 82.8 Cg_endo -75.29 140.15 24.37 Favored 'Trans proline' 0 N--CA 1.495 1.612 0 C-N-CA 122.473 2.116 . . . . 0.0 112.599 -179.833 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 71.0 mtt85 -132.74 132.58 42.45 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.35 -0.844 . . . . 0.0 108.834 178.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.0 p -135.62 143.21 37.22 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.327 -0.858 . . . . 0.0 109.707 -179.764 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 42.7 p90 -138.21 154.21 49.12 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.523 -0.736 . . . . 0.0 109.183 179.941 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.415 ' CE1' ' CE1' ' A' ' 61' ' ' TYR . 97.5 m-85 -124.18 137.54 54.52 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.481 -0.762 . . . . 0.0 109.788 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.4 t0 -93.39 117.94 30.7 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.359 -0.838 . . . . 0.0 108.801 179.425 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 77.1 mtp -112.12 151.21 29.71 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.151 -0.968 . . . . 0.0 110.457 -179.174 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 84.5 p -142.91 163.09 33.73 Favored 'General case' 0 N--CA 1.489 1.519 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 179.804 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.534 ' O ' ' N ' ' A' ' 20' ' ' GLY . 26.2 m -125.96 143.01 40.94 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.201 -0.937 . . . . 0.0 109.706 -179.87 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 47.89 11.5 0.11 Allowed Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.817 -1.313 . . . . 0.0 109.817 179.833 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.534 ' N ' ' O ' ' A' ' 18' ' ' VAL . . . 97.43 -13.98 63.82 Favored Glycine 0 N--CA 1.493 2.499 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 -179.927 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' GLN . . . . . 0.608 ' NE2' ' N ' ' A' ' 21' ' ' GLN . 2.1 mp0 -84.62 150.85 57.54 Favored Pre-proline 0 N--CA 1.492 1.675 0 O-C-N 121.26 -1.141 . . . . 0.0 109.112 179.757 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_endo -62.15 136.93 63.33 Favored 'Trans proline' 0 C--N 1.308 -1.584 0 C-N-CA 122.453 2.102 . . . . 0.0 112.012 -179.893 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -111.72 -65.59 1.16 Allowed 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.439 -0.788 . . . . 0.0 109.359 179.886 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 178.98 -170.1 41.75 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.348 -1.501 . . . . 0.0 109.348 -179.924 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 92.2 mtt180 -116.72 143.72 45.31 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.358 -1.083 . . . . 0.0 109.526 179.792 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 84.7 mt -121.06 122.77 68.49 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 179.304 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 38.8 t -118.47 132.75 67.43 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.434 0 O-C-N 121.376 -0.828 . . . . 0.0 109.154 -179.984 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 73.6 mtm -122.32 151.54 41.03 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.408 -0.807 . . . . 0.0 109.122 -179.886 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -99.32 130.79 45.63 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.298 -0.877 . . . . 0.0 109.847 -179.629 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.404 ' N ' ' CD2' ' A' ' 30' ' ' LEU . 2.7 mm? -107.07 129.12 54.86 Favored 'General case' 0 N--CA 1.491 1.575 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 179.535 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -99.63 120.23 39.36 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.244 -0.91 . . . . 0.0 109.082 179.572 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -78.95 -40.52 31.63 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.337 -0.852 . . . . 0.0 110.01 -179.753 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.537 ' OD1' ' N ' ' A' ' 34' ' ' THR . 31.9 p-10 -68.23 -41.22 81.54 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.228 -0.92 . . . . 0.0 110.72 -179.082 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' THR . . . . . 0.537 ' N ' ' OD1' ' A' ' 33' ' ' ASP . 17.1 m -67.66 -44.52 77.66 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.005 -1.06 . . . . 0.0 109.997 -179.375 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 28.5 p -155.23 83.62 3.73 Favored Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.226 -0.921 . . . . 0.0 109.217 -179.903 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 13.4 Cg_endo -70.55 -35.77 9.79 Favored 'Trans proline' 0 C--N 1.307 -1.654 0 C-N-CA 121.987 1.791 . . . . 0.0 112.088 -179.537 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 1.6 mpt_? -66.51 -41.93 88.07 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.077 -1.014 . . . . 0.0 109.702 179.771 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 56.1 m -65.16 -42.06 94.11 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.203 -0.936 . . . . 0.0 110.008 -179.519 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -61.88 -31.37 71.65 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.135 -0.978 . . . . 0.0 109.083 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -69.84 -37.99 76.37 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.397 -0.814 . . . . 0.0 110.052 -179.742 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 3.3 m120 -58.42 -41.99 86.25 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.026 -1.046 . . . . 0.0 109.965 -179.345 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 -87.13 -48.41 8.08 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.114 -0.991 . . . . 0.0 109.554 179.878 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 66.8 ttp85 -57.63 -42.27 83.01 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.208 -0.933 . . . . 0.0 109.563 -179.853 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -69.74 -46.4 65.98 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.267 -0.896 . . . . 0.0 109.829 -179.674 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 44.9 tp -63.64 -37.78 88.65 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.29 -0.881 . . . . 0.0 109.701 -179.594 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' CYS . . . . . . . . . . . . . 81.7 m -72.99 -48.76 33.69 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.171 -0.956 . . . . 0.0 109.782 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 69.8 p -70.93 -35.58 72.28 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.164 -0.96 . . . . 0.0 109.687 -179.93 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 73.46 25.26 73.13 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 179.906 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 22.7 pt-20 -64.77 -33.1 75.18 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.225 -1.162 . . . . 0.0 109.622 -179.768 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 47.2 mmtm -60.14 -33.81 72.68 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.305 -0.872 . . . . 0.0 109.362 179.771 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 92.24 174.84 42.12 Favored Glycine 0 N--CA 1.486 2.032 0 N-CA-C 109.283 -1.527 . . . . 0.0 109.283 -179.753 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 65.5 m -70.57 139.22 51.44 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.387 -1.067 . . . . 0.0 109.705 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -57.72 135.35 51.82 Favored Glycine 0 N--CA 1.488 2.137 0 N-CA-C 109.219 -1.552 . . . . 0.0 109.219 179.766 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 73.4 mtp180 -59.0 -33.88 71.22 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.178 -1.19 . . . . 0.0 109.958 -179.678 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 87.0 p -60.55 -24.46 65.41 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.18 -0.95 . . . . 0.0 109.684 -179.621 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 112.66 90.92 1.93 Allowed Glycine 0 N--CA 1.494 2.562 0 N-CA-C 109.049 -1.621 . . . . 0.0 109.049 -179.714 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . 0.509 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 33.0 tttm -174.72 78.61 0.33 Allowed Pre-proline 0 N--CA 1.488 1.437 0 O-C-N 121.425 -1.044 . . . . 0.0 108.365 -179.73 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 75.8 Cg_exo -49.47 130.75 26.3 Favored 'Trans proline' 0 C--N 1.304 -1.783 0 C-N-CA 122.787 2.325 . . . . 0.0 112.77 -179.087 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.509 ' CD1' ' O ' ' A' ' 57' ' ' LYS . 7.1 mp -97.48 120.38 37.74 Favored 'General case' 0 N--CA 1.49 1.572 0 N-CA-C 109.195 -0.669 . . . . 0.0 109.195 179.854 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 58.7 m80 -149.79 93.84 2.09 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.273 -0.892 . . . . 0.0 109.448 179.679 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . 0.415 ' CE1' ' CE1' ' A' ' 14' ' ' PHE . 24.3 t80 -60.65 -34.38 74.21 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 179.831 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 92.8 mttt -54.77 167.9 0.33 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.495 -0.753 . . . . 0.0 109.794 -179.686 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 83.0 m-20 57.24 47.16 17.44 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.5 -0.75 . . . . 0.0 110.02 179.609 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 96.3 p -114.12 154.03 28.49 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.383 -0.823 . . . . 0.0 108.918 179.366 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 28.2 t -131.66 149.04 52.63 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.255 -0.903 . . . . 0.0 109.668 -179.552 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 28.6 m-85 -77.51 125.0 28.65 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.306 -0.871 . . . . 0.0 109.369 179.852 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 62.0 t60 -67.93 -46.4 71.6 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.598 -0.689 . . . . 0.0 110.782 -179.176 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 94.5 mtt180 -132.39 150.05 52.23 Favored 'General case' 0 N--CA 1.498 1.925 0 O-C-N 121.041 -1.037 . . . . 0.0 110.739 -178.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.7 m -144.19 52.26 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 N-CA-C 108.744 -0.836 . . . . 0.0 108.744 179.471 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 14.4 mt -76.69 133.44 70.31 Favored Pre-proline 0 C--N 1.301 -1.537 0 O-C-N 121.193 -0.942 . . . . 0.0 110.07 -178.702 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_endo -70.09 149.95 65.53 Favored 'Trans proline' 0 N--CA 1.492 1.405 0 C-N-CA 122.408 2.072 . . . . 0.0 112.283 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 79.42 -55.19 4.38 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 179.864 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 90.9 m-85 -71.35 -87.7 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.249 -1.147 . . . . 0.0 109.702 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' MET . . . . . 0.602 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 12.1 ptt? 179.15 -178.83 0.35 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.184 -0.948 . . . . 0.0 109.763 -179.926 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 1.1 m -117.46 131.9 56.65 Favored 'General case' 0 N--CA 1.492 1.67 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 179.255 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 63.5 tt0 -95.04 146.16 24.46 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.161 -0.962 . . . . 0.0 110.222 -179.013 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -143.55 -175.07 16.31 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.186 -1.566 . . . . 0.0 109.186 179.841 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 93.24 10.55 59.43 Favored Glycine 0 N--CA 1.494 2.528 0 N-CA-C 109.426 -1.47 . . . . 0.0 109.426 -179.905 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.438 ' OD1' ' O ' ' A' ' 82' ' ' ALA . 62.4 t0 -56.18 -15.52 3.91 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.341 -1.094 . . . . 0.0 109.681 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 73.5 t80 -50.07 -47.86 53.37 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.174 -0.954 . . . . 0.0 110.17 -179.291 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.724 ' CB ' ' H ' ' A' ' 88' ' ' GLY . 65.6 p -71.53 -31.96 67.63 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.892 -1.13 . . . . 0.0 109.606 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . 0.503 ' CB ' ' O ' ' A' ' 81' ' ' THR . . . 164.51 -54.63 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.302 -0.874 . . . . 0.0 109.334 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 92.46 1.09 69.2 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.629 -1.388 . . . . 0.0 109.629 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 22.1 m120 -87.3 5.4 38.61 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.256 -1.144 . . . . 0.0 109.511 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 95.41 -39.61 2.82 Favored Glycine 0 N--CA 1.494 2.503 0 N-CA-C 109.243 -1.543 . . . . 0.0 109.243 -179.866 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 60.8 p -73.12 -16.92 61.44 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.24 -1.153 . . . . 0.0 109.085 179.634 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -81.77 -162.37 29.77 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.724 ' H ' ' CB ' ' A' ' 81' ' ' THR . . . 84.19 37.97 10.59 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 -179.951 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 78.1 mm-40 -58.02 149.7 22.65 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.266 -1.137 . . . . 0.0 109.808 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 50.8 m -115.57 147.08 41.15 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.666 -0.646 . . . . 0.0 109.273 179.925 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 18.1 pt -67.82 -35.53 72.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.264 -0.897 . . . . 0.0 110.037 -179.624 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 49.2 m-85 -67.43 -38.67 84.92 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.03 -1.044 . . . . 0.0 109.64 -179.809 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 77.87 13.74 83.09 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.342 -1.503 . . . . 0.0 109.342 -179.701 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -147.0 155.9 42.62 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.275 -1.132 . . . . 0.0 109.429 -179.838 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 53.5 mttp -95.08 148.65 22.13 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.339 -0.851 . . . . 0.0 109.807 -179.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 54.9 p90 -134.33 160.23 38.58 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.403 -0.811 . . . . 0.0 109.141 179.453 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -104.53 150.88 24.23 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.302 -0.874 . . . . 0.0 109.788 -179.633 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 60.1 t0 -137.77 81.58 1.87 Allowed 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.314 -0.866 . . . . 0.0 109.246 179.763 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -63.78 -29.03 70.28 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.429 -0.794 . . . . 0.0 109.956 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . 0.405 HD21 ' N ' ' A' ' 100' ' ' ASN . 2.7 m120 -56.58 141.34 43.52 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.134 -0.979 . . . . 0.0 110.075 -179.244 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' PHE . . . . . 0.537 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 74.4 t80 -150.33 46.51 0.89 Allowed 'General case' 0 N--CA 1.491 1.615 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.824 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 90.9 mt -59.03 -34.82 54.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.416 -0.803 . . . . 0.0 110.228 -179.492 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 71.8 mmtt -80.78 139.85 35.82 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.112 -0.993 . . . . 0.0 109.765 -179.393 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 35.5 tttm -93.32 156.0 17.07 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.394 -0.816 . . . . 0.0 109.571 -179.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' HIS . . . . . . . . . . . . . 85.2 t60 -96.36 78.48 3.05 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.334 -0.854 . . . . 0.0 108.77 179.356 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 14.9 m -56.56 -40.03 74.49 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.3 -0.875 . . . . 0.0 109.436 -179.42 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 130.09 -95.74 0.35 Allowed Glycine 0 N--CA 1.493 2.498 0 N-CA-C 110.044 -1.223 . . . . 0.0 110.044 179.575 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -68.81 141.24 48.65 Favored 'Trans proline' 0 N--CA 1.496 1.621 0 C-N-CA 122.694 2.263 . . . . 0.0 113.131 -179.233 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 75.95 22.65 73.85 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 110.241 -1.143 . . . . 0.0 110.241 179.033 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 33.5 mm -115.54 134.41 58.83 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 121.315 -1.109 . . . . 0.0 110.076 -179.782 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . 0.56 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 3.1 mm? -93.78 137.03 33.46 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.289 -0.882 . . . . 0.0 108.894 179.148 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 112' ' ' SER . . . . . 0.429 ' OG ' ' O ' ' A' ' 140' ' ' VAL . 34.0 t -146.05 141.17 27.35 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.226 -0.921 . . . . 0.0 109.691 179.781 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 72.0 mtm -85.53 137.04 33.15 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.245 -0.91 . . . . 0.0 109.181 179.715 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . 0.452 ' O ' ' OD1' ' A' ' 115' ' ' ASN . . . -61.83 138.32 58.33 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.148 -0.97 . . . . 0.0 109.333 -179.879 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . 0.452 ' OD1' ' O ' ' A' ' 114' ' ' ALA . 77.2 m-20 -148.51 114.01 5.62 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.328 -0.858 . . . . 0.0 109.206 179.828 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -69.21 -29.77 67.8 Favored 'General case' 0 C--N 1.297 -1.713 0 O-C-N 121.43 -0.794 . . . . 0.0 109.179 179.613 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -137.84 168.42 24.52 Favored Glycine 0 N--CA 1.494 2.503 0 N-CA-C 109.085 -1.606 . . . . 0.0 109.085 179.783 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -67.4 155.6 69.68 Favored 'Trans proline' 0 C--N 1.306 -1.666 0 C-N-CA 122.758 2.305 . . . . 0.0 111.946 -179.858 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 75.9 m-20 54.92 45.3 26.78 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.425 -0.797 . . . . 0.0 109.498 -179.907 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 94.1 m -130.27 125.93 36.02 Favored 'General case' 0 N--CA 1.485 1.314 0 O-C-N 121.386 -0.821 . . . . 0.0 108.79 179.725 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 25.1 t-20 -99.09 110.62 23.18 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.449 -0.782 . . . . 0.0 109.621 -179.838 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -106.61 121.27 6.55 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.271 -1.532 . . . . 0.0 109.271 179.646 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 20.1 m -56.84 -34.43 67.76 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.209 -1.171 . . . . 0.0 109.187 179.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.6 mt-30 -71.62 144.94 49.27 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.263 -0.898 . . . . 0.0 109.148 179.81 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 44.9 p90 -135.59 163.53 29.91 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.317 -0.865 . . . . 0.0 109.297 -179.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.602 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 52.8 p90 -132.15 157.38 44.41 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.405 -0.81 . . . . 0.0 109.503 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 67.1 mt -119.08 133.25 66.54 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.49 -0.756 . . . . 0.0 109.338 179.849 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 128' ' ' CYS . . . . . 0.53 ' SG ' ' O ' ' A' ' 130' ' ' ALA . 7.1 t -115.84 126.35 53.86 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.355 -0.841 . . . . 0.0 109.15 179.847 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 30.1 p -97.18 0.53 48.5 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.276 -0.89 . . . . 0.0 109.702 -179.708 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . 0.53 ' O ' ' SG ' ' A' ' 128' ' ' CYS . . . -148.86 164.26 35.0 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.235 -0.915 . . . . 0.0 109.429 -179.8 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -70.07 137.48 51.26 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.118 -0.989 . . . . 0.0 109.177 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 3.6 p -113.53 101.12 9.05 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.495 -0.753 . . . . 0.0 109.45 -179.737 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -64.35 -36.52 84.4 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.296 -0.878 . . . . 0.0 109.596 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 1.2 p90 -67.55 -33.29 74.74 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.15 -0.969 . . . . 0.0 109.59 -179.835 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . 0.546 ' O ' ' NE2' ' A' ' 139' ' ' HIS . 8.6 mt -93.11 12.15 25.23 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.102 -0.998 . . . . 0.0 109.322 179.358 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . 0.406 ' HA ' ' HE2' ' A' ' 139' ' ' HIS . 60.1 t0 -57.05 124.18 17.82 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.137 -0.977 . . . . 0.0 109.616 -179.577 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -176.11 -159.29 21.56 Favored Glycine 0 N--CA 1.486 1.987 0 N-CA-C 109.009 -1.636 . . . . 0.0 109.009 -179.852 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 87.6 mttt -57.24 -38.51 73.92 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.317 -1.107 . . . . 0.0 109.646 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 139' ' ' HIS . . . . . 0.546 ' NE2' ' O ' ' A' ' 135' ' ' LEU . 63.3 m-70 53.57 71.51 0.5 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.318 -0.864 . . . . 0.0 109.957 179.766 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.429 ' O ' ' OG ' ' A' ' 112' ' ' SER . 39.3 t -69.0 135.44 28.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.14 -0.975 . . . . 0.0 108.879 179.295 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 17.4 m -126.94 148.23 31.78 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 121.222 -0.924 . . . . 0.0 109.74 -179.489 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 43.3 p90 -120.06 -6.01 9.99 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.382 -0.824 . . . . 0.0 110.019 179.831 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -164.74 -179.77 38.97 Favored Glycine 0 N--CA 1.495 2.618 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 179.692 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.4 pt20 -143.85 166.53 24.65 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.23 -1.159 . . . . 0.0 109.566 -179.769 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 44.7 t -97.21 132.18 42.36 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.13 0 O-C-N 121.096 -1.002 . . . . 0.0 109.54 -179.742 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 17.2 m -110.45 -32.74 2.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 O-C-N 121.413 -0.805 . . . . 0.0 109.3 179.321 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -145.35 170.25 16.68 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.308 -0.87 . . . . 0.0 109.46 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 97.35 2.47 58.96 Favored Glycine 0 N--CA 1.494 2.539 0 N-CA-C 109.977 -1.249 . . . . 0.0 109.977 179.531 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 149' ' ' MET . . . . . 0.407 ' O ' HG13 ' A' ' 152' ' ' VAL . 88.3 mtp -61.06 -33.07 72.74 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.189 -1.183 . . . . 0.0 109.685 179.925 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -64.78 -42.43 95.1 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 120.876 -1.14 . . . . 0.0 109.987 -179.547 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.4 p -82.53 -34.01 11.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.128 -0.983 . . . . 0.0 110.591 -179.341 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 152' ' ' VAL . . . . . 0.445 ' CG1' ' N ' ' A' ' 153' ' ' LYS . 0.8 OUTLIER -53.74 -40.88 45.21 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 120.957 -1.09 . . . . 0.0 109.067 -179.408 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 153' ' ' LYS . . . . . 0.445 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 99.0 mttt -63.53 -34.12 77.08 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.113 -0.992 . . . . 0.0 109.292 179.201 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -61.51 -37.11 82.49 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.322 -0.861 . . . . 0.0 109.937 -179.638 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 97.9 mt -71.99 -35.05 52.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.173 -0.955 . . . . 0.0 109.981 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -75.93 -42.0 50.05 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.177 -0.952 . . . . 0.0 111.209 -178.894 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . 0.428 ' HG2' ' HZ3' ' A' ' 157' ' ' LYS . 15.4 pttm -61.81 -34.2 75.49 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 120.769 -1.207 . . . . 0.0 109.719 -178.924 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 34.0 m -79.91 -13.79 13.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.152 -0.968 . . . . 0.0 109.082 179.562 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -76.88 170.43 55.09 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.836 -1.306 . . . . 0.0 109.836 -179.826 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 23.1 t -159.02 173.95 15.69 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.409 -1.054 . . . . 0.0 109.315 -179.841 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 23.6 m -53.84 -32.47 53.01 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.236 -0.915 . . . . 0.0 109.121 179.663 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 24.0 m -56.45 -32.57 65.05 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.393 -0.817 . . . . 0.0 109.412 179.842 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 95.1 13.23 53.38 Favored Glycine 0 N--CA 1.493 2.465 0 N-CA-C 109.791 -1.323 . . . . 0.0 109.791 179.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 98.0 mtt180 -119.24 144.82 46.54 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.283 -1.128 . . . . 0.0 109.379 179.862 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 165' ' ' THR . . . . . . . . . . . . . 80.1 p -82.39 150.46 27.11 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.25 -0.906 . . . . 0.0 109.563 179.867 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -65.95 -35.5 80.78 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.339 -0.851 . . . . 0.0 108.896 179.523 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 66.6 mttm -112.58 157.68 20.89 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.524 -0.735 . . . . 0.0 109.07 179.731 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -69.7 130.75 43.21 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.134 -0.979 . . . . 0.0 109.324 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 43.0 t -123.2 125.32 71.77 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 121.201 -0.937 . . . . 0.0 109.575 -179.949 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 60.7 t -150.33 157.17 6.15 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 O-C-N 121.486 -0.758 . . . . 0.0 108.972 179.582 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -87.98 119.41 35.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.104 -0.998 . . . . 0.0 109.529 -179.727 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -65.91 -24.62 66.88 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.361 -0.837 . . . . 0.0 109.414 179.407 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 19.9 t70 -173.81 171.16 3.8 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.127 -0.983 . . . . 0.0 110.301 -179.51 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 11.0 p -151.84 153.15 33.65 Favored 'General case' 0 N--CA 1.492 1.66 0 N-CA-C 109.052 -0.721 . . . . 0.0 109.052 179.499 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -175.75 174.55 46.94 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 109.702 -1.359 . . . . 0.0 109.702 179.784 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 62.2 tt0 -107.89 120.67 42.94 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.3 -1.118 . . . . 0.0 109.652 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 32.4 tp -61.71 -37.03 82.66 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.135 -0.978 . . . . 0.0 109.032 179.434 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 25.0 t . . . . . 0 N--CA 1.49 1.559 0 CA-C-O 118.087 -0.959 . . . . 0.0 109.466 179.972 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.529 4.882 0 N-CA-C 119.38 2.512 . . . . 0.0 119.38 . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 54.5 p -70.38 160.99 31.29 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.219 -1.165 . . . . 0.0 109.573 179.96 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 98.6 m-85 -96.87 20.56 10.86 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.252 -0.905 . . . . 0.0 109.396 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 18.2 p -121.49 162.77 19.93 Favored 'General case' 0 N--CA 1.494 1.745 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -152.37 -118.7 0.77 Allowed Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 -179.907 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 86.7 p -61.26 -29.28 69.75 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.204 -1.174 . . . . 0.0 109.836 -179.812 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 25.6 ttp 49.88 70.05 2.28 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.06 -1.025 . . . . 0.0 109.229 -179.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -50.73 -33.19 39.33 Favored 'Trans proline' 0 C--N 1.306 -1.694 0 C-N-CA 122.833 2.355 . . . . 0.0 112.378 -179.457 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 8.2 p-10 -158.94 146.35 13.21 Favored Pre-proline 0 N--CA 1.489 1.489 0 O-C-N 121.131 -0.981 . . . . 0.0 109.555 179.782 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -73.76 145.87 37.32 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 122.803 2.335 . . . . 0.0 112.047 179.763 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.482 ' NH2' ' CB ' ' A' ' 178' ' ' SER . 95.5 mtm-85 -119.16 132.49 55.97 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.271 -0.893 . . . . 0.0 108.783 179.222 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.6 p -135.04 142.39 40.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.269 -0.895 . . . . 0.0 109.772 -179.192 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 42.8 p90 -141.12 155.61 46.09 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.434 -0.791 . . . . 0.0 109.506 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -128.18 142.32 51.21 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.421 -0.799 . . . . 0.0 109.887 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 59.4 t0 -94.6 124.26 38.52 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.227 -0.92 . . . . 0.0 108.734 179.151 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 39.1 mtp -119.66 147.51 44.47 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.136 -0.978 . . . . 0.0 110.279 -179.312 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.43 ' OG ' ' CD ' ' A' ' 172' ' ' GLU . 59.7 m -128.57 153.67 46.98 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.604 -0.685 . . . . 0.0 109.355 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 34.7 m -114.93 131.93 65.66 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.835 0 O-C-N 121.388 -0.82 . . . . 0.0 109.426 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 63.59 9.65 32.99 Favored Glycine 0 N--CA 1.492 2.398 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 179.858 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 94.67 -1.67 66.31 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 -179.895 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 75.0 mt-30 -103.69 151.2 38.74 Favored Pre-proline 0 N--CA 1.493 1.717 0 O-C-N 121.295 -1.121 . . . . 0.0 109.073 179.756 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 14.3 Cg_endo -58.36 134.23 60.08 Favored 'Trans proline' 0 C--N 1.309 -1.507 0 C-N-CA 122.412 2.074 . . . . 0.0 112.266 -179.532 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -114.23 -65.06 1.23 Allowed 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.514 -0.741 . . . . 0.0 109.274 179.775 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -176.77 -170.48 39.34 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.456 -1.457 . . . . 0.0 109.456 179.943 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 46.6 ptt85 -120.06 148.55 43.45 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.318 -1.107 . . . . 0.0 109.11 179.851 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 83.3 mt -122.57 129.15 75.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.496 -0.753 . . . . 0.0 109.32 -179.863 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 46.3 t -113.14 133.26 59.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.539 -0.725 . . . . 0.0 109.062 179.673 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 74.5 mtm -121.12 149.69 42.38 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.391 -0.818 . . . . 0.0 109.52 -179.753 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -97.57 132.51 43.17 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.388 -0.82 . . . . 0.0 109.542 -179.858 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -109.36 130.57 55.49 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.533 -0.729 . . . . 0.0 109.425 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 86.5 m-85 -94.55 118.41 31.63 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.126 -0.984 . . . . 0.0 108.483 178.89 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -93.38 -42.06 9.49 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.299 -0.875 . . . . 0.0 109.68 -179.683 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.6 m-20 -62.26 -49.23 76.53 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.09 -1.006 . . . . 0.0 109.764 -179.498 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' THR . . . . . 0.442 ' O ' ' OE1' ' A' ' 99' ' ' GLU . 61.9 m -73.52 -42.03 62.28 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.069 -1.02 . . . . 0.0 109.72 179.8 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.529 ' O ' ' OG1' ' A' ' 35' ' ' THR . 1.8 p -132.24 79.02 67.21 Favored Pre-proline 0 N--CA 1.492 1.657 0 O-C-N 121.3 -0.875 . . . . 0.0 109.439 -179.69 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 21.2 Cg_endo -66.77 -61.79 0.08 OUTLIER 'Trans proline' 0 C--N 1.31 -1.468 0 C-N-CA 122.376 2.051 . . . . 0.0 112.603 -179.48 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.623 ' NH2' ' CE1' ' A' ' 92' ' ' TYR . 68.7 mtp85 -60.9 -34.98 75.49 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.415 -0.803 . . . . 0.0 110.4 -179.308 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 25.7 m -59.98 -41.47 92.07 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.953 -1.092 . . . . 0.0 109.859 -179.559 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -62.62 -30.18 71.17 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.089 -1.007 . . . . 0.0 109.35 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.435 ' OE1' ' OH ' ' A' ' 92' ' ' TYR . 96.6 mt-10 -67.59 -34.91 77.98 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.284 -0.885 . . . . 0.0 109.761 -179.983 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 26.2 m120 -56.82 -39.08 73.54 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.149 -0.97 . . . . 0.0 109.768 -179.767 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . 0.443 ' O ' ' SG ' ' A' ' 46' ' ' CYS . 98.8 m-85 -94.16 -50.45 5.28 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.121 -0.987 . . . . 0.0 109.512 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . 0.858 ' HE ' HE22 ' A' ' 176' ' ' GLN . 75.8 ttt-85 -57.19 -42.01 80.43 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.41 -0.806 . . . . 0.0 110.491 -179.392 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -63.72 -44.87 92.29 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.999 -1.063 . . . . 0.0 110.077 -179.121 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.515 ' N ' ' CD2' ' A' ' 45' ' ' LEU . 2.7 mm? -67.64 -37.2 82.1 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.19 -0.944 . . . . 0.0 109.637 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' CYS . . . . . 0.443 ' SG ' ' O ' ' A' ' 42' ' ' PHE . 64.1 m -66.69 -48.99 67.57 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.136 -0.977 . . . . 0.0 110.108 -179.533 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 60.6 p -72.65 -30.71 64.52 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.192 -0.943 . . . . 0.0 109.694 -179.844 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 74.03 27.34 66.68 Favored Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 179.778 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 23.0 pt-20 -62.25 -35.59 79.41 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.212 -1.169 . . . . 0.0 109.381 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 43.6 mmtm -61.19 -33.2 73.07 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.289 -0.882 . . . . 0.0 109.128 179.588 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 93.64 168.4 38.29 Favored Glycine 0 N--CA 1.488 2.136 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 -179.793 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 68.4 m -76.45 139.9 41.05 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.306 -1.114 . . . . 0.0 109.686 -179.947 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -53.9 135.15 43.27 Favored Glycine 0 N--CA 1.488 2.165 0 N-CA-C 109.224 -1.551 . . . . 0.0 109.224 179.753 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 91.9 mtm-85 -58.92 -35.99 74.0 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.192 -1.181 . . . . 0.0 109.917 -179.551 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 22.7 t -59.14 -31.21 68.75 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.18 -0.95 . . . . 0.0 109.919 -179.587 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . 0.449 ' O ' ' CG ' ' A' ' 57' ' ' LYS . . . 117.91 81.05 0.77 Allowed Glycine 0 N--CA 1.495 2.614 0 N-CA-C 108.749 -1.74 . . . . 0.0 108.749 -179.381 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . 0.547 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 57.4 mttm -161.69 79.87 2.03 Favored Pre-proline 0 C--N 1.303 -1.434 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 -179.576 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 71.3 Cg_exo -50.9 133.02 39.19 Favored 'Trans proline' 0 C--N 1.301 -1.964 0 C-N-CA 122.894 2.396 . . . . 0.0 112.809 -178.734 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.571 ' O ' ' CG ' ' A' ' 60' ' ' HIS . 7.0 mp -100.19 98.32 9.03 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.613 -0.679 . . . . 0.0 109.524 -179.47 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . 0.571 ' CG ' ' O ' ' A' ' 59' ' ' LEU . 93.5 m-70 -160.45 125.91 3.93 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.167 -0.958 . . . . 0.0 109.948 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 9.5 m-85 -71.95 -5.98 38.73 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.136 -0.978 . . . . 0.0 108.811 178.889 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . 0.561 ' O ' ' O ' ' A' ' 171' ' ' VAL . 48.7 tttt -53.39 -25.88 17.34 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.527 -0.733 . . . . 0.0 109.57 179.891 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 89.3 m-20 -103.6 4.85 36.1 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.467 -0.771 . . . . 0.0 110.071 -179.402 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 63.8 p -82.04 162.35 22.62 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.069 -1.019 . . . . 0.0 109.856 -179.754 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 29.2 t -147.31 159.34 43.78 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.473 -0.767 . . . . 0.0 109.083 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.5 m-85 -64.18 123.5 19.26 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.079 -1.013 . . . . 0.0 108.929 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 61.7 t60 -66.62 -50.26 63.6 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.304 -0.872 . . . . 0.0 110.548 -179.112 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 93.2 mtt180 -141.47 150.47 42.29 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 120.951 -1.093 . . . . 0.0 110.287 -179.658 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 4.9 m -137.09 130.92 45.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 179.096 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 19.1 mt -149.33 128.39 6.2 Favored Pre-proline 0 N--CA 1.492 1.646 0 O-C-N 120.94 -1.1 . . . . 0.0 109.41 -179.785 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 65.3 Cg_endo -76.0 133.44 15.13 Favored 'Trans proline' 0 C--N 1.311 -1.429 0 C-N-CA 122.148 1.899 . . . . 0.0 112.014 179.707 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 90.49 3.88 71.27 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.793 -1.323 . . . . 0.0 109.793 179.662 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 82.6 m-85 -138.77 -94.37 0.18 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.129 -1.218 . . . . 0.0 109.811 179.845 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 7.3 ptt? -171.45 175.79 4.01 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.168 -0.957 . . . . 0.0 109.839 -179.655 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -122.28 136.28 54.88 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 108.231 -1.026 . . . . 0.0 108.231 179.363 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 92.4 mt-30 -94.56 136.0 35.37 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.88 -1.138 . . . . 0.0 110.198 -179.262 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -90.03 -173.52 45.15 Favored Glycine 0 N--CA 1.492 2.379 0 N-CA-C 108.941 -1.664 . . . . 0.0 108.941 179.395 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -155.63 174.3 33.67 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.779 -1.329 . . . . 0.0 109.779 179.84 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.547 ' OD1' ' N ' ' A' ' 83' ' ' GLY . 48.5 p30 -106.37 165.59 11.15 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.415 -1.05 . . . . 0.0 109.56 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 46.4 p90 -75.2 -19.95 59.54 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.309 -0.87 . . . . 0.0 109.66 -179.884 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.557 ' OG1' ' N ' ' A' ' 88' ' ' GLY . 71.2 p -65.93 -37.06 85.06 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.281 -0.887 . . . . 0.0 109.989 -179.629 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -174.46 -51.32 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.267 -0.896 . . . . 0.0 109.539 -179.934 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . 0.547 ' N ' ' OD1' ' A' ' 79' ' ' ASP . . . 94.71 2.2 63.23 Favored Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 78.7 m-20 -86.02 4.15 39.17 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.189 -1.183 . . . . 0.0 109.448 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 93.71 -37.47 3.39 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 51.6 p -69.99 -29.11 66.11 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.185 -1.185 . . . . 0.0 109.231 179.842 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -87.85 -168.23 44.24 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.983 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.557 ' N ' ' OG1' ' A' ' 81' ' ' THR . . . 84.03 45.07 6.43 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.571 -1.412 . . . . 0.0 109.571 179.879 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -56.37 144.37 30.94 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.344 -1.092 . . . . 0.0 109.43 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 27.4 t -78.24 144.57 36.1 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.159 -0.963 . . . . 0.0 109.552 -179.913 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 17.0 pt -66.34 -36.29 77.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.291 -0.881 . . . . 0.0 109.849 -179.871 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . 0.623 ' CE1' ' NH2' ' A' ' 37' ' ' ARG . 96.4 m-85 -66.21 -36.44 83.04 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.175 -0.953 . . . . 0.0 109.566 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.21 5.74 87.03 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.202 -1.559 . . . . 0.0 109.202 -179.752 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -150.97 158.0 43.6 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.348 -1.09 . . . . 0.0 109.381 -179.911 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -85.17 148.29 26.18 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.178 -0.951 . . . . 0.0 109.484 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 45.6 p90 -135.39 159.13 42.56 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.327 -0.858 . . . . 0.0 109.392 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -73.25 135.68 44.51 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.262 -0.899 . . . . 0.0 109.932 -179.678 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . 0.438 ' C ' ' OD1' ' A' ' 98' ' ' ASP . 54.4 p30 -99.84 -163.87 1.07 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.313 -0.867 . . . . 0.0 109.549 179.774 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . 0.442 ' OE1' ' O ' ' A' ' 34' ' ' THR . 94.5 mt-10 -108.02 163.01 13.52 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.371 -0.831 . . . . 0.0 109.455 179.77 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 82.9 m-20 -64.76 165.95 9.66 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.257 -0.902 . . . . 0.0 109.566 -179.809 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' PHE . . . . . 0.489 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 33.3 p90 -80.7 51.43 1.5 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.27 -0.894 . . . . 0.0 109.718 -179.811 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 90.7 mt -56.22 -41.08 68.96 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.101 -0.999 . . . . 0.0 109.547 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 43.6 mtpt -89.33 146.14 24.9 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.178 -0.951 . . . . 0.0 109.693 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 49.3 pttt -134.85 179.98 5.97 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.42 -0.8 . . . . 0.0 109.356 179.804 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' HIS . . . . . 0.532 ' O ' ' CG ' ' A' ' 105' ' ' HIS . 48.4 p-80 -92.64 100.75 13.2 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.292 -0.88 . . . . 0.0 109.407 -179.872 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 51.2 p -76.54 -22.46 54.34 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.331 -0.856 . . . . 0.0 109.628 -179.903 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -151.15 -179.46 26.89 Favored Glycine 0 N--CA 1.492 2.406 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 -179.688 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -72.65 158.87 49.94 Favored 'Trans proline' 0 C--N 1.307 -1.626 0 C-N-CA 122.951 2.434 . . . . 0.0 112.178 179.83 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 84.95 38.25 9.47 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 110.233 -1.147 . . . . 0.0 110.233 179.532 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.405 HD13 HG21 ' A' ' 110' ' ' ILE . 34.4 mm -113.38 138.39 43.13 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.29 -1.123 . . . . 0.0 108.979 179.598 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . 0.604 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 2.4 mm? -87.58 139.75 30.22 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.246 -0.909 . . . . 0.0 109.658 -179.754 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 112' ' ' SER . . . . . 0.427 ' OG ' ' O ' ' A' ' 140' ' ' VAL . 23.1 t -128.16 143.54 51.06 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.54 -0.725 . . . . 0.0 109.27 179.85 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 58.3 ttp -96.71 127.08 42.35 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.305 -0.872 . . . . 0.0 109.533 -179.9 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -66.16 146.5 54.58 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.236 -0.915 . . . . 0.0 109.633 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . 0.502 ' N ' ' OD1' ' A' ' 115' ' ' ASN . 9.1 p-10 -168.25 115.73 0.7 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.272 -0.893 . . . . 0.0 109.668 179.818 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -66.18 -33.95 76.92 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.379 -0.825 . . . . 0.0 109.347 179.806 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -145.52 166.92 27.65 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.352 -1.499 . . . . 0.0 109.352 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -66.59 158.58 55.04 Favored 'Trans proline' 0 C--N 1.306 -1.678 0 C-N-CA 122.822 2.348 . . . . 0.0 111.963 179.919 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 73.7 m-20 55.03 44.07 28.74 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.467 -0.771 . . . . 0.0 109.392 -179.886 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 87.2 m -137.28 129.33 29.22 Favored 'General case' 0 C--N 1.305 -1.359 0 O-C-N 121.405 -0.81 . . . . 0.0 109.113 179.943 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 22.4 t-20 -79.94 116.24 19.97 Favored 'General case' 0 C--N 1.298 -1.65 0 O-C-N 121.489 -0.757 . . . . 0.0 109.33 179.859 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -85.32 -179.54 50.69 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.736 -1.346 . . . . 0.0 109.736 -179.82 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -130.64 -14.25 3.66 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.367 -1.079 . . . . 0.0 109.749 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 94.3 mt-30 -121.89 159.42 26.89 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.299 -0.876 . . . . 0.0 109.622 -179.876 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 43.6 p90 -130.83 158.74 39.35 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.489 -0.757 . . . . 0.0 109.474 -179.898 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -117.47 143.84 45.63 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.49 -0.757 . . . . 0.0 110.02 -179.766 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.41 HD13 HG23 ' A' ' 127' ' ' ILE . 84.2 mt -120.77 134.27 64.75 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 121.613 -0.679 . . . . 0.0 109.224 179.246 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -125.27 126.36 45.01 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.293 -0.879 . . . . 0.0 109.376 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 30.3 p -98.32 3.39 48.64 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.348 -0.845 . . . . 0.0 109.301 179.868 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -153.62 159.63 42.16 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.243 -0.911 . . . . 0.0 109.428 -179.795 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 7.9 ttpm? -66.44 130.05 41.89 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.165 -0.959 . . . . 0.0 109.081 179.8 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 16.6 p -109.09 95.86 5.92 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.395 -0.816 . . . . 0.0 109.633 -179.658 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -65.74 -35.72 81.55 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.213 -0.929 . . . . 0.0 109.581 179.844 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 1.0 OUTLIER -66.47 -33.86 76.64 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.245 -0.91 . . . . 0.0 109.55 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 9.7 mt -90.06 7.17 39.09 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.166 -0.959 . . . . 0.0 109.201 179.295 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . 0.533 ' O ' ' OD1' ' A' ' 136' ' ' ASP . 47.2 p30 -46.79 138.45 6.22 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.184 -0.948 . . . . 0.0 109.783 -179.617 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 174.21 -161.88 32.12 Favored Glycine 0 N--CA 1.484 1.885 0 N-CA-C 108.873 -1.691 . . . . 0.0 108.873 -179.708 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . 0.477 ' O ' ' O ' ' A' ' 139' ' ' HIS . 88.8 mttt -57.36 -39.55 76.21 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 121.276 -1.132 . . . . 0.0 109.432 179.86 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 139' ' ' HIS . . . . . 0.477 ' O ' ' O ' ' A' ' 138' ' ' LYS . 66.3 m-70 53.18 109.22 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.51 -0.744 . . . . 0.0 110.049 179.63 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.427 ' O ' ' OG ' ' A' ' 112' ' ' SER . 40.6 t -107.42 136.54 42.27 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.36 -0.837 . . . . 0.0 108.825 179.435 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 23.5 m -125.09 142.47 41.87 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.307 -0.871 . . . . 0.0 109.587 -179.464 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 42.8 p90 -126.46 -9.89 6.29 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.5 -0.75 . . . . 0.0 109.751 179.73 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -156.52 175.72 34.07 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 179.631 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 58.6 tt0 -141.43 159.44 42.22 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.238 -1.154 . . . . 0.0 109.675 -179.614 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 9.8 t -97.83 134.39 36.24 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.22 0 O-C-N 121.124 -0.985 . . . . 0.0 109.126 179.904 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 11.6 m -113.62 -35.45 2.26 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.493 -0.754 . . . . 0.0 109.535 179.653 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 91.9 mt-10 -142.83 167.86 21.08 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.227 -0.92 . . . . 0.0 109.627 -179.849 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 97.78 4.36 57.95 Favored Glycine 0 N--CA 1.494 2.553 0 N-CA-C 110.079 -1.209 . . . . 0.0 110.079 179.534 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 149' ' ' MET . . . . . 0.414 ' O ' HG11 ' A' ' 152' ' ' VAL . 88.0 mtp -60.84 -33.22 72.72 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.062 -1.258 . . . . 0.0 109.741 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . 0.54 ' OD1' ' N ' ' A' ' 151' ' ' VAL . 30.9 p-10 -65.67 -38.26 88.8 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.9 -1.125 . . . . 0.0 110.107 -179.441 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . 0.54 ' N ' ' OD1' ' A' ' 150' ' ' ASP . 7.6 p -86.52 -33.9 7.51 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.066 -1.021 . . . . 0.0 110.262 -179.593 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 152' ' ' VAL . . . . . 0.469 ' CG1' ' N ' ' A' ' 153' ' ' LYS . 1.0 OUTLIER -56.1 -42.65 73.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 120.943 -1.098 . . . . 0.0 109.175 -179.503 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 153' ' ' LYS . . . . . 0.469 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 98.7 mttt -64.87 -33.88 77.06 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.189 -0.944 . . . . 0.0 109.537 179.431 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -62.33 -40.4 96.22 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.287 -0.883 . . . . 0.0 110.11 -179.321 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 75.4 mt -71.19 -36.79 63.81 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.228 -0.92 . . . . 0.0 110.394 -179.481 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -79.57 -41.45 27.15 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.085 -1.009 . . . . 0.0 111.406 -178.725 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 23.5 pttt -61.02 -34.0 74.15 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.705 -1.247 . . . . 0.0 110.193 -178.591 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 35.1 m -73.37 -10.44 13.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.027 -1.046 . . . . 0.0 109.2 179.906 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -76.38 176.36 52.11 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 -179.822 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 83.2 p -155.31 176.07 13.05 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.425 -1.044 . . . . 0.0 109.039 -179.641 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 22.7 m -52.28 -36.01 51.77 Favored 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 179.429 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 23.8 m -60.71 -33.19 72.52 Favored 'General case' 0 N--CA 1.487 1.387 0 O-C-N 121.377 -0.827 . . . . 0.0 108.93 179.164 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 96.31 8.94 57.29 Favored Glycine 0 N--CA 1.493 2.437 0 N-CA-C 109.805 -1.318 . . . . 0.0 109.805 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 69.6 ttp85 -101.74 138.69 38.39 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.348 -1.089 . . . . 0.0 109.521 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 165' ' ' THR . . . . . . . . . . . . . 65.2 p -84.12 151.85 24.67 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.175 -0.953 . . . . 0.0 109.544 179.81 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -67.28 -34.8 78.15 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.245 -0.909 . . . . 0.0 109.063 179.557 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 63.2 mttp -114.52 158.43 21.65 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.563 -0.711 . . . . 0.0 109.34 -179.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 63.1 mttp -73.79 137.81 44.12 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.148 -0.97 . . . . 0.0 109.353 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 2.7 m -132.65 119.71 39.23 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.35 -0.844 . . . . 0.0 109.843 -179.758 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 39.2 t -145.67 141.58 22.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 CA-C-O 121.898 0.856 . . . . 0.0 109.424 179.41 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . 0.561 ' O ' ' O ' ' A' ' 62' ' ' LYS . 22.1 t -61.36 132.36 26.89 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.783 0 C-N-CA 120.333 -0.547 . . . . 0.0 109.762 -179.608 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 172' ' ' GLU . . . . . 0.452 ' O ' ' OD1' ' A' ' 173' ' ' ASP . 95.6 mt-10 -105.87 -7.08 18.44 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.335 -0.853 . . . . 0.0 109.808 179.61 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 173' ' ' ASP . . . . . 0.452 ' OD1' ' O ' ' A' ' 172' ' ' GLU . 30.5 m-20 -158.44 168.22 27.55 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.082 -1.011 . . . . 0.0 110.007 -179.734 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 20.4 p -170.32 126.25 0.78 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.474 -0.766 . . . . 0.0 109.539 179.565 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -173.55 173.86 45.92 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 179.8 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 176' ' ' GLN . . . . . 0.858 HE22 ' HE ' ' A' ' 43' ' ' ARG . 58.7 tt0 -105.2 121.35 43.66 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.383 -1.069 . . . . 0.0 109.853 -179.787 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 36.8 tp -62.41 -36.57 82.77 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.239 -0.913 . . . . 0.0 108.95 179.125 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 178' ' ' SER . . . . . 0.513 ' OXT' ' NE2' ' A' ' 176' ' ' GLN . 7.2 t . . . . . 0 N--CA 1.491 1.589 0 CA-C-O 117.977 -1.011 . . . . 0.0 109.428 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.502 ' O ' ' ND2' ' A' ' 9' ' ' ASN . 2.2 p-10 . . . . . 0 N--CA 1.494 1.756 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -72.04 144.43 42.57 Favored 'Trans proline' 0 C--N 1.308 -1.561 0 C-N-CA 122.515 2.143 . . . . 0.0 111.752 179.582 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 92.9 mtt180 -126.26 142.2 51.62 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.304 -0.873 . . . . 0.0 109.643 -179.822 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 10.5 p -134.87 143.84 36.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.359 -0.838 . . . . 0.0 109.345 179.803 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 25.0 p90 -139.49 152.89 47.33 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.208 -0.933 . . . . 0.0 109.602 -179.843 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -124.62 133.09 53.37 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.426 -0.796 . . . . 0.0 109.471 179.529 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.7 t0 -91.06 111.95 23.64 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.144 -0.972 . . . . 0.0 108.611 179.248 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' MET . . . . . 0.426 ' SD ' HD12 ' A' ' 26' ' ' ILE . 78.9 mtp -106.39 138.91 41.72 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.239 -0.913 . . . . 0.0 110.437 -179.185 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.422 ' OG ' ' OE2' ' A' ' 172' ' ' GLU . 48.8 m -131.6 155.95 46.63 Favored 'General case' 0 N--CA 1.492 1.632 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 179.416 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 25.1 m -118.99 144.29 27.71 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.149 -0.969 . . . . 0.0 109.62 -179.738 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 57.6 -108.99 1.55 Allowed Glycine 0 N--CA 1.488 2.119 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -135.77 28.33 2.98 Favored Glycine 0 N--CA 1.493 2.479 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 32.6 mt-30 -137.44 153.02 74.19 Favored Pre-proline 0 N--CA 1.493 1.719 0 O-C-N 121.297 -1.119 . . . . 0.0 109.186 179.873 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_endo -63.96 139.16 66.32 Favored 'Trans proline' 0 N--CA 1.495 1.56 0 C-N-CA 122.528 2.152 . . . . 0.0 112.05 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -102.84 -60.59 1.52 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.276 -0.89 . . . . 0.0 109.4 179.874 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 179.89 -170.83 42.2 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 98.2 mtt180 -117.57 143.72 45.83 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.365 -1.079 . . . . 0.0 109.583 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.426 HD12 ' SD ' ' A' ' 16' ' ' MET . 86.5 mt -121.53 122.37 66.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 179.073 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 39.9 t -116.21 132.3 66.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.437 -0.789 . . . . 0.0 109.024 -179.901 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 71.7 mtm -124.76 152.19 44.15 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.403 -0.81 . . . . 0.0 109.346 -179.694 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -106.15 131.76 53.02 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.394 -0.816 . . . . 0.0 109.894 -179.616 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.542 HD13 ' HB1' ' A' ' 39' ' ' ALA . 17.3 mt -100.27 146.4 26.95 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.423 -0.798 . . . . 0.0 109.311 179.162 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 95.5 m-85 -95.43 124.19 39.34 Favored 'General case' 0 N--CA 1.49 1.567 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 178.804 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -99.17 21.48 11.79 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.206 -0.934 . . . . 0.0 109.694 -179.323 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.3 m-20 -120.76 -73.55 0.64 Allowed 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.289 -0.882 . . . . 0.0 110.21 -179.553 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' THR . . . . . 0.443 ' O ' ' OE1' ' A' ' 99' ' ' GLU . 41.3 m -61.15 -43.43 98.89 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.176 -0.953 . . . . 0.0 110.44 -179.117 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 9.4 m -139.95 78.37 24.74 Favored Pre-proline 0 N--CA 1.494 1.746 0 O-C-N 121.126 -0.984 . . . . 0.0 109.963 -179.543 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 68.3 Cg_endo -79.75 -36.94 0.52 Allowed 'Trans proline' 0 C--N 1.306 -1.689 0 C-N-CA 122.614 2.209 . . . . 0.0 112.461 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.418 ' O ' ' OH ' ' A' ' 92' ' ' TYR . 3.3 mtt-85 -59.63 -38.98 82.81 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.247 -0.908 . . . . 0.0 109.79 -179.761 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.477 HG23 ' SD ' ' A' ' 113' ' ' MET . 85.0 m -64.26 -41.01 97.13 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.187 -0.946 . . . . 0.0 109.793 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.542 ' HB1' HD13 ' A' ' 30' ' ' LEU . . . -60.72 -32.78 72.02 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.209 -0.932 . . . . 0.0 108.904 179.762 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -69.23 -34.98 75.67 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.486 -0.759 . . . . 0.0 109.744 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 45.2 t-20 -57.11 -41.0 78.13 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.177 -0.952 . . . . 0.0 109.746 -179.616 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 97.7 m-85 -82.54 -45.73 14.28 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.147 -0.971 . . . . 0.0 109.78 -179.892 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.496 ' NH1' ' OE2' ' A' ' 49' ' ' GLU . 72.1 ttp85 -59.2 -40.9 87.18 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.366 -0.834 . . . . 0.0 110.544 -179.377 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.498 ' O ' ' N ' ' A' ' 48' ' ' GLY . . . -69.55 -52.43 26.38 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.143 -0.973 . . . . 0.0 110.348 -179.117 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.45 ' N ' ' CD2' ' A' ' 45' ' ' LEU . 3.4 mm? -63.93 -39.68 94.71 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.066 -1.021 . . . . 0.0 109.702 -179.739 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 46' ' ' CYS . . . . . . . . . . . . . 95.2 m -63.85 -62.69 1.48 Allowed 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.066 -1.021 . . . . 0.0 109.278 -179.863 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 26.6 m -66.53 -36.24 82.22 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.294 -0.879 . . . . 0.0 109.178 179.586 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 48' ' ' GLY . . . . . 0.498 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 81.6 38.84 13.19 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 110.064 -1.214 . . . . 0.0 110.064 179.749 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.496 ' OE2' ' NH1' ' A' ' 43' ' ' ARG . 95.3 mt-10 -62.04 -35.79 79.65 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.079 -1.248 . . . . 0.0 109.47 179.883 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 31.2 mmtm -60.43 -34.55 74.14 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.308 -0.87 . . . . 0.0 109.546 -179.838 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 93.58 169.11 38.62 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.236 -1.546 . . . . 0.0 109.236 -179.687 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.539 HG23 ' HA ' ' A' ' 58' ' ' PRO . 68.4 m -79.47 141.12 37.04 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.292 -1.122 . . . . 0.0 109.963 -179.853 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -65.02 140.27 41.71 Favored Glycine 0 N--CA 1.489 2.172 0 N-CA-C 109.302 -1.519 . . . . 0.0 109.302 179.637 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 76.5 mtm180 -59.59 -33.24 71.21 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.229 -1.159 . . . . 0.0 110.046 -179.621 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 86.7 p -60.49 -23.44 64.51 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.204 -0.935 . . . . 0.0 110.122 -179.338 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' GLY . . . . . 0.427 ' O ' ' CG ' ' A' ' 57' ' ' LYS . . . 108.84 76.94 0.96 Allowed Glycine 0 N--CA 1.495 2.633 0 N-CA-C 108.951 -1.66 . . . . 0.0 108.951 -179.486 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 57' ' ' LYS . . . . . 0.479 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 54.2 mttm -161.2 76.91 2.41 Favored Pre-proline 0 N--CA 1.488 1.463 0 N-CA-C 107.914 -1.143 . . . . 0.0 107.914 -179.822 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.539 ' HA ' HG23 ' A' ' 52' ' ' THR . 89.0 Cg_exo -48.42 129.91 20.48 Favored 'Trans proline' 0 C--N 1.301 -1.936 0 C-N-CA 122.932 2.421 . . . . 0.0 112.578 -178.716 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.479 ' CD1' ' O ' ' A' ' 57' ' ' LYS . 8.1 mp -97.88 70.7 2.16 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.719 -0.613 . . . . 0.0 109.42 -179.434 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 96.3 m-70 -139.2 146.5 40.6 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.284 -0.885 . . . . 0.0 109.609 179.871 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 4.1 m-85 -97.0 16.87 18.29 Favored 'General case' 0 N--CA 1.492 1.644 0 N-CA-C 108.488 -0.93 . . . . 0.0 108.488 179.173 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 8.7 mtpm? -75.78 153.09 37.19 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.511 -0.743 . . . . 0.0 109.594 -179.692 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 83.8 m-20 55.19 46.23 24.24 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.468 -0.77 . . . . 0.0 109.796 179.745 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 92.1 p -112.94 150.8 31.33 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.418 -0.801 . . . . 0.0 109.038 179.595 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 29.1 t -120.71 148.08 44.42 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.369 -0.832 . . . . 0.0 109.594 -179.694 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -68.38 132.56 47.25 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.294 -0.879 . . . . 0.0 109.015 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 83.8 t60 -63.4 -49.25 74.53 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.278 -0.889 . . . . 0.0 110.367 -179.43 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 5.6 ttm180 -151.45 154.45 36.61 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.071 -1.018 . . . . 0.0 109.344 -179.351 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.479 HG21 HG22 ' A' ' 165' ' ' THR . 19.2 m -132.43 149.88 32.74 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 121.277 -0.889 . . . . 0.0 109.982 -179.737 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 13.3 mt -148.05 125.58 5.75 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.158 -0.963 . . . . 0.0 108.629 178.892 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -71.94 144.2 42.52 Favored 'Trans proline' 0 N--CA 1.493 1.463 0 C-N-CA 122.123 1.882 . . . . 0.0 112.588 -179.291 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 75.08 -53.37 2.61 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.94 -1.264 . . . . 0.0 109.94 179.566 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 84.4 m-85 -67.51 -83.28 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.196 -1.179 . . . . 0.0 110.082 -179.533 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 74' ' ' MET . . . . . 0.587 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 11.9 ptt? -179.49 158.45 0.84 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.114 -0.991 . . . . 0.0 109.619 -179.736 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 1.1 m -99.35 125.8 45.1 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.329 -0.857 . . . . 0.0 108.755 179.377 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 63.7 tt0 -97.94 121.16 39.53 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.21 -0.931 . . . . 0.0 109.766 -179.645 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -87.06 -176.59 49.09 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.14 -1.584 . . . . 0.0 109.14 179.571 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -142.74 162.79 27.37 Favored Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.666 -1.374 . . . . 0.0 109.666 179.857 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -75.04 147.53 40.63 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.344 -1.092 . . . . 0.0 109.553 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 44.4 p90 -68.11 -18.93 64.78 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.243 -0.91 . . . . 0.0 109.654 -179.842 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.539 ' OG1' ' N ' ' A' ' 88' ' ' GLY . 59.7 p -66.22 -30.27 70.68 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.213 -0.929 . . . . 0.0 109.438 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -177.42 -56.22 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.247 -0.908 . . . . 0.0 109.44 179.823 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 94.36 -4.31 70.0 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 78.7 m-20 -88.16 5.41 41.49 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.23 -1.159 . . . . 0.0 109.413 179.865 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 95.93 -38.78 3.0 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 -179.842 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 48.5 m -60.34 -39.51 87.36 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.248 -1.148 . . . . 0.0 109.218 179.738 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -86.06 -168.29 44.59 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 179.901 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.539 ' N ' ' OG1' ' A' ' 81' ' ' THR . . . 108.32 73.14 0.79 Allowed Glycine 0 N--CA 1.494 2.534 0 N-CA-C 109.753 -1.339 . . . . 0.0 109.753 179.865 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -94.8 135.82 35.84 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.254 -1.145 . . . . 0.0 109.189 179.732 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 50.2 m -122.41 147.9 45.74 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.39 -0.819 . . . . 0.0 109.569 -179.84 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 26.1 pt -67.48 -26.81 36.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.309 -0.869 . . . . 0.0 109.621 179.877 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 92' ' ' TYR . . . . . 0.418 ' OH ' ' O ' ' A' ' 37' ' ' ARG . 97.3 m-85 -65.23 -30.16 71.02 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.3 -0.875 . . . . 0.0 109.776 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 68.09 -107.61 2.13 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.284 -1.527 . . . . 0.0 109.284 -179.772 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -55.54 147.87 16.94 Favored 'General case' 0 N--CA 1.487 1.39 0 O-C-N 121.241 -1.152 . . . . 0.0 109.319 179.819 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 41.5 mttm -76.05 156.26 34.11 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.388 -0.82 . . . . 0.0 109.694 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 33.7 p90 -133.01 161.67 33.75 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.407 -0.808 . . . . 0.0 109.208 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -60.15 140.31 57.0 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.152 -0.967 . . . . 0.0 109.809 -179.349 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -76.68 135.28 39.09 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.29 -0.881 . . . . 0.0 109.812 -179.886 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 99' ' ' GLU . . . . . 0.443 ' OE1' ' O ' ' A' ' 34' ' ' THR . 95.9 mt-10 -64.84 148.44 51.33 Favored 'General case' 0 C--N 1.305 -1.348 0 O-C-N 121.32 -0.862 . . . . 0.0 109.245 179.556 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 21.3 m120 -55.84 145.7 23.85 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 121.362 -0.836 . . . . 0.0 109.365 -179.866 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 101' ' ' PHE . . . . . 0.586 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 25.0 p90 -110.27 69.88 0.71 Allowed 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.448 -0.782 . . . . 0.0 109.47 -179.781 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 86.4 mt -59.04 -34.8 54.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.257 -0.902 . . . . 0.0 109.575 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 27.1 mtmm -84.77 150.14 25.26 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.21 -0.931 . . . . 0.0 109.615 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 56.4 pttt -131.91 -179.64 5.52 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.371 -0.831 . . . . 0.0 109.362 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 105' ' ' HIS . . . . . 0.534 ' O ' ' CG ' ' A' ' 105' ' ' HIS . 50.4 p-80 -88.27 98.45 11.59 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.207 -0.933 . . . . 0.0 109.647 -179.832 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 55.5 p -77.44 -22.02 52.1 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.237 -0.915 . . . . 0.0 109.708 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.406 ' O ' HG12 ' A' ' 110' ' ' ILE . . . -150.46 179.34 27.27 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.524 -1.431 . . . . 0.0 109.524 -179.744 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -70.99 160.6 48.85 Favored 'Trans proline' 0 C--N 1.307 -1.617 0 C-N-CA 122.863 2.376 . . . . 0.0 112.183 179.886 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 85.62 36.94 9.94 Favored Glycine 0 N--CA 1.493 2.493 0 N-CA-C 109.95 -1.26 . . . . 0.0 109.95 179.725 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.411 ' C ' HD22 ' A' ' 111' ' ' LEU . 39.3 mm -114.98 135.32 55.28 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 O-C-N 121.364 -1.08 . . . . 0.0 109.364 179.857 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.811 ' N ' HD22 ' A' ' 111' ' ' LEU . 2.4 mm? -91.46 136.23 33.27 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.21 -0.931 . . . . 0.0 109.544 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 38.0 t -143.82 139.5 29.36 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.336 -0.852 . . . . 0.0 109.244 179.669 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 113' ' ' MET . . . . . 0.477 ' SD ' HG23 ' A' ' 38' ' ' THR . 82.6 mtp -84.96 130.62 34.6 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.169 -0.957 . . . . 0.0 109.247 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 114' ' ' ALA . . . . . 0.443 ' O ' ' OD1' ' A' ' 115' ' ' ASN . . . -68.79 141.25 55.23 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.222 -0.924 . . . . 0.0 109.565 -179.879 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 115' ' ' ASN . . . . . 0.443 ' OD1' ' O ' ' A' ' 114' ' ' ALA . 72.9 m-20 -145.83 112.75 6.05 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.247 -0.908 . . . . 0.0 109.054 179.554 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -69.07 -31.11 69.62 Favored 'General case' 0 C--N 1.296 -1.723 0 O-C-N 121.448 -0.783 . . . . 0.0 109.234 179.747 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -141.02 167.65 25.6 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.137 -1.585 . . . . 0.0 109.137 179.826 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_endo -66.46 157.46 60.34 Favored 'Trans proline' 0 C--N 1.304 -1.799 0 C-N-CA 122.737 2.292 . . . . 0.0 111.94 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 78.7 m-20 56.08 51.38 12.01 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.447 -0.783 . . . . 0.0 109.716 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 61.3 m -131.36 127.18 37.06 Favored 'General case' 0 N--CA 1.485 1.28 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 179.437 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 49.3 t-20 -53.13 -37.55 61.9 Favored 'General case' 0 C--N 1.296 -1.753 0 O-C-N 121.371 -0.831 . . . . 0.0 109.839 -179.274 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 77.0 63.52 2.27 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 109.766 -1.334 . . . . 0.0 109.766 179.826 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 24.0 m -54.76 -33.38 61.22 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.199 -1.177 . . . . 0.0 109.76 -179.796 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.3 mt-30 -92.07 147.4 22.98 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.113 -0.992 . . . . 0.0 109.511 -179.902 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 125' ' ' PHE . . . . . 0.403 ' HA ' ' H ' ' A' ' 114' ' ' ALA . 49.1 p90 -138.96 162.48 34.78 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.246 -0.909 . . . . 0.0 109.67 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 126' ' ' PHE . . . . . 0.587 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 48.8 p90 -139.27 160.79 38.98 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.398 -0.814 . . . . 0.0 109.355 179.911 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 69.8 mt -118.51 132.39 68.53 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.378 -0.826 . . . . 0.0 109.428 179.833 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -102.13 105.59 16.32 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.325 -0.859 . . . . 0.0 109.273 179.887 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 129' ' ' THR . . . . . 0.408 ' OG1' ' OE2' ' A' ' 156' ' ' GLU . 44.8 p -89.12 -1.38 58.06 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.283 -0.885 . . . . 0.0 109.642 179.937 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -141.71 153.13 44.44 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.261 -0.9 . . . . 0.0 109.485 -179.816 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 79.7 tttt -78.33 130.64 36.41 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.285 -0.884 . . . . 0.0 109.38 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 33.3 p -124.65 156.11 38.06 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.358 -0.838 . . . . 0.0 109.47 -179.863 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -111.81 -36.3 5.47 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.433 -0.792 . . . . 0.0 109.615 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 0.7 OUTLIER -66.84 -15.2 63.45 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.159 -0.963 . . . . 0.0 109.629 -179.722 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 135' ' ' LEU . . . . . 0.41 ' O ' ' NE2' ' A' ' 139' ' ' HIS . 7.9 mt -89.29 11.09 19.94 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.195 -0.941 . . . . 0.0 109.436 179.568 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -69.7 118.07 12.09 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.163 -0.961 . . . . 0.0 109.41 -179.617 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -177.68 -154.48 12.35 Favored Glycine 0 N--CA 1.487 2.062 0 N-CA-C 108.883 -1.687 . . . . 0.0 108.883 -179.84 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 32.3 mmtp -81.11 113.7 19.46 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.178 -1.189 . . . . 0.0 109.157 179.769 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 139' ' ' HIS . . . . . 0.41 ' NE2' ' O ' ' A' ' 135' ' ' LEU . 99.2 m-70 -137.17 154.83 50.14 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.367 -0.833 . . . . 0.0 109.348 -179.964 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 44.2 t -122.75 134.41 66.02 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.341 -0.849 . . . . 0.0 109.641 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 61.8 t -110.78 130.48 64.08 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 121.419 -0.801 . . . . 0.0 108.881 179.566 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 38.8 p90 -123.37 -4.88 8.31 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.19 -0.944 . . . . 0.0 110.704 -179.478 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -162.59 174.35 38.96 Favored Glycine 0 N--CA 1.493 2.463 0 C-N-CA 119.152 -1.499 . . . . 0.0 110.498 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 51.7 tt0 -138.96 159.98 40.84 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.604 -0.939 . . . . 0.0 109.169 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 79.7 t -97.31 129.39 47.46 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.188 0 O-C-N 121.105 -0.997 . . . . 0.0 109.521 -179.827 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 19.0 m -106.35 -32.19 2.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.376 -0.828 . . . . 0.0 109.425 179.638 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -145.5 173.15 12.27 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.253 -0.904 . . . . 0.0 109.505 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 98.35 1.93 57.9 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 109.89 -1.284 . . . . 0.0 109.89 179.65 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 149' ' ' MET . . . . . 0.502 ' O ' HG12 ' A' ' 152' ' ' VAL . 65.0 mtt -61.2 -32.35 72.1 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.127 -1.219 . . . . 0.0 109.782 179.979 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 150' ' ' ASP . . . . . 0.548 ' OD1' ' N ' ' A' ' 151' ' ' VAL . 33.8 p-10 -66.37 -38.73 88.22 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.811 -1.181 . . . . 0.0 110.211 -179.512 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.548 ' N ' ' OD1' ' A' ' 150' ' ' ASP . 6.3 p -85.25 -33.71 8.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.712 0 O-C-N 121.036 -1.04 . . . . 0.0 110.339 -179.545 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 152' ' ' VAL . . . . . 0.502 HG12 ' O ' ' A' ' 149' ' ' MET . 1.1 p -52.77 -41.09 37.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 120.952 -1.092 . . . . 0.0 108.832 -179.488 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 153' ' ' LYS . . . . . 0.442 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 99.4 mttt -64.66 -34.64 78.76 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.252 -0.905 . . . . 0.0 109.144 179.122 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -61.19 -35.38 76.99 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.375 -0.828 . . . . 0.0 109.95 -179.537 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 87.5 mt -71.33 -35.76 58.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.049 -1.032 . . . . 0.0 109.976 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 156' ' ' GLU . . . . . 0.408 ' OE2' ' OG1' ' A' ' 129' ' ' THR . 97.9 mt-10 -76.97 -40.69 45.98 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.079 -1.013 . . . . 0.0 111.474 -178.937 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 18.4 pttp -60.11 -36.44 77.45 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.592 -1.318 . . . . 0.0 109.208 -179.2 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 30.4 m -80.95 -12.88 12.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.163 -0.961 . . . . 0.0 108.562 178.91 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -78.89 175.8 54.89 Favored Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.707 -1.357 . . . . 0.0 109.707 -179.886 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 25.1 t -157.69 166.79 31.88 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.35 -1.088 . . . . 0.0 109.325 -179.859 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 86.9 p -57.67 -26.05 61.12 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.201 -0.937 . . . . 0.0 108.899 179.745 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 26.7 m -57.44 -30.33 64.92 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.444 -0.785 . . . . 0.0 109.394 179.661 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 95.04 15.62 44.39 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.714 -1.354 . . . . 0.0 109.714 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 77.8 ttt-85 -122.93 141.39 51.96 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.341 -1.093 . . . . 0.0 109.495 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 165' ' ' THR . . . . . 0.479 HG22 HG21 ' A' ' 69' ' ' VAL . 42.7 p -80.91 143.53 32.6 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.188 -0.945 . . . . 0.0 109.618 179.903 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -68.72 -38.34 80.13 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.262 -0.899 . . . . 0.0 109.185 179.559 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 67.2 mttm -107.75 159.75 16.25 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.485 -0.759 . . . . 0.0 109.325 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -73.39 131.7 42.15 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.18 -0.95 . . . . 0.0 109.227 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 40.2 t -121.2 125.0 73.3 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.341 -0.849 . . . . 0.0 109.431 179.915 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 41.6 t -147.06 150.81 14.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.343 -0.848 . . . . 0.0 109.219 179.861 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -88.04 120.37 36.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.233 -0.917 . . . . 0.0 109.625 -179.619 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 172' ' ' GLU . . . . . 0.422 ' OE2' ' OG ' ' A' ' 17' ' ' SER . 97.1 mt-10 -65.28 -26.47 68.09 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.413 -0.804 . . . . 0.0 109.324 179.479 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 173' ' ' ASP . . . . . 0.47 ' OD1' ' N ' ' A' ' 174' ' ' CYS . 47.2 t0 -174.8 169.26 3.53 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.201 -0.937 . . . . 0.0 110.412 -179.532 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 174' ' ' CYS . . . . . 0.47 ' N ' ' OD1' ' A' ' 173' ' ' ASP . 31.4 p -150.38 150.83 31.93 Favored 'General case' 0 N--CA 1.491 1.585 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 179.349 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -175.98 -176.49 44.23 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.823 -1.311 . . . . 0.0 109.823 -179.894 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 54.9 tt0 -104.43 119.67 39.49 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.415 -1.05 . . . . 0.0 109.713 -179.823 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 30.9 tp -62.71 -37.93 88.46 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.129 -0.982 . . . . 0.0 109.154 179.434 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 8.0 t . . . . . 0 N--CA 1.49 1.55 0 CA-C-O 118.017 -0.992 . . . . 0.0 109.433 -179.958 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 7.7 t-20 . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_endo -71.14 139.0 34.61 Favored 'Trans proline' 0 N--CA 1.494 1.502 0 C-N-CA 122.406 2.071 . . . . 0.0 112.493 -179.778 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' ARG . . . . . 0.571 ' H ' ' HG ' ' A' ' 178' ' ' SER . 86.6 mtt180 -131.65 134.04 45.56 Favored 'General case' 0 N--CA 1.493 1.697 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 179.119 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 12.6 p -136.4 144.52 32.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.412 -0.805 . . . . 0.0 109.353 -179.783 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 48.8 p90 -135.28 151.89 50.99 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.337 -0.852 . . . . 0.0 109.348 179.877 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 90.4 m-85 -119.39 127.52 53.21 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.451 -0.781 . . . . 0.0 110.122 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.4 t0 -92.54 120.31 32.87 Favored 'General case' 0 N--CA 1.493 1.678 0 N-CA-C 108.347 -0.982 . . . . 0.0 108.347 178.86 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 77.2 mtp -122.09 151.12 41.23 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.991 -1.068 . . . . 0.0 110.698 -179.065 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 93.8 p -145.12 160.63 41.11 Favored 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 108.744 -0.836 . . . . 0.0 108.744 179.671 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.419 ' O ' ' C ' ' A' ' 19' ' ' GLY . 18.9 m -128.71 143.55 40.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.274 -0.891 . . . . 0.0 109.488 179.963 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.419 ' C ' ' O ' ' A' ' 18' ' ' VAL . . . 42.11 -103.86 0.04 OUTLIER Glycine 0 N--CA 1.492 2.423 0 N-CA-C 109.692 -1.363 . . . . 0.0 109.692 179.925 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -135.48 22.56 3.51 Favored Glycine 0 N--CA 1.494 2.526 0 N-CA-C 109.32 -1.512 . . . . 0.0 109.32 179.685 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 62.1 mt-30 -127.41 88.61 53.45 Favored Pre-proline 0 N--CA 1.494 1.741 0 O-C-N 121.448 -1.031 . . . . 0.0 109.264 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_exo -48.63 133.17 26.43 Favored 'Trans proline' 0 C--N 1.309 -1.511 0 C-N-CA 122.505 2.137 . . . . 0.0 112.297 -179.637 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -82.47 -64.06 1.25 Allowed 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.405 -0.81 . . . . 0.0 109.772 -179.89 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 175.15 -167.56 39.7 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 -179.858 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 94.5 mtt-85 -106.27 150.23 26.13 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.447 -1.031 . . . . 0.0 109.186 179.886 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 79.6 mt -119.26 120.73 64.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 179.378 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 34.8 t -112.99 132.38 61.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.446 -0.784 . . . . 0.0 108.911 -179.909 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 70.6 mtm -127.45 156.68 41.74 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.323 -0.86 . . . . 0.0 109.679 -179.361 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -99.62 135.51 40.94 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.284 -0.885 . . . . 0.0 109.795 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -108.89 128.35 54.84 Favored 'General case' 0 N--CA 1.492 1.65 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 179.388 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -95.19 118.23 31.61 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.143 -0.973 . . . . 0.0 108.992 179.778 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -80.43 -42.47 22.64 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 121.473 -0.767 . . . . 0.0 109.839 -179.812 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 56.8 t0 -65.52 -46.26 80.28 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.237 -0.914 . . . . 0.0 110.435 -179.365 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 24.8 m -66.17 -45.73 79.88 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.002 -1.061 . . . . 0.0 109.854 -179.38 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.432 ' O ' ' OG1' ' A' ' 35' ' ' THR . 13.2 p -145.33 81.84 10.08 Favored Pre-proline 0 N--CA 1.493 1.711 0 O-C-N 121.317 -0.864 . . . . 0.0 109.332 -179.72 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -70.33 -47.07 0.82 Allowed 'Trans proline' 0 C--N 1.307 -1.615 0 C-N-CA 122.1 1.867 . . . . 0.0 112.215 -179.48 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 22.9 mmt85 -63.04 -39.75 95.68 Favored 'General case' 0 N--CA 1.487 1.409 0 O-C-N 121.1 -1.0 . . . . 0.0 109.581 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.407 HG23 ' SD ' ' A' ' 113' ' ' MET . 37.9 m -65.16 -40.92 95.01 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.224 -0.922 . . . . 0.0 110.069 -179.736 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -60.69 -31.8 71.05 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.312 -0.867 . . . . 0.0 109.278 -179.699 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -67.09 -38.44 85.7 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.335 -0.853 . . . . 0.0 109.758 -179.927 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 49.1 t30 -58.48 -42.52 87.72 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.264 -0.898 . . . . 0.0 109.932 -179.644 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.507 ' O ' ' SG ' ' A' ' 46' ' ' CYS . 97.6 m-85 -82.89 -45.72 13.87 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.061 -1.024 . . . . 0.0 109.859 -179.925 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.773 ' HE ' HE22 ' A' ' 176' ' ' GLN . 74.0 ttt-85 -58.73 -41.1 85.62 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.296 -0.878 . . . . 0.0 110.544 -179.342 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -71.77 -53.81 12.21 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.028 -1.045 . . . . 0.0 110.553 -179.019 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.473 ' N ' ' CD2' ' A' ' 45' ' ' LEU . 3.8 mm? -63.32 -38.9 92.95 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.948 -1.095 . . . . 0.0 109.776 -179.631 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 46' ' ' CYS . . . . . 0.507 ' SG ' ' O ' ' A' ' 42' ' ' PHE . 95.6 m -65.83 -55.65 16.02 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.108 -0.995 . . . . 0.0 109.138 179.864 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 50.7 m -66.13 -36.81 84.13 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.373 -0.83 . . . . 0.0 109.279 179.468 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 85.31 30.02 26.13 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 110.269 -1.133 . . . . 0.0 110.269 179.565 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -62.2 -38.71 90.15 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.05 -1.265 . . . . 0.0 109.359 179.83 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 59.7 mmtt -62.5 -31.27 72.0 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.386 -0.821 . . . . 0.0 109.686 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 74.34 -113.95 4.29 Favored Glycine 0 N--CA 1.488 2.125 0 N-CA-C 108.854 -1.698 . . . . 0.0 108.854 -179.37 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.615 HG23 ' HA ' ' A' ' 58' ' ' PRO . 87.4 m -127.61 143.42 51.17 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.339 -1.094 . . . . 0.0 109.749 179.624 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -64.99 137.2 38.31 Favored Glycine 0 N--CA 1.489 2.168 0 N-CA-C 109.221 -1.551 . . . . 0.0 109.221 179.685 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 81.4 mtm180 -59.1 -34.93 72.59 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.205 -1.173 . . . . 0.0 109.913 -179.7 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 86.1 p -61.95 -24.41 66.98 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.174 -0.954 . . . . 0.0 109.782 -179.746 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 112.45 89.6 1.84 Allowed Glycine 0 N--CA 1.495 2.569 0 N-CA-C 109.102 -1.599 . . . . 0.0 109.102 -179.682 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 57' ' ' LYS . . . . . 0.529 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 22.8 tttp -174.56 79.56 0.34 Allowed Pre-proline 0 N--CA 1.488 1.465 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 -179.677 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.615 ' HA ' HG23 ' A' ' 52' ' ' THR . 75.5 Cg_exo -50.47 131.99 33.92 Favored 'Trans proline' 0 C--N 1.304 -1.793 0 C-N-CA 122.892 2.394 . . . . 0.0 113.197 -178.779 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.529 ' CD1' ' O ' ' A' ' 57' ' ' LYS . 8.9 mp -104.49 122.32 45.3 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 108.782 -0.821 . . . . 0.0 108.782 179.325 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 16.8 p-80 -169.7 93.28 0.25 Allowed 'General case' 0 N--CA 1.486 1.375 0 O-C-N 120.971 -1.081 . . . . 0.0 110.272 -179.684 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 8.0 m-85 -64.29 -29.39 70.48 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.182 -0.949 . . . . 0.0 109.066 179.149 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 8.8 ptmm? -55.3 160.3 2.3 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.351 -0.843 . . . . 0.0 109.627 179.842 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' ASP . . . . . 0.449 ' N ' ' O ' ' A' ' 171' ' ' VAL . 85.0 m-20 54.62 48.01 21.31 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.498 -0.752 . . . . 0.0 109.416 -179.842 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.577 ' H ' ' CG1' ' A' ' 171' ' ' VAL . 89.6 p -126.46 155.07 42.83 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.277 -0.889 . . . . 0.0 109.134 179.754 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 32.1 t -106.48 141.98 36.9 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.335 -0.853 . . . . 0.0 109.056 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -69.61 143.43 53.28 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.343 -0.848 . . . . 0.0 108.892 -179.927 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 57.2 t-80 -57.33 -51.13 70.62 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.218 -0.927 . . . . 0.0 110.405 -178.851 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 15.6 ptm180 -171.0 163.68 7.45 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 120.896 -1.127 . . . . 0.0 109.697 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.405 HG11 HG22 ' A' ' 155' ' ' ILE . 0.1 OUTLIER -136.47 129.28 45.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.462 -0.774 . . . . 0.0 109.128 179.696 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 70.3 mt -128.92 109.14 18.35 Favored Pre-proline 0 N--CA 1.493 1.695 0 O-C-N 121.543 -0.723 . . . . 0.0 109.631 179.865 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -52.45 147.53 29.28 Favored 'Trans proline' 0 C--N 1.31 -1.482 0 C-N-CA 122.357 2.038 . . . . 0.0 112.62 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 87.12 -59.53 4.48 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 110.156 -1.177 . . . . 0.0 110.156 179.373 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 67.8 m-85 -70.21 -73.48 0.16 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.239 -1.154 . . . . 0.0 110.061 -179.493 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 74' ' ' MET . . . . . 0.528 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 13.4 ptt? 178.45 -165.66 0.05 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.225 -0.922 . . . . 0.0 109.618 -179.918 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -121.22 124.13 43.92 Favored 'General case' 0 N--CA 1.494 1.764 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 179.614 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 63.6 tt0 -102.44 124.49 48.09 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.231 -0.918 . . . . 0.0 109.827 -179.663 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -86.26 -173.88 49.34 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.259 -1.536 . . . . 0.0 109.259 179.457 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -136.83 154.5 22.21 Favored Glycine 0 N--CA 1.493 2.477 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 88.0 m-20 -83.77 143.81 29.73 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.432 -1.04 . . . . 0.0 109.642 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 41.3 p90 -65.43 -23.61 66.98 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.283 -0.886 . . . . 0.0 109.624 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.454 ' OG1' ' N ' ' A' ' 88' ' ' GLY . 52.7 p -64.2 -31.54 72.78 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.145 -0.972 . . . . 0.0 109.481 -179.891 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 82' ' ' ALA . . . . . 0.432 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 178.02 -54.08 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.403 -0.811 . . . . 0.0 109.334 179.855 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 96.58 -11.21 66.77 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 80.3 m-20 -88.66 2.77 52.63 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.186 -1.185 . . . . 0.0 109.315 179.795 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 93.66 -5.16 73.3 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.395 -1.482 . . . . 0.0 109.395 -179.868 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 61.7 p -74.47 -19.02 60.54 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.394 -1.062 . . . . 0.0 109.517 179.87 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -131.86 -132.75 3.38 Favored Glycine 0 N--CA 1.494 2.519 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.454 ' N ' ' OG1' ' A' ' 81' ' ' THR . . . 74.57 47.28 16.25 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.293 -1.523 . . . . 0.0 109.293 -179.915 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -93.3 135.36 34.59 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.295 -1.121 . . . . 0.0 109.753 -179.508 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 50.0 m -70.72 158.08 36.91 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.358 -0.839 . . . . 0.0 109.508 179.84 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 24.9 pt -65.94 -31.15 52.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.24 -0.912 . . . . 0.0 109.834 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 59.9 m-85 -64.0 -36.33 83.63 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.256 -0.902 . . . . 0.0 109.591 -179.746 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 82.79 10.16 83.52 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.321 -1.512 . . . . 0.0 109.321 -179.934 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -148.28 157.25 43.38 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.282 -1.128 . . . . 0.0 109.372 -179.915 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 62.0 mttp -86.57 153.03 22.12 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.22 -0.925 . . . . 0.0 109.466 179.912 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 36.9 p90 -129.09 157.87 40.53 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.425 -0.797 . . . . 0.0 109.329 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -65.68 143.98 57.21 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.294 -0.879 . . . . 0.0 110.052 -179.337 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 98' ' ' ASP . . . . . 0.574 ' CG ' ' H ' ' A' ' 119' ' ' ASN . 88.5 m-20 -67.01 148.0 52.51 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.35 -0.844 . . . . 0.0 109.617 179.845 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -100.14 161.91 13.3 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.345 -0.847 . . . . 0.0 109.268 179.844 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 81.4 m-20 -62.6 163.17 9.37 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.369 -0.832 . . . . 0.0 109.405 -179.846 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 101' ' ' PHE . . . . . 0.582 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 22.0 p90 -130.22 79.43 1.9 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.431 -0.793 . . . . 0.0 109.52 -179.898 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 87.8 mt -58.97 -33.94 51.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.183 -0.948 . . . . 0.0 109.376 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 67.2 mttm -83.51 143.18 30.38 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.187 -0.946 . . . . 0.0 109.386 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 104' ' ' LYS . . . . . 0.541 ' O ' ' N ' ' A' ' 106' ' ' THR . 50.0 tttp -127.35 158.24 37.79 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.406 -0.809 . . . . 0.0 109.331 -179.924 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 105' ' ' HIS . . . . . 0.455 ' CE1' ' O ' ' A' ' 107' ' ' GLY . 78.6 t60 -61.01 76.5 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.341 -0.849 . . . . 0.0 109.252 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 106' ' ' THR . . . . . 0.541 ' N ' ' O ' ' A' ' 104' ' ' LYS . 70.5 p -73.52 -27.15 61.21 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.199 -0.938 . . . . 0.0 109.878 -179.731 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.455 ' O ' ' CE1' ' A' ' 105' ' ' HIS . . . -153.75 177.12 31.43 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.561 -1.415 . . . . 0.0 109.561 -179.763 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -70.4 156.65 61.21 Favored 'Trans proline' 0 C--N 1.305 -1.724 0 C-N-CA 122.774 2.316 . . . . 0.0 112.131 179.881 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 86.07 43.59 6.27 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 110.095 -1.202 . . . . 0.0 110.095 179.728 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 45.4 mm -117.13 136.13 55.27 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 O-C-N 121.263 -1.139 . . . . 0.0 109.386 179.593 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.71 ' N ' HD22 ' A' ' 111' ' ' LEU . 2.9 mm? -88.65 137.36 32.39 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.21 -0.931 . . . . 0.0 109.413 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 112' ' ' SER . . . . . 0.457 ' OG ' ' O ' ' A' ' 140' ' ' VAL . 46.2 t -146.22 141.22 27.19 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.246 -0.909 . . . . 0.0 109.582 179.804 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 113' ' ' MET . . . . . 0.407 ' SD ' HG23 ' A' ' 38' ' ' THR . 88.5 mtp -88.51 135.59 33.41 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.259 -0.9 . . . . 0.0 109.416 179.67 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 114' ' ' ALA . . . . . 0.456 ' O ' ' OD1' ' A' ' 115' ' ' ASN . . . -73.73 137.54 44.07 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.202 -0.936 . . . . 0.0 109.585 -179.946 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 115' ' ' ASN . . . . . 0.456 ' OD1' ' O ' ' A' ' 114' ' ' ALA . 76.3 m-20 -146.58 114.17 6.39 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.203 -0.936 . . . . 0.0 108.945 179.535 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -69.15 -31.07 69.49 Favored 'General case' 0 C--N 1.297 -1.697 0 O-C-N 121.409 -0.807 . . . . 0.0 109.697 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -139.9 167.55 25.34 Favored Glycine 0 N--CA 1.494 2.543 0 N-CA-C 109.396 -1.482 . . . . 0.0 109.396 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -69.08 154.11 70.97 Favored 'Trans proline' 0 C--N 1.307 -1.653 0 C-N-CA 122.701 2.268 . . . . 0.0 111.849 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 119' ' ' ASN . . . . . 0.574 ' H ' ' CG ' ' A' ' 98' ' ' ASP . 80.3 m-20 53.49 43.22 31.58 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.436 -0.79 . . . . 0.0 109.317 -179.939 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 91.8 m -136.37 128.41 29.59 Favored 'General case' 0 C--N 1.305 -1.34 0 O-C-N 121.445 -0.784 . . . . 0.0 109.041 179.84 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 43.4 p-10 -80.76 168.11 19.19 Favored 'General case' 0 C--N 1.298 -1.668 0 O-C-N 121.377 -0.827 . . . . 0.0 109.311 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -159.79 105.94 0.28 Allowed Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.667 -1.373 . . . . 0.0 109.667 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 23.9 t -59.12 -32.61 69.99 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.252 -1.146 . . . . 0.0 109.389 179.85 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.6 mt-30 -71.23 142.96 50.58 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.214 -0.928 . . . . 0.0 109.575 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 48.5 p90 -140.46 162.27 35.73 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.342 -0.849 . . . . 0.0 109.322 179.866 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 126' ' ' PHE . . . . . 0.528 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 48.2 p90 -138.43 158.56 44.04 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.295 -0.878 . . . . 0.0 109.608 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 60.3 mt -120.34 132.29 70.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.411 -0.806 . . . . 0.0 109.208 179.85 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 128' ' ' CYS . . . . . 0.432 ' SG ' ' O ' ' A' ' 130' ' ' ALA . 4.4 t -100.99 116.8 33.69 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.135 -0.978 . . . . 0.0 109.389 179.886 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 129' ' ' THR . . . . . 0.421 ' OG1' ' OE1' ' A' ' 156' ' ' GLU . 51.0 p -91.45 0.78 57.47 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.301 -0.875 . . . . 0.0 109.622 -179.842 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 130' ' ' ALA . . . . . 0.432 ' O ' ' SG ' ' A' ' 128' ' ' CYS . . . -151.25 155.91 39.77 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.188 -0.945 . . . . 0.0 109.601 -179.811 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 77.8 tttt -69.33 140.56 54.32 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.186 -0.946 . . . . 0.0 109.261 179.832 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 17.0 p -113.19 159.68 19.04 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.349 -0.844 . . . . 0.0 109.506 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -154.57 -50.46 0.09 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.397 -0.814 . . . . 0.0 109.282 -179.876 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 134' ' ' TRP . . . . . 0.631 ' CD1' ' N ' ' A' ' 135' ' ' LEU . 35.3 p90 -56.43 -38.8 72.07 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.259 -0.901 . . . . 0.0 109.385 179.836 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 135' ' ' LEU . . . . . 0.631 ' N ' ' CD1' ' A' ' 134' ' ' TRP . 44.2 tp -60.01 -36.5 77.35 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.428 -0.795 . . . . 0.0 109.505 -179.782 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 59.4 t0 47.26 78.75 0.07 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.337 -0.852 . . . . 0.0 109.798 179.771 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -144.74 134.92 5.84 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.11 -1.596 . . . . 0.0 109.11 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 67.6 mmtt -82.96 135.06 35.01 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.261 -1.141 . . . . 0.0 109.42 -179.754 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 96.4 m-70 -136.02 175.5 9.54 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.414 -0.804 . . . . 0.0 109.376 -179.878 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.457 ' O ' ' OG ' ' A' ' 112' ' ' SER . 20.1 m -124.0 153.77 30.34 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 121.466 -0.771 . . . . 0.0 108.996 179.702 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 58.5 t -118.39 128.2 75.39 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.292 -0.88 . . . . 0.0 109.961 -179.607 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 142' ' ' PHE . . . . . 0.455 ' CE2' ' CE2' ' A' ' 42' ' ' PHE . 40.6 p90 -117.59 1.61 12.27 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.474 -0.766 . . . . 0.0 109.561 179.412 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -169.29 177.38 42.97 Favored Glycine 0 N--CA 1.495 2.593 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 179.64 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 144' ' ' GLN . . . . . 0.432 ' CG ' ' N ' ' A' ' 145' ' ' VAL . 48.0 tt0 -143.76 161.62 38.12 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.349 -1.089 . . . . 0.0 109.798 -179.643 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 145' ' ' VAL . . . . . 0.432 ' N ' ' CG ' ' A' ' 144' ' ' GLN . 79.9 t -100.03 135.59 35.04 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.112 0 O-C-N 121.283 -0.886 . . . . 0.0 109.653 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 6.8 m -118.8 -33.69 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.275 -0.89 . . . . 0.0 109.573 179.672 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -138.37 166.03 25.27 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.237 -0.915 . . . . 0.0 109.713 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 94.47 9.98 58.49 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.845 -1.302 . . . . 0.0 109.845 179.745 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 149' ' ' MET . . . . . 0.446 ' O ' HG12 ' A' ' 152' ' ' VAL . 88.7 mtp -59.84 -34.07 72.61 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.192 -1.181 . . . . 0.0 109.765 -179.935 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 89.0 m-20 -64.61 -39.68 94.15 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.896 -1.127 . . . . 0.0 109.846 -179.74 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 5.5 p -85.59 -33.27 7.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.132 -0.98 . . . . 0.0 110.522 -179.423 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 152' ' ' VAL . . . . . 0.446 HG12 ' O ' ' A' ' 149' ' ' MET . 0.7 OUTLIER -55.29 -38.77 49.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 120.953 -1.092 . . . . 0.0 109.376 -179.366 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 153' ' ' LYS . . . . . 0.412 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 50.7 pttt -81.16 -20.97 40.13 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.136 -0.978 . . . . 0.0 109.385 179.683 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -64.39 -39.82 94.6 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.252 -0.905 . . . . 0.0 109.579 -179.916 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.405 HG22 HG11 ' A' ' 69' ' ' VAL . 65.2 mt -72.05 -35.68 54.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.304 -0.873 . . . . 0.0 109.541 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 156' ' ' GLU . . . . . 0.421 ' OE1' ' OG1' ' A' ' 129' ' ' THR . 84.7 tt0 -76.26 -42.27 46.22 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.257 -0.902 . . . . 0.0 111.447 -178.772 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 16.4 pttp -61.59 -33.12 73.34 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 120.639 -1.288 . . . . 0.0 110.241 -178.56 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 35.2 m -77.02 -17.84 14.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.018 -1.051 . . . . 0.0 109.683 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -72.87 172.77 48.77 Favored Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.965 -1.254 . . . . 0.0 109.965 -179.655 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 85.0 p -150.09 170.07 19.76 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.476 -1.014 . . . . 0.0 109.381 -179.739 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 23.2 m -55.42 -34.72 64.67 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.177 -0.952 . . . . 0.0 108.965 179.705 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 86.5 p -62.57 -26.34 68.54 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.373 -0.83 . . . . 0.0 109.189 179.674 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 97.2 3.17 58.94 Favored Glycine 0 N--CA 1.494 2.529 0 N-CA-C 109.674 -1.37 . . . . 0.0 109.674 179.898 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 77.8 ttt180 -99.99 144.56 28.9 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.306 -1.114 . . . . 0.0 109.205 179.818 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 165' ' ' THR . . . . . . . . . . . . . 65.5 p -104.71 152.1 22.93 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.354 -0.841 . . . . 0.0 109.657 -179.877 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -68.47 -37.0 79.77 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.369 -0.832 . . . . 0.0 109.627 179.923 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 47.8 mtmt -112.41 157.82 20.58 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.53 -0.731 . . . . 0.0 109.628 -179.793 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 91.3 mttt -76.54 146.49 38.34 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.333 -0.854 . . . . 0.0 109.306 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 169' ' ' VAL . . . . . 0.475 ' O ' HG23 ' A' ' 169' ' ' VAL . 32.6 m -128.75 125.2 62.86 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 O-C-N 121.326 -0.859 . . . . 0.0 109.596 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 48.5 t -144.88 138.23 22.21 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.387 -0.821 . . . . 0.0 109.302 179.589 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.577 ' CG1' ' H ' ' A' ' 64' ' ' SER . 2.5 p -80.41 119.65 30.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 120.99 -1.069 . . . . 0.0 108.999 179.717 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -71.03 -44.41 65.88 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.133 -0.98 . . . . 0.0 111.177 -178.535 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 173' ' ' ASP . . . . . 0.46 ' OD1' ' N ' ' A' ' 174' ' ' CYS . 47.2 t0 -170.15 164.64 9.2 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.754 -1.216 . . . . 0.0 110.542 -179.325 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 174' ' ' CYS . . . . . 0.46 ' N ' ' OD1' ' A' ' 173' ' ' ASP . 1.4 p -151.63 151.86 32.07 Favored 'General case' 0 N--CA 1.49 1.573 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 179.484 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -160.75 178.37 36.77 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 176' ' ' GLN . . . . . 0.773 HE22 ' HE ' ' A' ' 43' ' ' ARG . 62.6 tt0 -99.05 113.96 26.42 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.326 -1.102 . . . . 0.0 109.713 -179.821 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 29.1 tp -63.37 -36.79 84.89 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.216 -0.928 . . . . 0.0 109.022 179.418 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 178' ' ' SER . . . . . 0.571 ' HG ' ' H ' ' A' ' 11' ' ' ARG . 11.8 p . . . . . 0 N--CA 1.491 1.62 0 CA-C-O 118.001 -0.999 . . . . 0.0 109.495 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 2.5 m-20 . . . . . 0 N--CA 1.492 1.661 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 93.3 Cg_endo -82.23 90.53 1.09 Allowed 'Trans proline' 0 C--N 1.308 -1.575 0 C-N-CA 122.898 2.399 . . . . 0.0 111.845 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 73.1 mtm180 -61.68 137.91 58.28 Favored 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.289 -0.882 . . . . 0.0 109.849 -179.595 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 12.7 p -138.29 143.53 32.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 179.497 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 45.1 p90 -141.54 153.96 45.19 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.179 -0.95 . . . . 0.0 110.107 -179.513 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 86.0 m-85 -123.73 140.25 53.18 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 179.162 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.5 t0 -86.88 116.31 24.87 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.053 -1.029 . . . . 0.0 109.259 179.768 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' MET . . . . . 0.577 ' SD ' HD12 ' A' ' 26' ' ' ILE . 80.4 mtp -103.96 147.45 27.34 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.291 -0.881 . . . . 0.0 110.19 -179.856 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 97.1 p -143.94 164.39 30.72 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 108.55 -0.907 . . . . 0.0 108.55 179.414 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 12.9 p -128.3 139.03 53.0 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.238 -0.914 . . . . 0.0 109.676 -179.752 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 57.02 -107.33 0.92 Allowed Glycine 0 N--CA 1.488 2.129 0 N-CA-C 109.364 -1.494 . . . . 0.0 109.364 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -136.04 37.15 1.93 Allowed Glycine 0 N--CA 1.493 2.487 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 6.5 pt20 -147.88 126.99 6.3 Favored Pre-proline 0 N--CA 1.492 1.649 0 O-C-N 121.264 -1.139 . . . . 0.0 109.349 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_exo -47.39 139.88 16.29 Favored 'Trans proline' 0 N--CA 1.493 1.455 0 C-N-CA 122.139 1.893 . . . . 0.0 112.17 179.74 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -101.49 -61.31 1.39 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.311 -0.868 . . . . 0.0 109.483 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -178.19 -170.3 40.16 Favored Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.409 -1.476 . . . . 0.0 109.409 -179.871 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 97.5 mtt180 -118.04 142.33 47.5 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.374 -1.074 . . . . 0.0 109.803 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.577 HD12 ' SD ' ' A' ' 16' ' ' MET . 70.1 mt -120.39 123.2 70.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 178.609 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 38.7 t -110.05 132.58 57.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.387 -0.82 . . . . 0.0 109.382 -179.535 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 76.2 mtm -114.79 149.32 37.16 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.591 -0.693 . . . . 0.0 109.381 -179.689 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.405 ' C ' HD22 ' A' ' 30' ' ' LEU . 84.3 tt0 -100.92 129.82 46.83 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.286 -0.884 . . . . 0.0 109.698 -179.668 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.408 ' N ' ' CD2' ' A' ' 30' ' ' LEU . 2.7 mm? -108.34 132.66 53.5 Favored 'General case' 0 N--CA 1.494 1.741 0 N-CA-C 108.909 -0.775 . . . . 0.0 108.909 179.588 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.483 ' O ' ' OG1' ' A' ' 35' ' ' THR . 92.7 m-85 -96.36 114.02 25.66 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.031 -1.043 . . . . 0.0 108.742 178.98 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -75.87 -42.43 49.4 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.155 -0.966 . . . . 0.0 109.869 -179.696 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.3 m-20 -66.63 -57.86 6.34 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.149 -0.97 . . . . 0.0 110.191 -179.356 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 54.9 m -67.03 -40.73 87.28 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.246 -0.909 . . . . 0.0 109.853 -179.759 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.546 HG21 ' HA ' ' A' ' 142' ' ' PHE . 81.7 p -130.04 77.5 76.42 Favored Pre-proline 0 N--CA 1.493 1.711 0 O-C-N 121.358 -0.839 . . . . 0.0 109.377 -179.64 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -72.84 -73.64 0.01 OUTLIER 'Trans proline' 0 N--CA 1.493 1.489 0 C-N-CA 122.676 2.251 . . . . 0.0 113.259 -179.38 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 80.1 mtt85 -59.37 -39.33 82.93 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.612 -0.68 . . . . 0.0 111.061 -178.624 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 42.8 m -61.66 -42.56 99.07 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.864 -1.148 . . . . 0.0 109.452 -179.848 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -63.9 -30.85 71.89 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.263 -0.898 . . . . 0.0 108.593 179.295 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 85.2 tt0 -66.25 -36.81 83.96 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.432 -0.792 . . . . 0.0 109.509 179.927 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' ASN . . . . . 0.49 ' O ' HD23 ' A' ' 45' ' ' LEU . 38.7 t30 -58.03 -41.2 82.69 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.229 -0.919 . . . . 0.0 109.514 -179.698 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.4 ' O ' ' SG ' ' A' ' 46' ' ' CYS . 98.0 m-85 -83.18 -44.99 14.43 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.058 -1.026 . . . . 0.0 109.661 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.712 ' NE ' HE22 ' A' ' 176' ' ' GLN . 77.5 ttt180 -59.32 -43.2 92.7 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.38 -0.825 . . . . 0.0 110.62 -179.216 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -68.1 -43.97 77.29 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.097 -1.002 . . . . 0.0 110.63 -178.834 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.49 HD23 ' O ' ' A' ' 41' ' ' ASN . 3.3 mm? -62.39 -39.05 91.95 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.971 -1.081 . . . . 0.0 109.593 -179.659 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 46' ' ' CYS . . . . . 0.4 ' SG ' ' O ' ' A' ' 42' ' ' PHE . 35.7 m -67.64 -47.89 68.27 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.146 -0.972 . . . . 0.0 109.391 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 48.3 p -74.49 -33.75 62.91 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.361 -0.837 . . . . 0.0 109.709 179.864 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 74.36 33.53 56.29 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 110.077 -1.209 . . . . 0.0 110.077 179.704 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -62.11 -37.55 85.54 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.07 -1.253 . . . . 0.0 109.61 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 72.2 mmtt -61.27 -35.32 76.96 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.262 -0.899 . . . . 0.0 109.578 -179.845 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 90.9 171.68 43.52 Favored Glycine 0 N--CA 1.488 2.113 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 -179.757 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.535 HG23 ' HA ' ' A' ' 58' ' ' PRO . 65.7 m -75.57 140.27 42.59 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.493 -1.004 . . . . 0.0 109.832 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -63.87 138.44 42.07 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.172 -1.571 . . . . 0.0 109.172 179.702 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 81.0 mmt-85 -59.37 -33.32 71.03 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.305 -1.115 . . . . 0.0 109.922 -179.656 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 86.1 p -60.91 -22.98 64.88 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.129 -0.982 . . . . 0.0 109.966 -179.532 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 56' ' ' GLY . . . . . 0.428 ' O ' ' CG ' ' A' ' 57' ' ' LYS . . . 110.03 77.55 0.95 Allowed Glycine 0 N--CA 1.496 2.636 0 N-CA-C 108.879 -1.688 . . . . 0.0 108.879 -179.586 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 57' ' ' LYS . . . . . 0.51 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 8.6 mtmp? -160.41 76.8 2.69 Favored Pre-proline 0 C--N 1.303 -1.455 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 -179.837 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.535 ' HA ' HG23 ' A' ' 52' ' ' THR . 81.8 Cg_exo -49.0 130.0 22.71 Favored 'Trans proline' 0 C--N 1.301 -1.945 0 C-N-CA 122.913 2.409 . . . . 0.0 112.614 -178.867 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.51 ' CD1' ' O ' ' A' ' 57' ' ' LYS . 8.3 mp -99.33 84.86 3.07 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.753 -0.592 . . . . 0.0 109.52 -179.697 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 99.2 m-70 -145.81 143.06 29.43 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.276 -0.89 . . . . 0.0 109.734 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 2.9 m-85 -102.33 17.03 24.48 Favored 'General case' 0 N--CA 1.493 1.724 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 179.317 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 91.7 mttt -81.01 158.84 25.01 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.303 -0.873 . . . . 0.0 109.885 -179.491 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 63' ' ' ASP . . . . . 0.455 ' H ' HG23 ' A' ' 171' ' ' VAL . 84.3 m-20 55.99 45.84 23.02 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.552 -0.717 . . . . 0.0 110.35 179.562 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.947 ' H ' HG22 ' A' ' 171' ' ' VAL . 66.7 p -98.74 153.35 18.8 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.143 -0.973 . . . . 0.0 108.616 179.077 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 28.6 t -122.3 145.06 48.6 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.37 -0.832 . . . . 0.0 109.664 -179.566 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 4.3 m-85 -72.7 129.04 37.31 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.314 -0.866 . . . . 0.0 109.034 179.782 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 67' ' ' HIS . . . . . 0.605 ' CD2' ' HE ' ' A' ' 68' ' ' ARG . 74.9 t60 -62.2 -49.94 73.79 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.358 -0.839 . . . . 0.0 110.116 -179.376 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.605 ' HE ' ' CD2' ' A' ' 67' ' ' HIS . 18.4 ptp180 -160.17 161.02 33.54 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.035 -1.041 . . . . 0.0 109.922 -179.982 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.556 HG21 HG22 ' A' ' 165' ' ' THR . 17.7 m -132.73 145.23 34.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.478 -0.764 . . . . 0.0 109.043 179.683 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 14.4 mt -148.17 129.5 7.2 Favored Pre-proline 0 N--CA 1.494 1.745 0 O-C-N 121.091 -1.005 . . . . 0.0 109.331 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -72.3 145.36 43.23 Favored 'Trans proline' 0 N--CA 1.492 1.393 0 C-N-CA 122.242 1.961 . . . . 0.0 112.379 179.849 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 82.25 -56.18 4.97 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.918 -1.273 . . . . 0.0 109.918 179.736 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -72.42 -86.16 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.117 -1.225 . . . . 0.0 109.874 -179.715 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 74' ' ' MET . . . . . 0.602 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 12.4 ptt? -179.52 -168.6 0.12 Allowed 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.236 -0.915 . . . . 0.0 109.759 -179.914 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -126.71 131.85 51.28 Favored 'General case' 0 N--CA 1.494 1.732 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.774 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 63.6 tt0 -103.07 126.4 50.23 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.151 -0.968 . . . . 0.0 109.908 -179.611 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -86.29 -174.03 49.38 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.242 -1.543 . . . . 0.0 109.242 179.548 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -138.35 154.9 23.19 Favored Glycine 0 N--CA 1.495 2.575 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.479 ' H ' ' HA2' ' A' ' 83' ' ' GLY . 88.4 m-20 -73.67 149.36 42.0 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.35 -1.088 . . . . 0.0 109.43 179.804 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 48.3 p90 -64.72 -26.33 68.32 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.161 -0.962 . . . . 0.0 109.437 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.504 ' O ' ' HB2' ' A' ' 82' ' ' ALA . 54.0 p -69.1 -29.08 67.09 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.165 -0.959 . . . . 0.0 109.462 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 82' ' ' ALA . . . . . 0.504 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 174.79 -55.11 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.386 -0.821 . . . . 0.0 109.254 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.479 ' HA2' ' H ' ' A' ' 79' ' ' ASP . . . 95.95 -6.5 66.9 Favored Glycine 0 N--CA 1.492 2.395 0 N-CA-C 109.658 -1.377 . . . . 0.0 109.658 179.878 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 78.5 m-20 -88.16 2.71 51.52 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.188 -1.184 . . . . 0.0 109.258 179.812 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 94.18 -6.61 72.32 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.321 -1.511 . . . . 0.0 109.321 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 59.0 p -75.15 -18.54 60.18 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.254 -1.145 . . . . 0.0 109.506 179.896 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -132.38 -128.47 2.92 Favored Glycine 0 N--CA 1.494 2.507 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.857 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 81.87 22.35 59.78 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.287 -1.525 . . . . 0.0 109.287 -179.856 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -57.96 145.43 35.91 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.339 -1.095 . . . . 0.0 109.669 -179.855 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 88.5 p -111.85 153.36 26.75 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.417 -0.802 . . . . 0.0 109.331 179.885 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 5.5 pt -63.56 -39.76 86.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.242 -0.911 . . . . 0.0 109.847 -179.76 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 3.1 m-30 -63.45 -38.87 92.8 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.089 -1.007 . . . . 0.0 109.459 179.758 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 76.7 19.03 78.39 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.282 -1.527 . . . . 0.0 109.282 -179.861 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -145.62 158.78 43.8 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.328 -1.101 . . . . 0.0 109.442 -179.853 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 62.9 mttp -85.01 153.62 22.64 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.336 -0.852 . . . . 0.0 109.709 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -100.68 133.12 45.61 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.41 -0.806 . . . . 0.0 109.1 179.775 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -83.47 119.73 25.04 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.162 -0.961 . . . . 0.0 109.684 -179.715 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 88.1 m-20 -75.55 143.09 42.61 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.283 -0.886 . . . . 0.0 109.259 179.638 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -153.29 -31.11 0.13 Allowed 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.174 -0.954 . . . . 0.0 110.05 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 84.6 m-20 -97.73 131.33 44.36 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.073 -1.017 . . . . 0.0 109.954 -179.579 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 101' ' ' PHE . . . . . 0.555 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 70.6 t80 -134.56 22.13 3.65 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 179.745 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 86.2 mt -56.77 -37.5 53.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.437 -0.79 . . . . 0.0 110.052 -179.512 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 56.6 mttm -83.34 138.27 33.6 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.008 -1.057 . . . . 0.0 109.891 -179.65 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 72.8 tttt -134.89 157.56 46.53 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.462 -0.774 . . . . 0.0 109.24 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 105' ' ' HIS . . . . . 0.542 ' O ' ' CG ' ' A' ' 105' ' ' HIS . 52.2 p-80 -68.02 83.5 0.22 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.12 -0.987 . . . . 0.0 109.271 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 57.0 p -77.04 -19.31 57.33 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.275 -0.891 . . . . 0.0 110.116 -179.54 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.423 ' O ' HG12 ' A' ' 110' ' ' ILE . . . -150.55 178.25 28.11 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 109.737 -1.345 . . . . 0.0 109.737 -179.654 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -74.9 156.72 43.46 Favored 'Trans proline' 0 C--N 1.306 -1.674 0 C-N-CA 123.027 2.484 . . . . 0.0 112.14 179.831 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 80.8 46.45 7.19 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 110.03 -1.228 . . . . 0.0 110.03 179.638 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.423 HG12 ' O ' ' A' ' 107' ' ' GLY . 32.9 mm -113.01 137.24 46.7 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.393 -1.063 . . . . 0.0 109.098 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.848 ' N ' HD22 ' A' ' 111' ' ' LEU . 2.3 mm? -89.88 131.81 35.61 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.261 -0.899 . . . . 0.0 109.836 -179.383 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 58.4 m -140.28 148.22 41.1 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.393 -0.817 . . . . 0.0 109.406 179.512 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 85.7 mtp -96.62 136.3 37.34 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.209 -0.932 . . . . 0.0 109.298 179.834 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 114' ' ' ALA . . . . . 0.4 ' O ' ' OD1' ' A' ' 115' ' ' ASN . . . -71.03 143.38 50.77 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.321 -0.862 . . . . 0.0 109.813 -179.872 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 115' ' ' ASN . . . . . 0.729 ' H ' ' CD2' ' A' ' 139' ' ' HIS . 56.9 m-20 -148.44 113.26 5.41 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.306 -0.871 . . . . 0.0 108.861 179.506 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -68.24 -31.99 71.86 Favored 'General case' 0 C--N 1.299 -1.623 0 O-C-N 121.333 -0.854 . . . . 0.0 109.655 -179.896 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -137.63 171.47 23.23 Favored Glycine 0 N--CA 1.492 2.414 0 N-CA-C 109.326 -1.51 . . . . 0.0 109.326 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -67.29 151.89 80.12 Favored 'Trans proline' 0 C--N 1.305 -1.728 0 C-N-CA 122.753 2.302 . . . . 0.0 111.732 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 75.2 m-20 52.57 44.09 30.43 Favored 'General case' 0 C--N 1.299 -1.601 0 O-C-N 121.459 -0.776 . . . . 0.0 109.294 -179.811 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 79.8 m -134.62 128.34 32.95 Favored 'General case' 0 C--N 1.304 -1.394 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 22.5 t30 -96.76 109.22 21.94 Favored 'General case' 0 C--N 1.297 -1.677 0 O-C-N 121.479 -0.763 . . . . 0.0 109.294 179.866 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -84.48 123.85 6.43 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.642 -1.383 . . . . 0.0 109.642 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 22.6 m -59.46 -33.29 71.11 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.347 -1.09 . . . . 0.0 109.542 179.806 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.8 mt-30 -75.96 144.12 41.17 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.233 -0.917 . . . . 0.0 109.926 -179.636 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 48.6 p90 -137.8 160.92 37.94 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.429 -0.794 . . . . 0.0 109.109 179.684 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 126' ' ' PHE . . . . . 0.602 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 52.3 p90 -142.53 159.64 41.83 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.147 -0.971 . . . . 0.0 110.012 -179.759 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 4.6 mp -119.68 138.77 49.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.474 -0.766 . . . . 0.0 109.049 179.695 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 17.1 t -121.04 126.74 50.64 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.236 -0.915 . . . . 0.0 109.599 -179.909 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -106.91 15.76 25.06 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.544 -0.722 . . . . 0.0 109.204 179.864 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -141.08 161.21 38.4 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.315 -0.866 . . . . 0.0 109.316 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 64.0 tttm -64.76 132.22 48.96 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.175 -0.953 . . . . 0.0 109.439 -179.79 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 58.6 p -147.66 69.86 1.15 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.287 -0.883 . . . . 0.0 109.24 -179.898 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -58.39 -37.85 76.14 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.295 -0.878 . . . . 0.0 110.033 -179.581 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 0.8 OUTLIER -61.46 -43.94 97.98 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.024 -1.047 . . . . 0.0 109.443 -179.875 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 28.3 mt -65.47 -30.81 71.63 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.186 -0.946 . . . . 0.0 109.754 179.326 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 136' ' ' ASP . . . . . 0.502 ' CB ' ' CE1' ' A' ' 105' ' ' HIS . 23.2 t70 -76.05 121.24 22.49 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.231 -0.918 . . . . 0.0 109.659 -179.627 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 178.61 -101.84 0.16 Allowed Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.202 -1.559 . . . . 0.0 109.202 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 33.4 mmtm -58.15 -28.56 64.82 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.327 -1.102 . . . . 0.0 109.058 179.506 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 139' ' ' HIS . . . . . 0.729 ' CD2' ' H ' ' A' ' 115' ' ' ASN . 56.3 m170 -83.78 153.2 24.24 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.348 -0.845 . . . . 0.0 109.479 -179.831 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 20.2 m -127.44 160.76 36.15 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 121.516 -0.74 . . . . 0.0 109.278 -179.858 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 141' ' ' VAL . . . . . 0.478 HG23 ' O ' ' A' ' 141' ' ' VAL . 21.5 m -96.69 129.25 47.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.245 -0.91 . . . . 0.0 109.519 -179.732 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 142' ' ' PHE . . . . . 0.546 ' HA ' HG21 ' A' ' 35' ' ' THR . 44.0 p90 -113.03 -9.07 13.61 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.189 -0.944 . . . . 0.0 110.271 -179.913 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -158.45 177.49 35.08 Favored Glycine 0 N--CA 1.492 2.41 0 C-N-CA 119.567 -1.302 . . . . 0.0 109.87 179.703 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 144' ' ' GLN . . . . . 0.403 ' HG2' ' N ' ' A' ' 145' ' ' VAL . 47.8 tt0 -139.63 158.78 43.53 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.303 -1.116 . . . . 0.0 109.633 -179.549 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 145' ' ' VAL . . . . . 0.511 HG23 HD21 ' A' ' 111' ' ' LEU . 13.2 t -94.73 134.07 33.44 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.235 0 O-C-N 121.042 -1.036 . . . . 0.0 109.241 179.666 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 17.4 m -112.03 -26.14 3.22 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.407 -0.808 . . . . 0.0 109.512 179.607 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 94.9 mt-10 -145.78 173.07 12.43 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.238 -0.914 . . . . 0.0 109.541 -179.878 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 98.51 2.35 57.64 Favored Glycine 0 N--CA 1.494 2.511 0 N-CA-C 110.085 -1.206 . . . . 0.0 110.085 179.486 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 149' ' ' MET . . . . . 0.467 ' O ' HG12 ' A' ' 152' ' ' VAL . 65.1 mtt -61.15 -33.07 72.82 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.035 -1.274 . . . . 0.0 109.736 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 89.1 m-20 -64.91 -42.13 94.99 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 120.765 -1.209 . . . . 0.0 110.036 -179.556 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.7 p -82.6 -34.46 11.83 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.078 -1.014 . . . . 0.0 110.485 -179.313 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 152' ' ' VAL . . . . . 0.467 HG12 ' O ' ' A' ' 149' ' ' MET . 0.8 OUTLIER -54.92 -41.82 60.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 120.963 -1.086 . . . . 0.0 109.188 -179.323 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 153' ' ' LYS . . . . . 0.453 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 59.1 mttp -64.25 -34.17 77.49 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.263 -0.898 . . . . 0.0 109.473 179.393 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -62.26 -37.36 85.15 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.308 -0.87 . . . . 0.0 110.217 -179.398 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 79.5 mt -71.96 -36.99 59.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.054 -1.029 . . . . 0.0 110.059 -179.752 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -74.08 -41.75 61.22 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.135 -0.978 . . . . 0.0 111.227 -178.706 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 17.4 pttp -61.69 -33.72 74.51 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 120.749 -1.219 . . . . 0.0 109.734 -179.001 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 27.2 m -86.39 -1.15 7.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.119 -0.988 . . . . 0.0 109.044 179.501 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -74.7 174.22 51.13 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.782 -1.327 . . . . 0.0 109.782 -179.706 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 97.0 p -152.33 162.94 40.44 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.328 -1.101 . . . . 0.0 109.942 -179.64 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 22.8 t -58.9 -31.49 68.66 Favored 'General case' 0 N--CA 1.488 1.441 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 179.297 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 23.1 t -55.96 -30.46 61.76 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.427 -0.796 . . . . 0.0 109.069 179.729 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 100.42 10.12 45.43 Favored Glycine 0 N--CA 1.493 2.489 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 179.784 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 34.5 mmt180 -118.26 147.63 43.24 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.224 -1.162 . . . . 0.0 109.282 179.713 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 165' ' ' THR . . . . . 0.556 HG22 HG21 ' A' ' 69' ' ' VAL . 82.1 p -81.64 152.72 27.0 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.364 -0.835 . . . . 0.0 109.384 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -65.98 -34.27 77.71 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.289 -0.882 . . . . 0.0 109.587 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 62.1 mttm -118.22 162.08 18.84 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.467 -0.77 . . . . 0.0 109.656 -179.664 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 62.8 mttp -75.15 142.44 43.56 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.355 -0.841 . . . . 0.0 109.594 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 1.8 m -133.45 124.67 49.0 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.308 -0.87 . . . . 0.0 109.738 179.763 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 88.8 t -139.45 142.26 33.49 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.461 -0.774 . . . . 0.0 109.395 179.769 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.947 HG22 ' H ' ' A' ' 64' ' ' SER . 3.0 m -71.69 124.84 29.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.014 -1.054 . . . . 0.0 109.55 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 77.9 mm-40 -70.88 -37.72 73.04 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.09 -1.006 . . . . 0.0 110.251 -179.669 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 173' ' ' ASP . . . . . 0.463 ' OD1' ' N ' ' A' ' 174' ' ' CYS . 49.5 t0 -164.84 166.62 19.54 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.063 -1.023 . . . . 0.0 110.032 -179.668 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 174' ' ' CYS . . . . . 0.463 ' N ' ' OD1' ' A' ' 173' ' ' ASP . 12.3 p -141.59 152.34 43.96 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.395 -0.815 . . . . 0.0 109.366 179.803 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -175.52 178.92 47.0 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.649 -1.38 . . . . 0.0 109.649 179.937 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 176' ' ' GLN . . . . . 0.712 HE22 ' NE ' ' A' ' 43' ' ' ARG . 63.3 tt0 -108.12 127.89 54.21 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.373 -1.075 . . . . 0.0 109.528 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 177' ' ' LEU . . . . . 0.603 HD13 ' O ' ' A' ' 177' ' ' LEU . 0.2 OUTLIER -61.24 -38.8 87.94 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.22 -0.925 . . . . 0.0 108.718 179.694 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 9.6 t . . . . . 0 N--CA 1.49 1.544 0 CA-C-O 117.979 -1.01 . . . . 0.0 109.47 179.81 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.511 ' ND2' ' O ' ' A' ' 30' ' ' LEU . 12.1 t-20 . . . . . 0 N--CA 1.49 1.543 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -68.34 140.22 47.87 Favored 'Trans proline' 0 N--CA 1.496 1.645 0 C-N-CA 122.424 2.082 . . . . 0.0 112.211 179.826 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 58.6 mtm180 -132.26 132.44 43.04 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.436 -0.79 . . . . 0.0 109.018 179.537 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.5 p -135.91 143.95 34.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.316 -0.865 . . . . 0.0 109.311 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 33.2 p90 -139.4 152.69 47.3 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.33 -0.856 . . . . 0.0 109.792 -179.633 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 94.3 m-85 -123.26 128.65 50.26 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.595 -0.69 . . . . 0.0 109.546 179.475 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.4 t0 -90.31 119.05 30.28 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.14 -0.975 . . . . 0.0 108.94 179.303 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' MET . . . . . 0.411 ' CE ' ' CE1' ' A' ' 66' ' ' PHE . 67.0 mtp -117.13 143.32 45.95 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.217 -0.927 . . . . 0.0 110.375 -179.315 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.465 ' HG ' ' CD ' ' A' ' 172' ' ' GLU . 50.8 m -132.16 155.14 48.71 Favored 'General case' 0 N--CA 1.491 1.612 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 179.639 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.433 HG23 ' O ' ' A' ' 18' ' ' VAL . 25.4 m -114.87 132.53 63.81 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.234 -0.917 . . . . 0.0 109.657 -179.765 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 65.86 9.9 48.33 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 179.836 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 93.36 -3.89 72.86 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.302 -1.519 . . . . 0.0 109.302 -179.951 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 33.9 mt-30 -99.11 128.39 32.18 Favored Pre-proline 0 N--CA 1.492 1.634 0 O-C-N 121.371 -1.076 . . . . 0.0 109.071 179.806 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 76.1 Cg_exo -43.69 130.11 7.3 Favored 'Trans proline' 0 C--N 1.312 -1.387 0 C-N-CA 122.12 1.88 . . . . 0.0 112.126 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -104.07 -65.25 1.03 Allowed 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.375 -0.828 . . . . 0.0 109.345 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -169.46 -171.21 34.87 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 92.2 mtm-85 -114.1 143.13 45.29 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.385 -1.068 . . . . 0.0 109.465 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 76.4 mt -120.95 117.84 54.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 179.091 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 41.8 t -116.38 132.8 64.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.552 -0.718 . . . . 0.0 109.327 -179.541 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 73.1 mtm -121.48 149.88 42.41 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.464 -0.772 . . . . 0.0 109.209 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -99.88 129.82 46.0 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.24 -0.912 . . . . 0.0 109.822 -179.636 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.511 ' O ' ' ND2' ' A' ' 9' ' ' ASN . 2.5 mm? -105.84 130.75 53.75 Favored 'General case' 0 N--CA 1.493 1.682 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.376 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -94.91 119.33 33.28 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.111 -0.993 . . . . 0.0 109.205 179.739 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -82.14 -42.67 18.76 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.361 -0.837 . . . . 0.0 109.803 -179.764 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -67.19 -44.74 78.88 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.278 -0.889 . . . . 0.0 110.514 -179.266 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' THR . . . . . 0.441 HG21 ' HE2' ' A' ' 103' ' ' LYS . 23.2 m -66.93 -45.35 78.14 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.175 -0.953 . . . . 0.0 109.959 -179.296 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 68.9 p -150.39 83.32 6.0 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 121.285 -0.884 . . . . 0.0 109.468 -179.691 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -70.92 -44.36 1.32 Allowed 'Trans proline' 0 C--N 1.308 -1.595 0 C-N-CA 122.19 1.927 . . . . 0.0 112.087 -179.702 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.431 ' O ' ' OH ' ' A' ' 92' ' ' TYR . 25.4 mtp180 -62.59 -39.63 94.32 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.465 -0.772 . . . . 0.0 110.201 -179.862 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 32.4 m -66.07 -41.76 90.3 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.116 -0.99 . . . . 0.0 110.086 -179.736 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -61.81 -31.04 71.24 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.228 -0.92 . . . . 0.0 109.324 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -68.19 -37.7 81.22 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.219 -0.926 . . . . 0.0 109.85 -179.755 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' ASN . . . . . 0.41 ' O ' HD23 ' A' ' 45' ' ' LEU . 51.9 t30 -57.45 -42.16 81.97 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.205 -0.935 . . . . 0.0 109.79 -179.437 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 -86.13 -48.07 8.93 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.151 -0.968 . . . . 0.0 109.754 -179.842 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 40.2 ttp180 -57.87 -39.47 77.88 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.457 -0.777 . . . . 0.0 110.3 -179.482 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.506 ' O ' ' N ' ' A' ' 48' ' ' GLY . . . -64.31 -43.13 95.66 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.04 -1.038 . . . . 0.0 110.451 -179.117 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.497 HD13 ' HB3' ' A' ' 59' ' ' LEU . 2.8 mm? -65.19 -40.02 93.66 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.008 -1.057 . . . . 0.0 109.655 -179.852 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 46' ' ' CYS . . . . . . . . . . . . . 75.7 m -69.22 -49.54 55.53 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.023 -1.048 . . . . 0.0 109.444 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 73.9 p -74.07 -34.04 63.89 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.18 -0.95 . . . . 0.0 109.554 179.828 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 48' ' ' GLY . . . . . 0.506 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 75.22 35.22 49.4 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 110.395 -1.082 . . . . 0.0 110.395 179.643 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -61.53 -37.26 83.1 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.005 -1.291 . . . . 0.0 109.235 179.836 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 48.2 mmtm -61.76 -33.59 74.35 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.343 -0.848 . . . . 0.0 109.384 179.783 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 94.35 167.54 36.98 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.295 -1.522 . . . . 0.0 109.295 -179.762 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.525 HG23 ' HA ' ' A' ' 58' ' ' PRO . 99.2 m -80.2 141.05 36.01 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.293 -1.121 . . . . 0.0 109.729 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -59.03 137.55 50.35 Favored Glycine 0 N--CA 1.489 2.173 0 N-CA-C 109.305 -1.518 . . . . 0.0 109.305 179.764 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 74.5 mtt85 -58.99 -35.35 73.07 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.294 -1.121 . . . . 0.0 109.913 -179.701 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 22.9 t -57.67 -31.9 66.79 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.25 -0.906 . . . . 0.0 109.887 -179.769 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 117.86 91.22 1.49 Allowed Glycine 0 N--CA 1.495 2.626 0 N-CA-C 108.896 -1.681 . . . . 0.0 108.896 -179.503 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' LYS . . . . . 0.492 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 78.6 tttt -176.62 80.21 0.27 Allowed Pre-proline 0 N--CA 1.488 1.459 0 O-C-N 121.546 -0.973 . . . . 0.0 108.442 -179.666 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.525 ' HA ' HG23 ' A' ' 52' ' ' THR . 72.5 Cg_exo -48.99 134.51 29.2 Favored 'Trans proline' 0 C--N 1.304 -1.794 0 C-N-CA 122.727 2.285 . . . . 0.0 112.457 -179.097 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.497 ' HB3' HD13 ' A' ' 45' ' ' LEU . 7.7 mp -100.5 71.67 1.54 Allowed 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.621 -0.674 . . . . 0.0 109.4 -179.557 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 79.9 m80 -147.06 130.52 16.73 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.197 -0.939 . . . . 0.0 109.887 179.902 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 58.8 m-85 -72.67 -5.04 34.83 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.119 -0.988 . . . . 0.0 108.402 178.748 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 50.4 tttt -53.54 140.58 28.01 Favored 'General case' 0 N--CA 1.487 1.409 0 O-C-N 121.622 -0.674 . . . . 0.0 109.973 -179.501 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 53.7 t0 56.97 43.5 24.52 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.572 -0.705 . . . . 0.0 110.28 179.646 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.739 ' H ' ' CG1' ' A' ' 171' ' ' VAL . 95.6 p -109.79 150.33 28.52 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.157 -0.965 . . . . 0.0 108.68 179.094 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 38.4 t -102.97 141.42 35.81 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.171 -0.956 . . . . 0.0 109.004 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.411 ' CE1' ' CE ' ' A' ' 16' ' ' MET . 3.2 m-85 -66.66 138.72 57.64 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.291 -0.88 . . . . 0.0 109.021 -179.728 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 81.5 t60 -59.05 -52.19 66.81 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.299 -0.876 . . . . 0.0 110.298 -178.94 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 15.5 ptm180 -166.68 164.01 16.72 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.083 -1.011 . . . . 0.0 109.952 -179.807 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.519 HG21 HG22 ' A' ' 165' ' ' THR . 33.9 m -131.98 147.86 32.3 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.48 -0.762 . . . . 0.0 109.169 179.678 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.408 HG21 HD13 ' A' ' 70' ' ' ILE . 11.6 mt -147.74 108.24 3.77 Favored Pre-proline 0 N--CA 1.492 1.648 0 O-C-N 120.965 -1.084 . . . . 0.0 109.74 179.72 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_exo -54.09 146.04 50.44 Favored 'Trans proline' 0 N--CA 1.493 1.485 0 C-N-CA 122.427 2.085 . . . . 0.0 112.448 179.723 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 77.57 -57.81 3.78 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 110.212 -1.155 . . . . 0.0 110.212 179.273 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 95.5 m-85 -69.67 -83.85 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.166 -1.197 . . . . 0.0 109.819 -179.498 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 74' ' ' MET . . . . . 0.471 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 12.2 ptp -178.93 -172.36 0.25 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.255 -0.903 . . . . 0.0 109.59 -179.764 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -127.76 137.15 52.33 Favored 'General case' 0 N--CA 1.494 1.746 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 179.734 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 93.5 mt-30 -110.63 154.46 23.76 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.256 -0.902 . . . . 0.0 109.603 -179.619 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -160.83 -166.93 20.56 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.426 -1.47 . . . . 0.0 109.426 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 88.74 23.66 35.28 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.439 ' C ' ' OD1' ' A' ' 79' ' ' ASP . 54.6 p30 -84.13 10.54 9.9 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.179 -1.189 . . . . 0.0 109.377 179.922 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 85.2 t80 -53.25 -46.25 69.12 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.36 -0.837 . . . . 0.0 109.804 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.579 ' O ' ' HB2' ' A' ' 82' ' ' ALA . 71.9 p -71.17 -28.71 64.45 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.013 -1.055 . . . . 0.0 109.568 179.906 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 82' ' ' ALA . . . . . 0.579 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 171.26 -57.46 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.205 -0.935 . . . . 0.0 109.405 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 93.65 1.51 65.89 Favored Glycine 0 N--CA 1.492 2.402 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 -180.0 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 23.6 m120 -86.61 6.31 31.57 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.244 -1.15 . . . . 0.0 109.446 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 95.79 -39.13 2.91 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.327 -1.509 . . . . 0.0 109.327 -179.781 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 52.2 p -74.14 -16.14 61.01 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.336 -1.096 . . . . 0.0 109.055 179.594 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -82.85 -167.25 40.7 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.671 -1.372 . . . . 0.0 109.671 -179.913 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.555 ' N ' ' OG1' ' A' ' 81' ' ' THR . . . 83.85 38.42 10.47 Favored Glycine 0 N--CA 1.488 2.104 0 N-CA-C 109.154 -1.578 . . . . 0.0 109.154 -179.708 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -57.42 144.87 34.77 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.46 -1.024 . . . . 0.0 109.671 -179.774 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 96.4 p -112.26 150.24 31.23 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.449 -0.782 . . . . 0.0 109.191 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 24.0 pt -70.82 -31.48 45.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.171 -0.956 . . . . 0.0 110.059 -179.684 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 92' ' ' TYR . . . . . 0.431 ' OH ' ' O ' ' A' ' 37' ' ' ARG . 59.2 m-85 -65.38 -37.99 88.68 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.166 -0.959 . . . . 0.0 109.7 -179.65 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 73.22 15.63 78.75 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -148.16 158.72 44.23 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.301 -1.117 . . . . 0.0 109.455 -179.834 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 63.4 mttp -84.95 150.29 25.03 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.366 -0.834 . . . . 0.0 109.473 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 55.4 p90 -132.25 160.52 35.94 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.279 -0.888 . . . . 0.0 109.538 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -110.52 154.18 24.06 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.496 -0.752 . . . . 0.0 109.723 -179.801 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 60.3 t0 -78.48 124.13 27.8 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.264 -0.897 . . . . 0.0 109.306 179.76 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 78.5 mm-40 -60.88 -37.49 82.35 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.278 -0.889 . . . . 0.0 110.003 -179.457 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 19.1 t-20 -166.51 171.11 12.14 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.95 -1.094 . . . . 0.0 109.943 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -109.81 44.09 1.25 Allowed 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.521 -0.737 . . . . 0.0 109.373 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 89.0 mt -52.32 -41.84 35.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.105 -0.997 . . . . 0.0 109.818 -179.514 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 103' ' ' LYS . . . . . 0.441 ' HE2' HG21 ' A' ' 34' ' ' THR . 59.6 mttm -91.72 144.42 25.53 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.144 -0.972 . . . . 0.0 109.756 -179.686 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 80.2 tttt -134.38 159.13 42.01 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.371 -0.831 . . . . 0.0 109.444 -179.788 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 105' ' ' HIS . . . . . 0.526 ' CE1' ' O ' ' A' ' 107' ' ' GLY . 70.7 t60 -89.63 111.29 22.2 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.304 -0.873 . . . . 0.0 109.264 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 48.2 p -125.86 1.22 7.37 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.364 -0.835 . . . . 0.0 109.942 -179.797 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.526 ' O ' ' CE1' ' A' ' 105' ' ' HIS . . . -155.62 170.32 33.53 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.811 -1.316 . . . . 0.0 109.811 -179.771 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -75.07 156.24 42.68 Favored 'Trans proline' 0 C--N 1.308 -1.573 0 C-N-CA 123.026 2.484 . . . . 0.0 112.213 179.614 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 84.15 43.27 7.16 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 110.328 -1.109 . . . . 0.0 110.328 179.51 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 37.1 mm -115.25 134.41 58.47 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.834 0 O-C-N 121.312 -1.111 . . . . 0.0 109.172 179.592 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.72 ' N ' HD22 ' A' ' 111' ' ' LEU . 2.9 mm? -90.36 124.91 35.31 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.237 -0.915 . . . . 0.0 109.22 179.903 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 50.4 m -137.95 144.96 41.46 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.208 -0.933 . . . . 0.0 109.779 179.806 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 87.8 mtp -90.35 131.41 36.15 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.352 -0.842 . . . . 0.0 109.114 179.429 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 114' ' ' ALA . . . . . 0.409 ' O ' ' OD1' ' A' ' 115' ' ' ASN . . . -65.73 143.76 57.32 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.195 -0.94 . . . . 0.0 109.513 -179.829 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 115' ' ' ASN . . . . . 0.409 ' OD1' ' O ' ' A' ' 114' ' ' ALA . 72.2 m-20 -144.22 113.31 6.85 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.174 -0.954 . . . . 0.0 108.976 179.601 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -70.22 -30.03 67.01 Favored 'General case' 0 C--N 1.297 -1.691 0 O-C-N 121.465 -0.772 . . . . 0.0 109.581 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -140.33 167.16 25.58 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.486 -1.446 . . . . 0.0 109.486 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 118' ' ' PRO . . . . . 0.464 ' O ' ' CG ' ' A' ' 119' ' ' ASN . 41.0 Cg_endo -67.26 158.36 57.33 Favored 'Trans proline' 0 C--N 1.305 -1.726 0 C-N-CA 122.875 2.383 . . . . 0.0 111.893 179.952 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 119' ' ' ASN . . . . . 0.591 ' ND2' ' O ' ' A' ' 119' ' ' ASN . 2.5 p-10 45.41 45.44 10.18 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.514 -0.741 . . . . 0.0 109.543 -179.898 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 89.4 m -134.61 132.26 38.81 Favored 'General case' 0 C--N 1.305 -1.332 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 179.684 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 43.3 p-10 -64.82 162.86 15.32 Favored 'General case' 0 C--N 1.295 -1.768 0 O-C-N 121.343 -0.848 . . . . 0.0 109.309 -179.807 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -109.74 101.47 1.45 Allowed Glycine 0 N--CA 1.494 2.517 0 N-CA-C 109.83 -1.308 . . . . 0.0 109.83 -179.7 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 86.1 p -63.12 -28.15 69.87 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.215 -1.167 . . . . 0.0 109.059 179.543 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.0 mt-30 -125.98 158.31 35.61 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.545 -0.722 . . . . 0.0 109.204 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 49.0 p90 -134.53 163.05 30.58 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.268 -0.895 . . . . 0.0 109.51 -179.925 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 126' ' ' PHE . . . . . 0.471 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 48.3 p90 -134.44 157.54 46.18 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.312 -0.867 . . . . 0.0 109.414 179.927 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 61.5 mt -122.97 134.35 66.38 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 O-C-N 121.391 -0.818 . . . . 0.0 109.581 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 2.9 t -108.68 125.2 51.63 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.211 -0.931 . . . . 0.0 109.155 179.65 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 129' ' ' THR . . . . . 0.448 ' OG1' ' OE1' ' A' ' 156' ' ' GLU . 7.3 p -114.22 18.05 17.27 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.388 -0.82 . . . . 0.0 109.61 -179.656 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -145.84 162.32 37.98 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.144 -0.973 . . . . 0.0 109.883 -179.548 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 62.5 tttm -59.87 134.11 56.72 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.365 -0.834 . . . . 0.0 109.093 179.863 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 132' ' ' THR . . . . . 0.437 ' OG1' ' OD1' ' A' ' 136' ' ' ASP . 21.9 p -79.17 105.48 10.53 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.26 -0.9 . . . . 0.0 109.909 -179.485 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -66.21 -38.39 87.85 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.087 -1.008 . . . . 0.0 108.672 179.198 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 20.4 p90 -155.31 6.55 0.24 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.44 -0.787 . . . . 0.0 109.968 179.458 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 135' ' ' LEU . . . . . 0.607 ' N ' HD22 ' A' ' 135' ' ' LEU . 3.5 mm? -68.65 -28.01 66.51 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.027 -1.045 . . . . 0.0 109.328 179.562 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 136' ' ' ASP . . . . . 0.437 ' OD1' ' OG1' ' A' ' 132' ' ' THR . 93.8 m-20 -52.38 144.85 12.27 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.357 -0.839 . . . . 0.0 110.025 -179.336 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 171.02 -128.38 1.6 Allowed Glycine 0 N--CA 1.489 2.202 0 N-CA-C 108.793 -1.723 . . . . 0.0 108.793 -179.909 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 4.3 mptp? -89.86 123.06 33.49 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.077 -1.249 . . . . 0.0 108.851 179.376 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 32.0 p80 -168.96 159.37 9.33 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.181 -0.95 . . . . 0.0 109.745 -179.787 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 38.9 t -123.46 136.65 59.34 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 O-C-N 121.389 -0.819 . . . . 0.0 109.317 179.896 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 141' ' ' VAL . . . . . 0.451 HG23 ' O ' ' A' ' 141' ' ' VAL . 17.6 m -108.58 131.41 59.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.231 -0.918 . . . . 0.0 109.014 179.77 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 39.7 p90 -117.01 -4.08 11.53 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.407 -0.808 . . . . 0.0 109.992 -179.609 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -165.53 179.2 40.04 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.648 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.2 pt20 -144.3 165.28 28.33 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.186 -1.185 . . . . 0.0 109.661 -179.787 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 60.4 t -97.56 130.1 46.73 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.224 0 O-C-N 121.269 -0.894 . . . . 0.0 109.449 -179.92 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 16.3 m -106.06 -32.45 2.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.37 -0.832 . . . . 0.0 109.48 179.612 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -144.6 174.37 11.01 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.174 -0.954 . . . . 0.0 109.526 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 99.12 1.21 57.06 Favored Glycine 0 N--CA 1.494 2.509 0 N-CA-C 109.974 -1.25 . . . . 0.0 109.974 179.569 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 149' ' ' MET . . . . . 0.436 ' O ' HG12 ' A' ' 152' ' ' VAL . 65.1 mtt -60.93 -34.16 74.28 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.105 -1.232 . . . . 0.0 109.718 179.945 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -64.51 -42.77 95.59 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.89 -1.131 . . . . 0.0 110.138 -179.576 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.7 p -83.08 -34.04 10.87 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.113 -0.992 . . . . 0.0 110.518 -179.486 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 152' ' ' VAL . . . . . 0.459 ' CG1' ' N ' ' A' ' 153' ' ' LYS . 0.6 OUTLIER -55.52 -41.65 64.53 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 120.889 -1.132 . . . . 0.0 109.122 -179.36 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 153' ' ' LYS . . . . . 0.459 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 57.3 mttp -63.23 -33.63 75.91 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.281 -0.887 . . . . 0.0 109.486 179.417 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -62.26 -40.52 96.49 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.327 -0.858 . . . . 0.0 109.873 -179.575 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 78.4 mt -72.92 -34.34 45.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.083 -1.011 . . . . 0.0 109.61 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 156' ' ' GLU . . . . . 0.448 ' OE1' ' OG1' ' A' ' 129' ' ' THR . 78.9 tt0 -75.95 -42.33 48.93 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.216 -0.928 . . . . 0.0 111.258 -178.796 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 43.2 pttt -61.84 -33.9 74.98 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 120.808 -1.183 . . . . 0.0 109.985 -178.831 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 34.5 m -80.34 -10.29 12.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.136 -0.978 . . . . 0.0 109.249 179.73 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -71.28 165.11 53.59 Favored Glycine 0 N--CA 1.488 2.163 0 N-CA-C 110.074 -1.21 . . . . 0.0 110.074 -179.487 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 22.8 t -155.17 171.39 19.88 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.537 -0.978 . . . . 0.0 109.34 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 24.9 m -54.44 -29.64 50.07 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.199 -0.938 . . . . 0.0 109.346 179.891 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 87.1 p -57.8 -26.6 62.18 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.282 -0.886 . . . . 0.0 109.663 -179.759 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 89.65 15.52 58.12 Favored Glycine 0 N--CA 1.493 2.437 0 N-CA-C 109.823 -1.311 . . . . 0.0 109.823 179.746 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 61.6 ttt180 -126.72 140.67 52.21 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.226 -1.161 . . . . 0.0 109.489 -179.941 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 165' ' ' THR . . . . . 0.519 HG22 HG21 ' A' ' 69' ' ' VAL . 68.7 p -75.08 148.66 39.56 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.157 -0.965 . . . . 0.0 109.279 179.813 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -66.12 -39.3 89.81 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.243 -0.911 . . . . 0.0 109.542 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -103.2 155.68 18.26 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.321 -0.862 . . . . 0.0 109.45 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 64.2 mttp -73.74 130.8 40.71 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.222 -0.924 . . . . 0.0 109.197 179.832 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 13.7 t -128.15 125.02 63.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.142 -0.974 . . . . 0.0 109.515 -179.827 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 62.7 t -142.08 135.01 28.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.267 -0.896 . . . . 0.0 109.343 179.332 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.739 ' CG1' ' H ' ' A' ' 64' ' ' SER . 0.4 OUTLIER -63.58 116.01 2.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.213 -0.929 . . . . 0.0 108.923 179.88 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 172' ' ' GLU . . . . . 0.507 ' O ' ' OD1' ' A' ' 173' ' ' ASP . 96.7 mt-10 -70.64 -40.6 72.99 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.04 -1.037 . . . . 0.0 110.649 -179.531 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 173' ' ' ASP . . . . . 0.507 ' OD1' ' O ' ' A' ' 172' ' ' GLU . 80.5 m-20 -145.13 159.03 43.62 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.08 -1.013 . . . . 0.0 110.377 -179.255 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 53.3 t -145.04 141.84 29.22 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.507 -0.746 . . . . 0.0 109.286 179.474 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -175.73 179.48 46.87 Favored Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.879 -1.288 . . . . 0.0 109.879 179.839 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 57.5 tt0 -107.87 121.75 45.4 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.32 -1.106 . . . . 0.0 109.608 -179.891 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 30.8 tp -62.66 -37.81 87.87 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.183 -0.948 . . . . 0.0 109.317 179.675 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 3.0 t . . . . . 0 N--CA 1.49 1.564 0 CA-C-O 117.977 -1.011 . . . . 0.0 109.439 -179.872 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 . . . . . 0 N--CA 1.491 1.592 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 78.2 Cg_endo -74.47 89.0 1.12 Allowed 'Trans proline' 0 C--N 1.311 -1.441 0 C-N-CA 122.48 2.12 . . . . 0.0 112.111 179.896 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 89.7 mtt-85 -72.02 134.61 45.98 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.306 -0.871 . . . . 0.0 109.578 -179.913 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.0 p -137.7 142.43 36.4 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.367 -0.833 . . . . 0.0 108.99 179.717 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 42.2 p90 -145.89 155.45 42.88 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.234 -0.916 . . . . 0.0 109.844 -179.671 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 91.1 m-85 -125.1 137.96 54.18 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.432 -0.793 . . . . 0.0 109.467 179.444 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 61.3 t0 -89.03 117.61 28.16 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.2 -0.938 . . . . 0.0 108.511 178.831 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' MET . . . . . 0.466 ' SD ' HD12 ' A' ' 26' ' ' ILE . 78.2 mtp -106.32 150.8 25.61 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.147 -0.97 . . . . 0.0 110.52 -178.997 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 84.6 p -146.5 168.65 20.69 Favored 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 109.02 -0.734 . . . . 0.0 109.02 179.822 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.437 ' O ' ' N ' ' A' ' 20' ' ' GLY . 27.2 m -126.09 155.85 36.1 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.804 0 O-C-N 121.267 -0.896 . . . . 0.0 109.457 -179.879 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -49.47 96.61 0.01 OUTLIER Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.366 -1.494 . . . . 0.0 109.366 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.437 ' N ' ' O ' ' A' ' 18' ' ' VAL . . . 150.88 -84.82 0.16 Allowed Glycine 0 N--CA 1.493 2.438 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 -179.93 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 12.9 mt-30 -139.36 160.67 60.98 Favored Pre-proline 0 N--CA 1.494 1.741 0 O-C-N 121.357 -1.084 . . . . 0.0 109.037 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_exo -47.74 134.15 22.22 Favored 'Trans proline' 0 C--N 1.312 -1.392 0 C-N-CA 122.251 1.967 . . . . 0.0 112.247 179.739 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -89.58 -60.32 1.97 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.303 -0.873 . . . . 0.0 109.578 -179.86 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 176.05 -166.99 38.46 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.7 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 35.8 ptt-85 -126.01 149.22 48.98 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.466 -1.02 . . . . 0.0 109.143 179.818 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.466 HD12 ' SD ' ' A' ' 16' ' ' MET . 89.3 mt -122.3 130.32 74.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.287 -0.883 . . . . 0.0 109.346 -179.893 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 44.1 t -109.95 132.61 57.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.444 -0.785 . . . . 0.0 109.427 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 74.8 mtm -119.95 147.13 45.13 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.424 -0.798 . . . . 0.0 109.143 179.875 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.404 ' C ' HD22 ' A' ' 30' ' ' LEU . 84.5 tt0 -101.03 132.1 46.61 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.23 -0.919 . . . . 0.0 109.987 -179.359 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.414 ' N ' ' CD2' ' A' ' 30' ' ' LEU . 2.6 mm? -108.42 132.13 54.08 Favored 'General case' 0 N--CA 1.492 1.626 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 179.44 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 93.3 m-85 -96.02 116.23 28.64 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 120.966 -1.083 . . . . 0.0 108.775 179.045 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -84.72 -43.7 14.06 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.287 -0.883 . . . . 0.0 109.735 -179.705 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.0 m-20 -63.88 -49.43 72.77 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.217 -0.927 . . . . 0.0 109.879 -179.585 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 28.3 m -71.14 -41.83 69.96 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.207 -0.933 . . . . 0.0 109.417 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.517 ' O ' ' OG1' ' A' ' 35' ' ' THR . 2.3 p -135.16 79.62 49.61 Favored Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 121.531 -0.731 . . . . 0.0 109.495 -179.642 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 29.8 Cg_endo -68.48 -62.83 0.05 OUTLIER 'Trans proline' 0 N--CA 1.494 1.557 0 C-N-CA 122.338 2.025 . . . . 0.0 112.867 -179.339 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 79.2 mtp180 -61.23 -37.0 81.49 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.375 -0.828 . . . . 0.0 110.844 -178.952 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 26.8 m -60.66 -43.39 97.7 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.928 -1.107 . . . . 0.0 109.761 -179.51 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -62.83 -30.85 71.81 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.17 -0.956 . . . . 0.0 108.867 179.698 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -68.44 -38.63 81.32 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.47 -0.768 . . . . 0.0 109.899 -179.881 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 47.5 t30 -57.86 -42.52 84.7 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.318 -0.864 . . . . 0.0 109.95 -179.518 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.533 ' O ' ' SG ' ' A' ' 46' ' ' CYS . 97.8 m-85 -84.67 -46.96 10.96 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.069 -1.019 . . . . 0.0 109.938 -179.869 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.676 ' CZ ' HE22 ' A' ' 176' ' ' GLN . 77.0 ttt180 -54.21 -41.13 68.28 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.338 -0.852 . . . . 0.0 110.361 -179.285 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -66.81 -47.62 71.5 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.108 -0.995 . . . . 0.0 110.319 -178.951 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.474 HD13 ' HB3' ' A' ' 59' ' ' LEU . 3.2 mm? -65.28 -39.06 92.08 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.078 -1.014 . . . . 0.0 109.96 -179.515 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 46' ' ' CYS . . . . . 0.533 ' SG ' ' O ' ' A' ' 42' ' ' PHE . 27.6 m -64.41 -62.3 1.69 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.939 -1.101 . . . . 0.0 109.392 -179.766 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 25.3 m -64.86 -36.47 84.46 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.282 -0.886 . . . . 0.0 109.183 179.606 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 83.59 35.62 16.24 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 110.176 -1.17 . . . . 0.0 110.176 179.558 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -61.56 -38.1 86.24 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.051 -1.264 . . . . 0.0 109.266 179.674 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 29.5 mmtm -62.27 -29.75 70.63 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.283 -0.885 . . . . 0.0 109.446 179.747 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 86.06 -115.67 4.24 Favored Glycine 0 N--CA 1.488 2.13 0 N-CA-C 108.778 -1.729 . . . . 0.0 108.778 -179.103 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.544 HG23 ' HA ' ' A' ' 58' ' ' PRO . 61.6 m -129.42 142.01 50.9 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.254 -1.145 . . . . 0.0 109.553 179.455 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -64.66 136.21 38.75 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 61.7 ttp85 -55.32 -37.98 68.11 Favored 'General case' 0 C--N 1.305 -1.328 0 O-C-N 121.254 -1.145 . . . . 0.0 110.056 -179.652 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 22.9 t -57.19 -32.7 66.73 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.288 -0.883 . . . . 0.0 109.797 -179.605 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 56' ' ' GLY . . . . . 0.409 ' O ' ' CB ' ' A' ' 57' ' ' LYS . . . 118.59 105.1 2.21 Favored Glycine 0 N--CA 1.494 2.508 0 N-CA-C 109.014 -1.635 . . . . 0.0 109.014 -179.726 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 57' ' ' LYS . . . . . 0.409 ' CB ' ' O ' ' A' ' 56' ' ' GLY . 0.8 OUTLIER 167.86 82.61 0.02 OUTLIER Pre-proline 0 N--CA 1.491 1.584 0 N-CA-C 108.104 -1.073 . . . . 0.0 108.104 -179.625 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.544 ' HA ' HG23 ' A' ' 52' ' ' THR . 81.4 Cg_exo -45.97 126.15 9.1 Favored 'Trans proline' 0 C--N 1.305 -1.742 0 C-N-CA 122.579 2.186 . . . . 0.0 112.269 -178.964 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.58 ' O ' ' CG ' ' A' ' 60' ' ' HIS . 53.2 mt -95.94 130.61 42.87 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.554 -0.716 . . . . 0.0 109.711 -179.62 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 60' ' ' HIS . . . . . 0.58 ' CG ' ' O ' ' A' ' 59' ' ' LEU . 0.4 OUTLIER 166.51 110.03 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.258 -0.901 . . . . 0.0 109.577 179.889 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 3.6 m-85 -68.39 -3.5 11.4 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.181 -0.95 . . . . 0.0 108.603 179.163 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 34.6 ttmt -57.52 149.35 21.36 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.378 -0.827 . . . . 0.0 109.523 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 63' ' ' ASP . . . . . 0.424 ' H ' HG23 ' A' ' 171' ' ' VAL . 83.2 m-20 57.35 47.76 16.04 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.478 -0.764 . . . . 0.0 110.231 179.839 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.929 ' H ' HG22 ' A' ' 171' ' ' VAL . 92.3 p -104.33 156.79 17.62 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.293 -0.879 . . . . 0.0 108.907 179.257 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 29.2 t -128.9 146.54 50.92 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.153 -0.967 . . . . 0.0 109.623 -179.609 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.7 m-30 -71.81 133.92 45.81 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.283 -0.885 . . . . 0.0 108.662 179.633 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 80.7 m80 -91.02 -31.58 16.25 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.087 -1.008 . . . . 0.0 110.819 -178.985 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 80.0 mtp180 -135.36 138.61 43.53 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 120.951 -1.093 . . . . 0.0 110.306 -179.458 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -150.8 80.04 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 179.0 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 59.9 mt -96.99 129.39 32.54 Favored Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.345 -0.847 . . . . 0.0 109.537 -179.627 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -74.61 134.67 18.82 Favored 'Trans proline' 0 N--CA 1.491 1.349 0 C-N-CA 122.114 1.876 . . . . 0.0 112.076 179.788 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 92.96 -1.2 70.4 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.899 -1.28 . . . . 0.0 109.899 179.597 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 77.4 m-85 -132.93 -94.02 0.34 Allowed 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.098 -1.236 . . . . 0.0 109.818 179.921 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 4.5 ptt? -163.39 177.48 8.89 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.946 -1.097 . . . . 0.0 110.031 -179.601 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -129.4 131.49 46.81 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.495 -0.753 . . . . 0.0 109.039 179.94 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 50.8 tt0 -97.16 118.5 33.72 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.138 -0.976 . . . . 0.0 109.322 179.816 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -61.86 -39.31 97.33 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 81.53 167.16 38.18 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.494 -1.442 . . . . 0.0 109.494 -179.916 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -104.25 149.83 24.96 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.42 -1.047 . . . . 0.0 109.456 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 45.2 p90 -65.29 -24.17 67.22 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.18 -0.95 . . . . 0.0 109.347 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.53 ' O ' ' HB2' ' A' ' 82' ' ' ALA . 58.9 p -66.31 -31.51 72.35 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.225 -0.922 . . . . 0.0 109.657 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 82' ' ' ALA . . . . . 0.53 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 173.46 -53.28 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.242 -0.911 . . . . 0.0 109.44 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 92.53 3.26 66.89 Favored Glycine 0 N--CA 1.492 2.378 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 40.7 p-10 -88.27 7.53 31.69 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.162 -1.199 . . . . 0.0 109.427 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 95.21 -43.52 2.23 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 109.272 -1.531 . . . . 0.0 109.272 -179.851 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 47.1 m -60.58 -38.41 84.5 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.208 -1.172 . . . . 0.0 109.049 179.759 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -84.38 -164.67 38.1 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.473 -1.451 . . . . 0.0 109.473 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.517 ' N ' ' OG1' ' A' ' 81' ' ' THR . . . 86.98 35.51 9.8 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.511 -1.435 . . . . 0.0 109.511 -179.952 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -56.56 146.04 26.31 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.296 -1.12 . . . . 0.0 109.441 179.878 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 29.7 t -100.35 144.02 29.85 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.284 -0.885 . . . . 0.0 109.461 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 21.9 pt -64.36 -32.44 57.6 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.382 -0.824 . . . . 0.0 109.863 -179.728 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 67.7 m-85 -64.12 -37.46 87.54 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.198 -0.939 . . . . 0.0 109.437 -179.795 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 81.43 7.47 88.24 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -151.82 156.92 41.16 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.204 -1.174 . . . . 0.0 109.537 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 86.9 mttt -88.27 148.29 24.4 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.285 -0.884 . . . . 0.0 109.542 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 96' ' ' PHE . . . . . 0.554 ' CZ ' ' OD1' ' A' ' 121' ' ' ASN . 40.4 p90 -134.33 161.82 33.91 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.253 -0.905 . . . . 0.0 108.973 179.495 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -54.99 138.36 43.9 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.146 -0.971 . . . . 0.0 109.851 -178.992 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 88.2 m-20 -74.66 141.15 44.62 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.428 -0.795 . . . . 0.0 109.761 -179.901 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 99' ' ' GLU . . . . . 0.459 ' OE1' HG22 ' A' ' 35' ' ' THR . 96.0 mt-10 -59.82 146.36 42.1 Favored 'General case' 0 C--N 1.305 -1.37 0 O-C-N 121.322 -0.861 . . . . 0.0 109.218 179.672 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 23.0 t-20 -58.26 159.63 5.87 Favored 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.461 -0.774 . . . . 0.0 109.429 -179.87 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 101' ' ' PHE . . . . . 0.482 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 29.3 p90 -96.43 52.26 1.23 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.303 -0.873 . . . . 0.0 109.72 -179.721 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 88.6 mt -56.77 -39.49 64.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.123 -0.986 . . . . 0.0 109.322 179.781 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -93.03 146.16 23.84 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.154 -0.966 . . . . 0.0 109.627 179.901 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 104' ' ' LYS . . . . . 0.546 ' O ' HG23 ' A' ' 106' ' ' THR . 81.0 tttt -126.8 157.62 38.74 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.439 -0.788 . . . . 0.0 109.346 -179.924 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 105' ' ' HIS . . . . . 0.53 ' ND1' ' OD1' ' A' ' 136' ' ' ASP . 23.2 m80 -59.06 81.25 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.272 -0.893 . . . . 0.0 109.061 179.937 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 106' ' ' THR . . . . . 0.546 HG23 ' O ' ' A' ' 104' ' ' LYS . 69.3 p -73.96 -22.79 59.51 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.164 -0.96 . . . . 0.0 110.147 -179.485 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.414 ' O ' HG12 ' A' ' 110' ' ' ILE . . . -152.75 177.66 30.33 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.734 -1.346 . . . . 0.0 109.734 -179.626 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -73.2 156.29 51.3 Favored 'Trans proline' 0 C--N 1.307 -1.648 0 C-N-CA 122.891 2.394 . . . . 0.0 112.193 179.793 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 109' ' ' GLY . . . . . 0.495 ' N ' ' O ' ' A' ' 128' ' ' CYS . . . 82.23 47.42 6.12 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.91 -1.276 . . . . 0.0 109.91 179.757 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.414 HG12 ' O ' ' A' ' 107' ' ' GLY . 40.7 mm -115.0 136.67 50.94 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.378 -1.071 . . . . 0.0 109.479 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.734 ' N ' HD22 ' A' ' 111' ' ' LEU . 2.7 mm? -89.32 142.34 27.74 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.349 -0.844 . . . . 0.0 109.762 -179.684 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 10.4 t -144.8 140.71 28.63 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.202 -0.936 . . . . 0.0 109.752 179.787 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 89.0 mtp -88.86 137.49 32.27 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.166 -0.959 . . . . 0.0 109.323 179.483 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 114' ' ' ALA . . . . . 0.418 ' HB2' ' CE2' ' A' ' 126' ' ' PHE . . . -68.9 143.52 54.47 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.202 -0.936 . . . . 0.0 109.811 -179.867 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 115' ' ' ASN . . . . . 0.433 ' OD1' ' O ' ' A' ' 120' ' ' THR . 47.0 t30 -140.83 151.03 44.03 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.334 -0.854 . . . . 0.0 109.474 179.737 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -132.17 -3.72 3.5 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.404 -0.81 . . . . 0.0 109.241 179.755 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -157.51 169.55 34.45 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.078 -1.609 . . . . 0.0 109.078 -179.925 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -70.66 147.91 58.13 Favored 'Trans proline' 0 C--N 1.306 -1.665 0 C-N-CA 122.603 2.202 . . . . 0.0 111.792 179.857 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 87.7 m-20 51.0 42.2 28.18 Favored 'General case' 0 C--N 1.297 -1.679 0 O-C-N 121.476 -0.765 . . . . 0.0 109.467 -179.801 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 120' ' ' THR . . . . . 0.433 ' O ' ' OD1' ' A' ' 115' ' ' ASN . 84.2 m -135.22 124.91 25.26 Favored 'General case' 0 N--CA 1.488 1.44 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 179.717 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 121' ' ' ASN . . . . . 0.554 ' OD1' ' CZ ' ' A' ' 96' ' ' PHE . 35.8 m120 -106.24 128.3 53.85 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.576 -0.703 . . . . 0.0 109.702 -179.919 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -99.52 130.84 10.35 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 179.921 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 22.9 t -60.19 -33.23 71.94 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.186 -1.185 . . . . 0.0 109.63 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 82.1 mt-30 -68.38 147.9 51.45 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.332 -0.855 . . . . 0.0 109.664 -179.668 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 50.2 p90 -137.31 161.14 37.06 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.334 -0.854 . . . . 0.0 109.209 179.905 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 126' ' ' PHE . . . . . 0.418 ' CE2' ' HB2' ' A' ' 114' ' ' ALA . 86.0 m-85 -118.87 151.35 38.27 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.266 -0.897 . . . . 0.0 109.711 -179.898 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 76.3 mt -116.82 134.05 61.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 N-CA-C 108.693 -0.854 . . . . 0.0 108.693 179.313 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 128' ' ' CYS . . . . . 0.495 ' O ' ' N ' ' A' ' 109' ' ' GLY . 1.3 m -121.59 132.45 54.69 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.278 -0.889 . . . . 0.0 109.389 -179.774 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 129' ' ' THR . . . . . 0.425 HG21 ' OE1' ' A' ' 156' ' ' GLU . 1.7 t -116.65 8.78 13.91 Favored 'General case' 0 N--CA 1.493 1.698 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 179.652 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -141.58 165.94 26.11 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.544 -0.723 . . . . 0.0 109.109 -179.885 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 69.1 mttm -65.5 134.13 52.75 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.114 -0.991 . . . . 0.0 109.453 -179.829 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 57.3 p -141.97 70.45 1.33 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.319 -0.863 . . . . 0.0 109.295 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -61.3 -36.16 79.33 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.277 -0.889 . . . . 0.0 109.992 -179.56 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 0.8 OUTLIER -62.6 -43.15 99.54 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.014 -1.054 . . . . 0.0 109.51 -179.942 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 25.0 mt -65.49 -33.84 76.88 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.14 -0.975 . . . . 0.0 109.765 179.508 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 136' ' ' ASP . . . . . 0.53 ' OD1' ' ND1' ' A' ' 105' ' ' HIS . 87.3 m-20 -65.76 141.59 58.27 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.277 -0.889 . . . . 0.0 109.611 -179.754 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 153.79 -92.83 0.13 Allowed Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 138' ' ' LYS . . . . . 0.418 ' HD2' ' N ' ' A' ' 138' ' ' LYS . 1.1 mptp? -87.7 10.54 17.89 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.333 -1.098 . . . . 0.0 109.523 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 63.3 m170 -96.41 140.74 30.63 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.235 -0.915 . . . . 0.0 109.594 -179.751 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 44.9 t -115.37 138.16 46.6 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 O-C-N 121.442 -0.786 . . . . 0.0 109.473 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 141' ' ' VAL . . . . . 0.439 HG23 ' O ' ' A' ' 141' ' ' VAL . 11.2 m -100.72 132.17 46.91 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.332 -0.855 . . . . 0.0 109.224 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 41.4 p90 -110.08 -11.08 14.65 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.222 -0.924 . . . . 0.0 110.219 -179.544 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -157.77 179.75 33.27 Favored Glycine 0 N--CA 1.493 2.458 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 179.738 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.5 pt20 -144.3 165.22 28.51 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.086 -1.244 . . . . 0.0 109.717 -179.749 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 75.6 t -97.12 129.66 46.86 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.19 0 O-C-N 121.318 -0.864 . . . . 0.0 109.299 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 16.1 m -101.86 -35.28 4.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.394 -0.816 . . . . 0.0 109.882 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 90.1 mt-10 -144.95 170.59 15.85 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.149 -0.97 . . . . 0.0 109.745 -179.819 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 97.78 4.14 58.02 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 110.315 -1.114 . . . . 0.0 110.315 179.308 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 149' ' ' MET . . . . . 0.49 ' O ' HG12 ' A' ' 152' ' ' VAL . 65.1 mtt -60.53 -32.37 71.41 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 120.991 -1.299 . . . . 0.0 109.518 179.872 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -64.79 -41.75 95.59 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 120.9 -1.125 . . . . 0.0 110.084 -179.652 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 6.6 p -82.21 -33.59 11.6 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.2 -0.938 . . . . 0.0 110.679 -179.425 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 152' ' ' VAL . . . . . 0.49 HG12 ' O ' ' A' ' 149' ' ' MET . 0.9 OUTLIER -55.82 -42.38 70.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 120.901 -1.124 . . . . 0.0 109.249 -179.304 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 153' ' ' LYS . . . . . 0.459 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 91.1 mttt -65.49 -35.49 81.03 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.043 -1.035 . . . . 0.0 109.409 179.429 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -63.01 -38.15 90.06 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.383 -0.823 . . . . 0.0 109.996 -179.532 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.46 HD13 ' CE ' ' A' ' 16' ' ' MET . 84.7 mt -71.09 -38.44 71.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.295 -0.878 . . . . 0.0 110.594 -179.555 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 156' ' ' GLU . . . . . 0.425 ' OE1' HG21 ' A' ' 129' ' ' THR . 83.1 tt0 -78.1 -39.25 41.99 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.1 -1.0 . . . . 0.0 111.573 -178.395 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 31.6 pttt -61.0 -34.16 74.39 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 120.723 -1.236 . . . . 0.0 110.21 -178.682 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.459 HG22 ' O ' ' A' ' 155' ' ' ILE . 23.8 m -69.8 -15.65 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 120.96 -1.087 . . . . 0.0 109.047 179.786 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -79.05 177.29 54.31 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 23.2 t -152.02 173.51 14.79 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.321 -1.105 . . . . 0.0 109.239 -179.855 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 23.4 m -53.09 -34.89 58.63 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.073 -1.017 . . . . 0.0 108.992 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 24.6 m -59.11 -30.33 68.04 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.373 -0.829 . . . . 0.0 109.363 179.527 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 96.82 11.14 54.23 Favored Glycine 0 N--CA 1.494 2.507 0 N-CA-C 109.35 -1.5 . . . . 0.0 109.35 -179.701 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 88.8 mtt180 -109.25 158.12 18.16 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.369 -1.077 . . . . 0.0 109.02 179.73 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 165' ' ' THR . . . . . . . . . . . . . 43.1 p -116.38 156.82 26.07 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.203 -0.936 . . . . 0.0 110.366 -179.399 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -68.17 -34.72 76.82 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.55 -0.718 . . . . 0.0 109.476 179.624 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -121.98 156.5 33.31 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.481 -0.762 . . . . 0.0 109.473 -179.73 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 90.5 mttt -80.7 141.16 35.14 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.298 -0.876 . . . . 0.0 109.301 -179.904 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 40.6 t -121.74 126.08 74.2 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.341 -0.849 . . . . 0.0 109.7 -179.88 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 43.5 t -141.57 140.68 30.88 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.275 -0.891 . . . . 0.0 109.202 179.712 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.929 HG22 ' H ' ' A' ' 64' ' ' SER . 4.0 m -68.58 123.24 21.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.118 -0.989 . . . . 0.0 109.464 179.935 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -68.65 -36.75 78.99 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.008 -1.057 . . . . 0.0 110.046 -179.802 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -160.04 163.05 34.29 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.073 -1.017 . . . . 0.0 110.07 -179.594 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 16.0 p -146.6 149.78 34.21 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.418 -0.801 . . . . 0.0 109.434 179.759 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . 176.84 -178.83 48.04 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 179.892 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 176' ' ' GLN . . . . . 0.676 HE22 ' CZ ' ' A' ' 43' ' ' ARG . 60.4 tt0 -106.69 120.26 41.52 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.343 -1.092 . . . . 0.0 109.651 -179.952 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 177' ' ' LEU . . . . . 0.437 ' O ' ' C ' ' A' ' 178' ' ' SER . 30.3 tp -61.9 -39.34 91.66 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.138 -0.976 . . . . 0.0 109.153 179.454 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 178' ' ' SER . . . . . 0.437 ' C ' ' O ' ' A' ' 177' ' ' LEU . 5.6 p . . . . . 0 N--CA 1.492 1.673 0 CA-C-O 118.046 -0.978 . . . . 0.0 109.806 179.898 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 6.8 m-20 . . . . . 0 N--CA 1.488 1.47 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -65.75 133.77 35.25 Favored 'Trans proline' 0 C--N 1.309 -1.55 0 C-N-CA 122.448 2.099 . . . . 0.0 112.24 -179.695 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 97.4 mtt180 -131.57 129.74 41.34 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.411 -0.805 . . . . 0.0 108.879 179.203 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.5 p -135.88 142.26 39.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.366 -0.834 . . . . 0.0 109.363 -179.822 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 45.1 p90 -142.31 153.4 43.85 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.418 -0.801 . . . . 0.0 109.573 -179.812 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -121.37 134.88 55.13 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.385 -0.822 . . . . 0.0 109.318 179.54 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -90.6 114.75 27.07 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.182 -0.949 . . . . 0.0 108.945 179.485 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' MET . . . . . 0.405 ' SD ' ' CD1' ' A' ' 26' ' ' ILE . 85.1 mtp -102.56 152.19 21.45 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.311 -0.868 . . . . 0.0 110.452 -179.404 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 96.5 p -143.15 163.15 33.68 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.781 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.53 ' O ' ' N ' ' A' ' 20' ' ' GLY . 29.4 m -123.43 139.8 48.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 121.07 -1.019 . . . . 0.0 109.501 -179.953 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 47.01 13.96 0.11 Allowed Glycine 0 N--CA 1.492 2.406 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 179.928 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.53 ' N ' ' O ' ' A' ' 18' ' ' VAL . . . 98.78 -16.3 59.76 Favored Glycine 0 N--CA 1.493 2.447 0 N-CA-C 109.616 -1.393 . . . . 0.0 109.616 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' GLN . . . . . 0.492 ' N ' ' O ' ' A' ' 18' ' ' VAL . 64.5 mm-40 -81.69 146.12 55.89 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.169 -1.195 . . . . 0.0 109.216 179.812 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_endo -63.48 138.89 67.7 Favored 'Trans proline' 0 N--CA 1.494 1.528 0 C-N-CA 122.366 2.044 . . . . 0.0 112.174 -179.736 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -112.6 -66.2 1.11 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.319 -0.863 . . . . 0.0 109.452 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -175.81 -169.97 38.06 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.315 -1.514 . . . . 0.0 109.315 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 71.3 mtp180 -114.95 144.03 44.22 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.226 -1.161 . . . . 0.0 109.587 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.405 ' CD1' ' SD ' ' A' ' 16' ' ' MET . 84.0 mt -120.72 116.07 48.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 N-CA-C 108.44 -0.948 . . . . 0.0 108.44 178.579 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 37.8 t -112.12 133.91 56.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.439 -0.788 . . . . 0.0 109.218 -179.537 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 76.5 mtm -119.53 155.25 32.51 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.454 -0.779 . . . . 0.0 109.532 -179.577 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.417 ' C ' HD22 ' A' ' 30' ' ' LEU . 84.7 tt0 -100.31 133.02 45.35 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.369 -0.832 . . . . 0.0 109.939 -179.601 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.417 HD22 ' C ' ' A' ' 29' ' ' GLU . 3.1 mm? -110.39 134.65 52.11 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.506 -0.746 . . . . 0.0 109.155 179.619 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 84.1 m-85 -95.1 122.84 38.18 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.2 -0.938 . . . . 0.0 108.999 179.388 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -92.9 -41.81 9.84 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.348 -0.845 . . . . 0.0 109.606 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 87.2 m-20 -69.62 -44.45 70.65 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.327 -0.858 . . . . 0.0 110.659 -179.338 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' THR . . . . . 0.439 ' O ' ' OE1' ' A' ' 99' ' ' GLU . 35.2 m -67.84 -46.82 70.69 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.16 -0.962 . . . . 0.0 110.526 -178.924 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.413 ' OG1' ' OG1' ' A' ' 38' ' ' THR . 0.0 OUTLIER -152.63 83.62 4.82 Favored Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.147 -0.971 . . . . 0.0 109.486 -179.447 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -71.92 -33.19 10.22 Favored 'Trans proline' 0 C--N 1.308 -1.593 0 C-N-CA 122.146 1.897 . . . . 0.0 112.12 -179.63 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 35.2 mmt180 -63.35 -40.28 96.85 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.326 -0.858 . . . . 0.0 109.491 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.413 ' OG1' ' OG1' ' A' ' 35' ' ' THR . 36.5 m -64.87 -41.17 95.88 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.274 -0.891 . . . . 0.0 109.929 -179.806 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -62.43 -30.77 71.46 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.286 -0.884 . . . . 0.0 109.282 179.973 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -67.11 -36.91 82.94 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.293 -0.879 . . . . 0.0 109.864 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' ASN . . . . . 0.437 ' O ' HD23 ' A' ' 45' ' ' LEU . 87.5 m-20 -57.95 -39.76 78.88 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.263 -0.898 . . . . 0.0 110.062 -179.498 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -90.42 -48.13 7.3 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.072 -1.017 . . . . 0.0 109.665 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 51.3 ttp180 -57.65 -40.71 79.9 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.48 -0.762 . . . . 0.0 110.508 -179.361 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.446 ' O ' ' N ' ' A' ' 48' ' ' GLY . . . -66.05 -46.8 76.51 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.976 -1.077 . . . . 0.0 110.425 -179.095 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.606 HD13 ' O ' ' A' ' 59' ' ' LEU . 3.6 mm? -64.98 -39.97 94.27 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 120.956 -1.09 . . . . 0.0 109.618 -179.809 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 46' ' ' CYS . . . . . . . . . . . . . 34.8 m -70.06 -47.85 60.26 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.084 -1.01 . . . . 0.0 109.347 179.769 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 74.8 p -72.55 -34.62 67.65 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.36 -0.837 . . . . 0.0 109.555 179.742 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 48' ' ' GLY . . . . . 0.446 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 73.61 31.88 60.13 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.978 -1.249 . . . . 0.0 109.978 179.646 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 78.0 mm-40 -62.03 -38.03 87.16 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.029 -1.277 . . . . 0.0 109.534 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 31.4 mmtp -62.18 -35.86 80.11 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.282 -0.886 . . . . 0.0 109.674 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 89.51 167.9 42.97 Favored Glycine 0 N--CA 1.488 2.154 0 N-CA-C 109.074 -1.611 . . . . 0.0 109.074 -179.653 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.566 HG23 ' HA ' ' A' ' 58' ' ' PRO . 85.2 m -75.1 138.73 42.28 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.119 -1.224 . . . . 0.0 109.559 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -59.5 137.18 50.11 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.393 -1.483 . . . . 0.0 109.393 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 83.5 mtm-85 -59.35 -36.09 75.08 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.19 -1.182 . . . . 0.0 109.846 -179.748 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 85.9 p -63.38 -24.26 67.77 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.113 -0.992 . . . . 0.0 109.779 -179.841 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 115.87 96.35 2.02 Favored Glycine 0 N--CA 1.494 2.524 0 N-CA-C 109.078 -1.609 . . . . 0.0 109.078 -179.572 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' LYS . . . . . 0.484 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 75.8 tttt -179.5 81.47 0.2 Allowed Pre-proline 0 N--CA 1.489 1.518 0 N-CA-C 108.377 -0.971 . . . . 0.0 108.377 -179.664 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.566 ' HA ' HG23 ' A' ' 52' ' ' THR . 75.9 Cg_exo -50.31 130.12 27.89 Favored 'Trans proline' 0 C--N 1.303 -1.828 0 C-N-CA 122.769 2.313 . . . . 0.0 112.597 -179.014 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.606 ' O ' HD13 ' A' ' 45' ' ' LEU . 9.0 mp -100.04 23.49 9.82 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.641 -0.662 . . . . 0.0 109.436 -179.833 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 60' ' ' HIS . . . . . 0.51 ' O ' ' CE1' ' A' ' 80' ' ' PHE . 93.2 m-70 -101.66 135.32 43.38 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.227 -0.92 . . . . 0.0 109.628 -179.804 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 61' ' ' TYR . . . . . 0.509 ' CE1' HD12 ' A' ' 45' ' ' LEU . 2.7 m-85 -94.95 12.67 27.55 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.293 -0.879 . . . . 0.0 108.98 179.575 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 62' ' ' LYS . . . . . 0.463 ' O ' ' CB ' ' A' ' 63' ' ' ASP . 62.1 tttt -62.73 142.82 57.97 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.416 -0.803 . . . . 0.0 109.674 -179.832 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 63' ' ' ASP . . . . . 0.463 ' CB ' ' O ' ' A' ' 62' ' ' LYS . 21.4 t0 74.76 33.72 0.77 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.581 -0.7 . . . . 0.0 109.736 179.859 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.788 ' H ' ' CG2' ' A' ' 171' ' ' VAL . 52.6 p -76.66 165.31 24.93 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.225 -0.922 . . . . 0.0 109.005 179.34 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 29.7 t -140.9 149.77 42.33 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.085 -1.01 . . . . 0.0 109.814 -179.783 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 58.3 m-85 -90.93 127.22 36.31 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.296 -0.878 . . . . 0.0 109.209 179.552 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 55.4 t-80 -94.85 -30.74 14.04 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.258 -0.901 . . . . 0.0 110.499 -179.27 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 83.0 mtp180 -126.26 140.87 52.19 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.057 -1.027 . . . . 0.0 110.341 -179.38 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.711 HG21 HG22 ' A' ' 165' ' ' THR . 15.8 m -151.57 49.05 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 179.424 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 19.4 mt -77.56 133.78 66.67 Favored Pre-proline 0 C--N 1.301 -1.507 0 O-C-N 121.361 -0.837 . . . . 0.0 110.156 -178.612 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -68.89 147.89 69.42 Favored 'Trans proline' 0 N--CA 1.492 1.421 0 C-N-CA 122.4 2.067 . . . . 0.0 112.266 179.852 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 80.42 -55.75 4.66 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.849 -1.3 . . . . 0.0 109.849 179.642 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 88.4 m-85 -68.36 -87.27 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.27 -1.135 . . . . 0.0 109.67 -179.75 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 11.3 ptt? -179.59 -175.16 0.32 Allowed 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.141 -0.975 . . . . 0.0 109.667 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 58.2 m -126.92 136.74 52.72 Favored 'General case' 0 N--CA 1.493 1.702 0 N-CA-C 108.763 -0.829 . . . . 0.0 108.763 179.608 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 63.2 tt0 -96.9 134.88 39.65 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.226 -0.921 . . . . 0.0 109.695 -179.527 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -139.75 176.19 21.33 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.06 -1.616 . . . . 0.0 109.06 179.769 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 77.14 36.84 34.03 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.235 -1.546 . . . . 0.0 109.235 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -83.72 13.97 4.29 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.321 -1.105 . . . . 0.0 109.413 -179.826 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.51 ' CE1' ' O ' ' A' ' 60' ' ' HIS . 81.0 t80 -51.67 -45.26 63.37 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.293 -0.88 . . . . 0.0 109.803 -179.874 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.657 ' O ' ' HB2' ' A' ' 82' ' ' ALA . 58.9 p -70.51 -28.17 64.75 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.1 -1.0 . . . . 0.0 109.506 179.857 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 82' ' ' ALA . . . . . 0.657 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 165.3 -56.9 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.342 -0.849 . . . . 0.0 109.238 179.898 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 93.39 -1.42 69.52 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 40.7 p-10 -90.02 5.95 44.39 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.126 -1.22 . . . . 0.0 109.473 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 96.44 -33.53 5.59 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.98 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 51.7 p -72.58 -22.26 61.01 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.14 -1.212 . . . . 0.0 109.217 179.76 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -84.97 -161.64 34.29 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 179.915 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.634 ' H ' ' CB ' ' A' ' 81' ' ' THR . . . 90.95 26.87 20.85 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 -179.869 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 89' ' ' GLU . . . . . 0.429 ' OE1' ' NZ ' ' A' ' 57' ' ' LYS . 96.0 mt-10 -57.1 145.52 30.69 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.375 -1.073 . . . . 0.0 109.577 -179.799 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 29.3 t -106.15 143.55 34.11 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.323 -0.861 . . . . 0.0 109.328 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 20.4 pt -64.58 -33.44 63.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.332 -0.855 . . . . 0.0 109.828 -179.722 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 73.5 m-85 -65.53 -38.12 88.72 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.23 -0.919 . . . . 0.0 109.604 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 81.64 14.5 77.89 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.449 -1.461 . . . . 0.0 109.449 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -146.46 155.77 42.79 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.14 -1.211 . . . . 0.0 109.655 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 97.1 mttt -94.07 142.24 27.62 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.291 -0.88 . . . . 0.0 109.549 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 99.4 m-85 -120.63 150.16 41.34 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.415 -0.803 . . . . 0.0 109.589 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -70.8 154.51 41.77 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.385 -0.822 . . . . 0.0 109.569 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 88.4 m-20 -59.48 147.66 35.85 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.251 -0.906 . . . . 0.0 109.341 179.901 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 99' ' ' GLU . . . . . 0.439 ' OE1' ' O ' ' A' ' 34' ' ' THR . 96.2 mt-10 -80.4 -89.35 0.06 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.145 -0.972 . . . . 0.0 110.008 -179.583 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 85.3 m-20 -124.86 145.91 49.55 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.301 -0.875 . . . . 0.0 110.049 -179.473 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -100.74 10.83 40.65 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.439 -0.788 . . . . 0.0 109.294 179.589 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 96.2 mt -53.49 -36.46 27.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.303 -0.873 . . . . 0.0 110.134 -179.391 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 9.2 mtpm? -80.45 136.12 36.27 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.98 -1.075 . . . . 0.0 109.633 -179.789 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 69.1 tttt -135.15 159.37 41.76 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.449 -0.782 . . . . 0.0 109.331 -179.705 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 105' ' ' HIS . . . . . 0.409 ' CE1' HG22 ' A' ' 141' ' ' VAL . 92.9 m-70 -74.19 106.55 5.9 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.092 -1.005 . . . . 0.0 109.477 179.865 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 62.3 p -96.03 -9.97 29.65 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.343 -0.848 . . . . 0.0 109.691 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -165.18 -179.03 38.83 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.76 -1.336 . . . . 0.0 109.76 -179.805 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -78.76 160.28 27.82 Favored 'Trans proline' 0 C--N 1.306 -1.677 0 C-N-CA 123.178 2.585 . . . . 0.0 112.23 179.791 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 82.17 40.9 9.78 Favored Glycine 0 N--CA 1.492 2.395 0 N-CA-C 109.995 -1.242 . . . . 0.0 109.995 179.715 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 33.7 mm -113.66 139.21 40.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.357 -1.084 . . . . 0.0 109.209 179.923 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.669 ' N ' HD22 ' A' ' 111' ' ' LEU . 3.4 mm? -86.88 136.18 33.05 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.156 -0.965 . . . . 0.0 109.737 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 30.8 t -144.69 143.41 30.71 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.348 -0.845 . . . . 0.0 109.098 179.47 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 113' ' ' MET . . . . . 0.404 ' H ' ' HG2' ' A' ' 113' ' ' MET . 15.1 ptm -87.4 126.06 34.64 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.231 -0.918 . . . . 0.0 109.532 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -66.27 147.77 52.83 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.263 -0.898 . . . . 0.0 109.715 -179.74 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 115' ' ' ASN . . . . . 0.525 ' N ' ' OD1' ' A' ' 115' ' ' ASN . 8.0 p-10 -157.76 115.56 3.05 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.272 -0.893 . . . . 0.0 109.169 179.634 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -65.46 -30.72 71.54 Favored 'General case' 0 C--N 1.299 -1.63 0 O-C-N 121.406 -0.809 . . . . 0.0 109.8 -179.761 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -135.57 166.09 24.61 Favored Glycine 0 N--CA 1.494 2.519 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -67.38 156.74 64.91 Favored 'Trans proline' 0 C--N 1.306 -1.659 0 C-N-CA 122.867 2.378 . . . . 0.0 111.816 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 75.8 m-20 54.33 45.4 27.3 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.411 -0.805 . . . . 0.0 109.232 -179.895 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 61.5 m -131.85 127.99 37.73 Favored 'General case' 0 C--N 1.305 -1.349 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 179.916 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 20.1 m120 -102.01 137.03 40.84 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.493 -0.755 . . . . 0.0 109.486 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -145.32 125.78 2.42 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 179.91 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 23.1 t -59.02 -30.86 68.32 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.374 -1.074 . . . . 0.0 109.482 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.6 mt-30 -63.22 143.2 58.0 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.194 -0.941 . . . . 0.0 109.537 -179.675 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 45.6 p90 -141.35 164.93 28.91 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.453 -0.78 . . . . 0.0 109.178 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 48.0 p90 -131.47 157.48 43.39 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.231 -0.918 . . . . 0.0 109.517 179.854 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 71.3 mt -120.25 136.36 57.55 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.492 -0.755 . . . . 0.0 109.593 -179.73 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 11.0 t -116.26 123.56 48.01 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.287 -0.883 . . . . 0.0 108.978 179.581 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 37.6 p -95.51 5.5 51.38 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.275 -0.891 . . . . 0.0 109.86 -179.446 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -148.44 155.58 41.39 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.142 -0.974 . . . . 0.0 109.725 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 34.7 ttmt -73.51 135.42 44.02 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.316 -0.865 . . . . 0.0 109.309 179.838 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 132' ' ' THR . . . . . 0.462 ' O ' ' OD2' ' A' ' 136' ' ' ASP . 16.9 p -120.87 159.33 25.74 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.447 -0.783 . . . . 0.0 109.431 -179.808 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 133' ' ' GLU . . . . . 0.436 ' O ' ' OD1' ' A' ' 136' ' ' ASP . 96.2 mt-10 -97.93 -48.24 5.24 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.286 -0.884 . . . . 0.0 110.011 -179.906 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 134' ' ' TRP . . . . . 0.602 ' CD1' ' N ' ' A' ' 135' ' ' LEU . 40.9 p90 -92.16 -44.06 9.0 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.199 -0.938 . . . . 0.0 110.174 -179.477 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 135' ' ' LEU . . . . . 0.602 ' N ' ' CD1' ' A' ' 134' ' ' TRP . 34.2 tp -61.66 -29.63 70.2 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.268 -0.895 . . . . 0.0 109.184 -179.646 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 136' ' ' ASP . . . . . 0.485 ' C ' ' OD1' ' A' ' 136' ' ' ASP . 53.4 p30 -70.14 9.06 0.63 Allowed 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.447 -0.783 . . . . 0.0 109.513 -179.747 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 137' ' ' GLY . . . . . 0.459 ' H ' ' C ' ' A' ' 135' ' ' LEU . . . -52.02 -30.31 30.13 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.618 -1.393 . . . . 0.0 109.618 -179.904 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 138' ' ' LYS . . . . . 0.44 ' CE ' ' OD1' ' A' ' 115' ' ' ASN . 46.4 mmtm -77.56 123.18 26.27 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.098 -1.236 . . . . 0.0 109.168 -179.879 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 71.1 m80 -110.61 15.66 21.91 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.398 -0.814 . . . . 0.0 109.754 -179.641 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 45.0 t -100.08 129.8 50.21 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.13 -0.981 . . . . 0.0 109.88 -179.536 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 141' ' ' VAL . . . . . 0.409 HG22 ' CE1' ' A' ' 105' ' ' HIS . 84.2 t -130.58 129.83 64.55 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 N-CA-C 109.021 -0.733 . . . . 0.0 109.021 179.651 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 39.5 p90 -110.72 -0.4 17.09 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.074 -1.016 . . . . 0.0 110.052 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -175.43 173.52 46.28 Favored Glycine 0 N--CA 1.493 2.495 0 N-CA-C 109.804 -1.319 . . . . 0.0 109.804 179.443 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 94.0 mt-30 -139.36 165.91 25.95 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.29 -1.123 . . . . 0.0 109.584 -179.83 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 55.1 t -95.56 129.54 45.53 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.222 0 O-C-N 121.175 -0.953 . . . . 0.0 109.162 179.816 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 17.3 m -106.73 -33.65 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.314 -0.866 . . . . 0.0 109.455 179.736 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -143.06 170.78 15.07 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.333 -0.855 . . . . 0.0 109.525 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 98.53 2.39 57.61 Favored Glycine 0 N--CA 1.494 2.558 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.74 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 149' ' ' MET . . . . . 0.511 ' O ' HG12 ' A' ' 152' ' ' VAL . 50.6 ttm -61.02 -32.85 72.44 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.063 -1.257 . . . . 0.0 109.667 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -65.33 -42.29 93.08 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.883 -1.135 . . . . 0.0 110.06 -179.596 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.6 p -81.84 -32.92 11.59 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.141 -0.974 . . . . 0.0 110.611 -179.232 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 152' ' ' VAL . . . . . 0.511 HG12 ' O ' ' A' ' 149' ' ' MET . 0.9 OUTLIER -53.76 -41.0 45.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 120.976 -1.077 . . . . 0.0 109.152 -179.285 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 153' ' ' LYS . . . . . 0.441 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 87.2 mttt -64.03 -34.62 78.42 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.122 -0.986 . . . . 0.0 109.188 179.169 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -62.08 -35.06 77.52 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.381 -0.824 . . . . 0.0 109.687 -179.798 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.404 HD11 ' SD ' ' A' ' 16' ' ' MET . 95.7 mt -70.79 -36.01 62.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.277 -0.889 . . . . 0.0 109.832 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 85.1 tt0 -75.24 -41.89 56.5 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.266 -0.896 . . . . 0.0 111.419 -178.755 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 55.4 pttt -61.27 -34.46 75.21 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.665 -1.272 . . . . 0.0 109.689 -179.047 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 32.6 m -82.82 -6.62 10.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.146 -0.971 . . . . 0.0 108.926 179.427 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -77.67 176.48 53.68 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 109.797 -1.321 . . . . 0.0 109.797 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 86.9 p -157.48 169.54 24.46 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.431 -1.041 . . . . 0.0 109.706 -179.58 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 22.8 t -57.1 -32.69 66.55 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.281 -0.887 . . . . 0.0 108.647 179.256 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 86.2 p -61.38 -27.25 68.39 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.329 -0.857 . . . . 0.0 109.096 179.654 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 93.24 18.04 40.79 Favored Glycine 0 N--CA 1.493 2.488 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 179.756 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 88.7 mtt180 -115.94 143.06 45.96 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.219 -1.165 . . . . 0.0 109.226 179.825 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 165' ' ' THR . . . . . 0.711 HG22 HG21 ' A' ' 69' ' ' VAL . 81.7 p -81.98 150.06 27.85 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.208 -0.933 . . . . 0.0 109.675 -179.894 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -68.96 -36.77 78.3 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.325 -0.859 . . . . 0.0 109.333 179.8 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -111.58 157.84 19.92 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.5 -0.75 . . . . 0.0 109.435 -179.914 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 92.1 mttt -73.02 135.84 44.96 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.309 -0.869 . . . . 0.0 109.175 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 3.4 m -130.94 123.02 53.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.725 0 O-C-N 121.365 -0.834 . . . . 0.0 109.772 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 39.0 t -143.21 138.0 26.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.386 -0.821 . . . . 0.0 108.804 179.557 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.788 ' CG2' ' H ' ' A' ' 64' ' ' SER . 3.0 m -67.7 119.56 13.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 120.826 -1.171 . . . . 0.0 109.547 -179.737 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -68.52 -35.57 77.66 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.233 -0.917 . . . . 0.0 110.086 -179.836 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -156.34 158.32 37.21 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.202 -0.936 . . . . 0.0 110.047 -179.6 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 19.0 p -147.06 148.58 31.79 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.435 -0.79 . . . . 0.0 109.16 179.688 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -177.93 179.72 48.29 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.704 -1.359 . . . . 0.0 109.704 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 61.3 tt0 -106.03 117.25 33.55 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.392 -1.064 . . . . 0.0 109.667 -179.896 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 31.3 tp -62.86 -38.8 92.29 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.094 -1.004 . . . . 0.0 109.216 179.589 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 2.6 p . . . . . 0 N--CA 1.492 1.651 0 CA-C-O 117.897 -1.049 . . . . 0.0 109.707 179.997 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 12.0 m120 . . . . . 0 N--CA 1.492 1.656 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -68.21 138.08 42.2 Favored 'Trans proline' 0 N--CA 1.496 1.648 0 C-N-CA 122.595 2.197 . . . . 0.0 112.272 179.891 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 95.5 mtt180 -128.72 132.27 47.97 Favored 'General case' 0 N--CA 1.492 1.657 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 179.114 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.5 p -133.24 142.3 42.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.363 -0.836 . . . . 0.0 109.607 -179.564 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 47.1 p90 -140.91 155.26 46.32 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.411 -0.806 . . . . 0.0 109.519 -179.838 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 69.8 m-85 -121.86 135.51 54.9 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.455 -0.778 . . . . 0.0 109.643 179.773 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.0 t0 -88.28 118.83 28.15 Favored 'General case' 0 N--CA 1.493 1.703 0 N-CA-C 108.307 -0.998 . . . . 0.0 108.307 178.864 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 75.2 mtp -116.32 142.86 46.28 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.263 -0.898 . . . . 0.0 110.742 -178.822 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.433 ' OG ' ' OE2' ' A' ' 172' ' ' GLU . 31.6 m -136.4 155.88 49.41 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 179.368 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 33.3 m -119.14 133.69 65.17 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.085 -1.009 . . . . 0.0 109.638 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 57.86 15.57 20.59 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.689 -1.365 . . . . 0.0 109.689 179.844 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 92.08 2.38 68.87 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.386 -1.486 . . . . 0.0 109.386 -179.804 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 41.5 tt0 -105.02 115.15 62.88 Favored Pre-proline 0 N--CA 1.492 1.658 0 O-C-N 121.437 -1.037 . . . . 0.0 109.112 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 77.4 Cg_exo -47.33 133.65 19.91 Favored 'Trans proline' 0 N--CA 1.492 1.412 0 C-N-CA 122.088 1.859 . . . . 0.0 112.106 -179.949 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -101.25 -57.67 2.04 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.292 -0.88 . . . . 0.0 109.568 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -178.02 -169.08 38.46 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.401 -1.48 . . . . 0.0 109.401 -179.775 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 50.9 mtp180 -113.22 144.22 43.07 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.415 -1.05 . . . . 0.0 109.383 179.849 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 76.3 mt -117.85 114.56 45.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 N-CA-C 108.183 -1.043 . . . . 0.0 108.183 178.757 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 38.3 t -109.58 135.21 49.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.437 -0.79 . . . . 0.0 109.628 -179.219 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 75.8 mtm -128.41 156.86 42.49 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.514 -0.741 . . . . 0.0 109.225 -179.588 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -103.83 133.93 48.0 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.283 -0.886 . . . . 0.0 109.706 179.882 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -105.37 128.97 53.78 Favored 'General case' 0 N--CA 1.492 1.638 0 N-CA-C 108.752 -0.832 . . . . 0.0 108.752 179.365 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.401 ' CG ' ' NZ ' ' A' ' 103' ' ' LYS . 94.9 m-85 -92.97 119.41 32.21 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.085 -1.009 . . . . 0.0 109.141 179.981 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -86.33 -42.6 13.57 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.346 -0.846 . . . . 0.0 109.535 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.3 m-20 -65.1 -47.49 76.99 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.368 -0.833 . . . . 0.0 110.298 -179.433 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 37.4 m -67.62 -44.63 77.56 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.211 -0.931 . . . . 0.0 109.775 -179.777 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 5.7 p -138.15 76.98 37.56 Favored Pre-proline 0 N--CA 1.492 1.658 0 N-CA-C 109.082 -0.71 . . . . 0.0 109.082 -179.912 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 10.7 Cg_endo -59.33 -63.31 0.13 Allowed 'Trans proline' 0 C--N 1.31 -1.489 0 C-N-CA 122.571 2.181 . . . . 0.0 112.801 -179.154 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 86.8 mtt-85 -61.24 -35.19 76.58 Favored 'General case' 0 C--N 1.297 -1.688 0 O-C-N 121.652 -0.655 . . . . 0.0 110.755 -178.77 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 25.3 m -60.27 -42.13 94.76 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 120.984 -1.073 . . . . 0.0 110.094 -179.418 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -59.95 -31.82 70.23 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.128 -0.983 . . . . 0.0 109.153 -179.794 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -67.7 -36.88 81.47 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.401 -0.812 . . . . 0.0 109.915 -179.9 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 37.8 t30 -56.6 -40.81 75.92 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.261 -0.899 . . . . 0.0 109.823 -179.458 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 98.4 m-85 -90.43 -48.6 7.01 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.069 -1.019 . . . . 0.0 109.828 -179.89 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.893 ' HE ' HE22 ' A' ' 176' ' ' GLN . 66.2 ttt-85 -57.41 -41.32 80.14 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.512 -0.742 . . . . 0.0 110.505 -179.375 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -65.55 -47.6 75.3 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.049 -1.032 . . . . 0.0 110.373 -178.916 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.469 ' N ' ' CD2' ' A' ' 45' ' ' LEU . 3.3 mm? -65.51 -39.87 92.36 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.124 -0.985 . . . . 0.0 109.665 -179.735 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 46' ' ' CYS . . . . . . . . . . . . . 72.3 m -68.24 -46.09 71.44 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.1 -1.0 . . . . 0.0 109.315 179.819 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 72.6 p -74.34 -33.53 63.16 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.313 -0.867 . . . . 0.0 109.721 179.877 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 75.03 30.81 58.6 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 110.037 -1.225 . . . . 0.0 110.037 179.739 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 77.9 mm-40 -61.97 -36.67 82.16 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.137 -1.214 . . . . 0.0 109.441 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 42.0 mmtm -60.66 -33.87 73.45 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.233 -0.917 . . . . 0.0 109.402 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 92.84 171.3 40.45 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.096 -1.602 . . . . 0.0 109.096 -179.692 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.636 HG23 ' HA ' ' A' ' 58' ' ' PRO . 99.2 m -75.88 141.39 42.38 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.317 -1.108 . . . . 0.0 109.76 -179.807 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -60.42 138.15 48.62 Favored Glycine 0 N--CA 1.488 2.164 0 N-CA-C 109.405 -1.478 . . . . 0.0 109.405 179.787 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 87.1 mtt-85 -60.24 -29.22 68.62 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.303 -1.116 . . . . 0.0 110.231 -179.803 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 75.4 m -78.52 11.0 2.7 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.181 -0.95 . . . . 0.0 110.32 -179.154 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 82.16 77.03 1.07 Allowed Glycine 0 N--CA 1.492 2.4 0 N-CA-C 109.217 -1.553 . . . . 0.0 109.217 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' LYS . . . . . 0.478 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 55.0 mttp -157.47 75.0 4.16 Favored Pre-proline 0 C--N 1.302 -1.463 0 O-C-N 121.449 -1.03 . . . . 0.0 108.3 -179.944 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.636 ' HA ' HG23 ' A' ' 52' ' ' THR . 73.1 Cg_exo -50.04 130.28 27.32 Favored 'Trans proline' 0 C--N 1.302 -1.909 0 C-N-CA 122.962 2.441 . . . . 0.0 112.517 -179.085 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.478 ' CD1' ' O ' ' A' ' 57' ' ' LYS . 8.6 mp -100.8 74.22 1.63 Allowed 'General case' 0 N--CA 1.489 1.524 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 -179.638 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 77.5 m80 -139.21 150.68 45.82 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.436 -0.79 . . . . 0.0 109.516 179.865 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 3.8 m-85 -101.95 20.48 16.41 Favored 'General case' 0 N--CA 1.493 1.691 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 179.573 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 85.0 mttt -77.57 157.55 30.26 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.434 -0.791 . . . . 0.0 109.525 -179.663 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 54.8 t0 56.89 48.9 15.04 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.486 -0.759 . . . . 0.0 109.805 179.788 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 87.4 p -111.71 154.25 25.26 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.4 -0.813 . . . . 0.0 109.077 179.69 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 27.8 t -131.03 149.3 52.68 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.227 -0.921 . . . . 0.0 109.74 -179.603 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -72.68 135.84 45.49 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.351 -0.843 . . . . 0.0 109.131 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 32.1 m-70 -77.84 -53.01 7.98 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.259 -0.901 . . . . 0.0 110.71 -179.219 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 98.1 mtt180 -130.27 148.96 52.16 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.043 -1.035 . . . . 0.0 110.541 -179.017 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.694 HG21 HG22 ' A' ' 165' ' ' THR . 8.5 m -143.67 59.6 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.585 -0.697 . . . . 0.0 109.135 179.497 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 18.6 mt -82.14 132.67 52.73 Favored Pre-proline 0 C--N 1.301 -1.543 0 O-C-N 121.164 -0.96 . . . . 0.0 109.771 -179.135 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -70.98 149.67 59.49 Favored 'Trans proline' 0 N--CA 1.492 1.437 0 C-N-CA 122.399 2.066 . . . . 0.0 112.113 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 81.33 -58.28 4.86 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 179.879 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -70.01 -84.83 0.03 OUTLIER 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.269 -1.136 . . . . 0.0 109.637 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 74' ' ' MET . . . . . 0.484 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 14.1 ptt? 178.03 -172.83 0.13 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.334 -0.854 . . . . 0.0 109.544 179.877 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 14.6 p -125.75 137.26 53.8 Favored 'General case' 0 N--CA 1.493 1.721 0 N-CA-C 108.595 -0.891 . . . . 0.0 108.595 179.45 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 93.1 mt-30 -111.53 153.99 25.44 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.167 -0.958 . . . . 0.0 109.771 -179.485 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -134.76 174.43 21.07 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.006 -1.638 . . . . 0.0 109.006 179.7 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -137.24 161.03 25.19 Favored Glycine 0 N--CA 1.493 2.477 0 N-CA-C 109.717 -1.353 . . . . 0.0 109.717 -179.88 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 90.3 m-20 -72.89 156.81 38.49 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.379 -1.071 . . . . 0.0 109.457 179.865 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.411 ' CE2' ' O ' ' A' ' 58' ' ' PRO . 50.7 p90 -61.97 -18.49 60.58 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.327 -0.858 . . . . 0.0 109.744 -179.666 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.583 ' OG1' ' N ' ' A' ' 88' ' ' GLY . 73.1 p -61.71 -34.39 75.69 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.046 -1.034 . . . . 0.0 109.534 -179.902 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 82' ' ' ALA . . . . . 0.559 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 172.24 -50.46 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.329 -0.857 . . . . 0.0 109.434 179.942 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 92.45 3.14 67.2 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 80.3 m-20 -86.9 5.91 34.6 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.218 -1.166 . . . . 0.0 109.306 179.975 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 95.13 -42.61 2.34 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 -179.804 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 47.8 m -61.23 -38.91 88.33 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.207 -1.172 . . . . 0.0 109.114 179.601 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -85.35 -166.46 41.92 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.583 ' N ' ' OG1' ' A' ' 81' ' ' THR . . . 83.52 43.69 7.25 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 -179.897 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -64.05 144.14 57.33 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.266 -1.138 . . . . 0.0 109.478 -179.848 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 29.3 t -102.91 142.12 34.55 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.34 -0.85 . . . . 0.0 109.369 -179.884 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.406 HG12 ' H ' ' A' ' 91' ' ' ILE . 6.4 pt -63.26 -42.68 97.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.339 -0.851 . . . . 0.0 109.915 -179.737 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 3.8 m-30 -69.85 -36.19 75.35 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.976 -1.077 . . . . 0.0 109.558 179.871 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 80.81 14.85 78.95 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.224 -1.55 . . . . 0.0 109.224 -179.728 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -145.3 158.11 43.9 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.372 -1.075 . . . . 0.0 109.451 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -86.43 154.46 21.14 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.182 -0.949 . . . . 0.0 109.56 -179.881 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 96' ' ' PHE . . . . . 0.401 ' H ' ' HB2' ' A' ' 121' ' ' ASN . 89.0 m-85 -100.23 130.64 46.38 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.281 -0.887 . . . . 0.0 109.305 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -76.62 138.75 40.29 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.159 -0.963 . . . . 0.0 109.496 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 98' ' ' ASP . . . . . 0.513 ' OD2' HG21 ' A' ' 140' ' ' VAL . 88.5 m-20 -75.54 131.25 39.92 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.267 -0.896 . . . . 0.0 109.266 179.836 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -104.28 -55.46 2.36 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.239 -0.913 . . . . 0.0 110.061 -179.797 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 84.9 m-20 -106.35 128.82 54.3 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.233 -0.917 . . . . 0.0 110.24 -179.149 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 90.2 m-85 -108.38 10.52 27.5 Favored 'General case' 0 N--CA 1.493 1.686 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 179.352 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 92.0 mt -54.9 -37.0 39.88 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.397 -0.814 . . . . 0.0 110.568 -178.974 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 103' ' ' LYS . . . . . 0.401 ' NZ ' ' CG ' ' A' ' 31' ' ' PHE . 87.2 mttt -77.2 127.99 33.59 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.871 -1.143 . . . . 0.0 109.909 -179.427 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 104' ' ' LYS . . . . . 0.593 ' O ' ' N ' ' A' ' 106' ' ' THR . 34.4 ttmt -139.08 149.96 45.18 Favored 'General case' 0 N--CA 1.492 1.636 0 N-CA-C 109.012 -0.736 . . . . 0.0 109.012 179.862 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 105' ' ' HIS . . . . . . . . . . . . . 85.5 m-70 -53.69 82.34 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.094 -1.004 . . . . 0.0 109.66 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 106' ' ' THR . . . . . 0.593 ' N ' ' O ' ' A' ' 104' ' ' LYS . 54.9 p -73.45 -28.0 61.72 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.235 -0.915 . . . . 0.0 109.525 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -150.21 -177.51 24.25 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.882 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 69.6 Cg_endo -76.14 156.33 37.96 Favored 'Trans proline' 0 C--N 1.306 -1.666 0 C-N-CA 123.025 2.483 . . . . 0.0 112.198 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 81.86 45.75 7.05 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 110.098 -1.201 . . . . 0.0 110.098 179.706 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 41.6 mm -115.98 136.91 51.39 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 121.287 -1.125 . . . . 0.0 109.459 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.543 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 2.4 mm? -87.54 128.28 35.25 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.199 -0.938 . . . . 0.0 109.263 179.716 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 87.7 p -143.16 150.84 39.96 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.332 -0.855 . . . . 0.0 109.547 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 113' ' ' MET . . . . . 0.458 ' CE ' ' OD1' ' A' ' 121' ' ' ASN . 86.5 mtp -95.35 139.47 31.6 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.343 -0.848 . . . . 0.0 109.329 179.621 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -64.38 145.35 56.2 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.237 -0.914 . . . . 0.0 109.54 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 115' ' ' ASN . . . . . 0.573 ' ND2' HG23 ' A' ' 140' ' ' VAL . 2.7 p30 -165.77 114.98 1.0 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.184 -0.948 . . . . 0.0 109.613 179.863 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -66.19 -31.31 72.06 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.383 -0.823 . . . . 0.0 109.356 179.721 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -136.84 169.81 23.72 Favored Glycine 0 N--CA 1.493 2.474 0 N-CA-C 109.351 -1.5 . . . . 0.0 109.351 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -65.84 157.67 57.82 Favored 'Trans proline' 0 C--N 1.305 -1.757 0 C-N-CA 122.819 2.346 . . . . 0.0 111.969 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 68.0 m-20 55.89 44.3 26.06 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.425 -0.797 . . . . 0.0 109.325 -179.857 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 61.2 m -135.96 127.83 29.37 Favored 'General case' 0 C--N 1.304 -1.383 0 N-CA-C 108.804 -0.814 . . . . 0.0 108.804 179.851 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 121' ' ' ASN . . . . . 0.458 ' OD1' ' CE ' ' A' ' 113' ' ' MET . 31.9 t30 -100.5 109.9 22.05 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.423 -0.798 . . . . 0.0 109.374 -179.954 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -85.8 135.33 13.29 Favored Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.644 -1.383 . . . . 0.0 109.644 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 85.3 p -65.1 -23.38 67.14 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.248 -1.148 . . . . 0.0 109.408 179.871 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.0 mt-30 -101.89 154.2 19.15 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.378 -0.826 . . . . 0.0 109.606 -179.728 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 49.3 p90 -133.6 160.95 35.96 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.471 -0.768 . . . . 0.0 109.461 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 126' ' ' PHE . . . . . 0.484 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 45.6 p90 -140.0 159.71 41.58 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.324 -0.86 . . . . 0.0 109.504 -179.91 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 72.5 mt -119.77 134.24 63.95 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.407 -0.808 . . . . 0.0 109.444 179.845 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 1.8 m -92.2 105.55 17.74 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.104 -0.998 . . . . 0.0 109.268 179.827 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 54.2 p -74.72 -9.12 58.26 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.271 -0.893 . . . . 0.0 109.463 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -150.44 156.15 40.91 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.362 -0.836 . . . . 0.0 109.277 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 82.5 tttt -68.01 135.16 51.88 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.216 -0.928 . . . . 0.0 109.23 179.855 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 6.5 p -122.11 158.0 30.24 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.409 -0.807 . . . . 0.0 109.558 -179.74 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -138.69 -35.66 0.58 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.317 -0.865 . . . . 0.0 109.081 179.812 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 0.7 OUTLIER -58.7 -29.43 66.64 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.447 -0.783 . . . . 0.0 109.219 179.713 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 18.2 mt -59.49 -35.77 74.77 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.32 -0.863 . . . . 0.0 109.628 179.638 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 57.5 t0 49.45 50.94 17.31 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.286 -0.884 . . . . 0.0 109.518 179.801 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -130.2 127.63 5.37 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.166 -1.574 . . . . 0.0 109.166 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 138' ' ' LYS . . . . . 0.515 ' O ' ' O ' ' A' ' 139' ' ' HIS . 88.2 mttt -56.58 -38.19 71.65 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.36 -1.083 . . . . 0.0 109.652 -179.846 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 139' ' ' HIS . . . . . 0.515 ' O ' ' O ' ' A' ' 138' ' ' LYS . 54.6 m170 56.86 147.88 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.644 -0.66 . . . . 0.0 109.824 179.936 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.573 HG23 ' ND2' ' A' ' 115' ' ' ASN . 41.0 t -116.05 133.6 62.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.413 -0.804 . . . . 0.0 109.296 -179.893 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 60.1 t -107.27 127.51 62.99 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 121.272 -0.893 . . . . 0.0 109.52 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 39.1 p90 -116.16 3.06 13.45 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.403 -0.81 . . . . 0.0 109.682 179.773 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -173.08 179.13 44.7 Favored Glycine 0 N--CA 1.494 2.528 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 179.612 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.3 pt20 -145.82 166.29 26.35 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.114 -1.227 . . . . 0.0 109.865 -179.855 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 74.6 t -100.63 132.11 46.92 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.122 0 O-C-N 121.278 -0.888 . . . . 0.0 109.581 -179.855 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 12.9 m -113.85 -31.52 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.308 -0.87 . . . . 0.0 109.422 179.563 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -139.62 167.25 22.52 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.356 -0.84 . . . . 0.0 109.469 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 97.67 4.0 58.18 Favored Glycine 0 N--CA 1.494 2.527 0 N-CA-C 109.941 -1.264 . . . . 0.0 109.941 179.765 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 149' ' ' MET . . . . . 0.436 ' O ' HG12 ' A' ' 152' ' ' VAL . 65.0 mtt -60.71 -33.44 72.89 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.098 -1.236 . . . . 0.0 109.479 179.934 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 89.3 m-20 -64.02 -41.64 97.38 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.913 -1.117 . . . . 0.0 109.852 -179.761 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.5 p -83.24 -34.37 10.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.199 -0.938 . . . . 0.0 110.402 -179.446 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 152' ' ' VAL . . . . . 0.464 ' CG1' ' N ' ' A' ' 153' ' ' LYS . 0.6 OUTLIER -57.02 -42.77 79.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 120.872 -1.142 . . . . 0.0 109.382 -179.219 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 153' ' ' LYS . . . . . 0.464 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 66.6 mttm -63.84 -34.41 77.87 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.242 -0.911 . . . . 0.0 109.517 179.503 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -61.48 -37.9 85.33 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.24 -0.913 . . . . 0.0 109.962 -179.492 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 88.3 mt -72.51 -35.14 50.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.189 -0.945 . . . . 0.0 110.047 -179.717 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -76.29 -41.64 48.04 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.202 -0.936 . . . . 0.0 111.191 -178.865 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 39.1 pttt -61.8 -33.92 74.98 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 120.852 -1.155 . . . . 0.0 109.89 -178.819 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.42 ' HB ' ' H ' ' A' ' 166' ' ' ALA . 35.3 m -77.8 -13.99 14.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.011 -1.056 . . . . 0.0 109.26 179.714 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -74.3 168.27 54.44 Favored Glycine 0 N--CA 1.489 2.2 0 N-CA-C 109.789 -1.324 . . . . 0.0 109.789 -179.718 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 22.8 t -157.67 176.36 12.71 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.418 -1.048 . . . . 0.0 109.361 -179.758 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 23.6 m -54.01 -31.78 52.16 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.282 -0.886 . . . . 0.0 109.182 179.817 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 23.9 m -55.56 -33.07 63.53 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.28 -0.888 . . . . 0.0 109.462 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 95.38 10.97 56.54 Favored Glycine 0 N--CA 1.493 2.482 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 179.828 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 81.7 mtm180 -121.44 146.57 46.76 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.303 -1.116 . . . . 0.0 109.474 179.874 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 165' ' ' THR . . . . . 0.694 HG22 HG21 ' A' ' 69' ' ' VAL . 80.5 p -80.49 151.42 29.24 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.224 -0.923 . . . . 0.0 109.646 -179.884 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 166' ' ' ALA . . . . . 0.42 ' H ' ' HB ' ' A' ' 158' ' ' VAL . . . -66.66 -37.06 84.02 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.322 -0.862 . . . . 0.0 109.077 179.592 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -108.71 158.69 17.39 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.555 -0.716 . . . . 0.0 109.096 179.721 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -71.4 130.78 42.2 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.14 -0.975 . . . . 0.0 109.394 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 43.6 t -122.15 124.24 70.67 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 121.38 -0.825 . . . . 0.0 109.435 179.795 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 48.8 t -149.1 154.61 9.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.48 -0.763 . . . . 0.0 109.141 179.865 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 2.1 t -90.15 124.87 43.0 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 O-C-N 121.258 -0.901 . . . . 0.0 109.932 -179.312 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 172' ' ' GLU . . . . . 0.433 ' OE2' ' OG ' ' A' ' 17' ' ' SER . 97.1 mt-10 -64.96 -28.87 69.81 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.449 -0.782 . . . . 0.0 109.192 179.46 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 173' ' ' ASP . . . . . 0.425 ' C ' ' OD1' ' A' ' 173' ' ' ASP . 53.1 p30 -175.14 179.58 1.53 Allowed 'General case' 0 N--CA 1.492 1.639 0 C-N-CA 119.449 -0.9 . . . . 0.0 110.352 -179.665 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 26.7 p -151.48 151.38 31.56 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.45 -0.781 . . . . 0.0 109.265 179.711 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -178.18 176.83 48.22 Favored Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.792 -1.323 . . . . 0.0 109.792 179.812 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 176' ' ' GLN . . . . . 0.893 HE22 ' HE ' ' A' ' 43' ' ' ARG . 59.3 tt0 -107.11 127.21 53.29 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.375 -1.073 . . . . 0.0 109.61 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 29.0 tp -60.98 -37.78 83.66 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.187 -0.945 . . . . 0.0 109.194 179.641 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 9.5 t . . . . . 0 N--CA 1.49 1.563 0 CA-C-O 117.945 -1.026 . . . . 0.0 109.483 -179.942 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 3.2 m-80 . . . . . 0 N--CA 1.489 1.485 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -70.65 140.24 38.9 Favored 'Trans proline' 0 N--CA 1.494 1.558 0 C-N-CA 122.777 2.318 . . . . 0.0 112.409 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 97.8 mtt180 -128.96 132.09 47.56 Favored 'General case' 0 N--CA 1.491 1.592 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 179.127 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.6 p -136.51 142.62 37.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.248 -0.907 . . . . 0.0 109.633 -179.441 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 38.5 p90 -144.19 154.79 43.5 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.344 -0.847 . . . . 0.0 109.589 -179.866 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 67.1 m-85 -126.66 138.14 53.38 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.332 -0.855 . . . . 0.0 109.597 179.648 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.468 ' CG ' ' NH1' ' A' ' 25' ' ' ARG . 90.2 m-20 -87.02 129.94 34.68 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.168 -0.957 . . . . 0.0 108.616 178.983 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' MET . . . . . 0.541 ' SD ' HD12 ' A' ' 26' ' ' ILE . 83.8 mtp -117.35 153.85 32.31 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.164 -0.96 . . . . 0.0 110.37 -179.441 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 76.9 p -148.14 167.33 25.32 Favored 'General case' 0 N--CA 1.487 1.42 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 179.629 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 7.9 p -127.4 134.24 66.19 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.244 -0.91 . . . . 0.0 109.717 -179.815 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 54.79 17.13 8.55 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.626 -1.389 . . . . 0.0 109.626 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 92.24 4.56 66.39 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 63.9 mt-30 -105.49 113.43 64.24 Favored Pre-proline 0 N--CA 1.494 1.728 0 O-C-N 121.345 -1.091 . . . . 0.0 109.241 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_exo -48.81 137.24 27.6 Favored 'Trans proline' 0 N--CA 1.492 1.406 0 C-N-CA 122.123 1.882 . . . . 0.0 112.086 179.913 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -111.22 -59.4 1.98 Allowed 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.411 -0.806 . . . . 0.0 109.498 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -170.44 -169.8 33.99 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.376 -1.49 . . . . 0.0 109.376 -179.859 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' ARG . . . . . 0.468 ' NH1' ' CG ' ' A' ' 15' ' ' ASP . 88.2 mtt-85 -116.46 145.8 43.03 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.308 -1.113 . . . . 0.0 109.784 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.541 HD12 ' SD ' ' A' ' 16' ' ' MET . 73.5 mt -119.8 122.45 68.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 178.863 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 46.1 t -111.02 133.3 57.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.3 -0.875 . . . . 0.0 109.3 -179.562 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 75.2 mtm -116.22 150.88 36.8 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.447 -0.783 . . . . 0.0 109.412 -179.767 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.419 ' C ' HD22 ' A' ' 30' ' ' LEU . 84.4 tt0 -101.47 130.92 47.81 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.277 -0.889 . . . . 0.0 109.926 -179.594 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.419 HD22 ' C ' ' A' ' 29' ' ' GLU . 2.9 mm? -109.86 127.74 54.9 Favored 'General case' 0 N--CA 1.493 1.683 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 179.277 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 96.3 m-85 -98.96 118.53 35.93 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.167 -0.958 . . . . 0.0 109.049 179.525 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -79.66 -41.94 25.86 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.379 -0.826 . . . . 0.0 109.776 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -64.35 -46.6 82.72 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.286 -0.884 . . . . 0.0 110.246 -179.333 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 33.1 m -67.38 -44.42 78.97 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.136 -0.978 . . . . 0.0 109.815 -179.72 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.449 ' O ' ' OG1' ' A' ' 35' ' ' THR . 6.8 p -141.61 79.65 16.85 Favored Pre-proline 0 N--CA 1.492 1.649 0 O-C-N 121.429 -0.794 . . . . 0.0 109.291 -179.859 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -64.25 -54.63 0.78 Allowed 'Trans proline' 0 C--N 1.308 -1.564 0 C-N-CA 122.286 1.991 . . . . 0.0 112.508 -179.404 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 70.9 mtp180 -62.43 -38.75 90.93 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.52 -0.737 . . . . 0.0 110.636 -179.196 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 28.6 m -65.16 -43.82 90.55 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.948 -1.095 . . . . 0.0 110.236 -179.474 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -63.14 -30.61 71.73 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.18 -0.95 . . . . 0.0 109.21 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -71.2 -43.78 66.72 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.345 -0.847 . . . . 0.0 109.837 -179.733 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 45.8 t30 -62.76 -47.82 81.86 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.248 -0.907 . . . . 0.0 109.992 -179.512 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 61.1 t80 -63.79 -47.75 79.64 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.208 -0.932 . . . . 0.0 109.567 -179.667 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.652 ' CZ ' HE22 ' A' ' 176' ' ' GLN . 74.4 ttt180 -57.83 -38.17 75.12 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.365 -0.835 . . . . 0.0 109.854 -179.849 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.512 ' O ' ' N ' ' A' ' 48' ' ' GLY . . . -62.32 -42.9 99.76 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.118 -0.989 . . . . 0.0 110.088 -179.247 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.591 HD12 ' CD1' ' A' ' 61' ' ' TYR . 4.4 mm? -66.28 -38.02 86.79 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.02 -1.05 . . . . 0.0 109.582 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 46' ' ' CYS . . . . . . . . . . . . . 3.8 m -65.9 -53.56 37.88 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.104 -0.997 . . . . 0.0 109.357 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 64.4 p -75.02 -31.46 61.37 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.336 -0.852 . . . . 0.0 109.451 179.674 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 48' ' ' GLY . . . . . 0.512 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 75.7 37.34 40.12 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 110.314 -1.114 . . . . 0.0 110.314 179.51 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -61.61 -37.66 84.77 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.858 -1.377 . . . . 0.0 109.418 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' LYS . . . . . 0.458 ' HZ1' ' CD1' ' A' ' 91' ' ' ILE . 27.0 mmtp -61.38 -34.0 74.6 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.28 -0.887 . . . . 0.0 109.279 179.819 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 82.13 -86.63 1.43 Allowed Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.654 -1.378 . . . . 0.0 109.654 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.566 HG23 ' C ' ' A' ' 57' ' ' LYS . 48.8 m -123.77 140.37 53.05 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.448 -1.03 . . . . 0.0 109.637 -179.779 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -56.58 -35.63 67.69 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.44 -1.464 . . . . 0.0 109.44 179.817 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 54' ' ' ARG . . . . . 0.533 ' H ' HG22 ' A' ' 52' ' ' THR . 74.3 mtp85 -140.22 -110.2 0.15 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.35 -1.088 . . . . 0.0 109.207 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 24.9 p -134.13 0.71 3.16 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.366 -0.833 . . . . 0.0 109.746 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -151.09 49.3 0.55 Allowed Glycine 0 N--CA 1.492 2.417 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' LYS . . . . . 0.566 ' C ' HG23 ' A' ' 52' ' ' THR . 59.7 tttm -172.8 74.29 0.42 Allowed Pre-proline 0 N--CA 1.488 1.474 0 O-C-N 121.364 -1.08 . . . . 0.0 108.855 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.402 ' N ' HG23 ' A' ' 52' ' ' THR . 72.0 Cg_exo -47.77 131.93 20.85 Favored 'Trans proline' 0 C--N 1.305 -1.757 0 C-N-CA 122.702 2.268 . . . . 0.0 112.128 -179.417 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.573 ' O ' ' CG ' ' A' ' 60' ' ' HIS . 14.6 tp -109.31 118.39 36.56 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.616 -0.678 . . . . 0.0 109.437 -179.413 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 60' ' ' HIS . . . . . 0.577 ' O ' ' CZ ' ' A' ' 80' ' ' PHE . 92.4 m-70 -160.62 135.31 7.51 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.244 -0.91 . . . . 0.0 109.944 179.889 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 61' ' ' TYR . . . . . 0.591 ' CD1' HD12 ' A' ' 45' ' ' LEU . 2.9 m-30 -87.39 3.38 47.26 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.163 -0.96 . . . . 0.0 108.882 179.104 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 62.2 tttt -68.07 146.31 53.61 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.383 -0.823 . . . . 0.0 109.7 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 46.7 t0 61.67 50.8 4.23 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.427 -0.795 . . . . 0.0 110.07 179.784 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.718 ' H ' ' CG2' ' A' ' 171' ' ' VAL . 96.7 p -97.69 157.24 16.16 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.187 -0.946 . . . . 0.0 109.146 179.531 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 29.0 t -128.84 150.09 50.48 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.438 -0.789 . . . . 0.0 109.378 -179.792 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 4.4 m-85 -75.55 125.77 29.69 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.227 -0.92 . . . . 0.0 109.144 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 79.0 t60 -62.76 -48.57 78.61 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.326 -0.859 . . . . 0.0 110.044 -179.354 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.68 HH21 ' NE2' ' A' ' 76' ' ' GLN . 36.8 ptt180 -163.64 162.38 24.18 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.223 -0.923 . . . . 0.0 109.378 -179.925 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -141.75 112.61 3.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.315 -0.866 . . . . 0.0 109.142 179.738 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 43.8 mt -107.56 124.33 35.33 Favored Pre-proline 0 N--CA 1.492 1.645 0 O-C-N 121.45 -0.781 . . . . 0.0 109.073 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_endo -71.75 137.46 29.91 Favored 'Trans proline' 0 N--CA 1.491 1.363 0 C-N-CA 122.031 1.82 . . . . 0.0 112.338 -179.729 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 94.46 -28.25 11.57 Favored Glycine 0 N--CA 1.493 2.466 0 N-CA-C 109.723 -1.351 . . . . 0.0 109.723 179.739 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 94.3 m-85 -100.87 -80.74 0.48 Allowed 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.271 -1.135 . . . . 0.0 109.789 -179.94 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 13.2 ptp -177.87 -168.95 0.19 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.283 -0.886 . . . . 0.0 109.873 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -124.55 130.44 52.45 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.486 -0.759 . . . . 0.0 109.03 179.822 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 76' ' ' GLN . . . . . 0.68 ' NE2' HH21 ' A' ' 68' ' ' ARG . 93.5 mt-30 -108.03 151.65 25.56 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.379 -0.826 . . . . 0.0 109.818 -179.633 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -169.18 -170.49 33.82 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.32 -1.512 . . . . 0.0 109.32 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 88.67 21.25 44.29 Favored Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.766 -1.334 . . . . 0.0 109.766 179.912 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 83.9 m-20 -84.38 12.64 6.43 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.233 -1.157 . . . . 0.0 109.433 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.577 ' CZ ' ' O ' ' A' ' 60' ' ' HIS . 83.1 t80 -50.08 -40.98 47.23 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.313 -0.867 . . . . 0.0 110.134 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.662 ' O ' ' HB2' ' A' ' 82' ' ' ALA . 60.6 p -65.35 -31.26 72.29 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.957 -1.089 . . . . 0.0 109.499 -179.956 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 82' ' ' ALA . . . . . 0.662 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 165.3 -53.37 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.415 -0.803 . . . . 0.0 109.32 179.898 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 88.51 2.36 79.53 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 78.5 m-20 -87.85 6.93 33.06 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.254 -1.145 . . . . 0.0 109.478 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 97.2 -39.31 2.82 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.26 -1.536 . . . . 0.0 109.26 -179.788 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 57.1 p -72.63 -21.35 61.12 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.335 -1.097 . . . . 0.0 109.008 179.49 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -84.65 -167.21 42.57 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.603 ' H ' ' CB ' ' A' ' 81' ' ' THR . . . 81.76 44.6 7.69 Favored Glycine 0 N--CA 1.488 2.134 0 N-CA-C 109.016 -1.634 . . . . 0.0 109.016 -179.871 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -94.36 142.49 27.36 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.377 -1.072 . . . . 0.0 109.708 -179.55 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 90.7 p -112.85 158.26 20.38 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.442 -0.786 . . . . 0.0 109.197 179.844 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.458 ' CD1' ' HZ1' ' A' ' 50' ' ' LYS . 29.1 pt -59.08 -32.02 47.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.142 -0.974 . . . . 0.0 109.634 -179.718 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 92' ' ' TYR . . . . . 0.53 ' O ' ' N ' ' A' ' 94' ' ' ALA . 56.8 m-85 -66.46 -30.12 70.39 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.223 -0.923 . . . . 0.0 109.631 179.636 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 64.07 -72.27 0.05 OUTLIER Glycine 0 N--CA 1.489 2.206 0 N-CA-C 109.336 -1.506 . . . . 0.0 109.336 -179.889 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 94' ' ' ALA . . . . . 0.53 ' N ' ' O ' ' A' ' 92' ' ' TYR . . . -63.55 143.96 57.39 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.376 -1.073 . . . . 0.0 109.119 179.719 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 95' ' ' LYS . . . . . 0.631 ' HD3' HG23 ' A' ' 120' ' ' THR . 59.0 mttp -88.58 149.33 23.63 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.379 -0.826 . . . . 0.0 109.71 -179.849 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 52.0 p90 -130.86 158.52 39.97 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.425 -0.797 . . . . 0.0 109.252 179.705 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -84.79 146.94 27.11 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.28 -0.887 . . . . 0.0 109.893 -179.577 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 60.4 t0 -78.88 124.8 28.59 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.336 -0.852 . . . . 0.0 109.113 179.747 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -54.42 -39.15 67.06 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.146 -0.972 . . . . 0.0 109.729 -179.518 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 100' ' ' ASN . . . . . 0.469 ' CG ' ' H ' ' A' ' 101' ' ' PHE . 15.1 t-20 -172.32 -177.45 1.81 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.097 -1.002 . . . . 0.0 109.808 179.855 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 101' ' ' PHE . . . . . 0.469 ' H ' ' CG ' ' A' ' 100' ' ' ASN . 15.7 p90 -147.42 62.57 1.16 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.487 -0.758 . . . . 0.0 109.067 179.861 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 80.6 mt -59.66 -37.34 70.42 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.268 -0.895 . . . . 0.0 110.216 -179.447 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 67.6 mttm -86.15 139.41 31.11 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.017 -1.052 . . . . 0.0 109.982 -179.436 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 59.2 mttp -129.12 -176.02 3.74 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.483 -0.761 . . . . 0.0 109.457 179.737 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 105' ' ' HIS . . . . . 0.53 ' O ' ' CG ' ' A' ' 105' ' ' HIS . 49.1 p-80 -109.57 100.36 9.42 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.519 -0.738 . . . . 0.0 109.276 179.704 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 63.7 p -106.96 -0.8 22.85 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.406 -0.809 . . . . 0.0 109.599 -179.831 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -146.62 171.29 27.45 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.336 -1.505 . . . . 0.0 109.336 -179.89 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -74.39 155.44 45.91 Favored 'Trans proline' 0 C--N 1.306 -1.672 0 C-N-CA 122.888 2.392 . . . . 0.0 112.17 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 83.22 44.9 6.8 Favored Glycine 0 N--CA 1.493 2.493 0 N-CA-C 110.234 -1.146 . . . . 0.0 110.234 179.488 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 44.0 mm -116.31 134.21 60.43 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 121.251 -1.146 . . . . 0.0 109.342 179.723 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.525 ' N ' HD22 ' A' ' 111' ' ' LEU . 3.4 mm? -91.44 130.91 37.21 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.251 -0.906 . . . . 0.0 109.385 179.709 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 47.2 t -143.68 142.24 30.9 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.238 -0.914 . . . . 0.0 109.439 179.826 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 72.1 mtm -82.87 131.21 35.2 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.193 -0.942 . . . . 0.0 109.205 179.769 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -65.87 141.71 58.17 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.192 -0.943 . . . . 0.0 109.587 -179.911 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 64.7 m-20 -146.27 113.03 6.03 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.322 -0.862 . . . . 0.0 109.027 179.664 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -68.51 -29.96 68.67 Favored 'General case' 0 C--N 1.297 -1.682 0 O-C-N 121.46 -0.775 . . . . 0.0 109.488 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -136.51 167.31 24.54 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 109.256 -1.538 . . . . 0.0 109.256 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -67.39 156.22 67.07 Favored 'Trans proline' 0 C--N 1.306 -1.696 0 C-N-CA 122.805 2.336 . . . . 0.0 111.889 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 30.1 m-20 54.35 45.26 27.55 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.422 -0.799 . . . . 0.0 109.35 -179.886 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 120' ' ' THR . . . . . 0.631 HG23 ' HD3' ' A' ' 95' ' ' LYS . 57.9 m -133.73 126.58 31.0 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 108.792 -0.818 . . . . 0.0 108.792 179.85 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 39.6 t30 -100.77 107.42 18.99 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.504 -0.748 . . . . 0.0 109.355 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -98.44 126.32 8.85 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 86.1 p -62.96 -25.96 68.6 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.268 -1.137 . . . . 0.0 109.385 179.795 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.3 mt-30 -73.86 148.18 42.58 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.283 -0.886 . . . . 0.0 109.399 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 48.8 p90 -136.3 162.75 32.14 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.326 -0.859 . . . . 0.0 109.446 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 49.0 p90 -136.48 160.8 37.67 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.371 -0.831 . . . . 0.0 109.445 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 69.2 mt -115.99 130.16 71.16 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.446 -0.784 . . . . 0.0 109.352 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -101.17 104.2 15.27 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.273 -0.892 . . . . 0.0 109.241 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 59.2 p -84.59 0.67 49.24 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.281 -0.887 . . . . 0.0 109.37 179.878 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -144.42 161.99 37.64 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.3 -0.875 . . . . 0.0 109.466 -179.768 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 92.4 mttt -76.0 150.65 37.37 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.254 -0.904 . . . . 0.0 109.486 -179.91 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 16.0 p -120.0 161.01 21.65 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.39 -0.819 . . . . 0.0 109.374 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -159.61 -44.12 0.05 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.19 -0.944 . . . . 0.0 109.758 -179.908 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 134' ' ' TRP . . . . . 0.4 ' CE2' ' CD2' ' A' ' 135' ' ' LEU . 33.3 p90 -73.71 -9.64 58.87 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.284 -0.885 . . . . 0.0 109.39 -179.802 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 135' ' ' LEU . . . . . 0.51 ' N ' ' CD2' ' A' ' 135' ' ' LEU . 2.8 mm? -61.59 -33.8 74.53 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.238 -0.914 . . . . 0.0 108.771 179.239 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 59.1 t0 49.16 49.91 18.83 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.44 -0.788 . . . . 0.0 109.754 179.648 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -143.83 163.79 27.59 Favored Glycine 0 N--CA 1.485 1.932 0 N-CA-C 108.915 -1.674 . . . . 0.0 108.915 179.847 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 13.6 mptt -97.21 142.73 28.77 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.472 -1.016 . . . . 0.0 109.465 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 99.3 m-70 -128.97 146.75 50.88 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.46 -0.775 . . . . 0.0 109.428 179.853 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 42.3 t -112.94 135.0 53.78 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.402 -0.811 . . . . 0.0 109.277 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 56.3 t -108.38 128.07 64.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 121.33 -0.856 . . . . 0.0 109.507 -179.757 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 45.9 p90 -112.88 -0.59 14.83 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.342 -0.849 . . . . 0.0 109.401 179.547 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -171.28 174.45 44.92 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 179.619 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 92.1 mt-30 -139.6 165.28 27.67 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.176 -1.19 . . . . 0.0 109.663 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 69.9 t -97.12 129.8 46.66 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.225 0 O-C-N 121.126 -0.984 . . . . 0.0 109.435 -179.952 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 16.0 m -106.99 -29.35 2.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.372 -0.83 . . . . 0.0 109.536 179.657 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -143.52 171.17 14.53 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.265 -0.897 . . . . 0.0 109.512 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 97.99 4.22 57.77 Favored Glycine 0 N--CA 1.493 2.46 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 179.64 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 149' ' ' MET . . . . . 0.466 ' O ' HG12 ' A' ' 152' ' ' VAL . 88.8 mtp -60.6 -33.95 73.51 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.13 -1.218 . . . . 0.0 109.672 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -64.98 -42.62 94.37 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.843 -1.161 . . . . 0.0 110.124 -179.624 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.1 p -82.79 -33.5 10.76 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.079 -1.013 . . . . 0.0 110.499 -179.429 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 152' ' ' VAL . . . . . 0.466 HG12 ' O ' ' A' ' 149' ' ' MET . 0.7 OUTLIER -55.17 -41.82 62.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 120.882 -1.136 . . . . 0.0 109.251 -179.335 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 153' ' ' LYS . . . . . 0.45 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 93.8 mttt -63.56 -34.8 78.6 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.171 -0.956 . . . . 0.0 109.298 179.356 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -63.0 -36.6 84.09 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.405 -0.809 . . . . 0.0 109.792 -179.599 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 69.9 mt -70.4 -38.6 74.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.211 -0.931 . . . . 0.0 110.036 -179.606 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -76.83 -41.14 45.37 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.067 -1.021 . . . . 0.0 111.63 -178.35 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 36.4 pttt -61.18 -34.19 74.65 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 120.729 -1.232 . . . . 0.0 110.261 -178.553 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 35.6 m -76.12 -20.09 15.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 120.917 -1.115 . . . . 0.0 109.469 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -72.91 165.24 54.81 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.652 -1.379 . . . . 0.0 109.652 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 22.9 t -151.42 171.71 17.09 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.376 -1.073 . . . . 0.0 109.382 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 22.6 t -53.7 -32.11 50.61 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.2 -0.938 . . . . 0.0 109.074 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 22.7 t -56.79 -30.94 64.16 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.251 -0.906 . . . . 0.0 109.34 179.722 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 96.41 8.04 57.75 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.678 -1.369 . . . . 0.0 109.678 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 98.6 mtt180 -120.71 144.14 48.39 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.244 -1.15 . . . . 0.0 109.29 179.831 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 165' ' ' THR . . . . . . . . . . . . . 59.6 p -91.23 157.29 17.25 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.197 -0.939 . . . . 0.0 109.728 -179.853 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -65.94 -33.79 76.63 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.367 -0.833 . . . . 0.0 109.613 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 60.8 mttp -119.41 161.03 21.19 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.406 -0.809 . . . . 0.0 109.905 -179.498 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 67.1 mttm -82.53 145.85 29.53 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.437 -0.789 . . . . 0.0 109.725 -179.918 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 1.9 m -133.75 127.08 52.1 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 O-C-N 121.277 -0.89 . . . . 0.0 109.575 179.783 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 44.3 t -137.99 139.05 43.15 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 O-C-N 121.392 -0.817 . . . . 0.0 109.407 179.837 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.718 ' CG2' ' H ' ' A' ' 64' ' ' SER . 9.5 m -67.06 124.51 22.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.0 -1.062 . . . . 0.0 109.208 179.819 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -69.29 -38.38 78.29 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.158 -0.964 . . . . 0.0 110.356 -179.63 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 173' ' ' ASP . . . . . 0.47 ' OD1' ' N ' ' A' ' 174' ' ' CYS . 48.0 t0 -168.7 168.82 10.48 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.958 -1.089 . . . . 0.0 110.209 -179.502 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 174' ' ' CYS . . . . . 0.47 ' N ' ' OD1' ' A' ' 173' ' ' ASP . 14.4 p -138.81 149.84 45.4 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.513 -0.742 . . . . 0.0 109.095 179.785 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -165.27 176.99 40.83 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.737 -1.345 . . . . 0.0 109.737 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 176' ' ' GLN . . . . . 0.652 HE22 ' CZ ' ' A' ' 43' ' ' ARG . 61.1 tt0 -109.83 113.9 27.03 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.331 -1.1 . . . . 0.0 109.614 -179.906 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 177' ' ' LEU . . . . . 0.407 ' O ' ' C ' ' A' ' 178' ' ' SER . 33.9 tp -64.4 -38.41 90.95 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.299 -0.876 . . . . 0.0 109.187 179.526 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 178' ' ' SER . . . . . 0.407 ' C ' ' O ' ' A' ' 177' ' ' LEU . 1.9 t . . . . . 0 N--CA 1.49 1.565 0 CA-C-O 118.04 -0.981 . . . . 0.0 109.621 179.96 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 75.1 m-20 . . . . . 0 N--CA 1.49 1.551 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -66.88 140.17 54.33 Favored 'Trans proline' 0 N--CA 1.496 1.632 0 C-N-CA 122.593 2.196 . . . . 0.0 112.237 179.966 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 98.0 mtt180 -132.49 131.12 41.33 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.33 -0.857 . . . . 0.0 109.187 179.494 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.8 p -138.47 142.63 34.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.306 -0.871 . . . . 0.0 109.39 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 49.3 p90 -142.46 153.85 44.04 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.298 -0.876 . . . . 0.0 109.624 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 77.0 m-85 -126.19 140.83 52.25 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.409 -0.807 . . . . 0.0 109.538 179.654 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 88.4 m-20 -86.85 129.75 34.75 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.156 -0.965 . . . . 0.0 108.925 179.31 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' MET . . . . . 0.562 ' SD ' HD12 ' A' ' 26' ' ' ILE . 84.7 mtp -115.03 153.33 30.86 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.331 -0.855 . . . . 0.0 110.079 -179.683 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 83.8 p -149.0 164.16 35.38 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.442 -0.787 . . . . 0.0 109.129 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.541 ' O ' ' N ' ' A' ' 20' ' ' GLY . 20.4 m -127.25 144.46 37.25 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 121.233 -0.917 . . . . 0.0 109.604 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 47.61 11.43 0.1 OUTLIER Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.822 -1.311 . . . . 0.0 109.822 179.812 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.541 ' N ' ' O ' ' A' ' 18' ' ' VAL . . . 96.49 -14.93 63.64 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.895 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' GLN . . . . . 0.448 ' N ' ' CD ' ' A' ' 21' ' ' GLN . 3.8 mp0 -82.95 149.31 59.13 Favored Pre-proline 0 N--CA 1.492 1.632 0 O-C-N 121.268 -1.137 . . . . 0.0 109.029 179.778 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -62.42 135.35 53.11 Favored 'Trans proline' 0 C--N 1.308 -1.557 0 C-N-CA 122.353 2.035 . . . . 0.0 112.036 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -113.49 -68.11 0.95 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.398 -0.814 . . . . 0.0 109.554 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -176.0 -171.64 40.02 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 -179.865 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 40.0 ttm180 -123.45 142.65 50.78 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.446 -1.032 . . . . 0.0 109.327 -179.931 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.562 HD12 ' SD ' ' A' ' 16' ' ' MET . 75.5 mt -119.99 132.06 70.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.372 -0.83 . . . . 0.0 109.03 179.641 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 44.5 t -113.3 133.22 59.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.306 -0.872 . . . . 0.0 109.086 179.765 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 72.8 mtm -118.52 148.95 42.09 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.369 -0.832 . . . . 0.0 109.299 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -102.05 131.68 48.35 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.308 -0.87 . . . . 0.0 109.575 -179.752 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -104.9 128.75 53.25 Favored 'General case' 0 N--CA 1.492 1.655 0 N-CA-C 109.044 -0.725 . . . . 0.0 109.044 179.615 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 90.2 m-85 -97.25 120.98 38.61 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.309 -0.869 . . . . 0.0 109.307 179.731 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -82.53 -41.51 19.58 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.321 -0.862 . . . . 0.0 109.875 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 56.8 t0 -69.02 -44.36 72.89 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.228 -0.92 . . . . 0.0 110.828 -179.22 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 32.9 m -67.22 -45.71 75.98 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.047 -1.033 . . . . 0.0 110.491 -178.986 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 4.3 m -156.4 84.36 3.21 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.127 -0.983 . . . . 0.0 109.484 -179.524 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -75.24 -37.04 2.08 Favored 'Trans proline' 0 C--N 1.307 -1.639 0 C-N-CA 122.334 2.023 . . . . 0.0 112.497 -179.518 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 37.7 mmt180 -61.76 -41.02 97.14 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.21 -0.931 . . . . 0.0 109.644 -179.803 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.459 HG23 ' SD ' ' A' ' 113' ' ' MET . 86.5 m -66.21 -39.95 89.98 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.253 -0.904 . . . . 0.0 110.106 -179.71 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -60.11 -32.3 70.86 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.077 -1.014 . . . . 0.0 109.521 -179.818 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -69.82 -36.26 75.47 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.268 -0.895 . . . . 0.0 110.077 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 48.3 t30 -57.9 -42.7 85.23 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.101 -0.999 . . . . 0.0 109.767 -179.629 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -85.79 -48.12 9.09 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.206 -0.934 . . . . 0.0 109.681 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 34.9 ttm180 -57.4 -42.63 82.63 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.407 -0.808 . . . . 0.0 109.842 -179.508 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -69.82 -44.89 69.05 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.306 -0.872 . . . . 0.0 110.182 -179.411 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 36.7 tp -61.92 -36.42 81.3 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.078 -1.014 . . . . 0.0 109.446 -179.652 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' CYS . . . . . . . . . . . . . 46.9 m -79.51 -49.93 11.51 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.09 -1.006 . . . . 0.0 109.757 179.589 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 71.2 p -68.75 -34.72 76.06 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.149 -0.97 . . . . 0.0 109.575 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 75.16 28.92 61.26 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.972 -1.251 . . . . 0.0 109.972 179.6 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 78.0 mm-40 -60.98 -38.35 85.68 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.088 -1.243 . . . . 0.0 109.246 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 29.1 mmtm -62.48 -31.35 72.07 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 121.308 -0.87 . . . . 0.0 109.152 179.484 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 97.75 -119.64 6.49 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 108.87 -1.692 . . . . 0.0 108.87 -179.49 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.586 HG23 ' HA ' ' A' ' 58' ' ' PRO . 95.1 m -126.55 142.09 51.65 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.419 -1.048 . . . . 0.0 109.751 179.739 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -55.48 135.72 47.77 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.093 -1.603 . . . . 0.0 109.093 179.615 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 94.5 mtt180 -59.11 -37.66 77.71 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.18 -1.188 . . . . 0.0 110.079 -179.484 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 22.9 t -59.47 -31.4 69.3 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.179 -0.95 . . . . 0.0 109.834 -179.615 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 119.77 95.54 1.57 Allowed Glycine 0 N--CA 1.495 2.592 0 N-CA-C 108.648 -1.781 . . . . 0.0 108.648 -179.379 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 32.6 tptt -178.56 80.5 0.22 Allowed Pre-proline 0 N--CA 1.489 1.497 0 N-CA-C 108.07 -1.085 . . . . 0.0 108.07 -179.501 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.586 ' HA ' HG23 ' A' ' 52' ' ' THR . 97.3 Cg_exo -45.26 127.96 9.45 Favored 'Trans proline' 0 C--N 1.301 -1.922 0 C-N-CA 122.667 2.245 . . . . 0.0 112.203 -178.9 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.564 ' O ' ' CG ' ' A' ' 60' ' ' HIS . 84.0 mt -91.52 124.65 35.84 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.718 -0.614 . . . . 0.0 109.92 -179.285 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 60' ' ' HIS . . . . . 0.564 ' CG ' ' O ' ' A' ' 59' ' ' LEU . 86.5 m-70 -162.25 96.35 0.97 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.443 -0.785 . . . . 0.0 109.258 179.833 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 18.5 t80 -57.32 -34.39 68.68 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.174 -0.954 . . . . 0.0 108.708 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 62' ' ' LYS . . . . . 0.406 ' HG2' ' N ' ' A' ' 63' ' ' ASP . 3.1 ttmp? -46.79 161.06 0.07 Allowed 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.612 -0.68 . . . . 0.0 109.706 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 63' ' ' ASP . . . . . 0.406 ' N ' ' HG2' ' A' ' 62' ' ' LYS . 80.5 m-20 62.34 48.82 4.51 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.686 -0.634 . . . . 0.0 110.494 179.8 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.877 ' H ' HG22 ' A' ' 171' ' ' VAL . 33.7 t -103.48 144.63 31.15 Favored 'General case' 0 N--CA 1.492 1.642 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 178.76 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 28.6 t -124.05 148.63 46.91 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.096 -1.002 . . . . 0.0 110.309 -179.003 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 32.8 m-85 -87.75 129.99 34.99 Favored 'General case' 0 N--CA 1.491 1.614 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 179.494 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 94.7 m-70 -90.97 -28.58 17.94 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.103 -0.998 . . . . 0.0 110.901 -178.937 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.409 ' O ' HG13 ' A' ' 69' ' ' VAL . 48.9 mtp180 -134.34 147.97 50.64 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 120.957 -1.089 . . . . 0.0 110.245 -179.367 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.71 HG21 HG22 ' A' ' 165' ' ' THR . 10.2 m -153.98 64.7 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.503 -0.748 . . . . 0.0 109.205 179.825 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 21.7 mt -86.82 131.79 44.11 Favored Pre-proline 0 C--N 1.301 -1.502 0 O-C-N 121.009 -1.057 . . . . 0.0 109.788 -179.277 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_endo -71.27 147.16 52.75 Favored 'Trans proline' 0 N--CA 1.492 1.401 0 C-N-CA 122.354 2.036 . . . . 0.0 112.288 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 83.62 -58.7 5.01 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.763 -1.335 . . . . 0.0 109.763 179.808 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 95.6 m-85 -69.74 -83.83 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.177 -1.19 . . . . 0.0 109.622 -179.796 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 74' ' ' MET . . . . . 0.403 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 12.6 ptt? 179.05 -173.29 0.17 Allowed 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.278 -0.889 . . . . 0.0 109.68 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 1.2 p -126.34 137.57 53.49 Favored 'General case' 0 N--CA 1.491 1.622 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 179.443 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 91.9 mt-30 -116.73 153.92 31.54 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.256 -0.902 . . . . 0.0 109.735 -179.573 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -163.29 -173.65 32.24 Favored Glycine 0 N--CA 1.488 2.151 0 N-CA-C 109.177 -1.569 . . . . 0.0 109.177 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -160.39 -177.4 33.45 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.717 -1.353 . . . . 0.0 109.717 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.514 ' C ' ' H ' ' A' ' 81' ' ' THR . 83.1 m-20 -66.95 154.93 39.87 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.379 -1.071 . . . . 0.0 109.507 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.558 ' CE1' ' O ' ' A' ' 60' ' ' HIS . 36.5 p90 -58.89 0.24 0.09 Allowed 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.413 -0.804 . . . . 0.0 109.762 -179.856 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.619 ' O ' ' HB2' ' A' ' 82' ' ' ALA . 72.4 p -63.85 -32.31 73.78 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.991 -1.068 . . . . 0.0 109.538 -179.706 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 82' ' ' ALA . . . . . 0.619 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 169.48 -53.12 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.335 -0.853 . . . . 0.0 109.37 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 86.04 2.8 85.78 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.556 -1.417 . . . . 0.0 109.556 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 39.9 t-20 -85.94 5.91 30.94 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.263 -1.14 . . . . 0.0 109.497 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 100.96 -40.19 2.5 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 -179.776 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 58.9 p -70.75 -27.22 63.79 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.273 -1.134 . . . . 0.0 108.837 179.392 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -86.47 -167.66 43.89 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.184 -1.566 . . . . 0.0 109.184 179.657 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.485 ' N ' ' OG1' ' A' ' 81' ' ' THR . . . 82.25 42.38 8.69 Favored Glycine 0 N--CA 1.489 2.179 0 N-CA-C 109.359 -1.496 . . . . 0.0 109.359 -179.919 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -57.03 143.81 36.79 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.303 -1.116 . . . . 0.0 109.391 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 99.3 p -113.44 147.87 36.98 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.348 -0.845 . . . . 0.0 109.268 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.415 HG21 HD13 ' A' ' 91' ' ' ILE . 20.0 pt -74.01 -33.64 36.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.297 -0.877 . . . . 0.0 109.993 -179.837 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 81.8 m-85 -66.46 -41.14 89.48 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.173 -0.954 . . . . 0.0 109.795 -179.668 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 71.3 9.57 68.14 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.278 -1.529 . . . . 0.0 109.278 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -152.34 160.76 43.27 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.294 -1.121 . . . . 0.0 109.389 -179.758 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 63.7 mttp -83.4 145.85 28.77 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.22 -0.925 . . . . 0.0 109.665 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 52.4 p90 -137.05 160.5 38.78 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.402 -0.811 . . . . 0.0 109.312 179.674 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -104.49 144.23 31.96 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.31 -0.869 . . . . 0.0 109.513 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 98' ' ' ASP . . . . . 0.523 ' O ' ' OD1' ' A' ' 98' ' ' ASP . 41.9 p30 -79.05 128.98 33.96 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.191 -0.943 . . . . 0.0 109.528 179.873 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -60.65 -37.73 82.49 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.159 -0.963 . . . . 0.0 109.693 -179.643 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 84.4 m-20 -124.42 144.18 50.21 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.251 -0.906 . . . . 0.0 109.849 -179.747 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 48.6 p90 -142.69 19.75 2.01 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.333 -0.854 . . . . 0.0 108.838 179.607 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 84.1 mt -59.47 -34.88 56.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.567 -0.708 . . . . 0.0 110.112 -179.649 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 93.0 mttt -79.65 135.65 36.61 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.069 -1.02 . . . . 0.0 109.768 -179.57 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 25.6 pttm -139.11 -178.69 5.46 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.412 -0.805 . . . . 0.0 109.439 -180.0 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 105' ' ' HIS . . . . . 0.535 ' O ' ' ND1' ' A' ' 105' ' ' HIS . 15.1 t-80 -74.27 88.02 2.0 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.174 -0.954 . . . . 0.0 109.256 179.825 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 58.8 p -75.05 -25.48 58.71 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.312 -0.867 . . . . 0.0 109.774 -179.781 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.533 ' O ' ' CE1' ' A' ' 105' ' ' HIS . . . -164.21 -166.95 23.97 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.397 -1.481 . . . . 0.0 109.397 -179.708 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -76.29 155.82 37.18 Favored 'Trans proline' 0 C--N 1.308 -1.574 0 C-N-CA 122.644 2.229 . . . . 0.0 112.117 179.901 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 88.32 24.29 34.51 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.869 -1.292 . . . . 0.0 109.869 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 36.6 mm -112.27 136.79 47.37 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.267 -1.137 . . . . 0.0 109.379 179.854 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.748 ' N ' HD22 ' A' ' 111' ' ' LEU . 2.7 mm? -88.2 132.57 34.3 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.283 -0.886 . . . . 0.0 109.152 179.77 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 112' ' ' SER . . . . . 0.401 ' OG ' ' O ' ' A' ' 140' ' ' VAL . 47.0 t -145.8 139.36 26.34 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.189 -0.944 . . . . 0.0 109.609 179.957 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 113' ' ' MET . . . . . 0.459 ' SD ' HG23 ' A' ' 38' ' ' THR . 71.9 mtm -89.23 139.03 30.9 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.243 -0.91 . . . . 0.0 109.267 179.651 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 114' ' ' ALA . . . . . 0.409 ' O ' ' OD1' ' A' ' 115' ' ' ASN . . . -60.74 138.31 58.11 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.242 -0.911 . . . . 0.0 109.152 179.983 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 115' ' ' ASN . . . . . 0.447 ' ND2' ' O ' ' A' ' 113' ' ' MET . 43.5 m-20 -148.81 112.95 5.2 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.173 -0.954 . . . . 0.0 109.19 179.93 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -68.31 -30.12 69.04 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 121.338 -0.851 . . . . 0.0 109.134 179.559 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -138.18 168.98 24.42 Favored Glycine 0 N--CA 1.493 2.451 0 N-CA-C 109.049 -1.621 . . . . 0.0 109.049 179.813 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -67.11 155.06 72.41 Favored 'Trans proline' 0 C--N 1.305 -1.739 0 C-N-CA 122.722 2.281 . . . . 0.0 112.027 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 75.6 m-20 53.99 44.34 29.48 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.448 -0.782 . . . . 0.0 109.432 -179.865 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 93.3 m -134.64 127.59 31.45 Favored 'General case' 0 N--CA 1.485 1.322 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 179.832 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 121' ' ' ASN . . . . . 0.413 ' OD1' ' SD ' ' A' ' 113' ' ' MET . 52.2 t30 -98.22 106.43 18.72 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.421 -0.8 . . . . 0.0 109.318 179.794 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -80.96 136.61 16.6 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 83.4 p -64.38 -23.73 67.39 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.268 -1.136 . . . . 0.0 109.442 179.853 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.2 mt-30 -103.73 150.89 23.63 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.267 -0.896 . . . . 0.0 109.675 -179.825 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 51.5 p90 -136.23 162.4 33.08 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.431 -0.793 . . . . 0.0 109.292 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 126' ' ' PHE . . . . . 0.403 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 48.5 p90 -136.34 156.64 48.35 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.193 -0.942 . . . . 0.0 109.636 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 64.9 mt -122.53 133.1 69.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.449 -0.782 . . . . 0.0 109.189 179.812 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 128' ' ' CYS . . . . . 0.45 ' SG ' ' O ' ' A' ' 130' ' ' ALA . 5.7 t -99.82 118.46 36.33 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.154 -0.966 . . . . 0.0 109.499 179.938 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 64.9 p -95.05 4.12 54.1 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.294 -0.879 . . . . 0.0 109.489 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 130' ' ' ALA . . . . . 0.45 ' O ' ' SG ' ' A' ' 128' ' ' CYS . . . -147.41 155.82 42.31 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.271 -0.893 . . . . 0.0 109.684 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 51.4 tttp -72.9 137.17 45.45 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.204 -0.935 . . . . 0.0 109.423 179.918 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 7.2 p -122.46 161.49 23.45 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.47 -0.769 . . . . 0.0 109.542 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -104.88 -74.98 0.63 Allowed 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.336 -0.853 . . . . 0.0 109.666 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 134' ' ' TRP . . . . . 0.672 ' CD1' ' N ' ' A' ' 135' ' ' LEU . 45.9 p90 -61.65 -45.8 92.48 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.333 -0.854 . . . . 0.0 110.198 -179.56 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 135' ' ' LEU . . . . . 0.672 ' N ' ' CD1' ' A' ' 134' ' ' TRP . 13.5 tp -61.28 -32.3 72.13 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.336 -0.852 . . . . 0.0 109.72 -179.348 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 60.4 t0 -56.5 136.61 54.1 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.231 -0.918 . . . . 0.0 109.924 -179.38 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 137' ' ' GLY . . . . . 0.716 ' H ' ' CD2' ' A' ' 139' ' ' HIS . . . -162.65 -161.15 11.84 Favored Glycine 0 N--CA 1.486 2.009 0 N-CA-C 108.664 -1.774 . . . . 0.0 108.664 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 138' ' ' LYS . . . . . 0.464 ' O ' ' O ' ' A' ' 139' ' ' HIS . 92.1 mttt -57.21 -41.14 78.86 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.055 -1.262 . . . . 0.0 109.582 179.887 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 139' ' ' HIS . . . . . 0.716 ' CD2' ' H ' ' A' ' 137' ' ' GLY . 66.2 m-70 37.4 94.66 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.58 -0.7 . . . . 0.0 110.428 179.738 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.401 ' O ' ' OG ' ' A' ' 112' ' ' SER . 39.0 t -61.61 132.43 27.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 120.99 -1.069 . . . . 0.0 108.791 179.579 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 82.3 t -111.38 129.0 67.51 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 O-C-N 121.376 -0.828 . . . . 0.0 109.824 -179.45 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 41.9 p90 -116.19 -1.55 12.37 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.511 -0.743 . . . . 0.0 109.505 179.449 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -168.47 172.73 43.08 Favored Glycine 0 N--CA 1.493 2.479 0 N-CA-C 109.861 -1.296 . . . . 0.0 109.861 179.447 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 55.2 tt0 -139.99 160.33 40.18 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.31 -1.112 . . . . 0.0 109.347 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 145' ' ' VAL . . . . . 0.438 HG23 HD21 ' A' ' 111' ' ' LEU . 54.4 t -96.75 131.22 44.04 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.182 0 O-C-N 121.047 -1.033 . . . . 0.0 109.56 -179.759 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 16.4 m -111.0 -28.75 2.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.444 -0.785 . . . . 0.0 109.32 179.472 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -144.42 169.35 18.11 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.326 -0.859 . . . . 0.0 109.448 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 96.2 6.36 58.94 Favored Glycine 0 N--CA 1.494 2.511 0 N-CA-C 109.946 -1.262 . . . . 0.0 109.946 179.519 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 149' ' ' MET . . . . . 0.524 ' O ' HG12 ' A' ' 152' ' ' VAL . 89.0 mtp -59.89 -32.24 70.55 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.165 -1.197 . . . . 0.0 109.8 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -66.67 -42.66 86.2 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.868 -1.145 . . . . 0.0 109.994 -179.542 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 6.2 p -81.36 -34.86 13.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.167 -0.958 . . . . 0.0 110.555 -179.479 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 152' ' ' VAL . . . . . 0.556 ' O ' ' OE1' ' A' ' 156' ' ' GLU . 1.2 p -50.85 -42.39 23.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 120.843 -1.161 . . . . 0.0 108.772 -179.078 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 153' ' ' LYS . . . . . 0.445 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 61.5 mttp -67.39 -32.91 74.14 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.28 -0.887 . . . . 0.0 109.274 179.094 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -61.03 -30.89 70.58 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.469 -0.769 . . . . 0.0 110.396 -179.244 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 89.8 mt -68.54 -37.31 77.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.035 -1.041 . . . . 0.0 110.616 -179.384 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 156' ' ' GLU . . . . . 0.556 ' OE1' ' O ' ' A' ' 152' ' ' VAL . 42.0 mp0 -80.35 -39.13 29.13 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 120.815 -1.178 . . . . 0.0 111.743 -178.849 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 19.2 pttp -58.3 -37.4 74.97 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 120.455 -1.403 . . . . 0.0 109.161 -178.91 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 32.1 m -77.99 -15.05 14.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.273 -0.892 . . . . 0.0 108.82 179.163 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -78.9 176.52 54.6 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.719 -1.353 . . . . 0.0 109.719 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 22.7 t -156.46 171.75 19.73 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.31 -1.112 . . . . 0.0 109.288 -179.769 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 22.6 t -54.71 -30.78 56.88 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.13 -0.981 . . . . 0.0 109.224 179.84 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 86.8 p -59.98 -26.56 66.12 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.175 -0.953 . . . . 0.0 109.56 179.958 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 90.21 17.07 54.5 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 109.828 -1.309 . . . . 0.0 109.828 179.804 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 28.4 ttm180 -119.12 142.56 47.81 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.311 -1.111 . . . . 0.0 109.221 -180.0 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 165' ' ' THR . . . . . 0.71 HG22 HG21 ' A' ' 69' ' ' VAL . 82.2 p -79.36 149.14 31.78 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.165 -0.959 . . . . 0.0 109.761 -179.911 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -67.25 -35.62 79.93 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.314 -0.866 . . . . 0.0 109.153 179.686 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 96.6 mttt -117.27 156.93 26.92 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.515 -0.74 . . . . 0.0 109.138 179.918 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 63.9 mttp -68.69 130.74 43.71 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.096 -1.003 . . . . 0.0 109.333 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 34.4 t -122.42 123.36 68.45 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 121.409 -0.807 . . . . 0.0 109.392 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 42.1 t -144.41 141.03 24.27 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.34 -0.85 . . . . 0.0 109.23 179.762 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.877 HG22 ' H ' ' A' ' 64' ' ' SER . 4.8 m -65.65 119.29 10.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.103 -0.998 . . . . 0.0 109.296 179.912 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 -70.92 -36.94 72.87 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.033 -1.042 . . . . 0.0 110.621 -179.638 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 173' ' ' ASP . . . . . 0.482 ' OD1' ' N ' ' A' ' 174' ' ' CYS . 52.1 t0 -155.09 161.72 41.21 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.952 -1.092 . . . . 0.0 110.276 -179.184 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 174' ' ' CYS . . . . . 0.482 ' N ' ' OD1' ' A' ' 173' ' ' ASP . 14.8 p -147.36 152.56 38.4 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.398 -0.814 . . . . 0.0 109.224 179.788 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . 178.41 170.81 41.01 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 179.702 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 64.1 tt0 -105.17 119.35 38.82 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.365 -1.08 . . . . 0.0 109.474 179.925 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 30.8 tp -61.68 -37.97 86.07 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.213 -0.929 . . . . 0.0 109.422 179.87 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 38.7 m . . . . . 0 N--CA 1.489 1.513 0 CA-C-O 118.027 -0.987 . . . . 0.0 109.498 179.988 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 16.3 m-80 . . . . . 0 N--CA 1.49 1.567 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -68.1 140.76 50.54 Favored 'Trans proline' 0 N--CA 1.496 1.627 0 C-N-CA 122.787 2.325 . . . . 0.0 112.501 -179.802 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' ARG . . . . . 0.557 ' NH2' HG11 ' A' ' 27' ' ' VAL . 55.2 ttt85 -133.0 129.91 38.78 Favored 'General case' 0 N--CA 1.489 1.524 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 179.027 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.7 p -135.22 144.75 33.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.18 -0.95 . . . . 0.0 110.133 -179.006 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 48.6 p90 -136.79 154.47 50.54 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.447 -0.783 . . . . 0.0 109.1 179.752 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.568 ' CE2' ' SG ' ' A' ' 174' ' ' CYS . 86.9 m-85 -121.42 137.49 54.69 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.437 -0.79 . . . . 0.0 109.934 -179.848 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.2 t0 -94.71 115.06 27.06 Favored 'General case' 0 N--CA 1.494 1.748 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 178.941 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' MET . . . . . 0.569 ' SD ' HD11 ' A' ' 155' ' ' ILE . 77.7 mtp -108.35 146.58 32.77 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.198 -0.939 . . . . 0.0 110.826 -178.824 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.415 ' OG ' ' O ' ' A' ' 21' ' ' GLN . 46.8 t -134.25 149.58 50.96 Favored 'General case' 0 N--CA 1.491 1.605 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 179.61 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.418 ' C ' ' N ' ' A' ' 20' ' ' GLY . 35.5 m -112.2 133.96 56.23 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 121.178 -0.951 . . . . 0.0 109.721 -179.664 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 52.95 12.88 1.94 Allowed Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.418 ' N ' ' C ' ' A' ' 18' ' ' VAL . . . 97.11 -10.22 65.62 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.45 -1.46 . . . . 0.0 109.45 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' GLN . . . . . 0.415 ' O ' ' OG ' ' A' ' 17' ' ' SER . 81.4 mt-30 -88.99 149.37 43.19 Favored Pre-proline 0 N--CA 1.49 1.53 0 O-C-N 121.243 -1.151 . . . . 0.0 109.084 179.733 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -62.38 133.89 45.51 Favored 'Trans proline' 0 C--N 1.309 -1.527 0 C-N-CA 122.288 1.992 . . . . 0.0 112.014 -179.772 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -112.33 -65.21 1.2 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.438 -0.789 . . . . 0.0 109.339 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 179.92 -172.28 43.84 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 61.0 ttp180 -119.1 143.08 47.35 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.422 -1.046 . . . . 0.0 109.198 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 82.7 mt -119.8 128.9 75.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.384 -0.823 . . . . 0.0 109.03 179.779 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.557 HG11 ' NH2' ' A' ' 11' ' ' ARG . 39.0 t -116.59 133.78 62.15 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.406 -0.809 . . . . 0.0 109.272 -179.947 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 72.6 mtm -122.5 152.07 40.7 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.422 -0.798 . . . . 0.0 109.277 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -100.58 131.58 46.41 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.271 -0.893 . . . . 0.0 109.825 -179.626 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.41 ' N ' ' CD2' ' A' ' 30' ' ' LEU . 2.6 mm? -106.12 133.16 51.26 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 179.487 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -96.57 120.81 37.57 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.025 -1.047 . . . . 0.0 109.054 179.459 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -88.02 -41.51 13.06 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.269 -0.895 . . . . 0.0 109.657 -179.809 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -65.28 -42.42 93.2 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.347 -0.846 . . . . 0.0 110.519 -179.214 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 54.6 m -66.32 -44.61 82.88 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.031 -1.043 . . . . 0.0 110.208 -179.324 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.454 ' OG1' ' OG1' ' A' ' 38' ' ' THR . 0.1 OUTLIER -155.67 84.48 3.45 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.261 -0.899 . . . . 0.0 109.301 -179.72 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 1.7 Cg_endo -62.14 -42.07 31.61 Favored 'Trans proline' 0 C--N 1.307 -1.638 0 C-N-CA 122.078 1.852 . . . . 0.0 112.412 -179.245 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 50.1 mtt180 -63.21 -39.54 94.94 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.426 -0.796 . . . . 0.0 110.81 -179.028 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.454 ' OG1' ' OG1' ' A' ' 35' ' ' THR . 75.6 m -63.27 -40.14 96.55 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 120.834 -1.167 . . . . 0.0 109.947 -179.666 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -61.33 -31.56 71.43 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.137 -0.977 . . . . 0.0 109.216 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -67.55 -36.53 81.14 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.303 -0.873 . . . . 0.0 109.885 -179.898 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 45.2 t-20 -57.88 -41.79 83.26 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.219 -0.926 . . . . 0.0 109.85 -179.622 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 98.8 m-85 -87.0 -46.98 9.33 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.106 -0.996 . . . . 0.0 109.804 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.658 ' CZ ' HE22 ' A' ' 176' ' ' GLN . 78.5 ttt180 -57.07 -39.27 74.6 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.363 -0.836 . . . . 0.0 110.147 -179.623 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -63.96 -48.24 77.25 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.02 -1.05 . . . . 0.0 110.214 -179.292 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.74 HD12 ' CD1' ' A' ' 61' ' ' TYR . 4.3 mm? -65.78 -38.93 90.35 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.092 -1.005 . . . . 0.0 109.663 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 46' ' ' CYS . . . . . 0.56 ' SG ' ' SG ' ' A' ' 174' ' ' CYS . 77.7 m -66.01 -47.97 72.73 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.12 -0.988 . . . . 0.0 109.469 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 63.9 p -76.78 -30.78 56.62 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.259 -0.901 . . . . 0.0 109.697 179.733 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 76.25 31.64 54.32 Favored Glycine 0 N--CA 1.492 2.379 0 N-CA-C 110.214 -1.154 . . . . 0.0 110.214 179.521 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 77.8 mm-40 -62.25 -36.07 80.91 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.944 -1.327 . . . . 0.0 109.573 179.798 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 61.1 mmtt -60.43 -34.03 73.38 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.17 -0.956 . . . . 0.0 109.494 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 76.4 -94.54 1.04 Allowed Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.475 -1.45 . . . . 0.0 109.475 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 31.8 m -118.01 142.46 47.35 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.372 -1.075 . . . . 0.0 109.296 -179.798 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -54.53 -42.43 76.15 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.838 -1.305 . . . . 0.0 109.838 -179.828 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 82.0 mtp180 -147.05 -113.06 0.08 Allowed 'General case' 0 N--CA 1.486 1.364 0 O-C-N 121.172 -1.193 . . . . 0.0 109.265 179.871 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 3.4 m -107.08 -24.72 11.86 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.401 -0.812 . . . . 0.0 109.521 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -144.31 73.23 0.34 Allowed Glycine 0 N--CA 1.493 2.461 0 N-CA-C 109.471 -1.452 . . . . 0.0 109.471 -179.722 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 46.6 tttm -171.46 74.21 0.51 Allowed Pre-proline 0 N--CA 1.489 1.496 0 O-C-N 121.383 -1.069 . . . . 0.0 108.833 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_exo -50.06 128.75 23.08 Favored 'Trans proline' 0 C--N 1.305 -1.76 0 C-N-CA 122.646 2.231 . . . . 0.0 111.977 -179.4 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.525 ' O ' ' CG ' ' A' ' 60' ' ' HIS . 11.5 tp -112.24 118.38 35.14 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.531 -0.731 . . . . 0.0 109.186 -179.593 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 60' ' ' HIS . . . . . 0.533 ' O ' ' CE1' ' A' ' 80' ' ' PHE . 95.6 m-70 -158.52 140.73 14.07 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.128 -0.983 . . . . 0.0 109.904 -179.952 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 61' ' ' TYR . . . . . 0.74 ' CD1' HD12 ' A' ' 45' ' ' LEU . 2.4 m-85 -102.17 12.26 37.01 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.254 -0.904 . . . . 0.0 108.851 179.211 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 83.7 mttt -86.73 156.64 19.86 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.383 -0.823 . . . . 0.0 109.619 -179.709 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 54.6 t0 55.8 46.78 21.65 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.401 -0.812 . . . . 0.0 109.454 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 99.4 p -116.85 155.3 29.25 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.411 -0.806 . . . . 0.0 109.301 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 28.6 t -113.16 147.43 37.4 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.362 -0.836 . . . . 0.0 109.323 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.7 m-30 -61.11 142.43 56.7 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.213 -0.929 . . . . 0.0 108.864 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 80.5 t60 -57.29 -50.72 72.03 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.127 -0.983 . . . . 0.0 109.934 -179.206 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.692 HH21 ' NE2' ' A' ' 76' ' ' GLN . 30.1 ptt180 -169.42 160.95 9.61 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.115 -0.99 . . . . 0.0 109.843 179.834 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.474 HG21 HG21 ' A' ' 165' ' ' THR . 0.0 OUTLIER -136.1 135.37 50.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 179.548 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 75.1 mt -136.61 128.25 16.92 Favored Pre-proline 0 N--CA 1.492 1.667 0 O-C-N 121.309 -0.87 . . . . 0.0 109.349 -179.699 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -75.41 136.74 19.97 Favored 'Trans proline' 0 C--N 1.312 -1.39 0 C-N-CA 122.091 1.86 . . . . 0.0 111.888 179.672 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 94.5 -5.23 70.34 Favored Glycine 0 N--CA 1.492 2.432 0 N-CA-C 109.821 -1.312 . . . . 0.0 109.821 179.705 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 77.6 m-85 -135.13 -94.96 0.27 Allowed 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.211 -1.17 . . . . 0.0 109.677 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 74' ' ' MET . . . . . 0.506 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 6.9 ptt? -170.81 -165.88 0.46 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.172 -0.955 . . . . 0.0 109.464 -179.653 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 15.4 p -132.7 151.61 51.93 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.423 -0.798 . . . . 0.0 109.054 179.741 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 76' ' ' GLN . . . . . 0.692 ' NE2' HH21 ' A' ' 68' ' ' ARG . 94.1 mt-30 -115.72 158.71 22.39 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.372 -0.83 . . . . 0.0 109.63 -179.703 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -140.28 -172.68 12.97 Favored Glycine 0 N--CA 1.494 2.516 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 -179.898 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 95.59 6.33 59.69 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.475 -1.45 . . . . 0.0 109.475 -179.771 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 56.0 t0 -57.44 -25.75 60.13 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.278 -1.131 . . . . 0.0 109.444 179.912 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.533 ' CE1' ' O ' ' A' ' 60' ' ' HIS . 91.3 t80 -49.19 -44.81 43.38 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.378 -0.826 . . . . 0.0 110.151 -179.483 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.688 ' CB ' ' H ' ' A' ' 88' ' ' GLY . 65.0 p -69.85 -29.52 66.78 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 120.989 -1.069 . . . . 0.0 109.487 179.874 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 82' ' ' ALA . . . . . 0.684 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 163.3 -55.53 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.344 -0.847 . . . . 0.0 109.244 179.724 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 91.02 1.46 72.84 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 179.884 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 84' ' ' ASN . . . . . 0.478 ' ND2' ' OG1' ' A' ' 86' ' ' THR . 39.9 p-10 -89.8 7.64 35.96 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.21 -1.171 . . . . 0.0 109.482 -179.931 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 95.8 -38.45 3.11 Favored Glycine 0 N--CA 1.492 2.389 0 N-CA-C 109.246 -1.541 . . . . 0.0 109.246 -179.793 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 86' ' ' THR . . . . . 0.478 ' OG1' ' ND2' ' A' ' 84' ' ' ASN . 56.7 p -73.16 -17.54 61.37 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.235 -1.156 . . . . 0.0 109.027 179.529 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -82.75 -164.82 36.02 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.589 -1.405 . . . . 0.0 109.589 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.688 ' H ' ' CB ' ' A' ' 81' ' ' THR . . . 81.94 47.76 6.07 Favored Glycine 0 N--CA 1.488 2.16 0 N-CA-C 109.264 -1.534 . . . . 0.0 109.264 -179.808 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -83.45 147.0 28.09 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.421 -1.046 . . . . 0.0 109.521 -179.722 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 50.5 m -107.84 150.12 27.41 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.485 -0.759 . . . . 0.0 109.275 -179.937 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 5.1 pt -59.6 -40.69 82.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.196 -0.94 . . . . 0.0 109.898 -179.759 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 3.4 m-30 -63.71 -41.42 98.09 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.013 -1.054 . . . . 0.0 109.321 179.733 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 72.58 24.53 76.04 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.719 -1.352 . . . . 0.0 109.719 179.725 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -147.28 153.82 40.22 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.135 -1.214 . . . . 0.0 109.698 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 94.6 mttt -96.73 142.08 29.19 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.361 -0.837 . . . . 0.0 109.552 179.88 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 96' ' ' PHE . . . . . 0.533 ' CZ ' ' OD1' ' A' ' 121' ' ' ASN . 38.1 p90 -141.07 156.25 46.03 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.322 -0.861 . . . . 0.0 109.42 179.705 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -70.91 145.44 50.16 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.29 -0.881 . . . . 0.0 109.748 -179.699 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 98' ' ' ASP . . . . . 0.539 ' OD2' HG21 ' A' ' 140' ' ' VAL . 87.8 m-20 -64.16 139.02 58.72 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.17 -0.957 . . . . 0.0 109.153 179.92 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 99' ' ' GLU . . . . . 0.482 ' O ' ' OD1' ' A' ' 100' ' ' ASN . 97.2 mt-10 -66.06 -41.13 91.21 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.178 -0.951 . . . . 0.0 110.56 -179.093 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 100' ' ' ASN . . . . . 0.482 ' OD1' ' O ' ' A' ' 99' ' ' GLU . 83.2 m-20 -149.96 149.16 29.99 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 120.948 -1.095 . . . . 0.0 110.466 -179.582 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -110.75 9.93 22.67 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.849 -0.797 . . . . 0.0 108.849 179.152 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 91.2 mt -54.97 -37.5 42.16 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.408 -0.807 . . . . 0.0 110.583 -179.069 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 57.0 mttm -76.52 134.46 39.46 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 120.899 -1.125 . . . . 0.0 109.63 -179.495 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 39.8 tttp -138.43 159.14 42.82 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.471 -0.768 . . . . 0.0 109.308 -179.735 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 105' ' ' HIS . . . . . 0.491 ' C ' ' ND1' ' A' ' 105' ' ' HIS . 6.8 t-80 -85.46 108.94 18.13 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.195 -0.941 . . . . 0.0 109.282 179.936 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 68.2 p -123.49 2.42 9.01 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.22 -0.925 . . . . 0.0 109.91 -179.888 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -155.05 175.06 33.19 Favored Glycine 0 N--CA 1.492 2.416 0 N-CA-C 109.818 -1.313 . . . . 0.0 109.818 -179.834 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -79.78 157.62 24.48 Favored 'Trans proline' 0 C--N 1.307 -1.617 0 C-N-CA 123.112 2.541 . . . . 0.0 112.142 179.714 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 78.11 45.17 10.5 Favored Glycine 0 N--CA 1.493 2.47 0 N-CA-C 109.678 -1.369 . . . . 0.0 109.678 179.604 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.72 137.33 50.92 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.378 -1.072 . . . . 0.0 109.754 -179.825 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.541 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 2.8 mm? -91.11 129.76 37.07 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.283 -0.886 . . . . 0.0 109.097 179.439 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 29.1 t -142.43 143.6 32.71 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.188 -0.945 . . . . 0.0 109.486 179.954 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 72.2 mtm -89.33 133.31 34.54 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.161 -0.962 . . . . 0.0 109.334 179.839 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -64.98 142.35 58.47 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.18 -0.95 . . . . 0.0 109.311 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 115' ' ' ASN . . . . . 0.525 ' ND2' ' O ' ' A' ' 117' ' ' GLY . 53.2 t-20 -143.04 153.16 42.67 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.204 -0.935 . . . . 0.0 109.85 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 116' ' ' ALA . . . . . 0.471 ' N ' ' OD1' ' A' ' 115' ' ' ASN . . . -123.91 -12.31 7.54 Favored 'General case' 0 N--CA 1.493 1.688 0 N-CA-C 108.836 -0.802 . . . . 0.0 108.836 179.624 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 117' ' ' GLY . . . . . 0.525 ' O ' ' ND2' ' A' ' 115' ' ' ASN . . . -145.52 166.34 27.75 Favored Glycine 0 N--CA 1.493 2.472 0 N-CA-C 109.236 -1.545 . . . . 0.0 109.236 179.934 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -70.74 152.28 64.1 Favored 'Trans proline' 0 C--N 1.306 -1.696 0 C-N-CA 122.72 2.28 . . . . 0.0 112.108 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 76.2 m-20 52.98 41.62 32.14 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.473 -0.767 . . . . 0.0 109.502 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 120' ' ' THR . . . . . 0.52 ' O ' ' ND2' ' A' ' 115' ' ' ASN . 62.2 m -138.75 125.79 21.27 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.339 -0.851 . . . . 0.0 109.223 179.771 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 121' ' ' ASN . . . . . 0.533 ' OD1' ' CZ ' ' A' ' 96' ' ' PHE . 28.7 m120 -106.32 121.89 45.13 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.532 -0.73 . . . . 0.0 109.383 179.844 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -93.6 132.85 11.4 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.669 -1.372 . . . . 0.0 109.669 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 18.8 m -58.83 -33.66 70.65 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.29 -1.123 . . . . 0.0 109.399 179.773 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.3 mt-30 -68.97 145.29 53.73 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.372 -0.83 . . . . 0.0 109.636 -179.793 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 48.8 p90 -135.66 162.54 32.45 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.408 -0.808 . . . . 0.0 109.133 179.83 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 126' ' ' PHE . . . . . 0.506 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 48.9 p90 -136.51 157.1 47.57 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.176 -0.953 . . . . 0.0 109.775 -179.927 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 68.3 mt -120.9 136.54 57.56 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.506 -0.746 . . . . 0.0 109.288 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 23.0 t -115.95 126.74 54.27 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.269 -0.894 . . . . 0.0 109.416 179.881 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 28.0 p -102.51 11.17 38.27 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.353 -0.842 . . . . 0.0 109.511 -179.891 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -140.39 163.29 33.2 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.306 -0.871 . . . . 0.0 109.431 -179.775 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 71.9 mmtt -67.51 138.29 56.44 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.252 -0.905 . . . . 0.0 109.205 -179.946 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 61.6 p -150.18 85.29 1.4 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.295 -0.878 . . . . 0.0 109.534 -179.868 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -62.82 -36.09 82.05 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.278 -0.889 . . . . 0.0 109.85 -179.895 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 0.9 OUTLIER -64.76 -46.3 82.74 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.125 -0.984 . . . . 0.0 109.515 -179.892 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 18.1 mt -65.83 -32.4 73.9 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.232 -0.918 . . . . 0.0 109.611 179.266 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 136' ' ' ASP . . . . . 0.445 ' OD2' ' O ' ' A' ' 105' ' ' HIS . 60.9 t0 -79.71 119.65 22.93 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.308 -0.87 . . . . 0.0 109.71 -179.816 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 165.57 -100.54 0.17 Allowed Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 62.5 mttp -57.45 -36.16 71.05 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.294 -1.121 . . . . 0.0 109.825 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 78.0 m80 -65.04 150.22 48.48 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.338 -0.851 . . . . 0.0 109.705 -179.501 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.539 HG21 ' OD2' ' A' ' 98' ' ' ASP . 49.8 t -123.33 144.7 32.02 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 121.542 -0.724 . . . . 0.0 109.423 -179.739 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 61.7 t -92.45 130.58 41.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.293 -0.879 . . . . 0.0 109.857 -179.548 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 40.2 p90 -112.98 -3.11 14.1 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.445 -0.784 . . . . 0.0 109.328 179.624 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -168.19 177.35 42.37 Favored Glycine 0 N--CA 1.492 2.402 0 N-CA-C 109.169 -1.572 . . . . 0.0 109.169 179.796 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.2 pt20 -146.61 166.94 25.0 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.075 -1.25 . . . . 0.0 109.741 -179.744 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 75.0 t -96.45 129.7 46.14 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.283 0 O-C-N 121.266 -0.896 . . . . 0.0 109.389 -179.843 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 15.8 m -105.65 -33.92 2.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.339 -0.851 . . . . 0.0 109.723 179.756 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -142.45 169.17 18.08 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.274 -0.891 . . . . 0.0 109.689 -179.75 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 95.89 7.97 58.36 Favored Glycine 0 N--CA 1.493 2.47 0 N-CA-C 109.929 -1.269 . . . . 0.0 109.929 179.612 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 149' ' ' MET . . . . . 0.493 ' O ' HG12 ' A' ' 152' ' ' VAL . 64.9 mtt -60.34 -34.05 73.29 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.155 -1.203 . . . . 0.0 109.776 179.989 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 89.1 m-20 -65.03 -42.33 94.46 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 120.865 -1.147 . . . . 0.0 110.03 -179.553 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.6 p -82.44 -32.09 10.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.21 -0.932 . . . . 0.0 110.653 -179.263 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 152' ' ' VAL . . . . . 0.493 HG12 ' O ' ' A' ' 149' ' ' MET . 0.8 OUTLIER -55.58 -40.67 60.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 120.833 -1.167 . . . . 0.0 109.008 -179.332 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 153' ' ' LYS . . . . . 0.43 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 67.0 mttm -62.92 -36.46 83.46 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.132 -0.98 . . . . 0.0 108.999 179.396 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -62.45 -35.08 78.16 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.305 -0.872 . . . . 0.0 109.414 179.825 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.569 HD11 ' SD ' ' A' ' 16' ' ' MET . 93.6 mt -67.35 -12.79 15.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.513 -0.742 . . . . 0.0 109.808 179.9 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -118.55 -19.48 8.76 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 -179.617 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 157' ' ' LYS . . . . . 0.403 ' N ' ' O ' ' A' ' 153' ' ' LYS . 38.9 tttm -58.83 -42.18 88.63 Favored 'General case' 0 C--N 1.299 -1.597 0 CA-C-O 121.376 0.608 . . . . 0.0 109.743 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 16.5 m -83.75 -12.56 11.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.533 -0.729 . . . . 0.0 109.25 179.449 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 159' ' ' GLY . . . . . 0.648 ' HA2' HG22 ' A' ' 165' ' ' THR . . . -59.97 151.98 37.0 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.941 -1.264 . . . . 0.0 109.941 -179.729 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 27.0 t -143.27 158.31 43.73 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.505 -0.997 . . . . 0.0 109.255 179.917 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 22.9 t -54.1 -33.85 58.73 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.151 -0.968 . . . . 0.0 109.307 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 24.5 m -57.75 -29.47 64.82 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.321 -0.862 . . . . 0.0 109.401 179.682 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 100.52 1.05 55.48 Favored Glycine 0 N--CA 1.493 2.45 0 N-CA-C 109.263 -1.535 . . . . 0.0 109.263 -179.656 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 72.2 ttt-85 -108.16 149.98 27.83 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.477 -1.013 . . . . 0.0 108.933 179.666 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 165' ' ' THR . . . . . 0.648 HG22 ' HA2' ' A' ' 159' ' ' GLY . 69.8 p -117.05 155.51 29.12 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.272 -0.892 . . . . 0.0 110.104 -179.582 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -70.14 -37.29 75.23 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.578 -0.702 . . . . 0.0 109.694 179.776 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 53.9 mttm -109.56 152.6 25.28 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.359 -0.838 . . . . 0.0 109.928 -179.392 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 63.7 mttm -87.95 151.33 22.88 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.404 -0.81 . . . . 0.0 109.43 179.911 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 169' ' ' VAL . . . . . 0.436 ' O ' HG23 ' A' ' 169' ' ' VAL . 34.5 m -125.7 127.61 71.59 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 121.247 -0.908 . . . . 0.0 109.744 -179.988 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 43.4 t -146.63 145.91 19.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.245 -0.909 . . . . 0.0 109.196 179.722 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -88.15 120.95 37.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.111 -0.993 . . . . 0.0 109.479 -179.727 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -62.69 -28.59 70.04 Favored 'General case' 0 C--N 1.3 -1.586 0 N-CA-C 108.901 -0.777 . . . . 0.0 108.901 179.489 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 52.0 p30 -178.67 170.15 1.62 Allowed 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.383 -0.823 . . . . 0.0 110.202 -179.881 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 174' ' ' CYS . . . . . 0.568 ' SG ' ' CE2' ' A' ' 14' ' ' PHE . 54.1 t -139.43 134.98 33.12 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.529 -0.732 . . . . 0.0 109.062 179.356 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -150.67 169.25 30.52 Favored Glycine 0 N--CA 1.493 2.496 0 N-CA-C 109.738 -1.345 . . . . 0.0 109.738 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 176' ' ' GLN . . . . . 0.658 HE22 ' CZ ' ' A' ' 43' ' ' ARG . 63.9 tt0 -108.52 122.75 47.71 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.453 -1.028 . . . . 0.0 109.497 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 177' ' ' LEU . . . . . 0.605 HD13 ' O ' ' A' ' 177' ' ' LEU . 0.2 OUTLIER -63.72 -38.59 91.67 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.23 -0.919 . . . . 0.0 108.908 179.714 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 27.0 t . . . . . 0 N--CA 1.49 1.526 0 O-C-N 121.027 -1.046 . . . . 0.0 109.455 179.872 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 . . . . . 0 N--CA 1.492 1.632 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -68.1 139.69 47.35 Favored 'Trans proline' 0 N--CA 1.497 1.706 0 C-N-CA 122.713 2.276 . . . . 0.0 112.464 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 82.3 mtp180 -132.28 134.47 45.31 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.419 -0.8 . . . . 0.0 108.869 179.071 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.8 p -135.29 143.49 36.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 O-C-N 121.256 -0.903 . . . . 0.0 109.539 -179.652 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 42.8 p90 -138.95 155.61 47.9 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.321 -0.862 . . . . 0.0 109.459 179.948 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.593 ' CE2' ' SG ' ' A' ' 174' ' ' CYS . 76.4 m-85 -122.13 137.87 54.67 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.451 -0.781 . . . . 0.0 109.697 179.883 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 22.8 t70 -88.04 117.02 26.63 Favored 'General case' 0 N--CA 1.493 1.719 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 179.123 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' MET . . . . . 0.412 ' SD ' HD12 ' A' ' 26' ' ' ILE . 83.3 mtp -104.63 143.87 32.48 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.342 -0.849 . . . . 0.0 110.713 -179.044 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.463 ' OG ' ' OE2' ' A' ' 172' ' ' GLU . 61.9 m -141.43 159.3 42.51 Favored 'General case' 0 N--CA 1.49 1.551 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 179.383 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.47 HG13 ' HB2' ' A' ' 23' ' ' ALA . 33.1 m -123.58 147.95 27.77 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.179 -0.95 . . . . 0.0 109.756 -179.759 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 49.09 -107.75 0.33 Allowed Glycine 0 N--CA 1.488 2.113 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.925 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -128.83 25.83 4.62 Favored Glycine 0 N--CA 1.494 2.53 0 N-CA-C 109.631 -1.387 . . . . 0.0 109.631 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 10.7 pt20 -141.58 149.5 54.15 Favored Pre-proline 0 N--CA 1.493 1.714 0 O-C-N 121.3 -1.118 . . . . 0.0 109.29 179.846 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -67.57 138.43 45.64 Favored 'Trans proline' 0 N--CA 1.494 1.544 0 C-N-CA 122.504 2.136 . . . . 0.0 112.108 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.47 ' HB2' HG13 ' A' ' 18' ' ' VAL . . . -101.72 -54.29 2.77 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.411 -0.806 . . . . 0.0 109.216 179.713 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -176.02 -171.25 39.67 Favored Glycine 0 N--CA 1.488 2.156 0 N-CA-C 109.317 -1.513 . . . . 0.0 109.317 -179.916 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 33.0 ptt180 -131.1 148.57 52.75 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.482 -1.011 . . . . 0.0 109.138 179.73 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.412 HD12 ' SD ' ' A' ' 16' ' ' MET . 82.8 mt -122.91 130.11 74.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.318 -0.864 . . . . 0.0 109.248 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 42.0 t -111.0 132.63 58.97 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.491 -0.756 . . . . 0.0 109.222 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 74.1 mtm -120.88 146.93 46.08 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.439 -0.788 . . . . 0.0 109.18 -179.894 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -101.13 131.12 47.23 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.294 -0.879 . . . . 0.0 109.794 -179.718 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.418 ' N ' ' CD2' ' A' ' 30' ' ' LEU . 2.5 mm? -106.2 131.67 53.17 Favored 'General case' 0 N--CA 1.493 1.693 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 179.512 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 95.4 m-85 -98.4 118.29 34.74 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.215 -0.928 . . . . 0.0 109.024 179.572 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -80.68 -42.82 21.38 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.341 -0.85 . . . . 0.0 109.771 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -64.7 -45.89 84.67 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.293 -0.879 . . . . 0.0 110.311 -179.328 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 34' ' ' THR . . . . . 0.409 HG21 ' CE ' ' A' ' 103' ' ' LYS . 26.4 m -67.8 -45.13 75.67 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.121 -0.987 . . . . 0.0 109.835 -179.57 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.472 ' O ' ' OG1' ' A' ' 35' ' ' THR . 4.6 p -142.67 81.4 13.37 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 121.282 -0.886 . . . . 0.0 109.325 -179.75 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -64.27 -58.29 0.26 Allowed 'Trans proline' 0 N--CA 1.494 1.537 0 C-N-CA 122.283 1.989 . . . . 0.0 112.582 -179.347 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 78.4 mtp180 -62.03 -37.11 83.68 Favored 'General case' 0 C--N 1.299 -1.602 0 O-C-N 121.428 -0.795 . . . . 0.0 110.647 -179.132 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 28.1 m -61.91 -41.34 97.81 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.87 -1.144 . . . . 0.0 109.981 -179.542 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -61.3 -31.23 71.07 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.11 -0.994 . . . . 0.0 109.311 -179.739 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.592 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 97.0 mt-10 -66.69 -35.34 79.91 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.351 -0.843 . . . . 0.0 109.885 -179.862 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 88.6 m-20 -55.98 -37.29 68.87 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.256 -0.903 . . . . 0.0 109.85 -179.688 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -97.67 -53.29 3.47 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.221 -0.925 . . . . 0.0 110.024 -179.852 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 59.7 ttp180 -57.94 -42.74 85.54 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.329 -0.857 . . . . 0.0 110.605 -179.179 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.592 ' HB3' ' O ' ' A' ' 40' ' ' GLU . . . -67.73 -44.67 77.05 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.904 -1.123 . . . . 0.0 110.305 -179.181 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.5 ' N ' ' CD2' ' A' ' 45' ' ' LEU . 2.5 mm? -65.74 -40.51 92.19 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.004 -1.06 . . . . 0.0 109.7 -179.801 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 46' ' ' CYS . . . . . . . . . . . . . 72.0 m -67.63 -49.54 62.47 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.067 -1.02 . . . . 0.0 109.334 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 57.5 p -74.46 -32.0 62.43 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.397 -0.814 . . . . 0.0 109.38 179.755 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 48' ' ' GLY . . . . . 0.459 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 75.85 33.63 50.46 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 110.217 -1.153 . . . . 0.0 110.217 179.457 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -62.23 -37.66 86.22 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.99 -1.3 . . . . 0.0 109.423 179.78 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 54.6 mmtt -61.94 -34.12 75.52 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.275 -0.89 . . . . 0.0 109.349 179.934 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 92.53 172.48 41.27 Favored Glycine 0 N--CA 1.486 2.012 0 N-CA-C 109.239 -1.544 . . . . 0.0 109.239 -179.677 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.536 HG23 ' HA ' ' A' ' 58' ' ' PRO . 89.3 m -73.85 140.73 45.95 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.322 -1.105 . . . . 0.0 109.833 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -57.62 136.17 50.99 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.284 -1.527 . . . . 0.0 109.284 179.829 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 75.6 mtm180 -59.25 -34.11 71.85 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.243 -1.151 . . . . 0.0 110.017 -179.647 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 86.6 p -61.0 -24.82 66.44 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.102 -0.999 . . . . 0.0 109.942 -179.699 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 112.74 90.45 1.89 Allowed Glycine 0 N--CA 1.494 2.507 0 N-CA-C 109.109 -1.596 . . . . 0.0 109.109 -179.696 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 57' ' ' LYS . . . . . 0.531 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 3.0 ttmp? -175.25 80.73 0.31 Allowed Pre-proline 0 N--CA 1.489 1.502 0 O-C-N 121.479 -1.012 . . . . 0.0 108.448 -179.708 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.536 ' HA ' HG23 ' A' ' 52' ' ' THR . 69.7 Cg_exo -51.18 132.33 38.5 Favored 'Trans proline' 0 C--N 1.303 -1.847 0 C-N-CA 122.942 2.428 . . . . 0.0 112.848 -179.05 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.531 ' CD1' ' O ' ' A' ' 57' ' ' LYS . 7.6 mp -101.09 127.39 47.64 Favored 'General case' 0 N--CA 1.493 1.7 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 179.811 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 6.1 p80 -176.14 132.4 0.24 Allowed 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.094 -1.004 . . . . 0.0 109.86 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 4.4 m-85 -96.95 13.34 29.23 Favored 'General case' 0 N--CA 1.492 1.65 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 179.091 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 85.8 mttt -77.46 149.77 35.01 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.416 -0.802 . . . . 0.0 109.639 -179.765 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 63' ' ' ASP . . . . . 0.408 ' N ' HG23 ' A' ' 171' ' ' VAL . 46.4 t0 61.4 35.03 17.99 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.581 -0.699 . . . . 0.0 109.618 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.814 ' H ' ' CG2' ' A' ' 171' ' ' VAL . 55.3 p -83.94 160.08 21.15 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.278 -0.889 . . . . 0.0 108.808 179.094 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 31.3 t -128.58 147.96 50.75 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.168 -0.957 . . . . 0.0 109.57 -179.776 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 22.3 m-85 -72.25 130.12 40.06 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.258 -0.901 . . . . 0.0 109.296 179.86 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 79.4 t60 -61.79 -48.99 78.12 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.16 -0.962 . . . . 0.0 109.481 -179.88 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 37.1 ptt180 -164.71 159.74 19.08 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.27 -0.894 . . . . 0.0 109.678 179.671 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.575 HG21 HG22 ' A' ' 165' ' ' THR . 23.0 m -132.51 148.46 31.8 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 179.539 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 11.5 mt -146.79 125.07 6.17 Favored Pre-proline 0 N--CA 1.494 1.735 0 O-C-N 120.956 -1.09 . . . . 0.0 109.576 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -75.34 135.36 18.37 Favored 'Trans proline' 0 N--CA 1.491 1.34 0 C-N-CA 122.264 1.976 . . . . 0.0 112.117 179.667 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 89.67 1.56 77.19 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.686 -1.365 . . . . 0.0 109.686 179.795 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 95.3 m-85 -134.25 -96.09 0.28 Allowed 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.359 -1.083 . . . . 0.0 109.558 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 74' ' ' MET . . . . . 0.6 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 5.9 ptt? -166.67 158.85 13.5 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.047 -1.033 . . . . 0.0 109.686 -179.659 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 1.7 m -98.45 123.35 42.54 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.417 -0.802 . . . . 0.0 109.008 179.402 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 63.6 tt0 -98.87 125.91 44.39 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.276 -0.89 . . . . 0.0 109.811 -179.584 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -84.85 -174.06 50.16 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 179.599 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -137.59 155.52 23.1 Favored Glycine 0 N--CA 1.494 2.513 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 87.7 m-20 -77.02 150.5 35.8 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.226 -1.161 . . . . 0.0 109.502 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 40.8 p90 -64.85 -22.87 67.07 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.142 -0.974 . . . . 0.0 109.443 -179.856 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.468 ' O ' ' HB2' ' A' ' 82' ' ' ALA . 58.9 p -67.11 -30.98 71.15 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.294 -0.879 . . . . 0.0 109.52 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 82' ' ' ALA . . . . . 0.468 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 176.77 -56.44 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.314 -0.866 . . . . 0.0 109.328 179.953 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 96.12 -10.69 67.76 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 78.7 m-20 -89.15 3.22 52.61 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.177 -1.19 . . . . 0.0 109.323 179.813 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 95.19 -5.54 68.26 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.404 -1.479 . . . . 0.0 109.404 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 64.5 p -72.79 -21.98 60.9 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.245 -1.15 . . . . 0.0 109.41 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -125.32 -123.5 2.71 Favored Glycine 0 N--CA 1.494 2.53 0 N-CA-C 109.384 -1.486 . . . . 0.0 109.384 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 75.6 42.01 27.9 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 179.896 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -79.7 146.55 32.36 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.369 -1.077 . . . . 0.0 109.439 -179.883 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 50.8 m -108.86 148.61 30.35 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.384 -0.822 . . . . 0.0 109.265 -179.83 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.405 HG13 ' N ' ' A' ' 92' ' ' TYR . 15.8 pt -62.6 -39.42 84.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.295 -0.878 . . . . 0.0 109.948 -179.62 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 92' ' ' TYR . . . . . 0.405 ' N ' HG13 ' A' ' 91' ' ' ILE . 73.6 m-85 -68.0 -37.26 81.24 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.112 -0.993 . . . . 0.0 109.578 179.932 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 78.14 14.66 82.03 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 -179.932 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -148.87 158.48 44.2 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.238 -1.154 . . . . 0.0 109.588 -179.825 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 95' ' ' LYS . . . . . 0.466 ' HD3' HG23 ' A' ' 120' ' ' THR . 42.7 mttm -85.3 149.51 25.41 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.238 -0.914 . . . . 0.0 109.596 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 96' ' ' PHE . . . . . 0.678 ' CE1' ' ND2' ' A' ' 121' ' ' ASN . 55.1 p90 -137.12 161.21 36.76 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.268 -0.895 . . . . 0.0 109.453 179.696 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -102.78 148.33 25.75 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.295 -0.878 . . . . 0.0 109.394 -179.785 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 89.3 m-20 -68.41 133.13 48.19 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.264 -0.897 . . . . 0.0 109.352 -179.897 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -66.26 -37.49 85.59 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.235 -0.916 . . . . 0.0 110.134 -179.731 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 86.9 m-20 -126.68 125.15 41.37 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.224 -0.922 . . . . 0.0 110.098 -179.477 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 101' ' ' PHE . . . . . 0.536 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 69.3 t80 -103.11 5.3 37.84 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.318 -0.864 . . . . 0.0 108.886 179.351 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 91.0 mt -57.19 -34.69 46.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.397 -0.814 . . . . 0.0 110.545 -179.187 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 103' ' ' LYS . . . . . 0.409 ' CE ' HG21 ' A' ' 34' ' ' THR . 91.7 mttt -72.55 135.08 45.52 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.808 -1.182 . . . . 0.0 109.951 -179.358 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 10.4 ptpp? -139.89 -179.05 5.72 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.435 -0.791 . . . . 0.0 109.382 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 105' ' ' HIS . . . . . 0.523 ' CE1' ' O ' ' A' ' 107' ' ' GLY . 82.3 t60 -84.33 77.6 9.96 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.149 -0.969 . . . . 0.0 109.165 179.872 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 54.6 p -75.5 -27.83 58.94 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.324 -0.86 . . . . 0.0 110.154 -179.581 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.523 ' O ' ' CE1' ' A' ' 105' ' ' HIS . . . -149.14 177.78 27.12 Favored Glycine 0 N--CA 1.494 2.517 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 -179.581 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -72.74 155.18 54.17 Favored 'Trans proline' 0 C--N 1.307 -1.65 0 C-N-CA 122.991 2.461 . . . . 0.0 112.314 179.792 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 82.6 47.0 6.15 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 110.138 -1.185 . . . . 0.0 110.138 179.588 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.417 HG12 ' O ' ' A' ' 107' ' ' GLY . 41.8 mm -115.7 138.09 47.24 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.819 0 O-C-N 121.302 -1.116 . . . . 0.0 109.628 179.857 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.418 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 3.7 mm? -89.15 126.72 35.59 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.267 -0.895 . . . . 0.0 109.216 179.627 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 112' ' ' SER . . . . . 0.4 ' OG ' ' O ' ' A' ' 140' ' ' VAL . 38.9 t -142.72 142.15 31.91 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.334 -0.854 . . . . 0.0 109.509 179.863 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER -91.55 141.27 28.9 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.319 -0.863 . . . . 0.0 109.174 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 114' ' ' ALA . . . . . 0.521 ' O ' ' N ' ' A' ' 122' ' ' GLY . . . -63.49 147.31 51.7 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.267 -0.896 . . . . 0.0 109.594 179.986 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 115' ' ' ASN . . . . . 0.42 ' OD1' ' O ' ' A' ' 114' ' ' ALA . 65.6 m-20 -137.23 112.72 9.35 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.332 -0.855 . . . . 0.0 109.002 179.612 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -72.23 -32.03 66.37 Favored 'General case' 0 C--N 1.294 -1.811 0 O-C-N 121.466 -0.771 . . . . 0.0 109.432 179.807 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -148.49 176.08 27.46 Favored Glycine 0 N--CA 1.492 2.393 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 179.848 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 118' ' ' PRO . . . . . 0.43 ' O ' ' CG ' ' A' ' 119' ' ' ASN . 71.6 Cg_exo -50.31 148.03 15.17 Favored 'Trans proline' 0 C--N 1.304 -1.786 0 C-N-CA 122.604 2.203 . . . . 0.0 112.903 179.855 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 119' ' ' ASN . . . . . 0.43 ' CG ' ' O ' ' A' ' 118' ' ' PRO . 7.0 p-10 41.83 49.04 3.9 Favored 'General case' 0 N--CA 1.494 1.751 0 CA-C-O 121.135 0.493 . . . . 0.0 110.11 179.451 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 120' ' ' THR . . . . . 0.466 HG23 ' HD3' ' A' ' 95' ' ' LYS . 87.9 m -131.38 124.9 31.31 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.308 -0.87 . . . . 0.0 109.004 179.55 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 121' ' ' ASN . . . . . 0.678 ' ND2' ' CE1' ' A' ' 96' ' ' PHE . 80.5 m-20 -101.93 119.1 38.25 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.535 -0.728 . . . . 0.0 109.237 179.768 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 122' ' ' GLY . . . . . 0.521 ' N ' ' O ' ' A' ' 114' ' ' ALA . . . -84.41 142.2 20.21 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.719 -1.352 . . . . 0.0 109.719 -179.751 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 88.1 p -64.26 -22.83 67.09 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.367 -1.078 . . . . 0.0 109.337 179.739 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 92.9 mt-30 -95.12 151.61 19.06 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.296 -0.878 . . . . 0.0 109.511 -179.873 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 49.3 p90 -134.79 161.57 34.83 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.364 -0.835 . . . . 0.0 109.428 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 126' ' ' PHE . . . . . 0.6 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 54.1 p90 -138.94 158.88 43.41 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.33 -0.856 . . . . 0.0 109.547 -179.955 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 72.6 mt -121.31 130.75 74.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.435 -0.791 . . . . 0.0 109.486 179.758 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 1.6 m -93.25 105.74 17.78 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.273 -0.892 . . . . 0.0 108.89 179.663 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 60.0 p -75.49 -7.05 53.14 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.379 -0.826 . . . . 0.0 109.711 -179.713 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -149.21 156.28 41.9 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.158 -0.964 . . . . 0.0 109.741 -179.769 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 55.7 tttp -69.38 141.27 54.18 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.212 -0.93 . . . . 0.0 109.236 179.808 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 20.7 p -114.66 153.95 29.28 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.397 -0.814 . . . . 0.0 109.604 -179.858 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 133' ' ' GLU . . . . . 0.423 ' O ' ' CG ' ' A' ' 136' ' ' ASP . 92.6 mt-10 -106.23 -73.49 0.68 Allowed 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.385 -0.822 . . . . 0.0 109.925 -179.925 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 134' ' ' TRP . . . . . 0.524 ' CD1' ' N ' ' A' ' 135' ' ' LEU . 42.8 p90 -56.03 -36.74 68.32 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.265 -0.897 . . . . 0.0 110.109 -179.535 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 135' ' ' LEU . . . . . 0.524 ' N ' ' CD1' ' A' ' 134' ' ' TRP . 6.9 tp -74.6 4.04 6.79 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.251 -0.906 . . . . 0.0 109.559 -179.327 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 136' ' ' ASP . . . . . 0.452 ' C ' ' OD1' ' A' ' 136' ' ' ASP . 53.5 p30 -67.36 167.29 12.77 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.99 -1.069 . . . . 0.0 109.569 -179.941 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 148.96 -134.0 4.77 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.17 -1.572 . . . . 0.0 109.17 -179.909 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 13.7 mptt -91.76 128.84 37.75 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.208 -1.172 . . . . 0.0 109.018 179.647 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 139' ' ' HIS . . . . . 0.459 ' O ' ' CE1' ' A' ' 101' ' ' PHE . 98.4 m-70 -135.72 152.61 51.32 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.287 -0.883 . . . . 0.0 109.647 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.4 ' O ' ' OG ' ' A' ' 112' ' ' SER . 24.5 m -127.73 149.82 33.02 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 121.351 -0.843 . . . . 0.0 109.022 179.573 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 46.1 t -132.08 125.81 55.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.272 -0.892 . . . . 0.0 109.763 -180.0 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 47.1 p90 -109.64 3.01 20.61 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.446 -0.784 . . . . 0.0 108.932 178.932 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -178.11 178.6 48.55 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.024 -1.63 . . . . 0.0 109.024 179.562 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.3 pt20 -145.95 166.68 25.3 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.09 -1.241 . . . . 0.0 109.614 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 69.7 t -97.04 128.37 48.33 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.245 0 O-C-N 121.21 -0.931 . . . . 0.0 109.4 -179.719 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 15.9 m -103.83 -32.01 2.91 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 O-C-N 121.421 -0.799 . . . . 0.0 109.395 179.588 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -143.45 170.07 16.49 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.329 -0.857 . . . . 0.0 109.407 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 96.55 5.13 59.08 Favored Glycine 0 N--CA 1.493 2.475 0 N-CA-C 109.909 -1.276 . . . . 0.0 109.909 179.61 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 149' ' ' MET . . . . . 0.545 ' O ' HG12 ' A' ' 152' ' ' VAL . 97.0 mmm -60.18 -32.22 70.86 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.144 -1.209 . . . . 0.0 109.458 179.778 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -65.36 -41.71 93.52 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.899 -1.125 . . . . 0.0 110.106 -179.548 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 6.7 p -80.96 -33.26 13.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 120.987 -1.07 . . . . 0.0 110.707 -179.279 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 152' ' ' VAL . . . . . 0.545 HG12 ' O ' ' A' ' 149' ' ' MET . 1.0 OUTLIER -51.92 -41.08 29.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 120.84 -1.162 . . . . 0.0 108.998 -179.264 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 153' ' ' LYS . . . . . 0.439 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 66.8 mttm -65.68 -33.38 75.75 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.214 -0.929 . . . . 0.0 109.214 179.213 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -60.63 -37.23 80.79 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.489 -0.757 . . . . 0.0 109.942 -179.42 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 88.4 mt -70.52 -37.63 70.75 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.524 0 O-C-N 121.156 -0.965 . . . . 0.0 110.066 -179.687 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -77.06 -41.16 43.53 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.196 -0.94 . . . . 0.0 111.556 -178.39 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 16.7 pttm -59.91 -35.4 74.8 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 120.57 -1.331 . . . . 0.0 109.735 -178.763 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 31.5 m -81.1 -10.39 12.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.041 -1.037 . . . . 0.0 109.017 179.395 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -71.95 165.61 53.84 Favored Glycine 0 N--CA 1.488 2.16 0 N-CA-C 110.056 -1.217 . . . . 0.0 110.056 -179.623 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 24.1 t -154.52 167.87 28.63 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.506 -0.996 . . . . 0.0 109.482 -179.858 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 24.8 m -54.46 -29.89 51.17 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.292 -0.88 . . . . 0.0 109.194 179.827 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 22.8 t -54.26 -30.79 51.8 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.307 -0.871 . . . . 0.0 109.506 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 95.41 12.22 54.5 Favored Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.817 -1.313 . . . . 0.0 109.817 179.916 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 42.1 ttp180 -125.78 143.67 50.96 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.298 -1.119 . . . . 0.0 109.467 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 165' ' ' THR . . . . . 0.575 HG22 HG21 ' A' ' 69' ' ' VAL . 71.5 p -74.63 151.28 39.35 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.094 -1.004 . . . . 0.0 109.326 179.936 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -66.31 -37.93 86.53 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.154 -0.967 . . . . 0.0 109.52 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 67.1 mttm -108.94 156.96 19.1 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.432 -0.792 . . . . 0.0 109.4 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 48.1 mtmt -72.53 130.61 41.04 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.205 -0.934 . . . . 0.0 109.268 179.816 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 25.0 t -124.75 124.14 67.35 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 O-C-N 121.434 -0.791 . . . . 0.0 109.427 -179.888 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 57.5 t -144.33 137.05 22.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.271 -0.893 . . . . 0.0 109.499 179.668 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.814 ' CG2' ' H ' ' A' ' 64' ' ' SER . 27.0 m -71.31 126.32 31.44 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.251 -0.905 . . . . 0.0 109.487 179.746 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 172' ' ' GLU . . . . . 0.49 ' O ' ' OD1' ' A' ' 173' ' ' ASP . 96.3 mt-10 -69.84 -40.72 75.65 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.077 -1.014 . . . . 0.0 109.901 179.855 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 173' ' ' ASP . . . . . 0.49 ' OD1' ' O ' ' A' ' 172' ' ' GLU . 49.7 m-20 -163.91 167.67 20.36 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.219 -0.925 . . . . 0.0 110.218 -179.641 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 174' ' ' CYS . . . . . 0.593 ' SG ' ' CE2' ' A' ' 14' ' ' PHE . 43.7 t -136.51 140.82 43.29 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.581 -0.7 . . . . 0.0 109.306 179.597 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -154.94 173.34 33.29 Favored Glycine 0 N--CA 1.493 2.491 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 179.907 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 63.8 tt0 -104.48 119.25 38.56 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.343 -1.092 . . . . 0.0 109.526 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 34.5 tp -61.83 -38.24 87.45 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.203 -0.936 . . . . 0.0 109.575 179.897 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 8.7 t . . . . . 0 N--CA 1.488 1.454 0 O-C-N 121.094 -1.004 . . . . 0.0 109.454 -179.964 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 86.7 m-20 . . . . . 0 N--CA 1.49 1.562 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -70.21 141.68 44.03 Favored 'Trans proline' 0 N--CA 1.496 1.634 0 C-N-CA 122.769 2.313 . . . . 0.0 112.244 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 59.2 mtm180 -127.89 134.52 49.38 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.376 -0.827 . . . . 0.0 108.902 179.294 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 9.6 p -136.21 144.36 33.31 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.389 -0.819 . . . . 0.0 109.309 -179.701 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 48.3 p90 -138.1 153.89 49.26 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.342 -0.849 . . . . 0.0 109.477 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 88.7 m-85 -121.28 136.36 54.98 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.568 -0.707 . . . . 0.0 109.735 179.755 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -93.62 131.4 38.94 Favored 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 179.228 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' MET . . . . . 0.424 ' SD ' ' CD1' ' A' ' 26' ' ' ILE . 74.2 mtp -125.45 153.24 43.79 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.118 -0.989 . . . . 0.0 110.282 -179.386 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 85.2 p -143.78 161.05 39.62 Favored 'General case' 0 N--CA 1.488 1.463 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 179.718 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.422 ' C ' ' N ' ' A' ' 20' ' ' GLY . 33.0 m -126.32 137.49 57.62 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.105 -0.997 . . . . 0.0 109.534 -179.925 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 53.43 11.62 1.84 Allowed Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 179.848 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.422 ' N ' ' C ' ' A' ' 18' ' ' VAL . . . 95.6 -1.39 63.89 Favored Glycine 0 N--CA 1.493 2.465 0 N-CA-C 109.779 -1.328 . . . . 0.0 109.779 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 2.6 mp0 -99.93 152.09 37.7 Favored Pre-proline 0 N--CA 1.495 1.806 0 O-C-N 121.229 -1.159 . . . . 0.0 109.149 179.876 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -61.66 138.52 75.58 Favored 'Trans proline' 0 C--N 1.308 -1.558 0 C-N-CA 122.581 2.187 . . . . 0.0 112.15 -179.83 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -111.69 -64.18 1.32 Allowed 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.441 -0.787 . . . . 0.0 109.471 179.893 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -179.9 -168.75 39.12 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.414 -1.475 . . . . 0.0 109.414 -179.882 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 79.7 mtm180 -114.37 142.18 46.67 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.381 -1.07 . . . . 0.0 109.759 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.424 ' CD1' ' SD ' ' A' ' 16' ' ' MET . 80.2 mt -122.93 121.1 62.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 179.11 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 40.2 t -120.85 134.6 63.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.469 -0.769 . . . . 0.0 109.27 -179.808 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 72.6 mtm -122.44 154.81 37.28 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.405 -0.809 . . . . 0.0 109.349 -179.845 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -100.85 132.0 46.47 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.347 -0.845 . . . . 0.0 109.968 -179.611 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -107.48 128.93 54.93 Favored 'General case' 0 N--CA 1.493 1.717 0 N-CA-C 108.914 -0.772 . . . . 0.0 108.914 179.318 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -98.04 119.66 37.08 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.189 -0.944 . . . . 0.0 109.058 179.661 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -78.84 -40.16 33.47 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.318 -0.864 . . . . 0.0 110.047 -179.623 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.531 ' OD1' ' N ' ' A' ' 34' ' ' THR . 31.6 p-10 -68.72 -40.79 79.75 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.258 -0.902 . . . . 0.0 110.859 -179.093 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 34' ' ' THR . . . . . 0.531 ' N ' ' OD1' ' A' ' 33' ' ' ASP . 17.4 m -67.51 -44.56 78.15 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.018 -1.051 . . . . 0.0 109.834 -179.4 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 38.2 p -154.03 83.99 4.16 Favored Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.385 -0.822 . . . . 0.0 109.018 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -70.53 -40.84 3.75 Favored 'Trans proline' 0 C--N 1.309 -1.544 0 C-N-CA 122.085 1.856 . . . . 0.0 112.333 -179.212 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.423 ' HD2' ' H ' ' A' ' 37' ' ' ARG . 1.5 mpt_? -63.71 -40.95 98.04 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.168 -0.958 . . . . 0.0 109.667 -179.973 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 38.3 m -66.16 -41.52 90.24 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.19 -0.944 . . . . 0.0 110.004 -179.755 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -60.66 -32.39 71.58 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.174 -0.953 . . . . 0.0 109.032 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -68.05 -38.23 82.24 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.433 -0.792 . . . . 0.0 109.735 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 46.4 t30 -58.23 -41.41 84.07 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.248 -0.908 . . . . 0.0 109.935 -179.436 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.494 ' O ' ' SG ' ' A' ' 46' ' ' CYS . 97.4 m-85 -86.15 -41.08 15.02 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.047 -1.033 . . . . 0.0 110.108 -179.664 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 61.3 ttp180 -59.14 -44.42 92.05 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.229 -0.919 . . . . 0.0 110.937 -178.925 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -71.17 -46.09 62.11 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 120.945 -1.097 . . . . 0.0 110.259 -179.271 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.498 ' N ' ' CD2' ' A' ' 45' ' ' LEU . 2.3 mm? -65.3 -38.13 89.26 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.164 -0.96 . . . . 0.0 109.69 -179.711 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 46' ' ' CYS . . . . . 0.494 ' SG ' ' O ' ' A' ' 42' ' ' PHE . 73.8 m -71.12 -50.5 32.82 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.098 -1.001 . . . . 0.0 109.576 -179.895 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 30.9 m -63.92 -36.72 84.89 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.329 -0.857 . . . . 0.0 109.589 -179.933 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 95.59 8.24 58.52 Favored Glycine 0 N--CA 1.493 2.46 0 N-CA-C 109.838 -1.305 . . . . 0.0 109.838 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 78.1 mm-40 -61.25 -32.24 72.04 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.238 -1.154 . . . . 0.0 109.526 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 20.9 tptp -58.25 -38.97 77.94 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.255 -0.903 . . . . 0.0 109.482 -179.11 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 90.65 171.45 43.75 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 110.018 -1.233 . . . . 0.0 110.018 179.558 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.555 ' O ' ' O ' ' A' ' 53' ' ' GLY . 81.7 m -79.08 148.44 32.42 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.585 -0.95 . . . . 0.0 109.479 179.925 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.555 ' O ' ' O ' ' A' ' 52' ' ' THR . . . -54.93 -122.36 0.01 OUTLIER Glycine 0 N--CA 1.492 2.389 0 N-CA-C 110.036 -1.226 . . . . 0.0 110.036 -179.839 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 54' ' ' ARG . . . . . 0.537 ' O ' ' CB ' ' A' ' 55' ' ' SER . 93.0 mtt180 -57.5 -41.15 80.2 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 120.971 -1.311 . . . . 0.0 109.766 -179.498 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 55' ' ' SER . . . . . 0.537 ' CB ' ' O ' ' A' ' 54' ' ' ARG . 1.1 t 157.72 -26.86 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.724 0 N-CA-C 108.574 -0.898 . . . . 0.0 108.574 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -119.06 59.94 0.51 Allowed Glycine 0 N--CA 1.493 2.442 0 N-CA-C 109.169 -1.572 . . . . 0.0 109.169 179.926 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 36.4 tptt -172.05 70.97 0.45 Allowed Pre-proline 0 C--N 1.302 -1.474 0 O-C-N 121.447 -1.031 . . . . 0.0 108.56 -179.768 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 92.1 Cg_exo -42.9 94.8 0.02 OUTLIER 'Trans proline' 0 C--N 1.304 -1.766 0 C-N-CA 122.743 2.295 . . . . 0.0 112.202 -179.405 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.484 ' O ' ' CD1' ' A' ' 45' ' ' LEU . 8.2 tp -73.65 54.61 0.48 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.581 -0.699 . . . . 0.0 109.276 -179.731 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 40.5 m80 -138.39 150.63 46.72 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.252 -0.905 . . . . 0.0 109.603 -179.753 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 -67.28 -9.1 37.4 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.233 -0.917 . . . . 0.0 109.26 179.369 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 64.0 tttt -49.18 151.3 1.41 Allowed 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.319 -0.863 . . . . 0.0 109.841 -179.881 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 59.67 47.76 10.18 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.616 -0.677 . . . . 0.0 110.03 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.414 ' HB2' ' H ' ' A' ' 79' ' ' ASP . 62.2 p -115.78 151.06 35.91 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.353 -0.842 . . . . 0.0 109.01 179.202 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 29.4 t -126.46 148.61 49.64 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.346 -0.846 . . . . 0.0 109.594 -179.694 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.8 m-85 -70.99 135.34 47.79 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.252 -0.905 . . . . 0.0 109.084 179.958 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 95.8 m-70 -97.02 -29.99 13.33 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.243 -0.911 . . . . 0.0 110.425 -179.58 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 98.6 mtt180 -134.35 139.95 46.0 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.092 -1.005 . . . . 0.0 110.254 -179.457 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.728 HG21 HG22 ' A' ' 165' ' ' THR . 14.5 m -148.4 42.35 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.497 -0.752 . . . . 0.0 108.973 179.401 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 25.7 mt -76.94 132.84 70.38 Favored Pre-proline 0 C--N 1.301 -1.53 0 O-C-N 121.227 -0.921 . . . . 0.0 109.692 -178.926 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -69.93 145.6 56.66 Favored 'Trans proline' 0 N--CA 1.491 1.363 0 C-N-CA 122.213 1.942 . . . . 0.0 112.154 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 84.63 -54.44 4.92 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.636 -1.386 . . . . 0.0 109.636 179.905 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 83.7 m-85 -69.67 -80.6 0.05 OUTLIER 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.201 -1.176 . . . . 0.0 109.763 -179.905 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 12.9 ptt? 179.37 -179.04 0.38 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.092 -1.005 . . . . 0.0 109.741 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 75' ' ' CYS . . . . . 0.443 ' SG ' ' O ' ' A' ' 127' ' ' ILE . 0.8 OUTLIER -131.8 126.79 35.24 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.499 -0.751 . . . . 0.0 109.068 179.689 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 49.5 tt0 -98.14 137.57 36.71 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.342 -0.849 . . . . 0.0 109.331 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -151.94 -177.72 25.94 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.726 -1.35 . . . . 0.0 109.726 -179.887 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 78.6 56.92 3.46 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.639 -1.384 . . . . 0.0 109.639 -179.925 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.414 ' H ' ' HB2' ' A' ' 64' ' ' SER . 59.2 t0 -69.46 90.63 0.54 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.147 -1.208 . . . . 0.0 108.983 -179.96 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 68.3 t80 -61.19 -49.4 77.33 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.371 -0.83 . . . . 0.0 109.803 -179.623 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 6.6 p -153.2 -98.78 0.05 OUTLIER 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.164 -0.96 . . . . 0.0 109.418 179.828 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -86.37 -64.08 1.21 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.326 -0.859 . . . . 0.0 109.664 -179.899 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 98.48 -15.11 61.54 Favored Glycine 0 N--CA 1.493 2.438 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 -179.857 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 86.5 m-20 -63.5 -31.82 73.1 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.27 -1.135 . . . . 0.0 108.858 179.477 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 152.61 -33.3 0.83 Allowed Glycine 0 N--CA 1.489 2.216 0 N-CA-C 108.7 -1.76 . . . . 0.0 108.7 -179.691 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 55.0 p -78.1 -28.75 48.73 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.393 -1.063 . . . . 0.0 109.102 179.532 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -88.18 -171.07 46.33 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 179.854 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.449 ' CA ' ' OG ' ' A' ' 123' ' ' SER . . . 78.77 46.3 8.67 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 179.905 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -88.73 141.1 28.79 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.205 -1.173 . . . . 0.0 109.451 -179.82 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 92.9 p -107.13 159.32 16.41 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.471 -0.768 . . . . 0.0 109.395 -179.931 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 19.5 pt -59.55 -32.11 48.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.268 -0.895 . . . . 0.0 109.51 -179.805 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 76.5 m-85 -66.33 -24.08 66.47 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.165 -0.959 . . . . 0.0 109.436 179.903 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 76.05 -97.79 1.17 Allowed Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.089 -1.604 . . . . 0.0 109.089 -179.614 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -59.74 147.85 36.37 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.319 -1.106 . . . . 0.0 109.019 179.643 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 9.2 mtmp? -72.27 156.33 39.24 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.417 -0.802 . . . . 0.0 109.418 -179.744 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 36.2 p90 -128.6 160.7 31.57 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.437 -0.789 . . . . 0.0 109.484 -179.818 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -61.52 142.59 56.96 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.292 -0.88 . . . . 0.0 110.123 -179.23 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 98' ' ' ASP . . . . . 0.425 ' H ' ' HA ' ' A' ' 119' ' ' ASN . 88.5 m-20 -70.24 151.42 45.36 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.226 -0.921 . . . . 0.0 109.615 179.772 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -94.93 164.73 12.78 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.324 -0.86 . . . . 0.0 109.185 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 81.5 m-20 -58.26 153.23 15.65 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.226 -0.922 . . . . 0.0 109.444 -179.765 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 101' ' ' PHE . . . . . 0.584 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 21.9 p90 -132.43 80.79 1.92 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.293 -0.879 . . . . 0.0 109.451 -179.853 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 87.4 mt -59.47 -34.38 54.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.248 -0.908 . . . . 0.0 109.378 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 63.3 mttp -85.77 145.21 27.34 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.232 -0.917 . . . . 0.0 109.385 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 104' ' ' LYS . . . . . 0.482 ' O ' ' N ' ' A' ' 106' ' ' THR . 19.8 pttm -134.66 -178.91 5.28 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.374 -0.829 . . . . 0.0 109.501 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 105' ' ' HIS . . . . . . . . . . . . . 96.5 m-70 -65.02 72.45 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.25 -0.906 . . . . 0.0 109.667 -179.971 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 106' ' ' THR . . . . . 0.545 ' O ' ' NZ ' ' A' ' 131' ' ' LYS . 68.7 p -70.82 -27.45 63.89 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.141 -0.974 . . . . 0.0 109.682 179.946 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.421 ' O ' HG12 ' A' ' 110' ' ' ILE . . . -152.97 176.56 31.04 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 109.342 -1.503 . . . . 0.0 109.342 -179.885 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -72.64 153.97 54.49 Favored 'Trans proline' 0 C--N 1.307 -1.638 0 C-N-CA 122.889 2.393 . . . . 0.0 112.095 179.821 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 82.28 49.27 5.31 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 179.632 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.421 HG12 ' O ' ' A' ' 107' ' ' GLY . 39.1 mm -115.2 138.4 45.63 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 121.333 -1.098 . . . . 0.0 109.498 179.938 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.508 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 2.9 mm? -89.57 126.93 35.8 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.297 -0.877 . . . . 0.0 109.595 179.84 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 37.4 t -143.61 139.0 29.42 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.365 -0.835 . . . . 0.0 109.098 179.624 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 113' ' ' MET . . . . . 0.403 ' CE ' HD21 ' A' ' 121' ' ' ASN . 88.5 mtp -81.13 137.13 35.96 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.117 -0.989 . . . . 0.0 109.499 -179.821 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 114' ' ' ALA . . . . . 0.459 ' O ' ' OD1' ' A' ' 115' ' ' ASN . . . -64.14 142.44 58.41 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.281 -0.887 . . . . 0.0 109.604 -179.865 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 115' ' ' ASN . . . . . 0.459 ' OD1' ' O ' ' A' ' 114' ' ' ALA . 73.6 m-20 -146.84 114.0 6.22 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.313 -0.867 . . . . 0.0 108.854 179.569 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -68.2 -35.6 78.25 Favored 'General case' 0 C--N 1.298 -1.641 0 O-C-N 121.312 -0.867 . . . . 0.0 109.559 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -150.89 165.59 30.22 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.263 -1.535 . . . . 0.0 109.263 179.823 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_exo -47.14 153.13 1.72 Allowed 'Trans proline' 0 C--N 1.308 -1.585 0 C-N-CA 122.611 2.207 . . . . 0.0 112.826 179.831 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 119' ' ' ASN . . . . . 0.425 ' HA ' ' H ' ' A' ' 98' ' ' ASP . 18.9 m120 54.89 46.46 24.37 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.73 -0.606 . . . . 0.0 109.635 179.695 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 120' ' ' THR . . . . . 0.43 ' O ' ' OD1' ' A' ' 115' ' ' ASN . 58.5 m -135.39 124.45 24.32 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.316 -0.865 . . . . 0.0 109.099 179.857 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 121' ' ' ASN . . . . . 0.403 HD21 ' CE ' ' A' ' 113' ' ' MET . 23.1 t-20 -104.38 107.94 19.11 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.511 -0.743 . . . . 0.0 109.123 179.646 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -87.84 128.39 9.01 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.772 -1.331 . . . . 0.0 109.772 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 123' ' ' SER . . . . . 0.449 ' OG ' ' CA ' ' A' ' 88' ' ' GLY . 87.3 p -64.32 -23.43 67.29 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.366 -1.079 . . . . 0.0 109.343 179.719 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.4 mt-30 -92.65 153.25 19.09 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.302 -0.874 . . . . 0.0 109.562 -179.869 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 54.4 p90 -134.3 161.62 34.45 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.368 -0.832 . . . . 0.0 109.185 179.881 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 49.0 p90 -134.45 156.41 48.62 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.335 -0.853 . . . . 0.0 109.649 -179.854 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.443 ' O ' ' SG ' ' A' ' 75' ' ' CYS . 77.1 mt -122.2 134.11 66.46 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.453 -0.779 . . . . 0.0 109.556 179.928 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 128' ' ' CYS . . . . . 0.444 ' SG ' ' O ' ' A' ' 130' ' ' ALA . 3.9 t -97.92 112.92 24.66 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.177 -0.952 . . . . 0.0 109.087 179.346 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 41.3 p -80.36 -5.1 55.85 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.308 -0.87 . . . . 0.0 109.856 -179.469 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 130' ' ' ALA . . . . . 0.444 ' O ' ' SG ' ' A' ' 128' ' ' CYS . . . -147.5 161.64 40.67 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.19 -0.944 . . . . 0.0 109.669 -179.626 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.545 ' NZ ' ' O ' ' A' ' 106' ' ' THR . 63.6 mttm -76.56 140.8 41.23 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.194 -0.941 . . . . 0.0 109.299 179.898 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 6.3 p -125.11 158.93 32.64 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.437 -0.789 . . . . 0.0 109.258 -179.918 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -101.98 -74.92 0.61 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.204 -0.935 . . . . 0.0 109.956 -179.81 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 134' ' ' TRP . . . . . 0.581 ' CD1' ' N ' ' A' ' 135' ' ' LEU . 41.7 p90 -61.13 -46.93 88.57 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.21 -0.931 . . . . 0.0 109.999 -179.452 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 135' ' ' LEU . . . . . 0.581 ' N ' ' CD1' ' A' ' 134' ' ' TRP . 32.9 tp -61.63 -33.83 74.61 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.252 -0.905 . . . . 0.0 109.446 -179.819 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 23.5 t70 -76.5 119.03 19.78 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.258 -0.901 . . . . 0.0 109.645 -179.812 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 137' ' ' GLY . . . . . 0.438 ' H ' ' CD2' ' A' ' 139' ' ' HIS . . . -153.18 -129.87 1.44 Allowed Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.075 -1.61 . . . . 0.0 109.075 179.879 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 47.3 mmtm -86.99 114.43 23.59 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.212 -1.17 . . . . 0.0 108.966 179.659 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 139' ' ' HIS . . . . . 0.438 ' CD2' ' H ' ' A' ' 137' ' ' GLY . 98.0 m-70 -138.25 165.69 26.07 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.427 -0.795 . . . . 0.0 109.474 -179.858 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 48.1 t -113.58 132.6 62.04 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 121.356 -0.84 . . . . 0.0 109.274 179.845 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 61.4 t -112.69 129.07 68.95 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 121.272 -0.893 . . . . 0.0 109.308 179.826 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 40.0 p90 -115.76 2.2 13.6 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.334 -0.854 . . . . 0.0 109.725 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -176.26 179.69 47.2 Favored Glycine 0 N--CA 1.493 2.447 0 N-CA-C 109.771 -1.332 . . . . 0.0 109.771 179.64 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 23.0 pt20 -145.21 167.83 21.85 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.309 -1.112 . . . . 0.0 109.449 -179.89 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 55.4 t -96.34 130.16 45.39 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 O-C-N 121.157 -0.964 . . . . 0.0 109.576 -179.866 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 15.6 m -109.29 -33.25 2.43 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 121.323 -0.861 . . . . 0.0 109.409 179.558 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -142.14 171.1 14.52 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.324 -0.86 . . . . 0.0 109.483 179.914 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 98.71 1.96 57.46 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 109.858 -1.297 . . . . 0.0 109.858 179.674 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 149' ' ' MET . . . . . 0.431 ' O ' HG12 ' A' ' 152' ' ' VAL . 72.0 mtm -61.09 -33.76 73.85 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.049 -1.265 . . . . 0.0 109.539 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 56.2 t0 -63.85 -42.6 97.54 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 120.945 -1.097 . . . . 0.0 109.993 -179.713 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.4 p -82.98 -34.49 11.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.152 -0.968 . . . . 0.0 110.547 -179.532 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 152' ' ' VAL . . . . . 0.459 ' CG1' ' N ' ' A' ' 153' ' ' LYS . 0.6 OUTLIER -56.83 -41.93 76.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 120.896 -1.127 . . . . 0.0 109.289 -179.301 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 153' ' ' LYS . . . . . 0.459 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 46.6 mtpt -63.02 -34.28 77.23 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.186 -0.946 . . . . 0.0 109.424 179.459 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -62.13 -39.47 92.66 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.345 -0.847 . . . . 0.0 109.935 -179.559 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 89.2 mt -72.5 -34.86 49.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.162 -0.962 . . . . 0.0 110.042 -179.824 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -76.71 -41.44 45.24 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.153 -0.967 . . . . 0.0 111.182 -178.881 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 16.9 pttp -62.31 -33.59 74.97 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 120.824 -1.173 . . . . 0.0 109.931 -178.846 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 35.1 m -78.3 -10.41 12.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.023 -1.048 . . . . 0.0 109.262 179.662 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -75.52 174.46 52.36 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.743 -1.343 . . . . 0.0 109.743 -179.772 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 22.6 t -161.7 174.54 13.11 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.328 -1.101 . . . . 0.0 109.448 -179.802 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 23.6 m -54.83 -32.03 60.04 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.205 -0.934 . . . . 0.0 109.233 179.813 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 23.5 m -55.72 -33.18 64.0 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.263 -0.898 . . . . 0.0 109.577 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 94.61 10.09 58.23 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.726 -1.35 . . . . 0.0 109.726 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 16.3 tpt180 -116.98 142.69 46.63 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.426 -1.043 . . . . 0.0 109.058 179.833 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 165' ' ' THR . . . . . 0.728 HG22 HG21 ' A' ' 69' ' ' VAL . 68.0 p -80.21 151.52 29.63 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.229 -0.92 . . . . 0.0 109.579 -179.808 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -68.39 -35.69 78.05 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.337 -0.852 . . . . 0.0 109.104 179.476 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 93.6 mttt -112.0 159.31 18.56 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.531 -0.731 . . . . 0.0 109.283 179.925 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -72.7 132.74 44.06 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.31 -0.869 . . . . 0.0 109.411 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 42.7 t -121.35 126.14 74.58 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.233 -0.917 . . . . 0.0 109.634 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 43.2 t -147.56 151.22 13.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.334 -0.854 . . . . 0.0 109.302 179.769 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 2.7 t -87.93 125.57 41.43 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 C-N-CA 119.708 -0.797 . . . . 0.0 109.854 -179.271 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 172' ' ' GLU . . . . . 0.423 ' O ' ' HB3' ' A' ' 173' ' ' ASP . 97.3 mt-10 -65.62 -30.82 71.58 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.379 -0.826 . . . . 0.0 109.097 179.509 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 173' ' ' ASP . . . . . 0.425 ' C ' ' OD1' ' A' ' 173' ' ' ASP . 53.0 p30 177.73 -177.78 0.21 Allowed 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.335 -0.853 . . . . 0.0 110.093 -179.864 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 28.5 p -154.04 150.4 28.19 Favored 'General case' 0 N--CA 1.49 1.571 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 179.476 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -172.17 178.46 44.33 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 176' ' ' GLN . . . . . 0.436 ' OE1' ' OG ' ' A' ' 178' ' ' SER . 7.0 tt0 -106.04 124.17 49.15 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.463 -1.022 . . . . 0.0 109.75 -179.954 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 28.9 tp -62.29 -37.97 87.57 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.202 -0.936 . . . . 0.0 109.382 179.604 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 178' ' ' SER . . . . . 0.436 ' OG ' ' OE1' ' A' ' 176' ' ' GLN . 4.5 p . . . . . 0 N--CA 1.491 1.596 0 CA-C-O 117.994 -1.003 . . . . 0.0 109.497 -179.91 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 34.7 m-80 . . . . . 0 N--CA 1.492 1.671 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -65.93 141.85 66.4 Favored 'Trans proline' 0 N--CA 1.496 1.663 0 C-N-CA 122.822 2.348 . . . . 0.0 112.206 179.828 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 98.5 mtt180 -128.73 133.22 48.06 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.373 -0.829 . . . . 0.0 108.887 179.237 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.0 p -136.52 142.97 36.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.725 0 O-C-N 121.333 -0.854 . . . . 0.0 109.626 -179.783 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' PHE . . . . . 0.462 ' CZ ' ' NH2' ' A' ' 25' ' ' ARG . 43.0 p90 -140.41 154.28 46.63 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.285 -0.884 . . . . 0.0 109.468 -179.998 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -127.83 140.06 52.26 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.424 -0.797 . . . . 0.0 109.584 179.836 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.417 ' O ' HG13 ' A' ' 171' ' ' VAL . 87.9 m-20 -91.44 132.94 35.89 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.263 -0.898 . . . . 0.0 108.91 179.368 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 16' ' ' MET . . . . . 0.424 ' SD ' HD12 ' A' ' 26' ' ' ILE . 65.6 mtp -124.72 153.53 42.25 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.198 -0.939 . . . . 0.0 110.259 -179.459 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 63.2 p -149.4 165.99 30.42 Favored 'General case' 0 N--CA 1.49 1.538 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 179.741 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.422 HG23 ' O ' ' A' ' 18' ' ' VAL . 24.0 m -125.54 133.88 68.11 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 121.25 -0.906 . . . . 0.0 109.544 179.975 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 54.75 17.08 8.37 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 179.797 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 92.33 4.55 66.22 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 33.7 mt-30 -105.58 111.57 64.77 Favored Pre-proline 0 N--CA 1.493 1.711 0 O-C-N 121.349 -1.089 . . . . 0.0 109.255 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 65.8 Cg_exo -48.35 135.23 25.84 Favored 'Trans proline' 0 N--CA 1.493 1.47 0 C-N-CA 122.171 1.914 . . . . 0.0 112.173 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -104.82 -57.73 1.99 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.42 -0.8 . . . . 0.0 109.417 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -171.55 -171.68 36.89 Favored Glycine 0 N--CA 1.488 2.118 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 -179.856 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' ARG . . . . . 0.462 ' NH2' ' CZ ' ' A' ' 13' ' ' PHE . 77.6 ttt180 -114.35 143.93 44.09 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.377 -1.072 . . . . 0.0 109.367 179.947 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.424 HD12 ' SD ' ' A' ' 16' ' ' MET . 83.2 mt -119.62 127.95 75.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.4 -0.812 . . . . 0.0 109.029 179.819 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 43.5 t -117.44 133.45 64.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.444 -0.785 . . . . 0.0 109.571 -179.773 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 73.2 mtm -121.35 150.49 41.38 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.423 -0.798 . . . . 0.0 109.03 179.699 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.424 ' C ' HD22 ' A' ' 30' ' ' LEU . 84.3 tt0 -101.89 131.15 48.42 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.253 -0.904 . . . . 0.0 109.997 -179.512 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.424 HD22 ' C ' ' A' ' 29' ' ' GLU . 2.8 mm? -109.59 130.15 55.53 Favored 'General case' 0 N--CA 1.493 1.701 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 179.357 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -97.77 118.26 33.91 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.039 -1.038 . . . . 0.0 108.981 179.427 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -79.6 -43.18 23.4 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.403 -0.811 . . . . 0.0 109.844 -179.739 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 57.6 t0 -65.25 -51.6 59.8 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.196 -0.94 . . . . 0.0 110.037 -179.301 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 49.4 m -67.86 -42.1 81.86 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.196 -0.94 . . . . 0.0 109.712 -179.871 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -137.34 80.37 33.84 Favored Pre-proline 0 N--CA 1.492 1.666 0 O-C-N 121.437 -0.789 . . . . 0.0 109.19 -179.73 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -70.83 -65.82 0.03 OUTLIER 'Trans proline' 0 C--N 1.308 -1.577 0 C-N-CA 122.579 2.186 . . . . 0.0 112.93 -179.601 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 62.7 mtp180 -61.5 -38.39 87.17 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.393 -0.817 . . . . 0.0 110.708 -179.036 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 36.9 m -62.49 -42.41 99.48 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 120.972 -1.08 . . . . 0.0 109.881 -179.691 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -62.65 -30.9 71.71 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.198 -0.939 . . . . 0.0 108.771 179.566 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.429 ' OE1' ' OH ' ' A' ' 92' ' ' TYR . 84.6 tt0 -65.65 -36.23 83.07 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.461 -0.774 . . . . 0.0 109.492 179.784 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 48.7 t-20 -58.59 -42.98 89.33 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.317 -0.864 . . . . 0.0 109.414 -179.794 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.42 ' CE2' ' CE2' ' A' ' 142' ' ' PHE . 90.6 m-85 -80.63 -45.34 17.41 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.31 -0.869 . . . . 0.0 109.625 179.886 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.424 ' HD2' HE22 ' A' ' 176' ' ' GLN . 61.9 ttp180 -57.31 -42.37 81.68 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.261 -0.899 . . . . 0.0 109.533 -179.769 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.505 ' O ' ' N ' ' A' ' 48' ' ' GLY . . . -68.41 -36.35 78.98 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.262 -0.899 . . . . 0.0 109.528 179.975 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.54 HD23 ' CD2' ' A' ' 61' ' ' TYR . 51.7 tp -60.36 -36.18 77.43 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.176 -0.953 . . . . 0.0 109.529 -179.702 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 46' ' ' CYS . . . . . . . . . . . . . 96.8 m -65.83 -59.73 3.58 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.212 -0.93 . . . . 0.0 110.068 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 57.3 p -74.97 -38.71 61.61 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.12 -0.988 . . . . 0.0 109.987 -179.761 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 48' ' ' GLY . . . . . 0.505 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 71.98 7.3 66.14 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.183 -1.567 . . . . 0.0 109.183 -179.842 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 22.4 pt-20 -72.63 -16.91 61.71 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.451 -1.029 . . . . 0.0 110.033 -179.726 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 44.7 tptt -56.22 -38.61 71.26 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.166 -0.959 . . . . 0.0 109.739 -179.393 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 173.23 -173.23 45.62 Favored Glycine 0 N--CA 1.49 2.245 0 C-N-CA 119.664 -1.255 . . . . 0.0 110.03 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.53 ' O ' ' C ' ' A' ' 53' ' ' GLY . 82.5 m -120.57 145.89 46.88 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.673 -0.899 . . . . 0.0 109.266 179.946 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.53 ' C ' ' O ' ' A' ' 52' ' ' THR . . . -30.74 -73.9 0.05 OUTLIER Glycine 0 N--CA 1.495 2.608 0 N-CA-C 110.513 -1.035 . . . . 0.0 110.513 -179.827 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 93.7 mtt180 -139.86 -112.69 0.15 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.061 -1.258 . . . . 0.0 109.606 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 80.0 p -86.03 -23.64 26.7 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.313 -0.867 . . . . 0.0 110.112 -179.485 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -164.36 93.58 0.11 Allowed Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.377 -1.489 . . . . 0.0 109.377 -179.838 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 11.4 ttmm -174.4 75.31 0.34 Allowed Pre-proline 0 C--N 1.301 -1.506 0 O-C-N 121.484 -1.009 . . . . 0.0 108.629 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_exo -47.89 129.18 17.44 Favored 'Trans proline' 0 C--N 1.303 -1.832 0 C-N-CA 122.539 2.159 . . . . 0.0 111.897 -179.422 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 12.6 tp -106.48 119.96 40.67 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.522 -0.736 . . . . 0.0 109.333 -179.371 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -150.43 140.57 22.13 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.169 -0.957 . . . . 0.0 109.719 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 61' ' ' TYR . . . . . 0.54 ' CD2' HD23 ' A' ' 45' ' ' LEU . 2.9 t80 -62.25 -35.75 79.9 Favored 'General case' 0 N--CA 1.492 1.657 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 179.431 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 42.6 tttm -50.47 152.66 1.82 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.501 -0.75 . . . . 0.0 109.868 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 34.8 t0 71.24 43.07 0.66 Allowed 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.645 -0.659 . . . . 0.0 109.501 -179.835 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 90.8 p -119.23 152.67 36.24 Favored 'General case' 0 N--CA 1.492 1.659 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 179.503 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 30.3 t -145.85 154.6 42.16 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.198 -0.938 . . . . 0.0 109.778 -179.611 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 47.3 m-85 -89.99 127.58 36.07 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.335 -0.853 . . . . 0.0 109.253 179.651 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 67' ' ' HIS . . . . . 0.403 ' O ' ' O ' ' A' ' 163' ' ' GLY . 97.3 m-70 -99.04 -18.47 17.74 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.319 -0.863 . . . . 0.0 110.291 -179.279 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 58.5 mtp85 -127.31 137.07 52.73 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.11 -0.994 . . . . 0.0 110.126 -179.693 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.668 HG21 HG22 ' A' ' 165' ' ' THR . 3.1 m -153.34 81.33 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 121.428 -0.795 . . . . 0.0 108.98 179.474 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 22.0 mt -95.96 126.04 46.24 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.097 -1.002 . . . . 0.0 109.452 -179.501 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -71.64 138.25 31.72 Favored 'Trans proline' 0 N--CA 1.493 1.491 0 C-N-CA 122.157 1.905 . . . . 0.0 112.332 -179.664 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 92.67 -30.04 7.32 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.684 -1.366 . . . . 0.0 109.684 179.623 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -102.7 -89.73 0.37 Allowed 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.301 -1.117 . . . . 0.0 109.741 -179.884 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 74' ' ' MET . . . . . 0.452 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 7.6 ptt? -171.86 -175.42 1.51 Allowed 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.22 -0.925 . . . . 0.0 109.716 -179.678 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -127.27 141.94 51.59 Favored 'General case' 0 N--CA 1.494 1.748 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 179.699 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 48.1 tt0 -105.85 143.53 33.86 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.209 -0.932 . . . . 0.0 109.843 -179.589 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -156.11 -173.55 24.84 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 96.32 2.34 60.49 Favored Glycine 0 N--CA 1.494 2.516 0 N-CA-C 109.676 -1.37 . . . . 0.0 109.676 -179.969 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.574 ' O ' ' N ' ' A' ' 83' ' ' GLY . 89.9 m-20 -92.42 14.72 15.77 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.339 -1.095 . . . . 0.0 109.203 179.848 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.541 ' CD1' ' N ' ' A' ' 81' ' ' THR . 42.4 p90 -44.27 -31.56 1.05 Allowed 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.351 -0.843 . . . . 0.0 110.292 -179.815 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.541 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 18.5 m -58.0 -37.46 74.31 Favored 'General case' 0 C--N 1.303 -1.445 0 O-C-N 121.169 -0.957 . . . . 0.0 109.666 -178.993 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -145.48 -32.89 0.37 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.191 -0.943 . . . . 0.0 110.048 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.574 ' N ' ' O ' ' A' ' 79' ' ' ASP . . . 100.16 -37.14 3.69 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.424 -1.471 . . . . 0.0 109.424 -180.0 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 78.4 m-20 -89.7 1.51 55.97 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.316 -1.108 . . . . 0.0 109.376 179.873 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 88.67 2.33 79.13 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.446 -1.462 . . . . 0.0 109.446 -179.934 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 49.5 m -59.71 -38.72 82.4 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.366 -1.079 . . . . 0.0 109.633 -179.919 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -96.31 -115.21 3.09 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.859 -1.296 . . . . 0.0 109.859 -179.706 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.446 ' O ' ' CB ' ' A' ' 123' ' ' SER . . . 81.97 27.71 44.52 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.193 -1.563 . . . . 0.0 109.193 -179.636 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -59.51 142.84 51.69 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.329 -1.1 . . . . 0.0 109.869 -179.83 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 32.9 t -141.93 146.81 36.12 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.353 -0.842 . . . . 0.0 109.278 179.738 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 14.1 pt -69.53 -11.34 14.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.136 -0.977 . . . . 0.0 109.468 -179.887 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 92' ' ' TYR . . . . . 0.429 ' OH ' ' OE1' ' A' ' 40' ' ' GLU . 80.9 m-85 -107.47 29.51 7.1 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.393 -0.817 . . . . 0.0 109.778 -179.988 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -46.98 -31.26 5.57 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.382 -1.487 . . . . 0.0 109.382 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -63.26 145.16 56.11 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.139 -1.212 . . . . 0.0 108.992 179.625 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 93.8 mttt -87.77 135.51 33.35 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.368 -0.832 . . . . 0.0 109.631 -179.637 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 96' ' ' PHE . . . . . 0.531 ' CE1' ' ND2' ' A' ' 121' ' ' ASN . 54.4 p90 -144.49 163.26 34.37 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.351 -0.843 . . . . 0.0 109.361 179.672 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -97.6 144.82 26.89 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.281 -0.887 . . . . 0.0 109.324 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 -67.93 135.34 52.27 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.213 -0.929 . . . . 0.0 109.345 -179.883 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -63.55 -38.21 90.27 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.275 -0.89 . . . . 0.0 110.117 -179.653 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 78.6 m-20 -144.18 171.04 14.84 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.996 -1.065 . . . . 0.0 110.041 -179.539 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 101' ' ' PHE . . . . . 0.43 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 38.3 p90 -151.17 37.85 0.63 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.471 -0.768 . . . . 0.0 109.094 179.772 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 90.3 mt -57.86 -34.13 47.51 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.318 -0.864 . . . . 0.0 109.936 -179.792 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 44.1 mtmt -75.63 144.27 41.8 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.992 -1.068 . . . . 0.0 109.511 -179.895 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 45.2 tttp -130.16 157.77 41.53 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.421 -0.799 . . . . 0.0 109.411 -179.872 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 105' ' ' HIS . . . . . 0.402 ' O ' ' OD2' ' A' ' 136' ' ' ASP . 85.5 t60 -98.93 127.09 44.77 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.328 -0.857 . . . . 0.0 109.39 -179.92 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -160.7 -6.66 0.05 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.229 -0.919 . . . . 0.0 109.698 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -127.72 171.48 19.07 Favored Glycine 0 N--CA 1.494 2.513 0 N-CA-C 109.456 -1.458 . . . . 0.0 109.456 -179.878 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 97.0 Cg_endo -80.61 154.72 20.84 Favored 'Trans proline' 0 C--N 1.306 -1.677 0 C-N-CA 123.023 2.482 . . . . 0.0 112.287 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 77.75 47.55 8.6 Favored Glycine 0 N--CA 1.494 2.536 0 N-CA-C 109.967 -1.253 . . . . 0.0 109.967 179.49 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 40.9 mm -115.29 134.74 57.49 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 O-C-N 121.437 -1.037 . . . . 0.0 109.511 -179.903 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.454 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 3.5 mm? -93.45 112.74 24.72 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.203 -0.936 . . . . 0.0 109.317 179.681 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 47.2 m -131.01 147.95 52.69 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.265 -0.897 . . . . 0.0 109.494 179.737 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 88.5 mtp -94.33 141.2 28.84 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.177 -0.952 . . . . 0.0 109.391 179.892 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -63.3 142.77 58.26 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.295 -0.878 . . . . 0.0 109.338 179.916 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 61.4 m-20 -144.7 113.26 6.65 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.21 -0.931 . . . . 0.0 109.057 179.885 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -68.22 -27.8 66.68 Favored 'General case' 0 C--N 1.297 -1.712 0 O-C-N 121.35 -0.844 . . . . 0.0 109.169 179.795 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 117' ' ' GLY . . . . . 0.441 ' H ' ' HB ' ' A' ' 120' ' ' THR . . . -132.55 167.7 23.01 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.254 -1.539 . . . . 0.0 109.254 179.86 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 14.3 Cg_endo -58.44 -25.51 73.95 Favored 'Trans proline' 0 C--N 1.305 -1.76 0 C-N-CA 122.809 2.339 . . . . 0.0 111.929 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 42.5 p-10 -128.38 42.5 3.31 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.354 -0.841 . . . . 0.0 109.489 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 120' ' ' THR . . . . . 0.441 ' HB ' ' H ' ' A' ' 117' ' ' GLY . 89.1 m -128.87 124.47 35.34 Favored 'General case' 0 N--CA 1.486 1.329 0 O-C-N 121.445 -0.785 . . . . 0.0 108.896 179.77 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 121' ' ' ASN . . . . . 0.531 ' ND2' ' CE1' ' A' ' 96' ' ' PHE . 83.0 m-20 -108.9 149.57 28.96 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.59 -0.694 . . . . 0.0 109.438 -179.842 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -133.78 166.93 23.81 Favored Glycine 0 N--CA 1.494 2.518 0 N-CA-C 109.544 -1.422 . . . . 0.0 109.544 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 123' ' ' SER . . . . . 0.446 ' CB ' ' O ' ' A' ' 88' ' ' GLY . 46.4 p -82.41 -2.08 52.02 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.248 -1.148 . . . . 0.0 109.674 -179.907 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.4 mt-30 -100.5 144.91 28.93 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.253 -0.904 . . . . 0.0 109.752 -179.836 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 50.9 p90 -139.12 163.6 31.98 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.504 -0.747 . . . . 0.0 109.171 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 126' ' ' PHE . . . . . 0.452 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 50.8 p90 -135.86 154.46 51.16 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.214 -0.928 . . . . 0.0 109.76 -179.89 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 64.5 mt -124.16 134.02 67.72 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.754 0 O-C-N 121.509 -0.745 . . . . 0.0 109.422 179.781 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 3.3 m -114.23 113.07 24.13 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.274 -0.891 . . . . 0.0 109.342 179.855 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 129' ' ' THR . . . . . 0.45 ' OG1' ' OE1' ' A' ' 156' ' ' GLU . 7.3 p -94.39 -0.9 54.52 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.257 -0.902 . . . . 0.0 109.406 -179.905 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -109.97 152.74 25.49 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.383 -0.823 . . . . 0.0 109.338 -179.746 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 49.3 mtpt -77.39 115.29 17.04 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.18 -0.95 . . . . 0.0 109.228 179.84 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 50.0 p -129.23 158.18 39.76 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.445 -0.784 . . . . 0.0 109.366 -179.938 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -110.39 -40.83 4.53 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.368 -0.833 . . . . 0.0 109.683 179.857 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 0.6 OUTLIER -62.58 -34.21 76.52 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.195 -0.941 . . . . 0.0 109.748 -179.602 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 12.5 mt -62.22 -33.09 73.9 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.984 -1.072 . . . . 0.0 109.668 179.648 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 136' ' ' ASP . . . . . 0.402 ' OD2' ' O ' ' A' ' 105' ' ' HIS . 61.7 t0 -79.33 119.12 21.92 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.2 -0.938 . . . . 0.0 109.517 -179.731 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -165.05 -117.4 0.4 Allowed Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 3.3 mppt? -86.53 7.39 26.3 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.403 -1.057 . . . . 0.0 109.769 -179.853 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 77.3 m80 -70.52 151.24 45.29 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.149 -0.97 . . . . 0.0 109.571 -179.667 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 41.2 t -118.69 140.78 41.18 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.489 -0.757 . . . . 0.0 109.459 -179.776 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 141' ' ' VAL . . . . . 0.412 HG12 ' H ' ' A' ' 143' ' ' GLY . 50.6 t -100.2 133.32 43.63 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.416 -0.802 . . . . 0.0 109.565 -179.844 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 142' ' ' PHE . . . . . 0.42 ' CE2' ' CE2' ' A' ' 42' ' ' PHE . 38.0 p90 -109.12 1.09 20.17 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.277 -0.889 . . . . 0.0 109.823 179.873 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 143' ' ' GLY . . . . . 0.412 ' H ' HG12 ' A' ' 141' ' ' VAL . . . -174.4 -179.42 45.0 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 179.663 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.3 pt20 -146.22 167.39 23.61 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.26 -1.141 . . . . 0.0 109.561 -179.644 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 54.0 t -97.84 131.39 44.91 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.187 0 O-C-N 121.178 -0.952 . . . . 0.0 109.473 -179.885 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 16.6 m -107.76 -34.81 2.81 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.357 -0.839 . . . . 0.0 109.664 179.685 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 94.4 mt-10 -144.32 166.92 23.72 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.212 -0.93 . . . . 0.0 109.705 -179.827 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 96.79 4.15 59.12 Favored Glycine 0 N--CA 1.495 2.583 0 N-CA-C 110.194 -1.162 . . . . 0.0 110.194 179.395 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 149' ' ' MET . . . . . 0.483 ' O ' HG12 ' A' ' 152' ' ' VAL . 71.8 mtm -60.79 -33.22 72.65 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.002 -1.293 . . . . 0.0 109.722 179.923 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 89.3 m-20 -65.11 -41.96 94.4 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.833 -1.167 . . . . 0.0 110.07 -179.541 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.2 p -82.04 -34.29 12.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.216 -0.928 . . . . 0.0 110.696 -179.406 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 152' ' ' VAL . . . . . 0.483 HG12 ' O ' ' A' ' 149' ' ' MET . 0.8 OUTLIER -55.63 -42.49 69.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 120.873 -1.142 . . . . 0.0 109.399 -179.248 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 153' ' ' LYS . . . . . 0.454 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 99.2 mttt -65.53 -33.3 75.6 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.137 -0.977 . . . . 0.0 109.757 179.5 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -60.25 -40.15 89.3 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.312 -0.867 . . . . 0.0 110.284 -179.154 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 91.9 mt -71.56 -36.21 59.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.029 -1.044 . . . . 0.0 110.466 -179.508 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 156' ' ' GLU . . . . . 0.45 ' OE1' ' OG1' ' A' ' 129' ' ' THR . 84.4 tt0 -78.49 -40.35 35.58 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.929 -1.107 . . . . 0.0 111.36 -178.587 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 39.8 pttt -61.05 -34.42 74.86 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 120.793 -1.192 . . . . 0.0 110.005 -178.806 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 28.3 m -73.36 -12.65 15.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.101 -0.999 . . . . 0.0 109.377 179.884 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -77.82 173.4 55.08 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.757 -1.337 . . . . 0.0 109.757 -179.891 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 21.4 t -154.62 178.72 9.79 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.41 -1.053 . . . . 0.0 109.395 -179.741 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 23.7 t -54.3 -30.45 51.08 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.233 -0.917 . . . . 0.0 109.262 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 86.6 p -59.3 -26.61 65.13 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.255 -0.903 . . . . 0.0 109.4 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 163' ' ' GLY . . . . . 0.403 ' O ' ' O ' ' A' ' 67' ' ' HIS . . . 87.16 20.31 53.13 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.713 -1.355 . . . . 0.0 109.713 179.794 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 87.7 mtt180 -122.38 145.39 48.32 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.195 -1.18 . . . . 0.0 109.364 179.911 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 165' ' ' THR . . . . . 0.668 HG22 HG21 ' A' ' 69' ' ' VAL . 72.6 p -82.19 151.52 26.85 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.153 -0.967 . . . . 0.0 109.647 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -67.06 -36.44 82.05 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.287 -0.883 . . . . 0.0 109.302 179.692 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 62.4 mttp -117.6 156.57 27.89 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.576 -0.702 . . . . 0.0 109.248 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 94.2 mttt -69.22 131.62 45.2 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.11 -0.994 . . . . 0.0 109.225 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 41.1 t -122.14 125.08 72.49 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.725 0 O-C-N 121.325 -0.859 . . . . 0.0 109.644 -179.896 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 43.7 t -144.94 144.88 21.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.386 -0.821 . . . . 0.0 109.17 179.63 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.417 HG13 ' O ' ' A' ' 15' ' ' ASP . 2.7 t -74.54 124.17 31.57 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.677 0 C-N-CA 119.722 -0.791 . . . . 0.0 109.787 -179.284 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -67.85 -27.91 67.1 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.363 -0.836 . . . . 0.0 109.593 179.471 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 44.3 t0 -174.38 174.76 2.73 Favored 'General case' 0 N--CA 1.494 1.754 0 C-N-CA 119.29 -0.964 . . . . 0.0 110.321 -179.286 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 26.4 p -146.42 150.25 35.28 Favored 'General case' 0 N--CA 1.491 1.622 0 N-CA-C 109.063 -0.718 . . . . 0.0 109.063 179.638 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -172.64 173.16 45.38 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.804 -1.318 . . . . 0.0 109.804 179.913 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 176' ' ' GLN . . . . . 0.513 ' NE2' ' OXT' ' A' ' 178' ' ' SER . 62.6 tt0 -114.23 118.89 35.24 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.413 -1.051 . . . . 0.0 109.637 -179.985 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 37.1 tp -63.39 -37.42 87.2 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.124 -0.985 . . . . 0.0 109.217 179.403 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 178' ' ' SER . . . . . 0.513 ' OXT' ' NE2' ' A' ' 176' ' ' GLN . 61.2 m . . . . . 0 N--CA 1.491 1.582 0 CA-C-O 118.0 -1.0 . . . . 0.0 109.441 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 2.3 m-80 . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 38.7 Cg_endo -64.85 141.65 72.36 Favored 'Trans proline' 0 N--CA 1.496 1.663 0 C-N-CA 122.616 2.211 . . . . 0.0 112.07 179.775 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 96.4 mtt180 -126.79 131.62 51.24 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.459 -0.776 . . . . 0.0 109.061 179.497 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.4 p -136.09 142.38 38.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.314 -0.866 . . . . 0.0 109.243 -179.905 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 41.2 p90 -142.3 154.01 44.36 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.297 -0.877 . . . . 0.0 109.572 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.58 ' CE2' ' SG ' ' A' ' 174' ' ' CYS . 44.3 m-85 -120.07 135.78 54.82 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.468 -0.77 . . . . 0.0 109.091 179.643 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.1 t0 -88.55 114.47 25.2 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.078 -1.013 . . . . 0.0 108.509 179.489 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 83.7 mtp -104.53 136.17 44.58 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.453 -0.779 . . . . 0.0 110.532 -179.08 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 44.5 m -135.1 154.23 51.74 Favored 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 179.195 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.405 ' O ' ' C ' ' A' ' 19' ' ' GLY . 34.3 m -125.98 141.45 45.61 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.148 -0.97 . . . . 0.0 109.891 -179.886 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.405 ' C ' ' O ' ' A' ' 18' ' ' VAL . . . 41.05 -114.7 0.61 Allowed Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.936 -1.266 . . . . 0.0 109.936 179.77 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -120.94 15.46 9.52 Favored Glycine 0 N--CA 1.496 2.644 0 N-CA-C 109.416 -1.474 . . . . 0.0 109.416 179.858 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 39.6 tt0 -124.12 88.03 53.0 Favored Pre-proline 0 N--CA 1.494 1.756 0 O-C-N 121.459 -1.024 . . . . 0.0 109.078 -179.826 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 75.7 Cg_exo -47.05 132.86 18.24 Favored 'Trans proline' 0 C--N 1.309 -1.548 0 C-N-CA 122.336 2.024 . . . . 0.0 112.294 -179.561 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -85.07 -63.25 1.36 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.313 -0.867 . . . . 0.0 109.834 -179.688 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 172.62 -167.08 39.91 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 -179.756 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 28.7 ptt180 -116.53 151.18 36.67 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.534 -0.98 . . . . 0.0 108.952 179.735 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 83.4 mt -120.1 129.11 75.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.377 -0.827 . . . . 0.0 109.06 -179.854 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 39.5 t -107.7 134.6 48.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.4 -0.813 . . . . 0.0 109.436 -179.599 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 76.3 mtm -120.86 148.9 43.4 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.557 -0.714 . . . . 0.0 109.215 179.932 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -95.77 133.7 39.58 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.277 -0.889 . . . . 0.0 109.731 -179.593 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -108.35 133.42 52.57 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.572 -0.705 . . . . 0.0 109.357 179.895 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -96.37 119.56 35.08 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.23 -0.919 . . . . 0.0 108.656 179.187 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -89.61 -42.48 11.37 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.295 -0.878 . . . . 0.0 109.835 -179.65 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.2 m-20 -64.58 -48.63 74.27 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.218 -0.926 . . . . 0.0 110.24 -179.263 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 33.3 m -70.91 -43.47 68.21 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.075 -1.016 . . . . 0.0 109.966 -179.652 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.469 ' O ' ' OG1' ' A' ' 35' ' ' THR . 5.1 p -136.38 79.85 41.21 Favored Pre-proline 0 N--CA 1.493 1.678 0 O-C-N 121.351 -0.843 . . . . 0.0 109.404 -179.604 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 27.2 Cg_endo -67.05 -60.88 0.09 OUTLIER 'Trans proline' 0 C--N 1.309 -1.525 0 C-N-CA 122.479 2.12 . . . . 0.0 112.849 -179.401 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.476 ' NH2' ' CG ' ' A' ' 92' ' ' TYR . 17.2 mtp-105 -60.8 -37.78 83.12 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.405 -0.809 . . . . 0.0 110.811 -178.878 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 26.3 m -61.8 -43.16 99.4 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.883 -1.136 . . . . 0.0 109.835 -179.764 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -64.81 -28.48 69.59 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.175 -0.953 . . . . 0.0 109.307 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -65.18 -37.72 88.22 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.341 -0.849 . . . . 0.0 109.687 -179.833 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 86.7 m-20 -59.59 -41.63 90.7 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.244 -0.91 . . . . 0.0 109.745 -179.652 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.489 ' O ' ' SG ' ' A' ' 46' ' ' CYS . 95.5 m-85 -81.37 -46.68 14.3 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.239 -0.913 . . . . 0.0 109.705 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.713 ' HE ' ' NE2' ' A' ' 176' ' ' GLN . 76.1 ttt180 -58.15 -43.09 87.21 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.346 -0.846 . . . . 0.0 110.019 -179.522 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -78.11 -47.9 17.2 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.141 -0.975 . . . . 0.0 110.165 -179.578 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.661 HD23 ' CZ ' ' A' ' 61' ' ' TYR . 58.4 tp -60.59 -38.83 85.93 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.254 -0.904 . . . . 0.0 109.838 -179.518 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 46' ' ' CYS . . . . . 0.489 ' SG ' ' O ' ' A' ' 42' ' ' PHE . 71.2 m -68.56 -58.74 3.84 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.032 -1.042 . . . . 0.0 109.417 -179.908 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 31.6 m -64.11 -37.45 87.5 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.135 -0.978 . . . . 0.0 109.278 179.703 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 81.53 34.27 25.9 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 179.648 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -61.1 -34.36 74.83 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.018 -1.283 . . . . 0.0 109.338 179.61 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 69.4 mmtt -59.57 -33.58 71.61 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.317 -0.864 . . . . 0.0 109.331 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 94.3 168.87 37.44 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.329 -1.508 . . . . 0.0 109.329 -179.771 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 91.7 m -77.79 139.18 39.31 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.413 -1.051 . . . . 0.0 109.737 -179.933 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -60.78 141.19 48.09 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.521 -1.432 . . . . 0.0 109.521 179.94 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 67.4 mtm180 -59.19 -37.12 76.65 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.277 -1.131 . . . . 0.0 109.765 -179.799 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 23.6 m -58.7 -33.75 70.53 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.273 -0.892 . . . . 0.0 109.709 -179.784 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 56' ' ' GLY . . . . . 0.427 ' O ' ' CB ' ' A' ' 57' ' ' LYS . . . 120.58 109.53 2.2 Favored Glycine 0 N--CA 1.495 2.577 0 N-CA-C 108.996 -1.642 . . . . 0.0 108.996 -179.645 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 57' ' ' LYS . . . . . 0.455 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 3.2 mmtp 166.14 85.93 0.02 OUTLIER Pre-proline 0 N--CA 1.492 1.628 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 -179.669 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 71.3 Cg_exo -50.96 133.73 40.98 Favored 'Trans proline' 0 C--N 1.304 -1.773 0 C-N-CA 122.559 2.173 . . . . 0.0 112.383 -179.308 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.455 ' CD1' ' O ' ' A' ' 57' ' ' LYS . 8.9 mp -99.65 44.77 1.01 Allowed 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.558 -0.714 . . . . 0.0 109.378 -179.793 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 71.3 m80 -123.82 133.31 53.82 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.413 -0.804 . . . . 0.0 109.672 -179.828 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 61' ' ' TYR . . . . . 0.661 ' CZ ' HD23 ' A' ' 45' ' ' LEU . 20.8 m-85 -69.12 -12.11 61.39 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.158 -0.964 . . . . 0.0 108.907 178.789 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 61.2 tttt -49.93 138.62 14.97 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.345 -0.847 . . . . 0.0 109.898 -179.703 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 63' ' ' ASP . . . . . 0.406 ' N ' HG23 ' A' ' 171' ' ' VAL . 41.0 t0 67.77 42.53 1.96 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.782 -0.574 . . . . 0.0 110.141 179.67 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.818 ' H ' ' CG2' ' A' ' 171' ' ' VAL . 83.2 p -110.47 149.76 29.84 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.233 -0.917 . . . . 0.0 108.595 178.807 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 28.7 t -117.45 144.23 45.22 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.172 -0.955 . . . . 0.0 109.697 -179.353 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -69.61 138.87 53.47 Favored 'General case' 0 N--CA 1.491 1.595 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 179.66 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 67' ' ' HIS . . . . . 0.717 ' CD2' ' HE ' ' A' ' 68' ' ' ARG . 77.8 t60 -59.59 -50.95 71.91 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.108 -0.995 . . . . 0.0 109.932 -179.416 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.717 ' HE ' ' CD2' ' A' ' 67' ' ' HIS . 20.2 ptp180 -172.81 163.05 4.98 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.213 -0.929 . . . . 0.0 109.684 179.669 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.403 HG11 HG22 ' A' ' 155' ' ' ILE . 0.1 OUTLIER -134.05 127.0 50.97 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.418 -0.802 . . . . 0.0 109.035 179.53 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 39.5 mt -121.9 118.38 29.36 Favored Pre-proline 0 N--CA 1.493 1.719 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 179.86 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -71.58 136.13 27.67 Favored 'Trans proline' 0 C--N 1.31 -1.473 0 C-N-CA 121.853 1.702 . . . . 0.0 111.894 -179.803 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 94.25 -1.07 66.79 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.731 -1.348 . . . . 0.0 109.731 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 85.7 m-85 -137.1 -96.13 0.21 Allowed 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.22 -1.164 . . . . 0.0 109.81 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 74' ' ' MET . . . . . 0.595 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 5.6 ptt? -163.95 160.86 22.46 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.157 -0.964 . . . . 0.0 109.896 -179.491 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 75' ' ' CYS . . . . . 0.492 ' O ' ' SG ' ' A' ' 75' ' ' CYS . 12.1 p -97.38 130.59 44.51 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.417 -0.802 . . . . 0.0 108.966 179.241 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 93.8 mt-30 -105.79 149.82 26.12 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.27 -0.894 . . . . 0.0 109.648 -179.712 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -143.91 126.24 2.69 Favored Glycine 0 N--CA 1.492 2.425 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 179.85 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -86.05 178.48 49.58 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.77 -1.332 . . . . 0.0 109.77 -179.76 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 88.1 m-20 -72.13 149.38 44.79 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.357 -1.084 . . . . 0.0 109.554 179.842 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 43.6 p90 -61.53 -22.97 65.62 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.201 -0.937 . . . . 0.0 109.571 -179.907 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.56 ' O ' ' HB2' ' A' ' 82' ' ' ALA . 61.6 p -65.98 -30.17 70.68 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.133 -0.979 . . . . 0.0 109.424 -179.926 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 82' ' ' ALA . . . . . 0.56 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 171.4 -55.7 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.339 -0.851 . . . . 0.0 109.284 179.809 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 94.79 -10.3 70.53 Favored Glycine 0 N--CA 1.493 2.462 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 179.889 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 50.4 t30 -86.18 1.71 49.66 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.176 -1.191 . . . . 0.0 109.345 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 97.21 -8.83 65.02 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.311 -1.516 . . . . 0.0 109.311 -179.865 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 68.0 p -73.34 -20.0 60.89 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.311 -1.111 . . . . 0.0 109.273 179.675 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -127.68 -130.51 3.35 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 109.334 -1.507 . . . . 0.0 109.334 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 72.48 55.02 7.06 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.175 -1.57 . . . . 0.0 109.175 -179.948 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -84.77 140.73 31.03 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.368 -1.077 . . . . 0.0 109.808 -179.506 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 27.8 t -111.65 143.07 43.14 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.453 -0.779 . . . . 0.0 109.111 179.773 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 15.4 pt -65.12 -38.64 83.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.18 -0.95 . . . . 0.0 110.061 -179.529 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 92' ' ' TYR . . . . . 0.476 ' CG ' ' NH2' ' A' ' 37' ' ' ARG . 50.7 m-85 -67.83 -38.5 83.3 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.09 -1.006 . . . . 0.0 109.677 -179.906 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 76.09 22.05 74.7 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.342 -1.503 . . . . 0.0 109.342 -179.8 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -147.28 162.69 38.42 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.283 -1.128 . . . . 0.0 109.592 -179.708 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 61.0 mttp -77.19 154.16 33.38 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.269 -0.895 . . . . 0.0 109.527 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 96' ' ' PHE . . . . . 0.463 ' CD1' ' N ' ' A' ' 96' ' ' PHE . 2.1 m-85 -100.37 133.19 45.16 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.303 -0.873 . . . . 0.0 109.059 179.969 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -91.44 130.45 37.27 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.092 -1.005 . . . . 0.0 109.582 -179.874 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 88.2 m-20 -72.05 143.4 49.11 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.269 -0.894 . . . . 0.0 109.362 179.76 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -141.0 -47.44 0.4 Allowed 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.242 -0.911 . . . . 0.0 109.734 -179.848 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 86.0 m-20 -105.0 122.08 45.11 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.242 -0.911 . . . . 0.0 109.905 -179.585 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 101' ' ' PHE . . . . . 0.553 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 71.7 t80 -120.43 14.48 11.98 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.461 -0.774 . . . . 0.0 108.965 179.549 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 89.7 mt -55.11 -38.31 46.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.417 -0.802 . . . . 0.0 110.237 -179.434 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 67.4 mttm -84.54 136.98 33.58 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.991 -1.068 . . . . 0.0 109.782 -179.528 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 104' ' ' LYS . . . . . 0.516 ' HZ3' ' CG2' ' A' ' 106' ' ' THR . 21.3 pttm -139.58 -177.12 4.81 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.457 -0.777 . . . . 0.0 109.274 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 105' ' ' HIS . . . . . 0.533 ' CE1' ' O ' ' A' ' 107' ' ' GLY . 8.5 t-80 -86.52 107.01 17.92 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.121 -0.987 . . . . 0.0 109.491 -179.881 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 106' ' ' THR . . . . . 0.516 ' CG2' ' HZ3' ' A' ' 104' ' ' LYS . 46.6 p -114.43 -1.31 13.51 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.348 -0.845 . . . . 0.0 109.779 179.955 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.533 ' O ' ' CE1' ' A' ' 105' ' ' HIS . . . -154.31 170.54 32.8 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 -179.756 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -77.01 153.7 32.68 Favored 'Trans proline' 0 C--N 1.307 -1.656 0 C-N-CA 122.909 2.406 . . . . 0.0 112.264 179.804 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 78.53 52.4 5.13 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 110.032 -1.227 . . . . 0.0 110.032 179.491 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 35.3 mm -114.27 137.31 47.99 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 O-C-N 121.27 -1.135 . . . . 0.0 109.825 -179.86 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.535 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 2.5 mm? -89.42 125.61 35.23 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.308 -0.87 . . . . 0.0 109.021 179.564 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 36.8 t -147.74 142.83 27.07 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.027 -1.046 . . . . 0.0 109.794 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 64.9 mtt -88.45 135.96 33.22 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.185 -0.947 . . . . 0.0 109.411 179.606 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -72.22 135.59 46.12 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.137 -0.977 . . . . 0.0 109.34 179.808 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 63.7 m-20 -145.37 113.32 6.45 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.162 -0.962 . . . . 0.0 109.336 179.77 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -70.15 -28.7 65.56 Favored 'General case' 0 C--N 1.297 -1.68 0 O-C-N 121.457 -0.777 . . . . 0.0 109.362 179.796 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -134.46 165.25 24.5 Favored Glycine 0 N--CA 1.493 2.484 0 N-CA-C 109.279 -1.528 . . . . 0.0 109.279 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -70.17 154.91 65.67 Favored 'Trans proline' 0 C--N 1.306 -1.667 0 C-N-CA 122.776 2.317 . . . . 0.0 112.199 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 77.5 m-20 54.72 46.9 23.67 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.467 -0.77 . . . . 0.0 109.559 179.841 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 87.3 m -132.27 129.75 40.0 Favored 'General case' 0 C--N 1.306 -1.312 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 179.709 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 121' ' ' ASN . . . . . 0.402 ' OD1' ' CE2' ' A' ' 96' ' ' PHE . 50.8 t30 -74.69 123.15 24.38 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 121.442 -0.786 . . . . 0.0 109.329 -179.855 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -90.74 103.64 3.06 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.839 -1.304 . . . . 0.0 109.839 -179.84 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 85.5 p -65.03 -23.63 67.25 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.248 -1.148 . . . . 0.0 109.245 179.596 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.0 mt-30 -109.19 151.83 25.96 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.434 -0.791 . . . . 0.0 109.622 -179.805 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 49.2 p90 -136.63 160.85 37.56 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.377 -0.827 . . . . 0.0 109.108 179.75 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 126' ' ' PHE . . . . . 0.595 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 50.2 p90 -140.58 158.5 43.9 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.224 -0.923 . . . . 0.0 109.724 -179.895 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 65.1 mt -120.98 133.6 67.1 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 O-C-N 121.593 -0.692 . . . . 0.0 109.325 179.674 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 6.7 m -97.48 108.64 21.4 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.169 -0.957 . . . . 0.0 109.305 179.779 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 60.2 p -76.39 -10.07 59.12 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.182 -0.949 . . . . 0.0 109.528 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -137.89 161.55 36.34 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.309 -0.87 . . . . 0.0 109.302 -179.818 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 49.0 tttp -62.22 133.21 54.87 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.226 -0.921 . . . . 0.0 109.433 -179.806 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 29.4 p -140.37 91.93 2.48 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.313 -0.867 . . . . 0.0 109.281 -179.898 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -63.57 -34.9 78.84 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.255 -0.903 . . . . 0.0 109.73 -179.813 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 0.9 OUTLIER -67.76 -47.9 67.93 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.068 -1.02 . . . . 0.0 109.646 -179.876 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 15.3 mt -66.79 -31.73 72.55 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.111 -0.993 . . . . 0.0 109.701 179.511 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 60.0 t0 -78.18 121.48 24.4 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.109 -0.994 . . . . 0.0 109.767 -179.566 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 179.88 -114.94 0.46 Allowed Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 138' ' ' LYS . . . . . 0.437 ' O ' ' C ' ' A' ' 139' ' ' HIS . 66.4 mttm -57.64 -36.24 71.57 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.297 -1.12 . . . . 0.0 109.748 179.886 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 139' ' ' HIS . . . . . 0.437 ' C ' ' O ' ' A' ' 138' ' ' LYS . 53.7 m170 -40.94 144.69 0.25 Allowed 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.543 -0.723 . . . . 0.0 109.816 -179.683 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 42.4 t -115.11 138.84 44.11 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 121.359 -0.838 . . . . 0.0 109.601 -179.678 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 91.8 t -97.97 129.06 48.72 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.341 -0.85 . . . . 0.0 109.441 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 39.1 p90 -115.15 0.54 13.61 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.348 -0.845 . . . . 0.0 109.492 179.844 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -176.19 175.6 47.48 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.349 -1.5 . . . . 0.0 109.349 179.558 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.4 pt20 -147.86 168.21 22.78 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.125 -1.221 . . . . 0.0 110.045 -179.837 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 82.1 t -94.61 131.28 41.9 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.245 0 O-C-N 121.333 -0.854 . . . . 0.0 109.363 -179.814 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 10.9 m -112.43 -30.71 2.2 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.325 -0.859 . . . . 0.0 109.853 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 92.9 mt-10 -141.91 169.45 17.56 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.152 -0.968 . . . . 0.0 109.611 -179.881 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 95.57 6.85 59.43 Favored Glycine 0 N--CA 1.493 2.452 0 N-CA-C 109.984 -1.246 . . . . 0.0 109.984 179.597 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 149' ' ' MET . . . . . 0.447 ' O ' HG12 ' A' ' 152' ' ' VAL . 65.0 mtt -60.14 -31.92 70.53 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.058 -1.26 . . . . 0.0 109.543 -179.978 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 150' ' ' ASP . . . . . 0.54 ' OD1' ' N ' ' A' ' 151' ' ' VAL . 31.8 p-10 -65.0 -36.96 86.08 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.812 -1.18 . . . . 0.0 109.821 -179.64 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.54 ' N ' ' OD1' ' A' ' 150' ' ' ASP . 3.5 p -87.08 -34.19 7.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.148 -0.97 . . . . 0.0 110.385 -179.64 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 152' ' ' VAL . . . . . 0.46 ' CG1' ' N ' ' A' ' 153' ' ' LYS . 0.9 OUTLIER -56.67 -41.87 75.32 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 120.991 -1.068 . . . . 0.0 109.188 -179.478 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 153' ' ' LYS . . . . . 0.46 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 66.8 mttm -63.99 -34.72 78.65 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.274 -0.891 . . . . 0.0 109.406 179.583 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -62.17 -36.81 83.01 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.29 -0.881 . . . . 0.0 109.934 -179.477 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.403 HG22 HG11 ' A' ' 69' ' ' VAL . 62.5 mt -74.36 -37.56 45.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.136 -0.977 . . . . 0.0 109.84 -179.786 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -73.73 -40.61 63.43 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.129 -0.982 . . . . 0.0 111.399 -178.493 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 18.1 pttp -59.86 -35.61 75.16 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.679 -1.263 . . . . 0.0 109.696 -178.955 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 27.1 m -77.04 -17.52 14.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.08 -1.012 . . . . 0.0 108.952 179.389 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -64.43 150.21 50.93 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 49.7 m -136.28 161.23 36.35 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.454 -1.027 . . . . 0.0 109.175 179.914 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 23.8 m -51.35 -33.12 28.17 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.187 -0.946 . . . . 0.0 108.966 179.875 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 22.6 t -57.89 -29.02 64.73 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.36 -0.837 . . . . 0.0 109.334 179.643 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.22 10.14 52.08 Favored Glycine 0 N--CA 1.493 2.465 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 -179.806 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 83.7 mtp180 -117.04 155.28 29.49 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.384 -1.068 . . . . 0.0 109.175 179.909 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 165' ' ' THR . . . . . 0.403 ' OG1' ' O ' ' A' ' 167' ' ' LYS . 44.8 p -110.71 156.43 21.04 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.243 -0.911 . . . . 0.0 109.62 -179.759 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -68.19 -37.28 80.76 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.414 -0.804 . . . . 0.0 109.435 179.676 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 167' ' ' LYS . . . . . 0.403 ' O ' ' OG1' ' A' ' 165' ' ' THR . 3.7 mptp? -105.18 158.67 16.43 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.405 -0.809 . . . . 0.0 109.597 -179.834 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 61.3 mttp -81.34 151.99 27.73 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.346 -0.846 . . . . 0.0 109.475 179.83 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 169' ' ' VAL . . . . . 0.476 ' O ' HG23 ' A' ' 169' ' ' VAL . 30.9 m -131.14 124.37 55.45 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.301 -0.874 . . . . 0.0 109.649 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 46.3 t -148.59 147.08 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.296 -0.877 . . . . 0.0 108.988 179.602 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.818 ' CG2' ' H ' ' A' ' 64' ' ' SER . 2.8 m -87.81 123.16 40.25 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.838 0 O-C-N 120.952 -1.093 . . . . 0.0 109.944 -179.9 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -74.29 -36.72 63.78 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.327 -0.858 . . . . 0.0 110.367 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 173' ' ' ASP . . . . . 0.465 ' OD1' ' N ' ' A' ' 174' ' ' CYS . 54.3 t0 -155.08 153.65 31.22 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 120.914 -1.116 . . . . 0.0 110.662 -179.1 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 174' ' ' CYS . . . . . 0.58 ' SG ' ' CE2' ' A' ' 14' ' ' PHE . 45.4 t -142.15 141.49 32.64 Favored 'General case' 0 N--CA 1.492 1.63 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.48 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -169.52 -178.86 40.99 Favored Glycine 0 N--CA 1.493 2.441 0 N-CA-C 109.806 -1.318 . . . . 0.0 109.806 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 176' ' ' GLN . . . . . 0.713 ' NE2' ' HE ' ' A' ' 43' ' ' ARG . 6.8 tt0 -105.22 120.49 41.67 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.406 -1.055 . . . . 0.0 109.66 -179.875 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 32.1 tp -63.59 -37.81 88.75 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.156 -0.965 . . . . 0.0 109.321 179.414 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 10.9 t . . . . . 0 N--CA 1.49 1.533 0 CA-C-O 118.001 -0.999 . . . . 0.0 109.432 -179.952 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 14.9 m-80 . . . . . 0 N--CA 1.494 1.73 0 N-CA-C 109.675 -0.491 . . . . 0.0 109.675 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -68.22 141.67 52.9 Favored 'Trans proline' 0 N--CA 1.496 1.67 0 C-N-CA 122.62 2.213 . . . . 0.0 112.144 179.877 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 78.4 mtm180 -128.08 133.43 49.04 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.463 -0.773 . . . . 0.0 108.981 179.428 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.2 p -135.57 143.38 36.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.329 -0.857 . . . . 0.0 109.576 -179.822 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 39.2 p90 -137.22 152.83 50.3 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.418 -0.801 . . . . 0.0 109.34 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.459 ' CE1' ' CE1' ' A' ' 61' ' ' TYR . 98.1 m-85 -124.08 132.84 53.71 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.563 -0.711 . . . . 0.0 109.399 179.8 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.6 t0 -91.29 114.56 27.12 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.224 -0.923 . . . . 0.0 108.776 179.485 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 79.7 mtp -107.26 137.33 45.52 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.255 -0.903 . . . . 0.0 110.031 -179.392 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 19.8 m -130.41 152.93 49.28 Favored 'General case' 0 N--CA 1.492 1.639 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 179.636 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.411 ' O ' ' N ' ' A' ' 21' ' ' GLN . 29.8 m -119.05 134.85 61.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.227 -0.921 . . . . 0.0 109.442 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 49.26 25.03 5.47 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 84.24 20.67 58.52 Favored Glycine 0 N--CA 1.492 2.398 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 -179.914 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' GLN . . . . . 0.411 ' N ' ' O ' ' A' ' 18' ' ' VAL . 40.6 mt-30 -120.11 99.19 48.79 Favored Pre-proline 0 N--CA 1.495 1.778 0 O-C-N 121.377 -1.072 . . . . 0.0 109.414 -179.904 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 75.2 Cg_exo -46.53 99.1 0.03 OUTLIER 'Trans proline' 0 N--CA 1.491 1.382 0 C-N-CA 122.353 2.035 . . . . 0.0 112.237 -179.883 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -65.27 -39.85 93.14 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.355 -0.841 . . . . 0.0 109.806 -179.799 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 167.36 -169.11 40.89 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.677 -1.369 . . . . 0.0 109.677 -179.798 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 97.1 mtt180 -115.26 147.05 40.86 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.5 -1.0 . . . . 0.0 109.45 179.812 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 77.2 mt -119.71 123.29 70.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 N-CA-C 108.463 -0.94 . . . . 0.0 108.463 179.118 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 24.8 t -114.26 132.95 61.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.373 -0.829 . . . . 0.0 109.423 -179.488 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' MET . . . . . 0.78 ' SD ' HD11 ' A' ' 111' ' ' LEU . 73.2 mtm -125.66 152.71 44.86 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.382 -0.824 . . . . 0.0 109.196 -179.84 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -99.01 133.26 43.53 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.259 -0.901 . . . . 0.0 109.761 179.877 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -108.85 131.16 55.27 Favored 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 179.794 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 98.2 m-85 -96.36 120.3 36.41 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.095 -1.003 . . . . 0.0 109.063 179.764 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -84.06 -41.1 17.54 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.338 -0.851 . . . . 0.0 109.865 -179.729 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -65.81 -44.71 84.83 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.275 -0.891 . . . . 0.0 110.624 -179.185 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 52.9 m -67.05 -44.87 79.06 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.09 -1.006 . . . . 0.0 110.241 -179.291 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 2.0 m -150.68 82.89 5.98 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.155 -0.966 . . . . 0.0 109.269 -179.666 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 39.9 Cg_endo -71.37 -38.32 4.79 Favored 'Trans proline' 0 C--N 1.308 -1.592 0 C-N-CA 122.19 1.927 . . . . 0.0 112.361 -179.361 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 35.2 mmt180 -64.5 -41.81 96.22 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.126 -0.983 . . . . 0.0 109.691 -179.858 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.48 HG23 ' SD ' ' A' ' 113' ' ' MET . 80.8 m -67.55 -42.66 82.32 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.194 -0.941 . . . . 0.0 110.034 -179.715 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -61.31 -31.81 71.66 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.11 -0.994 . . . . 0.0 108.962 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -70.33 -38.07 74.8 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.422 -0.799 . . . . 0.0 109.999 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 20.4 t-20 -57.91 -43.92 86.49 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.265 -0.897 . . . . 0.0 109.865 -179.534 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -85.3 -46.71 10.74 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.247 -0.908 . . . . 0.0 109.606 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 71.2 ttp85 -57.24 -42.88 82.32 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.312 -0.867 . . . . 0.0 109.663 -179.894 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.5 ' O ' ' N ' ' A' ' 48' ' ' GLY . . . -72.13 -46.27 57.22 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.288 -0.883 . . . . 0.0 109.899 -179.691 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 38.2 tp -61.97 -37.68 85.69 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.095 -1.003 . . . . 0.0 109.438 -179.817 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 46' ' ' CYS . . . . . . . . . . . . . 98.7 m -67.19 -65.93 0.62 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.305 -0.872 . . . . 0.0 109.579 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 31.0 m -64.6 -37.17 86.65 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.374 -0.829 . . . . 0.0 109.404 179.656 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 48' ' ' GLY . . . . . 0.5 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 80.94 37.8 17.86 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 110.037 -1.225 . . . . 0.0 110.037 179.831 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -61.72 -37.85 85.72 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.089 -1.242 . . . . 0.0 109.51 179.913 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 70.4 mmtt -61.37 -35.49 77.62 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.295 -0.878 . . . . 0.0 109.42 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 88.16 -174.89 44.25 Favored Glycine 0 N--CA 1.484 1.875 0 N-CA-C 108.979 -1.648 . . . . 0.0 108.979 -179.574 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.548 HG23 ' HA ' ' A' ' 58' ' ' PRO . 89.6 m -71.36 139.19 49.73 Favored 'General case' 0 C--N 1.295 -1.78 0 O-C-N 121.537 -0.978 . . . . 0.0 109.603 179.893 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -56.8 136.37 50.09 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.176 -1.57 . . . . 0.0 109.176 179.795 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 86.4 mtt-85 -58.77 -36.94 75.22 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.222 -1.164 . . . . 0.0 109.857 -179.617 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 24.8 m -59.59 -33.94 72.11 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.21 -0.931 . . . . 0.0 109.802 -179.825 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 124.96 91.92 0.91 Allowed Glycine 0 N--CA 1.494 2.514 0 N-CA-C 108.953 -1.659 . . . . 0.0 108.953 -179.658 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 57' ' ' LYS . . . . . 0.494 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 28.0 tttp -175.69 79.76 0.3 Allowed Pre-proline 0 N--CA 1.489 1.478 0 O-C-N 121.447 -1.031 . . . . 0.0 108.406 -179.709 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.548 ' HA ' HG23 ' A' ' 52' ' ' THR . 73.7 Cg_exo -49.65 131.8 29.38 Favored 'Trans proline' 0 C--N 1.303 -1.848 0 C-N-CA 122.923 2.415 . . . . 0.0 112.845 -178.927 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.494 ' CD1' ' O ' ' A' ' 57' ' ' LYS . 8.7 mp -103.35 113.09 26.3 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.591 -0.693 . . . . 0.0 109.365 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 60' ' ' HIS . . . . . 0.507 ' O ' ' CE1' ' A' ' 80' ' ' PHE . 70.8 m80 -141.1 126.25 18.43 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.203 -0.936 . . . . 0.0 109.544 179.473 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 61' ' ' TYR . . . . . 0.459 ' CE1' ' CE1' ' A' ' 14' ' ' PHE . 13.7 t80 -94.42 -11.67 29.36 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.359 -0.838 . . . . 0.0 108.936 179.743 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -78.68 160.52 27.46 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.451 -0.78 . . . . 0.0 109.775 -179.485 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 50.1 t0 60.44 45.8 10.48 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.513 -0.742 . . . . 0.0 109.932 179.647 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 92.5 p -116.25 150.9 36.82 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.328 -0.858 . . . . 0.0 108.841 179.291 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 65' ' ' SER . . . . . 0.408 ' O ' ' OD2' ' A' ' 79' ' ' ASP . 29.4 t -121.17 147.33 45.73 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.257 -0.902 . . . . 0.0 109.716 -179.514 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.3 m-30 -68.18 138.34 55.56 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.351 -0.843 . . . . 0.0 108.907 179.825 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 80.0 t60 -60.51 -51.2 70.48 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.218 -0.926 . . . . 0.0 110.138 -179.327 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.699 ' HE ' ' NE2' ' A' ' 76' ' ' GLN . 38.5 ptt180 -162.85 162.78 26.58 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.073 -1.017 . . . . 0.0 109.873 179.946 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.577 HG21 HG22 ' A' ' 165' ' ' THR . 18.4 m -131.52 150.01 33.68 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.725 0 O-C-N 121.445 -0.785 . . . . 0.0 109.052 179.761 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 14.3 mt -147.29 119.43 4.71 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.024 -1.047 . . . . 0.0 109.433 179.714 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -73.95 134.48 19.79 Favored 'Trans proline' 0 C--N 1.313 -1.316 0 C-N-CA 122.022 1.815 . . . . 0.0 111.868 179.948 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 89.54 2.58 76.04 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.456 ' C ' ' SD ' ' A' ' 74' ' ' MET . 80.2 m-85 -137.22 -94.32 0.22 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.312 -1.11 . . . . 0.0 109.711 179.9 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 74' ' ' MET . . . . . 0.456 ' SD ' ' C ' ' A' ' 73' ' ' PHE . 0.0 OUTLIER -162.98 172.71 14.62 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.161 -0.962 . . . . 0.0 109.81 -179.688 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 1.9 m -119.49 135.16 54.89 Favored 'General case' 0 N--CA 1.494 1.728 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 179.543 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 76' ' ' GLN . . . . . 0.699 ' NE2' ' HE ' ' A' ' 68' ' ' ARG . 25.1 mt-30 -104.06 153.75 20.51 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.286 -0.884 . . . . 0.0 109.816 -179.638 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -158.99 -170.89 24.08 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.329 -1.509 . . . . 0.0 109.329 -179.958 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 80.02 37.94 20.61 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.504 -1.439 . . . . 0.0 109.504 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.437 ' C ' ' OD1' ' A' ' 79' ' ' ASP . 54.2 p30 -85.24 12.16 8.6 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.291 -1.123 . . . . 0.0 109.46 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.507 ' CE1' ' O ' ' A' ' 60' ' ' HIS . 76.3 t80 -52.88 -44.9 67.2 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.348 -0.845 . . . . 0.0 109.937 -179.902 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.668 ' O ' ' HB2' ' A' ' 82' ' ' ALA . 69.0 p -69.45 -29.25 66.9 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.149 -0.969 . . . . 0.0 109.513 -179.928 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 82' ' ' ALA . . . . . 0.668 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 165.76 -55.88 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.229 -0.919 . . . . 0.0 109.365 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 92.28 0.29 70.76 Favored Glycine 0 N--CA 1.492 2.389 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 -179.928 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 77.7 m-20 -87.57 5.51 38.98 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.213 -1.169 . . . . 0.0 109.474 179.931 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 96.04 -36.81 3.67 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.329 -1.508 . . . . 0.0 109.329 -179.903 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 56.2 p -73.53 -18.9 61.03 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.271 -1.134 . . . . 0.0 109.164 179.638 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -83.34 -164.04 35.62 Favored Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.611 -1.395 . . . . 0.0 109.611 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.647 ' H ' ' CB ' ' A' ' 81' ' ' THR . . . 92.28 24.09 25.24 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.314 -1.514 . . . . 0.0 109.314 -179.785 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -57.3 145.59 31.6 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.432 -1.04 . . . . 0.0 109.687 -179.864 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 28.8 t -107.03 146.14 31.49 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.328 -0.858 . . . . 0.0 109.263 179.941 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 20.3 pt -61.26 -33.24 55.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.131 -0.98 . . . . 0.0 109.746 -179.812 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 91.7 m-85 -65.51 -36.15 82.98 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.285 -0.884 . . . . 0.0 109.653 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.09 15.24 70.12 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.319 -1.513 . . . . 0.0 109.319 -179.654 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -143.64 155.92 44.4 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.309 -1.113 . . . . 0.0 109.545 -179.859 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 63.1 mttp -94.03 137.89 32.72 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.287 -0.883 . . . . 0.0 109.586 -179.846 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -123.9 154.23 40.0 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.309 -0.869 . . . . 0.0 109.768 179.901 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -107.1 154.65 20.85 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.469 -0.769 . . . . 0.0 109.06 179.536 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 60.0 t0 -76.68 105.48 7.77 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.032 -1.042 . . . . 0.0 109.378 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -67.22 -34.15 76.88 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.284 -0.885 . . . . 0.0 110.062 -179.809 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 86.5 m-20 -105.0 124.71 50.0 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.251 -0.906 . . . . 0.0 110.052 -179.35 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 99.2 m-85 -108.13 12.78 26.46 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.462 -0.774 . . . . 0.0 109.067 179.556 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 92.6 mt -53.36 -39.25 34.86 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.326 -0.859 . . . . 0.0 110.048 -179.319 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 58.0 mttm -82.25 132.9 35.23 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.983 -1.073 . . . . 0.0 109.592 -179.849 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 80.7 tttt -138.65 158.85 43.46 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.41 -0.806 . . . . 0.0 109.335 -179.891 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 105' ' ' HIS . . . . . 0.611 ' CE1' ' SG ' ' A' ' 128' ' ' CYS . 85.2 t60 -86.07 99.17 11.29 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.233 -0.917 . . . . 0.0 109.431 179.886 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 65.9 p -115.78 -1.62 12.59 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.352 -0.842 . . . . 0.0 109.607 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.539 ' O ' ' CE1' ' A' ' 105' ' ' HIS . . . -153.84 169.92 32.47 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -73.88 158.86 45.92 Favored 'Trans proline' 0 C--N 1.306 -1.671 0 C-N-CA 122.935 2.424 . . . . 0.0 112.25 179.811 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 109' ' ' GLY . . . . . 0.468 ' O ' HG12 ' A' ' 145' ' ' VAL . . . 81.9 43.21 8.38 Favored Glycine 0 N--CA 1.493 2.459 0 N-CA-C 109.885 -1.286 . . . . 0.0 109.885 179.694 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 44.3 mm -117.0 132.7 66.0 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.725 0 O-C-N 121.287 -1.125 . . . . 0.0 109.598 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.78 HD11 ' SD ' ' A' ' 28' ' ' MET . 1.7 mm? -89.23 133.63 34.36 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.214 -0.929 . . . . 0.0 108.756 179.452 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 112' ' ' SER . . . . . 0.552 ' OG ' ' CZ ' ' A' ' 126' ' ' PHE . 99.0 p -143.38 154.26 43.54 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.109 -0.994 . . . . 0.0 109.628 -179.907 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 113' ' ' MET . . . . . 0.48 ' SD ' HG23 ' A' ' 38' ' ' THR . 72.1 mtm -93.64 136.66 33.7 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.305 -0.872 . . . . 0.0 109.213 179.556 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -65.09 138.09 58.08 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.215 -0.928 . . . . 0.0 109.185 179.815 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 70.6 m-20 -135.19 115.29 13.2 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.257 -0.902 . . . . 0.0 109.441 179.88 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -85.1 -9.89 57.43 Favored 'General case' 0 C--N 1.297 -1.675 0 O-C-N 121.501 -0.749 . . . . 0.0 109.096 179.501 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 117' ' ' GLY . . . . . 0.43 ' H ' HG21 ' A' ' 120' ' ' THR . . . -136.12 173.76 21.76 Favored Glycine 0 N--CA 1.492 2.367 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 -179.746 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -57.09 -25.4 63.41 Favored 'Trans proline' 0 C--N 1.307 -1.648 0 C-N-CA 122.747 2.298 . . . . 0.0 112.196 -179.905 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 119' ' ' ASN . . . . . 0.441 ' O ' ' OD1' ' A' ' 119' ' ' ASN . 42.4 p-10 -153.19 96.18 2.03 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.17 -0.956 . . . . 0.0 109.908 179.836 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 120' ' ' THR . . . . . 0.43 HG21 ' H ' ' A' ' 117' ' ' GLY . 0.5 OUTLIER -148.74 123.81 10.09 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 121.327 -0.858 . . . . 0.0 109.338 179.774 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 51.3 t-20 -100.38 121.84 42.18 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.355 -0.84 . . . . 0.0 109.449 -179.861 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -137.08 158.99 24.52 Favored Glycine 0 N--CA 1.493 2.473 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 78.5 p -69.06 -19.08 64.08 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.345 -1.091 . . . . 0.0 109.645 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.9 mt-30 -66.5 137.44 56.8 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.134 -0.978 . . . . 0.0 109.613 -179.593 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 44.5 p90 -146.49 161.68 39.91 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.33 -0.857 . . . . 0.0 109.323 179.892 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 126' ' ' PHE . . . . . 0.552 ' CZ ' ' OG ' ' A' ' 112' ' ' SER . 51.9 p90 -141.16 159.05 43.04 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.166 -0.959 . . . . 0.0 109.577 179.716 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 77.7 mt -116.43 135.1 57.77 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.354 -0.841 . . . . 0.0 109.425 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 128' ' ' CYS . . . . . 0.611 ' SG ' ' CE1' ' A' ' 105' ' ' HIS . 0.2 OUTLIER -99.23 99.79 10.81 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.388 -0.82 . . . . 0.0 109.423 -179.871 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 61.9 p -76.3 -6.86 53.37 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.322 -0.861 . . . . 0.0 109.321 179.812 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -139.91 162.76 34.41 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.369 -0.832 . . . . 0.0 109.316 -179.897 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.525 ' O ' ' CZ3' ' A' ' 134' ' ' TRP . 99.2 mttt -71.56 131.99 44.04 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.19 -0.944 . . . . 0.0 109.563 -179.654 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 132' ' ' THR . . . . . 0.408 HG22 ' CZ2' ' A' ' 134' ' ' TRP . 74.0 p -122.97 37.99 4.29 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.538 -0.726 . . . . 0.0 109.318 179.936 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 78.3 mm-40 -57.65 -31.12 65.99 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.272 -0.893 . . . . 0.0 109.733 -179.504 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 134' ' ' TRP . . . . . 0.525 ' CZ3' ' O ' ' A' ' 131' ' ' LYS . 12.7 p90 -55.24 -28.44 53.26 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.047 -1.033 . . . . 0.0 109.64 -179.805 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 135' ' ' LEU . . . . . 0.503 ' N ' ' CD1' ' A' ' 134' ' ' TRP . 69.0 mt -58.11 -35.93 72.18 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.055 -1.028 . . . . 0.0 109.473 179.3 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 57.2 t0 53.81 69.92 0.66 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.436 -0.79 . . . . 0.0 109.705 179.569 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -138.4 176.36 20.83 Favored Glycine 0 N--CA 1.484 1.857 0 N-CA-C 108.915 -1.674 . . . . 0.0 108.915 179.712 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 138' ' ' LYS . . . . . 0.427 ' O ' ' O ' ' A' ' 139' ' ' HIS . 63.0 mttp -59.21 -40.12 84.8 Favored 'General case' 0 C--N 1.296 -1.727 0 O-C-N 121.39 -1.065 . . . . 0.0 109.968 -179.768 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 139' ' ' HIS . . . . . 0.427 ' O ' ' O ' ' A' ' 138' ' ' LYS . 61.3 m170 51.75 98.89 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.414 -0.804 . . . . 0.0 109.542 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 52.1 t -105.49 135.18 44.69 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.751 0 O-C-N 121.461 -0.774 . . . . 0.0 109.395 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 48.5 t -117.04 128.71 74.38 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.485 -0.76 . . . . 0.0 109.691 -179.726 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 37.5 p90 -113.31 -1.21 14.32 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.376 -0.828 . . . . 0.0 109.539 179.458 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -173.84 -177.36 42.98 Favored Glycine 0 N--CA 1.493 2.438 0 N-CA-C 109.818 -1.313 . . . . 0.0 109.818 179.842 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.4 pt20 -144.22 171.39 14.37 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.311 -1.111 . . . . 0.0 109.475 -179.763 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 145' ' ' VAL . . . . . 0.468 HG12 ' O ' ' A' ' 109' ' ' GLY . 8.3 p -111.08 138.29 40.0 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.902 0 O-C-N 121.268 -0.895 . . . . 0.0 109.281 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 10.5 m -119.32 -28.16 2.05 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.483 -0.761 . . . . 0.0 109.679 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -138.06 167.16 22.37 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.249 -0.907 . . . . 0.0 109.567 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 97.49 3.23 58.6 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.779 -1.329 . . . . 0.0 109.779 179.652 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 149' ' ' MET . . . . . 0.432 ' O ' HG12 ' A' ' 152' ' ' VAL . 89.2 mtp -60.65 -32.56 71.73 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.183 -1.186 . . . . 0.0 109.771 179.951 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 150' ' ' ASP . . . . . 0.549 ' OD1' ' N ' ' A' ' 151' ' ' VAL . 32.9 p-10 -65.46 -37.44 86.86 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 120.85 -1.156 . . . . 0.0 109.902 -179.565 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.549 ' N ' ' OD1' ' A' ' 150' ' ' ASP . 5.2 p -87.31 -34.31 7.39 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.711 0 O-C-N 121.101 -0.999 . . . . 0.0 110.243 -179.672 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 152' ' ' VAL . . . . . 0.461 ' CG1' ' N ' ' A' ' 153' ' ' LYS . 0.9 OUTLIER -56.04 -42.35 71.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 120.996 -1.065 . . . . 0.0 109.101 -179.513 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 153' ' ' LYS . . . . . 0.461 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 98.7 mttt -64.42 -33.77 76.64 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.172 -0.955 . . . . 0.0 109.433 179.471 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -61.24 -38.8 87.95 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.351 -0.843 . . . . 0.0 110.132 -179.4 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 86.8 mt -72.3 -36.64 56.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.045 -1.034 . . . . 0.0 110.159 -179.728 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -76.29 -41.69 47.89 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.178 -0.951 . . . . 0.0 111.402 -178.784 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 16.8 pttp -60.45 -35.23 75.36 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 120.744 -1.223 . . . . 0.0 109.734 -178.845 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 32.7 m -82.46 -10.9 12.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.166 -0.958 . . . . 0.0 109.061 179.581 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -70.97 165.1 53.31 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.981 -1.248 . . . . 0.0 109.981 -179.565 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 24.1 t -154.08 168.55 26.1 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.421 -1.046 . . . . 0.0 109.439 -179.82 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 25.1 m -54.32 -29.6 48.33 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.279 -0.888 . . . . 0.0 109.341 179.808 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 24.7 m -53.31 -31.27 43.25 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.287 -0.883 . . . . 0.0 109.589 -179.882 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 96.05 8.98 57.55 Favored Glycine 0 N--CA 1.493 2.472 0 N-CA-C 109.766 -1.333 . . . . 0.0 109.766 179.896 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 82.3 mtm180 -122.93 145.56 48.36 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.209 -1.171 . . . . 0.0 109.471 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 165' ' ' THR . . . . . 0.577 HG22 HG21 ' A' ' 69' ' ' VAL . 80.9 p -80.57 153.52 28.01 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.189 -0.945 . . . . 0.0 109.36 179.79 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -66.0 -34.6 78.46 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.293 -0.879 . . . . 0.0 109.158 179.714 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 62.9 mttp -112.38 157.49 20.96 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.466 -0.771 . . . . 0.0 109.262 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 63.0 mttp -69.87 141.69 53.16 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.245 -0.91 . . . . 0.0 109.144 179.912 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 18.2 m -128.05 125.33 64.39 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 121.315 -0.866 . . . . 0.0 109.683 -179.819 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 46.5 t -148.33 152.13 12.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.43 -0.794 . . . . 0.0 109.114 179.766 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.401 HG23 ' H ' ' A' ' 171' ' ' VAL . 0.2 OUTLIER -91.15 114.94 29.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.23 -0.919 . . . . 0.0 109.374 -179.753 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -75.68 -11.47 60.01 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.521 -0.737 . . . . 0.0 110.072 -179.882 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 173' ' ' ASP . . . . . 0.475 ' OD1' ' N ' ' A' ' 174' ' ' CYS . 51.8 t0 -164.85 157.79 16.69 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 120.76 -1.212 . . . . 0.0 110.848 -179.31 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 174' ' ' CYS . . . . . 0.475 ' N ' ' OD1' ' A' ' 173' ' ' ASP . 16.7 t -154.85 141.64 19.05 Favored 'General case' 0 N--CA 1.492 1.657 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 179.372 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -178.05 178.08 48.46 Favored Glycine 0 N--CA 1.493 2.48 0 N-CA-C 109.749 -1.34 . . . . 0.0 109.749 179.776 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 176' ' ' GLN . . . . . 0.416 HE21 ' HB2' ' A' ' 178' ' ' SER . 60.9 tt0 -106.93 124.06 49.07 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.367 -1.078 . . . . 0.0 109.732 -179.981 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 30.6 tp -62.92 -37.99 89.22 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.132 -0.98 . . . . 0.0 109.264 179.509 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 178' ' ' SER . . . . . 0.416 ' HB2' HE21 ' A' ' 176' ' ' GLN . 33.1 m . . . . . 0 N--CA 1.49 1.549 0 CA-C-O 118.066 -0.969 . . . . 0.0 109.501 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 13.4 m-20 . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_endo -67.73 140.81 52.43 Favored 'Trans proline' 0 N--CA 1.494 1.556 0 C-N-CA 122.492 2.128 . . . . 0.0 112.07 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 80.9 mtm180 -126.58 139.18 53.39 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.316 -0.865 . . . . 0.0 109.166 179.614 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 15.0 p -133.71 142.81 40.47 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 121.327 -0.858 . . . . 0.0 109.519 -179.878 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' PHE . . . . . 0.483 ' CE2' ' NH2' ' A' ' 25' ' ' ARG . 28.6 p90 -141.85 155.94 45.54 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.304 -0.872 . . . . 0.0 109.683 -179.598 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -130.46 139.27 50.55 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.484 -0.76 . . . . 0.0 109.777 179.628 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -95.35 117.24 29.97 Favored 'General case' 0 N--CA 1.491 1.601 0 N-CA-C 108.188 -1.041 . . . . 0.0 108.188 178.788 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' MET . . . . . 0.414 ' SD ' HD12 ' A' ' 26' ' ' ILE . 76.9 mtp -107.74 147.44 30.79 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.121 -0.987 . . . . 0.0 110.443 -178.816 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.407 ' HA ' ' H ' ' A' ' 23' ' ' ALA . 88.4 p -143.3 163.25 33.51 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 179.574 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.401 ' O ' ' C ' ' A' ' 19' ' ' GLY . 29.1 m -122.97 140.55 46.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.218 -0.927 . . . . 0.0 109.476 179.921 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.401 ' C ' ' O ' ' A' ' 18' ' ' VAL . . . 44.46 -102.68 0.04 OUTLIER Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.636 -1.386 . . . . 0.0 109.636 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -130.38 38.15 2.01 Favored Glycine 0 N--CA 1.493 2.475 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 47.2 tt0 -147.18 133.49 9.68 Favored Pre-proline 0 N--CA 1.492 1.656 0 O-C-N 121.125 -1.221 . . . . 0.0 109.181 179.974 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 43.0 Cg_endo -69.9 126.7 13.52 Favored 'Trans proline' 0 N--CA 1.493 1.494 0 C-N-CA 122.193 1.929 . . . . 0.0 112.218 -179.788 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.407 ' H ' ' HA ' ' A' ' 17' ' ' SER . . . -80.39 -48.21 13.26 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.288 -0.883 . . . . 0.0 109.432 179.849 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 170.94 -169.41 42.42 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.37 -1.492 . . . . 0.0 109.37 -179.788 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' ARG . . . . . 0.483 ' NH2' ' CE2' ' A' ' 13' ' ' PHE . 66.4 ttt180 -116.93 142.47 46.9 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.413 -1.051 . . . . 0.0 109.291 179.942 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.414 HD12 ' SD ' ' A' ' 16' ' ' MET . 86.9 mt -120.68 128.03 75.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.424 -0.797 . . . . 0.0 108.998 179.804 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 46.1 t -116.99 133.81 62.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.508 -0.745 . . . . 0.0 109.311 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 71.3 mtm -125.38 147.37 49.19 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.343 -0.848 . . . . 0.0 109.251 179.91 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -112.56 132.6 55.03 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.267 -0.896 . . . . 0.0 109.84 -179.686 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.501 HD13 ' HA ' ' A' ' 39' ' ' ALA . 11.8 mt -103.09 139.66 38.33 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.416 -0.802 . . . . 0.0 109.36 179.262 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -95.6 113.32 24.95 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 108.342 -0.985 . . . . 0.0 108.342 178.795 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -73.96 -42.8 59.97 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 121.232 -0.917 . . . . 0.0 109.94 -179.376 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 56.6 t0 -61.33 -46.58 89.66 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.191 -0.943 . . . . 0.0 110.163 -179.36 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 34' ' ' THR . . . . . 0.487 HG21 ' HE2' ' A' ' 103' ' ' LYS . 24.0 m -72.41 -45.77 58.18 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.16 -0.962 . . . . 0.0 110.215 -179.596 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.553 HG22 ' OE1' ' A' ' 99' ' ' GLU . 6.4 p -137.87 80.66 29.95 Favored Pre-proline 0 N--CA 1.494 1.774 0 O-C-N 121.162 -0.962 . . . . 0.0 110.069 -179.224 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -77.24 -6.18 16.29 Favored 'Trans proline' 0 C--N 1.307 -1.645 0 C-N-CA 122.507 2.138 . . . . 0.0 111.642 179.546 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 4.5 tpt180 -94.29 -67.03 0.88 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.375 -0.828 . . . . 0.0 110.151 -178.797 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 46.4 m -56.46 -43.32 79.43 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.191 -0.943 . . . . 0.0 110.231 -179.058 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.501 ' HA ' HD13 ' A' ' 30' ' ' LEU . . . -61.77 -31.71 71.93 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.146 -0.971 . . . . 0.0 108.968 179.747 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -75.51 -51.18 13.55 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.272 -0.893 . . . . 0.0 109.9 -179.898 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 54.2 t-20 -60.39 -46.71 88.99 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.177 -0.952 . . . . 0.0 109.605 -179.707 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.51 ' CE2' ' SG ' ' A' ' 46' ' ' CYS . 71.8 t80 -61.28 -43.23 99.22 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.3 -0.875 . . . . 0.0 109.215 179.637 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 60.1 ttp180 -56.63 -38.37 72.02 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.466 -0.771 . . . . 0.0 109.844 179.825 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -62.85 -44.21 96.74 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.137 -0.977 . . . . 0.0 109.915 -179.507 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.652 HD13 ' O ' ' A' ' 59' ' ' LEU . 3.7 mm? -62.96 -39.06 93.52 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.097 -1.002 . . . . 0.0 109.131 179.729 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 46' ' ' CYS . . . . . 0.51 ' SG ' ' CE2' ' A' ' 42' ' ' PHE . 3.4 m -69.52 -62.4 1.4 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.259 -0.901 . . . . 0.0 109.473 -179.875 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 35.5 m -63.13 -38.57 91.71 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.398 -0.814 . . . . 0.0 109.272 179.889 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 80.83 35.33 25.18 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 110.197 -1.161 . . . . 0.0 110.197 179.555 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -62.52 -38.13 88.75 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.046 -1.267 . . . . 0.0 109.544 179.89 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 69.3 mmtt -62.56 -37.18 85.14 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.178 -0.951 . . . . 0.0 109.777 -179.83 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 89.34 170.01 44.58 Favored Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.297 -1.521 . . . . 0.0 109.297 -179.646 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.521 HG23 ' HA ' ' A' ' 58' ' ' PRO . 91.3 m -77.66 139.52 39.47 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.355 -1.085 . . . . 0.0 109.706 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -63.25 139.41 44.18 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 31.6 mmt180 -59.68 -34.37 72.78 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.33 -1.1 . . . . 0.0 109.767 -179.72 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 85.9 p -61.55 -25.58 67.39 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.222 -0.924 . . . . 0.0 109.902 -179.667 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 113.78 93.1 1.99 Allowed Glycine 0 N--CA 1.495 2.596 0 N-CA-C 109.063 -1.615 . . . . 0.0 109.063 -179.64 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 57' ' ' LYS . . . . . 0.477 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 30.3 ttmt -177.64 80.43 0.24 Allowed Pre-proline 0 N--CA 1.49 1.543 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 -179.769 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.523 ' O ' ' CE2' ' A' ' 80' ' ' PHE . 74.6 Cg_exo -49.64 127.23 18.07 Favored 'Trans proline' 0 C--N 1.304 -1.812 0 C-N-CA 122.847 2.365 . . . . 0.0 112.768 -178.898 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.652 ' O ' HD13 ' A' ' 45' ' ' LEU . 8.7 mp -96.97 19.68 12.39 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.57 -0.707 . . . . 0.0 109.263 179.808 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 27.2 m170 -112.44 132.01 55.27 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.354 -0.841 . . . . 0.0 109.759 -179.441 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 46.4 m-85 -71.93 -1.92 16.18 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.217 -0.927 . . . . 0.0 108.838 178.953 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 43.6 tttm -54.85 144.23 23.34 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.411 -0.805 . . . . 0.0 109.712 -179.88 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 51.1 t0 58.99 45.57 14.72 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.549 -0.719 . . . . 0.0 109.623 179.853 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 87.7 p -116.52 152.12 34.74 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.394 -0.817 . . . . 0.0 109.131 179.547 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 29.4 t -120.95 146.73 46.35 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.395 -0.816 . . . . 0.0 109.506 -179.725 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.449 ' HE2' ' HG ' ' A' ' 75' ' ' CYS . 3.8 m-30 -65.7 134.02 52.31 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.247 -0.908 . . . . 0.0 108.992 179.763 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 78.5 t60 -62.1 -50.73 70.74 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.265 -0.897 . . . . 0.0 110.1 -179.36 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 29.1 ptt180 -164.61 160.41 20.09 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.062 -1.024 . . . . 0.0 109.471 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -141.05 130.08 24.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.217 -0.927 . . . . 0.0 109.585 179.588 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 21.9 mt -121.93 110.11 33.39 Favored Pre-proline 0 N--CA 1.491 1.6 0 N-CA-C 108.874 -0.788 . . . . 0.0 108.874 179.443 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_exo -50.39 140.69 34.29 Favored 'Trans proline' 0 C--N 1.311 -1.438 0 C-N-CA 122.341 2.028 . . . . 0.0 112.758 -179.478 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 86.09 -56.29 4.8 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 110.407 -1.077 . . . . 0.0 110.407 179.038 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 81.2 m-85 -66.51 -75.18 0.1 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.005 -1.291 . . . . 0.0 110.178 -179.303 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 12.9 ptt? 179.63 -168.07 0.09 Allowed 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.01 -1.056 . . . . 0.0 109.912 -179.788 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 75' ' ' CYS . . . . . 0.449 ' HG ' ' HE2' ' A' ' 66' ' ' PHE . 7.7 t -128.76 129.34 45.57 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.544 -0.723 . . . . 0.0 109.276 179.743 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 63.7 tt0 -100.12 112.96 25.27 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.148 -0.97 . . . . 0.0 109.321 179.816 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -63.17 -37.32 94.71 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.772 -1.331 . . . . 0.0 109.772 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 82.23 -164.88 44.4 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.22 -1.552 . . . . 0.0 109.22 -179.671 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.523 ' OD2' HG23 ' A' ' 81' ' ' THR . 18.0 t70 -143.82 147.5 34.2 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.203 -1.175 . . . . 0.0 109.385 179.938 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.523 ' CE2' ' O ' ' A' ' 58' ' ' PRO . 50.5 p90 -70.89 -20.58 62.49 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.228 -0.92 . . . . 0.0 109.943 -179.79 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.523 HG23 ' OD2' ' A' ' 79' ' ' ASP . 59.0 p -69.26 -28.42 66.3 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.129 -0.982 . . . . 0.0 109.703 -179.817 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 82' ' ' ALA . . . . . 0.482 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 176.57 -58.13 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.277 -0.89 . . . . 0.0 109.47 179.904 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 90.7 2.54 72.32 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 109.413 -1.475 . . . . 0.0 109.413 -179.854 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 52.9 p-10 -88.55 7.26 34.03 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.279 -1.13 . . . . 0.0 109.589 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 98.29 -37.87 3.31 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 -179.88 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 49.4 p -71.38 -25.24 62.28 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.196 -1.179 . . . . 0.0 109.047 179.661 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -86.52 -165.92 41.69 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 179.96 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 85.44 37.08 9.97 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -60.17 148.4 36.33 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.249 -1.148 . . . . 0.0 109.421 179.925 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 50.3 m -108.01 149.13 28.79 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.402 -0.811 . . . . 0.0 109.391 -179.886 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 21.6 pt -66.24 -32.24 57.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.211 -0.931 . . . . 0.0 110.047 -179.534 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 49.1 m-85 -64.3 -37.4 87.35 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.012 -1.055 . . . . 0.0 109.448 -179.912 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 81.51 8.27 87.22 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.157 -1.577 . . . . 0.0 109.157 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -150.35 155.69 40.09 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.272 -1.134 . . . . 0.0 109.525 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 62.6 mttt -92.95 154.84 17.93 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.241 -0.912 . . . . 0.0 109.641 179.927 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 96' ' ' PHE . . . . . 0.475 ' CZ ' ' CG ' ' A' ' 121' ' ' ASN . 38.6 p90 -128.65 156.17 43.85 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.387 -0.82 . . . . 0.0 109.281 179.563 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -65.0 147.31 53.7 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.216 -0.927 . . . . 0.0 110.358 -179.139 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -62.48 154.33 28.86 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.315 -0.866 . . . . 0.0 109.609 179.912 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 99' ' ' GLU . . . . . 0.553 ' OE1' HG22 ' A' ' 35' ' ' THR . 94.6 mt-10 -85.35 -175.41 5.68 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.283 -0.886 . . . . 0.0 109.755 -179.833 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 18.5 m120 -60.3 162.78 5.67 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.416 -0.803 . . . . 0.0 109.94 -179.422 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 -98.67 23.63 8.46 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.43 -0.794 . . . . 0.0 109.585 -179.817 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 97.0 mt -48.38 -42.94 12.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.138 -0.977 . . . . 0.0 109.937 -179.327 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 103' ' ' LYS . . . . . 0.487 ' HE2' HG21 ' A' ' 34' ' ' THR . 59.0 mttm -89.47 139.29 30.67 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 120.931 -1.106 . . . . 0.0 109.689 179.972 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 87.5 mttt -127.28 -172.35 2.64 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.492 -0.755 . . . . 0.0 109.489 -179.898 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 105' ' ' HIS . . . . . 0.64 ' C ' ' CD2' ' A' ' 105' ' ' HIS . 5.9 t60 -113.77 111.67 22.16 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.531 -0.73 . . . . 0.0 109.189 179.752 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 60.6 p -131.16 4.82 4.43 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.276 -0.89 . . . . 0.0 109.922 -179.862 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -149.37 169.46 29.66 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.825 -1.31 . . . . 0.0 109.825 -179.824 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 76.6 Cg_endo -79.54 155.39 24.48 Favored 'Trans proline' 0 C--N 1.309 -1.543 0 C-N-CA 122.942 2.428 . . . . 0.0 112.083 179.783 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 76.89 52.61 5.72 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.894 -1.282 . . . . 0.0 109.894 179.628 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 38.1 mm -115.21 136.38 52.14 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.403 -1.057 . . . . 0.0 109.51 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.657 ' N ' HD22 ' A' ' 111' ' ' LEU . 3.3 mm? -88.27 134.37 33.82 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.227 -0.921 . . . . 0.0 109.537 179.786 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 28.9 t -146.3 142.79 28.65 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.255 -0.903 . . . . 0.0 109.374 179.729 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 87.6 mmm -87.64 132.06 34.22 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.231 -0.918 . . . . 0.0 109.284 179.902 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 114' ' ' ALA . . . . . 0.463 ' O ' ' OD1' ' A' ' 115' ' ' ASN . . . -68.23 139.69 56.04 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.123 -0.986 . . . . 0.0 109.405 -179.948 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 115' ' ' ASN . . . . . 0.463 ' OD1' ' O ' ' A' ' 114' ' ' ALA . 70.3 m-20 -145.94 113.44 6.31 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.247 -0.908 . . . . 0.0 109.01 179.642 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -69.15 -30.04 68.19 Favored 'General case' 0 C--N 1.297 -1.687 0 O-C-N 121.393 -0.817 . . . . 0.0 109.442 179.816 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -136.11 170.28 23.29 Favored Glycine 0 N--CA 1.494 2.525 0 N-CA-C 109.146 -1.582 . . . . 0.0 109.146 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -67.61 151.99 78.73 Favored 'Trans proline' 0 C--N 1.305 -1.719 0 C-N-CA 122.77 2.314 . . . . 0.0 111.847 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 69.0 m-20 53.34 44.26 30.32 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.33 -0.856 . . . . 0.0 109.143 -179.769 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 120' ' ' THR . . . . . 0.451 ' O ' ' OD1' ' A' ' 115' ' ' ASN . 58.3 m -132.26 123.83 27.69 Favored 'General case' 0 N--CA 1.486 1.373 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 179.924 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 121' ' ' ASN . . . . . 0.475 ' CG ' ' CZ ' ' A' ' 96' ' ' PHE . 26.5 m120 -113.39 138.62 49.8 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.506 -0.746 . . . . 0.0 109.537 -179.832 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -138.54 148.09 19.69 Favored Glycine 0 N--CA 1.493 2.489 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 23.3 m -61.23 -32.55 72.34 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.227 -1.16 . . . . 0.0 109.822 179.978 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.5 mt-30 -64.24 143.26 58.02 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.207 -0.933 . . . . 0.0 109.879 -179.481 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 48.7 p90 -141.42 163.9 31.68 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.346 -0.846 . . . . 0.0 109.028 179.858 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 45.3 p90 -136.91 158.14 45.14 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.299 -0.876 . . . . 0.0 109.696 -179.968 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 68.5 mt -120.39 136.53 57.13 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.519 -0.738 . . . . 0.0 109.273 179.799 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -108.5 120.82 43.54 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.457 -0.777 . . . . 0.0 109.358 -179.796 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 129' ' ' THR . . . . . 0.404 HG22 ' H ' ' A' ' 129' ' ' THR . 1.4 t -88.72 0.98 55.94 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.199 -0.938 . . . . 0.0 109.236 179.816 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -148.19 155.48 41.44 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.271 -0.893 . . . . 0.0 109.176 179.937 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 7.7 ttpm? -75.64 127.91 34.09 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.184 -0.947 . . . . 0.0 109.516 179.996 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 22.6 p -126.98 126.69 43.62 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.37 -0.831 . . . . 0.0 109.247 179.882 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -72.23 -36.56 69.16 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.28 -0.887 . . . . 0.0 110.366 -179.582 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 0.4 OUTLIER -65.03 -41.76 94.99 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.135 -0.978 . . . . 0.0 110.043 -179.157 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 135' ' ' LEU . . . . . 0.44 ' O ' ' CD2' ' A' ' 139' ' ' HIS . 12.9 mt -66.59 -33.83 76.53 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.985 -1.072 . . . . 0.0 109.8 179.701 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -68.46 140.85 55.75 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.15 -0.969 . . . . 0.0 109.522 -179.824 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 134.59 -86.19 0.26 Allowed Glycine 0 N--CA 1.492 2.417 0 N-CA-C 109.684 -1.366 . . . . 0.0 109.684 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 31.6 mmtp -85.97 5.32 33.79 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.132 -1.216 . . . . 0.0 109.507 -179.835 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 139' ' ' HIS . . . . . 0.44 ' CD2' ' O ' ' A' ' 135' ' ' LEU . 54.4 m-70 -103.26 138.19 40.38 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.286 -0.884 . . . . 0.0 109.477 -179.955 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 43.2 t -120.48 141.54 40.38 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 O-C-N 121.415 -0.803 . . . . 0.0 109.684 -179.565 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 96.1 t -94.8 128.96 45.61 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.361 -0.837 . . . . 0.0 109.245 179.821 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 142' ' ' PHE . . . . . 0.434 ' CE2' HD21 ' A' ' 30' ' ' LEU . 38.0 p90 -116.18 0.42 12.92 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.429 -0.794 . . . . 0.0 109.757 -179.77 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -169.42 178.04 42.71 Favored Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.676 -1.37 . . . . 0.0 109.676 179.684 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.2 pt20 -145.13 165.8 27.25 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.21 -1.171 . . . . 0.0 109.479 -179.865 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 77.7 t -96.54 127.28 48.82 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.265 0 O-C-N 121.193 -0.942 . . . . 0.0 109.274 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 22.2 m -94.7 -33.77 5.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.134 -0.979 . . . . 0.0 109.746 179.916 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -144.94 171.92 13.77 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.248 -0.907 . . . . 0.0 109.663 -179.797 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 96.68 4.93 58.99 Favored Glycine 0 N--CA 1.493 2.435 0 N-CA-C 109.915 -1.274 . . . . 0.0 109.915 179.642 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 149' ' ' MET . . . . . 0.491 ' O ' HG12 ' A' ' 152' ' ' VAL . 71.9 mtm -60.31 -33.05 71.82 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.071 -1.252 . . . . 0.0 109.809 179.888 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -65.63 -42.49 91.44 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 120.87 -1.144 . . . . 0.0 110.085 -179.586 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 6.5 p -81.73 -34.33 12.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.149 -0.969 . . . . 0.0 110.522 -179.484 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 152' ' ' VAL . . . . . 0.596 ' O ' ' OE1' ' A' ' 156' ' ' GLU . 0.8 OUTLIER -52.55 -43.07 41.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 120.816 -1.178 . . . . 0.0 109.0 -179.13 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 153' ' ' LYS . . . . . 0.454 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 48.5 mttp -63.12 -34.41 77.54 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.192 -0.942 . . . . 0.0 109.317 179.251 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -63.27 -32.11 73.43 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.429 -0.795 . . . . 0.0 110.176 -179.558 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.419 ' O ' HG22 ' A' ' 158' ' ' VAL . 69.1 mt -68.79 -43.14 82.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.124 -0.985 . . . . 0.0 110.836 -179.179 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 156' ' ' GLU . . . . . 0.596 ' OE1' ' O ' ' A' ' 152' ' ' VAL . 32.4 mp0 -77.21 -37.98 52.32 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 120.768 -1.207 . . . . 0.0 112.025 -178.683 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 12.1 pttm -57.48 -35.55 70.33 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 120.523 -1.36 . . . . 0.0 109.731 -178.516 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.419 HG22 ' O ' ' A' ' 155' ' ' ILE . 26.9 m -75.11 -19.8 16.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 120.969 -1.082 . . . . 0.0 109.013 179.042 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -67.33 167.46 40.04 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 -179.911 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 89.4 p -148.74 168.22 23.48 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.316 -1.108 . . . . 0.0 109.42 -179.798 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 22.9 m -54.55 -34.21 61.45 Favored 'General case' 0 N--CA 1.487 1.406 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 179.425 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 23.9 m -58.39 -30.77 67.07 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.472 -0.767 . . . . 0.0 109.063 179.438 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.69 7.49 55.52 Favored Glycine 0 N--CA 1.492 2.431 0 N-CA-C 109.814 -1.315 . . . . 0.0 109.814 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 75.3 ttt-85 -114.74 139.5 49.65 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.31 -1.112 . . . . 0.0 109.084 179.781 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 165' ' ' THR . . . . . . . . . . . . . 51.1 p -87.47 156.24 19.64 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.214 -0.929 . . . . 0.0 109.879 -179.768 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -66.8 -37.22 84.13 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.531 -0.731 . . . . 0.0 109.433 179.765 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 67.2 mttm -111.25 156.82 20.89 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.411 -0.805 . . . . 0.0 109.606 -179.835 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 94.3 mttt -76.24 139.77 41.31 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.287 -0.883 . . . . 0.0 109.331 179.871 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 43.1 t -118.02 126.35 74.84 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.265 -0.897 . . . . 0.0 109.636 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 42.6 t -146.0 150.3 15.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.345 -0.847 . . . . 0.0 109.294 179.608 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -88.54 122.12 39.62 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 O-C-N 121.288 -0.882 . . . . 0.0 109.691 -179.446 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -67.0 -25.61 66.39 Favored 'General case' 0 C--N 1.3 -1.565 0 O-C-N 121.438 -0.789 . . . . 0.0 109.536 179.56 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 173' ' ' ASP . . . . . 0.413 ' OD1' ' N ' ' A' ' 174' ' ' CYS . 44.9 t0 -173.06 169.96 4.52 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.01 -1.056 . . . . 0.0 110.542 -179.383 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 174' ' ' CYS . . . . . 0.413 ' N ' ' OD1' ' A' ' 173' ' ' ASP . 30.4 p -152.61 150.35 29.42 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.501 -0.749 . . . . 0.0 109.014 179.416 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . 179.71 -177.07 47.99 Favored Glycine 0 N--CA 1.494 2.528 0 N-CA-C 110.044 -1.222 . . . . 0.0 110.044 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 58.9 tt0 -105.33 122.39 45.86 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.529 -0.983 . . . . 0.0 109.632 -179.868 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 177' ' ' LEU . . . . . 0.591 HD13 ' O ' ' A' ' 177' ' ' LEU . 0.2 OUTLIER -65.2 -40.82 94.71 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.171 -0.956 . . . . 0.0 108.566 179.485 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 178' ' ' SER . . . . . 0.464 ' C ' ' O ' ' A' ' 177' ' ' LEU . 1.2 t . . . . . 0 N--CA 1.493 1.702 0 CA-C-O 118.022 -0.99 . . . . 0.0 109.935 179.859 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.494 1.738 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -69.18 138.53 39.92 Favored 'Trans proline' 0 N--CA 1.496 1.627 0 C-N-CA 122.744 2.296 . . . . 0.0 112.306 179.913 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' ARG . . . . . 0.701 HH21 HD23 ' A' ' 177' ' ' LEU . 50.8 ttp180 -133.69 126.53 30.96 Favored 'General case' 0 N--CA 1.49 1.568 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 179.143 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.5 p -131.88 141.83 44.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.29 -0.881 . . . . 0.0 109.521 -179.139 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 40.5 p90 -140.28 157.87 44.9 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.379 -0.826 . . . . 0.0 109.524 -179.602 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 95.2 m-85 -126.93 142.58 51.51 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.472 -0.768 . . . . 0.0 109.808 179.902 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 19.1 t70 -93.74 113.51 25.59 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.412 -0.958 . . . . 0.0 108.412 178.931 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 96.8 mmm -97.13 146.54 24.95 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.452 -0.78 . . . . 0.0 110.112 -179.164 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 41.8 t -149.58 162.07 40.91 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.457 -0.777 . . . . 0.0 109.036 179.628 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.536 HG22 ' O ' ' A' ' 21' ' ' GLN . 25.6 m -124.27 159.9 29.36 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.314 -0.867 . . . . 0.0 109.562 179.894 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -49.18 -30.45 10.64 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.822 -1.311 . . . . 0.0 109.822 -179.475 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -73.93 -79.65 0.52 Allowed Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.674 -1.37 . . . . 0.0 109.674 -179.837 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' GLN . . . . . 0.536 ' O ' HG22 ' A' ' 18' ' ' VAL . 4.2 pt20 -146.35 157.15 49.43 Favored Pre-proline 0 N--CA 1.494 1.727 0 O-C-N 121.177 -1.19 . . . . 0.0 109.129 -179.968 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 75.6 Cg_exo -45.78 130.31 12.51 Favored 'Trans proline' 0 C--N 1.31 -1.455 0 C-N-CA 122.25 1.967 . . . . 0.0 112.138 179.792 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -80.05 -56.42 4.25 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.28 -0.888 . . . . 0.0 109.703 -179.891 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 168.82 -170.74 42.54 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 -179.898 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 56.9 ttp180 -114.48 142.01 46.95 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.392 -1.063 . . . . 0.0 109.338 179.818 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 81.5 mt -120.04 130.5 74.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.429 -0.795 . . . . 0.0 109.012 179.877 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 43.6 t -110.56 134.63 52.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.386 -0.821 . . . . 0.0 109.717 -179.792 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 72.1 mtm -121.71 151.89 40.0 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.447 -0.783 . . . . 0.0 109.082 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -105.54 132.86 51.17 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.265 -0.897 . . . . 0.0 110.053 -179.517 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -105.18 129.52 53.55 Favored 'General case' 0 N--CA 1.494 1.767 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 179.143 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -97.7 119.0 35.5 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.207 -0.933 . . . . 0.0 109.131 179.716 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -81.39 -42.21 20.78 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.383 -0.823 . . . . 0.0 109.638 179.847 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -64.8 -46.11 83.42 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.281 -0.887 . . . . 0.0 110.215 -179.388 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 28.4 m -65.99 -45.4 81.74 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.163 -0.961 . . . . 0.0 109.589 -179.766 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.445 ' O ' ' OG1' ' A' ' 35' ' ' THR . 4.1 p -141.38 80.58 16.33 Favored Pre-proline 0 N--CA 1.492 1.668 0 N-CA-C 108.798 -0.816 . . . . 0.0 108.798 179.912 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_endo -59.49 -65.1 0.09 OUTLIER 'Trans proline' 0 N--CA 1.496 1.622 0 C-N-CA 122.419 2.079 . . . . 0.0 113.018 -178.843 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 94.8 mtt180 -60.62 -36.88 79.7 Favored 'General case' 0 C--N 1.298 -1.668 0 O-C-N 121.596 -0.69 . . . . 0.0 110.965 -178.769 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 23.0 m -60.85 -43.32 98.48 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 120.928 -1.107 . . . . 0.0 109.954 -179.423 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -61.94 -31.58 71.91 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.176 -0.952 . . . . 0.0 108.87 179.769 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -70.52 -41.73 72.21 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.352 -0.842 . . . . 0.0 109.937 -179.862 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 41' ' ' ASN . . . . . 0.439 ' O ' HD23 ' A' ' 45' ' ' LEU . 81.5 m-20 -60.71 -45.31 94.69 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.137 -0.977 . . . . 0.0 109.75 -179.585 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 56.3 t80 -71.76 -48.24 48.2 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.202 -0.936 . . . . 0.0 109.225 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 61.8 ttp180 -58.24 -38.92 77.82 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.47 -0.768 . . . . 0.0 109.887 179.917 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.489 ' O ' ' N ' ' A' ' 48' ' ' GLY . . . -60.99 -40.59 94.09 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.289 -0.882 . . . . 0.0 110.22 -178.925 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.439 HD23 ' O ' ' A' ' 41' ' ' ASN . 3.8 mm? -61.61 -39.38 91.03 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.056 -1.027 . . . . 0.0 109.473 179.946 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 46' ' ' CYS . . . . . . . . . . . . . 20.1 m -80.87 -53.13 6.74 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.015 -1.053 . . . . 0.0 109.71 -179.832 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 68.8 p -69.17 -36.74 77.67 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.336 -0.853 . . . . 0.0 109.855 -179.821 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 48' ' ' GLY . . . . . 0.489 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 73.6 32.79 59.09 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.815 -1.314 . . . . 0.0 109.815 179.636 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 78.1 mm-40 -60.91 -37.43 82.21 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.081 -1.246 . . . . 0.0 109.262 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 32.5 mmtm -61.39 -31.38 71.29 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.311 -0.868 . . . . 0.0 109.303 179.649 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 97.59 169.2 32.7 Favored Glycine 0 N--CA 1.489 2.168 0 N-CA-C 109.323 -1.511 . . . . 0.0 109.323 -179.773 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.493 HG23 ' HA ' ' A' ' 58' ' ' PRO . 98.1 m -75.32 141.68 43.33 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.289 -1.124 . . . . 0.0 109.749 -179.84 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -56.78 140.3 44.25 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.254 -1.538 . . . . 0.0 109.254 179.87 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 93.5 mtt-85 -59.04 -33.39 70.71 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.189 -1.183 . . . . 0.0 109.998 -179.787 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 86.6 p -60.55 -25.46 66.18 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.161 -0.962 . . . . 0.0 109.902 -179.397 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 108.8 90.45 2.11 Favored Glycine 0 N--CA 1.495 2.578 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 -179.756 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 57' ' ' LYS . . . . . 0.431 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 17.7 tttm -176.26 78.62 0.28 Allowed Pre-proline 0 N--CA 1.489 1.493 0 O-C-N 121.397 -1.06 . . . . 0.0 108.46 -179.683 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.493 ' HA ' HG23 ' A' ' 52' ' ' THR . 87.0 Cg_exo -47.31 128.9 15.26 Favored 'Trans proline' 0 C--N 1.304 -1.793 0 C-N-CA 122.66 2.24 . . . . 0.0 112.174 -179.046 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.537 ' O ' ' CG ' ' A' ' 60' ' ' HIS . 7.2 mp -91.62 94.78 9.57 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.684 -0.635 . . . . 0.0 109.753 -179.348 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 60' ' ' HIS . . . . . 0.537 ' CG ' ' O ' ' A' ' 59' ' ' LEU . 93.7 m-70 -159.75 125.39 4.17 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.358 -0.839 . . . . 0.0 109.531 179.685 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 61' ' ' TYR . . . . . 0.42 ' O ' ' OG ' ' A' ' 64' ' ' SER . 55.5 m-85 -68.59 -5.05 17.7 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.104 -0.997 . . . . 0.0 108.986 179.269 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 35.2 ttmt -54.74 144.9 20.8 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.463 -0.773 . . . . 0.0 109.743 -179.866 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 84.1 m-20 56.25 45.41 23.17 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.612 -0.68 . . . . 0.0 109.793 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.42 ' OG ' ' O ' ' A' ' 61' ' ' TYR . 39.3 m -120.23 147.91 44.35 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.413 -0.804 . . . . 0.0 108.996 179.528 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 30.0 t -113.12 147.04 38.15 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.424 -0.798 . . . . 0.0 109.554 -179.699 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 4.2 m-30 -64.79 136.31 56.77 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.279 -0.888 . . . . 0.0 108.959 179.951 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 53.3 t-80 -61.5 -50.53 72.34 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.274 -0.891 . . . . 0.0 110.285 -179.193 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.696 HH21 ' NE2' ' A' ' 76' ' ' GLN . 36.8 ptt180 -161.47 160.71 29.56 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.117 -0.989 . . . . 0.0 110.136 -179.757 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.585 HG21 HG22 ' A' ' 165' ' ' THR . 24.0 m -132.91 151.34 34.14 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.509 -0.744 . . . . 0.0 108.993 179.716 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 11.6 mt -146.92 119.83 4.91 Favored Pre-proline 0 N--CA 1.492 1.657 0 O-C-N 121.038 -1.039 . . . . 0.0 109.436 179.78 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -74.68 135.35 19.59 Favored 'Trans proline' 0 C--N 1.312 -1.368 0 C-N-CA 122.161 1.907 . . . . 0.0 111.997 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 90.39 1.1 75.47 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 93.1 m-85 -135.81 -90.76 0.29 Allowed 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.376 -1.073 . . . . 0.0 109.632 179.963 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 9.6 ptp -170.28 172.62 6.13 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.109 -0.994 . . . . 0.0 109.618 -179.946 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 1.7 m -116.14 138.9 50.86 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.403 -0.811 . . . . 0.0 108.877 179.748 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 76' ' ' GLN . . . . . 0.696 ' NE2' HH21 ' A' ' 68' ' ' ARG . 94.6 mt-30 -108.54 154.87 21.32 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.269 -0.894 . . . . 0.0 109.707 -179.683 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -147.04 -165.79 11.96 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 -179.816 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.47 ' O ' ' N ' ' A' ' 80' ' ' PHE . . . 94.37 11.59 57.03 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 109.459 -1.457 . . . . 0.0 109.459 -179.737 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -48.15 -15.4 0.07 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.391 -1.064 . . . . 0.0 109.594 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.47 ' N ' ' O ' ' A' ' 78' ' ' GLY . 81.2 t80 -48.21 -47.96 35.21 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.229 -0.919 . . . . 0.0 110.2 -179.535 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.808 ' CB ' ' H ' ' A' ' 88' ' ' GLY . 54.4 p -71.15 -32.18 68.62 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.916 -1.115 . . . . 0.0 109.49 -179.929 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 82' ' ' ALA . . . . . 0.694 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 163.21 -54.64 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.426 -0.796 . . . . 0.0 109.14 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 91.77 1.04 71.23 Favored Glycine 0 N--CA 1.492 2.42 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 179.947 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 78.6 m-20 -87.63 5.91 37.18 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.225 -1.162 . . . . 0.0 109.474 179.923 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 95.53 -39.82 2.78 Favored Glycine 0 N--CA 1.493 2.45 0 N-CA-C 109.263 -1.535 . . . . 0.0 109.263 -179.79 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 56.3 p -73.85 -14.2 61.05 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.418 -1.048 . . . . 0.0 108.944 179.665 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -80.66 -160.76 24.0 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 -179.881 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.808 ' H ' ' CB ' ' A' ' 81' ' ' THR . . . 89.54 23.18 34.54 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.426 -1.47 . . . . 0.0 109.426 -179.819 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -55.69 148.89 15.27 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.293 -1.122 . . . . 0.0 109.529 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 49.8 m -105.14 151.12 24.43 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.394 -0.816 . . . . 0.0 109.384 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.411 HD13 HG21 ' A' ' 91' ' ' ILE . 27.6 pt -62.78 -32.48 55.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.247 -0.908 . . . . 0.0 109.974 -179.549 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 89.6 m-85 -65.08 -35.19 80.36 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.155 -0.965 . . . . 0.0 109.606 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 87.1 7.43 77.23 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.391 -1.483 . . . . 0.0 109.391 -179.862 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -147.53 155.89 42.3 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.32 -1.106 . . . . 0.0 109.376 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 64.1 mttp -89.89 143.65 26.61 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.255 -0.903 . . . . 0.0 109.82 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 41.4 p90 -138.15 160.38 39.55 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.543 -0.723 . . . . 0.0 109.067 179.779 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -67.35 132.79 48.38 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.04 -1.037 . . . . 0.0 109.596 -179.599 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -75.27 140.02 42.91 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.4 -0.813 . . . . 0.0 109.799 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -59.83 149.06 32.41 Favored 'General case' 0 C--N 1.305 -1.35 0 O-C-N 121.309 -0.87 . . . . 0.0 109.093 179.581 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 37.7 m-20 -53.36 162.56 0.73 Allowed 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.409 -0.807 . . . . 0.0 109.309 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 101' ' ' PHE . . . . . 0.584 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 22.3 p90 -130.63 82.15 2.04 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.462 -0.774 . . . . 0.0 109.372 -179.787 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 87.8 mt -60.31 -33.97 55.79 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.18 -0.95 . . . . 0.0 109.478 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 91.6 mttt -84.45 136.29 33.9 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.311 -0.868 . . . . 0.0 109.342 179.932 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 61.9 mttp -116.31 -178.62 3.46 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.485 -0.759 . . . . 0.0 109.986 -179.877 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 105' ' ' HIS . . . . . 0.526 ' O ' ' CG ' ' A' ' 105' ' ' HIS . 49.9 p-80 -99.79 101.39 12.53 Favored 'General case' 0 N--CA 1.493 1.694 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 179.692 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 66.5 p -101.19 -2.16 32.01 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.273 -0.892 . . . . 0.0 109.768 -179.743 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -149.8 171.91 29.79 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -74.24 157.81 45.61 Favored 'Trans proline' 0 C--N 1.304 -1.785 0 C-N-CA 122.899 2.399 . . . . 0.0 112.027 179.784 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 84.91 40.47 8.1 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 110.158 -1.177 . . . . 0.0 110.158 179.663 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 43.0 mm -113.66 133.55 59.26 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.382 -1.07 . . . . 0.0 109.183 179.677 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.537 ' N ' HD22 ' A' ' 111' ' ' LEU . 3.4 mm? -90.61 133.15 35.31 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.145 -0.972 . . . . 0.0 109.825 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 42.9 t -144.8 142.6 30.1 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.353 -0.842 . . . . 0.0 109.197 179.744 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 113' ' ' MET . . . . . 0.586 ' SD ' ' CE1' ' A' ' 142' ' ' PHE . 83.8 mmm -83.97 129.79 34.91 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.12 -0.988 . . . . 0.0 109.288 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -69.6 143.94 53.16 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.283 -0.886 . . . . 0.0 109.462 -179.951 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 60.3 m-20 -142.94 112.72 6.96 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.363 -0.836 . . . . 0.0 108.961 179.463 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -69.45 -29.51 67.22 Favored 'General case' 0 C--N 1.298 -1.66 0 O-C-N 121.471 -0.768 . . . . 0.0 109.657 -179.872 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -134.43 166.73 24.09 Favored Glycine 0 N--CA 1.493 2.477 0 N-CA-C 109.406 -1.477 . . . . 0.0 109.406 179.888 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -68.88 153.82 72.08 Favored 'Trans proline' 0 C--N 1.305 -1.721 0 C-N-CA 122.81 2.34 . . . . 0.0 111.94 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 17.9 m120 54.19 43.17 31.01 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.483 -0.761 . . . . 0.0 109.441 -179.925 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 92.8 m -134.91 125.07 25.98 Favored 'General case' 0 N--CA 1.485 1.324 0 O-C-N 121.42 -0.8 . . . . 0.0 108.929 179.928 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 22.6 t-20 -103.05 102.6 12.63 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.469 -0.77 . . . . 0.0 109.391 179.828 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -92.93 133.93 11.95 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.414 -1.474 . . . . 0.0 109.414 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 83.3 p -63.77 -23.46 67.37 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.191 -1.182 . . . . 0.0 109.296 179.83 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 92.6 mt-30 -68.66 144.57 54.41 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.335 -0.853 . . . . 0.0 109.505 -179.882 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 49.7 p90 -137.53 163.07 32.06 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.396 -0.815 . . . . 0.0 109.166 179.773 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 48.9 p90 -135.81 160.93 37.05 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.271 -0.893 . . . . 0.0 109.776 -179.937 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 70.2 mt -117.61 132.68 66.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.444 -0.785 . . . . 0.0 109.568 -179.918 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 1.9 p -100.72 106.6 18.05 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.325 -0.859 . . . . 0.0 109.255 179.555 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 129' ' ' THR . . . . . 0.431 ' OG1' ' OE1' ' A' ' 156' ' ' GLU . 68.5 p -90.93 3.03 55.68 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.189 -0.945 . . . . 0.0 109.809 -179.765 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -146.0 154.63 42.1 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.12 -0.987 . . . . 0.0 109.674 -179.726 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 78.9 tttt -81.16 131.06 35.28 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.336 -0.853 . . . . 0.0 109.362 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 9.4 p -125.29 161.65 26.49 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.358 -0.839 . . . . 0.0 109.418 179.933 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -127.52 -28.79 2.73 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.236 -0.915 . . . . 0.0 109.642 -179.891 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 2.0 p90 -75.8 -6.53 51.11 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.159 -0.963 . . . . 0.0 109.777 -179.841 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 8.2 mt -90.78 7.69 38.47 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.242 -0.911 . . . . 0.0 109.548 179.486 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 136' ' ' ASP . . . . . 0.472 ' O ' ' OD1' ' A' ' 136' ' ' ASP . 52.2 p30 -53.63 153.34 4.43 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.301 -0.874 . . . . 0.0 109.724 -179.755 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 144.48 -129.6 3.64 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.012 -1.635 . . . . 0.0 109.012 -179.685 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 2.0 mptp? -90.4 127.55 36.23 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.214 -1.168 . . . . 0.0 108.91 179.643 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 139' ' ' HIS . . . . . 0.406 ' CE1' HG22 ' A' ' 141' ' ' VAL . 42.0 t-80 -140.57 127.58 20.75 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.375 -0.828 . . . . 0.0 109.694 -179.85 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 44.7 t -123.11 132.76 70.81 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 121.458 -0.776 . . . . 0.0 109.048 179.595 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 141' ' ' VAL . . . . . 0.406 HG22 ' CE1' ' A' ' 139' ' ' HIS . 38.8 t -116.5 129.36 73.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.321 -0.862 . . . . 0.0 109.211 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 142' ' ' PHE . . . . . 0.586 ' CE1' ' SD ' ' A' ' 113' ' ' MET . 38.3 p90 -119.93 5.89 10.89 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.323 -0.861 . . . . 0.0 109.734 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -179.43 177.66 48.37 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 179.655 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.2 pt20 -146.17 167.13 24.2 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.265 -1.138 . . . . 0.0 109.453 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 55.2 t -95.33 130.24 44.36 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 O-C-N 121.232 -0.918 . . . . 0.0 109.326 -179.886 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 13.3 m -108.51 -36.63 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.308 -0.87 . . . . 0.0 109.653 179.812 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 94.4 mt-10 -139.75 161.89 36.46 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.26 -0.9 . . . . 0.0 109.575 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 148' ' ' GLY . . . . . 0.43 ' O ' HG12 ' A' ' 151' ' ' VAL . . . 95.02 5.64 60.78 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 110.102 -1.199 . . . . 0.0 110.102 179.578 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 149' ' ' MET . . . . . 0.593 ' O ' HG12 ' A' ' 152' ' ' VAL . 65.0 mtt -60.0 -32.58 71.0 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.049 -1.266 . . . . 0.0 109.319 179.859 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 56.1 t0 -64.85 -41.89 95.33 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.954 -1.091 . . . . 0.0 110.291 -179.563 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.43 HG12 ' O ' ' A' ' 148' ' ' GLY . 7.6 p -78.15 -32.32 17.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.06 -1.025 . . . . 0.0 110.911 -179.266 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 152' ' ' VAL . . . . . 0.593 HG12 ' O ' ' A' ' 149' ' ' MET . 0.9 OUTLIER -51.62 -40.57 26.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 120.962 -1.087 . . . . 0.0 109.011 -179.18 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 153' ' ' LYS . . . . . 0.439 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 59.1 mttp -65.69 -32.63 74.3 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.242 -0.911 . . . . 0.0 109.441 179.09 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -60.11 -39.37 85.97 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.341 -0.849 . . . . 0.0 110.113 -179.28 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 90.0 mt -72.31 -33.95 47.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.048 -1.033 . . . . 0.0 109.757 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 156' ' ' GLU . . . . . 0.431 ' OE1' ' OG1' ' A' ' 129' ' ' THR . 84.5 tt0 -77.63 -41.72 37.43 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.231 -0.918 . . . . 0.0 111.34 -178.859 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 157' ' ' LYS . . . . . 0.431 ' HG2' ' HZ2' ' A' ' 157' ' ' LYS . 17.5 pttm -59.65 -35.57 74.66 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 120.682 -1.261 . . . . 0.0 109.579 -178.838 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 35.3 m -77.15 -10.34 13.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.155 -0.966 . . . . 0.0 108.798 179.228 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -73.89 163.45 54.63 Favored Glycine 0 N--CA 1.488 2.124 0 N-CA-C 110.178 -1.169 . . . . 0.0 110.178 -179.596 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 54.2 m -148.07 165.77 29.8 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.598 -0.942 . . . . 0.0 109.276 -179.895 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 23.9 t -55.08 -26.56 38.71 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.217 -0.927 . . . . 0.0 109.293 179.849 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 86.8 p -57.64 -25.65 60.48 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.243 -0.911 . . . . 0.0 109.639 -179.749 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 92.48 12.98 57.77 Favored Glycine 0 N--CA 1.492 2.414 0 N-CA-C 109.941 -1.264 . . . . 0.0 109.941 179.87 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 24.2 ttm180 -127.14 143.09 51.35 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.204 -1.174 . . . . 0.0 109.491 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 165' ' ' THR . . . . . 0.585 HG22 HG21 ' A' ' 69' ' ' VAL . 79.1 p -76.9 154.81 33.35 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.255 -0.903 . . . . 0.0 109.344 179.851 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -63.93 -35.88 82.13 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.24 -0.912 . . . . 0.0 109.231 179.813 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -116.78 154.69 30.23 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.571 -0.706 . . . . 0.0 109.151 179.794 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -66.44 142.43 57.57 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.121 -0.987 . . . . 0.0 109.095 -179.949 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 169' ' ' VAL . . . . . 0.465 ' O ' HG23 ' A' ' 169' ' ' VAL . 33.0 m -123.99 128.38 74.09 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.363 -0.836 . . . . 0.0 109.707 -179.716 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 40.7 t -144.16 147.76 19.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.395 -0.816 . . . . 0.0 109.011 179.649 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.407 HG23 ' H ' ' A' ' 171' ' ' VAL . 0.2 OUTLIER -83.86 115.53 26.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 120.935 -1.103 . . . . 0.0 109.464 -179.787 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -66.08 -22.39 66.41 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.364 -0.835 . . . . 0.0 109.213 179.469 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 173' ' ' ASP . . . . . 0.454 ' OD1' ' N ' ' A' ' 174' ' ' CYS . 48.0 t0 -167.38 163.39 15.07 Favored 'General case' 0 N--CA 1.492 1.654 0 C-N-CA 119.035 -1.066 . . . . 0.0 110.564 -179.493 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 174' ' ' CYS . . . . . 0.454 ' N ' ' OD1' ' A' ' 173' ' ' ASP . 18.5 p -161.78 146.62 13.06 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.592 -0.693 . . . . 0.0 109.325 179.535 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . 170.45 175.08 38.97 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 179.829 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 8.2 tt0 -102.58 121.02 41.55 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.228 -1.16 . . . . 0.0 109.779 179.925 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 177' ' ' LEU . . . . . 0.701 HD23 HH21 ' A' ' 11' ' ' ARG . 46.2 tp -64.74 -36.58 84.75 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.33 -0.856 . . . . 0.0 109.371 179.408 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 7.9 t . . . . . 0 N--CA 1.49 1.565 0 CA-C-O 118.025 -0.988 . . . . 0.0 109.368 179.999 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 2.4 m120 . . . . . 0 N--CA 1.493 1.686 0 N-CA-C 109.322 -0.621 . . . . 0.0 109.322 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -69.42 139.67 41.97 Favored 'Trans proline' 0 N--CA 1.496 1.65 0 C-N-CA 122.686 2.257 . . . . 0.0 112.152 179.887 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 75.1 mtt85 -128.93 132.87 47.69 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.387 -0.82 . . . . 0.0 109.077 179.092 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.7 p -135.06 142.68 39.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.488 -0.757 . . . . 0.0 109.223 -179.859 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 41.6 p90 -139.55 153.81 47.51 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.296 -0.878 . . . . 0.0 109.505 -179.786 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 93.4 m-85 -122.15 135.23 54.76 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.516 -0.74 . . . . 0.0 109.446 179.699 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.6 t0 -90.3 113.4 25.25 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.111 -0.993 . . . . 0.0 108.374 179.212 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 71.6 mtp -105.24 147.38 28.11 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.072 -1.017 . . . . 0.0 110.389 -179.168 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.435 ' HA ' ' H ' ' A' ' 23' ' ' ALA . 84.2 p -144.9 165.2 28.81 Favored 'General case' 0 N--CA 1.489 1.501 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 179.724 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 33.5 m -125.37 151.16 31.01 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.28 -0.888 . . . . 0.0 109.43 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -51.17 102.49 0.07 OUTLIER Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 140.43 -75.13 0.35 Allowed Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.714 -1.354 . . . . 0.0 109.714 179.873 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -138.41 158.78 70.0 Favored Pre-proline 0 N--CA 1.492 1.663 0 O-C-N 121.337 -1.096 . . . . 0.0 109.264 -179.763 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -58.63 138.77 87.64 Favored 'Trans proline' 0 N--CA 1.494 1.524 0 C-N-CA 122.581 2.187 . . . . 0.0 111.887 179.78 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.435 ' H ' ' HA ' ' A' ' 17' ' ' SER . . . -84.27 -62.47 1.55 Allowed 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.223 -0.923 . . . . 0.0 109.568 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 168.9 -169.69 41.96 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 -179.836 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 58.9 ttp180 -115.72 141.81 47.59 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.338 -1.095 . . . . 0.0 109.265 179.936 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 82.8 mt -121.24 128.96 76.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.331 -0.855 . . . . 0.0 109.237 179.831 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 46.5 t -114.18 134.09 58.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.335 -0.853 . . . . 0.0 109.26 179.908 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 28' ' ' MET . . . . . 0.421 ' HG2' HG22 ' A' ' 145' ' ' VAL . 73.9 mtm -119.93 151.74 38.47 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.384 -0.822 . . . . 0.0 109.318 -179.928 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -98.68 131.98 44.43 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.339 -0.851 . . . . 0.0 109.763 -179.57 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -107.34 132.62 52.93 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.494 -0.754 . . . . 0.0 109.143 179.681 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 95.7 m-85 -98.6 125.41 43.85 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.223 -0.923 . . . . 0.0 109.176 179.66 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -94.47 1.25 55.76 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.255 -0.903 . . . . 0.0 109.997 -179.692 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -95.45 -75.17 0.53 Allowed 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.046 -1.034 . . . . 0.0 110.581 -179.342 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 47.0 m -64.67 -40.65 95.79 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.354 -0.841 . . . . 0.0 111.017 -178.646 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.569 HG21 ' HA ' ' A' ' 142' ' ' PHE . 43.3 p -126.46 76.18 73.7 Favored Pre-proline 0 N--CA 1.496 1.829 0 O-C-N 121.089 -1.007 . . . . 0.0 110.149 -178.982 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 63.7 Cg_endo -78.21 -57.42 0.04 OUTLIER 'Trans proline' 0 C--N 1.308 -1.601 0 C-N-CA 122.764 2.31 . . . . 0.0 112.729 179.724 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 24.1 mmt85 -57.39 -38.47 74.32 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.247 -0.908 . . . . 0.0 110.151 -179.249 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.555 HG23 ' SD ' ' A' ' 113' ' ' MET . 41.5 m -61.41 -40.85 95.9 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.039 -1.038 . . . . 0.0 109.915 -179.581 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -61.89 -31.1 71.36 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.203 -0.936 . . . . 0.0 109.216 179.842 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -67.57 -37.19 82.29 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.389 -0.819 . . . . 0.0 109.766 -179.846 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 49.6 t-20 -58.64 -43.05 89.62 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.24 -0.912 . . . . 0.0 109.841 -179.678 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.495 ' O ' ' SG ' ' A' ' 46' ' ' CYS . 96.9 m-85 -83.31 -46.63 12.38 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.165 -0.96 . . . . 0.0 109.756 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.651 ' NE ' HE22 ' A' ' 176' ' ' GLN . 76.5 ttt180 -57.19 -42.06 80.53 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.295 -0.878 . . . . 0.0 109.901 -179.697 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.482 ' O ' ' N ' ' A' ' 48' ' ' GLY . . . -76.63 -48.54 18.76 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.132 -0.98 . . . . 0.0 110.29 -179.612 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.401 HD12 ' HA ' ' A' ' 45' ' ' LEU . 40.8 tp -58.1 -37.92 75.45 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.112 -0.993 . . . . 0.0 109.795 -179.4 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 46' ' ' CYS . . . . . 0.495 ' SG ' ' O ' ' A' ' 42' ' ' PHE . 39.8 m -77.32 -63.97 1.25 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.113 -0.992 . . . . 0.0 109.929 -179.795 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 26.0 m -63.17 -38.39 91.0 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.117 -0.989 . . . . 0.0 109.678 -179.813 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 48' ' ' GLY . . . . . 0.482 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 80.58 37.16 21.1 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 110.043 -1.223 . . . . 0.0 110.043 179.744 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -61.4 -37.57 83.94 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.058 -1.26 . . . . 0.0 109.367 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 42.2 mmtm -61.52 -32.56 72.61 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.287 -0.883 . . . . 0.0 109.458 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 95.71 172.4 36.21 Favored Glycine 0 N--CA 1.487 2.097 0 N-CA-C 109.173 -1.571 . . . . 0.0 109.173 -179.62 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.54 HG23 ' HA ' ' A' ' 58' ' ' PRO . 94.1 m -72.36 141.19 48.77 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.315 -1.109 . . . . 0.0 109.871 -179.824 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -58.5 137.84 49.75 Favored Glycine 0 N--CA 1.489 2.169 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 179.804 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 94.1 mtt180 -59.72 -34.14 72.53 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.397 -1.061 . . . . 0.0 109.983 -179.68 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 86.2 p -61.32 -24.95 66.8 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.312 -0.867 . . . . 0.0 109.952 -179.564 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 112.58 89.83 1.85 Allowed Glycine 0 N--CA 1.495 2.572 0 N-CA-C 109.094 -1.603 . . . . 0.0 109.094 -179.595 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 57' ' ' LYS . . . . . 0.51 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 15.4 tptp -175.98 81.0 0.29 Allowed Pre-proline 0 N--CA 1.488 1.461 0 O-C-N 121.438 -1.036 . . . . 0.0 108.444 -179.659 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.54 ' HA ' HG23 ' A' ' 52' ' ' THR . 75.2 Cg_exo -51.01 131.48 35.04 Favored 'Trans proline' 0 C--N 1.304 -1.808 0 C-N-CA 122.799 2.333 . . . . 0.0 112.728 -179.168 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.51 ' CD1' ' O ' ' A' ' 57' ' ' LYS . 8.8 mp -101.13 89.13 3.7 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.487 -0.758 . . . . 0.0 109.224 -179.919 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 60' ' ' HIS . . . . . 0.515 ' O ' ' CE1' ' A' ' 80' ' ' PHE . 77.2 m80 -138.78 136.25 35.49 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.362 -0.836 . . . . 0.0 109.531 179.778 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -87.31 -7.95 57.25 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.289 -0.882 . . . . 0.0 108.771 179.529 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 34.2 ttmt -64.15 151.33 43.6 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.524 -0.735 . . . . 0.0 109.958 -179.729 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 59.93 46.61 10.89 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.628 -0.67 . . . . 0.0 109.965 179.896 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 20.8 t -115.83 141.61 47.87 Favored 'General case' 0 N--CA 1.494 1.728 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.323 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 28.7 t -114.97 145.73 41.95 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.386 -0.821 . . . . 0.0 109.682 -179.64 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.5 m-30 -69.41 137.76 53.02 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.243 -0.91 . . . . 0.0 108.996 179.791 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 58.5 t-80 -60.76 -50.75 72.21 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.242 -0.912 . . . . 0.0 110.249 -179.378 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 37.7 ptt180 -163.72 162.21 23.87 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.061 -1.024 . . . . 0.0 109.939 -179.677 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.564 HG21 HG22 ' A' ' 165' ' ' THR . 15.1 m -131.65 142.81 42.19 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.424 -0.798 . . . . 0.0 108.946 179.615 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 10.3 mt -148.03 109.85 3.75 Favored Pre-proline 0 N--CA 1.494 1.739 0 O-C-N 120.907 -1.121 . . . . 0.0 109.83 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -53.36 145.89 43.4 Favored 'Trans proline' 0 N--CA 1.494 1.524 0 C-N-CA 122.347 2.031 . . . . 0.0 112.489 179.524 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 82.01 -57.52 4.96 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 110.161 -1.175 . . . . 0.0 110.161 179.428 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -70.46 -88.68 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.137 -1.214 . . . . 0.0 109.828 -179.544 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 11.3 ptt? -178.31 176.4 1.08 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.221 -0.925 . . . . 0.0 109.57 -179.753 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -111.1 131.58 54.96 Favored 'General case' 0 N--CA 1.493 1.69 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 179.54 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 63.5 tt0 -98.26 150.14 21.85 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.239 -0.913 . . . . 0.0 109.958 -179.439 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -140.66 -170.1 11.97 Favored Glycine 0 N--CA 1.493 2.487 0 N-CA-C 109.287 -1.525 . . . . 0.0 109.287 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 96.52 6.33 58.57 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.861 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 54.8 t0 -58.33 -24.98 61.37 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.35 -1.088 . . . . 0.0 109.728 179.906 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.515 ' CE1' ' O ' ' A' ' 60' ' ' HIS . 76.4 t80 -48.21 -46.37 35.07 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.359 -0.838 . . . . 0.0 110.068 -179.38 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.737 ' CB ' ' H ' ' A' ' 88' ' ' GLY . 69.1 p -70.95 -29.93 66.09 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 120.96 -1.088 . . . . 0.0 109.493 179.896 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 82' ' ' ALA . . . . . 0.672 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 163.85 -55.84 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.412 -0.805 . . . . 0.0 109.225 179.822 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 92.37 0.41 70.33 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.529 -1.429 . . . . 0.0 109.529 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 78.7 m-20 -87.81 5.88 38.0 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.27 -1.135 . . . . 0.0 109.459 -179.962 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 96.12 -38.55 3.07 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 109.253 -1.539 . . . . 0.0 109.253 -179.895 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 61.7 p -73.82 -15.7 61.16 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.242 -1.152 . . . . 0.0 109.092 179.526 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -81.39 -163.9 31.83 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 -179.919 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.737 ' H ' ' CB ' ' A' ' 81' ' ' THR . . . 81.86 50.82 4.76 Favored Glycine 0 N--CA 1.487 2.099 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 -179.896 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -90.31 147.32 23.57 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.342 -1.093 . . . . 0.0 109.665 -179.728 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 50.5 m -112.17 149.71 31.84 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.461 -0.774 . . . . 0.0 109.403 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 5.1 pt -60.8 -42.13 91.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.277 -0.89 . . . . 0.0 110.106 -179.584 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 3.9 m-30 -66.65 -38.82 87.66 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.113 -0.992 . . . . 0.0 109.582 179.915 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 74.29 26.04 69.23 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.118 -1.593 . . . . 0.0 109.118 -179.742 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -143.64 161.29 38.9 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.421 -1.046 . . . . 0.0 109.569 -179.708 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 83.6 mttt -83.24 148.32 27.48 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.405 -0.81 . . . . 0.0 109.74 -179.736 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 88.6 m-85 -104.1 131.85 50.95 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.376 -0.828 . . . . 0.0 108.865 179.618 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -77.27 136.12 38.48 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.139 -0.976 . . . . 0.0 109.573 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 98' ' ' ASP . . . . . 0.53 ' OD2' ' CE1' ' A' ' 101' ' ' PHE . 32.3 p-10 -87.86 128.22 35.35 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.215 -0.928 . . . . 0.0 109.279 179.714 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 99' ' ' GLU . . . . . 0.491 ' O ' ' OD1' ' A' ' 100' ' ' ASN . 84.6 tt0 -61.41 -43.15 99.36 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.155 -0.966 . . . . 0.0 109.989 -179.481 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 100' ' ' ASN . . . . . 0.491 ' OD1' ' O ' ' A' ' 99' ' ' GLU . 84.0 m-20 -155.24 165.4 36.77 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.145 -0.972 . . . . 0.0 110.071 -179.829 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 101' ' ' PHE . . . . . 0.53 ' CE1' ' OD2' ' A' ' 98' ' ' ASP . 98.6 m-85 -102.62 8.17 39.77 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.429 -0.794 . . . . 0.0 109.156 179.358 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 97.4 mt -53.79 -36.47 29.89 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.344 -0.847 . . . . 0.0 110.404 -179.404 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 33.3 mmtp -73.68 124.91 26.89 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.022 -1.049 . . . . 0.0 109.661 -179.512 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 12.9 pttm -142.77 -177.6 5.39 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.321 -0.862 . . . . 0.0 109.246 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 105' ' ' HIS . . . . . . . . . . . . . 93.6 m-70 -74.99 88.33 2.37 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.144 -0.973 . . . . 0.0 109.209 179.723 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 54.9 p -71.06 -26.81 63.24 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.188 -0.945 . . . . 0.0 109.572 -179.79 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -162.08 -168.45 24.0 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.305 -1.518 . . . . 0.0 109.305 -179.855 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -80.58 154.83 20.99 Favored 'Trans proline' 0 C--N 1.306 -1.705 0 C-N-CA 122.935 2.423 . . . . 0.0 112.175 179.783 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 80.33 43.45 9.49 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.944 -1.262 . . . . 0.0 109.944 179.667 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 41.7 mm -115.55 135.5 55.41 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.863 0 O-C-N 121.364 -1.08 . . . . 0.0 109.628 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.432 ' N ' HD22 ' A' ' 111' ' ' LEU . 4.3 mm? -91.25 124.4 35.42 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.25 -0.906 . . . . 0.0 109.272 179.654 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 30.9 t -140.72 141.07 34.95 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.176 -0.952 . . . . 0.0 109.501 179.867 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 113' ' ' MET . . . . . 0.555 ' SD ' HG23 ' A' ' 38' ' ' THR . 88.9 mtp -89.92 137.89 31.96 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.264 -0.897 . . . . 0.0 109.215 179.75 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -60.9 144.57 52.7 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.121 -0.987 . . . . 0.0 109.381 -179.955 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 16.4 m-20 -137.05 110.78 8.1 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.216 -0.928 . . . . 0.0 109.275 179.848 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -73.57 -29.46 62.44 Favored 'General case' 0 C--N 1.297 -1.677 0 O-C-N 121.406 -0.809 . . . . 0.0 109.4 179.684 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -140.6 175.39 22.08 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 179.926 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -68.17 151.89 76.63 Favored 'Trans proline' 0 C--N 1.305 -1.717 0 C-N-CA 122.746 2.297 . . . . 0.0 111.822 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 119' ' ' ASN . . . . . 0.429 ' OD1' ' OD1' ' A' ' 98' ' ' ASP . 71.8 m-20 52.84 40.52 30.87 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.453 -0.779 . . . . 0.0 109.278 -179.781 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 94.6 m -140.78 124.17 16.76 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.406 -0.809 . . . . 0.0 109.248 179.904 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 87.9 m-20 -109.86 114.81 28.67 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.568 -0.708 . . . . 0.0 109.16 179.503 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -78.05 135.52 16.26 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 179.947 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 22.8 t -55.83 -32.72 63.84 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.212 -1.169 . . . . 0.0 109.195 179.793 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 94.2 mt-30 -72.47 146.6 46.78 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.348 -0.845 . . . . 0.0 109.28 179.729 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 41.2 p90 -133.16 163.3 29.57 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.351 -0.843 . . . . 0.0 109.088 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 49.2 p90 -135.65 156.33 49.02 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.222 -0.923 . . . . 0.0 109.699 -179.931 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 76.2 mt -121.62 134.61 64.41 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 179.804 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 128' ' ' CYS . . . . . 0.435 ' SG ' ' O ' ' A' ' 130' ' ' ALA . 5.5 t -116.22 124.66 50.8 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.288 -0.883 . . . . 0.0 109.368 179.968 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 44.1 p -89.26 -2.1 58.34 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.448 -0.782 . . . . 0.0 109.766 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 130' ' ' ALA . . . . . 0.435 ' O ' ' SG ' ' A' ' 128' ' ' CYS . . . -149.0 156.96 43.02 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.18 -0.95 . . . . 0.0 109.691 -179.857 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 63.6 tttm -72.84 136.78 45.4 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.31 -0.869 . . . . 0.0 109.34 179.813 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 17.1 p -121.48 158.8 27.63 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.43 -0.794 . . . . 0.0 109.537 -179.846 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -103.05 -74.65 0.63 Allowed 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.246 -0.909 . . . . 0.0 109.915 -179.829 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 134' ' ' TRP . . . . . 0.605 ' CD1' ' N ' ' A' ' 135' ' ' LEU . 42.0 p90 -58.73 -47.76 83.52 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.291 -0.881 . . . . 0.0 110.08 -179.419 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 135' ' ' LEU . . . . . 0.605 ' N ' ' CD1' ' A' ' 134' ' ' TRP . 31.5 tp -60.98 -35.08 75.87 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.203 -0.936 . . . . 0.0 109.332 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 62.1 t0 -80.05 118.16 21.52 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.202 -0.936 . . . . 0.0 109.541 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 137' ' ' GLY . . . . . 0.544 ' H ' ' CE1' ' A' ' 139' ' ' HIS . . . -144.24 -126.58 1.95 Allowed Glycine 0 N--CA 1.492 2.4 0 N-CA-C 109.096 -1.602 . . . . 0.0 109.096 179.844 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 2.0 mptm? -84.71 105.5 15.55 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.112 -1.228 . . . . 0.0 108.959 179.629 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 139' ' ' HIS . . . . . 0.544 ' CE1' ' H ' ' A' ' 137' ' ' GLY . 76.9 m80 -138.16 161.07 37.76 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.353 -0.842 . . . . 0.0 109.483 -179.862 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 45.0 t -119.58 136.04 58.0 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 O-C-N 121.399 -0.813 . . . . 0.0 109.404 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 59.2 t -105.31 130.25 56.85 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 O-C-N 121.395 -0.816 . . . . 0.0 109.144 179.82 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 142' ' ' PHE . . . . . 0.569 ' HA ' HG21 ' A' ' 35' ' ' THR . 39.9 p90 -114.33 -0.81 13.72 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.306 -0.871 . . . . 0.0 109.766 -179.865 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -174.71 174.79 46.8 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.589 -1.405 . . . . 0.0 109.589 179.546 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 23.7 pt20 -146.72 167.23 24.34 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.213 -1.169 . . . . 0.0 109.665 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 145' ' ' VAL . . . . . 0.421 HG22 ' HG2' ' A' ' 28' ' ' MET . 9.5 t -96.73 132.63 40.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 O-C-N 121.218 -0.926 . . . . 0.0 109.529 -179.95 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 15.9 m -111.43 -30.19 2.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.541 -0.724 . . . . 0.0 109.145 179.577 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 78.6 mm-40 -140.02 166.0 25.83 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.342 -0.849 . . . . 0.0 109.344 179.876 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 96.69 4.9 58.98 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.889 -1.285 . . . . 0.0 109.889 179.649 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 149' ' ' MET . . . . . 0.493 ' O ' HG12 ' A' ' 152' ' ' VAL . 65.1 mtt -60.2 -32.24 70.91 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 121.056 -1.261 . . . . 0.0 109.467 179.932 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 89.0 m-20 -64.38 -40.35 95.65 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 120.894 -1.129 . . . . 0.0 109.805 -179.807 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.402 ' H ' HG12 ' A' ' 151' ' ' VAL . 4.4 p -83.69 -35.09 11.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.251 -0.906 . . . . 0.0 110.502 -179.504 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 152' ' ' VAL . . . . . 0.493 HG12 ' O ' ' A' ' 149' ' ' MET . 0.9 OUTLIER -53.9 -42.0 51.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 120.835 -1.166 . . . . 0.0 108.871 -179.336 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 153' ' ' LYS . . . . . 0.455 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 60.0 mttm -65.68 -32.94 74.77 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.12 -0.987 . . . . 0.0 109.123 179.064 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -60.08 -36.96 78.55 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.423 -0.798 . . . . 0.0 109.751 -179.512 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 98.5 mt -71.2 -34.74 55.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.092 -1.005 . . . . 0.0 109.945 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 83.0 tt0 -76.63 -42.17 43.19 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.246 -0.908 . . . . 0.0 111.324 -178.823 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 33.3 pttt -62.13 -33.38 74.38 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 120.798 -1.189 . . . . 0.0 109.822 -178.921 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 33.0 m -83.5 -0.59 5.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.036 -1.04 . . . . 0.0 108.828 179.523 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -75.32 173.01 53.34 Favored Glycine 0 N--CA 1.488 2.115 0 N-CA-C 110.048 -1.221 . . . . 0.0 110.048 -179.53 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 89.7 p -153.22 164.02 38.84 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.462 -1.022 . . . . 0.0 109.764 -179.711 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 23.3 m -58.69 -32.82 69.49 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.309 -0.869 . . . . 0.0 108.834 179.31 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 25.4 m -55.84 -31.57 62.84 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.386 -0.821 . . . . 0.0 109.172 179.86 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 101.08 9.08 46.18 Favored Glycine 0 N--CA 1.495 2.574 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 179.893 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 35.8 ttp180 -116.48 141.12 48.59 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.238 -1.154 . . . . 0.0 109.293 179.898 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 165' ' ' THR . . . . . 0.564 HG22 HG21 ' A' ' 69' ' ' VAL . 80.6 p -76.5 155.87 33.44 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.292 -0.88 . . . . 0.0 109.304 179.932 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -62.37 -35.83 80.37 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.231 -0.918 . . . . 0.0 109.298 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 62.5 mttp -118.93 152.98 35.34 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.475 -0.766 . . . . 0.0 109.157 179.764 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -64.67 141.55 58.74 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.021 -1.049 . . . . 0.0 108.957 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 169' ' ' VAL . . . . . 0.48 ' O ' HG23 ' A' ' 169' ' ' VAL . 33.9 m -121.66 126.63 74.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.226 -0.921 . . . . 0.0 109.8 -179.748 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 44.5 t -145.03 148.81 17.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 N-CA-C 108.839 -0.801 . . . . 0.0 108.839 179.704 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.454 ' H ' HG23 ' A' ' 171' ' ' VAL . 0.1 OUTLIER -80.91 115.7 23.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.119 -0.988 . . . . 0.0 109.463 -179.798 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 78.4 mm-40 -67.9 -20.31 65.09 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.396 -0.815 . . . . 0.0 109.505 179.629 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 20.2 t70 -167.66 162.18 13.93 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.015 -1.053 . . . . 0.0 110.364 -179.456 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 30.6 p -155.89 144.52 20.26 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.459 -0.776 . . . . 0.0 109.294 179.604 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . 177.25 179.98 47.8 Favored Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 176' ' ' GLN . . . . . 0.651 HE22 ' NE ' ' A' ' 43' ' ' ARG . 63.6 tt0 -105.62 124.0 48.83 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.41 -1.053 . . . . 0.0 109.77 -179.905 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 35.5 tp -61.23 -37.8 84.34 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.187 -0.946 . . . . 0.0 109.395 179.658 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 7.9 t . . . . . 0 N--CA 1.489 1.522 0 CA-C-O 117.994 -1.003 . . . . 0.0 109.475 -179.967 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 12.2 t-20 . . . . . 0 N--CA 1.491 1.615 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 82.8 Cg_endo -75.29 140.15 24.37 Favored 'Trans proline' 0 N--CA 1.495 1.612 0 C-N-CA 122.473 2.116 . . . . 0.0 112.599 -179.833 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 71.0 mtt85 -132.74 132.58 42.45 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.35 -0.844 . . . . 0.0 108.834 178.996 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.0 p -135.62 143.21 37.22 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.327 -0.858 . . . . 0.0 109.707 -179.764 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 42.7 p90 -138.21 154.21 49.12 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.523 -0.736 . . . . 0.0 109.183 179.941 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.415 ' CE1' ' CE1' ' A' ' 61' ' ' TYR . 97.5 m-85 -124.18 137.54 54.52 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.481 -0.762 . . . . 0.0 109.788 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.4 t0 -93.39 117.94 30.7 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.359 -0.838 . . . . 0.0 108.801 179.425 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' MET . . . . . 0.454 ' SD ' HD12 ' A' ' 26' ' ' ILE . 77.1 mtp -112.12 151.21 29.71 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.151 -0.968 . . . . 0.0 110.457 -179.174 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 84.5 p -142.91 163.09 33.73 Favored 'General case' 0 N--CA 1.489 1.519 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 179.804 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.534 ' O ' ' N ' ' A' ' 20' ' ' GLY . 26.2 m -125.96 143.01 40.94 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.201 -0.937 . . . . 0.0 109.706 -179.87 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 47.89 11.5 0.11 Allowed Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.817 -1.313 . . . . 0.0 109.817 179.833 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.534 ' N ' ' O ' ' A' ' 18' ' ' VAL . . . 97.43 -13.98 63.82 Favored Glycine 0 N--CA 1.493 2.499 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 -179.927 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 21' ' ' GLN . . . . . 0.458 ' N ' ' OE1' ' A' ' 21' ' ' GLN . 13.2 mp0 -84.62 150.85 57.54 Favored Pre-proline 0 N--CA 1.492 1.675 0 O-C-N 121.26 -1.141 . . . . 0.0 109.112 179.757 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_endo -62.15 136.93 63.33 Favored 'Trans proline' 0 C--N 1.308 -1.584 0 C-N-CA 122.453 2.102 . . . . 0.0 112.012 -179.893 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -111.72 -65.59 1.16 Allowed 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.439 -0.788 . . . . 0.0 109.359 179.886 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 178.98 -170.1 41.75 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.348 -1.501 . . . . 0.0 109.348 -179.924 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 92.2 mtt180 -116.72 143.72 45.31 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.358 -1.083 . . . . 0.0 109.526 179.792 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.454 HD12 ' SD ' ' A' ' 16' ' ' MET . 84.7 mt -121.06 122.77 68.49 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 179.304 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 38.8 t -118.47 132.75 67.43 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.434 0 O-C-N 121.376 -0.828 . . . . 0.0 109.154 -179.984 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 73.6 mtm -122.32 151.54 41.03 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.408 -0.807 . . . . 0.0 109.122 -179.886 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -99.32 130.79 45.63 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.298 -0.877 . . . . 0.0 109.847 -179.629 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.404 ' N ' ' CD2' ' A' ' 30' ' ' LEU . 2.7 mm? -107.07 129.12 54.86 Favored 'General case' 0 N--CA 1.491 1.575 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 179.535 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -99.63 120.23 39.36 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.244 -0.91 . . . . 0.0 109.082 179.572 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -78.95 -40.52 31.63 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.337 -0.852 . . . . 0.0 110.01 -179.753 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.537 ' OD1' ' N ' ' A' ' 34' ' ' THR . 31.9 p-10 -68.23 -41.22 81.54 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.228 -0.92 . . . . 0.0 110.72 -179.082 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 34' ' ' THR . . . . . 0.537 ' N ' ' OD1' ' A' ' 33' ' ' ASP . 17.1 m -67.66 -44.52 77.66 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.005 -1.06 . . . . 0.0 109.997 -179.375 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.414 HG23 ' O ' ' A' ' 34' ' ' THR . 28.5 p -155.23 83.62 3.73 Favored Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.226 -0.921 . . . . 0.0 109.217 -179.903 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 13.4 Cg_endo -70.55 -35.77 9.79 Favored 'Trans proline' 0 C--N 1.307 -1.654 0 C-N-CA 121.987 1.791 . . . . 0.0 112.088 -179.537 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.424 ' HD2' ' H ' ' A' ' 37' ' ' ARG . 1.6 mpt_? -66.51 -41.93 88.07 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.077 -1.014 . . . . 0.0 109.702 179.771 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.552 HG23 ' SD ' ' A' ' 113' ' ' MET . 56.1 m -65.16 -42.06 94.11 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.203 -0.936 . . . . 0.0 110.008 -179.519 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -61.88 -31.37 71.65 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.135 -0.978 . . . . 0.0 109.083 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -69.84 -37.99 76.37 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.397 -0.814 . . . . 0.0 110.052 -179.742 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 47.9 m-20 -58.42 -41.99 86.25 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.026 -1.046 . . . . 0.0 109.965 -179.345 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 -87.13 -48.41 8.08 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.114 -0.991 . . . . 0.0 109.554 179.878 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.47 ' O ' HG23 ' A' ' 47' ' ' THR . 66.8 ttp85 -57.63 -42.27 83.01 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.208 -0.933 . . . . 0.0 109.563 -179.853 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -69.74 -46.4 65.98 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.267 -0.896 . . . . 0.0 109.829 -179.674 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 44.9 tp -63.64 -37.78 88.65 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.29 -0.881 . . . . 0.0 109.701 -179.594 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 46' ' ' CYS . . . . . . . . . . . . . 81.7 m -72.99 -48.76 33.69 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.171 -0.956 . . . . 0.0 109.782 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 47' ' ' THR . . . . . 0.47 HG23 ' O ' ' A' ' 43' ' ' ARG . 69.8 p -70.93 -35.58 72.28 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.164 -0.96 . . . . 0.0 109.687 -179.93 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 73.46 25.26 73.13 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 179.906 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 22.7 pt-20 -64.77 -33.1 75.18 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.225 -1.162 . . . . 0.0 109.622 -179.768 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 47.2 mmtm -60.14 -33.81 72.68 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.305 -0.872 . . . . 0.0 109.362 179.771 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 92.24 174.84 42.12 Favored Glycine 0 N--CA 1.486 2.032 0 N-CA-C 109.283 -1.527 . . . . 0.0 109.283 -179.753 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.502 HG23 ' HA ' ' A' ' 58' ' ' PRO . 65.5 m -70.57 139.22 51.44 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.387 -1.067 . . . . 0.0 109.705 -179.971 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -57.72 135.35 51.82 Favored Glycine 0 N--CA 1.488 2.137 0 N-CA-C 109.219 -1.552 . . . . 0.0 109.219 179.766 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 73.4 mtp180 -59.0 -33.88 71.22 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.178 -1.19 . . . . 0.0 109.958 -179.678 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 87.0 p -60.55 -24.46 65.41 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.18 -0.95 . . . . 0.0 109.684 -179.621 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 112.66 90.92 1.93 Allowed Glycine 0 N--CA 1.494 2.562 0 N-CA-C 109.049 -1.621 . . . . 0.0 109.049 -179.714 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 57' ' ' LYS . . . . . 0.509 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 33.0 tttm -174.72 78.61 0.33 Allowed Pre-proline 0 N--CA 1.488 1.437 0 O-C-N 121.425 -1.044 . . . . 0.0 108.365 -179.73 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.502 ' HA ' HG23 ' A' ' 52' ' ' THR . 75.8 Cg_exo -49.47 130.75 26.3 Favored 'Trans proline' 0 C--N 1.304 -1.783 0 C-N-CA 122.787 2.325 . . . . 0.0 112.77 -179.087 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.509 ' CD1' ' O ' ' A' ' 57' ' ' LYS . 7.1 mp -97.48 120.38 37.74 Favored 'General case' 0 N--CA 1.49 1.572 0 N-CA-C 109.195 -0.669 . . . . 0.0 109.195 179.854 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 58.7 m80 -149.79 93.84 2.09 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.273 -0.892 . . . . 0.0 109.448 179.679 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 61' ' ' TYR . . . . . 0.415 ' CE1' ' CE1' ' A' ' 14' ' ' PHE . 24.3 t80 -60.65 -34.38 74.21 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 179.831 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 62' ' ' LYS . . . . . 0.425 ' HE2' ' H ' ' A' ' 174' ' ' CYS . 92.8 mttt -54.77 167.9 0.33 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.495 -0.753 . . . . 0.0 109.794 -179.686 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 83.0 m-20 57.24 47.16 17.44 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.5 -0.75 . . . . 0.0 110.02 179.609 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 96.3 p -114.12 154.03 28.49 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.383 -0.823 . . . . 0.0 108.918 179.366 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 28.2 t -131.66 149.04 52.63 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.255 -0.903 . . . . 0.0 109.668 -179.552 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 28.6 m-85 -77.51 125.0 28.65 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.306 -0.871 . . . . 0.0 109.369 179.852 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 15.3 t-80 -67.93 -46.4 71.6 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.598 -0.689 . . . . 0.0 110.782 -179.176 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 94.5 mtt180 -132.39 150.05 52.23 Favored 'General case' 0 N--CA 1.498 1.925 0 O-C-N 121.041 -1.037 . . . . 0.0 110.739 -178.972 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.714 HG21 HG22 ' A' ' 165' ' ' THR . 7.7 m -144.19 52.26 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 N-CA-C 108.744 -0.836 . . . . 0.0 108.744 179.471 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 14.4 mt -76.69 133.44 70.31 Favored Pre-proline 0 C--N 1.301 -1.537 0 O-C-N 121.193 -0.942 . . . . 0.0 110.07 -178.702 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_endo -70.09 149.95 65.53 Favored 'Trans proline' 0 N--CA 1.492 1.405 0 C-N-CA 122.408 2.072 . . . . 0.0 112.283 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 79.42 -55.19 4.38 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 179.864 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 90.9 m-85 -71.35 -87.7 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.249 -1.147 . . . . 0.0 109.702 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 74' ' ' MET . . . . . 0.602 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 12.1 ptt? 179.15 -178.83 0.35 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.184 -0.948 . . . . 0.0 109.763 -179.926 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 1.1 m -117.46 131.9 56.65 Favored 'General case' 0 N--CA 1.492 1.67 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 179.255 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 63.5 tt0 -95.04 146.16 24.46 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.161 -0.962 . . . . 0.0 110.222 -179.013 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -143.55 -175.07 16.31 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.186 -1.566 . . . . 0.0 109.186 179.841 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 93.24 10.55 59.43 Favored Glycine 0 N--CA 1.494 2.528 0 N-CA-C 109.426 -1.47 . . . . 0.0 109.426 -179.905 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.438 ' OD1' ' O ' ' A' ' 82' ' ' ALA . 62.4 t0 -56.18 -15.52 3.91 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.341 -1.094 . . . . 0.0 109.681 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 73.5 t80 -50.07 -47.86 53.37 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.174 -0.954 . . . . 0.0 110.17 -179.291 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.756 ' CB ' ' H ' ' A' ' 88' ' ' GLY . 65.6 p -71.53 -31.96 67.63 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.892 -1.13 . . . . 0.0 109.606 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 82' ' ' ALA . . . . . 0.685 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 164.51 -54.63 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.302 -0.874 . . . . 0.0 109.334 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 92.46 1.09 69.2 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.629 -1.388 . . . . 0.0 109.629 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 22.1 m120 -87.3 5.4 38.61 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.256 -1.144 . . . . 0.0 109.511 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 95.41 -39.61 2.82 Favored Glycine 0 N--CA 1.494 2.503 0 N-CA-C 109.243 -1.543 . . . . 0.0 109.243 -179.866 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 60.8 p -73.12 -16.92 61.44 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.24 -1.153 . . . . 0.0 109.085 179.634 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -81.77 -162.37 29.77 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.756 ' H ' ' CB ' ' A' ' 81' ' ' THR . . . 84.19 37.97 10.59 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 -179.951 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 78.1 mm-40 -58.02 149.7 22.65 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.266 -1.137 . . . . 0.0 109.808 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 50.8 m -115.57 147.08 41.15 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.666 -0.646 . . . . 0.0 109.273 179.925 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 18.1 pt -67.82 -35.53 72.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.264 -0.897 . . . . 0.0 110.037 -179.624 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 49.2 m-85 -67.43 -38.67 84.92 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.03 -1.044 . . . . 0.0 109.64 -179.809 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 77.87 13.74 83.09 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.342 -1.503 . . . . 0.0 109.342 -179.701 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -147.0 155.9 42.62 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.275 -1.132 . . . . 0.0 109.429 -179.838 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 53.5 mttp -95.08 148.65 22.13 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.339 -0.851 . . . . 0.0 109.807 -179.976 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 54.9 p90 -134.33 160.23 38.58 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.403 -0.811 . . . . 0.0 109.141 179.453 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -104.53 150.88 24.23 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.302 -0.874 . . . . 0.0 109.788 -179.633 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 60.1 t0 -137.77 81.58 1.87 Allowed 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.314 -0.866 . . . . 0.0 109.246 179.763 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -63.78 -29.03 70.28 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.429 -0.794 . . . . 0.0 109.956 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 36.2 m-20 -56.58 141.34 43.52 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.134 -0.979 . . . . 0.0 110.075 -179.244 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 101' ' ' PHE . . . . . 0.537 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 74.4 t80 -150.33 46.51 0.89 Allowed 'General case' 0 N--CA 1.491 1.615 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.824 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 90.9 mt -59.03 -34.82 54.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.416 -0.803 . . . . 0.0 110.228 -179.492 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 71.8 mmtt -80.78 139.85 35.82 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.112 -0.993 . . . . 0.0 109.765 -179.393 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 35.5 tttm -93.32 156.0 17.07 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.394 -0.816 . . . . 0.0 109.571 -179.961 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 105' ' ' HIS . . . . . . . . . . . . . 85.2 t60 -96.36 78.48 3.05 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.334 -0.854 . . . . 0.0 108.77 179.356 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 14.9 m -56.56 -40.03 74.49 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.3 -0.875 . . . . 0.0 109.436 -179.42 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.456 ' H ' HG13 ' A' ' 110' ' ' ILE . . . 130.09 -95.74 0.35 Allowed Glycine 0 N--CA 1.493 2.498 0 N-CA-C 110.044 -1.223 . . . . 0.0 110.044 179.575 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -68.81 141.24 48.65 Favored 'Trans proline' 0 N--CA 1.496 1.621 0 C-N-CA 122.694 2.263 . . . . 0.0 113.131 -179.233 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 75.95 22.65 73.85 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 110.241 -1.143 . . . . 0.0 110.241 179.033 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.456 HG13 ' H ' ' A' ' 107' ' ' GLY . 33.5 mm -115.54 134.41 58.83 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 121.315 -1.109 . . . . 0.0 110.076 -179.782 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.678 ' N ' HD22 ' A' ' 111' ' ' LEU . 3.1 mm? -93.78 137.03 33.46 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.289 -0.882 . . . . 0.0 108.894 179.148 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 34.0 t -146.05 141.17 27.35 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.226 -0.921 . . . . 0.0 109.691 179.781 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 113' ' ' MET . . . . . 0.552 ' SD ' HG23 ' A' ' 38' ' ' THR . 72.0 mtm -85.53 137.04 33.15 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.245 -0.91 . . . . 0.0 109.181 179.715 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 114' ' ' ALA . . . . . 0.452 ' O ' ' OD1' ' A' ' 115' ' ' ASN . . . -61.83 138.32 58.33 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.148 -0.97 . . . . 0.0 109.333 -179.879 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 115' ' ' ASN . . . . . 0.452 ' OD1' ' O ' ' A' ' 114' ' ' ALA . 77.2 m-20 -148.51 114.01 5.62 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.328 -0.858 . . . . 0.0 109.206 179.828 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -69.21 -29.77 67.8 Favored 'General case' 0 C--N 1.297 -1.713 0 O-C-N 121.43 -0.794 . . . . 0.0 109.179 179.613 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -137.84 168.42 24.52 Favored Glycine 0 N--CA 1.494 2.503 0 N-CA-C 109.085 -1.606 . . . . 0.0 109.085 179.783 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -67.4 155.6 69.68 Favored 'Trans proline' 0 C--N 1.306 -1.666 0 C-N-CA 122.758 2.305 . . . . 0.0 111.946 -179.858 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 75.9 m-20 54.92 45.3 26.78 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.425 -0.797 . . . . 0.0 109.498 -179.907 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 94.1 m -130.27 125.93 36.02 Favored 'General case' 0 N--CA 1.485 1.314 0 O-C-N 121.386 -0.821 . . . . 0.0 108.79 179.725 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 25.9 t30 -99.09 110.62 23.18 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.449 -0.782 . . . . 0.0 109.621 -179.838 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -106.61 121.27 6.55 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.271 -1.532 . . . . 0.0 109.271 179.646 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 20.1 m -56.84 -34.43 67.76 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.209 -1.171 . . . . 0.0 109.187 179.971 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.6 mt-30 -71.62 144.94 49.27 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.263 -0.898 . . . . 0.0 109.148 179.81 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 44.9 p90 -135.59 163.53 29.91 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.317 -0.865 . . . . 0.0 109.297 -179.961 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 126' ' ' PHE . . . . . 0.602 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 52.8 p90 -132.15 157.38 44.41 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.405 -0.81 . . . . 0.0 109.503 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 67.1 mt -119.08 133.25 66.54 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.49 -0.756 . . . . 0.0 109.338 179.849 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 128' ' ' CYS . . . . . 0.402 ' SG ' ' O ' ' A' ' 130' ' ' ALA . 7.1 t -115.84 126.35 53.86 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.355 -0.841 . . . . 0.0 109.15 179.847 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 30.1 p -97.18 0.53 48.5 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.276 -0.89 . . . . 0.0 109.702 -179.708 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 130' ' ' ALA . . . . . 0.402 ' O ' ' SG ' ' A' ' 128' ' ' CYS . . . -148.86 164.26 35.0 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.235 -0.915 . . . . 0.0 109.429 -179.8 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -70.07 137.48 51.26 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.118 -0.989 . . . . 0.0 109.177 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 3.6 p -113.53 101.12 9.05 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.495 -0.753 . . . . 0.0 109.45 -179.737 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -64.35 -36.52 84.4 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.296 -0.878 . . . . 0.0 109.596 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 1.2 p90 -67.55 -33.29 74.74 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.15 -0.969 . . . . 0.0 109.59 -179.835 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 135' ' ' LEU . . . . . 0.546 ' O ' ' NE2' ' A' ' 139' ' ' HIS . 8.6 mt -93.11 12.15 25.23 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.102 -0.998 . . . . 0.0 109.322 179.358 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 60.1 t0 -57.05 124.18 17.82 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.137 -0.977 . . . . 0.0 109.616 -179.577 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -176.11 -159.29 21.56 Favored Glycine 0 N--CA 1.486 1.987 0 N-CA-C 109.009 -1.636 . . . . 0.0 109.009 -179.852 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 87.6 mttt -57.24 -38.51 73.92 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.317 -1.107 . . . . 0.0 109.646 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 139' ' ' HIS . . . . . 0.546 ' NE2' ' O ' ' A' ' 135' ' ' LEU . 63.3 m-70 53.57 71.51 0.5 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.318 -0.864 . . . . 0.0 109.957 179.766 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 39.3 t -69.0 135.44 28.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.14 -0.975 . . . . 0.0 108.879 179.295 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 17.4 m -126.94 148.23 31.78 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 121.222 -0.924 . . . . 0.0 109.74 -179.489 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 142' ' ' PHE . . . . . 0.454 ' CB ' HG21 ' A' ' 38' ' ' THR . 43.3 p90 -120.06 -6.01 9.99 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.382 -0.824 . . . . 0.0 110.019 179.831 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -164.74 -179.77 38.97 Favored Glycine 0 N--CA 1.495 2.618 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 179.692 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.4 pt20 -143.85 166.53 24.65 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.23 -1.159 . . . . 0.0 109.566 -179.769 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 44.7 t -97.21 132.18 42.36 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.13 0 O-C-N 121.096 -1.002 . . . . 0.0 109.54 -179.742 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 17.2 m -110.45 -32.74 2.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 O-C-N 121.413 -0.805 . . . . 0.0 109.3 179.321 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -145.35 170.25 16.68 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.308 -0.87 . . . . 0.0 109.46 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 97.35 2.47 58.96 Favored Glycine 0 N--CA 1.494 2.539 0 N-CA-C 109.977 -1.249 . . . . 0.0 109.977 179.531 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 149' ' ' MET . . . . . 0.477 ' O ' HG12 ' A' ' 152' ' ' VAL . 88.3 mtp -61.06 -33.07 72.74 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.189 -1.183 . . . . 0.0 109.685 179.925 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -64.78 -42.43 95.1 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 120.876 -1.14 . . . . 0.0 109.987 -179.547 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.4 p -82.53 -34.01 11.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.128 -0.983 . . . . 0.0 110.591 -179.341 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 152' ' ' VAL . . . . . 0.477 HG12 ' O ' ' A' ' 149' ' ' MET . 0.8 OUTLIER -53.74 -40.88 45.21 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 120.957 -1.09 . . . . 0.0 109.067 -179.408 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 153' ' ' LYS . . . . . 0.445 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 99.0 mttt -63.53 -34.12 77.08 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.113 -0.992 . . . . 0.0 109.292 179.201 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -61.51 -37.11 82.49 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.322 -0.861 . . . . 0.0 109.937 -179.638 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 97.9 mt -71.99 -35.05 52.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.173 -0.955 . . . . 0.0 109.981 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -75.93 -42.0 50.05 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.177 -0.952 . . . . 0.0 111.209 -178.894 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 157' ' ' LYS . . . . . 0.422 ' HG2' ' HZ2' ' A' ' 157' ' ' LYS . 15.4 pttm -61.81 -34.2 75.49 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 120.769 -1.207 . . . . 0.0 109.719 -178.924 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.425 ' HB ' ' H ' ' A' ' 166' ' ' ALA . 34.0 m -79.91 -13.79 13.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.152 -0.968 . . . . 0.0 109.082 179.562 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -76.88 170.43 55.09 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.836 -1.306 . . . . 0.0 109.836 -179.826 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 23.1 t -159.02 173.95 15.69 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.409 -1.054 . . . . 0.0 109.315 -179.841 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 23.6 m -53.84 -32.47 53.01 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.236 -0.915 . . . . 0.0 109.121 179.663 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 24.0 m -56.45 -32.57 65.05 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.393 -0.817 . . . . 0.0 109.412 179.842 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 95.1 13.23 53.38 Favored Glycine 0 N--CA 1.493 2.465 0 N-CA-C 109.791 -1.323 . . . . 0.0 109.791 179.954 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 98.0 mtt180 -119.24 144.82 46.54 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.283 -1.128 . . . . 0.0 109.379 179.862 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 165' ' ' THR . . . . . 0.714 HG22 HG21 ' A' ' 69' ' ' VAL . 80.1 p -82.39 150.46 27.11 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.25 -0.906 . . . . 0.0 109.563 179.867 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 166' ' ' ALA . . . . . 0.425 ' H ' ' HB ' ' A' ' 158' ' ' VAL . . . -65.95 -35.5 80.78 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.339 -0.851 . . . . 0.0 108.896 179.523 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 66.6 mttm -112.58 157.68 20.89 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.524 -0.735 . . . . 0.0 109.07 179.731 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -69.7 130.75 43.21 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.134 -0.979 . . . . 0.0 109.324 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 43.0 t -123.2 125.32 71.77 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 121.201 -0.937 . . . . 0.0 109.575 -179.949 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 170' ' ' VAL . . . . . 0.43 HG12 ' N ' ' A' ' 171' ' ' VAL . 60.7 t -150.33 157.17 6.15 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 O-C-N 121.486 -0.758 . . . . 0.0 108.972 179.582 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.43 ' N ' HG12 ' A' ' 170' ' ' VAL . 0.2 OUTLIER -87.98 119.41 35.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.104 -0.998 . . . . 0.0 109.529 -179.727 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -65.91 -24.62 66.88 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.361 -0.837 . . . . 0.0 109.414 179.407 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 19.9 t70 -173.81 171.16 3.8 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.127 -0.983 . . . . 0.0 110.301 -179.51 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 174' ' ' CYS . . . . . 0.425 ' H ' ' HE2' ' A' ' 62' ' ' LYS . 11.0 p -151.84 153.15 33.65 Favored 'General case' 0 N--CA 1.492 1.66 0 N-CA-C 109.052 -0.721 . . . . 0.0 109.052 179.499 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -175.75 174.55 46.94 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 109.702 -1.359 . . . . 0.0 109.702 179.784 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 62.2 tt0 -107.89 120.67 42.94 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.3 -1.118 . . . . 0.0 109.652 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 32.4 tp -61.71 -37.03 82.66 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.135 -0.978 . . . . 0.0 109.032 179.434 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 25.0 t . . . . . 0 N--CA 1.49 1.559 0 CA-C-O 118.087 -0.959 . . . . 0.0 109.466 179.972 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 8.2 p-10 . . . . . 0 N--CA 1.489 1.489 0 N-CA-C 109.555 -0.535 . . . . 0.0 109.555 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -73.76 145.87 37.32 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 122.803 2.335 . . . . 0.0 112.047 179.763 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' ARG . . . . . 0.482 ' NH2' ' CB ' ' A' ' 178' ' ' SER . 95.5 mtm-85 -119.16 132.49 55.97 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.271 -0.893 . . . . 0.0 108.783 179.222 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.6 p -135.04 142.39 40.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.269 -0.895 . . . . 0.0 109.772 -179.192 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 42.8 p90 -141.12 155.61 46.09 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.434 -0.791 . . . . 0.0 109.506 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -128.18 142.32 51.21 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.421 -0.799 . . . . 0.0 109.887 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 59.4 t0 -94.6 124.26 38.52 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.227 -0.92 . . . . 0.0 108.734 179.151 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 39.1 mtp -119.66 147.51 44.47 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.136 -0.978 . . . . 0.0 110.279 -179.312 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.43 ' OG ' ' CD ' ' A' ' 172' ' ' GLU . 59.7 m -128.57 153.67 46.98 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.604 -0.685 . . . . 0.0 109.355 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.406 HG23 ' O ' ' A' ' 18' ' ' VAL . 34.7 m -114.93 131.93 65.66 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.835 0 O-C-N 121.388 -0.82 . . . . 0.0 109.426 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 63.59 9.65 32.99 Favored Glycine 0 N--CA 1.492 2.398 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 179.858 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 94.67 -1.67 66.31 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 -179.895 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 75.0 mt-30 -103.69 151.2 38.74 Favored Pre-proline 0 N--CA 1.493 1.717 0 O-C-N 121.295 -1.121 . . . . 0.0 109.073 179.756 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 14.3 Cg_endo -58.36 134.23 60.08 Favored 'Trans proline' 0 C--N 1.309 -1.507 0 C-N-CA 122.412 2.074 . . . . 0.0 112.266 -179.532 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -114.23 -65.06 1.23 Allowed 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.514 -0.741 . . . . 0.0 109.274 179.775 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -176.77 -170.48 39.34 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.456 -1.457 . . . . 0.0 109.456 179.943 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 25' ' ' ARG . . . . . 0.419 HH12 HG21 ' A' ' 27' ' ' VAL . 46.6 ptt85 -120.06 148.55 43.45 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.318 -1.107 . . . . 0.0 109.11 179.851 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 83.3 mt -122.57 129.15 75.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.496 -0.753 . . . . 0.0 109.32 -179.863 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.419 HG21 HH12 ' A' ' 25' ' ' ARG . 46.3 t -113.14 133.26 59.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.539 -0.725 . . . . 0.0 109.062 179.673 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 74.5 mtm -121.12 149.69 42.38 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.391 -0.818 . . . . 0.0 109.52 -179.753 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -97.57 132.51 43.17 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.388 -0.82 . . . . 0.0 109.542 -179.858 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -109.36 130.57 55.49 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.533 -0.729 . . . . 0.0 109.425 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 86.5 m-85 -94.55 118.41 31.63 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.126 -0.984 . . . . 0.0 108.483 178.89 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -93.38 -42.06 9.49 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.299 -0.875 . . . . 0.0 109.68 -179.683 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.6 m-20 -62.26 -49.23 76.53 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.09 -1.006 . . . . 0.0 109.764 -179.498 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 34' ' ' THR . . . . . 0.493 HG21 ' HD3' ' A' ' 103' ' ' LYS . 61.9 m -73.52 -42.03 62.28 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.069 -1.02 . . . . 0.0 109.72 179.8 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.529 ' O ' ' OG1' ' A' ' 35' ' ' THR . 1.8 p -132.24 79.02 67.21 Favored Pre-proline 0 N--CA 1.492 1.657 0 O-C-N 121.3 -0.875 . . . . 0.0 109.439 -179.69 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 21.2 Cg_endo -66.77 -61.79 0.08 OUTLIER 'Trans proline' 0 C--N 1.31 -1.468 0 C-N-CA 122.376 2.051 . . . . 0.0 112.603 -179.48 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.623 ' NH2' ' CE1' ' A' ' 92' ' ' TYR . 68.7 mtp85 -60.9 -34.98 75.49 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.415 -0.803 . . . . 0.0 110.4 -179.308 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 25.7 m -59.98 -41.47 92.07 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.953 -1.092 . . . . 0.0 109.859 -179.559 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -62.62 -30.18 71.17 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.089 -1.007 . . . . 0.0 109.35 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.401 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 96.6 mt-10 -67.59 -34.91 77.98 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.284 -0.885 . . . . 0.0 109.761 -179.983 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 41' ' ' ASN . . . . . 0.437 ' O ' HD23 ' A' ' 45' ' ' LEU . 26.2 m120 -56.82 -39.08 73.54 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.149 -0.97 . . . . 0.0 109.768 -179.767 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.4 ' O ' ' SG ' ' A' ' 46' ' ' CYS . 98.8 m-85 -94.16 -50.45 5.28 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.121 -0.987 . . . . 0.0 109.512 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.91 ' HE ' HE22 ' A' ' 176' ' ' GLN . 75.8 ttt-85 -57.19 -42.01 80.43 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.41 -0.806 . . . . 0.0 110.491 -179.392 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.401 ' HB3' ' O ' ' A' ' 40' ' ' GLU . . . -63.72 -44.87 92.29 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.999 -1.063 . . . . 0.0 110.077 -179.121 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.515 ' N ' ' CD2' ' A' ' 45' ' ' LEU . 2.7 mm? -67.64 -37.2 82.1 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.19 -0.944 . . . . 0.0 109.637 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 46' ' ' CYS . . . . . 0.4 ' SG ' ' O ' ' A' ' 42' ' ' PHE . 64.1 m -66.69 -48.99 67.57 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.136 -0.977 . . . . 0.0 110.108 -179.533 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 60.6 p -72.65 -30.71 64.52 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.192 -0.943 . . . . 0.0 109.694 -179.844 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 74.03 27.34 66.68 Favored Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 179.778 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 23.0 pt-20 -62.25 -35.59 79.41 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.212 -1.169 . . . . 0.0 109.381 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 43.6 mmtm -61.19 -33.2 73.07 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.289 -0.882 . . . . 0.0 109.128 179.588 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 93.64 168.4 38.29 Favored Glycine 0 N--CA 1.488 2.136 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 -179.793 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.541 HG23 ' HA ' ' A' ' 58' ' ' PRO . 68.4 m -76.45 139.9 41.05 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.306 -1.114 . . . . 0.0 109.686 -179.947 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -53.9 135.15 43.27 Favored Glycine 0 N--CA 1.488 2.165 0 N-CA-C 109.224 -1.551 . . . . 0.0 109.224 179.753 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 91.9 mtm-85 -58.92 -35.99 74.0 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.192 -1.181 . . . . 0.0 109.917 -179.551 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 22.7 t -59.14 -31.21 68.75 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.18 -0.95 . . . . 0.0 109.919 -179.587 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 56' ' ' GLY . . . . . 0.449 ' O ' ' CG ' ' A' ' 57' ' ' LYS . . . 117.91 81.05 0.77 Allowed Glycine 0 N--CA 1.495 2.614 0 N-CA-C 108.749 -1.74 . . . . 0.0 108.749 -179.381 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 57' ' ' LYS . . . . . 0.547 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 57.4 mttm -161.69 79.87 2.03 Favored Pre-proline 0 C--N 1.303 -1.434 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 -179.576 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.541 ' HA ' HG23 ' A' ' 52' ' ' THR . 71.3 Cg_exo -50.9 133.02 39.19 Favored 'Trans proline' 0 C--N 1.301 -1.964 0 C-N-CA 122.894 2.396 . . . . 0.0 112.809 -178.734 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.571 ' O ' ' CG ' ' A' ' 60' ' ' HIS . 7.0 mp -100.19 98.32 9.03 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.613 -0.679 . . . . 0.0 109.524 -179.47 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 60' ' ' HIS . . . . . 0.571 ' CG ' ' O ' ' A' ' 59' ' ' LEU . 93.5 m-70 -160.45 125.91 3.93 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.167 -0.958 . . . . 0.0 109.948 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 9.5 m-85 -71.95 -5.98 38.73 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.136 -0.978 . . . . 0.0 108.811 178.889 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 62' ' ' LYS . . . . . 0.561 ' O ' ' O ' ' A' ' 171' ' ' VAL . 48.7 tttt -53.39 -25.88 17.34 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.527 -0.733 . . . . 0.0 109.57 179.891 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 89.3 m-20 -103.6 4.85 36.1 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.467 -0.771 . . . . 0.0 110.071 -179.402 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 63.8 p -82.04 162.35 22.62 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.069 -1.019 . . . . 0.0 109.856 -179.754 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 29.2 t -147.31 159.34 43.78 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.473 -0.767 . . . . 0.0 109.083 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.5 m-85 -64.18 123.5 19.26 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.079 -1.013 . . . . 0.0 108.929 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 61.7 t60 -66.62 -50.26 63.6 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.304 -0.872 . . . . 0.0 110.548 -179.112 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 93.2 mtt180 -141.47 150.47 42.29 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 120.951 -1.093 . . . . 0.0 110.287 -179.658 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.642 HG21 HG22 ' A' ' 165' ' ' THR . 4.9 m -137.09 130.92 45.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 179.096 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 19.1 mt -149.33 128.39 6.2 Favored Pre-proline 0 N--CA 1.492 1.646 0 O-C-N 120.94 -1.1 . . . . 0.0 109.41 -179.785 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 65.3 Cg_endo -76.0 133.44 15.13 Favored 'Trans proline' 0 C--N 1.311 -1.429 0 C-N-CA 122.148 1.899 . . . . 0.0 112.014 179.707 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 90.49 3.88 71.27 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.793 -1.323 . . . . 0.0 109.793 179.662 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 82.6 m-85 -138.77 -94.37 0.18 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.129 -1.218 . . . . 0.0 109.811 179.845 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 7.3 ptt? -171.45 175.79 4.01 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.168 -0.957 . . . . 0.0 109.839 -179.655 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -122.28 136.28 54.88 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 108.231 -1.026 . . . . 0.0 108.231 179.363 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 92.4 mt-30 -94.56 136.0 35.37 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.88 -1.138 . . . . 0.0 110.198 -179.262 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -90.03 -173.52 45.15 Favored Glycine 0 N--CA 1.492 2.379 0 N-CA-C 108.941 -1.664 . . . . 0.0 108.941 179.395 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -155.63 174.3 33.67 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.779 -1.329 . . . . 0.0 109.779 179.84 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.547 ' OD1' ' N ' ' A' ' 83' ' ' GLY . 48.5 p30 -106.37 165.59 11.15 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.415 -1.05 . . . . 0.0 109.56 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 46.4 p90 -75.2 -19.95 59.54 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.309 -0.87 . . . . 0.0 109.66 -179.884 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.557 ' OG1' ' N ' ' A' ' 88' ' ' GLY . 71.2 p -65.93 -37.06 85.06 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.281 -0.887 . . . . 0.0 109.989 -179.629 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -174.46 -51.32 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.267 -0.896 . . . . 0.0 109.539 -179.934 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.547 ' N ' ' OD1' ' A' ' 79' ' ' ASP . . . 94.71 2.2 63.23 Favored Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 78.7 m-20 -86.02 4.15 39.17 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.189 -1.183 . . . . 0.0 109.448 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 93.71 -37.47 3.39 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 51.6 p -69.99 -29.11 66.11 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.185 -1.185 . . . . 0.0 109.231 179.842 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -87.85 -168.23 44.24 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.983 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.557 ' N ' ' OG1' ' A' ' 81' ' ' THR . . . 84.03 45.07 6.43 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.571 -1.412 . . . . 0.0 109.571 179.879 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -56.37 144.37 30.94 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.344 -1.092 . . . . 0.0 109.43 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 27.4 t -78.24 144.57 36.1 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.159 -0.963 . . . . 0.0 109.552 -179.913 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 17.0 pt -66.34 -36.29 77.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.291 -0.881 . . . . 0.0 109.849 -179.871 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 92' ' ' TYR . . . . . 0.623 ' CE1' ' NH2' ' A' ' 37' ' ' ARG . 96.4 m-85 -66.21 -36.44 83.04 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.175 -0.953 . . . . 0.0 109.566 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.21 5.74 87.03 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.202 -1.559 . . . . 0.0 109.202 -179.752 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -150.97 158.0 43.6 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.348 -1.09 . . . . 0.0 109.381 -179.911 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -85.17 148.29 26.18 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.178 -0.951 . . . . 0.0 109.484 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 45.6 p90 -135.39 159.13 42.56 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.327 -0.858 . . . . 0.0 109.392 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -73.25 135.68 44.51 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.262 -0.899 . . . . 0.0 109.932 -179.678 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 98' ' ' ASP . . . . . 0.438 ' C ' ' OD1' ' A' ' 98' ' ' ASP . 54.4 p30 -99.84 -163.87 1.07 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.313 -0.867 . . . . 0.0 109.549 179.774 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 99' ' ' GLU . . . . . 0.442 ' OE1' ' O ' ' A' ' 34' ' ' THR . 94.5 mt-10 -108.02 163.01 13.52 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.371 -0.831 . . . . 0.0 109.455 179.77 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 82.9 m-20 -64.76 165.95 9.66 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.257 -0.902 . . . . 0.0 109.566 -179.809 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 101' ' ' PHE . . . . . 0.489 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 33.3 p90 -80.7 51.43 1.5 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.27 -0.894 . . . . 0.0 109.718 -179.811 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 90.7 mt -56.22 -41.08 68.96 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.101 -0.999 . . . . 0.0 109.547 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 103' ' ' LYS . . . . . 0.493 ' HD3' HG21 ' A' ' 34' ' ' THR . 43.6 mtpt -89.33 146.14 24.9 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.178 -0.951 . . . . 0.0 109.693 -179.939 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 49.3 pttt -134.85 179.98 5.97 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.42 -0.8 . . . . 0.0 109.356 179.804 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 105' ' ' HIS . . . . . 0.532 ' O ' ' CG ' ' A' ' 105' ' ' HIS . 48.4 p-80 -92.64 100.75 13.2 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.292 -0.88 . . . . 0.0 109.407 -179.872 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 51.2 p -76.54 -22.46 54.34 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.331 -0.856 . . . . 0.0 109.628 -179.903 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.409 ' O ' HG12 ' A' ' 110' ' ' ILE . . . -151.15 -179.46 26.89 Favored Glycine 0 N--CA 1.492 2.406 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 -179.688 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -72.65 158.87 49.94 Favored 'Trans proline' 0 C--N 1.307 -1.626 0 C-N-CA 122.951 2.434 . . . . 0.0 112.178 179.83 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 84.95 38.25 9.47 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 110.233 -1.147 . . . . 0.0 110.233 179.532 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.409 HG12 ' O ' ' A' ' 107' ' ' GLY . 34.4 mm -113.38 138.39 43.13 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.29 -1.123 . . . . 0.0 108.979 179.598 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.827 ' N ' HD22 ' A' ' 111' ' ' LEU . 2.4 mm? -87.58 139.75 30.22 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.246 -0.909 . . . . 0.0 109.658 -179.754 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 23.1 t -128.16 143.54 51.06 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.54 -0.725 . . . . 0.0 109.27 179.85 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 58.3 ttp -96.71 127.08 42.35 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.305 -0.872 . . . . 0.0 109.533 -179.9 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -66.16 146.5 54.58 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.236 -0.915 . . . . 0.0 109.633 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 115' ' ' ASN . . . . . 0.502 ' N ' ' OD1' ' A' ' 115' ' ' ASN . 9.1 p-10 -168.25 115.73 0.7 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.272 -0.893 . . . . 0.0 109.668 179.818 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -66.18 -33.95 76.92 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.379 -0.825 . . . . 0.0 109.347 179.806 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -145.52 166.92 27.65 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.352 -1.499 . . . . 0.0 109.352 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -66.59 158.58 55.04 Favored 'Trans proline' 0 C--N 1.306 -1.678 0 C-N-CA 122.822 2.348 . . . . 0.0 111.963 179.919 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 73.7 m-20 55.03 44.07 28.74 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.467 -0.771 . . . . 0.0 109.392 -179.886 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 87.2 m -137.28 129.33 29.22 Favored 'General case' 0 C--N 1.305 -1.359 0 O-C-N 121.405 -0.81 . . . . 0.0 109.113 179.943 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 22.4 t-20 -79.94 116.24 19.97 Favored 'General case' 0 C--N 1.298 -1.65 0 O-C-N 121.489 -0.757 . . . . 0.0 109.33 179.859 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -85.32 -179.54 50.69 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.736 -1.346 . . . . 0.0 109.736 -179.82 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -130.64 -14.25 3.66 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.367 -1.079 . . . . 0.0 109.749 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 94.3 mt-30 -121.89 159.42 26.89 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.299 -0.876 . . . . 0.0 109.622 -179.876 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 43.6 p90 -130.83 158.74 39.35 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.489 -0.757 . . . . 0.0 109.474 -179.898 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -117.47 143.84 45.63 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.49 -0.757 . . . . 0.0 110.02 -179.766 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 84.2 mt -120.77 134.27 64.75 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 121.613 -0.679 . . . . 0.0 109.224 179.246 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -125.27 126.36 45.01 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.293 -0.879 . . . . 0.0 109.376 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 30.3 p -98.32 3.39 48.64 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.348 -0.845 . . . . 0.0 109.301 179.868 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -153.62 159.63 42.16 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.243 -0.911 . . . . 0.0 109.428 -179.795 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 7.9 ttpm? -66.44 130.05 41.89 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.165 -0.959 . . . . 0.0 109.081 179.8 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 16.6 p -109.09 95.86 5.92 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.395 -0.816 . . . . 0.0 109.633 -179.658 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -65.74 -35.72 81.55 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.213 -0.929 . . . . 0.0 109.581 179.844 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 1.0 OUTLIER -66.47 -33.86 76.64 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.245 -0.91 . . . . 0.0 109.55 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 9.7 mt -90.06 7.17 39.09 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.166 -0.959 . . . . 0.0 109.201 179.295 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 136' ' ' ASP . . . . . 0.533 ' O ' ' OD1' ' A' ' 136' ' ' ASP . 47.2 p30 -46.79 138.45 6.22 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.184 -0.948 . . . . 0.0 109.783 -179.617 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 174.21 -161.88 32.12 Favored Glycine 0 N--CA 1.484 1.885 0 N-CA-C 108.873 -1.691 . . . . 0.0 108.873 -179.708 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 138' ' ' LYS . . . . . 0.477 ' O ' ' O ' ' A' ' 139' ' ' HIS . 88.8 mttt -57.36 -39.55 76.21 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 121.276 -1.132 . . . . 0.0 109.432 179.86 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 139' ' ' HIS . . . . . 0.477 ' O ' ' O ' ' A' ' 138' ' ' LYS . 66.3 m-70 53.18 109.22 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.51 -0.744 . . . . 0.0 110.049 179.63 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 40.6 t -107.42 136.54 42.27 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.36 -0.837 . . . . 0.0 108.825 179.435 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 23.5 m -125.09 142.47 41.87 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.307 -0.871 . . . . 0.0 109.587 -179.464 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 42.8 p90 -126.46 -9.89 6.29 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.5 -0.75 . . . . 0.0 109.751 179.73 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -156.52 175.72 34.07 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 179.631 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 58.6 tt0 -141.43 159.44 42.22 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.238 -1.154 . . . . 0.0 109.675 -179.614 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 145' ' ' VAL . . . . . 0.483 HG23 HD21 ' A' ' 111' ' ' LEU . 9.8 t -97.83 134.39 36.24 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.22 0 O-C-N 121.124 -0.985 . . . . 0.0 109.126 179.904 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 11.6 m -113.62 -35.45 2.26 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.493 -0.754 . . . . 0.0 109.535 179.653 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 91.9 mt-10 -142.83 167.86 21.08 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.227 -0.92 . . . . 0.0 109.627 -179.849 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 97.78 4.36 57.95 Favored Glycine 0 N--CA 1.494 2.553 0 N-CA-C 110.079 -1.209 . . . . 0.0 110.079 179.534 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 149' ' ' MET . . . . . 0.458 ' O ' HG12 ' A' ' 152' ' ' VAL . 88.0 mtp -60.84 -33.22 72.72 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.062 -1.258 . . . . 0.0 109.741 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 150' ' ' ASP . . . . . 0.54 ' OD1' ' N ' ' A' ' 151' ' ' VAL . 30.9 p-10 -65.67 -38.26 88.8 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.9 -1.125 . . . . 0.0 110.107 -179.441 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.54 ' N ' ' OD1' ' A' ' 150' ' ' ASP . 7.6 p -86.52 -33.9 7.51 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.066 -1.021 . . . . 0.0 110.262 -179.593 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 152' ' ' VAL . . . . . 0.469 ' CG1' ' N ' ' A' ' 153' ' ' LYS . 1.0 OUTLIER -56.1 -42.65 73.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 120.943 -1.098 . . . . 0.0 109.175 -179.503 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 153' ' ' LYS . . . . . 0.469 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 98.7 mttt -64.87 -33.88 77.06 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.189 -0.944 . . . . 0.0 109.537 179.431 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -62.33 -40.4 96.22 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.287 -0.883 . . . . 0.0 110.11 -179.321 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 75.4 mt -71.19 -36.79 63.81 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.228 -0.92 . . . . 0.0 110.394 -179.481 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -79.57 -41.45 27.15 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.085 -1.009 . . . . 0.0 111.406 -178.725 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 23.5 pttt -61.02 -34.0 74.15 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.705 -1.247 . . . . 0.0 110.193 -178.591 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.425 ' HB ' ' H ' ' A' ' 166' ' ' ALA . 35.1 m -73.37 -10.44 13.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.027 -1.046 . . . . 0.0 109.2 179.906 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -76.38 176.36 52.11 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 -179.822 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 83.2 p -155.31 176.07 13.05 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.425 -1.044 . . . . 0.0 109.039 -179.641 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 22.7 m -52.28 -36.01 51.77 Favored 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 179.429 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 23.8 m -60.71 -33.19 72.52 Favored 'General case' 0 N--CA 1.487 1.387 0 O-C-N 121.377 -0.827 . . . . 0.0 108.93 179.164 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 96.31 8.94 57.29 Favored Glycine 0 N--CA 1.493 2.437 0 N-CA-C 109.805 -1.318 . . . . 0.0 109.805 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 69.6 ttp85 -101.74 138.69 38.39 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.348 -1.089 . . . . 0.0 109.521 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 165' ' ' THR . . . . . 0.642 HG22 HG21 ' A' ' 69' ' ' VAL . 65.2 p -84.12 151.85 24.67 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.175 -0.953 . . . . 0.0 109.544 179.81 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 166' ' ' ALA . . . . . 0.425 ' H ' ' HB ' ' A' ' 158' ' ' VAL . . . -67.28 -34.8 78.15 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.245 -0.909 . . . . 0.0 109.063 179.557 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 63.2 mttp -114.52 158.43 21.65 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.563 -0.711 . . . . 0.0 109.34 -179.994 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 63.1 mttp -73.79 137.81 44.12 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.148 -0.97 . . . . 0.0 109.353 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 2.7 m -132.65 119.71 39.23 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.35 -0.844 . . . . 0.0 109.843 -179.758 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 39.2 t -145.67 141.58 22.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 CA-C-O 121.898 0.856 . . . . 0.0 109.424 179.41 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.561 ' O ' ' O ' ' A' ' 62' ' ' LYS . 22.1 t -61.36 132.36 26.89 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.783 0 C-N-CA 120.333 -0.547 . . . . 0.0 109.762 -179.608 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 172' ' ' GLU . . . . . 0.452 ' O ' ' OD1' ' A' ' 173' ' ' ASP . 95.6 mt-10 -105.87 -7.08 18.44 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.335 -0.853 . . . . 0.0 109.808 179.61 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 173' ' ' ASP . . . . . 0.452 ' OD1' ' O ' ' A' ' 172' ' ' GLU . 30.5 m-20 -158.44 168.22 27.55 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.082 -1.011 . . . . 0.0 110.007 -179.734 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 20.4 p -170.32 126.25 0.78 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.474 -0.766 . . . . 0.0 109.539 179.565 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -173.55 173.86 45.92 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 179.8 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 176' ' ' GLN . . . . . 0.91 HE22 ' HE ' ' A' ' 43' ' ' ARG . 58.7 tt0 -105.2 121.35 43.66 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.383 -1.069 . . . . 0.0 109.853 -179.787 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 177' ' ' LEU . . . . . 0.473 HD23 ' HE ' ' A' ' 11' ' ' ARG . 36.8 tp -62.41 -36.57 82.77 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.239 -0.913 . . . . 0.0 108.95 179.125 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 178' ' ' SER . . . . . 0.513 ' OXT' ' NE2' ' A' ' 176' ' ' GLN . 7.2 t . . . . . 0 N--CA 1.491 1.589 0 CA-C-O 117.977 -1.011 . . . . 0.0 109.428 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.529 4.856 0 N-CA-C 119.398 2.519 . . . . 0.0 119.398 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 2' ' ' SER . . . . . 0.404 ' OG ' ' CD2' ' A' ' 3' ' ' PHE . 86.4 p -61.6 -27.6 68.75 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.186 -1.185 . . . . 0.0 109.441 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.404 ' CD2' ' OG ' ' A' ' 2' ' ' SER . 99.2 m-85 -111.03 124.37 52.03 Favored 'General case' 0 N--CA 1.485 1.291 0 N-CA-C 108.82 -0.808 . . . . 0.0 108.82 179.727 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 53.5 p -66.71 -26.86 67.22 Favored 'General case' 0 C--N 1.296 -1.723 0 O-C-N 121.491 -0.756 . . . . 0.0 109.494 -179.897 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 82.17 18.76 66.29 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 -179.952 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 28.5 t -117.91 146.75 43.72 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.43 -1.041 . . . . 0.0 109.502 -179.919 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' MET . . . . . 0.593 ' N ' ' SD ' ' A' ' 7' ' ' MET . 1.7 mpt? -123.31 69.35 40.8 Favored Pre-proline 0 N--CA 1.494 1.73 0 O-C-N 121.415 -0.803 . . . . 0.0 109.427 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.424 ' O ' ' HB3' ' A' ' 32' ' ' ALA . 39.9 Cg_endo -69.16 -9.62 26.8 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 122.657 2.238 . . . . 0.0 112.364 -179.905 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.502 ' O ' ' ND2' ' A' ' 9' ' ' ASN . 2.2 p-10 -123.73 70.09 46.96 Favored Pre-proline 0 N--CA 1.494 1.756 0 O-C-N 121.261 -0.899 . . . . 0.0 109.832 -179.65 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -72.04 144.43 42.57 Favored 'Trans proline' 0 C--N 1.308 -1.561 0 C-N-CA 122.515 2.143 . . . . 0.0 111.752 179.582 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 92.9 mtt180 -126.26 142.2 51.62 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.304 -0.873 . . . . 0.0 109.643 -179.822 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 10.5 p -134.87 143.84 36.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.359 -0.838 . . . . 0.0 109.345 179.803 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 25.0 p90 -139.49 152.89 47.33 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.208 -0.933 . . . . 0.0 109.602 -179.843 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -124.62 133.09 53.37 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.426 -0.796 . . . . 0.0 109.471 179.529 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.7 t0 -91.06 111.95 23.64 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.144 -0.972 . . . . 0.0 108.611 179.248 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' MET . . . . . 0.426 ' SD ' HD12 ' A' ' 26' ' ' ILE . 78.9 mtp -106.39 138.91 41.72 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.239 -0.913 . . . . 0.0 110.437 -179.185 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.422 ' OG ' ' OE2' ' A' ' 172' ' ' GLU . 48.8 m -131.6 155.95 46.63 Favored 'General case' 0 N--CA 1.492 1.632 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 179.416 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 25.1 m -118.99 144.29 27.71 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.149 -0.969 . . . . 0.0 109.62 -179.738 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 57.6 -108.99 1.55 Allowed Glycine 0 N--CA 1.488 2.119 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -135.77 28.33 2.98 Favored Glycine 0 N--CA 1.493 2.479 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 32.6 mt-30 -137.44 153.02 74.19 Favored Pre-proline 0 N--CA 1.493 1.719 0 O-C-N 121.297 -1.119 . . . . 0.0 109.186 179.873 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_endo -63.96 139.16 66.32 Favored 'Trans proline' 0 N--CA 1.495 1.56 0 C-N-CA 122.528 2.152 . . . . 0.0 112.05 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -102.84 -60.59 1.52 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.276 -0.89 . . . . 0.0 109.4 179.874 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 179.89 -170.83 42.2 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 98.2 mtt180 -117.57 143.72 45.83 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.365 -1.079 . . . . 0.0 109.583 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.426 HD12 ' SD ' ' A' ' 16' ' ' MET . 86.5 mt -121.53 122.37 66.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 179.073 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 39.9 t -116.21 132.3 66.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.437 -0.789 . . . . 0.0 109.024 -179.901 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 71.7 mtm -124.76 152.19 44.15 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.403 -0.81 . . . . 0.0 109.346 -179.694 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -106.15 131.76 53.02 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.394 -0.816 . . . . 0.0 109.894 -179.616 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.542 HD13 ' HB1' ' A' ' 39' ' ' ALA . 17.3 mt -100.27 146.4 26.95 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.423 -0.798 . . . . 0.0 109.311 179.162 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 95.5 m-85 -95.43 124.19 39.34 Favored 'General case' 0 N--CA 1.49 1.567 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 178.804 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.424 ' HB3' ' O ' ' A' ' 8' ' ' PRO . . . -99.17 21.48 11.79 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.206 -0.934 . . . . 0.0 109.694 -179.323 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.3 m-20 -120.76 -73.55 0.64 Allowed 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.289 -0.882 . . . . 0.0 110.21 -179.553 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' THR . . . . . 0.443 ' O ' ' OE1' ' A' ' 99' ' ' GLU . 41.3 m -61.15 -43.43 98.89 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.176 -0.953 . . . . 0.0 110.44 -179.117 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 9.4 m -139.95 78.37 24.74 Favored Pre-proline 0 N--CA 1.494 1.746 0 O-C-N 121.126 -0.984 . . . . 0.0 109.963 -179.543 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 68.3 Cg_endo -79.75 -36.94 0.52 Allowed 'Trans proline' 0 C--N 1.306 -1.689 0 C-N-CA 122.614 2.209 . . . . 0.0 112.461 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.418 ' O ' ' OH ' ' A' ' 92' ' ' TYR . 3.3 mtt-85 -59.63 -38.98 82.81 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.247 -0.908 . . . . 0.0 109.79 -179.761 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.477 HG23 ' SD ' ' A' ' 113' ' ' MET . 85.0 m -64.26 -41.01 97.13 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.187 -0.946 . . . . 0.0 109.793 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.542 ' HB1' HD13 ' A' ' 30' ' ' LEU . . . -60.72 -32.78 72.02 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.209 -0.932 . . . . 0.0 108.904 179.762 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -69.23 -34.98 75.67 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.486 -0.759 . . . . 0.0 109.744 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 45.2 t-20 -57.11 -41.0 78.13 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.177 -0.952 . . . . 0.0 109.746 -179.616 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 97.7 m-85 -82.54 -45.73 14.28 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.147 -0.971 . . . . 0.0 109.78 -179.892 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.496 ' NH1' ' OE2' ' A' ' 49' ' ' GLU . 72.1 ttp85 -59.2 -40.9 87.18 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.366 -0.834 . . . . 0.0 110.544 -179.377 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.498 ' O ' ' N ' ' A' ' 48' ' ' GLY . . . -69.55 -52.43 26.38 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.143 -0.973 . . . . 0.0 110.348 -179.117 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.45 ' N ' ' CD2' ' A' ' 45' ' ' LEU . 3.4 mm? -63.93 -39.68 94.71 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.066 -1.021 . . . . 0.0 109.702 -179.739 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 46' ' ' CYS . . . . . . . . . . . . . 95.2 m -63.85 -62.69 1.48 Allowed 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.066 -1.021 . . . . 0.0 109.278 -179.863 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 26.6 m -66.53 -36.24 82.22 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.294 -0.879 . . . . 0.0 109.178 179.586 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.498 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 81.6 38.84 13.19 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 110.064 -1.214 . . . . 0.0 110.064 179.749 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.496 ' OE2' ' NH1' ' A' ' 43' ' ' ARG . 95.3 mt-10 -62.04 -35.79 79.65 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.079 -1.248 . . . . 0.0 109.47 179.883 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 31.2 mmtm -60.43 -34.55 74.14 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.308 -0.87 . . . . 0.0 109.546 -179.838 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 93.58 169.11 38.62 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.236 -1.546 . . . . 0.0 109.236 -179.687 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.539 HG23 ' HA ' ' A' ' 58' ' ' PRO . 68.4 m -79.47 141.12 37.04 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.292 -1.122 . . . . 0.0 109.963 -179.853 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -65.02 140.27 41.71 Favored Glycine 0 N--CA 1.489 2.172 0 N-CA-C 109.302 -1.519 . . . . 0.0 109.302 179.637 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 76.5 mtm180 -59.59 -33.24 71.21 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.229 -1.159 . . . . 0.0 110.046 -179.621 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 86.7 p -60.49 -23.44 64.51 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.204 -0.935 . . . . 0.0 110.122 -179.338 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' GLY . . . . . 0.427 ' O ' ' CG ' ' A' ' 57' ' ' LYS . . . 108.84 76.94 0.96 Allowed Glycine 0 N--CA 1.495 2.633 0 N-CA-C 108.951 -1.66 . . . . 0.0 108.951 -179.486 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' LYS . . . . . 0.479 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 54.2 mttm -161.2 76.91 2.41 Favored Pre-proline 0 N--CA 1.488 1.463 0 N-CA-C 107.914 -1.143 . . . . 0.0 107.914 -179.822 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.539 ' HA ' HG23 ' A' ' 52' ' ' THR . 89.0 Cg_exo -48.42 129.91 20.48 Favored 'Trans proline' 0 C--N 1.301 -1.936 0 C-N-CA 122.932 2.421 . . . . 0.0 112.578 -178.716 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.479 ' CD1' ' O ' ' A' ' 57' ' ' LYS . 8.1 mp -97.88 70.7 2.16 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.719 -0.613 . . . . 0.0 109.42 -179.434 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 96.3 m-70 -139.2 146.5 40.6 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.284 -0.885 . . . . 0.0 109.609 179.871 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 4.1 m-85 -97.0 16.87 18.29 Favored 'General case' 0 N--CA 1.492 1.644 0 N-CA-C 108.488 -0.93 . . . . 0.0 108.488 179.173 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 8.7 mtpm? -75.78 153.09 37.19 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.511 -0.743 . . . . 0.0 109.594 -179.692 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 83.8 m-20 55.19 46.23 24.24 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.468 -0.77 . . . . 0.0 109.796 179.745 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 92.1 p -112.94 150.8 31.33 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.418 -0.801 . . . . 0.0 109.038 179.595 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 29.1 t -120.71 148.08 44.42 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.369 -0.832 . . . . 0.0 109.594 -179.694 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -68.38 132.56 47.25 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.294 -0.879 . . . . 0.0 109.015 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 83.8 t60 -63.4 -49.25 74.53 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.278 -0.889 . . . . 0.0 110.367 -179.43 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 5.6 ttm180 -151.45 154.45 36.61 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.071 -1.018 . . . . 0.0 109.344 -179.351 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.479 HG21 HG22 ' A' ' 165' ' ' THR . 19.2 m -132.43 149.88 32.74 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 121.277 -0.889 . . . . 0.0 109.982 -179.737 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 13.3 mt -148.05 125.58 5.75 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.158 -0.963 . . . . 0.0 108.629 178.892 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -71.94 144.2 42.52 Favored 'Trans proline' 0 N--CA 1.493 1.463 0 C-N-CA 122.123 1.882 . . . . 0.0 112.588 -179.291 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 75.08 -53.37 2.61 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.94 -1.264 . . . . 0.0 109.94 179.566 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 84.4 m-85 -67.51 -83.28 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.196 -1.179 . . . . 0.0 110.082 -179.533 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' MET . . . . . 0.587 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 11.9 ptt? -179.49 158.45 0.84 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.114 -0.991 . . . . 0.0 109.619 -179.736 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 1.1 m -99.35 125.8 45.1 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.329 -0.857 . . . . 0.0 108.755 179.377 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 63.7 tt0 -97.94 121.16 39.53 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.21 -0.931 . . . . 0.0 109.766 -179.645 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -87.06 -176.59 49.09 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.14 -1.584 . . . . 0.0 109.14 179.571 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -142.74 162.79 27.37 Favored Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.666 -1.374 . . . . 0.0 109.666 179.857 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -75.04 147.53 40.63 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.344 -1.092 . . . . 0.0 109.553 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 44.4 p90 -68.11 -18.93 64.78 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.243 -0.91 . . . . 0.0 109.654 -179.842 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.539 ' OG1' ' N ' ' A' ' 88' ' ' GLY . 59.7 p -66.22 -30.27 70.68 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.213 -0.929 . . . . 0.0 109.438 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -177.42 -56.22 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.247 -0.908 . . . . 0.0 109.44 179.823 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 94.36 -4.31 70.0 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 78.7 m-20 -88.16 5.41 41.49 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.23 -1.159 . . . . 0.0 109.413 179.865 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 95.93 -38.78 3.0 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 -179.842 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 48.5 m -60.34 -39.51 87.36 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.248 -1.148 . . . . 0.0 109.218 179.738 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -86.06 -168.29 44.59 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 179.901 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.539 ' N ' ' OG1' ' A' ' 81' ' ' THR . . . 108.32 73.14 0.79 Allowed Glycine 0 N--CA 1.494 2.534 0 N-CA-C 109.753 -1.339 . . . . 0.0 109.753 179.865 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -94.8 135.82 35.84 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.254 -1.145 . . . . 0.0 109.189 179.732 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 50.2 m -122.41 147.9 45.74 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.39 -0.819 . . . . 0.0 109.569 -179.84 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 26.1 pt -67.48 -26.81 36.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.309 -0.869 . . . . 0.0 109.621 179.877 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' TYR . . . . . 0.418 ' OH ' ' O ' ' A' ' 37' ' ' ARG . 97.3 m-85 -65.23 -30.16 71.02 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.3 -0.875 . . . . 0.0 109.776 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 68.09 -107.61 2.13 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.284 -1.527 . . . . 0.0 109.284 -179.772 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -55.54 147.87 16.94 Favored 'General case' 0 N--CA 1.487 1.39 0 O-C-N 121.241 -1.152 . . . . 0.0 109.319 179.819 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 41.5 mttm -76.05 156.26 34.11 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.388 -0.82 . . . . 0.0 109.694 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 33.7 p90 -133.01 161.67 33.75 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.407 -0.808 . . . . 0.0 109.208 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -60.15 140.31 57.0 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.152 -0.967 . . . . 0.0 109.809 -179.349 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -76.68 135.28 39.09 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.29 -0.881 . . . . 0.0 109.812 -179.886 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 99' ' ' GLU . . . . . 0.443 ' OE1' ' O ' ' A' ' 34' ' ' THR . 95.9 mt-10 -64.84 148.44 51.33 Favored 'General case' 0 C--N 1.305 -1.348 0 O-C-N 121.32 -0.862 . . . . 0.0 109.245 179.556 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 21.3 m120 -55.84 145.7 23.85 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 121.362 -0.836 . . . . 0.0 109.365 -179.866 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 101' ' ' PHE . . . . . 0.586 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 25.0 p90 -110.27 69.88 0.71 Allowed 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.448 -0.782 . . . . 0.0 109.47 -179.781 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 86.4 mt -59.04 -34.8 54.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.257 -0.902 . . . . 0.0 109.575 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 27.1 mtmm -84.77 150.14 25.26 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.21 -0.931 . . . . 0.0 109.615 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 56.4 pttt -131.91 -179.64 5.52 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.371 -0.831 . . . . 0.0 109.362 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 105' ' ' HIS . . . . . 0.534 ' O ' ' CG ' ' A' ' 105' ' ' HIS . 50.4 p-80 -88.27 98.45 11.59 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.207 -0.933 . . . . 0.0 109.647 -179.832 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 55.5 p -77.44 -22.02 52.1 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.237 -0.915 . . . . 0.0 109.708 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.406 ' O ' HG12 ' A' ' 110' ' ' ILE . . . -150.46 179.34 27.27 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.524 -1.431 . . . . 0.0 109.524 -179.744 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -70.99 160.6 48.85 Favored 'Trans proline' 0 C--N 1.307 -1.617 0 C-N-CA 122.863 2.376 . . . . 0.0 112.183 179.886 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 85.62 36.94 9.94 Favored Glycine 0 N--CA 1.493 2.493 0 N-CA-C 109.95 -1.26 . . . . 0.0 109.95 179.725 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.411 ' C ' HD22 ' A' ' 111' ' ' LEU . 39.3 mm -114.98 135.32 55.28 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 O-C-N 121.364 -1.08 . . . . 0.0 109.364 179.857 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.811 ' N ' HD22 ' A' ' 111' ' ' LEU . 2.4 mm? -91.46 136.23 33.27 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.21 -0.931 . . . . 0.0 109.544 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 38.0 t -143.82 139.5 29.36 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.336 -0.852 . . . . 0.0 109.244 179.669 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 113' ' ' MET . . . . . 0.477 ' SD ' HG23 ' A' ' 38' ' ' THR . 82.6 mtp -84.96 130.62 34.6 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.169 -0.957 . . . . 0.0 109.247 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 114' ' ' ALA . . . . . 0.443 ' O ' ' OD1' ' A' ' 115' ' ' ASN . . . -68.79 141.25 55.23 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.222 -0.924 . . . . 0.0 109.565 -179.879 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 115' ' ' ASN . . . . . 0.443 ' OD1' ' O ' ' A' ' 114' ' ' ALA . 72.9 m-20 -145.83 112.75 6.05 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.247 -0.908 . . . . 0.0 109.054 179.554 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -69.07 -31.11 69.62 Favored 'General case' 0 C--N 1.296 -1.723 0 O-C-N 121.448 -0.783 . . . . 0.0 109.234 179.747 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -141.02 167.65 25.6 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.137 -1.585 . . . . 0.0 109.137 179.826 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_endo -66.46 157.46 60.34 Favored 'Trans proline' 0 C--N 1.304 -1.799 0 C-N-CA 122.737 2.292 . . . . 0.0 111.94 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 78.7 m-20 56.08 51.38 12.01 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.447 -0.783 . . . . 0.0 109.716 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 61.3 m -131.36 127.18 37.06 Favored 'General case' 0 N--CA 1.485 1.28 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 179.437 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 49.3 t-20 -53.13 -37.55 61.9 Favored 'General case' 0 C--N 1.296 -1.753 0 O-C-N 121.371 -0.831 . . . . 0.0 109.839 -179.274 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 77.0 63.52 2.27 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 109.766 -1.334 . . . . 0.0 109.766 179.826 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 24.0 m -54.76 -33.38 61.22 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.199 -1.177 . . . . 0.0 109.76 -179.796 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.3 mt-30 -92.07 147.4 22.98 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.113 -0.992 . . . . 0.0 109.511 -179.902 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 125' ' ' PHE . . . . . 0.403 ' HA ' ' H ' ' A' ' 114' ' ' ALA . 49.1 p90 -138.96 162.48 34.78 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.246 -0.909 . . . . 0.0 109.67 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.587 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 48.8 p90 -139.27 160.79 38.98 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.398 -0.814 . . . . 0.0 109.355 179.911 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 69.8 mt -118.51 132.39 68.53 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.378 -0.826 . . . . 0.0 109.428 179.833 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -102.13 105.59 16.32 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.325 -0.859 . . . . 0.0 109.273 179.887 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 129' ' ' THR . . . . . 0.408 ' OG1' ' OE2' ' A' ' 156' ' ' GLU . 44.8 p -89.12 -1.38 58.06 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.283 -0.885 . . . . 0.0 109.642 179.937 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -141.71 153.13 44.44 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.261 -0.9 . . . . 0.0 109.485 -179.816 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 79.7 tttt -78.33 130.64 36.41 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.285 -0.884 . . . . 0.0 109.38 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 33.3 p -124.65 156.11 38.06 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.358 -0.838 . . . . 0.0 109.47 -179.863 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -111.81 -36.3 5.47 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.433 -0.792 . . . . 0.0 109.615 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 0.7 OUTLIER -66.84 -15.2 63.45 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.159 -0.963 . . . . 0.0 109.629 -179.722 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 135' ' ' LEU . . . . . 0.41 ' O ' ' NE2' ' A' ' 139' ' ' HIS . 7.9 mt -89.29 11.09 19.94 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.195 -0.941 . . . . 0.0 109.436 179.568 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -69.7 118.07 12.09 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.163 -0.961 . . . . 0.0 109.41 -179.617 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -177.68 -154.48 12.35 Favored Glycine 0 N--CA 1.487 2.062 0 N-CA-C 108.883 -1.687 . . . . 0.0 108.883 -179.84 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 32.3 mmtp -81.11 113.7 19.46 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.178 -1.189 . . . . 0.0 109.157 179.769 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 139' ' ' HIS . . . . . 0.41 ' NE2' ' O ' ' A' ' 135' ' ' LEU . 99.2 m-70 -137.17 154.83 50.14 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.367 -0.833 . . . . 0.0 109.348 -179.964 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 44.2 t -122.75 134.41 66.02 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.341 -0.849 . . . . 0.0 109.641 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 61.8 t -110.78 130.48 64.08 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 121.419 -0.801 . . . . 0.0 108.881 179.566 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 38.8 p90 -123.37 -4.88 8.31 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.19 -0.944 . . . . 0.0 110.704 -179.478 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -162.59 174.35 38.96 Favored Glycine 0 N--CA 1.493 2.463 0 C-N-CA 119.152 -1.499 . . . . 0.0 110.498 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 51.7 tt0 -138.96 159.98 40.84 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.604 -0.939 . . . . 0.0 109.169 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 79.7 t -97.31 129.39 47.46 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.188 0 O-C-N 121.105 -0.997 . . . . 0.0 109.521 -179.827 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 19.0 m -106.35 -32.19 2.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.376 -0.828 . . . . 0.0 109.425 179.638 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -145.5 173.15 12.27 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.253 -0.904 . . . . 0.0 109.505 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 98.35 1.93 57.9 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 109.89 -1.284 . . . . 0.0 109.89 179.65 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 149' ' ' MET . . . . . 0.502 ' O ' HG12 ' A' ' 152' ' ' VAL . 65.0 mtt -61.2 -32.35 72.1 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.127 -1.219 . . . . 0.0 109.782 179.979 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 150' ' ' ASP . . . . . 0.548 ' OD1' ' N ' ' A' ' 151' ' ' VAL . 33.8 p-10 -66.37 -38.73 88.22 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.811 -1.181 . . . . 0.0 110.211 -179.512 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.548 ' N ' ' OD1' ' A' ' 150' ' ' ASP . 6.3 p -85.25 -33.71 8.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.712 0 O-C-N 121.036 -1.04 . . . . 0.0 110.339 -179.545 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 152' ' ' VAL . . . . . 0.502 HG12 ' O ' ' A' ' 149' ' ' MET . 1.1 p -52.77 -41.09 37.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 120.952 -1.092 . . . . 0.0 108.832 -179.488 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 153' ' ' LYS . . . . . 0.442 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 99.4 mttt -64.66 -34.64 78.76 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.252 -0.905 . . . . 0.0 109.144 179.122 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -61.19 -35.38 76.99 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.375 -0.828 . . . . 0.0 109.95 -179.537 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 87.5 mt -71.33 -35.76 58.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.049 -1.032 . . . . 0.0 109.976 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 156' ' ' GLU . . . . . 0.408 ' OE2' ' OG1' ' A' ' 129' ' ' THR . 97.9 mt-10 -76.97 -40.69 45.98 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.079 -1.013 . . . . 0.0 111.474 -178.937 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 18.4 pttp -60.11 -36.44 77.45 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.592 -1.318 . . . . 0.0 109.208 -179.2 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 30.4 m -80.95 -12.88 12.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.163 -0.961 . . . . 0.0 108.562 178.91 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -78.89 175.8 54.89 Favored Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.707 -1.357 . . . . 0.0 109.707 -179.886 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 25.1 t -157.69 166.79 31.88 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.35 -1.088 . . . . 0.0 109.325 -179.859 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 86.9 p -57.67 -26.05 61.12 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.201 -0.937 . . . . 0.0 108.899 179.745 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 26.7 m -57.44 -30.33 64.92 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.444 -0.785 . . . . 0.0 109.394 179.661 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 95.04 15.62 44.39 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.714 -1.354 . . . . 0.0 109.714 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 77.8 ttt-85 -122.93 141.39 51.96 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.341 -1.093 . . . . 0.0 109.495 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 165' ' ' THR . . . . . 0.479 HG22 HG21 ' A' ' 69' ' ' VAL . 42.7 p -80.91 143.53 32.6 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.188 -0.945 . . . . 0.0 109.618 179.903 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -68.72 -38.34 80.13 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.262 -0.899 . . . . 0.0 109.185 179.559 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 67.2 mttm -107.75 159.75 16.25 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.485 -0.759 . . . . 0.0 109.325 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -73.39 131.7 42.15 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.18 -0.95 . . . . 0.0 109.227 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 40.2 t -121.2 125.0 73.3 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.341 -0.849 . . . . 0.0 109.431 179.915 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 41.6 t -147.06 150.81 14.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.343 -0.848 . . . . 0.0 109.219 179.861 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -88.04 120.37 36.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.233 -0.917 . . . . 0.0 109.625 -179.619 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 172' ' ' GLU . . . . . 0.422 ' OE2' ' OG ' ' A' ' 17' ' ' SER . 97.1 mt-10 -65.28 -26.47 68.09 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.413 -0.804 . . . . 0.0 109.324 179.479 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 173' ' ' ASP . . . . . 0.47 ' OD1' ' N ' ' A' ' 174' ' ' CYS . 47.2 t0 -174.8 169.26 3.53 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.201 -0.937 . . . . 0.0 110.412 -179.532 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 174' ' ' CYS . . . . . 0.47 ' N ' ' OD1' ' A' ' 173' ' ' ASP . 31.4 p -150.38 150.83 31.93 Favored 'General case' 0 N--CA 1.491 1.585 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 179.349 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -175.98 -176.49 44.23 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.823 -1.311 . . . . 0.0 109.823 -179.894 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 54.9 tt0 -104.43 119.67 39.49 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.415 -1.05 . . . . 0.0 109.713 -179.823 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 30.9 tp -62.71 -37.93 88.46 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.129 -0.982 . . . . 0.0 109.154 179.434 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 8.0 t . . . . . 0 N--CA 1.49 1.55 0 CA-C-O 118.017 -0.992 . . . . 0.0 109.433 -179.958 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.528 4.774 0 N-CA-C 119.35 2.5 . . . . 0.0 119.35 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 91.5 p -62.84 -23.11 67.12 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.275 -1.133 . . . . 0.0 109.452 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 55.6 p90 -134.25 136.34 43.55 Favored 'General case' 0 N--CA 1.486 1.332 0 O-C-N 121.263 -0.898 . . . . 0.0 108.973 179.569 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 43.4 m -61.84 -40.5 95.53 Favored 'General case' 0 C--N 1.297 -1.689 0 O-C-N 121.563 -0.711 . . . . 0.0 109.928 -179.832 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 90.51 8.04 66.36 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.514 -1.435 . . . . 0.0 109.514 -179.841 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 47.1 m -62.49 155.3 26.03 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.194 -1.18 . . . . 0.0 109.333 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' MET . . . . . 0.606 ' N ' ' SD ' ' A' ' 7' ' ' MET . 0.1 OUTLIER -64.62 150.31 94.17 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.231 -0.918 . . . . 0.0 109.273 -179.914 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -70.52 169.18 20.51 Favored 'Trans proline' 0 C--N 1.309 -1.547 0 C-N-CA 122.742 2.295 . . . . 0.0 112.1 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 7.7 t-20 -63.89 139.01 97.56 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.331 -0.856 . . . . 0.0 109.027 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_endo -71.14 139.0 34.61 Favored 'Trans proline' 0 N--CA 1.494 1.502 0 C-N-CA 122.406 2.071 . . . . 0.0 112.493 -179.778 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.571 ' H ' ' HG ' ' A' ' 178' ' ' SER . 86.6 mtt180 -131.65 134.04 45.56 Favored 'General case' 0 N--CA 1.493 1.697 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 179.119 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 12.6 p -136.4 144.52 32.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.412 -0.805 . . . . 0.0 109.353 -179.783 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 48.8 p90 -135.28 151.89 50.99 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.337 -0.852 . . . . 0.0 109.348 179.877 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 90.4 m-85 -119.39 127.52 53.21 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.451 -0.781 . . . . 0.0 110.122 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.4 t0 -92.54 120.31 32.87 Favored 'General case' 0 N--CA 1.493 1.678 0 N-CA-C 108.347 -0.982 . . . . 0.0 108.347 178.86 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 77.2 mtp -122.09 151.12 41.23 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.991 -1.068 . . . . 0.0 110.698 -179.065 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 93.8 p -145.12 160.63 41.11 Favored 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 108.744 -0.836 . . . . 0.0 108.744 179.671 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.419 ' O ' ' C ' ' A' ' 19' ' ' GLY . 18.9 m -128.71 143.55 40.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.274 -0.891 . . . . 0.0 109.488 179.963 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.419 ' C ' ' O ' ' A' ' 18' ' ' VAL . . . 42.11 -103.86 0.04 OUTLIER Glycine 0 N--CA 1.492 2.423 0 N-CA-C 109.692 -1.363 . . . . 0.0 109.692 179.925 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -135.48 22.56 3.51 Favored Glycine 0 N--CA 1.494 2.526 0 N-CA-C 109.32 -1.512 . . . . 0.0 109.32 179.685 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 62.1 mt-30 -127.41 88.61 53.45 Favored Pre-proline 0 N--CA 1.494 1.741 0 O-C-N 121.448 -1.031 . . . . 0.0 109.264 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_exo -48.63 133.17 26.43 Favored 'Trans proline' 0 C--N 1.309 -1.511 0 C-N-CA 122.505 2.137 . . . . 0.0 112.297 -179.637 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -82.47 -64.06 1.25 Allowed 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.405 -0.81 . . . . 0.0 109.772 -179.89 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 175.15 -167.56 39.7 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 -179.858 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 94.5 mtt-85 -106.27 150.23 26.13 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.447 -1.031 . . . . 0.0 109.186 179.886 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 79.6 mt -119.26 120.73 64.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 179.378 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 34.8 t -112.99 132.38 61.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.446 -0.784 . . . . 0.0 108.911 -179.909 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 70.6 mtm -127.45 156.68 41.74 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.323 -0.86 . . . . 0.0 109.679 -179.361 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -99.62 135.51 40.94 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.284 -0.885 . . . . 0.0 109.795 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -108.89 128.35 54.84 Favored 'General case' 0 N--CA 1.492 1.65 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 179.388 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -95.19 118.23 31.61 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.143 -0.973 . . . . 0.0 108.992 179.778 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -80.43 -42.47 22.64 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 121.473 -0.767 . . . . 0.0 109.839 -179.812 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 56.8 t0 -65.52 -46.26 80.28 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.237 -0.914 . . . . 0.0 110.435 -179.365 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 24.8 m -66.17 -45.73 79.88 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.002 -1.061 . . . . 0.0 109.854 -179.38 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.432 ' O ' ' OG1' ' A' ' 35' ' ' THR . 13.2 p -145.33 81.84 10.08 Favored Pre-proline 0 N--CA 1.493 1.711 0 O-C-N 121.317 -0.864 . . . . 0.0 109.332 -179.72 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -70.33 -47.07 0.82 Allowed 'Trans proline' 0 C--N 1.307 -1.615 0 C-N-CA 122.1 1.867 . . . . 0.0 112.215 -179.48 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 22.9 mmt85 -63.04 -39.75 95.68 Favored 'General case' 0 N--CA 1.487 1.409 0 O-C-N 121.1 -1.0 . . . . 0.0 109.581 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.407 HG23 ' SD ' ' A' ' 113' ' ' MET . 37.9 m -65.16 -40.92 95.01 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.224 -0.922 . . . . 0.0 110.069 -179.736 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -60.69 -31.8 71.05 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.312 -0.867 . . . . 0.0 109.278 -179.699 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -67.09 -38.44 85.7 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.335 -0.853 . . . . 0.0 109.758 -179.927 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 49.1 t30 -58.48 -42.52 87.72 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.264 -0.898 . . . . 0.0 109.932 -179.644 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.507 ' O ' ' SG ' ' A' ' 46' ' ' CYS . 97.6 m-85 -82.89 -45.72 13.87 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.061 -1.024 . . . . 0.0 109.859 -179.925 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.773 ' HE ' HE22 ' A' ' 176' ' ' GLN . 74.0 ttt-85 -58.73 -41.1 85.62 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.296 -0.878 . . . . 0.0 110.544 -179.342 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -71.77 -53.81 12.21 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.028 -1.045 . . . . 0.0 110.553 -179.019 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.473 ' N ' ' CD2' ' A' ' 45' ' ' LEU . 3.8 mm? -63.32 -38.9 92.95 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.948 -1.095 . . . . 0.0 109.776 -179.631 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 46' ' ' CYS . . . . . 0.507 ' SG ' ' O ' ' A' ' 42' ' ' PHE . 95.6 m -65.83 -55.65 16.02 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.108 -0.995 . . . . 0.0 109.138 179.864 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 50.7 m -66.13 -36.81 84.13 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.373 -0.83 . . . . 0.0 109.279 179.468 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 85.31 30.02 26.13 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 110.269 -1.133 . . . . 0.0 110.269 179.565 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -62.2 -38.71 90.15 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.05 -1.265 . . . . 0.0 109.359 179.83 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 59.7 mmtt -62.5 -31.27 72.0 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.386 -0.821 . . . . 0.0 109.686 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 74.34 -113.95 4.29 Favored Glycine 0 N--CA 1.488 2.125 0 N-CA-C 108.854 -1.698 . . . . 0.0 108.854 -179.37 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.615 HG23 ' HA ' ' A' ' 58' ' ' PRO . 87.4 m -127.61 143.42 51.17 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.339 -1.094 . . . . 0.0 109.749 179.624 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -64.99 137.2 38.31 Favored Glycine 0 N--CA 1.489 2.168 0 N-CA-C 109.221 -1.551 . . . . 0.0 109.221 179.685 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 81.4 mtm180 -59.1 -34.93 72.59 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.205 -1.173 . . . . 0.0 109.913 -179.7 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 86.1 p -61.95 -24.41 66.98 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.174 -0.954 . . . . 0.0 109.782 -179.746 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 112.45 89.6 1.84 Allowed Glycine 0 N--CA 1.495 2.569 0 N-CA-C 109.102 -1.599 . . . . 0.0 109.102 -179.682 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' LYS . . . . . 0.529 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 22.8 tttp -174.56 79.56 0.34 Allowed Pre-proline 0 N--CA 1.488 1.465 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 -179.677 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.615 ' HA ' HG23 ' A' ' 52' ' ' THR . 75.5 Cg_exo -50.47 131.99 33.92 Favored 'Trans proline' 0 C--N 1.304 -1.793 0 C-N-CA 122.892 2.394 . . . . 0.0 113.197 -178.779 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.529 ' CD1' ' O ' ' A' ' 57' ' ' LYS . 8.9 mp -104.49 122.32 45.3 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 108.782 -0.821 . . . . 0.0 108.782 179.325 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 16.8 p-80 -169.7 93.28 0.25 Allowed 'General case' 0 N--CA 1.486 1.375 0 O-C-N 120.971 -1.081 . . . . 0.0 110.272 -179.684 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 8.0 m-85 -64.29 -29.39 70.48 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.182 -0.949 . . . . 0.0 109.066 179.149 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 8.8 ptmm? -55.3 160.3 2.3 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.351 -0.843 . . . . 0.0 109.627 179.842 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' ASP . . . . . 0.449 ' N ' ' O ' ' A' ' 171' ' ' VAL . 85.0 m-20 54.62 48.01 21.31 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.498 -0.752 . . . . 0.0 109.416 -179.842 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.577 ' H ' ' CG1' ' A' ' 171' ' ' VAL . 89.6 p -126.46 155.07 42.83 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.277 -0.889 . . . . 0.0 109.134 179.754 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 32.1 t -106.48 141.98 36.9 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.335 -0.853 . . . . 0.0 109.056 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -69.61 143.43 53.28 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.343 -0.848 . . . . 0.0 108.892 -179.927 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 57.2 t-80 -57.33 -51.13 70.62 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.218 -0.927 . . . . 0.0 110.405 -178.851 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 15.6 ptm180 -171.0 163.68 7.45 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 120.896 -1.127 . . . . 0.0 109.697 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.405 HG11 HG22 ' A' ' 155' ' ' ILE . 0.1 OUTLIER -136.47 129.28 45.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.462 -0.774 . . . . 0.0 109.128 179.696 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 70.3 mt -128.92 109.14 18.35 Favored Pre-proline 0 N--CA 1.493 1.695 0 O-C-N 121.543 -0.723 . . . . 0.0 109.631 179.865 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -52.45 147.53 29.28 Favored 'Trans proline' 0 C--N 1.31 -1.482 0 C-N-CA 122.357 2.038 . . . . 0.0 112.62 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 87.12 -59.53 4.48 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 110.156 -1.177 . . . . 0.0 110.156 179.373 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 67.8 m-85 -70.21 -73.48 0.16 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.239 -1.154 . . . . 0.0 110.061 -179.493 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 74' ' ' MET . . . . . 0.528 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 13.4 ptt? 178.45 -165.66 0.05 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.225 -0.922 . . . . 0.0 109.618 -179.918 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -121.22 124.13 43.92 Favored 'General case' 0 N--CA 1.494 1.764 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 179.614 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 63.6 tt0 -102.44 124.49 48.09 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.231 -0.918 . . . . 0.0 109.827 -179.663 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -86.26 -173.88 49.34 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.259 -1.536 . . . . 0.0 109.259 179.457 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -136.83 154.5 22.21 Favored Glycine 0 N--CA 1.493 2.477 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 88.0 m-20 -83.77 143.81 29.73 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.432 -1.04 . . . . 0.0 109.642 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 41.3 p90 -65.43 -23.61 66.98 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.283 -0.886 . . . . 0.0 109.624 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.454 ' OG1' ' N ' ' A' ' 88' ' ' GLY . 52.7 p -64.2 -31.54 72.78 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.145 -0.972 . . . . 0.0 109.481 -179.891 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 82' ' ' ALA . . . . . 0.432 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 178.02 -54.08 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.403 -0.811 . . . . 0.0 109.334 179.855 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 96.58 -11.21 66.77 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 80.3 m-20 -88.66 2.77 52.63 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.186 -1.185 . . . . 0.0 109.315 179.795 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 93.66 -5.16 73.3 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.395 -1.482 . . . . 0.0 109.395 -179.868 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 61.7 p -74.47 -19.02 60.54 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.394 -1.062 . . . . 0.0 109.517 179.87 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -131.86 -132.75 3.38 Favored Glycine 0 N--CA 1.494 2.519 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.454 ' N ' ' OG1' ' A' ' 81' ' ' THR . . . 74.57 47.28 16.25 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.293 -1.523 . . . . 0.0 109.293 -179.915 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -93.3 135.36 34.59 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.295 -1.121 . . . . 0.0 109.753 -179.508 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 50.0 m -70.72 158.08 36.91 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.358 -0.839 . . . . 0.0 109.508 179.84 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 24.9 pt -65.94 -31.15 52.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.24 -0.912 . . . . 0.0 109.834 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 59.9 m-85 -64.0 -36.33 83.63 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.256 -0.902 . . . . 0.0 109.591 -179.746 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 82.79 10.16 83.52 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.321 -1.512 . . . . 0.0 109.321 -179.934 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -148.28 157.25 43.38 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.282 -1.128 . . . . 0.0 109.372 -179.915 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 62.0 mttp -86.57 153.03 22.12 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.22 -0.925 . . . . 0.0 109.466 179.912 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 36.9 p90 -129.09 157.87 40.53 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.425 -0.797 . . . . 0.0 109.329 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -65.68 143.98 57.21 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.294 -0.879 . . . . 0.0 110.052 -179.337 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.574 ' CG ' ' H ' ' A' ' 119' ' ' ASN . 88.5 m-20 -67.01 148.0 52.51 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.35 -0.844 . . . . 0.0 109.617 179.845 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -100.14 161.91 13.3 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.345 -0.847 . . . . 0.0 109.268 179.844 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 81.4 m-20 -62.6 163.17 9.37 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.369 -0.832 . . . . 0.0 109.405 -179.846 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 101' ' ' PHE . . . . . 0.582 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 22.0 p90 -130.22 79.43 1.9 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.431 -0.793 . . . . 0.0 109.52 -179.898 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 87.8 mt -58.97 -33.94 51.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.183 -0.948 . . . . 0.0 109.376 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 67.2 mttm -83.51 143.18 30.38 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.187 -0.946 . . . . 0.0 109.386 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 104' ' ' LYS . . . . . 0.541 ' O ' ' N ' ' A' ' 106' ' ' THR . 50.0 tttp -127.35 158.24 37.79 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.406 -0.809 . . . . 0.0 109.331 -179.924 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 105' ' ' HIS . . . . . 0.455 ' CE1' ' O ' ' A' ' 107' ' ' GLY . 78.6 t60 -61.01 76.5 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.341 -0.849 . . . . 0.0 109.252 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 106' ' ' THR . . . . . 0.541 ' N ' ' O ' ' A' ' 104' ' ' LYS . 70.5 p -73.52 -27.15 61.21 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.199 -0.938 . . . . 0.0 109.878 -179.731 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.455 ' O ' ' CE1' ' A' ' 105' ' ' HIS . . . -153.75 177.12 31.43 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.561 -1.415 . . . . 0.0 109.561 -179.763 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -70.4 156.65 61.21 Favored 'Trans proline' 0 C--N 1.305 -1.724 0 C-N-CA 122.774 2.316 . . . . 0.0 112.131 179.881 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 86.07 43.59 6.27 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 110.095 -1.202 . . . . 0.0 110.095 179.728 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 45.4 mm -117.13 136.13 55.27 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 O-C-N 121.263 -1.139 . . . . 0.0 109.386 179.593 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.71 ' N ' HD22 ' A' ' 111' ' ' LEU . 2.9 mm? -88.65 137.36 32.39 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.21 -0.931 . . . . 0.0 109.413 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 112' ' ' SER . . . . . 0.457 ' OG ' ' O ' ' A' ' 140' ' ' VAL . 46.2 t -146.22 141.22 27.19 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.246 -0.909 . . . . 0.0 109.582 179.804 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 113' ' ' MET . . . . . 0.407 ' SD ' HG23 ' A' ' 38' ' ' THR . 88.5 mtp -88.51 135.59 33.41 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.259 -0.9 . . . . 0.0 109.416 179.67 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 114' ' ' ALA . . . . . 0.456 ' O ' ' OD1' ' A' ' 115' ' ' ASN . . . -73.73 137.54 44.07 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.202 -0.936 . . . . 0.0 109.585 -179.946 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 115' ' ' ASN . . . . . 0.456 ' OD1' ' O ' ' A' ' 114' ' ' ALA . 76.3 m-20 -146.58 114.17 6.39 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.203 -0.936 . . . . 0.0 108.945 179.535 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -69.15 -31.07 69.49 Favored 'General case' 0 C--N 1.297 -1.697 0 O-C-N 121.409 -0.807 . . . . 0.0 109.697 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -139.9 167.55 25.34 Favored Glycine 0 N--CA 1.494 2.543 0 N-CA-C 109.396 -1.482 . . . . 0.0 109.396 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -69.08 154.11 70.97 Favored 'Trans proline' 0 C--N 1.307 -1.653 0 C-N-CA 122.701 2.268 . . . . 0.0 111.849 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 119' ' ' ASN . . . . . 0.574 ' H ' ' CG ' ' A' ' 98' ' ' ASP . 80.3 m-20 53.49 43.22 31.58 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.436 -0.79 . . . . 0.0 109.317 -179.939 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 91.8 m -136.37 128.41 29.59 Favored 'General case' 0 C--N 1.305 -1.34 0 O-C-N 121.445 -0.784 . . . . 0.0 109.041 179.84 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 43.4 p-10 -80.76 168.11 19.19 Favored 'General case' 0 C--N 1.298 -1.668 0 O-C-N 121.377 -0.827 . . . . 0.0 109.311 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -159.79 105.94 0.28 Allowed Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.667 -1.373 . . . . 0.0 109.667 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 23.9 t -59.12 -32.61 69.99 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.252 -1.146 . . . . 0.0 109.389 179.85 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.6 mt-30 -71.23 142.96 50.58 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.214 -0.928 . . . . 0.0 109.575 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 48.5 p90 -140.46 162.27 35.73 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.342 -0.849 . . . . 0.0 109.322 179.866 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.528 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 48.2 p90 -138.43 158.56 44.04 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.295 -0.878 . . . . 0.0 109.608 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 60.3 mt -120.34 132.29 70.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.411 -0.806 . . . . 0.0 109.208 179.85 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 128' ' ' CYS . . . . . 0.432 ' SG ' ' O ' ' A' ' 130' ' ' ALA . 4.4 t -100.99 116.8 33.69 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.135 -0.978 . . . . 0.0 109.389 179.886 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 129' ' ' THR . . . . . 0.421 ' OG1' ' OE1' ' A' ' 156' ' ' GLU . 51.0 p -91.45 0.78 57.47 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.301 -0.875 . . . . 0.0 109.622 -179.842 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 130' ' ' ALA . . . . . 0.432 ' O ' ' SG ' ' A' ' 128' ' ' CYS . . . -151.25 155.91 39.77 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.188 -0.945 . . . . 0.0 109.601 -179.811 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 77.8 tttt -69.33 140.56 54.32 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.186 -0.946 . . . . 0.0 109.261 179.832 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 17.0 p -113.19 159.68 19.04 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.349 -0.844 . . . . 0.0 109.506 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -154.57 -50.46 0.09 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.397 -0.814 . . . . 0.0 109.282 -179.876 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 134' ' ' TRP . . . . . 0.631 ' CD1' ' N ' ' A' ' 135' ' ' LEU . 35.3 p90 -56.43 -38.8 72.07 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.259 -0.901 . . . . 0.0 109.385 179.836 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 135' ' ' LEU . . . . . 0.631 ' N ' ' CD1' ' A' ' 134' ' ' TRP . 44.2 tp -60.01 -36.5 77.35 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.428 -0.795 . . . . 0.0 109.505 -179.782 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 59.4 t0 47.26 78.75 0.07 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.337 -0.852 . . . . 0.0 109.798 179.771 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -144.74 134.92 5.84 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.11 -1.596 . . . . 0.0 109.11 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 67.6 mmtt -82.96 135.06 35.01 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.261 -1.141 . . . . 0.0 109.42 -179.754 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 96.4 m-70 -136.02 175.5 9.54 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.414 -0.804 . . . . 0.0 109.376 -179.878 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.457 ' O ' ' OG ' ' A' ' 112' ' ' SER . 20.1 m -124.0 153.77 30.34 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 121.466 -0.771 . . . . 0.0 108.996 179.702 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 58.5 t -118.39 128.2 75.39 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.292 -0.88 . . . . 0.0 109.961 -179.607 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 142' ' ' PHE . . . . . 0.455 ' CE2' ' CE2' ' A' ' 42' ' ' PHE . 40.6 p90 -117.59 1.61 12.27 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.474 -0.766 . . . . 0.0 109.561 179.412 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -169.29 177.38 42.97 Favored Glycine 0 N--CA 1.495 2.593 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 179.64 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 144' ' ' GLN . . . . . 0.432 ' CG ' ' N ' ' A' ' 145' ' ' VAL . 48.0 tt0 -143.76 161.62 38.12 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.349 -1.089 . . . . 0.0 109.798 -179.643 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 145' ' ' VAL . . . . . 0.432 ' N ' ' CG ' ' A' ' 144' ' ' GLN . 79.9 t -100.03 135.59 35.04 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.112 0 O-C-N 121.283 -0.886 . . . . 0.0 109.653 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 6.8 m -118.8 -33.69 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.275 -0.89 . . . . 0.0 109.573 179.672 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -138.37 166.03 25.27 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.237 -0.915 . . . . 0.0 109.713 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 94.47 9.98 58.49 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.845 -1.302 . . . . 0.0 109.845 179.745 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 149' ' ' MET . . . . . 0.446 ' O ' HG12 ' A' ' 152' ' ' VAL . 88.7 mtp -59.84 -34.07 72.61 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.192 -1.181 . . . . 0.0 109.765 -179.935 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 89.0 m-20 -64.61 -39.68 94.15 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.896 -1.127 . . . . 0.0 109.846 -179.74 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 5.5 p -85.59 -33.27 7.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.132 -0.98 . . . . 0.0 110.522 -179.423 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 152' ' ' VAL . . . . . 0.446 HG12 ' O ' ' A' ' 149' ' ' MET . 0.7 OUTLIER -55.29 -38.77 49.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 120.953 -1.092 . . . . 0.0 109.376 -179.366 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 153' ' ' LYS . . . . . 0.412 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 50.7 pttt -81.16 -20.97 40.13 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.136 -0.978 . . . . 0.0 109.385 179.683 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -64.39 -39.82 94.6 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.252 -0.905 . . . . 0.0 109.579 -179.916 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.405 HG22 HG11 ' A' ' 69' ' ' VAL . 65.2 mt -72.05 -35.68 54.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.304 -0.873 . . . . 0.0 109.541 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 156' ' ' GLU . . . . . 0.421 ' OE1' ' OG1' ' A' ' 129' ' ' THR . 84.7 tt0 -76.26 -42.27 46.22 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.257 -0.902 . . . . 0.0 111.447 -178.772 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 16.4 pttp -61.59 -33.12 73.34 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 120.639 -1.288 . . . . 0.0 110.241 -178.56 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 35.2 m -77.02 -17.84 14.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.018 -1.051 . . . . 0.0 109.683 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -72.87 172.77 48.77 Favored Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.965 -1.254 . . . . 0.0 109.965 -179.655 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 85.0 p -150.09 170.07 19.76 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.476 -1.014 . . . . 0.0 109.381 -179.739 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 23.2 m -55.42 -34.72 64.67 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.177 -0.952 . . . . 0.0 108.965 179.705 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 86.5 p -62.57 -26.34 68.54 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.373 -0.83 . . . . 0.0 109.189 179.674 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 97.2 3.17 58.94 Favored Glycine 0 N--CA 1.494 2.529 0 N-CA-C 109.674 -1.37 . . . . 0.0 109.674 179.898 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 77.8 ttt180 -99.99 144.56 28.9 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.306 -1.114 . . . . 0.0 109.205 179.818 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 165' ' ' THR . . . . . . . . . . . . . 65.5 p -104.71 152.1 22.93 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.354 -0.841 . . . . 0.0 109.657 -179.877 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -68.47 -37.0 79.77 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.369 -0.832 . . . . 0.0 109.627 179.923 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 47.8 mtmt -112.41 157.82 20.58 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.53 -0.731 . . . . 0.0 109.628 -179.793 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 91.3 mttt -76.54 146.49 38.34 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.333 -0.854 . . . . 0.0 109.306 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 169' ' ' VAL . . . . . 0.475 ' O ' HG23 ' A' ' 169' ' ' VAL . 32.6 m -128.75 125.2 62.86 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 O-C-N 121.326 -0.859 . . . . 0.0 109.596 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 48.5 t -144.88 138.23 22.21 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.387 -0.821 . . . . 0.0 109.302 179.589 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.577 ' CG1' ' H ' ' A' ' 64' ' ' SER . 2.5 p -80.41 119.65 30.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 120.99 -1.069 . . . . 0.0 108.999 179.717 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -71.03 -44.41 65.88 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.133 -0.98 . . . . 0.0 111.177 -178.535 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 173' ' ' ASP . . . . . 0.46 ' OD1' ' N ' ' A' ' 174' ' ' CYS . 47.2 t0 -170.15 164.64 9.2 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.754 -1.216 . . . . 0.0 110.542 -179.325 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 174' ' ' CYS . . . . . 0.46 ' N ' ' OD1' ' A' ' 173' ' ' ASP . 1.4 p -151.63 151.86 32.07 Favored 'General case' 0 N--CA 1.49 1.573 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 179.484 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -160.75 178.37 36.77 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 176' ' ' GLN . . . . . 0.773 HE22 ' HE ' ' A' ' 43' ' ' ARG . 62.6 tt0 -99.05 113.96 26.42 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.326 -1.102 . . . . 0.0 109.713 -179.821 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 29.1 tp -63.37 -36.79 84.89 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.216 -0.928 . . . . 0.0 109.022 179.418 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 178' ' ' SER . . . . . 0.571 ' HG ' ' H ' ' A' ' 11' ' ' ARG . 11.8 p . . . . . 0 N--CA 1.491 1.62 0 CA-C-O 118.001 -0.999 . . . . 0.0 109.495 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.528 4.812 0 N-CA-C 119.429 2.532 . . . . 0.0 119.429 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 86.6 p -61.87 -27.12 68.57 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.203 -1.175 . . . . 0.0 109.445 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 68.1 t80 -107.53 120.5 42.36 Favored 'General case' 0 N--CA 1.484 1.268 0 O-C-N 121.399 -0.813 . . . . 0.0 108.958 179.689 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 18.1 p -124.23 162.41 23.74 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.663 -0.648 . . . . 0.0 109.343 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -176.84 -175.23 43.99 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 54.4 p -69.22 159.56 32.8 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.207 -1.172 . . . . 0.0 109.369 179.895 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 37.4 mtt -148.16 153.15 40.97 Favored Pre-proline 0 N--CA 1.492 1.641 0 O-C-N 121.241 -0.912 . . . . 0.0 109.463 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.44 ' O ' ' CB ' ' A' ' 9' ' ' ASN . 36.1 Cg_endo -66.83 -179.17 1.55 Allowed 'Trans proline' 0 C--N 1.309 -1.52 0 C-N-CA 122.715 2.277 . . . . 0.0 111.903 179.679 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.44 ' CB ' ' O ' ' A' ' 8' ' ' PRO . 2.5 m-20 73.99 78.23 0.19 Allowed Pre-proline 0 N--CA 1.492 1.661 0 O-C-N 121.408 -0.807 . . . . 0.0 109.624 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 93.3 Cg_endo -82.23 90.53 1.09 Allowed 'Trans proline' 0 C--N 1.308 -1.575 0 C-N-CA 122.898 2.399 . . . . 0.0 111.845 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 73.1 mtm180 -61.68 137.91 58.28 Favored 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.289 -0.882 . . . . 0.0 109.849 -179.595 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 12.7 p -138.29 143.53 32.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 179.497 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 45.1 p90 -141.54 153.96 45.19 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.179 -0.95 . . . . 0.0 110.107 -179.513 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 86.0 m-85 -123.73 140.25 53.18 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 179.162 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.5 t0 -86.88 116.31 24.87 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.053 -1.029 . . . . 0.0 109.259 179.768 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' MET . . . . . 0.577 ' SD ' HD12 ' A' ' 26' ' ' ILE . 80.4 mtp -103.96 147.45 27.34 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.291 -0.881 . . . . 0.0 110.19 -179.856 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 97.1 p -143.94 164.39 30.72 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 108.55 -0.907 . . . . 0.0 108.55 179.414 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 12.9 p -128.3 139.03 53.0 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.238 -0.914 . . . . 0.0 109.676 -179.752 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 57.02 -107.33 0.92 Allowed Glycine 0 N--CA 1.488 2.129 0 N-CA-C 109.364 -1.494 . . . . 0.0 109.364 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -136.04 37.15 1.93 Allowed Glycine 0 N--CA 1.493 2.487 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 6.5 pt20 -147.88 126.99 6.3 Favored Pre-proline 0 N--CA 1.492 1.649 0 O-C-N 121.264 -1.139 . . . . 0.0 109.349 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_exo -47.39 139.88 16.29 Favored 'Trans proline' 0 N--CA 1.493 1.455 0 C-N-CA 122.139 1.893 . . . . 0.0 112.17 179.74 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -101.49 -61.31 1.39 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.311 -0.868 . . . . 0.0 109.483 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -178.19 -170.3 40.16 Favored Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.409 -1.476 . . . . 0.0 109.409 -179.871 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 97.5 mtt180 -118.04 142.33 47.5 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.374 -1.074 . . . . 0.0 109.803 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.577 HD12 ' SD ' ' A' ' 16' ' ' MET . 70.1 mt -120.39 123.2 70.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 178.609 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 38.7 t -110.05 132.58 57.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.387 -0.82 . . . . 0.0 109.382 -179.535 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 76.2 mtm -114.79 149.32 37.16 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.591 -0.693 . . . . 0.0 109.381 -179.689 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.405 ' C ' HD22 ' A' ' 30' ' ' LEU . 84.3 tt0 -100.92 129.82 46.83 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.286 -0.884 . . . . 0.0 109.698 -179.668 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.408 ' N ' ' CD2' ' A' ' 30' ' ' LEU . 2.7 mm? -108.34 132.66 53.5 Favored 'General case' 0 N--CA 1.494 1.741 0 N-CA-C 108.909 -0.775 . . . . 0.0 108.909 179.588 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.483 ' O ' ' OG1' ' A' ' 35' ' ' THR . 92.7 m-85 -96.36 114.02 25.66 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.031 -1.043 . . . . 0.0 108.742 178.98 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -75.87 -42.43 49.4 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.155 -0.966 . . . . 0.0 109.869 -179.696 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.3 m-20 -66.63 -57.86 6.34 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.149 -0.97 . . . . 0.0 110.191 -179.356 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 54.9 m -67.03 -40.73 87.28 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.246 -0.909 . . . . 0.0 109.853 -179.759 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.546 HG21 ' HA ' ' A' ' 142' ' ' PHE . 81.7 p -130.04 77.5 76.42 Favored Pre-proline 0 N--CA 1.493 1.711 0 O-C-N 121.358 -0.839 . . . . 0.0 109.377 -179.64 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -72.84 -73.64 0.01 OUTLIER 'Trans proline' 0 N--CA 1.493 1.489 0 C-N-CA 122.676 2.251 . . . . 0.0 113.259 -179.38 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 80.1 mtt85 -59.37 -39.33 82.93 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.612 -0.68 . . . . 0.0 111.061 -178.624 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 42.8 m -61.66 -42.56 99.07 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.864 -1.148 . . . . 0.0 109.452 -179.848 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -63.9 -30.85 71.89 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.263 -0.898 . . . . 0.0 108.593 179.295 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 85.2 tt0 -66.25 -36.81 83.96 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.432 -0.792 . . . . 0.0 109.509 179.927 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' ASN . . . . . 0.49 ' O ' HD23 ' A' ' 45' ' ' LEU . 38.7 t30 -58.03 -41.2 82.69 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.229 -0.919 . . . . 0.0 109.514 -179.698 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.4 ' O ' ' SG ' ' A' ' 46' ' ' CYS . 98.0 m-85 -83.18 -44.99 14.43 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.058 -1.026 . . . . 0.0 109.661 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.712 ' NE ' HE22 ' A' ' 176' ' ' GLN . 77.5 ttt180 -59.32 -43.2 92.7 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.38 -0.825 . . . . 0.0 110.62 -179.216 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -68.1 -43.97 77.29 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.097 -1.002 . . . . 0.0 110.63 -178.834 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.49 HD23 ' O ' ' A' ' 41' ' ' ASN . 3.3 mm? -62.39 -39.05 91.95 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.971 -1.081 . . . . 0.0 109.593 -179.659 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 46' ' ' CYS . . . . . 0.4 ' SG ' ' O ' ' A' ' 42' ' ' PHE . 35.7 m -67.64 -47.89 68.27 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.146 -0.972 . . . . 0.0 109.391 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 48.3 p -74.49 -33.75 62.91 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.361 -0.837 . . . . 0.0 109.709 179.864 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 74.36 33.53 56.29 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 110.077 -1.209 . . . . 0.0 110.077 179.704 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -62.11 -37.55 85.54 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.07 -1.253 . . . . 0.0 109.61 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 72.2 mmtt -61.27 -35.32 76.96 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.262 -0.899 . . . . 0.0 109.578 -179.845 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 90.9 171.68 43.52 Favored Glycine 0 N--CA 1.488 2.113 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 -179.757 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.535 HG23 ' HA ' ' A' ' 58' ' ' PRO . 65.7 m -75.57 140.27 42.59 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.493 -1.004 . . . . 0.0 109.832 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -63.87 138.44 42.07 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.172 -1.571 . . . . 0.0 109.172 179.702 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 81.0 mmt-85 -59.37 -33.32 71.03 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.305 -1.115 . . . . 0.0 109.922 -179.656 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 86.1 p -60.91 -22.98 64.88 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.129 -0.982 . . . . 0.0 109.966 -179.532 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' GLY . . . . . 0.428 ' O ' ' CG ' ' A' ' 57' ' ' LYS . . . 110.03 77.55 0.95 Allowed Glycine 0 N--CA 1.496 2.636 0 N-CA-C 108.879 -1.688 . . . . 0.0 108.879 -179.586 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 57' ' ' LYS . . . . . 0.51 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 8.6 mtmp? -160.41 76.8 2.69 Favored Pre-proline 0 C--N 1.303 -1.455 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 -179.837 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.535 ' HA ' HG23 ' A' ' 52' ' ' THR . 81.8 Cg_exo -49.0 130.0 22.71 Favored 'Trans proline' 0 C--N 1.301 -1.945 0 C-N-CA 122.913 2.409 . . . . 0.0 112.614 -178.867 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.51 ' CD1' ' O ' ' A' ' 57' ' ' LYS . 8.3 mp -99.33 84.86 3.07 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.753 -0.592 . . . . 0.0 109.52 -179.697 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 99.2 m-70 -145.81 143.06 29.43 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.276 -0.89 . . . . 0.0 109.734 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 2.9 m-85 -102.33 17.03 24.48 Favored 'General case' 0 N--CA 1.493 1.724 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 179.317 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 91.7 mttt -81.01 158.84 25.01 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.303 -0.873 . . . . 0.0 109.885 -179.491 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' ASP . . . . . 0.455 ' H ' HG23 ' A' ' 171' ' ' VAL . 84.3 m-20 55.99 45.84 23.02 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.552 -0.717 . . . . 0.0 110.35 179.562 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.947 ' H ' HG22 ' A' ' 171' ' ' VAL . 66.7 p -98.74 153.35 18.8 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.143 -0.973 . . . . 0.0 108.616 179.077 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 28.6 t -122.3 145.06 48.6 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.37 -0.832 . . . . 0.0 109.664 -179.566 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 4.3 m-85 -72.7 129.04 37.31 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.314 -0.866 . . . . 0.0 109.034 179.782 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' HIS . . . . . 0.605 ' CD2' ' HE ' ' A' ' 68' ' ' ARG . 74.9 t60 -62.2 -49.94 73.79 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.358 -0.839 . . . . 0.0 110.116 -179.376 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.605 ' HE ' ' CD2' ' A' ' 67' ' ' HIS . 18.4 ptp180 -160.17 161.02 33.54 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.035 -1.041 . . . . 0.0 109.922 -179.982 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.556 HG21 HG22 ' A' ' 165' ' ' THR . 17.7 m -132.73 145.23 34.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.478 -0.764 . . . . 0.0 109.043 179.683 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 14.4 mt -148.17 129.5 7.2 Favored Pre-proline 0 N--CA 1.494 1.745 0 O-C-N 121.091 -1.005 . . . . 0.0 109.331 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -72.3 145.36 43.23 Favored 'Trans proline' 0 N--CA 1.492 1.393 0 C-N-CA 122.242 1.961 . . . . 0.0 112.379 179.849 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 82.25 -56.18 4.97 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.918 -1.273 . . . . 0.0 109.918 179.736 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -72.42 -86.16 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.117 -1.225 . . . . 0.0 109.874 -179.715 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 74' ' ' MET . . . . . 0.602 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 12.4 ptt? -179.52 -168.6 0.12 Allowed 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.236 -0.915 . . . . 0.0 109.759 -179.914 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -126.71 131.85 51.28 Favored 'General case' 0 N--CA 1.494 1.732 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.774 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 63.6 tt0 -103.07 126.4 50.23 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.151 -0.968 . . . . 0.0 109.908 -179.611 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -86.29 -174.03 49.38 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.242 -1.543 . . . . 0.0 109.242 179.548 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -138.35 154.9 23.19 Favored Glycine 0 N--CA 1.495 2.575 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.479 ' H ' ' HA2' ' A' ' 83' ' ' GLY . 88.4 m-20 -73.67 149.36 42.0 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.35 -1.088 . . . . 0.0 109.43 179.804 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 48.3 p90 -64.72 -26.33 68.32 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.161 -0.962 . . . . 0.0 109.437 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.504 ' O ' ' HB2' ' A' ' 82' ' ' ALA . 54.0 p -69.1 -29.08 67.09 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.165 -0.959 . . . . 0.0 109.462 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 82' ' ' ALA . . . . . 0.504 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 174.79 -55.11 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.386 -0.821 . . . . 0.0 109.254 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.479 ' HA2' ' H ' ' A' ' 79' ' ' ASP . . . 95.95 -6.5 66.9 Favored Glycine 0 N--CA 1.492 2.395 0 N-CA-C 109.658 -1.377 . . . . 0.0 109.658 179.878 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 78.5 m-20 -88.16 2.71 51.52 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.188 -1.184 . . . . 0.0 109.258 179.812 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 94.18 -6.61 72.32 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.321 -1.511 . . . . 0.0 109.321 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 59.0 p -75.15 -18.54 60.18 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.254 -1.145 . . . . 0.0 109.506 179.896 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -132.38 -128.47 2.92 Favored Glycine 0 N--CA 1.494 2.507 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.857 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 81.87 22.35 59.78 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.287 -1.525 . . . . 0.0 109.287 -179.856 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -57.96 145.43 35.91 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.339 -1.095 . . . . 0.0 109.669 -179.855 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 88.5 p -111.85 153.36 26.75 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.417 -0.802 . . . . 0.0 109.331 179.885 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 5.5 pt -63.56 -39.76 86.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.242 -0.911 . . . . 0.0 109.847 -179.76 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 3.1 m-30 -63.45 -38.87 92.8 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.089 -1.007 . . . . 0.0 109.459 179.758 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 76.7 19.03 78.39 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.282 -1.527 . . . . 0.0 109.282 -179.861 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -145.62 158.78 43.8 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.328 -1.101 . . . . 0.0 109.442 -179.853 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 62.9 mttp -85.01 153.62 22.64 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.336 -0.852 . . . . 0.0 109.709 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -100.68 133.12 45.61 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.41 -0.806 . . . . 0.0 109.1 179.775 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -83.47 119.73 25.04 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.162 -0.961 . . . . 0.0 109.684 -179.715 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 88.1 m-20 -75.55 143.09 42.61 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.283 -0.886 . . . . 0.0 109.259 179.638 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -153.29 -31.11 0.13 Allowed 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.174 -0.954 . . . . 0.0 110.05 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 84.6 m-20 -97.73 131.33 44.36 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.073 -1.017 . . . . 0.0 109.954 -179.579 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 101' ' ' PHE . . . . . 0.555 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 70.6 t80 -134.56 22.13 3.65 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 179.745 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 86.2 mt -56.77 -37.5 53.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.437 -0.79 . . . . 0.0 110.052 -179.512 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 56.6 mttm -83.34 138.27 33.6 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.008 -1.057 . . . . 0.0 109.891 -179.65 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 72.8 tttt -134.89 157.56 46.53 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.462 -0.774 . . . . 0.0 109.24 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 105' ' ' HIS . . . . . 0.542 ' O ' ' CG ' ' A' ' 105' ' ' HIS . 52.2 p-80 -68.02 83.5 0.22 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.12 -0.987 . . . . 0.0 109.271 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 57.0 p -77.04 -19.31 57.33 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.275 -0.891 . . . . 0.0 110.116 -179.54 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.423 ' O ' HG12 ' A' ' 110' ' ' ILE . . . -150.55 178.25 28.11 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 109.737 -1.345 . . . . 0.0 109.737 -179.654 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -74.9 156.72 43.46 Favored 'Trans proline' 0 C--N 1.306 -1.674 0 C-N-CA 123.027 2.484 . . . . 0.0 112.14 179.831 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 80.8 46.45 7.19 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 110.03 -1.228 . . . . 0.0 110.03 179.638 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.423 HG12 ' O ' ' A' ' 107' ' ' GLY . 32.9 mm -113.01 137.24 46.7 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.393 -1.063 . . . . 0.0 109.098 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.848 ' N ' HD22 ' A' ' 111' ' ' LEU . 2.3 mm? -89.88 131.81 35.61 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.261 -0.899 . . . . 0.0 109.836 -179.383 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 58.4 m -140.28 148.22 41.1 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.393 -0.817 . . . . 0.0 109.406 179.512 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 85.7 mtp -96.62 136.3 37.34 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.209 -0.932 . . . . 0.0 109.298 179.834 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 114' ' ' ALA . . . . . 0.4 ' O ' ' OD1' ' A' ' 115' ' ' ASN . . . -71.03 143.38 50.77 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.321 -0.862 . . . . 0.0 109.813 -179.872 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 115' ' ' ASN . . . . . 0.729 ' H ' ' CD2' ' A' ' 139' ' ' HIS . 56.9 m-20 -148.44 113.26 5.41 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.306 -0.871 . . . . 0.0 108.861 179.506 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -68.24 -31.99 71.86 Favored 'General case' 0 C--N 1.299 -1.623 0 O-C-N 121.333 -0.854 . . . . 0.0 109.655 -179.896 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -137.63 171.47 23.23 Favored Glycine 0 N--CA 1.492 2.414 0 N-CA-C 109.326 -1.51 . . . . 0.0 109.326 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -67.29 151.89 80.12 Favored 'Trans proline' 0 C--N 1.305 -1.728 0 C-N-CA 122.753 2.302 . . . . 0.0 111.732 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 75.2 m-20 52.57 44.09 30.43 Favored 'General case' 0 C--N 1.299 -1.601 0 O-C-N 121.459 -0.776 . . . . 0.0 109.294 -179.811 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 79.8 m -134.62 128.34 32.95 Favored 'General case' 0 C--N 1.304 -1.394 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 22.5 t30 -96.76 109.22 21.94 Favored 'General case' 0 C--N 1.297 -1.677 0 O-C-N 121.479 -0.763 . . . . 0.0 109.294 179.866 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -84.48 123.85 6.43 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.642 -1.383 . . . . 0.0 109.642 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 22.6 m -59.46 -33.29 71.11 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.347 -1.09 . . . . 0.0 109.542 179.806 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.8 mt-30 -75.96 144.12 41.17 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.233 -0.917 . . . . 0.0 109.926 -179.636 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 48.6 p90 -137.8 160.92 37.94 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.429 -0.794 . . . . 0.0 109.109 179.684 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.602 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 52.3 p90 -142.53 159.64 41.83 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.147 -0.971 . . . . 0.0 110.012 -179.759 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 4.6 mp -119.68 138.77 49.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.474 -0.766 . . . . 0.0 109.049 179.695 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 17.1 t -121.04 126.74 50.64 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.236 -0.915 . . . . 0.0 109.599 -179.909 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -106.91 15.76 25.06 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.544 -0.722 . . . . 0.0 109.204 179.864 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -141.08 161.21 38.4 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.315 -0.866 . . . . 0.0 109.316 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 64.0 tttm -64.76 132.22 48.96 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.175 -0.953 . . . . 0.0 109.439 -179.79 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 58.6 p -147.66 69.86 1.15 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.287 -0.883 . . . . 0.0 109.24 -179.898 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -58.39 -37.85 76.14 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.295 -0.878 . . . . 0.0 110.033 -179.581 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 0.8 OUTLIER -61.46 -43.94 97.98 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.024 -1.047 . . . . 0.0 109.443 -179.875 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 28.3 mt -65.47 -30.81 71.63 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.186 -0.946 . . . . 0.0 109.754 179.326 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 136' ' ' ASP . . . . . 0.502 ' CB ' ' CE1' ' A' ' 105' ' ' HIS . 23.2 t70 -76.05 121.24 22.49 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.231 -0.918 . . . . 0.0 109.659 -179.627 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 178.61 -101.84 0.16 Allowed Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.202 -1.559 . . . . 0.0 109.202 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 33.4 mmtm -58.15 -28.56 64.82 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.327 -1.102 . . . . 0.0 109.058 179.506 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 139' ' ' HIS . . . . . 0.729 ' CD2' ' H ' ' A' ' 115' ' ' ASN . 56.3 m170 -83.78 153.2 24.24 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.348 -0.845 . . . . 0.0 109.479 -179.831 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 20.2 m -127.44 160.76 36.15 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 121.516 -0.74 . . . . 0.0 109.278 -179.858 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 141' ' ' VAL . . . . . 0.478 HG23 ' O ' ' A' ' 141' ' ' VAL . 21.5 m -96.69 129.25 47.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.245 -0.91 . . . . 0.0 109.519 -179.732 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 142' ' ' PHE . . . . . 0.546 ' HA ' HG21 ' A' ' 35' ' ' THR . 44.0 p90 -113.03 -9.07 13.61 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.189 -0.944 . . . . 0.0 110.271 -179.913 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -158.45 177.49 35.08 Favored Glycine 0 N--CA 1.492 2.41 0 C-N-CA 119.567 -1.302 . . . . 0.0 109.87 179.703 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 144' ' ' GLN . . . . . 0.403 ' HG2' ' N ' ' A' ' 145' ' ' VAL . 47.8 tt0 -139.63 158.78 43.53 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.303 -1.116 . . . . 0.0 109.633 -179.549 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 145' ' ' VAL . . . . . 0.511 HG23 HD21 ' A' ' 111' ' ' LEU . 13.2 t -94.73 134.07 33.44 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.235 0 O-C-N 121.042 -1.036 . . . . 0.0 109.241 179.666 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 17.4 m -112.03 -26.14 3.22 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.407 -0.808 . . . . 0.0 109.512 179.607 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 94.9 mt-10 -145.78 173.07 12.43 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.238 -0.914 . . . . 0.0 109.541 -179.878 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 98.51 2.35 57.64 Favored Glycine 0 N--CA 1.494 2.511 0 N-CA-C 110.085 -1.206 . . . . 0.0 110.085 179.486 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 149' ' ' MET . . . . . 0.467 ' O ' HG12 ' A' ' 152' ' ' VAL . 65.1 mtt -61.15 -33.07 72.82 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.035 -1.274 . . . . 0.0 109.736 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 89.1 m-20 -64.91 -42.13 94.99 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 120.765 -1.209 . . . . 0.0 110.036 -179.556 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.7 p -82.6 -34.46 11.83 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.078 -1.014 . . . . 0.0 110.485 -179.313 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 152' ' ' VAL . . . . . 0.467 HG12 ' O ' ' A' ' 149' ' ' MET . 0.8 OUTLIER -54.92 -41.82 60.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 120.963 -1.086 . . . . 0.0 109.188 -179.323 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 153' ' ' LYS . . . . . 0.453 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 59.1 mttp -64.25 -34.17 77.49 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.263 -0.898 . . . . 0.0 109.473 179.393 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -62.26 -37.36 85.15 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.308 -0.87 . . . . 0.0 110.217 -179.398 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 79.5 mt -71.96 -36.99 59.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.054 -1.029 . . . . 0.0 110.059 -179.752 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -74.08 -41.75 61.22 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.135 -0.978 . . . . 0.0 111.227 -178.706 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 17.4 pttp -61.69 -33.72 74.51 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 120.749 -1.219 . . . . 0.0 109.734 -179.001 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 27.2 m -86.39 -1.15 7.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.119 -0.988 . . . . 0.0 109.044 179.501 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -74.7 174.22 51.13 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.782 -1.327 . . . . 0.0 109.782 -179.706 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 97.0 p -152.33 162.94 40.44 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.328 -1.101 . . . . 0.0 109.942 -179.64 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 22.8 t -58.9 -31.49 68.66 Favored 'General case' 0 N--CA 1.488 1.441 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 179.297 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 23.1 t -55.96 -30.46 61.76 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.427 -0.796 . . . . 0.0 109.069 179.729 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 100.42 10.12 45.43 Favored Glycine 0 N--CA 1.493 2.489 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 179.784 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 34.5 mmt180 -118.26 147.63 43.24 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.224 -1.162 . . . . 0.0 109.282 179.713 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 165' ' ' THR . . . . . 0.556 HG22 HG21 ' A' ' 69' ' ' VAL . 82.1 p -81.64 152.72 27.0 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.364 -0.835 . . . . 0.0 109.384 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -65.98 -34.27 77.71 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.289 -0.882 . . . . 0.0 109.587 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 62.1 mttm -118.22 162.08 18.84 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.467 -0.77 . . . . 0.0 109.656 -179.664 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 62.8 mttp -75.15 142.44 43.56 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.355 -0.841 . . . . 0.0 109.594 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 1.8 m -133.45 124.67 49.0 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.308 -0.87 . . . . 0.0 109.738 179.763 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 88.8 t -139.45 142.26 33.49 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.461 -0.774 . . . . 0.0 109.395 179.769 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.947 HG22 ' H ' ' A' ' 64' ' ' SER . 3.0 m -71.69 124.84 29.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.014 -1.054 . . . . 0.0 109.55 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 77.9 mm-40 -70.88 -37.72 73.04 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.09 -1.006 . . . . 0.0 110.251 -179.669 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 173' ' ' ASP . . . . . 0.463 ' OD1' ' N ' ' A' ' 174' ' ' CYS . 49.5 t0 -164.84 166.62 19.54 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.063 -1.023 . . . . 0.0 110.032 -179.668 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 174' ' ' CYS . . . . . 0.463 ' N ' ' OD1' ' A' ' 173' ' ' ASP . 12.3 p -141.59 152.34 43.96 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.395 -0.815 . . . . 0.0 109.366 179.803 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -175.52 178.92 47.0 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.649 -1.38 . . . . 0.0 109.649 179.937 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 176' ' ' GLN . . . . . 0.712 HE22 ' NE ' ' A' ' 43' ' ' ARG . 63.3 tt0 -108.12 127.89 54.21 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.373 -1.075 . . . . 0.0 109.528 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 177' ' ' LEU . . . . . 0.603 HD13 ' O ' ' A' ' 177' ' ' LEU . 0.2 OUTLIER -61.24 -38.8 87.94 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.22 -0.925 . . . . 0.0 108.718 179.694 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 9.6 t . . . . . 0 N--CA 1.49 1.544 0 CA-C-O 117.979 -1.01 . . . . 0.0 109.47 179.81 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.529 4.867 0 N-CA-C 119.425 2.53 . . . . 0.0 119.425 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 23.2 m -57.6 -35.04 69.91 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.257 -1.143 . . . . 0.0 109.495 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 67.4 t80 -108.3 120.84 43.54 Favored 'General case' 0 N--CA 1.484 1.271 0 O-C-N 121.372 -0.83 . . . . 0.0 108.969 179.646 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 8.5 t -137.07 158.26 44.86 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.674 -0.641 . . . . 0.0 109.468 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 165.42 -108.91 0.34 Allowed Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 -179.879 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 57.3 p -67.45 164.65 18.29 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.219 -1.165 . . . . 0.0 109.4 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 25.5 mtm -57.21 149.7 45.72 Favored Pre-proline 0 N--CA 1.489 1.486 0 O-C-N 121.251 -0.905 . . . . 0.0 109.358 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -62.02 -31.38 83.87 Favored 'Trans proline' 0 N--CA 1.493 1.498 0 C-N-CA 122.413 2.076 . . . . 0.0 112.316 -179.558 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.511 ' ND2' ' O ' ' A' ' 30' ' ' LEU . 12.1 t-20 -169.41 139.36 1.74 Allowed Pre-proline 0 N--CA 1.49 1.543 0 O-C-N 121.151 -0.968 . . . . 0.0 109.362 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -68.34 140.22 47.87 Favored 'Trans proline' 0 N--CA 1.496 1.645 0 C-N-CA 122.424 2.082 . . . . 0.0 112.211 179.826 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 58.6 mtm180 -132.26 132.44 43.04 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.436 -0.79 . . . . 0.0 109.018 179.537 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.5 p -135.91 143.95 34.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.316 -0.865 . . . . 0.0 109.311 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 33.2 p90 -139.4 152.69 47.3 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.33 -0.856 . . . . 0.0 109.792 -179.633 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 94.3 m-85 -123.26 128.65 50.26 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.595 -0.69 . . . . 0.0 109.546 179.475 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.4 t0 -90.31 119.05 30.28 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.14 -0.975 . . . . 0.0 108.94 179.303 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' MET . . . . . 0.411 ' CE ' ' CE1' ' A' ' 66' ' ' PHE . 67.0 mtp -117.13 143.32 45.95 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.217 -0.927 . . . . 0.0 110.375 -179.315 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.465 ' HG ' ' CD ' ' A' ' 172' ' ' GLU . 50.8 m -132.16 155.14 48.71 Favored 'General case' 0 N--CA 1.491 1.612 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 179.639 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.433 HG23 ' O ' ' A' ' 18' ' ' VAL . 25.4 m -114.87 132.53 63.81 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.234 -0.917 . . . . 0.0 109.657 -179.765 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 65.86 9.9 48.33 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 179.836 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 93.36 -3.89 72.86 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.302 -1.519 . . . . 0.0 109.302 -179.951 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 33.9 mt-30 -99.11 128.39 32.18 Favored Pre-proline 0 N--CA 1.492 1.634 0 O-C-N 121.371 -1.076 . . . . 0.0 109.071 179.806 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 76.1 Cg_exo -43.69 130.11 7.3 Favored 'Trans proline' 0 C--N 1.312 -1.387 0 C-N-CA 122.12 1.88 . . . . 0.0 112.126 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -104.07 -65.25 1.03 Allowed 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.375 -0.828 . . . . 0.0 109.345 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -169.46 -171.21 34.87 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 92.2 mtm-85 -114.1 143.13 45.29 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.385 -1.068 . . . . 0.0 109.465 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 76.4 mt -120.95 117.84 54.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 179.091 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 41.8 t -116.38 132.8 64.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.552 -0.718 . . . . 0.0 109.327 -179.541 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 73.1 mtm -121.48 149.88 42.41 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.464 -0.772 . . . . 0.0 109.209 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -99.88 129.82 46.0 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.24 -0.912 . . . . 0.0 109.822 -179.636 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.511 ' O ' ' ND2' ' A' ' 9' ' ' ASN . 2.5 mm? -105.84 130.75 53.75 Favored 'General case' 0 N--CA 1.493 1.682 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.376 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -94.91 119.33 33.28 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.111 -0.993 . . . . 0.0 109.205 179.739 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -82.14 -42.67 18.76 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.361 -0.837 . . . . 0.0 109.803 -179.764 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -67.19 -44.74 78.88 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.278 -0.889 . . . . 0.0 110.514 -179.266 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' THR . . . . . 0.441 HG21 ' HE2' ' A' ' 103' ' ' LYS . 23.2 m -66.93 -45.35 78.14 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.175 -0.953 . . . . 0.0 109.959 -179.296 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 68.9 p -150.39 83.32 6.0 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 121.285 -0.884 . . . . 0.0 109.468 -179.691 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -70.92 -44.36 1.32 Allowed 'Trans proline' 0 C--N 1.308 -1.595 0 C-N-CA 122.19 1.927 . . . . 0.0 112.087 -179.702 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.431 ' O ' ' OH ' ' A' ' 92' ' ' TYR . 25.4 mtp180 -62.59 -39.63 94.32 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.465 -0.772 . . . . 0.0 110.201 -179.862 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 32.4 m -66.07 -41.76 90.3 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.116 -0.99 . . . . 0.0 110.086 -179.736 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -61.81 -31.04 71.24 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.228 -0.92 . . . . 0.0 109.324 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -68.19 -37.7 81.22 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.219 -0.926 . . . . 0.0 109.85 -179.755 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' ASN . . . . . 0.41 ' O ' HD23 ' A' ' 45' ' ' LEU . 51.9 t30 -57.45 -42.16 81.97 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.205 -0.935 . . . . 0.0 109.79 -179.437 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 -86.13 -48.07 8.93 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.151 -0.968 . . . . 0.0 109.754 -179.842 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 40.2 ttp180 -57.87 -39.47 77.88 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.457 -0.777 . . . . 0.0 110.3 -179.482 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.506 ' O ' ' N ' ' A' ' 48' ' ' GLY . . . -64.31 -43.13 95.66 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.04 -1.038 . . . . 0.0 110.451 -179.117 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.497 HD13 ' HB3' ' A' ' 59' ' ' LEU . 2.8 mm? -65.19 -40.02 93.66 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.008 -1.057 . . . . 0.0 109.655 -179.852 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 46' ' ' CYS . . . . . . . . . . . . . 75.7 m -69.22 -49.54 55.53 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.023 -1.048 . . . . 0.0 109.444 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 73.9 p -74.07 -34.04 63.89 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.18 -0.95 . . . . 0.0 109.554 179.828 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.506 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 75.22 35.22 49.4 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 110.395 -1.082 . . . . 0.0 110.395 179.643 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -61.53 -37.26 83.1 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.005 -1.291 . . . . 0.0 109.235 179.836 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 48.2 mmtm -61.76 -33.59 74.35 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.343 -0.848 . . . . 0.0 109.384 179.783 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 94.35 167.54 36.98 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.295 -1.522 . . . . 0.0 109.295 -179.762 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.525 HG23 ' HA ' ' A' ' 58' ' ' PRO . 99.2 m -80.2 141.05 36.01 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.293 -1.121 . . . . 0.0 109.729 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -59.03 137.55 50.35 Favored Glycine 0 N--CA 1.489 2.173 0 N-CA-C 109.305 -1.518 . . . . 0.0 109.305 179.764 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 74.5 mtt85 -58.99 -35.35 73.07 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.294 -1.121 . . . . 0.0 109.913 -179.701 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 22.9 t -57.67 -31.9 66.79 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.25 -0.906 . . . . 0.0 109.887 -179.769 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 117.86 91.22 1.49 Allowed Glycine 0 N--CA 1.495 2.626 0 N-CA-C 108.896 -1.681 . . . . 0.0 108.896 -179.503 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' LYS . . . . . 0.492 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 78.6 tttt -176.62 80.21 0.27 Allowed Pre-proline 0 N--CA 1.488 1.459 0 O-C-N 121.546 -0.973 . . . . 0.0 108.442 -179.666 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.525 ' HA ' HG23 ' A' ' 52' ' ' THR . 72.5 Cg_exo -48.99 134.51 29.2 Favored 'Trans proline' 0 C--N 1.304 -1.794 0 C-N-CA 122.727 2.285 . . . . 0.0 112.457 -179.097 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.497 ' HB3' HD13 ' A' ' 45' ' ' LEU . 7.7 mp -100.5 71.67 1.54 Allowed 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.621 -0.674 . . . . 0.0 109.4 -179.557 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 79.9 m80 -147.06 130.52 16.73 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.197 -0.939 . . . . 0.0 109.887 179.902 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 58.8 m-85 -72.67 -5.04 34.83 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.119 -0.988 . . . . 0.0 108.402 178.748 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 50.4 tttt -53.54 140.58 28.01 Favored 'General case' 0 N--CA 1.487 1.409 0 O-C-N 121.622 -0.674 . . . . 0.0 109.973 -179.501 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 53.7 t0 56.97 43.5 24.52 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.572 -0.705 . . . . 0.0 110.28 179.646 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.739 ' H ' ' CG1' ' A' ' 171' ' ' VAL . 95.6 p -109.79 150.33 28.52 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.157 -0.965 . . . . 0.0 108.68 179.094 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 38.4 t -102.97 141.42 35.81 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.171 -0.956 . . . . 0.0 109.004 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.411 ' CE1' ' CE ' ' A' ' 16' ' ' MET . 3.2 m-85 -66.66 138.72 57.64 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.291 -0.88 . . . . 0.0 109.021 -179.728 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 81.5 t60 -59.05 -52.19 66.81 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.299 -0.876 . . . . 0.0 110.298 -178.94 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 15.5 ptm180 -166.68 164.01 16.72 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.083 -1.011 . . . . 0.0 109.952 -179.807 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.519 HG21 HG22 ' A' ' 165' ' ' THR . 33.9 m -131.98 147.86 32.3 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.48 -0.762 . . . . 0.0 109.169 179.678 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.408 HG21 HD13 ' A' ' 70' ' ' ILE . 11.6 mt -147.74 108.24 3.77 Favored Pre-proline 0 N--CA 1.492 1.648 0 O-C-N 120.965 -1.084 . . . . 0.0 109.74 179.72 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_exo -54.09 146.04 50.44 Favored 'Trans proline' 0 N--CA 1.493 1.485 0 C-N-CA 122.427 2.085 . . . . 0.0 112.448 179.723 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 77.57 -57.81 3.78 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 110.212 -1.155 . . . . 0.0 110.212 179.273 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 95.5 m-85 -69.67 -83.85 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.166 -1.197 . . . . 0.0 109.819 -179.498 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 74' ' ' MET . . . . . 0.471 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 12.2 ptp -178.93 -172.36 0.25 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.255 -0.903 . . . . 0.0 109.59 -179.764 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -127.76 137.15 52.33 Favored 'General case' 0 N--CA 1.494 1.746 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 179.734 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 93.5 mt-30 -110.63 154.46 23.76 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.256 -0.902 . . . . 0.0 109.603 -179.619 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -160.83 -166.93 20.56 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.426 -1.47 . . . . 0.0 109.426 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 88.74 23.66 35.28 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.439 ' C ' ' OD1' ' A' ' 79' ' ' ASP . 54.6 p30 -84.13 10.54 9.9 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.179 -1.189 . . . . 0.0 109.377 179.922 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 85.2 t80 -53.25 -46.25 69.12 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.36 -0.837 . . . . 0.0 109.804 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.579 ' O ' ' HB2' ' A' ' 82' ' ' ALA . 71.9 p -71.17 -28.71 64.45 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.013 -1.055 . . . . 0.0 109.568 179.906 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 82' ' ' ALA . . . . . 0.579 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 171.26 -57.46 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.205 -0.935 . . . . 0.0 109.405 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 93.65 1.51 65.89 Favored Glycine 0 N--CA 1.492 2.402 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 -180.0 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 23.6 m120 -86.61 6.31 31.57 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.244 -1.15 . . . . 0.0 109.446 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 95.79 -39.13 2.91 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.327 -1.509 . . . . 0.0 109.327 -179.781 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 52.2 p -74.14 -16.14 61.01 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.336 -1.096 . . . . 0.0 109.055 179.594 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -82.85 -167.25 40.7 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.671 -1.372 . . . . 0.0 109.671 -179.913 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.555 ' N ' ' OG1' ' A' ' 81' ' ' THR . . . 83.85 38.42 10.47 Favored Glycine 0 N--CA 1.488 2.104 0 N-CA-C 109.154 -1.578 . . . . 0.0 109.154 -179.708 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -57.42 144.87 34.77 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.46 -1.024 . . . . 0.0 109.671 -179.774 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 96.4 p -112.26 150.24 31.23 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.449 -0.782 . . . . 0.0 109.191 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 24.0 pt -70.82 -31.48 45.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.171 -0.956 . . . . 0.0 110.059 -179.684 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' TYR . . . . . 0.431 ' OH ' ' O ' ' A' ' 37' ' ' ARG . 59.2 m-85 -65.38 -37.99 88.68 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.166 -0.959 . . . . 0.0 109.7 -179.65 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 73.22 15.63 78.75 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -148.16 158.72 44.23 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.301 -1.117 . . . . 0.0 109.455 -179.834 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 63.4 mttp -84.95 150.29 25.03 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.366 -0.834 . . . . 0.0 109.473 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 55.4 p90 -132.25 160.52 35.94 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.279 -0.888 . . . . 0.0 109.538 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -110.52 154.18 24.06 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.496 -0.752 . . . . 0.0 109.723 -179.801 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 60.3 t0 -78.48 124.13 27.8 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.264 -0.897 . . . . 0.0 109.306 179.76 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 78.5 mm-40 -60.88 -37.49 82.35 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.278 -0.889 . . . . 0.0 110.003 -179.457 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 19.1 t-20 -166.51 171.11 12.14 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.95 -1.094 . . . . 0.0 109.943 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -109.81 44.09 1.25 Allowed 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.521 -0.737 . . . . 0.0 109.373 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 89.0 mt -52.32 -41.84 35.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.105 -0.997 . . . . 0.0 109.818 -179.514 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 103' ' ' LYS . . . . . 0.441 ' HE2' HG21 ' A' ' 34' ' ' THR . 59.6 mttm -91.72 144.42 25.53 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.144 -0.972 . . . . 0.0 109.756 -179.686 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 80.2 tttt -134.38 159.13 42.01 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.371 -0.831 . . . . 0.0 109.444 -179.788 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 105' ' ' HIS . . . . . 0.526 ' CE1' ' O ' ' A' ' 107' ' ' GLY . 70.7 t60 -89.63 111.29 22.2 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.304 -0.873 . . . . 0.0 109.264 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 48.2 p -125.86 1.22 7.37 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.364 -0.835 . . . . 0.0 109.942 -179.797 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.526 ' O ' ' CE1' ' A' ' 105' ' ' HIS . . . -155.62 170.32 33.53 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.811 -1.316 . . . . 0.0 109.811 -179.771 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -75.07 156.24 42.68 Favored 'Trans proline' 0 C--N 1.308 -1.573 0 C-N-CA 123.026 2.484 . . . . 0.0 112.213 179.614 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 84.15 43.27 7.16 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 110.328 -1.109 . . . . 0.0 110.328 179.51 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 37.1 mm -115.25 134.41 58.47 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.834 0 O-C-N 121.312 -1.111 . . . . 0.0 109.172 179.592 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.72 ' N ' HD22 ' A' ' 111' ' ' LEU . 2.9 mm? -90.36 124.91 35.31 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.237 -0.915 . . . . 0.0 109.22 179.903 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 50.4 m -137.95 144.96 41.46 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.208 -0.933 . . . . 0.0 109.779 179.806 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 87.8 mtp -90.35 131.41 36.15 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.352 -0.842 . . . . 0.0 109.114 179.429 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 114' ' ' ALA . . . . . 0.409 ' O ' ' OD1' ' A' ' 115' ' ' ASN . . . -65.73 143.76 57.32 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.195 -0.94 . . . . 0.0 109.513 -179.829 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 115' ' ' ASN . . . . . 0.409 ' OD1' ' O ' ' A' ' 114' ' ' ALA . 72.2 m-20 -144.22 113.31 6.85 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.174 -0.954 . . . . 0.0 108.976 179.601 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -70.22 -30.03 67.01 Favored 'General case' 0 C--N 1.297 -1.691 0 O-C-N 121.465 -0.772 . . . . 0.0 109.581 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -140.33 167.16 25.58 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.486 -1.446 . . . . 0.0 109.486 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 118' ' ' PRO . . . . . 0.464 ' O ' ' CG ' ' A' ' 119' ' ' ASN . 41.0 Cg_endo -67.26 158.36 57.33 Favored 'Trans proline' 0 C--N 1.305 -1.726 0 C-N-CA 122.875 2.383 . . . . 0.0 111.893 179.952 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 119' ' ' ASN . . . . . 0.591 ' ND2' ' O ' ' A' ' 119' ' ' ASN . 2.5 p-10 45.41 45.44 10.18 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.514 -0.741 . . . . 0.0 109.543 -179.898 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 89.4 m -134.61 132.26 38.81 Favored 'General case' 0 C--N 1.305 -1.332 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 179.684 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 43.3 p-10 -64.82 162.86 15.32 Favored 'General case' 0 C--N 1.295 -1.768 0 O-C-N 121.343 -0.848 . . . . 0.0 109.309 -179.807 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -109.74 101.47 1.45 Allowed Glycine 0 N--CA 1.494 2.517 0 N-CA-C 109.83 -1.308 . . . . 0.0 109.83 -179.7 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 86.1 p -63.12 -28.15 69.87 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.215 -1.167 . . . . 0.0 109.059 179.543 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.0 mt-30 -125.98 158.31 35.61 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.545 -0.722 . . . . 0.0 109.204 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 49.0 p90 -134.53 163.05 30.58 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.268 -0.895 . . . . 0.0 109.51 -179.925 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.471 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 48.3 p90 -134.44 157.54 46.18 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.312 -0.867 . . . . 0.0 109.414 179.927 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 61.5 mt -122.97 134.35 66.38 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 O-C-N 121.391 -0.818 . . . . 0.0 109.581 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 2.9 t -108.68 125.2 51.63 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.211 -0.931 . . . . 0.0 109.155 179.65 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 129' ' ' THR . . . . . 0.448 ' OG1' ' OE1' ' A' ' 156' ' ' GLU . 7.3 p -114.22 18.05 17.27 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.388 -0.82 . . . . 0.0 109.61 -179.656 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -145.84 162.32 37.98 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.144 -0.973 . . . . 0.0 109.883 -179.548 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 62.5 tttm -59.87 134.11 56.72 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.365 -0.834 . . . . 0.0 109.093 179.863 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 132' ' ' THR . . . . . 0.437 ' OG1' ' OD1' ' A' ' 136' ' ' ASP . 21.9 p -79.17 105.48 10.53 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.26 -0.9 . . . . 0.0 109.909 -179.485 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -66.21 -38.39 87.85 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.087 -1.008 . . . . 0.0 108.672 179.198 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 20.4 p90 -155.31 6.55 0.24 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.44 -0.787 . . . . 0.0 109.968 179.458 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 135' ' ' LEU . . . . . 0.607 ' N ' HD22 ' A' ' 135' ' ' LEU . 3.5 mm? -68.65 -28.01 66.51 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.027 -1.045 . . . . 0.0 109.328 179.562 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 136' ' ' ASP . . . . . 0.437 ' OD1' ' OG1' ' A' ' 132' ' ' THR . 93.8 m-20 -52.38 144.85 12.27 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.357 -0.839 . . . . 0.0 110.025 -179.336 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 171.02 -128.38 1.6 Allowed Glycine 0 N--CA 1.489 2.202 0 N-CA-C 108.793 -1.723 . . . . 0.0 108.793 -179.909 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 4.3 mptp? -89.86 123.06 33.49 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.077 -1.249 . . . . 0.0 108.851 179.376 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 32.0 p80 -168.96 159.37 9.33 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.181 -0.95 . . . . 0.0 109.745 -179.787 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 38.9 t -123.46 136.65 59.34 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 O-C-N 121.389 -0.819 . . . . 0.0 109.317 179.896 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 141' ' ' VAL . . . . . 0.451 HG23 ' O ' ' A' ' 141' ' ' VAL . 17.6 m -108.58 131.41 59.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.231 -0.918 . . . . 0.0 109.014 179.77 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 39.7 p90 -117.01 -4.08 11.53 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.407 -0.808 . . . . 0.0 109.992 -179.609 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -165.53 179.2 40.04 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.648 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.2 pt20 -144.3 165.28 28.33 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.186 -1.185 . . . . 0.0 109.661 -179.787 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 60.4 t -97.56 130.1 46.73 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.224 0 O-C-N 121.269 -0.894 . . . . 0.0 109.449 -179.92 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 16.3 m -106.06 -32.45 2.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.37 -0.832 . . . . 0.0 109.48 179.612 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -144.6 174.37 11.01 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.174 -0.954 . . . . 0.0 109.526 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 99.12 1.21 57.06 Favored Glycine 0 N--CA 1.494 2.509 0 N-CA-C 109.974 -1.25 . . . . 0.0 109.974 179.569 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 149' ' ' MET . . . . . 0.436 ' O ' HG12 ' A' ' 152' ' ' VAL . 65.1 mtt -60.93 -34.16 74.28 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.105 -1.232 . . . . 0.0 109.718 179.945 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -64.51 -42.77 95.59 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.89 -1.131 . . . . 0.0 110.138 -179.576 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.7 p -83.08 -34.04 10.87 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.113 -0.992 . . . . 0.0 110.518 -179.486 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 152' ' ' VAL . . . . . 0.459 ' CG1' ' N ' ' A' ' 153' ' ' LYS . 0.6 OUTLIER -55.52 -41.65 64.53 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 120.889 -1.132 . . . . 0.0 109.122 -179.36 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 153' ' ' LYS . . . . . 0.459 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 57.3 mttp -63.23 -33.63 75.91 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.281 -0.887 . . . . 0.0 109.486 179.417 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -62.26 -40.52 96.49 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.327 -0.858 . . . . 0.0 109.873 -179.575 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 78.4 mt -72.92 -34.34 45.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.083 -1.011 . . . . 0.0 109.61 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 156' ' ' GLU . . . . . 0.448 ' OE1' ' OG1' ' A' ' 129' ' ' THR . 78.9 tt0 -75.95 -42.33 48.93 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.216 -0.928 . . . . 0.0 111.258 -178.796 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 43.2 pttt -61.84 -33.9 74.98 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 120.808 -1.183 . . . . 0.0 109.985 -178.831 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 34.5 m -80.34 -10.29 12.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.136 -0.978 . . . . 0.0 109.249 179.73 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -71.28 165.11 53.59 Favored Glycine 0 N--CA 1.488 2.163 0 N-CA-C 110.074 -1.21 . . . . 0.0 110.074 -179.487 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 22.8 t -155.17 171.39 19.88 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.537 -0.978 . . . . 0.0 109.34 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 24.9 m -54.44 -29.64 50.07 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.199 -0.938 . . . . 0.0 109.346 179.891 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 87.1 p -57.8 -26.6 62.18 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.282 -0.886 . . . . 0.0 109.663 -179.759 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 89.65 15.52 58.12 Favored Glycine 0 N--CA 1.493 2.437 0 N-CA-C 109.823 -1.311 . . . . 0.0 109.823 179.746 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 61.6 ttt180 -126.72 140.67 52.21 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.226 -1.161 . . . . 0.0 109.489 -179.941 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 165' ' ' THR . . . . . 0.519 HG22 HG21 ' A' ' 69' ' ' VAL . 68.7 p -75.08 148.66 39.56 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.157 -0.965 . . . . 0.0 109.279 179.813 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -66.12 -39.3 89.81 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.243 -0.911 . . . . 0.0 109.542 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -103.2 155.68 18.26 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.321 -0.862 . . . . 0.0 109.45 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 64.2 mttp -73.74 130.8 40.71 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.222 -0.924 . . . . 0.0 109.197 179.832 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 13.7 t -128.15 125.02 63.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.142 -0.974 . . . . 0.0 109.515 -179.827 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 62.7 t -142.08 135.01 28.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.267 -0.896 . . . . 0.0 109.343 179.332 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.739 ' CG1' ' H ' ' A' ' 64' ' ' SER . 0.4 OUTLIER -63.58 116.01 2.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.213 -0.929 . . . . 0.0 108.923 179.88 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 172' ' ' GLU . . . . . 0.507 ' O ' ' OD1' ' A' ' 173' ' ' ASP . 96.7 mt-10 -70.64 -40.6 72.99 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.04 -1.037 . . . . 0.0 110.649 -179.531 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 173' ' ' ASP . . . . . 0.507 ' OD1' ' O ' ' A' ' 172' ' ' GLU . 80.5 m-20 -145.13 159.03 43.62 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.08 -1.013 . . . . 0.0 110.377 -179.255 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 53.3 t -145.04 141.84 29.22 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.507 -0.746 . . . . 0.0 109.286 179.474 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -175.73 179.48 46.87 Favored Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.879 -1.288 . . . . 0.0 109.879 179.839 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 57.5 tt0 -107.87 121.75 45.4 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.32 -1.106 . . . . 0.0 109.608 -179.891 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 30.8 tp -62.66 -37.81 87.87 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.183 -0.948 . . . . 0.0 109.317 179.675 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 3.0 t . . . . . 0 N--CA 1.49 1.564 0 CA-C-O 117.977 -1.011 . . . . 0.0 109.439 -179.872 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.529 4.851 0 N-CA-C 119.347 2.499 . . . . 0.0 119.347 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 35.4 m -57.74 -34.01 69.07 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.17 -1.194 . . . . 0.0 109.472 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 50.6 p90 -143.27 162.24 36.19 Favored 'General case' 0 C--N 1.307 -1.253 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 179.663 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 18.7 p -121.65 162.5 20.59 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.645 -0.66 . . . . 0.0 109.505 -179.895 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 88.4 176.86 47.26 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 -179.947 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 28.7 t -146.27 146.87 30.9 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.293 -1.122 . . . . 0.0 109.505 -179.945 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 13.9 mmt -129.44 71.31 82.08 Favored Pre-proline 0 N--CA 1.493 1.721 0 O-C-N 121.482 -0.761 . . . . 0.0 109.432 179.846 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 87.6 Cg_endo -81.11 166.19 18.78 Favored 'Trans proline' 0 C--N 1.307 -1.646 0 C-N-CA 122.889 2.393 . . . . 0.0 112.277 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 -69.9 150.56 96.41 Favored Pre-proline 0 N--CA 1.491 1.592 0 O-C-N 121.355 -0.841 . . . . 0.0 109.06 179.85 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 78.2 Cg_endo -74.47 89.0 1.12 Allowed 'Trans proline' 0 C--N 1.311 -1.441 0 C-N-CA 122.48 2.12 . . . . 0.0 112.111 179.896 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 89.7 mtt-85 -72.02 134.61 45.98 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.306 -0.871 . . . . 0.0 109.578 -179.913 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.0 p -137.7 142.43 36.4 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.367 -0.833 . . . . 0.0 108.99 179.717 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 42.2 p90 -145.89 155.45 42.88 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.234 -0.916 . . . . 0.0 109.844 -179.671 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 91.1 m-85 -125.1 137.96 54.18 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.432 -0.793 . . . . 0.0 109.467 179.444 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 61.3 t0 -89.03 117.61 28.16 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.2 -0.938 . . . . 0.0 108.511 178.831 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' MET . . . . . 0.466 ' SD ' HD12 ' A' ' 26' ' ' ILE . 78.2 mtp -106.32 150.8 25.61 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.147 -0.97 . . . . 0.0 110.52 -178.997 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 84.6 p -146.5 168.65 20.69 Favored 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 109.02 -0.734 . . . . 0.0 109.02 179.822 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.437 ' O ' ' N ' ' A' ' 20' ' ' GLY . 27.2 m -126.09 155.85 36.1 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.804 0 O-C-N 121.267 -0.896 . . . . 0.0 109.457 -179.879 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -49.47 96.61 0.01 OUTLIER Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.366 -1.494 . . . . 0.0 109.366 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.437 ' N ' ' O ' ' A' ' 18' ' ' VAL . . . 150.88 -84.82 0.16 Allowed Glycine 0 N--CA 1.493 2.438 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 -179.93 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 12.9 mt-30 -139.36 160.67 60.98 Favored Pre-proline 0 N--CA 1.494 1.741 0 O-C-N 121.357 -1.084 . . . . 0.0 109.037 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_exo -47.74 134.15 22.22 Favored 'Trans proline' 0 C--N 1.312 -1.392 0 C-N-CA 122.251 1.967 . . . . 0.0 112.247 179.739 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -89.58 -60.32 1.97 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.303 -0.873 . . . . 0.0 109.578 -179.86 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 176.05 -166.99 38.46 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.7 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 35.8 ptt-85 -126.01 149.22 48.98 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.466 -1.02 . . . . 0.0 109.143 179.818 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.466 HD12 ' SD ' ' A' ' 16' ' ' MET . 89.3 mt -122.3 130.32 74.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.287 -0.883 . . . . 0.0 109.346 -179.893 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 44.1 t -109.95 132.61 57.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.444 -0.785 . . . . 0.0 109.427 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 74.8 mtm -119.95 147.13 45.13 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.424 -0.798 . . . . 0.0 109.143 179.875 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.404 ' C ' HD22 ' A' ' 30' ' ' LEU . 84.5 tt0 -101.03 132.1 46.61 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.23 -0.919 . . . . 0.0 109.987 -179.359 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.414 ' N ' ' CD2' ' A' ' 30' ' ' LEU . 2.6 mm? -108.42 132.13 54.08 Favored 'General case' 0 N--CA 1.492 1.626 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 179.44 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 93.3 m-85 -96.02 116.23 28.64 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 120.966 -1.083 . . . . 0.0 108.775 179.045 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -84.72 -43.7 14.06 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.287 -0.883 . . . . 0.0 109.735 -179.705 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.0 m-20 -63.88 -49.43 72.77 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.217 -0.927 . . . . 0.0 109.879 -179.585 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 28.3 m -71.14 -41.83 69.96 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.207 -0.933 . . . . 0.0 109.417 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.517 ' O ' ' OG1' ' A' ' 35' ' ' THR . 2.3 p -135.16 79.62 49.61 Favored Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 121.531 -0.731 . . . . 0.0 109.495 -179.642 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 29.8 Cg_endo -68.48 -62.83 0.05 OUTLIER 'Trans proline' 0 N--CA 1.494 1.557 0 C-N-CA 122.338 2.025 . . . . 0.0 112.867 -179.339 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 79.2 mtp180 -61.23 -37.0 81.49 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.375 -0.828 . . . . 0.0 110.844 -178.952 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 26.8 m -60.66 -43.39 97.7 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.928 -1.107 . . . . 0.0 109.761 -179.51 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -62.83 -30.85 71.81 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.17 -0.956 . . . . 0.0 108.867 179.698 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -68.44 -38.63 81.32 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.47 -0.768 . . . . 0.0 109.899 -179.881 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 47.5 t30 -57.86 -42.52 84.7 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.318 -0.864 . . . . 0.0 109.95 -179.518 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.533 ' O ' ' SG ' ' A' ' 46' ' ' CYS . 97.8 m-85 -84.67 -46.96 10.96 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.069 -1.019 . . . . 0.0 109.938 -179.869 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.676 ' CZ ' HE22 ' A' ' 176' ' ' GLN . 77.0 ttt180 -54.21 -41.13 68.28 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.338 -0.852 . . . . 0.0 110.361 -179.285 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -66.81 -47.62 71.5 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.108 -0.995 . . . . 0.0 110.319 -178.951 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.474 HD13 ' HB3' ' A' ' 59' ' ' LEU . 3.2 mm? -65.28 -39.06 92.08 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.078 -1.014 . . . . 0.0 109.96 -179.515 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 46' ' ' CYS . . . . . 0.533 ' SG ' ' O ' ' A' ' 42' ' ' PHE . 27.6 m -64.41 -62.3 1.69 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.939 -1.101 . . . . 0.0 109.392 -179.766 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 25.3 m -64.86 -36.47 84.46 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.282 -0.886 . . . . 0.0 109.183 179.606 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 83.59 35.62 16.24 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 110.176 -1.17 . . . . 0.0 110.176 179.558 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -61.56 -38.1 86.24 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.051 -1.264 . . . . 0.0 109.266 179.674 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 29.5 mmtm -62.27 -29.75 70.63 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.283 -0.885 . . . . 0.0 109.446 179.747 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 86.06 -115.67 4.24 Favored Glycine 0 N--CA 1.488 2.13 0 N-CA-C 108.778 -1.729 . . . . 0.0 108.778 -179.103 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.544 HG23 ' HA ' ' A' ' 58' ' ' PRO . 61.6 m -129.42 142.01 50.9 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.254 -1.145 . . . . 0.0 109.553 179.455 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -64.66 136.21 38.75 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 61.7 ttp85 -55.32 -37.98 68.11 Favored 'General case' 0 C--N 1.305 -1.328 0 O-C-N 121.254 -1.145 . . . . 0.0 110.056 -179.652 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 22.9 t -57.19 -32.7 66.73 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.288 -0.883 . . . . 0.0 109.797 -179.605 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' GLY . . . . . 0.409 ' O ' ' CB ' ' A' ' 57' ' ' LYS . . . 118.59 105.1 2.21 Favored Glycine 0 N--CA 1.494 2.508 0 N-CA-C 109.014 -1.635 . . . . 0.0 109.014 -179.726 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 57' ' ' LYS . . . . . 0.409 ' CB ' ' O ' ' A' ' 56' ' ' GLY . 0.8 OUTLIER 167.86 82.61 0.02 OUTLIER Pre-proline 0 N--CA 1.491 1.584 0 N-CA-C 108.104 -1.073 . . . . 0.0 108.104 -179.625 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.544 ' HA ' HG23 ' A' ' 52' ' ' THR . 81.4 Cg_exo -45.97 126.15 9.1 Favored 'Trans proline' 0 C--N 1.305 -1.742 0 C-N-CA 122.579 2.186 . . . . 0.0 112.269 -178.964 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.58 ' O ' ' CG ' ' A' ' 60' ' ' HIS . 53.2 mt -95.94 130.61 42.87 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.554 -0.716 . . . . 0.0 109.711 -179.62 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 60' ' ' HIS . . . . . 0.58 ' CG ' ' O ' ' A' ' 59' ' ' LEU . 0.4 OUTLIER 166.51 110.03 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.258 -0.901 . . . . 0.0 109.577 179.889 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 3.6 m-85 -68.39 -3.5 11.4 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.181 -0.95 . . . . 0.0 108.603 179.163 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 34.6 ttmt -57.52 149.35 21.36 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.378 -0.827 . . . . 0.0 109.523 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' ASP . . . . . 0.424 ' H ' HG23 ' A' ' 171' ' ' VAL . 83.2 m-20 57.35 47.76 16.04 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.478 -0.764 . . . . 0.0 110.231 179.839 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.929 ' H ' HG22 ' A' ' 171' ' ' VAL . 92.3 p -104.33 156.79 17.62 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.293 -0.879 . . . . 0.0 108.907 179.257 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 29.2 t -128.9 146.54 50.92 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.153 -0.967 . . . . 0.0 109.623 -179.609 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.7 m-30 -71.81 133.92 45.81 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.283 -0.885 . . . . 0.0 108.662 179.633 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 80.7 m80 -91.02 -31.58 16.25 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.087 -1.008 . . . . 0.0 110.819 -178.985 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 80.0 mtp180 -135.36 138.61 43.53 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 120.951 -1.093 . . . . 0.0 110.306 -179.458 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -150.8 80.04 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 179.0 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 59.9 mt -96.99 129.39 32.54 Favored Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.345 -0.847 . . . . 0.0 109.537 -179.627 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -74.61 134.67 18.82 Favored 'Trans proline' 0 N--CA 1.491 1.349 0 C-N-CA 122.114 1.876 . . . . 0.0 112.076 179.788 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 92.96 -1.2 70.4 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.899 -1.28 . . . . 0.0 109.899 179.597 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 77.4 m-85 -132.93 -94.02 0.34 Allowed 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.098 -1.236 . . . . 0.0 109.818 179.921 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 4.5 ptt? -163.39 177.48 8.89 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.946 -1.097 . . . . 0.0 110.031 -179.601 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -129.4 131.49 46.81 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.495 -0.753 . . . . 0.0 109.039 179.94 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 50.8 tt0 -97.16 118.5 33.72 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.138 -0.976 . . . . 0.0 109.322 179.816 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -61.86 -39.31 97.33 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 81.53 167.16 38.18 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.494 -1.442 . . . . 0.0 109.494 -179.916 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -104.25 149.83 24.96 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.42 -1.047 . . . . 0.0 109.456 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 45.2 p90 -65.29 -24.17 67.22 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.18 -0.95 . . . . 0.0 109.347 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.53 ' O ' ' HB2' ' A' ' 82' ' ' ALA . 58.9 p -66.31 -31.51 72.35 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.225 -0.922 . . . . 0.0 109.657 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 82' ' ' ALA . . . . . 0.53 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 173.46 -53.28 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.242 -0.911 . . . . 0.0 109.44 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 92.53 3.26 66.89 Favored Glycine 0 N--CA 1.492 2.378 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 40.7 p-10 -88.27 7.53 31.69 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.162 -1.199 . . . . 0.0 109.427 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 95.21 -43.52 2.23 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 109.272 -1.531 . . . . 0.0 109.272 -179.851 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 47.1 m -60.58 -38.41 84.5 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.208 -1.172 . . . . 0.0 109.049 179.759 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -84.38 -164.67 38.1 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.473 -1.451 . . . . 0.0 109.473 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.517 ' N ' ' OG1' ' A' ' 81' ' ' THR . . . 86.98 35.51 9.8 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.511 -1.435 . . . . 0.0 109.511 -179.952 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -56.56 146.04 26.31 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.296 -1.12 . . . . 0.0 109.441 179.878 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 29.7 t -100.35 144.02 29.85 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.284 -0.885 . . . . 0.0 109.461 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 21.9 pt -64.36 -32.44 57.6 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.382 -0.824 . . . . 0.0 109.863 -179.728 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 67.7 m-85 -64.12 -37.46 87.54 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.198 -0.939 . . . . 0.0 109.437 -179.795 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 81.43 7.47 88.24 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -151.82 156.92 41.16 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.204 -1.174 . . . . 0.0 109.537 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 86.9 mttt -88.27 148.29 24.4 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.285 -0.884 . . . . 0.0 109.542 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.554 ' CZ ' ' OD1' ' A' ' 121' ' ' ASN . 40.4 p90 -134.33 161.82 33.91 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.253 -0.905 . . . . 0.0 108.973 179.495 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -54.99 138.36 43.9 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.146 -0.971 . . . . 0.0 109.851 -178.992 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 88.2 m-20 -74.66 141.15 44.62 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.428 -0.795 . . . . 0.0 109.761 -179.901 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 99' ' ' GLU . . . . . 0.459 ' OE1' HG22 ' A' ' 35' ' ' THR . 96.0 mt-10 -59.82 146.36 42.1 Favored 'General case' 0 C--N 1.305 -1.37 0 O-C-N 121.322 -0.861 . . . . 0.0 109.218 179.672 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 23.0 t-20 -58.26 159.63 5.87 Favored 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.461 -0.774 . . . . 0.0 109.429 -179.87 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 101' ' ' PHE . . . . . 0.482 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 29.3 p90 -96.43 52.26 1.23 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.303 -0.873 . . . . 0.0 109.72 -179.721 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 88.6 mt -56.77 -39.49 64.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.123 -0.986 . . . . 0.0 109.322 179.781 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -93.03 146.16 23.84 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.154 -0.966 . . . . 0.0 109.627 179.901 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 104' ' ' LYS . . . . . 0.546 ' O ' HG23 ' A' ' 106' ' ' THR . 81.0 tttt -126.8 157.62 38.74 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.439 -0.788 . . . . 0.0 109.346 -179.924 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 105' ' ' HIS . . . . . 0.53 ' ND1' ' OD1' ' A' ' 136' ' ' ASP . 23.2 m80 -59.06 81.25 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.272 -0.893 . . . . 0.0 109.061 179.937 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 106' ' ' THR . . . . . 0.546 HG23 ' O ' ' A' ' 104' ' ' LYS . 69.3 p -73.96 -22.79 59.51 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.164 -0.96 . . . . 0.0 110.147 -179.485 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.414 ' O ' HG12 ' A' ' 110' ' ' ILE . . . -152.75 177.66 30.33 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.734 -1.346 . . . . 0.0 109.734 -179.626 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -73.2 156.29 51.3 Favored 'Trans proline' 0 C--N 1.307 -1.648 0 C-N-CA 122.891 2.394 . . . . 0.0 112.193 179.793 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 109' ' ' GLY . . . . . 0.495 ' N ' ' O ' ' A' ' 128' ' ' CYS . . . 82.23 47.42 6.12 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.91 -1.276 . . . . 0.0 109.91 179.757 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.414 HG12 ' O ' ' A' ' 107' ' ' GLY . 40.7 mm -115.0 136.67 50.94 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.378 -1.071 . . . . 0.0 109.479 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.734 ' N ' HD22 ' A' ' 111' ' ' LEU . 2.7 mm? -89.32 142.34 27.74 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.349 -0.844 . . . . 0.0 109.762 -179.684 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 10.4 t -144.8 140.71 28.63 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.202 -0.936 . . . . 0.0 109.752 179.787 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 89.0 mtp -88.86 137.49 32.27 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.166 -0.959 . . . . 0.0 109.323 179.483 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 114' ' ' ALA . . . . . 0.418 ' HB2' ' CE2' ' A' ' 126' ' ' PHE . . . -68.9 143.52 54.47 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.202 -0.936 . . . . 0.0 109.811 -179.867 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 115' ' ' ASN . . . . . 0.433 ' OD1' ' O ' ' A' ' 120' ' ' THR . 47.0 t30 -140.83 151.03 44.03 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.334 -0.854 . . . . 0.0 109.474 179.737 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -132.17 -3.72 3.5 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.404 -0.81 . . . . 0.0 109.241 179.755 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -157.51 169.55 34.45 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.078 -1.609 . . . . 0.0 109.078 -179.925 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -70.66 147.91 58.13 Favored 'Trans proline' 0 C--N 1.306 -1.665 0 C-N-CA 122.603 2.202 . . . . 0.0 111.792 179.857 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 87.7 m-20 51.0 42.2 28.18 Favored 'General case' 0 C--N 1.297 -1.679 0 O-C-N 121.476 -0.765 . . . . 0.0 109.467 -179.801 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 120' ' ' THR . . . . . 0.433 ' O ' ' OD1' ' A' ' 115' ' ' ASN . 84.2 m -135.22 124.91 25.26 Favored 'General case' 0 N--CA 1.488 1.44 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 179.717 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 121' ' ' ASN . . . . . 0.554 ' OD1' ' CZ ' ' A' ' 96' ' ' PHE . 35.8 m120 -106.24 128.3 53.85 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.576 -0.703 . . . . 0.0 109.702 -179.919 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -99.52 130.84 10.35 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 179.921 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 22.9 t -60.19 -33.23 71.94 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.186 -1.185 . . . . 0.0 109.63 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 82.1 mt-30 -68.38 147.9 51.45 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.332 -0.855 . . . . 0.0 109.664 -179.668 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 50.2 p90 -137.31 161.14 37.06 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.334 -0.854 . . . . 0.0 109.209 179.905 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.418 ' CE2' ' HB2' ' A' ' 114' ' ' ALA . 86.0 m-85 -118.87 151.35 38.27 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.266 -0.897 . . . . 0.0 109.711 -179.898 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 76.3 mt -116.82 134.05 61.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 N-CA-C 108.693 -0.854 . . . . 0.0 108.693 179.313 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 128' ' ' CYS . . . . . 0.495 ' O ' ' N ' ' A' ' 109' ' ' GLY . 1.3 m -121.59 132.45 54.69 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.278 -0.889 . . . . 0.0 109.389 -179.774 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 129' ' ' THR . . . . . 0.425 HG21 ' OE1' ' A' ' 156' ' ' GLU . 1.7 t -116.65 8.78 13.91 Favored 'General case' 0 N--CA 1.493 1.698 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 179.652 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -141.58 165.94 26.11 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.544 -0.723 . . . . 0.0 109.109 -179.885 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 69.1 mttm -65.5 134.13 52.75 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.114 -0.991 . . . . 0.0 109.453 -179.829 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 57.3 p -141.97 70.45 1.33 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.319 -0.863 . . . . 0.0 109.295 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -61.3 -36.16 79.33 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.277 -0.889 . . . . 0.0 109.992 -179.56 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 0.8 OUTLIER -62.6 -43.15 99.54 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.014 -1.054 . . . . 0.0 109.51 -179.942 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 25.0 mt -65.49 -33.84 76.88 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.14 -0.975 . . . . 0.0 109.765 179.508 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 136' ' ' ASP . . . . . 0.53 ' OD1' ' ND1' ' A' ' 105' ' ' HIS . 87.3 m-20 -65.76 141.59 58.27 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.277 -0.889 . . . . 0.0 109.611 -179.754 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 153.79 -92.83 0.13 Allowed Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 138' ' ' LYS . . . . . 0.418 ' HD2' ' N ' ' A' ' 138' ' ' LYS . 1.1 mptp? -87.7 10.54 17.89 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.333 -1.098 . . . . 0.0 109.523 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 63.3 m170 -96.41 140.74 30.63 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.235 -0.915 . . . . 0.0 109.594 -179.751 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 44.9 t -115.37 138.16 46.6 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 O-C-N 121.442 -0.786 . . . . 0.0 109.473 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 141' ' ' VAL . . . . . 0.439 HG23 ' O ' ' A' ' 141' ' ' VAL . 11.2 m -100.72 132.17 46.91 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.332 -0.855 . . . . 0.0 109.224 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 41.4 p90 -110.08 -11.08 14.65 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.222 -0.924 . . . . 0.0 110.219 -179.544 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -157.77 179.75 33.27 Favored Glycine 0 N--CA 1.493 2.458 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 179.738 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.5 pt20 -144.3 165.22 28.51 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.086 -1.244 . . . . 0.0 109.717 -179.749 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 75.6 t -97.12 129.66 46.86 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.19 0 O-C-N 121.318 -0.864 . . . . 0.0 109.299 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 16.1 m -101.86 -35.28 4.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.394 -0.816 . . . . 0.0 109.882 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 90.1 mt-10 -144.95 170.59 15.85 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.149 -0.97 . . . . 0.0 109.745 -179.819 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 97.78 4.14 58.02 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 110.315 -1.114 . . . . 0.0 110.315 179.308 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 149' ' ' MET . . . . . 0.49 ' O ' HG12 ' A' ' 152' ' ' VAL . 65.1 mtt -60.53 -32.37 71.41 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 120.991 -1.299 . . . . 0.0 109.518 179.872 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -64.79 -41.75 95.59 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 120.9 -1.125 . . . . 0.0 110.084 -179.652 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 6.6 p -82.21 -33.59 11.6 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.2 -0.938 . . . . 0.0 110.679 -179.425 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 152' ' ' VAL . . . . . 0.49 HG12 ' O ' ' A' ' 149' ' ' MET . 0.9 OUTLIER -55.82 -42.38 70.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 120.901 -1.124 . . . . 0.0 109.249 -179.304 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 153' ' ' LYS . . . . . 0.459 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 91.1 mttt -65.49 -35.49 81.03 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.043 -1.035 . . . . 0.0 109.409 179.429 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -63.01 -38.15 90.06 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.383 -0.823 . . . . 0.0 109.996 -179.532 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.46 HD13 ' CE ' ' A' ' 16' ' ' MET . 84.7 mt -71.09 -38.44 71.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.295 -0.878 . . . . 0.0 110.594 -179.555 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 156' ' ' GLU . . . . . 0.425 ' OE1' HG21 ' A' ' 129' ' ' THR . 83.1 tt0 -78.1 -39.25 41.99 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.1 -1.0 . . . . 0.0 111.573 -178.395 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 31.6 pttt -61.0 -34.16 74.39 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 120.723 -1.236 . . . . 0.0 110.21 -178.682 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.459 HG22 ' O ' ' A' ' 155' ' ' ILE . 23.8 m -69.8 -15.65 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 120.96 -1.087 . . . . 0.0 109.047 179.786 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -79.05 177.29 54.31 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 23.2 t -152.02 173.51 14.79 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.321 -1.105 . . . . 0.0 109.239 -179.855 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 23.4 m -53.09 -34.89 58.63 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.073 -1.017 . . . . 0.0 108.992 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 24.6 m -59.11 -30.33 68.04 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.373 -0.829 . . . . 0.0 109.363 179.527 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 96.82 11.14 54.23 Favored Glycine 0 N--CA 1.494 2.507 0 N-CA-C 109.35 -1.5 . . . . 0.0 109.35 -179.701 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 88.8 mtt180 -109.25 158.12 18.16 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.369 -1.077 . . . . 0.0 109.02 179.73 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 165' ' ' THR . . . . . . . . . . . . . 43.1 p -116.38 156.82 26.07 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.203 -0.936 . . . . 0.0 110.366 -179.399 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -68.17 -34.72 76.82 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.55 -0.718 . . . . 0.0 109.476 179.624 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -121.98 156.5 33.31 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.481 -0.762 . . . . 0.0 109.473 -179.73 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 90.5 mttt -80.7 141.16 35.14 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.298 -0.876 . . . . 0.0 109.301 -179.904 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 40.6 t -121.74 126.08 74.2 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.341 -0.849 . . . . 0.0 109.7 -179.88 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 43.5 t -141.57 140.68 30.88 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.275 -0.891 . . . . 0.0 109.202 179.712 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.929 HG22 ' H ' ' A' ' 64' ' ' SER . 4.0 m -68.58 123.24 21.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.118 -0.989 . . . . 0.0 109.464 179.935 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -68.65 -36.75 78.99 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.008 -1.057 . . . . 0.0 110.046 -179.802 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -160.04 163.05 34.29 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.073 -1.017 . . . . 0.0 110.07 -179.594 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 16.0 p -146.6 149.78 34.21 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.418 -0.801 . . . . 0.0 109.434 179.759 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . 176.84 -178.83 48.04 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 179.892 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 176' ' ' GLN . . . . . 0.676 HE22 ' CZ ' ' A' ' 43' ' ' ARG . 60.4 tt0 -106.69 120.26 41.52 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.343 -1.092 . . . . 0.0 109.651 -179.952 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 177' ' ' LEU . . . . . 0.437 ' O ' ' C ' ' A' ' 178' ' ' SER . 30.3 tp -61.9 -39.34 91.66 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.138 -0.976 . . . . 0.0 109.153 179.454 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 178' ' ' SER . . . . . 0.437 ' C ' ' O ' ' A' ' 177' ' ' LEU . 5.6 p . . . . . 0 N--CA 1.492 1.673 0 CA-C-O 118.046 -0.978 . . . . 0.0 109.806 179.898 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.529 4.835 0 N-CA-C 119.401 2.52 . . . . 0.0 119.401 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 55.0 p -70.21 161.39 30.37 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.196 -1.179 . . . . 0.0 109.512 -179.941 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 99.3 m-85 -112.18 125.37 54.06 Favored 'General case' 0 N--CA 1.484 1.247 0 O-C-N 121.377 -0.827 . . . . 0.0 108.813 179.678 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 44.6 m -56.79 -37.75 71.58 Favored 'General case' 0 C--N 1.296 -1.759 0 O-C-N 121.441 -0.787 . . . . 0.0 109.477 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -78.18 8.16 40.57 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.798 -1.321 . . . . 0.0 109.798 -179.809 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 37.8 t -58.97 -32.88 70.05 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.136 -1.214 . . . . 0.0 109.748 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 13.5 mtt -124.79 79.18 64.07 Favored Pre-proline 0 N--CA 1.495 1.784 0 O-C-N 121.273 -0.892 . . . . 0.0 109.717 -179.781 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo -85.53 168.43 9.89 Favored 'Trans proline' 0 C--N 1.308 -1.562 0 C-N-CA 122.978 2.452 . . . . 0.0 112.125 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 6.8 m-20 -60.6 150.46 74.81 Favored Pre-proline 0 N--CA 1.488 1.47 0 O-C-N 121.22 -0.925 . . . . 0.0 109.0 179.711 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -65.75 133.77 35.25 Favored 'Trans proline' 0 C--N 1.309 -1.55 0 C-N-CA 122.448 2.099 . . . . 0.0 112.24 -179.695 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 97.4 mtt180 -131.57 129.74 41.34 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.411 -0.805 . . . . 0.0 108.879 179.203 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.5 p -135.88 142.26 39.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.366 -0.834 . . . . 0.0 109.363 -179.822 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 45.1 p90 -142.31 153.4 43.85 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.418 -0.801 . . . . 0.0 109.573 -179.812 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -121.37 134.88 55.13 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.385 -0.822 . . . . 0.0 109.318 179.54 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -90.6 114.75 27.07 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.182 -0.949 . . . . 0.0 108.945 179.485 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' MET . . . . . 0.405 ' SD ' ' CD1' ' A' ' 26' ' ' ILE . 85.1 mtp -102.56 152.19 21.45 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.311 -0.868 . . . . 0.0 110.452 -179.404 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 96.5 p -143.15 163.15 33.68 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.781 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.53 ' O ' ' N ' ' A' ' 20' ' ' GLY . 29.4 m -123.43 139.8 48.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 121.07 -1.019 . . . . 0.0 109.501 -179.953 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 47.01 13.96 0.11 Allowed Glycine 0 N--CA 1.492 2.406 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 179.928 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.53 ' N ' ' O ' ' A' ' 18' ' ' VAL . . . 98.78 -16.3 59.76 Favored Glycine 0 N--CA 1.493 2.447 0 N-CA-C 109.616 -1.393 . . . . 0.0 109.616 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' GLN . . . . . 0.492 ' N ' ' O ' ' A' ' 18' ' ' VAL . 64.5 mm-40 -81.69 146.12 55.89 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.169 -1.195 . . . . 0.0 109.216 179.812 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_endo -63.48 138.89 67.7 Favored 'Trans proline' 0 N--CA 1.494 1.528 0 C-N-CA 122.366 2.044 . . . . 0.0 112.174 -179.736 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -112.6 -66.2 1.11 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.319 -0.863 . . . . 0.0 109.452 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -175.81 -169.97 38.06 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.315 -1.514 . . . . 0.0 109.315 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 71.3 mtp180 -114.95 144.03 44.22 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.226 -1.161 . . . . 0.0 109.587 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.405 ' CD1' ' SD ' ' A' ' 16' ' ' MET . 84.0 mt -120.72 116.07 48.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 N-CA-C 108.44 -0.948 . . . . 0.0 108.44 178.579 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 37.8 t -112.12 133.91 56.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.439 -0.788 . . . . 0.0 109.218 -179.537 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 76.5 mtm -119.53 155.25 32.51 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.454 -0.779 . . . . 0.0 109.532 -179.577 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.417 ' C ' HD22 ' A' ' 30' ' ' LEU . 84.7 tt0 -100.31 133.02 45.35 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.369 -0.832 . . . . 0.0 109.939 -179.601 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.417 HD22 ' C ' ' A' ' 29' ' ' GLU . 3.1 mm? -110.39 134.65 52.11 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.506 -0.746 . . . . 0.0 109.155 179.619 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 84.1 m-85 -95.1 122.84 38.18 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.2 -0.938 . . . . 0.0 108.999 179.388 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -92.9 -41.81 9.84 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.348 -0.845 . . . . 0.0 109.606 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 87.2 m-20 -69.62 -44.45 70.65 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.327 -0.858 . . . . 0.0 110.659 -179.338 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' THR . . . . . 0.439 ' O ' ' OE1' ' A' ' 99' ' ' GLU . 35.2 m -67.84 -46.82 70.69 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.16 -0.962 . . . . 0.0 110.526 -178.924 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.413 ' OG1' ' OG1' ' A' ' 38' ' ' THR . 0.0 OUTLIER -152.63 83.62 4.82 Favored Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.147 -0.971 . . . . 0.0 109.486 -179.447 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -71.92 -33.19 10.22 Favored 'Trans proline' 0 C--N 1.308 -1.593 0 C-N-CA 122.146 1.897 . . . . 0.0 112.12 -179.63 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 35.2 mmt180 -63.35 -40.28 96.85 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.326 -0.858 . . . . 0.0 109.491 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.413 ' OG1' ' OG1' ' A' ' 35' ' ' THR . 36.5 m -64.87 -41.17 95.88 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.274 -0.891 . . . . 0.0 109.929 -179.806 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -62.43 -30.77 71.46 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.286 -0.884 . . . . 0.0 109.282 179.973 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -67.11 -36.91 82.94 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.293 -0.879 . . . . 0.0 109.864 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' ASN . . . . . 0.437 ' O ' HD23 ' A' ' 45' ' ' LEU . 87.5 m-20 -57.95 -39.76 78.88 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.263 -0.898 . . . . 0.0 110.062 -179.498 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -90.42 -48.13 7.3 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.072 -1.017 . . . . 0.0 109.665 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 51.3 ttp180 -57.65 -40.71 79.9 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.48 -0.762 . . . . 0.0 110.508 -179.361 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.446 ' O ' ' N ' ' A' ' 48' ' ' GLY . . . -66.05 -46.8 76.51 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.976 -1.077 . . . . 0.0 110.425 -179.095 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.606 HD13 ' O ' ' A' ' 59' ' ' LEU . 3.6 mm? -64.98 -39.97 94.27 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 120.956 -1.09 . . . . 0.0 109.618 -179.809 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 46' ' ' CYS . . . . . . . . . . . . . 34.8 m -70.06 -47.85 60.26 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.084 -1.01 . . . . 0.0 109.347 179.769 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 74.8 p -72.55 -34.62 67.65 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.36 -0.837 . . . . 0.0 109.555 179.742 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.446 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 73.61 31.88 60.13 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.978 -1.249 . . . . 0.0 109.978 179.646 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 78.0 mm-40 -62.03 -38.03 87.16 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.029 -1.277 . . . . 0.0 109.534 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 31.4 mmtp -62.18 -35.86 80.11 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.282 -0.886 . . . . 0.0 109.674 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 89.51 167.9 42.97 Favored Glycine 0 N--CA 1.488 2.154 0 N-CA-C 109.074 -1.611 . . . . 0.0 109.074 -179.653 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.566 HG23 ' HA ' ' A' ' 58' ' ' PRO . 85.2 m -75.1 138.73 42.28 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.119 -1.224 . . . . 0.0 109.559 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -59.5 137.18 50.11 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.393 -1.483 . . . . 0.0 109.393 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 83.5 mtm-85 -59.35 -36.09 75.08 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.19 -1.182 . . . . 0.0 109.846 -179.748 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 85.9 p -63.38 -24.26 67.77 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.113 -0.992 . . . . 0.0 109.779 -179.841 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 115.87 96.35 2.02 Favored Glycine 0 N--CA 1.494 2.524 0 N-CA-C 109.078 -1.609 . . . . 0.0 109.078 -179.572 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' LYS . . . . . 0.484 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 75.8 tttt -179.5 81.47 0.2 Allowed Pre-proline 0 N--CA 1.489 1.518 0 N-CA-C 108.377 -0.971 . . . . 0.0 108.377 -179.664 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.566 ' HA ' HG23 ' A' ' 52' ' ' THR . 75.9 Cg_exo -50.31 130.12 27.89 Favored 'Trans proline' 0 C--N 1.303 -1.828 0 C-N-CA 122.769 2.313 . . . . 0.0 112.597 -179.014 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.606 ' O ' HD13 ' A' ' 45' ' ' LEU . 9.0 mp -100.04 23.49 9.82 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.641 -0.662 . . . . 0.0 109.436 -179.833 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 60' ' ' HIS . . . . . 0.51 ' O ' ' CE1' ' A' ' 80' ' ' PHE . 93.2 m-70 -101.66 135.32 43.38 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.227 -0.92 . . . . 0.0 109.628 -179.804 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 61' ' ' TYR . . . . . 0.509 ' CE1' HD12 ' A' ' 45' ' ' LEU . 2.7 m-85 -94.95 12.67 27.55 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.293 -0.879 . . . . 0.0 108.98 179.575 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 62' ' ' LYS . . . . . 0.463 ' O ' ' CB ' ' A' ' 63' ' ' ASP . 62.1 tttt -62.73 142.82 57.97 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.416 -0.803 . . . . 0.0 109.674 -179.832 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 63' ' ' ASP . . . . . 0.463 ' CB ' ' O ' ' A' ' 62' ' ' LYS . 21.4 t0 74.76 33.72 0.77 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.581 -0.7 . . . . 0.0 109.736 179.859 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.788 ' H ' ' CG2' ' A' ' 171' ' ' VAL . 52.6 p -76.66 165.31 24.93 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.225 -0.922 . . . . 0.0 109.005 179.34 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 29.7 t -140.9 149.77 42.33 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.085 -1.01 . . . . 0.0 109.814 -179.783 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 58.3 m-85 -90.93 127.22 36.31 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.296 -0.878 . . . . 0.0 109.209 179.552 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 55.4 t-80 -94.85 -30.74 14.04 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.258 -0.901 . . . . 0.0 110.499 -179.27 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 83.0 mtp180 -126.26 140.87 52.19 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.057 -1.027 . . . . 0.0 110.341 -179.38 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.711 HG21 HG22 ' A' ' 165' ' ' THR . 15.8 m -151.57 49.05 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 179.424 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 19.4 mt -77.56 133.78 66.67 Favored Pre-proline 0 C--N 1.301 -1.507 0 O-C-N 121.361 -0.837 . . . . 0.0 110.156 -178.612 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -68.89 147.89 69.42 Favored 'Trans proline' 0 N--CA 1.492 1.421 0 C-N-CA 122.4 2.067 . . . . 0.0 112.266 179.852 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 80.42 -55.75 4.66 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.849 -1.3 . . . . 0.0 109.849 179.642 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 88.4 m-85 -68.36 -87.27 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.27 -1.135 . . . . 0.0 109.67 -179.75 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 11.3 ptt? -179.59 -175.16 0.32 Allowed 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.141 -0.975 . . . . 0.0 109.667 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 58.2 m -126.92 136.74 52.72 Favored 'General case' 0 N--CA 1.493 1.702 0 N-CA-C 108.763 -0.829 . . . . 0.0 108.763 179.608 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 63.2 tt0 -96.9 134.88 39.65 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.226 -0.921 . . . . 0.0 109.695 -179.527 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -139.75 176.19 21.33 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.06 -1.616 . . . . 0.0 109.06 179.769 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 77.14 36.84 34.03 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.235 -1.546 . . . . 0.0 109.235 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -83.72 13.97 4.29 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.321 -1.105 . . . . 0.0 109.413 -179.826 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.51 ' CE1' ' O ' ' A' ' 60' ' ' HIS . 81.0 t80 -51.67 -45.26 63.37 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.293 -0.88 . . . . 0.0 109.803 -179.874 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.657 ' O ' ' HB2' ' A' ' 82' ' ' ALA . 58.9 p -70.51 -28.17 64.75 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.1 -1.0 . . . . 0.0 109.506 179.857 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 82' ' ' ALA . . . . . 0.657 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 165.3 -56.9 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.342 -0.849 . . . . 0.0 109.238 179.898 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 93.39 -1.42 69.52 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 40.7 p-10 -90.02 5.95 44.39 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.126 -1.22 . . . . 0.0 109.473 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 96.44 -33.53 5.59 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.98 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 51.7 p -72.58 -22.26 61.01 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.14 -1.212 . . . . 0.0 109.217 179.76 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -84.97 -161.64 34.29 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 179.915 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.634 ' H ' ' CB ' ' A' ' 81' ' ' THR . . . 90.95 26.87 20.85 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 -179.869 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 89' ' ' GLU . . . . . 0.429 ' OE1' ' NZ ' ' A' ' 57' ' ' LYS . 96.0 mt-10 -57.1 145.52 30.69 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.375 -1.073 . . . . 0.0 109.577 -179.799 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 29.3 t -106.15 143.55 34.11 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.323 -0.861 . . . . 0.0 109.328 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 20.4 pt -64.58 -33.44 63.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.332 -0.855 . . . . 0.0 109.828 -179.722 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 73.5 m-85 -65.53 -38.12 88.72 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.23 -0.919 . . . . 0.0 109.604 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 81.64 14.5 77.89 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.449 -1.461 . . . . 0.0 109.449 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -146.46 155.77 42.79 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.14 -1.211 . . . . 0.0 109.655 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 97.1 mttt -94.07 142.24 27.62 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.291 -0.88 . . . . 0.0 109.549 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 99.4 m-85 -120.63 150.16 41.34 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.415 -0.803 . . . . 0.0 109.589 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -70.8 154.51 41.77 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.385 -0.822 . . . . 0.0 109.569 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 88.4 m-20 -59.48 147.66 35.85 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.251 -0.906 . . . . 0.0 109.341 179.901 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 99' ' ' GLU . . . . . 0.439 ' OE1' ' O ' ' A' ' 34' ' ' THR . 96.2 mt-10 -80.4 -89.35 0.06 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.145 -0.972 . . . . 0.0 110.008 -179.583 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 85.3 m-20 -124.86 145.91 49.55 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.301 -0.875 . . . . 0.0 110.049 -179.473 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -100.74 10.83 40.65 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.439 -0.788 . . . . 0.0 109.294 179.589 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 96.2 mt -53.49 -36.46 27.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.303 -0.873 . . . . 0.0 110.134 -179.391 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 9.2 mtpm? -80.45 136.12 36.27 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.98 -1.075 . . . . 0.0 109.633 -179.789 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 69.1 tttt -135.15 159.37 41.76 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.449 -0.782 . . . . 0.0 109.331 -179.705 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 105' ' ' HIS . . . . . 0.409 ' CE1' HG22 ' A' ' 141' ' ' VAL . 92.9 m-70 -74.19 106.55 5.9 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.092 -1.005 . . . . 0.0 109.477 179.865 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 62.3 p -96.03 -9.97 29.65 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.343 -0.848 . . . . 0.0 109.691 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -165.18 -179.03 38.83 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.76 -1.336 . . . . 0.0 109.76 -179.805 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -78.76 160.28 27.82 Favored 'Trans proline' 0 C--N 1.306 -1.677 0 C-N-CA 123.178 2.585 . . . . 0.0 112.23 179.791 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 82.17 40.9 9.78 Favored Glycine 0 N--CA 1.492 2.395 0 N-CA-C 109.995 -1.242 . . . . 0.0 109.995 179.715 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 33.7 mm -113.66 139.21 40.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.357 -1.084 . . . . 0.0 109.209 179.923 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.669 ' N ' HD22 ' A' ' 111' ' ' LEU . 3.4 mm? -86.88 136.18 33.05 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.156 -0.965 . . . . 0.0 109.737 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 30.8 t -144.69 143.41 30.71 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.348 -0.845 . . . . 0.0 109.098 179.47 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 113' ' ' MET . . . . . 0.404 ' H ' ' HG2' ' A' ' 113' ' ' MET . 15.1 ptm -87.4 126.06 34.64 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.231 -0.918 . . . . 0.0 109.532 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -66.27 147.77 52.83 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.263 -0.898 . . . . 0.0 109.715 -179.74 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 115' ' ' ASN . . . . . 0.525 ' N ' ' OD1' ' A' ' 115' ' ' ASN . 8.0 p-10 -157.76 115.56 3.05 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.272 -0.893 . . . . 0.0 109.169 179.634 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -65.46 -30.72 71.54 Favored 'General case' 0 C--N 1.299 -1.63 0 O-C-N 121.406 -0.809 . . . . 0.0 109.8 -179.761 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -135.57 166.09 24.61 Favored Glycine 0 N--CA 1.494 2.519 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -67.38 156.74 64.91 Favored 'Trans proline' 0 C--N 1.306 -1.659 0 C-N-CA 122.867 2.378 . . . . 0.0 111.816 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 75.8 m-20 54.33 45.4 27.3 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.411 -0.805 . . . . 0.0 109.232 -179.895 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 61.5 m -131.85 127.99 37.73 Favored 'General case' 0 C--N 1.305 -1.349 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 179.916 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 20.1 m120 -102.01 137.03 40.84 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.493 -0.755 . . . . 0.0 109.486 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -145.32 125.78 2.42 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 179.91 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 23.1 t -59.02 -30.86 68.32 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.374 -1.074 . . . . 0.0 109.482 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.6 mt-30 -63.22 143.2 58.0 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.194 -0.941 . . . . 0.0 109.537 -179.675 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 45.6 p90 -141.35 164.93 28.91 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.453 -0.78 . . . . 0.0 109.178 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 48.0 p90 -131.47 157.48 43.39 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.231 -0.918 . . . . 0.0 109.517 179.854 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 71.3 mt -120.25 136.36 57.55 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.492 -0.755 . . . . 0.0 109.593 -179.73 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 11.0 t -116.26 123.56 48.01 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.287 -0.883 . . . . 0.0 108.978 179.581 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 37.6 p -95.51 5.5 51.38 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.275 -0.891 . . . . 0.0 109.86 -179.446 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -148.44 155.58 41.39 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.142 -0.974 . . . . 0.0 109.725 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 34.7 ttmt -73.51 135.42 44.02 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.316 -0.865 . . . . 0.0 109.309 179.838 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 132' ' ' THR . . . . . 0.462 ' O ' ' OD2' ' A' ' 136' ' ' ASP . 16.9 p -120.87 159.33 25.74 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.447 -0.783 . . . . 0.0 109.431 -179.808 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 133' ' ' GLU . . . . . 0.436 ' O ' ' OD1' ' A' ' 136' ' ' ASP . 96.2 mt-10 -97.93 -48.24 5.24 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.286 -0.884 . . . . 0.0 110.011 -179.906 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 134' ' ' TRP . . . . . 0.602 ' CD1' ' N ' ' A' ' 135' ' ' LEU . 40.9 p90 -92.16 -44.06 9.0 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.199 -0.938 . . . . 0.0 110.174 -179.477 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 135' ' ' LEU . . . . . 0.602 ' N ' ' CD1' ' A' ' 134' ' ' TRP . 34.2 tp -61.66 -29.63 70.2 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.268 -0.895 . . . . 0.0 109.184 -179.646 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 136' ' ' ASP . . . . . 0.485 ' C ' ' OD1' ' A' ' 136' ' ' ASP . 53.4 p30 -70.14 9.06 0.63 Allowed 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.447 -0.783 . . . . 0.0 109.513 -179.747 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 137' ' ' GLY . . . . . 0.459 ' H ' ' C ' ' A' ' 135' ' ' LEU . . . -52.02 -30.31 30.13 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.618 -1.393 . . . . 0.0 109.618 -179.904 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 138' ' ' LYS . . . . . 0.44 ' CE ' ' OD1' ' A' ' 115' ' ' ASN . 46.4 mmtm -77.56 123.18 26.27 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.098 -1.236 . . . . 0.0 109.168 -179.879 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 71.1 m80 -110.61 15.66 21.91 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.398 -0.814 . . . . 0.0 109.754 -179.641 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 45.0 t -100.08 129.8 50.21 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.13 -0.981 . . . . 0.0 109.88 -179.536 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 141' ' ' VAL . . . . . 0.409 HG22 ' CE1' ' A' ' 105' ' ' HIS . 84.2 t -130.58 129.83 64.55 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 N-CA-C 109.021 -0.733 . . . . 0.0 109.021 179.651 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 39.5 p90 -110.72 -0.4 17.09 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.074 -1.016 . . . . 0.0 110.052 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -175.43 173.52 46.28 Favored Glycine 0 N--CA 1.493 2.495 0 N-CA-C 109.804 -1.319 . . . . 0.0 109.804 179.443 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 94.0 mt-30 -139.36 165.91 25.95 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.29 -1.123 . . . . 0.0 109.584 -179.83 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 55.1 t -95.56 129.54 45.53 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.222 0 O-C-N 121.175 -0.953 . . . . 0.0 109.162 179.816 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 17.3 m -106.73 -33.65 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.314 -0.866 . . . . 0.0 109.455 179.736 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -143.06 170.78 15.07 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.333 -0.855 . . . . 0.0 109.525 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 98.53 2.39 57.61 Favored Glycine 0 N--CA 1.494 2.558 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.74 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 149' ' ' MET . . . . . 0.511 ' O ' HG12 ' A' ' 152' ' ' VAL . 50.6 ttm -61.02 -32.85 72.44 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.063 -1.257 . . . . 0.0 109.667 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -65.33 -42.29 93.08 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.883 -1.135 . . . . 0.0 110.06 -179.596 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.6 p -81.84 -32.92 11.59 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.141 -0.974 . . . . 0.0 110.611 -179.232 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 152' ' ' VAL . . . . . 0.511 HG12 ' O ' ' A' ' 149' ' ' MET . 0.9 OUTLIER -53.76 -41.0 45.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 120.976 -1.077 . . . . 0.0 109.152 -179.285 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 153' ' ' LYS . . . . . 0.441 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 87.2 mttt -64.03 -34.62 78.42 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.122 -0.986 . . . . 0.0 109.188 179.169 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -62.08 -35.06 77.52 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.381 -0.824 . . . . 0.0 109.687 -179.798 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.404 HD11 ' SD ' ' A' ' 16' ' ' MET . 95.7 mt -70.79 -36.01 62.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.277 -0.889 . . . . 0.0 109.832 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 85.1 tt0 -75.24 -41.89 56.5 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.266 -0.896 . . . . 0.0 111.419 -178.755 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 55.4 pttt -61.27 -34.46 75.21 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.665 -1.272 . . . . 0.0 109.689 -179.047 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 32.6 m -82.82 -6.62 10.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.146 -0.971 . . . . 0.0 108.926 179.427 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -77.67 176.48 53.68 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 109.797 -1.321 . . . . 0.0 109.797 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 86.9 p -157.48 169.54 24.46 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.431 -1.041 . . . . 0.0 109.706 -179.58 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 22.8 t -57.1 -32.69 66.55 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.281 -0.887 . . . . 0.0 108.647 179.256 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 86.2 p -61.38 -27.25 68.39 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.329 -0.857 . . . . 0.0 109.096 179.654 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 93.24 18.04 40.79 Favored Glycine 0 N--CA 1.493 2.488 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 179.756 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 88.7 mtt180 -115.94 143.06 45.96 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.219 -1.165 . . . . 0.0 109.226 179.825 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 165' ' ' THR . . . . . 0.711 HG22 HG21 ' A' ' 69' ' ' VAL . 81.7 p -81.98 150.06 27.85 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.208 -0.933 . . . . 0.0 109.675 -179.894 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -68.96 -36.77 78.3 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.325 -0.859 . . . . 0.0 109.333 179.8 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -111.58 157.84 19.92 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.5 -0.75 . . . . 0.0 109.435 -179.914 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 92.1 mttt -73.02 135.84 44.96 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.309 -0.869 . . . . 0.0 109.175 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 3.4 m -130.94 123.02 53.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.725 0 O-C-N 121.365 -0.834 . . . . 0.0 109.772 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 39.0 t -143.21 138.0 26.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.386 -0.821 . . . . 0.0 108.804 179.557 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.788 ' CG2' ' H ' ' A' ' 64' ' ' SER . 3.0 m -67.7 119.56 13.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 120.826 -1.171 . . . . 0.0 109.547 -179.737 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -68.52 -35.57 77.66 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.233 -0.917 . . . . 0.0 110.086 -179.836 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -156.34 158.32 37.21 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.202 -0.936 . . . . 0.0 110.047 -179.6 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 19.0 p -147.06 148.58 31.79 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.435 -0.79 . . . . 0.0 109.16 179.688 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -177.93 179.72 48.29 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.704 -1.359 . . . . 0.0 109.704 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 61.3 tt0 -106.03 117.25 33.55 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.392 -1.064 . . . . 0.0 109.667 -179.896 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 31.3 tp -62.86 -38.8 92.29 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.094 -1.004 . . . . 0.0 109.216 179.589 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 2.6 p . . . . . 0 N--CA 1.492 1.651 0 CA-C-O 117.897 -1.049 . . . . 0.0 109.707 179.997 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.528 4.829 0 N-CA-C 119.389 2.515 . . . . 0.0 119.389 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 23.2 m -57.66 -35.28 70.34 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.325 -1.103 . . . . 0.0 109.489 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 99.3 m-85 -111.32 123.02 49.36 Favored 'General case' 0 N--CA 1.485 1.309 0 O-C-N 121.329 -0.857 . . . . 0.0 108.873 179.654 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 43.8 m -57.55 -39.74 77.33 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.515 -0.741 . . . . 0.0 109.42 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 83.58 16.82 67.54 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.617 -1.393 . . . . 0.0 109.617 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 86.3 p -138.58 160.22 40.13 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.232 -1.158 . . . . 0.0 109.447 -179.941 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 7.2 ttt -128.56 76.71 78.27 Favored Pre-proline 0 N--CA 1.493 1.695 0 O-C-N 121.388 -0.82 . . . . 0.0 109.517 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_exo -49.12 -175.97 0.0 OUTLIER 'Trans proline' 0 C--N 1.307 -1.628 0 C-N-CA 122.868 2.379 . . . . 0.0 112.614 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 12.0 m120 -98.86 151.3 37.35 Favored Pre-proline 0 N--CA 1.492 1.656 0 O-C-N 121.582 -0.699 . . . . 0.0 109.261 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -68.21 138.08 42.2 Favored 'Trans proline' 0 N--CA 1.496 1.648 0 C-N-CA 122.595 2.197 . . . . 0.0 112.272 179.891 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 95.5 mtt180 -128.72 132.27 47.97 Favored 'General case' 0 N--CA 1.492 1.657 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 179.114 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.5 p -133.24 142.3 42.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.363 -0.836 . . . . 0.0 109.607 -179.564 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 47.1 p90 -140.91 155.26 46.32 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.411 -0.806 . . . . 0.0 109.519 -179.838 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 69.8 m-85 -121.86 135.51 54.9 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.455 -0.778 . . . . 0.0 109.643 179.773 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.0 t0 -88.28 118.83 28.15 Favored 'General case' 0 N--CA 1.493 1.703 0 N-CA-C 108.307 -0.998 . . . . 0.0 108.307 178.864 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 75.2 mtp -116.32 142.86 46.28 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.263 -0.898 . . . . 0.0 110.742 -178.822 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.433 ' OG ' ' OE2' ' A' ' 172' ' ' GLU . 31.6 m -136.4 155.88 49.41 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 179.368 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 33.3 m -119.14 133.69 65.17 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.085 -1.009 . . . . 0.0 109.638 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 57.86 15.57 20.59 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.689 -1.365 . . . . 0.0 109.689 179.844 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 92.08 2.38 68.87 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.386 -1.486 . . . . 0.0 109.386 -179.804 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 41.5 tt0 -105.02 115.15 62.88 Favored Pre-proline 0 N--CA 1.492 1.658 0 O-C-N 121.437 -1.037 . . . . 0.0 109.112 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 77.4 Cg_exo -47.33 133.65 19.91 Favored 'Trans proline' 0 N--CA 1.492 1.412 0 C-N-CA 122.088 1.859 . . . . 0.0 112.106 -179.949 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -101.25 -57.67 2.04 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.292 -0.88 . . . . 0.0 109.568 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -178.02 -169.08 38.46 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.401 -1.48 . . . . 0.0 109.401 -179.775 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 50.9 mtp180 -113.22 144.22 43.07 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.415 -1.05 . . . . 0.0 109.383 179.849 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 76.3 mt -117.85 114.56 45.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 N-CA-C 108.183 -1.043 . . . . 0.0 108.183 178.757 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 38.3 t -109.58 135.21 49.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.437 -0.79 . . . . 0.0 109.628 -179.219 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 75.8 mtm -128.41 156.86 42.49 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.514 -0.741 . . . . 0.0 109.225 -179.588 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -103.83 133.93 48.0 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.283 -0.886 . . . . 0.0 109.706 179.882 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -105.37 128.97 53.78 Favored 'General case' 0 N--CA 1.492 1.638 0 N-CA-C 108.752 -0.832 . . . . 0.0 108.752 179.365 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.401 ' CG ' ' NZ ' ' A' ' 103' ' ' LYS . 94.9 m-85 -92.97 119.41 32.21 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.085 -1.009 . . . . 0.0 109.141 179.981 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -86.33 -42.6 13.57 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.346 -0.846 . . . . 0.0 109.535 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.3 m-20 -65.1 -47.49 76.99 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.368 -0.833 . . . . 0.0 110.298 -179.433 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 37.4 m -67.62 -44.63 77.56 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.211 -0.931 . . . . 0.0 109.775 -179.777 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 5.7 p -138.15 76.98 37.56 Favored Pre-proline 0 N--CA 1.492 1.658 0 N-CA-C 109.082 -0.71 . . . . 0.0 109.082 -179.912 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 10.7 Cg_endo -59.33 -63.31 0.13 Allowed 'Trans proline' 0 C--N 1.31 -1.489 0 C-N-CA 122.571 2.181 . . . . 0.0 112.801 -179.154 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 86.8 mtt-85 -61.24 -35.19 76.58 Favored 'General case' 0 C--N 1.297 -1.688 0 O-C-N 121.652 -0.655 . . . . 0.0 110.755 -178.77 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 25.3 m -60.27 -42.13 94.76 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 120.984 -1.073 . . . . 0.0 110.094 -179.418 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -59.95 -31.82 70.23 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.128 -0.983 . . . . 0.0 109.153 -179.794 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -67.7 -36.88 81.47 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.401 -0.812 . . . . 0.0 109.915 -179.9 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 37.8 t30 -56.6 -40.81 75.92 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.261 -0.899 . . . . 0.0 109.823 -179.458 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 98.4 m-85 -90.43 -48.6 7.01 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.069 -1.019 . . . . 0.0 109.828 -179.89 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.893 ' HE ' HE22 ' A' ' 176' ' ' GLN . 66.2 ttt-85 -57.41 -41.32 80.14 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.512 -0.742 . . . . 0.0 110.505 -179.375 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -65.55 -47.6 75.3 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.049 -1.032 . . . . 0.0 110.373 -178.916 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.469 ' N ' ' CD2' ' A' ' 45' ' ' LEU . 3.3 mm? -65.51 -39.87 92.36 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.124 -0.985 . . . . 0.0 109.665 -179.735 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' CYS . . . . . . . . . . . . . 72.3 m -68.24 -46.09 71.44 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.1 -1.0 . . . . 0.0 109.315 179.819 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 72.6 p -74.34 -33.53 63.16 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.313 -0.867 . . . . 0.0 109.721 179.877 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 75.03 30.81 58.6 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 110.037 -1.225 . . . . 0.0 110.037 179.739 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 77.9 mm-40 -61.97 -36.67 82.16 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.137 -1.214 . . . . 0.0 109.441 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 42.0 mmtm -60.66 -33.87 73.45 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.233 -0.917 . . . . 0.0 109.402 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 92.84 171.3 40.45 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.096 -1.602 . . . . 0.0 109.096 -179.692 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.636 HG23 ' HA ' ' A' ' 58' ' ' PRO . 99.2 m -75.88 141.39 42.38 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.317 -1.108 . . . . 0.0 109.76 -179.807 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -60.42 138.15 48.62 Favored Glycine 0 N--CA 1.488 2.164 0 N-CA-C 109.405 -1.478 . . . . 0.0 109.405 179.787 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 87.1 mtt-85 -60.24 -29.22 68.62 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.303 -1.116 . . . . 0.0 110.231 -179.803 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 75.4 m -78.52 11.0 2.7 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.181 -0.95 . . . . 0.0 110.32 -179.154 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 82.16 77.03 1.07 Allowed Glycine 0 N--CA 1.492 2.4 0 N-CA-C 109.217 -1.553 . . . . 0.0 109.217 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' LYS . . . . . 0.478 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 55.0 mttp -157.47 75.0 4.16 Favored Pre-proline 0 C--N 1.302 -1.463 0 O-C-N 121.449 -1.03 . . . . 0.0 108.3 -179.944 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.636 ' HA ' HG23 ' A' ' 52' ' ' THR . 73.1 Cg_exo -50.04 130.28 27.32 Favored 'Trans proline' 0 C--N 1.302 -1.909 0 C-N-CA 122.962 2.441 . . . . 0.0 112.517 -179.085 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.478 ' CD1' ' O ' ' A' ' 57' ' ' LYS . 8.6 mp -100.8 74.22 1.63 Allowed 'General case' 0 N--CA 1.489 1.524 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 -179.638 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 77.5 m80 -139.21 150.68 45.82 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.436 -0.79 . . . . 0.0 109.516 179.865 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 3.8 m-85 -101.95 20.48 16.41 Favored 'General case' 0 N--CA 1.493 1.691 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 179.573 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 85.0 mttt -77.57 157.55 30.26 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.434 -0.791 . . . . 0.0 109.525 -179.663 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 54.8 t0 56.89 48.9 15.04 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.486 -0.759 . . . . 0.0 109.805 179.788 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 87.4 p -111.71 154.25 25.26 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.4 -0.813 . . . . 0.0 109.077 179.69 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 27.8 t -131.03 149.3 52.68 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.227 -0.921 . . . . 0.0 109.74 -179.603 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -72.68 135.84 45.49 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.351 -0.843 . . . . 0.0 109.131 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 32.1 m-70 -77.84 -53.01 7.98 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.259 -0.901 . . . . 0.0 110.71 -179.219 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 98.1 mtt180 -130.27 148.96 52.16 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.043 -1.035 . . . . 0.0 110.541 -179.017 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.694 HG21 HG22 ' A' ' 165' ' ' THR . 8.5 m -143.67 59.6 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.585 -0.697 . . . . 0.0 109.135 179.497 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 18.6 mt -82.14 132.67 52.73 Favored Pre-proline 0 C--N 1.301 -1.543 0 O-C-N 121.164 -0.96 . . . . 0.0 109.771 -179.135 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -70.98 149.67 59.49 Favored 'Trans proline' 0 N--CA 1.492 1.437 0 C-N-CA 122.399 2.066 . . . . 0.0 112.113 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 81.33 -58.28 4.86 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 179.879 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -70.01 -84.83 0.03 OUTLIER 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.269 -1.136 . . . . 0.0 109.637 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' MET . . . . . 0.484 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 14.1 ptt? 178.03 -172.83 0.13 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.334 -0.854 . . . . 0.0 109.544 179.877 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 14.6 p -125.75 137.26 53.8 Favored 'General case' 0 N--CA 1.493 1.721 0 N-CA-C 108.595 -0.891 . . . . 0.0 108.595 179.45 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 93.1 mt-30 -111.53 153.99 25.44 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.167 -0.958 . . . . 0.0 109.771 -179.485 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -134.76 174.43 21.07 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.006 -1.638 . . . . 0.0 109.006 179.7 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -137.24 161.03 25.19 Favored Glycine 0 N--CA 1.493 2.477 0 N-CA-C 109.717 -1.353 . . . . 0.0 109.717 -179.88 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 90.3 m-20 -72.89 156.81 38.49 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.379 -1.071 . . . . 0.0 109.457 179.865 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.411 ' CE2' ' O ' ' A' ' 58' ' ' PRO . 50.7 p90 -61.97 -18.49 60.58 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.327 -0.858 . . . . 0.0 109.744 -179.666 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.583 ' OG1' ' N ' ' A' ' 88' ' ' GLY . 73.1 p -61.71 -34.39 75.69 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.046 -1.034 . . . . 0.0 109.534 -179.902 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 82' ' ' ALA . . . . . 0.559 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 172.24 -50.46 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.329 -0.857 . . . . 0.0 109.434 179.942 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 92.45 3.14 67.2 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 80.3 m-20 -86.9 5.91 34.6 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.218 -1.166 . . . . 0.0 109.306 179.975 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 95.13 -42.61 2.34 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 -179.804 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 47.8 m -61.23 -38.91 88.33 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.207 -1.172 . . . . 0.0 109.114 179.601 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -85.35 -166.46 41.92 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.583 ' N ' ' OG1' ' A' ' 81' ' ' THR . . . 83.52 43.69 7.25 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 -179.897 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -64.05 144.14 57.33 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.266 -1.138 . . . . 0.0 109.478 -179.848 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 29.3 t -102.91 142.12 34.55 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.34 -0.85 . . . . 0.0 109.369 -179.884 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.406 HG12 ' H ' ' A' ' 91' ' ' ILE . 6.4 pt -63.26 -42.68 97.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.339 -0.851 . . . . 0.0 109.915 -179.737 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 3.8 m-30 -69.85 -36.19 75.35 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.976 -1.077 . . . . 0.0 109.558 179.871 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 80.81 14.85 78.95 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.224 -1.55 . . . . 0.0 109.224 -179.728 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -145.3 158.11 43.9 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.372 -1.075 . . . . 0.0 109.451 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -86.43 154.46 21.14 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.182 -0.949 . . . . 0.0 109.56 -179.881 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.401 ' H ' ' HB2' ' A' ' 121' ' ' ASN . 89.0 m-85 -100.23 130.64 46.38 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.281 -0.887 . . . . 0.0 109.305 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -76.62 138.75 40.29 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.159 -0.963 . . . . 0.0 109.496 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.513 ' OD2' HG21 ' A' ' 140' ' ' VAL . 88.5 m-20 -75.54 131.25 39.92 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.267 -0.896 . . . . 0.0 109.266 179.836 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -104.28 -55.46 2.36 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.239 -0.913 . . . . 0.0 110.061 -179.797 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 84.9 m-20 -106.35 128.82 54.3 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.233 -0.917 . . . . 0.0 110.24 -179.149 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 90.2 m-85 -108.38 10.52 27.5 Favored 'General case' 0 N--CA 1.493 1.686 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 179.352 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 92.0 mt -54.9 -37.0 39.88 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.397 -0.814 . . . . 0.0 110.568 -178.974 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 103' ' ' LYS . . . . . 0.401 ' NZ ' ' CG ' ' A' ' 31' ' ' PHE . 87.2 mttt -77.2 127.99 33.59 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.871 -1.143 . . . . 0.0 109.909 -179.427 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 104' ' ' LYS . . . . . 0.593 ' O ' ' N ' ' A' ' 106' ' ' THR . 34.4 ttmt -139.08 149.96 45.18 Favored 'General case' 0 N--CA 1.492 1.636 0 N-CA-C 109.012 -0.736 . . . . 0.0 109.012 179.862 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 105' ' ' HIS . . . . . . . . . . . . . 85.5 m-70 -53.69 82.34 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.094 -1.004 . . . . 0.0 109.66 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 106' ' ' THR . . . . . 0.593 ' N ' ' O ' ' A' ' 104' ' ' LYS . 54.9 p -73.45 -28.0 61.72 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.235 -0.915 . . . . 0.0 109.525 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -150.21 -177.51 24.25 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.882 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 69.6 Cg_endo -76.14 156.33 37.96 Favored 'Trans proline' 0 C--N 1.306 -1.666 0 C-N-CA 123.025 2.483 . . . . 0.0 112.198 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 81.86 45.75 7.05 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 110.098 -1.201 . . . . 0.0 110.098 179.706 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 41.6 mm -115.98 136.91 51.39 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 121.287 -1.125 . . . . 0.0 109.459 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.543 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 2.4 mm? -87.54 128.28 35.25 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.199 -0.938 . . . . 0.0 109.263 179.716 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 87.7 p -143.16 150.84 39.96 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.332 -0.855 . . . . 0.0 109.547 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 113' ' ' MET . . . . . 0.458 ' CE ' ' OD1' ' A' ' 121' ' ' ASN . 86.5 mtp -95.35 139.47 31.6 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.343 -0.848 . . . . 0.0 109.329 179.621 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -64.38 145.35 56.2 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.237 -0.914 . . . . 0.0 109.54 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 115' ' ' ASN . . . . . 0.573 ' ND2' HG23 ' A' ' 140' ' ' VAL . 2.7 p30 -165.77 114.98 1.0 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.184 -0.948 . . . . 0.0 109.613 179.863 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -66.19 -31.31 72.06 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.383 -0.823 . . . . 0.0 109.356 179.721 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -136.84 169.81 23.72 Favored Glycine 0 N--CA 1.493 2.474 0 N-CA-C 109.351 -1.5 . . . . 0.0 109.351 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -65.84 157.67 57.82 Favored 'Trans proline' 0 C--N 1.305 -1.757 0 C-N-CA 122.819 2.346 . . . . 0.0 111.969 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 68.0 m-20 55.89 44.3 26.06 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.425 -0.797 . . . . 0.0 109.325 -179.857 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 61.2 m -135.96 127.83 29.37 Favored 'General case' 0 C--N 1.304 -1.383 0 N-CA-C 108.804 -0.814 . . . . 0.0 108.804 179.851 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 121' ' ' ASN . . . . . 0.458 ' OD1' ' CE ' ' A' ' 113' ' ' MET . 31.9 t30 -100.5 109.9 22.05 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.423 -0.798 . . . . 0.0 109.374 -179.954 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -85.8 135.33 13.29 Favored Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.644 -1.383 . . . . 0.0 109.644 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 85.3 p -65.1 -23.38 67.14 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.248 -1.148 . . . . 0.0 109.408 179.871 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.0 mt-30 -101.89 154.2 19.15 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.378 -0.826 . . . . 0.0 109.606 -179.728 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 49.3 p90 -133.6 160.95 35.96 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.471 -0.768 . . . . 0.0 109.461 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.484 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 45.6 p90 -140.0 159.71 41.58 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.324 -0.86 . . . . 0.0 109.504 -179.91 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 72.5 mt -119.77 134.24 63.95 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.407 -0.808 . . . . 0.0 109.444 179.845 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 1.8 m -92.2 105.55 17.74 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.104 -0.998 . . . . 0.0 109.268 179.827 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 54.2 p -74.72 -9.12 58.26 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.271 -0.893 . . . . 0.0 109.463 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -150.44 156.15 40.91 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.362 -0.836 . . . . 0.0 109.277 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 82.5 tttt -68.01 135.16 51.88 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.216 -0.928 . . . . 0.0 109.23 179.855 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 6.5 p -122.11 158.0 30.24 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.409 -0.807 . . . . 0.0 109.558 -179.74 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -138.69 -35.66 0.58 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.317 -0.865 . . . . 0.0 109.081 179.812 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 0.7 OUTLIER -58.7 -29.43 66.64 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.447 -0.783 . . . . 0.0 109.219 179.713 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 18.2 mt -59.49 -35.77 74.77 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.32 -0.863 . . . . 0.0 109.628 179.638 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 57.5 t0 49.45 50.94 17.31 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.286 -0.884 . . . . 0.0 109.518 179.801 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -130.2 127.63 5.37 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.166 -1.574 . . . . 0.0 109.166 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 138' ' ' LYS . . . . . 0.515 ' O ' ' O ' ' A' ' 139' ' ' HIS . 88.2 mttt -56.58 -38.19 71.65 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.36 -1.083 . . . . 0.0 109.652 -179.846 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 139' ' ' HIS . . . . . 0.515 ' O ' ' O ' ' A' ' 138' ' ' LYS . 54.6 m170 56.86 147.88 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.644 -0.66 . . . . 0.0 109.824 179.936 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.573 HG23 ' ND2' ' A' ' 115' ' ' ASN . 41.0 t -116.05 133.6 62.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.413 -0.804 . . . . 0.0 109.296 -179.893 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 60.1 t -107.27 127.51 62.99 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 121.272 -0.893 . . . . 0.0 109.52 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 39.1 p90 -116.16 3.06 13.45 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.403 -0.81 . . . . 0.0 109.682 179.773 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -173.08 179.13 44.7 Favored Glycine 0 N--CA 1.494 2.528 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 179.612 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.3 pt20 -145.82 166.29 26.35 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.114 -1.227 . . . . 0.0 109.865 -179.855 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 74.6 t -100.63 132.11 46.92 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.122 0 O-C-N 121.278 -0.888 . . . . 0.0 109.581 -179.855 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 12.9 m -113.85 -31.52 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.308 -0.87 . . . . 0.0 109.422 179.563 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -139.62 167.25 22.52 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.356 -0.84 . . . . 0.0 109.469 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 97.67 4.0 58.18 Favored Glycine 0 N--CA 1.494 2.527 0 N-CA-C 109.941 -1.264 . . . . 0.0 109.941 179.765 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 149' ' ' MET . . . . . 0.436 ' O ' HG12 ' A' ' 152' ' ' VAL . 65.0 mtt -60.71 -33.44 72.89 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.098 -1.236 . . . . 0.0 109.479 179.934 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 89.3 m-20 -64.02 -41.64 97.38 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.913 -1.117 . . . . 0.0 109.852 -179.761 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.5 p -83.24 -34.37 10.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.199 -0.938 . . . . 0.0 110.402 -179.446 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 152' ' ' VAL . . . . . 0.464 ' CG1' ' N ' ' A' ' 153' ' ' LYS . 0.6 OUTLIER -57.02 -42.77 79.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 120.872 -1.142 . . . . 0.0 109.382 -179.219 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 153' ' ' LYS . . . . . 0.464 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 66.6 mttm -63.84 -34.41 77.87 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.242 -0.911 . . . . 0.0 109.517 179.503 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -61.48 -37.9 85.33 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.24 -0.913 . . . . 0.0 109.962 -179.492 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 88.3 mt -72.51 -35.14 50.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.189 -0.945 . . . . 0.0 110.047 -179.717 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -76.29 -41.64 48.04 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.202 -0.936 . . . . 0.0 111.191 -178.865 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 39.1 pttt -61.8 -33.92 74.98 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 120.852 -1.155 . . . . 0.0 109.89 -178.819 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.42 ' HB ' ' H ' ' A' ' 166' ' ' ALA . 35.3 m -77.8 -13.99 14.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.011 -1.056 . . . . 0.0 109.26 179.714 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -74.3 168.27 54.44 Favored Glycine 0 N--CA 1.489 2.2 0 N-CA-C 109.789 -1.324 . . . . 0.0 109.789 -179.718 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 22.8 t -157.67 176.36 12.71 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.418 -1.048 . . . . 0.0 109.361 -179.758 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 23.6 m -54.01 -31.78 52.16 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.282 -0.886 . . . . 0.0 109.182 179.817 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 23.9 m -55.56 -33.07 63.53 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.28 -0.888 . . . . 0.0 109.462 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 95.38 10.97 56.54 Favored Glycine 0 N--CA 1.493 2.482 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 179.828 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 81.7 mtm180 -121.44 146.57 46.76 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.303 -1.116 . . . . 0.0 109.474 179.874 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 165' ' ' THR . . . . . 0.694 HG22 HG21 ' A' ' 69' ' ' VAL . 80.5 p -80.49 151.42 29.24 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.224 -0.923 . . . . 0.0 109.646 -179.884 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 166' ' ' ALA . . . . . 0.42 ' H ' ' HB ' ' A' ' 158' ' ' VAL . . . -66.66 -37.06 84.02 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.322 -0.862 . . . . 0.0 109.077 179.592 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -108.71 158.69 17.39 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.555 -0.716 . . . . 0.0 109.096 179.721 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -71.4 130.78 42.2 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.14 -0.975 . . . . 0.0 109.394 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 43.6 t -122.15 124.24 70.67 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 121.38 -0.825 . . . . 0.0 109.435 179.795 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 48.8 t -149.1 154.61 9.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.48 -0.763 . . . . 0.0 109.141 179.865 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 2.1 t -90.15 124.87 43.0 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 O-C-N 121.258 -0.901 . . . . 0.0 109.932 -179.312 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 172' ' ' GLU . . . . . 0.433 ' OE2' ' OG ' ' A' ' 17' ' ' SER . 97.1 mt-10 -64.96 -28.87 69.81 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.449 -0.782 . . . . 0.0 109.192 179.46 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 173' ' ' ASP . . . . . 0.425 ' C ' ' OD1' ' A' ' 173' ' ' ASP . 53.1 p30 -175.14 179.58 1.53 Allowed 'General case' 0 N--CA 1.492 1.639 0 C-N-CA 119.449 -0.9 . . . . 0.0 110.352 -179.665 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 26.7 p -151.48 151.38 31.56 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.45 -0.781 . . . . 0.0 109.265 179.711 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -178.18 176.83 48.22 Favored Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.792 -1.323 . . . . 0.0 109.792 179.812 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 176' ' ' GLN . . . . . 0.893 HE22 ' HE ' ' A' ' 43' ' ' ARG . 59.3 tt0 -107.11 127.21 53.29 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.375 -1.073 . . . . 0.0 109.61 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 29.0 tp -60.98 -37.78 83.66 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.187 -0.945 . . . . 0.0 109.194 179.641 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 9.5 t . . . . . 0 N--CA 1.49 1.563 0 CA-C-O 117.945 -1.026 . . . . 0.0 109.483 -179.942 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.528 4.816 0 N-CA-C 119.357 2.503 . . . . 0.0 119.357 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 55.3 p -70.47 160.59 32.13 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.213 -1.169 . . . . 0.0 109.479 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 99.4 m-85 -114.11 126.23 54.85 Favored 'General case' 0 N--CA 1.486 1.363 0 N-CA-C 108.822 -0.807 . . . . 0.0 108.822 179.563 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 56.2 p -64.04 -31.71 73.0 Favored 'General case' 0 C--N 1.297 -1.711 0 O-C-N 121.554 -0.716 . . . . 0.0 109.41 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 83.04 -170.19 49.18 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.716 -1.354 . . . . 0.0 109.716 179.841 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 49.9 m -66.65 158.02 31.08 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.32 -1.106 . . . . 0.0 109.624 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 57.3 mtp -62.86 150.55 87.3 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.25 -0.906 . . . . 0.0 109.232 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_endo -69.01 169.48 17.87 Favored 'Trans proline' 0 N--CA 1.493 1.462 0 C-N-CA 122.7 2.267 . . . . 0.0 112.108 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 6.5 m120 -66.91 148.34 98.87 Favored Pre-proline 0 N--CA 1.489 1.485 0 O-C-N 121.38 -0.825 . . . . 0.0 109.486 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -70.65 140.24 38.9 Favored 'Trans proline' 0 N--CA 1.494 1.558 0 C-N-CA 122.777 2.318 . . . . 0.0 112.409 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 97.8 mtt180 -128.96 132.09 47.56 Favored 'General case' 0 N--CA 1.491 1.592 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 179.127 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.6 p -136.51 142.62 37.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.248 -0.907 . . . . 0.0 109.633 -179.441 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 38.5 p90 -144.19 154.79 43.5 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.344 -0.847 . . . . 0.0 109.589 -179.866 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 67.1 m-85 -126.66 138.14 53.38 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.332 -0.855 . . . . 0.0 109.597 179.648 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.468 ' CG ' ' NH1' ' A' ' 25' ' ' ARG . 90.2 m-20 -87.02 129.94 34.68 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.168 -0.957 . . . . 0.0 108.616 178.983 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' MET . . . . . 0.541 ' SD ' HD12 ' A' ' 26' ' ' ILE . 83.8 mtp -117.35 153.85 32.31 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.164 -0.96 . . . . 0.0 110.37 -179.441 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 76.9 p -148.14 167.33 25.32 Favored 'General case' 0 N--CA 1.487 1.42 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 179.629 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 7.9 p -127.4 134.24 66.19 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.244 -0.91 . . . . 0.0 109.717 -179.815 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 54.79 17.13 8.55 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.626 -1.389 . . . . 0.0 109.626 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 92.24 4.56 66.39 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 63.9 mt-30 -105.49 113.43 64.24 Favored Pre-proline 0 N--CA 1.494 1.728 0 O-C-N 121.345 -1.091 . . . . 0.0 109.241 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_exo -48.81 137.24 27.6 Favored 'Trans proline' 0 N--CA 1.492 1.406 0 C-N-CA 122.123 1.882 . . . . 0.0 112.086 179.913 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -111.22 -59.4 1.98 Allowed 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.411 -0.806 . . . . 0.0 109.498 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -170.44 -169.8 33.99 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.376 -1.49 . . . . 0.0 109.376 -179.859 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' ARG . . . . . 0.468 ' NH1' ' CG ' ' A' ' 15' ' ' ASP . 88.2 mtt-85 -116.46 145.8 43.03 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.308 -1.113 . . . . 0.0 109.784 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.541 HD12 ' SD ' ' A' ' 16' ' ' MET . 73.5 mt -119.8 122.45 68.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 178.863 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 46.1 t -111.02 133.3 57.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.3 -0.875 . . . . 0.0 109.3 -179.562 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 75.2 mtm -116.22 150.88 36.8 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.447 -0.783 . . . . 0.0 109.412 -179.767 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.419 ' C ' HD22 ' A' ' 30' ' ' LEU . 84.4 tt0 -101.47 130.92 47.81 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.277 -0.889 . . . . 0.0 109.926 -179.594 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.419 HD22 ' C ' ' A' ' 29' ' ' GLU . 2.9 mm? -109.86 127.74 54.9 Favored 'General case' 0 N--CA 1.493 1.683 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 179.277 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 96.3 m-85 -98.96 118.53 35.93 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.167 -0.958 . . . . 0.0 109.049 179.525 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -79.66 -41.94 25.86 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.379 -0.826 . . . . 0.0 109.776 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -64.35 -46.6 82.72 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.286 -0.884 . . . . 0.0 110.246 -179.333 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 33.1 m -67.38 -44.42 78.97 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.136 -0.978 . . . . 0.0 109.815 -179.72 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.449 ' O ' ' OG1' ' A' ' 35' ' ' THR . 6.8 p -141.61 79.65 16.85 Favored Pre-proline 0 N--CA 1.492 1.649 0 O-C-N 121.429 -0.794 . . . . 0.0 109.291 -179.859 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -64.25 -54.63 0.78 Allowed 'Trans proline' 0 C--N 1.308 -1.564 0 C-N-CA 122.286 1.991 . . . . 0.0 112.508 -179.404 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 70.9 mtp180 -62.43 -38.75 90.93 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.52 -0.737 . . . . 0.0 110.636 -179.196 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 28.6 m -65.16 -43.82 90.55 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.948 -1.095 . . . . 0.0 110.236 -179.474 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -63.14 -30.61 71.73 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.18 -0.95 . . . . 0.0 109.21 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -71.2 -43.78 66.72 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.345 -0.847 . . . . 0.0 109.837 -179.733 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 45.8 t30 -62.76 -47.82 81.86 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.248 -0.907 . . . . 0.0 109.992 -179.512 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 61.1 t80 -63.79 -47.75 79.64 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.208 -0.932 . . . . 0.0 109.567 -179.667 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.652 ' CZ ' HE22 ' A' ' 176' ' ' GLN . 74.4 ttt180 -57.83 -38.17 75.12 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.365 -0.835 . . . . 0.0 109.854 -179.849 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.512 ' O ' ' N ' ' A' ' 48' ' ' GLY . . . -62.32 -42.9 99.76 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.118 -0.989 . . . . 0.0 110.088 -179.247 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.591 HD12 ' CD1' ' A' ' 61' ' ' TYR . 4.4 mm? -66.28 -38.02 86.79 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.02 -1.05 . . . . 0.0 109.582 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 46' ' ' CYS . . . . . . . . . . . . . 3.8 m -65.9 -53.56 37.88 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.104 -0.997 . . . . 0.0 109.357 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 64.4 p -75.02 -31.46 61.37 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.336 -0.852 . . . . 0.0 109.451 179.674 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.512 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 75.7 37.34 40.12 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 110.314 -1.114 . . . . 0.0 110.314 179.51 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -61.61 -37.66 84.77 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.858 -1.377 . . . . 0.0 109.418 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.458 ' HZ1' ' CD1' ' A' ' 91' ' ' ILE . 27.0 mmtp -61.38 -34.0 74.6 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.28 -0.887 . . . . 0.0 109.279 179.819 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 82.13 -86.63 1.43 Allowed Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.654 -1.378 . . . . 0.0 109.654 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.566 HG23 ' C ' ' A' ' 57' ' ' LYS . 48.8 m -123.77 140.37 53.05 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.448 -1.03 . . . . 0.0 109.637 -179.779 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -56.58 -35.63 67.69 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.44 -1.464 . . . . 0.0 109.44 179.817 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' ARG . . . . . 0.533 ' H ' HG22 ' A' ' 52' ' ' THR . 74.3 mtp85 -140.22 -110.2 0.15 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.35 -1.088 . . . . 0.0 109.207 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 24.9 p -134.13 0.71 3.16 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.366 -0.833 . . . . 0.0 109.746 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -151.09 49.3 0.55 Allowed Glycine 0 N--CA 1.492 2.417 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' LYS . . . . . 0.566 ' C ' HG23 ' A' ' 52' ' ' THR . 59.7 tttm -172.8 74.29 0.42 Allowed Pre-proline 0 N--CA 1.488 1.474 0 O-C-N 121.364 -1.08 . . . . 0.0 108.855 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.402 ' N ' HG23 ' A' ' 52' ' ' THR . 72.0 Cg_exo -47.77 131.93 20.85 Favored 'Trans proline' 0 C--N 1.305 -1.757 0 C-N-CA 122.702 2.268 . . . . 0.0 112.128 -179.417 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.573 ' O ' ' CG ' ' A' ' 60' ' ' HIS . 14.6 tp -109.31 118.39 36.56 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.616 -0.678 . . . . 0.0 109.437 -179.413 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 60' ' ' HIS . . . . . 0.577 ' O ' ' CZ ' ' A' ' 80' ' ' PHE . 92.4 m-70 -160.62 135.31 7.51 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.244 -0.91 . . . . 0.0 109.944 179.889 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 61' ' ' TYR . . . . . 0.591 ' CD1' HD12 ' A' ' 45' ' ' LEU . 2.9 m-30 -87.39 3.38 47.26 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.163 -0.96 . . . . 0.0 108.882 179.104 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 62.2 tttt -68.07 146.31 53.61 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.383 -0.823 . . . . 0.0 109.7 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 46.7 t0 61.67 50.8 4.23 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.427 -0.795 . . . . 0.0 110.07 179.784 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.718 ' H ' ' CG2' ' A' ' 171' ' ' VAL . 96.7 p -97.69 157.24 16.16 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.187 -0.946 . . . . 0.0 109.146 179.531 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 29.0 t -128.84 150.09 50.48 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.438 -0.789 . . . . 0.0 109.378 -179.792 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 4.4 m-85 -75.55 125.77 29.69 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.227 -0.92 . . . . 0.0 109.144 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 79.0 t60 -62.76 -48.57 78.61 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.326 -0.859 . . . . 0.0 110.044 -179.354 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.68 HH21 ' NE2' ' A' ' 76' ' ' GLN . 36.8 ptt180 -163.64 162.38 24.18 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.223 -0.923 . . . . 0.0 109.378 -179.925 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -141.75 112.61 3.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.315 -0.866 . . . . 0.0 109.142 179.738 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 43.8 mt -107.56 124.33 35.33 Favored Pre-proline 0 N--CA 1.492 1.645 0 O-C-N 121.45 -0.781 . . . . 0.0 109.073 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_endo -71.75 137.46 29.91 Favored 'Trans proline' 0 N--CA 1.491 1.363 0 C-N-CA 122.031 1.82 . . . . 0.0 112.338 -179.729 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 94.46 -28.25 11.57 Favored Glycine 0 N--CA 1.493 2.466 0 N-CA-C 109.723 -1.351 . . . . 0.0 109.723 179.739 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 94.3 m-85 -100.87 -80.74 0.48 Allowed 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.271 -1.135 . . . . 0.0 109.789 -179.94 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 13.2 ptp -177.87 -168.95 0.19 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.283 -0.886 . . . . 0.0 109.873 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -124.55 130.44 52.45 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.486 -0.759 . . . . 0.0 109.03 179.822 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 76' ' ' GLN . . . . . 0.68 ' NE2' HH21 ' A' ' 68' ' ' ARG . 93.5 mt-30 -108.03 151.65 25.56 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.379 -0.826 . . . . 0.0 109.818 -179.633 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -169.18 -170.49 33.82 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.32 -1.512 . . . . 0.0 109.32 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 88.67 21.25 44.29 Favored Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.766 -1.334 . . . . 0.0 109.766 179.912 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 83.9 m-20 -84.38 12.64 6.43 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.233 -1.157 . . . . 0.0 109.433 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.577 ' CZ ' ' O ' ' A' ' 60' ' ' HIS . 83.1 t80 -50.08 -40.98 47.23 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.313 -0.867 . . . . 0.0 110.134 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.662 ' O ' ' HB2' ' A' ' 82' ' ' ALA . 60.6 p -65.35 -31.26 72.29 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.957 -1.089 . . . . 0.0 109.499 -179.956 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 82' ' ' ALA . . . . . 0.662 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 165.3 -53.37 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.415 -0.803 . . . . 0.0 109.32 179.898 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 88.51 2.36 79.53 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 78.5 m-20 -87.85 6.93 33.06 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.254 -1.145 . . . . 0.0 109.478 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 97.2 -39.31 2.82 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.26 -1.536 . . . . 0.0 109.26 -179.788 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 57.1 p -72.63 -21.35 61.12 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.335 -1.097 . . . . 0.0 109.008 179.49 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -84.65 -167.21 42.57 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.603 ' H ' ' CB ' ' A' ' 81' ' ' THR . . . 81.76 44.6 7.69 Favored Glycine 0 N--CA 1.488 2.134 0 N-CA-C 109.016 -1.634 . . . . 0.0 109.016 -179.871 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -94.36 142.49 27.36 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.377 -1.072 . . . . 0.0 109.708 -179.55 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 90.7 p -112.85 158.26 20.38 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.442 -0.786 . . . . 0.0 109.197 179.844 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.458 ' CD1' ' HZ1' ' A' ' 50' ' ' LYS . 29.1 pt -59.08 -32.02 47.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.142 -0.974 . . . . 0.0 109.634 -179.718 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 92' ' ' TYR . . . . . 0.53 ' O ' ' N ' ' A' ' 94' ' ' ALA . 56.8 m-85 -66.46 -30.12 70.39 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.223 -0.923 . . . . 0.0 109.631 179.636 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 64.07 -72.27 0.05 OUTLIER Glycine 0 N--CA 1.489 2.206 0 N-CA-C 109.336 -1.506 . . . . 0.0 109.336 -179.889 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 94' ' ' ALA . . . . . 0.53 ' N ' ' O ' ' A' ' 92' ' ' TYR . . . -63.55 143.96 57.39 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.376 -1.073 . . . . 0.0 109.119 179.719 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 95' ' ' LYS . . . . . 0.631 ' HD3' HG23 ' A' ' 120' ' ' THR . 59.0 mttp -88.58 149.33 23.63 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.379 -0.826 . . . . 0.0 109.71 -179.849 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 52.0 p90 -130.86 158.52 39.97 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.425 -0.797 . . . . 0.0 109.252 179.705 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -84.79 146.94 27.11 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.28 -0.887 . . . . 0.0 109.893 -179.577 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 60.4 t0 -78.88 124.8 28.59 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.336 -0.852 . . . . 0.0 109.113 179.747 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -54.42 -39.15 67.06 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.146 -0.972 . . . . 0.0 109.729 -179.518 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 100' ' ' ASN . . . . . 0.469 ' CG ' ' H ' ' A' ' 101' ' ' PHE . 15.1 t-20 -172.32 -177.45 1.81 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.097 -1.002 . . . . 0.0 109.808 179.855 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 101' ' ' PHE . . . . . 0.469 ' H ' ' CG ' ' A' ' 100' ' ' ASN . 15.7 p90 -147.42 62.57 1.16 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.487 -0.758 . . . . 0.0 109.067 179.861 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 80.6 mt -59.66 -37.34 70.42 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.268 -0.895 . . . . 0.0 110.216 -179.447 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 67.6 mttm -86.15 139.41 31.11 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.017 -1.052 . . . . 0.0 109.982 -179.436 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 59.2 mttp -129.12 -176.02 3.74 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.483 -0.761 . . . . 0.0 109.457 179.737 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 105' ' ' HIS . . . . . 0.53 ' O ' ' CG ' ' A' ' 105' ' ' HIS . 49.1 p-80 -109.57 100.36 9.42 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.519 -0.738 . . . . 0.0 109.276 179.704 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 63.7 p -106.96 -0.8 22.85 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.406 -0.809 . . . . 0.0 109.599 -179.831 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -146.62 171.29 27.45 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.336 -1.505 . . . . 0.0 109.336 -179.89 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -74.39 155.44 45.91 Favored 'Trans proline' 0 C--N 1.306 -1.672 0 C-N-CA 122.888 2.392 . . . . 0.0 112.17 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 83.22 44.9 6.8 Favored Glycine 0 N--CA 1.493 2.493 0 N-CA-C 110.234 -1.146 . . . . 0.0 110.234 179.488 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 44.0 mm -116.31 134.21 60.43 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 121.251 -1.146 . . . . 0.0 109.342 179.723 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.525 ' N ' HD22 ' A' ' 111' ' ' LEU . 3.4 mm? -91.44 130.91 37.21 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.251 -0.906 . . . . 0.0 109.385 179.709 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 47.2 t -143.68 142.24 30.9 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.238 -0.914 . . . . 0.0 109.439 179.826 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 72.1 mtm -82.87 131.21 35.2 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.193 -0.942 . . . . 0.0 109.205 179.769 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -65.87 141.71 58.17 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.192 -0.943 . . . . 0.0 109.587 -179.911 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 64.7 m-20 -146.27 113.03 6.03 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.322 -0.862 . . . . 0.0 109.027 179.664 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -68.51 -29.96 68.67 Favored 'General case' 0 C--N 1.297 -1.682 0 O-C-N 121.46 -0.775 . . . . 0.0 109.488 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -136.51 167.31 24.54 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 109.256 -1.538 . . . . 0.0 109.256 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -67.39 156.22 67.07 Favored 'Trans proline' 0 C--N 1.306 -1.696 0 C-N-CA 122.805 2.336 . . . . 0.0 111.889 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 30.1 m-20 54.35 45.26 27.55 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.422 -0.799 . . . . 0.0 109.35 -179.886 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 120' ' ' THR . . . . . 0.631 HG23 ' HD3' ' A' ' 95' ' ' LYS . 57.9 m -133.73 126.58 31.0 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 108.792 -0.818 . . . . 0.0 108.792 179.85 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 39.6 t30 -100.77 107.42 18.99 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.504 -0.748 . . . . 0.0 109.355 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -98.44 126.32 8.85 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 86.1 p -62.96 -25.96 68.6 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.268 -1.137 . . . . 0.0 109.385 179.795 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.3 mt-30 -73.86 148.18 42.58 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.283 -0.886 . . . . 0.0 109.399 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 48.8 p90 -136.3 162.75 32.14 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.326 -0.859 . . . . 0.0 109.446 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 49.0 p90 -136.48 160.8 37.67 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.371 -0.831 . . . . 0.0 109.445 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 69.2 mt -115.99 130.16 71.16 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.446 -0.784 . . . . 0.0 109.352 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -101.17 104.2 15.27 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.273 -0.892 . . . . 0.0 109.241 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 59.2 p -84.59 0.67 49.24 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.281 -0.887 . . . . 0.0 109.37 179.878 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -144.42 161.99 37.64 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.3 -0.875 . . . . 0.0 109.466 -179.768 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 92.4 mttt -76.0 150.65 37.37 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.254 -0.904 . . . . 0.0 109.486 -179.91 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 16.0 p -120.0 161.01 21.65 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.39 -0.819 . . . . 0.0 109.374 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -159.61 -44.12 0.05 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.19 -0.944 . . . . 0.0 109.758 -179.908 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 134' ' ' TRP . . . . . 0.4 ' CE2' ' CD2' ' A' ' 135' ' ' LEU . 33.3 p90 -73.71 -9.64 58.87 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.284 -0.885 . . . . 0.0 109.39 -179.802 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 135' ' ' LEU . . . . . 0.51 ' N ' ' CD2' ' A' ' 135' ' ' LEU . 2.8 mm? -61.59 -33.8 74.53 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.238 -0.914 . . . . 0.0 108.771 179.239 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 59.1 t0 49.16 49.91 18.83 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.44 -0.788 . . . . 0.0 109.754 179.648 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -143.83 163.79 27.59 Favored Glycine 0 N--CA 1.485 1.932 0 N-CA-C 108.915 -1.674 . . . . 0.0 108.915 179.847 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 13.6 mptt -97.21 142.73 28.77 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.472 -1.016 . . . . 0.0 109.465 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 99.3 m-70 -128.97 146.75 50.88 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.46 -0.775 . . . . 0.0 109.428 179.853 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 42.3 t -112.94 135.0 53.78 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.402 -0.811 . . . . 0.0 109.277 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 56.3 t -108.38 128.07 64.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 121.33 -0.856 . . . . 0.0 109.507 -179.757 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 45.9 p90 -112.88 -0.59 14.83 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.342 -0.849 . . . . 0.0 109.401 179.547 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -171.28 174.45 44.92 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 179.619 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 92.1 mt-30 -139.6 165.28 27.67 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.176 -1.19 . . . . 0.0 109.663 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 69.9 t -97.12 129.8 46.66 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.225 0 O-C-N 121.126 -0.984 . . . . 0.0 109.435 -179.952 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 16.0 m -106.99 -29.35 2.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.372 -0.83 . . . . 0.0 109.536 179.657 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -143.52 171.17 14.53 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.265 -0.897 . . . . 0.0 109.512 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 97.99 4.22 57.77 Favored Glycine 0 N--CA 1.493 2.46 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 179.64 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 149' ' ' MET . . . . . 0.466 ' O ' HG12 ' A' ' 152' ' ' VAL . 88.8 mtp -60.6 -33.95 73.51 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.13 -1.218 . . . . 0.0 109.672 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -64.98 -42.62 94.37 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.843 -1.161 . . . . 0.0 110.124 -179.624 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.1 p -82.79 -33.5 10.76 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.079 -1.013 . . . . 0.0 110.499 -179.429 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 152' ' ' VAL . . . . . 0.466 HG12 ' O ' ' A' ' 149' ' ' MET . 0.7 OUTLIER -55.17 -41.82 62.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 120.882 -1.136 . . . . 0.0 109.251 -179.335 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 153' ' ' LYS . . . . . 0.45 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 93.8 mttt -63.56 -34.8 78.6 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.171 -0.956 . . . . 0.0 109.298 179.356 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -63.0 -36.6 84.09 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.405 -0.809 . . . . 0.0 109.792 -179.599 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 69.9 mt -70.4 -38.6 74.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.211 -0.931 . . . . 0.0 110.036 -179.606 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -76.83 -41.14 45.37 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.067 -1.021 . . . . 0.0 111.63 -178.35 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 36.4 pttt -61.18 -34.19 74.65 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 120.729 -1.232 . . . . 0.0 110.261 -178.553 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 35.6 m -76.12 -20.09 15.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 120.917 -1.115 . . . . 0.0 109.469 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -72.91 165.24 54.81 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.652 -1.379 . . . . 0.0 109.652 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 22.9 t -151.42 171.71 17.09 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.376 -1.073 . . . . 0.0 109.382 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 22.6 t -53.7 -32.11 50.61 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.2 -0.938 . . . . 0.0 109.074 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 22.7 t -56.79 -30.94 64.16 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.251 -0.906 . . . . 0.0 109.34 179.722 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 96.41 8.04 57.75 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.678 -1.369 . . . . 0.0 109.678 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 98.6 mtt180 -120.71 144.14 48.39 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.244 -1.15 . . . . 0.0 109.29 179.831 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 165' ' ' THR . . . . . . . . . . . . . 59.6 p -91.23 157.29 17.25 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.197 -0.939 . . . . 0.0 109.728 -179.853 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -65.94 -33.79 76.63 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.367 -0.833 . . . . 0.0 109.613 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 60.8 mttp -119.41 161.03 21.19 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.406 -0.809 . . . . 0.0 109.905 -179.498 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 67.1 mttm -82.53 145.85 29.53 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.437 -0.789 . . . . 0.0 109.725 -179.918 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 1.9 m -133.75 127.08 52.1 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 O-C-N 121.277 -0.89 . . . . 0.0 109.575 179.783 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 44.3 t -137.99 139.05 43.15 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 O-C-N 121.392 -0.817 . . . . 0.0 109.407 179.837 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.718 ' CG2' ' H ' ' A' ' 64' ' ' SER . 9.5 m -67.06 124.51 22.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.0 -1.062 . . . . 0.0 109.208 179.819 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -69.29 -38.38 78.29 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.158 -0.964 . . . . 0.0 110.356 -179.63 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 173' ' ' ASP . . . . . 0.47 ' OD1' ' N ' ' A' ' 174' ' ' CYS . 48.0 t0 -168.7 168.82 10.48 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.958 -1.089 . . . . 0.0 110.209 -179.502 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 174' ' ' CYS . . . . . 0.47 ' N ' ' OD1' ' A' ' 173' ' ' ASP . 14.4 p -138.81 149.84 45.4 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.513 -0.742 . . . . 0.0 109.095 179.785 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -165.27 176.99 40.83 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.737 -1.345 . . . . 0.0 109.737 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 176' ' ' GLN . . . . . 0.652 HE22 ' CZ ' ' A' ' 43' ' ' ARG . 61.1 tt0 -109.83 113.9 27.03 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.331 -1.1 . . . . 0.0 109.614 -179.906 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 177' ' ' LEU . . . . . 0.407 ' O ' ' C ' ' A' ' 178' ' ' SER . 33.9 tp -64.4 -38.41 90.95 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.299 -0.876 . . . . 0.0 109.187 179.526 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 178' ' ' SER . . . . . 0.407 ' C ' ' O ' ' A' ' 177' ' ' LEU . 1.9 t . . . . . 0 N--CA 1.49 1.565 0 CA-C-O 118.04 -0.981 . . . . 0.0 109.621 179.96 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.529 4.835 0 N-CA-C 119.383 2.513 . . . . 0.0 119.383 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 28.2 t -116.32 143.02 46.07 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.445 -1.033 . . . . 0.0 109.42 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 74.6 t80 -99.3 102.57 14.22 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.292 -0.88 . . . . 0.0 109.233 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 48.8 m -66.53 -41.98 87.92 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.254 -0.903 . . . . 0.0 109.94 -179.781 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 82.61 -171.01 50.91 Favored Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.479 -1.449 . . . . 0.0 109.479 -179.741 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 56.2 p -75.76 159.24 31.27 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.305 -1.114 . . . . 0.0 109.594 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 18.5 ptt? -78.1 148.18 74.46 Favored Pre-proline 0 N--CA 1.489 1.515 0 O-C-N 121.224 -0.923 . . . . 0.0 109.371 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -72.04 167.38 26.9 Favored 'Trans proline' 0 C--N 1.31 -1.46 0 C-N-CA 122.627 2.218 . . . . 0.0 112.039 179.947 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 75.1 m-20 -73.64 148.94 88.06 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.297 -0.877 . . . . 0.0 109.506 179.891 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -66.88 140.17 54.33 Favored 'Trans proline' 0 N--CA 1.496 1.632 0 C-N-CA 122.593 2.196 . . . . 0.0 112.237 179.966 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 98.0 mtt180 -132.49 131.12 41.33 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.33 -0.857 . . . . 0.0 109.187 179.494 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.8 p -138.47 142.63 34.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.306 -0.871 . . . . 0.0 109.39 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 49.3 p90 -142.46 153.85 44.04 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.298 -0.876 . . . . 0.0 109.624 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 77.0 m-85 -126.19 140.83 52.25 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.409 -0.807 . . . . 0.0 109.538 179.654 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 88.4 m-20 -86.85 129.75 34.75 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.156 -0.965 . . . . 0.0 108.925 179.31 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' MET . . . . . 0.562 ' SD ' HD12 ' A' ' 26' ' ' ILE . 84.7 mtp -115.03 153.33 30.86 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.331 -0.855 . . . . 0.0 110.079 -179.683 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 83.8 p -149.0 164.16 35.38 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.442 -0.787 . . . . 0.0 109.129 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.541 ' O ' ' N ' ' A' ' 20' ' ' GLY . 20.4 m -127.25 144.46 37.25 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 121.233 -0.917 . . . . 0.0 109.604 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 47.61 11.43 0.1 OUTLIER Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.822 -1.311 . . . . 0.0 109.822 179.812 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.541 ' N ' ' O ' ' A' ' 18' ' ' VAL . . . 96.49 -14.93 63.64 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.895 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' GLN . . . . . 0.448 ' N ' ' CD ' ' A' ' 21' ' ' GLN . 3.8 mp0 -82.95 149.31 59.13 Favored Pre-proline 0 N--CA 1.492 1.632 0 O-C-N 121.268 -1.137 . . . . 0.0 109.029 179.778 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -62.42 135.35 53.11 Favored 'Trans proline' 0 C--N 1.308 -1.557 0 C-N-CA 122.353 2.035 . . . . 0.0 112.036 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -113.49 -68.11 0.95 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.398 -0.814 . . . . 0.0 109.554 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -176.0 -171.64 40.02 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 -179.865 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 40.0 ttm180 -123.45 142.65 50.78 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.446 -1.032 . . . . 0.0 109.327 -179.931 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.562 HD12 ' SD ' ' A' ' 16' ' ' MET . 75.5 mt -119.99 132.06 70.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.372 -0.83 . . . . 0.0 109.03 179.641 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 44.5 t -113.3 133.22 59.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.306 -0.872 . . . . 0.0 109.086 179.765 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 72.8 mtm -118.52 148.95 42.09 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.369 -0.832 . . . . 0.0 109.299 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -102.05 131.68 48.35 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.308 -0.87 . . . . 0.0 109.575 -179.752 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -104.9 128.75 53.25 Favored 'General case' 0 N--CA 1.492 1.655 0 N-CA-C 109.044 -0.725 . . . . 0.0 109.044 179.615 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 90.2 m-85 -97.25 120.98 38.61 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.309 -0.869 . . . . 0.0 109.307 179.731 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -82.53 -41.51 19.58 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.321 -0.862 . . . . 0.0 109.875 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 56.8 t0 -69.02 -44.36 72.89 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.228 -0.92 . . . . 0.0 110.828 -179.22 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 32.9 m -67.22 -45.71 75.98 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.047 -1.033 . . . . 0.0 110.491 -178.986 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 4.3 m -156.4 84.36 3.21 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.127 -0.983 . . . . 0.0 109.484 -179.524 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -75.24 -37.04 2.08 Favored 'Trans proline' 0 C--N 1.307 -1.639 0 C-N-CA 122.334 2.023 . . . . 0.0 112.497 -179.518 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 37.7 mmt180 -61.76 -41.02 97.14 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.21 -0.931 . . . . 0.0 109.644 -179.803 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.459 HG23 ' SD ' ' A' ' 113' ' ' MET . 86.5 m -66.21 -39.95 89.98 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.253 -0.904 . . . . 0.0 110.106 -179.71 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -60.11 -32.3 70.86 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.077 -1.014 . . . . 0.0 109.521 -179.818 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -69.82 -36.26 75.47 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.268 -0.895 . . . . 0.0 110.077 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 48.3 t30 -57.9 -42.7 85.23 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.101 -0.999 . . . . 0.0 109.767 -179.629 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -85.79 -48.12 9.09 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.206 -0.934 . . . . 0.0 109.681 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 34.9 ttm180 -57.4 -42.63 82.63 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.407 -0.808 . . . . 0.0 109.842 -179.508 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -69.82 -44.89 69.05 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.306 -0.872 . . . . 0.0 110.182 -179.411 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 36.7 tp -61.92 -36.42 81.3 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.078 -1.014 . . . . 0.0 109.446 -179.652 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' CYS . . . . . . . . . . . . . 46.9 m -79.51 -49.93 11.51 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.09 -1.006 . . . . 0.0 109.757 179.589 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 71.2 p -68.75 -34.72 76.06 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.149 -0.97 . . . . 0.0 109.575 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 75.16 28.92 61.26 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.972 -1.251 . . . . 0.0 109.972 179.6 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 78.0 mm-40 -60.98 -38.35 85.68 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.088 -1.243 . . . . 0.0 109.246 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 29.1 mmtm -62.48 -31.35 72.07 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 121.308 -0.87 . . . . 0.0 109.152 179.484 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 97.75 -119.64 6.49 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 108.87 -1.692 . . . . 0.0 108.87 -179.49 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.586 HG23 ' HA ' ' A' ' 58' ' ' PRO . 95.1 m -126.55 142.09 51.65 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.419 -1.048 . . . . 0.0 109.751 179.739 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -55.48 135.72 47.77 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.093 -1.603 . . . . 0.0 109.093 179.615 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 94.5 mtt180 -59.11 -37.66 77.71 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.18 -1.188 . . . . 0.0 110.079 -179.484 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 22.9 t -59.47 -31.4 69.3 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.179 -0.95 . . . . 0.0 109.834 -179.615 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 119.77 95.54 1.57 Allowed Glycine 0 N--CA 1.495 2.592 0 N-CA-C 108.648 -1.781 . . . . 0.0 108.648 -179.379 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 32.6 tptt -178.56 80.5 0.22 Allowed Pre-proline 0 N--CA 1.489 1.497 0 N-CA-C 108.07 -1.085 . . . . 0.0 108.07 -179.501 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.586 ' HA ' HG23 ' A' ' 52' ' ' THR . 97.3 Cg_exo -45.26 127.96 9.45 Favored 'Trans proline' 0 C--N 1.301 -1.922 0 C-N-CA 122.667 2.245 . . . . 0.0 112.203 -178.9 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.564 ' O ' ' CG ' ' A' ' 60' ' ' HIS . 84.0 mt -91.52 124.65 35.84 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.718 -0.614 . . . . 0.0 109.92 -179.285 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 60' ' ' HIS . . . . . 0.564 ' CG ' ' O ' ' A' ' 59' ' ' LEU . 86.5 m-70 -162.25 96.35 0.97 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.443 -0.785 . . . . 0.0 109.258 179.833 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 18.5 t80 -57.32 -34.39 68.68 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.174 -0.954 . . . . 0.0 108.708 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' LYS . . . . . 0.406 ' HG2' ' N ' ' A' ' 63' ' ' ASP . 3.1 ttmp? -46.79 161.06 0.07 Allowed 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.612 -0.68 . . . . 0.0 109.706 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 63' ' ' ASP . . . . . 0.406 ' N ' ' HG2' ' A' ' 62' ' ' LYS . 80.5 m-20 62.34 48.82 4.51 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.686 -0.634 . . . . 0.0 110.494 179.8 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.877 ' H ' HG22 ' A' ' 171' ' ' VAL . 33.7 t -103.48 144.63 31.15 Favored 'General case' 0 N--CA 1.492 1.642 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 178.76 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 28.6 t -124.05 148.63 46.91 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.096 -1.002 . . . . 0.0 110.309 -179.003 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 32.8 m-85 -87.75 129.99 34.99 Favored 'General case' 0 N--CA 1.491 1.614 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 179.494 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 94.7 m-70 -90.97 -28.58 17.94 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.103 -0.998 . . . . 0.0 110.901 -178.937 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.409 ' O ' HG13 ' A' ' 69' ' ' VAL . 48.9 mtp180 -134.34 147.97 50.64 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 120.957 -1.089 . . . . 0.0 110.245 -179.367 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.71 HG21 HG22 ' A' ' 165' ' ' THR . 10.2 m -153.98 64.7 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.503 -0.748 . . . . 0.0 109.205 179.825 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 21.7 mt -86.82 131.79 44.11 Favored Pre-proline 0 C--N 1.301 -1.502 0 O-C-N 121.009 -1.057 . . . . 0.0 109.788 -179.277 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_endo -71.27 147.16 52.75 Favored 'Trans proline' 0 N--CA 1.492 1.401 0 C-N-CA 122.354 2.036 . . . . 0.0 112.288 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 83.62 -58.7 5.01 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.763 -1.335 . . . . 0.0 109.763 179.808 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 95.6 m-85 -69.74 -83.83 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.177 -1.19 . . . . 0.0 109.622 -179.796 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' MET . . . . . 0.403 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 12.6 ptt? 179.05 -173.29 0.17 Allowed 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.278 -0.889 . . . . 0.0 109.68 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 1.2 p -126.34 137.57 53.49 Favored 'General case' 0 N--CA 1.491 1.622 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 179.443 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 91.9 mt-30 -116.73 153.92 31.54 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.256 -0.902 . . . . 0.0 109.735 -179.573 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -163.29 -173.65 32.24 Favored Glycine 0 N--CA 1.488 2.151 0 N-CA-C 109.177 -1.569 . . . . 0.0 109.177 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -160.39 -177.4 33.45 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.717 -1.353 . . . . 0.0 109.717 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.514 ' C ' ' H ' ' A' ' 81' ' ' THR . 83.1 m-20 -66.95 154.93 39.87 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.379 -1.071 . . . . 0.0 109.507 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.558 ' CE1' ' O ' ' A' ' 60' ' ' HIS . 36.5 p90 -58.89 0.24 0.09 Allowed 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.413 -0.804 . . . . 0.0 109.762 -179.856 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.619 ' O ' ' HB2' ' A' ' 82' ' ' ALA . 72.4 p -63.85 -32.31 73.78 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.991 -1.068 . . . . 0.0 109.538 -179.706 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 82' ' ' ALA . . . . . 0.619 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 169.48 -53.12 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.335 -0.853 . . . . 0.0 109.37 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 86.04 2.8 85.78 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.556 -1.417 . . . . 0.0 109.556 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 39.9 t-20 -85.94 5.91 30.94 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.263 -1.14 . . . . 0.0 109.497 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 100.96 -40.19 2.5 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 -179.776 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 58.9 p -70.75 -27.22 63.79 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.273 -1.134 . . . . 0.0 108.837 179.392 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -86.47 -167.66 43.89 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.184 -1.566 . . . . 0.0 109.184 179.657 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.485 ' N ' ' OG1' ' A' ' 81' ' ' THR . . . 82.25 42.38 8.69 Favored Glycine 0 N--CA 1.489 2.179 0 N-CA-C 109.359 -1.496 . . . . 0.0 109.359 -179.919 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -57.03 143.81 36.79 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.303 -1.116 . . . . 0.0 109.391 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 99.3 p -113.44 147.87 36.98 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.348 -0.845 . . . . 0.0 109.268 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.415 HG21 HD13 ' A' ' 91' ' ' ILE . 20.0 pt -74.01 -33.64 36.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.297 -0.877 . . . . 0.0 109.993 -179.837 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 81.8 m-85 -66.46 -41.14 89.48 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.173 -0.954 . . . . 0.0 109.795 -179.668 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 71.3 9.57 68.14 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.278 -1.529 . . . . 0.0 109.278 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -152.34 160.76 43.27 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.294 -1.121 . . . . 0.0 109.389 -179.758 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 63.7 mttp -83.4 145.85 28.77 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.22 -0.925 . . . . 0.0 109.665 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 52.4 p90 -137.05 160.5 38.78 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.402 -0.811 . . . . 0.0 109.312 179.674 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -104.49 144.23 31.96 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.31 -0.869 . . . . 0.0 109.513 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.523 ' O ' ' OD1' ' A' ' 98' ' ' ASP . 41.9 p30 -79.05 128.98 33.96 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.191 -0.943 . . . . 0.0 109.528 179.873 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -60.65 -37.73 82.49 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.159 -0.963 . . . . 0.0 109.693 -179.643 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 84.4 m-20 -124.42 144.18 50.21 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.251 -0.906 . . . . 0.0 109.849 -179.747 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 48.6 p90 -142.69 19.75 2.01 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.333 -0.854 . . . . 0.0 108.838 179.607 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 84.1 mt -59.47 -34.88 56.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.567 -0.708 . . . . 0.0 110.112 -179.649 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 93.0 mttt -79.65 135.65 36.61 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.069 -1.02 . . . . 0.0 109.768 -179.57 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 25.6 pttm -139.11 -178.69 5.46 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.412 -0.805 . . . . 0.0 109.439 -180.0 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 105' ' ' HIS . . . . . 0.535 ' O ' ' ND1' ' A' ' 105' ' ' HIS . 15.1 t-80 -74.27 88.02 2.0 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.174 -0.954 . . . . 0.0 109.256 179.825 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 58.8 p -75.05 -25.48 58.71 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.312 -0.867 . . . . 0.0 109.774 -179.781 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.533 ' O ' ' CE1' ' A' ' 105' ' ' HIS . . . -164.21 -166.95 23.97 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.397 -1.481 . . . . 0.0 109.397 -179.708 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -76.29 155.82 37.18 Favored 'Trans proline' 0 C--N 1.308 -1.574 0 C-N-CA 122.644 2.229 . . . . 0.0 112.117 179.901 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 88.32 24.29 34.51 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.869 -1.292 . . . . 0.0 109.869 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 36.6 mm -112.27 136.79 47.37 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.267 -1.137 . . . . 0.0 109.379 179.854 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.748 ' N ' HD22 ' A' ' 111' ' ' LEU . 2.7 mm? -88.2 132.57 34.3 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.283 -0.886 . . . . 0.0 109.152 179.77 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 112' ' ' SER . . . . . 0.401 ' OG ' ' O ' ' A' ' 140' ' ' VAL . 47.0 t -145.8 139.36 26.34 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.189 -0.944 . . . . 0.0 109.609 179.957 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 113' ' ' MET . . . . . 0.459 ' SD ' HG23 ' A' ' 38' ' ' THR . 71.9 mtm -89.23 139.03 30.9 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.243 -0.91 . . . . 0.0 109.267 179.651 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 114' ' ' ALA . . . . . 0.409 ' O ' ' OD1' ' A' ' 115' ' ' ASN . . . -60.74 138.31 58.11 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.242 -0.911 . . . . 0.0 109.152 179.983 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 115' ' ' ASN . . . . . 0.447 ' ND2' ' O ' ' A' ' 113' ' ' MET . 43.5 m-20 -148.81 112.95 5.2 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.173 -0.954 . . . . 0.0 109.19 179.93 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -68.31 -30.12 69.04 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 121.338 -0.851 . . . . 0.0 109.134 179.559 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -138.18 168.98 24.42 Favored Glycine 0 N--CA 1.493 2.451 0 N-CA-C 109.049 -1.621 . . . . 0.0 109.049 179.813 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -67.11 155.06 72.41 Favored 'Trans proline' 0 C--N 1.305 -1.739 0 C-N-CA 122.722 2.281 . . . . 0.0 112.027 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 75.6 m-20 53.99 44.34 29.48 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.448 -0.782 . . . . 0.0 109.432 -179.865 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 93.3 m -134.64 127.59 31.45 Favored 'General case' 0 N--CA 1.485 1.322 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 179.832 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 121' ' ' ASN . . . . . 0.413 ' OD1' ' SD ' ' A' ' 113' ' ' MET . 52.2 t30 -98.22 106.43 18.72 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.421 -0.8 . . . . 0.0 109.318 179.794 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -80.96 136.61 16.6 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 83.4 p -64.38 -23.73 67.39 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.268 -1.136 . . . . 0.0 109.442 179.853 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.2 mt-30 -103.73 150.89 23.63 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.267 -0.896 . . . . 0.0 109.675 -179.825 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 51.5 p90 -136.23 162.4 33.08 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.431 -0.793 . . . . 0.0 109.292 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.403 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 48.5 p90 -136.34 156.64 48.35 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.193 -0.942 . . . . 0.0 109.636 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 64.9 mt -122.53 133.1 69.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.449 -0.782 . . . . 0.0 109.189 179.812 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 128' ' ' CYS . . . . . 0.45 ' SG ' ' O ' ' A' ' 130' ' ' ALA . 5.7 t -99.82 118.46 36.33 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.154 -0.966 . . . . 0.0 109.499 179.938 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 64.9 p -95.05 4.12 54.1 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.294 -0.879 . . . . 0.0 109.489 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 130' ' ' ALA . . . . . 0.45 ' O ' ' SG ' ' A' ' 128' ' ' CYS . . . -147.41 155.82 42.31 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.271 -0.893 . . . . 0.0 109.684 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 51.4 tttp -72.9 137.17 45.45 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.204 -0.935 . . . . 0.0 109.423 179.918 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 7.2 p -122.46 161.49 23.45 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.47 -0.769 . . . . 0.0 109.542 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -104.88 -74.98 0.63 Allowed 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.336 -0.853 . . . . 0.0 109.666 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 134' ' ' TRP . . . . . 0.672 ' CD1' ' N ' ' A' ' 135' ' ' LEU . 45.9 p90 -61.65 -45.8 92.48 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.333 -0.854 . . . . 0.0 110.198 -179.56 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 135' ' ' LEU . . . . . 0.672 ' N ' ' CD1' ' A' ' 134' ' ' TRP . 13.5 tp -61.28 -32.3 72.13 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.336 -0.852 . . . . 0.0 109.72 -179.348 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 60.4 t0 -56.5 136.61 54.1 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.231 -0.918 . . . . 0.0 109.924 -179.38 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 137' ' ' GLY . . . . . 0.716 ' H ' ' CD2' ' A' ' 139' ' ' HIS . . . -162.65 -161.15 11.84 Favored Glycine 0 N--CA 1.486 2.009 0 N-CA-C 108.664 -1.774 . . . . 0.0 108.664 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 138' ' ' LYS . . . . . 0.464 ' O ' ' O ' ' A' ' 139' ' ' HIS . 92.1 mttt -57.21 -41.14 78.86 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.055 -1.262 . . . . 0.0 109.582 179.887 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 139' ' ' HIS . . . . . 0.716 ' CD2' ' H ' ' A' ' 137' ' ' GLY . 66.2 m-70 37.4 94.66 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.58 -0.7 . . . . 0.0 110.428 179.738 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.401 ' O ' ' OG ' ' A' ' 112' ' ' SER . 39.0 t -61.61 132.43 27.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 120.99 -1.069 . . . . 0.0 108.791 179.579 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 82.3 t -111.38 129.0 67.51 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 O-C-N 121.376 -0.828 . . . . 0.0 109.824 -179.45 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 41.9 p90 -116.19 -1.55 12.37 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.511 -0.743 . . . . 0.0 109.505 179.449 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -168.47 172.73 43.08 Favored Glycine 0 N--CA 1.493 2.479 0 N-CA-C 109.861 -1.296 . . . . 0.0 109.861 179.447 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 55.2 tt0 -139.99 160.33 40.18 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.31 -1.112 . . . . 0.0 109.347 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 145' ' ' VAL . . . . . 0.438 HG23 HD21 ' A' ' 111' ' ' LEU . 54.4 t -96.75 131.22 44.04 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.182 0 O-C-N 121.047 -1.033 . . . . 0.0 109.56 -179.759 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 16.4 m -111.0 -28.75 2.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.444 -0.785 . . . . 0.0 109.32 179.472 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -144.42 169.35 18.11 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.326 -0.859 . . . . 0.0 109.448 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 96.2 6.36 58.94 Favored Glycine 0 N--CA 1.494 2.511 0 N-CA-C 109.946 -1.262 . . . . 0.0 109.946 179.519 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 149' ' ' MET . . . . . 0.524 ' O ' HG12 ' A' ' 152' ' ' VAL . 89.0 mtp -59.89 -32.24 70.55 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.165 -1.197 . . . . 0.0 109.8 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -66.67 -42.66 86.2 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.868 -1.145 . . . . 0.0 109.994 -179.542 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 6.2 p -81.36 -34.86 13.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.167 -0.958 . . . . 0.0 110.555 -179.479 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 152' ' ' VAL . . . . . 0.556 ' O ' ' OE1' ' A' ' 156' ' ' GLU . 1.2 p -50.85 -42.39 23.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 120.843 -1.161 . . . . 0.0 108.772 -179.078 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 153' ' ' LYS . . . . . 0.445 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 61.5 mttp -67.39 -32.91 74.14 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.28 -0.887 . . . . 0.0 109.274 179.094 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -61.03 -30.89 70.58 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.469 -0.769 . . . . 0.0 110.396 -179.244 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 89.8 mt -68.54 -37.31 77.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.035 -1.041 . . . . 0.0 110.616 -179.384 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 156' ' ' GLU . . . . . 0.556 ' OE1' ' O ' ' A' ' 152' ' ' VAL . 42.0 mp0 -80.35 -39.13 29.13 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 120.815 -1.178 . . . . 0.0 111.743 -178.849 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 19.2 pttp -58.3 -37.4 74.97 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 120.455 -1.403 . . . . 0.0 109.161 -178.91 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 32.1 m -77.99 -15.05 14.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.273 -0.892 . . . . 0.0 108.82 179.163 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -78.9 176.52 54.6 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.719 -1.353 . . . . 0.0 109.719 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 22.7 t -156.46 171.75 19.73 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.31 -1.112 . . . . 0.0 109.288 -179.769 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 22.6 t -54.71 -30.78 56.88 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.13 -0.981 . . . . 0.0 109.224 179.84 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 86.8 p -59.98 -26.56 66.12 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.175 -0.953 . . . . 0.0 109.56 179.958 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 90.21 17.07 54.5 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 109.828 -1.309 . . . . 0.0 109.828 179.804 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 28.4 ttm180 -119.12 142.56 47.81 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.311 -1.111 . . . . 0.0 109.221 -180.0 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 165' ' ' THR . . . . . 0.71 HG22 HG21 ' A' ' 69' ' ' VAL . 82.2 p -79.36 149.14 31.78 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.165 -0.959 . . . . 0.0 109.761 -179.911 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -67.25 -35.62 79.93 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.314 -0.866 . . . . 0.0 109.153 179.686 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 96.6 mttt -117.27 156.93 26.92 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.515 -0.74 . . . . 0.0 109.138 179.918 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 63.9 mttp -68.69 130.74 43.71 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.096 -1.003 . . . . 0.0 109.333 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 34.4 t -122.42 123.36 68.45 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 121.409 -0.807 . . . . 0.0 109.392 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 42.1 t -144.41 141.03 24.27 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.34 -0.85 . . . . 0.0 109.23 179.762 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.877 HG22 ' H ' ' A' ' 64' ' ' SER . 4.8 m -65.65 119.29 10.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.103 -0.998 . . . . 0.0 109.296 179.912 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 -70.92 -36.94 72.87 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.033 -1.042 . . . . 0.0 110.621 -179.638 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 173' ' ' ASP . . . . . 0.482 ' OD1' ' N ' ' A' ' 174' ' ' CYS . 52.1 t0 -155.09 161.72 41.21 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.952 -1.092 . . . . 0.0 110.276 -179.184 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 174' ' ' CYS . . . . . 0.482 ' N ' ' OD1' ' A' ' 173' ' ' ASP . 14.8 p -147.36 152.56 38.4 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.398 -0.814 . . . . 0.0 109.224 179.788 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . 178.41 170.81 41.01 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 179.702 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 64.1 tt0 -105.17 119.35 38.82 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.365 -1.08 . . . . 0.0 109.474 179.925 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 30.8 tp -61.68 -37.97 86.07 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.213 -0.929 . . . . 0.0 109.422 179.87 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 38.7 m . . . . . 0 N--CA 1.489 1.513 0 CA-C-O 118.027 -0.987 . . . . 0.0 109.498 179.988 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.528 4.812 0 N-CA-C 119.393 2.517 . . . . 0.0 119.393 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 45.5 m -62.7 153.92 31.04 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.266 -1.138 . . . . 0.0 109.529 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 99.2 m-85 -112.89 125.24 54.16 Favored 'General case' 0 C--N 1.308 -1.198 0 O-C-N 121.357 -0.839 . . . . 0.0 108.911 179.72 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 11.2 t -135.12 153.3 52.05 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.502 -0.749 . . . . 0.0 109.538 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -61.12 -38.81 96.19 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.838 -1.305 . . . . 0.0 109.838 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 28.4 t -147.45 149.94 33.66 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.178 -1.189 . . . . 0.0 109.58 -179.816 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' MET . . . . . 0.44 ' N ' ' SD ' ' A' ' 7' ' ' MET . 0.2 OUTLIER -60.64 153.48 61.96 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.345 -0.847 . . . . 0.0 109.235 179.841 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -65.02 172.34 7.45 Favored 'Trans proline' 0 C--N 1.308 -1.575 0 C-N-CA 122.686 2.257 . . . . 0.0 112.054 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 16.3 m-80 -63.61 149.01 93.26 Favored Pre-proline 0 N--CA 1.49 1.567 0 O-C-N 121.353 -0.842 . . . . 0.0 109.437 -179.707 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -68.1 140.76 50.54 Favored 'Trans proline' 0 N--CA 1.496 1.627 0 C-N-CA 122.787 2.325 . . . . 0.0 112.501 -179.802 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.557 ' NH2' HG11 ' A' ' 27' ' ' VAL . 55.2 ttt85 -133.0 129.91 38.78 Favored 'General case' 0 N--CA 1.489 1.524 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 179.027 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.7 p -135.22 144.75 33.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.18 -0.95 . . . . 0.0 110.133 -179.006 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 48.6 p90 -136.79 154.47 50.54 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.447 -0.783 . . . . 0.0 109.1 179.752 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.568 ' CE2' ' SG ' ' A' ' 174' ' ' CYS . 86.9 m-85 -121.42 137.49 54.69 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.437 -0.79 . . . . 0.0 109.934 -179.848 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.2 t0 -94.71 115.06 27.06 Favored 'General case' 0 N--CA 1.494 1.748 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 178.941 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' MET . . . . . 0.569 ' SD ' HD11 ' A' ' 155' ' ' ILE . 77.7 mtp -108.35 146.58 32.77 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.198 -0.939 . . . . 0.0 110.826 -178.824 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.415 ' OG ' ' O ' ' A' ' 21' ' ' GLN . 46.8 t -134.25 149.58 50.96 Favored 'General case' 0 N--CA 1.491 1.605 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 179.61 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.418 ' C ' ' N ' ' A' ' 20' ' ' GLY . 35.5 m -112.2 133.96 56.23 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 121.178 -0.951 . . . . 0.0 109.721 -179.664 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 52.95 12.88 1.94 Allowed Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.418 ' N ' ' C ' ' A' ' 18' ' ' VAL . . . 97.11 -10.22 65.62 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.45 -1.46 . . . . 0.0 109.45 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' GLN . . . . . 0.415 ' O ' ' OG ' ' A' ' 17' ' ' SER . 81.4 mt-30 -88.99 149.37 43.19 Favored Pre-proline 0 N--CA 1.49 1.53 0 O-C-N 121.243 -1.151 . . . . 0.0 109.084 179.733 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -62.38 133.89 45.51 Favored 'Trans proline' 0 C--N 1.309 -1.527 0 C-N-CA 122.288 1.992 . . . . 0.0 112.014 -179.772 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -112.33 -65.21 1.2 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.438 -0.789 . . . . 0.0 109.339 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 179.92 -172.28 43.84 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 61.0 ttp180 -119.1 143.08 47.35 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.422 -1.046 . . . . 0.0 109.198 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 82.7 mt -119.8 128.9 75.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.384 -0.823 . . . . 0.0 109.03 179.779 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.557 HG11 ' NH2' ' A' ' 11' ' ' ARG . 39.0 t -116.59 133.78 62.15 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.406 -0.809 . . . . 0.0 109.272 -179.947 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 72.6 mtm -122.5 152.07 40.7 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.422 -0.798 . . . . 0.0 109.277 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -100.58 131.58 46.41 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.271 -0.893 . . . . 0.0 109.825 -179.626 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.41 ' N ' ' CD2' ' A' ' 30' ' ' LEU . 2.6 mm? -106.12 133.16 51.26 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 179.487 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -96.57 120.81 37.57 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.025 -1.047 . . . . 0.0 109.054 179.459 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -88.02 -41.51 13.06 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.269 -0.895 . . . . 0.0 109.657 -179.809 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -65.28 -42.42 93.2 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.347 -0.846 . . . . 0.0 110.519 -179.214 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 54.6 m -66.32 -44.61 82.88 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.031 -1.043 . . . . 0.0 110.208 -179.324 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.454 ' OG1' ' OG1' ' A' ' 38' ' ' THR . 0.1 OUTLIER -155.67 84.48 3.45 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.261 -0.899 . . . . 0.0 109.301 -179.72 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 1.7 Cg_endo -62.14 -42.07 31.61 Favored 'Trans proline' 0 C--N 1.307 -1.638 0 C-N-CA 122.078 1.852 . . . . 0.0 112.412 -179.245 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 50.1 mtt180 -63.21 -39.54 94.94 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.426 -0.796 . . . . 0.0 110.81 -179.028 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.454 ' OG1' ' OG1' ' A' ' 35' ' ' THR . 75.6 m -63.27 -40.14 96.55 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 120.834 -1.167 . . . . 0.0 109.947 -179.666 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -61.33 -31.56 71.43 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.137 -0.977 . . . . 0.0 109.216 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -67.55 -36.53 81.14 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.303 -0.873 . . . . 0.0 109.885 -179.898 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 45.2 t-20 -57.88 -41.79 83.26 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.219 -0.926 . . . . 0.0 109.85 -179.622 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 98.8 m-85 -87.0 -46.98 9.33 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.106 -0.996 . . . . 0.0 109.804 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.658 ' CZ ' HE22 ' A' ' 176' ' ' GLN . 78.5 ttt180 -57.07 -39.27 74.6 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.363 -0.836 . . . . 0.0 110.147 -179.623 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -63.96 -48.24 77.25 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.02 -1.05 . . . . 0.0 110.214 -179.292 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.74 HD12 ' CD1' ' A' ' 61' ' ' TYR . 4.3 mm? -65.78 -38.93 90.35 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.092 -1.005 . . . . 0.0 109.663 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 46' ' ' CYS . . . . . 0.56 ' SG ' ' SG ' ' A' ' 174' ' ' CYS . 77.7 m -66.01 -47.97 72.73 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.12 -0.988 . . . . 0.0 109.469 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 63.9 p -76.78 -30.78 56.62 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.259 -0.901 . . . . 0.0 109.697 179.733 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 76.25 31.64 54.32 Favored Glycine 0 N--CA 1.492 2.379 0 N-CA-C 110.214 -1.154 . . . . 0.0 110.214 179.521 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 77.8 mm-40 -62.25 -36.07 80.91 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.944 -1.327 . . . . 0.0 109.573 179.798 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 61.1 mmtt -60.43 -34.03 73.38 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.17 -0.956 . . . . 0.0 109.494 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 76.4 -94.54 1.04 Allowed Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.475 -1.45 . . . . 0.0 109.475 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 31.8 m -118.01 142.46 47.35 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.372 -1.075 . . . . 0.0 109.296 -179.798 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -54.53 -42.43 76.15 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.838 -1.305 . . . . 0.0 109.838 -179.828 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 82.0 mtp180 -147.05 -113.06 0.08 Allowed 'General case' 0 N--CA 1.486 1.364 0 O-C-N 121.172 -1.193 . . . . 0.0 109.265 179.871 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 3.4 m -107.08 -24.72 11.86 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.401 -0.812 . . . . 0.0 109.521 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -144.31 73.23 0.34 Allowed Glycine 0 N--CA 1.493 2.461 0 N-CA-C 109.471 -1.452 . . . . 0.0 109.471 -179.722 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 46.6 tttm -171.46 74.21 0.51 Allowed Pre-proline 0 N--CA 1.489 1.496 0 O-C-N 121.383 -1.069 . . . . 0.0 108.833 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_exo -50.06 128.75 23.08 Favored 'Trans proline' 0 C--N 1.305 -1.76 0 C-N-CA 122.646 2.231 . . . . 0.0 111.977 -179.4 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.525 ' O ' ' CG ' ' A' ' 60' ' ' HIS . 11.5 tp -112.24 118.38 35.14 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.531 -0.731 . . . . 0.0 109.186 -179.593 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 60' ' ' HIS . . . . . 0.533 ' O ' ' CE1' ' A' ' 80' ' ' PHE . 95.6 m-70 -158.52 140.73 14.07 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.128 -0.983 . . . . 0.0 109.904 -179.952 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 61' ' ' TYR . . . . . 0.74 ' CD1' HD12 ' A' ' 45' ' ' LEU . 2.4 m-85 -102.17 12.26 37.01 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.254 -0.904 . . . . 0.0 108.851 179.211 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 83.7 mttt -86.73 156.64 19.86 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.383 -0.823 . . . . 0.0 109.619 -179.709 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 54.6 t0 55.8 46.78 21.65 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.401 -0.812 . . . . 0.0 109.454 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 99.4 p -116.85 155.3 29.25 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.411 -0.806 . . . . 0.0 109.301 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 28.6 t -113.16 147.43 37.4 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.362 -0.836 . . . . 0.0 109.323 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.7 m-30 -61.11 142.43 56.7 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.213 -0.929 . . . . 0.0 108.864 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 80.5 t60 -57.29 -50.72 72.03 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.127 -0.983 . . . . 0.0 109.934 -179.206 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.692 HH21 ' NE2' ' A' ' 76' ' ' GLN . 30.1 ptt180 -169.42 160.95 9.61 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.115 -0.99 . . . . 0.0 109.843 179.834 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.474 HG21 HG21 ' A' ' 165' ' ' THR . 0.0 OUTLIER -136.1 135.37 50.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 179.548 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 75.1 mt -136.61 128.25 16.92 Favored Pre-proline 0 N--CA 1.492 1.667 0 O-C-N 121.309 -0.87 . . . . 0.0 109.349 -179.699 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -75.41 136.74 19.97 Favored 'Trans proline' 0 C--N 1.312 -1.39 0 C-N-CA 122.091 1.86 . . . . 0.0 111.888 179.672 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 94.5 -5.23 70.34 Favored Glycine 0 N--CA 1.492 2.432 0 N-CA-C 109.821 -1.312 . . . . 0.0 109.821 179.705 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 77.6 m-85 -135.13 -94.96 0.27 Allowed 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.211 -1.17 . . . . 0.0 109.677 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 74' ' ' MET . . . . . 0.506 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 6.9 ptt? -170.81 -165.88 0.46 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.172 -0.955 . . . . 0.0 109.464 -179.653 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 15.4 p -132.7 151.61 51.93 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.423 -0.798 . . . . 0.0 109.054 179.741 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' GLN . . . . . 0.692 ' NE2' HH21 ' A' ' 68' ' ' ARG . 94.1 mt-30 -115.72 158.71 22.39 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.372 -0.83 . . . . 0.0 109.63 -179.703 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -140.28 -172.68 12.97 Favored Glycine 0 N--CA 1.494 2.516 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 -179.898 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 95.59 6.33 59.69 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.475 -1.45 . . . . 0.0 109.475 -179.771 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 56.0 t0 -57.44 -25.75 60.13 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.278 -1.131 . . . . 0.0 109.444 179.912 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.533 ' CE1' ' O ' ' A' ' 60' ' ' HIS . 91.3 t80 -49.19 -44.81 43.38 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.378 -0.826 . . . . 0.0 110.151 -179.483 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.688 ' CB ' ' H ' ' A' ' 88' ' ' GLY . 65.0 p -69.85 -29.52 66.78 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 120.989 -1.069 . . . . 0.0 109.487 179.874 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 82' ' ' ALA . . . . . 0.684 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 163.3 -55.53 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.344 -0.847 . . . . 0.0 109.244 179.724 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 91.02 1.46 72.84 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 179.884 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 84' ' ' ASN . . . . . 0.478 ' ND2' ' OG1' ' A' ' 86' ' ' THR . 39.9 p-10 -89.8 7.64 35.96 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.21 -1.171 . . . . 0.0 109.482 -179.931 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 95.8 -38.45 3.11 Favored Glycine 0 N--CA 1.492 2.389 0 N-CA-C 109.246 -1.541 . . . . 0.0 109.246 -179.793 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 86' ' ' THR . . . . . 0.478 ' OG1' ' ND2' ' A' ' 84' ' ' ASN . 56.7 p -73.16 -17.54 61.37 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.235 -1.156 . . . . 0.0 109.027 179.529 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -82.75 -164.82 36.02 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.589 -1.405 . . . . 0.0 109.589 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.688 ' H ' ' CB ' ' A' ' 81' ' ' THR . . . 81.94 47.76 6.07 Favored Glycine 0 N--CA 1.488 2.16 0 N-CA-C 109.264 -1.534 . . . . 0.0 109.264 -179.808 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -83.45 147.0 28.09 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.421 -1.046 . . . . 0.0 109.521 -179.722 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 50.5 m -107.84 150.12 27.41 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.485 -0.759 . . . . 0.0 109.275 -179.937 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 5.1 pt -59.6 -40.69 82.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.196 -0.94 . . . . 0.0 109.898 -179.759 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 3.4 m-30 -63.71 -41.42 98.09 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.013 -1.054 . . . . 0.0 109.321 179.733 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 72.58 24.53 76.04 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.719 -1.352 . . . . 0.0 109.719 179.725 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -147.28 153.82 40.22 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.135 -1.214 . . . . 0.0 109.698 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 94.6 mttt -96.73 142.08 29.19 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.361 -0.837 . . . . 0.0 109.552 179.88 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.533 ' CZ ' ' OD1' ' A' ' 121' ' ' ASN . 38.1 p90 -141.07 156.25 46.03 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.322 -0.861 . . . . 0.0 109.42 179.705 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -70.91 145.44 50.16 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.29 -0.881 . . . . 0.0 109.748 -179.699 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.539 ' OD2' HG21 ' A' ' 140' ' ' VAL . 87.8 m-20 -64.16 139.02 58.72 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.17 -0.957 . . . . 0.0 109.153 179.92 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 99' ' ' GLU . . . . . 0.482 ' O ' ' OD1' ' A' ' 100' ' ' ASN . 97.2 mt-10 -66.06 -41.13 91.21 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.178 -0.951 . . . . 0.0 110.56 -179.093 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 100' ' ' ASN . . . . . 0.482 ' OD1' ' O ' ' A' ' 99' ' ' GLU . 83.2 m-20 -149.96 149.16 29.99 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 120.948 -1.095 . . . . 0.0 110.466 -179.582 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -110.75 9.93 22.67 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.849 -0.797 . . . . 0.0 108.849 179.152 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 91.2 mt -54.97 -37.5 42.16 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.408 -0.807 . . . . 0.0 110.583 -179.069 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 57.0 mttm -76.52 134.46 39.46 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 120.899 -1.125 . . . . 0.0 109.63 -179.495 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 39.8 tttp -138.43 159.14 42.82 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.471 -0.768 . . . . 0.0 109.308 -179.735 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 105' ' ' HIS . . . . . 0.491 ' C ' ' ND1' ' A' ' 105' ' ' HIS . 6.8 t-80 -85.46 108.94 18.13 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.195 -0.941 . . . . 0.0 109.282 179.936 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 68.2 p -123.49 2.42 9.01 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.22 -0.925 . . . . 0.0 109.91 -179.888 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -155.05 175.06 33.19 Favored Glycine 0 N--CA 1.492 2.416 0 N-CA-C 109.818 -1.313 . . . . 0.0 109.818 -179.834 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -79.78 157.62 24.48 Favored 'Trans proline' 0 C--N 1.307 -1.617 0 C-N-CA 123.112 2.541 . . . . 0.0 112.142 179.714 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 78.11 45.17 10.5 Favored Glycine 0 N--CA 1.493 2.47 0 N-CA-C 109.678 -1.369 . . . . 0.0 109.678 179.604 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.72 137.33 50.92 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.378 -1.072 . . . . 0.0 109.754 -179.825 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.541 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 2.8 mm? -91.11 129.76 37.07 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.283 -0.886 . . . . 0.0 109.097 179.439 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 29.1 t -142.43 143.6 32.71 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.188 -0.945 . . . . 0.0 109.486 179.954 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 72.2 mtm -89.33 133.31 34.54 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.161 -0.962 . . . . 0.0 109.334 179.839 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -64.98 142.35 58.47 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.18 -0.95 . . . . 0.0 109.311 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 115' ' ' ASN . . . . . 0.525 ' ND2' ' O ' ' A' ' 117' ' ' GLY . 53.2 t-20 -143.04 153.16 42.67 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.204 -0.935 . . . . 0.0 109.85 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 116' ' ' ALA . . . . . 0.471 ' N ' ' OD1' ' A' ' 115' ' ' ASN . . . -123.91 -12.31 7.54 Favored 'General case' 0 N--CA 1.493 1.688 0 N-CA-C 108.836 -0.802 . . . . 0.0 108.836 179.624 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 117' ' ' GLY . . . . . 0.525 ' O ' ' ND2' ' A' ' 115' ' ' ASN . . . -145.52 166.34 27.75 Favored Glycine 0 N--CA 1.493 2.472 0 N-CA-C 109.236 -1.545 . . . . 0.0 109.236 179.934 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -70.74 152.28 64.1 Favored 'Trans proline' 0 C--N 1.306 -1.696 0 C-N-CA 122.72 2.28 . . . . 0.0 112.108 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 76.2 m-20 52.98 41.62 32.14 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.473 -0.767 . . . . 0.0 109.502 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 120' ' ' THR . . . . . 0.52 ' O ' ' ND2' ' A' ' 115' ' ' ASN . 62.2 m -138.75 125.79 21.27 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.339 -0.851 . . . . 0.0 109.223 179.771 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 121' ' ' ASN . . . . . 0.533 ' OD1' ' CZ ' ' A' ' 96' ' ' PHE . 28.7 m120 -106.32 121.89 45.13 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.532 -0.73 . . . . 0.0 109.383 179.844 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -93.6 132.85 11.4 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.669 -1.372 . . . . 0.0 109.669 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 18.8 m -58.83 -33.66 70.65 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.29 -1.123 . . . . 0.0 109.399 179.773 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.3 mt-30 -68.97 145.29 53.73 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.372 -0.83 . . . . 0.0 109.636 -179.793 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 48.8 p90 -135.66 162.54 32.45 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.408 -0.808 . . . . 0.0 109.133 179.83 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.506 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 48.9 p90 -136.51 157.1 47.57 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.176 -0.953 . . . . 0.0 109.775 -179.927 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 68.3 mt -120.9 136.54 57.56 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.506 -0.746 . . . . 0.0 109.288 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 23.0 t -115.95 126.74 54.27 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.269 -0.894 . . . . 0.0 109.416 179.881 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 28.0 p -102.51 11.17 38.27 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.353 -0.842 . . . . 0.0 109.511 -179.891 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -140.39 163.29 33.2 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.306 -0.871 . . . . 0.0 109.431 -179.775 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 71.9 mmtt -67.51 138.29 56.44 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.252 -0.905 . . . . 0.0 109.205 -179.946 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 61.6 p -150.18 85.29 1.4 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.295 -0.878 . . . . 0.0 109.534 -179.868 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -62.82 -36.09 82.05 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.278 -0.889 . . . . 0.0 109.85 -179.895 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 0.9 OUTLIER -64.76 -46.3 82.74 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.125 -0.984 . . . . 0.0 109.515 -179.892 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 18.1 mt -65.83 -32.4 73.9 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.232 -0.918 . . . . 0.0 109.611 179.266 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 136' ' ' ASP . . . . . 0.445 ' OD2' ' O ' ' A' ' 105' ' ' HIS . 60.9 t0 -79.71 119.65 22.93 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.308 -0.87 . . . . 0.0 109.71 -179.816 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 165.57 -100.54 0.17 Allowed Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 62.5 mttp -57.45 -36.16 71.05 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.294 -1.121 . . . . 0.0 109.825 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 78.0 m80 -65.04 150.22 48.48 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.338 -0.851 . . . . 0.0 109.705 -179.501 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.539 HG21 ' OD2' ' A' ' 98' ' ' ASP . 49.8 t -123.33 144.7 32.02 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 121.542 -0.724 . . . . 0.0 109.423 -179.739 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 61.7 t -92.45 130.58 41.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.293 -0.879 . . . . 0.0 109.857 -179.548 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 40.2 p90 -112.98 -3.11 14.1 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.445 -0.784 . . . . 0.0 109.328 179.624 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -168.19 177.35 42.37 Favored Glycine 0 N--CA 1.492 2.402 0 N-CA-C 109.169 -1.572 . . . . 0.0 109.169 179.796 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.2 pt20 -146.61 166.94 25.0 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.075 -1.25 . . . . 0.0 109.741 -179.744 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 75.0 t -96.45 129.7 46.14 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.283 0 O-C-N 121.266 -0.896 . . . . 0.0 109.389 -179.843 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 15.8 m -105.65 -33.92 2.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.339 -0.851 . . . . 0.0 109.723 179.756 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -142.45 169.17 18.08 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.274 -0.891 . . . . 0.0 109.689 -179.75 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 95.89 7.97 58.36 Favored Glycine 0 N--CA 1.493 2.47 0 N-CA-C 109.929 -1.269 . . . . 0.0 109.929 179.612 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 149' ' ' MET . . . . . 0.493 ' O ' HG12 ' A' ' 152' ' ' VAL . 64.9 mtt -60.34 -34.05 73.29 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.155 -1.203 . . . . 0.0 109.776 179.989 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 89.1 m-20 -65.03 -42.33 94.46 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 120.865 -1.147 . . . . 0.0 110.03 -179.553 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.6 p -82.44 -32.09 10.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.21 -0.932 . . . . 0.0 110.653 -179.263 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 152' ' ' VAL . . . . . 0.493 HG12 ' O ' ' A' ' 149' ' ' MET . 0.8 OUTLIER -55.58 -40.67 60.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 120.833 -1.167 . . . . 0.0 109.008 -179.332 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 153' ' ' LYS . . . . . 0.43 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 67.0 mttm -62.92 -36.46 83.46 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.132 -0.98 . . . . 0.0 108.999 179.396 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -62.45 -35.08 78.16 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.305 -0.872 . . . . 0.0 109.414 179.825 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.569 HD11 ' SD ' ' A' ' 16' ' ' MET . 93.6 mt -67.35 -12.79 15.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.513 -0.742 . . . . 0.0 109.808 179.9 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -118.55 -19.48 8.76 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 -179.617 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 157' ' ' LYS . . . . . 0.403 ' N ' ' O ' ' A' ' 153' ' ' LYS . 38.9 tttm -58.83 -42.18 88.63 Favored 'General case' 0 C--N 1.299 -1.597 0 CA-C-O 121.376 0.608 . . . . 0.0 109.743 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 16.5 m -83.75 -12.56 11.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.533 -0.729 . . . . 0.0 109.25 179.449 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 159' ' ' GLY . . . . . 0.648 ' HA2' HG22 ' A' ' 165' ' ' THR . . . -59.97 151.98 37.0 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.941 -1.264 . . . . 0.0 109.941 -179.729 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 27.0 t -143.27 158.31 43.73 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.505 -0.997 . . . . 0.0 109.255 179.917 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 22.9 t -54.1 -33.85 58.73 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.151 -0.968 . . . . 0.0 109.307 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 24.5 m -57.75 -29.47 64.82 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.321 -0.862 . . . . 0.0 109.401 179.682 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 100.52 1.05 55.48 Favored Glycine 0 N--CA 1.493 2.45 0 N-CA-C 109.263 -1.535 . . . . 0.0 109.263 -179.656 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 72.2 ttt-85 -108.16 149.98 27.83 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.477 -1.013 . . . . 0.0 108.933 179.666 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 165' ' ' THR . . . . . 0.648 HG22 ' HA2' ' A' ' 159' ' ' GLY . 69.8 p -117.05 155.51 29.12 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.272 -0.892 . . . . 0.0 110.104 -179.582 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -70.14 -37.29 75.23 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.578 -0.702 . . . . 0.0 109.694 179.776 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 53.9 mttm -109.56 152.6 25.28 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.359 -0.838 . . . . 0.0 109.928 -179.392 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 63.7 mttm -87.95 151.33 22.88 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.404 -0.81 . . . . 0.0 109.43 179.911 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 169' ' ' VAL . . . . . 0.436 ' O ' HG23 ' A' ' 169' ' ' VAL . 34.5 m -125.7 127.61 71.59 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 121.247 -0.908 . . . . 0.0 109.744 -179.988 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 43.4 t -146.63 145.91 19.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.245 -0.909 . . . . 0.0 109.196 179.722 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -88.15 120.95 37.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.111 -0.993 . . . . 0.0 109.479 -179.727 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -62.69 -28.59 70.04 Favored 'General case' 0 C--N 1.3 -1.586 0 N-CA-C 108.901 -0.777 . . . . 0.0 108.901 179.489 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 52.0 p30 -178.67 170.15 1.62 Allowed 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.383 -0.823 . . . . 0.0 110.202 -179.881 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 174' ' ' CYS . . . . . 0.568 ' SG ' ' CE2' ' A' ' 14' ' ' PHE . 54.1 t -139.43 134.98 33.12 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.529 -0.732 . . . . 0.0 109.062 179.356 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -150.67 169.25 30.52 Favored Glycine 0 N--CA 1.493 2.496 0 N-CA-C 109.738 -1.345 . . . . 0.0 109.738 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 176' ' ' GLN . . . . . 0.658 HE22 ' CZ ' ' A' ' 43' ' ' ARG . 63.9 tt0 -108.52 122.75 47.71 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.453 -1.028 . . . . 0.0 109.497 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 177' ' ' LEU . . . . . 0.605 HD13 ' O ' ' A' ' 177' ' ' LEU . 0.2 OUTLIER -63.72 -38.59 91.67 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.23 -0.919 . . . . 0.0 108.908 179.714 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 27.0 t . . . . . 0 N--CA 1.49 1.526 0 O-C-N 121.027 -1.046 . . . . 0.0 109.455 179.872 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.529 4.837 0 N-CA-C 119.426 2.53 . . . . 0.0 119.426 . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 29.5 t -118.91 142.41 47.78 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.351 -1.088 . . . . 0.0 109.414 179.966 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 73.2 t80 -107.86 116.52 32.1 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.444 -0.785 . . . . 0.0 109.018 179.634 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 66.1 p -112.18 10.71 20.22 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.674 -0.641 . . . . 0.0 109.769 -179.801 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.55 12.36 62.85 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 -179.779 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 24.2 m -58.18 -32.98 68.75 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.337 -1.096 . . . . 0.0 109.642 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 12.5 mmt -122.07 79.83 42.99 Favored Pre-proline 0 N--CA 1.493 1.702 0 O-C-N 121.316 -0.865 . . . . 0.0 109.619 -179.732 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 89.6 Cg_endo -80.79 168.28 17.74 Favored 'Trans proline' 0 C--N 1.308 -1.557 0 C-N-CA 122.837 2.358 . . . . 0.0 112.115 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 5.7 m120 -66.9 149.39 98.46 Favored Pre-proline 0 N--CA 1.492 1.632 0 O-C-N 121.254 -0.904 . . . . 0.0 109.332 -179.843 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -68.1 139.69 47.35 Favored 'Trans proline' 0 N--CA 1.497 1.706 0 C-N-CA 122.713 2.276 . . . . 0.0 112.464 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 82.3 mtp180 -132.28 134.47 45.31 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.419 -0.8 . . . . 0.0 108.869 179.071 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.8 p -135.29 143.49 36.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 O-C-N 121.256 -0.903 . . . . 0.0 109.539 -179.652 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 42.8 p90 -138.95 155.61 47.9 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.321 -0.862 . . . . 0.0 109.459 179.948 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.593 ' CE2' ' SG ' ' A' ' 174' ' ' CYS . 76.4 m-85 -122.13 137.87 54.67 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.451 -0.781 . . . . 0.0 109.697 179.883 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 22.8 t70 -88.04 117.02 26.63 Favored 'General case' 0 N--CA 1.493 1.719 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 179.123 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' MET . . . . . 0.412 ' SD ' HD12 ' A' ' 26' ' ' ILE . 83.3 mtp -104.63 143.87 32.48 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.342 -0.849 . . . . 0.0 110.713 -179.044 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.463 ' OG ' ' OE2' ' A' ' 172' ' ' GLU . 61.9 m -141.43 159.3 42.51 Favored 'General case' 0 N--CA 1.49 1.551 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 179.383 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.47 HG13 ' HB2' ' A' ' 23' ' ' ALA . 33.1 m -123.58 147.95 27.77 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.179 -0.95 . . . . 0.0 109.756 -179.759 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 49.09 -107.75 0.33 Allowed Glycine 0 N--CA 1.488 2.113 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.925 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -128.83 25.83 4.62 Favored Glycine 0 N--CA 1.494 2.53 0 N-CA-C 109.631 -1.387 . . . . 0.0 109.631 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 10.7 pt20 -141.58 149.5 54.15 Favored Pre-proline 0 N--CA 1.493 1.714 0 O-C-N 121.3 -1.118 . . . . 0.0 109.29 179.846 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -67.57 138.43 45.64 Favored 'Trans proline' 0 N--CA 1.494 1.544 0 C-N-CA 122.504 2.136 . . . . 0.0 112.108 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.47 ' HB2' HG13 ' A' ' 18' ' ' VAL . . . -101.72 -54.29 2.77 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.411 -0.806 . . . . 0.0 109.216 179.713 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -176.02 -171.25 39.67 Favored Glycine 0 N--CA 1.488 2.156 0 N-CA-C 109.317 -1.513 . . . . 0.0 109.317 -179.916 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 33.0 ptt180 -131.1 148.57 52.75 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.482 -1.011 . . . . 0.0 109.138 179.73 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.412 HD12 ' SD ' ' A' ' 16' ' ' MET . 82.8 mt -122.91 130.11 74.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.318 -0.864 . . . . 0.0 109.248 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 42.0 t -111.0 132.63 58.97 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.491 -0.756 . . . . 0.0 109.222 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 74.1 mtm -120.88 146.93 46.08 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.439 -0.788 . . . . 0.0 109.18 -179.894 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -101.13 131.12 47.23 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.294 -0.879 . . . . 0.0 109.794 -179.718 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.418 ' N ' ' CD2' ' A' ' 30' ' ' LEU . 2.5 mm? -106.2 131.67 53.17 Favored 'General case' 0 N--CA 1.493 1.693 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 179.512 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 95.4 m-85 -98.4 118.29 34.74 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.215 -0.928 . . . . 0.0 109.024 179.572 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -80.68 -42.82 21.38 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.341 -0.85 . . . . 0.0 109.771 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -64.7 -45.89 84.67 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.293 -0.879 . . . . 0.0 110.311 -179.328 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' THR . . . . . 0.409 HG21 ' CE ' ' A' ' 103' ' ' LYS . 26.4 m -67.8 -45.13 75.67 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.121 -0.987 . . . . 0.0 109.835 -179.57 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.472 ' O ' ' OG1' ' A' ' 35' ' ' THR . 4.6 p -142.67 81.4 13.37 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 121.282 -0.886 . . . . 0.0 109.325 -179.75 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -64.27 -58.29 0.26 Allowed 'Trans proline' 0 N--CA 1.494 1.537 0 C-N-CA 122.283 1.989 . . . . 0.0 112.582 -179.347 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 78.4 mtp180 -62.03 -37.11 83.68 Favored 'General case' 0 C--N 1.299 -1.602 0 O-C-N 121.428 -0.795 . . . . 0.0 110.647 -179.132 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 28.1 m -61.91 -41.34 97.81 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.87 -1.144 . . . . 0.0 109.981 -179.542 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -61.3 -31.23 71.07 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.11 -0.994 . . . . 0.0 109.311 -179.739 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.592 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 97.0 mt-10 -66.69 -35.34 79.91 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.351 -0.843 . . . . 0.0 109.885 -179.862 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 88.6 m-20 -55.98 -37.29 68.87 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.256 -0.903 . . . . 0.0 109.85 -179.688 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -97.67 -53.29 3.47 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.221 -0.925 . . . . 0.0 110.024 -179.852 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 59.7 ttp180 -57.94 -42.74 85.54 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.329 -0.857 . . . . 0.0 110.605 -179.179 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.592 ' HB3' ' O ' ' A' ' 40' ' ' GLU . . . -67.73 -44.67 77.05 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.904 -1.123 . . . . 0.0 110.305 -179.181 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.5 ' N ' ' CD2' ' A' ' 45' ' ' LEU . 2.5 mm? -65.74 -40.51 92.19 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.004 -1.06 . . . . 0.0 109.7 -179.801 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 46' ' ' CYS . . . . . . . . . . . . . 72.0 m -67.63 -49.54 62.47 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.067 -1.02 . . . . 0.0 109.334 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 57.5 p -74.46 -32.0 62.43 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.397 -0.814 . . . . 0.0 109.38 179.755 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.459 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 75.85 33.63 50.46 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 110.217 -1.153 . . . . 0.0 110.217 179.457 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -62.23 -37.66 86.22 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.99 -1.3 . . . . 0.0 109.423 179.78 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 54.6 mmtt -61.94 -34.12 75.52 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.275 -0.89 . . . . 0.0 109.349 179.934 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 92.53 172.48 41.27 Favored Glycine 0 N--CA 1.486 2.012 0 N-CA-C 109.239 -1.544 . . . . 0.0 109.239 -179.677 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.536 HG23 ' HA ' ' A' ' 58' ' ' PRO . 89.3 m -73.85 140.73 45.95 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.322 -1.105 . . . . 0.0 109.833 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -57.62 136.17 50.99 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.284 -1.527 . . . . 0.0 109.284 179.829 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 75.6 mtm180 -59.25 -34.11 71.85 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.243 -1.151 . . . . 0.0 110.017 -179.647 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 86.6 p -61.0 -24.82 66.44 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.102 -0.999 . . . . 0.0 109.942 -179.699 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 112.74 90.45 1.89 Allowed Glycine 0 N--CA 1.494 2.507 0 N-CA-C 109.109 -1.596 . . . . 0.0 109.109 -179.696 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' LYS . . . . . 0.531 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 3.0 ttmp? -175.25 80.73 0.31 Allowed Pre-proline 0 N--CA 1.489 1.502 0 O-C-N 121.479 -1.012 . . . . 0.0 108.448 -179.708 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.536 ' HA ' HG23 ' A' ' 52' ' ' THR . 69.7 Cg_exo -51.18 132.33 38.5 Favored 'Trans proline' 0 C--N 1.303 -1.847 0 C-N-CA 122.942 2.428 . . . . 0.0 112.848 -179.05 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.531 ' CD1' ' O ' ' A' ' 57' ' ' LYS . 7.6 mp -101.09 127.39 47.64 Favored 'General case' 0 N--CA 1.493 1.7 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 179.811 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 6.1 p80 -176.14 132.4 0.24 Allowed 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.094 -1.004 . . . . 0.0 109.86 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 4.4 m-85 -96.95 13.34 29.23 Favored 'General case' 0 N--CA 1.492 1.65 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 179.091 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 85.8 mttt -77.46 149.77 35.01 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.416 -0.802 . . . . 0.0 109.639 -179.765 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 63' ' ' ASP . . . . . 0.408 ' N ' HG23 ' A' ' 171' ' ' VAL . 46.4 t0 61.4 35.03 17.99 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.581 -0.699 . . . . 0.0 109.618 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.814 ' H ' ' CG2' ' A' ' 171' ' ' VAL . 55.3 p -83.94 160.08 21.15 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.278 -0.889 . . . . 0.0 108.808 179.094 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 31.3 t -128.58 147.96 50.75 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.168 -0.957 . . . . 0.0 109.57 -179.776 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 22.3 m-85 -72.25 130.12 40.06 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.258 -0.901 . . . . 0.0 109.296 179.86 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 79.4 t60 -61.79 -48.99 78.12 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.16 -0.962 . . . . 0.0 109.481 -179.88 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 37.1 ptt180 -164.71 159.74 19.08 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.27 -0.894 . . . . 0.0 109.678 179.671 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.575 HG21 HG22 ' A' ' 165' ' ' THR . 23.0 m -132.51 148.46 31.8 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 179.539 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 11.5 mt -146.79 125.07 6.17 Favored Pre-proline 0 N--CA 1.494 1.735 0 O-C-N 120.956 -1.09 . . . . 0.0 109.576 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -75.34 135.36 18.37 Favored 'Trans proline' 0 N--CA 1.491 1.34 0 C-N-CA 122.264 1.976 . . . . 0.0 112.117 179.667 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 89.67 1.56 77.19 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.686 -1.365 . . . . 0.0 109.686 179.795 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 95.3 m-85 -134.25 -96.09 0.28 Allowed 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.359 -1.083 . . . . 0.0 109.558 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 74' ' ' MET . . . . . 0.6 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 5.9 ptt? -166.67 158.85 13.5 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.047 -1.033 . . . . 0.0 109.686 -179.659 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 1.7 m -98.45 123.35 42.54 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.417 -0.802 . . . . 0.0 109.008 179.402 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 63.6 tt0 -98.87 125.91 44.39 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.276 -0.89 . . . . 0.0 109.811 -179.584 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -84.85 -174.06 50.16 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 179.599 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -137.59 155.52 23.1 Favored Glycine 0 N--CA 1.494 2.513 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 87.7 m-20 -77.02 150.5 35.8 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.226 -1.161 . . . . 0.0 109.502 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 40.8 p90 -64.85 -22.87 67.07 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.142 -0.974 . . . . 0.0 109.443 -179.856 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.468 ' O ' ' HB2' ' A' ' 82' ' ' ALA . 58.9 p -67.11 -30.98 71.15 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.294 -0.879 . . . . 0.0 109.52 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 82' ' ' ALA . . . . . 0.468 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 176.77 -56.44 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.314 -0.866 . . . . 0.0 109.328 179.953 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 96.12 -10.69 67.76 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 78.7 m-20 -89.15 3.22 52.61 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.177 -1.19 . . . . 0.0 109.323 179.813 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 95.19 -5.54 68.26 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.404 -1.479 . . . . 0.0 109.404 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 64.5 p -72.79 -21.98 60.9 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.245 -1.15 . . . . 0.0 109.41 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -125.32 -123.5 2.71 Favored Glycine 0 N--CA 1.494 2.53 0 N-CA-C 109.384 -1.486 . . . . 0.0 109.384 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 75.6 42.01 27.9 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 179.896 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -79.7 146.55 32.36 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.369 -1.077 . . . . 0.0 109.439 -179.883 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 50.8 m -108.86 148.61 30.35 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.384 -0.822 . . . . 0.0 109.265 -179.83 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.405 HG13 ' N ' ' A' ' 92' ' ' TYR . 15.8 pt -62.6 -39.42 84.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.295 -0.878 . . . . 0.0 109.948 -179.62 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 92' ' ' TYR . . . . . 0.405 ' N ' HG13 ' A' ' 91' ' ' ILE . 73.6 m-85 -68.0 -37.26 81.24 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.112 -0.993 . . . . 0.0 109.578 179.932 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 78.14 14.66 82.03 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 -179.932 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -148.87 158.48 44.2 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.238 -1.154 . . . . 0.0 109.588 -179.825 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 95' ' ' LYS . . . . . 0.466 ' HD3' HG23 ' A' ' 120' ' ' THR . 42.7 mttm -85.3 149.51 25.41 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.238 -0.914 . . . . 0.0 109.596 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.678 ' CE1' ' ND2' ' A' ' 121' ' ' ASN . 55.1 p90 -137.12 161.21 36.76 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.268 -0.895 . . . . 0.0 109.453 179.696 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -102.78 148.33 25.75 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.295 -0.878 . . . . 0.0 109.394 -179.785 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 89.3 m-20 -68.41 133.13 48.19 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.264 -0.897 . . . . 0.0 109.352 -179.897 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -66.26 -37.49 85.59 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.235 -0.916 . . . . 0.0 110.134 -179.731 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 86.9 m-20 -126.68 125.15 41.37 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.224 -0.922 . . . . 0.0 110.098 -179.477 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 101' ' ' PHE . . . . . 0.536 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 69.3 t80 -103.11 5.3 37.84 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.318 -0.864 . . . . 0.0 108.886 179.351 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 91.0 mt -57.19 -34.69 46.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.397 -0.814 . . . . 0.0 110.545 -179.187 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 103' ' ' LYS . . . . . 0.409 ' CE ' HG21 ' A' ' 34' ' ' THR . 91.7 mttt -72.55 135.08 45.52 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.808 -1.182 . . . . 0.0 109.951 -179.358 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 10.4 ptpp? -139.89 -179.05 5.72 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.435 -0.791 . . . . 0.0 109.382 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 105' ' ' HIS . . . . . 0.523 ' CE1' ' O ' ' A' ' 107' ' ' GLY . 82.3 t60 -84.33 77.6 9.96 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.149 -0.969 . . . . 0.0 109.165 179.872 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 54.6 p -75.5 -27.83 58.94 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.324 -0.86 . . . . 0.0 110.154 -179.581 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.523 ' O ' ' CE1' ' A' ' 105' ' ' HIS . . . -149.14 177.78 27.12 Favored Glycine 0 N--CA 1.494 2.517 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 -179.581 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -72.74 155.18 54.17 Favored 'Trans proline' 0 C--N 1.307 -1.65 0 C-N-CA 122.991 2.461 . . . . 0.0 112.314 179.792 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 82.6 47.0 6.15 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 110.138 -1.185 . . . . 0.0 110.138 179.588 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.417 HG12 ' O ' ' A' ' 107' ' ' GLY . 41.8 mm -115.7 138.09 47.24 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.819 0 O-C-N 121.302 -1.116 . . . . 0.0 109.628 179.857 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.418 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 3.7 mm? -89.15 126.72 35.59 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.267 -0.895 . . . . 0.0 109.216 179.627 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 112' ' ' SER . . . . . 0.4 ' OG ' ' O ' ' A' ' 140' ' ' VAL . 38.9 t -142.72 142.15 31.91 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.334 -0.854 . . . . 0.0 109.509 179.863 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER -91.55 141.27 28.9 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.319 -0.863 . . . . 0.0 109.174 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 114' ' ' ALA . . . . . 0.521 ' O ' ' N ' ' A' ' 122' ' ' GLY . . . -63.49 147.31 51.7 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.267 -0.896 . . . . 0.0 109.594 179.986 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 115' ' ' ASN . . . . . 0.42 ' OD1' ' O ' ' A' ' 114' ' ' ALA . 65.6 m-20 -137.23 112.72 9.35 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.332 -0.855 . . . . 0.0 109.002 179.612 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -72.23 -32.03 66.37 Favored 'General case' 0 C--N 1.294 -1.811 0 O-C-N 121.466 -0.771 . . . . 0.0 109.432 179.807 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -148.49 176.08 27.46 Favored Glycine 0 N--CA 1.492 2.393 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 179.848 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 118' ' ' PRO . . . . . 0.43 ' O ' ' CG ' ' A' ' 119' ' ' ASN . 71.6 Cg_exo -50.31 148.03 15.17 Favored 'Trans proline' 0 C--N 1.304 -1.786 0 C-N-CA 122.604 2.203 . . . . 0.0 112.903 179.855 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 119' ' ' ASN . . . . . 0.43 ' CG ' ' O ' ' A' ' 118' ' ' PRO . 7.0 p-10 41.83 49.04 3.9 Favored 'General case' 0 N--CA 1.494 1.751 0 CA-C-O 121.135 0.493 . . . . 0.0 110.11 179.451 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 120' ' ' THR . . . . . 0.466 HG23 ' HD3' ' A' ' 95' ' ' LYS . 87.9 m -131.38 124.9 31.31 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.308 -0.87 . . . . 0.0 109.004 179.55 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 121' ' ' ASN . . . . . 0.678 ' ND2' ' CE1' ' A' ' 96' ' ' PHE . 80.5 m-20 -101.93 119.1 38.25 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.535 -0.728 . . . . 0.0 109.237 179.768 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 122' ' ' GLY . . . . . 0.521 ' N ' ' O ' ' A' ' 114' ' ' ALA . . . -84.41 142.2 20.21 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.719 -1.352 . . . . 0.0 109.719 -179.751 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 88.1 p -64.26 -22.83 67.09 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.367 -1.078 . . . . 0.0 109.337 179.739 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 92.9 mt-30 -95.12 151.61 19.06 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.296 -0.878 . . . . 0.0 109.511 -179.873 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 49.3 p90 -134.79 161.57 34.83 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.364 -0.835 . . . . 0.0 109.428 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.6 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 54.1 p90 -138.94 158.88 43.41 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.33 -0.856 . . . . 0.0 109.547 -179.955 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 72.6 mt -121.31 130.75 74.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.435 -0.791 . . . . 0.0 109.486 179.758 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 1.6 m -93.25 105.74 17.78 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.273 -0.892 . . . . 0.0 108.89 179.663 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 60.0 p -75.49 -7.05 53.14 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.379 -0.826 . . . . 0.0 109.711 -179.713 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -149.21 156.28 41.9 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.158 -0.964 . . . . 0.0 109.741 -179.769 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 55.7 tttp -69.38 141.27 54.18 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.212 -0.93 . . . . 0.0 109.236 179.808 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 20.7 p -114.66 153.95 29.28 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.397 -0.814 . . . . 0.0 109.604 -179.858 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 133' ' ' GLU . . . . . 0.423 ' O ' ' CG ' ' A' ' 136' ' ' ASP . 92.6 mt-10 -106.23 -73.49 0.68 Allowed 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.385 -0.822 . . . . 0.0 109.925 -179.925 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 134' ' ' TRP . . . . . 0.524 ' CD1' ' N ' ' A' ' 135' ' ' LEU . 42.8 p90 -56.03 -36.74 68.32 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.265 -0.897 . . . . 0.0 110.109 -179.535 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 135' ' ' LEU . . . . . 0.524 ' N ' ' CD1' ' A' ' 134' ' ' TRP . 6.9 tp -74.6 4.04 6.79 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.251 -0.906 . . . . 0.0 109.559 -179.327 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 136' ' ' ASP . . . . . 0.452 ' C ' ' OD1' ' A' ' 136' ' ' ASP . 53.5 p30 -67.36 167.29 12.77 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.99 -1.069 . . . . 0.0 109.569 -179.941 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 148.96 -134.0 4.77 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.17 -1.572 . . . . 0.0 109.17 -179.909 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 13.7 mptt -91.76 128.84 37.75 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.208 -1.172 . . . . 0.0 109.018 179.647 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 139' ' ' HIS . . . . . 0.459 ' O ' ' CE1' ' A' ' 101' ' ' PHE . 98.4 m-70 -135.72 152.61 51.32 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.287 -0.883 . . . . 0.0 109.647 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.4 ' O ' ' OG ' ' A' ' 112' ' ' SER . 24.5 m -127.73 149.82 33.02 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 121.351 -0.843 . . . . 0.0 109.022 179.573 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 46.1 t -132.08 125.81 55.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.272 -0.892 . . . . 0.0 109.763 -180.0 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 47.1 p90 -109.64 3.01 20.61 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.446 -0.784 . . . . 0.0 108.932 178.932 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -178.11 178.6 48.55 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.024 -1.63 . . . . 0.0 109.024 179.562 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.3 pt20 -145.95 166.68 25.3 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.09 -1.241 . . . . 0.0 109.614 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 69.7 t -97.04 128.37 48.33 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.245 0 O-C-N 121.21 -0.931 . . . . 0.0 109.4 -179.719 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 15.9 m -103.83 -32.01 2.91 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 O-C-N 121.421 -0.799 . . . . 0.0 109.395 179.588 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -143.45 170.07 16.49 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.329 -0.857 . . . . 0.0 109.407 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 96.55 5.13 59.08 Favored Glycine 0 N--CA 1.493 2.475 0 N-CA-C 109.909 -1.276 . . . . 0.0 109.909 179.61 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 149' ' ' MET . . . . . 0.545 ' O ' HG12 ' A' ' 152' ' ' VAL . 97.0 mmm -60.18 -32.22 70.86 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.144 -1.209 . . . . 0.0 109.458 179.778 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -65.36 -41.71 93.52 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.899 -1.125 . . . . 0.0 110.106 -179.548 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 6.7 p -80.96 -33.26 13.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 120.987 -1.07 . . . . 0.0 110.707 -179.279 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 152' ' ' VAL . . . . . 0.545 HG12 ' O ' ' A' ' 149' ' ' MET . 1.0 OUTLIER -51.92 -41.08 29.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 120.84 -1.162 . . . . 0.0 108.998 -179.264 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 153' ' ' LYS . . . . . 0.439 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 66.8 mttm -65.68 -33.38 75.75 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.214 -0.929 . . . . 0.0 109.214 179.213 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -60.63 -37.23 80.79 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.489 -0.757 . . . . 0.0 109.942 -179.42 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 88.4 mt -70.52 -37.63 70.75 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.524 0 O-C-N 121.156 -0.965 . . . . 0.0 110.066 -179.687 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -77.06 -41.16 43.53 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.196 -0.94 . . . . 0.0 111.556 -178.39 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 16.7 pttm -59.91 -35.4 74.8 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 120.57 -1.331 . . . . 0.0 109.735 -178.763 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 31.5 m -81.1 -10.39 12.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.041 -1.037 . . . . 0.0 109.017 179.395 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -71.95 165.61 53.84 Favored Glycine 0 N--CA 1.488 2.16 0 N-CA-C 110.056 -1.217 . . . . 0.0 110.056 -179.623 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 24.1 t -154.52 167.87 28.63 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.506 -0.996 . . . . 0.0 109.482 -179.858 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 24.8 m -54.46 -29.89 51.17 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.292 -0.88 . . . . 0.0 109.194 179.827 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 22.8 t -54.26 -30.79 51.8 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.307 -0.871 . . . . 0.0 109.506 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 95.41 12.22 54.5 Favored Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.817 -1.313 . . . . 0.0 109.817 179.916 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 42.1 ttp180 -125.78 143.67 50.96 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.298 -1.119 . . . . 0.0 109.467 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 165' ' ' THR . . . . . 0.575 HG22 HG21 ' A' ' 69' ' ' VAL . 71.5 p -74.63 151.28 39.35 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.094 -1.004 . . . . 0.0 109.326 179.936 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -66.31 -37.93 86.53 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.154 -0.967 . . . . 0.0 109.52 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 67.1 mttm -108.94 156.96 19.1 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.432 -0.792 . . . . 0.0 109.4 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 48.1 mtmt -72.53 130.61 41.04 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.205 -0.934 . . . . 0.0 109.268 179.816 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 25.0 t -124.75 124.14 67.35 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 O-C-N 121.434 -0.791 . . . . 0.0 109.427 -179.888 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 57.5 t -144.33 137.05 22.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.271 -0.893 . . . . 0.0 109.499 179.668 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.814 ' CG2' ' H ' ' A' ' 64' ' ' SER . 27.0 m -71.31 126.32 31.44 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.251 -0.905 . . . . 0.0 109.487 179.746 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 172' ' ' GLU . . . . . 0.49 ' O ' ' OD1' ' A' ' 173' ' ' ASP . 96.3 mt-10 -69.84 -40.72 75.65 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.077 -1.014 . . . . 0.0 109.901 179.855 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 173' ' ' ASP . . . . . 0.49 ' OD1' ' O ' ' A' ' 172' ' ' GLU . 49.7 m-20 -163.91 167.67 20.36 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.219 -0.925 . . . . 0.0 110.218 -179.641 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 174' ' ' CYS . . . . . 0.593 ' SG ' ' CE2' ' A' ' 14' ' ' PHE . 43.7 t -136.51 140.82 43.29 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.581 -0.7 . . . . 0.0 109.306 179.597 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -154.94 173.34 33.29 Favored Glycine 0 N--CA 1.493 2.491 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 179.907 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 63.8 tt0 -104.48 119.25 38.56 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.343 -1.092 . . . . 0.0 109.526 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 34.5 tp -61.83 -38.24 87.45 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.203 -0.936 . . . . 0.0 109.575 179.897 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 8.7 t . . . . . 0 N--CA 1.488 1.454 0 O-C-N 121.094 -1.004 . . . . 0.0 109.454 -179.964 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.528 4.785 0 N-CA-C 119.379 2.512 . . . . 0.0 119.379 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 89.5 p -62.53 -23.5 67.0 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.236 -1.155 . . . . 0.0 109.537 179.91 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 46.7 p90 -140.27 164.43 30.1 Favored 'General case' 0 C--N 1.308 -1.23 0 N-CA-C 108.515 -0.92 . . . . 0.0 108.515 179.683 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 49.5 m -110.65 138.15 47.41 Favored 'General case' 0 C--N 1.295 -1.77 0 O-C-N 121.689 -0.632 . . . . 0.0 109.444 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 179.69 -174.04 45.72 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.413 -1.475 . . . . 0.0 109.413 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 29.8 t -117.66 139.09 51.48 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.337 -1.096 . . . . 0.0 109.395 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' MET . . . . . 0.586 ' N ' ' SD ' ' A' ' 7' ' ' MET . 2.4 mpp? -75.4 152.13 85.6 Favored Pre-proline 0 N--CA 1.491 1.604 0 O-C-N 121.361 -0.837 . . . . 0.0 109.191 179.908 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -69.49 168.64 20.62 Favored 'Trans proline' 0 C--N 1.311 -1.446 0 C-N-CA 122.636 2.224 . . . . 0.0 111.961 179.816 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 86.7 m-20 -69.78 148.05 96.44 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.274 -0.891 . . . . 0.0 109.443 -179.873 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -70.21 141.68 44.03 Favored 'Trans proline' 0 N--CA 1.496 1.634 0 C-N-CA 122.769 2.313 . . . . 0.0 112.244 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 59.2 mtm180 -127.89 134.52 49.38 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.376 -0.827 . . . . 0.0 108.902 179.294 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 9.6 p -136.21 144.36 33.31 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.389 -0.819 . . . . 0.0 109.309 -179.701 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 48.3 p90 -138.1 153.89 49.26 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.342 -0.849 . . . . 0.0 109.477 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 88.7 m-85 -121.28 136.36 54.98 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.568 -0.707 . . . . 0.0 109.735 179.755 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -93.62 131.4 38.94 Favored 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 179.228 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' MET . . . . . 0.424 ' SD ' ' CD1' ' A' ' 26' ' ' ILE . 74.2 mtp -125.45 153.24 43.79 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.118 -0.989 . . . . 0.0 110.282 -179.386 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 85.2 p -143.78 161.05 39.62 Favored 'General case' 0 N--CA 1.488 1.463 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 179.718 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.422 ' C ' ' N ' ' A' ' 20' ' ' GLY . 33.0 m -126.32 137.49 57.62 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.105 -0.997 . . . . 0.0 109.534 -179.925 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 53.43 11.62 1.84 Allowed Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 179.848 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.422 ' N ' ' C ' ' A' ' 18' ' ' VAL . . . 95.6 -1.39 63.89 Favored Glycine 0 N--CA 1.493 2.465 0 N-CA-C 109.779 -1.328 . . . . 0.0 109.779 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 2.6 mp0 -99.93 152.09 37.7 Favored Pre-proline 0 N--CA 1.495 1.806 0 O-C-N 121.229 -1.159 . . . . 0.0 109.149 179.876 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -61.66 138.52 75.58 Favored 'Trans proline' 0 C--N 1.308 -1.558 0 C-N-CA 122.581 2.187 . . . . 0.0 112.15 -179.83 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -111.69 -64.18 1.32 Allowed 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.441 -0.787 . . . . 0.0 109.471 179.893 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -179.9 -168.75 39.12 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.414 -1.475 . . . . 0.0 109.414 -179.882 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 79.7 mtm180 -114.37 142.18 46.67 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.381 -1.07 . . . . 0.0 109.759 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.424 ' CD1' ' SD ' ' A' ' 16' ' ' MET . 80.2 mt -122.93 121.1 62.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 179.11 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 40.2 t -120.85 134.6 63.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.469 -0.769 . . . . 0.0 109.27 -179.808 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 72.6 mtm -122.44 154.81 37.28 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.405 -0.809 . . . . 0.0 109.349 -179.845 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -100.85 132.0 46.47 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.347 -0.845 . . . . 0.0 109.968 -179.611 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -107.48 128.93 54.93 Favored 'General case' 0 N--CA 1.493 1.717 0 N-CA-C 108.914 -0.772 . . . . 0.0 108.914 179.318 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -98.04 119.66 37.08 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.189 -0.944 . . . . 0.0 109.058 179.661 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -78.84 -40.16 33.47 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.318 -0.864 . . . . 0.0 110.047 -179.623 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.531 ' OD1' ' N ' ' A' ' 34' ' ' THR . 31.6 p-10 -68.72 -40.79 79.75 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.258 -0.902 . . . . 0.0 110.859 -179.093 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' THR . . . . . 0.531 ' N ' ' OD1' ' A' ' 33' ' ' ASP . 17.4 m -67.51 -44.56 78.15 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.018 -1.051 . . . . 0.0 109.834 -179.4 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 38.2 p -154.03 83.99 4.16 Favored Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.385 -0.822 . . . . 0.0 109.018 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -70.53 -40.84 3.75 Favored 'Trans proline' 0 C--N 1.309 -1.544 0 C-N-CA 122.085 1.856 . . . . 0.0 112.333 -179.212 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.423 ' HD2' ' H ' ' A' ' 37' ' ' ARG . 1.5 mpt_? -63.71 -40.95 98.04 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.168 -0.958 . . . . 0.0 109.667 -179.973 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 38.3 m -66.16 -41.52 90.24 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.19 -0.944 . . . . 0.0 110.004 -179.755 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -60.66 -32.39 71.58 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.174 -0.953 . . . . 0.0 109.032 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -68.05 -38.23 82.24 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.433 -0.792 . . . . 0.0 109.735 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 46.4 t30 -58.23 -41.41 84.07 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.248 -0.908 . . . . 0.0 109.935 -179.436 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.494 ' O ' ' SG ' ' A' ' 46' ' ' CYS . 97.4 m-85 -86.15 -41.08 15.02 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.047 -1.033 . . . . 0.0 110.108 -179.664 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 61.3 ttp180 -59.14 -44.42 92.05 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.229 -0.919 . . . . 0.0 110.937 -178.925 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -71.17 -46.09 62.11 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 120.945 -1.097 . . . . 0.0 110.259 -179.271 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.498 ' N ' ' CD2' ' A' ' 45' ' ' LEU . 2.3 mm? -65.3 -38.13 89.26 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.164 -0.96 . . . . 0.0 109.69 -179.711 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 46' ' ' CYS . . . . . 0.494 ' SG ' ' O ' ' A' ' 42' ' ' PHE . 73.8 m -71.12 -50.5 32.82 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.098 -1.001 . . . . 0.0 109.576 -179.895 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 30.9 m -63.92 -36.72 84.89 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.329 -0.857 . . . . 0.0 109.589 -179.933 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 95.59 8.24 58.52 Favored Glycine 0 N--CA 1.493 2.46 0 N-CA-C 109.838 -1.305 . . . . 0.0 109.838 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 78.1 mm-40 -61.25 -32.24 72.04 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.238 -1.154 . . . . 0.0 109.526 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 20.9 tptp -58.25 -38.97 77.94 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.255 -0.903 . . . . 0.0 109.482 -179.11 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 90.65 171.45 43.75 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 110.018 -1.233 . . . . 0.0 110.018 179.558 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.555 ' O ' ' O ' ' A' ' 53' ' ' GLY . 81.7 m -79.08 148.44 32.42 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.585 -0.95 . . . . 0.0 109.479 179.925 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.555 ' O ' ' O ' ' A' ' 52' ' ' THR . . . -54.93 -122.36 0.01 OUTLIER Glycine 0 N--CA 1.492 2.389 0 N-CA-C 110.036 -1.226 . . . . 0.0 110.036 -179.839 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 54' ' ' ARG . . . . . 0.537 ' O ' ' CB ' ' A' ' 55' ' ' SER . 93.0 mtt180 -57.5 -41.15 80.2 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 120.971 -1.311 . . . . 0.0 109.766 -179.498 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 55' ' ' SER . . . . . 0.537 ' CB ' ' O ' ' A' ' 54' ' ' ARG . 1.1 t 157.72 -26.86 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.724 0 N-CA-C 108.574 -0.898 . . . . 0.0 108.574 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -119.06 59.94 0.51 Allowed Glycine 0 N--CA 1.493 2.442 0 N-CA-C 109.169 -1.572 . . . . 0.0 109.169 179.926 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 36.4 tptt -172.05 70.97 0.45 Allowed Pre-proline 0 C--N 1.302 -1.474 0 O-C-N 121.447 -1.031 . . . . 0.0 108.56 -179.768 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 92.1 Cg_exo -42.9 94.8 0.02 OUTLIER 'Trans proline' 0 C--N 1.304 -1.766 0 C-N-CA 122.743 2.295 . . . . 0.0 112.202 -179.405 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.484 ' O ' ' CD1' ' A' ' 45' ' ' LEU . 8.2 tp -73.65 54.61 0.48 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.581 -0.699 . . . . 0.0 109.276 -179.731 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 40.5 m80 -138.39 150.63 46.72 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.252 -0.905 . . . . 0.0 109.603 -179.753 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 -67.28 -9.1 37.4 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.233 -0.917 . . . . 0.0 109.26 179.369 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 64.0 tttt -49.18 151.3 1.41 Allowed 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.319 -0.863 . . . . 0.0 109.841 -179.881 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 59.67 47.76 10.18 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.616 -0.677 . . . . 0.0 110.03 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.414 ' HB2' ' H ' ' A' ' 79' ' ' ASP . 62.2 p -115.78 151.06 35.91 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.353 -0.842 . . . . 0.0 109.01 179.202 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 29.4 t -126.46 148.61 49.64 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.346 -0.846 . . . . 0.0 109.594 -179.694 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.8 m-85 -70.99 135.34 47.79 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.252 -0.905 . . . . 0.0 109.084 179.958 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 95.8 m-70 -97.02 -29.99 13.33 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.243 -0.911 . . . . 0.0 110.425 -179.58 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 98.6 mtt180 -134.35 139.95 46.0 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.092 -1.005 . . . . 0.0 110.254 -179.457 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.728 HG21 HG22 ' A' ' 165' ' ' THR . 14.5 m -148.4 42.35 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.497 -0.752 . . . . 0.0 108.973 179.401 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 25.7 mt -76.94 132.84 70.38 Favored Pre-proline 0 C--N 1.301 -1.53 0 O-C-N 121.227 -0.921 . . . . 0.0 109.692 -178.926 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -69.93 145.6 56.66 Favored 'Trans proline' 0 N--CA 1.491 1.363 0 C-N-CA 122.213 1.942 . . . . 0.0 112.154 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 84.63 -54.44 4.92 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.636 -1.386 . . . . 0.0 109.636 179.905 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 83.7 m-85 -69.67 -80.6 0.05 OUTLIER 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.201 -1.176 . . . . 0.0 109.763 -179.905 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 12.9 ptt? 179.37 -179.04 0.38 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.092 -1.005 . . . . 0.0 109.741 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' CYS . . . . . 0.443 ' SG ' ' O ' ' A' ' 127' ' ' ILE . 0.8 OUTLIER -131.8 126.79 35.24 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.499 -0.751 . . . . 0.0 109.068 179.689 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 49.5 tt0 -98.14 137.57 36.71 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.342 -0.849 . . . . 0.0 109.331 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -151.94 -177.72 25.94 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.726 -1.35 . . . . 0.0 109.726 -179.887 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 78.6 56.92 3.46 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.639 -1.384 . . . . 0.0 109.639 -179.925 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.414 ' H ' ' HB2' ' A' ' 64' ' ' SER . 59.2 t0 -69.46 90.63 0.54 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.147 -1.208 . . . . 0.0 108.983 -179.96 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 68.3 t80 -61.19 -49.4 77.33 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.371 -0.83 . . . . 0.0 109.803 -179.623 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 6.6 p -153.2 -98.78 0.05 OUTLIER 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.164 -0.96 . . . . 0.0 109.418 179.828 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -86.37 -64.08 1.21 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.326 -0.859 . . . . 0.0 109.664 -179.899 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 98.48 -15.11 61.54 Favored Glycine 0 N--CA 1.493 2.438 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 -179.857 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 86.5 m-20 -63.5 -31.82 73.1 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.27 -1.135 . . . . 0.0 108.858 179.477 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 152.61 -33.3 0.83 Allowed Glycine 0 N--CA 1.489 2.216 0 N-CA-C 108.7 -1.76 . . . . 0.0 108.7 -179.691 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 55.0 p -78.1 -28.75 48.73 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.393 -1.063 . . . . 0.0 109.102 179.532 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -88.18 -171.07 46.33 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 179.854 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.449 ' CA ' ' OG ' ' A' ' 123' ' ' SER . . . 78.77 46.3 8.67 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 179.905 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -88.73 141.1 28.79 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.205 -1.173 . . . . 0.0 109.451 -179.82 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 92.9 p -107.13 159.32 16.41 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.471 -0.768 . . . . 0.0 109.395 -179.931 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 19.5 pt -59.55 -32.11 48.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.268 -0.895 . . . . 0.0 109.51 -179.805 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 76.5 m-85 -66.33 -24.08 66.47 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.165 -0.959 . . . . 0.0 109.436 179.903 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 76.05 -97.79 1.17 Allowed Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.089 -1.604 . . . . 0.0 109.089 -179.614 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -59.74 147.85 36.37 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.319 -1.106 . . . . 0.0 109.019 179.643 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 9.2 mtmp? -72.27 156.33 39.24 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.417 -0.802 . . . . 0.0 109.418 -179.744 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 36.2 p90 -128.6 160.7 31.57 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.437 -0.789 . . . . 0.0 109.484 -179.818 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -61.52 142.59 56.96 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.292 -0.88 . . . . 0.0 110.123 -179.23 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.425 ' H ' ' HA ' ' A' ' 119' ' ' ASN . 88.5 m-20 -70.24 151.42 45.36 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.226 -0.921 . . . . 0.0 109.615 179.772 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -94.93 164.73 12.78 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.324 -0.86 . . . . 0.0 109.185 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 81.5 m-20 -58.26 153.23 15.65 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.226 -0.922 . . . . 0.0 109.444 -179.765 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 101' ' ' PHE . . . . . 0.584 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 21.9 p90 -132.43 80.79 1.92 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.293 -0.879 . . . . 0.0 109.451 -179.853 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 87.4 mt -59.47 -34.38 54.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.248 -0.908 . . . . 0.0 109.378 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 63.3 mttp -85.77 145.21 27.34 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.232 -0.917 . . . . 0.0 109.385 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 104' ' ' LYS . . . . . 0.482 ' O ' ' N ' ' A' ' 106' ' ' THR . 19.8 pttm -134.66 -178.91 5.28 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.374 -0.829 . . . . 0.0 109.501 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 105' ' ' HIS . . . . . . . . . . . . . 96.5 m-70 -65.02 72.45 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.25 -0.906 . . . . 0.0 109.667 -179.971 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 106' ' ' THR . . . . . 0.545 ' O ' ' NZ ' ' A' ' 131' ' ' LYS . 68.7 p -70.82 -27.45 63.89 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.141 -0.974 . . . . 0.0 109.682 179.946 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.421 ' O ' HG12 ' A' ' 110' ' ' ILE . . . -152.97 176.56 31.04 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 109.342 -1.503 . . . . 0.0 109.342 -179.885 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -72.64 153.97 54.49 Favored 'Trans proline' 0 C--N 1.307 -1.638 0 C-N-CA 122.889 2.393 . . . . 0.0 112.095 179.821 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 82.28 49.27 5.31 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 179.632 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.421 HG12 ' O ' ' A' ' 107' ' ' GLY . 39.1 mm -115.2 138.4 45.63 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 121.333 -1.098 . . . . 0.0 109.498 179.938 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.508 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 2.9 mm? -89.57 126.93 35.8 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.297 -0.877 . . . . 0.0 109.595 179.84 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 37.4 t -143.61 139.0 29.42 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.365 -0.835 . . . . 0.0 109.098 179.624 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 113' ' ' MET . . . . . 0.403 ' CE ' HD21 ' A' ' 121' ' ' ASN . 88.5 mtp -81.13 137.13 35.96 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.117 -0.989 . . . . 0.0 109.499 -179.821 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 114' ' ' ALA . . . . . 0.459 ' O ' ' OD1' ' A' ' 115' ' ' ASN . . . -64.14 142.44 58.41 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.281 -0.887 . . . . 0.0 109.604 -179.865 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 115' ' ' ASN . . . . . 0.459 ' OD1' ' O ' ' A' ' 114' ' ' ALA . 73.6 m-20 -146.84 114.0 6.22 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.313 -0.867 . . . . 0.0 108.854 179.569 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -68.2 -35.6 78.25 Favored 'General case' 0 C--N 1.298 -1.641 0 O-C-N 121.312 -0.867 . . . . 0.0 109.559 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -150.89 165.59 30.22 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.263 -1.535 . . . . 0.0 109.263 179.823 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_exo -47.14 153.13 1.72 Allowed 'Trans proline' 0 C--N 1.308 -1.585 0 C-N-CA 122.611 2.207 . . . . 0.0 112.826 179.831 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 119' ' ' ASN . . . . . 0.425 ' HA ' ' H ' ' A' ' 98' ' ' ASP . 18.9 m120 54.89 46.46 24.37 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.73 -0.606 . . . . 0.0 109.635 179.695 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 120' ' ' THR . . . . . 0.43 ' O ' ' OD1' ' A' ' 115' ' ' ASN . 58.5 m -135.39 124.45 24.32 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.316 -0.865 . . . . 0.0 109.099 179.857 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 121' ' ' ASN . . . . . 0.403 HD21 ' CE ' ' A' ' 113' ' ' MET . 23.1 t-20 -104.38 107.94 19.11 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.511 -0.743 . . . . 0.0 109.123 179.646 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -87.84 128.39 9.01 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.772 -1.331 . . . . 0.0 109.772 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 123' ' ' SER . . . . . 0.449 ' OG ' ' CA ' ' A' ' 88' ' ' GLY . 87.3 p -64.32 -23.43 67.29 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.366 -1.079 . . . . 0.0 109.343 179.719 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.4 mt-30 -92.65 153.25 19.09 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.302 -0.874 . . . . 0.0 109.562 -179.869 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 54.4 p90 -134.3 161.62 34.45 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.368 -0.832 . . . . 0.0 109.185 179.881 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 49.0 p90 -134.45 156.41 48.62 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.335 -0.853 . . . . 0.0 109.649 -179.854 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.443 ' O ' ' SG ' ' A' ' 75' ' ' CYS . 77.1 mt -122.2 134.11 66.46 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.453 -0.779 . . . . 0.0 109.556 179.928 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 128' ' ' CYS . . . . . 0.444 ' SG ' ' O ' ' A' ' 130' ' ' ALA . 3.9 t -97.92 112.92 24.66 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.177 -0.952 . . . . 0.0 109.087 179.346 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 41.3 p -80.36 -5.1 55.85 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.308 -0.87 . . . . 0.0 109.856 -179.469 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 130' ' ' ALA . . . . . 0.444 ' O ' ' SG ' ' A' ' 128' ' ' CYS . . . -147.5 161.64 40.67 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.19 -0.944 . . . . 0.0 109.669 -179.626 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.545 ' NZ ' ' O ' ' A' ' 106' ' ' THR . 63.6 mttm -76.56 140.8 41.23 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.194 -0.941 . . . . 0.0 109.299 179.898 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 6.3 p -125.11 158.93 32.64 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.437 -0.789 . . . . 0.0 109.258 -179.918 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -101.98 -74.92 0.61 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.204 -0.935 . . . . 0.0 109.956 -179.81 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 134' ' ' TRP . . . . . 0.581 ' CD1' ' N ' ' A' ' 135' ' ' LEU . 41.7 p90 -61.13 -46.93 88.57 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.21 -0.931 . . . . 0.0 109.999 -179.452 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 135' ' ' LEU . . . . . 0.581 ' N ' ' CD1' ' A' ' 134' ' ' TRP . 32.9 tp -61.63 -33.83 74.61 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.252 -0.905 . . . . 0.0 109.446 -179.819 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 23.5 t70 -76.5 119.03 19.78 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.258 -0.901 . . . . 0.0 109.645 -179.812 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 137' ' ' GLY . . . . . 0.438 ' H ' ' CD2' ' A' ' 139' ' ' HIS . . . -153.18 -129.87 1.44 Allowed Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.075 -1.61 . . . . 0.0 109.075 179.879 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 47.3 mmtm -86.99 114.43 23.59 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.212 -1.17 . . . . 0.0 108.966 179.659 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 139' ' ' HIS . . . . . 0.438 ' CD2' ' H ' ' A' ' 137' ' ' GLY . 98.0 m-70 -138.25 165.69 26.07 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.427 -0.795 . . . . 0.0 109.474 -179.858 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 48.1 t -113.58 132.6 62.04 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 121.356 -0.84 . . . . 0.0 109.274 179.845 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 61.4 t -112.69 129.07 68.95 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 121.272 -0.893 . . . . 0.0 109.308 179.826 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 40.0 p90 -115.76 2.2 13.6 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.334 -0.854 . . . . 0.0 109.725 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -176.26 179.69 47.2 Favored Glycine 0 N--CA 1.493 2.447 0 N-CA-C 109.771 -1.332 . . . . 0.0 109.771 179.64 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 23.0 pt20 -145.21 167.83 21.85 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.309 -1.112 . . . . 0.0 109.449 -179.89 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 55.4 t -96.34 130.16 45.39 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 O-C-N 121.157 -0.964 . . . . 0.0 109.576 -179.866 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 15.6 m -109.29 -33.25 2.43 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 121.323 -0.861 . . . . 0.0 109.409 179.558 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -142.14 171.1 14.52 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.324 -0.86 . . . . 0.0 109.483 179.914 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 98.71 1.96 57.46 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 109.858 -1.297 . . . . 0.0 109.858 179.674 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 149' ' ' MET . . . . . 0.431 ' O ' HG12 ' A' ' 152' ' ' VAL . 72.0 mtm -61.09 -33.76 73.85 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.049 -1.265 . . . . 0.0 109.539 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 56.2 t0 -63.85 -42.6 97.54 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 120.945 -1.097 . . . . 0.0 109.993 -179.713 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.4 p -82.98 -34.49 11.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.152 -0.968 . . . . 0.0 110.547 -179.532 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 152' ' ' VAL . . . . . 0.459 ' CG1' ' N ' ' A' ' 153' ' ' LYS . 0.6 OUTLIER -56.83 -41.93 76.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 120.896 -1.127 . . . . 0.0 109.289 -179.301 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 153' ' ' LYS . . . . . 0.459 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 46.6 mtpt -63.02 -34.28 77.23 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.186 -0.946 . . . . 0.0 109.424 179.459 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -62.13 -39.47 92.66 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.345 -0.847 . . . . 0.0 109.935 -179.559 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 89.2 mt -72.5 -34.86 49.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.162 -0.962 . . . . 0.0 110.042 -179.824 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -76.71 -41.44 45.24 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.153 -0.967 . . . . 0.0 111.182 -178.881 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 16.9 pttp -62.31 -33.59 74.97 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 120.824 -1.173 . . . . 0.0 109.931 -178.846 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 35.1 m -78.3 -10.41 12.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.023 -1.048 . . . . 0.0 109.262 179.662 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -75.52 174.46 52.36 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.743 -1.343 . . . . 0.0 109.743 -179.772 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 22.6 t -161.7 174.54 13.11 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.328 -1.101 . . . . 0.0 109.448 -179.802 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 23.6 m -54.83 -32.03 60.04 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.205 -0.934 . . . . 0.0 109.233 179.813 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 23.5 m -55.72 -33.18 64.0 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.263 -0.898 . . . . 0.0 109.577 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 94.61 10.09 58.23 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.726 -1.35 . . . . 0.0 109.726 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 16.3 tpt180 -116.98 142.69 46.63 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.426 -1.043 . . . . 0.0 109.058 179.833 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 165' ' ' THR . . . . . 0.728 HG22 HG21 ' A' ' 69' ' ' VAL . 68.0 p -80.21 151.52 29.63 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.229 -0.92 . . . . 0.0 109.579 -179.808 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -68.39 -35.69 78.05 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.337 -0.852 . . . . 0.0 109.104 179.476 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 93.6 mttt -112.0 159.31 18.56 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.531 -0.731 . . . . 0.0 109.283 179.925 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -72.7 132.74 44.06 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.31 -0.869 . . . . 0.0 109.411 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 42.7 t -121.35 126.14 74.58 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.233 -0.917 . . . . 0.0 109.634 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 43.2 t -147.56 151.22 13.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.334 -0.854 . . . . 0.0 109.302 179.769 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 2.7 t -87.93 125.57 41.43 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 C-N-CA 119.708 -0.797 . . . . 0.0 109.854 -179.271 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 172' ' ' GLU . . . . . 0.423 ' O ' ' HB3' ' A' ' 173' ' ' ASP . 97.3 mt-10 -65.62 -30.82 71.58 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.379 -0.826 . . . . 0.0 109.097 179.509 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 173' ' ' ASP . . . . . 0.425 ' C ' ' OD1' ' A' ' 173' ' ' ASP . 53.0 p30 177.73 -177.78 0.21 Allowed 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.335 -0.853 . . . . 0.0 110.093 -179.864 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 28.5 p -154.04 150.4 28.19 Favored 'General case' 0 N--CA 1.49 1.571 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 179.476 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -172.17 178.46 44.33 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 176' ' ' GLN . . . . . 0.436 ' OE1' ' OG ' ' A' ' 178' ' ' SER . 7.0 tt0 -106.04 124.17 49.15 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.463 -1.022 . . . . 0.0 109.75 -179.954 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 28.9 tp -62.29 -37.97 87.57 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.202 -0.936 . . . . 0.0 109.382 179.604 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 178' ' ' SER . . . . . 0.436 ' OG ' ' OE1' ' A' ' 176' ' ' GLN . 4.5 p . . . . . 0 N--CA 1.491 1.596 0 CA-C-O 117.994 -1.003 . . . . 0.0 109.497 -179.91 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.527 4.751 0 N-CA-C 119.449 2.539 . . . . 0.0 119.449 . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 2' ' ' SER . . . . . 0.47 ' OG ' ' CD2' ' A' ' 3' ' ' PHE . 87.3 p -62.18 -25.82 67.99 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.255 -1.144 . . . . 0.0 109.453 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.47 ' CD2' ' OG ' ' A' ' 2' ' ' SER . 99.5 m-85 -124.62 154.29 40.94 Favored 'General case' 0 C--N 1.308 -1.23 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 179.712 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 57.6 p -66.66 -16.82 64.48 Favored 'General case' 0 C--N 1.291 -1.939 0 O-C-N 121.605 -0.684 . . . . 0.0 109.525 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 68.19 -122.09 14.89 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.611 -1.396 . . . . 0.0 109.611 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 54.7 p -66.24 162.14 20.64 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.233 -1.157 . . . . 0.0 109.573 -179.916 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' MET . . . . . 0.518 ' N ' ' SD ' ' A' ' 7' ' ' MET . 1.3 mpt? -63.85 154.37 81.28 Favored Pre-proline 0 N--CA 1.489 1.517 0 O-C-N 121.37 -0.831 . . . . 0.0 109.275 -179.933 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -49.36 -26.15 11.29 Favored 'Trans proline' 0 C--N 1.311 -1.427 0 C-N-CA 122.237 1.958 . . . . 0.0 112.205 179.841 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 34.7 m-80 -142.32 152.38 60.64 Favored Pre-proline 0 N--CA 1.492 1.671 0 O-C-N 121.312 -0.867 . . . . 0.0 109.389 -179.948 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -65.93 141.85 66.4 Favored 'Trans proline' 0 N--CA 1.496 1.663 0 C-N-CA 122.822 2.348 . . . . 0.0 112.206 179.828 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 98.5 mtt180 -128.73 133.22 48.06 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.373 -0.829 . . . . 0.0 108.887 179.237 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.0 p -136.52 142.97 36.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.725 0 O-C-N 121.333 -0.854 . . . . 0.0 109.626 -179.783 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' PHE . . . . . 0.462 ' CZ ' ' NH2' ' A' ' 25' ' ' ARG . 43.0 p90 -140.41 154.28 46.63 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.285 -0.884 . . . . 0.0 109.468 -179.998 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -127.83 140.06 52.26 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.424 -0.797 . . . . 0.0 109.584 179.836 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.417 ' O ' HG13 ' A' ' 171' ' ' VAL . 87.9 m-20 -91.44 132.94 35.89 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.263 -0.898 . . . . 0.0 108.91 179.368 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' MET . . . . . 0.424 ' SD ' HD12 ' A' ' 26' ' ' ILE . 65.6 mtp -124.72 153.53 42.25 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.198 -0.939 . . . . 0.0 110.259 -179.459 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 63.2 p -149.4 165.99 30.42 Favored 'General case' 0 N--CA 1.49 1.538 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 179.741 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.422 HG23 ' O ' ' A' ' 18' ' ' VAL . 24.0 m -125.54 133.88 68.11 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 121.25 -0.906 . . . . 0.0 109.544 179.975 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 54.75 17.08 8.37 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 179.797 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 92.33 4.55 66.22 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 33.7 mt-30 -105.58 111.57 64.77 Favored Pre-proline 0 N--CA 1.493 1.711 0 O-C-N 121.349 -1.089 . . . . 0.0 109.255 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 65.8 Cg_exo -48.35 135.23 25.84 Favored 'Trans proline' 0 N--CA 1.493 1.47 0 C-N-CA 122.171 1.914 . . . . 0.0 112.173 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -104.82 -57.73 1.99 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.42 -0.8 . . . . 0.0 109.417 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -171.55 -171.68 36.89 Favored Glycine 0 N--CA 1.488 2.118 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 -179.856 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' ARG . . . . . 0.462 ' NH2' ' CZ ' ' A' ' 13' ' ' PHE . 77.6 ttt180 -114.35 143.93 44.09 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.377 -1.072 . . . . 0.0 109.367 179.947 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.424 HD12 ' SD ' ' A' ' 16' ' ' MET . 83.2 mt -119.62 127.95 75.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.4 -0.812 . . . . 0.0 109.029 179.819 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 43.5 t -117.44 133.45 64.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.444 -0.785 . . . . 0.0 109.571 -179.773 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 73.2 mtm -121.35 150.49 41.38 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.423 -0.798 . . . . 0.0 109.03 179.699 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.424 ' C ' HD22 ' A' ' 30' ' ' LEU . 84.3 tt0 -101.89 131.15 48.42 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.253 -0.904 . . . . 0.0 109.997 -179.512 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.424 HD22 ' C ' ' A' ' 29' ' ' GLU . 2.8 mm? -109.59 130.15 55.53 Favored 'General case' 0 N--CA 1.493 1.701 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 179.357 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -97.77 118.26 33.91 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.039 -1.038 . . . . 0.0 108.981 179.427 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -79.6 -43.18 23.4 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.403 -0.811 . . . . 0.0 109.844 -179.739 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 57.6 t0 -65.25 -51.6 59.8 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.196 -0.94 . . . . 0.0 110.037 -179.301 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 49.4 m -67.86 -42.1 81.86 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.196 -0.94 . . . . 0.0 109.712 -179.871 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -137.34 80.37 33.84 Favored Pre-proline 0 N--CA 1.492 1.666 0 O-C-N 121.437 -0.789 . . . . 0.0 109.19 -179.73 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -70.83 -65.82 0.03 OUTLIER 'Trans proline' 0 C--N 1.308 -1.577 0 C-N-CA 122.579 2.186 . . . . 0.0 112.93 -179.601 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 62.7 mtp180 -61.5 -38.39 87.17 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.393 -0.817 . . . . 0.0 110.708 -179.036 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 36.9 m -62.49 -42.41 99.48 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 120.972 -1.08 . . . . 0.0 109.881 -179.691 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -62.65 -30.9 71.71 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.198 -0.939 . . . . 0.0 108.771 179.566 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.429 ' OE1' ' OH ' ' A' ' 92' ' ' TYR . 84.6 tt0 -65.65 -36.23 83.07 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.461 -0.774 . . . . 0.0 109.492 179.784 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 48.7 t-20 -58.59 -42.98 89.33 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.317 -0.864 . . . . 0.0 109.414 -179.794 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.42 ' CE2' ' CE2' ' A' ' 142' ' ' PHE . 90.6 m-85 -80.63 -45.34 17.41 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.31 -0.869 . . . . 0.0 109.625 179.886 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.424 ' HD2' HE22 ' A' ' 176' ' ' GLN . 61.9 ttp180 -57.31 -42.37 81.68 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.261 -0.899 . . . . 0.0 109.533 -179.769 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.505 ' O ' ' N ' ' A' ' 48' ' ' GLY . . . -68.41 -36.35 78.98 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.262 -0.899 . . . . 0.0 109.528 179.975 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.54 HD23 ' CD2' ' A' ' 61' ' ' TYR . 51.7 tp -60.36 -36.18 77.43 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.176 -0.953 . . . . 0.0 109.529 -179.702 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 46' ' ' CYS . . . . . . . . . . . . . 96.8 m -65.83 -59.73 3.58 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.212 -0.93 . . . . 0.0 110.068 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 57.3 p -74.97 -38.71 61.61 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.12 -0.988 . . . . 0.0 109.987 -179.761 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.505 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 71.98 7.3 66.14 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.183 -1.567 . . . . 0.0 109.183 -179.842 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 22.4 pt-20 -72.63 -16.91 61.71 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.451 -1.029 . . . . 0.0 110.033 -179.726 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 44.7 tptt -56.22 -38.61 71.26 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.166 -0.959 . . . . 0.0 109.739 -179.393 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 173.23 -173.23 45.62 Favored Glycine 0 N--CA 1.49 2.245 0 C-N-CA 119.664 -1.255 . . . . 0.0 110.03 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.53 ' O ' ' C ' ' A' ' 53' ' ' GLY . 82.5 m -120.57 145.89 46.88 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.673 -0.899 . . . . 0.0 109.266 179.946 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.53 ' C ' ' O ' ' A' ' 52' ' ' THR . . . -30.74 -73.9 0.05 OUTLIER Glycine 0 N--CA 1.495 2.608 0 N-CA-C 110.513 -1.035 . . . . 0.0 110.513 -179.827 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 93.7 mtt180 -139.86 -112.69 0.15 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.061 -1.258 . . . . 0.0 109.606 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 80.0 p -86.03 -23.64 26.7 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.313 -0.867 . . . . 0.0 110.112 -179.485 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -164.36 93.58 0.11 Allowed Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.377 -1.489 . . . . 0.0 109.377 -179.838 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 11.4 ttmm -174.4 75.31 0.34 Allowed Pre-proline 0 C--N 1.301 -1.506 0 O-C-N 121.484 -1.009 . . . . 0.0 108.629 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_exo -47.89 129.18 17.44 Favored 'Trans proline' 0 C--N 1.303 -1.832 0 C-N-CA 122.539 2.159 . . . . 0.0 111.897 -179.422 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 12.6 tp -106.48 119.96 40.67 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.522 -0.736 . . . . 0.0 109.333 -179.371 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -150.43 140.57 22.13 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.169 -0.957 . . . . 0.0 109.719 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 61' ' ' TYR . . . . . 0.54 ' CD2' HD23 ' A' ' 45' ' ' LEU . 2.9 t80 -62.25 -35.75 79.9 Favored 'General case' 0 N--CA 1.492 1.657 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 179.431 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 42.6 tttm -50.47 152.66 1.82 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.501 -0.75 . . . . 0.0 109.868 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 34.8 t0 71.24 43.07 0.66 Allowed 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.645 -0.659 . . . . 0.0 109.501 -179.835 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 90.8 p -119.23 152.67 36.24 Favored 'General case' 0 N--CA 1.492 1.659 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 179.503 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 30.3 t -145.85 154.6 42.16 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.198 -0.938 . . . . 0.0 109.778 -179.611 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 47.3 m-85 -89.99 127.58 36.07 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.335 -0.853 . . . . 0.0 109.253 179.651 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 67' ' ' HIS . . . . . 0.403 ' O ' ' O ' ' A' ' 163' ' ' GLY . 97.3 m-70 -99.04 -18.47 17.74 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.319 -0.863 . . . . 0.0 110.291 -179.279 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 58.5 mtp85 -127.31 137.07 52.73 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.11 -0.994 . . . . 0.0 110.126 -179.693 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.668 HG21 HG22 ' A' ' 165' ' ' THR . 3.1 m -153.34 81.33 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 121.428 -0.795 . . . . 0.0 108.98 179.474 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 22.0 mt -95.96 126.04 46.24 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.097 -1.002 . . . . 0.0 109.452 -179.501 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -71.64 138.25 31.72 Favored 'Trans proline' 0 N--CA 1.493 1.491 0 C-N-CA 122.157 1.905 . . . . 0.0 112.332 -179.664 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 92.67 -30.04 7.32 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.684 -1.366 . . . . 0.0 109.684 179.623 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -102.7 -89.73 0.37 Allowed 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.301 -1.117 . . . . 0.0 109.741 -179.884 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 74' ' ' MET . . . . . 0.452 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 7.6 ptt? -171.86 -175.42 1.51 Allowed 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.22 -0.925 . . . . 0.0 109.716 -179.678 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -127.27 141.94 51.59 Favored 'General case' 0 N--CA 1.494 1.748 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 179.699 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 48.1 tt0 -105.85 143.53 33.86 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.209 -0.932 . . . . 0.0 109.843 -179.589 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -156.11 -173.55 24.84 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 96.32 2.34 60.49 Favored Glycine 0 N--CA 1.494 2.516 0 N-CA-C 109.676 -1.37 . . . . 0.0 109.676 -179.969 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.574 ' O ' ' N ' ' A' ' 83' ' ' GLY . 89.9 m-20 -92.42 14.72 15.77 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.339 -1.095 . . . . 0.0 109.203 179.848 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.541 ' CD1' ' N ' ' A' ' 81' ' ' THR . 42.4 p90 -44.27 -31.56 1.05 Allowed 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.351 -0.843 . . . . 0.0 110.292 -179.815 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.541 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 18.5 m -58.0 -37.46 74.31 Favored 'General case' 0 C--N 1.303 -1.445 0 O-C-N 121.169 -0.957 . . . . 0.0 109.666 -178.993 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -145.48 -32.89 0.37 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.191 -0.943 . . . . 0.0 110.048 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.574 ' N ' ' O ' ' A' ' 79' ' ' ASP . . . 100.16 -37.14 3.69 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.424 -1.471 . . . . 0.0 109.424 -180.0 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 78.4 m-20 -89.7 1.51 55.97 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.316 -1.108 . . . . 0.0 109.376 179.873 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 88.67 2.33 79.13 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.446 -1.462 . . . . 0.0 109.446 -179.934 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 49.5 m -59.71 -38.72 82.4 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.366 -1.079 . . . . 0.0 109.633 -179.919 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -96.31 -115.21 3.09 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.859 -1.296 . . . . 0.0 109.859 -179.706 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.446 ' O ' ' CB ' ' A' ' 123' ' ' SER . . . 81.97 27.71 44.52 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.193 -1.563 . . . . 0.0 109.193 -179.636 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -59.51 142.84 51.69 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.329 -1.1 . . . . 0.0 109.869 -179.83 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 32.9 t -141.93 146.81 36.12 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.353 -0.842 . . . . 0.0 109.278 179.738 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 14.1 pt -69.53 -11.34 14.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.136 -0.977 . . . . 0.0 109.468 -179.887 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 92' ' ' TYR . . . . . 0.429 ' OH ' ' OE1' ' A' ' 40' ' ' GLU . 80.9 m-85 -107.47 29.51 7.1 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.393 -0.817 . . . . 0.0 109.778 -179.988 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -46.98 -31.26 5.57 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.382 -1.487 . . . . 0.0 109.382 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -63.26 145.16 56.11 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.139 -1.212 . . . . 0.0 108.992 179.625 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 93.8 mttt -87.77 135.51 33.35 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.368 -0.832 . . . . 0.0 109.631 -179.637 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.531 ' CE1' ' ND2' ' A' ' 121' ' ' ASN . 54.4 p90 -144.49 163.26 34.37 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.351 -0.843 . . . . 0.0 109.361 179.672 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -97.6 144.82 26.89 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.281 -0.887 . . . . 0.0 109.324 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 -67.93 135.34 52.27 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.213 -0.929 . . . . 0.0 109.345 -179.883 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -63.55 -38.21 90.27 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.275 -0.89 . . . . 0.0 110.117 -179.653 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 78.6 m-20 -144.18 171.04 14.84 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.996 -1.065 . . . . 0.0 110.041 -179.539 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 101' ' ' PHE . . . . . 0.43 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 38.3 p90 -151.17 37.85 0.63 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.471 -0.768 . . . . 0.0 109.094 179.772 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 90.3 mt -57.86 -34.13 47.51 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.318 -0.864 . . . . 0.0 109.936 -179.792 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 44.1 mtmt -75.63 144.27 41.8 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.992 -1.068 . . . . 0.0 109.511 -179.895 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 45.2 tttp -130.16 157.77 41.53 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.421 -0.799 . . . . 0.0 109.411 -179.872 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 105' ' ' HIS . . . . . 0.402 ' O ' ' OD2' ' A' ' 136' ' ' ASP . 85.5 t60 -98.93 127.09 44.77 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.328 -0.857 . . . . 0.0 109.39 -179.92 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -160.7 -6.66 0.05 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.229 -0.919 . . . . 0.0 109.698 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -127.72 171.48 19.07 Favored Glycine 0 N--CA 1.494 2.513 0 N-CA-C 109.456 -1.458 . . . . 0.0 109.456 -179.878 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 97.0 Cg_endo -80.61 154.72 20.84 Favored 'Trans proline' 0 C--N 1.306 -1.677 0 C-N-CA 123.023 2.482 . . . . 0.0 112.287 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 77.75 47.55 8.6 Favored Glycine 0 N--CA 1.494 2.536 0 N-CA-C 109.967 -1.253 . . . . 0.0 109.967 179.49 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 40.9 mm -115.29 134.74 57.49 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 O-C-N 121.437 -1.037 . . . . 0.0 109.511 -179.903 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.454 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 3.5 mm? -93.45 112.74 24.72 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.203 -0.936 . . . . 0.0 109.317 179.681 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 47.2 m -131.01 147.95 52.69 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.265 -0.897 . . . . 0.0 109.494 179.737 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 88.5 mtp -94.33 141.2 28.84 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.177 -0.952 . . . . 0.0 109.391 179.892 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -63.3 142.77 58.26 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.295 -0.878 . . . . 0.0 109.338 179.916 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 61.4 m-20 -144.7 113.26 6.65 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.21 -0.931 . . . . 0.0 109.057 179.885 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -68.22 -27.8 66.68 Favored 'General case' 0 C--N 1.297 -1.712 0 O-C-N 121.35 -0.844 . . . . 0.0 109.169 179.795 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 117' ' ' GLY . . . . . 0.441 ' H ' ' HB ' ' A' ' 120' ' ' THR . . . -132.55 167.7 23.01 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.254 -1.539 . . . . 0.0 109.254 179.86 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 14.3 Cg_endo -58.44 -25.51 73.95 Favored 'Trans proline' 0 C--N 1.305 -1.76 0 C-N-CA 122.809 2.339 . . . . 0.0 111.929 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 42.5 p-10 -128.38 42.5 3.31 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.354 -0.841 . . . . 0.0 109.489 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 120' ' ' THR . . . . . 0.441 ' HB ' ' H ' ' A' ' 117' ' ' GLY . 89.1 m -128.87 124.47 35.34 Favored 'General case' 0 N--CA 1.486 1.329 0 O-C-N 121.445 -0.785 . . . . 0.0 108.896 179.77 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 121' ' ' ASN . . . . . 0.531 ' ND2' ' CE1' ' A' ' 96' ' ' PHE . 83.0 m-20 -108.9 149.57 28.96 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.59 -0.694 . . . . 0.0 109.438 -179.842 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -133.78 166.93 23.81 Favored Glycine 0 N--CA 1.494 2.518 0 N-CA-C 109.544 -1.422 . . . . 0.0 109.544 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 123' ' ' SER . . . . . 0.446 ' CB ' ' O ' ' A' ' 88' ' ' GLY . 46.4 p -82.41 -2.08 52.02 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.248 -1.148 . . . . 0.0 109.674 -179.907 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.4 mt-30 -100.5 144.91 28.93 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.253 -0.904 . . . . 0.0 109.752 -179.836 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 50.9 p90 -139.12 163.6 31.98 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.504 -0.747 . . . . 0.0 109.171 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.452 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 50.8 p90 -135.86 154.46 51.16 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.214 -0.928 . . . . 0.0 109.76 -179.89 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 64.5 mt -124.16 134.02 67.72 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.754 0 O-C-N 121.509 -0.745 . . . . 0.0 109.422 179.781 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 3.3 m -114.23 113.07 24.13 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.274 -0.891 . . . . 0.0 109.342 179.855 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 129' ' ' THR . . . . . 0.45 ' OG1' ' OE1' ' A' ' 156' ' ' GLU . 7.3 p -94.39 -0.9 54.52 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.257 -0.902 . . . . 0.0 109.406 -179.905 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -109.97 152.74 25.49 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.383 -0.823 . . . . 0.0 109.338 -179.746 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 49.3 mtpt -77.39 115.29 17.04 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.18 -0.95 . . . . 0.0 109.228 179.84 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 50.0 p -129.23 158.18 39.76 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.445 -0.784 . . . . 0.0 109.366 -179.938 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -110.39 -40.83 4.53 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.368 -0.833 . . . . 0.0 109.683 179.857 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 0.6 OUTLIER -62.58 -34.21 76.52 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.195 -0.941 . . . . 0.0 109.748 -179.602 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 12.5 mt -62.22 -33.09 73.9 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.984 -1.072 . . . . 0.0 109.668 179.648 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 136' ' ' ASP . . . . . 0.402 ' OD2' ' O ' ' A' ' 105' ' ' HIS . 61.7 t0 -79.33 119.12 21.92 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.2 -0.938 . . . . 0.0 109.517 -179.731 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -165.05 -117.4 0.4 Allowed Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 3.3 mppt? -86.53 7.39 26.3 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.403 -1.057 . . . . 0.0 109.769 -179.853 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 77.3 m80 -70.52 151.24 45.29 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.149 -0.97 . . . . 0.0 109.571 -179.667 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 41.2 t -118.69 140.78 41.18 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.489 -0.757 . . . . 0.0 109.459 -179.776 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 141' ' ' VAL . . . . . 0.412 HG12 ' H ' ' A' ' 143' ' ' GLY . 50.6 t -100.2 133.32 43.63 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.416 -0.802 . . . . 0.0 109.565 -179.844 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 142' ' ' PHE . . . . . 0.42 ' CE2' ' CE2' ' A' ' 42' ' ' PHE . 38.0 p90 -109.12 1.09 20.17 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.277 -0.889 . . . . 0.0 109.823 179.873 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 143' ' ' GLY . . . . . 0.412 ' H ' HG12 ' A' ' 141' ' ' VAL . . . -174.4 -179.42 45.0 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 179.663 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.3 pt20 -146.22 167.39 23.61 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.26 -1.141 . . . . 0.0 109.561 -179.644 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 54.0 t -97.84 131.39 44.91 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.187 0 O-C-N 121.178 -0.952 . . . . 0.0 109.473 -179.885 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 16.6 m -107.76 -34.81 2.81 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.357 -0.839 . . . . 0.0 109.664 179.685 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 94.4 mt-10 -144.32 166.92 23.72 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.212 -0.93 . . . . 0.0 109.705 -179.827 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 96.79 4.15 59.12 Favored Glycine 0 N--CA 1.495 2.583 0 N-CA-C 110.194 -1.162 . . . . 0.0 110.194 179.395 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 149' ' ' MET . . . . . 0.483 ' O ' HG12 ' A' ' 152' ' ' VAL . 71.8 mtm -60.79 -33.22 72.65 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.002 -1.293 . . . . 0.0 109.722 179.923 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 89.3 m-20 -65.11 -41.96 94.4 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.833 -1.167 . . . . 0.0 110.07 -179.541 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.2 p -82.04 -34.29 12.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.216 -0.928 . . . . 0.0 110.696 -179.406 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 152' ' ' VAL . . . . . 0.483 HG12 ' O ' ' A' ' 149' ' ' MET . 0.8 OUTLIER -55.63 -42.49 69.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 120.873 -1.142 . . . . 0.0 109.399 -179.248 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 153' ' ' LYS . . . . . 0.454 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 99.2 mttt -65.53 -33.3 75.6 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.137 -0.977 . . . . 0.0 109.757 179.5 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -60.25 -40.15 89.3 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.312 -0.867 . . . . 0.0 110.284 -179.154 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 91.9 mt -71.56 -36.21 59.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.029 -1.044 . . . . 0.0 110.466 -179.508 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 156' ' ' GLU . . . . . 0.45 ' OE1' ' OG1' ' A' ' 129' ' ' THR . 84.4 tt0 -78.49 -40.35 35.58 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.929 -1.107 . . . . 0.0 111.36 -178.587 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 39.8 pttt -61.05 -34.42 74.86 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 120.793 -1.192 . . . . 0.0 110.005 -178.806 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 28.3 m -73.36 -12.65 15.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.101 -0.999 . . . . 0.0 109.377 179.884 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -77.82 173.4 55.08 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.757 -1.337 . . . . 0.0 109.757 -179.891 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 21.4 t -154.62 178.72 9.79 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.41 -1.053 . . . . 0.0 109.395 -179.741 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 23.7 t -54.3 -30.45 51.08 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.233 -0.917 . . . . 0.0 109.262 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 86.6 p -59.3 -26.61 65.13 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.255 -0.903 . . . . 0.0 109.4 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 163' ' ' GLY . . . . . 0.403 ' O ' ' O ' ' A' ' 67' ' ' HIS . . . 87.16 20.31 53.13 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.713 -1.355 . . . . 0.0 109.713 179.794 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 87.7 mtt180 -122.38 145.39 48.32 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.195 -1.18 . . . . 0.0 109.364 179.911 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 165' ' ' THR . . . . . 0.668 HG22 HG21 ' A' ' 69' ' ' VAL . 72.6 p -82.19 151.52 26.85 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.153 -0.967 . . . . 0.0 109.647 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -67.06 -36.44 82.05 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.287 -0.883 . . . . 0.0 109.302 179.692 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 62.4 mttp -117.6 156.57 27.89 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.576 -0.702 . . . . 0.0 109.248 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 94.2 mttt -69.22 131.62 45.2 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.11 -0.994 . . . . 0.0 109.225 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 41.1 t -122.14 125.08 72.49 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.725 0 O-C-N 121.325 -0.859 . . . . 0.0 109.644 -179.896 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 43.7 t -144.94 144.88 21.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.386 -0.821 . . . . 0.0 109.17 179.63 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.417 HG13 ' O ' ' A' ' 15' ' ' ASP . 2.7 t -74.54 124.17 31.57 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.677 0 C-N-CA 119.722 -0.791 . . . . 0.0 109.787 -179.284 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -67.85 -27.91 67.1 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.363 -0.836 . . . . 0.0 109.593 179.471 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 44.3 t0 -174.38 174.76 2.73 Favored 'General case' 0 N--CA 1.494 1.754 0 C-N-CA 119.29 -0.964 . . . . 0.0 110.321 -179.286 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 26.4 p -146.42 150.25 35.28 Favored 'General case' 0 N--CA 1.491 1.622 0 N-CA-C 109.063 -0.718 . . . . 0.0 109.063 179.638 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -172.64 173.16 45.38 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.804 -1.318 . . . . 0.0 109.804 179.913 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 176' ' ' GLN . . . . . 0.513 ' NE2' ' OXT' ' A' ' 178' ' ' SER . 62.6 tt0 -114.23 118.89 35.24 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.413 -1.051 . . . . 0.0 109.637 -179.985 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 37.1 tp -63.39 -37.42 87.2 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.124 -0.985 . . . . 0.0 109.217 179.403 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 178' ' ' SER . . . . . 0.513 ' OXT' ' NE2' ' A' ' 176' ' ' GLN . 61.2 m . . . . . 0 N--CA 1.491 1.582 0 CA-C-O 118.0 -1.0 . . . . 0.0 109.441 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.53 4.925 0 N-CA-C 119.364 2.506 . . . . 0.0 119.364 . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 23.0 m -57.69 -35.26 70.37 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.194 -1.18 . . . . 0.0 109.502 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 99.2 m-85 -111.07 122.57 48.24 Favored 'General case' 0 N--CA 1.485 1.298 0 O-C-N 121.399 -0.813 . . . . 0.0 108.93 179.702 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 51.2 m -81.95 136.34 35.3 Favored 'General case' 0 C--N 1.296 -1.724 0 O-C-N 121.483 -0.76 . . . . 0.0 109.547 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 144.93 154.77 6.23 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 179.905 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 49.9 m -122.88 147.64 46.34 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.42 -1.047 . . . . 0.0 109.356 179.949 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 10.2 mmt -67.18 150.21 98.03 Favored Pre-proline 0 N--CA 1.489 1.48 0 O-C-N 121.23 -0.919 . . . . 0.0 109.28 179.882 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -71.7 166.75 28.5 Favored 'Trans proline' 0 C--N 1.309 -1.531 0 C-N-CA 122.606 2.204 . . . . 0.0 112.149 -179.881 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 2.3 m-80 -73.55 152.6 89.66 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.343 -0.848 . . . . 0.0 109.231 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 38.7 Cg_endo -64.85 141.65 72.36 Favored 'Trans proline' 0 N--CA 1.496 1.663 0 C-N-CA 122.616 2.211 . . . . 0.0 112.07 179.775 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 96.4 mtt180 -126.79 131.62 51.24 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.459 -0.776 . . . . 0.0 109.061 179.497 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.4 p -136.09 142.38 38.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.314 -0.866 . . . . 0.0 109.243 -179.905 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 41.2 p90 -142.3 154.01 44.36 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.297 -0.877 . . . . 0.0 109.572 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.58 ' CE2' ' SG ' ' A' ' 174' ' ' CYS . 44.3 m-85 -120.07 135.78 54.82 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.468 -0.77 . . . . 0.0 109.091 179.643 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.1 t0 -88.55 114.47 25.2 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.078 -1.013 . . . . 0.0 108.509 179.489 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 83.7 mtp -104.53 136.17 44.58 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.453 -0.779 . . . . 0.0 110.532 -179.08 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 44.5 m -135.1 154.23 51.74 Favored 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 179.195 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.405 ' O ' ' C ' ' A' ' 19' ' ' GLY . 34.3 m -125.98 141.45 45.61 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.148 -0.97 . . . . 0.0 109.891 -179.886 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.405 ' C ' ' O ' ' A' ' 18' ' ' VAL . . . 41.05 -114.7 0.61 Allowed Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.936 -1.266 . . . . 0.0 109.936 179.77 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -120.94 15.46 9.52 Favored Glycine 0 N--CA 1.496 2.644 0 N-CA-C 109.416 -1.474 . . . . 0.0 109.416 179.858 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 39.6 tt0 -124.12 88.03 53.0 Favored Pre-proline 0 N--CA 1.494 1.756 0 O-C-N 121.459 -1.024 . . . . 0.0 109.078 -179.826 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 75.7 Cg_exo -47.05 132.86 18.24 Favored 'Trans proline' 0 C--N 1.309 -1.548 0 C-N-CA 122.336 2.024 . . . . 0.0 112.294 -179.561 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -85.07 -63.25 1.36 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.313 -0.867 . . . . 0.0 109.834 -179.688 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 172.62 -167.08 39.91 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 -179.756 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 28.7 ptt180 -116.53 151.18 36.67 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.534 -0.98 . . . . 0.0 108.952 179.735 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 83.4 mt -120.1 129.11 75.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.377 -0.827 . . . . 0.0 109.06 -179.854 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 39.5 t -107.7 134.6 48.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.4 -0.813 . . . . 0.0 109.436 -179.599 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 76.3 mtm -120.86 148.9 43.4 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.557 -0.714 . . . . 0.0 109.215 179.932 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -95.77 133.7 39.58 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.277 -0.889 . . . . 0.0 109.731 -179.593 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -108.35 133.42 52.57 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.572 -0.705 . . . . 0.0 109.357 179.895 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -96.37 119.56 35.08 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.23 -0.919 . . . . 0.0 108.656 179.187 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -89.61 -42.48 11.37 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.295 -0.878 . . . . 0.0 109.835 -179.65 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.2 m-20 -64.58 -48.63 74.27 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.218 -0.926 . . . . 0.0 110.24 -179.263 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 33.3 m -70.91 -43.47 68.21 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.075 -1.016 . . . . 0.0 109.966 -179.652 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.469 ' O ' ' OG1' ' A' ' 35' ' ' THR . 5.1 p -136.38 79.85 41.21 Favored Pre-proline 0 N--CA 1.493 1.678 0 O-C-N 121.351 -0.843 . . . . 0.0 109.404 -179.604 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 27.2 Cg_endo -67.05 -60.88 0.09 OUTLIER 'Trans proline' 0 C--N 1.309 -1.525 0 C-N-CA 122.479 2.12 . . . . 0.0 112.849 -179.401 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.476 ' NH2' ' CG ' ' A' ' 92' ' ' TYR . 17.2 mtp-105 -60.8 -37.78 83.12 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.405 -0.809 . . . . 0.0 110.811 -178.878 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 26.3 m -61.8 -43.16 99.4 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.883 -1.136 . . . . 0.0 109.835 -179.764 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -64.81 -28.48 69.59 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.175 -0.953 . . . . 0.0 109.307 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -65.18 -37.72 88.22 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.341 -0.849 . . . . 0.0 109.687 -179.833 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 86.7 m-20 -59.59 -41.63 90.7 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.244 -0.91 . . . . 0.0 109.745 -179.652 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.489 ' O ' ' SG ' ' A' ' 46' ' ' CYS . 95.5 m-85 -81.37 -46.68 14.3 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.239 -0.913 . . . . 0.0 109.705 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.713 ' HE ' ' NE2' ' A' ' 176' ' ' GLN . 76.1 ttt180 -58.15 -43.09 87.21 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.346 -0.846 . . . . 0.0 110.019 -179.522 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -78.11 -47.9 17.2 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.141 -0.975 . . . . 0.0 110.165 -179.578 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.661 HD23 ' CZ ' ' A' ' 61' ' ' TYR . 58.4 tp -60.59 -38.83 85.93 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.254 -0.904 . . . . 0.0 109.838 -179.518 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 46' ' ' CYS . . . . . 0.489 ' SG ' ' O ' ' A' ' 42' ' ' PHE . 71.2 m -68.56 -58.74 3.84 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.032 -1.042 . . . . 0.0 109.417 -179.908 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 31.6 m -64.11 -37.45 87.5 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.135 -0.978 . . . . 0.0 109.278 179.703 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 81.53 34.27 25.9 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 179.648 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -61.1 -34.36 74.83 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.018 -1.283 . . . . 0.0 109.338 179.61 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 69.4 mmtt -59.57 -33.58 71.61 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.317 -0.864 . . . . 0.0 109.331 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 94.3 168.87 37.44 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.329 -1.508 . . . . 0.0 109.329 -179.771 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 91.7 m -77.79 139.18 39.31 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.413 -1.051 . . . . 0.0 109.737 -179.933 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -60.78 141.19 48.09 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.521 -1.432 . . . . 0.0 109.521 179.94 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 67.4 mtm180 -59.19 -37.12 76.65 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.277 -1.131 . . . . 0.0 109.765 -179.799 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 23.6 m -58.7 -33.75 70.53 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.273 -0.892 . . . . 0.0 109.709 -179.784 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 56' ' ' GLY . . . . . 0.427 ' O ' ' CB ' ' A' ' 57' ' ' LYS . . . 120.58 109.53 2.2 Favored Glycine 0 N--CA 1.495 2.577 0 N-CA-C 108.996 -1.642 . . . . 0.0 108.996 -179.645 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 57' ' ' LYS . . . . . 0.455 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 3.2 mmtp 166.14 85.93 0.02 OUTLIER Pre-proline 0 N--CA 1.492 1.628 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 -179.669 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 71.3 Cg_exo -50.96 133.73 40.98 Favored 'Trans proline' 0 C--N 1.304 -1.773 0 C-N-CA 122.559 2.173 . . . . 0.0 112.383 -179.308 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.455 ' CD1' ' O ' ' A' ' 57' ' ' LYS . 8.9 mp -99.65 44.77 1.01 Allowed 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.558 -0.714 . . . . 0.0 109.378 -179.793 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 71.3 m80 -123.82 133.31 53.82 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.413 -0.804 . . . . 0.0 109.672 -179.828 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' TYR . . . . . 0.661 ' CZ ' HD23 ' A' ' 45' ' ' LEU . 20.8 m-85 -69.12 -12.11 61.39 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.158 -0.964 . . . . 0.0 108.907 178.789 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 61.2 tttt -49.93 138.62 14.97 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.345 -0.847 . . . . 0.0 109.898 -179.703 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 63' ' ' ASP . . . . . 0.406 ' N ' HG23 ' A' ' 171' ' ' VAL . 41.0 t0 67.77 42.53 1.96 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.782 -0.574 . . . . 0.0 110.141 179.67 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.818 ' H ' ' CG2' ' A' ' 171' ' ' VAL . 83.2 p -110.47 149.76 29.84 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.233 -0.917 . . . . 0.0 108.595 178.807 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 28.7 t -117.45 144.23 45.22 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.172 -0.955 . . . . 0.0 109.697 -179.353 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -69.61 138.87 53.47 Favored 'General case' 0 N--CA 1.491 1.595 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 179.66 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 67' ' ' HIS . . . . . 0.717 ' CD2' ' HE ' ' A' ' 68' ' ' ARG . 77.8 t60 -59.59 -50.95 71.91 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.108 -0.995 . . . . 0.0 109.932 -179.416 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.717 ' HE ' ' CD2' ' A' ' 67' ' ' HIS . 20.2 ptp180 -172.81 163.05 4.98 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.213 -0.929 . . . . 0.0 109.684 179.669 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.403 HG11 HG22 ' A' ' 155' ' ' ILE . 0.1 OUTLIER -134.05 127.0 50.97 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.418 -0.802 . . . . 0.0 109.035 179.53 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 39.5 mt -121.9 118.38 29.36 Favored Pre-proline 0 N--CA 1.493 1.719 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 179.86 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -71.58 136.13 27.67 Favored 'Trans proline' 0 C--N 1.31 -1.473 0 C-N-CA 121.853 1.702 . . . . 0.0 111.894 -179.803 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 94.25 -1.07 66.79 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.731 -1.348 . . . . 0.0 109.731 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 85.7 m-85 -137.1 -96.13 0.21 Allowed 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.22 -1.164 . . . . 0.0 109.81 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 74' ' ' MET . . . . . 0.595 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 5.6 ptt? -163.95 160.86 22.46 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.157 -0.964 . . . . 0.0 109.896 -179.491 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 75' ' ' CYS . . . . . 0.492 ' O ' ' SG ' ' A' ' 75' ' ' CYS . 12.1 p -97.38 130.59 44.51 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.417 -0.802 . . . . 0.0 108.966 179.241 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 93.8 mt-30 -105.79 149.82 26.12 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.27 -0.894 . . . . 0.0 109.648 -179.712 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -143.91 126.24 2.69 Favored Glycine 0 N--CA 1.492 2.425 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 179.85 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -86.05 178.48 49.58 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.77 -1.332 . . . . 0.0 109.77 -179.76 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 88.1 m-20 -72.13 149.38 44.79 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.357 -1.084 . . . . 0.0 109.554 179.842 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 43.6 p90 -61.53 -22.97 65.62 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.201 -0.937 . . . . 0.0 109.571 -179.907 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.56 ' O ' ' HB2' ' A' ' 82' ' ' ALA . 61.6 p -65.98 -30.17 70.68 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.133 -0.979 . . . . 0.0 109.424 -179.926 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 82' ' ' ALA . . . . . 0.56 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 171.4 -55.7 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.339 -0.851 . . . . 0.0 109.284 179.809 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 94.79 -10.3 70.53 Favored Glycine 0 N--CA 1.493 2.462 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 179.889 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 50.4 t30 -86.18 1.71 49.66 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.176 -1.191 . . . . 0.0 109.345 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 97.21 -8.83 65.02 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.311 -1.516 . . . . 0.0 109.311 -179.865 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 68.0 p -73.34 -20.0 60.89 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.311 -1.111 . . . . 0.0 109.273 179.675 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -127.68 -130.51 3.35 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 109.334 -1.507 . . . . 0.0 109.334 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 72.48 55.02 7.06 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.175 -1.57 . . . . 0.0 109.175 -179.948 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -84.77 140.73 31.03 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.368 -1.077 . . . . 0.0 109.808 -179.506 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 27.8 t -111.65 143.07 43.14 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.453 -0.779 . . . . 0.0 109.111 179.773 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 15.4 pt -65.12 -38.64 83.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.18 -0.95 . . . . 0.0 110.061 -179.529 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 92' ' ' TYR . . . . . 0.476 ' CG ' ' NH2' ' A' ' 37' ' ' ARG . 50.7 m-85 -67.83 -38.5 83.3 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.09 -1.006 . . . . 0.0 109.677 -179.906 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 76.09 22.05 74.7 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.342 -1.503 . . . . 0.0 109.342 -179.8 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -147.28 162.69 38.42 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.283 -1.128 . . . . 0.0 109.592 -179.708 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 61.0 mttp -77.19 154.16 33.38 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.269 -0.895 . . . . 0.0 109.527 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.463 ' CD1' ' N ' ' A' ' 96' ' ' PHE . 2.1 m-85 -100.37 133.19 45.16 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.303 -0.873 . . . . 0.0 109.059 179.969 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -91.44 130.45 37.27 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.092 -1.005 . . . . 0.0 109.582 -179.874 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 88.2 m-20 -72.05 143.4 49.11 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.269 -0.894 . . . . 0.0 109.362 179.76 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -141.0 -47.44 0.4 Allowed 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.242 -0.911 . . . . 0.0 109.734 -179.848 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 86.0 m-20 -105.0 122.08 45.11 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.242 -0.911 . . . . 0.0 109.905 -179.585 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 101' ' ' PHE . . . . . 0.553 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 71.7 t80 -120.43 14.48 11.98 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.461 -0.774 . . . . 0.0 108.965 179.549 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 89.7 mt -55.11 -38.31 46.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.417 -0.802 . . . . 0.0 110.237 -179.434 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 67.4 mttm -84.54 136.98 33.58 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.991 -1.068 . . . . 0.0 109.782 -179.528 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 104' ' ' LYS . . . . . 0.516 ' HZ3' ' CG2' ' A' ' 106' ' ' THR . 21.3 pttm -139.58 -177.12 4.81 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.457 -0.777 . . . . 0.0 109.274 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 105' ' ' HIS . . . . . 0.533 ' CE1' ' O ' ' A' ' 107' ' ' GLY . 8.5 t-80 -86.52 107.01 17.92 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.121 -0.987 . . . . 0.0 109.491 -179.881 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 106' ' ' THR . . . . . 0.516 ' CG2' ' HZ3' ' A' ' 104' ' ' LYS . 46.6 p -114.43 -1.31 13.51 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.348 -0.845 . . . . 0.0 109.779 179.955 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.533 ' O ' ' CE1' ' A' ' 105' ' ' HIS . . . -154.31 170.54 32.8 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 -179.756 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -77.01 153.7 32.68 Favored 'Trans proline' 0 C--N 1.307 -1.656 0 C-N-CA 122.909 2.406 . . . . 0.0 112.264 179.804 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 78.53 52.4 5.13 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 110.032 -1.227 . . . . 0.0 110.032 179.491 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 35.3 mm -114.27 137.31 47.99 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 O-C-N 121.27 -1.135 . . . . 0.0 109.825 -179.86 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.535 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 2.5 mm? -89.42 125.61 35.23 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.308 -0.87 . . . . 0.0 109.021 179.564 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 36.8 t -147.74 142.83 27.07 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.027 -1.046 . . . . 0.0 109.794 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 64.9 mtt -88.45 135.96 33.22 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.185 -0.947 . . . . 0.0 109.411 179.606 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -72.22 135.59 46.12 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.137 -0.977 . . . . 0.0 109.34 179.808 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 63.7 m-20 -145.37 113.32 6.45 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.162 -0.962 . . . . 0.0 109.336 179.77 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -70.15 -28.7 65.56 Favored 'General case' 0 C--N 1.297 -1.68 0 O-C-N 121.457 -0.777 . . . . 0.0 109.362 179.796 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -134.46 165.25 24.5 Favored Glycine 0 N--CA 1.493 2.484 0 N-CA-C 109.279 -1.528 . . . . 0.0 109.279 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -70.17 154.91 65.67 Favored 'Trans proline' 0 C--N 1.306 -1.667 0 C-N-CA 122.776 2.317 . . . . 0.0 112.199 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 77.5 m-20 54.72 46.9 23.67 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.467 -0.77 . . . . 0.0 109.559 179.841 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 87.3 m -132.27 129.75 40.0 Favored 'General case' 0 C--N 1.306 -1.312 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 179.709 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 121' ' ' ASN . . . . . 0.402 ' OD1' ' CE2' ' A' ' 96' ' ' PHE . 50.8 t30 -74.69 123.15 24.38 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 121.442 -0.786 . . . . 0.0 109.329 -179.855 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -90.74 103.64 3.06 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.839 -1.304 . . . . 0.0 109.839 -179.84 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 85.5 p -65.03 -23.63 67.25 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.248 -1.148 . . . . 0.0 109.245 179.596 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.0 mt-30 -109.19 151.83 25.96 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.434 -0.791 . . . . 0.0 109.622 -179.805 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 49.2 p90 -136.63 160.85 37.56 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.377 -0.827 . . . . 0.0 109.108 179.75 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.595 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 50.2 p90 -140.58 158.5 43.9 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.224 -0.923 . . . . 0.0 109.724 -179.895 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 65.1 mt -120.98 133.6 67.1 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 O-C-N 121.593 -0.692 . . . . 0.0 109.325 179.674 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 6.7 m -97.48 108.64 21.4 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.169 -0.957 . . . . 0.0 109.305 179.779 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 60.2 p -76.39 -10.07 59.12 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.182 -0.949 . . . . 0.0 109.528 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -137.89 161.55 36.34 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.309 -0.87 . . . . 0.0 109.302 -179.818 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 49.0 tttp -62.22 133.21 54.87 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.226 -0.921 . . . . 0.0 109.433 -179.806 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 29.4 p -140.37 91.93 2.48 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.313 -0.867 . . . . 0.0 109.281 -179.898 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -63.57 -34.9 78.84 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.255 -0.903 . . . . 0.0 109.73 -179.813 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 0.9 OUTLIER -67.76 -47.9 67.93 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.068 -1.02 . . . . 0.0 109.646 -179.876 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 15.3 mt -66.79 -31.73 72.55 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.111 -0.993 . . . . 0.0 109.701 179.511 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 60.0 t0 -78.18 121.48 24.4 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.109 -0.994 . . . . 0.0 109.767 -179.566 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 179.88 -114.94 0.46 Allowed Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 138' ' ' LYS . . . . . 0.437 ' O ' ' C ' ' A' ' 139' ' ' HIS . 66.4 mttm -57.64 -36.24 71.57 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.297 -1.12 . . . . 0.0 109.748 179.886 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 139' ' ' HIS . . . . . 0.437 ' C ' ' O ' ' A' ' 138' ' ' LYS . 53.7 m170 -40.94 144.69 0.25 Allowed 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.543 -0.723 . . . . 0.0 109.816 -179.683 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 42.4 t -115.11 138.84 44.11 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 121.359 -0.838 . . . . 0.0 109.601 -179.678 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 91.8 t -97.97 129.06 48.72 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.341 -0.85 . . . . 0.0 109.441 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 39.1 p90 -115.15 0.54 13.61 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.348 -0.845 . . . . 0.0 109.492 179.844 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -176.19 175.6 47.48 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.349 -1.5 . . . . 0.0 109.349 179.558 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.4 pt20 -147.86 168.21 22.78 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.125 -1.221 . . . . 0.0 110.045 -179.837 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 82.1 t -94.61 131.28 41.9 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.245 0 O-C-N 121.333 -0.854 . . . . 0.0 109.363 -179.814 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 10.9 m -112.43 -30.71 2.2 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.325 -0.859 . . . . 0.0 109.853 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 92.9 mt-10 -141.91 169.45 17.56 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.152 -0.968 . . . . 0.0 109.611 -179.881 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 95.57 6.85 59.43 Favored Glycine 0 N--CA 1.493 2.452 0 N-CA-C 109.984 -1.246 . . . . 0.0 109.984 179.597 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 149' ' ' MET . . . . . 0.447 ' O ' HG12 ' A' ' 152' ' ' VAL . 65.0 mtt -60.14 -31.92 70.53 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.058 -1.26 . . . . 0.0 109.543 -179.978 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 150' ' ' ASP . . . . . 0.54 ' OD1' ' N ' ' A' ' 151' ' ' VAL . 31.8 p-10 -65.0 -36.96 86.08 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.812 -1.18 . . . . 0.0 109.821 -179.64 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.54 ' N ' ' OD1' ' A' ' 150' ' ' ASP . 3.5 p -87.08 -34.19 7.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.148 -0.97 . . . . 0.0 110.385 -179.64 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 152' ' ' VAL . . . . . 0.46 ' CG1' ' N ' ' A' ' 153' ' ' LYS . 0.9 OUTLIER -56.67 -41.87 75.32 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 120.991 -1.068 . . . . 0.0 109.188 -179.478 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 153' ' ' LYS . . . . . 0.46 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 66.8 mttm -63.99 -34.72 78.65 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.274 -0.891 . . . . 0.0 109.406 179.583 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -62.17 -36.81 83.01 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.29 -0.881 . . . . 0.0 109.934 -179.477 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.403 HG22 HG11 ' A' ' 69' ' ' VAL . 62.5 mt -74.36 -37.56 45.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.136 -0.977 . . . . 0.0 109.84 -179.786 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -73.73 -40.61 63.43 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.129 -0.982 . . . . 0.0 111.399 -178.493 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 18.1 pttp -59.86 -35.61 75.16 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.679 -1.263 . . . . 0.0 109.696 -178.955 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 27.1 m -77.04 -17.52 14.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.08 -1.012 . . . . 0.0 108.952 179.389 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -64.43 150.21 50.93 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 49.7 m -136.28 161.23 36.35 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.454 -1.027 . . . . 0.0 109.175 179.914 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 23.8 m -51.35 -33.12 28.17 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.187 -0.946 . . . . 0.0 108.966 179.875 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 22.6 t -57.89 -29.02 64.73 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.36 -0.837 . . . . 0.0 109.334 179.643 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.22 10.14 52.08 Favored Glycine 0 N--CA 1.493 2.465 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 -179.806 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 83.7 mtp180 -117.04 155.28 29.49 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.384 -1.068 . . . . 0.0 109.175 179.909 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 165' ' ' THR . . . . . 0.403 ' OG1' ' O ' ' A' ' 167' ' ' LYS . 44.8 p -110.71 156.43 21.04 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.243 -0.911 . . . . 0.0 109.62 -179.759 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -68.19 -37.28 80.76 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.414 -0.804 . . . . 0.0 109.435 179.676 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 167' ' ' LYS . . . . . 0.403 ' O ' ' OG1' ' A' ' 165' ' ' THR . 3.7 mptp? -105.18 158.67 16.43 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.405 -0.809 . . . . 0.0 109.597 -179.834 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 61.3 mttp -81.34 151.99 27.73 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.346 -0.846 . . . . 0.0 109.475 179.83 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 169' ' ' VAL . . . . . 0.476 ' O ' HG23 ' A' ' 169' ' ' VAL . 30.9 m -131.14 124.37 55.45 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.301 -0.874 . . . . 0.0 109.649 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 46.3 t -148.59 147.08 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.296 -0.877 . . . . 0.0 108.988 179.602 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.818 ' CG2' ' H ' ' A' ' 64' ' ' SER . 2.8 m -87.81 123.16 40.25 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.838 0 O-C-N 120.952 -1.093 . . . . 0.0 109.944 -179.9 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -74.29 -36.72 63.78 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.327 -0.858 . . . . 0.0 110.367 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 173' ' ' ASP . . . . . 0.465 ' OD1' ' N ' ' A' ' 174' ' ' CYS . 54.3 t0 -155.08 153.65 31.22 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 120.914 -1.116 . . . . 0.0 110.662 -179.1 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 174' ' ' CYS . . . . . 0.58 ' SG ' ' CE2' ' A' ' 14' ' ' PHE . 45.4 t -142.15 141.49 32.64 Favored 'General case' 0 N--CA 1.492 1.63 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.48 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -169.52 -178.86 40.99 Favored Glycine 0 N--CA 1.493 2.441 0 N-CA-C 109.806 -1.318 . . . . 0.0 109.806 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 176' ' ' GLN . . . . . 0.713 ' NE2' ' HE ' ' A' ' 43' ' ' ARG . 6.8 tt0 -105.22 120.49 41.67 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.406 -1.055 . . . . 0.0 109.66 -179.875 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 32.1 tp -63.59 -37.81 88.75 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.156 -0.965 . . . . 0.0 109.321 179.414 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 10.9 t . . . . . 0 N--CA 1.49 1.533 0 CA-C-O 118.001 -0.999 . . . . 0.0 109.432 -179.952 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.529 4.859 0 N-CA-C 119.357 2.503 . . . . 0.0 119.357 . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 55.1 p -69.89 161.73 29.36 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.273 -1.133 . . . . 0.0 109.518 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 99.1 m-85 -111.39 122.89 49.04 Favored 'General case' 0 N--CA 1.487 1.379 0 O-C-N 121.479 -0.763 . . . . 0.0 108.956 179.766 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 75.4 m -81.01 139.38 35.8 Favored 'General case' 0 C--N 1.299 -1.625 0 O-C-N 121.565 -0.709 . . . . 0.0 109.507 179.824 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 165.91 40.06 0.02 OUTLIER Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.631 -1.387 . . . . 0.0 109.631 -179.92 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 28.6 t -113.75 142.98 45.38 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.412 -1.052 . . . . 0.0 109.308 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 63.0 mtt -125.48 67.14 56.7 Favored Pre-proline 0 N--CA 1.493 1.714 0 O-C-N 121.371 -0.831 . . . . 0.0 109.521 -179.951 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_endo -66.79 -15.46 47.33 Favored 'Trans proline' 0 C--N 1.308 -1.6 0 C-N-CA 122.587 2.191 . . . . 0.0 112.138 179.926 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 12.7 m120 -124.19 72.23 55.94 Favored Pre-proline 0 N--CA 1.494 1.73 0 O-C-N 121.342 -0.849 . . . . 0.0 109.675 -179.768 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -68.22 141.67 52.9 Favored 'Trans proline' 0 N--CA 1.496 1.67 0 C-N-CA 122.62 2.213 . . . . 0.0 112.144 179.877 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 78.4 mtm180 -128.08 133.43 49.04 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.463 -0.773 . . . . 0.0 108.981 179.428 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.2 p -135.57 143.38 36.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.329 -0.857 . . . . 0.0 109.576 -179.822 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 39.2 p90 -137.22 152.83 50.3 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.418 -0.801 . . . . 0.0 109.34 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.459 ' CE1' ' CE1' ' A' ' 61' ' ' TYR . 98.1 m-85 -124.08 132.84 53.71 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.563 -0.711 . . . . 0.0 109.399 179.8 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.6 t0 -91.29 114.56 27.12 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.224 -0.923 . . . . 0.0 108.776 179.485 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 79.7 mtp -107.26 137.33 45.52 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.255 -0.903 . . . . 0.0 110.031 -179.392 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 19.8 m -130.41 152.93 49.28 Favored 'General case' 0 N--CA 1.492 1.639 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 179.636 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.411 ' O ' ' N ' ' A' ' 21' ' ' GLN . 29.8 m -119.05 134.85 61.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.227 -0.921 . . . . 0.0 109.442 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 49.26 25.03 5.47 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 84.24 20.67 58.52 Favored Glycine 0 N--CA 1.492 2.398 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 -179.914 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' GLN . . . . . 0.411 ' N ' ' O ' ' A' ' 18' ' ' VAL . 40.6 mt-30 -120.11 99.19 48.79 Favored Pre-proline 0 N--CA 1.495 1.778 0 O-C-N 121.377 -1.072 . . . . 0.0 109.414 -179.904 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 75.2 Cg_exo -46.53 99.1 0.03 OUTLIER 'Trans proline' 0 N--CA 1.491 1.382 0 C-N-CA 122.353 2.035 . . . . 0.0 112.237 -179.883 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -65.27 -39.85 93.14 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.355 -0.841 . . . . 0.0 109.806 -179.799 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 167.36 -169.11 40.89 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.677 -1.369 . . . . 0.0 109.677 -179.798 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 97.1 mtt180 -115.26 147.05 40.86 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.5 -1.0 . . . . 0.0 109.45 179.812 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 77.2 mt -119.71 123.29 70.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 N-CA-C 108.463 -0.94 . . . . 0.0 108.463 179.118 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 24.8 t -114.26 132.95 61.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.373 -0.829 . . . . 0.0 109.423 -179.488 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' MET . . . . . 0.78 ' SD ' HD11 ' A' ' 111' ' ' LEU . 73.2 mtm -125.66 152.71 44.86 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.382 -0.824 . . . . 0.0 109.196 -179.84 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -99.01 133.26 43.53 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.259 -0.901 . . . . 0.0 109.761 179.877 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -108.85 131.16 55.27 Favored 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 179.794 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 98.2 m-85 -96.36 120.3 36.41 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.095 -1.003 . . . . 0.0 109.063 179.764 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -84.06 -41.1 17.54 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.338 -0.851 . . . . 0.0 109.865 -179.729 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -65.81 -44.71 84.83 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.275 -0.891 . . . . 0.0 110.624 -179.185 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 52.9 m -67.05 -44.87 79.06 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.09 -1.006 . . . . 0.0 110.241 -179.291 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 2.0 m -150.68 82.89 5.98 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.155 -0.966 . . . . 0.0 109.269 -179.666 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 39.9 Cg_endo -71.37 -38.32 4.79 Favored 'Trans proline' 0 C--N 1.308 -1.592 0 C-N-CA 122.19 1.927 . . . . 0.0 112.361 -179.361 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 35.2 mmt180 -64.5 -41.81 96.22 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.126 -0.983 . . . . 0.0 109.691 -179.858 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.48 HG23 ' SD ' ' A' ' 113' ' ' MET . 80.8 m -67.55 -42.66 82.32 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.194 -0.941 . . . . 0.0 110.034 -179.715 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -61.31 -31.81 71.66 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.11 -0.994 . . . . 0.0 108.962 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -70.33 -38.07 74.8 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.422 -0.799 . . . . 0.0 109.999 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 20.4 t-20 -57.91 -43.92 86.49 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.265 -0.897 . . . . 0.0 109.865 -179.534 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -85.3 -46.71 10.74 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.247 -0.908 . . . . 0.0 109.606 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 71.2 ttp85 -57.24 -42.88 82.32 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.312 -0.867 . . . . 0.0 109.663 -179.894 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.5 ' O ' ' N ' ' A' ' 48' ' ' GLY . . . -72.13 -46.27 57.22 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.288 -0.883 . . . . 0.0 109.899 -179.691 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 38.2 tp -61.97 -37.68 85.69 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.095 -1.003 . . . . 0.0 109.438 -179.817 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' CYS . . . . . . . . . . . . . 98.7 m -67.19 -65.93 0.62 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.305 -0.872 . . . . 0.0 109.579 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 31.0 m -64.6 -37.17 86.65 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.374 -0.829 . . . . 0.0 109.404 179.656 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.5 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 80.94 37.8 17.86 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 110.037 -1.225 . . . . 0.0 110.037 179.831 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -61.72 -37.85 85.72 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.089 -1.242 . . . . 0.0 109.51 179.913 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 70.4 mmtt -61.37 -35.49 77.62 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.295 -0.878 . . . . 0.0 109.42 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 88.16 -174.89 44.25 Favored Glycine 0 N--CA 1.484 1.875 0 N-CA-C 108.979 -1.648 . . . . 0.0 108.979 -179.574 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.548 HG23 ' HA ' ' A' ' 58' ' ' PRO . 89.6 m -71.36 139.19 49.73 Favored 'General case' 0 C--N 1.295 -1.78 0 O-C-N 121.537 -0.978 . . . . 0.0 109.603 179.893 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -56.8 136.37 50.09 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.176 -1.57 . . . . 0.0 109.176 179.795 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 86.4 mtt-85 -58.77 -36.94 75.22 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.222 -1.164 . . . . 0.0 109.857 -179.617 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 24.8 m -59.59 -33.94 72.11 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.21 -0.931 . . . . 0.0 109.802 -179.825 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 124.96 91.92 0.91 Allowed Glycine 0 N--CA 1.494 2.514 0 N-CA-C 108.953 -1.659 . . . . 0.0 108.953 -179.658 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' LYS . . . . . 0.494 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 28.0 tttp -175.69 79.76 0.3 Allowed Pre-proline 0 N--CA 1.489 1.478 0 O-C-N 121.447 -1.031 . . . . 0.0 108.406 -179.709 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.548 ' HA ' HG23 ' A' ' 52' ' ' THR . 73.7 Cg_exo -49.65 131.8 29.38 Favored 'Trans proline' 0 C--N 1.303 -1.848 0 C-N-CA 122.923 2.415 . . . . 0.0 112.845 -178.927 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.494 ' CD1' ' O ' ' A' ' 57' ' ' LYS . 8.7 mp -103.35 113.09 26.3 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.591 -0.693 . . . . 0.0 109.365 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 60' ' ' HIS . . . . . 0.507 ' O ' ' CE1' ' A' ' 80' ' ' PHE . 70.8 m80 -141.1 126.25 18.43 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.203 -0.936 . . . . 0.0 109.544 179.473 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 61' ' ' TYR . . . . . 0.459 ' CE1' ' CE1' ' A' ' 14' ' ' PHE . 13.7 t80 -94.42 -11.67 29.36 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.359 -0.838 . . . . 0.0 108.936 179.743 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -78.68 160.52 27.46 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.451 -0.78 . . . . 0.0 109.775 -179.485 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 50.1 t0 60.44 45.8 10.48 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.513 -0.742 . . . . 0.0 109.932 179.647 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 92.5 p -116.25 150.9 36.82 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.328 -0.858 . . . . 0.0 108.841 179.291 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 65' ' ' SER . . . . . 0.408 ' O ' ' OD2' ' A' ' 79' ' ' ASP . 29.4 t -121.17 147.33 45.73 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.257 -0.902 . . . . 0.0 109.716 -179.514 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.3 m-30 -68.18 138.34 55.56 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.351 -0.843 . . . . 0.0 108.907 179.825 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 80.0 t60 -60.51 -51.2 70.48 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.218 -0.926 . . . . 0.0 110.138 -179.327 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.699 ' HE ' ' NE2' ' A' ' 76' ' ' GLN . 38.5 ptt180 -162.85 162.78 26.58 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.073 -1.017 . . . . 0.0 109.873 179.946 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.577 HG21 HG22 ' A' ' 165' ' ' THR . 18.4 m -131.52 150.01 33.68 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.725 0 O-C-N 121.445 -0.785 . . . . 0.0 109.052 179.761 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 14.3 mt -147.29 119.43 4.71 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.024 -1.047 . . . . 0.0 109.433 179.714 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -73.95 134.48 19.79 Favored 'Trans proline' 0 C--N 1.313 -1.316 0 C-N-CA 122.022 1.815 . . . . 0.0 111.868 179.948 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 89.54 2.58 76.04 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.456 ' C ' ' SD ' ' A' ' 74' ' ' MET . 80.2 m-85 -137.22 -94.32 0.22 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.312 -1.11 . . . . 0.0 109.711 179.9 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 74' ' ' MET . . . . . 0.456 ' SD ' ' C ' ' A' ' 73' ' ' PHE . 0.0 OUTLIER -162.98 172.71 14.62 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.161 -0.962 . . . . 0.0 109.81 -179.688 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 1.9 m -119.49 135.16 54.89 Favored 'General case' 0 N--CA 1.494 1.728 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 179.543 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 76' ' ' GLN . . . . . 0.699 ' NE2' ' HE ' ' A' ' 68' ' ' ARG . 25.1 mt-30 -104.06 153.75 20.51 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.286 -0.884 . . . . 0.0 109.816 -179.638 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -158.99 -170.89 24.08 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.329 -1.509 . . . . 0.0 109.329 -179.958 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 80.02 37.94 20.61 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.504 -1.439 . . . . 0.0 109.504 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.437 ' C ' ' OD1' ' A' ' 79' ' ' ASP . 54.2 p30 -85.24 12.16 8.6 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.291 -1.123 . . . . 0.0 109.46 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.507 ' CE1' ' O ' ' A' ' 60' ' ' HIS . 76.3 t80 -52.88 -44.9 67.2 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.348 -0.845 . . . . 0.0 109.937 -179.902 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.668 ' O ' ' HB2' ' A' ' 82' ' ' ALA . 69.0 p -69.45 -29.25 66.9 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.149 -0.969 . . . . 0.0 109.513 -179.928 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 82' ' ' ALA . . . . . 0.668 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 165.76 -55.88 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.229 -0.919 . . . . 0.0 109.365 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 92.28 0.29 70.76 Favored Glycine 0 N--CA 1.492 2.389 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 -179.928 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 77.7 m-20 -87.57 5.51 38.98 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.213 -1.169 . . . . 0.0 109.474 179.931 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 96.04 -36.81 3.67 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.329 -1.508 . . . . 0.0 109.329 -179.903 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 56.2 p -73.53 -18.9 61.03 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.271 -1.134 . . . . 0.0 109.164 179.638 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -83.34 -164.04 35.62 Favored Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.611 -1.395 . . . . 0.0 109.611 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.647 ' H ' ' CB ' ' A' ' 81' ' ' THR . . . 92.28 24.09 25.24 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.314 -1.514 . . . . 0.0 109.314 -179.785 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -57.3 145.59 31.6 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.432 -1.04 . . . . 0.0 109.687 -179.864 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 28.8 t -107.03 146.14 31.49 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.328 -0.858 . . . . 0.0 109.263 179.941 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 20.3 pt -61.26 -33.24 55.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.131 -0.98 . . . . 0.0 109.746 -179.812 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 91.7 m-85 -65.51 -36.15 82.98 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.285 -0.884 . . . . 0.0 109.653 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.09 15.24 70.12 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.319 -1.513 . . . . 0.0 109.319 -179.654 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -143.64 155.92 44.4 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.309 -1.113 . . . . 0.0 109.545 -179.859 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 63.1 mttp -94.03 137.89 32.72 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.287 -0.883 . . . . 0.0 109.586 -179.846 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -123.9 154.23 40.0 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.309 -0.869 . . . . 0.0 109.768 179.901 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -107.1 154.65 20.85 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.469 -0.769 . . . . 0.0 109.06 179.536 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 60.0 t0 -76.68 105.48 7.77 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.032 -1.042 . . . . 0.0 109.378 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -67.22 -34.15 76.88 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.284 -0.885 . . . . 0.0 110.062 -179.809 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 86.5 m-20 -105.0 124.71 50.0 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.251 -0.906 . . . . 0.0 110.052 -179.35 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 99.2 m-85 -108.13 12.78 26.46 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.462 -0.774 . . . . 0.0 109.067 179.556 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 92.6 mt -53.36 -39.25 34.86 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.326 -0.859 . . . . 0.0 110.048 -179.319 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 58.0 mttm -82.25 132.9 35.23 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.983 -1.073 . . . . 0.0 109.592 -179.849 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 80.7 tttt -138.65 158.85 43.46 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.41 -0.806 . . . . 0.0 109.335 -179.891 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 105' ' ' HIS . . . . . 0.611 ' CE1' ' SG ' ' A' ' 128' ' ' CYS . 85.2 t60 -86.07 99.17 11.29 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.233 -0.917 . . . . 0.0 109.431 179.886 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 65.9 p -115.78 -1.62 12.59 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.352 -0.842 . . . . 0.0 109.607 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.539 ' O ' ' CE1' ' A' ' 105' ' ' HIS . . . -153.84 169.92 32.47 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -73.88 158.86 45.92 Favored 'Trans proline' 0 C--N 1.306 -1.671 0 C-N-CA 122.935 2.424 . . . . 0.0 112.25 179.811 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 109' ' ' GLY . . . . . 0.468 ' O ' HG12 ' A' ' 145' ' ' VAL . . . 81.9 43.21 8.38 Favored Glycine 0 N--CA 1.493 2.459 0 N-CA-C 109.885 -1.286 . . . . 0.0 109.885 179.694 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 44.3 mm -117.0 132.7 66.0 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.725 0 O-C-N 121.287 -1.125 . . . . 0.0 109.598 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.78 HD11 ' SD ' ' A' ' 28' ' ' MET . 1.7 mm? -89.23 133.63 34.36 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.214 -0.929 . . . . 0.0 108.756 179.452 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 112' ' ' SER . . . . . 0.552 ' OG ' ' CZ ' ' A' ' 126' ' ' PHE . 99.0 p -143.38 154.26 43.54 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.109 -0.994 . . . . 0.0 109.628 -179.907 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 113' ' ' MET . . . . . 0.48 ' SD ' HG23 ' A' ' 38' ' ' THR . 72.1 mtm -93.64 136.66 33.7 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.305 -0.872 . . . . 0.0 109.213 179.556 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -65.09 138.09 58.08 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.215 -0.928 . . . . 0.0 109.185 179.815 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 70.6 m-20 -135.19 115.29 13.2 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.257 -0.902 . . . . 0.0 109.441 179.88 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -85.1 -9.89 57.43 Favored 'General case' 0 C--N 1.297 -1.675 0 O-C-N 121.501 -0.749 . . . . 0.0 109.096 179.501 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 117' ' ' GLY . . . . . 0.43 ' H ' HG21 ' A' ' 120' ' ' THR . . . -136.12 173.76 21.76 Favored Glycine 0 N--CA 1.492 2.367 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 -179.746 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -57.09 -25.4 63.41 Favored 'Trans proline' 0 C--N 1.307 -1.648 0 C-N-CA 122.747 2.298 . . . . 0.0 112.196 -179.905 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 119' ' ' ASN . . . . . 0.441 ' O ' ' OD1' ' A' ' 119' ' ' ASN . 42.4 p-10 -153.19 96.18 2.03 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.17 -0.956 . . . . 0.0 109.908 179.836 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 120' ' ' THR . . . . . 0.43 HG21 ' H ' ' A' ' 117' ' ' GLY . 0.5 OUTLIER -148.74 123.81 10.09 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 121.327 -0.858 . . . . 0.0 109.338 179.774 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 51.3 t-20 -100.38 121.84 42.18 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.355 -0.84 . . . . 0.0 109.449 -179.861 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -137.08 158.99 24.52 Favored Glycine 0 N--CA 1.493 2.473 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 78.5 p -69.06 -19.08 64.08 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.345 -1.091 . . . . 0.0 109.645 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.9 mt-30 -66.5 137.44 56.8 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.134 -0.978 . . . . 0.0 109.613 -179.593 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 44.5 p90 -146.49 161.68 39.91 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.33 -0.857 . . . . 0.0 109.323 179.892 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.552 ' CZ ' ' OG ' ' A' ' 112' ' ' SER . 51.9 p90 -141.16 159.05 43.04 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.166 -0.959 . . . . 0.0 109.577 179.716 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 77.7 mt -116.43 135.1 57.77 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.354 -0.841 . . . . 0.0 109.425 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 128' ' ' CYS . . . . . 0.611 ' SG ' ' CE1' ' A' ' 105' ' ' HIS . 0.2 OUTLIER -99.23 99.79 10.81 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.388 -0.82 . . . . 0.0 109.423 -179.871 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 61.9 p -76.3 -6.86 53.37 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.322 -0.861 . . . . 0.0 109.321 179.812 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -139.91 162.76 34.41 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.369 -0.832 . . . . 0.0 109.316 -179.897 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.525 ' O ' ' CZ3' ' A' ' 134' ' ' TRP . 99.2 mttt -71.56 131.99 44.04 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.19 -0.944 . . . . 0.0 109.563 -179.654 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 132' ' ' THR . . . . . 0.408 HG22 ' CZ2' ' A' ' 134' ' ' TRP . 74.0 p -122.97 37.99 4.29 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.538 -0.726 . . . . 0.0 109.318 179.936 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 78.3 mm-40 -57.65 -31.12 65.99 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.272 -0.893 . . . . 0.0 109.733 -179.504 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 134' ' ' TRP . . . . . 0.525 ' CZ3' ' O ' ' A' ' 131' ' ' LYS . 12.7 p90 -55.24 -28.44 53.26 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.047 -1.033 . . . . 0.0 109.64 -179.805 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 135' ' ' LEU . . . . . 0.503 ' N ' ' CD1' ' A' ' 134' ' ' TRP . 69.0 mt -58.11 -35.93 72.18 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.055 -1.028 . . . . 0.0 109.473 179.3 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 57.2 t0 53.81 69.92 0.66 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.436 -0.79 . . . . 0.0 109.705 179.569 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -138.4 176.36 20.83 Favored Glycine 0 N--CA 1.484 1.857 0 N-CA-C 108.915 -1.674 . . . . 0.0 108.915 179.712 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 138' ' ' LYS . . . . . 0.427 ' O ' ' O ' ' A' ' 139' ' ' HIS . 63.0 mttp -59.21 -40.12 84.8 Favored 'General case' 0 C--N 1.296 -1.727 0 O-C-N 121.39 -1.065 . . . . 0.0 109.968 -179.768 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 139' ' ' HIS . . . . . 0.427 ' O ' ' O ' ' A' ' 138' ' ' LYS . 61.3 m170 51.75 98.89 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.414 -0.804 . . . . 0.0 109.542 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 52.1 t -105.49 135.18 44.69 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.751 0 O-C-N 121.461 -0.774 . . . . 0.0 109.395 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 48.5 t -117.04 128.71 74.38 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.485 -0.76 . . . . 0.0 109.691 -179.726 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 37.5 p90 -113.31 -1.21 14.32 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.376 -0.828 . . . . 0.0 109.539 179.458 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -173.84 -177.36 42.98 Favored Glycine 0 N--CA 1.493 2.438 0 N-CA-C 109.818 -1.313 . . . . 0.0 109.818 179.842 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.4 pt20 -144.22 171.39 14.37 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.311 -1.111 . . . . 0.0 109.475 -179.763 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 145' ' ' VAL . . . . . 0.468 HG12 ' O ' ' A' ' 109' ' ' GLY . 8.3 p -111.08 138.29 40.0 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.902 0 O-C-N 121.268 -0.895 . . . . 0.0 109.281 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 10.5 m -119.32 -28.16 2.05 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.483 -0.761 . . . . 0.0 109.679 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -138.06 167.16 22.37 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.249 -0.907 . . . . 0.0 109.567 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 97.49 3.23 58.6 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.779 -1.329 . . . . 0.0 109.779 179.652 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 149' ' ' MET . . . . . 0.432 ' O ' HG12 ' A' ' 152' ' ' VAL . 89.2 mtp -60.65 -32.56 71.73 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.183 -1.186 . . . . 0.0 109.771 179.951 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 150' ' ' ASP . . . . . 0.549 ' OD1' ' N ' ' A' ' 151' ' ' VAL . 32.9 p-10 -65.46 -37.44 86.86 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 120.85 -1.156 . . . . 0.0 109.902 -179.565 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.549 ' N ' ' OD1' ' A' ' 150' ' ' ASP . 5.2 p -87.31 -34.31 7.39 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.711 0 O-C-N 121.101 -0.999 . . . . 0.0 110.243 -179.672 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 152' ' ' VAL . . . . . 0.461 ' CG1' ' N ' ' A' ' 153' ' ' LYS . 0.9 OUTLIER -56.04 -42.35 71.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 120.996 -1.065 . . . . 0.0 109.101 -179.513 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 153' ' ' LYS . . . . . 0.461 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 98.7 mttt -64.42 -33.77 76.64 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.172 -0.955 . . . . 0.0 109.433 179.471 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -61.24 -38.8 87.95 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.351 -0.843 . . . . 0.0 110.132 -179.4 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 86.8 mt -72.3 -36.64 56.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.045 -1.034 . . . . 0.0 110.159 -179.728 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -76.29 -41.69 47.89 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.178 -0.951 . . . . 0.0 111.402 -178.784 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 16.8 pttp -60.45 -35.23 75.36 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 120.744 -1.223 . . . . 0.0 109.734 -178.845 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 32.7 m -82.46 -10.9 12.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.166 -0.958 . . . . 0.0 109.061 179.581 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -70.97 165.1 53.31 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.981 -1.248 . . . . 0.0 109.981 -179.565 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 24.1 t -154.08 168.55 26.1 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.421 -1.046 . . . . 0.0 109.439 -179.82 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 25.1 m -54.32 -29.6 48.33 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.279 -0.888 . . . . 0.0 109.341 179.808 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 24.7 m -53.31 -31.27 43.25 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.287 -0.883 . . . . 0.0 109.589 -179.882 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 96.05 8.98 57.55 Favored Glycine 0 N--CA 1.493 2.472 0 N-CA-C 109.766 -1.333 . . . . 0.0 109.766 179.896 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 82.3 mtm180 -122.93 145.56 48.36 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.209 -1.171 . . . . 0.0 109.471 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 165' ' ' THR . . . . . 0.577 HG22 HG21 ' A' ' 69' ' ' VAL . 80.9 p -80.57 153.52 28.01 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.189 -0.945 . . . . 0.0 109.36 179.79 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -66.0 -34.6 78.46 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.293 -0.879 . . . . 0.0 109.158 179.714 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 62.9 mttp -112.38 157.49 20.96 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.466 -0.771 . . . . 0.0 109.262 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 63.0 mttp -69.87 141.69 53.16 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.245 -0.91 . . . . 0.0 109.144 179.912 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 18.2 m -128.05 125.33 64.39 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 121.315 -0.866 . . . . 0.0 109.683 -179.819 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 46.5 t -148.33 152.13 12.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.43 -0.794 . . . . 0.0 109.114 179.766 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.401 HG23 ' H ' ' A' ' 171' ' ' VAL . 0.2 OUTLIER -91.15 114.94 29.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.23 -0.919 . . . . 0.0 109.374 -179.753 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -75.68 -11.47 60.01 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.521 -0.737 . . . . 0.0 110.072 -179.882 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 173' ' ' ASP . . . . . 0.475 ' OD1' ' N ' ' A' ' 174' ' ' CYS . 51.8 t0 -164.85 157.79 16.69 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 120.76 -1.212 . . . . 0.0 110.848 -179.31 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 174' ' ' CYS . . . . . 0.475 ' N ' ' OD1' ' A' ' 173' ' ' ASP . 16.7 t -154.85 141.64 19.05 Favored 'General case' 0 N--CA 1.492 1.657 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 179.372 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -178.05 178.08 48.46 Favored Glycine 0 N--CA 1.493 2.48 0 N-CA-C 109.749 -1.34 . . . . 0.0 109.749 179.776 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 176' ' ' GLN . . . . . 0.416 HE21 ' HB2' ' A' ' 178' ' ' SER . 60.9 tt0 -106.93 124.06 49.07 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.367 -1.078 . . . . 0.0 109.732 -179.981 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 30.6 tp -62.92 -37.99 89.22 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.132 -0.98 . . . . 0.0 109.264 179.509 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 178' ' ' SER . . . . . 0.416 ' HB2' HE21 ' A' ' 176' ' ' GLN . 33.1 m . . . . . 0 N--CA 1.49 1.549 0 CA-C-O 118.066 -0.969 . . . . 0.0 109.501 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.529 4.881 0 N-CA-C 119.318 2.487 . . . . 0.0 119.318 . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 28.8 t -115.9 141.7 47.76 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.295 -1.121 . . . . 0.0 109.35 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 49.0 p90 -148.12 164.34 34.17 Favored 'General case' 0 C--N 1.306 -1.309 0 O-C-N 121.291 -0.88 . . . . 0.0 108.75 179.837 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 18.8 p -118.53 162.36 18.49 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.593 -0.692 . . . . 0.0 109.285 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -139.13 56.15 0.65 Allowed Glycine 0 N--CA 1.493 2.449 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 -179.761 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 54.5 p -67.2 159.36 29.2 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.089 -1.242 . . . . 0.0 109.257 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 55.1 mtt -74.67 149.78 86.17 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.194 -0.941 . . . . 0.0 109.518 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -71.53 169.67 20.38 Favored 'Trans proline' 0 C--N 1.31 -1.491 0 C-N-CA 122.648 2.232 . . . . 0.0 111.921 179.881 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 13.4 m-20 -64.18 146.62 97.5 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.254 -0.904 . . . . 0.0 109.088 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_endo -67.73 140.81 52.43 Favored 'Trans proline' 0 N--CA 1.494 1.556 0 C-N-CA 122.492 2.128 . . . . 0.0 112.07 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 80.9 mtm180 -126.58 139.18 53.39 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.316 -0.865 . . . . 0.0 109.166 179.614 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 15.0 p -133.71 142.81 40.47 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 121.327 -0.858 . . . . 0.0 109.519 -179.878 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' PHE . . . . . 0.483 ' CE2' ' NH2' ' A' ' 25' ' ' ARG . 28.6 p90 -141.85 155.94 45.54 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.304 -0.872 . . . . 0.0 109.683 -179.598 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -130.46 139.27 50.55 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.484 -0.76 . . . . 0.0 109.777 179.628 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -95.35 117.24 29.97 Favored 'General case' 0 N--CA 1.491 1.601 0 N-CA-C 108.188 -1.041 . . . . 0.0 108.188 178.788 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' MET . . . . . 0.414 ' SD ' HD12 ' A' ' 26' ' ' ILE . 76.9 mtp -107.74 147.44 30.79 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.121 -0.987 . . . . 0.0 110.443 -178.816 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.407 ' HA ' ' H ' ' A' ' 23' ' ' ALA . 88.4 p -143.3 163.25 33.51 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 179.574 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.401 ' O ' ' C ' ' A' ' 19' ' ' GLY . 29.1 m -122.97 140.55 46.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.218 -0.927 . . . . 0.0 109.476 179.921 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.401 ' C ' ' O ' ' A' ' 18' ' ' VAL . . . 44.46 -102.68 0.04 OUTLIER Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.636 -1.386 . . . . 0.0 109.636 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -130.38 38.15 2.01 Favored Glycine 0 N--CA 1.493 2.475 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 47.2 tt0 -147.18 133.49 9.68 Favored Pre-proline 0 N--CA 1.492 1.656 0 O-C-N 121.125 -1.221 . . . . 0.0 109.181 179.974 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 43.0 Cg_endo -69.9 126.7 13.52 Favored 'Trans proline' 0 N--CA 1.493 1.494 0 C-N-CA 122.193 1.929 . . . . 0.0 112.218 -179.788 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.407 ' H ' ' HA ' ' A' ' 17' ' ' SER . . . -80.39 -48.21 13.26 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.288 -0.883 . . . . 0.0 109.432 179.849 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 170.94 -169.41 42.42 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.37 -1.492 . . . . 0.0 109.37 -179.788 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' ARG . . . . . 0.483 ' NH2' ' CE2' ' A' ' 13' ' ' PHE . 66.4 ttt180 -116.93 142.47 46.9 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.413 -1.051 . . . . 0.0 109.291 179.942 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.414 HD12 ' SD ' ' A' ' 16' ' ' MET . 86.9 mt -120.68 128.03 75.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.424 -0.797 . . . . 0.0 108.998 179.804 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 46.1 t -116.99 133.81 62.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.508 -0.745 . . . . 0.0 109.311 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 71.3 mtm -125.38 147.37 49.19 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.343 -0.848 . . . . 0.0 109.251 179.91 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -112.56 132.6 55.03 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.267 -0.896 . . . . 0.0 109.84 -179.686 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.501 HD13 ' HA ' ' A' ' 39' ' ' ALA . 11.8 mt -103.09 139.66 38.33 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.416 -0.802 . . . . 0.0 109.36 179.262 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -95.6 113.32 24.95 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 108.342 -0.985 . . . . 0.0 108.342 178.795 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -73.96 -42.8 59.97 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 121.232 -0.917 . . . . 0.0 109.94 -179.376 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 56.6 t0 -61.33 -46.58 89.66 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.191 -0.943 . . . . 0.0 110.163 -179.36 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 34' ' ' THR . . . . . 0.487 HG21 ' HE2' ' A' ' 103' ' ' LYS . 24.0 m -72.41 -45.77 58.18 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.16 -0.962 . . . . 0.0 110.215 -179.596 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.553 HG22 ' OE1' ' A' ' 99' ' ' GLU . 6.4 p -137.87 80.66 29.95 Favored Pre-proline 0 N--CA 1.494 1.774 0 O-C-N 121.162 -0.962 . . . . 0.0 110.069 -179.224 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -77.24 -6.18 16.29 Favored 'Trans proline' 0 C--N 1.307 -1.645 0 C-N-CA 122.507 2.138 . . . . 0.0 111.642 179.546 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 4.5 tpt180 -94.29 -67.03 0.88 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.375 -0.828 . . . . 0.0 110.151 -178.797 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 46.4 m -56.46 -43.32 79.43 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.191 -0.943 . . . . 0.0 110.231 -179.058 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.501 ' HA ' HD13 ' A' ' 30' ' ' LEU . . . -61.77 -31.71 71.93 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.146 -0.971 . . . . 0.0 108.968 179.747 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -75.51 -51.18 13.55 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.272 -0.893 . . . . 0.0 109.9 -179.898 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 54.2 t-20 -60.39 -46.71 88.99 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.177 -0.952 . . . . 0.0 109.605 -179.707 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.51 ' CE2' ' SG ' ' A' ' 46' ' ' CYS . 71.8 t80 -61.28 -43.23 99.22 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.3 -0.875 . . . . 0.0 109.215 179.637 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 60.1 ttp180 -56.63 -38.37 72.02 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.466 -0.771 . . . . 0.0 109.844 179.825 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -62.85 -44.21 96.74 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.137 -0.977 . . . . 0.0 109.915 -179.507 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.652 HD13 ' O ' ' A' ' 59' ' ' LEU . 3.7 mm? -62.96 -39.06 93.52 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.097 -1.002 . . . . 0.0 109.131 179.729 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 46' ' ' CYS . . . . . 0.51 ' SG ' ' CE2' ' A' ' 42' ' ' PHE . 3.4 m -69.52 -62.4 1.4 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.259 -0.901 . . . . 0.0 109.473 -179.875 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 35.5 m -63.13 -38.57 91.71 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.398 -0.814 . . . . 0.0 109.272 179.889 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 80.83 35.33 25.18 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 110.197 -1.161 . . . . 0.0 110.197 179.555 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -62.52 -38.13 88.75 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.046 -1.267 . . . . 0.0 109.544 179.89 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 69.3 mmtt -62.56 -37.18 85.14 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.178 -0.951 . . . . 0.0 109.777 -179.83 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 89.34 170.01 44.58 Favored Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.297 -1.521 . . . . 0.0 109.297 -179.646 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.521 HG23 ' HA ' ' A' ' 58' ' ' PRO . 91.3 m -77.66 139.52 39.47 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.355 -1.085 . . . . 0.0 109.706 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -63.25 139.41 44.18 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 31.6 mmt180 -59.68 -34.37 72.78 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.33 -1.1 . . . . 0.0 109.767 -179.72 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 85.9 p -61.55 -25.58 67.39 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.222 -0.924 . . . . 0.0 109.902 -179.667 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 113.78 93.1 1.99 Allowed Glycine 0 N--CA 1.495 2.596 0 N-CA-C 109.063 -1.615 . . . . 0.0 109.063 -179.64 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 57' ' ' LYS . . . . . 0.477 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 30.3 ttmt -177.64 80.43 0.24 Allowed Pre-proline 0 N--CA 1.49 1.543 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 -179.769 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.523 ' O ' ' CE2' ' A' ' 80' ' ' PHE . 74.6 Cg_exo -49.64 127.23 18.07 Favored 'Trans proline' 0 C--N 1.304 -1.812 0 C-N-CA 122.847 2.365 . . . . 0.0 112.768 -178.898 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.652 ' O ' HD13 ' A' ' 45' ' ' LEU . 8.7 mp -96.97 19.68 12.39 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.57 -0.707 . . . . 0.0 109.263 179.808 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 27.2 m170 -112.44 132.01 55.27 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.354 -0.841 . . . . 0.0 109.759 -179.441 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 46.4 m-85 -71.93 -1.92 16.18 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.217 -0.927 . . . . 0.0 108.838 178.953 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 43.6 tttm -54.85 144.23 23.34 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.411 -0.805 . . . . 0.0 109.712 -179.88 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 51.1 t0 58.99 45.57 14.72 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.549 -0.719 . . . . 0.0 109.623 179.853 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 87.7 p -116.52 152.12 34.74 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.394 -0.817 . . . . 0.0 109.131 179.547 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 29.4 t -120.95 146.73 46.35 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.395 -0.816 . . . . 0.0 109.506 -179.725 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.449 ' HE2' ' HG ' ' A' ' 75' ' ' CYS . 3.8 m-30 -65.7 134.02 52.31 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.247 -0.908 . . . . 0.0 108.992 179.763 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 78.5 t60 -62.1 -50.73 70.74 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.265 -0.897 . . . . 0.0 110.1 -179.36 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 29.1 ptt180 -164.61 160.41 20.09 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.062 -1.024 . . . . 0.0 109.471 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -141.05 130.08 24.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.217 -0.927 . . . . 0.0 109.585 179.588 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 21.9 mt -121.93 110.11 33.39 Favored Pre-proline 0 N--CA 1.491 1.6 0 N-CA-C 108.874 -0.788 . . . . 0.0 108.874 179.443 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_exo -50.39 140.69 34.29 Favored 'Trans proline' 0 C--N 1.311 -1.438 0 C-N-CA 122.341 2.028 . . . . 0.0 112.758 -179.478 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 86.09 -56.29 4.8 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 110.407 -1.077 . . . . 0.0 110.407 179.038 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 81.2 m-85 -66.51 -75.18 0.1 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.005 -1.291 . . . . 0.0 110.178 -179.303 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 12.9 ptt? 179.63 -168.07 0.09 Allowed 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.01 -1.056 . . . . 0.0 109.912 -179.788 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 75' ' ' CYS . . . . . 0.449 ' HG ' ' HE2' ' A' ' 66' ' ' PHE . 7.7 t -128.76 129.34 45.57 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.544 -0.723 . . . . 0.0 109.276 179.743 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 63.7 tt0 -100.12 112.96 25.27 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.148 -0.97 . . . . 0.0 109.321 179.816 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -63.17 -37.32 94.71 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.772 -1.331 . . . . 0.0 109.772 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 82.23 -164.88 44.4 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.22 -1.552 . . . . 0.0 109.22 -179.671 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.523 ' OD2' HG23 ' A' ' 81' ' ' THR . 18.0 t70 -143.82 147.5 34.2 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.203 -1.175 . . . . 0.0 109.385 179.938 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.523 ' CE2' ' O ' ' A' ' 58' ' ' PRO . 50.5 p90 -70.89 -20.58 62.49 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.228 -0.92 . . . . 0.0 109.943 -179.79 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.523 HG23 ' OD2' ' A' ' 79' ' ' ASP . 59.0 p -69.26 -28.42 66.3 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.129 -0.982 . . . . 0.0 109.703 -179.817 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 82' ' ' ALA . . . . . 0.482 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 176.57 -58.13 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.277 -0.89 . . . . 0.0 109.47 179.904 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 90.7 2.54 72.32 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 109.413 -1.475 . . . . 0.0 109.413 -179.854 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 52.9 p-10 -88.55 7.26 34.03 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.279 -1.13 . . . . 0.0 109.589 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 98.29 -37.87 3.31 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 -179.88 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 49.4 p -71.38 -25.24 62.28 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.196 -1.179 . . . . 0.0 109.047 179.661 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -86.52 -165.92 41.69 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 179.96 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 85.44 37.08 9.97 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -60.17 148.4 36.33 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.249 -1.148 . . . . 0.0 109.421 179.925 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 50.3 m -108.01 149.13 28.79 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.402 -0.811 . . . . 0.0 109.391 -179.886 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 21.6 pt -66.24 -32.24 57.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.211 -0.931 . . . . 0.0 110.047 -179.534 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 49.1 m-85 -64.3 -37.4 87.35 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.012 -1.055 . . . . 0.0 109.448 -179.912 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 81.51 8.27 87.22 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.157 -1.577 . . . . 0.0 109.157 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -150.35 155.69 40.09 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.272 -1.134 . . . . 0.0 109.525 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 62.6 mttt -92.95 154.84 17.93 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.241 -0.912 . . . . 0.0 109.641 179.927 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.475 ' CZ ' ' CG ' ' A' ' 121' ' ' ASN . 38.6 p90 -128.65 156.17 43.85 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.387 -0.82 . . . . 0.0 109.281 179.563 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -65.0 147.31 53.7 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.216 -0.927 . . . . 0.0 110.358 -179.139 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -62.48 154.33 28.86 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.315 -0.866 . . . . 0.0 109.609 179.912 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 99' ' ' GLU . . . . . 0.553 ' OE1' HG22 ' A' ' 35' ' ' THR . 94.6 mt-10 -85.35 -175.41 5.68 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.283 -0.886 . . . . 0.0 109.755 -179.833 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 18.5 m120 -60.3 162.78 5.67 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.416 -0.803 . . . . 0.0 109.94 -179.422 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 -98.67 23.63 8.46 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.43 -0.794 . . . . 0.0 109.585 -179.817 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 97.0 mt -48.38 -42.94 12.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.138 -0.977 . . . . 0.0 109.937 -179.327 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 103' ' ' LYS . . . . . 0.487 ' HE2' HG21 ' A' ' 34' ' ' THR . 59.0 mttm -89.47 139.29 30.67 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 120.931 -1.106 . . . . 0.0 109.689 179.972 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 87.5 mttt -127.28 -172.35 2.64 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.492 -0.755 . . . . 0.0 109.489 -179.898 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 105' ' ' HIS . . . . . 0.64 ' C ' ' CD2' ' A' ' 105' ' ' HIS . 5.9 t60 -113.77 111.67 22.16 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.531 -0.73 . . . . 0.0 109.189 179.752 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 60.6 p -131.16 4.82 4.43 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.276 -0.89 . . . . 0.0 109.922 -179.862 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -149.37 169.46 29.66 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.825 -1.31 . . . . 0.0 109.825 -179.824 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 76.6 Cg_endo -79.54 155.39 24.48 Favored 'Trans proline' 0 C--N 1.309 -1.543 0 C-N-CA 122.942 2.428 . . . . 0.0 112.083 179.783 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 76.89 52.61 5.72 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.894 -1.282 . . . . 0.0 109.894 179.628 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 38.1 mm -115.21 136.38 52.14 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.403 -1.057 . . . . 0.0 109.51 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.657 ' N ' HD22 ' A' ' 111' ' ' LEU . 3.3 mm? -88.27 134.37 33.82 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.227 -0.921 . . . . 0.0 109.537 179.786 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 28.9 t -146.3 142.79 28.65 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.255 -0.903 . . . . 0.0 109.374 179.729 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 87.6 mmm -87.64 132.06 34.22 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.231 -0.918 . . . . 0.0 109.284 179.902 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 114' ' ' ALA . . . . . 0.463 ' O ' ' OD1' ' A' ' 115' ' ' ASN . . . -68.23 139.69 56.04 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.123 -0.986 . . . . 0.0 109.405 -179.948 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 115' ' ' ASN . . . . . 0.463 ' OD1' ' O ' ' A' ' 114' ' ' ALA . 70.3 m-20 -145.94 113.44 6.31 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.247 -0.908 . . . . 0.0 109.01 179.642 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -69.15 -30.04 68.19 Favored 'General case' 0 C--N 1.297 -1.687 0 O-C-N 121.393 -0.817 . . . . 0.0 109.442 179.816 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -136.11 170.28 23.29 Favored Glycine 0 N--CA 1.494 2.525 0 N-CA-C 109.146 -1.582 . . . . 0.0 109.146 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -67.61 151.99 78.73 Favored 'Trans proline' 0 C--N 1.305 -1.719 0 C-N-CA 122.77 2.314 . . . . 0.0 111.847 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 69.0 m-20 53.34 44.26 30.32 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.33 -0.856 . . . . 0.0 109.143 -179.769 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 120' ' ' THR . . . . . 0.451 ' O ' ' OD1' ' A' ' 115' ' ' ASN . 58.3 m -132.26 123.83 27.69 Favored 'General case' 0 N--CA 1.486 1.373 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 179.924 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 121' ' ' ASN . . . . . 0.475 ' CG ' ' CZ ' ' A' ' 96' ' ' PHE . 26.5 m120 -113.39 138.62 49.8 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.506 -0.746 . . . . 0.0 109.537 -179.832 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -138.54 148.09 19.69 Favored Glycine 0 N--CA 1.493 2.489 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 23.3 m -61.23 -32.55 72.34 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.227 -1.16 . . . . 0.0 109.822 179.978 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.5 mt-30 -64.24 143.26 58.02 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.207 -0.933 . . . . 0.0 109.879 -179.481 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 48.7 p90 -141.42 163.9 31.68 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.346 -0.846 . . . . 0.0 109.028 179.858 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 45.3 p90 -136.91 158.14 45.14 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.299 -0.876 . . . . 0.0 109.696 -179.968 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 68.5 mt -120.39 136.53 57.13 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.519 -0.738 . . . . 0.0 109.273 179.799 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -108.5 120.82 43.54 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.457 -0.777 . . . . 0.0 109.358 -179.796 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 129' ' ' THR . . . . . 0.404 HG22 ' H ' ' A' ' 129' ' ' THR . 1.4 t -88.72 0.98 55.94 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.199 -0.938 . . . . 0.0 109.236 179.816 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -148.19 155.48 41.44 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.271 -0.893 . . . . 0.0 109.176 179.937 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 7.7 ttpm? -75.64 127.91 34.09 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.184 -0.947 . . . . 0.0 109.516 179.996 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 22.6 p -126.98 126.69 43.62 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.37 -0.831 . . . . 0.0 109.247 179.882 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -72.23 -36.56 69.16 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.28 -0.887 . . . . 0.0 110.366 -179.582 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 0.4 OUTLIER -65.03 -41.76 94.99 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.135 -0.978 . . . . 0.0 110.043 -179.157 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 135' ' ' LEU . . . . . 0.44 ' O ' ' CD2' ' A' ' 139' ' ' HIS . 12.9 mt -66.59 -33.83 76.53 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.985 -1.072 . . . . 0.0 109.8 179.701 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -68.46 140.85 55.75 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.15 -0.969 . . . . 0.0 109.522 -179.824 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 134.59 -86.19 0.26 Allowed Glycine 0 N--CA 1.492 2.417 0 N-CA-C 109.684 -1.366 . . . . 0.0 109.684 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 31.6 mmtp -85.97 5.32 33.79 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.132 -1.216 . . . . 0.0 109.507 -179.835 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 139' ' ' HIS . . . . . 0.44 ' CD2' ' O ' ' A' ' 135' ' ' LEU . 54.4 m-70 -103.26 138.19 40.38 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.286 -0.884 . . . . 0.0 109.477 -179.955 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 43.2 t -120.48 141.54 40.38 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 O-C-N 121.415 -0.803 . . . . 0.0 109.684 -179.565 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 96.1 t -94.8 128.96 45.61 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.361 -0.837 . . . . 0.0 109.245 179.821 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 142' ' ' PHE . . . . . 0.434 ' CE2' HD21 ' A' ' 30' ' ' LEU . 38.0 p90 -116.18 0.42 12.92 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.429 -0.794 . . . . 0.0 109.757 -179.77 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -169.42 178.04 42.71 Favored Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.676 -1.37 . . . . 0.0 109.676 179.684 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.2 pt20 -145.13 165.8 27.25 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.21 -1.171 . . . . 0.0 109.479 -179.865 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 77.7 t -96.54 127.28 48.82 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.265 0 O-C-N 121.193 -0.942 . . . . 0.0 109.274 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 22.2 m -94.7 -33.77 5.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.134 -0.979 . . . . 0.0 109.746 179.916 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -144.94 171.92 13.77 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.248 -0.907 . . . . 0.0 109.663 -179.797 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 96.68 4.93 58.99 Favored Glycine 0 N--CA 1.493 2.435 0 N-CA-C 109.915 -1.274 . . . . 0.0 109.915 179.642 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 149' ' ' MET . . . . . 0.491 ' O ' HG12 ' A' ' 152' ' ' VAL . 71.9 mtm -60.31 -33.05 71.82 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.071 -1.252 . . . . 0.0 109.809 179.888 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -65.63 -42.49 91.44 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 120.87 -1.144 . . . . 0.0 110.085 -179.586 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 6.5 p -81.73 -34.33 12.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.149 -0.969 . . . . 0.0 110.522 -179.484 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 152' ' ' VAL . . . . . 0.596 ' O ' ' OE1' ' A' ' 156' ' ' GLU . 0.8 OUTLIER -52.55 -43.07 41.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 120.816 -1.178 . . . . 0.0 109.0 -179.13 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 153' ' ' LYS . . . . . 0.454 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 48.5 mttp -63.12 -34.41 77.54 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.192 -0.942 . . . . 0.0 109.317 179.251 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -63.27 -32.11 73.43 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.429 -0.795 . . . . 0.0 110.176 -179.558 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.419 ' O ' HG22 ' A' ' 158' ' ' VAL . 69.1 mt -68.79 -43.14 82.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.124 -0.985 . . . . 0.0 110.836 -179.179 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 156' ' ' GLU . . . . . 0.596 ' OE1' ' O ' ' A' ' 152' ' ' VAL . 32.4 mp0 -77.21 -37.98 52.32 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 120.768 -1.207 . . . . 0.0 112.025 -178.683 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 12.1 pttm -57.48 -35.55 70.33 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 120.523 -1.36 . . . . 0.0 109.731 -178.516 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.419 HG22 ' O ' ' A' ' 155' ' ' ILE . 26.9 m -75.11 -19.8 16.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 120.969 -1.082 . . . . 0.0 109.013 179.042 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -67.33 167.46 40.04 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 -179.911 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 89.4 p -148.74 168.22 23.48 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.316 -1.108 . . . . 0.0 109.42 -179.798 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 22.9 m -54.55 -34.21 61.45 Favored 'General case' 0 N--CA 1.487 1.406 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 179.425 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 23.9 m -58.39 -30.77 67.07 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.472 -0.767 . . . . 0.0 109.063 179.438 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.69 7.49 55.52 Favored Glycine 0 N--CA 1.492 2.431 0 N-CA-C 109.814 -1.315 . . . . 0.0 109.814 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 75.3 ttt-85 -114.74 139.5 49.65 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.31 -1.112 . . . . 0.0 109.084 179.781 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 165' ' ' THR . . . . . . . . . . . . . 51.1 p -87.47 156.24 19.64 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.214 -0.929 . . . . 0.0 109.879 -179.768 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -66.8 -37.22 84.13 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.531 -0.731 . . . . 0.0 109.433 179.765 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 67.2 mttm -111.25 156.82 20.89 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.411 -0.805 . . . . 0.0 109.606 -179.835 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 94.3 mttt -76.24 139.77 41.31 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.287 -0.883 . . . . 0.0 109.331 179.871 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 43.1 t -118.02 126.35 74.84 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.265 -0.897 . . . . 0.0 109.636 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 42.6 t -146.0 150.3 15.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.345 -0.847 . . . . 0.0 109.294 179.608 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -88.54 122.12 39.62 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 O-C-N 121.288 -0.882 . . . . 0.0 109.691 -179.446 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -67.0 -25.61 66.39 Favored 'General case' 0 C--N 1.3 -1.565 0 O-C-N 121.438 -0.789 . . . . 0.0 109.536 179.56 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 173' ' ' ASP . . . . . 0.413 ' OD1' ' N ' ' A' ' 174' ' ' CYS . 44.9 t0 -173.06 169.96 4.52 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.01 -1.056 . . . . 0.0 110.542 -179.383 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 174' ' ' CYS . . . . . 0.413 ' N ' ' OD1' ' A' ' 173' ' ' ASP . 30.4 p -152.61 150.35 29.42 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.501 -0.749 . . . . 0.0 109.014 179.416 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . 179.71 -177.07 47.99 Favored Glycine 0 N--CA 1.494 2.528 0 N-CA-C 110.044 -1.222 . . . . 0.0 110.044 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 58.9 tt0 -105.33 122.39 45.86 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.529 -0.983 . . . . 0.0 109.632 -179.868 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 177' ' ' LEU . . . . . 0.591 HD13 ' O ' ' A' ' 177' ' ' LEU . 0.2 OUTLIER -65.2 -40.82 94.71 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.171 -0.956 . . . . 0.0 108.566 179.485 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 178' ' ' SER . . . . . 0.464 ' C ' ' O ' ' A' ' 177' ' ' LEU . 1.2 t . . . . . 0 N--CA 1.493 1.702 0 CA-C-O 118.022 -0.99 . . . . 0.0 109.935 179.859 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.528 4.781 0 N-CA-C 119.433 2.533 . . . . 0.0 119.433 . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 44.0 m -62.68 154.13 30.27 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.187 -1.184 . . . . 0.0 109.445 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 99.2 m-85 -111.42 121.88 46.37 Favored 'General case' 0 N--CA 1.486 1.34 0 O-C-N 121.43 -0.794 . . . . 0.0 108.957 179.722 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -135.05 -6.65 2.35 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.515 -0.741 . . . . 0.0 109.489 179.856 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 86.97 9.64 73.57 Favored Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 85.9 p -63.19 -23.94 67.66 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.21 -1.171 . . . . 0.0 109.651 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 30.7 ttm -124.44 77.42 62.31 Favored Pre-proline 0 N--CA 1.494 1.746 0 O-C-N 121.323 -0.861 . . . . 0.0 109.587 -179.784 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -79.9 -61.14 0.03 OUTLIER 'Trans proline' 0 C--N 1.308 -1.555 0 C-N-CA 122.643 2.229 . . . . 0.0 112.239 179.897 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -123.26 153.91 65.23 Favored Pre-proline 0 N--CA 1.494 1.738 0 O-C-N 121.529 -0.732 . . . . 0.0 109.243 179.877 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -69.18 138.53 39.92 Favored 'Trans proline' 0 N--CA 1.496 1.627 0 C-N-CA 122.744 2.296 . . . . 0.0 112.306 179.913 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.701 HH21 HD23 ' A' ' 177' ' ' LEU . 50.8 ttp180 -133.69 126.53 30.96 Favored 'General case' 0 N--CA 1.49 1.568 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 179.143 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.5 p -131.88 141.83 44.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.29 -0.881 . . . . 0.0 109.521 -179.139 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 40.5 p90 -140.28 157.87 44.9 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.379 -0.826 . . . . 0.0 109.524 -179.602 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 95.2 m-85 -126.93 142.58 51.51 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.472 -0.768 . . . . 0.0 109.808 179.902 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 19.1 t70 -93.74 113.51 25.59 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.412 -0.958 . . . . 0.0 108.412 178.931 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 96.8 mmm -97.13 146.54 24.95 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.452 -0.78 . . . . 0.0 110.112 -179.164 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 41.8 t -149.58 162.07 40.91 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.457 -0.777 . . . . 0.0 109.036 179.628 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.536 HG22 ' O ' ' A' ' 21' ' ' GLN . 25.6 m -124.27 159.9 29.36 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.314 -0.867 . . . . 0.0 109.562 179.894 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -49.18 -30.45 10.64 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.822 -1.311 . . . . 0.0 109.822 -179.475 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -73.93 -79.65 0.52 Allowed Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.674 -1.37 . . . . 0.0 109.674 -179.837 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' GLN . . . . . 0.536 ' O ' HG22 ' A' ' 18' ' ' VAL . 4.2 pt20 -146.35 157.15 49.43 Favored Pre-proline 0 N--CA 1.494 1.727 0 O-C-N 121.177 -1.19 . . . . 0.0 109.129 -179.968 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 75.6 Cg_exo -45.78 130.31 12.51 Favored 'Trans proline' 0 C--N 1.31 -1.455 0 C-N-CA 122.25 1.967 . . . . 0.0 112.138 179.792 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -80.05 -56.42 4.25 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.28 -0.888 . . . . 0.0 109.703 -179.891 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 168.82 -170.74 42.54 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 -179.898 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 56.9 ttp180 -114.48 142.01 46.95 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.392 -1.063 . . . . 0.0 109.338 179.818 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 81.5 mt -120.04 130.5 74.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.429 -0.795 . . . . 0.0 109.012 179.877 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 43.6 t -110.56 134.63 52.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.386 -0.821 . . . . 0.0 109.717 -179.792 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 72.1 mtm -121.71 151.89 40.0 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.447 -0.783 . . . . 0.0 109.082 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -105.54 132.86 51.17 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.265 -0.897 . . . . 0.0 110.053 -179.517 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -105.18 129.52 53.55 Favored 'General case' 0 N--CA 1.494 1.767 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 179.143 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -97.7 119.0 35.5 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.207 -0.933 . . . . 0.0 109.131 179.716 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -81.39 -42.21 20.78 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.383 -0.823 . . . . 0.0 109.638 179.847 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -64.8 -46.11 83.42 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.281 -0.887 . . . . 0.0 110.215 -179.388 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 28.4 m -65.99 -45.4 81.74 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.163 -0.961 . . . . 0.0 109.589 -179.766 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.445 ' O ' ' OG1' ' A' ' 35' ' ' THR . 4.1 p -141.38 80.58 16.33 Favored Pre-proline 0 N--CA 1.492 1.668 0 N-CA-C 108.798 -0.816 . . . . 0.0 108.798 179.912 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_endo -59.49 -65.1 0.09 OUTLIER 'Trans proline' 0 N--CA 1.496 1.622 0 C-N-CA 122.419 2.079 . . . . 0.0 113.018 -178.843 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 94.8 mtt180 -60.62 -36.88 79.7 Favored 'General case' 0 C--N 1.298 -1.668 0 O-C-N 121.596 -0.69 . . . . 0.0 110.965 -178.769 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 23.0 m -60.85 -43.32 98.48 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 120.928 -1.107 . . . . 0.0 109.954 -179.423 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -61.94 -31.58 71.91 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.176 -0.952 . . . . 0.0 108.87 179.769 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -70.52 -41.73 72.21 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.352 -0.842 . . . . 0.0 109.937 -179.862 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' ASN . . . . . 0.439 ' O ' HD23 ' A' ' 45' ' ' LEU . 81.5 m-20 -60.71 -45.31 94.69 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.137 -0.977 . . . . 0.0 109.75 -179.585 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 56.3 t80 -71.76 -48.24 48.2 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.202 -0.936 . . . . 0.0 109.225 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 61.8 ttp180 -58.24 -38.92 77.82 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.47 -0.768 . . . . 0.0 109.887 179.917 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.489 ' O ' ' N ' ' A' ' 48' ' ' GLY . . . -60.99 -40.59 94.09 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.289 -0.882 . . . . 0.0 110.22 -178.925 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.439 HD23 ' O ' ' A' ' 41' ' ' ASN . 3.8 mm? -61.61 -39.38 91.03 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.056 -1.027 . . . . 0.0 109.473 179.946 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 46' ' ' CYS . . . . . . . . . . . . . 20.1 m -80.87 -53.13 6.74 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.015 -1.053 . . . . 0.0 109.71 -179.832 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 68.8 p -69.17 -36.74 77.67 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.336 -0.853 . . . . 0.0 109.855 -179.821 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.489 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 73.6 32.79 59.09 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.815 -1.314 . . . . 0.0 109.815 179.636 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 78.1 mm-40 -60.91 -37.43 82.21 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.081 -1.246 . . . . 0.0 109.262 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 32.5 mmtm -61.39 -31.38 71.29 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.311 -0.868 . . . . 0.0 109.303 179.649 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 97.59 169.2 32.7 Favored Glycine 0 N--CA 1.489 2.168 0 N-CA-C 109.323 -1.511 . . . . 0.0 109.323 -179.773 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.493 HG23 ' HA ' ' A' ' 58' ' ' PRO . 98.1 m -75.32 141.68 43.33 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.289 -1.124 . . . . 0.0 109.749 -179.84 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -56.78 140.3 44.25 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.254 -1.538 . . . . 0.0 109.254 179.87 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 93.5 mtt-85 -59.04 -33.39 70.71 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.189 -1.183 . . . . 0.0 109.998 -179.787 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 86.6 p -60.55 -25.46 66.18 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.161 -0.962 . . . . 0.0 109.902 -179.397 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 108.8 90.45 2.11 Favored Glycine 0 N--CA 1.495 2.578 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 -179.756 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 57' ' ' LYS . . . . . 0.431 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 17.7 tttm -176.26 78.62 0.28 Allowed Pre-proline 0 N--CA 1.489 1.493 0 O-C-N 121.397 -1.06 . . . . 0.0 108.46 -179.683 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.493 ' HA ' HG23 ' A' ' 52' ' ' THR . 87.0 Cg_exo -47.31 128.9 15.26 Favored 'Trans proline' 0 C--N 1.304 -1.793 0 C-N-CA 122.66 2.24 . . . . 0.0 112.174 -179.046 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.537 ' O ' ' CG ' ' A' ' 60' ' ' HIS . 7.2 mp -91.62 94.78 9.57 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.684 -0.635 . . . . 0.0 109.753 -179.348 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 60' ' ' HIS . . . . . 0.537 ' CG ' ' O ' ' A' ' 59' ' ' LEU . 93.7 m-70 -159.75 125.39 4.17 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.358 -0.839 . . . . 0.0 109.531 179.685 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 61' ' ' TYR . . . . . 0.42 ' O ' ' OG ' ' A' ' 64' ' ' SER . 55.5 m-85 -68.59 -5.05 17.7 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.104 -0.997 . . . . 0.0 108.986 179.269 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 35.2 ttmt -54.74 144.9 20.8 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.463 -0.773 . . . . 0.0 109.743 -179.866 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 84.1 m-20 56.25 45.41 23.17 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.612 -0.68 . . . . 0.0 109.793 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.42 ' OG ' ' O ' ' A' ' 61' ' ' TYR . 39.3 m -120.23 147.91 44.35 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.413 -0.804 . . . . 0.0 108.996 179.528 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 30.0 t -113.12 147.04 38.15 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.424 -0.798 . . . . 0.0 109.554 -179.699 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 4.2 m-30 -64.79 136.31 56.77 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.279 -0.888 . . . . 0.0 108.959 179.951 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 53.3 t-80 -61.5 -50.53 72.34 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.274 -0.891 . . . . 0.0 110.285 -179.193 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.696 HH21 ' NE2' ' A' ' 76' ' ' GLN . 36.8 ptt180 -161.47 160.71 29.56 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.117 -0.989 . . . . 0.0 110.136 -179.757 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.585 HG21 HG22 ' A' ' 165' ' ' THR . 24.0 m -132.91 151.34 34.14 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.509 -0.744 . . . . 0.0 108.993 179.716 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 11.6 mt -146.92 119.83 4.91 Favored Pre-proline 0 N--CA 1.492 1.657 0 O-C-N 121.038 -1.039 . . . . 0.0 109.436 179.78 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -74.68 135.35 19.59 Favored 'Trans proline' 0 C--N 1.312 -1.368 0 C-N-CA 122.161 1.907 . . . . 0.0 111.997 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 90.39 1.1 75.47 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 93.1 m-85 -135.81 -90.76 0.29 Allowed 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.376 -1.073 . . . . 0.0 109.632 179.963 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 9.6 ptp -170.28 172.62 6.13 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.109 -0.994 . . . . 0.0 109.618 -179.946 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 1.7 m -116.14 138.9 50.86 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.403 -0.811 . . . . 0.0 108.877 179.748 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 76' ' ' GLN . . . . . 0.696 ' NE2' HH21 ' A' ' 68' ' ' ARG . 94.6 mt-30 -108.54 154.87 21.32 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.269 -0.894 . . . . 0.0 109.707 -179.683 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -147.04 -165.79 11.96 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 -179.816 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.47 ' O ' ' N ' ' A' ' 80' ' ' PHE . . . 94.37 11.59 57.03 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 109.459 -1.457 . . . . 0.0 109.459 -179.737 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -48.15 -15.4 0.07 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.391 -1.064 . . . . 0.0 109.594 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.47 ' N ' ' O ' ' A' ' 78' ' ' GLY . 81.2 t80 -48.21 -47.96 35.21 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.229 -0.919 . . . . 0.0 110.2 -179.535 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.808 ' CB ' ' H ' ' A' ' 88' ' ' GLY . 54.4 p -71.15 -32.18 68.62 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.916 -1.115 . . . . 0.0 109.49 -179.929 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 82' ' ' ALA . . . . . 0.694 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 163.21 -54.64 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.426 -0.796 . . . . 0.0 109.14 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 91.77 1.04 71.23 Favored Glycine 0 N--CA 1.492 2.42 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 179.947 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 78.6 m-20 -87.63 5.91 37.18 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.225 -1.162 . . . . 0.0 109.474 179.923 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 95.53 -39.82 2.78 Favored Glycine 0 N--CA 1.493 2.45 0 N-CA-C 109.263 -1.535 . . . . 0.0 109.263 -179.79 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 56.3 p -73.85 -14.2 61.05 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.418 -1.048 . . . . 0.0 108.944 179.665 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -80.66 -160.76 24.0 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 -179.881 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.808 ' H ' ' CB ' ' A' ' 81' ' ' THR . . . 89.54 23.18 34.54 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.426 -1.47 . . . . 0.0 109.426 -179.819 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -55.69 148.89 15.27 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.293 -1.122 . . . . 0.0 109.529 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 49.8 m -105.14 151.12 24.43 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.394 -0.816 . . . . 0.0 109.384 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.411 HD13 HG21 ' A' ' 91' ' ' ILE . 27.6 pt -62.78 -32.48 55.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.247 -0.908 . . . . 0.0 109.974 -179.549 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 89.6 m-85 -65.08 -35.19 80.36 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.155 -0.965 . . . . 0.0 109.606 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 87.1 7.43 77.23 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.391 -1.483 . . . . 0.0 109.391 -179.862 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -147.53 155.89 42.3 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.32 -1.106 . . . . 0.0 109.376 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 64.1 mttp -89.89 143.65 26.61 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.255 -0.903 . . . . 0.0 109.82 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 41.4 p90 -138.15 160.38 39.55 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.543 -0.723 . . . . 0.0 109.067 179.779 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -67.35 132.79 48.38 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.04 -1.037 . . . . 0.0 109.596 -179.599 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -75.27 140.02 42.91 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.4 -0.813 . . . . 0.0 109.799 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -59.83 149.06 32.41 Favored 'General case' 0 C--N 1.305 -1.35 0 O-C-N 121.309 -0.87 . . . . 0.0 109.093 179.581 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 37.7 m-20 -53.36 162.56 0.73 Allowed 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.409 -0.807 . . . . 0.0 109.309 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 101' ' ' PHE . . . . . 0.584 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 22.3 p90 -130.63 82.15 2.04 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.462 -0.774 . . . . 0.0 109.372 -179.787 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 87.8 mt -60.31 -33.97 55.79 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.18 -0.95 . . . . 0.0 109.478 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 91.6 mttt -84.45 136.29 33.9 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.311 -0.868 . . . . 0.0 109.342 179.932 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 61.9 mttp -116.31 -178.62 3.46 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.485 -0.759 . . . . 0.0 109.986 -179.877 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 105' ' ' HIS . . . . . 0.526 ' O ' ' CG ' ' A' ' 105' ' ' HIS . 49.9 p-80 -99.79 101.39 12.53 Favored 'General case' 0 N--CA 1.493 1.694 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 179.692 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 66.5 p -101.19 -2.16 32.01 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.273 -0.892 . . . . 0.0 109.768 -179.743 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -149.8 171.91 29.79 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -74.24 157.81 45.61 Favored 'Trans proline' 0 C--N 1.304 -1.785 0 C-N-CA 122.899 2.399 . . . . 0.0 112.027 179.784 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 84.91 40.47 8.1 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 110.158 -1.177 . . . . 0.0 110.158 179.663 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 43.0 mm -113.66 133.55 59.26 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.382 -1.07 . . . . 0.0 109.183 179.677 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.537 ' N ' HD22 ' A' ' 111' ' ' LEU . 3.4 mm? -90.61 133.15 35.31 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.145 -0.972 . . . . 0.0 109.825 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 42.9 t -144.8 142.6 30.1 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.353 -0.842 . . . . 0.0 109.197 179.744 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 113' ' ' MET . . . . . 0.586 ' SD ' ' CE1' ' A' ' 142' ' ' PHE . 83.8 mmm -83.97 129.79 34.91 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.12 -0.988 . . . . 0.0 109.288 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -69.6 143.94 53.16 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.283 -0.886 . . . . 0.0 109.462 -179.951 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 60.3 m-20 -142.94 112.72 6.96 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.363 -0.836 . . . . 0.0 108.961 179.463 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -69.45 -29.51 67.22 Favored 'General case' 0 C--N 1.298 -1.66 0 O-C-N 121.471 -0.768 . . . . 0.0 109.657 -179.872 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -134.43 166.73 24.09 Favored Glycine 0 N--CA 1.493 2.477 0 N-CA-C 109.406 -1.477 . . . . 0.0 109.406 179.888 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -68.88 153.82 72.08 Favored 'Trans proline' 0 C--N 1.305 -1.721 0 C-N-CA 122.81 2.34 . . . . 0.0 111.94 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 17.9 m120 54.19 43.17 31.01 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.483 -0.761 . . . . 0.0 109.441 -179.925 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 92.8 m -134.91 125.07 25.98 Favored 'General case' 0 N--CA 1.485 1.324 0 O-C-N 121.42 -0.8 . . . . 0.0 108.929 179.928 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 22.6 t-20 -103.05 102.6 12.63 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.469 -0.77 . . . . 0.0 109.391 179.828 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -92.93 133.93 11.95 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.414 -1.474 . . . . 0.0 109.414 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 83.3 p -63.77 -23.46 67.37 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.191 -1.182 . . . . 0.0 109.296 179.83 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 92.6 mt-30 -68.66 144.57 54.41 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.335 -0.853 . . . . 0.0 109.505 -179.882 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 49.7 p90 -137.53 163.07 32.06 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.396 -0.815 . . . . 0.0 109.166 179.773 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 48.9 p90 -135.81 160.93 37.05 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.271 -0.893 . . . . 0.0 109.776 -179.937 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 70.2 mt -117.61 132.68 66.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.444 -0.785 . . . . 0.0 109.568 -179.918 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 1.9 p -100.72 106.6 18.05 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.325 -0.859 . . . . 0.0 109.255 179.555 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 129' ' ' THR . . . . . 0.431 ' OG1' ' OE1' ' A' ' 156' ' ' GLU . 68.5 p -90.93 3.03 55.68 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.189 -0.945 . . . . 0.0 109.809 -179.765 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -146.0 154.63 42.1 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.12 -0.987 . . . . 0.0 109.674 -179.726 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 78.9 tttt -81.16 131.06 35.28 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.336 -0.853 . . . . 0.0 109.362 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 9.4 p -125.29 161.65 26.49 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.358 -0.839 . . . . 0.0 109.418 179.933 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -127.52 -28.79 2.73 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.236 -0.915 . . . . 0.0 109.642 -179.891 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 2.0 p90 -75.8 -6.53 51.11 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.159 -0.963 . . . . 0.0 109.777 -179.841 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 8.2 mt -90.78 7.69 38.47 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.242 -0.911 . . . . 0.0 109.548 179.486 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 136' ' ' ASP . . . . . 0.472 ' O ' ' OD1' ' A' ' 136' ' ' ASP . 52.2 p30 -53.63 153.34 4.43 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.301 -0.874 . . . . 0.0 109.724 -179.755 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 144.48 -129.6 3.64 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.012 -1.635 . . . . 0.0 109.012 -179.685 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 2.0 mptp? -90.4 127.55 36.23 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.214 -1.168 . . . . 0.0 108.91 179.643 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 139' ' ' HIS . . . . . 0.406 ' CE1' HG22 ' A' ' 141' ' ' VAL . 42.0 t-80 -140.57 127.58 20.75 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.375 -0.828 . . . . 0.0 109.694 -179.85 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 44.7 t -123.11 132.76 70.81 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 121.458 -0.776 . . . . 0.0 109.048 179.595 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 141' ' ' VAL . . . . . 0.406 HG22 ' CE1' ' A' ' 139' ' ' HIS . 38.8 t -116.5 129.36 73.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.321 -0.862 . . . . 0.0 109.211 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 142' ' ' PHE . . . . . 0.586 ' CE1' ' SD ' ' A' ' 113' ' ' MET . 38.3 p90 -119.93 5.89 10.89 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.323 -0.861 . . . . 0.0 109.734 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -179.43 177.66 48.37 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 179.655 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.2 pt20 -146.17 167.13 24.2 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.265 -1.138 . . . . 0.0 109.453 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 55.2 t -95.33 130.24 44.36 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 O-C-N 121.232 -0.918 . . . . 0.0 109.326 -179.886 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 13.3 m -108.51 -36.63 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.308 -0.87 . . . . 0.0 109.653 179.812 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 94.4 mt-10 -139.75 161.89 36.46 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.26 -0.9 . . . . 0.0 109.575 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 148' ' ' GLY . . . . . 0.43 ' O ' HG12 ' A' ' 151' ' ' VAL . . . 95.02 5.64 60.78 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 110.102 -1.199 . . . . 0.0 110.102 179.578 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 149' ' ' MET . . . . . 0.593 ' O ' HG12 ' A' ' 152' ' ' VAL . 65.0 mtt -60.0 -32.58 71.0 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.049 -1.266 . . . . 0.0 109.319 179.859 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 56.1 t0 -64.85 -41.89 95.33 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.954 -1.091 . . . . 0.0 110.291 -179.563 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.43 HG12 ' O ' ' A' ' 148' ' ' GLY . 7.6 p -78.15 -32.32 17.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.06 -1.025 . . . . 0.0 110.911 -179.266 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 152' ' ' VAL . . . . . 0.593 HG12 ' O ' ' A' ' 149' ' ' MET . 0.9 OUTLIER -51.62 -40.57 26.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 120.962 -1.087 . . . . 0.0 109.011 -179.18 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 153' ' ' LYS . . . . . 0.439 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 59.1 mttp -65.69 -32.63 74.3 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.242 -0.911 . . . . 0.0 109.441 179.09 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -60.11 -39.37 85.97 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.341 -0.849 . . . . 0.0 110.113 -179.28 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 90.0 mt -72.31 -33.95 47.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.048 -1.033 . . . . 0.0 109.757 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 156' ' ' GLU . . . . . 0.431 ' OE1' ' OG1' ' A' ' 129' ' ' THR . 84.5 tt0 -77.63 -41.72 37.43 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.231 -0.918 . . . . 0.0 111.34 -178.859 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 157' ' ' LYS . . . . . 0.431 ' HG2' ' HZ2' ' A' ' 157' ' ' LYS . 17.5 pttm -59.65 -35.57 74.66 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 120.682 -1.261 . . . . 0.0 109.579 -178.838 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 35.3 m -77.15 -10.34 13.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.155 -0.966 . . . . 0.0 108.798 179.228 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -73.89 163.45 54.63 Favored Glycine 0 N--CA 1.488 2.124 0 N-CA-C 110.178 -1.169 . . . . 0.0 110.178 -179.596 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 54.2 m -148.07 165.77 29.8 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.598 -0.942 . . . . 0.0 109.276 -179.895 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 23.9 t -55.08 -26.56 38.71 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.217 -0.927 . . . . 0.0 109.293 179.849 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 86.8 p -57.64 -25.65 60.48 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.243 -0.911 . . . . 0.0 109.639 -179.749 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 92.48 12.98 57.77 Favored Glycine 0 N--CA 1.492 2.414 0 N-CA-C 109.941 -1.264 . . . . 0.0 109.941 179.87 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 24.2 ttm180 -127.14 143.09 51.35 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.204 -1.174 . . . . 0.0 109.491 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 165' ' ' THR . . . . . 0.585 HG22 HG21 ' A' ' 69' ' ' VAL . 79.1 p -76.9 154.81 33.35 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.255 -0.903 . . . . 0.0 109.344 179.851 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -63.93 -35.88 82.13 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.24 -0.912 . . . . 0.0 109.231 179.813 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -116.78 154.69 30.23 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.571 -0.706 . . . . 0.0 109.151 179.794 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -66.44 142.43 57.57 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.121 -0.987 . . . . 0.0 109.095 -179.949 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 169' ' ' VAL . . . . . 0.465 ' O ' HG23 ' A' ' 169' ' ' VAL . 33.0 m -123.99 128.38 74.09 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.363 -0.836 . . . . 0.0 109.707 -179.716 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 40.7 t -144.16 147.76 19.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.395 -0.816 . . . . 0.0 109.011 179.649 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.407 HG23 ' H ' ' A' ' 171' ' ' VAL . 0.2 OUTLIER -83.86 115.53 26.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 120.935 -1.103 . . . . 0.0 109.464 -179.787 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -66.08 -22.39 66.41 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.364 -0.835 . . . . 0.0 109.213 179.469 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 173' ' ' ASP . . . . . 0.454 ' OD1' ' N ' ' A' ' 174' ' ' CYS . 48.0 t0 -167.38 163.39 15.07 Favored 'General case' 0 N--CA 1.492 1.654 0 C-N-CA 119.035 -1.066 . . . . 0.0 110.564 -179.493 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 174' ' ' CYS . . . . . 0.454 ' N ' ' OD1' ' A' ' 173' ' ' ASP . 18.5 p -161.78 146.62 13.06 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.592 -0.693 . . . . 0.0 109.325 179.535 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . 170.45 175.08 38.97 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 179.829 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 8.2 tt0 -102.58 121.02 41.55 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.228 -1.16 . . . . 0.0 109.779 179.925 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 177' ' ' LEU . . . . . 0.701 HD23 HH21 ' A' ' 11' ' ' ARG . 46.2 tp -64.74 -36.58 84.75 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.33 -0.856 . . . . 0.0 109.371 179.408 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 7.9 t . . . . . 0 N--CA 1.49 1.565 0 CA-C-O 118.025 -0.988 . . . . 0.0 109.368 179.999 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.757 ' O ' HG23 ' A' ' 4' ' ' THR . . . . . . . . 1 N--CA 1.528 4.821 0 N-CA-C 119.397 2.519 . . . . 0.0 119.397 . . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 85.1 p -64.64 -23.5 67.28 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.179 -1.189 . . . . 0.0 109.958 -179.806 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 98.8 m-85 -95.34 18.74 11.92 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.175 -0.953 . . . . 0.0 110.229 -179.323 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.757 HG23 ' O ' ' A' ' 1' ' ' GLY . 60.2 p -68.58 -30.61 69.4 Favored 'General case' 0 C--N 1.297 -1.68 0 O-C-N 121.37 -0.831 . . . . 0.0 109.459 179.644 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 75.67 31.67 55.8 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.73 -1.348 . . . . 0.0 109.73 179.682 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 23.2 t -60.71 -37.97 83.49 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.2 -1.177 . . . . 0.0 109.709 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 1.4 ptm -132.36 80.12 63.96 Favored Pre-proline 0 N--CA 1.496 1.855 0 O-C-N 121.329 -0.857 . . . . 0.0 109.303 -179.884 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -80.82 -24.18 5.11 Favored 'Trans proline' 0 C--N 1.308 -1.596 0 C-N-CA 122.77 2.313 . . . . 0.0 112.488 -179.486 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -141.74 157.55 64.61 Favored Pre-proline 0 N--CA 1.493 1.686 0 O-C-N 121.263 -0.898 . . . . 0.0 109.322 -179.922 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -69.42 139.67 41.97 Favored 'Trans proline' 0 N--CA 1.496 1.65 0 C-N-CA 122.686 2.257 . . . . 0.0 112.152 179.887 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 75.1 mtt85 -128.93 132.87 47.69 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.387 -0.82 . . . . 0.0 109.077 179.092 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.7 p -135.06 142.68 39.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.488 -0.757 . . . . 0.0 109.223 -179.859 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 41.6 p90 -139.55 153.81 47.51 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.296 -0.878 . . . . 0.0 109.505 -179.786 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 93.4 m-85 -122.15 135.23 54.76 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.516 -0.74 . . . . 0.0 109.446 179.699 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.6 t0 -90.3 113.4 25.25 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.111 -0.993 . . . . 0.0 108.374 179.212 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 71.6 mtp -105.24 147.38 28.11 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.072 -1.017 . . . . 0.0 110.389 -179.168 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.435 ' HA ' ' H ' ' A' ' 23' ' ' ALA . 84.2 p -144.9 165.2 28.81 Favored 'General case' 0 N--CA 1.489 1.501 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 179.724 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 33.5 m -125.37 151.16 31.01 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.28 -0.888 . . . . 0.0 109.43 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -51.17 102.49 0.07 OUTLIER Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 140.43 -75.13 0.35 Allowed Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.714 -1.354 . . . . 0.0 109.714 179.873 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -138.41 158.78 70.0 Favored Pre-proline 0 N--CA 1.492 1.663 0 O-C-N 121.337 -1.096 . . . . 0.0 109.264 -179.763 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -58.63 138.77 87.64 Favored 'Trans proline' 0 N--CA 1.494 1.524 0 C-N-CA 122.581 2.187 . . . . 0.0 111.887 179.78 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.435 ' H ' ' HA ' ' A' ' 17' ' ' SER . . . -84.27 -62.47 1.55 Allowed 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.223 -0.923 . . . . 0.0 109.568 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 168.9 -169.69 41.96 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 -179.836 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 58.9 ttp180 -115.72 141.81 47.59 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.338 -1.095 . . . . 0.0 109.265 179.936 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 82.8 mt -121.24 128.96 76.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.331 -0.855 . . . . 0.0 109.237 179.831 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 46.5 t -114.18 134.09 58.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.335 -0.853 . . . . 0.0 109.26 179.908 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' MET . . . . . 0.421 ' HG2' HG22 ' A' ' 145' ' ' VAL . 73.9 mtm -119.93 151.74 38.47 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.384 -0.822 . . . . 0.0 109.318 -179.928 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -98.68 131.98 44.43 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.339 -0.851 . . . . 0.0 109.763 -179.57 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -107.34 132.62 52.93 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.494 -0.754 . . . . 0.0 109.143 179.681 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 95.7 m-85 -98.6 125.41 43.85 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.223 -0.923 . . . . 0.0 109.176 179.66 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -94.47 1.25 55.76 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.255 -0.903 . . . . 0.0 109.997 -179.692 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -95.45 -75.17 0.53 Allowed 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.046 -1.034 . . . . 0.0 110.581 -179.342 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 47.0 m -64.67 -40.65 95.79 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.354 -0.841 . . . . 0.0 111.017 -178.646 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.569 HG21 ' HA ' ' A' ' 142' ' ' PHE . 43.3 p -126.46 76.18 73.7 Favored Pre-proline 0 N--CA 1.496 1.829 0 O-C-N 121.089 -1.007 . . . . 0.0 110.149 -178.982 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 63.7 Cg_endo -78.21 -57.42 0.04 OUTLIER 'Trans proline' 0 C--N 1.308 -1.601 0 C-N-CA 122.764 2.31 . . . . 0.0 112.729 179.724 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 24.1 mmt85 -57.39 -38.47 74.32 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.247 -0.908 . . . . 0.0 110.151 -179.249 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.555 HG23 ' SD ' ' A' ' 113' ' ' MET . 41.5 m -61.41 -40.85 95.9 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.039 -1.038 . . . . 0.0 109.915 -179.581 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -61.89 -31.1 71.36 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.203 -0.936 . . . . 0.0 109.216 179.842 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -67.57 -37.19 82.29 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.389 -0.819 . . . . 0.0 109.766 -179.846 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 49.6 t-20 -58.64 -43.05 89.62 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.24 -0.912 . . . . 0.0 109.841 -179.678 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.495 ' O ' ' SG ' ' A' ' 46' ' ' CYS . 96.9 m-85 -83.31 -46.63 12.38 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.165 -0.96 . . . . 0.0 109.756 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.651 ' NE ' HE22 ' A' ' 176' ' ' GLN . 76.5 ttt180 -57.19 -42.06 80.53 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.295 -0.878 . . . . 0.0 109.901 -179.697 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.482 ' O ' ' N ' ' A' ' 48' ' ' GLY . . . -76.63 -48.54 18.76 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.132 -0.98 . . . . 0.0 110.29 -179.612 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.401 HD12 ' HA ' ' A' ' 45' ' ' LEU . 40.8 tp -58.1 -37.92 75.45 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.112 -0.993 . . . . 0.0 109.795 -179.4 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 46' ' ' CYS . . . . . 0.495 ' SG ' ' O ' ' A' ' 42' ' ' PHE . 39.8 m -77.32 -63.97 1.25 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.113 -0.992 . . . . 0.0 109.929 -179.795 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 26.0 m -63.17 -38.39 91.0 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.117 -0.989 . . . . 0.0 109.678 -179.813 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.482 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 80.58 37.16 21.1 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 110.043 -1.223 . . . . 0.0 110.043 179.744 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -61.4 -37.57 83.94 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.058 -1.26 . . . . 0.0 109.367 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 42.2 mmtm -61.52 -32.56 72.61 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.287 -0.883 . . . . 0.0 109.458 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 95.71 172.4 36.21 Favored Glycine 0 N--CA 1.487 2.097 0 N-CA-C 109.173 -1.571 . . . . 0.0 109.173 -179.62 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.54 HG23 ' HA ' ' A' ' 58' ' ' PRO . 94.1 m -72.36 141.19 48.77 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.315 -1.109 . . . . 0.0 109.871 -179.824 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -58.5 137.84 49.75 Favored Glycine 0 N--CA 1.489 2.169 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 179.804 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 94.1 mtt180 -59.72 -34.14 72.53 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.397 -1.061 . . . . 0.0 109.983 -179.68 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 86.2 p -61.32 -24.95 66.8 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.312 -0.867 . . . . 0.0 109.952 -179.564 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 112.58 89.83 1.85 Allowed Glycine 0 N--CA 1.495 2.572 0 N-CA-C 109.094 -1.603 . . . . 0.0 109.094 -179.595 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 57' ' ' LYS . . . . . 0.51 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 15.4 tptp -175.98 81.0 0.29 Allowed Pre-proline 0 N--CA 1.488 1.461 0 O-C-N 121.438 -1.036 . . . . 0.0 108.444 -179.659 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.54 ' HA ' HG23 ' A' ' 52' ' ' THR . 75.2 Cg_exo -51.01 131.48 35.04 Favored 'Trans proline' 0 C--N 1.304 -1.808 0 C-N-CA 122.799 2.333 . . . . 0.0 112.728 -179.168 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.51 ' CD1' ' O ' ' A' ' 57' ' ' LYS . 8.8 mp -101.13 89.13 3.7 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.487 -0.758 . . . . 0.0 109.224 -179.919 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 60' ' ' HIS . . . . . 0.515 ' O ' ' CE1' ' A' ' 80' ' ' PHE . 77.2 m80 -138.78 136.25 35.49 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.362 -0.836 . . . . 0.0 109.531 179.778 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -87.31 -7.95 57.25 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.289 -0.882 . . . . 0.0 108.771 179.529 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 34.2 ttmt -64.15 151.33 43.6 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.524 -0.735 . . . . 0.0 109.958 -179.729 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 59.93 46.61 10.89 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.628 -0.67 . . . . 0.0 109.965 179.896 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 20.8 t -115.83 141.61 47.87 Favored 'General case' 0 N--CA 1.494 1.728 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.323 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 28.7 t -114.97 145.73 41.95 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.386 -0.821 . . . . 0.0 109.682 -179.64 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.5 m-30 -69.41 137.76 53.02 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.243 -0.91 . . . . 0.0 108.996 179.791 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 58.5 t-80 -60.76 -50.75 72.21 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.242 -0.912 . . . . 0.0 110.249 -179.378 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 37.7 ptt180 -163.72 162.21 23.87 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.061 -1.024 . . . . 0.0 109.939 -179.677 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.564 HG21 HG22 ' A' ' 165' ' ' THR . 15.1 m -131.65 142.81 42.19 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.424 -0.798 . . . . 0.0 108.946 179.615 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 10.3 mt -148.03 109.85 3.75 Favored Pre-proline 0 N--CA 1.494 1.739 0 O-C-N 120.907 -1.121 . . . . 0.0 109.83 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -53.36 145.89 43.4 Favored 'Trans proline' 0 N--CA 1.494 1.524 0 C-N-CA 122.347 2.031 . . . . 0.0 112.489 179.524 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 82.01 -57.52 4.96 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 110.161 -1.175 . . . . 0.0 110.161 179.428 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -70.46 -88.68 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.137 -1.214 . . . . 0.0 109.828 -179.544 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 11.3 ptt? -178.31 176.4 1.08 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.221 -0.925 . . . . 0.0 109.57 -179.753 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -111.1 131.58 54.96 Favored 'General case' 0 N--CA 1.493 1.69 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 179.54 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 63.5 tt0 -98.26 150.14 21.85 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.239 -0.913 . . . . 0.0 109.958 -179.439 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -140.66 -170.1 11.97 Favored Glycine 0 N--CA 1.493 2.487 0 N-CA-C 109.287 -1.525 . . . . 0.0 109.287 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 96.52 6.33 58.57 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.861 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 54.8 t0 -58.33 -24.98 61.37 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.35 -1.088 . . . . 0.0 109.728 179.906 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.515 ' CE1' ' O ' ' A' ' 60' ' ' HIS . 76.4 t80 -48.21 -46.37 35.07 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.359 -0.838 . . . . 0.0 110.068 -179.38 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.737 ' CB ' ' H ' ' A' ' 88' ' ' GLY . 69.1 p -70.95 -29.93 66.09 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 120.96 -1.088 . . . . 0.0 109.493 179.896 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 82' ' ' ALA . . . . . 0.672 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 163.85 -55.84 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.412 -0.805 . . . . 0.0 109.225 179.822 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 92.37 0.41 70.33 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.529 -1.429 . . . . 0.0 109.529 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 78.7 m-20 -87.81 5.88 38.0 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.27 -1.135 . . . . 0.0 109.459 -179.962 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 96.12 -38.55 3.07 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 109.253 -1.539 . . . . 0.0 109.253 -179.895 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 61.7 p -73.82 -15.7 61.16 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.242 -1.152 . . . . 0.0 109.092 179.526 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -81.39 -163.9 31.83 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 -179.919 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.737 ' H ' ' CB ' ' A' ' 81' ' ' THR . . . 81.86 50.82 4.76 Favored Glycine 0 N--CA 1.487 2.099 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 -179.896 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -90.31 147.32 23.57 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.342 -1.093 . . . . 0.0 109.665 -179.728 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 50.5 m -112.17 149.71 31.84 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.461 -0.774 . . . . 0.0 109.403 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 5.1 pt -60.8 -42.13 91.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.277 -0.89 . . . . 0.0 110.106 -179.584 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 3.9 m-30 -66.65 -38.82 87.66 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.113 -0.992 . . . . 0.0 109.582 179.915 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 74.29 26.04 69.23 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.118 -1.593 . . . . 0.0 109.118 -179.742 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -143.64 161.29 38.9 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.421 -1.046 . . . . 0.0 109.569 -179.708 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 83.6 mttt -83.24 148.32 27.48 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.405 -0.81 . . . . 0.0 109.74 -179.736 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 88.6 m-85 -104.1 131.85 50.95 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.376 -0.828 . . . . 0.0 108.865 179.618 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -77.27 136.12 38.48 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.139 -0.976 . . . . 0.0 109.573 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.53 ' OD2' ' CE1' ' A' ' 101' ' ' PHE . 32.3 p-10 -87.86 128.22 35.35 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.215 -0.928 . . . . 0.0 109.279 179.714 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 99' ' ' GLU . . . . . 0.491 ' O ' ' OD1' ' A' ' 100' ' ' ASN . 84.6 tt0 -61.41 -43.15 99.36 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.155 -0.966 . . . . 0.0 109.989 -179.481 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 100' ' ' ASN . . . . . 0.491 ' OD1' ' O ' ' A' ' 99' ' ' GLU . 84.0 m-20 -155.24 165.4 36.77 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.145 -0.972 . . . . 0.0 110.071 -179.829 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 101' ' ' PHE . . . . . 0.53 ' CE1' ' OD2' ' A' ' 98' ' ' ASP . 98.6 m-85 -102.62 8.17 39.77 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.429 -0.794 . . . . 0.0 109.156 179.358 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 97.4 mt -53.79 -36.47 29.89 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.344 -0.847 . . . . 0.0 110.404 -179.404 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 33.3 mmtp -73.68 124.91 26.89 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.022 -1.049 . . . . 0.0 109.661 -179.512 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 12.9 pttm -142.77 -177.6 5.39 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.321 -0.862 . . . . 0.0 109.246 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 105' ' ' HIS . . . . . . . . . . . . . 93.6 m-70 -74.99 88.33 2.37 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.144 -0.973 . . . . 0.0 109.209 179.723 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 54.9 p -71.06 -26.81 63.24 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.188 -0.945 . . . . 0.0 109.572 -179.79 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -162.08 -168.45 24.0 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.305 -1.518 . . . . 0.0 109.305 -179.855 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -80.58 154.83 20.99 Favored 'Trans proline' 0 C--N 1.306 -1.705 0 C-N-CA 122.935 2.423 . . . . 0.0 112.175 179.783 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 80.33 43.45 9.49 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.944 -1.262 . . . . 0.0 109.944 179.667 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 41.7 mm -115.55 135.5 55.41 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.863 0 O-C-N 121.364 -1.08 . . . . 0.0 109.628 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.432 ' N ' HD22 ' A' ' 111' ' ' LEU . 4.3 mm? -91.25 124.4 35.42 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.25 -0.906 . . . . 0.0 109.272 179.654 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 30.9 t -140.72 141.07 34.95 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.176 -0.952 . . . . 0.0 109.501 179.867 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 113' ' ' MET . . . . . 0.555 ' SD ' HG23 ' A' ' 38' ' ' THR . 88.9 mtp -89.92 137.89 31.96 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.264 -0.897 . . . . 0.0 109.215 179.75 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -60.9 144.57 52.7 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.121 -0.987 . . . . 0.0 109.381 -179.955 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 16.4 m-20 -137.05 110.78 8.1 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.216 -0.928 . . . . 0.0 109.275 179.848 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -73.57 -29.46 62.44 Favored 'General case' 0 C--N 1.297 -1.677 0 O-C-N 121.406 -0.809 . . . . 0.0 109.4 179.684 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -140.6 175.39 22.08 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 179.926 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -68.17 151.89 76.63 Favored 'Trans proline' 0 C--N 1.305 -1.717 0 C-N-CA 122.746 2.297 . . . . 0.0 111.822 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 119' ' ' ASN . . . . . 0.429 ' OD1' ' OD1' ' A' ' 98' ' ' ASP . 71.8 m-20 52.84 40.52 30.87 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.453 -0.779 . . . . 0.0 109.278 -179.781 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 94.6 m -140.78 124.17 16.76 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.406 -0.809 . . . . 0.0 109.248 179.904 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 87.9 m-20 -109.86 114.81 28.67 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.568 -0.708 . . . . 0.0 109.16 179.503 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -78.05 135.52 16.26 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 179.947 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 22.8 t -55.83 -32.72 63.84 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.212 -1.169 . . . . 0.0 109.195 179.793 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 94.2 mt-30 -72.47 146.6 46.78 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.348 -0.845 . . . . 0.0 109.28 179.729 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 41.2 p90 -133.16 163.3 29.57 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.351 -0.843 . . . . 0.0 109.088 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 49.2 p90 -135.65 156.33 49.02 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.222 -0.923 . . . . 0.0 109.699 -179.931 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 76.2 mt -121.62 134.61 64.41 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 179.804 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 128' ' ' CYS . . . . . 0.435 ' SG ' ' O ' ' A' ' 130' ' ' ALA . 5.5 t -116.22 124.66 50.8 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.288 -0.883 . . . . 0.0 109.368 179.968 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 44.1 p -89.26 -2.1 58.34 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.448 -0.782 . . . . 0.0 109.766 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 130' ' ' ALA . . . . . 0.435 ' O ' ' SG ' ' A' ' 128' ' ' CYS . . . -149.0 156.96 43.02 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.18 -0.95 . . . . 0.0 109.691 -179.857 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 63.6 tttm -72.84 136.78 45.4 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.31 -0.869 . . . . 0.0 109.34 179.813 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 17.1 p -121.48 158.8 27.63 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.43 -0.794 . . . . 0.0 109.537 -179.846 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -103.05 -74.65 0.63 Allowed 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.246 -0.909 . . . . 0.0 109.915 -179.829 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 134' ' ' TRP . . . . . 0.605 ' CD1' ' N ' ' A' ' 135' ' ' LEU . 42.0 p90 -58.73 -47.76 83.52 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.291 -0.881 . . . . 0.0 110.08 -179.419 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 135' ' ' LEU . . . . . 0.605 ' N ' ' CD1' ' A' ' 134' ' ' TRP . 31.5 tp -60.98 -35.08 75.87 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.203 -0.936 . . . . 0.0 109.332 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 62.1 t0 -80.05 118.16 21.52 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.202 -0.936 . . . . 0.0 109.541 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 137' ' ' GLY . . . . . 0.544 ' H ' ' CE1' ' A' ' 139' ' ' HIS . . . -144.24 -126.58 1.95 Allowed Glycine 0 N--CA 1.492 2.4 0 N-CA-C 109.096 -1.602 . . . . 0.0 109.096 179.844 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 2.0 mptm? -84.71 105.5 15.55 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.112 -1.228 . . . . 0.0 108.959 179.629 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 139' ' ' HIS . . . . . 0.544 ' CE1' ' H ' ' A' ' 137' ' ' GLY . 76.9 m80 -138.16 161.07 37.76 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.353 -0.842 . . . . 0.0 109.483 -179.862 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 45.0 t -119.58 136.04 58.0 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 O-C-N 121.399 -0.813 . . . . 0.0 109.404 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 59.2 t -105.31 130.25 56.85 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 O-C-N 121.395 -0.816 . . . . 0.0 109.144 179.82 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 142' ' ' PHE . . . . . 0.569 ' HA ' HG21 ' A' ' 35' ' ' THR . 39.9 p90 -114.33 -0.81 13.72 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.306 -0.871 . . . . 0.0 109.766 -179.865 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -174.71 174.79 46.8 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.589 -1.405 . . . . 0.0 109.589 179.546 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 23.7 pt20 -146.72 167.23 24.34 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.213 -1.169 . . . . 0.0 109.665 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 145' ' ' VAL . . . . . 0.421 HG22 ' HG2' ' A' ' 28' ' ' MET . 9.5 t -96.73 132.63 40.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 O-C-N 121.218 -0.926 . . . . 0.0 109.529 -179.95 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 15.9 m -111.43 -30.19 2.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.541 -0.724 . . . . 0.0 109.145 179.577 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 78.6 mm-40 -140.02 166.0 25.83 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.342 -0.849 . . . . 0.0 109.344 179.876 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 96.69 4.9 58.98 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.889 -1.285 . . . . 0.0 109.889 179.649 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 149' ' ' MET . . . . . 0.493 ' O ' HG12 ' A' ' 152' ' ' VAL . 65.1 mtt -60.2 -32.24 70.91 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 121.056 -1.261 . . . . 0.0 109.467 179.932 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 89.0 m-20 -64.38 -40.35 95.65 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 120.894 -1.129 . . . . 0.0 109.805 -179.807 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.402 ' H ' HG12 ' A' ' 151' ' ' VAL . 4.4 p -83.69 -35.09 11.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.251 -0.906 . . . . 0.0 110.502 -179.504 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 152' ' ' VAL . . . . . 0.493 HG12 ' O ' ' A' ' 149' ' ' MET . 0.9 OUTLIER -53.9 -42.0 51.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 120.835 -1.166 . . . . 0.0 108.871 -179.336 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 153' ' ' LYS . . . . . 0.455 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 60.0 mttm -65.68 -32.94 74.77 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.12 -0.987 . . . . 0.0 109.123 179.064 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -60.08 -36.96 78.55 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.423 -0.798 . . . . 0.0 109.751 -179.512 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 98.5 mt -71.2 -34.74 55.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.092 -1.005 . . . . 0.0 109.945 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 83.0 tt0 -76.63 -42.17 43.19 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.246 -0.908 . . . . 0.0 111.324 -178.823 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 33.3 pttt -62.13 -33.38 74.38 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 120.798 -1.189 . . . . 0.0 109.822 -178.921 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 33.0 m -83.5 -0.59 5.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.036 -1.04 . . . . 0.0 108.828 179.523 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -75.32 173.01 53.34 Favored Glycine 0 N--CA 1.488 2.115 0 N-CA-C 110.048 -1.221 . . . . 0.0 110.048 -179.53 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 89.7 p -153.22 164.02 38.84 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.462 -1.022 . . . . 0.0 109.764 -179.711 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 23.3 m -58.69 -32.82 69.49 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.309 -0.869 . . . . 0.0 108.834 179.31 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 25.4 m -55.84 -31.57 62.84 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.386 -0.821 . . . . 0.0 109.172 179.86 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 101.08 9.08 46.18 Favored Glycine 0 N--CA 1.495 2.574 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 179.893 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 35.8 ttp180 -116.48 141.12 48.59 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.238 -1.154 . . . . 0.0 109.293 179.898 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 165' ' ' THR . . . . . 0.564 HG22 HG21 ' A' ' 69' ' ' VAL . 80.6 p -76.5 155.87 33.44 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.292 -0.88 . . . . 0.0 109.304 179.932 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -62.37 -35.83 80.37 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.231 -0.918 . . . . 0.0 109.298 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 62.5 mttp -118.93 152.98 35.34 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.475 -0.766 . . . . 0.0 109.157 179.764 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -64.67 141.55 58.74 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.021 -1.049 . . . . 0.0 108.957 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 169' ' ' VAL . . . . . 0.48 ' O ' HG23 ' A' ' 169' ' ' VAL . 33.9 m -121.66 126.63 74.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.226 -0.921 . . . . 0.0 109.8 -179.748 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 44.5 t -145.03 148.81 17.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 N-CA-C 108.839 -0.801 . . . . 0.0 108.839 179.704 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.454 ' H ' HG23 ' A' ' 171' ' ' VAL . 0.1 OUTLIER -80.91 115.7 23.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.119 -0.988 . . . . 0.0 109.463 -179.798 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 78.4 mm-40 -67.9 -20.31 65.09 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.396 -0.815 . . . . 0.0 109.505 179.629 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 20.2 t70 -167.66 162.18 13.93 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.015 -1.053 . . . . 0.0 110.364 -179.456 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 30.6 p -155.89 144.52 20.26 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.459 -0.776 . . . . 0.0 109.294 179.604 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . 177.25 179.98 47.8 Favored Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 176' ' ' GLN . . . . . 0.651 HE22 ' NE ' ' A' ' 43' ' ' ARG . 63.6 tt0 -105.62 124.0 48.83 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.41 -1.053 . . . . 0.0 109.77 -179.905 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 35.5 tp -61.23 -37.8 84.34 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.187 -0.946 . . . . 0.0 109.395 179.658 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 7.9 t . . . . . 0 N--CA 1.489 1.522 0 CA-C-O 117.994 -1.003 . . . . 0.0 109.475 -179.967 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.529 4.839 0 N-CA-C 119.402 2.521 . . . . 0.0 119.402 . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 29.8 t -119.66 143.62 47.61 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.295 -1.12 . . . . 0.0 109.455 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 49.6 p90 -145.52 158.28 43.86 Favored 'General case' 0 C--N 1.306 -1.29 0 O-C-N 121.183 -0.948 . . . . 0.0 108.647 179.721 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.551 HG22 ' H ' ' A' ' 6' ' ' SER . 45.1 m -86.23 132.36 34.02 Favored 'General case' 0 C--N 1.297 -1.694 0 O-C-N 121.398 -0.814 . . . . 0.0 109.596 -179.819 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -60.79 -31.92 77.4 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.774 -1.33 . . . . 0.0 109.774 179.88 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.551 ' H ' HG22 ' A' ' 4' ' ' THR . 29.5 t -89.44 146.09 24.88 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.304 -1.115 . . . . 0.0 109.701 -179.536 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' MET . . . . . 0.418 ' HB2' HH22 ' A' ' 11' ' ' ARG . 44.3 mtt -66.88 151.67 96.63 Favored Pre-proline 0 N--CA 1.489 1.517 0 O-C-N 121.265 -0.897 . . . . 0.0 109.318 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 26.0 Cg_endo -63.32 -20.17 69.82 Favored 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 122.723 2.282 . . . . 0.0 112.377 -179.878 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 12.2 t-20 -62.13 136.67 95.47 Favored Pre-proline 0 N--CA 1.491 1.615 0 O-C-N 121.102 -0.999 . . . . 0.0 109.342 -179.736 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 82.8 Cg_endo -75.29 140.15 24.37 Favored 'Trans proline' 0 N--CA 1.495 1.612 0 C-N-CA 122.473 2.116 . . . . 0.0 112.599 -179.833 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.418 HH22 ' HB2' ' A' ' 7' ' ' MET . 71.0 mtt85 -132.74 132.58 42.45 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.35 -0.844 . . . . 0.0 108.834 178.996 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.0 p -135.62 143.21 37.22 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.327 -0.858 . . . . 0.0 109.707 -179.764 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 42.7 p90 -138.21 154.21 49.12 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.523 -0.736 . . . . 0.0 109.183 179.941 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.415 ' CE1' ' CE1' ' A' ' 61' ' ' TYR . 97.5 m-85 -124.18 137.54 54.52 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.481 -0.762 . . . . 0.0 109.788 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.4 t0 -93.39 117.94 30.7 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.359 -0.838 . . . . 0.0 108.801 179.425 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' MET . . . . . 0.454 ' SD ' HD12 ' A' ' 26' ' ' ILE . 77.1 mtp -112.12 151.21 29.71 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.151 -0.968 . . . . 0.0 110.457 -179.174 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 84.5 p -142.91 163.09 33.73 Favored 'General case' 0 N--CA 1.489 1.519 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 179.804 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.534 ' O ' ' N ' ' A' ' 20' ' ' GLY . 26.2 m -125.96 143.01 40.94 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.201 -0.937 . . . . 0.0 109.706 -179.87 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 47.89 11.5 0.11 Allowed Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.817 -1.313 . . . . 0.0 109.817 179.833 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.534 ' N ' ' O ' ' A' ' 18' ' ' VAL . . . 97.43 -13.98 63.82 Favored Glycine 0 N--CA 1.493 2.499 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 -179.927 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' GLN . . . . . 0.458 ' N ' ' OE1' ' A' ' 21' ' ' GLN . 13.2 mp0 -84.62 150.85 57.54 Favored Pre-proline 0 N--CA 1.492 1.675 0 O-C-N 121.26 -1.141 . . . . 0.0 109.112 179.757 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_endo -62.15 136.93 63.33 Favored 'Trans proline' 0 C--N 1.308 -1.584 0 C-N-CA 122.453 2.102 . . . . 0.0 112.012 -179.893 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -111.72 -65.59 1.16 Allowed 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.439 -0.788 . . . . 0.0 109.359 179.886 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 178.98 -170.1 41.75 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.348 -1.501 . . . . 0.0 109.348 -179.924 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 92.2 mtt180 -116.72 143.72 45.31 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.358 -1.083 . . . . 0.0 109.526 179.792 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.454 HD12 ' SD ' ' A' ' 16' ' ' MET . 84.7 mt -121.06 122.77 68.49 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 179.304 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 38.8 t -118.47 132.75 67.43 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.434 0 O-C-N 121.376 -0.828 . . . . 0.0 109.154 -179.984 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 73.6 mtm -122.32 151.54 41.03 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.408 -0.807 . . . . 0.0 109.122 -179.886 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -99.32 130.79 45.63 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.298 -0.877 . . . . 0.0 109.847 -179.629 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.404 ' N ' ' CD2' ' A' ' 30' ' ' LEU . 2.7 mm? -107.07 129.12 54.86 Favored 'General case' 0 N--CA 1.491 1.575 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 179.535 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -99.63 120.23 39.36 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.244 -0.91 . . . . 0.0 109.082 179.572 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -78.95 -40.52 31.63 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.337 -0.852 . . . . 0.0 110.01 -179.753 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.537 ' OD1' ' N ' ' A' ' 34' ' ' THR . 31.9 p-10 -68.23 -41.22 81.54 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.228 -0.92 . . . . 0.0 110.72 -179.082 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 34' ' ' THR . . . . . 0.537 ' N ' ' OD1' ' A' ' 33' ' ' ASP . 17.1 m -67.66 -44.52 77.66 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.005 -1.06 . . . . 0.0 109.997 -179.375 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.414 HG23 ' O ' ' A' ' 34' ' ' THR . 28.5 p -155.23 83.62 3.73 Favored Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.226 -0.921 . . . . 0.0 109.217 -179.903 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 13.4 Cg_endo -70.55 -35.77 9.79 Favored 'Trans proline' 0 C--N 1.307 -1.654 0 C-N-CA 121.987 1.791 . . . . 0.0 112.088 -179.537 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.424 ' HD2' ' H ' ' A' ' 37' ' ' ARG . 1.6 mpt_? -66.51 -41.93 88.07 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.077 -1.014 . . . . 0.0 109.702 179.771 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.552 HG23 ' SD ' ' A' ' 113' ' ' MET . 56.1 m -65.16 -42.06 94.11 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.203 -0.936 . . . . 0.0 110.008 -179.519 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -61.88 -31.37 71.65 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.135 -0.978 . . . . 0.0 109.083 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -69.84 -37.99 76.37 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.397 -0.814 . . . . 0.0 110.052 -179.742 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 47.9 m-20 -58.42 -41.99 86.25 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.026 -1.046 . . . . 0.0 109.965 -179.345 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 -87.13 -48.41 8.08 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.114 -0.991 . . . . 0.0 109.554 179.878 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.47 ' O ' HG23 ' A' ' 47' ' ' THR . 66.8 ttp85 -57.63 -42.27 83.01 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.208 -0.933 . . . . 0.0 109.563 -179.853 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -69.74 -46.4 65.98 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.267 -0.896 . . . . 0.0 109.829 -179.674 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 44.9 tp -63.64 -37.78 88.65 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.29 -0.881 . . . . 0.0 109.701 -179.594 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' CYS . . . . . . . . . . . . . 81.7 m -72.99 -48.76 33.69 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.171 -0.956 . . . . 0.0 109.782 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' THR . . . . . 0.47 HG23 ' O ' ' A' ' 43' ' ' ARG . 69.8 p -70.93 -35.58 72.28 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.164 -0.96 . . . . 0.0 109.687 -179.93 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 73.46 25.26 73.13 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 179.906 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 22.7 pt-20 -64.77 -33.1 75.18 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.225 -1.162 . . . . 0.0 109.622 -179.768 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 47.2 mmtm -60.14 -33.81 72.68 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.305 -0.872 . . . . 0.0 109.362 179.771 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 92.24 174.84 42.12 Favored Glycine 0 N--CA 1.486 2.032 0 N-CA-C 109.283 -1.527 . . . . 0.0 109.283 -179.753 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.502 HG23 ' HA ' ' A' ' 58' ' ' PRO . 65.5 m -70.57 139.22 51.44 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.387 -1.067 . . . . 0.0 109.705 -179.971 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -57.72 135.35 51.82 Favored Glycine 0 N--CA 1.488 2.137 0 N-CA-C 109.219 -1.552 . . . . 0.0 109.219 179.766 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 73.4 mtp180 -59.0 -33.88 71.22 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.178 -1.19 . . . . 0.0 109.958 -179.678 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 87.0 p -60.55 -24.46 65.41 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.18 -0.95 . . . . 0.0 109.684 -179.621 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 112.66 90.92 1.93 Allowed Glycine 0 N--CA 1.494 2.562 0 N-CA-C 109.049 -1.621 . . . . 0.0 109.049 -179.714 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 57' ' ' LYS . . . . . 0.509 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 33.0 tttm -174.72 78.61 0.33 Allowed Pre-proline 0 N--CA 1.488 1.437 0 O-C-N 121.425 -1.044 . . . . 0.0 108.365 -179.73 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.502 ' HA ' HG23 ' A' ' 52' ' ' THR . 75.8 Cg_exo -49.47 130.75 26.3 Favored 'Trans proline' 0 C--N 1.304 -1.783 0 C-N-CA 122.787 2.325 . . . . 0.0 112.77 -179.087 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.509 ' CD1' ' O ' ' A' ' 57' ' ' LYS . 7.1 mp -97.48 120.38 37.74 Favored 'General case' 0 N--CA 1.49 1.572 0 N-CA-C 109.195 -0.669 . . . . 0.0 109.195 179.854 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 58.7 m80 -149.79 93.84 2.09 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.273 -0.892 . . . . 0.0 109.448 179.679 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 61' ' ' TYR . . . . . 0.415 ' CE1' ' CE1' ' A' ' 14' ' ' PHE . 24.3 t80 -60.65 -34.38 74.21 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 179.831 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 62' ' ' LYS . . . . . 0.425 ' HE2' ' H ' ' A' ' 174' ' ' CYS . 92.8 mttt -54.77 167.9 0.33 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.495 -0.753 . . . . 0.0 109.794 -179.686 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 83.0 m-20 57.24 47.16 17.44 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.5 -0.75 . . . . 0.0 110.02 179.609 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 96.3 p -114.12 154.03 28.49 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.383 -0.823 . . . . 0.0 108.918 179.366 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 28.2 t -131.66 149.04 52.63 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.255 -0.903 . . . . 0.0 109.668 -179.552 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 28.6 m-85 -77.51 125.0 28.65 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.306 -0.871 . . . . 0.0 109.369 179.852 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 15.3 t-80 -67.93 -46.4 71.6 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.598 -0.689 . . . . 0.0 110.782 -179.176 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 94.5 mtt180 -132.39 150.05 52.23 Favored 'General case' 0 N--CA 1.498 1.925 0 O-C-N 121.041 -1.037 . . . . 0.0 110.739 -178.972 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.714 HG21 HG22 ' A' ' 165' ' ' THR . 7.7 m -144.19 52.26 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 N-CA-C 108.744 -0.836 . . . . 0.0 108.744 179.471 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 14.4 mt -76.69 133.44 70.31 Favored Pre-proline 0 C--N 1.301 -1.537 0 O-C-N 121.193 -0.942 . . . . 0.0 110.07 -178.702 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_endo -70.09 149.95 65.53 Favored 'Trans proline' 0 N--CA 1.492 1.405 0 C-N-CA 122.408 2.072 . . . . 0.0 112.283 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 79.42 -55.19 4.38 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 179.864 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 90.9 m-85 -71.35 -87.7 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.249 -1.147 . . . . 0.0 109.702 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 74' ' ' MET . . . . . 0.602 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 12.1 ptt? 179.15 -178.83 0.35 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.184 -0.948 . . . . 0.0 109.763 -179.926 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 1.1 m -117.46 131.9 56.65 Favored 'General case' 0 N--CA 1.492 1.67 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 179.255 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 63.5 tt0 -95.04 146.16 24.46 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.161 -0.962 . . . . 0.0 110.222 -179.013 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -143.55 -175.07 16.31 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.186 -1.566 . . . . 0.0 109.186 179.841 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 93.24 10.55 59.43 Favored Glycine 0 N--CA 1.494 2.528 0 N-CA-C 109.426 -1.47 . . . . 0.0 109.426 -179.905 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.438 ' OD1' ' O ' ' A' ' 82' ' ' ALA . 62.4 t0 -56.18 -15.52 3.91 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.341 -1.094 . . . . 0.0 109.681 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 73.5 t80 -50.07 -47.86 53.37 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.174 -0.954 . . . . 0.0 110.17 -179.291 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.756 ' CB ' ' H ' ' A' ' 88' ' ' GLY . 65.6 p -71.53 -31.96 67.63 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.892 -1.13 . . . . 0.0 109.606 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 82' ' ' ALA . . . . . 0.685 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 164.51 -54.63 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.302 -0.874 . . . . 0.0 109.334 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 92.46 1.09 69.2 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.629 -1.388 . . . . 0.0 109.629 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 22.1 m120 -87.3 5.4 38.61 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.256 -1.144 . . . . 0.0 109.511 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 95.41 -39.61 2.82 Favored Glycine 0 N--CA 1.494 2.503 0 N-CA-C 109.243 -1.543 . . . . 0.0 109.243 -179.866 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 60.8 p -73.12 -16.92 61.44 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.24 -1.153 . . . . 0.0 109.085 179.634 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -81.77 -162.37 29.77 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.756 ' H ' ' CB ' ' A' ' 81' ' ' THR . . . 84.19 37.97 10.59 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 -179.951 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 78.1 mm-40 -58.02 149.7 22.65 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.266 -1.137 . . . . 0.0 109.808 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 50.8 m -115.57 147.08 41.15 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.666 -0.646 . . . . 0.0 109.273 179.925 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 18.1 pt -67.82 -35.53 72.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.264 -0.897 . . . . 0.0 110.037 -179.624 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 49.2 m-85 -67.43 -38.67 84.92 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.03 -1.044 . . . . 0.0 109.64 -179.809 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 77.87 13.74 83.09 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.342 -1.503 . . . . 0.0 109.342 -179.701 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -147.0 155.9 42.62 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.275 -1.132 . . . . 0.0 109.429 -179.838 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 53.5 mttp -95.08 148.65 22.13 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.339 -0.851 . . . . 0.0 109.807 -179.976 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 54.9 p90 -134.33 160.23 38.58 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.403 -0.811 . . . . 0.0 109.141 179.453 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -104.53 150.88 24.23 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.302 -0.874 . . . . 0.0 109.788 -179.633 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 60.1 t0 -137.77 81.58 1.87 Allowed 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.314 -0.866 . . . . 0.0 109.246 179.763 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -63.78 -29.03 70.28 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.429 -0.794 . . . . 0.0 109.956 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 36.2 m-20 -56.58 141.34 43.52 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.134 -0.979 . . . . 0.0 110.075 -179.244 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 101' ' ' PHE . . . . . 0.537 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 74.4 t80 -150.33 46.51 0.89 Allowed 'General case' 0 N--CA 1.491 1.615 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.824 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 90.9 mt -59.03 -34.82 54.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.416 -0.803 . . . . 0.0 110.228 -179.492 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 71.8 mmtt -80.78 139.85 35.82 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.112 -0.993 . . . . 0.0 109.765 -179.393 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 35.5 tttm -93.32 156.0 17.07 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.394 -0.816 . . . . 0.0 109.571 -179.961 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 105' ' ' HIS . . . . . . . . . . . . . 85.2 t60 -96.36 78.48 3.05 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.334 -0.854 . . . . 0.0 108.77 179.356 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 14.9 m -56.56 -40.03 74.49 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.3 -0.875 . . . . 0.0 109.436 -179.42 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.456 ' H ' HG13 ' A' ' 110' ' ' ILE . . . 130.09 -95.74 0.35 Allowed Glycine 0 N--CA 1.493 2.498 0 N-CA-C 110.044 -1.223 . . . . 0.0 110.044 179.575 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -68.81 141.24 48.65 Favored 'Trans proline' 0 N--CA 1.496 1.621 0 C-N-CA 122.694 2.263 . . . . 0.0 113.131 -179.233 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 75.95 22.65 73.85 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 110.241 -1.143 . . . . 0.0 110.241 179.033 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.456 HG13 ' H ' ' A' ' 107' ' ' GLY . 33.5 mm -115.54 134.41 58.83 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 121.315 -1.109 . . . . 0.0 110.076 -179.782 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.678 ' N ' HD22 ' A' ' 111' ' ' LEU . 3.1 mm? -93.78 137.03 33.46 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.289 -0.882 . . . . 0.0 108.894 179.148 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 34.0 t -146.05 141.17 27.35 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.226 -0.921 . . . . 0.0 109.691 179.781 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 113' ' ' MET . . . . . 0.552 ' SD ' HG23 ' A' ' 38' ' ' THR . 72.0 mtm -85.53 137.04 33.15 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.245 -0.91 . . . . 0.0 109.181 179.715 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 114' ' ' ALA . . . . . 0.452 ' O ' ' OD1' ' A' ' 115' ' ' ASN . . . -61.83 138.32 58.33 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.148 -0.97 . . . . 0.0 109.333 -179.879 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 115' ' ' ASN . . . . . 0.452 ' OD1' ' O ' ' A' ' 114' ' ' ALA . 77.2 m-20 -148.51 114.01 5.62 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.328 -0.858 . . . . 0.0 109.206 179.828 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -69.21 -29.77 67.8 Favored 'General case' 0 C--N 1.297 -1.713 0 O-C-N 121.43 -0.794 . . . . 0.0 109.179 179.613 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -137.84 168.42 24.52 Favored Glycine 0 N--CA 1.494 2.503 0 N-CA-C 109.085 -1.606 . . . . 0.0 109.085 179.783 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -67.4 155.6 69.68 Favored 'Trans proline' 0 C--N 1.306 -1.666 0 C-N-CA 122.758 2.305 . . . . 0.0 111.946 -179.858 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 75.9 m-20 54.92 45.3 26.78 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.425 -0.797 . . . . 0.0 109.498 -179.907 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 94.1 m -130.27 125.93 36.02 Favored 'General case' 0 N--CA 1.485 1.314 0 O-C-N 121.386 -0.821 . . . . 0.0 108.79 179.725 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 25.9 t30 -99.09 110.62 23.18 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.449 -0.782 . . . . 0.0 109.621 -179.838 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -106.61 121.27 6.55 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.271 -1.532 . . . . 0.0 109.271 179.646 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 20.1 m -56.84 -34.43 67.76 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.209 -1.171 . . . . 0.0 109.187 179.971 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.6 mt-30 -71.62 144.94 49.27 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.263 -0.898 . . . . 0.0 109.148 179.81 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 44.9 p90 -135.59 163.53 29.91 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.317 -0.865 . . . . 0.0 109.297 -179.961 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.602 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 52.8 p90 -132.15 157.38 44.41 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.405 -0.81 . . . . 0.0 109.503 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 67.1 mt -119.08 133.25 66.54 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.49 -0.756 . . . . 0.0 109.338 179.849 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 128' ' ' CYS . . . . . 0.402 ' SG ' ' O ' ' A' ' 130' ' ' ALA . 7.1 t -115.84 126.35 53.86 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.355 -0.841 . . . . 0.0 109.15 179.847 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 30.1 p -97.18 0.53 48.5 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.276 -0.89 . . . . 0.0 109.702 -179.708 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 130' ' ' ALA . . . . . 0.402 ' O ' ' SG ' ' A' ' 128' ' ' CYS . . . -148.86 164.26 35.0 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.235 -0.915 . . . . 0.0 109.429 -179.8 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -70.07 137.48 51.26 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.118 -0.989 . . . . 0.0 109.177 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 3.6 p -113.53 101.12 9.05 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.495 -0.753 . . . . 0.0 109.45 -179.737 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -64.35 -36.52 84.4 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.296 -0.878 . . . . 0.0 109.596 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 1.2 p90 -67.55 -33.29 74.74 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.15 -0.969 . . . . 0.0 109.59 -179.835 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 135' ' ' LEU . . . . . 0.546 ' O ' ' NE2' ' A' ' 139' ' ' HIS . 8.6 mt -93.11 12.15 25.23 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.102 -0.998 . . . . 0.0 109.322 179.358 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 60.1 t0 -57.05 124.18 17.82 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.137 -0.977 . . . . 0.0 109.616 -179.577 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -176.11 -159.29 21.56 Favored Glycine 0 N--CA 1.486 1.987 0 N-CA-C 109.009 -1.636 . . . . 0.0 109.009 -179.852 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 87.6 mttt -57.24 -38.51 73.92 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.317 -1.107 . . . . 0.0 109.646 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 139' ' ' HIS . . . . . 0.546 ' NE2' ' O ' ' A' ' 135' ' ' LEU . 63.3 m-70 53.57 71.51 0.5 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.318 -0.864 . . . . 0.0 109.957 179.766 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 39.3 t -69.0 135.44 28.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.14 -0.975 . . . . 0.0 108.879 179.295 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 17.4 m -126.94 148.23 31.78 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 121.222 -0.924 . . . . 0.0 109.74 -179.489 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 142' ' ' PHE . . . . . 0.454 ' CB ' HG21 ' A' ' 38' ' ' THR . 43.3 p90 -120.06 -6.01 9.99 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.382 -0.824 . . . . 0.0 110.019 179.831 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -164.74 -179.77 38.97 Favored Glycine 0 N--CA 1.495 2.618 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 179.692 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.4 pt20 -143.85 166.53 24.65 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.23 -1.159 . . . . 0.0 109.566 -179.769 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 44.7 t -97.21 132.18 42.36 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.13 0 O-C-N 121.096 -1.002 . . . . 0.0 109.54 -179.742 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 17.2 m -110.45 -32.74 2.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 O-C-N 121.413 -0.805 . . . . 0.0 109.3 179.321 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -145.35 170.25 16.68 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.308 -0.87 . . . . 0.0 109.46 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 97.35 2.47 58.96 Favored Glycine 0 N--CA 1.494 2.539 0 N-CA-C 109.977 -1.249 . . . . 0.0 109.977 179.531 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 149' ' ' MET . . . . . 0.477 ' O ' HG12 ' A' ' 152' ' ' VAL . 88.3 mtp -61.06 -33.07 72.74 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.189 -1.183 . . . . 0.0 109.685 179.925 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -64.78 -42.43 95.1 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 120.876 -1.14 . . . . 0.0 109.987 -179.547 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.4 p -82.53 -34.01 11.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.128 -0.983 . . . . 0.0 110.591 -179.341 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 152' ' ' VAL . . . . . 0.477 HG12 ' O ' ' A' ' 149' ' ' MET . 0.8 OUTLIER -53.74 -40.88 45.21 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 120.957 -1.09 . . . . 0.0 109.067 -179.408 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 153' ' ' LYS . . . . . 0.445 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 99.0 mttt -63.53 -34.12 77.08 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.113 -0.992 . . . . 0.0 109.292 179.201 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -61.51 -37.11 82.49 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.322 -0.861 . . . . 0.0 109.937 -179.638 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 97.9 mt -71.99 -35.05 52.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.173 -0.955 . . . . 0.0 109.981 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -75.93 -42.0 50.05 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.177 -0.952 . . . . 0.0 111.209 -178.894 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 157' ' ' LYS . . . . . 0.422 ' HG2' ' HZ2' ' A' ' 157' ' ' LYS . 15.4 pttm -61.81 -34.2 75.49 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 120.769 -1.207 . . . . 0.0 109.719 -178.924 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.425 ' HB ' ' H ' ' A' ' 166' ' ' ALA . 34.0 m -79.91 -13.79 13.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.152 -0.968 . . . . 0.0 109.082 179.562 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -76.88 170.43 55.09 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.836 -1.306 . . . . 0.0 109.836 -179.826 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 23.1 t -159.02 173.95 15.69 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.409 -1.054 . . . . 0.0 109.315 -179.841 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 23.6 m -53.84 -32.47 53.01 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.236 -0.915 . . . . 0.0 109.121 179.663 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 24.0 m -56.45 -32.57 65.05 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.393 -0.817 . . . . 0.0 109.412 179.842 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 95.1 13.23 53.38 Favored Glycine 0 N--CA 1.493 2.465 0 N-CA-C 109.791 -1.323 . . . . 0.0 109.791 179.954 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 98.0 mtt180 -119.24 144.82 46.54 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.283 -1.128 . . . . 0.0 109.379 179.862 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 165' ' ' THR . . . . . 0.714 HG22 HG21 ' A' ' 69' ' ' VAL . 80.1 p -82.39 150.46 27.11 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.25 -0.906 . . . . 0.0 109.563 179.867 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 166' ' ' ALA . . . . . 0.425 ' H ' ' HB ' ' A' ' 158' ' ' VAL . . . -65.95 -35.5 80.78 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.339 -0.851 . . . . 0.0 108.896 179.523 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 66.6 mttm -112.58 157.68 20.89 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.524 -0.735 . . . . 0.0 109.07 179.731 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -69.7 130.75 43.21 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.134 -0.979 . . . . 0.0 109.324 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 43.0 t -123.2 125.32 71.77 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 121.201 -0.937 . . . . 0.0 109.575 -179.949 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 170' ' ' VAL . . . . . 0.43 HG12 ' N ' ' A' ' 171' ' ' VAL . 60.7 t -150.33 157.17 6.15 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 O-C-N 121.486 -0.758 . . . . 0.0 108.972 179.582 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.43 ' N ' HG12 ' A' ' 170' ' ' VAL . 0.2 OUTLIER -87.98 119.41 35.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.104 -0.998 . . . . 0.0 109.529 -179.727 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -65.91 -24.62 66.88 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.361 -0.837 . . . . 0.0 109.414 179.407 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 19.9 t70 -173.81 171.16 3.8 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.127 -0.983 . . . . 0.0 110.301 -179.51 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 174' ' ' CYS . . . . . 0.425 ' H ' ' HE2' ' A' ' 62' ' ' LYS . 11.0 p -151.84 153.15 33.65 Favored 'General case' 0 N--CA 1.492 1.66 0 N-CA-C 109.052 -0.721 . . . . 0.0 109.052 179.499 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -175.75 174.55 46.94 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 109.702 -1.359 . . . . 0.0 109.702 179.784 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 62.2 tt0 -107.89 120.67 42.94 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.3 -1.118 . . . . 0.0 109.652 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 32.4 tp -61.71 -37.03 82.66 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.135 -0.978 . . . . 0.0 109.032 179.434 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 25.0 t . . . . . 0 N--CA 1.49 1.559 0 CA-C-O 118.087 -0.959 . . . . 0.0 109.466 179.972 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.529 4.882 0 N-CA-C 119.38 2.512 . . . . 0.0 119.38 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 54.5 p -70.38 160.99 31.29 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.219 -1.165 . . . . 0.0 109.573 179.96 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 98.6 m-85 -96.87 20.56 10.86 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.252 -0.905 . . . . 0.0 109.396 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 18.2 p -121.49 162.77 19.93 Favored 'General case' 0 N--CA 1.494 1.745 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -152.37 -118.7 0.77 Allowed Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 -179.907 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 86.7 p -61.26 -29.28 69.75 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.204 -1.174 . . . . 0.0 109.836 -179.812 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 25.6 ttp 49.88 70.05 2.28 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.06 -1.025 . . . . 0.0 109.229 -179.924 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -50.73 -33.19 39.33 Favored 'Trans proline' 0 C--N 1.306 -1.694 0 C-N-CA 122.833 2.355 . . . . 0.0 112.378 -179.457 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 8.2 p-10 -158.94 146.35 13.21 Favored Pre-proline 0 N--CA 1.489 1.489 0 O-C-N 121.131 -0.981 . . . . 0.0 109.555 179.782 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -73.76 145.87 37.32 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 122.803 2.335 . . . . 0.0 112.047 179.763 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.482 ' NH2' ' CB ' ' A' ' 178' ' ' SER . 95.5 mtm-85 -119.16 132.49 55.97 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.271 -0.893 . . . . 0.0 108.783 179.222 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.6 p -135.04 142.39 40.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.269 -0.895 . . . . 0.0 109.772 -179.192 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 42.8 p90 -141.12 155.61 46.09 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.434 -0.791 . . . . 0.0 109.506 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -128.18 142.32 51.21 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.421 -0.799 . . . . 0.0 109.887 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 59.4 t0 -94.6 124.26 38.52 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.227 -0.92 . . . . 0.0 108.734 179.151 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 39.1 mtp -119.66 147.51 44.47 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.136 -0.978 . . . . 0.0 110.279 -179.312 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.43 ' OG ' ' CD ' ' A' ' 172' ' ' GLU . 59.7 m -128.57 153.67 46.98 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.604 -0.685 . . . . 0.0 109.355 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.406 HG23 ' O ' ' A' ' 18' ' ' VAL . 34.7 m -114.93 131.93 65.66 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.835 0 O-C-N 121.388 -0.82 . . . . 0.0 109.426 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 63.59 9.65 32.99 Favored Glycine 0 N--CA 1.492 2.398 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 179.858 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 94.67 -1.67 66.31 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 -179.895 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 75.0 mt-30 -103.69 151.2 38.74 Favored Pre-proline 0 N--CA 1.493 1.717 0 O-C-N 121.295 -1.121 . . . . 0.0 109.073 179.756 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 14.3 Cg_endo -58.36 134.23 60.08 Favored 'Trans proline' 0 C--N 1.309 -1.507 0 C-N-CA 122.412 2.074 . . . . 0.0 112.266 -179.532 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -114.23 -65.06 1.23 Allowed 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.514 -0.741 . . . . 0.0 109.274 179.775 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -176.77 -170.48 39.34 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.456 -1.457 . . . . 0.0 109.456 179.943 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' ARG . . . . . 0.419 HH12 HG21 ' A' ' 27' ' ' VAL . 46.6 ptt85 -120.06 148.55 43.45 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.318 -1.107 . . . . 0.0 109.11 179.851 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 83.3 mt -122.57 129.15 75.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.496 -0.753 . . . . 0.0 109.32 -179.863 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.419 HG21 HH12 ' A' ' 25' ' ' ARG . 46.3 t -113.14 133.26 59.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.539 -0.725 . . . . 0.0 109.062 179.673 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 74.5 mtm -121.12 149.69 42.38 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.391 -0.818 . . . . 0.0 109.52 -179.753 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -97.57 132.51 43.17 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.388 -0.82 . . . . 0.0 109.542 -179.858 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -109.36 130.57 55.49 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.533 -0.729 . . . . 0.0 109.425 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 86.5 m-85 -94.55 118.41 31.63 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.126 -0.984 . . . . 0.0 108.483 178.89 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -93.38 -42.06 9.49 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.299 -0.875 . . . . 0.0 109.68 -179.683 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.6 m-20 -62.26 -49.23 76.53 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.09 -1.006 . . . . 0.0 109.764 -179.498 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 34' ' ' THR . . . . . 0.493 HG21 ' HD3' ' A' ' 103' ' ' LYS . 61.9 m -73.52 -42.03 62.28 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.069 -1.02 . . . . 0.0 109.72 179.8 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.529 ' O ' ' OG1' ' A' ' 35' ' ' THR . 1.8 p -132.24 79.02 67.21 Favored Pre-proline 0 N--CA 1.492 1.657 0 O-C-N 121.3 -0.875 . . . . 0.0 109.439 -179.69 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 21.2 Cg_endo -66.77 -61.79 0.08 OUTLIER 'Trans proline' 0 C--N 1.31 -1.468 0 C-N-CA 122.376 2.051 . . . . 0.0 112.603 -179.48 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.623 ' NH2' ' CE1' ' A' ' 92' ' ' TYR . 68.7 mtp85 -60.9 -34.98 75.49 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.415 -0.803 . . . . 0.0 110.4 -179.308 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 25.7 m -59.98 -41.47 92.07 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.953 -1.092 . . . . 0.0 109.859 -179.559 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -62.62 -30.18 71.17 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.089 -1.007 . . . . 0.0 109.35 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.401 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 96.6 mt-10 -67.59 -34.91 77.98 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.284 -0.885 . . . . 0.0 109.761 -179.983 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 41' ' ' ASN . . . . . 0.437 ' O ' HD23 ' A' ' 45' ' ' LEU . 26.2 m120 -56.82 -39.08 73.54 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.149 -0.97 . . . . 0.0 109.768 -179.767 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.4 ' O ' ' SG ' ' A' ' 46' ' ' CYS . 98.8 m-85 -94.16 -50.45 5.28 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.121 -0.987 . . . . 0.0 109.512 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.91 ' HE ' HE22 ' A' ' 176' ' ' GLN . 75.8 ttt-85 -57.19 -42.01 80.43 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.41 -0.806 . . . . 0.0 110.491 -179.392 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.401 ' HB3' ' O ' ' A' ' 40' ' ' GLU . . . -63.72 -44.87 92.29 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.999 -1.063 . . . . 0.0 110.077 -179.121 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.515 ' N ' ' CD2' ' A' ' 45' ' ' LEU . 2.7 mm? -67.64 -37.2 82.1 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.19 -0.944 . . . . 0.0 109.637 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 46' ' ' CYS . . . . . 0.4 ' SG ' ' O ' ' A' ' 42' ' ' PHE . 64.1 m -66.69 -48.99 67.57 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.136 -0.977 . . . . 0.0 110.108 -179.533 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 60.6 p -72.65 -30.71 64.52 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.192 -0.943 . . . . 0.0 109.694 -179.844 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 74.03 27.34 66.68 Favored Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 179.778 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 23.0 pt-20 -62.25 -35.59 79.41 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.212 -1.169 . . . . 0.0 109.381 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 43.6 mmtm -61.19 -33.2 73.07 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.289 -0.882 . . . . 0.0 109.128 179.588 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 93.64 168.4 38.29 Favored Glycine 0 N--CA 1.488 2.136 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 -179.793 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.541 HG23 ' HA ' ' A' ' 58' ' ' PRO . 68.4 m -76.45 139.9 41.05 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.306 -1.114 . . . . 0.0 109.686 -179.947 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -53.9 135.15 43.27 Favored Glycine 0 N--CA 1.488 2.165 0 N-CA-C 109.224 -1.551 . . . . 0.0 109.224 179.753 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 91.9 mtm-85 -58.92 -35.99 74.0 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.192 -1.181 . . . . 0.0 109.917 -179.551 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 22.7 t -59.14 -31.21 68.75 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.18 -0.95 . . . . 0.0 109.919 -179.587 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 56' ' ' GLY . . . . . 0.449 ' O ' ' CG ' ' A' ' 57' ' ' LYS . . . 117.91 81.05 0.77 Allowed Glycine 0 N--CA 1.495 2.614 0 N-CA-C 108.749 -1.74 . . . . 0.0 108.749 -179.381 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 57' ' ' LYS . . . . . 0.547 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 57.4 mttm -161.69 79.87 2.03 Favored Pre-proline 0 C--N 1.303 -1.434 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 -179.576 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.541 ' HA ' HG23 ' A' ' 52' ' ' THR . 71.3 Cg_exo -50.9 133.02 39.19 Favored 'Trans proline' 0 C--N 1.301 -1.964 0 C-N-CA 122.894 2.396 . . . . 0.0 112.809 -178.734 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.571 ' O ' ' CG ' ' A' ' 60' ' ' HIS . 7.0 mp -100.19 98.32 9.03 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.613 -0.679 . . . . 0.0 109.524 -179.47 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 60' ' ' HIS . . . . . 0.571 ' CG ' ' O ' ' A' ' 59' ' ' LEU . 93.5 m-70 -160.45 125.91 3.93 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.167 -0.958 . . . . 0.0 109.948 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 9.5 m-85 -71.95 -5.98 38.73 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.136 -0.978 . . . . 0.0 108.811 178.889 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 62' ' ' LYS . . . . . 0.561 ' O ' ' O ' ' A' ' 171' ' ' VAL . 48.7 tttt -53.39 -25.88 17.34 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.527 -0.733 . . . . 0.0 109.57 179.891 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 89.3 m-20 -103.6 4.85 36.1 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.467 -0.771 . . . . 0.0 110.071 -179.402 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 63.8 p -82.04 162.35 22.62 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.069 -1.019 . . . . 0.0 109.856 -179.754 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 29.2 t -147.31 159.34 43.78 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.473 -0.767 . . . . 0.0 109.083 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.5 m-85 -64.18 123.5 19.26 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.079 -1.013 . . . . 0.0 108.929 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 61.7 t60 -66.62 -50.26 63.6 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.304 -0.872 . . . . 0.0 110.548 -179.112 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 93.2 mtt180 -141.47 150.47 42.29 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 120.951 -1.093 . . . . 0.0 110.287 -179.658 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.642 HG21 HG22 ' A' ' 165' ' ' THR . 4.9 m -137.09 130.92 45.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 179.096 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 19.1 mt -149.33 128.39 6.2 Favored Pre-proline 0 N--CA 1.492 1.646 0 O-C-N 120.94 -1.1 . . . . 0.0 109.41 -179.785 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 65.3 Cg_endo -76.0 133.44 15.13 Favored 'Trans proline' 0 C--N 1.311 -1.429 0 C-N-CA 122.148 1.899 . . . . 0.0 112.014 179.707 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 90.49 3.88 71.27 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.793 -1.323 . . . . 0.0 109.793 179.662 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 82.6 m-85 -138.77 -94.37 0.18 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.129 -1.218 . . . . 0.0 109.811 179.845 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 7.3 ptt? -171.45 175.79 4.01 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.168 -0.957 . . . . 0.0 109.839 -179.655 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -122.28 136.28 54.88 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 108.231 -1.026 . . . . 0.0 108.231 179.363 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 92.4 mt-30 -94.56 136.0 35.37 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.88 -1.138 . . . . 0.0 110.198 -179.262 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -90.03 -173.52 45.15 Favored Glycine 0 N--CA 1.492 2.379 0 N-CA-C 108.941 -1.664 . . . . 0.0 108.941 179.395 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -155.63 174.3 33.67 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.779 -1.329 . . . . 0.0 109.779 179.84 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.547 ' OD1' ' N ' ' A' ' 83' ' ' GLY . 48.5 p30 -106.37 165.59 11.15 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.415 -1.05 . . . . 0.0 109.56 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 46.4 p90 -75.2 -19.95 59.54 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.309 -0.87 . . . . 0.0 109.66 -179.884 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.557 ' OG1' ' N ' ' A' ' 88' ' ' GLY . 71.2 p -65.93 -37.06 85.06 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.281 -0.887 . . . . 0.0 109.989 -179.629 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -174.46 -51.32 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.267 -0.896 . . . . 0.0 109.539 -179.934 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.547 ' N ' ' OD1' ' A' ' 79' ' ' ASP . . . 94.71 2.2 63.23 Favored Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 78.7 m-20 -86.02 4.15 39.17 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.189 -1.183 . . . . 0.0 109.448 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 93.71 -37.47 3.39 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 51.6 p -69.99 -29.11 66.11 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.185 -1.185 . . . . 0.0 109.231 179.842 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -87.85 -168.23 44.24 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.983 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.557 ' N ' ' OG1' ' A' ' 81' ' ' THR . . . 84.03 45.07 6.43 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.571 -1.412 . . . . 0.0 109.571 179.879 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -56.37 144.37 30.94 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.344 -1.092 . . . . 0.0 109.43 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 27.4 t -78.24 144.57 36.1 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.159 -0.963 . . . . 0.0 109.552 -179.913 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 17.0 pt -66.34 -36.29 77.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.291 -0.881 . . . . 0.0 109.849 -179.871 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 92' ' ' TYR . . . . . 0.623 ' CE1' ' NH2' ' A' ' 37' ' ' ARG . 96.4 m-85 -66.21 -36.44 83.04 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.175 -0.953 . . . . 0.0 109.566 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.21 5.74 87.03 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.202 -1.559 . . . . 0.0 109.202 -179.752 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -150.97 158.0 43.6 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.348 -1.09 . . . . 0.0 109.381 -179.911 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -85.17 148.29 26.18 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.178 -0.951 . . . . 0.0 109.484 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 45.6 p90 -135.39 159.13 42.56 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.327 -0.858 . . . . 0.0 109.392 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -73.25 135.68 44.51 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.262 -0.899 . . . . 0.0 109.932 -179.678 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.438 ' C ' ' OD1' ' A' ' 98' ' ' ASP . 54.4 p30 -99.84 -163.87 1.07 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.313 -0.867 . . . . 0.0 109.549 179.774 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 99' ' ' GLU . . . . . 0.442 ' OE1' ' O ' ' A' ' 34' ' ' THR . 94.5 mt-10 -108.02 163.01 13.52 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.371 -0.831 . . . . 0.0 109.455 179.77 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 82.9 m-20 -64.76 165.95 9.66 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.257 -0.902 . . . . 0.0 109.566 -179.809 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 101' ' ' PHE . . . . . 0.489 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 33.3 p90 -80.7 51.43 1.5 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.27 -0.894 . . . . 0.0 109.718 -179.811 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 90.7 mt -56.22 -41.08 68.96 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.101 -0.999 . . . . 0.0 109.547 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 103' ' ' LYS . . . . . 0.493 ' HD3' HG21 ' A' ' 34' ' ' THR . 43.6 mtpt -89.33 146.14 24.9 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.178 -0.951 . . . . 0.0 109.693 -179.939 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 49.3 pttt -134.85 179.98 5.97 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.42 -0.8 . . . . 0.0 109.356 179.804 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 105' ' ' HIS . . . . . 0.532 ' O ' ' CG ' ' A' ' 105' ' ' HIS . 48.4 p-80 -92.64 100.75 13.2 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.292 -0.88 . . . . 0.0 109.407 -179.872 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 51.2 p -76.54 -22.46 54.34 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.331 -0.856 . . . . 0.0 109.628 -179.903 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.409 ' O ' HG12 ' A' ' 110' ' ' ILE . . . -151.15 -179.46 26.89 Favored Glycine 0 N--CA 1.492 2.406 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 -179.688 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -72.65 158.87 49.94 Favored 'Trans proline' 0 C--N 1.307 -1.626 0 C-N-CA 122.951 2.434 . . . . 0.0 112.178 179.83 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 84.95 38.25 9.47 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 110.233 -1.147 . . . . 0.0 110.233 179.532 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.409 HG12 ' O ' ' A' ' 107' ' ' GLY . 34.4 mm -113.38 138.39 43.13 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.29 -1.123 . . . . 0.0 108.979 179.598 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.827 ' N ' HD22 ' A' ' 111' ' ' LEU . 2.4 mm? -87.58 139.75 30.22 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.246 -0.909 . . . . 0.0 109.658 -179.754 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 23.1 t -128.16 143.54 51.06 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.54 -0.725 . . . . 0.0 109.27 179.85 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 58.3 ttp -96.71 127.08 42.35 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.305 -0.872 . . . . 0.0 109.533 -179.9 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -66.16 146.5 54.58 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.236 -0.915 . . . . 0.0 109.633 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 115' ' ' ASN . . . . . 0.502 ' N ' ' OD1' ' A' ' 115' ' ' ASN . 9.1 p-10 -168.25 115.73 0.7 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.272 -0.893 . . . . 0.0 109.668 179.818 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -66.18 -33.95 76.92 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.379 -0.825 . . . . 0.0 109.347 179.806 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -145.52 166.92 27.65 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.352 -1.499 . . . . 0.0 109.352 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -66.59 158.58 55.04 Favored 'Trans proline' 0 C--N 1.306 -1.678 0 C-N-CA 122.822 2.348 . . . . 0.0 111.963 179.919 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 73.7 m-20 55.03 44.07 28.74 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.467 -0.771 . . . . 0.0 109.392 -179.886 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 87.2 m -137.28 129.33 29.22 Favored 'General case' 0 C--N 1.305 -1.359 0 O-C-N 121.405 -0.81 . . . . 0.0 109.113 179.943 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 22.4 t-20 -79.94 116.24 19.97 Favored 'General case' 0 C--N 1.298 -1.65 0 O-C-N 121.489 -0.757 . . . . 0.0 109.33 179.859 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -85.32 -179.54 50.69 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.736 -1.346 . . . . 0.0 109.736 -179.82 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -130.64 -14.25 3.66 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.367 -1.079 . . . . 0.0 109.749 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 94.3 mt-30 -121.89 159.42 26.89 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.299 -0.876 . . . . 0.0 109.622 -179.876 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 43.6 p90 -130.83 158.74 39.35 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.489 -0.757 . . . . 0.0 109.474 -179.898 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -117.47 143.84 45.63 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.49 -0.757 . . . . 0.0 110.02 -179.766 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 84.2 mt -120.77 134.27 64.75 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 121.613 -0.679 . . . . 0.0 109.224 179.246 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -125.27 126.36 45.01 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.293 -0.879 . . . . 0.0 109.376 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 30.3 p -98.32 3.39 48.64 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.348 -0.845 . . . . 0.0 109.301 179.868 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -153.62 159.63 42.16 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.243 -0.911 . . . . 0.0 109.428 -179.795 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 7.9 ttpm? -66.44 130.05 41.89 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.165 -0.959 . . . . 0.0 109.081 179.8 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 16.6 p -109.09 95.86 5.92 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.395 -0.816 . . . . 0.0 109.633 -179.658 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -65.74 -35.72 81.55 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.213 -0.929 . . . . 0.0 109.581 179.844 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 1.0 OUTLIER -66.47 -33.86 76.64 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.245 -0.91 . . . . 0.0 109.55 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 9.7 mt -90.06 7.17 39.09 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.166 -0.959 . . . . 0.0 109.201 179.295 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 136' ' ' ASP . . . . . 0.533 ' O ' ' OD1' ' A' ' 136' ' ' ASP . 47.2 p30 -46.79 138.45 6.22 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.184 -0.948 . . . . 0.0 109.783 -179.617 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 174.21 -161.88 32.12 Favored Glycine 0 N--CA 1.484 1.885 0 N-CA-C 108.873 -1.691 . . . . 0.0 108.873 -179.708 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 138' ' ' LYS . . . . . 0.477 ' O ' ' O ' ' A' ' 139' ' ' HIS . 88.8 mttt -57.36 -39.55 76.21 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 121.276 -1.132 . . . . 0.0 109.432 179.86 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 139' ' ' HIS . . . . . 0.477 ' O ' ' O ' ' A' ' 138' ' ' LYS . 66.3 m-70 53.18 109.22 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.51 -0.744 . . . . 0.0 110.049 179.63 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 40.6 t -107.42 136.54 42.27 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.36 -0.837 . . . . 0.0 108.825 179.435 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 23.5 m -125.09 142.47 41.87 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.307 -0.871 . . . . 0.0 109.587 -179.464 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 42.8 p90 -126.46 -9.89 6.29 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.5 -0.75 . . . . 0.0 109.751 179.73 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -156.52 175.72 34.07 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 179.631 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 58.6 tt0 -141.43 159.44 42.22 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.238 -1.154 . . . . 0.0 109.675 -179.614 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 145' ' ' VAL . . . . . 0.483 HG23 HD21 ' A' ' 111' ' ' LEU . 9.8 t -97.83 134.39 36.24 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.22 0 O-C-N 121.124 -0.985 . . . . 0.0 109.126 179.904 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 11.6 m -113.62 -35.45 2.26 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.493 -0.754 . . . . 0.0 109.535 179.653 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 91.9 mt-10 -142.83 167.86 21.08 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.227 -0.92 . . . . 0.0 109.627 -179.849 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 97.78 4.36 57.95 Favored Glycine 0 N--CA 1.494 2.553 0 N-CA-C 110.079 -1.209 . . . . 0.0 110.079 179.534 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 149' ' ' MET . . . . . 0.458 ' O ' HG12 ' A' ' 152' ' ' VAL . 88.0 mtp -60.84 -33.22 72.72 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.062 -1.258 . . . . 0.0 109.741 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 150' ' ' ASP . . . . . 0.54 ' OD1' ' N ' ' A' ' 151' ' ' VAL . 30.9 p-10 -65.67 -38.26 88.8 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.9 -1.125 . . . . 0.0 110.107 -179.441 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.54 ' N ' ' OD1' ' A' ' 150' ' ' ASP . 7.6 p -86.52 -33.9 7.51 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.066 -1.021 . . . . 0.0 110.262 -179.593 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 152' ' ' VAL . . . . . 0.469 ' CG1' ' N ' ' A' ' 153' ' ' LYS . 1.0 OUTLIER -56.1 -42.65 73.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 120.943 -1.098 . . . . 0.0 109.175 -179.503 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 153' ' ' LYS . . . . . 0.469 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 98.7 mttt -64.87 -33.88 77.06 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.189 -0.944 . . . . 0.0 109.537 179.431 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -62.33 -40.4 96.22 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.287 -0.883 . . . . 0.0 110.11 -179.321 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 75.4 mt -71.19 -36.79 63.81 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.228 -0.92 . . . . 0.0 110.394 -179.481 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -79.57 -41.45 27.15 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.085 -1.009 . . . . 0.0 111.406 -178.725 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 23.5 pttt -61.02 -34.0 74.15 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.705 -1.247 . . . . 0.0 110.193 -178.591 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.425 ' HB ' ' H ' ' A' ' 166' ' ' ALA . 35.1 m -73.37 -10.44 13.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.027 -1.046 . . . . 0.0 109.2 179.906 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -76.38 176.36 52.11 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 -179.822 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 83.2 p -155.31 176.07 13.05 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.425 -1.044 . . . . 0.0 109.039 -179.641 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 22.7 m -52.28 -36.01 51.77 Favored 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 179.429 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 23.8 m -60.71 -33.19 72.52 Favored 'General case' 0 N--CA 1.487 1.387 0 O-C-N 121.377 -0.827 . . . . 0.0 108.93 179.164 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 96.31 8.94 57.29 Favored Glycine 0 N--CA 1.493 2.437 0 N-CA-C 109.805 -1.318 . . . . 0.0 109.805 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 69.6 ttp85 -101.74 138.69 38.39 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.348 -1.089 . . . . 0.0 109.521 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 165' ' ' THR . . . . . 0.642 HG22 HG21 ' A' ' 69' ' ' VAL . 65.2 p -84.12 151.85 24.67 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.175 -0.953 . . . . 0.0 109.544 179.81 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 166' ' ' ALA . . . . . 0.425 ' H ' ' HB ' ' A' ' 158' ' ' VAL . . . -67.28 -34.8 78.15 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.245 -0.909 . . . . 0.0 109.063 179.557 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 63.2 mttp -114.52 158.43 21.65 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.563 -0.711 . . . . 0.0 109.34 -179.994 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 63.1 mttp -73.79 137.81 44.12 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.148 -0.97 . . . . 0.0 109.353 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 2.7 m -132.65 119.71 39.23 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.35 -0.844 . . . . 0.0 109.843 -179.758 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 39.2 t -145.67 141.58 22.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 CA-C-O 121.898 0.856 . . . . 0.0 109.424 179.41 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.561 ' O ' ' O ' ' A' ' 62' ' ' LYS . 22.1 t -61.36 132.36 26.89 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.783 0 C-N-CA 120.333 -0.547 . . . . 0.0 109.762 -179.608 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 172' ' ' GLU . . . . . 0.452 ' O ' ' OD1' ' A' ' 173' ' ' ASP . 95.6 mt-10 -105.87 -7.08 18.44 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.335 -0.853 . . . . 0.0 109.808 179.61 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 173' ' ' ASP . . . . . 0.452 ' OD1' ' O ' ' A' ' 172' ' ' GLU . 30.5 m-20 -158.44 168.22 27.55 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.082 -1.011 . . . . 0.0 110.007 -179.734 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 20.4 p -170.32 126.25 0.78 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.474 -0.766 . . . . 0.0 109.539 179.565 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -173.55 173.86 45.92 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 179.8 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 176' ' ' GLN . . . . . 0.91 HE22 ' HE ' ' A' ' 43' ' ' ARG . 58.7 tt0 -105.2 121.35 43.66 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.383 -1.069 . . . . 0.0 109.853 -179.787 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 177' ' ' LEU . . . . . 0.473 HD23 ' HE ' ' A' ' 11' ' ' ARG . 36.8 tp -62.41 -36.57 82.77 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.239 -0.913 . . . . 0.0 108.95 179.125 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 178' ' ' SER . . . . . 0.513 ' OXT' ' NE2' ' A' ' 176' ' ' GLN . 7.2 t . . . . . 0 N--CA 1.491 1.589 0 CA-C-O 117.977 -1.011 . . . . 0.0 109.428 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 5.3 p30 . . . . . 0 N--CA 1.494 1.756 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -72.04 144.43 42.57 Favored 'Trans proline' 0 C--N 1.308 -1.561 0 C-N-CA 122.515 2.143 . . . . 0.0 111.752 179.582 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 92.9 mtt180 -126.26 142.2 51.62 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.304 -0.873 . . . . 0.0 109.643 -179.822 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 10.5 p -134.87 143.84 36.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.359 -0.838 . . . . 0.0 109.345 179.803 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 25.0 p90 -139.49 152.89 47.33 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.208 -0.933 . . . . 0.0 109.602 -179.843 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -124.62 133.09 53.37 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.426 -0.796 . . . . 0.0 109.471 179.529 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.7 t0 -91.06 111.95 23.64 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.144 -0.972 . . . . 0.0 108.611 179.248 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' MET . . . . . 0.426 ' SD ' HD12 ' A' ' 26' ' ' ILE . 78.9 mtp -106.39 138.91 41.72 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.239 -0.913 . . . . 0.0 110.437 -179.185 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.422 ' OG ' ' OE2' ' A' ' 172' ' ' GLU . 48.8 m -131.6 155.95 46.63 Favored 'General case' 0 N--CA 1.492 1.632 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 179.416 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 25.1 m -118.99 144.29 27.71 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.149 -0.969 . . . . 0.0 109.62 -179.738 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 57.6 -108.99 1.55 Allowed Glycine 0 N--CA 1.488 2.119 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -135.77 28.33 2.98 Favored Glycine 0 N--CA 1.493 2.479 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 32.6 mt-30 -137.44 153.02 74.19 Favored Pre-proline 0 N--CA 1.493 1.719 0 O-C-N 121.297 -1.119 . . . . 0.0 109.186 179.873 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_endo -63.96 139.16 66.32 Favored 'Trans proline' 0 N--CA 1.495 1.56 0 C-N-CA 122.528 2.152 . . . . 0.0 112.05 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -102.84 -60.59 1.52 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.276 -0.89 . . . . 0.0 109.4 179.874 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 179.89 -170.83 42.2 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 98.2 mtt180 -117.57 143.72 45.83 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.365 -1.079 . . . . 0.0 109.583 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.426 HD12 ' SD ' ' A' ' 16' ' ' MET . 86.5 mt -121.53 122.37 66.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 179.073 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 39.9 t -116.21 132.3 66.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.437 -0.789 . . . . 0.0 109.024 -179.901 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 71.7 mtm -124.76 152.19 44.15 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.403 -0.81 . . . . 0.0 109.346 -179.694 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -106.15 131.76 53.02 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.394 -0.816 . . . . 0.0 109.894 -179.616 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.542 HD13 ' HB1' ' A' ' 39' ' ' ALA . 17.3 mt -100.27 146.4 26.95 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.423 -0.798 . . . . 0.0 109.311 179.162 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 95.5 m-85 -95.43 124.19 39.34 Favored 'General case' 0 N--CA 1.49 1.567 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 178.804 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -99.17 21.48 11.79 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.206 -0.934 . . . . 0.0 109.694 -179.323 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.3 m-20 -120.76 -73.55 0.64 Allowed 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.289 -0.882 . . . . 0.0 110.21 -179.553 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . 0.443 ' O ' ' OE1' ' A' ' 99' ' ' GLU . 41.3 m -61.15 -43.43 98.89 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.176 -0.953 . . . . 0.0 110.44 -179.117 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 9.4 m -139.95 78.37 24.74 Favored Pre-proline 0 N--CA 1.494 1.746 0 O-C-N 121.126 -0.984 . . . . 0.0 109.963 -179.543 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 68.3 Cg_endo -79.75 -36.94 0.52 Allowed 'Trans proline' 0 C--N 1.306 -1.689 0 C-N-CA 122.614 2.209 . . . . 0.0 112.461 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.418 ' O ' ' OH ' ' A' ' 92' ' ' TYR . 3.3 mtt-85 -59.63 -38.98 82.81 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.247 -0.908 . . . . 0.0 109.79 -179.761 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.477 HG23 ' SD ' ' A' ' 113' ' ' MET . 85.0 m -64.26 -41.01 97.13 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.187 -0.946 . . . . 0.0 109.793 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.542 ' HB1' HD13 ' A' ' 30' ' ' LEU . . . -60.72 -32.78 72.02 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.209 -0.932 . . . . 0.0 108.904 179.762 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -69.23 -34.98 75.67 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.486 -0.759 . . . . 0.0 109.744 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 45.2 t-20 -57.11 -41.0 78.13 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.177 -0.952 . . . . 0.0 109.746 -179.616 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 97.7 m-85 -82.54 -45.73 14.28 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.147 -0.971 . . . . 0.0 109.78 -179.892 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.496 ' NH1' ' OE2' ' A' ' 49' ' ' GLU . 72.1 ttp85 -59.2 -40.9 87.18 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.366 -0.834 . . . . 0.0 110.544 -179.377 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.498 ' O ' ' N ' ' A' ' 48' ' ' GLY . . . -69.55 -52.43 26.38 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.143 -0.973 . . . . 0.0 110.348 -179.117 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.45 ' N ' ' CD2' ' A' ' 45' ' ' LEU . 3.4 mm? -63.93 -39.68 94.71 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.066 -1.021 . . . . 0.0 109.702 -179.739 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' CYS . . . . . . . . . . . . . 95.2 m -63.85 -62.69 1.48 Allowed 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.066 -1.021 . . . . 0.0 109.278 -179.863 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 26.6 m -66.53 -36.24 82.22 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.294 -0.879 . . . . 0.0 109.178 179.586 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . 0.498 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 81.6 38.84 13.19 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 110.064 -1.214 . . . . 0.0 110.064 179.749 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.496 ' OE2' ' NH1' ' A' ' 43' ' ' ARG . 95.3 mt-10 -62.04 -35.79 79.65 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.079 -1.248 . . . . 0.0 109.47 179.883 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 31.2 mmtm -60.43 -34.55 74.14 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.308 -0.87 . . . . 0.0 109.546 -179.838 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 93.58 169.11 38.62 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.236 -1.546 . . . . 0.0 109.236 -179.687 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.539 HG23 ' HA ' ' A' ' 58' ' ' PRO . 68.4 m -79.47 141.12 37.04 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.292 -1.122 . . . . 0.0 109.963 -179.853 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -65.02 140.27 41.71 Favored Glycine 0 N--CA 1.489 2.172 0 N-CA-C 109.302 -1.519 . . . . 0.0 109.302 179.637 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 76.5 mtm180 -59.59 -33.24 71.21 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.229 -1.159 . . . . 0.0 110.046 -179.621 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 86.7 p -60.49 -23.44 64.51 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.204 -0.935 . . . . 0.0 110.122 -179.338 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . 0.427 ' O ' ' CG ' ' A' ' 57' ' ' LYS . . . 108.84 76.94 0.96 Allowed Glycine 0 N--CA 1.495 2.633 0 N-CA-C 108.951 -1.66 . . . . 0.0 108.951 -179.486 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . 0.479 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 54.2 mttm -161.2 76.91 2.41 Favored Pre-proline 0 N--CA 1.488 1.463 0 N-CA-C 107.914 -1.143 . . . . 0.0 107.914 -179.822 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.539 ' HA ' HG23 ' A' ' 52' ' ' THR . 89.0 Cg_exo -48.42 129.91 20.48 Favored 'Trans proline' 0 C--N 1.301 -1.936 0 C-N-CA 122.932 2.421 . . . . 0.0 112.578 -178.716 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.479 ' CD1' ' O ' ' A' ' 57' ' ' LYS . 8.1 mp -97.88 70.7 2.16 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.719 -0.613 . . . . 0.0 109.42 -179.434 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 96.3 m-70 -139.2 146.5 40.6 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.284 -0.885 . . . . 0.0 109.609 179.871 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 4.1 m-85 -97.0 16.87 18.29 Favored 'General case' 0 N--CA 1.492 1.644 0 N-CA-C 108.488 -0.93 . . . . 0.0 108.488 179.173 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 8.7 mtpm? -75.78 153.09 37.19 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.511 -0.743 . . . . 0.0 109.594 -179.692 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 83.8 m-20 55.19 46.23 24.24 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.468 -0.77 . . . . 0.0 109.796 179.745 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 92.1 p -112.94 150.8 31.33 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.418 -0.801 . . . . 0.0 109.038 179.595 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 29.1 t -120.71 148.08 44.42 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.369 -0.832 . . . . 0.0 109.594 -179.694 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -68.38 132.56 47.25 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.294 -0.879 . . . . 0.0 109.015 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 83.8 t60 -63.4 -49.25 74.53 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.278 -0.889 . . . . 0.0 110.367 -179.43 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 5.6 ttm180 -151.45 154.45 36.61 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.071 -1.018 . . . . 0.0 109.344 -179.351 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.479 HG21 HG22 ' A' ' 165' ' ' THR . 19.2 m -132.43 149.88 32.74 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 121.277 -0.889 . . . . 0.0 109.982 -179.737 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 13.3 mt -148.05 125.58 5.75 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.158 -0.963 . . . . 0.0 108.629 178.892 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -71.94 144.2 42.52 Favored 'Trans proline' 0 N--CA 1.493 1.463 0 C-N-CA 122.123 1.882 . . . . 0.0 112.588 -179.291 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 75.08 -53.37 2.61 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.94 -1.264 . . . . 0.0 109.94 179.566 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 84.4 m-85 -67.51 -83.28 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.196 -1.179 . . . . 0.0 110.082 -179.533 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' MET . . . . . 0.587 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 11.9 ptt? -179.49 158.45 0.84 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.114 -0.991 . . . . 0.0 109.619 -179.736 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 1.1 m -99.35 125.8 45.1 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.329 -0.857 . . . . 0.0 108.755 179.377 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 63.7 tt0 -97.94 121.16 39.53 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.21 -0.931 . . . . 0.0 109.766 -179.645 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -87.06 -176.59 49.09 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.14 -1.584 . . . . 0.0 109.14 179.571 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -142.74 162.79 27.37 Favored Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.666 -1.374 . . . . 0.0 109.666 179.857 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -75.04 147.53 40.63 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.344 -1.092 . . . . 0.0 109.553 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 44.4 p90 -68.11 -18.93 64.78 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.243 -0.91 . . . . 0.0 109.654 -179.842 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.539 ' OG1' ' N ' ' A' ' 88' ' ' GLY . 59.7 p -66.22 -30.27 70.68 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.213 -0.929 . . . . 0.0 109.438 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -177.42 -56.22 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.247 -0.908 . . . . 0.0 109.44 179.823 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 94.36 -4.31 70.0 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 78.7 m-20 -88.16 5.41 41.49 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.23 -1.159 . . . . 0.0 109.413 179.865 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 95.93 -38.78 3.0 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 -179.842 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 48.5 m -60.34 -39.51 87.36 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.248 -1.148 . . . . 0.0 109.218 179.738 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -86.06 -168.29 44.59 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 179.901 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.539 ' N ' ' OG1' ' A' ' 81' ' ' THR . . . 108.32 73.14 0.79 Allowed Glycine 0 N--CA 1.494 2.534 0 N-CA-C 109.753 -1.339 . . . . 0.0 109.753 179.865 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -94.8 135.82 35.84 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.254 -1.145 . . . . 0.0 109.189 179.732 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 50.2 m -122.41 147.9 45.74 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.39 -0.819 . . . . 0.0 109.569 -179.84 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 26.1 pt -67.48 -26.81 36.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.309 -0.869 . . . . 0.0 109.621 179.877 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . 0.418 ' OH ' ' O ' ' A' ' 37' ' ' ARG . 97.3 m-85 -65.23 -30.16 71.02 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.3 -0.875 . . . . 0.0 109.776 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 68.09 -107.61 2.13 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.284 -1.527 . . . . 0.0 109.284 -179.772 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -55.54 147.87 16.94 Favored 'General case' 0 N--CA 1.487 1.39 0 O-C-N 121.241 -1.152 . . . . 0.0 109.319 179.819 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 41.5 mttm -76.05 156.26 34.11 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.388 -0.82 . . . . 0.0 109.694 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 33.7 p90 -133.01 161.67 33.75 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.407 -0.808 . . . . 0.0 109.208 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -60.15 140.31 57.0 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.152 -0.967 . . . . 0.0 109.809 -179.349 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -76.68 135.28 39.09 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.29 -0.881 . . . . 0.0 109.812 -179.886 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . 0.443 ' OE1' ' O ' ' A' ' 34' ' ' THR . 95.9 mt-10 -64.84 148.44 51.33 Favored 'General case' 0 C--N 1.305 -1.348 0 O-C-N 121.32 -0.862 . . . . 0.0 109.245 179.556 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 21.3 m120 -55.84 145.7 23.85 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 121.362 -0.836 . . . . 0.0 109.365 -179.866 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' PHE . . . . . 0.586 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 25.0 p90 -110.27 69.88 0.71 Allowed 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.448 -0.782 . . . . 0.0 109.47 -179.781 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 86.4 mt -59.04 -34.8 54.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.257 -0.902 . . . . 0.0 109.575 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 27.1 mtmm -84.77 150.14 25.26 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.21 -0.931 . . . . 0.0 109.615 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 56.4 pttt -131.91 -179.64 5.52 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.371 -0.831 . . . . 0.0 109.362 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' HIS . . . . . 0.534 ' O ' ' CG ' ' A' ' 105' ' ' HIS . 50.4 p-80 -88.27 98.45 11.59 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.207 -0.933 . . . . 0.0 109.647 -179.832 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 55.5 p -77.44 -22.02 52.1 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.237 -0.915 . . . . 0.0 109.708 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.406 ' O ' HG12 ' A' ' 110' ' ' ILE . . . -150.46 179.34 27.27 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.524 -1.431 . . . . 0.0 109.524 -179.744 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -70.99 160.6 48.85 Favored 'Trans proline' 0 C--N 1.307 -1.617 0 C-N-CA 122.863 2.376 . . . . 0.0 112.183 179.886 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 85.62 36.94 9.94 Favored Glycine 0 N--CA 1.493 2.493 0 N-CA-C 109.95 -1.26 . . . . 0.0 109.95 179.725 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.411 ' C ' HD22 ' A' ' 111' ' ' LEU . 39.3 mm -114.98 135.32 55.28 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 O-C-N 121.364 -1.08 . . . . 0.0 109.364 179.857 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.811 ' N ' HD22 ' A' ' 111' ' ' LEU . 2.4 mm? -91.46 136.23 33.27 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.21 -0.931 . . . . 0.0 109.544 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 38.0 t -143.82 139.5 29.36 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.336 -0.852 . . . . 0.0 109.244 179.669 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 113' ' ' MET . . . . . 0.477 ' SD ' HG23 ' A' ' 38' ' ' THR . 82.6 mtp -84.96 130.62 34.6 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.169 -0.957 . . . . 0.0 109.247 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . 0.443 ' O ' ' OD1' ' A' ' 115' ' ' ASN . . . -68.79 141.25 55.23 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.222 -0.924 . . . . 0.0 109.565 -179.879 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . 0.443 ' OD1' ' O ' ' A' ' 114' ' ' ALA . 72.9 m-20 -145.83 112.75 6.05 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.247 -0.908 . . . . 0.0 109.054 179.554 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -69.07 -31.11 69.62 Favored 'General case' 0 C--N 1.296 -1.723 0 O-C-N 121.448 -0.783 . . . . 0.0 109.234 179.747 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -141.02 167.65 25.6 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.137 -1.585 . . . . 0.0 109.137 179.826 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_endo -66.46 157.46 60.34 Favored 'Trans proline' 0 C--N 1.304 -1.799 0 C-N-CA 122.737 2.292 . . . . 0.0 111.94 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 22.3 m120 56.08 51.38 12.01 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.447 -0.783 . . . . 0.0 109.716 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 61.3 m -131.36 127.18 37.06 Favored 'General case' 0 N--CA 1.485 1.28 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 179.437 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 49.3 t-20 -53.13 -37.55 61.9 Favored 'General case' 0 C--N 1.296 -1.753 0 O-C-N 121.371 -0.831 . . . . 0.0 109.839 -179.274 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 77.0 63.52 2.27 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 109.766 -1.334 . . . . 0.0 109.766 179.826 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 24.0 m -54.76 -33.38 61.22 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.199 -1.177 . . . . 0.0 109.76 -179.796 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.3 mt-30 -92.07 147.4 22.98 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.113 -0.992 . . . . 0.0 109.511 -179.902 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 125' ' ' PHE . . . . . 0.403 ' HA ' ' H ' ' A' ' 114' ' ' ALA . 49.1 p90 -138.96 162.48 34.78 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.246 -0.909 . . . . 0.0 109.67 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . 0.587 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 48.8 p90 -139.27 160.79 38.98 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.398 -0.814 . . . . 0.0 109.355 179.911 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 69.8 mt -118.51 132.39 68.53 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.378 -0.826 . . . . 0.0 109.428 179.833 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -102.13 105.59 16.32 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.325 -0.859 . . . . 0.0 109.273 179.887 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . 0.408 ' OG1' ' OE2' ' A' ' 156' ' ' GLU . 44.8 p -89.12 -1.38 58.06 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.283 -0.885 . . . . 0.0 109.642 179.937 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -141.71 153.13 44.44 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.261 -0.9 . . . . 0.0 109.485 -179.816 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 79.7 tttt -78.33 130.64 36.41 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.285 -0.884 . . . . 0.0 109.38 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 33.3 p -124.65 156.11 38.06 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.358 -0.838 . . . . 0.0 109.47 -179.863 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -111.81 -36.3 5.47 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.433 -0.792 . . . . 0.0 109.615 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 0.7 OUTLIER -66.84 -15.2 63.45 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.159 -0.963 . . . . 0.0 109.629 -179.722 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . 0.41 ' O ' ' NE2' ' A' ' 139' ' ' HIS . 7.9 mt -89.29 11.09 19.94 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.195 -0.941 . . . . 0.0 109.436 179.568 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -69.7 118.07 12.09 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.163 -0.961 . . . . 0.0 109.41 -179.617 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -177.68 -154.48 12.35 Favored Glycine 0 N--CA 1.487 2.062 0 N-CA-C 108.883 -1.687 . . . . 0.0 108.883 -179.84 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 32.3 mmtp -81.11 113.7 19.46 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.178 -1.189 . . . . 0.0 109.157 179.769 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 139' ' ' HIS . . . . . 0.41 ' NE2' ' O ' ' A' ' 135' ' ' LEU . 99.2 m-70 -137.17 154.83 50.14 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.367 -0.833 . . . . 0.0 109.348 -179.964 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 44.2 t -122.75 134.41 66.02 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.341 -0.849 . . . . 0.0 109.641 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 61.8 t -110.78 130.48 64.08 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 121.419 -0.801 . . . . 0.0 108.881 179.566 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 38.8 p90 -123.37 -4.88 8.31 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.19 -0.944 . . . . 0.0 110.704 -179.478 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -162.59 174.35 38.96 Favored Glycine 0 N--CA 1.493 2.463 0 C-N-CA 119.152 -1.499 . . . . 0.0 110.498 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 51.7 tt0 -138.96 159.98 40.84 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.604 -0.939 . . . . 0.0 109.169 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 79.7 t -97.31 129.39 47.46 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.188 0 O-C-N 121.105 -0.997 . . . . 0.0 109.521 -179.827 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 19.0 m -106.35 -32.19 2.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.376 -0.828 . . . . 0.0 109.425 179.638 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -145.5 173.15 12.27 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.253 -0.904 . . . . 0.0 109.505 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 98.35 1.93 57.9 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 109.89 -1.284 . . . . 0.0 109.89 179.65 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 149' ' ' MET . . . . . 0.502 ' O ' HG12 ' A' ' 152' ' ' VAL . 65.0 mtt -61.2 -32.35 72.1 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.127 -1.219 . . . . 0.0 109.782 179.979 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . 0.548 ' OD1' ' N ' ' A' ' 151' ' ' VAL . 33.8 p-10 -66.37 -38.73 88.22 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.811 -1.181 . . . . 0.0 110.211 -179.512 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.548 ' N ' ' OD1' ' A' ' 150' ' ' ASP . 6.3 p -85.25 -33.71 8.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.712 0 O-C-N 121.036 -1.04 . . . . 0.0 110.339 -179.545 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 152' ' ' VAL . . . . . 0.502 HG12 ' O ' ' A' ' 149' ' ' MET . 1.1 p -52.77 -41.09 37.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 120.952 -1.092 . . . . 0.0 108.832 -179.488 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 153' ' ' LYS . . . . . 0.442 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 99.4 mttt -64.66 -34.64 78.76 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.252 -0.905 . . . . 0.0 109.144 179.122 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -61.19 -35.38 76.99 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.375 -0.828 . . . . 0.0 109.95 -179.537 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 87.5 mt -71.33 -35.76 58.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.049 -1.032 . . . . 0.0 109.976 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . 0.408 ' OE2' ' OG1' ' A' ' 129' ' ' THR . 97.9 mt-10 -76.97 -40.69 45.98 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.079 -1.013 . . . . 0.0 111.474 -178.937 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 18.4 pttp -60.11 -36.44 77.45 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.592 -1.318 . . . . 0.0 109.208 -179.2 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 30.4 m -80.95 -12.88 12.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.163 -0.961 . . . . 0.0 108.562 178.91 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -78.89 175.8 54.89 Favored Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.707 -1.357 . . . . 0.0 109.707 -179.886 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 25.1 t -157.69 166.79 31.88 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.35 -1.088 . . . . 0.0 109.325 -179.859 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 86.9 p -57.67 -26.05 61.12 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.201 -0.937 . . . . 0.0 108.899 179.745 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 26.7 m -57.44 -30.33 64.92 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.444 -0.785 . . . . 0.0 109.394 179.661 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 95.04 15.62 44.39 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.714 -1.354 . . . . 0.0 109.714 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 77.8 ttt-85 -122.93 141.39 51.96 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.341 -1.093 . . . . 0.0 109.495 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 165' ' ' THR . . . . . 0.479 HG22 HG21 ' A' ' 69' ' ' VAL . 42.7 p -80.91 143.53 32.6 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.188 -0.945 . . . . 0.0 109.618 179.903 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -68.72 -38.34 80.13 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.262 -0.899 . . . . 0.0 109.185 179.559 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 67.2 mttm -107.75 159.75 16.25 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.485 -0.759 . . . . 0.0 109.325 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -73.39 131.7 42.15 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.18 -0.95 . . . . 0.0 109.227 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 40.2 t -121.2 125.0 73.3 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.341 -0.849 . . . . 0.0 109.431 179.915 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 41.6 t -147.06 150.81 14.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.343 -0.848 . . . . 0.0 109.219 179.861 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -88.04 120.37 36.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.233 -0.917 . . . . 0.0 109.625 -179.619 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 172' ' ' GLU . . . . . 0.422 ' OE2' ' OG ' ' A' ' 17' ' ' SER . 97.1 mt-10 -65.28 -26.47 68.09 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.413 -0.804 . . . . 0.0 109.324 179.479 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 173' ' ' ASP . . . . . 0.47 ' OD1' ' N ' ' A' ' 174' ' ' CYS . 47.2 t0 -174.8 169.26 3.53 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.201 -0.937 . . . . 0.0 110.412 -179.532 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 174' ' ' CYS . . . . . 0.47 ' N ' ' OD1' ' A' ' 173' ' ' ASP . 31.4 p -150.38 150.83 31.93 Favored 'General case' 0 N--CA 1.491 1.585 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 179.349 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -175.98 -176.49 44.23 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.823 -1.311 . . . . 0.0 109.823 -179.894 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 6.7 tt0 -104.43 119.67 39.49 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.415 -1.05 . . . . 0.0 109.713 -179.823 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 30.9 tp -62.71 -37.93 88.46 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.129 -0.982 . . . . 0.0 109.154 179.434 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 8.0 t . . . . . 0 N--CA 1.49 1.55 0 CA-C-O 118.017 -0.992 . . . . 0.0 109.433 -179.958 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 7.7 t-20 . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_endo -71.14 139.0 34.61 Favored 'Trans proline' 0 N--CA 1.494 1.502 0 C-N-CA 122.406 2.071 . . . . 0.0 112.493 -179.778 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . 0.571 ' H ' ' HG ' ' A' ' 178' ' ' SER . 86.6 mtt180 -131.65 134.04 45.56 Favored 'General case' 0 N--CA 1.493 1.697 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 179.119 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 12.6 p -136.4 144.52 32.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.412 -0.805 . . . . 0.0 109.353 -179.783 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 48.8 p90 -135.28 151.89 50.99 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.337 -0.852 . . . . 0.0 109.348 179.877 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 90.4 m-85 -119.39 127.52 53.21 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.451 -0.781 . . . . 0.0 110.122 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.4 t0 -92.54 120.31 32.87 Favored 'General case' 0 N--CA 1.493 1.678 0 N-CA-C 108.347 -0.982 . . . . 0.0 108.347 178.86 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 77.2 mtp -122.09 151.12 41.23 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.991 -1.068 . . . . 0.0 110.698 -179.065 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 93.8 p -145.12 160.63 41.11 Favored 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 108.744 -0.836 . . . . 0.0 108.744 179.671 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.419 ' O ' ' C ' ' A' ' 19' ' ' GLY . 18.9 m -128.71 143.55 40.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.274 -0.891 . . . . 0.0 109.488 179.963 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.419 ' C ' ' O ' ' A' ' 18' ' ' VAL . . . 42.11 -103.86 0.04 OUTLIER Glycine 0 N--CA 1.492 2.423 0 N-CA-C 109.692 -1.363 . . . . 0.0 109.692 179.925 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -135.48 22.56 3.51 Favored Glycine 0 N--CA 1.494 2.526 0 N-CA-C 109.32 -1.512 . . . . 0.0 109.32 179.685 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 62.1 mt-30 -127.41 88.61 53.45 Favored Pre-proline 0 N--CA 1.494 1.741 0 O-C-N 121.448 -1.031 . . . . 0.0 109.264 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_exo -48.63 133.17 26.43 Favored 'Trans proline' 0 C--N 1.309 -1.511 0 C-N-CA 122.505 2.137 . . . . 0.0 112.297 -179.637 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -82.47 -64.06 1.25 Allowed 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.405 -0.81 . . . . 0.0 109.772 -179.89 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 175.15 -167.56 39.7 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 -179.858 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 94.5 mtt-85 -106.27 150.23 26.13 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.447 -1.031 . . . . 0.0 109.186 179.886 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 79.6 mt -119.26 120.73 64.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 179.378 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 34.8 t -112.99 132.38 61.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.446 -0.784 . . . . 0.0 108.911 -179.909 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 70.6 mtm -127.45 156.68 41.74 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.323 -0.86 . . . . 0.0 109.679 -179.361 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -99.62 135.51 40.94 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.284 -0.885 . . . . 0.0 109.795 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -108.89 128.35 54.84 Favored 'General case' 0 N--CA 1.492 1.65 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 179.388 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -95.19 118.23 31.61 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.143 -0.973 . . . . 0.0 108.992 179.778 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -80.43 -42.47 22.64 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 121.473 -0.767 . . . . 0.0 109.839 -179.812 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 56.8 t0 -65.52 -46.26 80.28 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.237 -0.914 . . . . 0.0 110.435 -179.365 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 24.8 m -66.17 -45.73 79.88 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.002 -1.061 . . . . 0.0 109.854 -179.38 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.432 ' O ' ' OG1' ' A' ' 35' ' ' THR . 13.2 p -145.33 81.84 10.08 Favored Pre-proline 0 N--CA 1.493 1.711 0 O-C-N 121.317 -0.864 . . . . 0.0 109.332 -179.72 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -70.33 -47.07 0.82 Allowed 'Trans proline' 0 C--N 1.307 -1.615 0 C-N-CA 122.1 1.867 . . . . 0.0 112.215 -179.48 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 22.9 mmt85 -63.04 -39.75 95.68 Favored 'General case' 0 N--CA 1.487 1.409 0 O-C-N 121.1 -1.0 . . . . 0.0 109.581 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.407 HG23 ' SD ' ' A' ' 113' ' ' MET . 37.9 m -65.16 -40.92 95.01 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.224 -0.922 . . . . 0.0 110.069 -179.736 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -60.69 -31.8 71.05 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.312 -0.867 . . . . 0.0 109.278 -179.699 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -67.09 -38.44 85.7 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.335 -0.853 . . . . 0.0 109.758 -179.927 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 49.1 t30 -58.48 -42.52 87.72 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.264 -0.898 . . . . 0.0 109.932 -179.644 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.507 ' O ' ' SG ' ' A' ' 46' ' ' CYS . 97.6 m-85 -82.89 -45.72 13.87 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.061 -1.024 . . . . 0.0 109.859 -179.925 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.773 ' HE ' HE22 ' A' ' 176' ' ' GLN . 74.0 ttt-85 -58.73 -41.1 85.62 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.296 -0.878 . . . . 0.0 110.544 -179.342 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -71.77 -53.81 12.21 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.028 -1.045 . . . . 0.0 110.553 -179.019 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.473 ' N ' ' CD2' ' A' ' 45' ' ' LEU . 3.8 mm? -63.32 -38.9 92.95 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.948 -1.095 . . . . 0.0 109.776 -179.631 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' CYS . . . . . 0.507 ' SG ' ' O ' ' A' ' 42' ' ' PHE . 95.6 m -65.83 -55.65 16.02 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.108 -0.995 . . . . 0.0 109.138 179.864 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 50.7 m -66.13 -36.81 84.13 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.373 -0.83 . . . . 0.0 109.279 179.468 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 85.31 30.02 26.13 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 110.269 -1.133 . . . . 0.0 110.269 179.565 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -62.2 -38.71 90.15 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.05 -1.265 . . . . 0.0 109.359 179.83 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 59.7 mmtt -62.5 -31.27 72.0 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.386 -0.821 . . . . 0.0 109.686 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 74.34 -113.95 4.29 Favored Glycine 0 N--CA 1.488 2.125 0 N-CA-C 108.854 -1.698 . . . . 0.0 108.854 -179.37 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.615 HG23 ' HA ' ' A' ' 58' ' ' PRO . 87.4 m -127.61 143.42 51.17 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.339 -1.094 . . . . 0.0 109.749 179.624 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -64.99 137.2 38.31 Favored Glycine 0 N--CA 1.489 2.168 0 N-CA-C 109.221 -1.551 . . . . 0.0 109.221 179.685 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 81.4 mtm180 -59.1 -34.93 72.59 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.205 -1.173 . . . . 0.0 109.913 -179.7 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 86.1 p -61.95 -24.41 66.98 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.174 -0.954 . . . . 0.0 109.782 -179.746 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 112.45 89.6 1.84 Allowed Glycine 0 N--CA 1.495 2.569 0 N-CA-C 109.102 -1.599 . . . . 0.0 109.102 -179.682 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . 0.529 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 22.8 tttp -174.56 79.56 0.34 Allowed Pre-proline 0 N--CA 1.488 1.465 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 -179.677 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.615 ' HA ' HG23 ' A' ' 52' ' ' THR . 75.5 Cg_exo -50.47 131.99 33.92 Favored 'Trans proline' 0 C--N 1.304 -1.793 0 C-N-CA 122.892 2.394 . . . . 0.0 113.197 -178.779 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.529 ' CD1' ' O ' ' A' ' 57' ' ' LYS . 8.9 mp -104.49 122.32 45.3 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 108.782 -0.821 . . . . 0.0 108.782 179.325 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . 0.421 ' CD2' ' N ' ' A' ' 60' ' ' HIS . 5.1 p80 -169.7 93.28 0.25 Allowed 'General case' 0 N--CA 1.486 1.375 0 O-C-N 120.971 -1.081 . . . . 0.0 110.272 -179.684 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 8.0 m-85 -64.29 -29.39 70.48 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.182 -0.949 . . . . 0.0 109.066 179.149 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 8.8 ptmm? -55.3 160.3 2.3 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.351 -0.843 . . . . 0.0 109.627 179.842 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . 0.449 ' N ' ' O ' ' A' ' 171' ' ' VAL . 85.0 m-20 54.62 48.01 21.31 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.498 -0.752 . . . . 0.0 109.416 -179.842 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.577 ' H ' ' CG1' ' A' ' 171' ' ' VAL . 89.6 p -126.46 155.07 42.83 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.277 -0.889 . . . . 0.0 109.134 179.754 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 32.1 t -106.48 141.98 36.9 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.335 -0.853 . . . . 0.0 109.056 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -69.61 143.43 53.28 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.343 -0.848 . . . . 0.0 108.892 -179.927 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 57.2 t-80 -57.33 -51.13 70.62 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.218 -0.927 . . . . 0.0 110.405 -178.851 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 15.6 ptm180 -171.0 163.68 7.45 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 120.896 -1.127 . . . . 0.0 109.697 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.405 HG11 HG22 ' A' ' 155' ' ' ILE . 0.1 OUTLIER -136.47 129.28 45.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.462 -0.774 . . . . 0.0 109.128 179.696 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 70.3 mt -128.92 109.14 18.35 Favored Pre-proline 0 N--CA 1.493 1.695 0 O-C-N 121.543 -0.723 . . . . 0.0 109.631 179.865 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -52.45 147.53 29.28 Favored 'Trans proline' 0 C--N 1.31 -1.482 0 C-N-CA 122.357 2.038 . . . . 0.0 112.62 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 87.12 -59.53 4.48 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 110.156 -1.177 . . . . 0.0 110.156 179.373 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 67.8 m-85 -70.21 -73.48 0.16 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.239 -1.154 . . . . 0.0 110.061 -179.493 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' MET . . . . . 0.528 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 13.4 ptt? 178.45 -165.66 0.05 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.225 -0.922 . . . . 0.0 109.618 -179.918 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -121.22 124.13 43.92 Favored 'General case' 0 N--CA 1.494 1.764 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 179.614 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 63.6 tt0 -102.44 124.49 48.09 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.231 -0.918 . . . . 0.0 109.827 -179.663 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -86.26 -173.88 49.34 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.259 -1.536 . . . . 0.0 109.259 179.457 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -136.83 154.5 22.21 Favored Glycine 0 N--CA 1.493 2.477 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 88.0 m-20 -83.77 143.81 29.73 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.432 -1.04 . . . . 0.0 109.642 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 41.3 p90 -65.43 -23.61 66.98 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.283 -0.886 . . . . 0.0 109.624 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.454 ' OG1' ' N ' ' A' ' 88' ' ' GLY . 52.7 p -64.2 -31.54 72.78 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.145 -0.972 . . . . 0.0 109.481 -179.891 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . 0.432 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 178.02 -54.08 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.403 -0.811 . . . . 0.0 109.334 179.855 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 96.58 -11.21 66.77 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 80.3 m-20 -88.66 2.77 52.63 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.186 -1.185 . . . . 0.0 109.315 179.795 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 93.66 -5.16 73.3 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.395 -1.482 . . . . 0.0 109.395 -179.868 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 61.7 p -74.47 -19.02 60.54 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.394 -1.062 . . . . 0.0 109.517 179.87 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -131.86 -132.75 3.38 Favored Glycine 0 N--CA 1.494 2.519 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.454 ' N ' ' OG1' ' A' ' 81' ' ' THR . . . 74.57 47.28 16.25 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.293 -1.523 . . . . 0.0 109.293 -179.915 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -93.3 135.36 34.59 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.295 -1.121 . . . . 0.0 109.753 -179.508 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 50.0 m -70.72 158.08 36.91 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.358 -0.839 . . . . 0.0 109.508 179.84 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 24.9 pt -65.94 -31.15 52.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.24 -0.912 . . . . 0.0 109.834 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 59.9 m-85 -64.0 -36.33 83.63 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.256 -0.902 . . . . 0.0 109.591 -179.746 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 82.79 10.16 83.52 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.321 -1.512 . . . . 0.0 109.321 -179.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -148.28 157.25 43.38 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.282 -1.128 . . . . 0.0 109.372 -179.915 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 62.0 mttp -86.57 153.03 22.12 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.22 -0.925 . . . . 0.0 109.466 179.912 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 36.9 p90 -129.09 157.87 40.53 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.425 -0.797 . . . . 0.0 109.329 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -65.68 143.98 57.21 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.294 -0.879 . . . . 0.0 110.052 -179.337 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . 0.574 ' CG ' ' H ' ' A' ' 119' ' ' ASN . 88.5 m-20 -67.01 148.0 52.51 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.35 -0.844 . . . . 0.0 109.617 179.845 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -100.14 161.91 13.3 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.345 -0.847 . . . . 0.0 109.268 179.844 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 81.4 m-20 -62.6 163.17 9.37 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.369 -0.832 . . . . 0.0 109.405 -179.846 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' PHE . . . . . 0.582 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 22.0 p90 -130.22 79.43 1.9 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.431 -0.793 . . . . 0.0 109.52 -179.898 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 87.8 mt -58.97 -33.94 51.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.183 -0.948 . . . . 0.0 109.376 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 67.2 mttm -83.51 143.18 30.38 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.187 -0.946 . . . . 0.0 109.386 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' LYS . . . . . 0.541 ' O ' ' N ' ' A' ' 106' ' ' THR . 50.0 tttp -127.35 158.24 37.79 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.406 -0.809 . . . . 0.0 109.331 -179.924 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' HIS . . . . . 0.455 ' CE1' ' O ' ' A' ' 107' ' ' GLY . 78.6 t60 -61.01 76.5 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.341 -0.849 . . . . 0.0 109.252 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . 0.541 ' N ' ' O ' ' A' ' 104' ' ' LYS . 70.5 p -73.52 -27.15 61.21 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.199 -0.938 . . . . 0.0 109.878 -179.731 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.455 ' O ' ' CE1' ' A' ' 105' ' ' HIS . . . -153.75 177.12 31.43 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.561 -1.415 . . . . 0.0 109.561 -179.763 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -70.4 156.65 61.21 Favored 'Trans proline' 0 C--N 1.305 -1.724 0 C-N-CA 122.774 2.316 . . . . 0.0 112.131 179.881 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 86.07 43.59 6.27 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 110.095 -1.202 . . . . 0.0 110.095 179.728 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 45.4 mm -117.13 136.13 55.27 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 O-C-N 121.263 -1.139 . . . . 0.0 109.386 179.593 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.71 ' N ' HD22 ' A' ' 111' ' ' LEU . 2.9 mm? -88.65 137.36 32.39 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.21 -0.931 . . . . 0.0 109.413 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . 0.457 ' OG ' ' O ' ' A' ' 140' ' ' VAL . 46.2 t -146.22 141.22 27.19 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.246 -0.909 . . . . 0.0 109.582 179.804 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 113' ' ' MET . . . . . 0.407 ' SD ' HG23 ' A' ' 38' ' ' THR . 88.5 mtp -88.51 135.59 33.41 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.259 -0.9 . . . . 0.0 109.416 179.67 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . 0.456 ' O ' ' OD1' ' A' ' 115' ' ' ASN . . . -73.73 137.54 44.07 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.202 -0.936 . . . . 0.0 109.585 -179.946 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . 0.456 ' OD1' ' O ' ' A' ' 114' ' ' ALA . 76.3 m-20 -146.58 114.17 6.39 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.203 -0.936 . . . . 0.0 108.945 179.535 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -69.15 -31.07 69.49 Favored 'General case' 0 C--N 1.297 -1.697 0 O-C-N 121.409 -0.807 . . . . 0.0 109.697 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -139.9 167.55 25.34 Favored Glycine 0 N--CA 1.494 2.543 0 N-CA-C 109.396 -1.482 . . . . 0.0 109.396 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -69.08 154.11 70.97 Favored 'Trans proline' 0 C--N 1.307 -1.653 0 C-N-CA 122.701 2.268 . . . . 0.0 111.849 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 119' ' ' ASN . . . . . 0.574 ' H ' ' CG ' ' A' ' 98' ' ' ASP . 80.3 m-20 53.49 43.22 31.58 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.436 -0.79 . . . . 0.0 109.317 -179.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 91.8 m -136.37 128.41 29.59 Favored 'General case' 0 C--N 1.305 -1.34 0 O-C-N 121.445 -0.784 . . . . 0.0 109.041 179.84 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 43.4 p-10 -80.76 168.11 19.19 Favored 'General case' 0 C--N 1.298 -1.668 0 O-C-N 121.377 -0.827 . . . . 0.0 109.311 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -159.79 105.94 0.28 Allowed Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.667 -1.373 . . . . 0.0 109.667 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 23.9 t -59.12 -32.61 69.99 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.252 -1.146 . . . . 0.0 109.389 179.85 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.6 mt-30 -71.23 142.96 50.58 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.214 -0.928 . . . . 0.0 109.575 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 48.5 p90 -140.46 162.27 35.73 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.342 -0.849 . . . . 0.0 109.322 179.866 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . 0.528 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 48.2 p90 -138.43 158.56 44.04 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.295 -0.878 . . . . 0.0 109.608 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 60.3 mt -120.34 132.29 70.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.411 -0.806 . . . . 0.0 109.208 179.85 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 128' ' ' CYS . . . . . 0.432 ' SG ' ' O ' ' A' ' 130' ' ' ALA . 4.4 t -100.99 116.8 33.69 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.135 -0.978 . . . . 0.0 109.389 179.886 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . 0.421 ' OG1' ' OE1' ' A' ' 156' ' ' GLU . 51.0 p -91.45 0.78 57.47 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.301 -0.875 . . . . 0.0 109.622 -179.842 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . 0.432 ' O ' ' SG ' ' A' ' 128' ' ' CYS . . . -151.25 155.91 39.77 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.188 -0.945 . . . . 0.0 109.601 -179.811 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 77.8 tttt -69.33 140.56 54.32 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.186 -0.946 . . . . 0.0 109.261 179.832 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 17.0 p -113.19 159.68 19.04 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.349 -0.844 . . . . 0.0 109.506 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -154.57 -50.46 0.09 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.397 -0.814 . . . . 0.0 109.282 -179.876 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 134' ' ' TRP . . . . . 0.631 ' CD1' ' N ' ' A' ' 135' ' ' LEU . 35.3 p90 -56.43 -38.8 72.07 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.259 -0.901 . . . . 0.0 109.385 179.836 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . 0.631 ' N ' ' CD1' ' A' ' 134' ' ' TRP . 44.2 tp -60.01 -36.5 77.35 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.428 -0.795 . . . . 0.0 109.505 -179.782 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 59.4 t0 47.26 78.75 0.07 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.337 -0.852 . . . . 0.0 109.798 179.771 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -144.74 134.92 5.84 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.11 -1.596 . . . . 0.0 109.11 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 67.6 mmtt -82.96 135.06 35.01 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.261 -1.141 . . . . 0.0 109.42 -179.754 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 96.4 m-70 -136.02 175.5 9.54 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.414 -0.804 . . . . 0.0 109.376 -179.878 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.457 ' O ' ' OG ' ' A' ' 112' ' ' SER . 20.1 m -124.0 153.77 30.34 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 121.466 -0.771 . . . . 0.0 108.996 179.702 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 58.5 t -118.39 128.2 75.39 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.292 -0.88 . . . . 0.0 109.961 -179.607 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . 0.455 ' CE2' ' CE2' ' A' ' 42' ' ' PHE . 40.6 p90 -117.59 1.61 12.27 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.474 -0.766 . . . . 0.0 109.561 179.412 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -169.29 177.38 42.97 Favored Glycine 0 N--CA 1.495 2.593 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 179.64 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . 0.432 ' CG ' ' N ' ' A' ' 145' ' ' VAL . 48.0 tt0 -143.76 161.62 38.12 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.349 -1.089 . . . . 0.0 109.798 -179.643 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . 0.432 ' N ' ' CG ' ' A' ' 144' ' ' GLN . 79.9 t -100.03 135.59 35.04 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.112 0 O-C-N 121.283 -0.886 . . . . 0.0 109.653 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 6.8 m -118.8 -33.69 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.275 -0.89 . . . . 0.0 109.573 179.672 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -138.37 166.03 25.27 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.237 -0.915 . . . . 0.0 109.713 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 94.47 9.98 58.49 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.845 -1.302 . . . . 0.0 109.845 179.745 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 149' ' ' MET . . . . . 0.446 ' O ' HG12 ' A' ' 152' ' ' VAL . 88.7 mtp -59.84 -34.07 72.61 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.192 -1.181 . . . . 0.0 109.765 -179.935 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 89.0 m-20 -64.61 -39.68 94.15 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.896 -1.127 . . . . 0.0 109.846 -179.74 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 5.5 p -85.59 -33.27 7.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.132 -0.98 . . . . 0.0 110.522 -179.423 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 152' ' ' VAL . . . . . 0.446 HG12 ' O ' ' A' ' 149' ' ' MET . 0.7 OUTLIER -55.29 -38.77 49.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 120.953 -1.092 . . . . 0.0 109.376 -179.366 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 153' ' ' LYS . . . . . 0.412 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 50.7 pttt -81.16 -20.97 40.13 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.136 -0.978 . . . . 0.0 109.385 179.683 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -64.39 -39.82 94.6 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.252 -0.905 . . . . 0.0 109.579 -179.916 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.405 HG22 HG11 ' A' ' 69' ' ' VAL . 65.2 mt -72.05 -35.68 54.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.304 -0.873 . . . . 0.0 109.541 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . 0.421 ' OE1' ' OG1' ' A' ' 129' ' ' THR . 84.7 tt0 -76.26 -42.27 46.22 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.257 -0.902 . . . . 0.0 111.447 -178.772 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 16.4 pttp -61.59 -33.12 73.34 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 120.639 -1.288 . . . . 0.0 110.241 -178.56 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 35.2 m -77.02 -17.84 14.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.018 -1.051 . . . . 0.0 109.683 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -72.87 172.77 48.77 Favored Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.965 -1.254 . . . . 0.0 109.965 -179.655 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 85.0 p -150.09 170.07 19.76 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.476 -1.014 . . . . 0.0 109.381 -179.739 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 23.2 m -55.42 -34.72 64.67 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.177 -0.952 . . . . 0.0 108.965 179.705 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 86.5 p -62.57 -26.34 68.54 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.373 -0.83 . . . . 0.0 109.189 179.674 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 97.2 3.17 58.94 Favored Glycine 0 N--CA 1.494 2.529 0 N-CA-C 109.674 -1.37 . . . . 0.0 109.674 179.898 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 77.8 ttt180 -99.99 144.56 28.9 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.306 -1.114 . . . . 0.0 109.205 179.818 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 165' ' ' THR . . . . . . . . . . . . . 65.5 p -104.71 152.1 22.93 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.354 -0.841 . . . . 0.0 109.657 -179.877 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -68.47 -37.0 79.77 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.369 -0.832 . . . . 0.0 109.627 179.923 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 47.8 mtmt -112.41 157.82 20.58 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.53 -0.731 . . . . 0.0 109.628 -179.793 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 91.3 mttt -76.54 146.49 38.34 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.333 -0.854 . . . . 0.0 109.306 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . 0.475 ' O ' HG23 ' A' ' 169' ' ' VAL . 32.6 m -128.75 125.2 62.86 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 O-C-N 121.326 -0.859 . . . . 0.0 109.596 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 48.5 t -144.88 138.23 22.21 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.387 -0.821 . . . . 0.0 109.302 179.589 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.577 ' CG1' ' H ' ' A' ' 64' ' ' SER . 2.5 p -80.41 119.65 30.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 120.99 -1.069 . . . . 0.0 108.999 179.717 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -71.03 -44.41 65.88 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.133 -0.98 . . . . 0.0 111.177 -178.535 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 173' ' ' ASP . . . . . 0.46 ' OD1' ' N ' ' A' ' 174' ' ' CYS . 47.2 t0 -170.15 164.64 9.2 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.754 -1.216 . . . . 0.0 110.542 -179.325 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 174' ' ' CYS . . . . . 0.46 ' N ' ' OD1' ' A' ' 173' ' ' ASP . 1.4 p -151.63 151.86 32.07 Favored 'General case' 0 N--CA 1.49 1.573 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 179.484 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -160.75 178.37 36.77 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 176' ' ' GLN . . . . . 0.773 HE22 ' HE ' ' A' ' 43' ' ' ARG . 62.6 tt0 -99.05 113.96 26.42 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.326 -1.102 . . . . 0.0 109.713 -179.821 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 29.1 tp -63.37 -36.79 84.89 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.216 -0.928 . . . . 0.0 109.022 179.418 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 178' ' ' SER . . . . . 0.571 ' HG ' ' H ' ' A' ' 11' ' ' ARG . 11.8 p . . . . . 0 N--CA 1.491 1.62 0 CA-C-O 118.001 -0.999 . . . . 0.0 109.495 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 2.5 m-20 . . . . . 0 N--CA 1.492 1.661 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 93.3 Cg_endo -82.23 90.53 1.09 Allowed 'Trans proline' 0 C--N 1.308 -1.575 0 C-N-CA 122.898 2.399 . . . . 0.0 111.845 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 73.1 mtm180 -61.68 137.91 58.28 Favored 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.289 -0.882 . . . . 0.0 109.849 -179.595 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 12.7 p -138.29 143.53 32.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 179.497 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 45.1 p90 -141.54 153.96 45.19 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.179 -0.95 . . . . 0.0 110.107 -179.513 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 86.0 m-85 -123.73 140.25 53.18 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 179.162 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.5 t0 -86.88 116.31 24.87 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.053 -1.029 . . . . 0.0 109.259 179.768 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' MET . . . . . 0.577 ' SD ' HD12 ' A' ' 26' ' ' ILE . 80.4 mtp -103.96 147.45 27.34 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.291 -0.881 . . . . 0.0 110.19 -179.856 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 97.1 p -143.94 164.39 30.72 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 108.55 -0.907 . . . . 0.0 108.55 179.414 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 12.9 p -128.3 139.03 53.0 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.238 -0.914 . . . . 0.0 109.676 -179.752 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 57.02 -107.33 0.92 Allowed Glycine 0 N--CA 1.488 2.129 0 N-CA-C 109.364 -1.494 . . . . 0.0 109.364 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -136.04 37.15 1.93 Allowed Glycine 0 N--CA 1.493 2.487 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 6.5 pt20 -147.88 126.99 6.3 Favored Pre-proline 0 N--CA 1.492 1.649 0 O-C-N 121.264 -1.139 . . . . 0.0 109.349 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_exo -47.39 139.88 16.29 Favored 'Trans proline' 0 N--CA 1.493 1.455 0 C-N-CA 122.139 1.893 . . . . 0.0 112.17 179.74 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -101.49 -61.31 1.39 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.311 -0.868 . . . . 0.0 109.483 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -178.19 -170.3 40.16 Favored Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.409 -1.476 . . . . 0.0 109.409 -179.871 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 97.5 mtt180 -118.04 142.33 47.5 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.374 -1.074 . . . . 0.0 109.803 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.577 HD12 ' SD ' ' A' ' 16' ' ' MET . 70.1 mt -120.39 123.2 70.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 178.609 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 38.7 t -110.05 132.58 57.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.387 -0.82 . . . . 0.0 109.382 -179.535 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 76.2 mtm -114.79 149.32 37.16 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.591 -0.693 . . . . 0.0 109.381 -179.689 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.405 ' C ' HD22 ' A' ' 30' ' ' LEU . 84.3 tt0 -100.92 129.82 46.83 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.286 -0.884 . . . . 0.0 109.698 -179.668 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.408 ' N ' ' CD2' ' A' ' 30' ' ' LEU . 2.7 mm? -108.34 132.66 53.5 Favored 'General case' 0 N--CA 1.494 1.741 0 N-CA-C 108.909 -0.775 . . . . 0.0 108.909 179.588 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.483 ' O ' ' OG1' ' A' ' 35' ' ' THR . 92.7 m-85 -96.36 114.02 25.66 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.031 -1.043 . . . . 0.0 108.742 178.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -75.87 -42.43 49.4 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.155 -0.966 . . . . 0.0 109.869 -179.696 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.3 m-20 -66.63 -57.86 6.34 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.149 -0.97 . . . . 0.0 110.191 -179.356 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 54.9 m -67.03 -40.73 87.28 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.246 -0.909 . . . . 0.0 109.853 -179.759 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.546 HG21 ' HA ' ' A' ' 142' ' ' PHE . 81.7 p -130.04 77.5 76.42 Favored Pre-proline 0 N--CA 1.493 1.711 0 O-C-N 121.358 -0.839 . . . . 0.0 109.377 -179.64 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -72.84 -73.64 0.01 OUTLIER 'Trans proline' 0 N--CA 1.493 1.489 0 C-N-CA 122.676 2.251 . . . . 0.0 113.259 -179.38 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 80.1 mtt85 -59.37 -39.33 82.93 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.612 -0.68 . . . . 0.0 111.061 -178.624 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 42.8 m -61.66 -42.56 99.07 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.864 -1.148 . . . . 0.0 109.452 -179.848 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -63.9 -30.85 71.89 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.263 -0.898 . . . . 0.0 108.593 179.295 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 85.2 tt0 -66.25 -36.81 83.96 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.432 -0.792 . . . . 0.0 109.509 179.927 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' ASN . . . . . 0.49 ' O ' HD23 ' A' ' 45' ' ' LEU . 38.7 t30 -58.03 -41.2 82.69 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.229 -0.919 . . . . 0.0 109.514 -179.698 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.4 ' O ' ' SG ' ' A' ' 46' ' ' CYS . 98.0 m-85 -83.18 -44.99 14.43 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.058 -1.026 . . . . 0.0 109.661 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.712 ' NE ' HE22 ' A' ' 176' ' ' GLN . 77.5 ttt180 -59.32 -43.2 92.7 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.38 -0.825 . . . . 0.0 110.62 -179.216 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -68.1 -43.97 77.29 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.097 -1.002 . . . . 0.0 110.63 -178.834 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.49 HD23 ' O ' ' A' ' 41' ' ' ASN . 3.3 mm? -62.39 -39.05 91.95 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.971 -1.081 . . . . 0.0 109.593 -179.659 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' CYS . . . . . 0.4 ' SG ' ' O ' ' A' ' 42' ' ' PHE . 35.7 m -67.64 -47.89 68.27 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.146 -0.972 . . . . 0.0 109.391 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 48.3 p -74.49 -33.75 62.91 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.361 -0.837 . . . . 0.0 109.709 179.864 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 74.36 33.53 56.29 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 110.077 -1.209 . . . . 0.0 110.077 179.704 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -62.11 -37.55 85.54 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.07 -1.253 . . . . 0.0 109.61 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 72.2 mmtt -61.27 -35.32 76.96 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.262 -0.899 . . . . 0.0 109.578 -179.845 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 90.9 171.68 43.52 Favored Glycine 0 N--CA 1.488 2.113 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 -179.757 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.535 HG23 ' HA ' ' A' ' 58' ' ' PRO . 65.7 m -75.57 140.27 42.59 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.493 -1.004 . . . . 0.0 109.832 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -63.87 138.44 42.07 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.172 -1.571 . . . . 0.0 109.172 179.702 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 81.0 mmt-85 -59.37 -33.32 71.03 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.305 -1.115 . . . . 0.0 109.922 -179.656 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 86.1 p -60.91 -22.98 64.88 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.129 -0.982 . . . . 0.0 109.966 -179.532 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . 0.428 ' O ' ' CG ' ' A' ' 57' ' ' LYS . . . 110.03 77.55 0.95 Allowed Glycine 0 N--CA 1.496 2.636 0 N-CA-C 108.879 -1.688 . . . . 0.0 108.879 -179.586 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . 0.51 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 8.6 mtmp? -160.41 76.8 2.69 Favored Pre-proline 0 C--N 1.303 -1.455 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 -179.837 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.535 ' HA ' HG23 ' A' ' 52' ' ' THR . 81.8 Cg_exo -49.0 130.0 22.71 Favored 'Trans proline' 0 C--N 1.301 -1.945 0 C-N-CA 122.913 2.409 . . . . 0.0 112.614 -178.867 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.51 ' CD1' ' O ' ' A' ' 57' ' ' LYS . 8.3 mp -99.33 84.86 3.07 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.753 -0.592 . . . . 0.0 109.52 -179.697 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 99.2 m-70 -145.81 143.06 29.43 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.276 -0.89 . . . . 0.0 109.734 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 2.9 m-85 -102.33 17.03 24.48 Favored 'General case' 0 N--CA 1.493 1.724 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 179.317 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 91.7 mttt -81.01 158.84 25.01 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.303 -0.873 . . . . 0.0 109.885 -179.491 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . 0.455 ' H ' HG23 ' A' ' 171' ' ' VAL . 84.3 m-20 55.99 45.84 23.02 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.552 -0.717 . . . . 0.0 110.35 179.562 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.947 ' H ' HG22 ' A' ' 171' ' ' VAL . 66.7 p -98.74 153.35 18.8 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.143 -0.973 . . . . 0.0 108.616 179.077 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 28.6 t -122.3 145.06 48.6 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.37 -0.832 . . . . 0.0 109.664 -179.566 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 4.3 m-85 -72.7 129.04 37.31 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.314 -0.866 . . . . 0.0 109.034 179.782 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' HIS . . . . . 0.605 ' CD2' ' HE ' ' A' ' 68' ' ' ARG . 74.9 t60 -62.2 -49.94 73.79 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.358 -0.839 . . . . 0.0 110.116 -179.376 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.605 ' HE ' ' CD2' ' A' ' 67' ' ' HIS . 18.4 ptp180 -160.17 161.02 33.54 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.035 -1.041 . . . . 0.0 109.922 -179.982 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.556 HG21 HG22 ' A' ' 165' ' ' THR . 17.7 m -132.73 145.23 34.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.478 -0.764 . . . . 0.0 109.043 179.683 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 14.4 mt -148.17 129.5 7.2 Favored Pre-proline 0 N--CA 1.494 1.745 0 O-C-N 121.091 -1.005 . . . . 0.0 109.331 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -72.3 145.36 43.23 Favored 'Trans proline' 0 N--CA 1.492 1.393 0 C-N-CA 122.242 1.961 . . . . 0.0 112.379 179.849 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 82.25 -56.18 4.97 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.918 -1.273 . . . . 0.0 109.918 179.736 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -72.42 -86.16 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.117 -1.225 . . . . 0.0 109.874 -179.715 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' MET . . . . . 0.602 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 12.4 ptt? -179.52 -168.6 0.12 Allowed 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.236 -0.915 . . . . 0.0 109.759 -179.914 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -126.71 131.85 51.28 Favored 'General case' 0 N--CA 1.494 1.732 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.774 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 63.6 tt0 -103.07 126.4 50.23 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.151 -0.968 . . . . 0.0 109.908 -179.611 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -86.29 -174.03 49.38 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.242 -1.543 . . . . 0.0 109.242 179.548 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -138.35 154.9 23.19 Favored Glycine 0 N--CA 1.495 2.575 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.479 ' H ' ' HA2' ' A' ' 83' ' ' GLY . 88.4 m-20 -73.67 149.36 42.0 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.35 -1.088 . . . . 0.0 109.43 179.804 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 48.3 p90 -64.72 -26.33 68.32 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.161 -0.962 . . . . 0.0 109.437 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.504 ' O ' ' HB2' ' A' ' 82' ' ' ALA . 54.0 p -69.1 -29.08 67.09 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.165 -0.959 . . . . 0.0 109.462 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . 0.504 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 174.79 -55.11 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.386 -0.821 . . . . 0.0 109.254 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.479 ' HA2' ' H ' ' A' ' 79' ' ' ASP . . . 95.95 -6.5 66.9 Favored Glycine 0 N--CA 1.492 2.395 0 N-CA-C 109.658 -1.377 . . . . 0.0 109.658 179.878 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 78.5 m-20 -88.16 2.71 51.52 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.188 -1.184 . . . . 0.0 109.258 179.812 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 94.18 -6.61 72.32 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.321 -1.511 . . . . 0.0 109.321 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 59.0 p -75.15 -18.54 60.18 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.254 -1.145 . . . . 0.0 109.506 179.896 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -132.38 -128.47 2.92 Favored Glycine 0 N--CA 1.494 2.507 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.857 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 81.87 22.35 59.78 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.287 -1.525 . . . . 0.0 109.287 -179.856 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -57.96 145.43 35.91 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.339 -1.095 . . . . 0.0 109.669 -179.855 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 88.5 p -111.85 153.36 26.75 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.417 -0.802 . . . . 0.0 109.331 179.885 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 5.5 pt -63.56 -39.76 86.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.242 -0.911 . . . . 0.0 109.847 -179.76 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 3.1 m-30 -63.45 -38.87 92.8 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.089 -1.007 . . . . 0.0 109.459 179.758 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 76.7 19.03 78.39 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.282 -1.527 . . . . 0.0 109.282 -179.861 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -145.62 158.78 43.8 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.328 -1.101 . . . . 0.0 109.442 -179.853 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 62.9 mttp -85.01 153.62 22.64 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.336 -0.852 . . . . 0.0 109.709 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -100.68 133.12 45.61 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.41 -0.806 . . . . 0.0 109.1 179.775 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -83.47 119.73 25.04 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.162 -0.961 . . . . 0.0 109.684 -179.715 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 88.1 m-20 -75.55 143.09 42.61 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.283 -0.886 . . . . 0.0 109.259 179.638 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -153.29 -31.11 0.13 Allowed 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.174 -0.954 . . . . 0.0 110.05 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 84.6 m-20 -97.73 131.33 44.36 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.073 -1.017 . . . . 0.0 109.954 -179.579 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' PHE . . . . . 0.555 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 70.6 t80 -134.56 22.13 3.65 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 179.745 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 86.2 mt -56.77 -37.5 53.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.437 -0.79 . . . . 0.0 110.052 -179.512 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 56.6 mttm -83.34 138.27 33.6 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.008 -1.057 . . . . 0.0 109.891 -179.65 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 72.8 tttt -134.89 157.56 46.53 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.462 -0.774 . . . . 0.0 109.24 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' HIS . . . . . 0.542 ' O ' ' CG ' ' A' ' 105' ' ' HIS . 52.2 p-80 -68.02 83.5 0.22 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.12 -0.987 . . . . 0.0 109.271 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 57.0 p -77.04 -19.31 57.33 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.275 -0.891 . . . . 0.0 110.116 -179.54 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.423 ' O ' HG12 ' A' ' 110' ' ' ILE . . . -150.55 178.25 28.11 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 109.737 -1.345 . . . . 0.0 109.737 -179.654 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -74.9 156.72 43.46 Favored 'Trans proline' 0 C--N 1.306 -1.674 0 C-N-CA 123.027 2.484 . . . . 0.0 112.14 179.831 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 80.8 46.45 7.19 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 110.03 -1.228 . . . . 0.0 110.03 179.638 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.423 HG12 ' O ' ' A' ' 107' ' ' GLY . 32.9 mm -113.01 137.24 46.7 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.393 -1.063 . . . . 0.0 109.098 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.848 ' N ' HD22 ' A' ' 111' ' ' LEU . 2.3 mm? -89.88 131.81 35.61 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.261 -0.899 . . . . 0.0 109.836 -179.383 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 58.4 m -140.28 148.22 41.1 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.393 -0.817 . . . . 0.0 109.406 179.512 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 113' ' ' MET . . . . . 0.606 ' CE ' HD21 ' A' ' 121' ' ' ASN . 85.7 mtp -96.62 136.3 37.34 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.209 -0.932 . . . . 0.0 109.298 179.834 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . 0.55 ' O ' ' ND2' ' A' ' 115' ' ' ASN . . . -71.03 143.38 50.77 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.321 -0.862 . . . . 0.0 109.813 -179.872 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . 0.729 ' H ' ' CD2' ' A' ' 139' ' ' HIS . 18.8 m120 -148.44 113.26 5.41 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.306 -0.871 . . . . 0.0 108.861 179.506 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -68.24 -31.99 71.86 Favored 'General case' 0 C--N 1.299 -1.623 0 O-C-N 121.333 -0.854 . . . . 0.0 109.655 -179.896 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -137.63 171.47 23.23 Favored Glycine 0 N--CA 1.492 2.414 0 N-CA-C 109.326 -1.51 . . . . 0.0 109.326 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -67.29 151.89 80.12 Favored 'Trans proline' 0 C--N 1.305 -1.728 0 C-N-CA 122.753 2.302 . . . . 0.0 111.732 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 75.2 m-20 52.57 44.09 30.43 Favored 'General case' 0 C--N 1.299 -1.601 0 O-C-N 121.459 -0.776 . . . . 0.0 109.294 -179.811 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 120' ' ' THR . . . . . 0.471 ' O ' ' ND2' ' A' ' 115' ' ' ASN . 79.8 m -134.62 128.34 32.95 Favored 'General case' 0 C--N 1.304 -1.394 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 179.875 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 121' ' ' ASN . . . . . 0.606 HD21 ' CE ' ' A' ' 113' ' ' MET . 21.2 t-20 -96.76 109.22 21.94 Favored 'General case' 0 C--N 1.297 -1.677 0 O-C-N 121.479 -0.763 . . . . 0.0 109.294 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -84.48 123.85 6.43 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.642 -1.383 . . . . 0.0 109.642 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 22.6 m -59.46 -33.29 71.11 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.347 -1.09 . . . . 0.0 109.542 179.806 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.8 mt-30 -75.96 144.12 41.17 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.233 -0.917 . . . . 0.0 109.926 -179.636 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 48.6 p90 -137.8 160.92 37.94 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.429 -0.794 . . . . 0.0 109.109 179.684 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . 0.602 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 52.3 p90 -142.53 159.64 41.83 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.147 -0.971 . . . . 0.0 110.012 -179.759 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 4.6 mp -119.68 138.77 49.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.474 -0.766 . . . . 0.0 109.049 179.695 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 17.1 t -121.04 126.74 50.64 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.236 -0.915 . . . . 0.0 109.599 -179.909 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -106.91 15.76 25.06 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.544 -0.722 . . . . 0.0 109.204 179.864 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -141.08 161.21 38.4 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.315 -0.866 . . . . 0.0 109.316 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 64.0 tttm -64.76 132.22 48.96 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.175 -0.953 . . . . 0.0 109.439 -179.79 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 58.6 p -147.66 69.86 1.15 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.287 -0.883 . . . . 0.0 109.24 -179.898 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -58.39 -37.85 76.14 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.295 -0.878 . . . . 0.0 110.033 -179.581 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 0.8 OUTLIER -61.46 -43.94 97.98 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.024 -1.047 . . . . 0.0 109.443 -179.875 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 28.3 mt -65.47 -30.81 71.63 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.186 -0.946 . . . . 0.0 109.754 179.326 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . 0.502 ' CB ' ' CE1' ' A' ' 105' ' ' HIS . 23.2 t70 -76.05 121.24 22.49 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.231 -0.918 . . . . 0.0 109.659 -179.627 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 178.61 -101.84 0.16 Allowed Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.202 -1.559 . . . . 0.0 109.202 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 33.4 mmtm -58.15 -28.56 64.82 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.327 -1.102 . . . . 0.0 109.058 179.506 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 139' ' ' HIS . . . . . 0.729 ' CD2' ' H ' ' A' ' 115' ' ' ASN . 56.3 m170 -83.78 153.2 24.24 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.348 -0.845 . . . . 0.0 109.479 -179.831 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 20.2 m -127.44 160.76 36.15 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 121.516 -0.74 . . . . 0.0 109.278 -179.858 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . 0.478 HG23 ' O ' ' A' ' 141' ' ' VAL . 21.5 m -96.69 129.25 47.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.245 -0.91 . . . . 0.0 109.519 -179.732 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . 0.546 ' HA ' HG21 ' A' ' 35' ' ' THR . 44.0 p90 -113.03 -9.07 13.61 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.189 -0.944 . . . . 0.0 110.271 -179.913 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -158.45 177.49 35.08 Favored Glycine 0 N--CA 1.492 2.41 0 C-N-CA 119.567 -1.302 . . . . 0.0 109.87 179.703 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . 0.403 ' HG2' ' N ' ' A' ' 145' ' ' VAL . 47.8 tt0 -139.63 158.78 43.53 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.303 -1.116 . . . . 0.0 109.633 -179.549 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . 0.511 HG23 HD21 ' A' ' 111' ' ' LEU . 13.2 t -94.73 134.07 33.44 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.235 0 O-C-N 121.042 -1.036 . . . . 0.0 109.241 179.666 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 17.4 m -112.03 -26.14 3.22 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.407 -0.808 . . . . 0.0 109.512 179.607 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 94.9 mt-10 -145.78 173.07 12.43 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.238 -0.914 . . . . 0.0 109.541 -179.878 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 98.51 2.35 57.64 Favored Glycine 0 N--CA 1.494 2.511 0 N-CA-C 110.085 -1.206 . . . . 0.0 110.085 179.486 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 149' ' ' MET . . . . . 0.467 ' O ' HG12 ' A' ' 152' ' ' VAL . 65.1 mtt -61.15 -33.07 72.82 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.035 -1.274 . . . . 0.0 109.736 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 89.1 m-20 -64.91 -42.13 94.99 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 120.765 -1.209 . . . . 0.0 110.036 -179.556 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.7 p -82.6 -34.46 11.83 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.078 -1.014 . . . . 0.0 110.485 -179.313 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 152' ' ' VAL . . . . . 0.467 HG12 ' O ' ' A' ' 149' ' ' MET . 0.8 OUTLIER -54.92 -41.82 60.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 120.963 -1.086 . . . . 0.0 109.188 -179.323 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 153' ' ' LYS . . . . . 0.453 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 59.1 mttp -64.25 -34.17 77.49 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.263 -0.898 . . . . 0.0 109.473 179.393 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -62.26 -37.36 85.15 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.308 -0.87 . . . . 0.0 110.217 -179.398 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 79.5 mt -71.96 -36.99 59.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.054 -1.029 . . . . 0.0 110.059 -179.752 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -74.08 -41.75 61.22 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.135 -0.978 . . . . 0.0 111.227 -178.706 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 17.4 pttp -61.69 -33.72 74.51 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 120.749 -1.219 . . . . 0.0 109.734 -179.001 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 27.2 m -86.39 -1.15 7.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.119 -0.988 . . . . 0.0 109.044 179.501 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -74.7 174.22 51.13 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.782 -1.327 . . . . 0.0 109.782 -179.706 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 97.0 p -152.33 162.94 40.44 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.328 -1.101 . . . . 0.0 109.942 -179.64 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 22.8 t -58.9 -31.49 68.66 Favored 'General case' 0 N--CA 1.488 1.441 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 179.297 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 23.1 t -55.96 -30.46 61.76 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.427 -0.796 . . . . 0.0 109.069 179.729 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 100.42 10.12 45.43 Favored Glycine 0 N--CA 1.493 2.489 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 179.784 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 34.5 mmt180 -118.26 147.63 43.24 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.224 -1.162 . . . . 0.0 109.282 179.713 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 165' ' ' THR . . . . . 0.556 HG22 HG21 ' A' ' 69' ' ' VAL . 82.1 p -81.64 152.72 27.0 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.364 -0.835 . . . . 0.0 109.384 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -65.98 -34.27 77.71 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.289 -0.882 . . . . 0.0 109.587 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 62.1 mttm -118.22 162.08 18.84 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.467 -0.77 . . . . 0.0 109.656 -179.664 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 62.8 mttp -75.15 142.44 43.56 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.355 -0.841 . . . . 0.0 109.594 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 1.8 m -133.45 124.67 49.0 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.308 -0.87 . . . . 0.0 109.738 179.763 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 88.8 t -139.45 142.26 33.49 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.461 -0.774 . . . . 0.0 109.395 179.769 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.947 HG22 ' H ' ' A' ' 64' ' ' SER . 3.0 m -71.69 124.84 29.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.014 -1.054 . . . . 0.0 109.55 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 77.9 mm-40 -70.88 -37.72 73.04 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.09 -1.006 . . . . 0.0 110.251 -179.669 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 173' ' ' ASP . . . . . 0.463 ' OD1' ' N ' ' A' ' 174' ' ' CYS . 49.5 t0 -164.84 166.62 19.54 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.063 -1.023 . . . . 0.0 110.032 -179.668 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 174' ' ' CYS . . . . . 0.463 ' N ' ' OD1' ' A' ' 173' ' ' ASP . 12.3 p -141.59 152.34 43.96 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.395 -0.815 . . . . 0.0 109.366 179.803 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -175.52 178.92 47.0 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.649 -1.38 . . . . 0.0 109.649 179.937 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 176' ' ' GLN . . . . . 0.712 HE22 ' NE ' ' A' ' 43' ' ' ARG . 63.3 tt0 -108.12 127.89 54.21 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.373 -1.075 . . . . 0.0 109.528 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 177' ' ' LEU . . . . . 0.603 HD13 ' O ' ' A' ' 177' ' ' LEU . 0.2 OUTLIER -61.24 -38.8 87.94 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.22 -0.925 . . . . 0.0 108.718 179.694 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 9.6 t . . . . . 0 N--CA 1.49 1.544 0 CA-C-O 117.979 -1.01 . . . . 0.0 109.47 179.81 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.459 ' ND2' ' O ' ' A' ' 10' ' ' PRO . 1.5 t30 . . . . . 0 N--CA 1.49 1.543 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . 0.459 ' O ' ' ND2' ' A' ' 9' ' ' ASN . 53.1 Cg_endo -68.34 140.22 47.87 Favored 'Trans proline' 0 N--CA 1.496 1.645 0 C-N-CA 122.424 2.082 . . . . 0.0 112.211 179.826 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 58.6 mtm180 -132.26 132.44 43.04 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.436 -0.79 . . . . 0.0 109.018 179.537 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.5 p -135.91 143.95 34.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.316 -0.865 . . . . 0.0 109.311 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 33.2 p90 -139.4 152.69 47.3 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.33 -0.856 . . . . 0.0 109.792 -179.633 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 94.3 m-85 -123.26 128.65 50.26 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.595 -0.69 . . . . 0.0 109.546 179.475 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.4 t0 -90.31 119.05 30.28 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.14 -0.975 . . . . 0.0 108.94 179.303 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' MET . . . . . 0.411 ' CE ' ' CE1' ' A' ' 66' ' ' PHE . 67.0 mtp -117.13 143.32 45.95 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.217 -0.927 . . . . 0.0 110.375 -179.315 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.465 ' HG ' ' CD ' ' A' ' 172' ' ' GLU . 50.8 m -132.16 155.14 48.71 Favored 'General case' 0 N--CA 1.491 1.612 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 179.639 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.433 HG23 ' O ' ' A' ' 18' ' ' VAL . 25.4 m -114.87 132.53 63.81 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.234 -0.917 . . . . 0.0 109.657 -179.765 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 65.86 9.9 48.33 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 179.836 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 93.36 -3.89 72.86 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.302 -1.519 . . . . 0.0 109.302 -179.951 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 33.9 mt-30 -99.11 128.39 32.18 Favored Pre-proline 0 N--CA 1.492 1.634 0 O-C-N 121.371 -1.076 . . . . 0.0 109.071 179.806 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 76.1 Cg_exo -43.69 130.11 7.3 Favored 'Trans proline' 0 C--N 1.312 -1.387 0 C-N-CA 122.12 1.88 . . . . 0.0 112.126 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -104.07 -65.25 1.03 Allowed 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.375 -0.828 . . . . 0.0 109.345 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -169.46 -171.21 34.87 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 92.2 mtm-85 -114.1 143.13 45.29 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.385 -1.068 . . . . 0.0 109.465 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 76.4 mt -120.95 117.84 54.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 179.091 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 41.8 t -116.38 132.8 64.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.552 -0.718 . . . . 0.0 109.327 -179.541 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 73.1 mtm -121.48 149.88 42.41 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.464 -0.772 . . . . 0.0 109.209 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -99.88 129.82 46.0 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.24 -0.912 . . . . 0.0 109.822 -179.636 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.429 ' N ' ' CD2' ' A' ' 30' ' ' LEU . 2.5 mm? -105.84 130.75 53.75 Favored 'General case' 0 N--CA 1.493 1.682 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.376 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -94.91 119.33 33.28 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.111 -0.993 . . . . 0.0 109.205 179.739 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -82.14 -42.67 18.76 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.361 -0.837 . . . . 0.0 109.803 -179.764 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -67.19 -44.74 78.88 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.278 -0.889 . . . . 0.0 110.514 -179.266 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . 0.441 HG21 ' HE2' ' A' ' 103' ' ' LYS . 23.2 m -66.93 -45.35 78.14 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.175 -0.953 . . . . 0.0 109.959 -179.296 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 68.9 p -150.39 83.32 6.0 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 121.285 -0.884 . . . . 0.0 109.468 -179.691 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -70.92 -44.36 1.32 Allowed 'Trans proline' 0 C--N 1.308 -1.595 0 C-N-CA 122.19 1.927 . . . . 0.0 112.087 -179.702 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.431 ' O ' ' OH ' ' A' ' 92' ' ' TYR . 25.4 mtp180 -62.59 -39.63 94.32 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.465 -0.772 . . . . 0.0 110.201 -179.862 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 32.4 m -66.07 -41.76 90.3 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.116 -0.99 . . . . 0.0 110.086 -179.736 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -61.81 -31.04 71.24 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.228 -0.92 . . . . 0.0 109.324 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -68.19 -37.7 81.22 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.219 -0.926 . . . . 0.0 109.85 -179.755 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' ASN . . . . . 0.41 ' O ' HD23 ' A' ' 45' ' ' LEU . 51.9 t30 -57.45 -42.16 81.97 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.205 -0.935 . . . . 0.0 109.79 -179.437 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 -86.13 -48.07 8.93 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.151 -0.968 . . . . 0.0 109.754 -179.842 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 40.2 ttp180 -57.87 -39.47 77.88 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.457 -0.777 . . . . 0.0 110.3 -179.482 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.506 ' O ' ' N ' ' A' ' 48' ' ' GLY . . . -64.31 -43.13 95.66 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.04 -1.038 . . . . 0.0 110.451 -179.117 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.497 HD13 ' HB3' ' A' ' 59' ' ' LEU . 2.8 mm? -65.19 -40.02 93.66 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.008 -1.057 . . . . 0.0 109.655 -179.852 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' CYS . . . . . . . . . . . . . 75.7 m -69.22 -49.54 55.53 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.023 -1.048 . . . . 0.0 109.444 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 73.9 p -74.07 -34.04 63.89 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.18 -0.95 . . . . 0.0 109.554 179.828 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . 0.506 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 75.22 35.22 49.4 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 110.395 -1.082 . . . . 0.0 110.395 179.643 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -61.53 -37.26 83.1 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.005 -1.291 . . . . 0.0 109.235 179.836 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 48.2 mmtm -61.76 -33.59 74.35 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.343 -0.848 . . . . 0.0 109.384 179.783 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 94.35 167.54 36.98 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.295 -1.522 . . . . 0.0 109.295 -179.762 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.525 HG23 ' HA ' ' A' ' 58' ' ' PRO . 99.2 m -80.2 141.05 36.01 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.293 -1.121 . . . . 0.0 109.729 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -59.03 137.55 50.35 Favored Glycine 0 N--CA 1.489 2.173 0 N-CA-C 109.305 -1.518 . . . . 0.0 109.305 179.764 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 74.5 mtt85 -58.99 -35.35 73.07 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.294 -1.121 . . . . 0.0 109.913 -179.701 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 22.9 t -57.67 -31.9 66.79 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.25 -0.906 . . . . 0.0 109.887 -179.769 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 117.86 91.22 1.49 Allowed Glycine 0 N--CA 1.495 2.626 0 N-CA-C 108.896 -1.681 . . . . 0.0 108.896 -179.503 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . 0.492 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 78.6 tttt -176.62 80.21 0.27 Allowed Pre-proline 0 N--CA 1.488 1.459 0 O-C-N 121.546 -0.973 . . . . 0.0 108.442 -179.666 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.525 ' HA ' HG23 ' A' ' 52' ' ' THR . 72.5 Cg_exo -48.99 134.51 29.2 Favored 'Trans proline' 0 C--N 1.304 -1.794 0 C-N-CA 122.727 2.285 . . . . 0.0 112.457 -179.097 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.497 ' HB3' HD13 ' A' ' 45' ' ' LEU . 7.7 mp -100.5 71.67 1.54 Allowed 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.621 -0.674 . . . . 0.0 109.4 -179.557 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 79.9 m80 -147.06 130.52 16.73 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.197 -0.939 . . . . 0.0 109.887 179.902 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 58.8 m-85 -72.67 -5.04 34.83 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.119 -0.988 . . . . 0.0 108.402 178.748 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 50.4 tttt -53.54 140.58 28.01 Favored 'General case' 0 N--CA 1.487 1.409 0 O-C-N 121.622 -0.674 . . . . 0.0 109.973 -179.501 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 53.7 t0 56.97 43.5 24.52 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.572 -0.705 . . . . 0.0 110.28 179.646 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.739 ' H ' ' CG1' ' A' ' 171' ' ' VAL . 95.6 p -109.79 150.33 28.52 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.157 -0.965 . . . . 0.0 108.68 179.094 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 38.4 t -102.97 141.42 35.81 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.171 -0.956 . . . . 0.0 109.004 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.411 ' CE1' ' CE ' ' A' ' 16' ' ' MET . 3.2 m-85 -66.66 138.72 57.64 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.291 -0.88 . . . . 0.0 109.021 -179.728 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 81.5 t60 -59.05 -52.19 66.81 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.299 -0.876 . . . . 0.0 110.298 -178.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 15.5 ptm180 -166.68 164.01 16.72 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.083 -1.011 . . . . 0.0 109.952 -179.807 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.519 HG21 HG22 ' A' ' 165' ' ' THR . 33.9 m -131.98 147.86 32.3 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.48 -0.762 . . . . 0.0 109.169 179.678 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.408 HG21 HD13 ' A' ' 70' ' ' ILE . 11.6 mt -147.74 108.24 3.77 Favored Pre-proline 0 N--CA 1.492 1.648 0 O-C-N 120.965 -1.084 . . . . 0.0 109.74 179.72 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_exo -54.09 146.04 50.44 Favored 'Trans proline' 0 N--CA 1.493 1.485 0 C-N-CA 122.427 2.085 . . . . 0.0 112.448 179.723 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 77.57 -57.81 3.78 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 110.212 -1.155 . . . . 0.0 110.212 179.273 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 95.5 m-85 -69.67 -83.85 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.166 -1.197 . . . . 0.0 109.819 -179.498 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' MET . . . . . 0.471 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 12.2 ptp -178.93 -172.36 0.25 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.255 -0.903 . . . . 0.0 109.59 -179.764 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -127.76 137.15 52.33 Favored 'General case' 0 N--CA 1.494 1.746 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 179.734 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 93.5 mt-30 -110.63 154.46 23.76 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.256 -0.902 . . . . 0.0 109.603 -179.619 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -160.83 -166.93 20.56 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.426 -1.47 . . . . 0.0 109.426 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 88.74 23.66 35.28 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.439 ' C ' ' OD1' ' A' ' 79' ' ' ASP . 54.6 p30 -84.13 10.54 9.9 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.179 -1.189 . . . . 0.0 109.377 179.922 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 85.2 t80 -53.25 -46.25 69.12 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.36 -0.837 . . . . 0.0 109.804 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.579 ' O ' ' HB2' ' A' ' 82' ' ' ALA . 71.9 p -71.17 -28.71 64.45 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.013 -1.055 . . . . 0.0 109.568 179.906 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . 0.579 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 171.26 -57.46 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.205 -0.935 . . . . 0.0 109.405 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 93.65 1.51 65.89 Favored Glycine 0 N--CA 1.492 2.402 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 -180.0 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 23.6 m120 -86.61 6.31 31.57 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.244 -1.15 . . . . 0.0 109.446 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 95.79 -39.13 2.91 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.327 -1.509 . . . . 0.0 109.327 -179.781 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 52.2 p -74.14 -16.14 61.01 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.336 -1.096 . . . . 0.0 109.055 179.594 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -82.85 -167.25 40.7 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.671 -1.372 . . . . 0.0 109.671 -179.913 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.555 ' N ' ' OG1' ' A' ' 81' ' ' THR . . . 83.85 38.42 10.47 Favored Glycine 0 N--CA 1.488 2.104 0 N-CA-C 109.154 -1.578 . . . . 0.0 109.154 -179.708 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -57.42 144.87 34.77 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.46 -1.024 . . . . 0.0 109.671 -179.774 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 96.4 p -112.26 150.24 31.23 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.449 -0.782 . . . . 0.0 109.191 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 24.0 pt -70.82 -31.48 45.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.171 -0.956 . . . . 0.0 110.059 -179.684 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . 0.431 ' OH ' ' O ' ' A' ' 37' ' ' ARG . 59.2 m-85 -65.38 -37.99 88.68 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.166 -0.959 . . . . 0.0 109.7 -179.65 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 73.22 15.63 78.75 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -148.16 158.72 44.23 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.301 -1.117 . . . . 0.0 109.455 -179.834 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 63.4 mttp -84.95 150.29 25.03 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.366 -0.834 . . . . 0.0 109.473 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 55.4 p90 -132.25 160.52 35.94 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.279 -0.888 . . . . 0.0 109.538 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -110.52 154.18 24.06 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.496 -0.752 . . . . 0.0 109.723 -179.801 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 60.3 t0 -78.48 124.13 27.8 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.264 -0.897 . . . . 0.0 109.306 179.76 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 78.5 mm-40 -60.88 -37.49 82.35 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.278 -0.889 . . . . 0.0 110.003 -179.457 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 19.1 t-20 -166.51 171.11 12.14 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.95 -1.094 . . . . 0.0 109.943 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -109.81 44.09 1.25 Allowed 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.521 -0.737 . . . . 0.0 109.373 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 89.0 mt -52.32 -41.84 35.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.105 -0.997 . . . . 0.0 109.818 -179.514 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' LYS . . . . . 0.441 ' HE2' HG21 ' A' ' 34' ' ' THR . 59.6 mttm -91.72 144.42 25.53 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.144 -0.972 . . . . 0.0 109.756 -179.686 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 80.2 tttt -134.38 159.13 42.01 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.371 -0.831 . . . . 0.0 109.444 -179.788 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' HIS . . . . . 0.526 ' CE1' ' O ' ' A' ' 107' ' ' GLY . 70.7 t60 -89.63 111.29 22.2 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.304 -0.873 . . . . 0.0 109.264 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 48.2 p -125.86 1.22 7.37 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.364 -0.835 . . . . 0.0 109.942 -179.797 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.526 ' O ' ' CE1' ' A' ' 105' ' ' HIS . . . -155.62 170.32 33.53 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.811 -1.316 . . . . 0.0 109.811 -179.771 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -75.07 156.24 42.68 Favored 'Trans proline' 0 C--N 1.308 -1.573 0 C-N-CA 123.026 2.484 . . . . 0.0 112.213 179.614 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 84.15 43.27 7.16 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 110.328 -1.109 . . . . 0.0 110.328 179.51 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 37.1 mm -115.25 134.41 58.47 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.834 0 O-C-N 121.312 -1.111 . . . . 0.0 109.172 179.592 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.72 ' N ' HD22 ' A' ' 111' ' ' LEU . 2.9 mm? -90.36 124.91 35.31 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.237 -0.915 . . . . 0.0 109.22 179.903 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 50.4 m -137.95 144.96 41.46 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.208 -0.933 . . . . 0.0 109.779 179.806 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 87.8 mtp -90.35 131.41 36.15 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.352 -0.842 . . . . 0.0 109.114 179.429 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . 0.409 ' O ' ' OD1' ' A' ' 115' ' ' ASN . . . -65.73 143.76 57.32 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.195 -0.94 . . . . 0.0 109.513 -179.829 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . 0.409 ' OD1' ' O ' ' A' ' 114' ' ' ALA . 72.2 m-20 -144.22 113.31 6.85 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.174 -0.954 . . . . 0.0 108.976 179.601 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -70.22 -30.03 67.01 Favored 'General case' 0 C--N 1.297 -1.691 0 O-C-N 121.465 -0.772 . . . . 0.0 109.581 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -140.33 167.16 25.58 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.486 -1.446 . . . . 0.0 109.486 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . 0.533 ' O ' ' ND2' ' A' ' 119' ' ' ASN . 41.0 Cg_endo -67.26 158.36 57.33 Favored 'Trans proline' 0 C--N 1.305 -1.726 0 C-N-CA 122.875 2.383 . . . . 0.0 111.893 179.952 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 119' ' ' ASN . . . . . 0.533 ' ND2' ' O ' ' A' ' 118' ' ' PRO . 9.5 p30 45.41 45.44 10.18 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.514 -0.741 . . . . 0.0 109.543 -179.898 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 89.4 m -134.61 132.26 38.81 Favored 'General case' 0 C--N 1.305 -1.332 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 179.684 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 43.3 p-10 -64.82 162.86 15.32 Favored 'General case' 0 C--N 1.295 -1.768 0 O-C-N 121.343 -0.848 . . . . 0.0 109.309 -179.807 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -109.74 101.47 1.45 Allowed Glycine 0 N--CA 1.494 2.517 0 N-CA-C 109.83 -1.308 . . . . 0.0 109.83 -179.7 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 86.1 p -63.12 -28.15 69.87 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.215 -1.167 . . . . 0.0 109.059 179.543 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.0 mt-30 -125.98 158.31 35.61 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.545 -0.722 . . . . 0.0 109.204 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 49.0 p90 -134.53 163.05 30.58 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.268 -0.895 . . . . 0.0 109.51 -179.925 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . 0.471 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 48.3 p90 -134.44 157.54 46.18 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.312 -0.867 . . . . 0.0 109.414 179.927 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 61.5 mt -122.97 134.35 66.38 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 O-C-N 121.391 -0.818 . . . . 0.0 109.581 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 2.9 t -108.68 125.2 51.63 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.211 -0.931 . . . . 0.0 109.155 179.65 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . 0.448 ' OG1' ' OE1' ' A' ' 156' ' ' GLU . 7.3 p -114.22 18.05 17.27 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.388 -0.82 . . . . 0.0 109.61 -179.656 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -145.84 162.32 37.98 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.144 -0.973 . . . . 0.0 109.883 -179.548 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 62.5 tttm -59.87 134.11 56.72 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.365 -0.834 . . . . 0.0 109.093 179.863 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . 0.437 ' OG1' ' OD1' ' A' ' 136' ' ' ASP . 21.9 p -79.17 105.48 10.53 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.26 -0.9 . . . . 0.0 109.909 -179.485 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -66.21 -38.39 87.85 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.087 -1.008 . . . . 0.0 108.672 179.198 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 20.4 p90 -155.31 6.55 0.24 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.44 -0.787 . . . . 0.0 109.968 179.458 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . 0.607 ' N ' HD22 ' A' ' 135' ' ' LEU . 3.5 mm? -68.65 -28.01 66.51 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.027 -1.045 . . . . 0.0 109.328 179.562 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . 0.437 ' OD1' ' OG1' ' A' ' 132' ' ' THR . 93.8 m-20 -52.38 144.85 12.27 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.357 -0.839 . . . . 0.0 110.025 -179.336 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 171.02 -128.38 1.6 Allowed Glycine 0 N--CA 1.489 2.202 0 N-CA-C 108.793 -1.723 . . . . 0.0 108.793 -179.909 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 4.3 mptp? -89.86 123.06 33.49 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.077 -1.249 . . . . 0.0 108.851 179.376 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 32.0 p80 -168.96 159.37 9.33 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.181 -0.95 . . . . 0.0 109.745 -179.787 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 38.9 t -123.46 136.65 59.34 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 O-C-N 121.389 -0.819 . . . . 0.0 109.317 179.896 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . 0.451 HG23 ' O ' ' A' ' 141' ' ' VAL . 17.6 m -108.58 131.41 59.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.231 -0.918 . . . . 0.0 109.014 179.77 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 39.7 p90 -117.01 -4.08 11.53 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.407 -0.808 . . . . 0.0 109.992 -179.609 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -165.53 179.2 40.04 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.648 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.2 pt20 -144.3 165.28 28.33 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.186 -1.185 . . . . 0.0 109.661 -179.787 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 60.4 t -97.56 130.1 46.73 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.224 0 O-C-N 121.269 -0.894 . . . . 0.0 109.449 -179.92 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 16.3 m -106.06 -32.45 2.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.37 -0.832 . . . . 0.0 109.48 179.612 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -144.6 174.37 11.01 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.174 -0.954 . . . . 0.0 109.526 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 99.12 1.21 57.06 Favored Glycine 0 N--CA 1.494 2.509 0 N-CA-C 109.974 -1.25 . . . . 0.0 109.974 179.569 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 149' ' ' MET . . . . . 0.436 ' O ' HG12 ' A' ' 152' ' ' VAL . 65.1 mtt -60.93 -34.16 74.28 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.105 -1.232 . . . . 0.0 109.718 179.945 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -64.51 -42.77 95.59 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.89 -1.131 . . . . 0.0 110.138 -179.576 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.7 p -83.08 -34.04 10.87 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.113 -0.992 . . . . 0.0 110.518 -179.486 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 152' ' ' VAL . . . . . 0.459 ' CG1' ' N ' ' A' ' 153' ' ' LYS . 0.6 OUTLIER -55.52 -41.65 64.53 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 120.889 -1.132 . . . . 0.0 109.122 -179.36 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 153' ' ' LYS . . . . . 0.459 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 57.3 mttp -63.23 -33.63 75.91 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.281 -0.887 . . . . 0.0 109.486 179.417 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -62.26 -40.52 96.49 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.327 -0.858 . . . . 0.0 109.873 -179.575 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 78.4 mt -72.92 -34.34 45.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.083 -1.011 . . . . 0.0 109.61 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . 0.448 ' OE1' ' OG1' ' A' ' 129' ' ' THR . 78.9 tt0 -75.95 -42.33 48.93 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.216 -0.928 . . . . 0.0 111.258 -178.796 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 43.2 pttt -61.84 -33.9 74.98 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 120.808 -1.183 . . . . 0.0 109.985 -178.831 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 34.5 m -80.34 -10.29 12.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.136 -0.978 . . . . 0.0 109.249 179.73 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -71.28 165.11 53.59 Favored Glycine 0 N--CA 1.488 2.163 0 N-CA-C 110.074 -1.21 . . . . 0.0 110.074 -179.487 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 22.8 t -155.17 171.39 19.88 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.537 -0.978 . . . . 0.0 109.34 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 24.9 m -54.44 -29.64 50.07 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.199 -0.938 . . . . 0.0 109.346 179.891 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 87.1 p -57.8 -26.6 62.18 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.282 -0.886 . . . . 0.0 109.663 -179.759 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 89.65 15.52 58.12 Favored Glycine 0 N--CA 1.493 2.437 0 N-CA-C 109.823 -1.311 . . . . 0.0 109.823 179.746 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 61.6 ttt180 -126.72 140.67 52.21 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.226 -1.161 . . . . 0.0 109.489 -179.941 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 165' ' ' THR . . . . . 0.519 HG22 HG21 ' A' ' 69' ' ' VAL . 68.7 p -75.08 148.66 39.56 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.157 -0.965 . . . . 0.0 109.279 179.813 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -66.12 -39.3 89.81 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.243 -0.911 . . . . 0.0 109.542 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -103.2 155.68 18.26 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.321 -0.862 . . . . 0.0 109.45 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 64.2 mttp -73.74 130.8 40.71 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.222 -0.924 . . . . 0.0 109.197 179.832 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 13.7 t -128.15 125.02 63.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.142 -0.974 . . . . 0.0 109.515 -179.827 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 62.7 t -142.08 135.01 28.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.267 -0.896 . . . . 0.0 109.343 179.332 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.739 ' CG1' ' H ' ' A' ' 64' ' ' SER . 0.4 OUTLIER -63.58 116.01 2.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.213 -0.929 . . . . 0.0 108.923 179.88 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 172' ' ' GLU . . . . . 0.507 ' O ' ' OD1' ' A' ' 173' ' ' ASP . 96.7 mt-10 -70.64 -40.6 72.99 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.04 -1.037 . . . . 0.0 110.649 -179.531 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 173' ' ' ASP . . . . . 0.507 ' OD1' ' O ' ' A' ' 172' ' ' GLU . 80.5 m-20 -145.13 159.03 43.62 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.08 -1.013 . . . . 0.0 110.377 -179.255 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 53.3 t -145.04 141.84 29.22 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.507 -0.746 . . . . 0.0 109.286 179.474 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -175.73 179.48 46.87 Favored Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.879 -1.288 . . . . 0.0 109.879 179.839 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 6.9 tt0 -107.87 121.75 45.4 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.32 -1.106 . . . . 0.0 109.608 -179.891 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 30.8 tp -62.66 -37.81 87.87 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.183 -0.948 . . . . 0.0 109.317 179.675 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 3.0 t . . . . . 0 N--CA 1.49 1.564 0 CA-C-O 117.977 -1.011 . . . . 0.0 109.439 -179.872 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 . . . . . 0 N--CA 1.491 1.592 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 78.2 Cg_endo -74.47 89.0 1.12 Allowed 'Trans proline' 0 C--N 1.311 -1.441 0 C-N-CA 122.48 2.12 . . . . 0.0 112.111 179.896 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 89.7 mtt-85 -72.02 134.61 45.98 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.306 -0.871 . . . . 0.0 109.578 -179.913 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.0 p -137.7 142.43 36.4 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.367 -0.833 . . . . 0.0 108.99 179.717 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 42.2 p90 -145.89 155.45 42.88 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.234 -0.916 . . . . 0.0 109.844 -179.671 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 91.1 m-85 -125.1 137.96 54.18 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.432 -0.793 . . . . 0.0 109.467 179.444 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 61.3 t0 -89.03 117.61 28.16 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.2 -0.938 . . . . 0.0 108.511 178.831 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' MET . . . . . 0.466 ' SD ' HD12 ' A' ' 26' ' ' ILE . 78.2 mtp -106.32 150.8 25.61 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.147 -0.97 . . . . 0.0 110.52 -178.997 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 84.6 p -146.5 168.65 20.69 Favored 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 109.02 -0.734 . . . . 0.0 109.02 179.822 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.437 ' O ' ' N ' ' A' ' 20' ' ' GLY . 27.2 m -126.09 155.85 36.1 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.804 0 O-C-N 121.267 -0.896 . . . . 0.0 109.457 -179.879 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -49.47 96.61 0.01 OUTLIER Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.366 -1.494 . . . . 0.0 109.366 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.437 ' N ' ' O ' ' A' ' 18' ' ' VAL . . . 150.88 -84.82 0.16 Allowed Glycine 0 N--CA 1.493 2.438 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 -179.93 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 12.9 mt-30 -139.36 160.67 60.98 Favored Pre-proline 0 N--CA 1.494 1.741 0 O-C-N 121.357 -1.084 . . . . 0.0 109.037 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_exo -47.74 134.15 22.22 Favored 'Trans proline' 0 C--N 1.312 -1.392 0 C-N-CA 122.251 1.967 . . . . 0.0 112.247 179.739 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -89.58 -60.32 1.97 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.303 -0.873 . . . . 0.0 109.578 -179.86 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 176.05 -166.99 38.46 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.7 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 35.8 ptt-85 -126.01 149.22 48.98 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.466 -1.02 . . . . 0.0 109.143 179.818 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.466 HD12 ' SD ' ' A' ' 16' ' ' MET . 89.3 mt -122.3 130.32 74.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.287 -0.883 . . . . 0.0 109.346 -179.893 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 44.1 t -109.95 132.61 57.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.444 -0.785 . . . . 0.0 109.427 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 74.8 mtm -119.95 147.13 45.13 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.424 -0.798 . . . . 0.0 109.143 179.875 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.404 ' C ' HD22 ' A' ' 30' ' ' LEU . 84.5 tt0 -101.03 132.1 46.61 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.23 -0.919 . . . . 0.0 109.987 -179.359 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.414 ' N ' ' CD2' ' A' ' 30' ' ' LEU . 2.6 mm? -108.42 132.13 54.08 Favored 'General case' 0 N--CA 1.492 1.626 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 179.44 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 93.3 m-85 -96.02 116.23 28.64 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 120.966 -1.083 . . . . 0.0 108.775 179.045 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -84.72 -43.7 14.06 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.287 -0.883 . . . . 0.0 109.735 -179.705 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.0 m-20 -63.88 -49.43 72.77 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.217 -0.927 . . . . 0.0 109.879 -179.585 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 28.3 m -71.14 -41.83 69.96 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.207 -0.933 . . . . 0.0 109.417 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.517 ' O ' ' OG1' ' A' ' 35' ' ' THR . 2.3 p -135.16 79.62 49.61 Favored Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 121.531 -0.731 . . . . 0.0 109.495 -179.642 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 29.8 Cg_endo -68.48 -62.83 0.05 OUTLIER 'Trans proline' 0 N--CA 1.494 1.557 0 C-N-CA 122.338 2.025 . . . . 0.0 112.867 -179.339 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 79.2 mtp180 -61.23 -37.0 81.49 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.375 -0.828 . . . . 0.0 110.844 -178.952 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 26.8 m -60.66 -43.39 97.7 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.928 -1.107 . . . . 0.0 109.761 -179.51 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -62.83 -30.85 71.81 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.17 -0.956 . . . . 0.0 108.867 179.698 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -68.44 -38.63 81.32 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.47 -0.768 . . . . 0.0 109.899 -179.881 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 47.5 t30 -57.86 -42.52 84.7 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.318 -0.864 . . . . 0.0 109.95 -179.518 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.533 ' O ' ' SG ' ' A' ' 46' ' ' CYS . 97.8 m-85 -84.67 -46.96 10.96 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.069 -1.019 . . . . 0.0 109.938 -179.869 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.676 ' CZ ' HE22 ' A' ' 176' ' ' GLN . 77.0 ttt180 -54.21 -41.13 68.28 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.338 -0.852 . . . . 0.0 110.361 -179.285 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -66.81 -47.62 71.5 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.108 -0.995 . . . . 0.0 110.319 -178.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.474 HD13 ' HB3' ' A' ' 59' ' ' LEU . 3.2 mm? -65.28 -39.06 92.08 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.078 -1.014 . . . . 0.0 109.96 -179.515 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' CYS . . . . . 0.533 ' SG ' ' O ' ' A' ' 42' ' ' PHE . 27.6 m -64.41 -62.3 1.69 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.939 -1.101 . . . . 0.0 109.392 -179.766 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 25.3 m -64.86 -36.47 84.46 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.282 -0.886 . . . . 0.0 109.183 179.606 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 83.59 35.62 16.24 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 110.176 -1.17 . . . . 0.0 110.176 179.558 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -61.56 -38.1 86.24 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.051 -1.264 . . . . 0.0 109.266 179.674 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 29.5 mmtm -62.27 -29.75 70.63 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.283 -0.885 . . . . 0.0 109.446 179.747 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 86.06 -115.67 4.24 Favored Glycine 0 N--CA 1.488 2.13 0 N-CA-C 108.778 -1.729 . . . . 0.0 108.778 -179.103 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.544 HG23 ' HA ' ' A' ' 58' ' ' PRO . 61.6 m -129.42 142.01 50.9 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.254 -1.145 . . . . 0.0 109.553 179.455 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -64.66 136.21 38.75 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 61.7 ttp85 -55.32 -37.98 68.11 Favored 'General case' 0 C--N 1.305 -1.328 0 O-C-N 121.254 -1.145 . . . . 0.0 110.056 -179.652 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 22.9 t -57.19 -32.7 66.73 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.288 -0.883 . . . . 0.0 109.797 -179.605 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . 0.409 ' O ' ' CB ' ' A' ' 57' ' ' LYS . . . 118.59 105.1 2.21 Favored Glycine 0 N--CA 1.494 2.508 0 N-CA-C 109.014 -1.635 . . . . 0.0 109.014 -179.726 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . 0.409 ' CB ' ' O ' ' A' ' 56' ' ' GLY . 0.8 OUTLIER 167.86 82.61 0.02 OUTLIER Pre-proline 0 N--CA 1.491 1.584 0 N-CA-C 108.104 -1.073 . . . . 0.0 108.104 -179.625 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.544 ' HA ' HG23 ' A' ' 52' ' ' THR . 81.4 Cg_exo -45.97 126.15 9.1 Favored 'Trans proline' 0 C--N 1.305 -1.742 0 C-N-CA 122.579 2.186 . . . . 0.0 112.269 -178.964 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.58 ' O ' ' CG ' ' A' ' 60' ' ' HIS . 53.2 mt -95.94 130.61 42.87 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.554 -0.716 . . . . 0.0 109.711 -179.62 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . 0.58 ' CG ' ' O ' ' A' ' 59' ' ' LEU . 0.4 OUTLIER 166.51 110.03 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.258 -0.901 . . . . 0.0 109.577 179.889 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 3.6 m-85 -68.39 -3.5 11.4 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.181 -0.95 . . . . 0.0 108.603 179.163 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 34.6 ttmt -57.52 149.35 21.36 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.378 -0.827 . . . . 0.0 109.523 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . 0.424 ' H ' HG23 ' A' ' 171' ' ' VAL . 83.2 m-20 57.35 47.76 16.04 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.478 -0.764 . . . . 0.0 110.231 179.839 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.929 ' H ' HG22 ' A' ' 171' ' ' VAL . 92.3 p -104.33 156.79 17.62 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.293 -0.879 . . . . 0.0 108.907 179.257 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 29.2 t -128.9 146.54 50.92 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.153 -0.967 . . . . 0.0 109.623 -179.609 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.7 m-30 -71.81 133.92 45.81 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.283 -0.885 . . . . 0.0 108.662 179.633 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 80.7 m80 -91.02 -31.58 16.25 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.087 -1.008 . . . . 0.0 110.819 -178.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 80.0 mtp180 -135.36 138.61 43.53 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 120.951 -1.093 . . . . 0.0 110.306 -179.458 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -150.8 80.04 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 179.0 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 59.9 mt -96.99 129.39 32.54 Favored Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.345 -0.847 . . . . 0.0 109.537 -179.627 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -74.61 134.67 18.82 Favored 'Trans proline' 0 N--CA 1.491 1.349 0 C-N-CA 122.114 1.876 . . . . 0.0 112.076 179.788 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 92.96 -1.2 70.4 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.899 -1.28 . . . . 0.0 109.899 179.597 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 77.4 m-85 -132.93 -94.02 0.34 Allowed 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.098 -1.236 . . . . 0.0 109.818 179.921 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 4.5 ptt? -163.39 177.48 8.89 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.946 -1.097 . . . . 0.0 110.031 -179.601 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -129.4 131.49 46.81 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.495 -0.753 . . . . 0.0 109.039 179.94 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 50.8 tt0 -97.16 118.5 33.72 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.138 -0.976 . . . . 0.0 109.322 179.816 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -61.86 -39.31 97.33 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 81.53 167.16 38.18 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.494 -1.442 . . . . 0.0 109.494 -179.916 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -104.25 149.83 24.96 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.42 -1.047 . . . . 0.0 109.456 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 45.2 p90 -65.29 -24.17 67.22 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.18 -0.95 . . . . 0.0 109.347 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.53 ' O ' ' HB2' ' A' ' 82' ' ' ALA . 58.9 p -66.31 -31.51 72.35 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.225 -0.922 . . . . 0.0 109.657 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . 0.53 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 173.46 -53.28 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.242 -0.911 . . . . 0.0 109.44 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 92.53 3.26 66.89 Favored Glycine 0 N--CA 1.492 2.378 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 40.7 p-10 -88.27 7.53 31.69 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.162 -1.199 . . . . 0.0 109.427 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 95.21 -43.52 2.23 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 109.272 -1.531 . . . . 0.0 109.272 -179.851 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 47.1 m -60.58 -38.41 84.5 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.208 -1.172 . . . . 0.0 109.049 179.759 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -84.38 -164.67 38.1 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.473 -1.451 . . . . 0.0 109.473 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.517 ' N ' ' OG1' ' A' ' 81' ' ' THR . . . 86.98 35.51 9.8 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.511 -1.435 . . . . 0.0 109.511 -179.952 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -56.56 146.04 26.31 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.296 -1.12 . . . . 0.0 109.441 179.878 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 29.7 t -100.35 144.02 29.85 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.284 -0.885 . . . . 0.0 109.461 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 21.9 pt -64.36 -32.44 57.6 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.382 -0.824 . . . . 0.0 109.863 -179.728 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 67.7 m-85 -64.12 -37.46 87.54 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.198 -0.939 . . . . 0.0 109.437 -179.795 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 81.43 7.47 88.24 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -151.82 156.92 41.16 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.204 -1.174 . . . . 0.0 109.537 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 86.9 mttt -88.27 148.29 24.4 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.285 -0.884 . . . . 0.0 109.542 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . 0.554 ' CZ ' ' OD1' ' A' ' 121' ' ' ASN . 40.4 p90 -134.33 161.82 33.91 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.253 -0.905 . . . . 0.0 108.973 179.495 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -54.99 138.36 43.9 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.146 -0.971 . . . . 0.0 109.851 -178.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 88.2 m-20 -74.66 141.15 44.62 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.428 -0.795 . . . . 0.0 109.761 -179.901 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . 0.459 ' OE1' HG22 ' A' ' 35' ' ' THR . 96.0 mt-10 -59.82 146.36 42.1 Favored 'General case' 0 C--N 1.305 -1.37 0 O-C-N 121.322 -0.861 . . . . 0.0 109.218 179.672 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 23.0 t-20 -58.26 159.63 5.87 Favored 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.461 -0.774 . . . . 0.0 109.429 -179.87 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' PHE . . . . . 0.482 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 29.3 p90 -96.43 52.26 1.23 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.303 -0.873 . . . . 0.0 109.72 -179.721 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 88.6 mt -56.77 -39.49 64.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.123 -0.986 . . . . 0.0 109.322 179.781 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -93.03 146.16 23.84 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.154 -0.966 . . . . 0.0 109.627 179.901 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' LYS . . . . . 0.546 ' O ' HG23 ' A' ' 106' ' ' THR . 81.0 tttt -126.8 157.62 38.74 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.439 -0.788 . . . . 0.0 109.346 -179.924 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' HIS . . . . . 0.53 ' ND1' ' OD1' ' A' ' 136' ' ' ASP . 23.2 m80 -59.06 81.25 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.272 -0.893 . . . . 0.0 109.061 179.937 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . 0.546 HG23 ' O ' ' A' ' 104' ' ' LYS . 69.3 p -73.96 -22.79 59.51 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.164 -0.96 . . . . 0.0 110.147 -179.485 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.414 ' O ' HG12 ' A' ' 110' ' ' ILE . . . -152.75 177.66 30.33 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.734 -1.346 . . . . 0.0 109.734 -179.626 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -73.2 156.29 51.3 Favored 'Trans proline' 0 C--N 1.307 -1.648 0 C-N-CA 122.891 2.394 . . . . 0.0 112.193 179.793 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 109' ' ' GLY . . . . . 0.495 ' N ' ' O ' ' A' ' 128' ' ' CYS . . . 82.23 47.42 6.12 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.91 -1.276 . . . . 0.0 109.91 179.757 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.414 HG12 ' O ' ' A' ' 107' ' ' GLY . 40.7 mm -115.0 136.67 50.94 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.378 -1.071 . . . . 0.0 109.479 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.734 ' N ' HD22 ' A' ' 111' ' ' LEU . 2.7 mm? -89.32 142.34 27.74 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.349 -0.844 . . . . 0.0 109.762 -179.684 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 10.4 t -144.8 140.71 28.63 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.202 -0.936 . . . . 0.0 109.752 179.787 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 89.0 mtp -88.86 137.49 32.27 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.166 -0.959 . . . . 0.0 109.323 179.483 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . 0.418 ' HB2' ' CE2' ' A' ' 126' ' ' PHE . . . -68.9 143.52 54.47 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.202 -0.936 . . . . 0.0 109.811 -179.867 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . 0.433 ' OD1' ' O ' ' A' ' 120' ' ' THR . 47.0 t30 -140.83 151.03 44.03 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.334 -0.854 . . . . 0.0 109.474 179.737 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -132.17 -3.72 3.5 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.404 -0.81 . . . . 0.0 109.241 179.755 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -157.51 169.55 34.45 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.078 -1.609 . . . . 0.0 109.078 -179.925 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -70.66 147.91 58.13 Favored 'Trans proline' 0 C--N 1.306 -1.665 0 C-N-CA 122.603 2.202 . . . . 0.0 111.792 179.857 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 87.7 m-20 51.0 42.2 28.18 Favored 'General case' 0 C--N 1.297 -1.679 0 O-C-N 121.476 -0.765 . . . . 0.0 109.467 -179.801 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 120' ' ' THR . . . . . 0.433 ' O ' ' OD1' ' A' ' 115' ' ' ASN . 84.2 m -135.22 124.91 25.26 Favored 'General case' 0 N--CA 1.488 1.44 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 179.717 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 121' ' ' ASN . . . . . 0.554 ' OD1' ' CZ ' ' A' ' 96' ' ' PHE . 35.8 m120 -106.24 128.3 53.85 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.576 -0.703 . . . . 0.0 109.702 -179.919 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -99.52 130.84 10.35 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 179.921 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 22.9 t -60.19 -33.23 71.94 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.186 -1.185 . . . . 0.0 109.63 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 25.7 mt-30 -68.38 147.9 51.45 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.332 -0.855 . . . . 0.0 109.664 -179.668 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 50.2 p90 -137.31 161.14 37.06 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.334 -0.854 . . . . 0.0 109.209 179.905 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . 0.418 ' CE2' ' HB2' ' A' ' 114' ' ' ALA . 86.0 m-85 -118.87 151.35 38.27 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.266 -0.897 . . . . 0.0 109.711 -179.898 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 76.3 mt -116.82 134.05 61.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 N-CA-C 108.693 -0.854 . . . . 0.0 108.693 179.313 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 128' ' ' CYS . . . . . 0.495 ' O ' ' N ' ' A' ' 109' ' ' GLY . 1.3 m -121.59 132.45 54.69 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.278 -0.889 . . . . 0.0 109.389 -179.774 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . 0.425 HG21 ' OE1' ' A' ' 156' ' ' GLU . 1.7 t -116.65 8.78 13.91 Favored 'General case' 0 N--CA 1.493 1.698 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 179.652 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -141.58 165.94 26.11 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.544 -0.723 . . . . 0.0 109.109 -179.885 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 69.1 mttm -65.5 134.13 52.75 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.114 -0.991 . . . . 0.0 109.453 -179.829 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 57.3 p -141.97 70.45 1.33 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.319 -0.863 . . . . 0.0 109.295 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -61.3 -36.16 79.33 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.277 -0.889 . . . . 0.0 109.992 -179.56 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 0.8 OUTLIER -62.6 -43.15 99.54 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.014 -1.054 . . . . 0.0 109.51 -179.942 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 25.0 mt -65.49 -33.84 76.88 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.14 -0.975 . . . . 0.0 109.765 179.508 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . 0.53 ' OD1' ' ND1' ' A' ' 105' ' ' HIS . 87.3 m-20 -65.76 141.59 58.27 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.277 -0.889 . . . . 0.0 109.611 -179.754 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 153.79 -92.83 0.13 Allowed Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . 0.418 ' HD2' ' N ' ' A' ' 138' ' ' LYS . 1.1 mptp? -87.7 10.54 17.89 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.333 -1.098 . . . . 0.0 109.523 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 63.3 m170 -96.41 140.74 30.63 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.235 -0.915 . . . . 0.0 109.594 -179.751 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 44.9 t -115.37 138.16 46.6 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 O-C-N 121.442 -0.786 . . . . 0.0 109.473 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . 0.439 HG23 ' O ' ' A' ' 141' ' ' VAL . 11.2 m -100.72 132.17 46.91 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.332 -0.855 . . . . 0.0 109.224 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 41.4 p90 -110.08 -11.08 14.65 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.222 -0.924 . . . . 0.0 110.219 -179.544 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -157.77 179.75 33.27 Favored Glycine 0 N--CA 1.493 2.458 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 179.738 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.5 pt20 -144.3 165.22 28.51 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.086 -1.244 . . . . 0.0 109.717 -179.749 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 75.6 t -97.12 129.66 46.86 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.19 0 O-C-N 121.318 -0.864 . . . . 0.0 109.299 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 16.1 m -101.86 -35.28 4.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.394 -0.816 . . . . 0.0 109.882 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 90.1 mt-10 -144.95 170.59 15.85 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.149 -0.97 . . . . 0.0 109.745 -179.819 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 97.78 4.14 58.02 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 110.315 -1.114 . . . . 0.0 110.315 179.308 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 149' ' ' MET . . . . . 0.49 ' O ' HG12 ' A' ' 152' ' ' VAL . 65.1 mtt -60.53 -32.37 71.41 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 120.991 -1.299 . . . . 0.0 109.518 179.872 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -64.79 -41.75 95.59 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 120.9 -1.125 . . . . 0.0 110.084 -179.652 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 6.6 p -82.21 -33.59 11.6 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.2 -0.938 . . . . 0.0 110.679 -179.425 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 152' ' ' VAL . . . . . 0.49 HG12 ' O ' ' A' ' 149' ' ' MET . 0.9 OUTLIER -55.82 -42.38 70.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 120.901 -1.124 . . . . 0.0 109.249 -179.304 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 153' ' ' LYS . . . . . 0.459 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 91.1 mttt -65.49 -35.49 81.03 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.043 -1.035 . . . . 0.0 109.409 179.429 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -63.01 -38.15 90.06 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.383 -0.823 . . . . 0.0 109.996 -179.532 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.46 HD13 ' CE ' ' A' ' 16' ' ' MET . 84.7 mt -71.09 -38.44 71.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.295 -0.878 . . . . 0.0 110.594 -179.555 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . 0.425 ' OE1' HG21 ' A' ' 129' ' ' THR . 83.1 tt0 -78.1 -39.25 41.99 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.1 -1.0 . . . . 0.0 111.573 -178.395 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 31.6 pttt -61.0 -34.16 74.39 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 120.723 -1.236 . . . . 0.0 110.21 -178.682 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.459 HG22 ' O ' ' A' ' 155' ' ' ILE . 23.8 m -69.8 -15.65 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 120.96 -1.087 . . . . 0.0 109.047 179.786 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -79.05 177.29 54.31 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 23.2 t -152.02 173.51 14.79 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.321 -1.105 . . . . 0.0 109.239 -179.855 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 23.4 m -53.09 -34.89 58.63 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.073 -1.017 . . . . 0.0 108.992 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 24.6 m -59.11 -30.33 68.04 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.373 -0.829 . . . . 0.0 109.363 179.527 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 96.82 11.14 54.23 Favored Glycine 0 N--CA 1.494 2.507 0 N-CA-C 109.35 -1.5 . . . . 0.0 109.35 -179.701 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 88.8 mtt180 -109.25 158.12 18.16 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.369 -1.077 . . . . 0.0 109.02 179.73 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 165' ' ' THR . . . . . . . . . . . . . 43.1 p -116.38 156.82 26.07 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.203 -0.936 . . . . 0.0 110.366 -179.399 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -68.17 -34.72 76.82 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.55 -0.718 . . . . 0.0 109.476 179.624 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -121.98 156.5 33.31 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.481 -0.762 . . . . 0.0 109.473 -179.73 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 90.5 mttt -80.7 141.16 35.14 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.298 -0.876 . . . . 0.0 109.301 -179.904 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 40.6 t -121.74 126.08 74.2 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.341 -0.849 . . . . 0.0 109.7 -179.88 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 43.5 t -141.57 140.68 30.88 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.275 -0.891 . . . . 0.0 109.202 179.712 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.929 HG22 ' H ' ' A' ' 64' ' ' SER . 4.0 m -68.58 123.24 21.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.118 -0.989 . . . . 0.0 109.464 179.935 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -68.65 -36.75 78.99 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.008 -1.057 . . . . 0.0 110.046 -179.802 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -160.04 163.05 34.29 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.073 -1.017 . . . . 0.0 110.07 -179.594 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 16.0 p -146.6 149.78 34.21 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.418 -0.801 . . . . 0.0 109.434 179.759 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . 176.84 -178.83 48.04 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 179.892 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 176' ' ' GLN . . . . . 0.676 HE22 ' CZ ' ' A' ' 43' ' ' ARG . 60.4 tt0 -106.69 120.26 41.52 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.343 -1.092 . . . . 0.0 109.651 -179.952 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 177' ' ' LEU . . . . . 0.437 ' O ' ' C ' ' A' ' 178' ' ' SER . 30.3 tp -61.9 -39.34 91.66 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.138 -0.976 . . . . 0.0 109.153 179.454 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 178' ' ' SER . . . . . 0.437 ' C ' ' O ' ' A' ' 177' ' ' LEU . 5.6 p . . . . . 0 N--CA 1.492 1.673 0 CA-C-O 118.046 -0.978 . . . . 0.0 109.806 179.898 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 6.8 m-20 . . . . . 0 N--CA 1.488 1.47 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -65.75 133.77 35.25 Favored 'Trans proline' 0 C--N 1.309 -1.55 0 C-N-CA 122.448 2.099 . . . . 0.0 112.24 -179.695 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 97.4 mtt180 -131.57 129.74 41.34 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.411 -0.805 . . . . 0.0 108.879 179.203 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.5 p -135.88 142.26 39.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.366 -0.834 . . . . 0.0 109.363 -179.822 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 45.1 p90 -142.31 153.4 43.85 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.418 -0.801 . . . . 0.0 109.573 -179.812 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -121.37 134.88 55.13 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.385 -0.822 . . . . 0.0 109.318 179.54 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -90.6 114.75 27.07 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.182 -0.949 . . . . 0.0 108.945 179.485 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' MET . . . . . 0.405 ' SD ' ' CD1' ' A' ' 26' ' ' ILE . 85.1 mtp -102.56 152.19 21.45 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.311 -0.868 . . . . 0.0 110.452 -179.404 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 96.5 p -143.15 163.15 33.68 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.781 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.53 ' O ' ' N ' ' A' ' 20' ' ' GLY . 29.4 m -123.43 139.8 48.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 121.07 -1.019 . . . . 0.0 109.501 -179.953 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 47.01 13.96 0.11 Allowed Glycine 0 N--CA 1.492 2.406 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 179.928 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.53 ' N ' ' O ' ' A' ' 18' ' ' VAL . . . 98.78 -16.3 59.76 Favored Glycine 0 N--CA 1.493 2.447 0 N-CA-C 109.616 -1.393 . . . . 0.0 109.616 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' GLN . . . . . 0.492 ' N ' ' O ' ' A' ' 18' ' ' VAL . 64.5 mm-40 -81.69 146.12 55.89 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.169 -1.195 . . . . 0.0 109.216 179.812 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_endo -63.48 138.89 67.7 Favored 'Trans proline' 0 N--CA 1.494 1.528 0 C-N-CA 122.366 2.044 . . . . 0.0 112.174 -179.736 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -112.6 -66.2 1.11 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.319 -0.863 . . . . 0.0 109.452 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -175.81 -169.97 38.06 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.315 -1.514 . . . . 0.0 109.315 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 71.3 mtp180 -114.95 144.03 44.22 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.226 -1.161 . . . . 0.0 109.587 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.405 ' CD1' ' SD ' ' A' ' 16' ' ' MET . 84.0 mt -120.72 116.07 48.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 N-CA-C 108.44 -0.948 . . . . 0.0 108.44 178.579 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 37.8 t -112.12 133.91 56.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.439 -0.788 . . . . 0.0 109.218 -179.537 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 76.5 mtm -119.53 155.25 32.51 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.454 -0.779 . . . . 0.0 109.532 -179.577 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.417 ' C ' HD22 ' A' ' 30' ' ' LEU . 84.7 tt0 -100.31 133.02 45.35 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.369 -0.832 . . . . 0.0 109.939 -179.601 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.417 HD22 ' C ' ' A' ' 29' ' ' GLU . 3.1 mm? -110.39 134.65 52.11 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.506 -0.746 . . . . 0.0 109.155 179.619 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 84.1 m-85 -95.1 122.84 38.18 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.2 -0.938 . . . . 0.0 108.999 179.388 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -92.9 -41.81 9.84 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.348 -0.845 . . . . 0.0 109.606 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 87.2 m-20 -69.62 -44.45 70.65 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.327 -0.858 . . . . 0.0 110.659 -179.338 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . 0.439 ' O ' ' OE1' ' A' ' 99' ' ' GLU . 35.2 m -67.84 -46.82 70.69 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.16 -0.962 . . . . 0.0 110.526 -178.924 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.413 ' OG1' ' OG1' ' A' ' 38' ' ' THR . 0.0 OUTLIER -152.63 83.62 4.82 Favored Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.147 -0.971 . . . . 0.0 109.486 -179.447 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -71.92 -33.19 10.22 Favored 'Trans proline' 0 C--N 1.308 -1.593 0 C-N-CA 122.146 1.897 . . . . 0.0 112.12 -179.63 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 35.2 mmt180 -63.35 -40.28 96.85 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.326 -0.858 . . . . 0.0 109.491 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.413 ' OG1' ' OG1' ' A' ' 35' ' ' THR . 36.5 m -64.87 -41.17 95.88 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.274 -0.891 . . . . 0.0 109.929 -179.806 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -62.43 -30.77 71.46 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.286 -0.884 . . . . 0.0 109.282 179.973 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -67.11 -36.91 82.94 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.293 -0.879 . . . . 0.0 109.864 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' ASN . . . . . 0.437 ' O ' HD23 ' A' ' 45' ' ' LEU . 87.5 m-20 -57.95 -39.76 78.88 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.263 -0.898 . . . . 0.0 110.062 -179.498 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -90.42 -48.13 7.3 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.072 -1.017 . . . . 0.0 109.665 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 51.3 ttp180 -57.65 -40.71 79.9 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.48 -0.762 . . . . 0.0 110.508 -179.361 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.446 ' O ' ' N ' ' A' ' 48' ' ' GLY . . . -66.05 -46.8 76.51 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.976 -1.077 . . . . 0.0 110.425 -179.095 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.606 HD13 ' O ' ' A' ' 59' ' ' LEU . 3.6 mm? -64.98 -39.97 94.27 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 120.956 -1.09 . . . . 0.0 109.618 -179.809 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' CYS . . . . . . . . . . . . . 34.8 m -70.06 -47.85 60.26 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.084 -1.01 . . . . 0.0 109.347 179.769 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 74.8 p -72.55 -34.62 67.65 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.36 -0.837 . . . . 0.0 109.555 179.742 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . 0.446 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 73.61 31.88 60.13 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.978 -1.249 . . . . 0.0 109.978 179.646 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 78.0 mm-40 -62.03 -38.03 87.16 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.029 -1.277 . . . . 0.0 109.534 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 31.4 mmtp -62.18 -35.86 80.11 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.282 -0.886 . . . . 0.0 109.674 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 89.51 167.9 42.97 Favored Glycine 0 N--CA 1.488 2.154 0 N-CA-C 109.074 -1.611 . . . . 0.0 109.074 -179.653 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.566 HG23 ' HA ' ' A' ' 58' ' ' PRO . 85.2 m -75.1 138.73 42.28 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.119 -1.224 . . . . 0.0 109.559 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -59.5 137.18 50.11 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.393 -1.483 . . . . 0.0 109.393 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 83.5 mtm-85 -59.35 -36.09 75.08 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.19 -1.182 . . . . 0.0 109.846 -179.748 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 85.9 p -63.38 -24.26 67.77 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.113 -0.992 . . . . 0.0 109.779 -179.841 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 115.87 96.35 2.02 Favored Glycine 0 N--CA 1.494 2.524 0 N-CA-C 109.078 -1.609 . . . . 0.0 109.078 -179.572 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . 0.484 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 75.8 tttt -179.5 81.47 0.2 Allowed Pre-proline 0 N--CA 1.489 1.518 0 N-CA-C 108.377 -0.971 . . . . 0.0 108.377 -179.664 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.566 ' HA ' HG23 ' A' ' 52' ' ' THR . 75.9 Cg_exo -50.31 130.12 27.89 Favored 'Trans proline' 0 C--N 1.303 -1.828 0 C-N-CA 122.769 2.313 . . . . 0.0 112.597 -179.014 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.606 ' O ' HD13 ' A' ' 45' ' ' LEU . 9.0 mp -100.04 23.49 9.82 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.641 -0.662 . . . . 0.0 109.436 -179.833 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . 0.51 ' O ' ' CE1' ' A' ' 80' ' ' PHE . 93.2 m-70 -101.66 135.32 43.38 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.227 -0.92 . . . . 0.0 109.628 -179.804 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . 0.509 ' CE1' HD12 ' A' ' 45' ' ' LEU . 2.7 m-85 -94.95 12.67 27.55 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.293 -0.879 . . . . 0.0 108.98 179.575 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . 0.463 ' O ' ' CB ' ' A' ' 63' ' ' ASP . 62.1 tttt -62.73 142.82 57.97 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.416 -0.803 . . . . 0.0 109.674 -179.832 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . 0.463 ' CB ' ' O ' ' A' ' 62' ' ' LYS . 21.4 t0 74.76 33.72 0.77 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.581 -0.7 . . . . 0.0 109.736 179.859 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.788 ' H ' ' CG2' ' A' ' 171' ' ' VAL . 52.6 p -76.66 165.31 24.93 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.225 -0.922 . . . . 0.0 109.005 179.34 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 29.7 t -140.9 149.77 42.33 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.085 -1.01 . . . . 0.0 109.814 -179.783 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 58.3 m-85 -90.93 127.22 36.31 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.296 -0.878 . . . . 0.0 109.209 179.552 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 55.4 t-80 -94.85 -30.74 14.04 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.258 -0.901 . . . . 0.0 110.499 -179.27 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 83.0 mtp180 -126.26 140.87 52.19 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.057 -1.027 . . . . 0.0 110.341 -179.38 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.711 HG21 HG22 ' A' ' 165' ' ' THR . 15.8 m -151.57 49.05 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 179.424 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 19.4 mt -77.56 133.78 66.67 Favored Pre-proline 0 C--N 1.301 -1.507 0 O-C-N 121.361 -0.837 . . . . 0.0 110.156 -178.612 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -68.89 147.89 69.42 Favored 'Trans proline' 0 N--CA 1.492 1.421 0 C-N-CA 122.4 2.067 . . . . 0.0 112.266 179.852 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 80.42 -55.75 4.66 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.849 -1.3 . . . . 0.0 109.849 179.642 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 88.4 m-85 -68.36 -87.27 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.27 -1.135 . . . . 0.0 109.67 -179.75 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 11.3 ptt? -179.59 -175.16 0.32 Allowed 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.141 -0.975 . . . . 0.0 109.667 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 58.2 m -126.92 136.74 52.72 Favored 'General case' 0 N--CA 1.493 1.702 0 N-CA-C 108.763 -0.829 . . . . 0.0 108.763 179.608 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 63.2 tt0 -96.9 134.88 39.65 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.226 -0.921 . . . . 0.0 109.695 -179.527 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -139.75 176.19 21.33 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.06 -1.616 . . . . 0.0 109.06 179.769 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 77.14 36.84 34.03 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.235 -1.546 . . . . 0.0 109.235 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -83.72 13.97 4.29 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.321 -1.105 . . . . 0.0 109.413 -179.826 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.51 ' CE1' ' O ' ' A' ' 60' ' ' HIS . 81.0 t80 -51.67 -45.26 63.37 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.293 -0.88 . . . . 0.0 109.803 -179.874 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.657 ' O ' ' HB2' ' A' ' 82' ' ' ALA . 58.9 p -70.51 -28.17 64.75 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.1 -1.0 . . . . 0.0 109.506 179.857 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . 0.657 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 165.3 -56.9 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.342 -0.849 . . . . 0.0 109.238 179.898 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 93.39 -1.42 69.52 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 40.7 p-10 -90.02 5.95 44.39 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.126 -1.22 . . . . 0.0 109.473 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 96.44 -33.53 5.59 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.98 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 51.7 p -72.58 -22.26 61.01 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.14 -1.212 . . . . 0.0 109.217 179.76 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -84.97 -161.64 34.29 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 179.915 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.634 ' H ' ' CB ' ' A' ' 81' ' ' THR . . . 90.95 26.87 20.85 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 -179.869 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . 0.429 ' OE1' ' NZ ' ' A' ' 57' ' ' LYS . 96.0 mt-10 -57.1 145.52 30.69 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.375 -1.073 . . . . 0.0 109.577 -179.799 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 29.3 t -106.15 143.55 34.11 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.323 -0.861 . . . . 0.0 109.328 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 20.4 pt -64.58 -33.44 63.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.332 -0.855 . . . . 0.0 109.828 -179.722 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 73.5 m-85 -65.53 -38.12 88.72 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.23 -0.919 . . . . 0.0 109.604 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 81.64 14.5 77.89 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.449 -1.461 . . . . 0.0 109.449 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -146.46 155.77 42.79 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.14 -1.211 . . . . 0.0 109.655 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 97.1 mttt -94.07 142.24 27.62 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.291 -0.88 . . . . 0.0 109.549 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 99.4 m-85 -120.63 150.16 41.34 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.415 -0.803 . . . . 0.0 109.589 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -70.8 154.51 41.77 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.385 -0.822 . . . . 0.0 109.569 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 88.4 m-20 -59.48 147.66 35.85 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.251 -0.906 . . . . 0.0 109.341 179.901 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . 0.439 ' OE1' ' O ' ' A' ' 34' ' ' THR . 96.2 mt-10 -80.4 -89.35 0.06 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.145 -0.972 . . . . 0.0 110.008 -179.583 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 85.3 m-20 -124.86 145.91 49.55 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.301 -0.875 . . . . 0.0 110.049 -179.473 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -100.74 10.83 40.65 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.439 -0.788 . . . . 0.0 109.294 179.589 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 96.2 mt -53.49 -36.46 27.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.303 -0.873 . . . . 0.0 110.134 -179.391 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 9.2 mtpm? -80.45 136.12 36.27 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.98 -1.075 . . . . 0.0 109.633 -179.789 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 69.1 tttt -135.15 159.37 41.76 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.449 -0.782 . . . . 0.0 109.331 -179.705 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' HIS . . . . . 0.409 ' CE1' HG22 ' A' ' 141' ' ' VAL . 92.9 m-70 -74.19 106.55 5.9 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.092 -1.005 . . . . 0.0 109.477 179.865 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 62.3 p -96.03 -9.97 29.65 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.343 -0.848 . . . . 0.0 109.691 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -165.18 -179.03 38.83 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.76 -1.336 . . . . 0.0 109.76 -179.805 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -78.76 160.28 27.82 Favored 'Trans proline' 0 C--N 1.306 -1.677 0 C-N-CA 123.178 2.585 . . . . 0.0 112.23 179.791 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 82.17 40.9 9.78 Favored Glycine 0 N--CA 1.492 2.395 0 N-CA-C 109.995 -1.242 . . . . 0.0 109.995 179.715 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 33.7 mm -113.66 139.21 40.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.357 -1.084 . . . . 0.0 109.209 179.923 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.669 ' N ' HD22 ' A' ' 111' ' ' LEU . 3.4 mm? -86.88 136.18 33.05 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.156 -0.965 . . . . 0.0 109.737 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 30.8 t -144.69 143.41 30.71 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.348 -0.845 . . . . 0.0 109.098 179.47 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 113' ' ' MET . . . . . 0.404 ' H ' ' HG2' ' A' ' 113' ' ' MET . 15.1 ptm -87.4 126.06 34.64 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.231 -0.918 . . . . 0.0 109.532 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -66.27 147.77 52.83 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.263 -0.898 . . . . 0.0 109.715 -179.74 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . 0.525 ' N ' ' OD1' ' A' ' 115' ' ' ASN . 8.0 p-10 -157.76 115.56 3.05 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.272 -0.893 . . . . 0.0 109.169 179.634 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -65.46 -30.72 71.54 Favored 'General case' 0 C--N 1.299 -1.63 0 O-C-N 121.406 -0.809 . . . . 0.0 109.8 -179.761 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -135.57 166.09 24.61 Favored Glycine 0 N--CA 1.494 2.519 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -67.38 156.74 64.91 Favored 'Trans proline' 0 C--N 1.306 -1.659 0 C-N-CA 122.867 2.378 . . . . 0.0 111.816 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 75.8 m-20 54.33 45.4 27.3 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.411 -0.805 . . . . 0.0 109.232 -179.895 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 61.5 m -131.85 127.99 37.73 Favored 'General case' 0 C--N 1.305 -1.349 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 179.916 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 20.1 m120 -102.01 137.03 40.84 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.493 -0.755 . . . . 0.0 109.486 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -145.32 125.78 2.42 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 179.91 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 23.1 t -59.02 -30.86 68.32 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.374 -1.074 . . . . 0.0 109.482 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.6 mt-30 -63.22 143.2 58.0 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.194 -0.941 . . . . 0.0 109.537 -179.675 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 45.6 p90 -141.35 164.93 28.91 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.453 -0.78 . . . . 0.0 109.178 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 48.0 p90 -131.47 157.48 43.39 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.231 -0.918 . . . . 0.0 109.517 179.854 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 71.3 mt -120.25 136.36 57.55 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.492 -0.755 . . . . 0.0 109.593 -179.73 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 11.0 t -116.26 123.56 48.01 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.287 -0.883 . . . . 0.0 108.978 179.581 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 37.6 p -95.51 5.5 51.38 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.275 -0.891 . . . . 0.0 109.86 -179.446 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -148.44 155.58 41.39 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.142 -0.974 . . . . 0.0 109.725 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 34.7 ttmt -73.51 135.42 44.02 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.316 -0.865 . . . . 0.0 109.309 179.838 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . 0.462 ' O ' ' OD2' ' A' ' 136' ' ' ASP . 16.9 p -120.87 159.33 25.74 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.447 -0.783 . . . . 0.0 109.431 -179.808 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . 0.436 ' O ' ' OD1' ' A' ' 136' ' ' ASP . 96.2 mt-10 -97.93 -48.24 5.24 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.286 -0.884 . . . . 0.0 110.011 -179.906 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 134' ' ' TRP . . . . . 0.602 ' CD1' ' N ' ' A' ' 135' ' ' LEU . 40.9 p90 -92.16 -44.06 9.0 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.199 -0.938 . . . . 0.0 110.174 -179.477 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . 0.602 ' N ' ' CD1' ' A' ' 134' ' ' TRP . 34.2 tp -61.66 -29.63 70.2 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.268 -0.895 . . . . 0.0 109.184 -179.646 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . 0.485 ' C ' ' OD1' ' A' ' 136' ' ' ASP . 53.4 p30 -70.14 9.06 0.63 Allowed 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.447 -0.783 . . . . 0.0 109.513 -179.747 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 137' ' ' GLY . . . . . 0.459 ' H ' ' C ' ' A' ' 135' ' ' LEU . . . -52.02 -30.31 30.13 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.618 -1.393 . . . . 0.0 109.618 -179.904 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . 0.44 ' CE ' ' OD1' ' A' ' 115' ' ' ASN . 46.4 mmtm -77.56 123.18 26.27 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.098 -1.236 . . . . 0.0 109.168 -179.879 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 71.1 m80 -110.61 15.66 21.91 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.398 -0.814 . . . . 0.0 109.754 -179.641 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 45.0 t -100.08 129.8 50.21 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.13 -0.981 . . . . 0.0 109.88 -179.536 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . 0.409 HG22 ' CE1' ' A' ' 105' ' ' HIS . 84.2 t -130.58 129.83 64.55 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 N-CA-C 109.021 -0.733 . . . . 0.0 109.021 179.651 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 39.5 p90 -110.72 -0.4 17.09 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.074 -1.016 . . . . 0.0 110.052 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -175.43 173.52 46.28 Favored Glycine 0 N--CA 1.493 2.495 0 N-CA-C 109.804 -1.319 . . . . 0.0 109.804 179.443 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 94.0 mt-30 -139.36 165.91 25.95 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.29 -1.123 . . . . 0.0 109.584 -179.83 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 55.1 t -95.56 129.54 45.53 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.222 0 O-C-N 121.175 -0.953 . . . . 0.0 109.162 179.816 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 17.3 m -106.73 -33.65 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.314 -0.866 . . . . 0.0 109.455 179.736 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -143.06 170.78 15.07 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.333 -0.855 . . . . 0.0 109.525 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 98.53 2.39 57.61 Favored Glycine 0 N--CA 1.494 2.558 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.74 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 149' ' ' MET . . . . . 0.511 ' O ' HG12 ' A' ' 152' ' ' VAL . 50.6 ttm -61.02 -32.85 72.44 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.063 -1.257 . . . . 0.0 109.667 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -65.33 -42.29 93.08 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.883 -1.135 . . . . 0.0 110.06 -179.596 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.6 p -81.84 -32.92 11.59 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.141 -0.974 . . . . 0.0 110.611 -179.232 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 152' ' ' VAL . . . . . 0.511 HG12 ' O ' ' A' ' 149' ' ' MET . 0.9 OUTLIER -53.76 -41.0 45.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 120.976 -1.077 . . . . 0.0 109.152 -179.285 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 153' ' ' LYS . . . . . 0.441 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 87.2 mttt -64.03 -34.62 78.42 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.122 -0.986 . . . . 0.0 109.188 179.169 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -62.08 -35.06 77.52 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.381 -0.824 . . . . 0.0 109.687 -179.798 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.404 HD11 ' SD ' ' A' ' 16' ' ' MET . 95.7 mt -70.79 -36.01 62.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.277 -0.889 . . . . 0.0 109.832 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 85.1 tt0 -75.24 -41.89 56.5 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.266 -0.896 . . . . 0.0 111.419 -178.755 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 55.4 pttt -61.27 -34.46 75.21 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.665 -1.272 . . . . 0.0 109.689 -179.047 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 32.6 m -82.82 -6.62 10.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.146 -0.971 . . . . 0.0 108.926 179.427 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -77.67 176.48 53.68 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 109.797 -1.321 . . . . 0.0 109.797 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 86.9 p -157.48 169.54 24.46 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.431 -1.041 . . . . 0.0 109.706 -179.58 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 22.8 t -57.1 -32.69 66.55 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.281 -0.887 . . . . 0.0 108.647 179.256 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 86.2 p -61.38 -27.25 68.39 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.329 -0.857 . . . . 0.0 109.096 179.654 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 93.24 18.04 40.79 Favored Glycine 0 N--CA 1.493 2.488 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 179.756 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 88.7 mtt180 -115.94 143.06 45.96 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.219 -1.165 . . . . 0.0 109.226 179.825 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 165' ' ' THR . . . . . 0.711 HG22 HG21 ' A' ' 69' ' ' VAL . 81.7 p -81.98 150.06 27.85 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.208 -0.933 . . . . 0.0 109.675 -179.894 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -68.96 -36.77 78.3 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.325 -0.859 . . . . 0.0 109.333 179.8 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -111.58 157.84 19.92 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.5 -0.75 . . . . 0.0 109.435 -179.914 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 92.1 mttt -73.02 135.84 44.96 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.309 -0.869 . . . . 0.0 109.175 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 3.4 m -130.94 123.02 53.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.725 0 O-C-N 121.365 -0.834 . . . . 0.0 109.772 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 39.0 t -143.21 138.0 26.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.386 -0.821 . . . . 0.0 108.804 179.557 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.788 ' CG2' ' H ' ' A' ' 64' ' ' SER . 3.0 m -67.7 119.56 13.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 120.826 -1.171 . . . . 0.0 109.547 -179.737 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -68.52 -35.57 77.66 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.233 -0.917 . . . . 0.0 110.086 -179.836 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -156.34 158.32 37.21 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.202 -0.936 . . . . 0.0 110.047 -179.6 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 19.0 p -147.06 148.58 31.79 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.435 -0.79 . . . . 0.0 109.16 179.688 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -177.93 179.72 48.29 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.704 -1.359 . . . . 0.0 109.704 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 61.3 tt0 -106.03 117.25 33.55 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.392 -1.064 . . . . 0.0 109.667 -179.896 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 31.3 tp -62.86 -38.8 92.29 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.094 -1.004 . . . . 0.0 109.216 179.589 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 2.6 p . . . . . 0 N--CA 1.492 1.651 0 CA-C-O 117.897 -1.049 . . . . 0.0 109.707 179.997 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 12.0 m120 . . . . . 0 N--CA 1.492 1.656 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -68.21 138.08 42.2 Favored 'Trans proline' 0 N--CA 1.496 1.648 0 C-N-CA 122.595 2.197 . . . . 0.0 112.272 179.891 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 95.5 mtt180 -128.72 132.27 47.97 Favored 'General case' 0 N--CA 1.492 1.657 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 179.114 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.5 p -133.24 142.3 42.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.363 -0.836 . . . . 0.0 109.607 -179.564 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 47.1 p90 -140.91 155.26 46.32 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.411 -0.806 . . . . 0.0 109.519 -179.838 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 69.8 m-85 -121.86 135.51 54.9 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.455 -0.778 . . . . 0.0 109.643 179.773 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.0 t0 -88.28 118.83 28.15 Favored 'General case' 0 N--CA 1.493 1.703 0 N-CA-C 108.307 -0.998 . . . . 0.0 108.307 178.864 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 75.2 mtp -116.32 142.86 46.28 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.263 -0.898 . . . . 0.0 110.742 -178.822 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.433 ' OG ' ' OE2' ' A' ' 172' ' ' GLU . 31.6 m -136.4 155.88 49.41 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 179.368 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 33.3 m -119.14 133.69 65.17 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.085 -1.009 . . . . 0.0 109.638 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 57.86 15.57 20.59 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.689 -1.365 . . . . 0.0 109.689 179.844 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 92.08 2.38 68.87 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.386 -1.486 . . . . 0.0 109.386 -179.804 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 41.5 tt0 -105.02 115.15 62.88 Favored Pre-proline 0 N--CA 1.492 1.658 0 O-C-N 121.437 -1.037 . . . . 0.0 109.112 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 77.4 Cg_exo -47.33 133.65 19.91 Favored 'Trans proline' 0 N--CA 1.492 1.412 0 C-N-CA 122.088 1.859 . . . . 0.0 112.106 -179.949 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -101.25 -57.67 2.04 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.292 -0.88 . . . . 0.0 109.568 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -178.02 -169.08 38.46 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.401 -1.48 . . . . 0.0 109.401 -179.775 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 50.9 mtp180 -113.22 144.22 43.07 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.415 -1.05 . . . . 0.0 109.383 179.849 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 76.3 mt -117.85 114.56 45.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 N-CA-C 108.183 -1.043 . . . . 0.0 108.183 178.757 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 38.3 t -109.58 135.21 49.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.437 -0.79 . . . . 0.0 109.628 -179.219 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 75.8 mtm -128.41 156.86 42.49 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.514 -0.741 . . . . 0.0 109.225 -179.588 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -103.83 133.93 48.0 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.283 -0.886 . . . . 0.0 109.706 179.882 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -105.37 128.97 53.78 Favored 'General case' 0 N--CA 1.492 1.638 0 N-CA-C 108.752 -0.832 . . . . 0.0 108.752 179.365 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.401 ' CG ' ' NZ ' ' A' ' 103' ' ' LYS . 94.9 m-85 -92.97 119.41 32.21 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.085 -1.009 . . . . 0.0 109.141 179.981 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -86.33 -42.6 13.57 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.346 -0.846 . . . . 0.0 109.535 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.3 m-20 -65.1 -47.49 76.99 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.368 -0.833 . . . . 0.0 110.298 -179.433 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 37.4 m -67.62 -44.63 77.56 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.211 -0.931 . . . . 0.0 109.775 -179.777 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 5.7 p -138.15 76.98 37.56 Favored Pre-proline 0 N--CA 1.492 1.658 0 N-CA-C 109.082 -0.71 . . . . 0.0 109.082 -179.912 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 10.7 Cg_endo -59.33 -63.31 0.13 Allowed 'Trans proline' 0 C--N 1.31 -1.489 0 C-N-CA 122.571 2.181 . . . . 0.0 112.801 -179.154 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 86.8 mtt-85 -61.24 -35.19 76.58 Favored 'General case' 0 C--N 1.297 -1.688 0 O-C-N 121.652 -0.655 . . . . 0.0 110.755 -178.77 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 25.3 m -60.27 -42.13 94.76 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 120.984 -1.073 . . . . 0.0 110.094 -179.418 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -59.95 -31.82 70.23 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.128 -0.983 . . . . 0.0 109.153 -179.794 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -67.7 -36.88 81.47 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.401 -0.812 . . . . 0.0 109.915 -179.9 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 37.8 t30 -56.6 -40.81 75.92 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.261 -0.899 . . . . 0.0 109.823 -179.458 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 98.4 m-85 -90.43 -48.6 7.01 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.069 -1.019 . . . . 0.0 109.828 -179.89 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.893 ' HE ' HE22 ' A' ' 176' ' ' GLN . 66.2 ttt-85 -57.41 -41.32 80.14 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.512 -0.742 . . . . 0.0 110.505 -179.375 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -65.55 -47.6 75.3 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.049 -1.032 . . . . 0.0 110.373 -178.916 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.469 ' N ' ' CD2' ' A' ' 45' ' ' LEU . 3.3 mm? -65.51 -39.87 92.36 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.124 -0.985 . . . . 0.0 109.665 -179.735 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' CYS . . . . . . . . . . . . . 72.3 m -68.24 -46.09 71.44 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.1 -1.0 . . . . 0.0 109.315 179.819 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 72.6 p -74.34 -33.53 63.16 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.313 -0.867 . . . . 0.0 109.721 179.877 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 75.03 30.81 58.6 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 110.037 -1.225 . . . . 0.0 110.037 179.739 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 77.9 mm-40 -61.97 -36.67 82.16 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.137 -1.214 . . . . 0.0 109.441 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 42.0 mmtm -60.66 -33.87 73.45 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.233 -0.917 . . . . 0.0 109.402 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 92.84 171.3 40.45 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.096 -1.602 . . . . 0.0 109.096 -179.692 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.636 HG23 ' HA ' ' A' ' 58' ' ' PRO . 99.2 m -75.88 141.39 42.38 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.317 -1.108 . . . . 0.0 109.76 -179.807 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -60.42 138.15 48.62 Favored Glycine 0 N--CA 1.488 2.164 0 N-CA-C 109.405 -1.478 . . . . 0.0 109.405 179.787 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 87.1 mtt-85 -60.24 -29.22 68.62 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.303 -1.116 . . . . 0.0 110.231 -179.803 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 75.4 m -78.52 11.0 2.7 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.181 -0.95 . . . . 0.0 110.32 -179.154 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 82.16 77.03 1.07 Allowed Glycine 0 N--CA 1.492 2.4 0 N-CA-C 109.217 -1.553 . . . . 0.0 109.217 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . 0.478 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 55.0 mttp -157.47 75.0 4.16 Favored Pre-proline 0 C--N 1.302 -1.463 0 O-C-N 121.449 -1.03 . . . . 0.0 108.3 -179.944 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.636 ' HA ' HG23 ' A' ' 52' ' ' THR . 73.1 Cg_exo -50.04 130.28 27.32 Favored 'Trans proline' 0 C--N 1.302 -1.909 0 C-N-CA 122.962 2.441 . . . . 0.0 112.517 -179.085 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.478 ' CD1' ' O ' ' A' ' 57' ' ' LYS . 8.6 mp -100.8 74.22 1.63 Allowed 'General case' 0 N--CA 1.489 1.524 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 -179.638 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 77.5 m80 -139.21 150.68 45.82 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.436 -0.79 . . . . 0.0 109.516 179.865 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 3.8 m-85 -101.95 20.48 16.41 Favored 'General case' 0 N--CA 1.493 1.691 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 179.573 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 85.0 mttt -77.57 157.55 30.26 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.434 -0.791 . . . . 0.0 109.525 -179.663 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 54.8 t0 56.89 48.9 15.04 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.486 -0.759 . . . . 0.0 109.805 179.788 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 87.4 p -111.71 154.25 25.26 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.4 -0.813 . . . . 0.0 109.077 179.69 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 27.8 t -131.03 149.3 52.68 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.227 -0.921 . . . . 0.0 109.74 -179.603 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -72.68 135.84 45.49 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.351 -0.843 . . . . 0.0 109.131 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 32.1 m-70 -77.84 -53.01 7.98 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.259 -0.901 . . . . 0.0 110.71 -179.219 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 98.1 mtt180 -130.27 148.96 52.16 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.043 -1.035 . . . . 0.0 110.541 -179.017 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.694 HG21 HG22 ' A' ' 165' ' ' THR . 8.5 m -143.67 59.6 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.585 -0.697 . . . . 0.0 109.135 179.497 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 18.6 mt -82.14 132.67 52.73 Favored Pre-proline 0 C--N 1.301 -1.543 0 O-C-N 121.164 -0.96 . . . . 0.0 109.771 -179.135 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -70.98 149.67 59.49 Favored 'Trans proline' 0 N--CA 1.492 1.437 0 C-N-CA 122.399 2.066 . . . . 0.0 112.113 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 81.33 -58.28 4.86 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 179.879 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -70.01 -84.83 0.03 OUTLIER 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.269 -1.136 . . . . 0.0 109.637 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' MET . . . . . 0.484 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 14.1 ptt? 178.03 -172.83 0.13 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.334 -0.854 . . . . 0.0 109.544 179.877 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 14.6 p -125.75 137.26 53.8 Favored 'General case' 0 N--CA 1.493 1.721 0 N-CA-C 108.595 -0.891 . . . . 0.0 108.595 179.45 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 93.1 mt-30 -111.53 153.99 25.44 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.167 -0.958 . . . . 0.0 109.771 -179.485 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -134.76 174.43 21.07 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.006 -1.638 . . . . 0.0 109.006 179.7 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -137.24 161.03 25.19 Favored Glycine 0 N--CA 1.493 2.477 0 N-CA-C 109.717 -1.353 . . . . 0.0 109.717 -179.88 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 90.3 m-20 -72.89 156.81 38.49 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.379 -1.071 . . . . 0.0 109.457 179.865 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.411 ' CE2' ' O ' ' A' ' 58' ' ' PRO . 50.7 p90 -61.97 -18.49 60.58 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.327 -0.858 . . . . 0.0 109.744 -179.666 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.583 ' OG1' ' N ' ' A' ' 88' ' ' GLY . 73.1 p -61.71 -34.39 75.69 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.046 -1.034 . . . . 0.0 109.534 -179.902 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . 0.559 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 172.24 -50.46 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.329 -0.857 . . . . 0.0 109.434 179.942 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 92.45 3.14 67.2 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 80.3 m-20 -86.9 5.91 34.6 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.218 -1.166 . . . . 0.0 109.306 179.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 95.13 -42.61 2.34 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 -179.804 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 47.8 m -61.23 -38.91 88.33 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.207 -1.172 . . . . 0.0 109.114 179.601 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -85.35 -166.46 41.92 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.583 ' N ' ' OG1' ' A' ' 81' ' ' THR . . . 83.52 43.69 7.25 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 -179.897 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -64.05 144.14 57.33 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.266 -1.138 . . . . 0.0 109.478 -179.848 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 29.3 t -102.91 142.12 34.55 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.34 -0.85 . . . . 0.0 109.369 -179.884 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.406 HG12 ' H ' ' A' ' 91' ' ' ILE . 6.4 pt -63.26 -42.68 97.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.339 -0.851 . . . . 0.0 109.915 -179.737 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 3.8 m-30 -69.85 -36.19 75.35 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.976 -1.077 . . . . 0.0 109.558 179.871 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 80.81 14.85 78.95 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.224 -1.55 . . . . 0.0 109.224 -179.728 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -145.3 158.11 43.9 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.372 -1.075 . . . . 0.0 109.451 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -86.43 154.46 21.14 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.182 -0.949 . . . . 0.0 109.56 -179.881 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . 0.401 ' H ' ' HB2' ' A' ' 121' ' ' ASN . 89.0 m-85 -100.23 130.64 46.38 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.281 -0.887 . . . . 0.0 109.305 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -76.62 138.75 40.29 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.159 -0.963 . . . . 0.0 109.496 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . 0.768 ' H ' HD22 ' A' ' 119' ' ' ASN . 88.5 m-20 -75.54 131.25 39.92 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.267 -0.896 . . . . 0.0 109.266 179.836 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -104.28 -55.46 2.36 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.239 -0.913 . . . . 0.0 110.061 -179.797 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 84.9 m-20 -106.35 128.82 54.3 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.233 -0.917 . . . . 0.0 110.24 -179.149 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 90.2 m-85 -108.38 10.52 27.5 Favored 'General case' 0 N--CA 1.493 1.686 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 179.352 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 92.0 mt -54.9 -37.0 39.88 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.397 -0.814 . . . . 0.0 110.568 -178.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' LYS . . . . . 0.401 ' NZ ' ' CG ' ' A' ' 31' ' ' PHE . 87.2 mttt -77.2 127.99 33.59 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.871 -1.143 . . . . 0.0 109.909 -179.427 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' LYS . . . . . 0.593 ' O ' ' N ' ' A' ' 106' ' ' THR . 34.4 ttmt -139.08 149.96 45.18 Favored 'General case' 0 N--CA 1.492 1.636 0 N-CA-C 109.012 -0.736 . . . . 0.0 109.012 179.862 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' HIS . . . . . . . . . . . . . 85.5 m-70 -53.69 82.34 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.094 -1.004 . . . . 0.0 109.66 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . 0.593 ' N ' ' O ' ' A' ' 104' ' ' LYS . 54.9 p -73.45 -28.0 61.72 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.235 -0.915 . . . . 0.0 109.525 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -150.21 -177.51 24.25 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.882 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 69.6 Cg_endo -76.14 156.33 37.96 Favored 'Trans proline' 0 C--N 1.306 -1.666 0 C-N-CA 123.025 2.483 . . . . 0.0 112.198 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 81.86 45.75 7.05 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 110.098 -1.201 . . . . 0.0 110.098 179.706 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 41.6 mm -115.98 136.91 51.39 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 121.287 -1.125 . . . . 0.0 109.459 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.543 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 2.4 mm? -87.54 128.28 35.25 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.199 -0.938 . . . . 0.0 109.263 179.716 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 87.7 p -143.16 150.84 39.96 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.332 -0.855 . . . . 0.0 109.547 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 113' ' ' MET . . . . . 0.458 ' CE ' ' OD1' ' A' ' 121' ' ' ASN . 86.5 mtp -95.35 139.47 31.6 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.343 -0.848 . . . . 0.0 109.329 179.621 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -64.38 145.35 56.2 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.237 -0.914 . . . . 0.0 109.54 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . 0.573 ' ND2' HG23 ' A' ' 140' ' ' VAL . 2.7 p30 -165.77 114.98 1.0 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.184 -0.948 . . . . 0.0 109.613 179.863 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -66.19 -31.31 72.06 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.383 -0.823 . . . . 0.0 109.356 179.721 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -136.84 169.81 23.72 Favored Glycine 0 N--CA 1.493 2.474 0 N-CA-C 109.351 -1.5 . . . . 0.0 109.351 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -65.84 157.67 57.82 Favored 'Trans proline' 0 C--N 1.305 -1.757 0 C-N-CA 122.819 2.346 . . . . 0.0 111.969 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 119' ' ' ASN . . . . . 0.768 HD22 ' H ' ' A' ' 98' ' ' ASP . 16.4 m120 55.89 44.3 26.06 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.425 -0.797 . . . . 0.0 109.325 -179.857 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 61.2 m -135.96 127.83 29.37 Favored 'General case' 0 C--N 1.304 -1.383 0 N-CA-C 108.804 -0.814 . . . . 0.0 108.804 179.851 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 121' ' ' ASN . . . . . 0.458 ' OD1' ' CE ' ' A' ' 113' ' ' MET . 31.9 t30 -100.5 109.9 22.05 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.423 -0.798 . . . . 0.0 109.374 -179.954 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -85.8 135.33 13.29 Favored Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.644 -1.383 . . . . 0.0 109.644 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 85.3 p -65.1 -23.38 67.14 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.248 -1.148 . . . . 0.0 109.408 179.871 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.0 mt-30 -101.89 154.2 19.15 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.378 -0.826 . . . . 0.0 109.606 -179.728 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 49.3 p90 -133.6 160.95 35.96 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.471 -0.768 . . . . 0.0 109.461 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . 0.484 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 45.6 p90 -140.0 159.71 41.58 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.324 -0.86 . . . . 0.0 109.504 -179.91 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 72.5 mt -119.77 134.24 63.95 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.407 -0.808 . . . . 0.0 109.444 179.845 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 1.8 m -92.2 105.55 17.74 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.104 -0.998 . . . . 0.0 109.268 179.827 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 54.2 p -74.72 -9.12 58.26 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.271 -0.893 . . . . 0.0 109.463 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -150.44 156.15 40.91 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.362 -0.836 . . . . 0.0 109.277 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 82.5 tttt -68.01 135.16 51.88 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.216 -0.928 . . . . 0.0 109.23 179.855 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 6.5 p -122.11 158.0 30.24 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.409 -0.807 . . . . 0.0 109.558 -179.74 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -138.69 -35.66 0.58 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.317 -0.865 . . . . 0.0 109.081 179.812 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 0.7 OUTLIER -58.7 -29.43 66.64 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.447 -0.783 . . . . 0.0 109.219 179.713 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 18.2 mt -59.49 -35.77 74.77 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.32 -0.863 . . . . 0.0 109.628 179.638 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 57.5 t0 49.45 50.94 17.31 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.286 -0.884 . . . . 0.0 109.518 179.801 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -130.2 127.63 5.37 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.166 -1.574 . . . . 0.0 109.166 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . 0.515 ' O ' ' O ' ' A' ' 139' ' ' HIS . 88.2 mttt -56.58 -38.19 71.65 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.36 -1.083 . . . . 0.0 109.652 -179.846 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 139' ' ' HIS . . . . . 0.515 ' O ' ' O ' ' A' ' 138' ' ' LYS . 54.6 m170 56.86 147.88 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.644 -0.66 . . . . 0.0 109.824 179.936 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.573 HG23 ' ND2' ' A' ' 115' ' ' ASN . 41.0 t -116.05 133.6 62.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.413 -0.804 . . . . 0.0 109.296 -179.893 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 60.1 t -107.27 127.51 62.99 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 121.272 -0.893 . . . . 0.0 109.52 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 39.1 p90 -116.16 3.06 13.45 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.403 -0.81 . . . . 0.0 109.682 179.773 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -173.08 179.13 44.7 Favored Glycine 0 N--CA 1.494 2.528 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 179.612 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.3 pt20 -145.82 166.29 26.35 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.114 -1.227 . . . . 0.0 109.865 -179.855 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 74.6 t -100.63 132.11 46.92 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.122 0 O-C-N 121.278 -0.888 . . . . 0.0 109.581 -179.855 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 12.9 m -113.85 -31.52 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.308 -0.87 . . . . 0.0 109.422 179.563 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -139.62 167.25 22.52 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.356 -0.84 . . . . 0.0 109.469 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 97.67 4.0 58.18 Favored Glycine 0 N--CA 1.494 2.527 0 N-CA-C 109.941 -1.264 . . . . 0.0 109.941 179.765 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 149' ' ' MET . . . . . 0.436 ' O ' HG12 ' A' ' 152' ' ' VAL . 65.0 mtt -60.71 -33.44 72.89 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.098 -1.236 . . . . 0.0 109.479 179.934 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 89.3 m-20 -64.02 -41.64 97.38 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.913 -1.117 . . . . 0.0 109.852 -179.761 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.5 p -83.24 -34.37 10.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.199 -0.938 . . . . 0.0 110.402 -179.446 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 152' ' ' VAL . . . . . 0.464 ' CG1' ' N ' ' A' ' 153' ' ' LYS . 0.6 OUTLIER -57.02 -42.77 79.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 120.872 -1.142 . . . . 0.0 109.382 -179.219 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 153' ' ' LYS . . . . . 0.464 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 66.6 mttm -63.84 -34.41 77.87 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.242 -0.911 . . . . 0.0 109.517 179.503 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -61.48 -37.9 85.33 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.24 -0.913 . . . . 0.0 109.962 -179.492 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 88.3 mt -72.51 -35.14 50.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.189 -0.945 . . . . 0.0 110.047 -179.717 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -76.29 -41.64 48.04 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.202 -0.936 . . . . 0.0 111.191 -178.865 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 39.1 pttt -61.8 -33.92 74.98 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 120.852 -1.155 . . . . 0.0 109.89 -178.819 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.42 ' HB ' ' H ' ' A' ' 166' ' ' ALA . 35.3 m -77.8 -13.99 14.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.011 -1.056 . . . . 0.0 109.26 179.714 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -74.3 168.27 54.44 Favored Glycine 0 N--CA 1.489 2.2 0 N-CA-C 109.789 -1.324 . . . . 0.0 109.789 -179.718 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 22.8 t -157.67 176.36 12.71 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.418 -1.048 . . . . 0.0 109.361 -179.758 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 23.6 m -54.01 -31.78 52.16 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.282 -0.886 . . . . 0.0 109.182 179.817 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 23.9 m -55.56 -33.07 63.53 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.28 -0.888 . . . . 0.0 109.462 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 95.38 10.97 56.54 Favored Glycine 0 N--CA 1.493 2.482 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 179.828 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 81.7 mtm180 -121.44 146.57 46.76 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.303 -1.116 . . . . 0.0 109.474 179.874 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 165' ' ' THR . . . . . 0.694 HG22 HG21 ' A' ' 69' ' ' VAL . 80.5 p -80.49 151.42 29.24 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.224 -0.923 . . . . 0.0 109.646 -179.884 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 166' ' ' ALA . . . . . 0.42 ' H ' ' HB ' ' A' ' 158' ' ' VAL . . . -66.66 -37.06 84.02 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.322 -0.862 . . . . 0.0 109.077 179.592 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -108.71 158.69 17.39 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.555 -0.716 . . . . 0.0 109.096 179.721 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -71.4 130.78 42.2 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.14 -0.975 . . . . 0.0 109.394 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 43.6 t -122.15 124.24 70.67 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 121.38 -0.825 . . . . 0.0 109.435 179.795 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 48.8 t -149.1 154.61 9.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.48 -0.763 . . . . 0.0 109.141 179.865 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 2.1 t -90.15 124.87 43.0 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 O-C-N 121.258 -0.901 . . . . 0.0 109.932 -179.312 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 172' ' ' GLU . . . . . 0.433 ' OE2' ' OG ' ' A' ' 17' ' ' SER . 97.1 mt-10 -64.96 -28.87 69.81 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.449 -0.782 . . . . 0.0 109.192 179.46 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 173' ' ' ASP . . . . . 0.425 ' C ' ' OD1' ' A' ' 173' ' ' ASP . 53.1 p30 -175.14 179.58 1.53 Allowed 'General case' 0 N--CA 1.492 1.639 0 C-N-CA 119.449 -0.9 . . . . 0.0 110.352 -179.665 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 26.7 p -151.48 151.38 31.56 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.45 -0.781 . . . . 0.0 109.265 179.711 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -178.18 176.83 48.22 Favored Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.792 -1.323 . . . . 0.0 109.792 179.812 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 176' ' ' GLN . . . . . 0.893 HE22 ' HE ' ' A' ' 43' ' ' ARG . 59.3 tt0 -107.11 127.21 53.29 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.375 -1.073 . . . . 0.0 109.61 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 29.0 tp -60.98 -37.78 83.66 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.187 -0.945 . . . . 0.0 109.194 179.641 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 9.5 t . . . . . 0 N--CA 1.49 1.563 0 CA-C-O 117.945 -1.026 . . . . 0.0 109.483 -179.942 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 3.2 m-80 . . . . . 0 N--CA 1.489 1.485 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -70.65 140.24 38.9 Favored 'Trans proline' 0 N--CA 1.494 1.558 0 C-N-CA 122.777 2.318 . . . . 0.0 112.409 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 97.8 mtt180 -128.96 132.09 47.56 Favored 'General case' 0 N--CA 1.491 1.592 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 179.127 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.6 p -136.51 142.62 37.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.248 -0.907 . . . . 0.0 109.633 -179.441 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 38.5 p90 -144.19 154.79 43.5 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.344 -0.847 . . . . 0.0 109.589 -179.866 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 67.1 m-85 -126.66 138.14 53.38 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.332 -0.855 . . . . 0.0 109.597 179.648 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.468 ' CG ' ' NH1' ' A' ' 25' ' ' ARG . 90.2 m-20 -87.02 129.94 34.68 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.168 -0.957 . . . . 0.0 108.616 178.983 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' MET . . . . . 0.541 ' SD ' HD12 ' A' ' 26' ' ' ILE . 83.8 mtp -117.35 153.85 32.31 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.164 -0.96 . . . . 0.0 110.37 -179.441 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 76.9 p -148.14 167.33 25.32 Favored 'General case' 0 N--CA 1.487 1.42 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 179.629 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 7.9 p -127.4 134.24 66.19 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.244 -0.91 . . . . 0.0 109.717 -179.815 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 54.79 17.13 8.55 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.626 -1.389 . . . . 0.0 109.626 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 92.24 4.56 66.39 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 63.9 mt-30 -105.49 113.43 64.24 Favored Pre-proline 0 N--CA 1.494 1.728 0 O-C-N 121.345 -1.091 . . . . 0.0 109.241 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_exo -48.81 137.24 27.6 Favored 'Trans proline' 0 N--CA 1.492 1.406 0 C-N-CA 122.123 1.882 . . . . 0.0 112.086 179.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -111.22 -59.4 1.98 Allowed 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.411 -0.806 . . . . 0.0 109.498 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -170.44 -169.8 33.99 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.376 -1.49 . . . . 0.0 109.376 -179.859 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . 0.468 ' NH1' ' CG ' ' A' ' 15' ' ' ASP . 88.2 mtt-85 -116.46 145.8 43.03 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.308 -1.113 . . . . 0.0 109.784 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.541 HD12 ' SD ' ' A' ' 16' ' ' MET . 73.5 mt -119.8 122.45 68.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 178.863 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 46.1 t -111.02 133.3 57.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.3 -0.875 . . . . 0.0 109.3 -179.562 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 75.2 mtm -116.22 150.88 36.8 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.447 -0.783 . . . . 0.0 109.412 -179.767 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.419 ' C ' HD22 ' A' ' 30' ' ' LEU . 84.4 tt0 -101.47 130.92 47.81 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.277 -0.889 . . . . 0.0 109.926 -179.594 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.419 HD22 ' C ' ' A' ' 29' ' ' GLU . 2.9 mm? -109.86 127.74 54.9 Favored 'General case' 0 N--CA 1.493 1.683 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 179.277 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 96.3 m-85 -98.96 118.53 35.93 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.167 -0.958 . . . . 0.0 109.049 179.525 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -79.66 -41.94 25.86 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.379 -0.826 . . . . 0.0 109.776 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -64.35 -46.6 82.72 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.286 -0.884 . . . . 0.0 110.246 -179.333 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 33.1 m -67.38 -44.42 78.97 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.136 -0.978 . . . . 0.0 109.815 -179.72 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.449 ' O ' ' OG1' ' A' ' 35' ' ' THR . 6.8 p -141.61 79.65 16.85 Favored Pre-proline 0 N--CA 1.492 1.649 0 O-C-N 121.429 -0.794 . . . . 0.0 109.291 -179.859 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -64.25 -54.63 0.78 Allowed 'Trans proline' 0 C--N 1.308 -1.564 0 C-N-CA 122.286 1.991 . . . . 0.0 112.508 -179.404 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 70.9 mtp180 -62.43 -38.75 90.93 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.52 -0.737 . . . . 0.0 110.636 -179.196 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 28.6 m -65.16 -43.82 90.55 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.948 -1.095 . . . . 0.0 110.236 -179.474 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -63.14 -30.61 71.73 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.18 -0.95 . . . . 0.0 109.21 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -71.2 -43.78 66.72 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.345 -0.847 . . . . 0.0 109.837 -179.733 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 45.8 t30 -62.76 -47.82 81.86 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.248 -0.907 . . . . 0.0 109.992 -179.512 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 61.1 t80 -63.79 -47.75 79.64 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.208 -0.932 . . . . 0.0 109.567 -179.667 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.652 ' CZ ' HE22 ' A' ' 176' ' ' GLN . 74.4 ttt180 -57.83 -38.17 75.12 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.365 -0.835 . . . . 0.0 109.854 -179.849 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.512 ' O ' ' N ' ' A' ' 48' ' ' GLY . . . -62.32 -42.9 99.76 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.118 -0.989 . . . . 0.0 110.088 -179.247 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.591 HD12 ' CD1' ' A' ' 61' ' ' TYR . 4.4 mm? -66.28 -38.02 86.79 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.02 -1.05 . . . . 0.0 109.582 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' CYS . . . . . . . . . . . . . 3.8 m -65.9 -53.56 37.88 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.104 -0.997 . . . . 0.0 109.357 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 64.4 p -75.02 -31.46 61.37 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.336 -0.852 . . . . 0.0 109.451 179.674 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . 0.512 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 75.7 37.34 40.12 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 110.314 -1.114 . . . . 0.0 110.314 179.51 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -61.61 -37.66 84.77 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.858 -1.377 . . . . 0.0 109.418 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . 0.458 ' HZ1' ' CD1' ' A' ' 91' ' ' ILE . 27.0 mmtp -61.38 -34.0 74.6 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.28 -0.887 . . . . 0.0 109.279 179.819 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 82.13 -86.63 1.43 Allowed Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.654 -1.378 . . . . 0.0 109.654 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.566 HG23 ' C ' ' A' ' 57' ' ' LYS . 48.8 m -123.77 140.37 53.05 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.448 -1.03 . . . . 0.0 109.637 -179.779 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -56.58 -35.63 67.69 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.44 -1.464 . . . . 0.0 109.44 179.817 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . 0.533 ' H ' HG22 ' A' ' 52' ' ' THR . 74.3 mtp85 -140.22 -110.2 0.15 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.35 -1.088 . . . . 0.0 109.207 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 24.9 p -134.13 0.71 3.16 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.366 -0.833 . . . . 0.0 109.746 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -151.09 49.3 0.55 Allowed Glycine 0 N--CA 1.492 2.417 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . 0.566 ' C ' HG23 ' A' ' 52' ' ' THR . 59.7 tttm -172.8 74.29 0.42 Allowed Pre-proline 0 N--CA 1.488 1.474 0 O-C-N 121.364 -1.08 . . . . 0.0 108.855 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.402 ' N ' HG23 ' A' ' 52' ' ' THR . 72.0 Cg_exo -47.77 131.93 20.85 Favored 'Trans proline' 0 C--N 1.305 -1.757 0 C-N-CA 122.702 2.268 . . . . 0.0 112.128 -179.417 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.573 ' O ' ' CG ' ' A' ' 60' ' ' HIS . 14.6 tp -109.31 118.39 36.56 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.616 -0.678 . . . . 0.0 109.437 -179.413 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . 0.577 ' O ' ' CZ ' ' A' ' 80' ' ' PHE . 92.4 m-70 -160.62 135.31 7.51 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.244 -0.91 . . . . 0.0 109.944 179.889 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . 0.591 ' CD1' HD12 ' A' ' 45' ' ' LEU . 2.9 m-30 -87.39 3.38 47.26 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.163 -0.96 . . . . 0.0 108.882 179.104 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 62.2 tttt -68.07 146.31 53.61 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.383 -0.823 . . . . 0.0 109.7 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 46.7 t0 61.67 50.8 4.23 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.427 -0.795 . . . . 0.0 110.07 179.784 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.718 ' H ' ' CG2' ' A' ' 171' ' ' VAL . 96.7 p -97.69 157.24 16.16 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.187 -0.946 . . . . 0.0 109.146 179.531 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 29.0 t -128.84 150.09 50.48 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.438 -0.789 . . . . 0.0 109.378 -179.792 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 4.4 m-85 -75.55 125.77 29.69 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.227 -0.92 . . . . 0.0 109.144 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 79.0 t60 -62.76 -48.57 78.61 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.326 -0.859 . . . . 0.0 110.044 -179.354 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.68 HH21 ' NE2' ' A' ' 76' ' ' GLN . 36.8 ptt180 -163.64 162.38 24.18 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.223 -0.923 . . . . 0.0 109.378 -179.925 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -141.75 112.61 3.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.315 -0.866 . . . . 0.0 109.142 179.738 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 43.8 mt -107.56 124.33 35.33 Favored Pre-proline 0 N--CA 1.492 1.645 0 O-C-N 121.45 -0.781 . . . . 0.0 109.073 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_endo -71.75 137.46 29.91 Favored 'Trans proline' 0 N--CA 1.491 1.363 0 C-N-CA 122.031 1.82 . . . . 0.0 112.338 -179.729 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 94.46 -28.25 11.57 Favored Glycine 0 N--CA 1.493 2.466 0 N-CA-C 109.723 -1.351 . . . . 0.0 109.723 179.739 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 94.3 m-85 -100.87 -80.74 0.48 Allowed 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.271 -1.135 . . . . 0.0 109.789 -179.94 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 13.2 ptp -177.87 -168.95 0.19 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.283 -0.886 . . . . 0.0 109.873 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -124.55 130.44 52.45 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.486 -0.759 . . . . 0.0 109.03 179.822 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' GLN . . . . . 0.68 ' NE2' HH21 ' A' ' 68' ' ' ARG . 93.5 mt-30 -108.03 151.65 25.56 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.379 -0.826 . . . . 0.0 109.818 -179.633 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -169.18 -170.49 33.82 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.32 -1.512 . . . . 0.0 109.32 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 88.67 21.25 44.29 Favored Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.766 -1.334 . . . . 0.0 109.766 179.912 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 83.9 m-20 -84.38 12.64 6.43 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.233 -1.157 . . . . 0.0 109.433 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.577 ' CZ ' ' O ' ' A' ' 60' ' ' HIS . 83.1 t80 -50.08 -40.98 47.23 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.313 -0.867 . . . . 0.0 110.134 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.662 ' O ' ' HB2' ' A' ' 82' ' ' ALA . 60.6 p -65.35 -31.26 72.29 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.957 -1.089 . . . . 0.0 109.499 -179.956 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . 0.662 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 165.3 -53.37 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.415 -0.803 . . . . 0.0 109.32 179.898 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 88.51 2.36 79.53 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 78.5 m-20 -87.85 6.93 33.06 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.254 -1.145 . . . . 0.0 109.478 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 97.2 -39.31 2.82 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.26 -1.536 . . . . 0.0 109.26 -179.788 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 57.1 p -72.63 -21.35 61.12 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.335 -1.097 . . . . 0.0 109.008 179.49 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -84.65 -167.21 42.57 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.603 ' H ' ' CB ' ' A' ' 81' ' ' THR . . . 81.76 44.6 7.69 Favored Glycine 0 N--CA 1.488 2.134 0 N-CA-C 109.016 -1.634 . . . . 0.0 109.016 -179.871 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -94.36 142.49 27.36 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.377 -1.072 . . . . 0.0 109.708 -179.55 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 90.7 p -112.85 158.26 20.38 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.442 -0.786 . . . . 0.0 109.197 179.844 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.458 ' CD1' ' HZ1' ' A' ' 50' ' ' LYS . 29.1 pt -59.08 -32.02 47.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.142 -0.974 . . . . 0.0 109.634 -179.718 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . 0.53 ' O ' ' N ' ' A' ' 94' ' ' ALA . 56.8 m-85 -66.46 -30.12 70.39 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.223 -0.923 . . . . 0.0 109.631 179.636 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 64.07 -72.27 0.05 OUTLIER Glycine 0 N--CA 1.489 2.206 0 N-CA-C 109.336 -1.506 . . . . 0.0 109.336 -179.889 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . 0.53 ' N ' ' O ' ' A' ' 92' ' ' TYR . . . -63.55 143.96 57.39 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.376 -1.073 . . . . 0.0 109.119 179.719 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . 0.631 ' HD3' HG23 ' A' ' 120' ' ' THR . 59.0 mttp -88.58 149.33 23.63 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.379 -0.826 . . . . 0.0 109.71 -179.849 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 52.0 p90 -130.86 158.52 39.97 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.425 -0.797 . . . . 0.0 109.252 179.705 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -84.79 146.94 27.11 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.28 -0.887 . . . . 0.0 109.893 -179.577 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 60.4 t0 -78.88 124.8 28.59 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.336 -0.852 . . . . 0.0 109.113 179.747 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -54.42 -39.15 67.06 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.146 -0.972 . . . . 0.0 109.729 -179.518 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . 0.469 ' CG ' ' H ' ' A' ' 101' ' ' PHE . 15.1 t-20 -172.32 -177.45 1.81 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.097 -1.002 . . . . 0.0 109.808 179.855 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' PHE . . . . . 0.469 ' H ' ' CG ' ' A' ' 100' ' ' ASN . 15.7 p90 -147.42 62.57 1.16 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.487 -0.758 . . . . 0.0 109.067 179.861 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 80.6 mt -59.66 -37.34 70.42 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.268 -0.895 . . . . 0.0 110.216 -179.447 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 67.6 mttm -86.15 139.41 31.11 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.017 -1.052 . . . . 0.0 109.982 -179.436 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 59.2 mttp -129.12 -176.02 3.74 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.483 -0.761 . . . . 0.0 109.457 179.737 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' HIS . . . . . 0.53 ' O ' ' CG ' ' A' ' 105' ' ' HIS . 49.1 p-80 -109.57 100.36 9.42 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.519 -0.738 . . . . 0.0 109.276 179.704 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 63.7 p -106.96 -0.8 22.85 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.406 -0.809 . . . . 0.0 109.599 -179.831 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -146.62 171.29 27.45 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.336 -1.505 . . . . 0.0 109.336 -179.89 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -74.39 155.44 45.91 Favored 'Trans proline' 0 C--N 1.306 -1.672 0 C-N-CA 122.888 2.392 . . . . 0.0 112.17 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 83.22 44.9 6.8 Favored Glycine 0 N--CA 1.493 2.493 0 N-CA-C 110.234 -1.146 . . . . 0.0 110.234 179.488 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 44.0 mm -116.31 134.21 60.43 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 121.251 -1.146 . . . . 0.0 109.342 179.723 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.525 ' N ' HD22 ' A' ' 111' ' ' LEU . 3.4 mm? -91.44 130.91 37.21 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.251 -0.906 . . . . 0.0 109.385 179.709 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 47.2 t -143.68 142.24 30.9 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.238 -0.914 . . . . 0.0 109.439 179.826 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 72.1 mtm -82.87 131.21 35.2 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.193 -0.942 . . . . 0.0 109.205 179.769 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . 0.539 ' O ' ' ND2' ' A' ' 115' ' ' ASN . . . -65.87 141.71 58.17 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.192 -0.943 . . . . 0.0 109.587 -179.911 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . 0.539 ' ND2' ' O ' ' A' ' 114' ' ' ALA . 18.3 m120 -146.27 113.03 6.03 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.322 -0.862 . . . . 0.0 109.027 179.664 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -68.51 -29.96 68.67 Favored 'General case' 0 C--N 1.297 -1.682 0 O-C-N 121.46 -0.775 . . . . 0.0 109.488 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -136.51 167.31 24.54 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 109.256 -1.538 . . . . 0.0 109.256 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -67.39 156.22 67.07 Favored 'Trans proline' 0 C--N 1.306 -1.696 0 C-N-CA 122.805 2.336 . . . . 0.0 111.889 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 119' ' ' ASN . . . . . 0.466 ' N ' HD22 ' A' ' 119' ' ' ASN . 2.5 m120 54.35 45.26 27.55 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.422 -0.799 . . . . 0.0 109.35 -179.886 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 120' ' ' THR . . . . . 0.631 HG23 ' HD3' ' A' ' 95' ' ' LYS . 57.9 m -133.73 126.58 31.0 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 108.792 -0.818 . . . . 0.0 108.792 179.85 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 39.6 t30 -100.77 107.42 18.99 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.504 -0.748 . . . . 0.0 109.355 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -98.44 126.32 8.85 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 86.1 p -62.96 -25.96 68.6 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.268 -1.137 . . . . 0.0 109.385 179.795 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.3 mt-30 -73.86 148.18 42.58 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.283 -0.886 . . . . 0.0 109.399 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 48.8 p90 -136.3 162.75 32.14 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.326 -0.859 . . . . 0.0 109.446 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 49.0 p90 -136.48 160.8 37.67 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.371 -0.831 . . . . 0.0 109.445 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 69.2 mt -115.99 130.16 71.16 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.446 -0.784 . . . . 0.0 109.352 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -101.17 104.2 15.27 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.273 -0.892 . . . . 0.0 109.241 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 59.2 p -84.59 0.67 49.24 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.281 -0.887 . . . . 0.0 109.37 179.878 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -144.42 161.99 37.64 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.3 -0.875 . . . . 0.0 109.466 -179.768 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 92.4 mttt -76.0 150.65 37.37 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.254 -0.904 . . . . 0.0 109.486 -179.91 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 16.0 p -120.0 161.01 21.65 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.39 -0.819 . . . . 0.0 109.374 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -159.61 -44.12 0.05 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.19 -0.944 . . . . 0.0 109.758 -179.908 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 134' ' ' TRP . . . . . 0.4 ' CE2' ' CD2' ' A' ' 135' ' ' LEU . 33.3 p90 -73.71 -9.64 58.87 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.284 -0.885 . . . . 0.0 109.39 -179.802 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . 0.51 ' N ' ' CD2' ' A' ' 135' ' ' LEU . 2.8 mm? -61.59 -33.8 74.53 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.238 -0.914 . . . . 0.0 108.771 179.239 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 59.1 t0 49.16 49.91 18.83 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.44 -0.788 . . . . 0.0 109.754 179.648 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -143.83 163.79 27.59 Favored Glycine 0 N--CA 1.485 1.932 0 N-CA-C 108.915 -1.674 . . . . 0.0 108.915 179.847 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 13.6 mptt -97.21 142.73 28.77 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.472 -1.016 . . . . 0.0 109.465 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 99.3 m-70 -128.97 146.75 50.88 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.46 -0.775 . . . . 0.0 109.428 179.853 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 42.3 t -112.94 135.0 53.78 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.402 -0.811 . . . . 0.0 109.277 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 56.3 t -108.38 128.07 64.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 121.33 -0.856 . . . . 0.0 109.507 -179.757 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 45.9 p90 -112.88 -0.59 14.83 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.342 -0.849 . . . . 0.0 109.401 179.547 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -171.28 174.45 44.92 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 179.619 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 92.1 mt-30 -139.6 165.28 27.67 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.176 -1.19 . . . . 0.0 109.663 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 69.9 t -97.12 129.8 46.66 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.225 0 O-C-N 121.126 -0.984 . . . . 0.0 109.435 -179.952 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 16.0 m -106.99 -29.35 2.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.372 -0.83 . . . . 0.0 109.536 179.657 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -143.52 171.17 14.53 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.265 -0.897 . . . . 0.0 109.512 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 97.99 4.22 57.77 Favored Glycine 0 N--CA 1.493 2.46 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 179.64 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 149' ' ' MET . . . . . 0.466 ' O ' HG12 ' A' ' 152' ' ' VAL . 88.8 mtp -60.6 -33.95 73.51 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.13 -1.218 . . . . 0.0 109.672 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -64.98 -42.62 94.37 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.843 -1.161 . . . . 0.0 110.124 -179.624 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.1 p -82.79 -33.5 10.76 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.079 -1.013 . . . . 0.0 110.499 -179.429 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 152' ' ' VAL . . . . . 0.466 HG12 ' O ' ' A' ' 149' ' ' MET . 0.7 OUTLIER -55.17 -41.82 62.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 120.882 -1.136 . . . . 0.0 109.251 -179.335 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 153' ' ' LYS . . . . . 0.45 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 93.8 mttt -63.56 -34.8 78.6 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.171 -0.956 . . . . 0.0 109.298 179.356 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -63.0 -36.6 84.09 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.405 -0.809 . . . . 0.0 109.792 -179.599 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 69.9 mt -70.4 -38.6 74.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.211 -0.931 . . . . 0.0 110.036 -179.606 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -76.83 -41.14 45.37 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.067 -1.021 . . . . 0.0 111.63 -178.35 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 36.4 pttt -61.18 -34.19 74.65 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 120.729 -1.232 . . . . 0.0 110.261 -178.553 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 35.6 m -76.12 -20.09 15.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 120.917 -1.115 . . . . 0.0 109.469 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -72.91 165.24 54.81 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.652 -1.379 . . . . 0.0 109.652 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 22.9 t -151.42 171.71 17.09 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.376 -1.073 . . . . 0.0 109.382 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 22.6 t -53.7 -32.11 50.61 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.2 -0.938 . . . . 0.0 109.074 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 22.7 t -56.79 -30.94 64.16 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.251 -0.906 . . . . 0.0 109.34 179.722 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 96.41 8.04 57.75 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.678 -1.369 . . . . 0.0 109.678 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 98.6 mtt180 -120.71 144.14 48.39 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.244 -1.15 . . . . 0.0 109.29 179.831 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 165' ' ' THR . . . . . . . . . . . . . 59.6 p -91.23 157.29 17.25 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.197 -0.939 . . . . 0.0 109.728 -179.853 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -65.94 -33.79 76.63 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.367 -0.833 . . . . 0.0 109.613 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 60.8 mttp -119.41 161.03 21.19 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.406 -0.809 . . . . 0.0 109.905 -179.498 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 67.1 mttm -82.53 145.85 29.53 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.437 -0.789 . . . . 0.0 109.725 -179.918 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 1.9 m -133.75 127.08 52.1 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 O-C-N 121.277 -0.89 . . . . 0.0 109.575 179.783 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 44.3 t -137.99 139.05 43.15 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 O-C-N 121.392 -0.817 . . . . 0.0 109.407 179.837 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.718 ' CG2' ' H ' ' A' ' 64' ' ' SER . 9.5 m -67.06 124.51 22.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.0 -1.062 . . . . 0.0 109.208 179.819 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -69.29 -38.38 78.29 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.158 -0.964 . . . . 0.0 110.356 -179.63 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 173' ' ' ASP . . . . . 0.47 ' OD1' ' N ' ' A' ' 174' ' ' CYS . 48.0 t0 -168.7 168.82 10.48 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.958 -1.089 . . . . 0.0 110.209 -179.502 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 174' ' ' CYS . . . . . 0.47 ' N ' ' OD1' ' A' ' 173' ' ' ASP . 14.4 p -138.81 149.84 45.4 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.513 -0.742 . . . . 0.0 109.095 179.785 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -165.27 176.99 40.83 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.737 -1.345 . . . . 0.0 109.737 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 176' ' ' GLN . . . . . 0.652 HE22 ' CZ ' ' A' ' 43' ' ' ARG . 61.1 tt0 -109.83 113.9 27.03 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.331 -1.1 . . . . 0.0 109.614 -179.906 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 177' ' ' LEU . . . . . 0.407 ' O ' ' C ' ' A' ' 178' ' ' SER . 33.9 tp -64.4 -38.41 90.95 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.299 -0.876 . . . . 0.0 109.187 179.526 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 178' ' ' SER . . . . . 0.407 ' C ' ' O ' ' A' ' 177' ' ' LEU . 1.9 t . . . . . 0 N--CA 1.49 1.565 0 CA-C-O 118.04 -0.981 . . . . 0.0 109.621 179.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 75.1 m-20 . . . . . 0 N--CA 1.49 1.551 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -66.88 140.17 54.33 Favored 'Trans proline' 0 N--CA 1.496 1.632 0 C-N-CA 122.593 2.196 . . . . 0.0 112.237 179.966 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 98.0 mtt180 -132.49 131.12 41.33 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.33 -0.857 . . . . 0.0 109.187 179.494 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.8 p -138.47 142.63 34.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.306 -0.871 . . . . 0.0 109.39 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 49.3 p90 -142.46 153.85 44.04 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.298 -0.876 . . . . 0.0 109.624 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 77.0 m-85 -126.19 140.83 52.25 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.409 -0.807 . . . . 0.0 109.538 179.654 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 88.4 m-20 -86.85 129.75 34.75 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.156 -0.965 . . . . 0.0 108.925 179.31 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' MET . . . . . 0.562 ' SD ' HD12 ' A' ' 26' ' ' ILE . 84.7 mtp -115.03 153.33 30.86 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.331 -0.855 . . . . 0.0 110.079 -179.683 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 83.8 p -149.0 164.16 35.38 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.442 -0.787 . . . . 0.0 109.129 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.541 ' O ' ' N ' ' A' ' 20' ' ' GLY . 20.4 m -127.25 144.46 37.25 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 121.233 -0.917 . . . . 0.0 109.604 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 47.61 11.43 0.1 OUTLIER Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.822 -1.311 . . . . 0.0 109.822 179.812 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.541 ' N ' ' O ' ' A' ' 18' ' ' VAL . . . 96.49 -14.93 63.64 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.895 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' GLN . . . . . 0.448 ' N ' ' CD ' ' A' ' 21' ' ' GLN . 8.1 mp0 -82.95 149.31 59.13 Favored Pre-proline 0 N--CA 1.492 1.632 0 O-C-N 121.268 -1.137 . . . . 0.0 109.029 179.778 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -62.42 135.35 53.11 Favored 'Trans proline' 0 C--N 1.308 -1.557 0 C-N-CA 122.353 2.035 . . . . 0.0 112.036 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -113.49 -68.11 0.95 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.398 -0.814 . . . . 0.0 109.554 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -176.0 -171.64 40.02 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 -179.865 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 40.0 ttm180 -123.45 142.65 50.78 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.446 -1.032 . . . . 0.0 109.327 -179.931 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.562 HD12 ' SD ' ' A' ' 16' ' ' MET . 75.5 mt -119.99 132.06 70.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.372 -0.83 . . . . 0.0 109.03 179.641 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 44.5 t -113.3 133.22 59.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.306 -0.872 . . . . 0.0 109.086 179.765 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 72.8 mtm -118.52 148.95 42.09 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.369 -0.832 . . . . 0.0 109.299 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -102.05 131.68 48.35 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.308 -0.87 . . . . 0.0 109.575 -179.752 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -104.9 128.75 53.25 Favored 'General case' 0 N--CA 1.492 1.655 0 N-CA-C 109.044 -0.725 . . . . 0.0 109.044 179.615 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 90.2 m-85 -97.25 120.98 38.61 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.309 -0.869 . . . . 0.0 109.307 179.731 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -82.53 -41.51 19.58 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.321 -0.862 . . . . 0.0 109.875 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 56.8 t0 -69.02 -44.36 72.89 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.228 -0.92 . . . . 0.0 110.828 -179.22 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 32.9 m -67.22 -45.71 75.98 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.047 -1.033 . . . . 0.0 110.491 -178.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 4.3 m -156.4 84.36 3.21 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.127 -0.983 . . . . 0.0 109.484 -179.524 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -75.24 -37.04 2.08 Favored 'Trans proline' 0 C--N 1.307 -1.639 0 C-N-CA 122.334 2.023 . . . . 0.0 112.497 -179.518 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 37.7 mmt180 -61.76 -41.02 97.14 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.21 -0.931 . . . . 0.0 109.644 -179.803 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.459 HG23 ' SD ' ' A' ' 113' ' ' MET . 86.5 m -66.21 -39.95 89.98 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.253 -0.904 . . . . 0.0 110.106 -179.71 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -60.11 -32.3 70.86 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.077 -1.014 . . . . 0.0 109.521 -179.818 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -69.82 -36.26 75.47 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.268 -0.895 . . . . 0.0 110.077 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 48.3 t30 -57.9 -42.7 85.23 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.101 -0.999 . . . . 0.0 109.767 -179.629 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -85.79 -48.12 9.09 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.206 -0.934 . . . . 0.0 109.681 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 34.9 ttm180 -57.4 -42.63 82.63 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.407 -0.808 . . . . 0.0 109.842 -179.508 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -69.82 -44.89 69.05 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.306 -0.872 . . . . 0.0 110.182 -179.411 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 36.7 tp -61.92 -36.42 81.3 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.078 -1.014 . . . . 0.0 109.446 -179.652 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' CYS . . . . . . . . . . . . . 46.9 m -79.51 -49.93 11.51 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.09 -1.006 . . . . 0.0 109.757 179.589 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 71.2 p -68.75 -34.72 76.06 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.149 -0.97 . . . . 0.0 109.575 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 75.16 28.92 61.26 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.972 -1.251 . . . . 0.0 109.972 179.6 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 78.0 mm-40 -60.98 -38.35 85.68 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.088 -1.243 . . . . 0.0 109.246 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 29.1 mmtm -62.48 -31.35 72.07 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 121.308 -0.87 . . . . 0.0 109.152 179.484 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 97.75 -119.64 6.49 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 108.87 -1.692 . . . . 0.0 108.87 -179.49 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.586 HG23 ' HA ' ' A' ' 58' ' ' PRO . 95.1 m -126.55 142.09 51.65 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.419 -1.048 . . . . 0.0 109.751 179.739 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -55.48 135.72 47.77 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.093 -1.603 . . . . 0.0 109.093 179.615 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 94.5 mtt180 -59.11 -37.66 77.71 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.18 -1.188 . . . . 0.0 110.079 -179.484 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 22.9 t -59.47 -31.4 69.3 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.179 -0.95 . . . . 0.0 109.834 -179.615 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 119.77 95.54 1.57 Allowed Glycine 0 N--CA 1.495 2.592 0 N-CA-C 108.648 -1.781 . . . . 0.0 108.648 -179.379 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 32.6 tptt -178.56 80.5 0.22 Allowed Pre-proline 0 N--CA 1.489 1.497 0 N-CA-C 108.07 -1.085 . . . . 0.0 108.07 -179.501 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.586 ' HA ' HG23 ' A' ' 52' ' ' THR . 97.3 Cg_exo -45.26 127.96 9.45 Favored 'Trans proline' 0 C--N 1.301 -1.922 0 C-N-CA 122.667 2.245 . . . . 0.0 112.203 -178.9 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.564 ' O ' ' CG ' ' A' ' 60' ' ' HIS . 84.0 mt -91.52 124.65 35.84 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.718 -0.614 . . . . 0.0 109.92 -179.285 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . 0.564 ' CG ' ' O ' ' A' ' 59' ' ' LEU . 86.5 m-70 -162.25 96.35 0.97 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.443 -0.785 . . . . 0.0 109.258 179.833 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 18.5 t80 -57.32 -34.39 68.68 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.174 -0.954 . . . . 0.0 108.708 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . 0.406 ' HG2' ' N ' ' A' ' 63' ' ' ASP . 3.1 ttmp? -46.79 161.06 0.07 Allowed 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.612 -0.68 . . . . 0.0 109.706 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . 0.406 ' N ' ' HG2' ' A' ' 62' ' ' LYS . 80.5 m-20 62.34 48.82 4.51 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.686 -0.634 . . . . 0.0 110.494 179.8 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.877 ' H ' HG22 ' A' ' 171' ' ' VAL . 33.7 t -103.48 144.63 31.15 Favored 'General case' 0 N--CA 1.492 1.642 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 178.76 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 28.6 t -124.05 148.63 46.91 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.096 -1.002 . . . . 0.0 110.309 -179.003 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 32.8 m-85 -87.75 129.99 34.99 Favored 'General case' 0 N--CA 1.491 1.614 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 179.494 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 94.7 m-70 -90.97 -28.58 17.94 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.103 -0.998 . . . . 0.0 110.901 -178.937 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.409 ' O ' HG13 ' A' ' 69' ' ' VAL . 48.9 mtp180 -134.34 147.97 50.64 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 120.957 -1.089 . . . . 0.0 110.245 -179.367 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.71 HG21 HG22 ' A' ' 165' ' ' THR . 10.2 m -153.98 64.7 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.503 -0.748 . . . . 0.0 109.205 179.825 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 21.7 mt -86.82 131.79 44.11 Favored Pre-proline 0 C--N 1.301 -1.502 0 O-C-N 121.009 -1.057 . . . . 0.0 109.788 -179.277 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_endo -71.27 147.16 52.75 Favored 'Trans proline' 0 N--CA 1.492 1.401 0 C-N-CA 122.354 2.036 . . . . 0.0 112.288 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 83.62 -58.7 5.01 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.763 -1.335 . . . . 0.0 109.763 179.808 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 95.6 m-85 -69.74 -83.83 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.177 -1.19 . . . . 0.0 109.622 -179.796 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' MET . . . . . 0.403 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 12.6 ptt? 179.05 -173.29 0.17 Allowed 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.278 -0.889 . . . . 0.0 109.68 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 1.2 p -126.34 137.57 53.49 Favored 'General case' 0 N--CA 1.491 1.622 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 179.443 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 91.9 mt-30 -116.73 153.92 31.54 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.256 -0.902 . . . . 0.0 109.735 -179.573 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -163.29 -173.65 32.24 Favored Glycine 0 N--CA 1.488 2.151 0 N-CA-C 109.177 -1.569 . . . . 0.0 109.177 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -160.39 -177.4 33.45 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.717 -1.353 . . . . 0.0 109.717 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.514 ' C ' ' H ' ' A' ' 81' ' ' THR . 83.1 m-20 -66.95 154.93 39.87 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.379 -1.071 . . . . 0.0 109.507 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.558 ' CE1' ' O ' ' A' ' 60' ' ' HIS . 36.5 p90 -58.89 0.24 0.09 Allowed 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.413 -0.804 . . . . 0.0 109.762 -179.856 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.619 ' O ' ' HB2' ' A' ' 82' ' ' ALA . 72.4 p -63.85 -32.31 73.78 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.991 -1.068 . . . . 0.0 109.538 -179.706 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . 0.619 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 169.48 -53.12 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.335 -0.853 . . . . 0.0 109.37 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 86.04 2.8 85.78 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.556 -1.417 . . . . 0.0 109.556 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 39.9 t-20 -85.94 5.91 30.94 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.263 -1.14 . . . . 0.0 109.497 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 100.96 -40.19 2.5 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 -179.776 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 58.9 p -70.75 -27.22 63.79 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.273 -1.134 . . . . 0.0 108.837 179.392 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -86.47 -167.66 43.89 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.184 -1.566 . . . . 0.0 109.184 179.657 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.485 ' N ' ' OG1' ' A' ' 81' ' ' THR . . . 82.25 42.38 8.69 Favored Glycine 0 N--CA 1.489 2.179 0 N-CA-C 109.359 -1.496 . . . . 0.0 109.359 -179.919 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -57.03 143.81 36.79 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.303 -1.116 . . . . 0.0 109.391 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 99.3 p -113.44 147.87 36.98 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.348 -0.845 . . . . 0.0 109.268 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.415 HG21 HD13 ' A' ' 91' ' ' ILE . 20.0 pt -74.01 -33.64 36.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.297 -0.877 . . . . 0.0 109.993 -179.837 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 81.8 m-85 -66.46 -41.14 89.48 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.173 -0.954 . . . . 0.0 109.795 -179.668 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 71.3 9.57 68.14 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.278 -1.529 . . . . 0.0 109.278 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -152.34 160.76 43.27 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.294 -1.121 . . . . 0.0 109.389 -179.758 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 63.7 mttp -83.4 145.85 28.77 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.22 -0.925 . . . . 0.0 109.665 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 52.4 p90 -137.05 160.5 38.78 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.402 -0.811 . . . . 0.0 109.312 179.674 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -104.49 144.23 31.96 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.31 -0.869 . . . . 0.0 109.513 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . 0.523 ' O ' ' OD1' ' A' ' 98' ' ' ASP . 41.9 p30 -79.05 128.98 33.96 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.191 -0.943 . . . . 0.0 109.528 179.873 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -60.65 -37.73 82.49 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.159 -0.963 . . . . 0.0 109.693 -179.643 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 84.4 m-20 -124.42 144.18 50.21 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.251 -0.906 . . . . 0.0 109.849 -179.747 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 48.6 p90 -142.69 19.75 2.01 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.333 -0.854 . . . . 0.0 108.838 179.607 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 84.1 mt -59.47 -34.88 56.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.567 -0.708 . . . . 0.0 110.112 -179.649 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 93.0 mttt -79.65 135.65 36.61 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.069 -1.02 . . . . 0.0 109.768 -179.57 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 25.6 pttm -139.11 -178.69 5.46 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.412 -0.805 . . . . 0.0 109.439 -180.0 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' HIS . . . . . 0.535 ' O ' ' ND1' ' A' ' 105' ' ' HIS . 15.1 t-80 -74.27 88.02 2.0 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.174 -0.954 . . . . 0.0 109.256 179.825 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 58.8 p -75.05 -25.48 58.71 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.312 -0.867 . . . . 0.0 109.774 -179.781 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.533 ' O ' ' CE1' ' A' ' 105' ' ' HIS . . . -164.21 -166.95 23.97 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.397 -1.481 . . . . 0.0 109.397 -179.708 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -76.29 155.82 37.18 Favored 'Trans proline' 0 C--N 1.308 -1.574 0 C-N-CA 122.644 2.229 . . . . 0.0 112.117 179.901 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 88.32 24.29 34.51 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.869 -1.292 . . . . 0.0 109.869 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 36.6 mm -112.27 136.79 47.37 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.267 -1.137 . . . . 0.0 109.379 179.854 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.748 ' N ' HD22 ' A' ' 111' ' ' LEU . 2.7 mm? -88.2 132.57 34.3 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.283 -0.886 . . . . 0.0 109.152 179.77 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . 0.401 ' OG ' ' O ' ' A' ' 140' ' ' VAL . 47.0 t -145.8 139.36 26.34 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.189 -0.944 . . . . 0.0 109.609 179.957 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 113' ' ' MET . . . . . 0.459 ' SD ' HG23 ' A' ' 38' ' ' THR . 71.9 mtm -89.23 139.03 30.9 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.243 -0.91 . . . . 0.0 109.267 179.651 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . 0.572 ' O ' ' ND2' ' A' ' 115' ' ' ASN . . . -60.74 138.31 58.11 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.242 -0.911 . . . . 0.0 109.152 179.983 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . 0.572 ' ND2' ' O ' ' A' ' 114' ' ' ALA . 15.0 m120 -148.81 112.95 5.2 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.173 -0.954 . . . . 0.0 109.19 179.93 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -68.31 -30.12 69.04 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 121.338 -0.851 . . . . 0.0 109.134 179.559 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -138.18 168.98 24.42 Favored Glycine 0 N--CA 1.493 2.451 0 N-CA-C 109.049 -1.621 . . . . 0.0 109.049 179.813 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -67.11 155.06 72.41 Favored 'Trans proline' 0 C--N 1.305 -1.739 0 C-N-CA 122.722 2.281 . . . . 0.0 112.027 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 75.6 m-20 53.99 44.34 29.48 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.448 -0.782 . . . . 0.0 109.432 -179.865 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 120' ' ' THR . . . . . 0.546 ' O ' ' ND2' ' A' ' 115' ' ' ASN . 93.3 m -134.64 127.59 31.45 Favored 'General case' 0 N--CA 1.485 1.322 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 179.832 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 121' ' ' ASN . . . . . 0.413 ' OD1' ' SD ' ' A' ' 113' ' ' MET . 52.2 t30 -98.22 106.43 18.72 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.421 -0.8 . . . . 0.0 109.318 179.794 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -80.96 136.61 16.6 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 83.4 p -64.38 -23.73 67.39 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.268 -1.136 . . . . 0.0 109.442 179.853 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.2 mt-30 -103.73 150.89 23.63 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.267 -0.896 . . . . 0.0 109.675 -179.825 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 51.5 p90 -136.23 162.4 33.08 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.431 -0.793 . . . . 0.0 109.292 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . 0.403 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 48.5 p90 -136.34 156.64 48.35 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.193 -0.942 . . . . 0.0 109.636 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 64.9 mt -122.53 133.1 69.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.449 -0.782 . . . . 0.0 109.189 179.812 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 128' ' ' CYS . . . . . 0.45 ' SG ' ' O ' ' A' ' 130' ' ' ALA . 5.7 t -99.82 118.46 36.33 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.154 -0.966 . . . . 0.0 109.499 179.938 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 64.9 p -95.05 4.12 54.1 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.294 -0.879 . . . . 0.0 109.489 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . 0.45 ' O ' ' SG ' ' A' ' 128' ' ' CYS . . . -147.41 155.82 42.31 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.271 -0.893 . . . . 0.0 109.684 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 51.4 tttp -72.9 137.17 45.45 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.204 -0.935 . . . . 0.0 109.423 179.918 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 7.2 p -122.46 161.49 23.45 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.47 -0.769 . . . . 0.0 109.542 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -104.88 -74.98 0.63 Allowed 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.336 -0.853 . . . . 0.0 109.666 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 134' ' ' TRP . . . . . 0.672 ' CD1' ' N ' ' A' ' 135' ' ' LEU . 45.9 p90 -61.65 -45.8 92.48 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.333 -0.854 . . . . 0.0 110.198 -179.56 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . 0.672 ' N ' ' CD1' ' A' ' 134' ' ' TRP . 13.5 tp -61.28 -32.3 72.13 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.336 -0.852 . . . . 0.0 109.72 -179.348 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 60.4 t0 -56.5 136.61 54.1 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.231 -0.918 . . . . 0.0 109.924 -179.38 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 137' ' ' GLY . . . . . 0.716 ' H ' ' CD2' ' A' ' 139' ' ' HIS . . . -162.65 -161.15 11.84 Favored Glycine 0 N--CA 1.486 2.009 0 N-CA-C 108.664 -1.774 . . . . 0.0 108.664 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . 0.464 ' O ' ' O ' ' A' ' 139' ' ' HIS . 92.1 mttt -57.21 -41.14 78.86 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.055 -1.262 . . . . 0.0 109.582 179.887 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 139' ' ' HIS . . . . . 0.716 ' CD2' ' H ' ' A' ' 137' ' ' GLY . 66.2 m-70 37.4 94.66 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.58 -0.7 . . . . 0.0 110.428 179.738 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.401 ' O ' ' OG ' ' A' ' 112' ' ' SER . 39.0 t -61.61 132.43 27.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 120.99 -1.069 . . . . 0.0 108.791 179.579 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 82.3 t -111.38 129.0 67.51 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 O-C-N 121.376 -0.828 . . . . 0.0 109.824 -179.45 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 41.9 p90 -116.19 -1.55 12.37 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.511 -0.743 . . . . 0.0 109.505 179.449 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -168.47 172.73 43.08 Favored Glycine 0 N--CA 1.493 2.479 0 N-CA-C 109.861 -1.296 . . . . 0.0 109.861 179.447 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 55.2 tt0 -139.99 160.33 40.18 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.31 -1.112 . . . . 0.0 109.347 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . 0.438 HG23 HD21 ' A' ' 111' ' ' LEU . 54.4 t -96.75 131.22 44.04 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.182 0 O-C-N 121.047 -1.033 . . . . 0.0 109.56 -179.759 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 16.4 m -111.0 -28.75 2.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.444 -0.785 . . . . 0.0 109.32 179.472 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -144.42 169.35 18.11 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.326 -0.859 . . . . 0.0 109.448 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 96.2 6.36 58.94 Favored Glycine 0 N--CA 1.494 2.511 0 N-CA-C 109.946 -1.262 . . . . 0.0 109.946 179.519 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 149' ' ' MET . . . . . 0.524 ' O ' HG12 ' A' ' 152' ' ' VAL . 89.0 mtp -59.89 -32.24 70.55 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.165 -1.197 . . . . 0.0 109.8 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -66.67 -42.66 86.2 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.868 -1.145 . . . . 0.0 109.994 -179.542 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 6.2 p -81.36 -34.86 13.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.167 -0.958 . . . . 0.0 110.555 -179.479 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 152' ' ' VAL . . . . . 0.556 ' O ' ' OE1' ' A' ' 156' ' ' GLU . 1.2 p -50.85 -42.39 23.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 120.843 -1.161 . . . . 0.0 108.772 -179.078 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 153' ' ' LYS . . . . . 0.445 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 61.5 mttp -67.39 -32.91 74.14 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.28 -0.887 . . . . 0.0 109.274 179.094 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -61.03 -30.89 70.58 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.469 -0.769 . . . . 0.0 110.396 -179.244 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 89.8 mt -68.54 -37.31 77.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.035 -1.041 . . . . 0.0 110.616 -179.384 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . 0.556 ' OE1' ' O ' ' A' ' 152' ' ' VAL . 42.0 mp0 -80.35 -39.13 29.13 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 120.815 -1.178 . . . . 0.0 111.743 -178.849 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 19.2 pttp -58.3 -37.4 74.97 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 120.455 -1.403 . . . . 0.0 109.161 -178.91 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 32.1 m -77.99 -15.05 14.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.273 -0.892 . . . . 0.0 108.82 179.163 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -78.9 176.52 54.6 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.719 -1.353 . . . . 0.0 109.719 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 22.7 t -156.46 171.75 19.73 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.31 -1.112 . . . . 0.0 109.288 -179.769 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 22.6 t -54.71 -30.78 56.88 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.13 -0.981 . . . . 0.0 109.224 179.84 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 86.8 p -59.98 -26.56 66.12 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.175 -0.953 . . . . 0.0 109.56 179.958 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 90.21 17.07 54.5 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 109.828 -1.309 . . . . 0.0 109.828 179.804 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 28.4 ttm180 -119.12 142.56 47.81 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.311 -1.111 . . . . 0.0 109.221 -180.0 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 165' ' ' THR . . . . . 0.71 HG22 HG21 ' A' ' 69' ' ' VAL . 82.2 p -79.36 149.14 31.78 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.165 -0.959 . . . . 0.0 109.761 -179.911 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -67.25 -35.62 79.93 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.314 -0.866 . . . . 0.0 109.153 179.686 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 96.6 mttt -117.27 156.93 26.92 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.515 -0.74 . . . . 0.0 109.138 179.918 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 63.9 mttp -68.69 130.74 43.71 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.096 -1.003 . . . . 0.0 109.333 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 34.4 t -122.42 123.36 68.45 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 121.409 -0.807 . . . . 0.0 109.392 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 42.1 t -144.41 141.03 24.27 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.34 -0.85 . . . . 0.0 109.23 179.762 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.877 HG22 ' H ' ' A' ' 64' ' ' SER . 4.8 m -65.65 119.29 10.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.103 -0.998 . . . . 0.0 109.296 179.912 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 -70.92 -36.94 72.87 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.033 -1.042 . . . . 0.0 110.621 -179.638 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 173' ' ' ASP . . . . . 0.482 ' OD1' ' N ' ' A' ' 174' ' ' CYS . 52.1 t0 -155.09 161.72 41.21 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.952 -1.092 . . . . 0.0 110.276 -179.184 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 174' ' ' CYS . . . . . 0.482 ' N ' ' OD1' ' A' ' 173' ' ' ASP . 14.8 p -147.36 152.56 38.4 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.398 -0.814 . . . . 0.0 109.224 179.788 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . 178.41 170.81 41.01 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 179.702 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 64.1 tt0 -105.17 119.35 38.82 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.365 -1.08 . . . . 0.0 109.474 179.925 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 30.8 tp -61.68 -37.97 86.07 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.213 -0.929 . . . . 0.0 109.422 179.87 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 38.7 m . . . . . 0 N--CA 1.489 1.513 0 CA-C-O 118.027 -0.987 . . . . 0.0 109.498 179.988 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 16.3 m-80 . . . . . 0 N--CA 1.49 1.567 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -68.1 140.76 50.54 Favored 'Trans proline' 0 N--CA 1.496 1.627 0 C-N-CA 122.787 2.325 . . . . 0.0 112.501 -179.802 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . 0.557 ' NH2' HG11 ' A' ' 27' ' ' VAL . 55.2 ttt85 -133.0 129.91 38.78 Favored 'General case' 0 N--CA 1.489 1.524 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 179.027 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.7 p -135.22 144.75 33.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.18 -0.95 . . . . 0.0 110.133 -179.006 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 48.6 p90 -136.79 154.47 50.54 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.447 -0.783 . . . . 0.0 109.1 179.752 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.568 ' CE2' ' SG ' ' A' ' 174' ' ' CYS . 86.9 m-85 -121.42 137.49 54.69 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.437 -0.79 . . . . 0.0 109.934 -179.848 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.2 t0 -94.71 115.06 27.06 Favored 'General case' 0 N--CA 1.494 1.748 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 178.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' MET . . . . . 0.569 ' SD ' HD11 ' A' ' 155' ' ' ILE . 77.7 mtp -108.35 146.58 32.77 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.198 -0.939 . . . . 0.0 110.826 -178.824 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.415 ' OG ' ' O ' ' A' ' 21' ' ' GLN . 46.8 t -134.25 149.58 50.96 Favored 'General case' 0 N--CA 1.491 1.605 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 179.61 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.418 ' C ' ' N ' ' A' ' 20' ' ' GLY . 35.5 m -112.2 133.96 56.23 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 121.178 -0.951 . . . . 0.0 109.721 -179.664 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 52.95 12.88 1.94 Allowed Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.418 ' N ' ' C ' ' A' ' 18' ' ' VAL . . . 97.11 -10.22 65.62 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.45 -1.46 . . . . 0.0 109.45 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' GLN . . . . . 0.415 ' O ' ' OG ' ' A' ' 17' ' ' SER . 81.4 mt-30 -88.99 149.37 43.19 Favored Pre-proline 0 N--CA 1.49 1.53 0 O-C-N 121.243 -1.151 . . . . 0.0 109.084 179.733 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -62.38 133.89 45.51 Favored 'Trans proline' 0 C--N 1.309 -1.527 0 C-N-CA 122.288 1.992 . . . . 0.0 112.014 -179.772 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -112.33 -65.21 1.2 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.438 -0.789 . . . . 0.0 109.339 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 179.92 -172.28 43.84 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 61.0 ttp180 -119.1 143.08 47.35 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.422 -1.046 . . . . 0.0 109.198 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 82.7 mt -119.8 128.9 75.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.384 -0.823 . . . . 0.0 109.03 179.779 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.557 HG11 ' NH2' ' A' ' 11' ' ' ARG . 39.0 t -116.59 133.78 62.15 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.406 -0.809 . . . . 0.0 109.272 -179.947 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 72.6 mtm -122.5 152.07 40.7 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.422 -0.798 . . . . 0.0 109.277 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -100.58 131.58 46.41 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.271 -0.893 . . . . 0.0 109.825 -179.626 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.41 ' N ' ' CD2' ' A' ' 30' ' ' LEU . 2.6 mm? -106.12 133.16 51.26 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 179.487 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -96.57 120.81 37.57 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.025 -1.047 . . . . 0.0 109.054 179.459 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -88.02 -41.51 13.06 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.269 -0.895 . . . . 0.0 109.657 -179.809 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -65.28 -42.42 93.2 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.347 -0.846 . . . . 0.0 110.519 -179.214 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 54.6 m -66.32 -44.61 82.88 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.031 -1.043 . . . . 0.0 110.208 -179.324 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.454 ' OG1' ' OG1' ' A' ' 38' ' ' THR . 0.1 OUTLIER -155.67 84.48 3.45 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.261 -0.899 . . . . 0.0 109.301 -179.72 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 1.7 Cg_endo -62.14 -42.07 31.61 Favored 'Trans proline' 0 C--N 1.307 -1.638 0 C-N-CA 122.078 1.852 . . . . 0.0 112.412 -179.245 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 50.1 mtt180 -63.21 -39.54 94.94 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.426 -0.796 . . . . 0.0 110.81 -179.028 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.454 ' OG1' ' OG1' ' A' ' 35' ' ' THR . 75.6 m -63.27 -40.14 96.55 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 120.834 -1.167 . . . . 0.0 109.947 -179.666 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -61.33 -31.56 71.43 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.137 -0.977 . . . . 0.0 109.216 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -67.55 -36.53 81.14 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.303 -0.873 . . . . 0.0 109.885 -179.898 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 45.2 t-20 -57.88 -41.79 83.26 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.219 -0.926 . . . . 0.0 109.85 -179.622 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 98.8 m-85 -87.0 -46.98 9.33 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.106 -0.996 . . . . 0.0 109.804 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.658 ' CZ ' HE22 ' A' ' 176' ' ' GLN . 78.5 ttt180 -57.07 -39.27 74.6 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.363 -0.836 . . . . 0.0 110.147 -179.623 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -63.96 -48.24 77.25 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.02 -1.05 . . . . 0.0 110.214 -179.292 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.74 HD12 ' CD1' ' A' ' 61' ' ' TYR . 4.3 mm? -65.78 -38.93 90.35 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.092 -1.005 . . . . 0.0 109.663 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' CYS . . . . . 0.56 ' SG ' ' SG ' ' A' ' 174' ' ' CYS . 77.7 m -66.01 -47.97 72.73 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.12 -0.988 . . . . 0.0 109.469 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 63.9 p -76.78 -30.78 56.62 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.259 -0.901 . . . . 0.0 109.697 179.733 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 76.25 31.64 54.32 Favored Glycine 0 N--CA 1.492 2.379 0 N-CA-C 110.214 -1.154 . . . . 0.0 110.214 179.521 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 77.8 mm-40 -62.25 -36.07 80.91 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.944 -1.327 . . . . 0.0 109.573 179.798 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 61.1 mmtt -60.43 -34.03 73.38 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.17 -0.956 . . . . 0.0 109.494 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 76.4 -94.54 1.04 Allowed Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.475 -1.45 . . . . 0.0 109.475 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 31.8 m -118.01 142.46 47.35 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.372 -1.075 . . . . 0.0 109.296 -179.798 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -54.53 -42.43 76.15 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.838 -1.305 . . . . 0.0 109.838 -179.828 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 82.0 mtp180 -147.05 -113.06 0.08 Allowed 'General case' 0 N--CA 1.486 1.364 0 O-C-N 121.172 -1.193 . . . . 0.0 109.265 179.871 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 3.4 m -107.08 -24.72 11.86 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.401 -0.812 . . . . 0.0 109.521 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -144.31 73.23 0.34 Allowed Glycine 0 N--CA 1.493 2.461 0 N-CA-C 109.471 -1.452 . . . . 0.0 109.471 -179.722 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 46.6 tttm -171.46 74.21 0.51 Allowed Pre-proline 0 N--CA 1.489 1.496 0 O-C-N 121.383 -1.069 . . . . 0.0 108.833 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_exo -50.06 128.75 23.08 Favored 'Trans proline' 0 C--N 1.305 -1.76 0 C-N-CA 122.646 2.231 . . . . 0.0 111.977 -179.4 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.525 ' O ' ' CG ' ' A' ' 60' ' ' HIS . 11.5 tp -112.24 118.38 35.14 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.531 -0.731 . . . . 0.0 109.186 -179.593 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . 0.533 ' O ' ' CE1' ' A' ' 80' ' ' PHE . 95.6 m-70 -158.52 140.73 14.07 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.128 -0.983 . . . . 0.0 109.904 -179.952 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . 0.74 ' CD1' HD12 ' A' ' 45' ' ' LEU . 2.4 m-85 -102.17 12.26 37.01 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.254 -0.904 . . . . 0.0 108.851 179.211 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 83.7 mttt -86.73 156.64 19.86 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.383 -0.823 . . . . 0.0 109.619 -179.709 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 54.6 t0 55.8 46.78 21.65 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.401 -0.812 . . . . 0.0 109.454 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 99.4 p -116.85 155.3 29.25 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.411 -0.806 . . . . 0.0 109.301 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 28.6 t -113.16 147.43 37.4 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.362 -0.836 . . . . 0.0 109.323 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.7 m-30 -61.11 142.43 56.7 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.213 -0.929 . . . . 0.0 108.864 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 80.5 t60 -57.29 -50.72 72.03 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.127 -0.983 . . . . 0.0 109.934 -179.206 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.692 HH21 ' NE2' ' A' ' 76' ' ' GLN . 30.1 ptt180 -169.42 160.95 9.61 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.115 -0.99 . . . . 0.0 109.843 179.834 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.474 HG21 HG21 ' A' ' 165' ' ' THR . 0.0 OUTLIER -136.1 135.37 50.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 179.548 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 75.1 mt -136.61 128.25 16.92 Favored Pre-proline 0 N--CA 1.492 1.667 0 O-C-N 121.309 -0.87 . . . . 0.0 109.349 -179.699 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -75.41 136.74 19.97 Favored 'Trans proline' 0 C--N 1.312 -1.39 0 C-N-CA 122.091 1.86 . . . . 0.0 111.888 179.672 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 94.5 -5.23 70.34 Favored Glycine 0 N--CA 1.492 2.432 0 N-CA-C 109.821 -1.312 . . . . 0.0 109.821 179.705 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 77.6 m-85 -135.13 -94.96 0.27 Allowed 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.211 -1.17 . . . . 0.0 109.677 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' MET . . . . . 0.506 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 6.9 ptt? -170.81 -165.88 0.46 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.172 -0.955 . . . . 0.0 109.464 -179.653 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 15.4 p -132.7 151.61 51.93 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.423 -0.798 . . . . 0.0 109.054 179.741 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' GLN . . . . . 0.692 ' NE2' HH21 ' A' ' 68' ' ' ARG . 94.1 mt-30 -115.72 158.71 22.39 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.372 -0.83 . . . . 0.0 109.63 -179.703 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -140.28 -172.68 12.97 Favored Glycine 0 N--CA 1.494 2.516 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 -179.898 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 95.59 6.33 59.69 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.475 -1.45 . . . . 0.0 109.475 -179.771 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 56.0 t0 -57.44 -25.75 60.13 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.278 -1.131 . . . . 0.0 109.444 179.912 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.533 ' CE1' ' O ' ' A' ' 60' ' ' HIS . 91.3 t80 -49.19 -44.81 43.38 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.378 -0.826 . . . . 0.0 110.151 -179.483 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.688 ' CB ' ' H ' ' A' ' 88' ' ' GLY . 65.0 p -69.85 -29.52 66.78 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 120.989 -1.069 . . . . 0.0 109.487 179.874 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . 0.684 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 163.3 -55.53 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.344 -0.847 . . . . 0.0 109.244 179.724 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 91.02 1.46 72.84 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 179.884 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . 0.478 ' ND2' ' OG1' ' A' ' 86' ' ' THR . 39.9 p-10 -89.8 7.64 35.96 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.21 -1.171 . . . . 0.0 109.482 -179.931 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 95.8 -38.45 3.11 Favored Glycine 0 N--CA 1.492 2.389 0 N-CA-C 109.246 -1.541 . . . . 0.0 109.246 -179.793 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . 0.478 ' OG1' ' ND2' ' A' ' 84' ' ' ASN . 56.7 p -73.16 -17.54 61.37 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.235 -1.156 . . . . 0.0 109.027 179.529 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -82.75 -164.82 36.02 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.589 -1.405 . . . . 0.0 109.589 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.688 ' H ' ' CB ' ' A' ' 81' ' ' THR . . . 81.94 47.76 6.07 Favored Glycine 0 N--CA 1.488 2.16 0 N-CA-C 109.264 -1.534 . . . . 0.0 109.264 -179.808 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -83.45 147.0 28.09 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.421 -1.046 . . . . 0.0 109.521 -179.722 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 50.5 m -107.84 150.12 27.41 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.485 -0.759 . . . . 0.0 109.275 -179.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 5.1 pt -59.6 -40.69 82.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.196 -0.94 . . . . 0.0 109.898 -179.759 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 3.4 m-30 -63.71 -41.42 98.09 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.013 -1.054 . . . . 0.0 109.321 179.733 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 72.58 24.53 76.04 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.719 -1.352 . . . . 0.0 109.719 179.725 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -147.28 153.82 40.22 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.135 -1.214 . . . . 0.0 109.698 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 94.6 mttt -96.73 142.08 29.19 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.361 -0.837 . . . . 0.0 109.552 179.88 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . 0.533 ' CZ ' ' OD1' ' A' ' 121' ' ' ASN . 38.1 p90 -141.07 156.25 46.03 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.322 -0.861 . . . . 0.0 109.42 179.705 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -70.91 145.44 50.16 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.29 -0.881 . . . . 0.0 109.748 -179.699 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . 0.539 ' OD2' HG21 ' A' ' 140' ' ' VAL . 87.8 m-20 -64.16 139.02 58.72 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.17 -0.957 . . . . 0.0 109.153 179.92 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . 0.482 ' O ' ' OD1' ' A' ' 100' ' ' ASN . 97.2 mt-10 -66.06 -41.13 91.21 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.178 -0.951 . . . . 0.0 110.56 -179.093 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . 0.482 ' OD1' ' O ' ' A' ' 99' ' ' GLU . 83.2 m-20 -149.96 149.16 29.99 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 120.948 -1.095 . . . . 0.0 110.466 -179.582 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -110.75 9.93 22.67 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.849 -0.797 . . . . 0.0 108.849 179.152 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 91.2 mt -54.97 -37.5 42.16 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.408 -0.807 . . . . 0.0 110.583 -179.069 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 57.0 mttm -76.52 134.46 39.46 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 120.899 -1.125 . . . . 0.0 109.63 -179.495 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 39.8 tttp -138.43 159.14 42.82 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.471 -0.768 . . . . 0.0 109.308 -179.735 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' HIS . . . . . 0.491 ' C ' ' ND1' ' A' ' 105' ' ' HIS . 6.8 t-80 -85.46 108.94 18.13 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.195 -0.941 . . . . 0.0 109.282 179.936 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 68.2 p -123.49 2.42 9.01 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.22 -0.925 . . . . 0.0 109.91 -179.888 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -155.05 175.06 33.19 Favored Glycine 0 N--CA 1.492 2.416 0 N-CA-C 109.818 -1.313 . . . . 0.0 109.818 -179.834 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -79.78 157.62 24.48 Favored 'Trans proline' 0 C--N 1.307 -1.617 0 C-N-CA 123.112 2.541 . . . . 0.0 112.142 179.714 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 78.11 45.17 10.5 Favored Glycine 0 N--CA 1.493 2.47 0 N-CA-C 109.678 -1.369 . . . . 0.0 109.678 179.604 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.72 137.33 50.92 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.378 -1.072 . . . . 0.0 109.754 -179.825 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.541 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 2.8 mm? -91.11 129.76 37.07 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.283 -0.886 . . . . 0.0 109.097 179.439 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 29.1 t -142.43 143.6 32.71 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.188 -0.945 . . . . 0.0 109.486 179.954 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 72.2 mtm -89.33 133.31 34.54 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.161 -0.962 . . . . 0.0 109.334 179.839 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -64.98 142.35 58.47 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.18 -0.95 . . . . 0.0 109.311 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . 0.525 ' ND2' ' O ' ' A' ' 117' ' ' GLY . 53.2 t-20 -143.04 153.16 42.67 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.204 -0.935 . . . . 0.0 109.85 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . 0.471 ' N ' ' OD1' ' A' ' 115' ' ' ASN . . . -123.91 -12.31 7.54 Favored 'General case' 0 N--CA 1.493 1.688 0 N-CA-C 108.836 -0.802 . . . . 0.0 108.836 179.624 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . 0.525 ' O ' ' ND2' ' A' ' 115' ' ' ASN . . . -145.52 166.34 27.75 Favored Glycine 0 N--CA 1.493 2.472 0 N-CA-C 109.236 -1.545 . . . . 0.0 109.236 179.934 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -70.74 152.28 64.1 Favored 'Trans proline' 0 C--N 1.306 -1.696 0 C-N-CA 122.72 2.28 . . . . 0.0 112.108 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 76.2 m-20 52.98 41.62 32.14 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.473 -0.767 . . . . 0.0 109.502 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 120' ' ' THR . . . . . 0.52 ' O ' ' ND2' ' A' ' 115' ' ' ASN . 62.2 m -138.75 125.79 21.27 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.339 -0.851 . . . . 0.0 109.223 179.771 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 121' ' ' ASN . . . . . 0.533 ' OD1' ' CZ ' ' A' ' 96' ' ' PHE . 28.7 m120 -106.32 121.89 45.13 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.532 -0.73 . . . . 0.0 109.383 179.844 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -93.6 132.85 11.4 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.669 -1.372 . . . . 0.0 109.669 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 18.8 m -58.83 -33.66 70.65 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.29 -1.123 . . . . 0.0 109.399 179.773 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.3 mt-30 -68.97 145.29 53.73 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.372 -0.83 . . . . 0.0 109.636 -179.793 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 48.8 p90 -135.66 162.54 32.45 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.408 -0.808 . . . . 0.0 109.133 179.83 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . 0.506 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 48.9 p90 -136.51 157.1 47.57 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.176 -0.953 . . . . 0.0 109.775 -179.927 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 68.3 mt -120.9 136.54 57.56 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.506 -0.746 . . . . 0.0 109.288 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 23.0 t -115.95 126.74 54.27 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.269 -0.894 . . . . 0.0 109.416 179.881 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 28.0 p -102.51 11.17 38.27 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.353 -0.842 . . . . 0.0 109.511 -179.891 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -140.39 163.29 33.2 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.306 -0.871 . . . . 0.0 109.431 -179.775 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 71.9 mmtt -67.51 138.29 56.44 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.252 -0.905 . . . . 0.0 109.205 -179.946 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 61.6 p -150.18 85.29 1.4 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.295 -0.878 . . . . 0.0 109.534 -179.868 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -62.82 -36.09 82.05 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.278 -0.889 . . . . 0.0 109.85 -179.895 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 0.9 OUTLIER -64.76 -46.3 82.74 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.125 -0.984 . . . . 0.0 109.515 -179.892 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 18.1 mt -65.83 -32.4 73.9 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.232 -0.918 . . . . 0.0 109.611 179.266 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . 0.445 ' OD2' ' O ' ' A' ' 105' ' ' HIS . 60.9 t0 -79.71 119.65 22.93 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.308 -0.87 . . . . 0.0 109.71 -179.816 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 165.57 -100.54 0.17 Allowed Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 62.5 mttp -57.45 -36.16 71.05 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.294 -1.121 . . . . 0.0 109.825 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 78.0 m80 -65.04 150.22 48.48 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.338 -0.851 . . . . 0.0 109.705 -179.501 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.539 HG21 ' OD2' ' A' ' 98' ' ' ASP . 49.8 t -123.33 144.7 32.02 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 121.542 -0.724 . . . . 0.0 109.423 -179.739 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 61.7 t -92.45 130.58 41.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.293 -0.879 . . . . 0.0 109.857 -179.548 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 40.2 p90 -112.98 -3.11 14.1 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.445 -0.784 . . . . 0.0 109.328 179.624 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -168.19 177.35 42.37 Favored Glycine 0 N--CA 1.492 2.402 0 N-CA-C 109.169 -1.572 . . . . 0.0 109.169 179.796 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.2 pt20 -146.61 166.94 25.0 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.075 -1.25 . . . . 0.0 109.741 -179.744 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 75.0 t -96.45 129.7 46.14 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.283 0 O-C-N 121.266 -0.896 . . . . 0.0 109.389 -179.843 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 15.8 m -105.65 -33.92 2.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.339 -0.851 . . . . 0.0 109.723 179.756 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -142.45 169.17 18.08 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.274 -0.891 . . . . 0.0 109.689 -179.75 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 95.89 7.97 58.36 Favored Glycine 0 N--CA 1.493 2.47 0 N-CA-C 109.929 -1.269 . . . . 0.0 109.929 179.612 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 149' ' ' MET . . . . . 0.493 ' O ' HG12 ' A' ' 152' ' ' VAL . 64.9 mtt -60.34 -34.05 73.29 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.155 -1.203 . . . . 0.0 109.776 179.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 89.1 m-20 -65.03 -42.33 94.46 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 120.865 -1.147 . . . . 0.0 110.03 -179.553 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.6 p -82.44 -32.09 10.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.21 -0.932 . . . . 0.0 110.653 -179.263 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 152' ' ' VAL . . . . . 0.493 HG12 ' O ' ' A' ' 149' ' ' MET . 0.8 OUTLIER -55.58 -40.67 60.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 120.833 -1.167 . . . . 0.0 109.008 -179.332 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 153' ' ' LYS . . . . . 0.43 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 67.0 mttm -62.92 -36.46 83.46 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.132 -0.98 . . . . 0.0 108.999 179.396 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -62.45 -35.08 78.16 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.305 -0.872 . . . . 0.0 109.414 179.825 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.569 HD11 ' SD ' ' A' ' 16' ' ' MET . 93.6 mt -67.35 -12.79 15.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.513 -0.742 . . . . 0.0 109.808 179.9 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -118.55 -19.48 8.76 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 -179.617 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 157' ' ' LYS . . . . . 0.403 ' N ' ' O ' ' A' ' 153' ' ' LYS . 38.9 tttm -58.83 -42.18 88.63 Favored 'General case' 0 C--N 1.299 -1.597 0 CA-C-O 121.376 0.608 . . . . 0.0 109.743 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 16.5 m -83.75 -12.56 11.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.533 -0.729 . . . . 0.0 109.25 179.449 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . 0.648 ' HA2' HG22 ' A' ' 165' ' ' THR . . . -59.97 151.98 37.0 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.941 -1.264 . . . . 0.0 109.941 -179.729 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 27.0 t -143.27 158.31 43.73 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.505 -0.997 . . . . 0.0 109.255 179.917 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 22.9 t -54.1 -33.85 58.73 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.151 -0.968 . . . . 0.0 109.307 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 24.5 m -57.75 -29.47 64.82 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.321 -0.862 . . . . 0.0 109.401 179.682 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 100.52 1.05 55.48 Favored Glycine 0 N--CA 1.493 2.45 0 N-CA-C 109.263 -1.535 . . . . 0.0 109.263 -179.656 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 72.2 ttt-85 -108.16 149.98 27.83 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.477 -1.013 . . . . 0.0 108.933 179.666 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 165' ' ' THR . . . . . 0.648 HG22 ' HA2' ' A' ' 159' ' ' GLY . 69.8 p -117.05 155.51 29.12 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.272 -0.892 . . . . 0.0 110.104 -179.582 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -70.14 -37.29 75.23 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.578 -0.702 . . . . 0.0 109.694 179.776 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 53.9 mttm -109.56 152.6 25.28 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.359 -0.838 . . . . 0.0 109.928 -179.392 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 63.7 mttm -87.95 151.33 22.88 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.404 -0.81 . . . . 0.0 109.43 179.911 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . 0.436 ' O ' HG23 ' A' ' 169' ' ' VAL . 34.5 m -125.7 127.61 71.59 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 121.247 -0.908 . . . . 0.0 109.744 -179.988 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 43.4 t -146.63 145.91 19.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.245 -0.909 . . . . 0.0 109.196 179.722 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -88.15 120.95 37.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.111 -0.993 . . . . 0.0 109.479 -179.727 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -62.69 -28.59 70.04 Favored 'General case' 0 C--N 1.3 -1.586 0 N-CA-C 108.901 -0.777 . . . . 0.0 108.901 179.489 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 52.0 p30 -178.67 170.15 1.62 Allowed 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.383 -0.823 . . . . 0.0 110.202 -179.881 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 174' ' ' CYS . . . . . 0.568 ' SG ' ' CE2' ' A' ' 14' ' ' PHE . 54.1 t -139.43 134.98 33.12 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.529 -0.732 . . . . 0.0 109.062 179.356 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -150.67 169.25 30.52 Favored Glycine 0 N--CA 1.493 2.496 0 N-CA-C 109.738 -1.345 . . . . 0.0 109.738 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 176' ' ' GLN . . . . . 0.658 HE22 ' CZ ' ' A' ' 43' ' ' ARG . 63.9 tt0 -108.52 122.75 47.71 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.453 -1.028 . . . . 0.0 109.497 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 177' ' ' LEU . . . . . 0.605 HD13 ' O ' ' A' ' 177' ' ' LEU . 0.2 OUTLIER -63.72 -38.59 91.67 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.23 -0.919 . . . . 0.0 108.908 179.714 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 27.0 t . . . . . 0 N--CA 1.49 1.526 0 O-C-N 121.027 -1.046 . . . . 0.0 109.455 179.872 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 . . . . . 0 N--CA 1.492 1.632 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -68.1 139.69 47.35 Favored 'Trans proline' 0 N--CA 1.497 1.706 0 C-N-CA 122.713 2.276 . . . . 0.0 112.464 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 82.3 mtp180 -132.28 134.47 45.31 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.419 -0.8 . . . . 0.0 108.869 179.071 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.8 p -135.29 143.49 36.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 O-C-N 121.256 -0.903 . . . . 0.0 109.539 -179.652 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 42.8 p90 -138.95 155.61 47.9 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.321 -0.862 . . . . 0.0 109.459 179.948 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.593 ' CE2' ' SG ' ' A' ' 174' ' ' CYS . 76.4 m-85 -122.13 137.87 54.67 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.451 -0.781 . . . . 0.0 109.697 179.883 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 22.8 t70 -88.04 117.02 26.63 Favored 'General case' 0 N--CA 1.493 1.719 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 179.123 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' MET . . . . . 0.412 ' SD ' HD12 ' A' ' 26' ' ' ILE . 83.3 mtp -104.63 143.87 32.48 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.342 -0.849 . . . . 0.0 110.713 -179.044 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.463 ' OG ' ' OE2' ' A' ' 172' ' ' GLU . 61.9 m -141.43 159.3 42.51 Favored 'General case' 0 N--CA 1.49 1.551 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 179.383 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.47 HG13 ' HB2' ' A' ' 23' ' ' ALA . 33.1 m -123.58 147.95 27.77 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.179 -0.95 . . . . 0.0 109.756 -179.759 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 49.09 -107.75 0.33 Allowed Glycine 0 N--CA 1.488 2.113 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.925 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -128.83 25.83 4.62 Favored Glycine 0 N--CA 1.494 2.53 0 N-CA-C 109.631 -1.387 . . . . 0.0 109.631 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 10.7 pt20 -141.58 149.5 54.15 Favored Pre-proline 0 N--CA 1.493 1.714 0 O-C-N 121.3 -1.118 . . . . 0.0 109.29 179.846 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -67.57 138.43 45.64 Favored 'Trans proline' 0 N--CA 1.494 1.544 0 C-N-CA 122.504 2.136 . . . . 0.0 112.108 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.47 ' HB2' HG13 ' A' ' 18' ' ' VAL . . . -101.72 -54.29 2.77 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.411 -0.806 . . . . 0.0 109.216 179.713 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -176.02 -171.25 39.67 Favored Glycine 0 N--CA 1.488 2.156 0 N-CA-C 109.317 -1.513 . . . . 0.0 109.317 -179.916 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 33.0 ptt180 -131.1 148.57 52.75 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.482 -1.011 . . . . 0.0 109.138 179.73 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.412 HD12 ' SD ' ' A' ' 16' ' ' MET . 82.8 mt -122.91 130.11 74.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.318 -0.864 . . . . 0.0 109.248 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 42.0 t -111.0 132.63 58.97 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.491 -0.756 . . . . 0.0 109.222 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 74.1 mtm -120.88 146.93 46.08 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.439 -0.788 . . . . 0.0 109.18 -179.894 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -101.13 131.12 47.23 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.294 -0.879 . . . . 0.0 109.794 -179.718 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.418 ' N ' ' CD2' ' A' ' 30' ' ' LEU . 2.5 mm? -106.2 131.67 53.17 Favored 'General case' 0 N--CA 1.493 1.693 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 179.512 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 95.4 m-85 -98.4 118.29 34.74 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.215 -0.928 . . . . 0.0 109.024 179.572 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -80.68 -42.82 21.38 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.341 -0.85 . . . . 0.0 109.771 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -64.7 -45.89 84.67 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.293 -0.879 . . . . 0.0 110.311 -179.328 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . 0.409 HG21 ' CE ' ' A' ' 103' ' ' LYS . 26.4 m -67.8 -45.13 75.67 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.121 -0.987 . . . . 0.0 109.835 -179.57 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.472 ' O ' ' OG1' ' A' ' 35' ' ' THR . 4.6 p -142.67 81.4 13.37 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 121.282 -0.886 . . . . 0.0 109.325 -179.75 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -64.27 -58.29 0.26 Allowed 'Trans proline' 0 N--CA 1.494 1.537 0 C-N-CA 122.283 1.989 . . . . 0.0 112.582 -179.347 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 78.4 mtp180 -62.03 -37.11 83.68 Favored 'General case' 0 C--N 1.299 -1.602 0 O-C-N 121.428 -0.795 . . . . 0.0 110.647 -179.132 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 28.1 m -61.91 -41.34 97.81 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.87 -1.144 . . . . 0.0 109.981 -179.542 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -61.3 -31.23 71.07 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.11 -0.994 . . . . 0.0 109.311 -179.739 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.592 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 97.0 mt-10 -66.69 -35.34 79.91 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.351 -0.843 . . . . 0.0 109.885 -179.862 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 88.6 m-20 -55.98 -37.29 68.87 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.256 -0.903 . . . . 0.0 109.85 -179.688 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -97.67 -53.29 3.47 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.221 -0.925 . . . . 0.0 110.024 -179.852 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 59.7 ttp180 -57.94 -42.74 85.54 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.329 -0.857 . . . . 0.0 110.605 -179.179 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.592 ' HB3' ' O ' ' A' ' 40' ' ' GLU . . . -67.73 -44.67 77.05 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.904 -1.123 . . . . 0.0 110.305 -179.181 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.5 ' N ' ' CD2' ' A' ' 45' ' ' LEU . 2.5 mm? -65.74 -40.51 92.19 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.004 -1.06 . . . . 0.0 109.7 -179.801 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' CYS . . . . . . . . . . . . . 72.0 m -67.63 -49.54 62.47 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.067 -1.02 . . . . 0.0 109.334 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 57.5 p -74.46 -32.0 62.43 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.397 -0.814 . . . . 0.0 109.38 179.755 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . 0.459 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 75.85 33.63 50.46 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 110.217 -1.153 . . . . 0.0 110.217 179.457 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -62.23 -37.66 86.22 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.99 -1.3 . . . . 0.0 109.423 179.78 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 54.6 mmtt -61.94 -34.12 75.52 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.275 -0.89 . . . . 0.0 109.349 179.934 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 92.53 172.48 41.27 Favored Glycine 0 N--CA 1.486 2.012 0 N-CA-C 109.239 -1.544 . . . . 0.0 109.239 -179.677 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.536 HG23 ' HA ' ' A' ' 58' ' ' PRO . 89.3 m -73.85 140.73 45.95 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.322 -1.105 . . . . 0.0 109.833 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -57.62 136.17 50.99 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.284 -1.527 . . . . 0.0 109.284 179.829 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 75.6 mtm180 -59.25 -34.11 71.85 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.243 -1.151 . . . . 0.0 110.017 -179.647 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 86.6 p -61.0 -24.82 66.44 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.102 -0.999 . . . . 0.0 109.942 -179.699 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 112.74 90.45 1.89 Allowed Glycine 0 N--CA 1.494 2.507 0 N-CA-C 109.109 -1.596 . . . . 0.0 109.109 -179.696 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . 0.531 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 3.0 ttmp? -175.25 80.73 0.31 Allowed Pre-proline 0 N--CA 1.489 1.502 0 O-C-N 121.479 -1.012 . . . . 0.0 108.448 -179.708 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.536 ' HA ' HG23 ' A' ' 52' ' ' THR . 69.7 Cg_exo -51.18 132.33 38.5 Favored 'Trans proline' 0 C--N 1.303 -1.847 0 C-N-CA 122.942 2.428 . . . . 0.0 112.848 -179.05 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.531 ' CD1' ' O ' ' A' ' 57' ' ' LYS . 7.6 mp -101.09 127.39 47.64 Favored 'General case' 0 N--CA 1.493 1.7 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 179.811 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 6.1 p80 -176.14 132.4 0.24 Allowed 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.094 -1.004 . . . . 0.0 109.86 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 4.4 m-85 -96.95 13.34 29.23 Favored 'General case' 0 N--CA 1.492 1.65 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 179.091 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 85.8 mttt -77.46 149.77 35.01 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.416 -0.802 . . . . 0.0 109.639 -179.765 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . 0.408 ' N ' HG23 ' A' ' 171' ' ' VAL . 46.4 t0 61.4 35.03 17.99 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.581 -0.699 . . . . 0.0 109.618 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.814 ' H ' ' CG2' ' A' ' 171' ' ' VAL . 55.3 p -83.94 160.08 21.15 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.278 -0.889 . . . . 0.0 108.808 179.094 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 31.3 t -128.58 147.96 50.75 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.168 -0.957 . . . . 0.0 109.57 -179.776 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 22.3 m-85 -72.25 130.12 40.06 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.258 -0.901 . . . . 0.0 109.296 179.86 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 79.4 t60 -61.79 -48.99 78.12 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.16 -0.962 . . . . 0.0 109.481 -179.88 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 37.1 ptt180 -164.71 159.74 19.08 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.27 -0.894 . . . . 0.0 109.678 179.671 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.575 HG21 HG22 ' A' ' 165' ' ' THR . 23.0 m -132.51 148.46 31.8 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 179.539 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 11.5 mt -146.79 125.07 6.17 Favored Pre-proline 0 N--CA 1.494 1.735 0 O-C-N 120.956 -1.09 . . . . 0.0 109.576 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -75.34 135.36 18.37 Favored 'Trans proline' 0 N--CA 1.491 1.34 0 C-N-CA 122.264 1.976 . . . . 0.0 112.117 179.667 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 89.67 1.56 77.19 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.686 -1.365 . . . . 0.0 109.686 179.795 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 95.3 m-85 -134.25 -96.09 0.28 Allowed 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.359 -1.083 . . . . 0.0 109.558 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' MET . . . . . 0.6 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 5.9 ptt? -166.67 158.85 13.5 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.047 -1.033 . . . . 0.0 109.686 -179.659 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 1.7 m -98.45 123.35 42.54 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.417 -0.802 . . . . 0.0 109.008 179.402 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 63.6 tt0 -98.87 125.91 44.39 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.276 -0.89 . . . . 0.0 109.811 -179.584 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -84.85 -174.06 50.16 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 179.599 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -137.59 155.52 23.1 Favored Glycine 0 N--CA 1.494 2.513 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 87.7 m-20 -77.02 150.5 35.8 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.226 -1.161 . . . . 0.0 109.502 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 40.8 p90 -64.85 -22.87 67.07 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.142 -0.974 . . . . 0.0 109.443 -179.856 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.468 ' O ' ' HB2' ' A' ' 82' ' ' ALA . 58.9 p -67.11 -30.98 71.15 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.294 -0.879 . . . . 0.0 109.52 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . 0.468 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 176.77 -56.44 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.314 -0.866 . . . . 0.0 109.328 179.953 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 96.12 -10.69 67.76 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 78.7 m-20 -89.15 3.22 52.61 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.177 -1.19 . . . . 0.0 109.323 179.813 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 95.19 -5.54 68.26 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.404 -1.479 . . . . 0.0 109.404 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 64.5 p -72.79 -21.98 60.9 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.245 -1.15 . . . . 0.0 109.41 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -125.32 -123.5 2.71 Favored Glycine 0 N--CA 1.494 2.53 0 N-CA-C 109.384 -1.486 . . . . 0.0 109.384 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 75.6 42.01 27.9 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 179.896 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -79.7 146.55 32.36 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.369 -1.077 . . . . 0.0 109.439 -179.883 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 50.8 m -108.86 148.61 30.35 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.384 -0.822 . . . . 0.0 109.265 -179.83 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.405 HG13 ' N ' ' A' ' 92' ' ' TYR . 15.8 pt -62.6 -39.42 84.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.295 -0.878 . . . . 0.0 109.948 -179.62 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . 0.405 ' N ' HG13 ' A' ' 91' ' ' ILE . 73.6 m-85 -68.0 -37.26 81.24 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.112 -0.993 . . . . 0.0 109.578 179.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 78.14 14.66 82.03 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 -179.932 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -148.87 158.48 44.2 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.238 -1.154 . . . . 0.0 109.588 -179.825 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . 0.466 ' HD3' HG23 ' A' ' 120' ' ' THR . 42.7 mttm -85.3 149.51 25.41 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.238 -0.914 . . . . 0.0 109.596 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . 0.538 ' CE1' ' OD1' ' A' ' 121' ' ' ASN . 55.1 p90 -137.12 161.21 36.76 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.268 -0.895 . . . . 0.0 109.453 179.696 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -102.78 148.33 25.75 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.295 -0.878 . . . . 0.0 109.394 -179.785 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 89.3 m-20 -68.41 133.13 48.19 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.264 -0.897 . . . . 0.0 109.352 -179.897 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -66.26 -37.49 85.59 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.235 -0.916 . . . . 0.0 110.134 -179.731 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 86.9 m-20 -126.68 125.15 41.37 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.224 -0.922 . . . . 0.0 110.098 -179.477 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' PHE . . . . . 0.536 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 69.3 t80 -103.11 5.3 37.84 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.318 -0.864 . . . . 0.0 108.886 179.351 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 91.0 mt -57.19 -34.69 46.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.397 -0.814 . . . . 0.0 110.545 -179.187 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' LYS . . . . . 0.409 ' CE ' HG21 ' A' ' 34' ' ' THR . 91.7 mttt -72.55 135.08 45.52 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.808 -1.182 . . . . 0.0 109.951 -179.358 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 10.4 ptpp? -139.89 -179.05 5.72 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.435 -0.791 . . . . 0.0 109.382 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 105' ' ' HIS . . . . . 0.523 ' CE1' ' O ' ' A' ' 107' ' ' GLY . 82.3 t60 -84.33 77.6 9.96 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.149 -0.969 . . . . 0.0 109.165 179.872 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 54.6 p -75.5 -27.83 58.94 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.324 -0.86 . . . . 0.0 110.154 -179.581 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.523 ' O ' ' CE1' ' A' ' 105' ' ' HIS . . . -149.14 177.78 27.12 Favored Glycine 0 N--CA 1.494 2.517 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 -179.581 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -72.74 155.18 54.17 Favored 'Trans proline' 0 C--N 1.307 -1.65 0 C-N-CA 122.991 2.461 . . . . 0.0 112.314 179.792 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 82.6 47.0 6.15 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 110.138 -1.185 . . . . 0.0 110.138 179.588 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.417 HG12 ' O ' ' A' ' 107' ' ' GLY . 41.8 mm -115.7 138.09 47.24 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.819 0 O-C-N 121.302 -1.116 . . . . 0.0 109.628 179.857 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.418 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 3.7 mm? -89.15 126.72 35.59 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.267 -0.895 . . . . 0.0 109.216 179.627 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . 0.4 ' OG ' ' O ' ' A' ' 140' ' ' VAL . 38.9 t -142.72 142.15 31.91 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.334 -0.854 . . . . 0.0 109.509 179.863 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER -91.55 141.27 28.9 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.319 -0.863 . . . . 0.0 109.174 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . 0.521 ' O ' ' N ' ' A' ' 122' ' ' GLY . . . -63.49 147.31 51.7 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.267 -0.896 . . . . 0.0 109.594 179.986 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . 0.42 ' OD1' ' O ' ' A' ' 114' ' ' ALA . 65.6 m-20 -137.23 112.72 9.35 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.332 -0.855 . . . . 0.0 109.002 179.612 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -72.23 -32.03 66.37 Favored 'General case' 0 C--N 1.294 -1.811 0 O-C-N 121.466 -0.771 . . . . 0.0 109.432 179.807 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -148.49 176.08 27.46 Favored Glycine 0 N--CA 1.492 2.393 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 179.848 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . 0.43 ' O ' ' CG ' ' A' ' 119' ' ' ASN . 71.6 Cg_exo -50.31 148.03 15.17 Favored 'Trans proline' 0 C--N 1.304 -1.786 0 C-N-CA 122.604 2.203 . . . . 0.0 112.903 179.855 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 119' ' ' ASN . . . . . 0.43 ' CG ' ' O ' ' A' ' 118' ' ' PRO . 7.0 p-10 41.83 49.04 3.9 Favored 'General case' 0 N--CA 1.494 1.751 0 CA-C-O 121.135 0.493 . . . . 0.0 110.11 179.451 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 120' ' ' THR . . . . . 0.466 HG23 ' HD3' ' A' ' 95' ' ' LYS . 87.9 m -131.38 124.9 31.31 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.308 -0.87 . . . . 0.0 109.004 179.55 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 121' ' ' ASN . . . . . 0.538 ' OD1' ' CE1' ' A' ' 96' ' ' PHE . 25.4 m120 -101.93 119.1 38.25 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.535 -0.728 . . . . 0.0 109.237 179.768 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . 0.521 ' N ' ' O ' ' A' ' 114' ' ' ALA . . . -84.41 142.2 20.21 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.719 -1.352 . . . . 0.0 109.719 -179.751 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 88.1 p -64.26 -22.83 67.09 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.367 -1.078 . . . . 0.0 109.337 179.739 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 92.9 mt-30 -95.12 151.61 19.06 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.296 -0.878 . . . . 0.0 109.511 -179.873 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 49.3 p90 -134.79 161.57 34.83 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.364 -0.835 . . . . 0.0 109.428 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . 0.6 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 54.1 p90 -138.94 158.88 43.41 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.33 -0.856 . . . . 0.0 109.547 -179.955 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 72.6 mt -121.31 130.75 74.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.435 -0.791 . . . . 0.0 109.486 179.758 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 1.6 m -93.25 105.74 17.78 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.273 -0.892 . . . . 0.0 108.89 179.663 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 60.0 p -75.49 -7.05 53.14 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.379 -0.826 . . . . 0.0 109.711 -179.713 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -149.21 156.28 41.9 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.158 -0.964 . . . . 0.0 109.741 -179.769 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 55.7 tttp -69.38 141.27 54.18 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.212 -0.93 . . . . 0.0 109.236 179.808 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 20.7 p -114.66 153.95 29.28 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.397 -0.814 . . . . 0.0 109.604 -179.858 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . 0.423 ' O ' ' CG ' ' A' ' 136' ' ' ASP . 92.6 mt-10 -106.23 -73.49 0.68 Allowed 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.385 -0.822 . . . . 0.0 109.925 -179.925 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 134' ' ' TRP . . . . . 0.524 ' CD1' ' N ' ' A' ' 135' ' ' LEU . 42.8 p90 -56.03 -36.74 68.32 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.265 -0.897 . . . . 0.0 110.109 -179.535 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . 0.524 ' N ' ' CD1' ' A' ' 134' ' ' TRP . 6.9 tp -74.6 4.04 6.79 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.251 -0.906 . . . . 0.0 109.559 -179.327 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . 0.452 ' C ' ' OD1' ' A' ' 136' ' ' ASP . 53.5 p30 -67.36 167.29 12.77 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.99 -1.069 . . . . 0.0 109.569 -179.941 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 148.96 -134.0 4.77 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.17 -1.572 . . . . 0.0 109.17 -179.909 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 13.7 mptt -91.76 128.84 37.75 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.208 -1.172 . . . . 0.0 109.018 179.647 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 139' ' ' HIS . . . . . 0.459 ' O ' ' CE1' ' A' ' 101' ' ' PHE . 98.4 m-70 -135.72 152.61 51.32 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.287 -0.883 . . . . 0.0 109.647 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.4 ' O ' ' OG ' ' A' ' 112' ' ' SER . 24.5 m -127.73 149.82 33.02 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 121.351 -0.843 . . . . 0.0 109.022 179.573 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 46.1 t -132.08 125.81 55.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.272 -0.892 . . . . 0.0 109.763 -180.0 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 47.1 p90 -109.64 3.01 20.61 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.446 -0.784 . . . . 0.0 108.932 178.932 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -178.11 178.6 48.55 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.024 -1.63 . . . . 0.0 109.024 179.562 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.3 pt20 -145.95 166.68 25.3 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.09 -1.241 . . . . 0.0 109.614 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 69.7 t -97.04 128.37 48.33 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.245 0 O-C-N 121.21 -0.931 . . . . 0.0 109.4 -179.719 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 15.9 m -103.83 -32.01 2.91 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 O-C-N 121.421 -0.799 . . . . 0.0 109.395 179.588 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -143.45 170.07 16.49 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.329 -0.857 . . . . 0.0 109.407 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 96.55 5.13 59.08 Favored Glycine 0 N--CA 1.493 2.475 0 N-CA-C 109.909 -1.276 . . . . 0.0 109.909 179.61 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 149' ' ' MET . . . . . 0.545 ' O ' HG12 ' A' ' 152' ' ' VAL . 97.0 mmm -60.18 -32.22 70.86 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.144 -1.209 . . . . 0.0 109.458 179.778 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -65.36 -41.71 93.52 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.899 -1.125 . . . . 0.0 110.106 -179.548 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 6.7 p -80.96 -33.26 13.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 120.987 -1.07 . . . . 0.0 110.707 -179.279 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 152' ' ' VAL . . . . . 0.545 HG12 ' O ' ' A' ' 149' ' ' MET . 1.0 OUTLIER -51.92 -41.08 29.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 120.84 -1.162 . . . . 0.0 108.998 -179.264 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 153' ' ' LYS . . . . . 0.439 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 66.8 mttm -65.68 -33.38 75.75 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.214 -0.929 . . . . 0.0 109.214 179.213 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -60.63 -37.23 80.79 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.489 -0.757 . . . . 0.0 109.942 -179.42 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 88.4 mt -70.52 -37.63 70.75 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.524 0 O-C-N 121.156 -0.965 . . . . 0.0 110.066 -179.687 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -77.06 -41.16 43.53 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.196 -0.94 . . . . 0.0 111.556 -178.39 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 16.7 pttm -59.91 -35.4 74.8 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 120.57 -1.331 . . . . 0.0 109.735 -178.763 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 31.5 m -81.1 -10.39 12.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.041 -1.037 . . . . 0.0 109.017 179.395 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -71.95 165.61 53.84 Favored Glycine 0 N--CA 1.488 2.16 0 N-CA-C 110.056 -1.217 . . . . 0.0 110.056 -179.623 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 24.1 t -154.52 167.87 28.63 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.506 -0.996 . . . . 0.0 109.482 -179.858 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 24.8 m -54.46 -29.89 51.17 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.292 -0.88 . . . . 0.0 109.194 179.827 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 22.8 t -54.26 -30.79 51.8 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.307 -0.871 . . . . 0.0 109.506 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 95.41 12.22 54.5 Favored Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.817 -1.313 . . . . 0.0 109.817 179.916 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 42.1 ttp180 -125.78 143.67 50.96 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.298 -1.119 . . . . 0.0 109.467 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 165' ' ' THR . . . . . 0.575 HG22 HG21 ' A' ' 69' ' ' VAL . 71.5 p -74.63 151.28 39.35 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.094 -1.004 . . . . 0.0 109.326 179.936 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -66.31 -37.93 86.53 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.154 -0.967 . . . . 0.0 109.52 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 67.1 mttm -108.94 156.96 19.1 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.432 -0.792 . . . . 0.0 109.4 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 48.1 mtmt -72.53 130.61 41.04 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.205 -0.934 . . . . 0.0 109.268 179.816 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 25.0 t -124.75 124.14 67.35 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 O-C-N 121.434 -0.791 . . . . 0.0 109.427 -179.888 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 57.5 t -144.33 137.05 22.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.271 -0.893 . . . . 0.0 109.499 179.668 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.814 ' CG2' ' H ' ' A' ' 64' ' ' SER . 27.0 m -71.31 126.32 31.44 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.251 -0.905 . . . . 0.0 109.487 179.746 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 172' ' ' GLU . . . . . 0.49 ' O ' ' OD1' ' A' ' 173' ' ' ASP . 96.3 mt-10 -69.84 -40.72 75.65 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.077 -1.014 . . . . 0.0 109.901 179.855 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 173' ' ' ASP . . . . . 0.49 ' OD1' ' O ' ' A' ' 172' ' ' GLU . 49.7 m-20 -163.91 167.67 20.36 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.219 -0.925 . . . . 0.0 110.218 -179.641 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 174' ' ' CYS . . . . . 0.593 ' SG ' ' CE2' ' A' ' 14' ' ' PHE . 43.7 t -136.51 140.82 43.29 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.581 -0.7 . . . . 0.0 109.306 179.597 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -154.94 173.34 33.29 Favored Glycine 0 N--CA 1.493 2.491 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 179.907 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 63.8 tt0 -104.48 119.25 38.56 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.343 -1.092 . . . . 0.0 109.526 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 34.5 tp -61.83 -38.24 87.45 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.203 -0.936 . . . . 0.0 109.575 179.897 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 8.7 t . . . . . 0 N--CA 1.488 1.454 0 O-C-N 121.094 -1.004 . . . . 0.0 109.454 -179.964 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 16.4 m120 . . . . . 0 N--CA 1.49 1.562 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -70.21 141.68 44.03 Favored 'Trans proline' 0 N--CA 1.496 1.634 0 C-N-CA 122.769 2.313 . . . . 0.0 112.244 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 59.2 mtm180 -127.89 134.52 49.38 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.376 -0.827 . . . . 0.0 108.902 179.294 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 9.6 p -136.21 144.36 33.31 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.389 -0.819 . . . . 0.0 109.309 -179.701 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 48.3 p90 -138.1 153.89 49.26 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.342 -0.849 . . . . 0.0 109.477 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 88.7 m-85 -121.28 136.36 54.98 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.568 -0.707 . . . . 0.0 109.735 179.755 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -93.62 131.4 38.94 Favored 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 179.228 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' MET . . . . . 0.424 ' SD ' ' CD1' ' A' ' 26' ' ' ILE . 74.2 mtp -125.45 153.24 43.79 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.118 -0.989 . . . . 0.0 110.282 -179.386 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 85.2 p -143.78 161.05 39.62 Favored 'General case' 0 N--CA 1.488 1.463 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 179.718 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.422 ' C ' ' N ' ' A' ' 20' ' ' GLY . 33.0 m -126.32 137.49 57.62 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.105 -0.997 . . . . 0.0 109.534 -179.925 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 53.43 11.62 1.84 Allowed Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 179.848 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.422 ' N ' ' C ' ' A' ' 18' ' ' VAL . . . 95.6 -1.39 63.89 Favored Glycine 0 N--CA 1.493 2.465 0 N-CA-C 109.779 -1.328 . . . . 0.0 109.779 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 2.6 mp0 -99.93 152.09 37.7 Favored Pre-proline 0 N--CA 1.495 1.806 0 O-C-N 121.229 -1.159 . . . . 0.0 109.149 179.876 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -61.66 138.52 75.58 Favored 'Trans proline' 0 C--N 1.308 -1.558 0 C-N-CA 122.581 2.187 . . . . 0.0 112.15 -179.83 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -111.69 -64.18 1.32 Allowed 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.441 -0.787 . . . . 0.0 109.471 179.893 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -179.9 -168.75 39.12 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.414 -1.475 . . . . 0.0 109.414 -179.882 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 79.7 mtm180 -114.37 142.18 46.67 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.381 -1.07 . . . . 0.0 109.759 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.424 ' CD1' ' SD ' ' A' ' 16' ' ' MET . 80.2 mt -122.93 121.1 62.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 179.11 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 40.2 t -120.85 134.6 63.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.469 -0.769 . . . . 0.0 109.27 -179.808 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 72.6 mtm -122.44 154.81 37.28 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.405 -0.809 . . . . 0.0 109.349 -179.845 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -100.85 132.0 46.47 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.347 -0.845 . . . . 0.0 109.968 -179.611 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -107.48 128.93 54.93 Favored 'General case' 0 N--CA 1.493 1.717 0 N-CA-C 108.914 -0.772 . . . . 0.0 108.914 179.318 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -98.04 119.66 37.08 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.189 -0.944 . . . . 0.0 109.058 179.661 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -78.84 -40.16 33.47 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.318 -0.864 . . . . 0.0 110.047 -179.623 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.531 ' OD1' ' N ' ' A' ' 34' ' ' THR . 31.6 p-10 -68.72 -40.79 79.75 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.258 -0.902 . . . . 0.0 110.859 -179.093 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . 0.531 ' N ' ' OD1' ' A' ' 33' ' ' ASP . 17.4 m -67.51 -44.56 78.15 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.018 -1.051 . . . . 0.0 109.834 -179.4 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 38.2 p -154.03 83.99 4.16 Favored Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.385 -0.822 . . . . 0.0 109.018 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -70.53 -40.84 3.75 Favored 'Trans proline' 0 C--N 1.309 -1.544 0 C-N-CA 122.085 1.856 . . . . 0.0 112.333 -179.212 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.423 ' HD2' ' H ' ' A' ' 37' ' ' ARG . 1.5 mpt_? -63.71 -40.95 98.04 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.168 -0.958 . . . . 0.0 109.667 -179.973 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 38.3 m -66.16 -41.52 90.24 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.19 -0.944 . . . . 0.0 110.004 -179.755 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -60.66 -32.39 71.58 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.174 -0.953 . . . . 0.0 109.032 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -68.05 -38.23 82.24 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.433 -0.792 . . . . 0.0 109.735 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 46.4 t30 -58.23 -41.41 84.07 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.248 -0.908 . . . . 0.0 109.935 -179.436 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.494 ' O ' ' SG ' ' A' ' 46' ' ' CYS . 97.4 m-85 -86.15 -41.08 15.02 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.047 -1.033 . . . . 0.0 110.108 -179.664 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 61.3 ttp180 -59.14 -44.42 92.05 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.229 -0.919 . . . . 0.0 110.937 -178.925 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -71.17 -46.09 62.11 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 120.945 -1.097 . . . . 0.0 110.259 -179.271 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.498 ' N ' ' CD2' ' A' ' 45' ' ' LEU . 2.3 mm? -65.3 -38.13 89.26 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.164 -0.96 . . . . 0.0 109.69 -179.711 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' CYS . . . . . 0.494 ' SG ' ' O ' ' A' ' 42' ' ' PHE . 73.8 m -71.12 -50.5 32.82 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.098 -1.001 . . . . 0.0 109.576 -179.895 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 30.9 m -63.92 -36.72 84.89 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.329 -0.857 . . . . 0.0 109.589 -179.933 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 95.59 8.24 58.52 Favored Glycine 0 N--CA 1.493 2.46 0 N-CA-C 109.838 -1.305 . . . . 0.0 109.838 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 78.1 mm-40 -61.25 -32.24 72.04 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.238 -1.154 . . . . 0.0 109.526 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 20.9 tptp -58.25 -38.97 77.94 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.255 -0.903 . . . . 0.0 109.482 -179.11 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 90.65 171.45 43.75 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 110.018 -1.233 . . . . 0.0 110.018 179.558 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.555 ' O ' ' O ' ' A' ' 53' ' ' GLY . 81.7 m -79.08 148.44 32.42 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.585 -0.95 . . . . 0.0 109.479 179.925 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.555 ' O ' ' O ' ' A' ' 52' ' ' THR . . . -54.93 -122.36 0.01 OUTLIER Glycine 0 N--CA 1.492 2.389 0 N-CA-C 110.036 -1.226 . . . . 0.0 110.036 -179.839 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . 0.537 ' O ' ' CB ' ' A' ' 55' ' ' SER . 93.0 mtt180 -57.5 -41.15 80.2 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 120.971 -1.311 . . . . 0.0 109.766 -179.498 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . 0.537 ' CB ' ' O ' ' A' ' 54' ' ' ARG . 1.1 t 157.72 -26.86 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.724 0 N-CA-C 108.574 -0.898 . . . . 0.0 108.574 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -119.06 59.94 0.51 Allowed Glycine 0 N--CA 1.493 2.442 0 N-CA-C 109.169 -1.572 . . . . 0.0 109.169 179.926 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 36.4 tptt -172.05 70.97 0.45 Allowed Pre-proline 0 C--N 1.302 -1.474 0 O-C-N 121.447 -1.031 . . . . 0.0 108.56 -179.768 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 92.1 Cg_exo -42.9 94.8 0.02 OUTLIER 'Trans proline' 0 C--N 1.304 -1.766 0 C-N-CA 122.743 2.295 . . . . 0.0 112.202 -179.405 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.484 ' O ' ' CD1' ' A' ' 45' ' ' LEU . 8.2 tp -73.65 54.61 0.48 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.581 -0.699 . . . . 0.0 109.276 -179.731 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 40.5 m80 -138.39 150.63 46.72 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.252 -0.905 . . . . 0.0 109.603 -179.753 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 -67.28 -9.1 37.4 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.233 -0.917 . . . . 0.0 109.26 179.369 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 64.0 tttt -49.18 151.3 1.41 Allowed 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.319 -0.863 . . . . 0.0 109.841 -179.881 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 59.67 47.76 10.18 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.616 -0.677 . . . . 0.0 110.03 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.414 ' HB2' ' H ' ' A' ' 79' ' ' ASP . 62.2 p -115.78 151.06 35.91 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.353 -0.842 . . . . 0.0 109.01 179.202 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 29.4 t -126.46 148.61 49.64 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.346 -0.846 . . . . 0.0 109.594 -179.694 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.8 m-85 -70.99 135.34 47.79 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.252 -0.905 . . . . 0.0 109.084 179.958 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 95.8 m-70 -97.02 -29.99 13.33 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.243 -0.911 . . . . 0.0 110.425 -179.58 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 98.6 mtt180 -134.35 139.95 46.0 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.092 -1.005 . . . . 0.0 110.254 -179.457 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.728 HG21 HG22 ' A' ' 165' ' ' THR . 14.5 m -148.4 42.35 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.497 -0.752 . . . . 0.0 108.973 179.401 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 25.7 mt -76.94 132.84 70.38 Favored Pre-proline 0 C--N 1.301 -1.53 0 O-C-N 121.227 -0.921 . . . . 0.0 109.692 -178.926 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -69.93 145.6 56.66 Favored 'Trans proline' 0 N--CA 1.491 1.363 0 C-N-CA 122.213 1.942 . . . . 0.0 112.154 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 84.63 -54.44 4.92 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.636 -1.386 . . . . 0.0 109.636 179.905 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 83.7 m-85 -69.67 -80.6 0.05 OUTLIER 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.201 -1.176 . . . . 0.0 109.763 -179.905 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 12.9 ptt? 179.37 -179.04 0.38 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.092 -1.005 . . . . 0.0 109.741 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' CYS . . . . . 0.443 ' SG ' ' O ' ' A' ' 127' ' ' ILE . 0.8 OUTLIER -131.8 126.79 35.24 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.499 -0.751 . . . . 0.0 109.068 179.689 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 49.5 tt0 -98.14 137.57 36.71 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.342 -0.849 . . . . 0.0 109.331 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -151.94 -177.72 25.94 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.726 -1.35 . . . . 0.0 109.726 -179.887 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 78.6 56.92 3.46 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.639 -1.384 . . . . 0.0 109.639 -179.925 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.414 ' H ' ' HB2' ' A' ' 64' ' ' SER . 59.2 t0 -69.46 90.63 0.54 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.147 -1.208 . . . . 0.0 108.983 -179.96 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 68.3 t80 -61.19 -49.4 77.33 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.371 -0.83 . . . . 0.0 109.803 -179.623 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 6.6 p -153.2 -98.78 0.05 OUTLIER 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.164 -0.96 . . . . 0.0 109.418 179.828 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -86.37 -64.08 1.21 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.326 -0.859 . . . . 0.0 109.664 -179.899 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 98.48 -15.11 61.54 Favored Glycine 0 N--CA 1.493 2.438 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 -179.857 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 86.5 m-20 -63.5 -31.82 73.1 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.27 -1.135 . . . . 0.0 108.858 179.477 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 152.61 -33.3 0.83 Allowed Glycine 0 N--CA 1.489 2.216 0 N-CA-C 108.7 -1.76 . . . . 0.0 108.7 -179.691 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 55.0 p -78.1 -28.75 48.73 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.393 -1.063 . . . . 0.0 109.102 179.532 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -88.18 -171.07 46.33 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 179.854 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.449 ' CA ' ' OG ' ' A' ' 123' ' ' SER . . . 78.77 46.3 8.67 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 179.905 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -88.73 141.1 28.79 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.205 -1.173 . . . . 0.0 109.451 -179.82 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 92.9 p -107.13 159.32 16.41 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.471 -0.768 . . . . 0.0 109.395 -179.931 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 19.5 pt -59.55 -32.11 48.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.268 -0.895 . . . . 0.0 109.51 -179.805 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 76.5 m-85 -66.33 -24.08 66.47 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.165 -0.959 . . . . 0.0 109.436 179.903 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 76.05 -97.79 1.17 Allowed Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.089 -1.604 . . . . 0.0 109.089 -179.614 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -59.74 147.85 36.37 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.319 -1.106 . . . . 0.0 109.019 179.643 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 9.2 mtmp? -72.27 156.33 39.24 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.417 -0.802 . . . . 0.0 109.418 -179.744 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 36.2 p90 -128.6 160.7 31.57 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.437 -0.789 . . . . 0.0 109.484 -179.818 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -61.52 142.59 56.96 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.292 -0.88 . . . . 0.0 110.123 -179.23 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . 0.425 ' H ' ' HA ' ' A' ' 119' ' ' ASN . 88.5 m-20 -70.24 151.42 45.36 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.226 -0.921 . . . . 0.0 109.615 179.772 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -94.93 164.73 12.78 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.324 -0.86 . . . . 0.0 109.185 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 81.5 m-20 -58.26 153.23 15.65 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.226 -0.922 . . . . 0.0 109.444 -179.765 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' PHE . . . . . 0.584 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 21.9 p90 -132.43 80.79 1.92 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.293 -0.879 . . . . 0.0 109.451 -179.853 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 87.4 mt -59.47 -34.38 54.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.248 -0.908 . . . . 0.0 109.378 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 63.3 mttp -85.77 145.21 27.34 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.232 -0.917 . . . . 0.0 109.385 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 104' ' ' LYS . . . . . 0.482 ' O ' ' N ' ' A' ' 106' ' ' THR . 19.8 pttm -134.66 -178.91 5.28 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.374 -0.829 . . . . 0.0 109.501 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 105' ' ' HIS . . . . . . . . . . . . . 96.5 m-70 -65.02 72.45 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.25 -0.906 . . . . 0.0 109.667 -179.971 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . 0.545 ' O ' ' NZ ' ' A' ' 131' ' ' LYS . 68.7 p -70.82 -27.45 63.89 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.141 -0.974 . . . . 0.0 109.682 179.946 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.421 ' O ' HG12 ' A' ' 110' ' ' ILE . . . -152.97 176.56 31.04 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 109.342 -1.503 . . . . 0.0 109.342 -179.885 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -72.64 153.97 54.49 Favored 'Trans proline' 0 C--N 1.307 -1.638 0 C-N-CA 122.889 2.393 . . . . 0.0 112.095 179.821 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 82.28 49.27 5.31 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 179.632 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.421 HG12 ' O ' ' A' ' 107' ' ' GLY . 39.1 mm -115.2 138.4 45.63 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 121.333 -1.098 . . . . 0.0 109.498 179.938 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.508 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 2.9 mm? -89.57 126.93 35.8 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.297 -0.877 . . . . 0.0 109.595 179.84 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 37.4 t -143.61 139.0 29.42 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.365 -0.835 . . . . 0.0 109.098 179.624 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 113' ' ' MET . . . . . 0.403 ' CE ' HD21 ' A' ' 121' ' ' ASN . 88.5 mtp -81.13 137.13 35.96 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.117 -0.989 . . . . 0.0 109.499 -179.821 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . 0.459 ' O ' ' OD1' ' A' ' 115' ' ' ASN . . . -64.14 142.44 58.41 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.281 -0.887 . . . . 0.0 109.604 -179.865 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . 0.459 ' OD1' ' O ' ' A' ' 114' ' ' ALA . 73.6 m-20 -146.84 114.0 6.22 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.313 -0.867 . . . . 0.0 108.854 179.569 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -68.2 -35.6 78.25 Favored 'General case' 0 C--N 1.298 -1.641 0 O-C-N 121.312 -0.867 . . . . 0.0 109.559 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -150.89 165.59 30.22 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.263 -1.535 . . . . 0.0 109.263 179.823 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_exo -47.14 153.13 1.72 Allowed 'Trans proline' 0 C--N 1.308 -1.585 0 C-N-CA 122.611 2.207 . . . . 0.0 112.826 179.831 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 119' ' ' ASN . . . . . 0.425 ' HA ' ' H ' ' A' ' 98' ' ' ASP . 18.9 m120 54.89 46.46 24.37 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.73 -0.606 . . . . 0.0 109.635 179.695 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 120' ' ' THR . . . . . 0.43 ' O ' ' OD1' ' A' ' 115' ' ' ASN . 58.5 m -135.39 124.45 24.32 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.316 -0.865 . . . . 0.0 109.099 179.857 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 121' ' ' ASN . . . . . 0.403 HD21 ' CE ' ' A' ' 113' ' ' MET . 23.1 t-20 -104.38 107.94 19.11 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.511 -0.743 . . . . 0.0 109.123 179.646 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -87.84 128.39 9.01 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.772 -1.331 . . . . 0.0 109.772 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 123' ' ' SER . . . . . 0.449 ' OG ' ' CA ' ' A' ' 88' ' ' GLY . 87.3 p -64.32 -23.43 67.29 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.366 -1.079 . . . . 0.0 109.343 179.719 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.4 mt-30 -92.65 153.25 19.09 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.302 -0.874 . . . . 0.0 109.562 -179.869 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 54.4 p90 -134.3 161.62 34.45 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.368 -0.832 . . . . 0.0 109.185 179.881 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 49.0 p90 -134.45 156.41 48.62 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.335 -0.853 . . . . 0.0 109.649 -179.854 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.443 ' O ' ' SG ' ' A' ' 75' ' ' CYS . 77.1 mt -122.2 134.11 66.46 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.453 -0.779 . . . . 0.0 109.556 179.928 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 128' ' ' CYS . . . . . 0.444 ' SG ' ' O ' ' A' ' 130' ' ' ALA . 3.9 t -97.92 112.92 24.66 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.177 -0.952 . . . . 0.0 109.087 179.346 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 41.3 p -80.36 -5.1 55.85 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.308 -0.87 . . . . 0.0 109.856 -179.469 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . 0.444 ' O ' ' SG ' ' A' ' 128' ' ' CYS . . . -147.5 161.64 40.67 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.19 -0.944 . . . . 0.0 109.669 -179.626 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.545 ' NZ ' ' O ' ' A' ' 106' ' ' THR . 63.6 mttm -76.56 140.8 41.23 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.194 -0.941 . . . . 0.0 109.299 179.898 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 6.3 p -125.11 158.93 32.64 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.437 -0.789 . . . . 0.0 109.258 -179.918 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -101.98 -74.92 0.61 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.204 -0.935 . . . . 0.0 109.956 -179.81 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 134' ' ' TRP . . . . . 0.581 ' CD1' ' N ' ' A' ' 135' ' ' LEU . 41.7 p90 -61.13 -46.93 88.57 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.21 -0.931 . . . . 0.0 109.999 -179.452 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . 0.581 ' N ' ' CD1' ' A' ' 134' ' ' TRP . 32.9 tp -61.63 -33.83 74.61 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.252 -0.905 . . . . 0.0 109.446 -179.819 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 23.5 t70 -76.5 119.03 19.78 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.258 -0.901 . . . . 0.0 109.645 -179.812 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 137' ' ' GLY . . . . . 0.438 ' H ' ' CD2' ' A' ' 139' ' ' HIS . . . -153.18 -129.87 1.44 Allowed Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.075 -1.61 . . . . 0.0 109.075 179.879 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 47.3 mmtm -86.99 114.43 23.59 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.212 -1.17 . . . . 0.0 108.966 179.659 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 139' ' ' HIS . . . . . 0.438 ' CD2' ' H ' ' A' ' 137' ' ' GLY . 98.0 m-70 -138.25 165.69 26.07 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.427 -0.795 . . . . 0.0 109.474 -179.858 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 48.1 t -113.58 132.6 62.04 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 121.356 -0.84 . . . . 0.0 109.274 179.845 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 61.4 t -112.69 129.07 68.95 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 121.272 -0.893 . . . . 0.0 109.308 179.826 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 40.0 p90 -115.76 2.2 13.6 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.334 -0.854 . . . . 0.0 109.725 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -176.26 179.69 47.2 Favored Glycine 0 N--CA 1.493 2.447 0 N-CA-C 109.771 -1.332 . . . . 0.0 109.771 179.64 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 2.6 pt20 -145.21 167.83 21.85 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.309 -1.112 . . . . 0.0 109.449 -179.89 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 55.4 t -96.34 130.16 45.39 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 O-C-N 121.157 -0.964 . . . . 0.0 109.576 -179.866 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 15.6 m -109.29 -33.25 2.43 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 121.323 -0.861 . . . . 0.0 109.409 179.558 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -142.14 171.1 14.52 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.324 -0.86 . . . . 0.0 109.483 179.914 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 98.71 1.96 57.46 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 109.858 -1.297 . . . . 0.0 109.858 179.674 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 149' ' ' MET . . . . . 0.431 ' O ' HG12 ' A' ' 152' ' ' VAL . 72.0 mtm -61.09 -33.76 73.85 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.049 -1.265 . . . . 0.0 109.539 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 56.2 t0 -63.85 -42.6 97.54 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 120.945 -1.097 . . . . 0.0 109.993 -179.713 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.4 p -82.98 -34.49 11.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.152 -0.968 . . . . 0.0 110.547 -179.532 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 152' ' ' VAL . . . . . 0.459 ' CG1' ' N ' ' A' ' 153' ' ' LYS . 0.6 OUTLIER -56.83 -41.93 76.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 120.896 -1.127 . . . . 0.0 109.289 -179.301 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 153' ' ' LYS . . . . . 0.459 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 46.6 mtpt -63.02 -34.28 77.23 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.186 -0.946 . . . . 0.0 109.424 179.459 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -62.13 -39.47 92.66 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.345 -0.847 . . . . 0.0 109.935 -179.559 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 89.2 mt -72.5 -34.86 49.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.162 -0.962 . . . . 0.0 110.042 -179.824 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -76.71 -41.44 45.24 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.153 -0.967 . . . . 0.0 111.182 -178.881 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 16.9 pttp -62.31 -33.59 74.97 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 120.824 -1.173 . . . . 0.0 109.931 -178.846 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 35.1 m -78.3 -10.41 12.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.023 -1.048 . . . . 0.0 109.262 179.662 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -75.52 174.46 52.36 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.743 -1.343 . . . . 0.0 109.743 -179.772 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 22.6 t -161.7 174.54 13.11 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.328 -1.101 . . . . 0.0 109.448 -179.802 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 23.6 m -54.83 -32.03 60.04 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.205 -0.934 . . . . 0.0 109.233 179.813 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 23.5 m -55.72 -33.18 64.0 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.263 -0.898 . . . . 0.0 109.577 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 94.61 10.09 58.23 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.726 -1.35 . . . . 0.0 109.726 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 16.3 tpt180 -116.98 142.69 46.63 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.426 -1.043 . . . . 0.0 109.058 179.833 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 165' ' ' THR . . . . . 0.728 HG22 HG21 ' A' ' 69' ' ' VAL . 68.0 p -80.21 151.52 29.63 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.229 -0.92 . . . . 0.0 109.579 -179.808 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -68.39 -35.69 78.05 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.337 -0.852 . . . . 0.0 109.104 179.476 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 93.6 mttt -112.0 159.31 18.56 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.531 -0.731 . . . . 0.0 109.283 179.925 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -72.7 132.74 44.06 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.31 -0.869 . . . . 0.0 109.411 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 42.7 t -121.35 126.14 74.58 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.233 -0.917 . . . . 0.0 109.634 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 43.2 t -147.56 151.22 13.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.334 -0.854 . . . . 0.0 109.302 179.769 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 2.7 t -87.93 125.57 41.43 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 C-N-CA 119.708 -0.797 . . . . 0.0 109.854 -179.271 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 172' ' ' GLU . . . . . 0.423 ' O ' ' HB3' ' A' ' 173' ' ' ASP . 97.3 mt-10 -65.62 -30.82 71.58 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.379 -0.826 . . . . 0.0 109.097 179.509 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 173' ' ' ASP . . . . . 0.425 ' C ' ' OD1' ' A' ' 173' ' ' ASP . 53.0 p30 177.73 -177.78 0.21 Allowed 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.335 -0.853 . . . . 0.0 110.093 -179.864 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 28.5 p -154.04 150.4 28.19 Favored 'General case' 0 N--CA 1.49 1.571 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 179.476 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -172.17 178.46 44.33 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 176' ' ' GLN . . . . . 0.436 ' OE1' ' OG ' ' A' ' 178' ' ' SER . 7.0 tt0 -106.04 124.17 49.15 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.463 -1.022 . . . . 0.0 109.75 -179.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 28.9 tp -62.29 -37.97 87.57 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.202 -0.936 . . . . 0.0 109.382 179.604 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 178' ' ' SER . . . . . 0.436 ' OG ' ' OE1' ' A' ' 176' ' ' GLN . 4.5 p . . . . . 0 N--CA 1.491 1.596 0 CA-C-O 117.994 -1.003 . . . . 0.0 109.497 -179.91 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 11.1 m120 . . . . . 0 N--CA 1.492 1.671 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -65.93 141.85 66.4 Favored 'Trans proline' 0 N--CA 1.496 1.663 0 C-N-CA 122.822 2.348 . . . . 0.0 112.206 179.828 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 98.5 mtt180 -128.73 133.22 48.06 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.373 -0.829 . . . . 0.0 108.887 179.237 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.0 p -136.52 142.97 36.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.725 0 O-C-N 121.333 -0.854 . . . . 0.0 109.626 -179.783 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' PHE . . . . . 0.462 ' CZ ' ' NH2' ' A' ' 25' ' ' ARG . 43.0 p90 -140.41 154.28 46.63 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.285 -0.884 . . . . 0.0 109.468 -179.998 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -127.83 140.06 52.26 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.424 -0.797 . . . . 0.0 109.584 179.836 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.417 ' O ' HG13 ' A' ' 171' ' ' VAL . 87.9 m-20 -91.44 132.94 35.89 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.263 -0.898 . . . . 0.0 108.91 179.368 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' MET . . . . . 0.424 ' SD ' HD12 ' A' ' 26' ' ' ILE . 65.6 mtp -124.72 153.53 42.25 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.198 -0.939 . . . . 0.0 110.259 -179.459 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 63.2 p -149.4 165.99 30.42 Favored 'General case' 0 N--CA 1.49 1.538 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 179.741 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.422 HG23 ' O ' ' A' ' 18' ' ' VAL . 24.0 m -125.54 133.88 68.11 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 121.25 -0.906 . . . . 0.0 109.544 179.975 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 54.75 17.08 8.37 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 179.797 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 92.33 4.55 66.22 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 33.7 mt-30 -105.58 111.57 64.77 Favored Pre-proline 0 N--CA 1.493 1.711 0 O-C-N 121.349 -1.089 . . . . 0.0 109.255 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 65.8 Cg_exo -48.35 135.23 25.84 Favored 'Trans proline' 0 N--CA 1.493 1.47 0 C-N-CA 122.171 1.914 . . . . 0.0 112.173 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -104.82 -57.73 1.99 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.42 -0.8 . . . . 0.0 109.417 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -171.55 -171.68 36.89 Favored Glycine 0 N--CA 1.488 2.118 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 -179.856 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . 0.462 ' NH2' ' CZ ' ' A' ' 13' ' ' PHE . 77.6 ttt180 -114.35 143.93 44.09 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.377 -1.072 . . . . 0.0 109.367 179.947 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.424 HD12 ' SD ' ' A' ' 16' ' ' MET . 83.2 mt -119.62 127.95 75.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.4 -0.812 . . . . 0.0 109.029 179.819 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 43.5 t -117.44 133.45 64.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.444 -0.785 . . . . 0.0 109.571 -179.773 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 73.2 mtm -121.35 150.49 41.38 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.423 -0.798 . . . . 0.0 109.03 179.699 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.424 ' C ' HD22 ' A' ' 30' ' ' LEU . 84.3 tt0 -101.89 131.15 48.42 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.253 -0.904 . . . . 0.0 109.997 -179.512 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.424 HD22 ' C ' ' A' ' 29' ' ' GLU . 2.8 mm? -109.59 130.15 55.53 Favored 'General case' 0 N--CA 1.493 1.701 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 179.357 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -97.77 118.26 33.91 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.039 -1.038 . . . . 0.0 108.981 179.427 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -79.6 -43.18 23.4 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.403 -0.811 . . . . 0.0 109.844 -179.739 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 57.6 t0 -65.25 -51.6 59.8 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.196 -0.94 . . . . 0.0 110.037 -179.301 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 49.4 m -67.86 -42.1 81.86 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.196 -0.94 . . . . 0.0 109.712 -179.871 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -137.34 80.37 33.84 Favored Pre-proline 0 N--CA 1.492 1.666 0 O-C-N 121.437 -0.789 . . . . 0.0 109.19 -179.73 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -70.83 -65.82 0.03 OUTLIER 'Trans proline' 0 C--N 1.308 -1.577 0 C-N-CA 122.579 2.186 . . . . 0.0 112.93 -179.601 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 62.7 mtp180 -61.5 -38.39 87.17 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.393 -0.817 . . . . 0.0 110.708 -179.036 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 36.9 m -62.49 -42.41 99.48 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 120.972 -1.08 . . . . 0.0 109.881 -179.691 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -62.65 -30.9 71.71 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.198 -0.939 . . . . 0.0 108.771 179.566 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.429 ' OE1' ' OH ' ' A' ' 92' ' ' TYR . 84.6 tt0 -65.65 -36.23 83.07 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.461 -0.774 . . . . 0.0 109.492 179.784 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 48.7 t-20 -58.59 -42.98 89.33 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.317 -0.864 . . . . 0.0 109.414 -179.794 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.42 ' CE2' ' CE2' ' A' ' 142' ' ' PHE . 90.6 m-85 -80.63 -45.34 17.41 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.31 -0.869 . . . . 0.0 109.625 179.886 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.424 ' HD2' HE22 ' A' ' 176' ' ' GLN . 61.9 ttp180 -57.31 -42.37 81.68 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.261 -0.899 . . . . 0.0 109.533 -179.769 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.505 ' O ' ' N ' ' A' ' 48' ' ' GLY . . . -68.41 -36.35 78.98 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.262 -0.899 . . . . 0.0 109.528 179.975 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.54 HD23 ' CD2' ' A' ' 61' ' ' TYR . 51.7 tp -60.36 -36.18 77.43 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.176 -0.953 . . . . 0.0 109.529 -179.702 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' CYS . . . . . . . . . . . . . 96.8 m -65.83 -59.73 3.58 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.212 -0.93 . . . . 0.0 110.068 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 57.3 p -74.97 -38.71 61.61 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.12 -0.988 . . . . 0.0 109.987 -179.761 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . 0.505 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 71.98 7.3 66.14 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.183 -1.567 . . . . 0.0 109.183 -179.842 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 22.4 pt-20 -72.63 -16.91 61.71 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.451 -1.029 . . . . 0.0 110.033 -179.726 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 44.7 tptt -56.22 -38.61 71.26 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.166 -0.959 . . . . 0.0 109.739 -179.393 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 173.23 -173.23 45.62 Favored Glycine 0 N--CA 1.49 2.245 0 C-N-CA 119.664 -1.255 . . . . 0.0 110.03 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.53 ' O ' ' C ' ' A' ' 53' ' ' GLY . 82.5 m -120.57 145.89 46.88 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.673 -0.899 . . . . 0.0 109.266 179.946 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.53 ' C ' ' O ' ' A' ' 52' ' ' THR . . . -30.74 -73.9 0.05 OUTLIER Glycine 0 N--CA 1.495 2.608 0 N-CA-C 110.513 -1.035 . . . . 0.0 110.513 -179.827 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 93.7 mtt180 -139.86 -112.69 0.15 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.061 -1.258 . . . . 0.0 109.606 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 80.0 p -86.03 -23.64 26.7 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.313 -0.867 . . . . 0.0 110.112 -179.485 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -164.36 93.58 0.11 Allowed Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.377 -1.489 . . . . 0.0 109.377 -179.838 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 11.4 ttmm -174.4 75.31 0.34 Allowed Pre-proline 0 C--N 1.301 -1.506 0 O-C-N 121.484 -1.009 . . . . 0.0 108.629 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_exo -47.89 129.18 17.44 Favored 'Trans proline' 0 C--N 1.303 -1.832 0 C-N-CA 122.539 2.159 . . . . 0.0 111.897 -179.422 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 12.6 tp -106.48 119.96 40.67 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.522 -0.736 . . . . 0.0 109.333 -179.371 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -150.43 140.57 22.13 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.169 -0.957 . . . . 0.0 109.719 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . 0.54 ' CD2' HD23 ' A' ' 45' ' ' LEU . 2.9 t80 -62.25 -35.75 79.9 Favored 'General case' 0 N--CA 1.492 1.657 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 179.431 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 42.6 tttm -50.47 152.66 1.82 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.501 -0.75 . . . . 0.0 109.868 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 34.8 t0 71.24 43.07 0.66 Allowed 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.645 -0.659 . . . . 0.0 109.501 -179.835 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 90.8 p -119.23 152.67 36.24 Favored 'General case' 0 N--CA 1.492 1.659 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 179.503 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 30.3 t -145.85 154.6 42.16 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.198 -0.938 . . . . 0.0 109.778 -179.611 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 47.3 m-85 -89.99 127.58 36.07 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.335 -0.853 . . . . 0.0 109.253 179.651 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' HIS . . . . . 0.403 ' O ' ' O ' ' A' ' 163' ' ' GLY . 97.3 m-70 -99.04 -18.47 17.74 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.319 -0.863 . . . . 0.0 110.291 -179.279 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 58.5 mtp85 -127.31 137.07 52.73 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.11 -0.994 . . . . 0.0 110.126 -179.693 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.668 HG21 HG22 ' A' ' 165' ' ' THR . 3.1 m -153.34 81.33 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 121.428 -0.795 . . . . 0.0 108.98 179.474 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 22.0 mt -95.96 126.04 46.24 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.097 -1.002 . . . . 0.0 109.452 -179.501 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -71.64 138.25 31.72 Favored 'Trans proline' 0 N--CA 1.493 1.491 0 C-N-CA 122.157 1.905 . . . . 0.0 112.332 -179.664 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 92.67 -30.04 7.32 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.684 -1.366 . . . . 0.0 109.684 179.623 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -102.7 -89.73 0.37 Allowed 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.301 -1.117 . . . . 0.0 109.741 -179.884 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' MET . . . . . 0.452 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 7.6 ptt? -171.86 -175.42 1.51 Allowed 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.22 -0.925 . . . . 0.0 109.716 -179.678 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -127.27 141.94 51.59 Favored 'General case' 0 N--CA 1.494 1.748 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 179.699 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 48.1 tt0 -105.85 143.53 33.86 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.209 -0.932 . . . . 0.0 109.843 -179.589 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -156.11 -173.55 24.84 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 96.32 2.34 60.49 Favored Glycine 0 N--CA 1.494 2.516 0 N-CA-C 109.676 -1.37 . . . . 0.0 109.676 -179.969 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.574 ' O ' ' N ' ' A' ' 83' ' ' GLY . 89.9 m-20 -92.42 14.72 15.77 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.339 -1.095 . . . . 0.0 109.203 179.848 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.541 ' CD1' ' N ' ' A' ' 81' ' ' THR . 42.4 p90 -44.27 -31.56 1.05 Allowed 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.351 -0.843 . . . . 0.0 110.292 -179.815 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.541 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 18.5 m -58.0 -37.46 74.31 Favored 'General case' 0 C--N 1.303 -1.445 0 O-C-N 121.169 -0.957 . . . . 0.0 109.666 -178.993 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -145.48 -32.89 0.37 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.191 -0.943 . . . . 0.0 110.048 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.574 ' N ' ' O ' ' A' ' 79' ' ' ASP . . . 100.16 -37.14 3.69 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.424 -1.471 . . . . 0.0 109.424 -180.0 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 78.4 m-20 -89.7 1.51 55.97 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.316 -1.108 . . . . 0.0 109.376 179.873 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 88.67 2.33 79.13 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.446 -1.462 . . . . 0.0 109.446 -179.934 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 49.5 m -59.71 -38.72 82.4 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.366 -1.079 . . . . 0.0 109.633 -179.919 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -96.31 -115.21 3.09 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.859 -1.296 . . . . 0.0 109.859 -179.706 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.446 ' O ' ' CB ' ' A' ' 123' ' ' SER . . . 81.97 27.71 44.52 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.193 -1.563 . . . . 0.0 109.193 -179.636 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -59.51 142.84 51.69 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.329 -1.1 . . . . 0.0 109.869 -179.83 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 32.9 t -141.93 146.81 36.12 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.353 -0.842 . . . . 0.0 109.278 179.738 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 14.1 pt -69.53 -11.34 14.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.136 -0.977 . . . . 0.0 109.468 -179.887 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . 0.429 ' OH ' ' OE1' ' A' ' 40' ' ' GLU . 80.9 m-85 -107.47 29.51 7.1 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.393 -0.817 . . . . 0.0 109.778 -179.988 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -46.98 -31.26 5.57 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.382 -1.487 . . . . 0.0 109.382 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -63.26 145.16 56.11 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.139 -1.212 . . . . 0.0 108.992 179.625 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 93.8 mttt -87.77 135.51 33.35 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.368 -0.832 . . . . 0.0 109.631 -179.637 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . 0.531 ' CE1' ' ND2' ' A' ' 121' ' ' ASN . 54.4 p90 -144.49 163.26 34.37 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.351 -0.843 . . . . 0.0 109.361 179.672 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -97.6 144.82 26.89 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.281 -0.887 . . . . 0.0 109.324 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 -67.93 135.34 52.27 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.213 -0.929 . . . . 0.0 109.345 -179.883 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . 0.525 ' O ' ' ND2' ' A' ' 100' ' ' ASN . 84.4 tt0 -63.55 -38.21 90.27 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.275 -0.89 . . . . 0.0 110.117 -179.653 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . 0.525 ' ND2' ' O ' ' A' ' 99' ' ' GLU . 24.0 m120 -144.18 171.04 14.84 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.996 -1.065 . . . . 0.0 110.041 -179.539 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' PHE . . . . . 0.43 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 38.3 p90 -151.17 37.85 0.63 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.471 -0.768 . . . . 0.0 109.094 179.772 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 90.3 mt -57.86 -34.13 47.51 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.318 -0.864 . . . . 0.0 109.936 -179.792 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 44.1 mtmt -75.63 144.27 41.8 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.992 -1.068 . . . . 0.0 109.511 -179.895 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 45.2 tttp -130.16 157.77 41.53 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.421 -0.799 . . . . 0.0 109.411 -179.872 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 105' ' ' HIS . . . . . 0.402 ' O ' ' OD2' ' A' ' 136' ' ' ASP . 85.5 t60 -98.93 127.09 44.77 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.328 -0.857 . . . . 0.0 109.39 -179.92 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -160.7 -6.66 0.05 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.229 -0.919 . . . . 0.0 109.698 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -127.72 171.48 19.07 Favored Glycine 0 N--CA 1.494 2.513 0 N-CA-C 109.456 -1.458 . . . . 0.0 109.456 -179.878 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 97.0 Cg_endo -80.61 154.72 20.84 Favored 'Trans proline' 0 C--N 1.306 -1.677 0 C-N-CA 123.023 2.482 . . . . 0.0 112.287 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 77.75 47.55 8.6 Favored Glycine 0 N--CA 1.494 2.536 0 N-CA-C 109.967 -1.253 . . . . 0.0 109.967 179.49 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 40.9 mm -115.29 134.74 57.49 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 O-C-N 121.437 -1.037 . . . . 0.0 109.511 -179.903 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.454 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 3.5 mm? -93.45 112.74 24.72 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.203 -0.936 . . . . 0.0 109.317 179.681 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 47.2 m -131.01 147.95 52.69 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.265 -0.897 . . . . 0.0 109.494 179.737 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 88.5 mtp -94.33 141.2 28.84 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.177 -0.952 . . . . 0.0 109.391 179.892 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . 0.55 ' O ' ' ND2' ' A' ' 115' ' ' ASN . . . -63.3 142.77 58.26 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.295 -0.878 . . . . 0.0 109.338 179.916 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . 0.55 ' ND2' ' O ' ' A' ' 114' ' ' ALA . 16.0 m120 -144.7 113.26 6.65 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.21 -0.931 . . . . 0.0 109.057 179.885 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -68.22 -27.8 66.68 Favored 'General case' 0 C--N 1.297 -1.712 0 O-C-N 121.35 -0.844 . . . . 0.0 109.169 179.795 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . 0.441 ' H ' ' HB ' ' A' ' 120' ' ' THR . . . -132.55 167.7 23.01 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.254 -1.539 . . . . 0.0 109.254 179.86 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 14.3 Cg_endo -58.44 -25.51 73.95 Favored 'Trans proline' 0 C--N 1.305 -1.76 0 C-N-CA 122.809 2.339 . . . . 0.0 111.929 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 42.5 p-10 -128.38 42.5 3.31 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.354 -0.841 . . . . 0.0 109.489 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 120' ' ' THR . . . . . 0.441 ' HB ' ' H ' ' A' ' 117' ' ' GLY . 89.1 m -128.87 124.47 35.34 Favored 'General case' 0 N--CA 1.486 1.329 0 O-C-N 121.445 -0.785 . . . . 0.0 108.896 179.77 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 121' ' ' ASN . . . . . 0.531 ' ND2' ' CE1' ' A' ' 96' ' ' PHE . 83.0 m-20 -108.9 149.57 28.96 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.59 -0.694 . . . . 0.0 109.438 -179.842 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -133.78 166.93 23.81 Favored Glycine 0 N--CA 1.494 2.518 0 N-CA-C 109.544 -1.422 . . . . 0.0 109.544 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 123' ' ' SER . . . . . 0.446 ' CB ' ' O ' ' A' ' 88' ' ' GLY . 46.4 p -82.41 -2.08 52.02 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.248 -1.148 . . . . 0.0 109.674 -179.907 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.4 mt-30 -100.5 144.91 28.93 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.253 -0.904 . . . . 0.0 109.752 -179.836 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 50.9 p90 -139.12 163.6 31.98 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.504 -0.747 . . . . 0.0 109.171 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . 0.452 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 50.8 p90 -135.86 154.46 51.16 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.214 -0.928 . . . . 0.0 109.76 -179.89 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 64.5 mt -124.16 134.02 67.72 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.754 0 O-C-N 121.509 -0.745 . . . . 0.0 109.422 179.781 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 3.3 m -114.23 113.07 24.13 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.274 -0.891 . . . . 0.0 109.342 179.855 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . 0.45 ' OG1' ' OE1' ' A' ' 156' ' ' GLU . 7.3 p -94.39 -0.9 54.52 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.257 -0.902 . . . . 0.0 109.406 -179.905 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -109.97 152.74 25.49 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.383 -0.823 . . . . 0.0 109.338 -179.746 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 49.3 mtpt -77.39 115.29 17.04 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.18 -0.95 . . . . 0.0 109.228 179.84 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 50.0 p -129.23 158.18 39.76 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.445 -0.784 . . . . 0.0 109.366 -179.938 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -110.39 -40.83 4.53 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.368 -0.833 . . . . 0.0 109.683 179.857 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 0.6 OUTLIER -62.58 -34.21 76.52 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.195 -0.941 . . . . 0.0 109.748 -179.602 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 12.5 mt -62.22 -33.09 73.9 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.984 -1.072 . . . . 0.0 109.668 179.648 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . 0.402 ' OD2' ' O ' ' A' ' 105' ' ' HIS . 61.7 t0 -79.33 119.12 21.92 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.2 -0.938 . . . . 0.0 109.517 -179.731 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -165.05 -117.4 0.4 Allowed Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 3.3 mppt? -86.53 7.39 26.3 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.403 -1.057 . . . . 0.0 109.769 -179.853 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 77.3 m80 -70.52 151.24 45.29 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.149 -0.97 . . . . 0.0 109.571 -179.667 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 41.2 t -118.69 140.78 41.18 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.489 -0.757 . . . . 0.0 109.459 -179.776 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . 0.412 HG12 ' H ' ' A' ' 143' ' ' GLY . 50.6 t -100.2 133.32 43.63 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.416 -0.802 . . . . 0.0 109.565 -179.844 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . 0.42 ' CE2' ' CE2' ' A' ' 42' ' ' PHE . 38.0 p90 -109.12 1.09 20.17 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.277 -0.889 . . . . 0.0 109.823 179.873 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . 0.412 ' H ' HG12 ' A' ' 141' ' ' VAL . . . -174.4 -179.42 45.0 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 179.663 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.3 pt20 -146.22 167.39 23.61 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.26 -1.141 . . . . 0.0 109.561 -179.644 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 54.0 t -97.84 131.39 44.91 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.187 0 O-C-N 121.178 -0.952 . . . . 0.0 109.473 -179.885 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 16.6 m -107.76 -34.81 2.81 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.357 -0.839 . . . . 0.0 109.664 179.685 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 94.4 mt-10 -144.32 166.92 23.72 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.212 -0.93 . . . . 0.0 109.705 -179.827 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 96.79 4.15 59.12 Favored Glycine 0 N--CA 1.495 2.583 0 N-CA-C 110.194 -1.162 . . . . 0.0 110.194 179.395 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 149' ' ' MET . . . . . 0.483 ' O ' HG12 ' A' ' 152' ' ' VAL . 71.8 mtm -60.79 -33.22 72.65 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.002 -1.293 . . . . 0.0 109.722 179.923 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 89.3 m-20 -65.11 -41.96 94.4 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.833 -1.167 . . . . 0.0 110.07 -179.541 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.2 p -82.04 -34.29 12.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.216 -0.928 . . . . 0.0 110.696 -179.406 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 152' ' ' VAL . . . . . 0.483 HG12 ' O ' ' A' ' 149' ' ' MET . 0.8 OUTLIER -55.63 -42.49 69.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 120.873 -1.142 . . . . 0.0 109.399 -179.248 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 153' ' ' LYS . . . . . 0.454 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 99.2 mttt -65.53 -33.3 75.6 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.137 -0.977 . . . . 0.0 109.757 179.5 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -60.25 -40.15 89.3 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.312 -0.867 . . . . 0.0 110.284 -179.154 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 91.9 mt -71.56 -36.21 59.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.029 -1.044 . . . . 0.0 110.466 -179.508 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . 0.45 ' OE1' ' OG1' ' A' ' 129' ' ' THR . 84.4 tt0 -78.49 -40.35 35.58 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.929 -1.107 . . . . 0.0 111.36 -178.587 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 39.8 pttt -61.05 -34.42 74.86 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 120.793 -1.192 . . . . 0.0 110.005 -178.806 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 28.3 m -73.36 -12.65 15.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.101 -0.999 . . . . 0.0 109.377 179.884 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -77.82 173.4 55.08 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.757 -1.337 . . . . 0.0 109.757 -179.891 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 21.4 t -154.62 178.72 9.79 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.41 -1.053 . . . . 0.0 109.395 -179.741 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 23.7 t -54.3 -30.45 51.08 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.233 -0.917 . . . . 0.0 109.262 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 86.6 p -59.3 -26.61 65.13 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.255 -0.903 . . . . 0.0 109.4 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 163' ' ' GLY . . . . . 0.403 ' O ' ' O ' ' A' ' 67' ' ' HIS . . . 87.16 20.31 53.13 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.713 -1.355 . . . . 0.0 109.713 179.794 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 87.7 mtt180 -122.38 145.39 48.32 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.195 -1.18 . . . . 0.0 109.364 179.911 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 165' ' ' THR . . . . . 0.668 HG22 HG21 ' A' ' 69' ' ' VAL . 72.6 p -82.19 151.52 26.85 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.153 -0.967 . . . . 0.0 109.647 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -67.06 -36.44 82.05 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.287 -0.883 . . . . 0.0 109.302 179.692 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 62.4 mttp -117.6 156.57 27.89 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.576 -0.702 . . . . 0.0 109.248 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 94.2 mttt -69.22 131.62 45.2 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.11 -0.994 . . . . 0.0 109.225 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 41.1 t -122.14 125.08 72.49 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.725 0 O-C-N 121.325 -0.859 . . . . 0.0 109.644 -179.896 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 43.7 t -144.94 144.88 21.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.386 -0.821 . . . . 0.0 109.17 179.63 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.417 HG13 ' O ' ' A' ' 15' ' ' ASP . 2.7 t -74.54 124.17 31.57 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.677 0 C-N-CA 119.722 -0.791 . . . . 0.0 109.787 -179.284 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -67.85 -27.91 67.1 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.363 -0.836 . . . . 0.0 109.593 179.471 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 44.3 t0 -174.38 174.76 2.73 Favored 'General case' 0 N--CA 1.494 1.754 0 C-N-CA 119.29 -0.964 . . . . 0.0 110.321 -179.286 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 26.4 p -146.42 150.25 35.28 Favored 'General case' 0 N--CA 1.491 1.622 0 N-CA-C 109.063 -0.718 . . . . 0.0 109.063 179.638 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -172.64 173.16 45.38 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.804 -1.318 . . . . 0.0 109.804 179.913 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 176' ' ' GLN . . . . . 0.513 ' NE2' ' OXT' ' A' ' 178' ' ' SER . 62.6 tt0 -114.23 118.89 35.24 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.413 -1.051 . . . . 0.0 109.637 -179.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 37.1 tp -63.39 -37.42 87.2 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.124 -0.985 . . . . 0.0 109.217 179.403 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 178' ' ' SER . . . . . 0.513 ' OXT' ' NE2' ' A' ' 176' ' ' GLN . 61.2 m . . . . . 0 N--CA 1.491 1.582 0 CA-C-O 118.0 -1.0 . . . . 0.0 109.441 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 2.3 m-80 . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 38.7 Cg_endo -64.85 141.65 72.36 Favored 'Trans proline' 0 N--CA 1.496 1.663 0 C-N-CA 122.616 2.211 . . . . 0.0 112.07 179.775 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 96.4 mtt180 -126.79 131.62 51.24 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.459 -0.776 . . . . 0.0 109.061 179.497 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.4 p -136.09 142.38 38.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.314 -0.866 . . . . 0.0 109.243 -179.905 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 41.2 p90 -142.3 154.01 44.36 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.297 -0.877 . . . . 0.0 109.572 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.58 ' CE2' ' SG ' ' A' ' 174' ' ' CYS . 44.3 m-85 -120.07 135.78 54.82 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.468 -0.77 . . . . 0.0 109.091 179.643 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.1 t0 -88.55 114.47 25.2 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.078 -1.013 . . . . 0.0 108.509 179.489 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 83.7 mtp -104.53 136.17 44.58 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.453 -0.779 . . . . 0.0 110.532 -179.08 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 44.5 m -135.1 154.23 51.74 Favored 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 179.195 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.405 ' O ' ' C ' ' A' ' 19' ' ' GLY . 34.3 m -125.98 141.45 45.61 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.148 -0.97 . . . . 0.0 109.891 -179.886 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.405 ' C ' ' O ' ' A' ' 18' ' ' VAL . . . 41.05 -114.7 0.61 Allowed Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.936 -1.266 . . . . 0.0 109.936 179.77 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -120.94 15.46 9.52 Favored Glycine 0 N--CA 1.496 2.644 0 N-CA-C 109.416 -1.474 . . . . 0.0 109.416 179.858 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 39.6 tt0 -124.12 88.03 53.0 Favored Pre-proline 0 N--CA 1.494 1.756 0 O-C-N 121.459 -1.024 . . . . 0.0 109.078 -179.826 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 75.7 Cg_exo -47.05 132.86 18.24 Favored 'Trans proline' 0 C--N 1.309 -1.548 0 C-N-CA 122.336 2.024 . . . . 0.0 112.294 -179.561 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -85.07 -63.25 1.36 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.313 -0.867 . . . . 0.0 109.834 -179.688 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 172.62 -167.08 39.91 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 -179.756 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 28.7 ptt180 -116.53 151.18 36.67 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.534 -0.98 . . . . 0.0 108.952 179.735 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 83.4 mt -120.1 129.11 75.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.377 -0.827 . . . . 0.0 109.06 -179.854 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 39.5 t -107.7 134.6 48.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.4 -0.813 . . . . 0.0 109.436 -179.599 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 76.3 mtm -120.86 148.9 43.4 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.557 -0.714 . . . . 0.0 109.215 179.932 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -95.77 133.7 39.58 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.277 -0.889 . . . . 0.0 109.731 -179.593 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -108.35 133.42 52.57 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.572 -0.705 . . . . 0.0 109.357 179.895 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -96.37 119.56 35.08 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.23 -0.919 . . . . 0.0 108.656 179.187 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -89.61 -42.48 11.37 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.295 -0.878 . . . . 0.0 109.835 -179.65 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.2 m-20 -64.58 -48.63 74.27 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.218 -0.926 . . . . 0.0 110.24 -179.263 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 33.3 m -70.91 -43.47 68.21 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.075 -1.016 . . . . 0.0 109.966 -179.652 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.469 ' O ' ' OG1' ' A' ' 35' ' ' THR . 5.1 p -136.38 79.85 41.21 Favored Pre-proline 0 N--CA 1.493 1.678 0 O-C-N 121.351 -0.843 . . . . 0.0 109.404 -179.604 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 27.2 Cg_endo -67.05 -60.88 0.09 OUTLIER 'Trans proline' 0 C--N 1.309 -1.525 0 C-N-CA 122.479 2.12 . . . . 0.0 112.849 -179.401 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.476 ' NH2' ' CG ' ' A' ' 92' ' ' TYR . 17.2 mtp-105 -60.8 -37.78 83.12 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.405 -0.809 . . . . 0.0 110.811 -178.878 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 26.3 m -61.8 -43.16 99.4 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.883 -1.136 . . . . 0.0 109.835 -179.764 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -64.81 -28.48 69.59 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.175 -0.953 . . . . 0.0 109.307 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -65.18 -37.72 88.22 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.341 -0.849 . . . . 0.0 109.687 -179.833 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 86.7 m-20 -59.59 -41.63 90.7 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.244 -0.91 . . . . 0.0 109.745 -179.652 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.489 ' O ' ' SG ' ' A' ' 46' ' ' CYS . 95.5 m-85 -81.37 -46.68 14.3 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.239 -0.913 . . . . 0.0 109.705 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.713 ' HE ' ' NE2' ' A' ' 176' ' ' GLN . 76.1 ttt180 -58.15 -43.09 87.21 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.346 -0.846 . . . . 0.0 110.019 -179.522 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -78.11 -47.9 17.2 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.141 -0.975 . . . . 0.0 110.165 -179.578 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.661 HD23 ' CZ ' ' A' ' 61' ' ' TYR . 58.4 tp -60.59 -38.83 85.93 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.254 -0.904 . . . . 0.0 109.838 -179.518 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' CYS . . . . . 0.489 ' SG ' ' O ' ' A' ' 42' ' ' PHE . 71.2 m -68.56 -58.74 3.84 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.032 -1.042 . . . . 0.0 109.417 -179.908 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 31.6 m -64.11 -37.45 87.5 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.135 -0.978 . . . . 0.0 109.278 179.703 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 81.53 34.27 25.9 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 179.648 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -61.1 -34.36 74.83 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.018 -1.283 . . . . 0.0 109.338 179.61 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 69.4 mmtt -59.57 -33.58 71.61 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.317 -0.864 . . . . 0.0 109.331 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 94.3 168.87 37.44 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.329 -1.508 . . . . 0.0 109.329 -179.771 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 91.7 m -77.79 139.18 39.31 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.413 -1.051 . . . . 0.0 109.737 -179.933 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -60.78 141.19 48.09 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.521 -1.432 . . . . 0.0 109.521 179.94 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 67.4 mtm180 -59.19 -37.12 76.65 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.277 -1.131 . . . . 0.0 109.765 -179.799 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 23.6 m -58.7 -33.75 70.53 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.273 -0.892 . . . . 0.0 109.709 -179.784 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . 0.427 ' O ' ' CB ' ' A' ' 57' ' ' LYS . . . 120.58 109.53 2.2 Favored Glycine 0 N--CA 1.495 2.577 0 N-CA-C 108.996 -1.642 . . . . 0.0 108.996 -179.645 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . 0.455 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 3.2 mmtp 166.14 85.93 0.02 OUTLIER Pre-proline 0 N--CA 1.492 1.628 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 -179.669 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 71.3 Cg_exo -50.96 133.73 40.98 Favored 'Trans proline' 0 C--N 1.304 -1.773 0 C-N-CA 122.559 2.173 . . . . 0.0 112.383 -179.308 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.455 ' CD1' ' O ' ' A' ' 57' ' ' LYS . 8.9 mp -99.65 44.77 1.01 Allowed 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.558 -0.714 . . . . 0.0 109.378 -179.793 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 88.4 m-70 -123.82 133.31 53.82 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.413 -0.804 . . . . 0.0 109.672 -179.828 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . 0.661 ' CZ ' HD23 ' A' ' 45' ' ' LEU . 20.8 m-85 -69.12 -12.11 61.39 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.158 -0.964 . . . . 0.0 108.907 178.789 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 61.2 tttt -49.93 138.62 14.97 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.345 -0.847 . . . . 0.0 109.898 -179.703 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . 0.406 ' N ' HG23 ' A' ' 171' ' ' VAL . 41.0 t0 67.77 42.53 1.96 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.782 -0.574 . . . . 0.0 110.141 179.67 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.818 ' H ' ' CG2' ' A' ' 171' ' ' VAL . 83.2 p -110.47 149.76 29.84 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.233 -0.917 . . . . 0.0 108.595 178.807 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 28.7 t -117.45 144.23 45.22 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.172 -0.955 . . . . 0.0 109.697 -179.353 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -69.61 138.87 53.47 Favored 'General case' 0 N--CA 1.491 1.595 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 179.66 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' HIS . . . . . 0.717 ' CD2' ' HE ' ' A' ' 68' ' ' ARG . 77.8 t60 -59.59 -50.95 71.91 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.108 -0.995 . . . . 0.0 109.932 -179.416 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.717 ' HE ' ' CD2' ' A' ' 67' ' ' HIS . 20.2 ptp180 -172.81 163.05 4.98 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.213 -0.929 . . . . 0.0 109.684 179.669 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.403 HG11 HG22 ' A' ' 155' ' ' ILE . 0.1 OUTLIER -134.05 127.0 50.97 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.418 -0.802 . . . . 0.0 109.035 179.53 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 39.5 mt -121.9 118.38 29.36 Favored Pre-proline 0 N--CA 1.493 1.719 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 179.86 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -71.58 136.13 27.67 Favored 'Trans proline' 0 C--N 1.31 -1.473 0 C-N-CA 121.853 1.702 . . . . 0.0 111.894 -179.803 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 94.25 -1.07 66.79 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.731 -1.348 . . . . 0.0 109.731 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 85.7 m-85 -137.1 -96.13 0.21 Allowed 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.22 -1.164 . . . . 0.0 109.81 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' MET . . . . . 0.595 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 5.6 ptt? -163.95 160.86 22.46 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.157 -0.964 . . . . 0.0 109.896 -179.491 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' CYS . . . . . 0.492 ' O ' ' SG ' ' A' ' 75' ' ' CYS . 12.1 p -97.38 130.59 44.51 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.417 -0.802 . . . . 0.0 108.966 179.241 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 93.8 mt-30 -105.79 149.82 26.12 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.27 -0.894 . . . . 0.0 109.648 -179.712 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -143.91 126.24 2.69 Favored Glycine 0 N--CA 1.492 2.425 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 179.85 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -86.05 178.48 49.58 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.77 -1.332 . . . . 0.0 109.77 -179.76 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 88.1 m-20 -72.13 149.38 44.79 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.357 -1.084 . . . . 0.0 109.554 179.842 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 43.6 p90 -61.53 -22.97 65.62 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.201 -0.937 . . . . 0.0 109.571 -179.907 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.56 ' O ' ' HB2' ' A' ' 82' ' ' ALA . 61.6 p -65.98 -30.17 70.68 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.133 -0.979 . . . . 0.0 109.424 -179.926 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . 0.56 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 171.4 -55.7 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.339 -0.851 . . . . 0.0 109.284 179.809 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 94.79 -10.3 70.53 Favored Glycine 0 N--CA 1.493 2.462 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 179.889 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 50.4 t30 -86.18 1.71 49.66 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.176 -1.191 . . . . 0.0 109.345 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 97.21 -8.83 65.02 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.311 -1.516 . . . . 0.0 109.311 -179.865 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 68.0 p -73.34 -20.0 60.89 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.311 -1.111 . . . . 0.0 109.273 179.675 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -127.68 -130.51 3.35 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 109.334 -1.507 . . . . 0.0 109.334 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 72.48 55.02 7.06 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.175 -1.57 . . . . 0.0 109.175 -179.948 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -84.77 140.73 31.03 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.368 -1.077 . . . . 0.0 109.808 -179.506 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 27.8 t -111.65 143.07 43.14 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.453 -0.779 . . . . 0.0 109.111 179.773 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 15.4 pt -65.12 -38.64 83.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.18 -0.95 . . . . 0.0 110.061 -179.529 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . 0.476 ' CG ' ' NH2' ' A' ' 37' ' ' ARG . 50.7 m-85 -67.83 -38.5 83.3 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.09 -1.006 . . . . 0.0 109.677 -179.906 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 76.09 22.05 74.7 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.342 -1.503 . . . . 0.0 109.342 -179.8 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -147.28 162.69 38.42 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.283 -1.128 . . . . 0.0 109.592 -179.708 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 61.0 mttp -77.19 154.16 33.38 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.269 -0.895 . . . . 0.0 109.527 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . 0.463 ' CD1' ' N ' ' A' ' 96' ' ' PHE . 2.1 m-85 -100.37 133.19 45.16 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.303 -0.873 . . . . 0.0 109.059 179.969 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -91.44 130.45 37.27 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.092 -1.005 . . . . 0.0 109.582 -179.874 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 88.2 m-20 -72.05 143.4 49.11 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.269 -0.894 . . . . 0.0 109.362 179.76 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -141.0 -47.44 0.4 Allowed 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.242 -0.911 . . . . 0.0 109.734 -179.848 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 86.0 m-20 -105.0 122.08 45.11 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.242 -0.911 . . . . 0.0 109.905 -179.585 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' PHE . . . . . 0.553 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 71.7 t80 -120.43 14.48 11.98 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.461 -0.774 . . . . 0.0 108.965 179.549 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 89.7 mt -55.11 -38.31 46.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.417 -0.802 . . . . 0.0 110.237 -179.434 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 67.4 mttm -84.54 136.98 33.58 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.991 -1.068 . . . . 0.0 109.782 -179.528 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 104' ' ' LYS . . . . . 0.516 ' HZ3' ' CG2' ' A' ' 106' ' ' THR . 21.3 pttm -139.58 -177.12 4.81 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.457 -0.777 . . . . 0.0 109.274 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 105' ' ' HIS . . . . . 0.533 ' CE1' ' O ' ' A' ' 107' ' ' GLY . 8.5 t-80 -86.52 107.01 17.92 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.121 -0.987 . . . . 0.0 109.491 -179.881 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . 0.516 ' CG2' ' HZ3' ' A' ' 104' ' ' LYS . 46.6 p -114.43 -1.31 13.51 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.348 -0.845 . . . . 0.0 109.779 179.955 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.533 ' O ' ' CE1' ' A' ' 105' ' ' HIS . . . -154.31 170.54 32.8 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 -179.756 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -77.01 153.7 32.68 Favored 'Trans proline' 0 C--N 1.307 -1.656 0 C-N-CA 122.909 2.406 . . . . 0.0 112.264 179.804 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 78.53 52.4 5.13 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 110.032 -1.227 . . . . 0.0 110.032 179.491 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 35.3 mm -114.27 137.31 47.99 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 O-C-N 121.27 -1.135 . . . . 0.0 109.825 -179.86 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.535 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 2.5 mm? -89.42 125.61 35.23 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.308 -0.87 . . . . 0.0 109.021 179.564 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 36.8 t -147.74 142.83 27.07 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.027 -1.046 . . . . 0.0 109.794 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 64.9 mtt -88.45 135.96 33.22 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.185 -0.947 . . . . 0.0 109.411 179.606 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . 0.535 ' O ' ' ND2' ' A' ' 115' ' ' ASN . . . -72.22 135.59 46.12 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.137 -0.977 . . . . 0.0 109.34 179.808 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . 0.535 ' ND2' ' O ' ' A' ' 114' ' ' ALA . 17.6 m120 -145.37 113.32 6.45 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.162 -0.962 . . . . 0.0 109.336 179.77 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -70.15 -28.7 65.56 Favored 'General case' 0 C--N 1.297 -1.68 0 O-C-N 121.457 -0.777 . . . . 0.0 109.362 179.796 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -134.46 165.25 24.5 Favored Glycine 0 N--CA 1.493 2.484 0 N-CA-C 109.279 -1.528 . . . . 0.0 109.279 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -70.17 154.91 65.67 Favored 'Trans proline' 0 C--N 1.306 -1.667 0 C-N-CA 122.776 2.317 . . . . 0.0 112.199 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 77.5 m-20 54.72 46.9 23.67 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.467 -0.77 . . . . 0.0 109.559 179.841 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 87.3 m -132.27 129.75 40.0 Favored 'General case' 0 C--N 1.306 -1.312 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 179.709 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 121' ' ' ASN . . . . . 0.402 ' OD1' ' CE2' ' A' ' 96' ' ' PHE . 50.8 t30 -74.69 123.15 24.38 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 121.442 -0.786 . . . . 0.0 109.329 -179.855 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -90.74 103.64 3.06 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.839 -1.304 . . . . 0.0 109.839 -179.84 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 85.5 p -65.03 -23.63 67.25 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.248 -1.148 . . . . 0.0 109.245 179.596 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.0 mt-30 -109.19 151.83 25.96 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.434 -0.791 . . . . 0.0 109.622 -179.805 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 49.2 p90 -136.63 160.85 37.56 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.377 -0.827 . . . . 0.0 109.108 179.75 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . 0.595 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 50.2 p90 -140.58 158.5 43.9 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.224 -0.923 . . . . 0.0 109.724 -179.895 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 65.1 mt -120.98 133.6 67.1 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 O-C-N 121.593 -0.692 . . . . 0.0 109.325 179.674 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 6.7 m -97.48 108.64 21.4 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.169 -0.957 . . . . 0.0 109.305 179.779 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 60.2 p -76.39 -10.07 59.12 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.182 -0.949 . . . . 0.0 109.528 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -137.89 161.55 36.34 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.309 -0.87 . . . . 0.0 109.302 -179.818 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 49.0 tttp -62.22 133.21 54.87 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.226 -0.921 . . . . 0.0 109.433 -179.806 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 29.4 p -140.37 91.93 2.48 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.313 -0.867 . . . . 0.0 109.281 -179.898 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -63.57 -34.9 78.84 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.255 -0.903 . . . . 0.0 109.73 -179.813 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 0.9 OUTLIER -67.76 -47.9 67.93 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.068 -1.02 . . . . 0.0 109.646 -179.876 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 15.3 mt -66.79 -31.73 72.55 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.111 -0.993 . . . . 0.0 109.701 179.511 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 60.0 t0 -78.18 121.48 24.4 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.109 -0.994 . . . . 0.0 109.767 -179.566 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 179.88 -114.94 0.46 Allowed Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . 0.437 ' O ' ' C ' ' A' ' 139' ' ' HIS . 66.4 mttm -57.64 -36.24 71.57 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.297 -1.12 . . . . 0.0 109.748 179.886 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 139' ' ' HIS . . . . . 0.437 ' C ' ' O ' ' A' ' 138' ' ' LYS . 53.7 m170 -40.94 144.69 0.25 Allowed 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.543 -0.723 . . . . 0.0 109.816 -179.683 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 42.4 t -115.11 138.84 44.11 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 121.359 -0.838 . . . . 0.0 109.601 -179.678 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 91.8 t -97.97 129.06 48.72 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.341 -0.85 . . . . 0.0 109.441 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 39.1 p90 -115.15 0.54 13.61 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.348 -0.845 . . . . 0.0 109.492 179.844 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -176.19 175.6 47.48 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.349 -1.5 . . . . 0.0 109.349 179.558 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.4 pt20 -147.86 168.21 22.78 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.125 -1.221 . . . . 0.0 110.045 -179.837 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 82.1 t -94.61 131.28 41.9 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.245 0 O-C-N 121.333 -0.854 . . . . 0.0 109.363 -179.814 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 10.9 m -112.43 -30.71 2.2 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.325 -0.859 . . . . 0.0 109.853 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 92.9 mt-10 -141.91 169.45 17.56 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.152 -0.968 . . . . 0.0 109.611 -179.881 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 95.57 6.85 59.43 Favored Glycine 0 N--CA 1.493 2.452 0 N-CA-C 109.984 -1.246 . . . . 0.0 109.984 179.597 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 149' ' ' MET . . . . . 0.447 ' O ' HG12 ' A' ' 152' ' ' VAL . 65.0 mtt -60.14 -31.92 70.53 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.058 -1.26 . . . . 0.0 109.543 -179.978 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . 0.54 ' OD1' ' N ' ' A' ' 151' ' ' VAL . 31.8 p-10 -65.0 -36.96 86.08 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.812 -1.18 . . . . 0.0 109.821 -179.64 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.54 ' N ' ' OD1' ' A' ' 150' ' ' ASP . 3.5 p -87.08 -34.19 7.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.148 -0.97 . . . . 0.0 110.385 -179.64 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 152' ' ' VAL . . . . . 0.46 ' CG1' ' N ' ' A' ' 153' ' ' LYS . 0.9 OUTLIER -56.67 -41.87 75.32 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 120.991 -1.068 . . . . 0.0 109.188 -179.478 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 153' ' ' LYS . . . . . 0.46 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 66.8 mttm -63.99 -34.72 78.65 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.274 -0.891 . . . . 0.0 109.406 179.583 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -62.17 -36.81 83.01 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.29 -0.881 . . . . 0.0 109.934 -179.477 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.403 HG22 HG11 ' A' ' 69' ' ' VAL . 62.5 mt -74.36 -37.56 45.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.136 -0.977 . . . . 0.0 109.84 -179.786 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -73.73 -40.61 63.43 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.129 -0.982 . . . . 0.0 111.399 -178.493 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 18.1 pttp -59.86 -35.61 75.16 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.679 -1.263 . . . . 0.0 109.696 -178.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 27.1 m -77.04 -17.52 14.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.08 -1.012 . . . . 0.0 108.952 179.389 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -64.43 150.21 50.93 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 49.7 m -136.28 161.23 36.35 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.454 -1.027 . . . . 0.0 109.175 179.914 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 23.8 m -51.35 -33.12 28.17 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.187 -0.946 . . . . 0.0 108.966 179.875 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 22.6 t -57.89 -29.02 64.73 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.36 -0.837 . . . . 0.0 109.334 179.643 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.22 10.14 52.08 Favored Glycine 0 N--CA 1.493 2.465 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 -179.806 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 83.7 mtp180 -117.04 155.28 29.49 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.384 -1.068 . . . . 0.0 109.175 179.909 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 165' ' ' THR . . . . . 0.403 ' OG1' ' O ' ' A' ' 167' ' ' LYS . 44.8 p -110.71 156.43 21.04 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.243 -0.911 . . . . 0.0 109.62 -179.759 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -68.19 -37.28 80.76 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.414 -0.804 . . . . 0.0 109.435 179.676 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 167' ' ' LYS . . . . . 0.403 ' O ' ' OG1' ' A' ' 165' ' ' THR . 3.7 mptp? -105.18 158.67 16.43 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.405 -0.809 . . . . 0.0 109.597 -179.834 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 61.3 mttp -81.34 151.99 27.73 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.346 -0.846 . . . . 0.0 109.475 179.83 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . 0.476 ' O ' HG23 ' A' ' 169' ' ' VAL . 30.9 m -131.14 124.37 55.45 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.301 -0.874 . . . . 0.0 109.649 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 46.3 t -148.59 147.08 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.296 -0.877 . . . . 0.0 108.988 179.602 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.818 ' CG2' ' H ' ' A' ' 64' ' ' SER . 2.8 m -87.81 123.16 40.25 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.838 0 O-C-N 120.952 -1.093 . . . . 0.0 109.944 -179.9 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -74.29 -36.72 63.78 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.327 -0.858 . . . . 0.0 110.367 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 173' ' ' ASP . . . . . 0.465 ' OD1' ' N ' ' A' ' 174' ' ' CYS . 54.3 t0 -155.08 153.65 31.22 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 120.914 -1.116 . . . . 0.0 110.662 -179.1 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 174' ' ' CYS . . . . . 0.58 ' SG ' ' CE2' ' A' ' 14' ' ' PHE . 45.4 t -142.15 141.49 32.64 Favored 'General case' 0 N--CA 1.492 1.63 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.48 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -169.52 -178.86 40.99 Favored Glycine 0 N--CA 1.493 2.441 0 N-CA-C 109.806 -1.318 . . . . 0.0 109.806 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 176' ' ' GLN . . . . . 0.713 ' NE2' ' HE ' ' A' ' 43' ' ' ARG . 6.8 tt0 -105.22 120.49 41.67 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.406 -1.055 . . . . 0.0 109.66 -179.875 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 32.1 tp -63.59 -37.81 88.75 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.156 -0.965 . . . . 0.0 109.321 179.414 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 10.9 t . . . . . 0 N--CA 1.49 1.533 0 CA-C-O 118.001 -0.999 . . . . 0.0 109.432 -179.952 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 14.9 m-80 . . . . . 0 N--CA 1.494 1.73 0 N-CA-C 109.675 -0.491 . . . . 0.0 109.675 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -68.22 141.67 52.9 Favored 'Trans proline' 0 N--CA 1.496 1.67 0 C-N-CA 122.62 2.213 . . . . 0.0 112.144 179.877 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 78.4 mtm180 -128.08 133.43 49.04 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.463 -0.773 . . . . 0.0 108.981 179.428 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.2 p -135.57 143.38 36.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.329 -0.857 . . . . 0.0 109.576 -179.822 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 39.2 p90 -137.22 152.83 50.3 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.418 -0.801 . . . . 0.0 109.34 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.459 ' CE1' ' CE1' ' A' ' 61' ' ' TYR . 98.1 m-85 -124.08 132.84 53.71 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.563 -0.711 . . . . 0.0 109.399 179.8 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.6 t0 -91.29 114.56 27.12 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.224 -0.923 . . . . 0.0 108.776 179.485 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 79.7 mtp -107.26 137.33 45.52 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.255 -0.903 . . . . 0.0 110.031 -179.392 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 19.8 m -130.41 152.93 49.28 Favored 'General case' 0 N--CA 1.492 1.639 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 179.636 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.411 ' O ' ' N ' ' A' ' 21' ' ' GLN . 29.8 m -119.05 134.85 61.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.227 -0.921 . . . . 0.0 109.442 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 49.26 25.03 5.47 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 84.24 20.67 58.52 Favored Glycine 0 N--CA 1.492 2.398 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 -179.914 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' GLN . . . . . 0.411 ' N ' ' O ' ' A' ' 18' ' ' VAL . 40.6 mt-30 -120.11 99.19 48.79 Favored Pre-proline 0 N--CA 1.495 1.778 0 O-C-N 121.377 -1.072 . . . . 0.0 109.414 -179.904 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 75.2 Cg_exo -46.53 99.1 0.03 OUTLIER 'Trans proline' 0 N--CA 1.491 1.382 0 C-N-CA 122.353 2.035 . . . . 0.0 112.237 -179.883 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -65.27 -39.85 93.14 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.355 -0.841 . . . . 0.0 109.806 -179.799 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 167.36 -169.11 40.89 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.677 -1.369 . . . . 0.0 109.677 -179.798 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 97.1 mtt180 -115.26 147.05 40.86 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.5 -1.0 . . . . 0.0 109.45 179.812 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 77.2 mt -119.71 123.29 70.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 N-CA-C 108.463 -0.94 . . . . 0.0 108.463 179.118 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 24.8 t -114.26 132.95 61.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.373 -0.829 . . . . 0.0 109.423 -179.488 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' MET . . . . . 0.78 ' SD ' HD11 ' A' ' 111' ' ' LEU . 73.2 mtm -125.66 152.71 44.86 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.382 -0.824 . . . . 0.0 109.196 -179.84 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -99.01 133.26 43.53 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.259 -0.901 . . . . 0.0 109.761 179.877 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -108.85 131.16 55.27 Favored 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 179.794 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 98.2 m-85 -96.36 120.3 36.41 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.095 -1.003 . . . . 0.0 109.063 179.764 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -84.06 -41.1 17.54 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.338 -0.851 . . . . 0.0 109.865 -179.729 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -65.81 -44.71 84.83 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.275 -0.891 . . . . 0.0 110.624 -179.185 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 52.9 m -67.05 -44.87 79.06 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.09 -1.006 . . . . 0.0 110.241 -179.291 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 2.0 m -150.68 82.89 5.98 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.155 -0.966 . . . . 0.0 109.269 -179.666 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 39.9 Cg_endo -71.37 -38.32 4.79 Favored 'Trans proline' 0 C--N 1.308 -1.592 0 C-N-CA 122.19 1.927 . . . . 0.0 112.361 -179.361 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 35.2 mmt180 -64.5 -41.81 96.22 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.126 -0.983 . . . . 0.0 109.691 -179.858 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.48 HG23 ' SD ' ' A' ' 113' ' ' MET . 80.8 m -67.55 -42.66 82.32 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.194 -0.941 . . . . 0.0 110.034 -179.715 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -61.31 -31.81 71.66 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.11 -0.994 . . . . 0.0 108.962 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -70.33 -38.07 74.8 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.422 -0.799 . . . . 0.0 109.999 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 20.4 t-20 -57.91 -43.92 86.49 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.265 -0.897 . . . . 0.0 109.865 -179.534 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -85.3 -46.71 10.74 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.247 -0.908 . . . . 0.0 109.606 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 71.2 ttp85 -57.24 -42.88 82.32 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.312 -0.867 . . . . 0.0 109.663 -179.894 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.5 ' O ' ' N ' ' A' ' 48' ' ' GLY . . . -72.13 -46.27 57.22 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.288 -0.883 . . . . 0.0 109.899 -179.691 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 38.2 tp -61.97 -37.68 85.69 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.095 -1.003 . . . . 0.0 109.438 -179.817 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' CYS . . . . . . . . . . . . . 98.7 m -67.19 -65.93 0.62 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.305 -0.872 . . . . 0.0 109.579 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 31.0 m -64.6 -37.17 86.65 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.374 -0.829 . . . . 0.0 109.404 179.656 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . 0.5 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 80.94 37.8 17.86 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 110.037 -1.225 . . . . 0.0 110.037 179.831 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -61.72 -37.85 85.72 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.089 -1.242 . . . . 0.0 109.51 179.913 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 70.4 mmtt -61.37 -35.49 77.62 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.295 -0.878 . . . . 0.0 109.42 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 88.16 -174.89 44.25 Favored Glycine 0 N--CA 1.484 1.875 0 N-CA-C 108.979 -1.648 . . . . 0.0 108.979 -179.574 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.548 HG23 ' HA ' ' A' ' 58' ' ' PRO . 89.6 m -71.36 139.19 49.73 Favored 'General case' 0 C--N 1.295 -1.78 0 O-C-N 121.537 -0.978 . . . . 0.0 109.603 179.893 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -56.8 136.37 50.09 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.176 -1.57 . . . . 0.0 109.176 179.795 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 86.4 mtt-85 -58.77 -36.94 75.22 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.222 -1.164 . . . . 0.0 109.857 -179.617 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 24.8 m -59.59 -33.94 72.11 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.21 -0.931 . . . . 0.0 109.802 -179.825 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 124.96 91.92 0.91 Allowed Glycine 0 N--CA 1.494 2.514 0 N-CA-C 108.953 -1.659 . . . . 0.0 108.953 -179.658 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . 0.494 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 28.0 tttp -175.69 79.76 0.3 Allowed Pre-proline 0 N--CA 1.489 1.478 0 O-C-N 121.447 -1.031 . . . . 0.0 108.406 -179.709 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.548 ' HA ' HG23 ' A' ' 52' ' ' THR . 73.7 Cg_exo -49.65 131.8 29.38 Favored 'Trans proline' 0 C--N 1.303 -1.848 0 C-N-CA 122.923 2.415 . . . . 0.0 112.845 -178.927 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.494 ' CD1' ' O ' ' A' ' 57' ' ' LYS . 8.7 mp -103.35 113.09 26.3 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.591 -0.693 . . . . 0.0 109.365 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . 0.507 ' O ' ' CE1' ' A' ' 80' ' ' PHE . 70.8 m80 -141.1 126.25 18.43 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.203 -0.936 . . . . 0.0 109.544 179.473 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . 0.459 ' CE1' ' CE1' ' A' ' 14' ' ' PHE . 13.7 t80 -94.42 -11.67 29.36 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.359 -0.838 . . . . 0.0 108.936 179.743 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -78.68 160.52 27.46 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.451 -0.78 . . . . 0.0 109.775 -179.485 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 50.1 t0 60.44 45.8 10.48 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.513 -0.742 . . . . 0.0 109.932 179.647 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 92.5 p -116.25 150.9 36.82 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.328 -0.858 . . . . 0.0 108.841 179.291 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . 0.408 ' O ' ' OD2' ' A' ' 79' ' ' ASP . 29.4 t -121.17 147.33 45.73 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.257 -0.902 . . . . 0.0 109.716 -179.514 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.3 m-30 -68.18 138.34 55.56 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.351 -0.843 . . . . 0.0 108.907 179.825 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 80.0 t60 -60.51 -51.2 70.48 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.218 -0.926 . . . . 0.0 110.138 -179.327 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.689 HH21 ' NE2' ' A' ' 76' ' ' GLN . 38.5 ptt180 -162.85 162.78 26.58 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.073 -1.017 . . . . 0.0 109.873 179.946 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.577 HG21 HG22 ' A' ' 165' ' ' THR . 18.4 m -131.52 150.01 33.68 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.725 0 O-C-N 121.445 -0.785 . . . . 0.0 109.052 179.761 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 14.3 mt -147.29 119.43 4.71 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.024 -1.047 . . . . 0.0 109.433 179.714 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -73.95 134.48 19.79 Favored 'Trans proline' 0 C--N 1.313 -1.316 0 C-N-CA 122.022 1.815 . . . . 0.0 111.868 179.948 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 89.54 2.58 76.04 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.456 ' C ' ' SD ' ' A' ' 74' ' ' MET . 80.2 m-85 -137.22 -94.32 0.22 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.312 -1.11 . . . . 0.0 109.711 179.9 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' MET . . . . . 0.456 ' SD ' ' C ' ' A' ' 73' ' ' PHE . 0.0 OUTLIER -162.98 172.71 14.62 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.161 -0.962 . . . . 0.0 109.81 -179.688 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 1.9 m -119.49 135.16 54.89 Favored 'General case' 0 N--CA 1.494 1.728 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 179.543 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' GLN . . . . . 0.689 ' NE2' HH21 ' A' ' 68' ' ' ARG . 93.8 mt-30 -104.06 153.75 20.51 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.286 -0.884 . . . . 0.0 109.816 -179.638 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -158.99 -170.89 24.08 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.329 -1.509 . . . . 0.0 109.329 -179.958 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 80.02 37.94 20.61 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.504 -1.439 . . . . 0.0 109.504 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.437 ' C ' ' OD1' ' A' ' 79' ' ' ASP . 54.2 p30 -85.24 12.16 8.6 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.291 -1.123 . . . . 0.0 109.46 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.507 ' CE1' ' O ' ' A' ' 60' ' ' HIS . 76.3 t80 -52.88 -44.9 67.2 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.348 -0.845 . . . . 0.0 109.937 -179.902 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.668 ' O ' ' HB2' ' A' ' 82' ' ' ALA . 69.0 p -69.45 -29.25 66.9 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.149 -0.969 . . . . 0.0 109.513 -179.928 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . 0.668 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 165.76 -55.88 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.229 -0.919 . . . . 0.0 109.365 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 92.28 0.29 70.76 Favored Glycine 0 N--CA 1.492 2.389 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 -179.928 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 77.7 m-20 -87.57 5.51 38.98 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.213 -1.169 . . . . 0.0 109.474 179.931 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 96.04 -36.81 3.67 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.329 -1.508 . . . . 0.0 109.329 -179.903 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 56.2 p -73.53 -18.9 61.03 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.271 -1.134 . . . . 0.0 109.164 179.638 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -83.34 -164.04 35.62 Favored Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.611 -1.395 . . . . 0.0 109.611 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.647 ' H ' ' CB ' ' A' ' 81' ' ' THR . . . 92.28 24.09 25.24 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.314 -1.514 . . . . 0.0 109.314 -179.785 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -57.3 145.59 31.6 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.432 -1.04 . . . . 0.0 109.687 -179.864 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 28.8 t -107.03 146.14 31.49 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.328 -0.858 . . . . 0.0 109.263 179.941 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 20.3 pt -61.26 -33.24 55.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.131 -0.98 . . . . 0.0 109.746 -179.812 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 91.7 m-85 -65.51 -36.15 82.98 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.285 -0.884 . . . . 0.0 109.653 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.09 15.24 70.12 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.319 -1.513 . . . . 0.0 109.319 -179.654 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -143.64 155.92 44.4 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.309 -1.113 . . . . 0.0 109.545 -179.859 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 63.1 mttp -94.03 137.89 32.72 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.287 -0.883 . . . . 0.0 109.586 -179.846 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -123.9 154.23 40.0 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.309 -0.869 . . . . 0.0 109.768 179.901 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -107.1 154.65 20.85 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.469 -0.769 . . . . 0.0 109.06 179.536 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 60.0 t0 -76.68 105.48 7.77 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.032 -1.042 . . . . 0.0 109.378 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -67.22 -34.15 76.88 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.284 -0.885 . . . . 0.0 110.062 -179.809 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 86.5 m-20 -105.0 124.71 50.0 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.251 -0.906 . . . . 0.0 110.052 -179.35 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 99.2 m-85 -108.13 12.78 26.46 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.462 -0.774 . . . . 0.0 109.067 179.556 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 92.6 mt -53.36 -39.25 34.86 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.326 -0.859 . . . . 0.0 110.048 -179.319 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 58.0 mttm -82.25 132.9 35.23 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.983 -1.073 . . . . 0.0 109.592 -179.849 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 80.7 tttt -138.65 158.85 43.46 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.41 -0.806 . . . . 0.0 109.335 -179.891 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 105' ' ' HIS . . . . . 0.611 ' CE1' ' SG ' ' A' ' 128' ' ' CYS . 85.2 t60 -86.07 99.17 11.29 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.233 -0.917 . . . . 0.0 109.431 179.886 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 65.9 p -115.78 -1.62 12.59 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.352 -0.842 . . . . 0.0 109.607 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.539 ' O ' ' CE1' ' A' ' 105' ' ' HIS . . . -153.84 169.92 32.47 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -73.88 158.86 45.92 Favored 'Trans proline' 0 C--N 1.306 -1.671 0 C-N-CA 122.935 2.424 . . . . 0.0 112.25 179.811 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 109' ' ' GLY . . . . . 0.468 ' O ' HG12 ' A' ' 145' ' ' VAL . . . 81.9 43.21 8.38 Favored Glycine 0 N--CA 1.493 2.459 0 N-CA-C 109.885 -1.286 . . . . 0.0 109.885 179.694 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 44.3 mm -117.0 132.7 66.0 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.725 0 O-C-N 121.287 -1.125 . . . . 0.0 109.598 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.78 HD11 ' SD ' ' A' ' 28' ' ' MET . 1.7 mm? -89.23 133.63 34.36 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.214 -0.929 . . . . 0.0 108.756 179.452 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . 0.552 ' OG ' ' CZ ' ' A' ' 126' ' ' PHE . 99.0 p -143.38 154.26 43.54 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.109 -0.994 . . . . 0.0 109.628 -179.907 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 113' ' ' MET . . . . . 0.48 ' SD ' HG23 ' A' ' 38' ' ' THR . 72.1 mtm -93.64 136.66 33.7 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.305 -0.872 . . . . 0.0 109.213 179.556 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -65.09 138.09 58.08 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.215 -0.928 . . . . 0.0 109.185 179.815 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 70.6 m-20 -135.19 115.29 13.2 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.257 -0.902 . . . . 0.0 109.441 179.88 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -85.1 -9.89 57.43 Favored 'General case' 0 C--N 1.297 -1.675 0 O-C-N 121.501 -0.749 . . . . 0.0 109.096 179.501 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . 0.43 ' H ' HG21 ' A' ' 120' ' ' THR . . . -136.12 173.76 21.76 Favored Glycine 0 N--CA 1.492 2.367 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 -179.746 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -57.09 -25.4 63.41 Favored 'Trans proline' 0 C--N 1.307 -1.648 0 C-N-CA 122.747 2.298 . . . . 0.0 112.196 -179.905 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 119' ' ' ASN . . . . . 0.441 ' O ' ' OD1' ' A' ' 119' ' ' ASN . 42.4 p-10 -153.19 96.18 2.03 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.17 -0.956 . . . . 0.0 109.908 179.836 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 120' ' ' THR . . . . . 0.43 HG21 ' H ' ' A' ' 117' ' ' GLY . 0.5 OUTLIER -148.74 123.81 10.09 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 121.327 -0.858 . . . . 0.0 109.338 179.774 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 51.3 t-20 -100.38 121.84 42.18 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.355 -0.84 . . . . 0.0 109.449 -179.861 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -137.08 158.99 24.52 Favored Glycine 0 N--CA 1.493 2.473 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 78.5 p -69.06 -19.08 64.08 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.345 -1.091 . . . . 0.0 109.645 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.9 mt-30 -66.5 137.44 56.8 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.134 -0.978 . . . . 0.0 109.613 -179.593 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 44.5 p90 -146.49 161.68 39.91 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.33 -0.857 . . . . 0.0 109.323 179.892 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . 0.552 ' CZ ' ' OG ' ' A' ' 112' ' ' SER . 51.9 p90 -141.16 159.05 43.04 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.166 -0.959 . . . . 0.0 109.577 179.716 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 77.7 mt -116.43 135.1 57.77 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.354 -0.841 . . . . 0.0 109.425 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 128' ' ' CYS . . . . . 0.611 ' SG ' ' CE1' ' A' ' 105' ' ' HIS . 0.2 OUTLIER -99.23 99.79 10.81 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.388 -0.82 . . . . 0.0 109.423 -179.871 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 61.9 p -76.3 -6.86 53.37 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.322 -0.861 . . . . 0.0 109.321 179.812 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -139.91 162.76 34.41 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.369 -0.832 . . . . 0.0 109.316 -179.897 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.525 ' O ' ' CZ3' ' A' ' 134' ' ' TRP . 99.2 mttt -71.56 131.99 44.04 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.19 -0.944 . . . . 0.0 109.563 -179.654 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . 0.408 HG22 ' CZ2' ' A' ' 134' ' ' TRP . 74.0 p -122.97 37.99 4.29 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.538 -0.726 . . . . 0.0 109.318 179.936 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 78.3 mm-40 -57.65 -31.12 65.99 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.272 -0.893 . . . . 0.0 109.733 -179.504 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 134' ' ' TRP . . . . . 0.525 ' CZ3' ' O ' ' A' ' 131' ' ' LYS . 12.7 p90 -55.24 -28.44 53.26 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.047 -1.033 . . . . 0.0 109.64 -179.805 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . 0.503 ' N ' ' CD1' ' A' ' 134' ' ' TRP . 69.0 mt -58.11 -35.93 72.18 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.055 -1.028 . . . . 0.0 109.473 179.3 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 57.2 t0 53.81 69.92 0.66 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.436 -0.79 . . . . 0.0 109.705 179.569 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -138.4 176.36 20.83 Favored Glycine 0 N--CA 1.484 1.857 0 N-CA-C 108.915 -1.674 . . . . 0.0 108.915 179.712 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . 0.427 ' O ' ' O ' ' A' ' 139' ' ' HIS . 63.0 mttp -59.21 -40.12 84.8 Favored 'General case' 0 C--N 1.296 -1.727 0 O-C-N 121.39 -1.065 . . . . 0.0 109.968 -179.768 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 139' ' ' HIS . . . . . 0.427 ' O ' ' O ' ' A' ' 138' ' ' LYS . 61.3 m170 51.75 98.89 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.414 -0.804 . . . . 0.0 109.542 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 52.1 t -105.49 135.18 44.69 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.751 0 O-C-N 121.461 -0.774 . . . . 0.0 109.395 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 48.5 t -117.04 128.71 74.38 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.485 -0.76 . . . . 0.0 109.691 -179.726 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 37.5 p90 -113.31 -1.21 14.32 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.376 -0.828 . . . . 0.0 109.539 179.458 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -173.84 -177.36 42.98 Favored Glycine 0 N--CA 1.493 2.438 0 N-CA-C 109.818 -1.313 . . . . 0.0 109.818 179.842 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.4 pt20 -144.22 171.39 14.37 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.311 -1.111 . . . . 0.0 109.475 -179.763 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . 0.468 HG12 ' O ' ' A' ' 109' ' ' GLY . 8.3 p -111.08 138.29 40.0 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.902 0 O-C-N 121.268 -0.895 . . . . 0.0 109.281 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 10.5 m -119.32 -28.16 2.05 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.483 -0.761 . . . . 0.0 109.679 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -138.06 167.16 22.37 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.249 -0.907 . . . . 0.0 109.567 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 97.49 3.23 58.6 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.779 -1.329 . . . . 0.0 109.779 179.652 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 149' ' ' MET . . . . . 0.432 ' O ' HG12 ' A' ' 152' ' ' VAL . 89.2 mtp -60.65 -32.56 71.73 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.183 -1.186 . . . . 0.0 109.771 179.951 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . 0.549 ' OD1' ' N ' ' A' ' 151' ' ' VAL . 32.9 p-10 -65.46 -37.44 86.86 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 120.85 -1.156 . . . . 0.0 109.902 -179.565 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.549 ' N ' ' OD1' ' A' ' 150' ' ' ASP . 5.2 p -87.31 -34.31 7.39 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.711 0 O-C-N 121.101 -0.999 . . . . 0.0 110.243 -179.672 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 152' ' ' VAL . . . . . 0.461 ' CG1' ' N ' ' A' ' 153' ' ' LYS . 0.9 OUTLIER -56.04 -42.35 71.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 120.996 -1.065 . . . . 0.0 109.101 -179.513 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 153' ' ' LYS . . . . . 0.461 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 98.7 mttt -64.42 -33.77 76.64 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.172 -0.955 . . . . 0.0 109.433 179.471 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -61.24 -38.8 87.95 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.351 -0.843 . . . . 0.0 110.132 -179.4 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 86.8 mt -72.3 -36.64 56.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.045 -1.034 . . . . 0.0 110.159 -179.728 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -76.29 -41.69 47.89 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.178 -0.951 . . . . 0.0 111.402 -178.784 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 16.8 pttp -60.45 -35.23 75.36 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 120.744 -1.223 . . . . 0.0 109.734 -178.845 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 32.7 m -82.46 -10.9 12.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.166 -0.958 . . . . 0.0 109.061 179.581 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -70.97 165.1 53.31 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.981 -1.248 . . . . 0.0 109.981 -179.565 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 24.1 t -154.08 168.55 26.1 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.421 -1.046 . . . . 0.0 109.439 -179.82 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 25.1 m -54.32 -29.6 48.33 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.279 -0.888 . . . . 0.0 109.341 179.808 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 24.7 m -53.31 -31.27 43.25 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.287 -0.883 . . . . 0.0 109.589 -179.882 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 96.05 8.98 57.55 Favored Glycine 0 N--CA 1.493 2.472 0 N-CA-C 109.766 -1.333 . . . . 0.0 109.766 179.896 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 82.3 mtm180 -122.93 145.56 48.36 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.209 -1.171 . . . . 0.0 109.471 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 165' ' ' THR . . . . . 0.577 HG22 HG21 ' A' ' 69' ' ' VAL . 80.9 p -80.57 153.52 28.01 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.189 -0.945 . . . . 0.0 109.36 179.79 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -66.0 -34.6 78.46 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.293 -0.879 . . . . 0.0 109.158 179.714 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 62.9 mttp -112.38 157.49 20.96 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.466 -0.771 . . . . 0.0 109.262 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 63.0 mttp -69.87 141.69 53.16 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.245 -0.91 . . . . 0.0 109.144 179.912 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 18.2 m -128.05 125.33 64.39 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 121.315 -0.866 . . . . 0.0 109.683 -179.819 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 46.5 t -148.33 152.13 12.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.43 -0.794 . . . . 0.0 109.114 179.766 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.401 HG23 ' H ' ' A' ' 171' ' ' VAL . 0.2 OUTLIER -91.15 114.94 29.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.23 -0.919 . . . . 0.0 109.374 -179.753 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -75.68 -11.47 60.01 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.521 -0.737 . . . . 0.0 110.072 -179.882 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 173' ' ' ASP . . . . . 0.475 ' OD1' ' N ' ' A' ' 174' ' ' CYS . 51.8 t0 -164.85 157.79 16.69 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 120.76 -1.212 . . . . 0.0 110.848 -179.31 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 174' ' ' CYS . . . . . 0.475 ' N ' ' OD1' ' A' ' 173' ' ' ASP . 16.7 t -154.85 141.64 19.05 Favored 'General case' 0 N--CA 1.492 1.657 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 179.372 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -178.05 178.08 48.46 Favored Glycine 0 N--CA 1.493 2.48 0 N-CA-C 109.749 -1.34 . . . . 0.0 109.749 179.776 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 176' ' ' GLN . . . . . 0.416 HE21 ' HB2' ' A' ' 178' ' ' SER . 60.9 tt0 -106.93 124.06 49.07 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.367 -1.078 . . . . 0.0 109.732 -179.981 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 30.6 tp -62.92 -37.99 89.22 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.132 -0.98 . . . . 0.0 109.264 179.509 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 178' ' ' SER . . . . . 0.416 ' HB2' HE21 ' A' ' 176' ' ' GLN . 33.1 m . . . . . 0 N--CA 1.49 1.549 0 CA-C-O 118.066 -0.969 . . . . 0.0 109.501 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 13.4 m-20 . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_endo -67.73 140.81 52.43 Favored 'Trans proline' 0 N--CA 1.494 1.556 0 C-N-CA 122.492 2.128 . . . . 0.0 112.07 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 80.9 mtm180 -126.58 139.18 53.39 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.316 -0.865 . . . . 0.0 109.166 179.614 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 15.0 p -133.71 142.81 40.47 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 121.327 -0.858 . . . . 0.0 109.519 -179.878 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' PHE . . . . . 0.483 ' CE2' ' NH2' ' A' ' 25' ' ' ARG . 28.6 p90 -141.85 155.94 45.54 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.304 -0.872 . . . . 0.0 109.683 -179.598 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -130.46 139.27 50.55 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.484 -0.76 . . . . 0.0 109.777 179.628 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -95.35 117.24 29.97 Favored 'General case' 0 N--CA 1.491 1.601 0 N-CA-C 108.188 -1.041 . . . . 0.0 108.188 178.788 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' MET . . . . . 0.414 ' SD ' HD12 ' A' ' 26' ' ' ILE . 76.9 mtp -107.74 147.44 30.79 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.121 -0.987 . . . . 0.0 110.443 -178.816 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.407 ' HA ' ' H ' ' A' ' 23' ' ' ALA . 88.4 p -143.3 163.25 33.51 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 179.574 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.401 ' O ' ' C ' ' A' ' 19' ' ' GLY . 29.1 m -122.97 140.55 46.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.218 -0.927 . . . . 0.0 109.476 179.921 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.401 ' C ' ' O ' ' A' ' 18' ' ' VAL . . . 44.46 -102.68 0.04 OUTLIER Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.636 -1.386 . . . . 0.0 109.636 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -130.38 38.15 2.01 Favored Glycine 0 N--CA 1.493 2.475 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 8.4 tt0 -147.18 133.49 9.68 Favored Pre-proline 0 N--CA 1.492 1.656 0 O-C-N 121.125 -1.221 . . . . 0.0 109.181 179.974 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 43.0 Cg_endo -69.9 126.7 13.52 Favored 'Trans proline' 0 N--CA 1.493 1.494 0 C-N-CA 122.193 1.929 . . . . 0.0 112.218 -179.788 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.407 ' H ' ' HA ' ' A' ' 17' ' ' SER . . . -80.39 -48.21 13.26 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.288 -0.883 . . . . 0.0 109.432 179.849 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 170.94 -169.41 42.42 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.37 -1.492 . . . . 0.0 109.37 -179.788 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . 0.483 ' NH2' ' CE2' ' A' ' 13' ' ' PHE . 66.4 ttt180 -116.93 142.47 46.9 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.413 -1.051 . . . . 0.0 109.291 179.942 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.414 HD12 ' SD ' ' A' ' 16' ' ' MET . 86.9 mt -120.68 128.03 75.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.424 -0.797 . . . . 0.0 108.998 179.804 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 46.1 t -116.99 133.81 62.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.508 -0.745 . . . . 0.0 109.311 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 71.3 mtm -125.38 147.37 49.19 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.343 -0.848 . . . . 0.0 109.251 179.91 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -112.56 132.6 55.03 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.267 -0.896 . . . . 0.0 109.84 -179.686 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.501 HD13 ' HA ' ' A' ' 39' ' ' ALA . 11.8 mt -103.09 139.66 38.33 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.416 -0.802 . . . . 0.0 109.36 179.262 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -95.6 113.32 24.95 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 108.342 -0.985 . . . . 0.0 108.342 178.795 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -73.96 -42.8 59.97 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 121.232 -0.917 . . . . 0.0 109.94 -179.376 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 56.6 t0 -61.33 -46.58 89.66 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.191 -0.943 . . . . 0.0 110.163 -179.36 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . 0.487 HG21 ' HE2' ' A' ' 103' ' ' LYS . 24.0 m -72.41 -45.77 58.18 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.16 -0.962 . . . . 0.0 110.215 -179.596 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.553 HG22 ' OE1' ' A' ' 99' ' ' GLU . 6.4 p -137.87 80.66 29.95 Favored Pre-proline 0 N--CA 1.494 1.774 0 O-C-N 121.162 -0.962 . . . . 0.0 110.069 -179.224 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -77.24 -6.18 16.29 Favored 'Trans proline' 0 C--N 1.307 -1.645 0 C-N-CA 122.507 2.138 . . . . 0.0 111.642 179.546 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 4.5 tpt180 -94.29 -67.03 0.88 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.375 -0.828 . . . . 0.0 110.151 -178.797 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 46.4 m -56.46 -43.32 79.43 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.191 -0.943 . . . . 0.0 110.231 -179.058 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.501 ' HA ' HD13 ' A' ' 30' ' ' LEU . . . -61.77 -31.71 71.93 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.146 -0.971 . . . . 0.0 108.968 179.747 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -75.51 -51.18 13.55 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.272 -0.893 . . . . 0.0 109.9 -179.898 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 54.2 t-20 -60.39 -46.71 88.99 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.177 -0.952 . . . . 0.0 109.605 -179.707 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.51 ' CE2' ' SG ' ' A' ' 46' ' ' CYS . 71.8 t80 -61.28 -43.23 99.22 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.3 -0.875 . . . . 0.0 109.215 179.637 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 60.1 ttp180 -56.63 -38.37 72.02 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.466 -0.771 . . . . 0.0 109.844 179.825 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -62.85 -44.21 96.74 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.137 -0.977 . . . . 0.0 109.915 -179.507 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.652 HD13 ' O ' ' A' ' 59' ' ' LEU . 3.7 mm? -62.96 -39.06 93.52 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.097 -1.002 . . . . 0.0 109.131 179.729 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' CYS . . . . . 0.51 ' SG ' ' CE2' ' A' ' 42' ' ' PHE . 3.4 m -69.52 -62.4 1.4 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.259 -0.901 . . . . 0.0 109.473 -179.875 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 35.5 m -63.13 -38.57 91.71 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.398 -0.814 . . . . 0.0 109.272 179.889 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 80.83 35.33 25.18 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 110.197 -1.161 . . . . 0.0 110.197 179.555 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -62.52 -38.13 88.75 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.046 -1.267 . . . . 0.0 109.544 179.89 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 69.3 mmtt -62.56 -37.18 85.14 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.178 -0.951 . . . . 0.0 109.777 -179.83 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 89.34 170.01 44.58 Favored Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.297 -1.521 . . . . 0.0 109.297 -179.646 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.521 HG23 ' HA ' ' A' ' 58' ' ' PRO . 91.3 m -77.66 139.52 39.47 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.355 -1.085 . . . . 0.0 109.706 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -63.25 139.41 44.18 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 31.6 mmt180 -59.68 -34.37 72.78 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.33 -1.1 . . . . 0.0 109.767 -179.72 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 85.9 p -61.55 -25.58 67.39 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.222 -0.924 . . . . 0.0 109.902 -179.667 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 113.78 93.1 1.99 Allowed Glycine 0 N--CA 1.495 2.596 0 N-CA-C 109.063 -1.615 . . . . 0.0 109.063 -179.64 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . 0.477 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 30.3 ttmt -177.64 80.43 0.24 Allowed Pre-proline 0 N--CA 1.49 1.543 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 -179.769 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.523 ' O ' ' CE2' ' A' ' 80' ' ' PHE . 74.6 Cg_exo -49.64 127.23 18.07 Favored 'Trans proline' 0 C--N 1.304 -1.812 0 C-N-CA 122.847 2.365 . . . . 0.0 112.768 -178.898 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.652 ' O ' HD13 ' A' ' 45' ' ' LEU . 8.7 mp -96.97 19.68 12.39 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.57 -0.707 . . . . 0.0 109.263 179.808 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 27.2 m170 -112.44 132.01 55.27 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.354 -0.841 . . . . 0.0 109.759 -179.441 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 46.4 m-85 -71.93 -1.92 16.18 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.217 -0.927 . . . . 0.0 108.838 178.953 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 43.6 tttm -54.85 144.23 23.34 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.411 -0.805 . . . . 0.0 109.712 -179.88 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 51.1 t0 58.99 45.57 14.72 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.549 -0.719 . . . . 0.0 109.623 179.853 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 87.7 p -116.52 152.12 34.74 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.394 -0.817 . . . . 0.0 109.131 179.547 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 29.4 t -120.95 146.73 46.35 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.395 -0.816 . . . . 0.0 109.506 -179.725 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.449 ' HE2' ' HG ' ' A' ' 75' ' ' CYS . 3.8 m-30 -65.7 134.02 52.31 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.247 -0.908 . . . . 0.0 108.992 179.763 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 78.5 t60 -62.1 -50.73 70.74 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.265 -0.897 . . . . 0.0 110.1 -179.36 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 29.1 ptt180 -164.61 160.41 20.09 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.062 -1.024 . . . . 0.0 109.471 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -141.05 130.08 24.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.217 -0.927 . . . . 0.0 109.585 179.588 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 21.9 mt -121.93 110.11 33.39 Favored Pre-proline 0 N--CA 1.491 1.6 0 N-CA-C 108.874 -0.788 . . . . 0.0 108.874 179.443 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_exo -50.39 140.69 34.29 Favored 'Trans proline' 0 C--N 1.311 -1.438 0 C-N-CA 122.341 2.028 . . . . 0.0 112.758 -179.478 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 86.09 -56.29 4.8 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 110.407 -1.077 . . . . 0.0 110.407 179.038 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 81.2 m-85 -66.51 -75.18 0.1 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.005 -1.291 . . . . 0.0 110.178 -179.303 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 12.9 ptt? 179.63 -168.07 0.09 Allowed 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.01 -1.056 . . . . 0.0 109.912 -179.788 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' CYS . . . . . 0.449 ' HG ' ' HE2' ' A' ' 66' ' ' PHE . 7.7 t -128.76 129.34 45.57 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.544 -0.723 . . . . 0.0 109.276 179.743 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 63.7 tt0 -100.12 112.96 25.27 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.148 -0.97 . . . . 0.0 109.321 179.816 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -63.17 -37.32 94.71 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.772 -1.331 . . . . 0.0 109.772 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 82.23 -164.88 44.4 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.22 -1.552 . . . . 0.0 109.22 -179.671 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.523 ' OD2' HG23 ' A' ' 81' ' ' THR . 18.0 t70 -143.82 147.5 34.2 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.203 -1.175 . . . . 0.0 109.385 179.938 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.523 ' CE2' ' O ' ' A' ' 58' ' ' PRO . 50.5 p90 -70.89 -20.58 62.49 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.228 -0.92 . . . . 0.0 109.943 -179.79 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.523 HG23 ' OD2' ' A' ' 79' ' ' ASP . 59.0 p -69.26 -28.42 66.3 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.129 -0.982 . . . . 0.0 109.703 -179.817 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . 0.482 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 176.57 -58.13 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.277 -0.89 . . . . 0.0 109.47 179.904 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 90.7 2.54 72.32 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 109.413 -1.475 . . . . 0.0 109.413 -179.854 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . 0.63 ' ND2' ' H ' ' A' ' 86' ' ' THR . 0.0 OUTLIER -88.55 7.26 34.03 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.279 -1.13 . . . . 0.0 109.589 179.919 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . 0.538 ' N ' HD22 ' A' ' 84' ' ' ASN . . . 98.29 -37.87 3.31 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 -179.88 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . 0.63 ' H ' ' ND2' ' A' ' 84' ' ' ASN . 49.4 p -71.38 -25.24 62.28 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.196 -1.179 . . . . 0.0 109.047 179.661 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -86.52 -165.92 41.69 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 179.96 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 85.44 37.08 9.97 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -60.17 148.4 36.33 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.249 -1.148 . . . . 0.0 109.421 179.925 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 50.3 m -108.01 149.13 28.79 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.402 -0.811 . . . . 0.0 109.391 -179.886 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 21.6 pt -66.24 -32.24 57.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.211 -0.931 . . . . 0.0 110.047 -179.534 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 49.1 m-85 -64.3 -37.4 87.35 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.012 -1.055 . . . . 0.0 109.448 -179.912 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 81.51 8.27 87.22 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.157 -1.577 . . . . 0.0 109.157 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -150.35 155.69 40.09 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.272 -1.134 . . . . 0.0 109.525 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 62.6 mttt -92.95 154.84 17.93 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.241 -0.912 . . . . 0.0 109.641 179.927 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . 0.621 ' CG ' ' ND2' ' A' ' 121' ' ' ASN . 38.6 p90 -128.65 156.17 43.85 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.387 -0.82 . . . . 0.0 109.281 179.563 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -65.0 147.31 53.7 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.216 -0.927 . . . . 0.0 110.358 -179.139 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -62.48 154.33 28.86 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.315 -0.866 . . . . 0.0 109.609 179.912 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . 0.553 ' OE1' HG22 ' A' ' 35' ' ' THR . 94.6 mt-10 -85.35 -175.41 5.68 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.283 -0.886 . . . . 0.0 109.755 -179.833 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 18.5 m120 -60.3 162.78 5.67 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.416 -0.803 . . . . 0.0 109.94 -179.422 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 -98.67 23.63 8.46 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.43 -0.794 . . . . 0.0 109.585 -179.817 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 97.0 mt -48.38 -42.94 12.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.138 -0.977 . . . . 0.0 109.937 -179.327 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 103' ' ' LYS . . . . . 0.487 ' HE2' HG21 ' A' ' 34' ' ' THR . 59.0 mttm -89.47 139.29 30.67 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 120.931 -1.106 . . . . 0.0 109.689 179.972 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 87.5 mttt -127.28 -172.35 2.64 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.492 -0.755 . . . . 0.0 109.489 -179.898 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 105' ' ' HIS . . . . . 0.428 ' C ' ' ND1' ' A' ' 105' ' ' HIS . 12.3 t-80 -113.77 111.67 22.16 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.531 -0.73 . . . . 0.0 109.189 179.752 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 60.6 p -131.16 4.82 4.43 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.276 -0.89 . . . . 0.0 109.922 -179.862 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -149.37 169.46 29.66 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.825 -1.31 . . . . 0.0 109.825 -179.824 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 76.6 Cg_endo -79.54 155.39 24.48 Favored 'Trans proline' 0 C--N 1.309 -1.543 0 C-N-CA 122.942 2.428 . . . . 0.0 112.083 179.783 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 76.89 52.61 5.72 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.894 -1.282 . . . . 0.0 109.894 179.628 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 38.1 mm -115.21 136.38 52.14 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.403 -1.057 . . . . 0.0 109.51 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.657 ' N ' HD22 ' A' ' 111' ' ' LEU . 3.3 mm? -88.27 134.37 33.82 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.227 -0.921 . . . . 0.0 109.537 179.786 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 28.9 t -146.3 142.79 28.65 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.255 -0.903 . . . . 0.0 109.374 179.729 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 87.6 mmm -87.64 132.06 34.22 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.231 -0.918 . . . . 0.0 109.284 179.902 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . 0.463 ' O ' ' OD1' ' A' ' 115' ' ' ASN . . . -68.23 139.69 56.04 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.123 -0.986 . . . . 0.0 109.405 -179.948 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . 0.463 ' OD1' ' O ' ' A' ' 114' ' ' ALA . 70.3 m-20 -145.94 113.44 6.31 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.247 -0.908 . . . . 0.0 109.01 179.642 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -69.15 -30.04 68.19 Favored 'General case' 0 C--N 1.297 -1.687 0 O-C-N 121.393 -0.817 . . . . 0.0 109.442 179.816 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -136.11 170.28 23.29 Favored Glycine 0 N--CA 1.494 2.525 0 N-CA-C 109.146 -1.582 . . . . 0.0 109.146 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -67.61 151.99 78.73 Favored 'Trans proline' 0 C--N 1.305 -1.719 0 C-N-CA 122.77 2.314 . . . . 0.0 111.847 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 16.9 m120 53.34 44.26 30.32 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.33 -0.856 . . . . 0.0 109.143 -179.769 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 120' ' ' THR . . . . . 0.451 ' O ' ' OD1' ' A' ' 115' ' ' ASN . 58.3 m -132.26 123.83 27.69 Favored 'General case' 0 N--CA 1.486 1.373 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 179.924 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 121' ' ' ASN . . . . . 0.621 ' ND2' ' CG ' ' A' ' 96' ' ' PHE . 81.0 m-20 -113.39 138.62 49.8 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.506 -0.746 . . . . 0.0 109.537 -179.832 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -138.54 148.09 19.69 Favored Glycine 0 N--CA 1.493 2.489 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 23.3 m -61.23 -32.55 72.34 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.227 -1.16 . . . . 0.0 109.822 179.978 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.5 mt-30 -64.24 143.26 58.02 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.207 -0.933 . . . . 0.0 109.879 -179.481 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 48.7 p90 -141.42 163.9 31.68 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.346 -0.846 . . . . 0.0 109.028 179.858 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 45.3 p90 -136.91 158.14 45.14 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.299 -0.876 . . . . 0.0 109.696 -179.968 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 68.5 mt -120.39 136.53 57.13 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.519 -0.738 . . . . 0.0 109.273 179.799 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -108.5 120.82 43.54 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.457 -0.777 . . . . 0.0 109.358 -179.796 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . 0.404 HG22 ' H ' ' A' ' 129' ' ' THR . 1.4 t -88.72 0.98 55.94 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.199 -0.938 . . . . 0.0 109.236 179.816 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -148.19 155.48 41.44 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.271 -0.893 . . . . 0.0 109.176 179.937 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 7.7 ttpm? -75.64 127.91 34.09 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.184 -0.947 . . . . 0.0 109.516 179.996 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 22.6 p -126.98 126.69 43.62 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.37 -0.831 . . . . 0.0 109.247 179.882 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -72.23 -36.56 69.16 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.28 -0.887 . . . . 0.0 110.366 -179.582 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 0.4 OUTLIER -65.03 -41.76 94.99 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.135 -0.978 . . . . 0.0 110.043 -179.157 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . 0.44 ' O ' ' CD2' ' A' ' 139' ' ' HIS . 12.9 mt -66.59 -33.83 76.53 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.985 -1.072 . . . . 0.0 109.8 179.701 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -68.46 140.85 55.75 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.15 -0.969 . . . . 0.0 109.522 -179.824 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 134.59 -86.19 0.26 Allowed Glycine 0 N--CA 1.492 2.417 0 N-CA-C 109.684 -1.366 . . . . 0.0 109.684 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 31.6 mmtp -85.97 5.32 33.79 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.132 -1.216 . . . . 0.0 109.507 -179.835 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 139' ' ' HIS . . . . . 0.44 ' CD2' ' O ' ' A' ' 135' ' ' LEU . 54.4 m-70 -103.26 138.19 40.38 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.286 -0.884 . . . . 0.0 109.477 -179.955 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 43.2 t -120.48 141.54 40.38 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 O-C-N 121.415 -0.803 . . . . 0.0 109.684 -179.565 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 96.1 t -94.8 128.96 45.61 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.361 -0.837 . . . . 0.0 109.245 179.821 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . 0.434 ' CE2' HD21 ' A' ' 30' ' ' LEU . 38.0 p90 -116.18 0.42 12.92 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.429 -0.794 . . . . 0.0 109.757 -179.77 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -169.42 178.04 42.71 Favored Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.676 -1.37 . . . . 0.0 109.676 179.684 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.2 pt20 -145.13 165.8 27.25 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.21 -1.171 . . . . 0.0 109.479 -179.865 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 77.7 t -96.54 127.28 48.82 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.265 0 O-C-N 121.193 -0.942 . . . . 0.0 109.274 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 22.2 m -94.7 -33.77 5.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.134 -0.979 . . . . 0.0 109.746 179.916 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -144.94 171.92 13.77 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.248 -0.907 . . . . 0.0 109.663 -179.797 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 96.68 4.93 58.99 Favored Glycine 0 N--CA 1.493 2.435 0 N-CA-C 109.915 -1.274 . . . . 0.0 109.915 179.642 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 149' ' ' MET . . . . . 0.491 ' O ' HG12 ' A' ' 152' ' ' VAL . 71.9 mtm -60.31 -33.05 71.82 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.071 -1.252 . . . . 0.0 109.809 179.888 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -65.63 -42.49 91.44 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 120.87 -1.144 . . . . 0.0 110.085 -179.586 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 6.5 p -81.73 -34.33 12.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.149 -0.969 . . . . 0.0 110.522 -179.484 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 152' ' ' VAL . . . . . 0.596 ' O ' ' OE1' ' A' ' 156' ' ' GLU . 0.8 OUTLIER -52.55 -43.07 41.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 120.816 -1.178 . . . . 0.0 109.0 -179.13 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 153' ' ' LYS . . . . . 0.454 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 48.5 mttp -63.12 -34.41 77.54 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.192 -0.942 . . . . 0.0 109.317 179.251 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -63.27 -32.11 73.43 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.429 -0.795 . . . . 0.0 110.176 -179.558 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.419 ' O ' HG22 ' A' ' 158' ' ' VAL . 69.1 mt -68.79 -43.14 82.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.124 -0.985 . . . . 0.0 110.836 -179.179 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . 0.596 ' OE1' ' O ' ' A' ' 152' ' ' VAL . 32.4 mp0 -77.21 -37.98 52.32 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 120.768 -1.207 . . . . 0.0 112.025 -178.683 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 12.1 pttm -57.48 -35.55 70.33 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 120.523 -1.36 . . . . 0.0 109.731 -178.516 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.419 HG22 ' O ' ' A' ' 155' ' ' ILE . 26.9 m -75.11 -19.8 16.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 120.969 -1.082 . . . . 0.0 109.013 179.042 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -67.33 167.46 40.04 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 -179.911 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 89.4 p -148.74 168.22 23.48 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.316 -1.108 . . . . 0.0 109.42 -179.798 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 22.9 m -54.55 -34.21 61.45 Favored 'General case' 0 N--CA 1.487 1.406 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 179.425 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 23.9 m -58.39 -30.77 67.07 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.472 -0.767 . . . . 0.0 109.063 179.438 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.69 7.49 55.52 Favored Glycine 0 N--CA 1.492 2.431 0 N-CA-C 109.814 -1.315 . . . . 0.0 109.814 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 75.3 ttt-85 -114.74 139.5 49.65 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.31 -1.112 . . . . 0.0 109.084 179.781 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 165' ' ' THR . . . . . . . . . . . . . 51.1 p -87.47 156.24 19.64 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.214 -0.929 . . . . 0.0 109.879 -179.768 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -66.8 -37.22 84.13 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.531 -0.731 . . . . 0.0 109.433 179.765 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 67.2 mttm -111.25 156.82 20.89 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.411 -0.805 . . . . 0.0 109.606 -179.835 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 94.3 mttt -76.24 139.77 41.31 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.287 -0.883 . . . . 0.0 109.331 179.871 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 43.1 t -118.02 126.35 74.84 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.265 -0.897 . . . . 0.0 109.636 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 42.6 t -146.0 150.3 15.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.345 -0.847 . . . . 0.0 109.294 179.608 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -88.54 122.12 39.62 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 O-C-N 121.288 -0.882 . . . . 0.0 109.691 -179.446 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -67.0 -25.61 66.39 Favored 'General case' 0 C--N 1.3 -1.565 0 O-C-N 121.438 -0.789 . . . . 0.0 109.536 179.56 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 173' ' ' ASP . . . . . 0.413 ' OD1' ' N ' ' A' ' 174' ' ' CYS . 44.9 t0 -173.06 169.96 4.52 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.01 -1.056 . . . . 0.0 110.542 -179.383 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 174' ' ' CYS . . . . . 0.413 ' N ' ' OD1' ' A' ' 173' ' ' ASP . 30.4 p -152.61 150.35 29.42 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.501 -0.749 . . . . 0.0 109.014 179.416 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . 179.71 -177.07 47.99 Favored Glycine 0 N--CA 1.494 2.528 0 N-CA-C 110.044 -1.222 . . . . 0.0 110.044 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 58.9 tt0 -105.33 122.39 45.86 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.529 -0.983 . . . . 0.0 109.632 -179.868 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 177' ' ' LEU . . . . . 0.591 HD13 ' O ' ' A' ' 177' ' ' LEU . 0.2 OUTLIER -65.2 -40.82 94.71 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.171 -0.956 . . . . 0.0 108.566 179.485 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 178' ' ' SER . . . . . 0.464 ' C ' ' O ' ' A' ' 177' ' ' LEU . 1.2 t . . . . . 0 N--CA 1.493 1.702 0 CA-C-O 118.022 -0.99 . . . . 0.0 109.935 179.859 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.494 1.738 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -69.18 138.53 39.92 Favored 'Trans proline' 0 N--CA 1.496 1.627 0 C-N-CA 122.744 2.296 . . . . 0.0 112.306 179.913 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . 0.701 HH21 HD23 ' A' ' 177' ' ' LEU . 50.8 ttp180 -133.69 126.53 30.96 Favored 'General case' 0 N--CA 1.49 1.568 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 179.143 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.5 p -131.88 141.83 44.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.29 -0.881 . . . . 0.0 109.521 -179.139 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 40.5 p90 -140.28 157.87 44.9 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.379 -0.826 . . . . 0.0 109.524 -179.602 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 95.2 m-85 -126.93 142.58 51.51 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.472 -0.768 . . . . 0.0 109.808 179.902 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 19.1 t70 -93.74 113.51 25.59 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.412 -0.958 . . . . 0.0 108.412 178.931 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 96.8 mmm -97.13 146.54 24.95 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.452 -0.78 . . . . 0.0 110.112 -179.164 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 41.8 t -149.58 162.07 40.91 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.457 -0.777 . . . . 0.0 109.036 179.628 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.536 HG22 ' O ' ' A' ' 21' ' ' GLN . 25.6 m -124.27 159.9 29.36 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.314 -0.867 . . . . 0.0 109.562 179.894 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -49.18 -30.45 10.64 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.822 -1.311 . . . . 0.0 109.822 -179.475 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -73.93 -79.65 0.52 Allowed Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.674 -1.37 . . . . 0.0 109.674 -179.837 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' GLN . . . . . 0.536 ' O ' HG22 ' A' ' 18' ' ' VAL . 4.2 pt20 -146.35 157.15 49.43 Favored Pre-proline 0 N--CA 1.494 1.727 0 O-C-N 121.177 -1.19 . . . . 0.0 109.129 -179.968 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 75.6 Cg_exo -45.78 130.31 12.51 Favored 'Trans proline' 0 C--N 1.31 -1.455 0 C-N-CA 122.25 1.967 . . . . 0.0 112.138 179.792 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -80.05 -56.42 4.25 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.28 -0.888 . . . . 0.0 109.703 -179.891 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 168.82 -170.74 42.54 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 -179.898 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 56.9 ttp180 -114.48 142.01 46.95 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.392 -1.063 . . . . 0.0 109.338 179.818 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 81.5 mt -120.04 130.5 74.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.429 -0.795 . . . . 0.0 109.012 179.877 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 43.6 t -110.56 134.63 52.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.386 -0.821 . . . . 0.0 109.717 -179.792 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 72.1 mtm -121.71 151.89 40.0 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.447 -0.783 . . . . 0.0 109.082 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -105.54 132.86 51.17 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.265 -0.897 . . . . 0.0 110.053 -179.517 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -105.18 129.52 53.55 Favored 'General case' 0 N--CA 1.494 1.767 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 179.143 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -97.7 119.0 35.5 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.207 -0.933 . . . . 0.0 109.131 179.716 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -81.39 -42.21 20.78 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.383 -0.823 . . . . 0.0 109.638 179.847 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -64.8 -46.11 83.42 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.281 -0.887 . . . . 0.0 110.215 -179.388 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 28.4 m -65.99 -45.4 81.74 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.163 -0.961 . . . . 0.0 109.589 -179.766 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.445 ' O ' ' OG1' ' A' ' 35' ' ' THR . 4.1 p -141.38 80.58 16.33 Favored Pre-proline 0 N--CA 1.492 1.668 0 N-CA-C 108.798 -0.816 . . . . 0.0 108.798 179.912 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_endo -59.49 -65.1 0.09 OUTLIER 'Trans proline' 0 N--CA 1.496 1.622 0 C-N-CA 122.419 2.079 . . . . 0.0 113.018 -178.843 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 94.8 mtt180 -60.62 -36.88 79.7 Favored 'General case' 0 C--N 1.298 -1.668 0 O-C-N 121.596 -0.69 . . . . 0.0 110.965 -178.769 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 23.0 m -60.85 -43.32 98.48 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 120.928 -1.107 . . . . 0.0 109.954 -179.423 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -61.94 -31.58 71.91 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.176 -0.952 . . . . 0.0 108.87 179.769 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -70.52 -41.73 72.21 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.352 -0.842 . . . . 0.0 109.937 -179.862 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' ASN . . . . . 0.439 ' O ' HD23 ' A' ' 45' ' ' LEU . 81.5 m-20 -60.71 -45.31 94.69 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.137 -0.977 . . . . 0.0 109.75 -179.585 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 56.3 t80 -71.76 -48.24 48.2 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.202 -0.936 . . . . 0.0 109.225 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.509 ' CD ' ' NE2' ' A' ' 176' ' ' GLN . 61.8 ttp180 -58.24 -38.92 77.82 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.47 -0.768 . . . . 0.0 109.887 179.917 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.489 ' O ' ' N ' ' A' ' 48' ' ' GLY . . . -60.99 -40.59 94.09 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.289 -0.882 . . . . 0.0 110.22 -178.925 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.439 HD23 ' O ' ' A' ' 41' ' ' ASN . 3.8 mm? -61.61 -39.38 91.03 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.056 -1.027 . . . . 0.0 109.473 179.946 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' CYS . . . . . . . . . . . . . 20.1 m -80.87 -53.13 6.74 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.015 -1.053 . . . . 0.0 109.71 -179.832 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 68.8 p -69.17 -36.74 77.67 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.336 -0.853 . . . . 0.0 109.855 -179.821 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . 0.489 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 73.6 32.79 59.09 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.815 -1.314 . . . . 0.0 109.815 179.636 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 78.1 mm-40 -60.91 -37.43 82.21 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.081 -1.246 . . . . 0.0 109.262 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 32.5 mmtm -61.39 -31.38 71.29 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.311 -0.868 . . . . 0.0 109.303 179.649 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 97.59 169.2 32.7 Favored Glycine 0 N--CA 1.489 2.168 0 N-CA-C 109.323 -1.511 . . . . 0.0 109.323 -179.773 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.493 HG23 ' HA ' ' A' ' 58' ' ' PRO . 98.1 m -75.32 141.68 43.33 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.289 -1.124 . . . . 0.0 109.749 -179.84 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -56.78 140.3 44.25 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.254 -1.538 . . . . 0.0 109.254 179.87 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 93.5 mtt-85 -59.04 -33.39 70.71 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.189 -1.183 . . . . 0.0 109.998 -179.787 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 86.6 p -60.55 -25.46 66.18 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.161 -0.962 . . . . 0.0 109.902 -179.397 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 108.8 90.45 2.11 Favored Glycine 0 N--CA 1.495 2.578 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 -179.756 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . 0.431 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 17.7 tttm -176.26 78.62 0.28 Allowed Pre-proline 0 N--CA 1.489 1.493 0 O-C-N 121.397 -1.06 . . . . 0.0 108.46 -179.683 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.493 ' HA ' HG23 ' A' ' 52' ' ' THR . 87.0 Cg_exo -47.31 128.9 15.26 Favored 'Trans proline' 0 C--N 1.304 -1.793 0 C-N-CA 122.66 2.24 . . . . 0.0 112.174 -179.046 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.537 ' O ' ' CG ' ' A' ' 60' ' ' HIS . 7.2 mp -91.62 94.78 9.57 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.684 -0.635 . . . . 0.0 109.753 -179.348 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . 0.537 ' CG ' ' O ' ' A' ' 59' ' ' LEU . 93.7 m-70 -159.75 125.39 4.17 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.358 -0.839 . . . . 0.0 109.531 179.685 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . 0.42 ' O ' ' OG ' ' A' ' 64' ' ' SER . 55.5 m-85 -68.59 -5.05 17.7 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.104 -0.997 . . . . 0.0 108.986 179.269 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 35.2 ttmt -54.74 144.9 20.8 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.463 -0.773 . . . . 0.0 109.743 -179.866 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 84.1 m-20 56.25 45.41 23.17 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.612 -0.68 . . . . 0.0 109.793 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.42 ' OG ' ' O ' ' A' ' 61' ' ' TYR . 39.3 m -120.23 147.91 44.35 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.413 -0.804 . . . . 0.0 108.996 179.528 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 30.0 t -113.12 147.04 38.15 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.424 -0.798 . . . . 0.0 109.554 -179.699 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 4.2 m-30 -64.79 136.31 56.77 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.279 -0.888 . . . . 0.0 108.959 179.951 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 53.3 t-80 -61.5 -50.53 72.34 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.274 -0.891 . . . . 0.0 110.285 -179.193 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.696 HH21 ' NE2' ' A' ' 76' ' ' GLN . 36.8 ptt180 -161.47 160.71 29.56 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.117 -0.989 . . . . 0.0 110.136 -179.757 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.585 HG21 HG22 ' A' ' 165' ' ' THR . 24.0 m -132.91 151.34 34.14 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.509 -0.744 . . . . 0.0 108.993 179.716 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 11.6 mt -146.92 119.83 4.91 Favored Pre-proline 0 N--CA 1.492 1.657 0 O-C-N 121.038 -1.039 . . . . 0.0 109.436 179.78 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -74.68 135.35 19.59 Favored 'Trans proline' 0 C--N 1.312 -1.368 0 C-N-CA 122.161 1.907 . . . . 0.0 111.997 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 90.39 1.1 75.47 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 93.1 m-85 -135.81 -90.76 0.29 Allowed 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.376 -1.073 . . . . 0.0 109.632 179.963 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 9.6 ptp -170.28 172.62 6.13 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.109 -0.994 . . . . 0.0 109.618 -179.946 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 1.7 m -116.14 138.9 50.86 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.403 -0.811 . . . . 0.0 108.877 179.748 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' GLN . . . . . 0.696 ' NE2' HH21 ' A' ' 68' ' ' ARG . 94.6 mt-30 -108.54 154.87 21.32 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.269 -0.894 . . . . 0.0 109.707 -179.683 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -147.04 -165.79 11.96 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 -179.816 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.47 ' O ' ' N ' ' A' ' 80' ' ' PHE . . . 94.37 11.59 57.03 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 109.459 -1.457 . . . . 0.0 109.459 -179.737 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -48.15 -15.4 0.07 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.391 -1.064 . . . . 0.0 109.594 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.47 ' N ' ' O ' ' A' ' 78' ' ' GLY . 81.2 t80 -48.21 -47.96 35.21 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.229 -0.919 . . . . 0.0 110.2 -179.535 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.808 ' CB ' ' H ' ' A' ' 88' ' ' GLY . 54.4 p -71.15 -32.18 68.62 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.916 -1.115 . . . . 0.0 109.49 -179.929 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . 0.694 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 163.21 -54.64 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.426 -0.796 . . . . 0.0 109.14 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 91.77 1.04 71.23 Favored Glycine 0 N--CA 1.492 2.42 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 179.947 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 78.6 m-20 -87.63 5.91 37.18 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.225 -1.162 . . . . 0.0 109.474 179.923 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 95.53 -39.82 2.78 Favored Glycine 0 N--CA 1.493 2.45 0 N-CA-C 109.263 -1.535 . . . . 0.0 109.263 -179.79 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 56.3 p -73.85 -14.2 61.05 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.418 -1.048 . . . . 0.0 108.944 179.665 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -80.66 -160.76 24.0 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 -179.881 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.808 ' H ' ' CB ' ' A' ' 81' ' ' THR . . . 89.54 23.18 34.54 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.426 -1.47 . . . . 0.0 109.426 -179.819 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -55.69 148.89 15.27 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.293 -1.122 . . . . 0.0 109.529 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 49.8 m -105.14 151.12 24.43 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.394 -0.816 . . . . 0.0 109.384 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.411 HD13 HG21 ' A' ' 91' ' ' ILE . 27.6 pt -62.78 -32.48 55.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.247 -0.908 . . . . 0.0 109.974 -179.549 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 89.6 m-85 -65.08 -35.19 80.36 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.155 -0.965 . . . . 0.0 109.606 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 87.1 7.43 77.23 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.391 -1.483 . . . . 0.0 109.391 -179.862 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -147.53 155.89 42.3 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.32 -1.106 . . . . 0.0 109.376 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 64.1 mttp -89.89 143.65 26.61 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.255 -0.903 . . . . 0.0 109.82 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 41.4 p90 -138.15 160.38 39.55 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.543 -0.723 . . . . 0.0 109.067 179.779 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -67.35 132.79 48.38 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.04 -1.037 . . . . 0.0 109.596 -179.599 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -75.27 140.02 42.91 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.4 -0.813 . . . . 0.0 109.799 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -59.83 149.06 32.41 Favored 'General case' 0 C--N 1.305 -1.35 0 O-C-N 121.309 -0.87 . . . . 0.0 109.093 179.581 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . 0.425 ' N ' HD22 ' A' ' 100' ' ' ASN . 2.8 m120 -53.36 162.56 0.73 Allowed 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.409 -0.807 . . . . 0.0 109.309 -179.942 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 101' ' ' PHE . . . . . 0.584 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 22.3 p90 -130.63 82.15 2.04 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.462 -0.774 . . . . 0.0 109.372 -179.787 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 87.8 mt -60.31 -33.97 55.79 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.18 -0.95 . . . . 0.0 109.478 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 91.6 mttt -84.45 136.29 33.9 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.311 -0.868 . . . . 0.0 109.342 179.932 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 61.9 mttp -116.31 -178.62 3.46 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.485 -0.759 . . . . 0.0 109.986 -179.877 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 105' ' ' HIS . . . . . 0.526 ' O ' ' CG ' ' A' ' 105' ' ' HIS . 49.9 p-80 -99.79 101.39 12.53 Favored 'General case' 0 N--CA 1.493 1.694 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 179.692 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 66.5 p -101.19 -2.16 32.01 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.273 -0.892 . . . . 0.0 109.768 -179.743 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -149.8 171.91 29.79 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -74.24 157.81 45.61 Favored 'Trans proline' 0 C--N 1.304 -1.785 0 C-N-CA 122.899 2.399 . . . . 0.0 112.027 179.784 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 84.91 40.47 8.1 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 110.158 -1.177 . . . . 0.0 110.158 179.663 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 43.0 mm -113.66 133.55 59.26 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.382 -1.07 . . . . 0.0 109.183 179.677 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.537 ' N ' HD22 ' A' ' 111' ' ' LEU . 3.4 mm? -90.61 133.15 35.31 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.145 -0.972 . . . . 0.0 109.825 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 42.9 t -144.8 142.6 30.1 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.353 -0.842 . . . . 0.0 109.197 179.744 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 113' ' ' MET . . . . . 0.586 ' SD ' ' CE1' ' A' ' 142' ' ' PHE . 83.8 mmm -83.97 129.79 34.91 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.12 -0.988 . . . . 0.0 109.288 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . 0.531 ' O ' ' ND2' ' A' ' 115' ' ' ASN . . . -69.6 143.94 53.16 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.283 -0.886 . . . . 0.0 109.462 -179.951 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . 0.531 ' ND2' ' O ' ' A' ' 114' ' ' ALA . 14.6 m120 -142.94 112.72 6.96 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.363 -0.836 . . . . 0.0 108.961 179.463 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -69.45 -29.51 67.22 Favored 'General case' 0 C--N 1.298 -1.66 0 O-C-N 121.471 -0.768 . . . . 0.0 109.657 -179.872 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -134.43 166.73 24.09 Favored Glycine 0 N--CA 1.493 2.477 0 N-CA-C 109.406 -1.477 . . . . 0.0 109.406 179.888 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -68.88 153.82 72.08 Favored 'Trans proline' 0 C--N 1.305 -1.721 0 C-N-CA 122.81 2.34 . . . . 0.0 111.94 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 17.9 m120 54.19 43.17 31.01 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.483 -0.761 . . . . 0.0 109.441 -179.925 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 92.8 m -134.91 125.07 25.98 Favored 'General case' 0 N--CA 1.485 1.324 0 O-C-N 121.42 -0.8 . . . . 0.0 108.929 179.928 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 22.6 t-20 -103.05 102.6 12.63 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.469 -0.77 . . . . 0.0 109.391 179.828 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -92.93 133.93 11.95 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.414 -1.474 . . . . 0.0 109.414 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 83.3 p -63.77 -23.46 67.37 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.191 -1.182 . . . . 0.0 109.296 179.83 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 92.6 mt-30 -68.66 144.57 54.41 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.335 -0.853 . . . . 0.0 109.505 -179.882 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 49.7 p90 -137.53 163.07 32.06 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.396 -0.815 . . . . 0.0 109.166 179.773 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 48.9 p90 -135.81 160.93 37.05 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.271 -0.893 . . . . 0.0 109.776 -179.937 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 70.2 mt -117.61 132.68 66.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.444 -0.785 . . . . 0.0 109.568 -179.918 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 1.9 p -100.72 106.6 18.05 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.325 -0.859 . . . . 0.0 109.255 179.555 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . 0.431 ' OG1' ' OE1' ' A' ' 156' ' ' GLU . 68.5 p -90.93 3.03 55.68 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.189 -0.945 . . . . 0.0 109.809 -179.765 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -146.0 154.63 42.1 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.12 -0.987 . . . . 0.0 109.674 -179.726 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 78.9 tttt -81.16 131.06 35.28 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.336 -0.853 . . . . 0.0 109.362 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 9.4 p -125.29 161.65 26.49 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.358 -0.839 . . . . 0.0 109.418 179.933 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -127.52 -28.79 2.73 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.236 -0.915 . . . . 0.0 109.642 -179.891 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 2.0 p90 -75.8 -6.53 51.11 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.159 -0.963 . . . . 0.0 109.777 -179.841 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 8.2 mt -90.78 7.69 38.47 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.242 -0.911 . . . . 0.0 109.548 179.486 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . 0.472 ' O ' ' OD1' ' A' ' 136' ' ' ASP . 52.2 p30 -53.63 153.34 4.43 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.301 -0.874 . . . . 0.0 109.724 -179.755 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 144.48 -129.6 3.64 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.012 -1.635 . . . . 0.0 109.012 -179.685 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 2.0 mptp? -90.4 127.55 36.23 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.214 -1.168 . . . . 0.0 108.91 179.643 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 85.6 t60 -140.57 127.58 20.75 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.375 -0.828 . . . . 0.0 109.694 -179.85 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 44.7 t -123.11 132.76 70.81 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 121.458 -0.776 . . . . 0.0 109.048 179.595 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 38.8 t -116.5 129.36 73.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.321 -0.862 . . . . 0.0 109.211 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . 0.586 ' CE1' ' SD ' ' A' ' 113' ' ' MET . 38.3 p90 -119.93 5.89 10.89 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.323 -0.861 . . . . 0.0 109.734 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -179.43 177.66 48.37 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 179.655 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.2 pt20 -146.17 167.13 24.2 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.265 -1.138 . . . . 0.0 109.453 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 55.2 t -95.33 130.24 44.36 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 O-C-N 121.232 -0.918 . . . . 0.0 109.326 -179.886 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 13.3 m -108.51 -36.63 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.308 -0.87 . . . . 0.0 109.653 179.812 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 94.4 mt-10 -139.75 161.89 36.46 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.26 -0.9 . . . . 0.0 109.575 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . 0.43 ' O ' HG12 ' A' ' 151' ' ' VAL . . . 95.02 5.64 60.78 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 110.102 -1.199 . . . . 0.0 110.102 179.578 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 149' ' ' MET . . . . . 0.593 ' O ' HG12 ' A' ' 152' ' ' VAL . 65.0 mtt -60.0 -32.58 71.0 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.049 -1.266 . . . . 0.0 109.319 179.859 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 56.1 t0 -64.85 -41.89 95.33 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.954 -1.091 . . . . 0.0 110.291 -179.563 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.43 HG12 ' O ' ' A' ' 148' ' ' GLY . 7.6 p -78.15 -32.32 17.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.06 -1.025 . . . . 0.0 110.911 -179.266 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 152' ' ' VAL . . . . . 0.593 HG12 ' O ' ' A' ' 149' ' ' MET . 0.9 OUTLIER -51.62 -40.57 26.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 120.962 -1.087 . . . . 0.0 109.011 -179.18 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 153' ' ' LYS . . . . . 0.439 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 59.1 mttp -65.69 -32.63 74.3 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.242 -0.911 . . . . 0.0 109.441 179.09 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -60.11 -39.37 85.97 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.341 -0.849 . . . . 0.0 110.113 -179.28 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 90.0 mt -72.31 -33.95 47.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.048 -1.033 . . . . 0.0 109.757 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . 0.431 ' OE1' ' OG1' ' A' ' 129' ' ' THR . 84.5 tt0 -77.63 -41.72 37.43 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.231 -0.918 . . . . 0.0 111.34 -178.859 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 157' ' ' LYS . . . . . 0.431 ' HG2' ' HZ2' ' A' ' 157' ' ' LYS . 17.5 pttm -59.65 -35.57 74.66 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 120.682 -1.261 . . . . 0.0 109.579 -178.838 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 35.3 m -77.15 -10.34 13.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.155 -0.966 . . . . 0.0 108.798 179.228 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -73.89 163.45 54.63 Favored Glycine 0 N--CA 1.488 2.124 0 N-CA-C 110.178 -1.169 . . . . 0.0 110.178 -179.596 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 54.2 m -148.07 165.77 29.8 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.598 -0.942 . . . . 0.0 109.276 -179.895 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 23.9 t -55.08 -26.56 38.71 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.217 -0.927 . . . . 0.0 109.293 179.849 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 86.8 p -57.64 -25.65 60.48 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.243 -0.911 . . . . 0.0 109.639 -179.749 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 92.48 12.98 57.77 Favored Glycine 0 N--CA 1.492 2.414 0 N-CA-C 109.941 -1.264 . . . . 0.0 109.941 179.87 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 24.2 ttm180 -127.14 143.09 51.35 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.204 -1.174 . . . . 0.0 109.491 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 165' ' ' THR . . . . . 0.585 HG22 HG21 ' A' ' 69' ' ' VAL . 79.1 p -76.9 154.81 33.35 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.255 -0.903 . . . . 0.0 109.344 179.851 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -63.93 -35.88 82.13 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.24 -0.912 . . . . 0.0 109.231 179.813 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -116.78 154.69 30.23 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.571 -0.706 . . . . 0.0 109.151 179.794 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -66.44 142.43 57.57 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.121 -0.987 . . . . 0.0 109.095 -179.949 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . 0.465 ' O ' HG23 ' A' ' 169' ' ' VAL . 33.0 m -123.99 128.38 74.09 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.363 -0.836 . . . . 0.0 109.707 -179.716 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 40.7 t -144.16 147.76 19.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.395 -0.816 . . . . 0.0 109.011 179.649 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.407 HG23 ' H ' ' A' ' 171' ' ' VAL . 0.2 OUTLIER -83.86 115.53 26.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 120.935 -1.103 . . . . 0.0 109.464 -179.787 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -66.08 -22.39 66.41 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.364 -0.835 . . . . 0.0 109.213 179.469 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 173' ' ' ASP . . . . . 0.454 ' OD1' ' N ' ' A' ' 174' ' ' CYS . 48.0 t0 -167.38 163.39 15.07 Favored 'General case' 0 N--CA 1.492 1.654 0 C-N-CA 119.035 -1.066 . . . . 0.0 110.564 -179.493 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 174' ' ' CYS . . . . . 0.454 ' N ' ' OD1' ' A' ' 173' ' ' ASP . 18.5 p -161.78 146.62 13.06 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.592 -0.693 . . . . 0.0 109.325 179.535 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . 170.45 175.08 38.97 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 179.829 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 176' ' ' GLN . . . . . 0.509 ' NE2' ' CD ' ' A' ' 43' ' ' ARG . 47.9 tt0 -102.58 121.02 41.55 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.228 -1.16 . . . . 0.0 109.779 179.925 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 177' ' ' LEU . . . . . 0.701 HD23 HH21 ' A' ' 11' ' ' ARG . 46.2 tp -64.74 -36.58 84.75 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.33 -0.856 . . . . 0.0 109.371 179.408 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 7.9 t . . . . . 0 N--CA 1.49 1.565 0 CA-C-O 118.025 -0.988 . . . . 0.0 109.368 179.999 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 2.4 m120 . . . . . 0 N--CA 1.493 1.686 0 N-CA-C 109.322 -0.621 . . . . 0.0 109.322 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -69.42 139.67 41.97 Favored 'Trans proline' 0 N--CA 1.496 1.65 0 C-N-CA 122.686 2.257 . . . . 0.0 112.152 179.887 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 75.1 mtt85 -128.93 132.87 47.69 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.387 -0.82 . . . . 0.0 109.077 179.092 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.7 p -135.06 142.68 39.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.488 -0.757 . . . . 0.0 109.223 -179.859 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 41.6 p90 -139.55 153.81 47.51 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.296 -0.878 . . . . 0.0 109.505 -179.786 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 93.4 m-85 -122.15 135.23 54.76 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.516 -0.74 . . . . 0.0 109.446 179.699 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.6 t0 -90.3 113.4 25.25 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.111 -0.993 . . . . 0.0 108.374 179.212 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 71.6 mtp -105.24 147.38 28.11 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.072 -1.017 . . . . 0.0 110.389 -179.168 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.435 ' HA ' ' H ' ' A' ' 23' ' ' ALA . 84.2 p -144.9 165.2 28.81 Favored 'General case' 0 N--CA 1.489 1.501 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 179.724 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 33.5 m -125.37 151.16 31.01 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.28 -0.888 . . . . 0.0 109.43 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -51.17 102.49 0.07 OUTLIER Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 140.43 -75.13 0.35 Allowed Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.714 -1.354 . . . . 0.0 109.714 179.873 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -138.41 158.78 70.0 Favored Pre-proline 0 N--CA 1.492 1.663 0 O-C-N 121.337 -1.096 . . . . 0.0 109.264 -179.763 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -58.63 138.77 87.64 Favored 'Trans proline' 0 N--CA 1.494 1.524 0 C-N-CA 122.581 2.187 . . . . 0.0 111.887 179.78 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.435 ' H ' ' HA ' ' A' ' 17' ' ' SER . . . -84.27 -62.47 1.55 Allowed 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.223 -0.923 . . . . 0.0 109.568 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 168.9 -169.69 41.96 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 -179.836 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 58.9 ttp180 -115.72 141.81 47.59 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.338 -1.095 . . . . 0.0 109.265 179.936 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 82.8 mt -121.24 128.96 76.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.331 -0.855 . . . . 0.0 109.237 179.831 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 46.5 t -114.18 134.09 58.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.335 -0.853 . . . . 0.0 109.26 179.908 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' MET . . . . . 0.421 ' HG2' HG22 ' A' ' 145' ' ' VAL . 73.9 mtm -119.93 151.74 38.47 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.384 -0.822 . . . . 0.0 109.318 -179.928 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -98.68 131.98 44.43 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.339 -0.851 . . . . 0.0 109.763 -179.57 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -107.34 132.62 52.93 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.494 -0.754 . . . . 0.0 109.143 179.681 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 95.7 m-85 -98.6 125.41 43.85 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.223 -0.923 . . . . 0.0 109.176 179.66 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -94.47 1.25 55.76 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.255 -0.903 . . . . 0.0 109.997 -179.692 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -95.45 -75.17 0.53 Allowed 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.046 -1.034 . . . . 0.0 110.581 -179.342 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 47.0 m -64.67 -40.65 95.79 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.354 -0.841 . . . . 0.0 111.017 -178.646 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.569 HG21 ' HA ' ' A' ' 142' ' ' PHE . 43.3 p -126.46 76.18 73.7 Favored Pre-proline 0 N--CA 1.496 1.829 0 O-C-N 121.089 -1.007 . . . . 0.0 110.149 -178.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 63.7 Cg_endo -78.21 -57.42 0.04 OUTLIER 'Trans proline' 0 C--N 1.308 -1.601 0 C-N-CA 122.764 2.31 . . . . 0.0 112.729 179.724 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 24.1 mmt85 -57.39 -38.47 74.32 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.247 -0.908 . . . . 0.0 110.151 -179.249 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.555 HG23 ' SD ' ' A' ' 113' ' ' MET . 41.5 m -61.41 -40.85 95.9 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.039 -1.038 . . . . 0.0 109.915 -179.581 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -61.89 -31.1 71.36 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.203 -0.936 . . . . 0.0 109.216 179.842 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -67.57 -37.19 82.29 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.389 -0.819 . . . . 0.0 109.766 -179.846 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 49.6 t-20 -58.64 -43.05 89.62 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.24 -0.912 . . . . 0.0 109.841 -179.678 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.495 ' O ' ' SG ' ' A' ' 46' ' ' CYS . 96.9 m-85 -83.31 -46.63 12.38 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.165 -0.96 . . . . 0.0 109.756 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.651 ' NE ' HE22 ' A' ' 176' ' ' GLN . 76.5 ttt180 -57.19 -42.06 80.53 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.295 -0.878 . . . . 0.0 109.901 -179.697 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.482 ' O ' ' N ' ' A' ' 48' ' ' GLY . . . -76.63 -48.54 18.76 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.132 -0.98 . . . . 0.0 110.29 -179.612 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.401 HD12 ' HA ' ' A' ' 45' ' ' LEU . 40.8 tp -58.1 -37.92 75.45 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.112 -0.993 . . . . 0.0 109.795 -179.4 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' CYS . . . . . 0.495 ' SG ' ' O ' ' A' ' 42' ' ' PHE . 39.8 m -77.32 -63.97 1.25 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.113 -0.992 . . . . 0.0 109.929 -179.795 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 26.0 m -63.17 -38.39 91.0 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.117 -0.989 . . . . 0.0 109.678 -179.813 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . 0.482 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 80.58 37.16 21.1 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 110.043 -1.223 . . . . 0.0 110.043 179.744 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -61.4 -37.57 83.94 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.058 -1.26 . . . . 0.0 109.367 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 42.2 mmtm -61.52 -32.56 72.61 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.287 -0.883 . . . . 0.0 109.458 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 95.71 172.4 36.21 Favored Glycine 0 N--CA 1.487 2.097 0 N-CA-C 109.173 -1.571 . . . . 0.0 109.173 -179.62 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.54 HG23 ' HA ' ' A' ' 58' ' ' PRO . 94.1 m -72.36 141.19 48.77 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.315 -1.109 . . . . 0.0 109.871 -179.824 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -58.5 137.84 49.75 Favored Glycine 0 N--CA 1.489 2.169 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 179.804 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 94.1 mtt180 -59.72 -34.14 72.53 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.397 -1.061 . . . . 0.0 109.983 -179.68 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 86.2 p -61.32 -24.95 66.8 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.312 -0.867 . . . . 0.0 109.952 -179.564 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 112.58 89.83 1.85 Allowed Glycine 0 N--CA 1.495 2.572 0 N-CA-C 109.094 -1.603 . . . . 0.0 109.094 -179.595 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . 0.51 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 15.4 tptp -175.98 81.0 0.29 Allowed Pre-proline 0 N--CA 1.488 1.461 0 O-C-N 121.438 -1.036 . . . . 0.0 108.444 -179.659 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.54 ' HA ' HG23 ' A' ' 52' ' ' THR . 75.2 Cg_exo -51.01 131.48 35.04 Favored 'Trans proline' 0 C--N 1.304 -1.808 0 C-N-CA 122.799 2.333 . . . . 0.0 112.728 -179.168 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.51 ' CD1' ' O ' ' A' ' 57' ' ' LYS . 8.8 mp -101.13 89.13 3.7 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.487 -0.758 . . . . 0.0 109.224 -179.919 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . 0.515 ' O ' ' CE1' ' A' ' 80' ' ' PHE . 77.2 m80 -138.78 136.25 35.49 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.362 -0.836 . . . . 0.0 109.531 179.778 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -87.31 -7.95 57.25 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.289 -0.882 . . . . 0.0 108.771 179.529 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 34.2 ttmt -64.15 151.33 43.6 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.524 -0.735 . . . . 0.0 109.958 -179.729 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 59.93 46.61 10.89 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.628 -0.67 . . . . 0.0 109.965 179.896 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 20.8 t -115.83 141.61 47.87 Favored 'General case' 0 N--CA 1.494 1.728 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.323 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 28.7 t -114.97 145.73 41.95 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.386 -0.821 . . . . 0.0 109.682 -179.64 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.5 m-30 -69.41 137.76 53.02 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.243 -0.91 . . . . 0.0 108.996 179.791 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 58.5 t-80 -60.76 -50.75 72.21 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.242 -0.912 . . . . 0.0 110.249 -179.378 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 37.7 ptt180 -163.72 162.21 23.87 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.061 -1.024 . . . . 0.0 109.939 -179.677 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.564 HG21 HG22 ' A' ' 165' ' ' THR . 15.1 m -131.65 142.81 42.19 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.424 -0.798 . . . . 0.0 108.946 179.615 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 10.3 mt -148.03 109.85 3.75 Favored Pre-proline 0 N--CA 1.494 1.739 0 O-C-N 120.907 -1.121 . . . . 0.0 109.83 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -53.36 145.89 43.4 Favored 'Trans proline' 0 N--CA 1.494 1.524 0 C-N-CA 122.347 2.031 . . . . 0.0 112.489 179.524 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 82.01 -57.52 4.96 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 110.161 -1.175 . . . . 0.0 110.161 179.428 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -70.46 -88.68 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.137 -1.214 . . . . 0.0 109.828 -179.544 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 11.3 ptt? -178.31 176.4 1.08 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.221 -0.925 . . . . 0.0 109.57 -179.753 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -111.1 131.58 54.96 Favored 'General case' 0 N--CA 1.493 1.69 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 179.54 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 63.5 tt0 -98.26 150.14 21.85 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.239 -0.913 . . . . 0.0 109.958 -179.439 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -140.66 -170.1 11.97 Favored Glycine 0 N--CA 1.493 2.487 0 N-CA-C 109.287 -1.525 . . . . 0.0 109.287 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 96.52 6.33 58.57 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.861 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 54.8 t0 -58.33 -24.98 61.37 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.35 -1.088 . . . . 0.0 109.728 179.906 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.515 ' CE1' ' O ' ' A' ' 60' ' ' HIS . 76.4 t80 -48.21 -46.37 35.07 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.359 -0.838 . . . . 0.0 110.068 -179.38 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.737 ' CB ' ' H ' ' A' ' 88' ' ' GLY . 69.1 p -70.95 -29.93 66.09 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 120.96 -1.088 . . . . 0.0 109.493 179.896 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . 0.672 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 163.85 -55.84 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.412 -0.805 . . . . 0.0 109.225 179.822 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 92.37 0.41 70.33 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.529 -1.429 . . . . 0.0 109.529 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 78.7 m-20 -87.81 5.88 38.0 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.27 -1.135 . . . . 0.0 109.459 -179.962 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 96.12 -38.55 3.07 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 109.253 -1.539 . . . . 0.0 109.253 -179.895 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 61.7 p -73.82 -15.7 61.16 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.242 -1.152 . . . . 0.0 109.092 179.526 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -81.39 -163.9 31.83 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 -179.919 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.737 ' H ' ' CB ' ' A' ' 81' ' ' THR . . . 81.86 50.82 4.76 Favored Glycine 0 N--CA 1.487 2.099 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 -179.896 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -90.31 147.32 23.57 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.342 -1.093 . . . . 0.0 109.665 -179.728 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 50.5 m -112.17 149.71 31.84 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.461 -0.774 . . . . 0.0 109.403 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 5.1 pt -60.8 -42.13 91.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.277 -0.89 . . . . 0.0 110.106 -179.584 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 3.9 m-30 -66.65 -38.82 87.66 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.113 -0.992 . . . . 0.0 109.582 179.915 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 74.29 26.04 69.23 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.118 -1.593 . . . . 0.0 109.118 -179.742 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -143.64 161.29 38.9 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.421 -1.046 . . . . 0.0 109.569 -179.708 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 83.6 mttt -83.24 148.32 27.48 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.405 -0.81 . . . . 0.0 109.74 -179.736 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 88.6 m-85 -104.1 131.85 50.95 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.376 -0.828 . . . . 0.0 108.865 179.618 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -77.27 136.12 38.48 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.139 -0.976 . . . . 0.0 109.573 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . 0.53 ' OD2' ' CE1' ' A' ' 101' ' ' PHE . 32.3 p-10 -87.86 128.22 35.35 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.215 -0.928 . . . . 0.0 109.279 179.714 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . 0.491 ' O ' ' OD1' ' A' ' 100' ' ' ASN . 84.6 tt0 -61.41 -43.15 99.36 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.155 -0.966 . . . . 0.0 109.989 -179.481 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . 0.491 ' OD1' ' O ' ' A' ' 99' ' ' GLU . 84.0 m-20 -155.24 165.4 36.77 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.145 -0.972 . . . . 0.0 110.071 -179.829 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 101' ' ' PHE . . . . . 0.53 ' CE1' ' OD2' ' A' ' 98' ' ' ASP . 98.6 m-85 -102.62 8.17 39.77 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.429 -0.794 . . . . 0.0 109.156 179.358 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 97.4 mt -53.79 -36.47 29.89 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.344 -0.847 . . . . 0.0 110.404 -179.404 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 33.3 mmtp -73.68 124.91 26.89 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.022 -1.049 . . . . 0.0 109.661 -179.512 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 12.9 pttm -142.77 -177.6 5.39 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.321 -0.862 . . . . 0.0 109.246 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 105' ' ' HIS . . . . . . . . . . . . . 93.6 m-70 -74.99 88.33 2.37 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.144 -0.973 . . . . 0.0 109.209 179.723 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 54.9 p -71.06 -26.81 63.24 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.188 -0.945 . . . . 0.0 109.572 -179.79 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -162.08 -168.45 24.0 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.305 -1.518 . . . . 0.0 109.305 -179.855 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -80.58 154.83 20.99 Favored 'Trans proline' 0 C--N 1.306 -1.705 0 C-N-CA 122.935 2.423 . . . . 0.0 112.175 179.783 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 80.33 43.45 9.49 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.944 -1.262 . . . . 0.0 109.944 179.667 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 41.7 mm -115.55 135.5 55.41 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.863 0 O-C-N 121.364 -1.08 . . . . 0.0 109.628 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.432 ' N ' HD22 ' A' ' 111' ' ' LEU . 4.3 mm? -91.25 124.4 35.42 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.25 -0.906 . . . . 0.0 109.272 179.654 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 30.9 t -140.72 141.07 34.95 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.176 -0.952 . . . . 0.0 109.501 179.867 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 113' ' ' MET . . . . . 0.555 ' SD ' HG23 ' A' ' 38' ' ' THR . 88.9 mtp -89.92 137.89 31.96 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.264 -0.897 . . . . 0.0 109.215 179.75 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . 0.531 ' O ' ' ND2' ' A' ' 115' ' ' ASN . . . -60.9 144.57 52.7 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.121 -0.987 . . . . 0.0 109.381 -179.955 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . 0.531 ' ND2' ' O ' ' A' ' 114' ' ' ALA . 5.0 m120 -137.05 110.78 8.1 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.216 -0.928 . . . . 0.0 109.275 179.848 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -73.57 -29.46 62.44 Favored 'General case' 0 C--N 1.297 -1.677 0 O-C-N 121.406 -0.809 . . . . 0.0 109.4 179.684 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -140.6 175.39 22.08 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 179.926 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -68.17 151.89 76.63 Favored 'Trans proline' 0 C--N 1.305 -1.717 0 C-N-CA 122.746 2.297 . . . . 0.0 111.822 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 119' ' ' ASN . . . . . 0.429 ' OD1' ' OD1' ' A' ' 98' ' ' ASP . 71.8 m-20 52.84 40.52 30.87 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.453 -0.779 . . . . 0.0 109.278 -179.781 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 94.6 m -140.78 124.17 16.76 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.406 -0.809 . . . . 0.0 109.248 179.904 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 87.9 m-20 -109.86 114.81 28.67 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.568 -0.708 . . . . 0.0 109.16 179.503 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -78.05 135.52 16.26 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 179.947 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 22.8 t -55.83 -32.72 63.84 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.212 -1.169 . . . . 0.0 109.195 179.793 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 94.2 mt-30 -72.47 146.6 46.78 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.348 -0.845 . . . . 0.0 109.28 179.729 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 41.2 p90 -133.16 163.3 29.57 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.351 -0.843 . . . . 0.0 109.088 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 49.2 p90 -135.65 156.33 49.02 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.222 -0.923 . . . . 0.0 109.699 -179.931 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 76.2 mt -121.62 134.61 64.41 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 179.804 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 128' ' ' CYS . . . . . 0.435 ' SG ' ' O ' ' A' ' 130' ' ' ALA . 5.5 t -116.22 124.66 50.8 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.288 -0.883 . . . . 0.0 109.368 179.968 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 44.1 p -89.26 -2.1 58.34 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.448 -0.782 . . . . 0.0 109.766 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . 0.435 ' O ' ' SG ' ' A' ' 128' ' ' CYS . . . -149.0 156.96 43.02 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.18 -0.95 . . . . 0.0 109.691 -179.857 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 63.6 tttm -72.84 136.78 45.4 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.31 -0.869 . . . . 0.0 109.34 179.813 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 17.1 p -121.48 158.8 27.63 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.43 -0.794 . . . . 0.0 109.537 -179.846 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -103.05 -74.65 0.63 Allowed 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.246 -0.909 . . . . 0.0 109.915 -179.829 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 134' ' ' TRP . . . . . 0.605 ' CD1' ' N ' ' A' ' 135' ' ' LEU . 42.0 p90 -58.73 -47.76 83.52 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.291 -0.881 . . . . 0.0 110.08 -179.419 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . 0.605 ' N ' ' CD1' ' A' ' 134' ' ' TRP . 31.5 tp -60.98 -35.08 75.87 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.203 -0.936 . . . . 0.0 109.332 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 62.1 t0 -80.05 118.16 21.52 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.202 -0.936 . . . . 0.0 109.541 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 137' ' ' GLY . . . . . 0.544 ' H ' ' CE1' ' A' ' 139' ' ' HIS . . . -144.24 -126.58 1.95 Allowed Glycine 0 N--CA 1.492 2.4 0 N-CA-C 109.096 -1.602 . . . . 0.0 109.096 179.844 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 2.0 mptm? -84.71 105.5 15.55 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.112 -1.228 . . . . 0.0 108.959 179.629 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 139' ' ' HIS . . . . . 0.544 ' CE1' ' H ' ' A' ' 137' ' ' GLY . 76.9 m80 -138.16 161.07 37.76 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.353 -0.842 . . . . 0.0 109.483 -179.862 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 45.0 t -119.58 136.04 58.0 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 O-C-N 121.399 -0.813 . . . . 0.0 109.404 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 59.2 t -105.31 130.25 56.85 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 O-C-N 121.395 -0.816 . . . . 0.0 109.144 179.82 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . 0.569 ' HA ' HG21 ' A' ' 35' ' ' THR . 39.9 p90 -114.33 -0.81 13.72 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.306 -0.871 . . . . 0.0 109.766 -179.865 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -174.71 174.79 46.8 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.589 -1.405 . . . . 0.0 109.589 179.546 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 2.6 pt20 -146.72 167.23 24.34 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.213 -1.169 . . . . 0.0 109.665 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . 0.421 HG22 ' HG2' ' A' ' 28' ' ' MET . 9.5 t -96.73 132.63 40.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 O-C-N 121.218 -0.926 . . . . 0.0 109.529 -179.95 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 15.9 m -111.43 -30.19 2.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.541 -0.724 . . . . 0.0 109.145 179.577 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 78.6 mm-40 -140.02 166.0 25.83 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.342 -0.849 . . . . 0.0 109.344 179.876 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 96.69 4.9 58.98 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.889 -1.285 . . . . 0.0 109.889 179.649 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 149' ' ' MET . . . . . 0.493 ' O ' HG12 ' A' ' 152' ' ' VAL . 65.1 mtt -60.2 -32.24 70.91 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 121.056 -1.261 . . . . 0.0 109.467 179.932 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 89.0 m-20 -64.38 -40.35 95.65 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 120.894 -1.129 . . . . 0.0 109.805 -179.807 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.402 ' H ' HG12 ' A' ' 151' ' ' VAL . 4.4 p -83.69 -35.09 11.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.251 -0.906 . . . . 0.0 110.502 -179.504 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 152' ' ' VAL . . . . . 0.493 HG12 ' O ' ' A' ' 149' ' ' MET . 0.9 OUTLIER -53.9 -42.0 51.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 120.835 -1.166 . . . . 0.0 108.871 -179.336 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 153' ' ' LYS . . . . . 0.455 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 60.0 mttm -65.68 -32.94 74.77 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.12 -0.987 . . . . 0.0 109.123 179.064 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -60.08 -36.96 78.55 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.423 -0.798 . . . . 0.0 109.751 -179.512 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 98.5 mt -71.2 -34.74 55.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.092 -1.005 . . . . 0.0 109.945 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 83.0 tt0 -76.63 -42.17 43.19 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.246 -0.908 . . . . 0.0 111.324 -178.823 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 33.3 pttt -62.13 -33.38 74.38 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 120.798 -1.189 . . . . 0.0 109.822 -178.921 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 33.0 m -83.5 -0.59 5.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.036 -1.04 . . . . 0.0 108.828 179.523 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -75.32 173.01 53.34 Favored Glycine 0 N--CA 1.488 2.115 0 N-CA-C 110.048 -1.221 . . . . 0.0 110.048 -179.53 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 89.7 p -153.22 164.02 38.84 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.462 -1.022 . . . . 0.0 109.764 -179.711 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 23.3 m -58.69 -32.82 69.49 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.309 -0.869 . . . . 0.0 108.834 179.31 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 25.4 m -55.84 -31.57 62.84 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.386 -0.821 . . . . 0.0 109.172 179.86 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 101.08 9.08 46.18 Favored Glycine 0 N--CA 1.495 2.574 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 179.893 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 35.8 ttp180 -116.48 141.12 48.59 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.238 -1.154 . . . . 0.0 109.293 179.898 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 165' ' ' THR . . . . . 0.564 HG22 HG21 ' A' ' 69' ' ' VAL . 80.6 p -76.5 155.87 33.44 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.292 -0.88 . . . . 0.0 109.304 179.932 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -62.37 -35.83 80.37 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.231 -0.918 . . . . 0.0 109.298 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 62.5 mttp -118.93 152.98 35.34 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.475 -0.766 . . . . 0.0 109.157 179.764 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -64.67 141.55 58.74 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.021 -1.049 . . . . 0.0 108.957 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . 0.48 ' O ' HG23 ' A' ' 169' ' ' VAL . 33.9 m -121.66 126.63 74.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.226 -0.921 . . . . 0.0 109.8 -179.748 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 44.5 t -145.03 148.81 17.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 N-CA-C 108.839 -0.801 . . . . 0.0 108.839 179.704 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.454 ' H ' HG23 ' A' ' 171' ' ' VAL . 0.1 OUTLIER -80.91 115.7 23.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.119 -0.988 . . . . 0.0 109.463 -179.798 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 78.4 mm-40 -67.9 -20.31 65.09 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.396 -0.815 . . . . 0.0 109.505 179.629 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 20.2 t70 -167.66 162.18 13.93 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.015 -1.053 . . . . 0.0 110.364 -179.456 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 30.6 p -155.89 144.52 20.26 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.459 -0.776 . . . . 0.0 109.294 179.604 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . 177.25 179.98 47.8 Favored Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 176' ' ' GLN . . . . . 0.651 HE22 ' NE ' ' A' ' 43' ' ' ARG . 63.6 tt0 -105.62 124.0 48.83 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.41 -1.053 . . . . 0.0 109.77 -179.905 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 35.5 tp -61.23 -37.8 84.34 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.187 -0.946 . . . . 0.0 109.395 179.658 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 7.9 t . . . . . 0 N--CA 1.489 1.522 0 CA-C-O 117.994 -1.003 . . . . 0.0 109.475 -179.967 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.446 ' ND2' ' O ' ' A' ' 10' ' ' PRO . 0.5 OUTLIER . . . . . 0 N--CA 1.491 1.615 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 . . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . 0.446 ' O ' ' ND2' ' A' ' 9' ' ' ASN . 82.8 Cg_endo -75.29 140.15 24.37 Favored 'Trans proline' 0 N--CA 1.495 1.612 0 C-N-CA 122.473 2.116 . . . . 0.0 112.599 -179.833 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 71.0 mtt85 -132.74 132.58 42.45 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.35 -0.844 . . . . 0.0 108.834 178.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.0 p -135.62 143.21 37.22 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.327 -0.858 . . . . 0.0 109.707 -179.764 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 42.7 p90 -138.21 154.21 49.12 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.523 -0.736 . . . . 0.0 109.183 179.941 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.415 ' CE1' ' CE1' ' A' ' 61' ' ' TYR . 97.5 m-85 -124.18 137.54 54.52 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.481 -0.762 . . . . 0.0 109.788 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.4 t0 -93.39 117.94 30.7 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.359 -0.838 . . . . 0.0 108.801 179.425 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' MET . . . . . 0.454 ' SD ' HD12 ' A' ' 26' ' ' ILE . 77.1 mtp -112.12 151.21 29.71 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.151 -0.968 . . . . 0.0 110.457 -179.174 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 84.5 p -142.91 163.09 33.73 Favored 'General case' 0 N--CA 1.489 1.519 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 179.804 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.534 ' O ' ' N ' ' A' ' 20' ' ' GLY . 26.2 m -125.96 143.01 40.94 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.201 -0.937 . . . . 0.0 109.706 -179.87 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 47.89 11.5 0.11 Allowed Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.817 -1.313 . . . . 0.0 109.817 179.833 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.534 ' N ' ' O ' ' A' ' 18' ' ' VAL . . . 97.43 -13.98 63.82 Favored Glycine 0 N--CA 1.493 2.499 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 -179.927 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' GLN . . . . . 0.608 ' NE2' ' N ' ' A' ' 21' ' ' GLN . 2.1 mp0 -84.62 150.85 57.54 Favored Pre-proline 0 N--CA 1.492 1.675 0 O-C-N 121.26 -1.141 . . . . 0.0 109.112 179.757 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_endo -62.15 136.93 63.33 Favored 'Trans proline' 0 C--N 1.308 -1.584 0 C-N-CA 122.453 2.102 . . . . 0.0 112.012 -179.893 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -111.72 -65.59 1.16 Allowed 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.439 -0.788 . . . . 0.0 109.359 179.886 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 178.98 -170.1 41.75 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.348 -1.501 . . . . 0.0 109.348 -179.924 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 92.2 mtt180 -116.72 143.72 45.31 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.358 -1.083 . . . . 0.0 109.526 179.792 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.454 HD12 ' SD ' ' A' ' 16' ' ' MET . 84.7 mt -121.06 122.77 68.49 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 179.304 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 38.8 t -118.47 132.75 67.43 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.434 0 O-C-N 121.376 -0.828 . . . . 0.0 109.154 -179.984 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 73.6 mtm -122.32 151.54 41.03 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.408 -0.807 . . . . 0.0 109.122 -179.886 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -99.32 130.79 45.63 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.298 -0.877 . . . . 0.0 109.847 -179.629 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.404 ' N ' ' CD2' ' A' ' 30' ' ' LEU . 2.7 mm? -107.07 129.12 54.86 Favored 'General case' 0 N--CA 1.491 1.575 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 179.535 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -99.63 120.23 39.36 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.244 -0.91 . . . . 0.0 109.082 179.572 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -78.95 -40.52 31.63 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.337 -0.852 . . . . 0.0 110.01 -179.753 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.537 ' OD1' ' N ' ' A' ' 34' ' ' THR . 31.9 p-10 -68.23 -41.22 81.54 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.228 -0.92 . . . . 0.0 110.72 -179.082 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . 0.537 ' N ' ' OD1' ' A' ' 33' ' ' ASP . 17.1 m -67.66 -44.52 77.66 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.005 -1.06 . . . . 0.0 109.997 -179.375 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.414 HG23 ' O ' ' A' ' 34' ' ' THR . 28.5 p -155.23 83.62 3.73 Favored Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.226 -0.921 . . . . 0.0 109.217 -179.903 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 13.4 Cg_endo -70.55 -35.77 9.79 Favored 'Trans proline' 0 C--N 1.307 -1.654 0 C-N-CA 121.987 1.791 . . . . 0.0 112.088 -179.537 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.424 ' HD2' ' H ' ' A' ' 37' ' ' ARG . 1.6 mpt_? -66.51 -41.93 88.07 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.077 -1.014 . . . . 0.0 109.702 179.771 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.552 HG23 ' SD ' ' A' ' 113' ' ' MET . 56.1 m -65.16 -42.06 94.11 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.203 -0.936 . . . . 0.0 110.008 -179.519 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -61.88 -31.37 71.65 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.135 -0.978 . . . . 0.0 109.083 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -69.84 -37.99 76.37 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.397 -0.814 . . . . 0.0 110.052 -179.742 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 3.3 m120 -58.42 -41.99 86.25 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.026 -1.046 . . . . 0.0 109.965 -179.345 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 -87.13 -48.41 8.08 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.114 -0.991 . . . . 0.0 109.554 179.878 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.47 ' O ' HG23 ' A' ' 47' ' ' THR . 66.8 ttp85 -57.63 -42.27 83.01 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.208 -0.933 . . . . 0.0 109.563 -179.853 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -69.74 -46.4 65.98 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.267 -0.896 . . . . 0.0 109.829 -179.674 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 44.9 tp -63.64 -37.78 88.65 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.29 -0.881 . . . . 0.0 109.701 -179.594 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' CYS . . . . . . . . . . . . . 81.7 m -72.99 -48.76 33.69 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.171 -0.956 . . . . 0.0 109.782 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . 0.47 HG23 ' O ' ' A' ' 43' ' ' ARG . 69.8 p -70.93 -35.58 72.28 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.164 -0.96 . . . . 0.0 109.687 -179.93 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 73.46 25.26 73.13 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 179.906 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 22.7 pt-20 -64.77 -33.1 75.18 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.225 -1.162 . . . . 0.0 109.622 -179.768 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 47.2 mmtm -60.14 -33.81 72.68 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.305 -0.872 . . . . 0.0 109.362 179.771 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 92.24 174.84 42.12 Favored Glycine 0 N--CA 1.486 2.032 0 N-CA-C 109.283 -1.527 . . . . 0.0 109.283 -179.753 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.502 HG23 ' HA ' ' A' ' 58' ' ' PRO . 65.5 m -70.57 139.22 51.44 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.387 -1.067 . . . . 0.0 109.705 -179.971 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -57.72 135.35 51.82 Favored Glycine 0 N--CA 1.488 2.137 0 N-CA-C 109.219 -1.552 . . . . 0.0 109.219 179.766 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 73.4 mtp180 -59.0 -33.88 71.22 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.178 -1.19 . . . . 0.0 109.958 -179.678 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 87.0 p -60.55 -24.46 65.41 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.18 -0.95 . . . . 0.0 109.684 -179.621 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 112.66 90.92 1.93 Allowed Glycine 0 N--CA 1.494 2.562 0 N-CA-C 109.049 -1.621 . . . . 0.0 109.049 -179.714 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . 0.509 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 33.0 tttm -174.72 78.61 0.33 Allowed Pre-proline 0 N--CA 1.488 1.437 0 O-C-N 121.425 -1.044 . . . . 0.0 108.365 -179.73 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.502 ' HA ' HG23 ' A' ' 52' ' ' THR . 75.8 Cg_exo -49.47 130.75 26.3 Favored 'Trans proline' 0 C--N 1.304 -1.783 0 C-N-CA 122.787 2.325 . . . . 0.0 112.77 -179.087 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.509 ' CD1' ' O ' ' A' ' 57' ' ' LYS . 7.1 mp -97.48 120.38 37.74 Favored 'General case' 0 N--CA 1.49 1.572 0 N-CA-C 109.195 -0.669 . . . . 0.0 109.195 179.854 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 58.7 m80 -149.79 93.84 2.09 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.273 -0.892 . . . . 0.0 109.448 179.679 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . 0.415 ' CE1' ' CE1' ' A' ' 14' ' ' PHE . 24.3 t80 -60.65 -34.38 74.21 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 179.831 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . 0.425 ' HE2' ' H ' ' A' ' 174' ' ' CYS . 92.8 mttt -54.77 167.9 0.33 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.495 -0.753 . . . . 0.0 109.794 -179.686 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 83.0 m-20 57.24 47.16 17.44 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.5 -0.75 . . . . 0.0 110.02 179.609 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 96.3 p -114.12 154.03 28.49 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.383 -0.823 . . . . 0.0 108.918 179.366 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 28.2 t -131.66 149.04 52.63 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.255 -0.903 . . . . 0.0 109.668 -179.552 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 28.6 m-85 -77.51 125.0 28.65 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.306 -0.871 . . . . 0.0 109.369 179.852 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 62.0 t60 -67.93 -46.4 71.6 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.598 -0.689 . . . . 0.0 110.782 -179.176 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 94.5 mtt180 -132.39 150.05 52.23 Favored 'General case' 0 N--CA 1.498 1.925 0 O-C-N 121.041 -1.037 . . . . 0.0 110.739 -178.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.714 HG21 HG22 ' A' ' 165' ' ' THR . 7.7 m -144.19 52.26 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 N-CA-C 108.744 -0.836 . . . . 0.0 108.744 179.471 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 14.4 mt -76.69 133.44 70.31 Favored Pre-proline 0 C--N 1.301 -1.537 0 O-C-N 121.193 -0.942 . . . . 0.0 110.07 -178.702 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_endo -70.09 149.95 65.53 Favored 'Trans proline' 0 N--CA 1.492 1.405 0 C-N-CA 122.408 2.072 . . . . 0.0 112.283 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 79.42 -55.19 4.38 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 179.864 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 90.9 m-85 -71.35 -87.7 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.249 -1.147 . . . . 0.0 109.702 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' MET . . . . . 0.602 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 12.1 ptt? 179.15 -178.83 0.35 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.184 -0.948 . . . . 0.0 109.763 -179.926 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 1.1 m -117.46 131.9 56.65 Favored 'General case' 0 N--CA 1.492 1.67 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 179.255 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 63.5 tt0 -95.04 146.16 24.46 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.161 -0.962 . . . . 0.0 110.222 -179.013 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -143.55 -175.07 16.31 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.186 -1.566 . . . . 0.0 109.186 179.841 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 93.24 10.55 59.43 Favored Glycine 0 N--CA 1.494 2.528 0 N-CA-C 109.426 -1.47 . . . . 0.0 109.426 -179.905 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.438 ' OD1' ' O ' ' A' ' 82' ' ' ALA . 62.4 t0 -56.18 -15.52 3.91 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.341 -1.094 . . . . 0.0 109.681 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 73.5 t80 -50.07 -47.86 53.37 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.174 -0.954 . . . . 0.0 110.17 -179.291 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.756 ' CB ' ' H ' ' A' ' 88' ' ' GLY . 65.6 p -71.53 -31.96 67.63 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.892 -1.13 . . . . 0.0 109.606 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . 0.685 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 164.51 -54.63 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.302 -0.874 . . . . 0.0 109.334 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 92.46 1.09 69.2 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.629 -1.388 . . . . 0.0 109.629 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 22.1 m120 -87.3 5.4 38.61 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.256 -1.144 . . . . 0.0 109.511 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 95.41 -39.61 2.82 Favored Glycine 0 N--CA 1.494 2.503 0 N-CA-C 109.243 -1.543 . . . . 0.0 109.243 -179.866 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 60.8 p -73.12 -16.92 61.44 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.24 -1.153 . . . . 0.0 109.085 179.634 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -81.77 -162.37 29.77 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.756 ' H ' ' CB ' ' A' ' 81' ' ' THR . . . 84.19 37.97 10.59 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 -179.951 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 78.1 mm-40 -58.02 149.7 22.65 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.266 -1.137 . . . . 0.0 109.808 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 50.8 m -115.57 147.08 41.15 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.666 -0.646 . . . . 0.0 109.273 179.925 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 18.1 pt -67.82 -35.53 72.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.264 -0.897 . . . . 0.0 110.037 -179.624 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 49.2 m-85 -67.43 -38.67 84.92 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.03 -1.044 . . . . 0.0 109.64 -179.809 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 77.87 13.74 83.09 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.342 -1.503 . . . . 0.0 109.342 -179.701 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -147.0 155.9 42.62 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.275 -1.132 . . . . 0.0 109.429 -179.838 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 53.5 mttp -95.08 148.65 22.13 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.339 -0.851 . . . . 0.0 109.807 -179.976 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 54.9 p90 -134.33 160.23 38.58 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.403 -0.811 . . . . 0.0 109.141 179.453 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -104.53 150.88 24.23 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.302 -0.874 . . . . 0.0 109.788 -179.633 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 60.1 t0 -137.77 81.58 1.87 Allowed 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.314 -0.866 . . . . 0.0 109.246 179.763 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -63.78 -29.03 70.28 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.429 -0.794 . . . . 0.0 109.956 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . 0.421 HD22 ' N ' ' A' ' 100' ' ' ASN . 2.7 m120 -56.58 141.34 43.52 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.134 -0.979 . . . . 0.0 110.075 -179.244 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 101' ' ' PHE . . . . . 0.537 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 74.4 t80 -150.33 46.51 0.89 Allowed 'General case' 0 N--CA 1.491 1.615 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.824 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 90.9 mt -59.03 -34.82 54.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.416 -0.803 . . . . 0.0 110.228 -179.492 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 71.8 mmtt -80.78 139.85 35.82 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.112 -0.993 . . . . 0.0 109.765 -179.393 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 35.5 tttm -93.32 156.0 17.07 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.394 -0.816 . . . . 0.0 109.571 -179.961 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 105' ' ' HIS . . . . . . . . . . . . . 85.2 t60 -96.36 78.48 3.05 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.334 -0.854 . . . . 0.0 108.77 179.356 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 14.9 m -56.56 -40.03 74.49 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.3 -0.875 . . . . 0.0 109.436 -179.42 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.456 ' H ' HG13 ' A' ' 110' ' ' ILE . . . 130.09 -95.74 0.35 Allowed Glycine 0 N--CA 1.493 2.498 0 N-CA-C 110.044 -1.223 . . . . 0.0 110.044 179.575 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -68.81 141.24 48.65 Favored 'Trans proline' 0 N--CA 1.496 1.621 0 C-N-CA 122.694 2.263 . . . . 0.0 113.131 -179.233 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 75.95 22.65 73.85 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 110.241 -1.143 . . . . 0.0 110.241 179.033 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.456 HG13 ' H ' ' A' ' 107' ' ' GLY . 33.5 mm -115.54 134.41 58.83 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 121.315 -1.109 . . . . 0.0 110.076 -179.782 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.678 ' N ' HD22 ' A' ' 111' ' ' LEU . 3.1 mm? -93.78 137.03 33.46 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.289 -0.882 . . . . 0.0 108.894 179.148 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 34.0 t -146.05 141.17 27.35 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.226 -0.921 . . . . 0.0 109.691 179.781 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 113' ' ' MET . . . . . 0.552 ' SD ' HG23 ' A' ' 38' ' ' THR . 72.0 mtm -85.53 137.04 33.15 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.245 -0.91 . . . . 0.0 109.181 179.715 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . 0.452 ' O ' ' OD1' ' A' ' 115' ' ' ASN . . . -61.83 138.32 58.33 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.148 -0.97 . . . . 0.0 109.333 -179.879 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . 0.452 ' OD1' ' O ' ' A' ' 114' ' ' ALA . 77.2 m-20 -148.51 114.01 5.62 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.328 -0.858 . . . . 0.0 109.206 179.828 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -69.21 -29.77 67.8 Favored 'General case' 0 C--N 1.297 -1.713 0 O-C-N 121.43 -0.794 . . . . 0.0 109.179 179.613 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -137.84 168.42 24.52 Favored Glycine 0 N--CA 1.494 2.503 0 N-CA-C 109.085 -1.606 . . . . 0.0 109.085 179.783 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -67.4 155.6 69.68 Favored 'Trans proline' 0 C--N 1.306 -1.666 0 C-N-CA 122.758 2.305 . . . . 0.0 111.946 -179.858 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 75.9 m-20 54.92 45.3 26.78 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.425 -0.797 . . . . 0.0 109.498 -179.907 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 94.1 m -130.27 125.93 36.02 Favored 'General case' 0 N--CA 1.485 1.314 0 O-C-N 121.386 -0.821 . . . . 0.0 108.79 179.725 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 25.1 t-20 -99.09 110.62 23.18 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.449 -0.782 . . . . 0.0 109.621 -179.838 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -106.61 121.27 6.55 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.271 -1.532 . . . . 0.0 109.271 179.646 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 20.1 m -56.84 -34.43 67.76 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.209 -1.171 . . . . 0.0 109.187 179.971 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.6 mt-30 -71.62 144.94 49.27 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.263 -0.898 . . . . 0.0 109.148 179.81 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 44.9 p90 -135.59 163.53 29.91 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.317 -0.865 . . . . 0.0 109.297 -179.961 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . 0.602 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 52.8 p90 -132.15 157.38 44.41 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.405 -0.81 . . . . 0.0 109.503 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 67.1 mt -119.08 133.25 66.54 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.49 -0.756 . . . . 0.0 109.338 179.849 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 128' ' ' CYS . . . . . 0.402 ' SG ' ' O ' ' A' ' 130' ' ' ALA . 7.1 t -115.84 126.35 53.86 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.355 -0.841 . . . . 0.0 109.15 179.847 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 30.1 p -97.18 0.53 48.5 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.276 -0.89 . . . . 0.0 109.702 -179.708 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . 0.402 ' O ' ' SG ' ' A' ' 128' ' ' CYS . . . -148.86 164.26 35.0 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.235 -0.915 . . . . 0.0 109.429 -179.8 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -70.07 137.48 51.26 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.118 -0.989 . . . . 0.0 109.177 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 3.6 p -113.53 101.12 9.05 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.495 -0.753 . . . . 0.0 109.45 -179.737 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -64.35 -36.52 84.4 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.296 -0.878 . . . . 0.0 109.596 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 1.2 p90 -67.55 -33.29 74.74 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.15 -0.969 . . . . 0.0 109.59 -179.835 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . 0.546 ' O ' ' NE2' ' A' ' 139' ' ' HIS . 8.6 mt -93.11 12.15 25.23 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.102 -0.998 . . . . 0.0 109.322 179.358 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 60.1 t0 -57.05 124.18 17.82 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.137 -0.977 . . . . 0.0 109.616 -179.577 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -176.11 -159.29 21.56 Favored Glycine 0 N--CA 1.486 1.987 0 N-CA-C 109.009 -1.636 . . . . 0.0 109.009 -179.852 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 87.6 mttt -57.24 -38.51 73.92 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.317 -1.107 . . . . 0.0 109.646 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 139' ' ' HIS . . . . . 0.546 ' NE2' ' O ' ' A' ' 135' ' ' LEU . 63.3 m-70 53.57 71.51 0.5 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.318 -0.864 . . . . 0.0 109.957 179.766 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 39.3 t -69.0 135.44 28.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.14 -0.975 . . . . 0.0 108.879 179.295 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 17.4 m -126.94 148.23 31.78 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 121.222 -0.924 . . . . 0.0 109.74 -179.489 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . 0.454 ' CB ' HG21 ' A' ' 38' ' ' THR . 43.3 p90 -120.06 -6.01 9.99 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.382 -0.824 . . . . 0.0 110.019 179.831 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -164.74 -179.77 38.97 Favored Glycine 0 N--CA 1.495 2.618 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 179.692 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.4 pt20 -143.85 166.53 24.65 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.23 -1.159 . . . . 0.0 109.566 -179.769 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 44.7 t -97.21 132.18 42.36 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.13 0 O-C-N 121.096 -1.002 . . . . 0.0 109.54 -179.742 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 17.2 m -110.45 -32.74 2.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 O-C-N 121.413 -0.805 . . . . 0.0 109.3 179.321 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -145.35 170.25 16.68 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.308 -0.87 . . . . 0.0 109.46 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 97.35 2.47 58.96 Favored Glycine 0 N--CA 1.494 2.539 0 N-CA-C 109.977 -1.249 . . . . 0.0 109.977 179.531 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 149' ' ' MET . . . . . 0.477 ' O ' HG12 ' A' ' 152' ' ' VAL . 88.3 mtp -61.06 -33.07 72.74 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.189 -1.183 . . . . 0.0 109.685 179.925 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -64.78 -42.43 95.1 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 120.876 -1.14 . . . . 0.0 109.987 -179.547 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.4 p -82.53 -34.01 11.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.128 -0.983 . . . . 0.0 110.591 -179.341 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 152' ' ' VAL . . . . . 0.477 HG12 ' O ' ' A' ' 149' ' ' MET . 0.8 OUTLIER -53.74 -40.88 45.21 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 120.957 -1.09 . . . . 0.0 109.067 -179.408 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 153' ' ' LYS . . . . . 0.445 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 99.0 mttt -63.53 -34.12 77.08 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.113 -0.992 . . . . 0.0 109.292 179.201 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -61.51 -37.11 82.49 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.322 -0.861 . . . . 0.0 109.937 -179.638 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 97.9 mt -71.99 -35.05 52.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.173 -0.955 . . . . 0.0 109.981 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -75.93 -42.0 50.05 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.177 -0.952 . . . . 0.0 111.209 -178.894 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 157' ' ' LYS . . . . . 0.422 ' HG2' ' HZ2' ' A' ' 157' ' ' LYS . 15.4 pttm -61.81 -34.2 75.49 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 120.769 -1.207 . . . . 0.0 109.719 -178.924 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.425 ' HB ' ' H ' ' A' ' 166' ' ' ALA . 34.0 m -79.91 -13.79 13.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.152 -0.968 . . . . 0.0 109.082 179.562 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -76.88 170.43 55.09 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.836 -1.306 . . . . 0.0 109.836 -179.826 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 23.1 t -159.02 173.95 15.69 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.409 -1.054 . . . . 0.0 109.315 -179.841 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 23.6 m -53.84 -32.47 53.01 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.236 -0.915 . . . . 0.0 109.121 179.663 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 24.0 m -56.45 -32.57 65.05 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.393 -0.817 . . . . 0.0 109.412 179.842 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 95.1 13.23 53.38 Favored Glycine 0 N--CA 1.493 2.465 0 N-CA-C 109.791 -1.323 . . . . 0.0 109.791 179.954 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 98.0 mtt180 -119.24 144.82 46.54 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.283 -1.128 . . . . 0.0 109.379 179.862 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 165' ' ' THR . . . . . 0.714 HG22 HG21 ' A' ' 69' ' ' VAL . 80.1 p -82.39 150.46 27.11 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.25 -0.906 . . . . 0.0 109.563 179.867 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 166' ' ' ALA . . . . . 0.425 ' H ' ' HB ' ' A' ' 158' ' ' VAL . . . -65.95 -35.5 80.78 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.339 -0.851 . . . . 0.0 108.896 179.523 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 66.6 mttm -112.58 157.68 20.89 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.524 -0.735 . . . . 0.0 109.07 179.731 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -69.7 130.75 43.21 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.134 -0.979 . . . . 0.0 109.324 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 43.0 t -123.2 125.32 71.77 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 121.201 -0.937 . . . . 0.0 109.575 -179.949 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . 0.43 HG12 ' N ' ' A' ' 171' ' ' VAL . 60.7 t -150.33 157.17 6.15 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 O-C-N 121.486 -0.758 . . . . 0.0 108.972 179.582 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.43 ' N ' HG12 ' A' ' 170' ' ' VAL . 0.2 OUTLIER -87.98 119.41 35.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.104 -0.998 . . . . 0.0 109.529 -179.727 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -65.91 -24.62 66.88 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.361 -0.837 . . . . 0.0 109.414 179.407 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 19.9 t70 -173.81 171.16 3.8 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.127 -0.983 . . . . 0.0 110.301 -179.51 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 174' ' ' CYS . . . . . 0.425 ' H ' ' HE2' ' A' ' 62' ' ' LYS . 11.0 p -151.84 153.15 33.65 Favored 'General case' 0 N--CA 1.492 1.66 0 N-CA-C 109.052 -0.721 . . . . 0.0 109.052 179.499 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -175.75 174.55 46.94 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 109.702 -1.359 . . . . 0.0 109.702 179.784 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 62.2 tt0 -107.89 120.67 42.94 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.3 -1.118 . . . . 0.0 109.652 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 32.4 tp -61.71 -37.03 82.66 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.135 -0.978 . . . . 0.0 109.032 179.434 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 25.0 t . . . . . 0 N--CA 1.49 1.559 0 CA-C-O 118.087 -0.959 . . . . 0.0 109.466 179.972 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 8.2 p-10 . . . . . 0 N--CA 1.489 1.489 0 N-CA-C 109.555 -0.535 . . . . 0.0 109.555 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -73.76 145.87 37.32 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 122.803 2.335 . . . . 0.0 112.047 179.763 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . 0.482 ' NH2' ' CB ' ' A' ' 178' ' ' SER . 95.5 mtm-85 -119.16 132.49 55.97 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.271 -0.893 . . . . 0.0 108.783 179.222 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.6 p -135.04 142.39 40.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.269 -0.895 . . . . 0.0 109.772 -179.192 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 42.8 p90 -141.12 155.61 46.09 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.434 -0.791 . . . . 0.0 109.506 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -128.18 142.32 51.21 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.421 -0.799 . . . . 0.0 109.887 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 59.4 t0 -94.6 124.26 38.52 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.227 -0.92 . . . . 0.0 108.734 179.151 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 39.1 mtp -119.66 147.51 44.47 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.136 -0.978 . . . . 0.0 110.279 -179.312 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.43 ' OG ' ' CD ' ' A' ' 172' ' ' GLU . 59.7 m -128.57 153.67 46.98 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.604 -0.685 . . . . 0.0 109.355 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.406 HG23 ' O ' ' A' ' 18' ' ' VAL . 34.7 m -114.93 131.93 65.66 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.835 0 O-C-N 121.388 -0.82 . . . . 0.0 109.426 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 63.59 9.65 32.99 Favored Glycine 0 N--CA 1.492 2.398 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 179.858 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 94.67 -1.67 66.31 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 -179.895 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 75.0 mt-30 -103.69 151.2 38.74 Favored Pre-proline 0 N--CA 1.493 1.717 0 O-C-N 121.295 -1.121 . . . . 0.0 109.073 179.756 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 14.3 Cg_endo -58.36 134.23 60.08 Favored 'Trans proline' 0 C--N 1.309 -1.507 0 C-N-CA 122.412 2.074 . . . . 0.0 112.266 -179.532 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -114.23 -65.06 1.23 Allowed 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.514 -0.741 . . . . 0.0 109.274 179.775 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -176.77 -170.48 39.34 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.456 -1.457 . . . . 0.0 109.456 179.943 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . 0.419 HH12 HG21 ' A' ' 27' ' ' VAL . 46.6 ptt85 -120.06 148.55 43.45 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.318 -1.107 . . . . 0.0 109.11 179.851 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 83.3 mt -122.57 129.15 75.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.496 -0.753 . . . . 0.0 109.32 -179.863 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.419 HG21 HH12 ' A' ' 25' ' ' ARG . 46.3 t -113.14 133.26 59.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.539 -0.725 . . . . 0.0 109.062 179.673 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 74.5 mtm -121.12 149.69 42.38 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.391 -0.818 . . . . 0.0 109.52 -179.753 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -97.57 132.51 43.17 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.388 -0.82 . . . . 0.0 109.542 -179.858 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -109.36 130.57 55.49 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.533 -0.729 . . . . 0.0 109.425 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 86.5 m-85 -94.55 118.41 31.63 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.126 -0.984 . . . . 0.0 108.483 178.89 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -93.38 -42.06 9.49 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.299 -0.875 . . . . 0.0 109.68 -179.683 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.6 m-20 -62.26 -49.23 76.53 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.09 -1.006 . . . . 0.0 109.764 -179.498 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . 0.493 HG21 ' HD3' ' A' ' 103' ' ' LYS . 61.9 m -73.52 -42.03 62.28 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.069 -1.02 . . . . 0.0 109.72 179.8 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.529 ' O ' ' OG1' ' A' ' 35' ' ' THR . 1.8 p -132.24 79.02 67.21 Favored Pre-proline 0 N--CA 1.492 1.657 0 O-C-N 121.3 -0.875 . . . . 0.0 109.439 -179.69 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 21.2 Cg_endo -66.77 -61.79 0.08 OUTLIER 'Trans proline' 0 C--N 1.31 -1.468 0 C-N-CA 122.376 2.051 . . . . 0.0 112.603 -179.48 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.623 ' NH2' ' CE1' ' A' ' 92' ' ' TYR . 68.7 mtp85 -60.9 -34.98 75.49 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.415 -0.803 . . . . 0.0 110.4 -179.308 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 25.7 m -59.98 -41.47 92.07 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.953 -1.092 . . . . 0.0 109.859 -179.559 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -62.62 -30.18 71.17 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.089 -1.007 . . . . 0.0 109.35 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.401 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 96.6 mt-10 -67.59 -34.91 77.98 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.284 -0.885 . . . . 0.0 109.761 -179.983 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' ASN . . . . . 0.437 ' O ' HD23 ' A' ' 45' ' ' LEU . 26.2 m120 -56.82 -39.08 73.54 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.149 -0.97 . . . . 0.0 109.768 -179.767 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.4 ' O ' ' SG ' ' A' ' 46' ' ' CYS . 98.8 m-85 -94.16 -50.45 5.28 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.121 -0.987 . . . . 0.0 109.512 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.91 ' HE ' HE22 ' A' ' 176' ' ' GLN . 75.8 ttt-85 -57.19 -42.01 80.43 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.41 -0.806 . . . . 0.0 110.491 -179.392 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.401 ' HB3' ' O ' ' A' ' 40' ' ' GLU . . . -63.72 -44.87 92.29 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.999 -1.063 . . . . 0.0 110.077 -179.121 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.515 ' N ' ' CD2' ' A' ' 45' ' ' LEU . 2.7 mm? -67.64 -37.2 82.1 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.19 -0.944 . . . . 0.0 109.637 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' CYS . . . . . 0.4 ' SG ' ' O ' ' A' ' 42' ' ' PHE . 64.1 m -66.69 -48.99 67.57 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.136 -0.977 . . . . 0.0 110.108 -179.533 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 60.6 p -72.65 -30.71 64.52 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.192 -0.943 . . . . 0.0 109.694 -179.844 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 74.03 27.34 66.68 Favored Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 179.778 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 23.0 pt-20 -62.25 -35.59 79.41 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.212 -1.169 . . . . 0.0 109.381 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 43.6 mmtm -61.19 -33.2 73.07 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.289 -0.882 . . . . 0.0 109.128 179.588 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 93.64 168.4 38.29 Favored Glycine 0 N--CA 1.488 2.136 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 -179.793 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.541 HG23 ' HA ' ' A' ' 58' ' ' PRO . 68.4 m -76.45 139.9 41.05 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.306 -1.114 . . . . 0.0 109.686 -179.947 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -53.9 135.15 43.27 Favored Glycine 0 N--CA 1.488 2.165 0 N-CA-C 109.224 -1.551 . . . . 0.0 109.224 179.753 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 91.9 mtm-85 -58.92 -35.99 74.0 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.192 -1.181 . . . . 0.0 109.917 -179.551 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 22.7 t -59.14 -31.21 68.75 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.18 -0.95 . . . . 0.0 109.919 -179.587 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . 0.449 ' O ' ' CG ' ' A' ' 57' ' ' LYS . . . 117.91 81.05 0.77 Allowed Glycine 0 N--CA 1.495 2.614 0 N-CA-C 108.749 -1.74 . . . . 0.0 108.749 -179.381 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . 0.547 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 57.4 mttm -161.69 79.87 2.03 Favored Pre-proline 0 C--N 1.303 -1.434 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 -179.576 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.541 ' HA ' HG23 ' A' ' 52' ' ' THR . 71.3 Cg_exo -50.9 133.02 39.19 Favored 'Trans proline' 0 C--N 1.301 -1.964 0 C-N-CA 122.894 2.396 . . . . 0.0 112.809 -178.734 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.571 ' O ' ' CG ' ' A' ' 60' ' ' HIS . 7.0 mp -100.19 98.32 9.03 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.613 -0.679 . . . . 0.0 109.524 -179.47 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . 0.571 ' CG ' ' O ' ' A' ' 59' ' ' LEU . 93.5 m-70 -160.45 125.91 3.93 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.167 -0.958 . . . . 0.0 109.948 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 9.5 m-85 -71.95 -5.98 38.73 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.136 -0.978 . . . . 0.0 108.811 178.889 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . 0.561 ' O ' ' O ' ' A' ' 171' ' ' VAL . 48.7 tttt -53.39 -25.88 17.34 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.527 -0.733 . . . . 0.0 109.57 179.891 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 89.3 m-20 -103.6 4.85 36.1 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.467 -0.771 . . . . 0.0 110.071 -179.402 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 63.8 p -82.04 162.35 22.62 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.069 -1.019 . . . . 0.0 109.856 -179.754 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 29.2 t -147.31 159.34 43.78 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.473 -0.767 . . . . 0.0 109.083 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.5 m-85 -64.18 123.5 19.26 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.079 -1.013 . . . . 0.0 108.929 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 61.7 t60 -66.62 -50.26 63.6 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.304 -0.872 . . . . 0.0 110.548 -179.112 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 93.2 mtt180 -141.47 150.47 42.29 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 120.951 -1.093 . . . . 0.0 110.287 -179.658 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.642 HG21 HG22 ' A' ' 165' ' ' THR . 4.9 m -137.09 130.92 45.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 179.096 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 19.1 mt -149.33 128.39 6.2 Favored Pre-proline 0 N--CA 1.492 1.646 0 O-C-N 120.94 -1.1 . . . . 0.0 109.41 -179.785 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 65.3 Cg_endo -76.0 133.44 15.13 Favored 'Trans proline' 0 C--N 1.311 -1.429 0 C-N-CA 122.148 1.899 . . . . 0.0 112.014 179.707 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 90.49 3.88 71.27 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.793 -1.323 . . . . 0.0 109.793 179.662 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 82.6 m-85 -138.77 -94.37 0.18 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.129 -1.218 . . . . 0.0 109.811 179.845 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 7.3 ptt? -171.45 175.79 4.01 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.168 -0.957 . . . . 0.0 109.839 -179.655 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -122.28 136.28 54.88 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 108.231 -1.026 . . . . 0.0 108.231 179.363 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 92.4 mt-30 -94.56 136.0 35.37 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.88 -1.138 . . . . 0.0 110.198 -179.262 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -90.03 -173.52 45.15 Favored Glycine 0 N--CA 1.492 2.379 0 N-CA-C 108.941 -1.664 . . . . 0.0 108.941 179.395 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -155.63 174.3 33.67 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.779 -1.329 . . . . 0.0 109.779 179.84 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.547 ' OD1' ' N ' ' A' ' 83' ' ' GLY . 48.5 p30 -106.37 165.59 11.15 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.415 -1.05 . . . . 0.0 109.56 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 46.4 p90 -75.2 -19.95 59.54 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.309 -0.87 . . . . 0.0 109.66 -179.884 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.557 ' OG1' ' N ' ' A' ' 88' ' ' GLY . 71.2 p -65.93 -37.06 85.06 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.281 -0.887 . . . . 0.0 109.989 -179.629 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -174.46 -51.32 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.267 -0.896 . . . . 0.0 109.539 -179.934 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.547 ' N ' ' OD1' ' A' ' 79' ' ' ASP . . . 94.71 2.2 63.23 Favored Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 78.7 m-20 -86.02 4.15 39.17 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.189 -1.183 . . . . 0.0 109.448 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 93.71 -37.47 3.39 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 51.6 p -69.99 -29.11 66.11 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.185 -1.185 . . . . 0.0 109.231 179.842 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -87.85 -168.23 44.24 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.983 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.557 ' N ' ' OG1' ' A' ' 81' ' ' THR . . . 84.03 45.07 6.43 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.571 -1.412 . . . . 0.0 109.571 179.879 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -56.37 144.37 30.94 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.344 -1.092 . . . . 0.0 109.43 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 27.4 t -78.24 144.57 36.1 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.159 -0.963 . . . . 0.0 109.552 -179.913 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 17.0 pt -66.34 -36.29 77.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.291 -0.881 . . . . 0.0 109.849 -179.871 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . 0.623 ' CE1' ' NH2' ' A' ' 37' ' ' ARG . 96.4 m-85 -66.21 -36.44 83.04 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.175 -0.953 . . . . 0.0 109.566 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.21 5.74 87.03 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.202 -1.559 . . . . 0.0 109.202 -179.752 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -150.97 158.0 43.6 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.348 -1.09 . . . . 0.0 109.381 -179.911 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -85.17 148.29 26.18 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.178 -0.951 . . . . 0.0 109.484 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 45.6 p90 -135.39 159.13 42.56 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.327 -0.858 . . . . 0.0 109.392 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -73.25 135.68 44.51 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.262 -0.899 . . . . 0.0 109.932 -179.678 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . 0.438 ' C ' ' OD1' ' A' ' 98' ' ' ASP . 54.4 p30 -99.84 -163.87 1.07 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.313 -0.867 . . . . 0.0 109.549 179.774 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . 0.442 ' OE1' ' O ' ' A' ' 34' ' ' THR . 94.5 mt-10 -108.02 163.01 13.52 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.371 -0.831 . . . . 0.0 109.455 179.77 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 82.9 m-20 -64.76 165.95 9.66 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.257 -0.902 . . . . 0.0 109.566 -179.809 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 101' ' ' PHE . . . . . 0.489 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 33.3 p90 -80.7 51.43 1.5 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.27 -0.894 . . . . 0.0 109.718 -179.811 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 90.7 mt -56.22 -41.08 68.96 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.101 -0.999 . . . . 0.0 109.547 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 103' ' ' LYS . . . . . 0.493 ' HD3' HG21 ' A' ' 34' ' ' THR . 43.6 mtpt -89.33 146.14 24.9 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.178 -0.951 . . . . 0.0 109.693 -179.939 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 49.3 pttt -134.85 179.98 5.97 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.42 -0.8 . . . . 0.0 109.356 179.804 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 105' ' ' HIS . . . . . 0.532 ' O ' ' CG ' ' A' ' 105' ' ' HIS . 48.4 p-80 -92.64 100.75 13.2 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.292 -0.88 . . . . 0.0 109.407 -179.872 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 51.2 p -76.54 -22.46 54.34 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.331 -0.856 . . . . 0.0 109.628 -179.903 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.409 ' O ' HG12 ' A' ' 110' ' ' ILE . . . -151.15 -179.46 26.89 Favored Glycine 0 N--CA 1.492 2.406 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 -179.688 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -72.65 158.87 49.94 Favored 'Trans proline' 0 C--N 1.307 -1.626 0 C-N-CA 122.951 2.434 . . . . 0.0 112.178 179.83 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 84.95 38.25 9.47 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 110.233 -1.147 . . . . 0.0 110.233 179.532 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.409 HG12 ' O ' ' A' ' 107' ' ' GLY . 34.4 mm -113.38 138.39 43.13 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.29 -1.123 . . . . 0.0 108.979 179.598 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.827 ' N ' HD22 ' A' ' 111' ' ' LEU . 2.4 mm? -87.58 139.75 30.22 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.246 -0.909 . . . . 0.0 109.658 -179.754 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 23.1 t -128.16 143.54 51.06 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.54 -0.725 . . . . 0.0 109.27 179.85 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 58.3 ttp -96.71 127.08 42.35 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.305 -0.872 . . . . 0.0 109.533 -179.9 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -66.16 146.5 54.58 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.236 -0.915 . . . . 0.0 109.633 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . 0.502 ' N ' ' OD1' ' A' ' 115' ' ' ASN . 9.1 p-10 -168.25 115.73 0.7 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.272 -0.893 . . . . 0.0 109.668 179.818 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -66.18 -33.95 76.92 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.379 -0.825 . . . . 0.0 109.347 179.806 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -145.52 166.92 27.65 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.352 -1.499 . . . . 0.0 109.352 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -66.59 158.58 55.04 Favored 'Trans proline' 0 C--N 1.306 -1.678 0 C-N-CA 122.822 2.348 . . . . 0.0 111.963 179.919 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 73.7 m-20 55.03 44.07 28.74 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.467 -0.771 . . . . 0.0 109.392 -179.886 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 87.2 m -137.28 129.33 29.22 Favored 'General case' 0 C--N 1.305 -1.359 0 O-C-N 121.405 -0.81 . . . . 0.0 109.113 179.943 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 22.4 t-20 -79.94 116.24 19.97 Favored 'General case' 0 C--N 1.298 -1.65 0 O-C-N 121.489 -0.757 . . . . 0.0 109.33 179.859 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -85.32 -179.54 50.69 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.736 -1.346 . . . . 0.0 109.736 -179.82 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -130.64 -14.25 3.66 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.367 -1.079 . . . . 0.0 109.749 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 94.3 mt-30 -121.89 159.42 26.89 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.299 -0.876 . . . . 0.0 109.622 -179.876 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 43.6 p90 -130.83 158.74 39.35 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.489 -0.757 . . . . 0.0 109.474 -179.898 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -117.47 143.84 45.63 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.49 -0.757 . . . . 0.0 110.02 -179.766 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 84.2 mt -120.77 134.27 64.75 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 121.613 -0.679 . . . . 0.0 109.224 179.246 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -125.27 126.36 45.01 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.293 -0.879 . . . . 0.0 109.376 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 30.3 p -98.32 3.39 48.64 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.348 -0.845 . . . . 0.0 109.301 179.868 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -153.62 159.63 42.16 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.243 -0.911 . . . . 0.0 109.428 -179.795 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 7.9 ttpm? -66.44 130.05 41.89 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.165 -0.959 . . . . 0.0 109.081 179.8 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 16.6 p -109.09 95.86 5.92 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.395 -0.816 . . . . 0.0 109.633 -179.658 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -65.74 -35.72 81.55 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.213 -0.929 . . . . 0.0 109.581 179.844 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 1.0 OUTLIER -66.47 -33.86 76.64 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.245 -0.91 . . . . 0.0 109.55 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 9.7 mt -90.06 7.17 39.09 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.166 -0.959 . . . . 0.0 109.201 179.295 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . 0.533 ' O ' ' OD1' ' A' ' 136' ' ' ASP . 47.2 p30 -46.79 138.45 6.22 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.184 -0.948 . . . . 0.0 109.783 -179.617 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 174.21 -161.88 32.12 Favored Glycine 0 N--CA 1.484 1.885 0 N-CA-C 108.873 -1.691 . . . . 0.0 108.873 -179.708 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . 0.477 ' O ' ' O ' ' A' ' 139' ' ' HIS . 88.8 mttt -57.36 -39.55 76.21 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 121.276 -1.132 . . . . 0.0 109.432 179.86 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 139' ' ' HIS . . . . . 0.477 ' O ' ' O ' ' A' ' 138' ' ' LYS . 66.3 m-70 53.18 109.22 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.51 -0.744 . . . . 0.0 110.049 179.63 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 40.6 t -107.42 136.54 42.27 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.36 -0.837 . . . . 0.0 108.825 179.435 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 23.5 m -125.09 142.47 41.87 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.307 -0.871 . . . . 0.0 109.587 -179.464 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 42.8 p90 -126.46 -9.89 6.29 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.5 -0.75 . . . . 0.0 109.751 179.73 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -156.52 175.72 34.07 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 179.631 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 58.6 tt0 -141.43 159.44 42.22 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.238 -1.154 . . . . 0.0 109.675 -179.614 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . 0.483 HG23 HD21 ' A' ' 111' ' ' LEU . 9.8 t -97.83 134.39 36.24 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.22 0 O-C-N 121.124 -0.985 . . . . 0.0 109.126 179.904 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 11.6 m -113.62 -35.45 2.26 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.493 -0.754 . . . . 0.0 109.535 179.653 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 91.9 mt-10 -142.83 167.86 21.08 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.227 -0.92 . . . . 0.0 109.627 -179.849 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 97.78 4.36 57.95 Favored Glycine 0 N--CA 1.494 2.553 0 N-CA-C 110.079 -1.209 . . . . 0.0 110.079 179.534 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 149' ' ' MET . . . . . 0.458 ' O ' HG12 ' A' ' 152' ' ' VAL . 88.0 mtp -60.84 -33.22 72.72 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.062 -1.258 . . . . 0.0 109.741 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . 0.54 ' OD1' ' N ' ' A' ' 151' ' ' VAL . 30.9 p-10 -65.67 -38.26 88.8 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.9 -1.125 . . . . 0.0 110.107 -179.441 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.54 ' N ' ' OD1' ' A' ' 150' ' ' ASP . 7.6 p -86.52 -33.9 7.51 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.066 -1.021 . . . . 0.0 110.262 -179.593 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 152' ' ' VAL . . . . . 0.469 ' CG1' ' N ' ' A' ' 153' ' ' LYS . 1.0 OUTLIER -56.1 -42.65 73.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 120.943 -1.098 . . . . 0.0 109.175 -179.503 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 153' ' ' LYS . . . . . 0.469 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 98.7 mttt -64.87 -33.88 77.06 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.189 -0.944 . . . . 0.0 109.537 179.431 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -62.33 -40.4 96.22 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.287 -0.883 . . . . 0.0 110.11 -179.321 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 75.4 mt -71.19 -36.79 63.81 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.228 -0.92 . . . . 0.0 110.394 -179.481 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -79.57 -41.45 27.15 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.085 -1.009 . . . . 0.0 111.406 -178.725 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 23.5 pttt -61.02 -34.0 74.15 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.705 -1.247 . . . . 0.0 110.193 -178.591 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.425 ' HB ' ' H ' ' A' ' 166' ' ' ALA . 35.1 m -73.37 -10.44 13.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.027 -1.046 . . . . 0.0 109.2 179.906 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -76.38 176.36 52.11 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 -179.822 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 83.2 p -155.31 176.07 13.05 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.425 -1.044 . . . . 0.0 109.039 -179.641 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 22.7 m -52.28 -36.01 51.77 Favored 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 179.429 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 23.8 m -60.71 -33.19 72.52 Favored 'General case' 0 N--CA 1.487 1.387 0 O-C-N 121.377 -0.827 . . . . 0.0 108.93 179.164 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 96.31 8.94 57.29 Favored Glycine 0 N--CA 1.493 2.437 0 N-CA-C 109.805 -1.318 . . . . 0.0 109.805 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 69.6 ttp85 -101.74 138.69 38.39 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.348 -1.089 . . . . 0.0 109.521 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 165' ' ' THR . . . . . 0.642 HG22 HG21 ' A' ' 69' ' ' VAL . 65.2 p -84.12 151.85 24.67 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.175 -0.953 . . . . 0.0 109.544 179.81 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 166' ' ' ALA . . . . . 0.425 ' H ' ' HB ' ' A' ' 158' ' ' VAL . . . -67.28 -34.8 78.15 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.245 -0.909 . . . . 0.0 109.063 179.557 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 63.2 mttp -114.52 158.43 21.65 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.563 -0.711 . . . . 0.0 109.34 -179.994 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 63.1 mttp -73.79 137.81 44.12 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.148 -0.97 . . . . 0.0 109.353 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 2.7 m -132.65 119.71 39.23 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.35 -0.844 . . . . 0.0 109.843 -179.758 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 39.2 t -145.67 141.58 22.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 CA-C-O 121.898 0.856 . . . . 0.0 109.424 179.41 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.561 ' O ' ' O ' ' A' ' 62' ' ' LYS . 22.1 t -61.36 132.36 26.89 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.783 0 C-N-CA 120.333 -0.547 . . . . 0.0 109.762 -179.608 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 172' ' ' GLU . . . . . 0.452 ' O ' ' OD1' ' A' ' 173' ' ' ASP . 95.6 mt-10 -105.87 -7.08 18.44 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.335 -0.853 . . . . 0.0 109.808 179.61 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 173' ' ' ASP . . . . . 0.452 ' OD1' ' O ' ' A' ' 172' ' ' GLU . 30.5 m-20 -158.44 168.22 27.55 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.082 -1.011 . . . . 0.0 110.007 -179.734 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 20.4 p -170.32 126.25 0.78 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.474 -0.766 . . . . 0.0 109.539 179.565 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -173.55 173.86 45.92 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 179.8 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 176' ' ' GLN . . . . . 0.91 HE22 ' HE ' ' A' ' 43' ' ' ARG . 58.7 tt0 -105.2 121.35 43.66 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.383 -1.069 . . . . 0.0 109.853 -179.787 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 177' ' ' LEU . . . . . 0.473 HD23 ' HE ' ' A' ' 11' ' ' ARG . 36.8 tp -62.41 -36.57 82.77 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.239 -0.913 . . . . 0.0 108.95 179.125 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 178' ' ' SER . . . . . 0.513 ' OXT' ' NE2' ' A' ' 176' ' ' GLN . 7.2 t . . . . . 0 N--CA 1.491 1.589 0 CA-C-O 117.977 -1.011 . . . . 0.0 109.428 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.529 4.856 0 N-CA-C 119.398 2.519 . . . . 0.0 119.398 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . 0.404 ' OG ' ' CD2' ' A' ' 3' ' ' PHE . 86.4 p -61.6 -27.6 68.75 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.186 -1.185 . . . . 0.0 109.441 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.404 ' CD2' ' OG ' ' A' ' 2' ' ' SER . 99.2 m-85 -111.03 124.37 52.03 Favored 'General case' 0 N--CA 1.485 1.291 0 N-CA-C 108.82 -0.808 . . . . 0.0 108.82 179.727 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 53.5 p -66.71 -26.86 67.22 Favored 'General case' 0 C--N 1.296 -1.723 0 O-C-N 121.491 -0.756 . . . . 0.0 109.494 -179.897 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 82.17 18.76 66.29 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 -179.952 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 28.5 t -117.91 146.75 43.72 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.43 -1.041 . . . . 0.0 109.502 -179.919 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' MET . . . . . 0.593 ' N ' ' SD ' ' A' ' 7' ' ' MET . 1.7 mpt? -123.31 69.35 40.8 Favored Pre-proline 0 N--CA 1.494 1.73 0 O-C-N 121.415 -0.803 . . . . 0.0 109.427 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.424 ' O ' ' HB3' ' A' ' 32' ' ' ALA . 39.9 Cg_endo -69.16 -9.62 26.8 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 122.657 2.238 . . . . 0.0 112.364 -179.905 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 5.3 p30 -123.73 70.09 46.96 Favored Pre-proline 0 N--CA 1.494 1.756 0 O-C-N 121.261 -0.899 . . . . 0.0 109.832 -179.65 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -72.04 144.43 42.57 Favored 'Trans proline' 0 C--N 1.308 -1.561 0 C-N-CA 122.515 2.143 . . . . 0.0 111.752 179.582 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 92.9 mtt180 -126.26 142.2 51.62 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.304 -0.873 . . . . 0.0 109.643 -179.822 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 10.5 p -134.87 143.84 36.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.359 -0.838 . . . . 0.0 109.345 179.803 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 25.0 p90 -139.49 152.89 47.33 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.208 -0.933 . . . . 0.0 109.602 -179.843 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -124.62 133.09 53.37 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.426 -0.796 . . . . 0.0 109.471 179.529 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.7 t0 -91.06 111.95 23.64 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.144 -0.972 . . . . 0.0 108.611 179.248 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' MET . . . . . 0.426 ' SD ' HD12 ' A' ' 26' ' ' ILE . 78.9 mtp -106.39 138.91 41.72 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.239 -0.913 . . . . 0.0 110.437 -179.185 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.422 ' OG ' ' OE2' ' A' ' 172' ' ' GLU . 48.8 m -131.6 155.95 46.63 Favored 'General case' 0 N--CA 1.492 1.632 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 179.416 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 25.1 m -118.99 144.29 27.71 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.149 -0.969 . . . . 0.0 109.62 -179.738 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 57.6 -108.99 1.55 Allowed Glycine 0 N--CA 1.488 2.119 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -135.77 28.33 2.98 Favored Glycine 0 N--CA 1.493 2.479 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 32.6 mt-30 -137.44 153.02 74.19 Favored Pre-proline 0 N--CA 1.493 1.719 0 O-C-N 121.297 -1.119 . . . . 0.0 109.186 179.873 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_endo -63.96 139.16 66.32 Favored 'Trans proline' 0 N--CA 1.495 1.56 0 C-N-CA 122.528 2.152 . . . . 0.0 112.05 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -102.84 -60.59 1.52 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.276 -0.89 . . . . 0.0 109.4 179.874 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 179.89 -170.83 42.2 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 98.2 mtt180 -117.57 143.72 45.83 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.365 -1.079 . . . . 0.0 109.583 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.426 HD12 ' SD ' ' A' ' 16' ' ' MET . 86.5 mt -121.53 122.37 66.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 179.073 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 39.9 t -116.21 132.3 66.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.437 -0.789 . . . . 0.0 109.024 -179.901 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 71.7 mtm -124.76 152.19 44.15 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.403 -0.81 . . . . 0.0 109.346 -179.694 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -106.15 131.76 53.02 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.394 -0.816 . . . . 0.0 109.894 -179.616 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.542 HD13 ' HB1' ' A' ' 39' ' ' ALA . 17.3 mt -100.27 146.4 26.95 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.423 -0.798 . . . . 0.0 109.311 179.162 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 95.5 m-85 -95.43 124.19 39.34 Favored 'General case' 0 N--CA 1.49 1.567 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 178.804 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.424 ' HB3' ' O ' ' A' ' 8' ' ' PRO . . . -99.17 21.48 11.79 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.206 -0.934 . . . . 0.0 109.694 -179.323 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.3 m-20 -120.76 -73.55 0.64 Allowed 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.289 -0.882 . . . . 0.0 110.21 -179.553 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . 0.443 ' O ' ' OE1' ' A' ' 99' ' ' GLU . 41.3 m -61.15 -43.43 98.89 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.176 -0.953 . . . . 0.0 110.44 -179.117 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 9.4 m -139.95 78.37 24.74 Favored Pre-proline 0 N--CA 1.494 1.746 0 O-C-N 121.126 -0.984 . . . . 0.0 109.963 -179.543 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 68.3 Cg_endo -79.75 -36.94 0.52 Allowed 'Trans proline' 0 C--N 1.306 -1.689 0 C-N-CA 122.614 2.209 . . . . 0.0 112.461 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.418 ' O ' ' OH ' ' A' ' 92' ' ' TYR . 3.3 mtt-85 -59.63 -38.98 82.81 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.247 -0.908 . . . . 0.0 109.79 -179.761 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.477 HG23 ' SD ' ' A' ' 113' ' ' MET . 85.0 m -64.26 -41.01 97.13 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.187 -0.946 . . . . 0.0 109.793 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.542 ' HB1' HD13 ' A' ' 30' ' ' LEU . . . -60.72 -32.78 72.02 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.209 -0.932 . . . . 0.0 108.904 179.762 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -69.23 -34.98 75.67 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.486 -0.759 . . . . 0.0 109.744 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 45.2 t-20 -57.11 -41.0 78.13 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.177 -0.952 . . . . 0.0 109.746 -179.616 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 97.7 m-85 -82.54 -45.73 14.28 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.147 -0.971 . . . . 0.0 109.78 -179.892 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.496 ' NH1' ' OE2' ' A' ' 49' ' ' GLU . 72.1 ttp85 -59.2 -40.9 87.18 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.366 -0.834 . . . . 0.0 110.544 -179.377 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.498 ' O ' ' N ' ' A' ' 48' ' ' GLY . . . -69.55 -52.43 26.38 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.143 -0.973 . . . . 0.0 110.348 -179.117 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.45 ' N ' ' CD2' ' A' ' 45' ' ' LEU . 3.4 mm? -63.93 -39.68 94.71 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.066 -1.021 . . . . 0.0 109.702 -179.739 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' CYS . . . . . . . . . . . . . 95.2 m -63.85 -62.69 1.48 Allowed 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.066 -1.021 . . . . 0.0 109.278 -179.863 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 26.6 m -66.53 -36.24 82.22 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.294 -0.879 . . . . 0.0 109.178 179.586 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.498 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 81.6 38.84 13.19 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 110.064 -1.214 . . . . 0.0 110.064 179.749 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.496 ' OE2' ' NH1' ' A' ' 43' ' ' ARG . 95.3 mt-10 -62.04 -35.79 79.65 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.079 -1.248 . . . . 0.0 109.47 179.883 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 31.2 mmtm -60.43 -34.55 74.14 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.308 -0.87 . . . . 0.0 109.546 -179.838 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 93.58 169.11 38.62 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.236 -1.546 . . . . 0.0 109.236 -179.687 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.539 HG23 ' HA ' ' A' ' 58' ' ' PRO . 68.4 m -79.47 141.12 37.04 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.292 -1.122 . . . . 0.0 109.963 -179.853 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -65.02 140.27 41.71 Favored Glycine 0 N--CA 1.489 2.172 0 N-CA-C 109.302 -1.519 . . . . 0.0 109.302 179.637 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 76.5 mtm180 -59.59 -33.24 71.21 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.229 -1.159 . . . . 0.0 110.046 -179.621 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 86.7 p -60.49 -23.44 64.51 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.204 -0.935 . . . . 0.0 110.122 -179.338 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . 0.427 ' O ' ' CG ' ' A' ' 57' ' ' LYS . . . 108.84 76.94 0.96 Allowed Glycine 0 N--CA 1.495 2.633 0 N-CA-C 108.951 -1.66 . . . . 0.0 108.951 -179.486 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . 0.479 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 54.2 mttm -161.2 76.91 2.41 Favored Pre-proline 0 N--CA 1.488 1.463 0 N-CA-C 107.914 -1.143 . . . . 0.0 107.914 -179.822 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.539 ' HA ' HG23 ' A' ' 52' ' ' THR . 89.0 Cg_exo -48.42 129.91 20.48 Favored 'Trans proline' 0 C--N 1.301 -1.936 0 C-N-CA 122.932 2.421 . . . . 0.0 112.578 -178.716 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.479 ' CD1' ' O ' ' A' ' 57' ' ' LYS . 8.1 mp -97.88 70.7 2.16 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.719 -0.613 . . . . 0.0 109.42 -179.434 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 96.3 m-70 -139.2 146.5 40.6 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.284 -0.885 . . . . 0.0 109.609 179.871 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 4.1 m-85 -97.0 16.87 18.29 Favored 'General case' 0 N--CA 1.492 1.644 0 N-CA-C 108.488 -0.93 . . . . 0.0 108.488 179.173 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 8.7 mtpm? -75.78 153.09 37.19 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.511 -0.743 . . . . 0.0 109.594 -179.692 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 83.8 m-20 55.19 46.23 24.24 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.468 -0.77 . . . . 0.0 109.796 179.745 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 92.1 p -112.94 150.8 31.33 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.418 -0.801 . . . . 0.0 109.038 179.595 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 29.1 t -120.71 148.08 44.42 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.369 -0.832 . . . . 0.0 109.594 -179.694 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -68.38 132.56 47.25 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.294 -0.879 . . . . 0.0 109.015 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 83.8 t60 -63.4 -49.25 74.53 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.278 -0.889 . . . . 0.0 110.367 -179.43 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 5.6 ttm180 -151.45 154.45 36.61 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.071 -1.018 . . . . 0.0 109.344 -179.351 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.479 HG21 HG22 ' A' ' 165' ' ' THR . 19.2 m -132.43 149.88 32.74 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 121.277 -0.889 . . . . 0.0 109.982 -179.737 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 13.3 mt -148.05 125.58 5.75 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.158 -0.963 . . . . 0.0 108.629 178.892 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -71.94 144.2 42.52 Favored 'Trans proline' 0 N--CA 1.493 1.463 0 C-N-CA 122.123 1.882 . . . . 0.0 112.588 -179.291 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 75.08 -53.37 2.61 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.94 -1.264 . . . . 0.0 109.94 179.566 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 84.4 m-85 -67.51 -83.28 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.196 -1.179 . . . . 0.0 110.082 -179.533 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' MET . . . . . 0.587 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 11.9 ptt? -179.49 158.45 0.84 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.114 -0.991 . . . . 0.0 109.619 -179.736 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 1.1 m -99.35 125.8 45.1 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.329 -0.857 . . . . 0.0 108.755 179.377 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 63.7 tt0 -97.94 121.16 39.53 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.21 -0.931 . . . . 0.0 109.766 -179.645 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -87.06 -176.59 49.09 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.14 -1.584 . . . . 0.0 109.14 179.571 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -142.74 162.79 27.37 Favored Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.666 -1.374 . . . . 0.0 109.666 179.857 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -75.04 147.53 40.63 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.344 -1.092 . . . . 0.0 109.553 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 44.4 p90 -68.11 -18.93 64.78 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.243 -0.91 . . . . 0.0 109.654 -179.842 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.539 ' OG1' ' N ' ' A' ' 88' ' ' GLY . 59.7 p -66.22 -30.27 70.68 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.213 -0.929 . . . . 0.0 109.438 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -177.42 -56.22 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.247 -0.908 . . . . 0.0 109.44 179.823 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 94.36 -4.31 70.0 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 78.7 m-20 -88.16 5.41 41.49 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.23 -1.159 . . . . 0.0 109.413 179.865 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 95.93 -38.78 3.0 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 -179.842 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 48.5 m -60.34 -39.51 87.36 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.248 -1.148 . . . . 0.0 109.218 179.738 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -86.06 -168.29 44.59 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 179.901 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.539 ' N ' ' OG1' ' A' ' 81' ' ' THR . . . 108.32 73.14 0.79 Allowed Glycine 0 N--CA 1.494 2.534 0 N-CA-C 109.753 -1.339 . . . . 0.0 109.753 179.865 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -94.8 135.82 35.84 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.254 -1.145 . . . . 0.0 109.189 179.732 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 50.2 m -122.41 147.9 45.74 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.39 -0.819 . . . . 0.0 109.569 -179.84 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 26.1 pt -67.48 -26.81 36.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.309 -0.869 . . . . 0.0 109.621 179.877 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . 0.418 ' OH ' ' O ' ' A' ' 37' ' ' ARG . 97.3 m-85 -65.23 -30.16 71.02 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.3 -0.875 . . . . 0.0 109.776 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 68.09 -107.61 2.13 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.284 -1.527 . . . . 0.0 109.284 -179.772 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -55.54 147.87 16.94 Favored 'General case' 0 N--CA 1.487 1.39 0 O-C-N 121.241 -1.152 . . . . 0.0 109.319 179.819 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 41.5 mttm -76.05 156.26 34.11 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.388 -0.82 . . . . 0.0 109.694 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 33.7 p90 -133.01 161.67 33.75 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.407 -0.808 . . . . 0.0 109.208 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -60.15 140.31 57.0 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.152 -0.967 . . . . 0.0 109.809 -179.349 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -76.68 135.28 39.09 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.29 -0.881 . . . . 0.0 109.812 -179.886 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . 0.443 ' OE1' ' O ' ' A' ' 34' ' ' THR . 95.9 mt-10 -64.84 148.44 51.33 Favored 'General case' 0 C--N 1.305 -1.348 0 O-C-N 121.32 -0.862 . . . . 0.0 109.245 179.556 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 21.3 m120 -55.84 145.7 23.85 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 121.362 -0.836 . . . . 0.0 109.365 -179.866 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' PHE . . . . . 0.586 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 25.0 p90 -110.27 69.88 0.71 Allowed 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.448 -0.782 . . . . 0.0 109.47 -179.781 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 86.4 mt -59.04 -34.8 54.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.257 -0.902 . . . . 0.0 109.575 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 27.1 mtmm -84.77 150.14 25.26 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.21 -0.931 . . . . 0.0 109.615 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 56.4 pttt -131.91 -179.64 5.52 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.371 -0.831 . . . . 0.0 109.362 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' HIS . . . . . 0.534 ' O ' ' CG ' ' A' ' 105' ' ' HIS . 50.4 p-80 -88.27 98.45 11.59 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.207 -0.933 . . . . 0.0 109.647 -179.832 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 55.5 p -77.44 -22.02 52.1 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.237 -0.915 . . . . 0.0 109.708 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.406 ' O ' HG12 ' A' ' 110' ' ' ILE . . . -150.46 179.34 27.27 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.524 -1.431 . . . . 0.0 109.524 -179.744 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -70.99 160.6 48.85 Favored 'Trans proline' 0 C--N 1.307 -1.617 0 C-N-CA 122.863 2.376 . . . . 0.0 112.183 179.886 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 85.62 36.94 9.94 Favored Glycine 0 N--CA 1.493 2.493 0 N-CA-C 109.95 -1.26 . . . . 0.0 109.95 179.725 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.411 ' C ' HD22 ' A' ' 111' ' ' LEU . 39.3 mm -114.98 135.32 55.28 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 O-C-N 121.364 -1.08 . . . . 0.0 109.364 179.857 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.811 ' N ' HD22 ' A' ' 111' ' ' LEU . 2.4 mm? -91.46 136.23 33.27 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.21 -0.931 . . . . 0.0 109.544 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 38.0 t -143.82 139.5 29.36 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.336 -0.852 . . . . 0.0 109.244 179.669 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' MET . . . . . 0.477 ' SD ' HG23 ' A' ' 38' ' ' THR . 82.6 mtp -84.96 130.62 34.6 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.169 -0.957 . . . . 0.0 109.247 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . 0.443 ' O ' ' OD1' ' A' ' 115' ' ' ASN . . . -68.79 141.25 55.23 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.222 -0.924 . . . . 0.0 109.565 -179.879 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . 0.443 ' OD1' ' O ' ' A' ' 114' ' ' ALA . 72.9 m-20 -145.83 112.75 6.05 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.247 -0.908 . . . . 0.0 109.054 179.554 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -69.07 -31.11 69.62 Favored 'General case' 0 C--N 1.296 -1.723 0 O-C-N 121.448 -0.783 . . . . 0.0 109.234 179.747 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -141.02 167.65 25.6 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.137 -1.585 . . . . 0.0 109.137 179.826 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_endo -66.46 157.46 60.34 Favored 'Trans proline' 0 C--N 1.304 -1.799 0 C-N-CA 122.737 2.292 . . . . 0.0 111.94 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 22.3 m120 56.08 51.38 12.01 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.447 -0.783 . . . . 0.0 109.716 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 61.3 m -131.36 127.18 37.06 Favored 'General case' 0 N--CA 1.485 1.28 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 179.437 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 49.3 t-20 -53.13 -37.55 61.9 Favored 'General case' 0 C--N 1.296 -1.753 0 O-C-N 121.371 -0.831 . . . . 0.0 109.839 -179.274 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 77.0 63.52 2.27 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 109.766 -1.334 . . . . 0.0 109.766 179.826 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 24.0 m -54.76 -33.38 61.22 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.199 -1.177 . . . . 0.0 109.76 -179.796 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.3 mt-30 -92.07 147.4 22.98 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.113 -0.992 . . . . 0.0 109.511 -179.902 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' PHE . . . . . 0.403 ' HA ' ' H ' ' A' ' 114' ' ' ALA . 49.1 p90 -138.96 162.48 34.78 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.246 -0.909 . . . . 0.0 109.67 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.587 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 48.8 p90 -139.27 160.79 38.98 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.398 -0.814 . . . . 0.0 109.355 179.911 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 69.8 mt -118.51 132.39 68.53 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.378 -0.826 . . . . 0.0 109.428 179.833 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -102.13 105.59 16.32 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.325 -0.859 . . . . 0.0 109.273 179.887 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . 0.408 ' OG1' ' OE2' ' A' ' 156' ' ' GLU . 44.8 p -89.12 -1.38 58.06 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.283 -0.885 . . . . 0.0 109.642 179.937 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -141.71 153.13 44.44 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.261 -0.9 . . . . 0.0 109.485 -179.816 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 79.7 tttt -78.33 130.64 36.41 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.285 -0.884 . . . . 0.0 109.38 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 33.3 p -124.65 156.11 38.06 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.358 -0.838 . . . . 0.0 109.47 -179.863 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -111.81 -36.3 5.47 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.433 -0.792 . . . . 0.0 109.615 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 0.7 OUTLIER -66.84 -15.2 63.45 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.159 -0.963 . . . . 0.0 109.629 -179.722 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . 0.41 ' O ' ' NE2' ' A' ' 139' ' ' HIS . 7.9 mt -89.29 11.09 19.94 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.195 -0.941 . . . . 0.0 109.436 179.568 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -69.7 118.07 12.09 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.163 -0.961 . . . . 0.0 109.41 -179.617 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -177.68 -154.48 12.35 Favored Glycine 0 N--CA 1.487 2.062 0 N-CA-C 108.883 -1.687 . . . . 0.0 108.883 -179.84 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 32.3 mmtp -81.11 113.7 19.46 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.178 -1.189 . . . . 0.0 109.157 179.769 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 139' ' ' HIS . . . . . 0.41 ' NE2' ' O ' ' A' ' 135' ' ' LEU . 99.2 m-70 -137.17 154.83 50.14 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.367 -0.833 . . . . 0.0 109.348 -179.964 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 44.2 t -122.75 134.41 66.02 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.341 -0.849 . . . . 0.0 109.641 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 61.8 t -110.78 130.48 64.08 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 121.419 -0.801 . . . . 0.0 108.881 179.566 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 38.8 p90 -123.37 -4.88 8.31 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.19 -0.944 . . . . 0.0 110.704 -179.478 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -162.59 174.35 38.96 Favored Glycine 0 N--CA 1.493 2.463 0 C-N-CA 119.152 -1.499 . . . . 0.0 110.498 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 51.7 tt0 -138.96 159.98 40.84 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.604 -0.939 . . . . 0.0 109.169 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 79.7 t -97.31 129.39 47.46 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.188 0 O-C-N 121.105 -0.997 . . . . 0.0 109.521 -179.827 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 19.0 m -106.35 -32.19 2.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.376 -0.828 . . . . 0.0 109.425 179.638 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -145.5 173.15 12.27 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.253 -0.904 . . . . 0.0 109.505 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 98.35 1.93 57.9 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 109.89 -1.284 . . . . 0.0 109.89 179.65 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 149' ' ' MET . . . . . 0.502 ' O ' HG12 ' A' ' 152' ' ' VAL . 65.0 mtt -61.2 -32.35 72.1 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.127 -1.219 . . . . 0.0 109.782 179.979 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . 0.548 ' OD1' ' N ' ' A' ' 151' ' ' VAL . 33.8 p-10 -66.37 -38.73 88.22 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.811 -1.181 . . . . 0.0 110.211 -179.512 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.548 ' N ' ' OD1' ' A' ' 150' ' ' ASP . 6.3 p -85.25 -33.71 8.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.712 0 O-C-N 121.036 -1.04 . . . . 0.0 110.339 -179.545 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 152' ' ' VAL . . . . . 0.502 HG12 ' O ' ' A' ' 149' ' ' MET . 1.1 p -52.77 -41.09 37.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 120.952 -1.092 . . . . 0.0 108.832 -179.488 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 153' ' ' LYS . . . . . 0.442 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 99.4 mttt -64.66 -34.64 78.76 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.252 -0.905 . . . . 0.0 109.144 179.122 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -61.19 -35.38 76.99 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.375 -0.828 . . . . 0.0 109.95 -179.537 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 87.5 mt -71.33 -35.76 58.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.049 -1.032 . . . . 0.0 109.976 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . 0.408 ' OE2' ' OG1' ' A' ' 129' ' ' THR . 97.9 mt-10 -76.97 -40.69 45.98 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.079 -1.013 . . . . 0.0 111.474 -178.937 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 18.4 pttp -60.11 -36.44 77.45 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.592 -1.318 . . . . 0.0 109.208 -179.2 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 30.4 m -80.95 -12.88 12.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.163 -0.961 . . . . 0.0 108.562 178.91 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -78.89 175.8 54.89 Favored Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.707 -1.357 . . . . 0.0 109.707 -179.886 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 25.1 t -157.69 166.79 31.88 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.35 -1.088 . . . . 0.0 109.325 -179.859 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 86.9 p -57.67 -26.05 61.12 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.201 -0.937 . . . . 0.0 108.899 179.745 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 26.7 m -57.44 -30.33 64.92 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.444 -0.785 . . . . 0.0 109.394 179.661 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 95.04 15.62 44.39 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.714 -1.354 . . . . 0.0 109.714 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 77.8 ttt-85 -122.93 141.39 51.96 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.341 -1.093 . . . . 0.0 109.495 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 165' ' ' THR . . . . . 0.479 HG22 HG21 ' A' ' 69' ' ' VAL . 42.7 p -80.91 143.53 32.6 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.188 -0.945 . . . . 0.0 109.618 179.903 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -68.72 -38.34 80.13 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.262 -0.899 . . . . 0.0 109.185 179.559 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 67.2 mttm -107.75 159.75 16.25 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.485 -0.759 . . . . 0.0 109.325 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -73.39 131.7 42.15 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.18 -0.95 . . . . 0.0 109.227 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 40.2 t -121.2 125.0 73.3 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.341 -0.849 . . . . 0.0 109.431 179.915 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 41.6 t -147.06 150.81 14.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.343 -0.848 . . . . 0.0 109.219 179.861 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -88.04 120.37 36.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.233 -0.917 . . . . 0.0 109.625 -179.619 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 172' ' ' GLU . . . . . 0.422 ' OE2' ' OG ' ' A' ' 17' ' ' SER . 97.1 mt-10 -65.28 -26.47 68.09 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.413 -0.804 . . . . 0.0 109.324 179.479 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 173' ' ' ASP . . . . . 0.47 ' OD1' ' N ' ' A' ' 174' ' ' CYS . 47.2 t0 -174.8 169.26 3.53 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.201 -0.937 . . . . 0.0 110.412 -179.532 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 174' ' ' CYS . . . . . 0.47 ' N ' ' OD1' ' A' ' 173' ' ' ASP . 31.4 p -150.38 150.83 31.93 Favored 'General case' 0 N--CA 1.491 1.585 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 179.349 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -175.98 -176.49 44.23 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.823 -1.311 . . . . 0.0 109.823 -179.894 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 6.7 tt0 -104.43 119.67 39.49 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.415 -1.05 . . . . 0.0 109.713 -179.823 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 30.9 tp -62.71 -37.93 88.46 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.129 -0.982 . . . . 0.0 109.154 179.434 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 8.0 t . . . . . 0 N--CA 1.49 1.55 0 CA-C-O 118.017 -0.992 . . . . 0.0 109.433 -179.958 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.528 4.774 0 N-CA-C 119.35 2.5 . . . . 0.0 119.35 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 91.5 p -62.84 -23.11 67.12 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.275 -1.133 . . . . 0.0 109.452 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 55.6 p90 -134.25 136.34 43.55 Favored 'General case' 0 N--CA 1.486 1.332 0 O-C-N 121.263 -0.898 . . . . 0.0 108.973 179.569 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 43.4 m -61.84 -40.5 95.53 Favored 'General case' 0 C--N 1.297 -1.689 0 O-C-N 121.563 -0.711 . . . . 0.0 109.928 -179.832 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 90.51 8.04 66.36 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.514 -1.435 . . . . 0.0 109.514 -179.841 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 47.1 m -62.49 155.3 26.03 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.194 -1.18 . . . . 0.0 109.333 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' MET . . . . . 0.606 ' N ' ' SD ' ' A' ' 7' ' ' MET . 0.1 OUTLIER -64.62 150.31 94.17 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.231 -0.918 . . . . 0.0 109.273 -179.914 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -70.52 169.18 20.51 Favored 'Trans proline' 0 C--N 1.309 -1.547 0 C-N-CA 122.742 2.295 . . . . 0.0 112.1 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 7.7 t-20 -63.89 139.01 97.56 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.331 -0.856 . . . . 0.0 109.027 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_endo -71.14 139.0 34.61 Favored 'Trans proline' 0 N--CA 1.494 1.502 0 C-N-CA 122.406 2.071 . . . . 0.0 112.493 -179.778 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.571 ' H ' ' HG ' ' A' ' 178' ' ' SER . 86.6 mtt180 -131.65 134.04 45.56 Favored 'General case' 0 N--CA 1.493 1.697 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 179.119 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 12.6 p -136.4 144.52 32.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.412 -0.805 . . . . 0.0 109.353 -179.783 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 48.8 p90 -135.28 151.89 50.99 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.337 -0.852 . . . . 0.0 109.348 179.877 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 90.4 m-85 -119.39 127.52 53.21 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.451 -0.781 . . . . 0.0 110.122 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.4 t0 -92.54 120.31 32.87 Favored 'General case' 0 N--CA 1.493 1.678 0 N-CA-C 108.347 -0.982 . . . . 0.0 108.347 178.86 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 77.2 mtp -122.09 151.12 41.23 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.991 -1.068 . . . . 0.0 110.698 -179.065 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 93.8 p -145.12 160.63 41.11 Favored 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 108.744 -0.836 . . . . 0.0 108.744 179.671 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.419 ' O ' ' C ' ' A' ' 19' ' ' GLY . 18.9 m -128.71 143.55 40.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.274 -0.891 . . . . 0.0 109.488 179.963 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.419 ' C ' ' O ' ' A' ' 18' ' ' VAL . . . 42.11 -103.86 0.04 OUTLIER Glycine 0 N--CA 1.492 2.423 0 N-CA-C 109.692 -1.363 . . . . 0.0 109.692 179.925 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -135.48 22.56 3.51 Favored Glycine 0 N--CA 1.494 2.526 0 N-CA-C 109.32 -1.512 . . . . 0.0 109.32 179.685 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 62.1 mt-30 -127.41 88.61 53.45 Favored Pre-proline 0 N--CA 1.494 1.741 0 O-C-N 121.448 -1.031 . . . . 0.0 109.264 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_exo -48.63 133.17 26.43 Favored 'Trans proline' 0 C--N 1.309 -1.511 0 C-N-CA 122.505 2.137 . . . . 0.0 112.297 -179.637 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -82.47 -64.06 1.25 Allowed 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.405 -0.81 . . . . 0.0 109.772 -179.89 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 175.15 -167.56 39.7 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 -179.858 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 94.5 mtt-85 -106.27 150.23 26.13 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.447 -1.031 . . . . 0.0 109.186 179.886 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 79.6 mt -119.26 120.73 64.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 179.378 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 34.8 t -112.99 132.38 61.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.446 -0.784 . . . . 0.0 108.911 -179.909 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 70.6 mtm -127.45 156.68 41.74 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.323 -0.86 . . . . 0.0 109.679 -179.361 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -99.62 135.51 40.94 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.284 -0.885 . . . . 0.0 109.795 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -108.89 128.35 54.84 Favored 'General case' 0 N--CA 1.492 1.65 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 179.388 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -95.19 118.23 31.61 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.143 -0.973 . . . . 0.0 108.992 179.778 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -80.43 -42.47 22.64 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 121.473 -0.767 . . . . 0.0 109.839 -179.812 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 56.8 t0 -65.52 -46.26 80.28 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.237 -0.914 . . . . 0.0 110.435 -179.365 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 24.8 m -66.17 -45.73 79.88 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.002 -1.061 . . . . 0.0 109.854 -179.38 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.432 ' O ' ' OG1' ' A' ' 35' ' ' THR . 13.2 p -145.33 81.84 10.08 Favored Pre-proline 0 N--CA 1.493 1.711 0 O-C-N 121.317 -0.864 . . . . 0.0 109.332 -179.72 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -70.33 -47.07 0.82 Allowed 'Trans proline' 0 C--N 1.307 -1.615 0 C-N-CA 122.1 1.867 . . . . 0.0 112.215 -179.48 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 22.9 mmt85 -63.04 -39.75 95.68 Favored 'General case' 0 N--CA 1.487 1.409 0 O-C-N 121.1 -1.0 . . . . 0.0 109.581 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.407 HG23 ' SD ' ' A' ' 113' ' ' MET . 37.9 m -65.16 -40.92 95.01 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.224 -0.922 . . . . 0.0 110.069 -179.736 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -60.69 -31.8 71.05 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.312 -0.867 . . . . 0.0 109.278 -179.699 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -67.09 -38.44 85.7 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.335 -0.853 . . . . 0.0 109.758 -179.927 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 49.1 t30 -58.48 -42.52 87.72 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.264 -0.898 . . . . 0.0 109.932 -179.644 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.507 ' O ' ' SG ' ' A' ' 46' ' ' CYS . 97.6 m-85 -82.89 -45.72 13.87 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.061 -1.024 . . . . 0.0 109.859 -179.925 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.773 ' HE ' HE22 ' A' ' 176' ' ' GLN . 74.0 ttt-85 -58.73 -41.1 85.62 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.296 -0.878 . . . . 0.0 110.544 -179.342 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -71.77 -53.81 12.21 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.028 -1.045 . . . . 0.0 110.553 -179.019 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.473 ' N ' ' CD2' ' A' ' 45' ' ' LEU . 3.8 mm? -63.32 -38.9 92.95 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.948 -1.095 . . . . 0.0 109.776 -179.631 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' CYS . . . . . 0.507 ' SG ' ' O ' ' A' ' 42' ' ' PHE . 95.6 m -65.83 -55.65 16.02 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.108 -0.995 . . . . 0.0 109.138 179.864 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 50.7 m -66.13 -36.81 84.13 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.373 -0.83 . . . . 0.0 109.279 179.468 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 85.31 30.02 26.13 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 110.269 -1.133 . . . . 0.0 110.269 179.565 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -62.2 -38.71 90.15 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.05 -1.265 . . . . 0.0 109.359 179.83 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 59.7 mmtt -62.5 -31.27 72.0 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.386 -0.821 . . . . 0.0 109.686 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 74.34 -113.95 4.29 Favored Glycine 0 N--CA 1.488 2.125 0 N-CA-C 108.854 -1.698 . . . . 0.0 108.854 -179.37 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.615 HG23 ' HA ' ' A' ' 58' ' ' PRO . 87.4 m -127.61 143.42 51.17 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.339 -1.094 . . . . 0.0 109.749 179.624 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -64.99 137.2 38.31 Favored Glycine 0 N--CA 1.489 2.168 0 N-CA-C 109.221 -1.551 . . . . 0.0 109.221 179.685 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 81.4 mtm180 -59.1 -34.93 72.59 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.205 -1.173 . . . . 0.0 109.913 -179.7 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 86.1 p -61.95 -24.41 66.98 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.174 -0.954 . . . . 0.0 109.782 -179.746 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 112.45 89.6 1.84 Allowed Glycine 0 N--CA 1.495 2.569 0 N-CA-C 109.102 -1.599 . . . . 0.0 109.102 -179.682 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . 0.529 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 22.8 tttp -174.56 79.56 0.34 Allowed Pre-proline 0 N--CA 1.488 1.465 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 -179.677 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.615 ' HA ' HG23 ' A' ' 52' ' ' THR . 75.5 Cg_exo -50.47 131.99 33.92 Favored 'Trans proline' 0 C--N 1.304 -1.793 0 C-N-CA 122.892 2.394 . . . . 0.0 113.197 -178.779 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.529 ' CD1' ' O ' ' A' ' 57' ' ' LYS . 8.9 mp -104.49 122.32 45.3 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 108.782 -0.821 . . . . 0.0 108.782 179.325 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . 0.421 ' CD2' ' N ' ' A' ' 60' ' ' HIS . 5.1 p80 -169.7 93.28 0.25 Allowed 'General case' 0 N--CA 1.486 1.375 0 O-C-N 120.971 -1.081 . . . . 0.0 110.272 -179.684 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 8.0 m-85 -64.29 -29.39 70.48 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.182 -0.949 . . . . 0.0 109.066 179.149 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 8.8 ptmm? -55.3 160.3 2.3 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.351 -0.843 . . . . 0.0 109.627 179.842 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . 0.449 ' N ' ' O ' ' A' ' 171' ' ' VAL . 85.0 m-20 54.62 48.01 21.31 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.498 -0.752 . . . . 0.0 109.416 -179.842 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.577 ' H ' ' CG1' ' A' ' 171' ' ' VAL . 89.6 p -126.46 155.07 42.83 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.277 -0.889 . . . . 0.0 109.134 179.754 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 32.1 t -106.48 141.98 36.9 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.335 -0.853 . . . . 0.0 109.056 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -69.61 143.43 53.28 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.343 -0.848 . . . . 0.0 108.892 -179.927 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 57.2 t-80 -57.33 -51.13 70.62 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.218 -0.927 . . . . 0.0 110.405 -178.851 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 15.6 ptm180 -171.0 163.68 7.45 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 120.896 -1.127 . . . . 0.0 109.697 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.405 HG11 HG22 ' A' ' 155' ' ' ILE . 0.1 OUTLIER -136.47 129.28 45.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.462 -0.774 . . . . 0.0 109.128 179.696 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 70.3 mt -128.92 109.14 18.35 Favored Pre-proline 0 N--CA 1.493 1.695 0 O-C-N 121.543 -0.723 . . . . 0.0 109.631 179.865 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -52.45 147.53 29.28 Favored 'Trans proline' 0 C--N 1.31 -1.482 0 C-N-CA 122.357 2.038 . . . . 0.0 112.62 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 87.12 -59.53 4.48 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 110.156 -1.177 . . . . 0.0 110.156 179.373 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 67.8 m-85 -70.21 -73.48 0.16 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.239 -1.154 . . . . 0.0 110.061 -179.493 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' MET . . . . . 0.528 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 13.4 ptt? 178.45 -165.66 0.05 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.225 -0.922 . . . . 0.0 109.618 -179.918 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -121.22 124.13 43.92 Favored 'General case' 0 N--CA 1.494 1.764 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 179.614 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 63.6 tt0 -102.44 124.49 48.09 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.231 -0.918 . . . . 0.0 109.827 -179.663 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -86.26 -173.88 49.34 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.259 -1.536 . . . . 0.0 109.259 179.457 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -136.83 154.5 22.21 Favored Glycine 0 N--CA 1.493 2.477 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 88.0 m-20 -83.77 143.81 29.73 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.432 -1.04 . . . . 0.0 109.642 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 41.3 p90 -65.43 -23.61 66.98 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.283 -0.886 . . . . 0.0 109.624 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.454 ' OG1' ' N ' ' A' ' 88' ' ' GLY . 52.7 p -64.2 -31.54 72.78 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.145 -0.972 . . . . 0.0 109.481 -179.891 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . 0.432 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 178.02 -54.08 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.403 -0.811 . . . . 0.0 109.334 179.855 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 96.58 -11.21 66.77 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 80.3 m-20 -88.66 2.77 52.63 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.186 -1.185 . . . . 0.0 109.315 179.795 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 93.66 -5.16 73.3 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.395 -1.482 . . . . 0.0 109.395 -179.868 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 61.7 p -74.47 -19.02 60.54 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.394 -1.062 . . . . 0.0 109.517 179.87 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -131.86 -132.75 3.38 Favored Glycine 0 N--CA 1.494 2.519 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.454 ' N ' ' OG1' ' A' ' 81' ' ' THR . . . 74.57 47.28 16.25 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.293 -1.523 . . . . 0.0 109.293 -179.915 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -93.3 135.36 34.59 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.295 -1.121 . . . . 0.0 109.753 -179.508 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 50.0 m -70.72 158.08 36.91 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.358 -0.839 . . . . 0.0 109.508 179.84 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 24.9 pt -65.94 -31.15 52.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.24 -0.912 . . . . 0.0 109.834 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 59.9 m-85 -64.0 -36.33 83.63 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.256 -0.902 . . . . 0.0 109.591 -179.746 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 82.79 10.16 83.52 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.321 -1.512 . . . . 0.0 109.321 -179.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -148.28 157.25 43.38 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.282 -1.128 . . . . 0.0 109.372 -179.915 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 62.0 mttp -86.57 153.03 22.12 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.22 -0.925 . . . . 0.0 109.466 179.912 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 36.9 p90 -129.09 157.87 40.53 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.425 -0.797 . . . . 0.0 109.329 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -65.68 143.98 57.21 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.294 -0.879 . . . . 0.0 110.052 -179.337 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.574 ' CG ' ' H ' ' A' ' 119' ' ' ASN . 88.5 m-20 -67.01 148.0 52.51 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.35 -0.844 . . . . 0.0 109.617 179.845 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -100.14 161.91 13.3 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.345 -0.847 . . . . 0.0 109.268 179.844 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 81.4 m-20 -62.6 163.17 9.37 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.369 -0.832 . . . . 0.0 109.405 -179.846 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' PHE . . . . . 0.582 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 22.0 p90 -130.22 79.43 1.9 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.431 -0.793 . . . . 0.0 109.52 -179.898 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 87.8 mt -58.97 -33.94 51.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.183 -0.948 . . . . 0.0 109.376 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 67.2 mttm -83.51 143.18 30.38 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.187 -0.946 . . . . 0.0 109.386 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . 0.541 ' O ' ' N ' ' A' ' 106' ' ' THR . 50.0 tttp -127.35 158.24 37.79 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.406 -0.809 . . . . 0.0 109.331 -179.924 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' HIS . . . . . 0.455 ' CE1' ' O ' ' A' ' 107' ' ' GLY . 78.6 t60 -61.01 76.5 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.341 -0.849 . . . . 0.0 109.252 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . 0.541 ' N ' ' O ' ' A' ' 104' ' ' LYS . 70.5 p -73.52 -27.15 61.21 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.199 -0.938 . . . . 0.0 109.878 -179.731 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.455 ' O ' ' CE1' ' A' ' 105' ' ' HIS . . . -153.75 177.12 31.43 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.561 -1.415 . . . . 0.0 109.561 -179.763 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -70.4 156.65 61.21 Favored 'Trans proline' 0 C--N 1.305 -1.724 0 C-N-CA 122.774 2.316 . . . . 0.0 112.131 179.881 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 86.07 43.59 6.27 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 110.095 -1.202 . . . . 0.0 110.095 179.728 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 45.4 mm -117.13 136.13 55.27 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 O-C-N 121.263 -1.139 . . . . 0.0 109.386 179.593 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.71 ' N ' HD22 ' A' ' 111' ' ' LEU . 2.9 mm? -88.65 137.36 32.39 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.21 -0.931 . . . . 0.0 109.413 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . 0.457 ' OG ' ' O ' ' A' ' 140' ' ' VAL . 46.2 t -146.22 141.22 27.19 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.246 -0.909 . . . . 0.0 109.582 179.804 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' MET . . . . . 0.407 ' SD ' HG23 ' A' ' 38' ' ' THR . 88.5 mtp -88.51 135.59 33.41 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.259 -0.9 . . . . 0.0 109.416 179.67 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . 0.456 ' O ' ' OD1' ' A' ' 115' ' ' ASN . . . -73.73 137.54 44.07 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.202 -0.936 . . . . 0.0 109.585 -179.946 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . 0.456 ' OD1' ' O ' ' A' ' 114' ' ' ALA . 76.3 m-20 -146.58 114.17 6.39 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.203 -0.936 . . . . 0.0 108.945 179.535 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -69.15 -31.07 69.49 Favored 'General case' 0 C--N 1.297 -1.697 0 O-C-N 121.409 -0.807 . . . . 0.0 109.697 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -139.9 167.55 25.34 Favored Glycine 0 N--CA 1.494 2.543 0 N-CA-C 109.396 -1.482 . . . . 0.0 109.396 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -69.08 154.11 70.97 Favored 'Trans proline' 0 C--N 1.307 -1.653 0 C-N-CA 122.701 2.268 . . . . 0.0 111.849 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' ASN . . . . . 0.574 ' H ' ' CG ' ' A' ' 98' ' ' ASP . 80.3 m-20 53.49 43.22 31.58 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.436 -0.79 . . . . 0.0 109.317 -179.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 91.8 m -136.37 128.41 29.59 Favored 'General case' 0 C--N 1.305 -1.34 0 O-C-N 121.445 -0.784 . . . . 0.0 109.041 179.84 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 43.4 p-10 -80.76 168.11 19.19 Favored 'General case' 0 C--N 1.298 -1.668 0 O-C-N 121.377 -0.827 . . . . 0.0 109.311 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -159.79 105.94 0.28 Allowed Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.667 -1.373 . . . . 0.0 109.667 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 23.9 t -59.12 -32.61 69.99 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.252 -1.146 . . . . 0.0 109.389 179.85 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.6 mt-30 -71.23 142.96 50.58 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.214 -0.928 . . . . 0.0 109.575 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 48.5 p90 -140.46 162.27 35.73 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.342 -0.849 . . . . 0.0 109.322 179.866 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.528 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 48.2 p90 -138.43 158.56 44.04 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.295 -0.878 . . . . 0.0 109.608 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 60.3 mt -120.34 132.29 70.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.411 -0.806 . . . . 0.0 109.208 179.85 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' CYS . . . . . 0.432 ' SG ' ' O ' ' A' ' 130' ' ' ALA . 4.4 t -100.99 116.8 33.69 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.135 -0.978 . . . . 0.0 109.389 179.886 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . 0.421 ' OG1' ' OE1' ' A' ' 156' ' ' GLU . 51.0 p -91.45 0.78 57.47 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.301 -0.875 . . . . 0.0 109.622 -179.842 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . 0.432 ' O ' ' SG ' ' A' ' 128' ' ' CYS . . . -151.25 155.91 39.77 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.188 -0.945 . . . . 0.0 109.601 -179.811 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 77.8 tttt -69.33 140.56 54.32 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.186 -0.946 . . . . 0.0 109.261 179.832 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 17.0 p -113.19 159.68 19.04 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.349 -0.844 . . . . 0.0 109.506 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -154.57 -50.46 0.09 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.397 -0.814 . . . . 0.0 109.282 -179.876 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 134' ' ' TRP . . . . . 0.631 ' CD1' ' N ' ' A' ' 135' ' ' LEU . 35.3 p90 -56.43 -38.8 72.07 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.259 -0.901 . . . . 0.0 109.385 179.836 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . 0.631 ' N ' ' CD1' ' A' ' 134' ' ' TRP . 44.2 tp -60.01 -36.5 77.35 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.428 -0.795 . . . . 0.0 109.505 -179.782 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 59.4 t0 47.26 78.75 0.07 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.337 -0.852 . . . . 0.0 109.798 179.771 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -144.74 134.92 5.84 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.11 -1.596 . . . . 0.0 109.11 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 67.6 mmtt -82.96 135.06 35.01 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.261 -1.141 . . . . 0.0 109.42 -179.754 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 96.4 m-70 -136.02 175.5 9.54 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.414 -0.804 . . . . 0.0 109.376 -179.878 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.457 ' O ' ' OG ' ' A' ' 112' ' ' SER . 20.1 m -124.0 153.77 30.34 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 121.466 -0.771 . . . . 0.0 108.996 179.702 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 58.5 t -118.39 128.2 75.39 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.292 -0.88 . . . . 0.0 109.961 -179.607 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . 0.455 ' CE2' ' CE2' ' A' ' 42' ' ' PHE . 40.6 p90 -117.59 1.61 12.27 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.474 -0.766 . . . . 0.0 109.561 179.412 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -169.29 177.38 42.97 Favored Glycine 0 N--CA 1.495 2.593 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 179.64 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . 0.432 ' CG ' ' N ' ' A' ' 145' ' ' VAL . 48.0 tt0 -143.76 161.62 38.12 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.349 -1.089 . . . . 0.0 109.798 -179.643 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . 0.432 ' N ' ' CG ' ' A' ' 144' ' ' GLN . 79.9 t -100.03 135.59 35.04 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.112 0 O-C-N 121.283 -0.886 . . . . 0.0 109.653 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 6.8 m -118.8 -33.69 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.275 -0.89 . . . . 0.0 109.573 179.672 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -138.37 166.03 25.27 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.237 -0.915 . . . . 0.0 109.713 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 94.47 9.98 58.49 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.845 -1.302 . . . . 0.0 109.845 179.745 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 149' ' ' MET . . . . . 0.446 ' O ' HG12 ' A' ' 152' ' ' VAL . 88.7 mtp -59.84 -34.07 72.61 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.192 -1.181 . . . . 0.0 109.765 -179.935 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 89.0 m-20 -64.61 -39.68 94.15 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.896 -1.127 . . . . 0.0 109.846 -179.74 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 5.5 p -85.59 -33.27 7.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.132 -0.98 . . . . 0.0 110.522 -179.423 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 152' ' ' VAL . . . . . 0.446 HG12 ' O ' ' A' ' 149' ' ' MET . 0.7 OUTLIER -55.29 -38.77 49.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 120.953 -1.092 . . . . 0.0 109.376 -179.366 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 153' ' ' LYS . . . . . 0.412 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 50.7 pttt -81.16 -20.97 40.13 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.136 -0.978 . . . . 0.0 109.385 179.683 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -64.39 -39.82 94.6 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.252 -0.905 . . . . 0.0 109.579 -179.916 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.405 HG22 HG11 ' A' ' 69' ' ' VAL . 65.2 mt -72.05 -35.68 54.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.304 -0.873 . . . . 0.0 109.541 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . 0.421 ' OE1' ' OG1' ' A' ' 129' ' ' THR . 84.7 tt0 -76.26 -42.27 46.22 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.257 -0.902 . . . . 0.0 111.447 -178.772 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 16.4 pttp -61.59 -33.12 73.34 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 120.639 -1.288 . . . . 0.0 110.241 -178.56 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 35.2 m -77.02 -17.84 14.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.018 -1.051 . . . . 0.0 109.683 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -72.87 172.77 48.77 Favored Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.965 -1.254 . . . . 0.0 109.965 -179.655 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 85.0 p -150.09 170.07 19.76 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.476 -1.014 . . . . 0.0 109.381 -179.739 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 23.2 m -55.42 -34.72 64.67 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.177 -0.952 . . . . 0.0 108.965 179.705 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 86.5 p -62.57 -26.34 68.54 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.373 -0.83 . . . . 0.0 109.189 179.674 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 97.2 3.17 58.94 Favored Glycine 0 N--CA 1.494 2.529 0 N-CA-C 109.674 -1.37 . . . . 0.0 109.674 179.898 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 77.8 ttt180 -99.99 144.56 28.9 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.306 -1.114 . . . . 0.0 109.205 179.818 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 165' ' ' THR . . . . . . . . . . . . . 65.5 p -104.71 152.1 22.93 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.354 -0.841 . . . . 0.0 109.657 -179.877 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -68.47 -37.0 79.77 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.369 -0.832 . . . . 0.0 109.627 179.923 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 47.8 mtmt -112.41 157.82 20.58 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.53 -0.731 . . . . 0.0 109.628 -179.793 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 91.3 mttt -76.54 146.49 38.34 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.333 -0.854 . . . . 0.0 109.306 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . 0.475 ' O ' HG23 ' A' ' 169' ' ' VAL . 32.6 m -128.75 125.2 62.86 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 O-C-N 121.326 -0.859 . . . . 0.0 109.596 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 48.5 t -144.88 138.23 22.21 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.387 -0.821 . . . . 0.0 109.302 179.589 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.577 ' CG1' ' H ' ' A' ' 64' ' ' SER . 2.5 p -80.41 119.65 30.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 120.99 -1.069 . . . . 0.0 108.999 179.717 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -71.03 -44.41 65.88 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.133 -0.98 . . . . 0.0 111.177 -178.535 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 173' ' ' ASP . . . . . 0.46 ' OD1' ' N ' ' A' ' 174' ' ' CYS . 47.2 t0 -170.15 164.64 9.2 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.754 -1.216 . . . . 0.0 110.542 -179.325 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 174' ' ' CYS . . . . . 0.46 ' N ' ' OD1' ' A' ' 173' ' ' ASP . 1.4 p -151.63 151.86 32.07 Favored 'General case' 0 N--CA 1.49 1.573 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 179.484 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -160.75 178.37 36.77 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 176' ' ' GLN . . . . . 0.773 HE22 ' HE ' ' A' ' 43' ' ' ARG . 62.6 tt0 -99.05 113.96 26.42 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.326 -1.102 . . . . 0.0 109.713 -179.821 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 29.1 tp -63.37 -36.79 84.89 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.216 -0.928 . . . . 0.0 109.022 179.418 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 178' ' ' SER . . . . . 0.571 ' HG ' ' H ' ' A' ' 11' ' ' ARG . 11.8 p . . . . . 0 N--CA 1.491 1.62 0 CA-C-O 118.001 -0.999 . . . . 0.0 109.495 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.528 4.812 0 N-CA-C 119.429 2.532 . . . . 0.0 119.429 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 86.6 p -61.87 -27.12 68.57 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.203 -1.175 . . . . 0.0 109.445 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 68.1 t80 -107.53 120.5 42.36 Favored 'General case' 0 N--CA 1.484 1.268 0 O-C-N 121.399 -0.813 . . . . 0.0 108.958 179.689 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 18.1 p -124.23 162.41 23.74 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.663 -0.648 . . . . 0.0 109.343 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -176.84 -175.23 43.99 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 54.4 p -69.22 159.56 32.8 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.207 -1.172 . . . . 0.0 109.369 179.895 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 37.4 mtt -148.16 153.15 40.97 Favored Pre-proline 0 N--CA 1.492 1.641 0 O-C-N 121.241 -0.912 . . . . 0.0 109.463 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.44 ' O ' ' CB ' ' A' ' 9' ' ' ASN . 36.1 Cg_endo -66.83 -179.17 1.55 Allowed 'Trans proline' 0 C--N 1.309 -1.52 0 C-N-CA 122.715 2.277 . . . . 0.0 111.903 179.679 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.44 ' CB ' ' O ' ' A' ' 8' ' ' PRO . 2.5 m-20 73.99 78.23 0.19 Allowed Pre-proline 0 N--CA 1.492 1.661 0 O-C-N 121.408 -0.807 . . . . 0.0 109.624 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 93.3 Cg_endo -82.23 90.53 1.09 Allowed 'Trans proline' 0 C--N 1.308 -1.575 0 C-N-CA 122.898 2.399 . . . . 0.0 111.845 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 73.1 mtm180 -61.68 137.91 58.28 Favored 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.289 -0.882 . . . . 0.0 109.849 -179.595 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 12.7 p -138.29 143.53 32.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 179.497 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 45.1 p90 -141.54 153.96 45.19 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.179 -0.95 . . . . 0.0 110.107 -179.513 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 86.0 m-85 -123.73 140.25 53.18 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 179.162 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.5 t0 -86.88 116.31 24.87 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.053 -1.029 . . . . 0.0 109.259 179.768 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' MET . . . . . 0.577 ' SD ' HD12 ' A' ' 26' ' ' ILE . 80.4 mtp -103.96 147.45 27.34 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.291 -0.881 . . . . 0.0 110.19 -179.856 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 97.1 p -143.94 164.39 30.72 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 108.55 -0.907 . . . . 0.0 108.55 179.414 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 12.9 p -128.3 139.03 53.0 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.238 -0.914 . . . . 0.0 109.676 -179.752 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 57.02 -107.33 0.92 Allowed Glycine 0 N--CA 1.488 2.129 0 N-CA-C 109.364 -1.494 . . . . 0.0 109.364 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -136.04 37.15 1.93 Allowed Glycine 0 N--CA 1.493 2.487 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 6.5 pt20 -147.88 126.99 6.3 Favored Pre-proline 0 N--CA 1.492 1.649 0 O-C-N 121.264 -1.139 . . . . 0.0 109.349 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_exo -47.39 139.88 16.29 Favored 'Trans proline' 0 N--CA 1.493 1.455 0 C-N-CA 122.139 1.893 . . . . 0.0 112.17 179.74 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -101.49 -61.31 1.39 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.311 -0.868 . . . . 0.0 109.483 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -178.19 -170.3 40.16 Favored Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.409 -1.476 . . . . 0.0 109.409 -179.871 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 97.5 mtt180 -118.04 142.33 47.5 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.374 -1.074 . . . . 0.0 109.803 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.577 HD12 ' SD ' ' A' ' 16' ' ' MET . 70.1 mt -120.39 123.2 70.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 178.609 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 38.7 t -110.05 132.58 57.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.387 -0.82 . . . . 0.0 109.382 -179.535 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 76.2 mtm -114.79 149.32 37.16 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.591 -0.693 . . . . 0.0 109.381 -179.689 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.405 ' C ' HD22 ' A' ' 30' ' ' LEU . 84.3 tt0 -100.92 129.82 46.83 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.286 -0.884 . . . . 0.0 109.698 -179.668 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.408 ' N ' ' CD2' ' A' ' 30' ' ' LEU . 2.7 mm? -108.34 132.66 53.5 Favored 'General case' 0 N--CA 1.494 1.741 0 N-CA-C 108.909 -0.775 . . . . 0.0 108.909 179.588 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.483 ' O ' ' OG1' ' A' ' 35' ' ' THR . 92.7 m-85 -96.36 114.02 25.66 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.031 -1.043 . . . . 0.0 108.742 178.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -75.87 -42.43 49.4 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.155 -0.966 . . . . 0.0 109.869 -179.696 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.3 m-20 -66.63 -57.86 6.34 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.149 -0.97 . . . . 0.0 110.191 -179.356 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 54.9 m -67.03 -40.73 87.28 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.246 -0.909 . . . . 0.0 109.853 -179.759 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.546 HG21 ' HA ' ' A' ' 142' ' ' PHE . 81.7 p -130.04 77.5 76.42 Favored Pre-proline 0 N--CA 1.493 1.711 0 O-C-N 121.358 -0.839 . . . . 0.0 109.377 -179.64 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -72.84 -73.64 0.01 OUTLIER 'Trans proline' 0 N--CA 1.493 1.489 0 C-N-CA 122.676 2.251 . . . . 0.0 113.259 -179.38 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 80.1 mtt85 -59.37 -39.33 82.93 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.612 -0.68 . . . . 0.0 111.061 -178.624 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 42.8 m -61.66 -42.56 99.07 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.864 -1.148 . . . . 0.0 109.452 -179.848 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -63.9 -30.85 71.89 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.263 -0.898 . . . . 0.0 108.593 179.295 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 85.2 tt0 -66.25 -36.81 83.96 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.432 -0.792 . . . . 0.0 109.509 179.927 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . 0.49 ' O ' HD23 ' A' ' 45' ' ' LEU . 38.7 t30 -58.03 -41.2 82.69 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.229 -0.919 . . . . 0.0 109.514 -179.698 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.4 ' O ' ' SG ' ' A' ' 46' ' ' CYS . 98.0 m-85 -83.18 -44.99 14.43 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.058 -1.026 . . . . 0.0 109.661 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.712 ' NE ' HE22 ' A' ' 176' ' ' GLN . 77.5 ttt180 -59.32 -43.2 92.7 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.38 -0.825 . . . . 0.0 110.62 -179.216 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -68.1 -43.97 77.29 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.097 -1.002 . . . . 0.0 110.63 -178.834 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.49 HD23 ' O ' ' A' ' 41' ' ' ASN . 3.3 mm? -62.39 -39.05 91.95 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.971 -1.081 . . . . 0.0 109.593 -179.659 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' CYS . . . . . 0.4 ' SG ' ' O ' ' A' ' 42' ' ' PHE . 35.7 m -67.64 -47.89 68.27 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.146 -0.972 . . . . 0.0 109.391 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 48.3 p -74.49 -33.75 62.91 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.361 -0.837 . . . . 0.0 109.709 179.864 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 74.36 33.53 56.29 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 110.077 -1.209 . . . . 0.0 110.077 179.704 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -62.11 -37.55 85.54 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.07 -1.253 . . . . 0.0 109.61 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 72.2 mmtt -61.27 -35.32 76.96 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.262 -0.899 . . . . 0.0 109.578 -179.845 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 90.9 171.68 43.52 Favored Glycine 0 N--CA 1.488 2.113 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 -179.757 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.535 HG23 ' HA ' ' A' ' 58' ' ' PRO . 65.7 m -75.57 140.27 42.59 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.493 -1.004 . . . . 0.0 109.832 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -63.87 138.44 42.07 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.172 -1.571 . . . . 0.0 109.172 179.702 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 81.0 mmt-85 -59.37 -33.32 71.03 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.305 -1.115 . . . . 0.0 109.922 -179.656 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 86.1 p -60.91 -22.98 64.88 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.129 -0.982 . . . . 0.0 109.966 -179.532 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . 0.428 ' O ' ' CG ' ' A' ' 57' ' ' LYS . . . 110.03 77.55 0.95 Allowed Glycine 0 N--CA 1.496 2.636 0 N-CA-C 108.879 -1.688 . . . . 0.0 108.879 -179.586 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . 0.51 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 8.6 mtmp? -160.41 76.8 2.69 Favored Pre-proline 0 C--N 1.303 -1.455 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 -179.837 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.535 ' HA ' HG23 ' A' ' 52' ' ' THR . 81.8 Cg_exo -49.0 130.0 22.71 Favored 'Trans proline' 0 C--N 1.301 -1.945 0 C-N-CA 122.913 2.409 . . . . 0.0 112.614 -178.867 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.51 ' CD1' ' O ' ' A' ' 57' ' ' LYS . 8.3 mp -99.33 84.86 3.07 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.753 -0.592 . . . . 0.0 109.52 -179.697 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 99.2 m-70 -145.81 143.06 29.43 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.276 -0.89 . . . . 0.0 109.734 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 2.9 m-85 -102.33 17.03 24.48 Favored 'General case' 0 N--CA 1.493 1.724 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 179.317 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 91.7 mttt -81.01 158.84 25.01 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.303 -0.873 . . . . 0.0 109.885 -179.491 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . 0.455 ' H ' HG23 ' A' ' 171' ' ' VAL . 84.3 m-20 55.99 45.84 23.02 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.552 -0.717 . . . . 0.0 110.35 179.562 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.947 ' H ' HG22 ' A' ' 171' ' ' VAL . 66.7 p -98.74 153.35 18.8 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.143 -0.973 . . . . 0.0 108.616 179.077 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 28.6 t -122.3 145.06 48.6 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.37 -0.832 . . . . 0.0 109.664 -179.566 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 4.3 m-85 -72.7 129.04 37.31 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.314 -0.866 . . . . 0.0 109.034 179.782 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' HIS . . . . . 0.605 ' CD2' ' HE ' ' A' ' 68' ' ' ARG . 74.9 t60 -62.2 -49.94 73.79 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.358 -0.839 . . . . 0.0 110.116 -179.376 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.605 ' HE ' ' CD2' ' A' ' 67' ' ' HIS . 18.4 ptp180 -160.17 161.02 33.54 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.035 -1.041 . . . . 0.0 109.922 -179.982 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.556 HG21 HG22 ' A' ' 165' ' ' THR . 17.7 m -132.73 145.23 34.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.478 -0.764 . . . . 0.0 109.043 179.683 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 14.4 mt -148.17 129.5 7.2 Favored Pre-proline 0 N--CA 1.494 1.745 0 O-C-N 121.091 -1.005 . . . . 0.0 109.331 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -72.3 145.36 43.23 Favored 'Trans proline' 0 N--CA 1.492 1.393 0 C-N-CA 122.242 1.961 . . . . 0.0 112.379 179.849 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 82.25 -56.18 4.97 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.918 -1.273 . . . . 0.0 109.918 179.736 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -72.42 -86.16 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.117 -1.225 . . . . 0.0 109.874 -179.715 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' MET . . . . . 0.602 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 12.4 ptt? -179.52 -168.6 0.12 Allowed 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.236 -0.915 . . . . 0.0 109.759 -179.914 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -126.71 131.85 51.28 Favored 'General case' 0 N--CA 1.494 1.732 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.774 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 63.6 tt0 -103.07 126.4 50.23 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.151 -0.968 . . . . 0.0 109.908 -179.611 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -86.29 -174.03 49.38 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.242 -1.543 . . . . 0.0 109.242 179.548 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -138.35 154.9 23.19 Favored Glycine 0 N--CA 1.495 2.575 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.479 ' H ' ' HA2' ' A' ' 83' ' ' GLY . 88.4 m-20 -73.67 149.36 42.0 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.35 -1.088 . . . . 0.0 109.43 179.804 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 48.3 p90 -64.72 -26.33 68.32 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.161 -0.962 . . . . 0.0 109.437 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.504 ' O ' ' HB2' ' A' ' 82' ' ' ALA . 54.0 p -69.1 -29.08 67.09 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.165 -0.959 . . . . 0.0 109.462 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . 0.504 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 174.79 -55.11 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.386 -0.821 . . . . 0.0 109.254 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.479 ' HA2' ' H ' ' A' ' 79' ' ' ASP . . . 95.95 -6.5 66.9 Favored Glycine 0 N--CA 1.492 2.395 0 N-CA-C 109.658 -1.377 . . . . 0.0 109.658 179.878 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 78.5 m-20 -88.16 2.71 51.52 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.188 -1.184 . . . . 0.0 109.258 179.812 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 94.18 -6.61 72.32 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.321 -1.511 . . . . 0.0 109.321 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 59.0 p -75.15 -18.54 60.18 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.254 -1.145 . . . . 0.0 109.506 179.896 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -132.38 -128.47 2.92 Favored Glycine 0 N--CA 1.494 2.507 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.857 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 81.87 22.35 59.78 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.287 -1.525 . . . . 0.0 109.287 -179.856 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -57.96 145.43 35.91 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.339 -1.095 . . . . 0.0 109.669 -179.855 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 88.5 p -111.85 153.36 26.75 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.417 -0.802 . . . . 0.0 109.331 179.885 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 5.5 pt -63.56 -39.76 86.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.242 -0.911 . . . . 0.0 109.847 -179.76 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 3.1 m-30 -63.45 -38.87 92.8 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.089 -1.007 . . . . 0.0 109.459 179.758 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 76.7 19.03 78.39 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.282 -1.527 . . . . 0.0 109.282 -179.861 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -145.62 158.78 43.8 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.328 -1.101 . . . . 0.0 109.442 -179.853 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 62.9 mttp -85.01 153.62 22.64 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.336 -0.852 . . . . 0.0 109.709 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -100.68 133.12 45.61 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.41 -0.806 . . . . 0.0 109.1 179.775 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -83.47 119.73 25.04 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.162 -0.961 . . . . 0.0 109.684 -179.715 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 88.1 m-20 -75.55 143.09 42.61 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.283 -0.886 . . . . 0.0 109.259 179.638 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -153.29 -31.11 0.13 Allowed 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.174 -0.954 . . . . 0.0 110.05 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 84.6 m-20 -97.73 131.33 44.36 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.073 -1.017 . . . . 0.0 109.954 -179.579 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' PHE . . . . . 0.555 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 70.6 t80 -134.56 22.13 3.65 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 179.745 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 86.2 mt -56.77 -37.5 53.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.437 -0.79 . . . . 0.0 110.052 -179.512 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 56.6 mttm -83.34 138.27 33.6 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.008 -1.057 . . . . 0.0 109.891 -179.65 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 72.8 tttt -134.89 157.56 46.53 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.462 -0.774 . . . . 0.0 109.24 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' HIS . . . . . 0.542 ' O ' ' CG ' ' A' ' 105' ' ' HIS . 52.2 p-80 -68.02 83.5 0.22 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.12 -0.987 . . . . 0.0 109.271 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 57.0 p -77.04 -19.31 57.33 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.275 -0.891 . . . . 0.0 110.116 -179.54 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.423 ' O ' HG12 ' A' ' 110' ' ' ILE . . . -150.55 178.25 28.11 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 109.737 -1.345 . . . . 0.0 109.737 -179.654 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -74.9 156.72 43.46 Favored 'Trans proline' 0 C--N 1.306 -1.674 0 C-N-CA 123.027 2.484 . . . . 0.0 112.14 179.831 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 80.8 46.45 7.19 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 110.03 -1.228 . . . . 0.0 110.03 179.638 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.423 HG12 ' O ' ' A' ' 107' ' ' GLY . 32.9 mm -113.01 137.24 46.7 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.393 -1.063 . . . . 0.0 109.098 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.848 ' N ' HD22 ' A' ' 111' ' ' LEU . 2.3 mm? -89.88 131.81 35.61 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.261 -0.899 . . . . 0.0 109.836 -179.383 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 58.4 m -140.28 148.22 41.1 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.393 -0.817 . . . . 0.0 109.406 179.512 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' MET . . . . . 0.606 ' CE ' HD21 ' A' ' 121' ' ' ASN . 85.7 mtp -96.62 136.3 37.34 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.209 -0.932 . . . . 0.0 109.298 179.834 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . 0.55 ' O ' ' ND2' ' A' ' 115' ' ' ASN . . . -71.03 143.38 50.77 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.321 -0.862 . . . . 0.0 109.813 -179.872 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . 0.729 ' H ' ' CD2' ' A' ' 139' ' ' HIS . 18.8 m120 -148.44 113.26 5.41 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.306 -0.871 . . . . 0.0 108.861 179.506 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -68.24 -31.99 71.86 Favored 'General case' 0 C--N 1.299 -1.623 0 O-C-N 121.333 -0.854 . . . . 0.0 109.655 -179.896 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -137.63 171.47 23.23 Favored Glycine 0 N--CA 1.492 2.414 0 N-CA-C 109.326 -1.51 . . . . 0.0 109.326 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -67.29 151.89 80.12 Favored 'Trans proline' 0 C--N 1.305 -1.728 0 C-N-CA 122.753 2.302 . . . . 0.0 111.732 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 75.2 m-20 52.57 44.09 30.43 Favored 'General case' 0 C--N 1.299 -1.601 0 O-C-N 121.459 -0.776 . . . . 0.0 109.294 -179.811 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' THR . . . . . 0.471 ' O ' ' ND2' ' A' ' 115' ' ' ASN . 79.8 m -134.62 128.34 32.95 Favored 'General case' 0 C--N 1.304 -1.394 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 179.875 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' ASN . . . . . 0.606 HD21 ' CE ' ' A' ' 113' ' ' MET . 21.2 t-20 -96.76 109.22 21.94 Favored 'General case' 0 C--N 1.297 -1.677 0 O-C-N 121.479 -0.763 . . . . 0.0 109.294 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -84.48 123.85 6.43 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.642 -1.383 . . . . 0.0 109.642 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 22.6 m -59.46 -33.29 71.11 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.347 -1.09 . . . . 0.0 109.542 179.806 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.8 mt-30 -75.96 144.12 41.17 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.233 -0.917 . . . . 0.0 109.926 -179.636 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 48.6 p90 -137.8 160.92 37.94 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.429 -0.794 . . . . 0.0 109.109 179.684 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.602 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 52.3 p90 -142.53 159.64 41.83 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.147 -0.971 . . . . 0.0 110.012 -179.759 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 4.6 mp -119.68 138.77 49.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.474 -0.766 . . . . 0.0 109.049 179.695 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 17.1 t -121.04 126.74 50.64 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.236 -0.915 . . . . 0.0 109.599 -179.909 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -106.91 15.76 25.06 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.544 -0.722 . . . . 0.0 109.204 179.864 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -141.08 161.21 38.4 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.315 -0.866 . . . . 0.0 109.316 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 64.0 tttm -64.76 132.22 48.96 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.175 -0.953 . . . . 0.0 109.439 -179.79 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 58.6 p -147.66 69.86 1.15 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.287 -0.883 . . . . 0.0 109.24 -179.898 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -58.39 -37.85 76.14 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.295 -0.878 . . . . 0.0 110.033 -179.581 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 0.8 OUTLIER -61.46 -43.94 97.98 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.024 -1.047 . . . . 0.0 109.443 -179.875 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 28.3 mt -65.47 -30.81 71.63 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.186 -0.946 . . . . 0.0 109.754 179.326 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . 0.502 ' CB ' ' CE1' ' A' ' 105' ' ' HIS . 23.2 t70 -76.05 121.24 22.49 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.231 -0.918 . . . . 0.0 109.659 -179.627 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 178.61 -101.84 0.16 Allowed Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.202 -1.559 . . . . 0.0 109.202 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 33.4 mmtm -58.15 -28.56 64.82 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.327 -1.102 . . . . 0.0 109.058 179.506 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 139' ' ' HIS . . . . . 0.729 ' CD2' ' H ' ' A' ' 115' ' ' ASN . 56.3 m170 -83.78 153.2 24.24 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.348 -0.845 . . . . 0.0 109.479 -179.831 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 20.2 m -127.44 160.76 36.15 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 121.516 -0.74 . . . . 0.0 109.278 -179.858 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . 0.478 HG23 ' O ' ' A' ' 141' ' ' VAL . 21.5 m -96.69 129.25 47.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.245 -0.91 . . . . 0.0 109.519 -179.732 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . 0.546 ' HA ' HG21 ' A' ' 35' ' ' THR . 44.0 p90 -113.03 -9.07 13.61 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.189 -0.944 . . . . 0.0 110.271 -179.913 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -158.45 177.49 35.08 Favored Glycine 0 N--CA 1.492 2.41 0 C-N-CA 119.567 -1.302 . . . . 0.0 109.87 179.703 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . 0.403 ' HG2' ' N ' ' A' ' 145' ' ' VAL . 47.8 tt0 -139.63 158.78 43.53 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.303 -1.116 . . . . 0.0 109.633 -179.549 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . 0.511 HG23 HD21 ' A' ' 111' ' ' LEU . 13.2 t -94.73 134.07 33.44 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.235 0 O-C-N 121.042 -1.036 . . . . 0.0 109.241 179.666 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 17.4 m -112.03 -26.14 3.22 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.407 -0.808 . . . . 0.0 109.512 179.607 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 94.9 mt-10 -145.78 173.07 12.43 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.238 -0.914 . . . . 0.0 109.541 -179.878 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 98.51 2.35 57.64 Favored Glycine 0 N--CA 1.494 2.511 0 N-CA-C 110.085 -1.206 . . . . 0.0 110.085 179.486 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 149' ' ' MET . . . . . 0.467 ' O ' HG12 ' A' ' 152' ' ' VAL . 65.1 mtt -61.15 -33.07 72.82 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.035 -1.274 . . . . 0.0 109.736 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 89.1 m-20 -64.91 -42.13 94.99 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 120.765 -1.209 . . . . 0.0 110.036 -179.556 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.7 p -82.6 -34.46 11.83 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.078 -1.014 . . . . 0.0 110.485 -179.313 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 152' ' ' VAL . . . . . 0.467 HG12 ' O ' ' A' ' 149' ' ' MET . 0.8 OUTLIER -54.92 -41.82 60.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 120.963 -1.086 . . . . 0.0 109.188 -179.323 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 153' ' ' LYS . . . . . 0.453 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 59.1 mttp -64.25 -34.17 77.49 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.263 -0.898 . . . . 0.0 109.473 179.393 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -62.26 -37.36 85.15 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.308 -0.87 . . . . 0.0 110.217 -179.398 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 79.5 mt -71.96 -36.99 59.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.054 -1.029 . . . . 0.0 110.059 -179.752 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -74.08 -41.75 61.22 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.135 -0.978 . . . . 0.0 111.227 -178.706 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 17.4 pttp -61.69 -33.72 74.51 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 120.749 -1.219 . . . . 0.0 109.734 -179.001 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 27.2 m -86.39 -1.15 7.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.119 -0.988 . . . . 0.0 109.044 179.501 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -74.7 174.22 51.13 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.782 -1.327 . . . . 0.0 109.782 -179.706 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 97.0 p -152.33 162.94 40.44 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.328 -1.101 . . . . 0.0 109.942 -179.64 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 22.8 t -58.9 -31.49 68.66 Favored 'General case' 0 N--CA 1.488 1.441 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 179.297 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 23.1 t -55.96 -30.46 61.76 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.427 -0.796 . . . . 0.0 109.069 179.729 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 100.42 10.12 45.43 Favored Glycine 0 N--CA 1.493 2.489 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 179.784 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 34.5 mmt180 -118.26 147.63 43.24 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.224 -1.162 . . . . 0.0 109.282 179.713 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 165' ' ' THR . . . . . 0.556 HG22 HG21 ' A' ' 69' ' ' VAL . 82.1 p -81.64 152.72 27.0 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.364 -0.835 . . . . 0.0 109.384 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -65.98 -34.27 77.71 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.289 -0.882 . . . . 0.0 109.587 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 62.1 mttm -118.22 162.08 18.84 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.467 -0.77 . . . . 0.0 109.656 -179.664 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 62.8 mttp -75.15 142.44 43.56 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.355 -0.841 . . . . 0.0 109.594 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 1.8 m -133.45 124.67 49.0 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.308 -0.87 . . . . 0.0 109.738 179.763 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 88.8 t -139.45 142.26 33.49 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.461 -0.774 . . . . 0.0 109.395 179.769 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.947 HG22 ' H ' ' A' ' 64' ' ' SER . 3.0 m -71.69 124.84 29.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.014 -1.054 . . . . 0.0 109.55 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 77.9 mm-40 -70.88 -37.72 73.04 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.09 -1.006 . . . . 0.0 110.251 -179.669 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 173' ' ' ASP . . . . . 0.463 ' OD1' ' N ' ' A' ' 174' ' ' CYS . 49.5 t0 -164.84 166.62 19.54 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.063 -1.023 . . . . 0.0 110.032 -179.668 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 174' ' ' CYS . . . . . 0.463 ' N ' ' OD1' ' A' ' 173' ' ' ASP . 12.3 p -141.59 152.34 43.96 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.395 -0.815 . . . . 0.0 109.366 179.803 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -175.52 178.92 47.0 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.649 -1.38 . . . . 0.0 109.649 179.937 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 176' ' ' GLN . . . . . 0.712 HE22 ' NE ' ' A' ' 43' ' ' ARG . 63.3 tt0 -108.12 127.89 54.21 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.373 -1.075 . . . . 0.0 109.528 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 177' ' ' LEU . . . . . 0.603 HD13 ' O ' ' A' ' 177' ' ' LEU . 0.2 OUTLIER -61.24 -38.8 87.94 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.22 -0.925 . . . . 0.0 108.718 179.694 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 9.6 t . . . . . 0 N--CA 1.49 1.544 0 CA-C-O 117.979 -1.01 . . . . 0.0 109.47 179.81 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.529 4.867 0 N-CA-C 119.425 2.53 . . . . 0.0 119.425 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 23.2 m -57.6 -35.04 69.91 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.257 -1.143 . . . . 0.0 109.495 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 67.4 t80 -108.3 120.84 43.54 Favored 'General case' 0 N--CA 1.484 1.271 0 O-C-N 121.372 -0.83 . . . . 0.0 108.969 179.646 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 8.5 t -137.07 158.26 44.86 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.674 -0.641 . . . . 0.0 109.468 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 165.42 -108.91 0.34 Allowed Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 -179.879 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 57.3 p -67.45 164.65 18.29 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.219 -1.165 . . . . 0.0 109.4 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 25.5 mtm -57.21 149.7 45.72 Favored Pre-proline 0 N--CA 1.489 1.486 0 O-C-N 121.251 -0.905 . . . . 0.0 109.358 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -62.02 -31.38 83.87 Favored 'Trans proline' 0 N--CA 1.493 1.498 0 C-N-CA 122.413 2.076 . . . . 0.0 112.316 -179.558 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.459 ' ND2' ' O ' ' A' ' 10' ' ' PRO . 1.5 t30 -169.41 139.36 1.74 Allowed Pre-proline 0 N--CA 1.49 1.543 0 O-C-N 121.151 -0.968 . . . . 0.0 109.362 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.459 ' O ' ' ND2' ' A' ' 9' ' ' ASN . 53.1 Cg_endo -68.34 140.22 47.87 Favored 'Trans proline' 0 N--CA 1.496 1.645 0 C-N-CA 122.424 2.082 . . . . 0.0 112.211 179.826 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 58.6 mtm180 -132.26 132.44 43.04 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.436 -0.79 . . . . 0.0 109.018 179.537 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.5 p -135.91 143.95 34.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.316 -0.865 . . . . 0.0 109.311 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 33.2 p90 -139.4 152.69 47.3 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.33 -0.856 . . . . 0.0 109.792 -179.633 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 94.3 m-85 -123.26 128.65 50.26 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.595 -0.69 . . . . 0.0 109.546 179.475 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.4 t0 -90.31 119.05 30.28 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.14 -0.975 . . . . 0.0 108.94 179.303 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' MET . . . . . 0.411 ' CE ' ' CE1' ' A' ' 66' ' ' PHE . 67.0 mtp -117.13 143.32 45.95 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.217 -0.927 . . . . 0.0 110.375 -179.315 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.465 ' HG ' ' CD ' ' A' ' 172' ' ' GLU . 50.8 m -132.16 155.14 48.71 Favored 'General case' 0 N--CA 1.491 1.612 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 179.639 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.433 HG23 ' O ' ' A' ' 18' ' ' VAL . 25.4 m -114.87 132.53 63.81 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.234 -0.917 . . . . 0.0 109.657 -179.765 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 65.86 9.9 48.33 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 179.836 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 93.36 -3.89 72.86 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.302 -1.519 . . . . 0.0 109.302 -179.951 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 33.9 mt-30 -99.11 128.39 32.18 Favored Pre-proline 0 N--CA 1.492 1.634 0 O-C-N 121.371 -1.076 . . . . 0.0 109.071 179.806 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 76.1 Cg_exo -43.69 130.11 7.3 Favored 'Trans proline' 0 C--N 1.312 -1.387 0 C-N-CA 122.12 1.88 . . . . 0.0 112.126 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -104.07 -65.25 1.03 Allowed 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.375 -0.828 . . . . 0.0 109.345 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -169.46 -171.21 34.87 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 92.2 mtm-85 -114.1 143.13 45.29 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.385 -1.068 . . . . 0.0 109.465 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 76.4 mt -120.95 117.84 54.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 179.091 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 41.8 t -116.38 132.8 64.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.552 -0.718 . . . . 0.0 109.327 -179.541 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 73.1 mtm -121.48 149.88 42.41 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.464 -0.772 . . . . 0.0 109.209 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -99.88 129.82 46.0 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.24 -0.912 . . . . 0.0 109.822 -179.636 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.429 ' N ' ' CD2' ' A' ' 30' ' ' LEU . 2.5 mm? -105.84 130.75 53.75 Favored 'General case' 0 N--CA 1.493 1.682 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.376 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -94.91 119.33 33.28 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.111 -0.993 . . . . 0.0 109.205 179.739 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -82.14 -42.67 18.76 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.361 -0.837 . . . . 0.0 109.803 -179.764 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -67.19 -44.74 78.88 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.278 -0.889 . . . . 0.0 110.514 -179.266 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . 0.441 HG21 ' HE2' ' A' ' 103' ' ' LYS . 23.2 m -66.93 -45.35 78.14 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.175 -0.953 . . . . 0.0 109.959 -179.296 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 68.9 p -150.39 83.32 6.0 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 121.285 -0.884 . . . . 0.0 109.468 -179.691 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -70.92 -44.36 1.32 Allowed 'Trans proline' 0 C--N 1.308 -1.595 0 C-N-CA 122.19 1.927 . . . . 0.0 112.087 -179.702 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.431 ' O ' ' OH ' ' A' ' 92' ' ' TYR . 25.4 mtp180 -62.59 -39.63 94.32 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.465 -0.772 . . . . 0.0 110.201 -179.862 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 32.4 m -66.07 -41.76 90.3 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.116 -0.99 . . . . 0.0 110.086 -179.736 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -61.81 -31.04 71.24 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.228 -0.92 . . . . 0.0 109.324 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -68.19 -37.7 81.22 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.219 -0.926 . . . . 0.0 109.85 -179.755 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . 0.41 ' O ' HD23 ' A' ' 45' ' ' LEU . 51.9 t30 -57.45 -42.16 81.97 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.205 -0.935 . . . . 0.0 109.79 -179.437 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 -86.13 -48.07 8.93 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.151 -0.968 . . . . 0.0 109.754 -179.842 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 40.2 ttp180 -57.87 -39.47 77.88 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.457 -0.777 . . . . 0.0 110.3 -179.482 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.506 ' O ' ' N ' ' A' ' 48' ' ' GLY . . . -64.31 -43.13 95.66 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.04 -1.038 . . . . 0.0 110.451 -179.117 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.497 HD13 ' HB3' ' A' ' 59' ' ' LEU . 2.8 mm? -65.19 -40.02 93.66 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.008 -1.057 . . . . 0.0 109.655 -179.852 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' CYS . . . . . . . . . . . . . 75.7 m -69.22 -49.54 55.53 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.023 -1.048 . . . . 0.0 109.444 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 73.9 p -74.07 -34.04 63.89 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.18 -0.95 . . . . 0.0 109.554 179.828 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.506 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 75.22 35.22 49.4 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 110.395 -1.082 . . . . 0.0 110.395 179.643 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -61.53 -37.26 83.1 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.005 -1.291 . . . . 0.0 109.235 179.836 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 48.2 mmtm -61.76 -33.59 74.35 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.343 -0.848 . . . . 0.0 109.384 179.783 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 94.35 167.54 36.98 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.295 -1.522 . . . . 0.0 109.295 -179.762 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.525 HG23 ' HA ' ' A' ' 58' ' ' PRO . 99.2 m -80.2 141.05 36.01 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.293 -1.121 . . . . 0.0 109.729 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -59.03 137.55 50.35 Favored Glycine 0 N--CA 1.489 2.173 0 N-CA-C 109.305 -1.518 . . . . 0.0 109.305 179.764 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 74.5 mtt85 -58.99 -35.35 73.07 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.294 -1.121 . . . . 0.0 109.913 -179.701 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 22.9 t -57.67 -31.9 66.79 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.25 -0.906 . . . . 0.0 109.887 -179.769 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 117.86 91.22 1.49 Allowed Glycine 0 N--CA 1.495 2.626 0 N-CA-C 108.896 -1.681 . . . . 0.0 108.896 -179.503 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . 0.492 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 78.6 tttt -176.62 80.21 0.27 Allowed Pre-proline 0 N--CA 1.488 1.459 0 O-C-N 121.546 -0.973 . . . . 0.0 108.442 -179.666 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.525 ' HA ' HG23 ' A' ' 52' ' ' THR . 72.5 Cg_exo -48.99 134.51 29.2 Favored 'Trans proline' 0 C--N 1.304 -1.794 0 C-N-CA 122.727 2.285 . . . . 0.0 112.457 -179.097 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.497 ' HB3' HD13 ' A' ' 45' ' ' LEU . 7.7 mp -100.5 71.67 1.54 Allowed 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.621 -0.674 . . . . 0.0 109.4 -179.557 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 79.9 m80 -147.06 130.52 16.73 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.197 -0.939 . . . . 0.0 109.887 179.902 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 58.8 m-85 -72.67 -5.04 34.83 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.119 -0.988 . . . . 0.0 108.402 178.748 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 50.4 tttt -53.54 140.58 28.01 Favored 'General case' 0 N--CA 1.487 1.409 0 O-C-N 121.622 -0.674 . . . . 0.0 109.973 -179.501 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 53.7 t0 56.97 43.5 24.52 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.572 -0.705 . . . . 0.0 110.28 179.646 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.739 ' H ' ' CG1' ' A' ' 171' ' ' VAL . 95.6 p -109.79 150.33 28.52 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.157 -0.965 . . . . 0.0 108.68 179.094 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 38.4 t -102.97 141.42 35.81 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.171 -0.956 . . . . 0.0 109.004 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.411 ' CE1' ' CE ' ' A' ' 16' ' ' MET . 3.2 m-85 -66.66 138.72 57.64 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.291 -0.88 . . . . 0.0 109.021 -179.728 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 81.5 t60 -59.05 -52.19 66.81 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.299 -0.876 . . . . 0.0 110.298 -178.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 15.5 ptm180 -166.68 164.01 16.72 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.083 -1.011 . . . . 0.0 109.952 -179.807 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.519 HG21 HG22 ' A' ' 165' ' ' THR . 33.9 m -131.98 147.86 32.3 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.48 -0.762 . . . . 0.0 109.169 179.678 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.408 HG21 HD13 ' A' ' 70' ' ' ILE . 11.6 mt -147.74 108.24 3.77 Favored Pre-proline 0 N--CA 1.492 1.648 0 O-C-N 120.965 -1.084 . . . . 0.0 109.74 179.72 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_exo -54.09 146.04 50.44 Favored 'Trans proline' 0 N--CA 1.493 1.485 0 C-N-CA 122.427 2.085 . . . . 0.0 112.448 179.723 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 77.57 -57.81 3.78 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 110.212 -1.155 . . . . 0.0 110.212 179.273 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 95.5 m-85 -69.67 -83.85 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.166 -1.197 . . . . 0.0 109.819 -179.498 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' MET . . . . . 0.471 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 12.2 ptp -178.93 -172.36 0.25 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.255 -0.903 . . . . 0.0 109.59 -179.764 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -127.76 137.15 52.33 Favored 'General case' 0 N--CA 1.494 1.746 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 179.734 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 93.5 mt-30 -110.63 154.46 23.76 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.256 -0.902 . . . . 0.0 109.603 -179.619 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -160.83 -166.93 20.56 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.426 -1.47 . . . . 0.0 109.426 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 88.74 23.66 35.28 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.439 ' C ' ' OD1' ' A' ' 79' ' ' ASP . 54.6 p30 -84.13 10.54 9.9 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.179 -1.189 . . . . 0.0 109.377 179.922 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 85.2 t80 -53.25 -46.25 69.12 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.36 -0.837 . . . . 0.0 109.804 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.579 ' O ' ' HB2' ' A' ' 82' ' ' ALA . 71.9 p -71.17 -28.71 64.45 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.013 -1.055 . . . . 0.0 109.568 179.906 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . 0.579 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 171.26 -57.46 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.205 -0.935 . . . . 0.0 109.405 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 93.65 1.51 65.89 Favored Glycine 0 N--CA 1.492 2.402 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 -180.0 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 23.6 m120 -86.61 6.31 31.57 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.244 -1.15 . . . . 0.0 109.446 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 95.79 -39.13 2.91 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.327 -1.509 . . . . 0.0 109.327 -179.781 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 52.2 p -74.14 -16.14 61.01 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.336 -1.096 . . . . 0.0 109.055 179.594 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -82.85 -167.25 40.7 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.671 -1.372 . . . . 0.0 109.671 -179.913 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.555 ' N ' ' OG1' ' A' ' 81' ' ' THR . . . 83.85 38.42 10.47 Favored Glycine 0 N--CA 1.488 2.104 0 N-CA-C 109.154 -1.578 . . . . 0.0 109.154 -179.708 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -57.42 144.87 34.77 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.46 -1.024 . . . . 0.0 109.671 -179.774 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 96.4 p -112.26 150.24 31.23 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.449 -0.782 . . . . 0.0 109.191 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 24.0 pt -70.82 -31.48 45.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.171 -0.956 . . . . 0.0 110.059 -179.684 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . 0.431 ' OH ' ' O ' ' A' ' 37' ' ' ARG . 59.2 m-85 -65.38 -37.99 88.68 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.166 -0.959 . . . . 0.0 109.7 -179.65 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 73.22 15.63 78.75 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -148.16 158.72 44.23 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.301 -1.117 . . . . 0.0 109.455 -179.834 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 63.4 mttp -84.95 150.29 25.03 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.366 -0.834 . . . . 0.0 109.473 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 55.4 p90 -132.25 160.52 35.94 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.279 -0.888 . . . . 0.0 109.538 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -110.52 154.18 24.06 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.496 -0.752 . . . . 0.0 109.723 -179.801 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 60.3 t0 -78.48 124.13 27.8 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.264 -0.897 . . . . 0.0 109.306 179.76 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 78.5 mm-40 -60.88 -37.49 82.35 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.278 -0.889 . . . . 0.0 110.003 -179.457 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 19.1 t-20 -166.51 171.11 12.14 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.95 -1.094 . . . . 0.0 109.943 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -109.81 44.09 1.25 Allowed 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.521 -0.737 . . . . 0.0 109.373 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 89.0 mt -52.32 -41.84 35.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.105 -0.997 . . . . 0.0 109.818 -179.514 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . 0.441 ' HE2' HG21 ' A' ' 34' ' ' THR . 59.6 mttm -91.72 144.42 25.53 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.144 -0.972 . . . . 0.0 109.756 -179.686 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 80.2 tttt -134.38 159.13 42.01 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.371 -0.831 . . . . 0.0 109.444 -179.788 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' HIS . . . . . 0.526 ' CE1' ' O ' ' A' ' 107' ' ' GLY . 70.7 t60 -89.63 111.29 22.2 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.304 -0.873 . . . . 0.0 109.264 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 48.2 p -125.86 1.22 7.37 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.364 -0.835 . . . . 0.0 109.942 -179.797 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.526 ' O ' ' CE1' ' A' ' 105' ' ' HIS . . . -155.62 170.32 33.53 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.811 -1.316 . . . . 0.0 109.811 -179.771 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -75.07 156.24 42.68 Favored 'Trans proline' 0 C--N 1.308 -1.573 0 C-N-CA 123.026 2.484 . . . . 0.0 112.213 179.614 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 84.15 43.27 7.16 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 110.328 -1.109 . . . . 0.0 110.328 179.51 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 37.1 mm -115.25 134.41 58.47 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.834 0 O-C-N 121.312 -1.111 . . . . 0.0 109.172 179.592 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.72 ' N ' HD22 ' A' ' 111' ' ' LEU . 2.9 mm? -90.36 124.91 35.31 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.237 -0.915 . . . . 0.0 109.22 179.903 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 50.4 m -137.95 144.96 41.46 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.208 -0.933 . . . . 0.0 109.779 179.806 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 87.8 mtp -90.35 131.41 36.15 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.352 -0.842 . . . . 0.0 109.114 179.429 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . 0.409 ' O ' ' OD1' ' A' ' 115' ' ' ASN . . . -65.73 143.76 57.32 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.195 -0.94 . . . . 0.0 109.513 -179.829 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . 0.409 ' OD1' ' O ' ' A' ' 114' ' ' ALA . 72.2 m-20 -144.22 113.31 6.85 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.174 -0.954 . . . . 0.0 108.976 179.601 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -70.22 -30.03 67.01 Favored 'General case' 0 C--N 1.297 -1.691 0 O-C-N 121.465 -0.772 . . . . 0.0 109.581 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -140.33 167.16 25.58 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.486 -1.446 . . . . 0.0 109.486 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . 0.533 ' O ' ' ND2' ' A' ' 119' ' ' ASN . 41.0 Cg_endo -67.26 158.36 57.33 Favored 'Trans proline' 0 C--N 1.305 -1.726 0 C-N-CA 122.875 2.383 . . . . 0.0 111.893 179.952 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' ASN . . . . . 0.533 ' ND2' ' O ' ' A' ' 118' ' ' PRO . 9.5 p30 45.41 45.44 10.18 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.514 -0.741 . . . . 0.0 109.543 -179.898 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 89.4 m -134.61 132.26 38.81 Favored 'General case' 0 C--N 1.305 -1.332 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 179.684 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 43.3 p-10 -64.82 162.86 15.32 Favored 'General case' 0 C--N 1.295 -1.768 0 O-C-N 121.343 -0.848 . . . . 0.0 109.309 -179.807 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -109.74 101.47 1.45 Allowed Glycine 0 N--CA 1.494 2.517 0 N-CA-C 109.83 -1.308 . . . . 0.0 109.83 -179.7 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 86.1 p -63.12 -28.15 69.87 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.215 -1.167 . . . . 0.0 109.059 179.543 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.0 mt-30 -125.98 158.31 35.61 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.545 -0.722 . . . . 0.0 109.204 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 49.0 p90 -134.53 163.05 30.58 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.268 -0.895 . . . . 0.0 109.51 -179.925 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.471 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 48.3 p90 -134.44 157.54 46.18 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.312 -0.867 . . . . 0.0 109.414 179.927 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 61.5 mt -122.97 134.35 66.38 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 O-C-N 121.391 -0.818 . . . . 0.0 109.581 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 2.9 t -108.68 125.2 51.63 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.211 -0.931 . . . . 0.0 109.155 179.65 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . 0.448 ' OG1' ' OE1' ' A' ' 156' ' ' GLU . 7.3 p -114.22 18.05 17.27 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.388 -0.82 . . . . 0.0 109.61 -179.656 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -145.84 162.32 37.98 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.144 -0.973 . . . . 0.0 109.883 -179.548 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 62.5 tttm -59.87 134.11 56.72 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.365 -0.834 . . . . 0.0 109.093 179.863 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . 0.437 ' OG1' ' OD1' ' A' ' 136' ' ' ASP . 21.9 p -79.17 105.48 10.53 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.26 -0.9 . . . . 0.0 109.909 -179.485 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -66.21 -38.39 87.85 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.087 -1.008 . . . . 0.0 108.672 179.198 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 20.4 p90 -155.31 6.55 0.24 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.44 -0.787 . . . . 0.0 109.968 179.458 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . 0.607 ' N ' HD22 ' A' ' 135' ' ' LEU . 3.5 mm? -68.65 -28.01 66.51 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.027 -1.045 . . . . 0.0 109.328 179.562 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . 0.437 ' OD1' ' OG1' ' A' ' 132' ' ' THR . 93.8 m-20 -52.38 144.85 12.27 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.357 -0.839 . . . . 0.0 110.025 -179.336 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 171.02 -128.38 1.6 Allowed Glycine 0 N--CA 1.489 2.202 0 N-CA-C 108.793 -1.723 . . . . 0.0 108.793 -179.909 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 4.3 mptp? -89.86 123.06 33.49 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.077 -1.249 . . . . 0.0 108.851 179.376 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 32.0 p80 -168.96 159.37 9.33 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.181 -0.95 . . . . 0.0 109.745 -179.787 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 38.9 t -123.46 136.65 59.34 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 O-C-N 121.389 -0.819 . . . . 0.0 109.317 179.896 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . 0.451 HG23 ' O ' ' A' ' 141' ' ' VAL . 17.6 m -108.58 131.41 59.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.231 -0.918 . . . . 0.0 109.014 179.77 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 39.7 p90 -117.01 -4.08 11.53 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.407 -0.808 . . . . 0.0 109.992 -179.609 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -165.53 179.2 40.04 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.648 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.2 pt20 -144.3 165.28 28.33 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.186 -1.185 . . . . 0.0 109.661 -179.787 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 60.4 t -97.56 130.1 46.73 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.224 0 O-C-N 121.269 -0.894 . . . . 0.0 109.449 -179.92 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 16.3 m -106.06 -32.45 2.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.37 -0.832 . . . . 0.0 109.48 179.612 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -144.6 174.37 11.01 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.174 -0.954 . . . . 0.0 109.526 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 99.12 1.21 57.06 Favored Glycine 0 N--CA 1.494 2.509 0 N-CA-C 109.974 -1.25 . . . . 0.0 109.974 179.569 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 149' ' ' MET . . . . . 0.436 ' O ' HG12 ' A' ' 152' ' ' VAL . 65.1 mtt -60.93 -34.16 74.28 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.105 -1.232 . . . . 0.0 109.718 179.945 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -64.51 -42.77 95.59 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.89 -1.131 . . . . 0.0 110.138 -179.576 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.7 p -83.08 -34.04 10.87 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.113 -0.992 . . . . 0.0 110.518 -179.486 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 152' ' ' VAL . . . . . 0.459 ' CG1' ' N ' ' A' ' 153' ' ' LYS . 0.6 OUTLIER -55.52 -41.65 64.53 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 120.889 -1.132 . . . . 0.0 109.122 -179.36 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 153' ' ' LYS . . . . . 0.459 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 57.3 mttp -63.23 -33.63 75.91 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.281 -0.887 . . . . 0.0 109.486 179.417 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -62.26 -40.52 96.49 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.327 -0.858 . . . . 0.0 109.873 -179.575 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 78.4 mt -72.92 -34.34 45.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.083 -1.011 . . . . 0.0 109.61 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . 0.448 ' OE1' ' OG1' ' A' ' 129' ' ' THR . 78.9 tt0 -75.95 -42.33 48.93 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.216 -0.928 . . . . 0.0 111.258 -178.796 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 43.2 pttt -61.84 -33.9 74.98 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 120.808 -1.183 . . . . 0.0 109.985 -178.831 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 34.5 m -80.34 -10.29 12.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.136 -0.978 . . . . 0.0 109.249 179.73 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -71.28 165.11 53.59 Favored Glycine 0 N--CA 1.488 2.163 0 N-CA-C 110.074 -1.21 . . . . 0.0 110.074 -179.487 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 22.8 t -155.17 171.39 19.88 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.537 -0.978 . . . . 0.0 109.34 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 24.9 m -54.44 -29.64 50.07 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.199 -0.938 . . . . 0.0 109.346 179.891 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 87.1 p -57.8 -26.6 62.18 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.282 -0.886 . . . . 0.0 109.663 -179.759 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 89.65 15.52 58.12 Favored Glycine 0 N--CA 1.493 2.437 0 N-CA-C 109.823 -1.311 . . . . 0.0 109.823 179.746 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 61.6 ttt180 -126.72 140.67 52.21 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.226 -1.161 . . . . 0.0 109.489 -179.941 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 165' ' ' THR . . . . . 0.519 HG22 HG21 ' A' ' 69' ' ' VAL . 68.7 p -75.08 148.66 39.56 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.157 -0.965 . . . . 0.0 109.279 179.813 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -66.12 -39.3 89.81 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.243 -0.911 . . . . 0.0 109.542 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -103.2 155.68 18.26 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.321 -0.862 . . . . 0.0 109.45 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 64.2 mttp -73.74 130.8 40.71 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.222 -0.924 . . . . 0.0 109.197 179.832 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 13.7 t -128.15 125.02 63.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.142 -0.974 . . . . 0.0 109.515 -179.827 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 62.7 t -142.08 135.01 28.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.267 -0.896 . . . . 0.0 109.343 179.332 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.739 ' CG1' ' H ' ' A' ' 64' ' ' SER . 0.4 OUTLIER -63.58 116.01 2.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.213 -0.929 . . . . 0.0 108.923 179.88 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 172' ' ' GLU . . . . . 0.507 ' O ' ' OD1' ' A' ' 173' ' ' ASP . 96.7 mt-10 -70.64 -40.6 72.99 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.04 -1.037 . . . . 0.0 110.649 -179.531 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 173' ' ' ASP . . . . . 0.507 ' OD1' ' O ' ' A' ' 172' ' ' GLU . 80.5 m-20 -145.13 159.03 43.62 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.08 -1.013 . . . . 0.0 110.377 -179.255 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 53.3 t -145.04 141.84 29.22 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.507 -0.746 . . . . 0.0 109.286 179.474 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -175.73 179.48 46.87 Favored Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.879 -1.288 . . . . 0.0 109.879 179.839 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 6.9 tt0 -107.87 121.75 45.4 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.32 -1.106 . . . . 0.0 109.608 -179.891 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 30.8 tp -62.66 -37.81 87.87 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.183 -0.948 . . . . 0.0 109.317 179.675 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 3.0 t . . . . . 0 N--CA 1.49 1.564 0 CA-C-O 117.977 -1.011 . . . . 0.0 109.439 -179.872 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.529 4.851 0 N-CA-C 119.347 2.499 . . . . 0.0 119.347 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 35.4 m -57.74 -34.01 69.07 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.17 -1.194 . . . . 0.0 109.472 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 50.6 p90 -143.27 162.24 36.19 Favored 'General case' 0 C--N 1.307 -1.253 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 179.663 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 18.7 p -121.65 162.5 20.59 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.645 -0.66 . . . . 0.0 109.505 -179.895 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 88.4 176.86 47.26 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 -179.947 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 28.7 t -146.27 146.87 30.9 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.293 -1.122 . . . . 0.0 109.505 -179.945 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 13.9 mmt -129.44 71.31 82.08 Favored Pre-proline 0 N--CA 1.493 1.721 0 O-C-N 121.482 -0.761 . . . . 0.0 109.432 179.846 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 87.6 Cg_endo -81.11 166.19 18.78 Favored 'Trans proline' 0 C--N 1.307 -1.646 0 C-N-CA 122.889 2.393 . . . . 0.0 112.277 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 -69.9 150.56 96.41 Favored Pre-proline 0 N--CA 1.491 1.592 0 O-C-N 121.355 -0.841 . . . . 0.0 109.06 179.85 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 78.2 Cg_endo -74.47 89.0 1.12 Allowed 'Trans proline' 0 C--N 1.311 -1.441 0 C-N-CA 122.48 2.12 . . . . 0.0 112.111 179.896 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 89.7 mtt-85 -72.02 134.61 45.98 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.306 -0.871 . . . . 0.0 109.578 -179.913 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.0 p -137.7 142.43 36.4 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.367 -0.833 . . . . 0.0 108.99 179.717 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 42.2 p90 -145.89 155.45 42.88 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.234 -0.916 . . . . 0.0 109.844 -179.671 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 91.1 m-85 -125.1 137.96 54.18 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.432 -0.793 . . . . 0.0 109.467 179.444 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 61.3 t0 -89.03 117.61 28.16 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.2 -0.938 . . . . 0.0 108.511 178.831 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' MET . . . . . 0.466 ' SD ' HD12 ' A' ' 26' ' ' ILE . 78.2 mtp -106.32 150.8 25.61 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.147 -0.97 . . . . 0.0 110.52 -178.997 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 84.6 p -146.5 168.65 20.69 Favored 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 109.02 -0.734 . . . . 0.0 109.02 179.822 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.437 ' O ' ' N ' ' A' ' 20' ' ' GLY . 27.2 m -126.09 155.85 36.1 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.804 0 O-C-N 121.267 -0.896 . . . . 0.0 109.457 -179.879 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -49.47 96.61 0.01 OUTLIER Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.366 -1.494 . . . . 0.0 109.366 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.437 ' N ' ' O ' ' A' ' 18' ' ' VAL . . . 150.88 -84.82 0.16 Allowed Glycine 0 N--CA 1.493 2.438 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 -179.93 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 12.9 mt-30 -139.36 160.67 60.98 Favored Pre-proline 0 N--CA 1.494 1.741 0 O-C-N 121.357 -1.084 . . . . 0.0 109.037 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_exo -47.74 134.15 22.22 Favored 'Trans proline' 0 C--N 1.312 -1.392 0 C-N-CA 122.251 1.967 . . . . 0.0 112.247 179.739 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -89.58 -60.32 1.97 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.303 -0.873 . . . . 0.0 109.578 -179.86 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 176.05 -166.99 38.46 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.7 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 35.8 ptt-85 -126.01 149.22 48.98 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.466 -1.02 . . . . 0.0 109.143 179.818 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.466 HD12 ' SD ' ' A' ' 16' ' ' MET . 89.3 mt -122.3 130.32 74.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.287 -0.883 . . . . 0.0 109.346 -179.893 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 44.1 t -109.95 132.61 57.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.444 -0.785 . . . . 0.0 109.427 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 74.8 mtm -119.95 147.13 45.13 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.424 -0.798 . . . . 0.0 109.143 179.875 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.404 ' C ' HD22 ' A' ' 30' ' ' LEU . 84.5 tt0 -101.03 132.1 46.61 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.23 -0.919 . . . . 0.0 109.987 -179.359 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.414 ' N ' ' CD2' ' A' ' 30' ' ' LEU . 2.6 mm? -108.42 132.13 54.08 Favored 'General case' 0 N--CA 1.492 1.626 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 179.44 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 93.3 m-85 -96.02 116.23 28.64 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 120.966 -1.083 . . . . 0.0 108.775 179.045 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -84.72 -43.7 14.06 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.287 -0.883 . . . . 0.0 109.735 -179.705 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.0 m-20 -63.88 -49.43 72.77 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.217 -0.927 . . . . 0.0 109.879 -179.585 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 28.3 m -71.14 -41.83 69.96 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.207 -0.933 . . . . 0.0 109.417 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.517 ' O ' ' OG1' ' A' ' 35' ' ' THR . 2.3 p -135.16 79.62 49.61 Favored Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 121.531 -0.731 . . . . 0.0 109.495 -179.642 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 29.8 Cg_endo -68.48 -62.83 0.05 OUTLIER 'Trans proline' 0 N--CA 1.494 1.557 0 C-N-CA 122.338 2.025 . . . . 0.0 112.867 -179.339 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 79.2 mtp180 -61.23 -37.0 81.49 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.375 -0.828 . . . . 0.0 110.844 -178.952 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 26.8 m -60.66 -43.39 97.7 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.928 -1.107 . . . . 0.0 109.761 -179.51 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -62.83 -30.85 71.81 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.17 -0.956 . . . . 0.0 108.867 179.698 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -68.44 -38.63 81.32 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.47 -0.768 . . . . 0.0 109.899 -179.881 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 47.5 t30 -57.86 -42.52 84.7 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.318 -0.864 . . . . 0.0 109.95 -179.518 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.533 ' O ' ' SG ' ' A' ' 46' ' ' CYS . 97.8 m-85 -84.67 -46.96 10.96 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.069 -1.019 . . . . 0.0 109.938 -179.869 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.676 ' CZ ' HE22 ' A' ' 176' ' ' GLN . 77.0 ttt180 -54.21 -41.13 68.28 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.338 -0.852 . . . . 0.0 110.361 -179.285 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -66.81 -47.62 71.5 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.108 -0.995 . . . . 0.0 110.319 -178.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.474 HD13 ' HB3' ' A' ' 59' ' ' LEU . 3.2 mm? -65.28 -39.06 92.08 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.078 -1.014 . . . . 0.0 109.96 -179.515 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' CYS . . . . . 0.533 ' SG ' ' O ' ' A' ' 42' ' ' PHE . 27.6 m -64.41 -62.3 1.69 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.939 -1.101 . . . . 0.0 109.392 -179.766 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 25.3 m -64.86 -36.47 84.46 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.282 -0.886 . . . . 0.0 109.183 179.606 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 83.59 35.62 16.24 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 110.176 -1.17 . . . . 0.0 110.176 179.558 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -61.56 -38.1 86.24 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.051 -1.264 . . . . 0.0 109.266 179.674 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 29.5 mmtm -62.27 -29.75 70.63 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.283 -0.885 . . . . 0.0 109.446 179.747 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 86.06 -115.67 4.24 Favored Glycine 0 N--CA 1.488 2.13 0 N-CA-C 108.778 -1.729 . . . . 0.0 108.778 -179.103 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.544 HG23 ' HA ' ' A' ' 58' ' ' PRO . 61.6 m -129.42 142.01 50.9 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.254 -1.145 . . . . 0.0 109.553 179.455 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -64.66 136.21 38.75 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 61.7 ttp85 -55.32 -37.98 68.11 Favored 'General case' 0 C--N 1.305 -1.328 0 O-C-N 121.254 -1.145 . . . . 0.0 110.056 -179.652 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 22.9 t -57.19 -32.7 66.73 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.288 -0.883 . . . . 0.0 109.797 -179.605 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . 0.409 ' O ' ' CB ' ' A' ' 57' ' ' LYS . . . 118.59 105.1 2.21 Favored Glycine 0 N--CA 1.494 2.508 0 N-CA-C 109.014 -1.635 . . . . 0.0 109.014 -179.726 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . 0.409 ' CB ' ' O ' ' A' ' 56' ' ' GLY . 0.8 OUTLIER 167.86 82.61 0.02 OUTLIER Pre-proline 0 N--CA 1.491 1.584 0 N-CA-C 108.104 -1.073 . . . . 0.0 108.104 -179.625 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.544 ' HA ' HG23 ' A' ' 52' ' ' THR . 81.4 Cg_exo -45.97 126.15 9.1 Favored 'Trans proline' 0 C--N 1.305 -1.742 0 C-N-CA 122.579 2.186 . . . . 0.0 112.269 -178.964 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.58 ' O ' ' CG ' ' A' ' 60' ' ' HIS . 53.2 mt -95.94 130.61 42.87 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.554 -0.716 . . . . 0.0 109.711 -179.62 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . 0.58 ' CG ' ' O ' ' A' ' 59' ' ' LEU . 0.4 OUTLIER 166.51 110.03 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.258 -0.901 . . . . 0.0 109.577 179.889 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 3.6 m-85 -68.39 -3.5 11.4 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.181 -0.95 . . . . 0.0 108.603 179.163 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 34.6 ttmt -57.52 149.35 21.36 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.378 -0.827 . . . . 0.0 109.523 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . 0.424 ' H ' HG23 ' A' ' 171' ' ' VAL . 83.2 m-20 57.35 47.76 16.04 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.478 -0.764 . . . . 0.0 110.231 179.839 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.929 ' H ' HG22 ' A' ' 171' ' ' VAL . 92.3 p -104.33 156.79 17.62 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.293 -0.879 . . . . 0.0 108.907 179.257 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 29.2 t -128.9 146.54 50.92 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.153 -0.967 . . . . 0.0 109.623 -179.609 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.7 m-30 -71.81 133.92 45.81 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.283 -0.885 . . . . 0.0 108.662 179.633 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 80.7 m80 -91.02 -31.58 16.25 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.087 -1.008 . . . . 0.0 110.819 -178.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 80.0 mtp180 -135.36 138.61 43.53 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 120.951 -1.093 . . . . 0.0 110.306 -179.458 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -150.8 80.04 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 179.0 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 59.9 mt -96.99 129.39 32.54 Favored Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.345 -0.847 . . . . 0.0 109.537 -179.627 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -74.61 134.67 18.82 Favored 'Trans proline' 0 N--CA 1.491 1.349 0 C-N-CA 122.114 1.876 . . . . 0.0 112.076 179.788 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 92.96 -1.2 70.4 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.899 -1.28 . . . . 0.0 109.899 179.597 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 77.4 m-85 -132.93 -94.02 0.34 Allowed 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.098 -1.236 . . . . 0.0 109.818 179.921 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 4.5 ptt? -163.39 177.48 8.89 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.946 -1.097 . . . . 0.0 110.031 -179.601 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -129.4 131.49 46.81 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.495 -0.753 . . . . 0.0 109.039 179.94 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 50.8 tt0 -97.16 118.5 33.72 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.138 -0.976 . . . . 0.0 109.322 179.816 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -61.86 -39.31 97.33 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 81.53 167.16 38.18 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.494 -1.442 . . . . 0.0 109.494 -179.916 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -104.25 149.83 24.96 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.42 -1.047 . . . . 0.0 109.456 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 45.2 p90 -65.29 -24.17 67.22 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.18 -0.95 . . . . 0.0 109.347 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.53 ' O ' ' HB2' ' A' ' 82' ' ' ALA . 58.9 p -66.31 -31.51 72.35 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.225 -0.922 . . . . 0.0 109.657 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . 0.53 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 173.46 -53.28 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.242 -0.911 . . . . 0.0 109.44 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 92.53 3.26 66.89 Favored Glycine 0 N--CA 1.492 2.378 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 40.7 p-10 -88.27 7.53 31.69 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.162 -1.199 . . . . 0.0 109.427 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 95.21 -43.52 2.23 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 109.272 -1.531 . . . . 0.0 109.272 -179.851 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 47.1 m -60.58 -38.41 84.5 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.208 -1.172 . . . . 0.0 109.049 179.759 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -84.38 -164.67 38.1 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.473 -1.451 . . . . 0.0 109.473 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.517 ' N ' ' OG1' ' A' ' 81' ' ' THR . . . 86.98 35.51 9.8 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.511 -1.435 . . . . 0.0 109.511 -179.952 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -56.56 146.04 26.31 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.296 -1.12 . . . . 0.0 109.441 179.878 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 29.7 t -100.35 144.02 29.85 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.284 -0.885 . . . . 0.0 109.461 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 21.9 pt -64.36 -32.44 57.6 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.382 -0.824 . . . . 0.0 109.863 -179.728 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 67.7 m-85 -64.12 -37.46 87.54 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.198 -0.939 . . . . 0.0 109.437 -179.795 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 81.43 7.47 88.24 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -151.82 156.92 41.16 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.204 -1.174 . . . . 0.0 109.537 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 86.9 mttt -88.27 148.29 24.4 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.285 -0.884 . . . . 0.0 109.542 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.554 ' CZ ' ' OD1' ' A' ' 121' ' ' ASN . 40.4 p90 -134.33 161.82 33.91 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.253 -0.905 . . . . 0.0 108.973 179.495 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -54.99 138.36 43.9 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.146 -0.971 . . . . 0.0 109.851 -178.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 88.2 m-20 -74.66 141.15 44.62 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.428 -0.795 . . . . 0.0 109.761 -179.901 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . 0.459 ' OE1' HG22 ' A' ' 35' ' ' THR . 96.0 mt-10 -59.82 146.36 42.1 Favored 'General case' 0 C--N 1.305 -1.37 0 O-C-N 121.322 -0.861 . . . . 0.0 109.218 179.672 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 23.0 t-20 -58.26 159.63 5.87 Favored 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.461 -0.774 . . . . 0.0 109.429 -179.87 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' PHE . . . . . 0.482 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 29.3 p90 -96.43 52.26 1.23 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.303 -0.873 . . . . 0.0 109.72 -179.721 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 88.6 mt -56.77 -39.49 64.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.123 -0.986 . . . . 0.0 109.322 179.781 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -93.03 146.16 23.84 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.154 -0.966 . . . . 0.0 109.627 179.901 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . 0.546 ' O ' HG23 ' A' ' 106' ' ' THR . 81.0 tttt -126.8 157.62 38.74 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.439 -0.788 . . . . 0.0 109.346 -179.924 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' HIS . . . . . 0.53 ' ND1' ' OD1' ' A' ' 136' ' ' ASP . 23.2 m80 -59.06 81.25 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.272 -0.893 . . . . 0.0 109.061 179.937 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . 0.546 HG23 ' O ' ' A' ' 104' ' ' LYS . 69.3 p -73.96 -22.79 59.51 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.164 -0.96 . . . . 0.0 110.147 -179.485 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.414 ' O ' HG12 ' A' ' 110' ' ' ILE . . . -152.75 177.66 30.33 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.734 -1.346 . . . . 0.0 109.734 -179.626 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -73.2 156.29 51.3 Favored 'Trans proline' 0 C--N 1.307 -1.648 0 C-N-CA 122.891 2.394 . . . . 0.0 112.193 179.793 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . 0.495 ' N ' ' O ' ' A' ' 128' ' ' CYS . . . 82.23 47.42 6.12 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.91 -1.276 . . . . 0.0 109.91 179.757 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.414 HG12 ' O ' ' A' ' 107' ' ' GLY . 40.7 mm -115.0 136.67 50.94 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.378 -1.071 . . . . 0.0 109.479 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.734 ' N ' HD22 ' A' ' 111' ' ' LEU . 2.7 mm? -89.32 142.34 27.74 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.349 -0.844 . . . . 0.0 109.762 -179.684 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 10.4 t -144.8 140.71 28.63 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.202 -0.936 . . . . 0.0 109.752 179.787 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 89.0 mtp -88.86 137.49 32.27 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.166 -0.959 . . . . 0.0 109.323 179.483 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . 0.418 ' HB2' ' CE2' ' A' ' 126' ' ' PHE . . . -68.9 143.52 54.47 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.202 -0.936 . . . . 0.0 109.811 -179.867 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . 0.433 ' OD1' ' O ' ' A' ' 120' ' ' THR . 47.0 t30 -140.83 151.03 44.03 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.334 -0.854 . . . . 0.0 109.474 179.737 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -132.17 -3.72 3.5 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.404 -0.81 . . . . 0.0 109.241 179.755 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -157.51 169.55 34.45 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.078 -1.609 . . . . 0.0 109.078 -179.925 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -70.66 147.91 58.13 Favored 'Trans proline' 0 C--N 1.306 -1.665 0 C-N-CA 122.603 2.202 . . . . 0.0 111.792 179.857 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 87.7 m-20 51.0 42.2 28.18 Favored 'General case' 0 C--N 1.297 -1.679 0 O-C-N 121.476 -0.765 . . . . 0.0 109.467 -179.801 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' THR . . . . . 0.433 ' O ' ' OD1' ' A' ' 115' ' ' ASN . 84.2 m -135.22 124.91 25.26 Favored 'General case' 0 N--CA 1.488 1.44 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 179.717 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' ASN . . . . . 0.554 ' OD1' ' CZ ' ' A' ' 96' ' ' PHE . 35.8 m120 -106.24 128.3 53.85 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.576 -0.703 . . . . 0.0 109.702 -179.919 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -99.52 130.84 10.35 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 179.921 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 22.9 t -60.19 -33.23 71.94 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.186 -1.185 . . . . 0.0 109.63 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 25.7 mt-30 -68.38 147.9 51.45 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.332 -0.855 . . . . 0.0 109.664 -179.668 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 50.2 p90 -137.31 161.14 37.06 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.334 -0.854 . . . . 0.0 109.209 179.905 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.418 ' CE2' ' HB2' ' A' ' 114' ' ' ALA . 86.0 m-85 -118.87 151.35 38.27 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.266 -0.897 . . . . 0.0 109.711 -179.898 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 76.3 mt -116.82 134.05 61.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 N-CA-C 108.693 -0.854 . . . . 0.0 108.693 179.313 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 128' ' ' CYS . . . . . 0.495 ' O ' ' N ' ' A' ' 109' ' ' GLY . 1.3 m -121.59 132.45 54.69 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.278 -0.889 . . . . 0.0 109.389 -179.774 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . 0.425 HG21 ' OE1' ' A' ' 156' ' ' GLU . 1.7 t -116.65 8.78 13.91 Favored 'General case' 0 N--CA 1.493 1.698 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 179.652 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -141.58 165.94 26.11 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.544 -0.723 . . . . 0.0 109.109 -179.885 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 69.1 mttm -65.5 134.13 52.75 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.114 -0.991 . . . . 0.0 109.453 -179.829 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 57.3 p -141.97 70.45 1.33 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.319 -0.863 . . . . 0.0 109.295 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -61.3 -36.16 79.33 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.277 -0.889 . . . . 0.0 109.992 -179.56 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 0.8 OUTLIER -62.6 -43.15 99.54 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.014 -1.054 . . . . 0.0 109.51 -179.942 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 25.0 mt -65.49 -33.84 76.88 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.14 -0.975 . . . . 0.0 109.765 179.508 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . 0.53 ' OD1' ' ND1' ' A' ' 105' ' ' HIS . 87.3 m-20 -65.76 141.59 58.27 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.277 -0.889 . . . . 0.0 109.611 -179.754 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 153.79 -92.83 0.13 Allowed Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . 0.418 ' HD2' ' N ' ' A' ' 138' ' ' LYS . 1.1 mptp? -87.7 10.54 17.89 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.333 -1.098 . . . . 0.0 109.523 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 63.3 m170 -96.41 140.74 30.63 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.235 -0.915 . . . . 0.0 109.594 -179.751 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 44.9 t -115.37 138.16 46.6 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 O-C-N 121.442 -0.786 . . . . 0.0 109.473 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . 0.439 HG23 ' O ' ' A' ' 141' ' ' VAL . 11.2 m -100.72 132.17 46.91 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.332 -0.855 . . . . 0.0 109.224 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 41.4 p90 -110.08 -11.08 14.65 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.222 -0.924 . . . . 0.0 110.219 -179.544 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -157.77 179.75 33.27 Favored Glycine 0 N--CA 1.493 2.458 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 179.738 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.5 pt20 -144.3 165.22 28.51 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.086 -1.244 . . . . 0.0 109.717 -179.749 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 75.6 t -97.12 129.66 46.86 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.19 0 O-C-N 121.318 -0.864 . . . . 0.0 109.299 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 16.1 m -101.86 -35.28 4.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.394 -0.816 . . . . 0.0 109.882 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 90.1 mt-10 -144.95 170.59 15.85 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.149 -0.97 . . . . 0.0 109.745 -179.819 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 97.78 4.14 58.02 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 110.315 -1.114 . . . . 0.0 110.315 179.308 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 149' ' ' MET . . . . . 0.49 ' O ' HG12 ' A' ' 152' ' ' VAL . 65.1 mtt -60.53 -32.37 71.41 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 120.991 -1.299 . . . . 0.0 109.518 179.872 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -64.79 -41.75 95.59 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 120.9 -1.125 . . . . 0.0 110.084 -179.652 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 6.6 p -82.21 -33.59 11.6 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.2 -0.938 . . . . 0.0 110.679 -179.425 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 152' ' ' VAL . . . . . 0.49 HG12 ' O ' ' A' ' 149' ' ' MET . 0.9 OUTLIER -55.82 -42.38 70.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 120.901 -1.124 . . . . 0.0 109.249 -179.304 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 153' ' ' LYS . . . . . 0.459 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 91.1 mttt -65.49 -35.49 81.03 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.043 -1.035 . . . . 0.0 109.409 179.429 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -63.01 -38.15 90.06 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.383 -0.823 . . . . 0.0 109.996 -179.532 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.46 HD13 ' CE ' ' A' ' 16' ' ' MET . 84.7 mt -71.09 -38.44 71.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.295 -0.878 . . . . 0.0 110.594 -179.555 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . 0.425 ' OE1' HG21 ' A' ' 129' ' ' THR . 83.1 tt0 -78.1 -39.25 41.99 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.1 -1.0 . . . . 0.0 111.573 -178.395 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 31.6 pttt -61.0 -34.16 74.39 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 120.723 -1.236 . . . . 0.0 110.21 -178.682 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.459 HG22 ' O ' ' A' ' 155' ' ' ILE . 23.8 m -69.8 -15.65 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 120.96 -1.087 . . . . 0.0 109.047 179.786 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -79.05 177.29 54.31 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 23.2 t -152.02 173.51 14.79 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.321 -1.105 . . . . 0.0 109.239 -179.855 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 23.4 m -53.09 -34.89 58.63 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.073 -1.017 . . . . 0.0 108.992 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 24.6 m -59.11 -30.33 68.04 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.373 -0.829 . . . . 0.0 109.363 179.527 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 96.82 11.14 54.23 Favored Glycine 0 N--CA 1.494 2.507 0 N-CA-C 109.35 -1.5 . . . . 0.0 109.35 -179.701 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 88.8 mtt180 -109.25 158.12 18.16 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.369 -1.077 . . . . 0.0 109.02 179.73 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 165' ' ' THR . . . . . . . . . . . . . 43.1 p -116.38 156.82 26.07 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.203 -0.936 . . . . 0.0 110.366 -179.399 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -68.17 -34.72 76.82 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.55 -0.718 . . . . 0.0 109.476 179.624 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -121.98 156.5 33.31 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.481 -0.762 . . . . 0.0 109.473 -179.73 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 90.5 mttt -80.7 141.16 35.14 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.298 -0.876 . . . . 0.0 109.301 -179.904 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 40.6 t -121.74 126.08 74.2 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.341 -0.849 . . . . 0.0 109.7 -179.88 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 43.5 t -141.57 140.68 30.88 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.275 -0.891 . . . . 0.0 109.202 179.712 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.929 HG22 ' H ' ' A' ' 64' ' ' SER . 4.0 m -68.58 123.24 21.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.118 -0.989 . . . . 0.0 109.464 179.935 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -68.65 -36.75 78.99 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.008 -1.057 . . . . 0.0 110.046 -179.802 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -160.04 163.05 34.29 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.073 -1.017 . . . . 0.0 110.07 -179.594 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 16.0 p -146.6 149.78 34.21 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.418 -0.801 . . . . 0.0 109.434 179.759 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . 176.84 -178.83 48.04 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 179.892 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 176' ' ' GLN . . . . . 0.676 HE22 ' CZ ' ' A' ' 43' ' ' ARG . 60.4 tt0 -106.69 120.26 41.52 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.343 -1.092 . . . . 0.0 109.651 -179.952 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 177' ' ' LEU . . . . . 0.437 ' O ' ' C ' ' A' ' 178' ' ' SER . 30.3 tp -61.9 -39.34 91.66 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.138 -0.976 . . . . 0.0 109.153 179.454 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 178' ' ' SER . . . . . 0.437 ' C ' ' O ' ' A' ' 177' ' ' LEU . 5.6 p . . . . . 0 N--CA 1.492 1.673 0 CA-C-O 118.046 -0.978 . . . . 0.0 109.806 179.898 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.529 4.835 0 N-CA-C 119.401 2.52 . . . . 0.0 119.401 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 55.0 p -70.21 161.39 30.37 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.196 -1.179 . . . . 0.0 109.512 -179.941 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 99.3 m-85 -112.18 125.37 54.06 Favored 'General case' 0 N--CA 1.484 1.247 0 O-C-N 121.377 -0.827 . . . . 0.0 108.813 179.678 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 44.6 m -56.79 -37.75 71.58 Favored 'General case' 0 C--N 1.296 -1.759 0 O-C-N 121.441 -0.787 . . . . 0.0 109.477 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -78.18 8.16 40.57 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.798 -1.321 . . . . 0.0 109.798 -179.809 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 37.8 t -58.97 -32.88 70.05 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.136 -1.214 . . . . 0.0 109.748 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 13.5 mtt -124.79 79.18 64.07 Favored Pre-proline 0 N--CA 1.495 1.784 0 O-C-N 121.273 -0.892 . . . . 0.0 109.717 -179.781 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo -85.53 168.43 9.89 Favored 'Trans proline' 0 C--N 1.308 -1.562 0 C-N-CA 122.978 2.452 . . . . 0.0 112.125 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 6.8 m-20 -60.6 150.46 74.81 Favored Pre-proline 0 N--CA 1.488 1.47 0 O-C-N 121.22 -0.925 . . . . 0.0 109.0 179.711 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -65.75 133.77 35.25 Favored 'Trans proline' 0 C--N 1.309 -1.55 0 C-N-CA 122.448 2.099 . . . . 0.0 112.24 -179.695 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 97.4 mtt180 -131.57 129.74 41.34 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.411 -0.805 . . . . 0.0 108.879 179.203 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.5 p -135.88 142.26 39.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.366 -0.834 . . . . 0.0 109.363 -179.822 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 45.1 p90 -142.31 153.4 43.85 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.418 -0.801 . . . . 0.0 109.573 -179.812 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -121.37 134.88 55.13 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.385 -0.822 . . . . 0.0 109.318 179.54 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -90.6 114.75 27.07 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.182 -0.949 . . . . 0.0 108.945 179.485 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' MET . . . . . 0.405 ' SD ' ' CD1' ' A' ' 26' ' ' ILE . 85.1 mtp -102.56 152.19 21.45 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.311 -0.868 . . . . 0.0 110.452 -179.404 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 96.5 p -143.15 163.15 33.68 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.781 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.53 ' O ' ' N ' ' A' ' 20' ' ' GLY . 29.4 m -123.43 139.8 48.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 121.07 -1.019 . . . . 0.0 109.501 -179.953 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 47.01 13.96 0.11 Allowed Glycine 0 N--CA 1.492 2.406 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 179.928 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.53 ' N ' ' O ' ' A' ' 18' ' ' VAL . . . 98.78 -16.3 59.76 Favored Glycine 0 N--CA 1.493 2.447 0 N-CA-C 109.616 -1.393 . . . . 0.0 109.616 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' GLN . . . . . 0.492 ' N ' ' O ' ' A' ' 18' ' ' VAL . 64.5 mm-40 -81.69 146.12 55.89 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.169 -1.195 . . . . 0.0 109.216 179.812 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_endo -63.48 138.89 67.7 Favored 'Trans proline' 0 N--CA 1.494 1.528 0 C-N-CA 122.366 2.044 . . . . 0.0 112.174 -179.736 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -112.6 -66.2 1.11 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.319 -0.863 . . . . 0.0 109.452 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -175.81 -169.97 38.06 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.315 -1.514 . . . . 0.0 109.315 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 71.3 mtp180 -114.95 144.03 44.22 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.226 -1.161 . . . . 0.0 109.587 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.405 ' CD1' ' SD ' ' A' ' 16' ' ' MET . 84.0 mt -120.72 116.07 48.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 N-CA-C 108.44 -0.948 . . . . 0.0 108.44 178.579 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 37.8 t -112.12 133.91 56.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.439 -0.788 . . . . 0.0 109.218 -179.537 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 76.5 mtm -119.53 155.25 32.51 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.454 -0.779 . . . . 0.0 109.532 -179.577 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.417 ' C ' HD22 ' A' ' 30' ' ' LEU . 84.7 tt0 -100.31 133.02 45.35 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.369 -0.832 . . . . 0.0 109.939 -179.601 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.417 HD22 ' C ' ' A' ' 29' ' ' GLU . 3.1 mm? -110.39 134.65 52.11 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.506 -0.746 . . . . 0.0 109.155 179.619 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 84.1 m-85 -95.1 122.84 38.18 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.2 -0.938 . . . . 0.0 108.999 179.388 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -92.9 -41.81 9.84 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.348 -0.845 . . . . 0.0 109.606 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 87.2 m-20 -69.62 -44.45 70.65 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.327 -0.858 . . . . 0.0 110.659 -179.338 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . 0.439 ' O ' ' OE1' ' A' ' 99' ' ' GLU . 35.2 m -67.84 -46.82 70.69 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.16 -0.962 . . . . 0.0 110.526 -178.924 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.413 ' OG1' ' OG1' ' A' ' 38' ' ' THR . 0.0 OUTLIER -152.63 83.62 4.82 Favored Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.147 -0.971 . . . . 0.0 109.486 -179.447 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -71.92 -33.19 10.22 Favored 'Trans proline' 0 C--N 1.308 -1.593 0 C-N-CA 122.146 1.897 . . . . 0.0 112.12 -179.63 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 35.2 mmt180 -63.35 -40.28 96.85 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.326 -0.858 . . . . 0.0 109.491 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.413 ' OG1' ' OG1' ' A' ' 35' ' ' THR . 36.5 m -64.87 -41.17 95.88 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.274 -0.891 . . . . 0.0 109.929 -179.806 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -62.43 -30.77 71.46 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.286 -0.884 . . . . 0.0 109.282 179.973 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -67.11 -36.91 82.94 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.293 -0.879 . . . . 0.0 109.864 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . 0.437 ' O ' HD23 ' A' ' 45' ' ' LEU . 87.5 m-20 -57.95 -39.76 78.88 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.263 -0.898 . . . . 0.0 110.062 -179.498 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -90.42 -48.13 7.3 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.072 -1.017 . . . . 0.0 109.665 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 51.3 ttp180 -57.65 -40.71 79.9 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.48 -0.762 . . . . 0.0 110.508 -179.361 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.446 ' O ' ' N ' ' A' ' 48' ' ' GLY . . . -66.05 -46.8 76.51 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.976 -1.077 . . . . 0.0 110.425 -179.095 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.606 HD13 ' O ' ' A' ' 59' ' ' LEU . 3.6 mm? -64.98 -39.97 94.27 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 120.956 -1.09 . . . . 0.0 109.618 -179.809 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' CYS . . . . . . . . . . . . . 34.8 m -70.06 -47.85 60.26 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.084 -1.01 . . . . 0.0 109.347 179.769 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 74.8 p -72.55 -34.62 67.65 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.36 -0.837 . . . . 0.0 109.555 179.742 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.446 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 73.61 31.88 60.13 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.978 -1.249 . . . . 0.0 109.978 179.646 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 78.0 mm-40 -62.03 -38.03 87.16 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.029 -1.277 . . . . 0.0 109.534 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 31.4 mmtp -62.18 -35.86 80.11 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.282 -0.886 . . . . 0.0 109.674 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 89.51 167.9 42.97 Favored Glycine 0 N--CA 1.488 2.154 0 N-CA-C 109.074 -1.611 . . . . 0.0 109.074 -179.653 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.566 HG23 ' HA ' ' A' ' 58' ' ' PRO . 85.2 m -75.1 138.73 42.28 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.119 -1.224 . . . . 0.0 109.559 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -59.5 137.18 50.11 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.393 -1.483 . . . . 0.0 109.393 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 83.5 mtm-85 -59.35 -36.09 75.08 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.19 -1.182 . . . . 0.0 109.846 -179.748 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 85.9 p -63.38 -24.26 67.77 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.113 -0.992 . . . . 0.0 109.779 -179.841 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 115.87 96.35 2.02 Favored Glycine 0 N--CA 1.494 2.524 0 N-CA-C 109.078 -1.609 . . . . 0.0 109.078 -179.572 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . 0.484 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 75.8 tttt -179.5 81.47 0.2 Allowed Pre-proline 0 N--CA 1.489 1.518 0 N-CA-C 108.377 -0.971 . . . . 0.0 108.377 -179.664 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.566 ' HA ' HG23 ' A' ' 52' ' ' THR . 75.9 Cg_exo -50.31 130.12 27.89 Favored 'Trans proline' 0 C--N 1.303 -1.828 0 C-N-CA 122.769 2.313 . . . . 0.0 112.597 -179.014 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.606 ' O ' HD13 ' A' ' 45' ' ' LEU . 9.0 mp -100.04 23.49 9.82 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.641 -0.662 . . . . 0.0 109.436 -179.833 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . 0.51 ' O ' ' CE1' ' A' ' 80' ' ' PHE . 93.2 m-70 -101.66 135.32 43.38 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.227 -0.92 . . . . 0.0 109.628 -179.804 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . 0.509 ' CE1' HD12 ' A' ' 45' ' ' LEU . 2.7 m-85 -94.95 12.67 27.55 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.293 -0.879 . . . . 0.0 108.98 179.575 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . 0.463 ' O ' ' CB ' ' A' ' 63' ' ' ASP . 62.1 tttt -62.73 142.82 57.97 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.416 -0.803 . . . . 0.0 109.674 -179.832 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . 0.463 ' CB ' ' O ' ' A' ' 62' ' ' LYS . 21.4 t0 74.76 33.72 0.77 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.581 -0.7 . . . . 0.0 109.736 179.859 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.788 ' H ' ' CG2' ' A' ' 171' ' ' VAL . 52.6 p -76.66 165.31 24.93 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.225 -0.922 . . . . 0.0 109.005 179.34 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 29.7 t -140.9 149.77 42.33 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.085 -1.01 . . . . 0.0 109.814 -179.783 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 58.3 m-85 -90.93 127.22 36.31 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.296 -0.878 . . . . 0.0 109.209 179.552 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 55.4 t-80 -94.85 -30.74 14.04 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.258 -0.901 . . . . 0.0 110.499 -179.27 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 83.0 mtp180 -126.26 140.87 52.19 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.057 -1.027 . . . . 0.0 110.341 -179.38 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.711 HG21 HG22 ' A' ' 165' ' ' THR . 15.8 m -151.57 49.05 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 179.424 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 19.4 mt -77.56 133.78 66.67 Favored Pre-proline 0 C--N 1.301 -1.507 0 O-C-N 121.361 -0.837 . . . . 0.0 110.156 -178.612 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -68.89 147.89 69.42 Favored 'Trans proline' 0 N--CA 1.492 1.421 0 C-N-CA 122.4 2.067 . . . . 0.0 112.266 179.852 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 80.42 -55.75 4.66 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.849 -1.3 . . . . 0.0 109.849 179.642 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 88.4 m-85 -68.36 -87.27 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.27 -1.135 . . . . 0.0 109.67 -179.75 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 11.3 ptt? -179.59 -175.16 0.32 Allowed 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.141 -0.975 . . . . 0.0 109.667 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 58.2 m -126.92 136.74 52.72 Favored 'General case' 0 N--CA 1.493 1.702 0 N-CA-C 108.763 -0.829 . . . . 0.0 108.763 179.608 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 63.2 tt0 -96.9 134.88 39.65 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.226 -0.921 . . . . 0.0 109.695 -179.527 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -139.75 176.19 21.33 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.06 -1.616 . . . . 0.0 109.06 179.769 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 77.14 36.84 34.03 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.235 -1.546 . . . . 0.0 109.235 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -83.72 13.97 4.29 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.321 -1.105 . . . . 0.0 109.413 -179.826 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.51 ' CE1' ' O ' ' A' ' 60' ' ' HIS . 81.0 t80 -51.67 -45.26 63.37 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.293 -0.88 . . . . 0.0 109.803 -179.874 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.657 ' O ' ' HB2' ' A' ' 82' ' ' ALA . 58.9 p -70.51 -28.17 64.75 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.1 -1.0 . . . . 0.0 109.506 179.857 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . 0.657 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 165.3 -56.9 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.342 -0.849 . . . . 0.0 109.238 179.898 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 93.39 -1.42 69.52 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 40.7 p-10 -90.02 5.95 44.39 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.126 -1.22 . . . . 0.0 109.473 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 96.44 -33.53 5.59 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.98 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 51.7 p -72.58 -22.26 61.01 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.14 -1.212 . . . . 0.0 109.217 179.76 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -84.97 -161.64 34.29 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 179.915 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.634 ' H ' ' CB ' ' A' ' 81' ' ' THR . . . 90.95 26.87 20.85 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 -179.869 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . 0.429 ' OE1' ' NZ ' ' A' ' 57' ' ' LYS . 96.0 mt-10 -57.1 145.52 30.69 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.375 -1.073 . . . . 0.0 109.577 -179.799 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 29.3 t -106.15 143.55 34.11 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.323 -0.861 . . . . 0.0 109.328 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 20.4 pt -64.58 -33.44 63.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.332 -0.855 . . . . 0.0 109.828 -179.722 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 73.5 m-85 -65.53 -38.12 88.72 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.23 -0.919 . . . . 0.0 109.604 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 81.64 14.5 77.89 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.449 -1.461 . . . . 0.0 109.449 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -146.46 155.77 42.79 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.14 -1.211 . . . . 0.0 109.655 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 97.1 mttt -94.07 142.24 27.62 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.291 -0.88 . . . . 0.0 109.549 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 99.4 m-85 -120.63 150.16 41.34 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.415 -0.803 . . . . 0.0 109.589 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -70.8 154.51 41.77 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.385 -0.822 . . . . 0.0 109.569 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 88.4 m-20 -59.48 147.66 35.85 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.251 -0.906 . . . . 0.0 109.341 179.901 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . 0.439 ' OE1' ' O ' ' A' ' 34' ' ' THR . 96.2 mt-10 -80.4 -89.35 0.06 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.145 -0.972 . . . . 0.0 110.008 -179.583 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 85.3 m-20 -124.86 145.91 49.55 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.301 -0.875 . . . . 0.0 110.049 -179.473 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -100.74 10.83 40.65 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.439 -0.788 . . . . 0.0 109.294 179.589 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 96.2 mt -53.49 -36.46 27.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.303 -0.873 . . . . 0.0 110.134 -179.391 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 9.2 mtpm? -80.45 136.12 36.27 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.98 -1.075 . . . . 0.0 109.633 -179.789 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 69.1 tttt -135.15 159.37 41.76 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.449 -0.782 . . . . 0.0 109.331 -179.705 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' HIS . . . . . 0.409 ' CE1' HG22 ' A' ' 141' ' ' VAL . 92.9 m-70 -74.19 106.55 5.9 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.092 -1.005 . . . . 0.0 109.477 179.865 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 62.3 p -96.03 -9.97 29.65 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.343 -0.848 . . . . 0.0 109.691 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -165.18 -179.03 38.83 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.76 -1.336 . . . . 0.0 109.76 -179.805 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -78.76 160.28 27.82 Favored 'Trans proline' 0 C--N 1.306 -1.677 0 C-N-CA 123.178 2.585 . . . . 0.0 112.23 179.791 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 82.17 40.9 9.78 Favored Glycine 0 N--CA 1.492 2.395 0 N-CA-C 109.995 -1.242 . . . . 0.0 109.995 179.715 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 33.7 mm -113.66 139.21 40.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.357 -1.084 . . . . 0.0 109.209 179.923 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.669 ' N ' HD22 ' A' ' 111' ' ' LEU . 3.4 mm? -86.88 136.18 33.05 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.156 -0.965 . . . . 0.0 109.737 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 30.8 t -144.69 143.41 30.71 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.348 -0.845 . . . . 0.0 109.098 179.47 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' MET . . . . . 0.404 ' H ' ' HG2' ' A' ' 113' ' ' MET . 15.1 ptm -87.4 126.06 34.64 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.231 -0.918 . . . . 0.0 109.532 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -66.27 147.77 52.83 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.263 -0.898 . . . . 0.0 109.715 -179.74 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . 0.525 ' N ' ' OD1' ' A' ' 115' ' ' ASN . 8.0 p-10 -157.76 115.56 3.05 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.272 -0.893 . . . . 0.0 109.169 179.634 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -65.46 -30.72 71.54 Favored 'General case' 0 C--N 1.299 -1.63 0 O-C-N 121.406 -0.809 . . . . 0.0 109.8 -179.761 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -135.57 166.09 24.61 Favored Glycine 0 N--CA 1.494 2.519 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -67.38 156.74 64.91 Favored 'Trans proline' 0 C--N 1.306 -1.659 0 C-N-CA 122.867 2.378 . . . . 0.0 111.816 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 75.8 m-20 54.33 45.4 27.3 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.411 -0.805 . . . . 0.0 109.232 -179.895 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 61.5 m -131.85 127.99 37.73 Favored 'General case' 0 C--N 1.305 -1.349 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 179.916 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 20.1 m120 -102.01 137.03 40.84 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.493 -0.755 . . . . 0.0 109.486 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -145.32 125.78 2.42 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 179.91 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 23.1 t -59.02 -30.86 68.32 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.374 -1.074 . . . . 0.0 109.482 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.6 mt-30 -63.22 143.2 58.0 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.194 -0.941 . . . . 0.0 109.537 -179.675 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 45.6 p90 -141.35 164.93 28.91 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.453 -0.78 . . . . 0.0 109.178 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 48.0 p90 -131.47 157.48 43.39 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.231 -0.918 . . . . 0.0 109.517 179.854 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 71.3 mt -120.25 136.36 57.55 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.492 -0.755 . . . . 0.0 109.593 -179.73 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 11.0 t -116.26 123.56 48.01 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.287 -0.883 . . . . 0.0 108.978 179.581 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 37.6 p -95.51 5.5 51.38 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.275 -0.891 . . . . 0.0 109.86 -179.446 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -148.44 155.58 41.39 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.142 -0.974 . . . . 0.0 109.725 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 34.7 ttmt -73.51 135.42 44.02 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.316 -0.865 . . . . 0.0 109.309 179.838 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . 0.462 ' O ' ' OD2' ' A' ' 136' ' ' ASP . 16.9 p -120.87 159.33 25.74 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.447 -0.783 . . . . 0.0 109.431 -179.808 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . 0.436 ' O ' ' OD1' ' A' ' 136' ' ' ASP . 96.2 mt-10 -97.93 -48.24 5.24 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.286 -0.884 . . . . 0.0 110.011 -179.906 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 134' ' ' TRP . . . . . 0.602 ' CD1' ' N ' ' A' ' 135' ' ' LEU . 40.9 p90 -92.16 -44.06 9.0 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.199 -0.938 . . . . 0.0 110.174 -179.477 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . 0.602 ' N ' ' CD1' ' A' ' 134' ' ' TRP . 34.2 tp -61.66 -29.63 70.2 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.268 -0.895 . . . . 0.0 109.184 -179.646 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . 0.485 ' C ' ' OD1' ' A' ' 136' ' ' ASP . 53.4 p30 -70.14 9.06 0.63 Allowed 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.447 -0.783 . . . . 0.0 109.513 -179.747 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . 0.459 ' H ' ' C ' ' A' ' 135' ' ' LEU . . . -52.02 -30.31 30.13 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.618 -1.393 . . . . 0.0 109.618 -179.904 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . 0.44 ' CE ' ' OD1' ' A' ' 115' ' ' ASN . 46.4 mmtm -77.56 123.18 26.27 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.098 -1.236 . . . . 0.0 109.168 -179.879 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 71.1 m80 -110.61 15.66 21.91 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.398 -0.814 . . . . 0.0 109.754 -179.641 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 45.0 t -100.08 129.8 50.21 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.13 -0.981 . . . . 0.0 109.88 -179.536 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . 0.409 HG22 ' CE1' ' A' ' 105' ' ' HIS . 84.2 t -130.58 129.83 64.55 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 N-CA-C 109.021 -0.733 . . . . 0.0 109.021 179.651 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 39.5 p90 -110.72 -0.4 17.09 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.074 -1.016 . . . . 0.0 110.052 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -175.43 173.52 46.28 Favored Glycine 0 N--CA 1.493 2.495 0 N-CA-C 109.804 -1.319 . . . . 0.0 109.804 179.443 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 94.0 mt-30 -139.36 165.91 25.95 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.29 -1.123 . . . . 0.0 109.584 -179.83 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 55.1 t -95.56 129.54 45.53 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.222 0 O-C-N 121.175 -0.953 . . . . 0.0 109.162 179.816 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 17.3 m -106.73 -33.65 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.314 -0.866 . . . . 0.0 109.455 179.736 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -143.06 170.78 15.07 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.333 -0.855 . . . . 0.0 109.525 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 98.53 2.39 57.61 Favored Glycine 0 N--CA 1.494 2.558 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.74 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 149' ' ' MET . . . . . 0.511 ' O ' HG12 ' A' ' 152' ' ' VAL . 50.6 ttm -61.02 -32.85 72.44 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.063 -1.257 . . . . 0.0 109.667 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -65.33 -42.29 93.08 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.883 -1.135 . . . . 0.0 110.06 -179.596 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.6 p -81.84 -32.92 11.59 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.141 -0.974 . . . . 0.0 110.611 -179.232 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 152' ' ' VAL . . . . . 0.511 HG12 ' O ' ' A' ' 149' ' ' MET . 0.9 OUTLIER -53.76 -41.0 45.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 120.976 -1.077 . . . . 0.0 109.152 -179.285 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 153' ' ' LYS . . . . . 0.441 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 87.2 mttt -64.03 -34.62 78.42 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.122 -0.986 . . . . 0.0 109.188 179.169 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -62.08 -35.06 77.52 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.381 -0.824 . . . . 0.0 109.687 -179.798 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.404 HD11 ' SD ' ' A' ' 16' ' ' MET . 95.7 mt -70.79 -36.01 62.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.277 -0.889 . . . . 0.0 109.832 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 85.1 tt0 -75.24 -41.89 56.5 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.266 -0.896 . . . . 0.0 111.419 -178.755 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 55.4 pttt -61.27 -34.46 75.21 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.665 -1.272 . . . . 0.0 109.689 -179.047 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 32.6 m -82.82 -6.62 10.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.146 -0.971 . . . . 0.0 108.926 179.427 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -77.67 176.48 53.68 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 109.797 -1.321 . . . . 0.0 109.797 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 86.9 p -157.48 169.54 24.46 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.431 -1.041 . . . . 0.0 109.706 -179.58 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 22.8 t -57.1 -32.69 66.55 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.281 -0.887 . . . . 0.0 108.647 179.256 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 86.2 p -61.38 -27.25 68.39 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.329 -0.857 . . . . 0.0 109.096 179.654 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 93.24 18.04 40.79 Favored Glycine 0 N--CA 1.493 2.488 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 179.756 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 88.7 mtt180 -115.94 143.06 45.96 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.219 -1.165 . . . . 0.0 109.226 179.825 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 165' ' ' THR . . . . . 0.711 HG22 HG21 ' A' ' 69' ' ' VAL . 81.7 p -81.98 150.06 27.85 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.208 -0.933 . . . . 0.0 109.675 -179.894 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -68.96 -36.77 78.3 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.325 -0.859 . . . . 0.0 109.333 179.8 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -111.58 157.84 19.92 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.5 -0.75 . . . . 0.0 109.435 -179.914 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 92.1 mttt -73.02 135.84 44.96 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.309 -0.869 . . . . 0.0 109.175 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 3.4 m -130.94 123.02 53.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.725 0 O-C-N 121.365 -0.834 . . . . 0.0 109.772 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 39.0 t -143.21 138.0 26.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.386 -0.821 . . . . 0.0 108.804 179.557 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.788 ' CG2' ' H ' ' A' ' 64' ' ' SER . 3.0 m -67.7 119.56 13.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 120.826 -1.171 . . . . 0.0 109.547 -179.737 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -68.52 -35.57 77.66 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.233 -0.917 . . . . 0.0 110.086 -179.836 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -156.34 158.32 37.21 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.202 -0.936 . . . . 0.0 110.047 -179.6 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 19.0 p -147.06 148.58 31.79 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.435 -0.79 . . . . 0.0 109.16 179.688 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -177.93 179.72 48.29 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.704 -1.359 . . . . 0.0 109.704 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 61.3 tt0 -106.03 117.25 33.55 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.392 -1.064 . . . . 0.0 109.667 -179.896 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 31.3 tp -62.86 -38.8 92.29 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.094 -1.004 . . . . 0.0 109.216 179.589 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 2.6 p . . . . . 0 N--CA 1.492 1.651 0 CA-C-O 117.897 -1.049 . . . . 0.0 109.707 179.997 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.528 4.829 0 N-CA-C 119.389 2.515 . . . . 0.0 119.389 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 23.2 m -57.66 -35.28 70.34 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.325 -1.103 . . . . 0.0 109.489 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 99.3 m-85 -111.32 123.02 49.36 Favored 'General case' 0 N--CA 1.485 1.309 0 O-C-N 121.329 -0.857 . . . . 0.0 108.873 179.654 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 43.8 m -57.55 -39.74 77.33 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.515 -0.741 . . . . 0.0 109.42 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 83.58 16.82 67.54 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.617 -1.393 . . . . 0.0 109.617 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 86.3 p -138.58 160.22 40.13 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.232 -1.158 . . . . 0.0 109.447 -179.941 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 7.2 ttt -128.56 76.71 78.27 Favored Pre-proline 0 N--CA 1.493 1.695 0 O-C-N 121.388 -0.82 . . . . 0.0 109.517 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_exo -49.12 -175.97 0.0 OUTLIER 'Trans proline' 0 C--N 1.307 -1.628 0 C-N-CA 122.868 2.379 . . . . 0.0 112.614 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 12.0 m120 -98.86 151.3 37.35 Favored Pre-proline 0 N--CA 1.492 1.656 0 O-C-N 121.582 -0.699 . . . . 0.0 109.261 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -68.21 138.08 42.2 Favored 'Trans proline' 0 N--CA 1.496 1.648 0 C-N-CA 122.595 2.197 . . . . 0.0 112.272 179.891 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 95.5 mtt180 -128.72 132.27 47.97 Favored 'General case' 0 N--CA 1.492 1.657 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 179.114 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.5 p -133.24 142.3 42.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.363 -0.836 . . . . 0.0 109.607 -179.564 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 47.1 p90 -140.91 155.26 46.32 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.411 -0.806 . . . . 0.0 109.519 -179.838 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 69.8 m-85 -121.86 135.51 54.9 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.455 -0.778 . . . . 0.0 109.643 179.773 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.0 t0 -88.28 118.83 28.15 Favored 'General case' 0 N--CA 1.493 1.703 0 N-CA-C 108.307 -0.998 . . . . 0.0 108.307 178.864 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 75.2 mtp -116.32 142.86 46.28 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.263 -0.898 . . . . 0.0 110.742 -178.822 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.433 ' OG ' ' OE2' ' A' ' 172' ' ' GLU . 31.6 m -136.4 155.88 49.41 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 179.368 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 33.3 m -119.14 133.69 65.17 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.085 -1.009 . . . . 0.0 109.638 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 57.86 15.57 20.59 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.689 -1.365 . . . . 0.0 109.689 179.844 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 92.08 2.38 68.87 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.386 -1.486 . . . . 0.0 109.386 -179.804 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 41.5 tt0 -105.02 115.15 62.88 Favored Pre-proline 0 N--CA 1.492 1.658 0 O-C-N 121.437 -1.037 . . . . 0.0 109.112 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 77.4 Cg_exo -47.33 133.65 19.91 Favored 'Trans proline' 0 N--CA 1.492 1.412 0 C-N-CA 122.088 1.859 . . . . 0.0 112.106 -179.949 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -101.25 -57.67 2.04 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.292 -0.88 . . . . 0.0 109.568 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -178.02 -169.08 38.46 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.401 -1.48 . . . . 0.0 109.401 -179.775 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 50.9 mtp180 -113.22 144.22 43.07 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.415 -1.05 . . . . 0.0 109.383 179.849 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 76.3 mt -117.85 114.56 45.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 N-CA-C 108.183 -1.043 . . . . 0.0 108.183 178.757 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 38.3 t -109.58 135.21 49.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.437 -0.79 . . . . 0.0 109.628 -179.219 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 75.8 mtm -128.41 156.86 42.49 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.514 -0.741 . . . . 0.0 109.225 -179.588 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -103.83 133.93 48.0 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.283 -0.886 . . . . 0.0 109.706 179.882 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -105.37 128.97 53.78 Favored 'General case' 0 N--CA 1.492 1.638 0 N-CA-C 108.752 -0.832 . . . . 0.0 108.752 179.365 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.401 ' CG ' ' NZ ' ' A' ' 103' ' ' LYS . 94.9 m-85 -92.97 119.41 32.21 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.085 -1.009 . . . . 0.0 109.141 179.981 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -86.33 -42.6 13.57 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.346 -0.846 . . . . 0.0 109.535 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.3 m-20 -65.1 -47.49 76.99 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.368 -0.833 . . . . 0.0 110.298 -179.433 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 37.4 m -67.62 -44.63 77.56 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.211 -0.931 . . . . 0.0 109.775 -179.777 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 5.7 p -138.15 76.98 37.56 Favored Pre-proline 0 N--CA 1.492 1.658 0 N-CA-C 109.082 -0.71 . . . . 0.0 109.082 -179.912 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 10.7 Cg_endo -59.33 -63.31 0.13 Allowed 'Trans proline' 0 C--N 1.31 -1.489 0 C-N-CA 122.571 2.181 . . . . 0.0 112.801 -179.154 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 86.8 mtt-85 -61.24 -35.19 76.58 Favored 'General case' 0 C--N 1.297 -1.688 0 O-C-N 121.652 -0.655 . . . . 0.0 110.755 -178.77 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 25.3 m -60.27 -42.13 94.76 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 120.984 -1.073 . . . . 0.0 110.094 -179.418 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -59.95 -31.82 70.23 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.128 -0.983 . . . . 0.0 109.153 -179.794 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -67.7 -36.88 81.47 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.401 -0.812 . . . . 0.0 109.915 -179.9 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 37.8 t30 -56.6 -40.81 75.92 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.261 -0.899 . . . . 0.0 109.823 -179.458 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 98.4 m-85 -90.43 -48.6 7.01 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.069 -1.019 . . . . 0.0 109.828 -179.89 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.893 ' HE ' HE22 ' A' ' 176' ' ' GLN . 66.2 ttt-85 -57.41 -41.32 80.14 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.512 -0.742 . . . . 0.0 110.505 -179.375 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -65.55 -47.6 75.3 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.049 -1.032 . . . . 0.0 110.373 -178.916 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.469 ' N ' ' CD2' ' A' ' 45' ' ' LEU . 3.3 mm? -65.51 -39.87 92.36 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.124 -0.985 . . . . 0.0 109.665 -179.735 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' CYS . . . . . . . . . . . . . 72.3 m -68.24 -46.09 71.44 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.1 -1.0 . . . . 0.0 109.315 179.819 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 72.6 p -74.34 -33.53 63.16 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.313 -0.867 . . . . 0.0 109.721 179.877 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 75.03 30.81 58.6 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 110.037 -1.225 . . . . 0.0 110.037 179.739 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 77.9 mm-40 -61.97 -36.67 82.16 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.137 -1.214 . . . . 0.0 109.441 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 42.0 mmtm -60.66 -33.87 73.45 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.233 -0.917 . . . . 0.0 109.402 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 92.84 171.3 40.45 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.096 -1.602 . . . . 0.0 109.096 -179.692 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.636 HG23 ' HA ' ' A' ' 58' ' ' PRO . 99.2 m -75.88 141.39 42.38 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.317 -1.108 . . . . 0.0 109.76 -179.807 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -60.42 138.15 48.62 Favored Glycine 0 N--CA 1.488 2.164 0 N-CA-C 109.405 -1.478 . . . . 0.0 109.405 179.787 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 87.1 mtt-85 -60.24 -29.22 68.62 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.303 -1.116 . . . . 0.0 110.231 -179.803 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 75.4 m -78.52 11.0 2.7 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.181 -0.95 . . . . 0.0 110.32 -179.154 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 82.16 77.03 1.07 Allowed Glycine 0 N--CA 1.492 2.4 0 N-CA-C 109.217 -1.553 . . . . 0.0 109.217 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . 0.478 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 55.0 mttp -157.47 75.0 4.16 Favored Pre-proline 0 C--N 1.302 -1.463 0 O-C-N 121.449 -1.03 . . . . 0.0 108.3 -179.944 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.636 ' HA ' HG23 ' A' ' 52' ' ' THR . 73.1 Cg_exo -50.04 130.28 27.32 Favored 'Trans proline' 0 C--N 1.302 -1.909 0 C-N-CA 122.962 2.441 . . . . 0.0 112.517 -179.085 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.478 ' CD1' ' O ' ' A' ' 57' ' ' LYS . 8.6 mp -100.8 74.22 1.63 Allowed 'General case' 0 N--CA 1.489 1.524 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 -179.638 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 77.5 m80 -139.21 150.68 45.82 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.436 -0.79 . . . . 0.0 109.516 179.865 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 3.8 m-85 -101.95 20.48 16.41 Favored 'General case' 0 N--CA 1.493 1.691 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 179.573 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 85.0 mttt -77.57 157.55 30.26 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.434 -0.791 . . . . 0.0 109.525 -179.663 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 54.8 t0 56.89 48.9 15.04 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.486 -0.759 . . . . 0.0 109.805 179.788 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 87.4 p -111.71 154.25 25.26 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.4 -0.813 . . . . 0.0 109.077 179.69 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 27.8 t -131.03 149.3 52.68 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.227 -0.921 . . . . 0.0 109.74 -179.603 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -72.68 135.84 45.49 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.351 -0.843 . . . . 0.0 109.131 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 32.1 m-70 -77.84 -53.01 7.98 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.259 -0.901 . . . . 0.0 110.71 -179.219 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 98.1 mtt180 -130.27 148.96 52.16 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.043 -1.035 . . . . 0.0 110.541 -179.017 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.694 HG21 HG22 ' A' ' 165' ' ' THR . 8.5 m -143.67 59.6 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.585 -0.697 . . . . 0.0 109.135 179.497 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 18.6 mt -82.14 132.67 52.73 Favored Pre-proline 0 C--N 1.301 -1.543 0 O-C-N 121.164 -0.96 . . . . 0.0 109.771 -179.135 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -70.98 149.67 59.49 Favored 'Trans proline' 0 N--CA 1.492 1.437 0 C-N-CA 122.399 2.066 . . . . 0.0 112.113 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 81.33 -58.28 4.86 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 179.879 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -70.01 -84.83 0.03 OUTLIER 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.269 -1.136 . . . . 0.0 109.637 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' MET . . . . . 0.484 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 14.1 ptt? 178.03 -172.83 0.13 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.334 -0.854 . . . . 0.0 109.544 179.877 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 14.6 p -125.75 137.26 53.8 Favored 'General case' 0 N--CA 1.493 1.721 0 N-CA-C 108.595 -0.891 . . . . 0.0 108.595 179.45 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 93.1 mt-30 -111.53 153.99 25.44 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.167 -0.958 . . . . 0.0 109.771 -179.485 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -134.76 174.43 21.07 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.006 -1.638 . . . . 0.0 109.006 179.7 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -137.24 161.03 25.19 Favored Glycine 0 N--CA 1.493 2.477 0 N-CA-C 109.717 -1.353 . . . . 0.0 109.717 -179.88 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 90.3 m-20 -72.89 156.81 38.49 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.379 -1.071 . . . . 0.0 109.457 179.865 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.411 ' CE2' ' O ' ' A' ' 58' ' ' PRO . 50.7 p90 -61.97 -18.49 60.58 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.327 -0.858 . . . . 0.0 109.744 -179.666 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.583 ' OG1' ' N ' ' A' ' 88' ' ' GLY . 73.1 p -61.71 -34.39 75.69 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.046 -1.034 . . . . 0.0 109.534 -179.902 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . 0.559 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 172.24 -50.46 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.329 -0.857 . . . . 0.0 109.434 179.942 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 92.45 3.14 67.2 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 80.3 m-20 -86.9 5.91 34.6 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.218 -1.166 . . . . 0.0 109.306 179.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 95.13 -42.61 2.34 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 -179.804 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 47.8 m -61.23 -38.91 88.33 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.207 -1.172 . . . . 0.0 109.114 179.601 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -85.35 -166.46 41.92 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.583 ' N ' ' OG1' ' A' ' 81' ' ' THR . . . 83.52 43.69 7.25 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 -179.897 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -64.05 144.14 57.33 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.266 -1.138 . . . . 0.0 109.478 -179.848 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 29.3 t -102.91 142.12 34.55 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.34 -0.85 . . . . 0.0 109.369 -179.884 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.406 HG12 ' H ' ' A' ' 91' ' ' ILE . 6.4 pt -63.26 -42.68 97.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.339 -0.851 . . . . 0.0 109.915 -179.737 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 3.8 m-30 -69.85 -36.19 75.35 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.976 -1.077 . . . . 0.0 109.558 179.871 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 80.81 14.85 78.95 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.224 -1.55 . . . . 0.0 109.224 -179.728 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -145.3 158.11 43.9 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.372 -1.075 . . . . 0.0 109.451 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -86.43 154.46 21.14 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.182 -0.949 . . . . 0.0 109.56 -179.881 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.401 ' H ' ' HB2' ' A' ' 121' ' ' ASN . 89.0 m-85 -100.23 130.64 46.38 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.281 -0.887 . . . . 0.0 109.305 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -76.62 138.75 40.29 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.159 -0.963 . . . . 0.0 109.496 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.768 ' H ' HD22 ' A' ' 119' ' ' ASN . 88.5 m-20 -75.54 131.25 39.92 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.267 -0.896 . . . . 0.0 109.266 179.836 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -104.28 -55.46 2.36 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.239 -0.913 . . . . 0.0 110.061 -179.797 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 84.9 m-20 -106.35 128.82 54.3 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.233 -0.917 . . . . 0.0 110.24 -179.149 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 90.2 m-85 -108.38 10.52 27.5 Favored 'General case' 0 N--CA 1.493 1.686 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 179.352 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 92.0 mt -54.9 -37.0 39.88 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.397 -0.814 . . . . 0.0 110.568 -178.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . 0.401 ' NZ ' ' CG ' ' A' ' 31' ' ' PHE . 87.2 mttt -77.2 127.99 33.59 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.871 -1.143 . . . . 0.0 109.909 -179.427 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . 0.593 ' O ' ' N ' ' A' ' 106' ' ' THR . 34.4 ttmt -139.08 149.96 45.18 Favored 'General case' 0 N--CA 1.492 1.636 0 N-CA-C 109.012 -0.736 . . . . 0.0 109.012 179.862 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' HIS . . . . . . . . . . . . . 85.5 m-70 -53.69 82.34 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.094 -1.004 . . . . 0.0 109.66 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . 0.593 ' N ' ' O ' ' A' ' 104' ' ' LYS . 54.9 p -73.45 -28.0 61.72 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.235 -0.915 . . . . 0.0 109.525 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -150.21 -177.51 24.25 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.882 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 69.6 Cg_endo -76.14 156.33 37.96 Favored 'Trans proline' 0 C--N 1.306 -1.666 0 C-N-CA 123.025 2.483 . . . . 0.0 112.198 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 81.86 45.75 7.05 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 110.098 -1.201 . . . . 0.0 110.098 179.706 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 41.6 mm -115.98 136.91 51.39 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 121.287 -1.125 . . . . 0.0 109.459 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.543 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 2.4 mm? -87.54 128.28 35.25 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.199 -0.938 . . . . 0.0 109.263 179.716 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 87.7 p -143.16 150.84 39.96 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.332 -0.855 . . . . 0.0 109.547 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' MET . . . . . 0.458 ' CE ' ' OD1' ' A' ' 121' ' ' ASN . 86.5 mtp -95.35 139.47 31.6 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.343 -0.848 . . . . 0.0 109.329 179.621 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -64.38 145.35 56.2 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.237 -0.914 . . . . 0.0 109.54 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . 0.573 ' ND2' HG23 ' A' ' 140' ' ' VAL . 2.7 p30 -165.77 114.98 1.0 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.184 -0.948 . . . . 0.0 109.613 179.863 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -66.19 -31.31 72.06 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.383 -0.823 . . . . 0.0 109.356 179.721 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -136.84 169.81 23.72 Favored Glycine 0 N--CA 1.493 2.474 0 N-CA-C 109.351 -1.5 . . . . 0.0 109.351 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -65.84 157.67 57.82 Favored 'Trans proline' 0 C--N 1.305 -1.757 0 C-N-CA 122.819 2.346 . . . . 0.0 111.969 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' ASN . . . . . 0.768 HD22 ' H ' ' A' ' 98' ' ' ASP . 16.4 m120 55.89 44.3 26.06 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.425 -0.797 . . . . 0.0 109.325 -179.857 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 61.2 m -135.96 127.83 29.37 Favored 'General case' 0 C--N 1.304 -1.383 0 N-CA-C 108.804 -0.814 . . . . 0.0 108.804 179.851 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 121' ' ' ASN . . . . . 0.458 ' OD1' ' CE ' ' A' ' 113' ' ' MET . 31.9 t30 -100.5 109.9 22.05 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.423 -0.798 . . . . 0.0 109.374 -179.954 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -85.8 135.33 13.29 Favored Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.644 -1.383 . . . . 0.0 109.644 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 85.3 p -65.1 -23.38 67.14 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.248 -1.148 . . . . 0.0 109.408 179.871 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.0 mt-30 -101.89 154.2 19.15 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.378 -0.826 . . . . 0.0 109.606 -179.728 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 49.3 p90 -133.6 160.95 35.96 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.471 -0.768 . . . . 0.0 109.461 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.484 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 45.6 p90 -140.0 159.71 41.58 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.324 -0.86 . . . . 0.0 109.504 -179.91 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 72.5 mt -119.77 134.24 63.95 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.407 -0.808 . . . . 0.0 109.444 179.845 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 1.8 m -92.2 105.55 17.74 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.104 -0.998 . . . . 0.0 109.268 179.827 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 54.2 p -74.72 -9.12 58.26 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.271 -0.893 . . . . 0.0 109.463 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -150.44 156.15 40.91 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.362 -0.836 . . . . 0.0 109.277 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 82.5 tttt -68.01 135.16 51.88 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.216 -0.928 . . . . 0.0 109.23 179.855 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 6.5 p -122.11 158.0 30.24 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.409 -0.807 . . . . 0.0 109.558 -179.74 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -138.69 -35.66 0.58 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.317 -0.865 . . . . 0.0 109.081 179.812 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 0.7 OUTLIER -58.7 -29.43 66.64 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.447 -0.783 . . . . 0.0 109.219 179.713 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 18.2 mt -59.49 -35.77 74.77 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.32 -0.863 . . . . 0.0 109.628 179.638 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 57.5 t0 49.45 50.94 17.31 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.286 -0.884 . . . . 0.0 109.518 179.801 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -130.2 127.63 5.37 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.166 -1.574 . . . . 0.0 109.166 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . 0.515 ' O ' ' O ' ' A' ' 139' ' ' HIS . 88.2 mttt -56.58 -38.19 71.65 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.36 -1.083 . . . . 0.0 109.652 -179.846 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 139' ' ' HIS . . . . . 0.515 ' O ' ' O ' ' A' ' 138' ' ' LYS . 54.6 m170 56.86 147.88 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.644 -0.66 . . . . 0.0 109.824 179.936 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.573 HG23 ' ND2' ' A' ' 115' ' ' ASN . 41.0 t -116.05 133.6 62.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.413 -0.804 . . . . 0.0 109.296 -179.893 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 60.1 t -107.27 127.51 62.99 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 121.272 -0.893 . . . . 0.0 109.52 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 39.1 p90 -116.16 3.06 13.45 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.403 -0.81 . . . . 0.0 109.682 179.773 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -173.08 179.13 44.7 Favored Glycine 0 N--CA 1.494 2.528 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 179.612 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.3 pt20 -145.82 166.29 26.35 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.114 -1.227 . . . . 0.0 109.865 -179.855 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 74.6 t -100.63 132.11 46.92 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.122 0 O-C-N 121.278 -0.888 . . . . 0.0 109.581 -179.855 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 12.9 m -113.85 -31.52 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.308 -0.87 . . . . 0.0 109.422 179.563 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -139.62 167.25 22.52 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.356 -0.84 . . . . 0.0 109.469 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 97.67 4.0 58.18 Favored Glycine 0 N--CA 1.494 2.527 0 N-CA-C 109.941 -1.264 . . . . 0.0 109.941 179.765 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 149' ' ' MET . . . . . 0.436 ' O ' HG12 ' A' ' 152' ' ' VAL . 65.0 mtt -60.71 -33.44 72.89 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.098 -1.236 . . . . 0.0 109.479 179.934 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 89.3 m-20 -64.02 -41.64 97.38 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.913 -1.117 . . . . 0.0 109.852 -179.761 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.5 p -83.24 -34.37 10.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.199 -0.938 . . . . 0.0 110.402 -179.446 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 152' ' ' VAL . . . . . 0.464 ' CG1' ' N ' ' A' ' 153' ' ' LYS . 0.6 OUTLIER -57.02 -42.77 79.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 120.872 -1.142 . . . . 0.0 109.382 -179.219 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 153' ' ' LYS . . . . . 0.464 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 66.6 mttm -63.84 -34.41 77.87 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.242 -0.911 . . . . 0.0 109.517 179.503 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -61.48 -37.9 85.33 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.24 -0.913 . . . . 0.0 109.962 -179.492 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 88.3 mt -72.51 -35.14 50.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.189 -0.945 . . . . 0.0 110.047 -179.717 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -76.29 -41.64 48.04 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.202 -0.936 . . . . 0.0 111.191 -178.865 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 39.1 pttt -61.8 -33.92 74.98 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 120.852 -1.155 . . . . 0.0 109.89 -178.819 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.42 ' HB ' ' H ' ' A' ' 166' ' ' ALA . 35.3 m -77.8 -13.99 14.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.011 -1.056 . . . . 0.0 109.26 179.714 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -74.3 168.27 54.44 Favored Glycine 0 N--CA 1.489 2.2 0 N-CA-C 109.789 -1.324 . . . . 0.0 109.789 -179.718 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 22.8 t -157.67 176.36 12.71 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.418 -1.048 . . . . 0.0 109.361 -179.758 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 23.6 m -54.01 -31.78 52.16 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.282 -0.886 . . . . 0.0 109.182 179.817 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 23.9 m -55.56 -33.07 63.53 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.28 -0.888 . . . . 0.0 109.462 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 95.38 10.97 56.54 Favored Glycine 0 N--CA 1.493 2.482 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 179.828 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 81.7 mtm180 -121.44 146.57 46.76 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.303 -1.116 . . . . 0.0 109.474 179.874 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 165' ' ' THR . . . . . 0.694 HG22 HG21 ' A' ' 69' ' ' VAL . 80.5 p -80.49 151.42 29.24 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.224 -0.923 . . . . 0.0 109.646 -179.884 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 166' ' ' ALA . . . . . 0.42 ' H ' ' HB ' ' A' ' 158' ' ' VAL . . . -66.66 -37.06 84.02 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.322 -0.862 . . . . 0.0 109.077 179.592 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -108.71 158.69 17.39 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.555 -0.716 . . . . 0.0 109.096 179.721 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -71.4 130.78 42.2 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.14 -0.975 . . . . 0.0 109.394 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 43.6 t -122.15 124.24 70.67 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 121.38 -0.825 . . . . 0.0 109.435 179.795 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 48.8 t -149.1 154.61 9.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.48 -0.763 . . . . 0.0 109.141 179.865 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 2.1 t -90.15 124.87 43.0 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 O-C-N 121.258 -0.901 . . . . 0.0 109.932 -179.312 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 172' ' ' GLU . . . . . 0.433 ' OE2' ' OG ' ' A' ' 17' ' ' SER . 97.1 mt-10 -64.96 -28.87 69.81 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.449 -0.782 . . . . 0.0 109.192 179.46 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 173' ' ' ASP . . . . . 0.425 ' C ' ' OD1' ' A' ' 173' ' ' ASP . 53.1 p30 -175.14 179.58 1.53 Allowed 'General case' 0 N--CA 1.492 1.639 0 C-N-CA 119.449 -0.9 . . . . 0.0 110.352 -179.665 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 26.7 p -151.48 151.38 31.56 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.45 -0.781 . . . . 0.0 109.265 179.711 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -178.18 176.83 48.22 Favored Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.792 -1.323 . . . . 0.0 109.792 179.812 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 176' ' ' GLN . . . . . 0.893 HE22 ' HE ' ' A' ' 43' ' ' ARG . 59.3 tt0 -107.11 127.21 53.29 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.375 -1.073 . . . . 0.0 109.61 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 29.0 tp -60.98 -37.78 83.66 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.187 -0.945 . . . . 0.0 109.194 179.641 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 9.5 t . . . . . 0 N--CA 1.49 1.563 0 CA-C-O 117.945 -1.026 . . . . 0.0 109.483 -179.942 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.528 4.816 0 N-CA-C 119.357 2.503 . . . . 0.0 119.357 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 55.3 p -70.47 160.59 32.13 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.213 -1.169 . . . . 0.0 109.479 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 99.4 m-85 -114.11 126.23 54.85 Favored 'General case' 0 N--CA 1.486 1.363 0 N-CA-C 108.822 -0.807 . . . . 0.0 108.822 179.563 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 56.2 p -64.04 -31.71 73.0 Favored 'General case' 0 C--N 1.297 -1.711 0 O-C-N 121.554 -0.716 . . . . 0.0 109.41 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 83.04 -170.19 49.18 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.716 -1.354 . . . . 0.0 109.716 179.841 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 49.9 m -66.65 158.02 31.08 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.32 -1.106 . . . . 0.0 109.624 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 57.3 mtp -62.86 150.55 87.3 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.25 -0.906 . . . . 0.0 109.232 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_endo -69.01 169.48 17.87 Favored 'Trans proline' 0 N--CA 1.493 1.462 0 C-N-CA 122.7 2.267 . . . . 0.0 112.108 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 3.2 m-80 -66.91 148.34 98.87 Favored Pre-proline 0 N--CA 1.489 1.485 0 O-C-N 121.38 -0.825 . . . . 0.0 109.486 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -70.65 140.24 38.9 Favored 'Trans proline' 0 N--CA 1.494 1.558 0 C-N-CA 122.777 2.318 . . . . 0.0 112.409 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 97.8 mtt180 -128.96 132.09 47.56 Favored 'General case' 0 N--CA 1.491 1.592 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 179.127 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.6 p -136.51 142.62 37.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.248 -0.907 . . . . 0.0 109.633 -179.441 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 38.5 p90 -144.19 154.79 43.5 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.344 -0.847 . . . . 0.0 109.589 -179.866 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 67.1 m-85 -126.66 138.14 53.38 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.332 -0.855 . . . . 0.0 109.597 179.648 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.468 ' CG ' ' NH1' ' A' ' 25' ' ' ARG . 90.2 m-20 -87.02 129.94 34.68 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.168 -0.957 . . . . 0.0 108.616 178.983 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' MET . . . . . 0.541 ' SD ' HD12 ' A' ' 26' ' ' ILE . 83.8 mtp -117.35 153.85 32.31 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.164 -0.96 . . . . 0.0 110.37 -179.441 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 76.9 p -148.14 167.33 25.32 Favored 'General case' 0 N--CA 1.487 1.42 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 179.629 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 7.9 p -127.4 134.24 66.19 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.244 -0.91 . . . . 0.0 109.717 -179.815 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 54.79 17.13 8.55 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.626 -1.389 . . . . 0.0 109.626 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 92.24 4.56 66.39 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 63.9 mt-30 -105.49 113.43 64.24 Favored Pre-proline 0 N--CA 1.494 1.728 0 O-C-N 121.345 -1.091 . . . . 0.0 109.241 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_exo -48.81 137.24 27.6 Favored 'Trans proline' 0 N--CA 1.492 1.406 0 C-N-CA 122.123 1.882 . . . . 0.0 112.086 179.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -111.22 -59.4 1.98 Allowed 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.411 -0.806 . . . . 0.0 109.498 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -170.44 -169.8 33.99 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.376 -1.49 . . . . 0.0 109.376 -179.859 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . 0.468 ' NH1' ' CG ' ' A' ' 15' ' ' ASP . 88.2 mtt-85 -116.46 145.8 43.03 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.308 -1.113 . . . . 0.0 109.784 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.541 HD12 ' SD ' ' A' ' 16' ' ' MET . 73.5 mt -119.8 122.45 68.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 178.863 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 46.1 t -111.02 133.3 57.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.3 -0.875 . . . . 0.0 109.3 -179.562 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 75.2 mtm -116.22 150.88 36.8 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.447 -0.783 . . . . 0.0 109.412 -179.767 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.419 ' C ' HD22 ' A' ' 30' ' ' LEU . 84.4 tt0 -101.47 130.92 47.81 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.277 -0.889 . . . . 0.0 109.926 -179.594 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.419 HD22 ' C ' ' A' ' 29' ' ' GLU . 2.9 mm? -109.86 127.74 54.9 Favored 'General case' 0 N--CA 1.493 1.683 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 179.277 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 96.3 m-85 -98.96 118.53 35.93 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.167 -0.958 . . . . 0.0 109.049 179.525 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -79.66 -41.94 25.86 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.379 -0.826 . . . . 0.0 109.776 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -64.35 -46.6 82.72 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.286 -0.884 . . . . 0.0 110.246 -179.333 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 33.1 m -67.38 -44.42 78.97 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.136 -0.978 . . . . 0.0 109.815 -179.72 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.449 ' O ' ' OG1' ' A' ' 35' ' ' THR . 6.8 p -141.61 79.65 16.85 Favored Pre-proline 0 N--CA 1.492 1.649 0 O-C-N 121.429 -0.794 . . . . 0.0 109.291 -179.859 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -64.25 -54.63 0.78 Allowed 'Trans proline' 0 C--N 1.308 -1.564 0 C-N-CA 122.286 1.991 . . . . 0.0 112.508 -179.404 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 70.9 mtp180 -62.43 -38.75 90.93 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.52 -0.737 . . . . 0.0 110.636 -179.196 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 28.6 m -65.16 -43.82 90.55 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.948 -1.095 . . . . 0.0 110.236 -179.474 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -63.14 -30.61 71.73 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.18 -0.95 . . . . 0.0 109.21 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -71.2 -43.78 66.72 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.345 -0.847 . . . . 0.0 109.837 -179.733 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 45.8 t30 -62.76 -47.82 81.86 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.248 -0.907 . . . . 0.0 109.992 -179.512 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 61.1 t80 -63.79 -47.75 79.64 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.208 -0.932 . . . . 0.0 109.567 -179.667 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.652 ' CZ ' HE22 ' A' ' 176' ' ' GLN . 74.4 ttt180 -57.83 -38.17 75.12 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.365 -0.835 . . . . 0.0 109.854 -179.849 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.512 ' O ' ' N ' ' A' ' 48' ' ' GLY . . . -62.32 -42.9 99.76 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.118 -0.989 . . . . 0.0 110.088 -179.247 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.591 HD12 ' CD1' ' A' ' 61' ' ' TYR . 4.4 mm? -66.28 -38.02 86.79 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.02 -1.05 . . . . 0.0 109.582 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' CYS . . . . . . . . . . . . . 3.8 m -65.9 -53.56 37.88 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.104 -0.997 . . . . 0.0 109.357 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 64.4 p -75.02 -31.46 61.37 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.336 -0.852 . . . . 0.0 109.451 179.674 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.512 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 75.7 37.34 40.12 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 110.314 -1.114 . . . . 0.0 110.314 179.51 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -61.61 -37.66 84.77 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.858 -1.377 . . . . 0.0 109.418 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.458 ' HZ1' ' CD1' ' A' ' 91' ' ' ILE . 27.0 mmtp -61.38 -34.0 74.6 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.28 -0.887 . . . . 0.0 109.279 179.819 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 82.13 -86.63 1.43 Allowed Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.654 -1.378 . . . . 0.0 109.654 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.566 HG23 ' C ' ' A' ' 57' ' ' LYS . 48.8 m -123.77 140.37 53.05 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.448 -1.03 . . . . 0.0 109.637 -179.779 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -56.58 -35.63 67.69 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.44 -1.464 . . . . 0.0 109.44 179.817 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . 0.533 ' H ' HG22 ' A' ' 52' ' ' THR . 74.3 mtp85 -140.22 -110.2 0.15 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.35 -1.088 . . . . 0.0 109.207 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 24.9 p -134.13 0.71 3.16 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.366 -0.833 . . . . 0.0 109.746 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -151.09 49.3 0.55 Allowed Glycine 0 N--CA 1.492 2.417 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . 0.566 ' C ' HG23 ' A' ' 52' ' ' THR . 59.7 tttm -172.8 74.29 0.42 Allowed Pre-proline 0 N--CA 1.488 1.474 0 O-C-N 121.364 -1.08 . . . . 0.0 108.855 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.402 ' N ' HG23 ' A' ' 52' ' ' THR . 72.0 Cg_exo -47.77 131.93 20.85 Favored 'Trans proline' 0 C--N 1.305 -1.757 0 C-N-CA 122.702 2.268 . . . . 0.0 112.128 -179.417 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.573 ' O ' ' CG ' ' A' ' 60' ' ' HIS . 14.6 tp -109.31 118.39 36.56 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.616 -0.678 . . . . 0.0 109.437 -179.413 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . 0.577 ' O ' ' CZ ' ' A' ' 80' ' ' PHE . 92.4 m-70 -160.62 135.31 7.51 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.244 -0.91 . . . . 0.0 109.944 179.889 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . 0.591 ' CD1' HD12 ' A' ' 45' ' ' LEU . 2.9 m-30 -87.39 3.38 47.26 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.163 -0.96 . . . . 0.0 108.882 179.104 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 62.2 tttt -68.07 146.31 53.61 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.383 -0.823 . . . . 0.0 109.7 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 46.7 t0 61.67 50.8 4.23 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.427 -0.795 . . . . 0.0 110.07 179.784 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.718 ' H ' ' CG2' ' A' ' 171' ' ' VAL . 96.7 p -97.69 157.24 16.16 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.187 -0.946 . . . . 0.0 109.146 179.531 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 29.0 t -128.84 150.09 50.48 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.438 -0.789 . . . . 0.0 109.378 -179.792 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 4.4 m-85 -75.55 125.77 29.69 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.227 -0.92 . . . . 0.0 109.144 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 79.0 t60 -62.76 -48.57 78.61 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.326 -0.859 . . . . 0.0 110.044 -179.354 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.68 HH21 ' NE2' ' A' ' 76' ' ' GLN . 36.8 ptt180 -163.64 162.38 24.18 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.223 -0.923 . . . . 0.0 109.378 -179.925 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -141.75 112.61 3.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.315 -0.866 . . . . 0.0 109.142 179.738 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 43.8 mt -107.56 124.33 35.33 Favored Pre-proline 0 N--CA 1.492 1.645 0 O-C-N 121.45 -0.781 . . . . 0.0 109.073 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_endo -71.75 137.46 29.91 Favored 'Trans proline' 0 N--CA 1.491 1.363 0 C-N-CA 122.031 1.82 . . . . 0.0 112.338 -179.729 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 94.46 -28.25 11.57 Favored Glycine 0 N--CA 1.493 2.466 0 N-CA-C 109.723 -1.351 . . . . 0.0 109.723 179.739 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 94.3 m-85 -100.87 -80.74 0.48 Allowed 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.271 -1.135 . . . . 0.0 109.789 -179.94 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 13.2 ptp -177.87 -168.95 0.19 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.283 -0.886 . . . . 0.0 109.873 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -124.55 130.44 52.45 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.486 -0.759 . . . . 0.0 109.03 179.822 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' GLN . . . . . 0.68 ' NE2' HH21 ' A' ' 68' ' ' ARG . 93.5 mt-30 -108.03 151.65 25.56 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.379 -0.826 . . . . 0.0 109.818 -179.633 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -169.18 -170.49 33.82 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.32 -1.512 . . . . 0.0 109.32 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 88.67 21.25 44.29 Favored Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.766 -1.334 . . . . 0.0 109.766 179.912 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 83.9 m-20 -84.38 12.64 6.43 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.233 -1.157 . . . . 0.0 109.433 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.577 ' CZ ' ' O ' ' A' ' 60' ' ' HIS . 83.1 t80 -50.08 -40.98 47.23 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.313 -0.867 . . . . 0.0 110.134 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.662 ' O ' ' HB2' ' A' ' 82' ' ' ALA . 60.6 p -65.35 -31.26 72.29 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.957 -1.089 . . . . 0.0 109.499 -179.956 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . 0.662 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 165.3 -53.37 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.415 -0.803 . . . . 0.0 109.32 179.898 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 88.51 2.36 79.53 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 78.5 m-20 -87.85 6.93 33.06 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.254 -1.145 . . . . 0.0 109.478 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 97.2 -39.31 2.82 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.26 -1.536 . . . . 0.0 109.26 -179.788 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 57.1 p -72.63 -21.35 61.12 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.335 -1.097 . . . . 0.0 109.008 179.49 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -84.65 -167.21 42.57 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.603 ' H ' ' CB ' ' A' ' 81' ' ' THR . . . 81.76 44.6 7.69 Favored Glycine 0 N--CA 1.488 2.134 0 N-CA-C 109.016 -1.634 . . . . 0.0 109.016 -179.871 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -94.36 142.49 27.36 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.377 -1.072 . . . . 0.0 109.708 -179.55 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 90.7 p -112.85 158.26 20.38 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.442 -0.786 . . . . 0.0 109.197 179.844 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.458 ' CD1' ' HZ1' ' A' ' 50' ' ' LYS . 29.1 pt -59.08 -32.02 47.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.142 -0.974 . . . . 0.0 109.634 -179.718 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . 0.53 ' O ' ' N ' ' A' ' 94' ' ' ALA . 56.8 m-85 -66.46 -30.12 70.39 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.223 -0.923 . . . . 0.0 109.631 179.636 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 64.07 -72.27 0.05 OUTLIER Glycine 0 N--CA 1.489 2.206 0 N-CA-C 109.336 -1.506 . . . . 0.0 109.336 -179.889 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . 0.53 ' N ' ' O ' ' A' ' 92' ' ' TYR . . . -63.55 143.96 57.39 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.376 -1.073 . . . . 0.0 109.119 179.719 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . 0.631 ' HD3' HG23 ' A' ' 120' ' ' THR . 59.0 mttp -88.58 149.33 23.63 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.379 -0.826 . . . . 0.0 109.71 -179.849 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 52.0 p90 -130.86 158.52 39.97 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.425 -0.797 . . . . 0.0 109.252 179.705 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -84.79 146.94 27.11 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.28 -0.887 . . . . 0.0 109.893 -179.577 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 60.4 t0 -78.88 124.8 28.59 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.336 -0.852 . . . . 0.0 109.113 179.747 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -54.42 -39.15 67.06 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.146 -0.972 . . . . 0.0 109.729 -179.518 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . 0.469 ' CG ' ' H ' ' A' ' 101' ' ' PHE . 15.1 t-20 -172.32 -177.45 1.81 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.097 -1.002 . . . . 0.0 109.808 179.855 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' PHE . . . . . 0.469 ' H ' ' CG ' ' A' ' 100' ' ' ASN . 15.7 p90 -147.42 62.57 1.16 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.487 -0.758 . . . . 0.0 109.067 179.861 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 80.6 mt -59.66 -37.34 70.42 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.268 -0.895 . . . . 0.0 110.216 -179.447 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 67.6 mttm -86.15 139.41 31.11 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.017 -1.052 . . . . 0.0 109.982 -179.436 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 59.2 mttp -129.12 -176.02 3.74 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.483 -0.761 . . . . 0.0 109.457 179.737 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' HIS . . . . . 0.53 ' O ' ' CG ' ' A' ' 105' ' ' HIS . 49.1 p-80 -109.57 100.36 9.42 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.519 -0.738 . . . . 0.0 109.276 179.704 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 63.7 p -106.96 -0.8 22.85 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.406 -0.809 . . . . 0.0 109.599 -179.831 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -146.62 171.29 27.45 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.336 -1.505 . . . . 0.0 109.336 -179.89 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -74.39 155.44 45.91 Favored 'Trans proline' 0 C--N 1.306 -1.672 0 C-N-CA 122.888 2.392 . . . . 0.0 112.17 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 83.22 44.9 6.8 Favored Glycine 0 N--CA 1.493 2.493 0 N-CA-C 110.234 -1.146 . . . . 0.0 110.234 179.488 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 44.0 mm -116.31 134.21 60.43 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 121.251 -1.146 . . . . 0.0 109.342 179.723 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.525 ' N ' HD22 ' A' ' 111' ' ' LEU . 3.4 mm? -91.44 130.91 37.21 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.251 -0.906 . . . . 0.0 109.385 179.709 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 47.2 t -143.68 142.24 30.9 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.238 -0.914 . . . . 0.0 109.439 179.826 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 72.1 mtm -82.87 131.21 35.2 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.193 -0.942 . . . . 0.0 109.205 179.769 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . 0.539 ' O ' ' ND2' ' A' ' 115' ' ' ASN . . . -65.87 141.71 58.17 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.192 -0.943 . . . . 0.0 109.587 -179.911 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . 0.539 ' ND2' ' O ' ' A' ' 114' ' ' ALA . 18.3 m120 -146.27 113.03 6.03 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.322 -0.862 . . . . 0.0 109.027 179.664 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -68.51 -29.96 68.67 Favored 'General case' 0 C--N 1.297 -1.682 0 O-C-N 121.46 -0.775 . . . . 0.0 109.488 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -136.51 167.31 24.54 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 109.256 -1.538 . . . . 0.0 109.256 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -67.39 156.22 67.07 Favored 'Trans proline' 0 C--N 1.306 -1.696 0 C-N-CA 122.805 2.336 . . . . 0.0 111.889 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' ASN . . . . . 0.466 ' N ' HD22 ' A' ' 119' ' ' ASN . 2.5 m120 54.35 45.26 27.55 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.422 -0.799 . . . . 0.0 109.35 -179.886 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' THR . . . . . 0.631 HG23 ' HD3' ' A' ' 95' ' ' LYS . 57.9 m -133.73 126.58 31.0 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 108.792 -0.818 . . . . 0.0 108.792 179.85 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 39.6 t30 -100.77 107.42 18.99 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.504 -0.748 . . . . 0.0 109.355 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -98.44 126.32 8.85 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 86.1 p -62.96 -25.96 68.6 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.268 -1.137 . . . . 0.0 109.385 179.795 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.3 mt-30 -73.86 148.18 42.58 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.283 -0.886 . . . . 0.0 109.399 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 48.8 p90 -136.3 162.75 32.14 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.326 -0.859 . . . . 0.0 109.446 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 49.0 p90 -136.48 160.8 37.67 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.371 -0.831 . . . . 0.0 109.445 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 69.2 mt -115.99 130.16 71.16 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.446 -0.784 . . . . 0.0 109.352 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -101.17 104.2 15.27 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.273 -0.892 . . . . 0.0 109.241 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 59.2 p -84.59 0.67 49.24 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.281 -0.887 . . . . 0.0 109.37 179.878 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -144.42 161.99 37.64 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.3 -0.875 . . . . 0.0 109.466 -179.768 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 92.4 mttt -76.0 150.65 37.37 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.254 -0.904 . . . . 0.0 109.486 -179.91 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 16.0 p -120.0 161.01 21.65 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.39 -0.819 . . . . 0.0 109.374 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -159.61 -44.12 0.05 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.19 -0.944 . . . . 0.0 109.758 -179.908 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 134' ' ' TRP . . . . . 0.4 ' CE2' ' CD2' ' A' ' 135' ' ' LEU . 33.3 p90 -73.71 -9.64 58.87 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.284 -0.885 . . . . 0.0 109.39 -179.802 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . 0.51 ' N ' ' CD2' ' A' ' 135' ' ' LEU . 2.8 mm? -61.59 -33.8 74.53 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.238 -0.914 . . . . 0.0 108.771 179.239 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 59.1 t0 49.16 49.91 18.83 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.44 -0.788 . . . . 0.0 109.754 179.648 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -143.83 163.79 27.59 Favored Glycine 0 N--CA 1.485 1.932 0 N-CA-C 108.915 -1.674 . . . . 0.0 108.915 179.847 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 13.6 mptt -97.21 142.73 28.77 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.472 -1.016 . . . . 0.0 109.465 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 99.3 m-70 -128.97 146.75 50.88 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.46 -0.775 . . . . 0.0 109.428 179.853 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 42.3 t -112.94 135.0 53.78 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.402 -0.811 . . . . 0.0 109.277 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 56.3 t -108.38 128.07 64.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 121.33 -0.856 . . . . 0.0 109.507 -179.757 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 45.9 p90 -112.88 -0.59 14.83 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.342 -0.849 . . . . 0.0 109.401 179.547 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -171.28 174.45 44.92 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 179.619 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 92.1 mt-30 -139.6 165.28 27.67 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.176 -1.19 . . . . 0.0 109.663 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 69.9 t -97.12 129.8 46.66 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.225 0 O-C-N 121.126 -0.984 . . . . 0.0 109.435 -179.952 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 16.0 m -106.99 -29.35 2.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.372 -0.83 . . . . 0.0 109.536 179.657 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -143.52 171.17 14.53 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.265 -0.897 . . . . 0.0 109.512 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 97.99 4.22 57.77 Favored Glycine 0 N--CA 1.493 2.46 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 179.64 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 149' ' ' MET . . . . . 0.466 ' O ' HG12 ' A' ' 152' ' ' VAL . 88.8 mtp -60.6 -33.95 73.51 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.13 -1.218 . . . . 0.0 109.672 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -64.98 -42.62 94.37 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.843 -1.161 . . . . 0.0 110.124 -179.624 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.1 p -82.79 -33.5 10.76 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.079 -1.013 . . . . 0.0 110.499 -179.429 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 152' ' ' VAL . . . . . 0.466 HG12 ' O ' ' A' ' 149' ' ' MET . 0.7 OUTLIER -55.17 -41.82 62.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 120.882 -1.136 . . . . 0.0 109.251 -179.335 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 153' ' ' LYS . . . . . 0.45 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 93.8 mttt -63.56 -34.8 78.6 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.171 -0.956 . . . . 0.0 109.298 179.356 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -63.0 -36.6 84.09 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.405 -0.809 . . . . 0.0 109.792 -179.599 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 69.9 mt -70.4 -38.6 74.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.211 -0.931 . . . . 0.0 110.036 -179.606 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -76.83 -41.14 45.37 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.067 -1.021 . . . . 0.0 111.63 -178.35 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 36.4 pttt -61.18 -34.19 74.65 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 120.729 -1.232 . . . . 0.0 110.261 -178.553 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 35.6 m -76.12 -20.09 15.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 120.917 -1.115 . . . . 0.0 109.469 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -72.91 165.24 54.81 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.652 -1.379 . . . . 0.0 109.652 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 22.9 t -151.42 171.71 17.09 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.376 -1.073 . . . . 0.0 109.382 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 22.6 t -53.7 -32.11 50.61 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.2 -0.938 . . . . 0.0 109.074 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 22.7 t -56.79 -30.94 64.16 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.251 -0.906 . . . . 0.0 109.34 179.722 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 96.41 8.04 57.75 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.678 -1.369 . . . . 0.0 109.678 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 98.6 mtt180 -120.71 144.14 48.39 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.244 -1.15 . . . . 0.0 109.29 179.831 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 165' ' ' THR . . . . . . . . . . . . . 59.6 p -91.23 157.29 17.25 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.197 -0.939 . . . . 0.0 109.728 -179.853 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -65.94 -33.79 76.63 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.367 -0.833 . . . . 0.0 109.613 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 60.8 mttp -119.41 161.03 21.19 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.406 -0.809 . . . . 0.0 109.905 -179.498 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 67.1 mttm -82.53 145.85 29.53 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.437 -0.789 . . . . 0.0 109.725 -179.918 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 1.9 m -133.75 127.08 52.1 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 O-C-N 121.277 -0.89 . . . . 0.0 109.575 179.783 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 44.3 t -137.99 139.05 43.15 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 O-C-N 121.392 -0.817 . . . . 0.0 109.407 179.837 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.718 ' CG2' ' H ' ' A' ' 64' ' ' SER . 9.5 m -67.06 124.51 22.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.0 -1.062 . . . . 0.0 109.208 179.819 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -69.29 -38.38 78.29 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.158 -0.964 . . . . 0.0 110.356 -179.63 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 173' ' ' ASP . . . . . 0.47 ' OD1' ' N ' ' A' ' 174' ' ' CYS . 48.0 t0 -168.7 168.82 10.48 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.958 -1.089 . . . . 0.0 110.209 -179.502 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 174' ' ' CYS . . . . . 0.47 ' N ' ' OD1' ' A' ' 173' ' ' ASP . 14.4 p -138.81 149.84 45.4 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.513 -0.742 . . . . 0.0 109.095 179.785 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -165.27 176.99 40.83 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.737 -1.345 . . . . 0.0 109.737 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 176' ' ' GLN . . . . . 0.652 HE22 ' CZ ' ' A' ' 43' ' ' ARG . 61.1 tt0 -109.83 113.9 27.03 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.331 -1.1 . . . . 0.0 109.614 -179.906 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 177' ' ' LEU . . . . . 0.407 ' O ' ' C ' ' A' ' 178' ' ' SER . 33.9 tp -64.4 -38.41 90.95 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.299 -0.876 . . . . 0.0 109.187 179.526 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 178' ' ' SER . . . . . 0.407 ' C ' ' O ' ' A' ' 177' ' ' LEU . 1.9 t . . . . . 0 N--CA 1.49 1.565 0 CA-C-O 118.04 -0.981 . . . . 0.0 109.621 179.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.529 4.835 0 N-CA-C 119.383 2.513 . . . . 0.0 119.383 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 28.2 t -116.32 143.02 46.07 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.445 -1.033 . . . . 0.0 109.42 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 74.6 t80 -99.3 102.57 14.22 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.292 -0.88 . . . . 0.0 109.233 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 48.8 m -66.53 -41.98 87.92 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.254 -0.903 . . . . 0.0 109.94 -179.781 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 82.61 -171.01 50.91 Favored Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.479 -1.449 . . . . 0.0 109.479 -179.741 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 56.2 p -75.76 159.24 31.27 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.305 -1.114 . . . . 0.0 109.594 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 18.5 ptt? -78.1 148.18 74.46 Favored Pre-proline 0 N--CA 1.489 1.515 0 O-C-N 121.224 -0.923 . . . . 0.0 109.371 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -72.04 167.38 26.9 Favored 'Trans proline' 0 C--N 1.31 -1.46 0 C-N-CA 122.627 2.218 . . . . 0.0 112.039 179.947 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 75.1 m-20 -73.64 148.94 88.06 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.297 -0.877 . . . . 0.0 109.506 179.891 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -66.88 140.17 54.33 Favored 'Trans proline' 0 N--CA 1.496 1.632 0 C-N-CA 122.593 2.196 . . . . 0.0 112.237 179.966 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 98.0 mtt180 -132.49 131.12 41.33 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.33 -0.857 . . . . 0.0 109.187 179.494 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.8 p -138.47 142.63 34.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.306 -0.871 . . . . 0.0 109.39 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 49.3 p90 -142.46 153.85 44.04 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.298 -0.876 . . . . 0.0 109.624 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 77.0 m-85 -126.19 140.83 52.25 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.409 -0.807 . . . . 0.0 109.538 179.654 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 88.4 m-20 -86.85 129.75 34.75 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.156 -0.965 . . . . 0.0 108.925 179.31 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' MET . . . . . 0.562 ' SD ' HD12 ' A' ' 26' ' ' ILE . 84.7 mtp -115.03 153.33 30.86 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.331 -0.855 . . . . 0.0 110.079 -179.683 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 83.8 p -149.0 164.16 35.38 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.442 -0.787 . . . . 0.0 109.129 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.541 ' O ' ' N ' ' A' ' 20' ' ' GLY . 20.4 m -127.25 144.46 37.25 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 121.233 -0.917 . . . . 0.0 109.604 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 47.61 11.43 0.1 OUTLIER Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.822 -1.311 . . . . 0.0 109.822 179.812 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.541 ' N ' ' O ' ' A' ' 18' ' ' VAL . . . 96.49 -14.93 63.64 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.895 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' GLN . . . . . 0.448 ' N ' ' CD ' ' A' ' 21' ' ' GLN . 8.1 mp0 -82.95 149.31 59.13 Favored Pre-proline 0 N--CA 1.492 1.632 0 O-C-N 121.268 -1.137 . . . . 0.0 109.029 179.778 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -62.42 135.35 53.11 Favored 'Trans proline' 0 C--N 1.308 -1.557 0 C-N-CA 122.353 2.035 . . . . 0.0 112.036 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -113.49 -68.11 0.95 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.398 -0.814 . . . . 0.0 109.554 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -176.0 -171.64 40.02 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 -179.865 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 40.0 ttm180 -123.45 142.65 50.78 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.446 -1.032 . . . . 0.0 109.327 -179.931 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.562 HD12 ' SD ' ' A' ' 16' ' ' MET . 75.5 mt -119.99 132.06 70.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.372 -0.83 . . . . 0.0 109.03 179.641 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 44.5 t -113.3 133.22 59.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.306 -0.872 . . . . 0.0 109.086 179.765 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 72.8 mtm -118.52 148.95 42.09 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.369 -0.832 . . . . 0.0 109.299 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -102.05 131.68 48.35 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.308 -0.87 . . . . 0.0 109.575 -179.752 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -104.9 128.75 53.25 Favored 'General case' 0 N--CA 1.492 1.655 0 N-CA-C 109.044 -0.725 . . . . 0.0 109.044 179.615 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 90.2 m-85 -97.25 120.98 38.61 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.309 -0.869 . . . . 0.0 109.307 179.731 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -82.53 -41.51 19.58 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.321 -0.862 . . . . 0.0 109.875 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 56.8 t0 -69.02 -44.36 72.89 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.228 -0.92 . . . . 0.0 110.828 -179.22 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 32.9 m -67.22 -45.71 75.98 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.047 -1.033 . . . . 0.0 110.491 -178.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 4.3 m -156.4 84.36 3.21 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.127 -0.983 . . . . 0.0 109.484 -179.524 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -75.24 -37.04 2.08 Favored 'Trans proline' 0 C--N 1.307 -1.639 0 C-N-CA 122.334 2.023 . . . . 0.0 112.497 -179.518 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 37.7 mmt180 -61.76 -41.02 97.14 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.21 -0.931 . . . . 0.0 109.644 -179.803 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.459 HG23 ' SD ' ' A' ' 113' ' ' MET . 86.5 m -66.21 -39.95 89.98 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.253 -0.904 . . . . 0.0 110.106 -179.71 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -60.11 -32.3 70.86 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.077 -1.014 . . . . 0.0 109.521 -179.818 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -69.82 -36.26 75.47 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.268 -0.895 . . . . 0.0 110.077 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 48.3 t30 -57.9 -42.7 85.23 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.101 -0.999 . . . . 0.0 109.767 -179.629 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -85.79 -48.12 9.09 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.206 -0.934 . . . . 0.0 109.681 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 34.9 ttm180 -57.4 -42.63 82.63 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.407 -0.808 . . . . 0.0 109.842 -179.508 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -69.82 -44.89 69.05 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.306 -0.872 . . . . 0.0 110.182 -179.411 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 36.7 tp -61.92 -36.42 81.3 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.078 -1.014 . . . . 0.0 109.446 -179.652 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' CYS . . . . . . . . . . . . . 46.9 m -79.51 -49.93 11.51 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.09 -1.006 . . . . 0.0 109.757 179.589 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 71.2 p -68.75 -34.72 76.06 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.149 -0.97 . . . . 0.0 109.575 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 75.16 28.92 61.26 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.972 -1.251 . . . . 0.0 109.972 179.6 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 78.0 mm-40 -60.98 -38.35 85.68 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.088 -1.243 . . . . 0.0 109.246 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 29.1 mmtm -62.48 -31.35 72.07 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 121.308 -0.87 . . . . 0.0 109.152 179.484 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 97.75 -119.64 6.49 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 108.87 -1.692 . . . . 0.0 108.87 -179.49 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.586 HG23 ' HA ' ' A' ' 58' ' ' PRO . 95.1 m -126.55 142.09 51.65 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.419 -1.048 . . . . 0.0 109.751 179.739 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -55.48 135.72 47.77 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.093 -1.603 . . . . 0.0 109.093 179.615 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 94.5 mtt180 -59.11 -37.66 77.71 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.18 -1.188 . . . . 0.0 110.079 -179.484 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 22.9 t -59.47 -31.4 69.3 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.179 -0.95 . . . . 0.0 109.834 -179.615 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 119.77 95.54 1.57 Allowed Glycine 0 N--CA 1.495 2.592 0 N-CA-C 108.648 -1.781 . . . . 0.0 108.648 -179.379 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 32.6 tptt -178.56 80.5 0.22 Allowed Pre-proline 0 N--CA 1.489 1.497 0 N-CA-C 108.07 -1.085 . . . . 0.0 108.07 -179.501 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.586 ' HA ' HG23 ' A' ' 52' ' ' THR . 97.3 Cg_exo -45.26 127.96 9.45 Favored 'Trans proline' 0 C--N 1.301 -1.922 0 C-N-CA 122.667 2.245 . . . . 0.0 112.203 -178.9 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.564 ' O ' ' CG ' ' A' ' 60' ' ' HIS . 84.0 mt -91.52 124.65 35.84 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.718 -0.614 . . . . 0.0 109.92 -179.285 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . 0.564 ' CG ' ' O ' ' A' ' 59' ' ' LEU . 86.5 m-70 -162.25 96.35 0.97 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.443 -0.785 . . . . 0.0 109.258 179.833 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 18.5 t80 -57.32 -34.39 68.68 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.174 -0.954 . . . . 0.0 108.708 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . 0.406 ' HG2' ' N ' ' A' ' 63' ' ' ASP . 3.1 ttmp? -46.79 161.06 0.07 Allowed 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.612 -0.68 . . . . 0.0 109.706 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . 0.406 ' N ' ' HG2' ' A' ' 62' ' ' LYS . 80.5 m-20 62.34 48.82 4.51 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.686 -0.634 . . . . 0.0 110.494 179.8 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.877 ' H ' HG22 ' A' ' 171' ' ' VAL . 33.7 t -103.48 144.63 31.15 Favored 'General case' 0 N--CA 1.492 1.642 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 178.76 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 28.6 t -124.05 148.63 46.91 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.096 -1.002 . . . . 0.0 110.309 -179.003 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 32.8 m-85 -87.75 129.99 34.99 Favored 'General case' 0 N--CA 1.491 1.614 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 179.494 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 94.7 m-70 -90.97 -28.58 17.94 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.103 -0.998 . . . . 0.0 110.901 -178.937 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.409 ' O ' HG13 ' A' ' 69' ' ' VAL . 48.9 mtp180 -134.34 147.97 50.64 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 120.957 -1.089 . . . . 0.0 110.245 -179.367 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.71 HG21 HG22 ' A' ' 165' ' ' THR . 10.2 m -153.98 64.7 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.503 -0.748 . . . . 0.0 109.205 179.825 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 21.7 mt -86.82 131.79 44.11 Favored Pre-proline 0 C--N 1.301 -1.502 0 O-C-N 121.009 -1.057 . . . . 0.0 109.788 -179.277 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_endo -71.27 147.16 52.75 Favored 'Trans proline' 0 N--CA 1.492 1.401 0 C-N-CA 122.354 2.036 . . . . 0.0 112.288 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 83.62 -58.7 5.01 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.763 -1.335 . . . . 0.0 109.763 179.808 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 95.6 m-85 -69.74 -83.83 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.177 -1.19 . . . . 0.0 109.622 -179.796 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' MET . . . . . 0.403 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 12.6 ptt? 179.05 -173.29 0.17 Allowed 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.278 -0.889 . . . . 0.0 109.68 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 1.2 p -126.34 137.57 53.49 Favored 'General case' 0 N--CA 1.491 1.622 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 179.443 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 91.9 mt-30 -116.73 153.92 31.54 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.256 -0.902 . . . . 0.0 109.735 -179.573 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -163.29 -173.65 32.24 Favored Glycine 0 N--CA 1.488 2.151 0 N-CA-C 109.177 -1.569 . . . . 0.0 109.177 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -160.39 -177.4 33.45 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.717 -1.353 . . . . 0.0 109.717 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.514 ' C ' ' H ' ' A' ' 81' ' ' THR . 83.1 m-20 -66.95 154.93 39.87 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.379 -1.071 . . . . 0.0 109.507 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.558 ' CE1' ' O ' ' A' ' 60' ' ' HIS . 36.5 p90 -58.89 0.24 0.09 Allowed 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.413 -0.804 . . . . 0.0 109.762 -179.856 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.619 ' O ' ' HB2' ' A' ' 82' ' ' ALA . 72.4 p -63.85 -32.31 73.78 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.991 -1.068 . . . . 0.0 109.538 -179.706 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . 0.619 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 169.48 -53.12 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.335 -0.853 . . . . 0.0 109.37 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 86.04 2.8 85.78 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.556 -1.417 . . . . 0.0 109.556 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 39.9 t-20 -85.94 5.91 30.94 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.263 -1.14 . . . . 0.0 109.497 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 100.96 -40.19 2.5 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 -179.776 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 58.9 p -70.75 -27.22 63.79 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.273 -1.134 . . . . 0.0 108.837 179.392 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -86.47 -167.66 43.89 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.184 -1.566 . . . . 0.0 109.184 179.657 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.485 ' N ' ' OG1' ' A' ' 81' ' ' THR . . . 82.25 42.38 8.69 Favored Glycine 0 N--CA 1.489 2.179 0 N-CA-C 109.359 -1.496 . . . . 0.0 109.359 -179.919 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -57.03 143.81 36.79 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.303 -1.116 . . . . 0.0 109.391 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 99.3 p -113.44 147.87 36.98 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.348 -0.845 . . . . 0.0 109.268 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.415 HG21 HD13 ' A' ' 91' ' ' ILE . 20.0 pt -74.01 -33.64 36.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.297 -0.877 . . . . 0.0 109.993 -179.837 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 81.8 m-85 -66.46 -41.14 89.48 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.173 -0.954 . . . . 0.0 109.795 -179.668 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 71.3 9.57 68.14 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.278 -1.529 . . . . 0.0 109.278 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -152.34 160.76 43.27 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.294 -1.121 . . . . 0.0 109.389 -179.758 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 63.7 mttp -83.4 145.85 28.77 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.22 -0.925 . . . . 0.0 109.665 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 52.4 p90 -137.05 160.5 38.78 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.402 -0.811 . . . . 0.0 109.312 179.674 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -104.49 144.23 31.96 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.31 -0.869 . . . . 0.0 109.513 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.523 ' O ' ' OD1' ' A' ' 98' ' ' ASP . 41.9 p30 -79.05 128.98 33.96 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.191 -0.943 . . . . 0.0 109.528 179.873 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -60.65 -37.73 82.49 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.159 -0.963 . . . . 0.0 109.693 -179.643 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 84.4 m-20 -124.42 144.18 50.21 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.251 -0.906 . . . . 0.0 109.849 -179.747 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 48.6 p90 -142.69 19.75 2.01 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.333 -0.854 . . . . 0.0 108.838 179.607 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 84.1 mt -59.47 -34.88 56.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.567 -0.708 . . . . 0.0 110.112 -179.649 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 93.0 mttt -79.65 135.65 36.61 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.069 -1.02 . . . . 0.0 109.768 -179.57 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 25.6 pttm -139.11 -178.69 5.46 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.412 -0.805 . . . . 0.0 109.439 -180.0 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' HIS . . . . . 0.535 ' O ' ' ND1' ' A' ' 105' ' ' HIS . 15.1 t-80 -74.27 88.02 2.0 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.174 -0.954 . . . . 0.0 109.256 179.825 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 58.8 p -75.05 -25.48 58.71 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.312 -0.867 . . . . 0.0 109.774 -179.781 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.533 ' O ' ' CE1' ' A' ' 105' ' ' HIS . . . -164.21 -166.95 23.97 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.397 -1.481 . . . . 0.0 109.397 -179.708 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -76.29 155.82 37.18 Favored 'Trans proline' 0 C--N 1.308 -1.574 0 C-N-CA 122.644 2.229 . . . . 0.0 112.117 179.901 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 88.32 24.29 34.51 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.869 -1.292 . . . . 0.0 109.869 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 36.6 mm -112.27 136.79 47.37 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.267 -1.137 . . . . 0.0 109.379 179.854 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.748 ' N ' HD22 ' A' ' 111' ' ' LEU . 2.7 mm? -88.2 132.57 34.3 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.283 -0.886 . . . . 0.0 109.152 179.77 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . 0.401 ' OG ' ' O ' ' A' ' 140' ' ' VAL . 47.0 t -145.8 139.36 26.34 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.189 -0.944 . . . . 0.0 109.609 179.957 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' MET . . . . . 0.459 ' SD ' HG23 ' A' ' 38' ' ' THR . 71.9 mtm -89.23 139.03 30.9 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.243 -0.91 . . . . 0.0 109.267 179.651 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . 0.572 ' O ' ' ND2' ' A' ' 115' ' ' ASN . . . -60.74 138.31 58.11 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.242 -0.911 . . . . 0.0 109.152 179.983 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . 0.572 ' ND2' ' O ' ' A' ' 114' ' ' ALA . 15.0 m120 -148.81 112.95 5.2 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.173 -0.954 . . . . 0.0 109.19 179.93 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -68.31 -30.12 69.04 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 121.338 -0.851 . . . . 0.0 109.134 179.559 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -138.18 168.98 24.42 Favored Glycine 0 N--CA 1.493 2.451 0 N-CA-C 109.049 -1.621 . . . . 0.0 109.049 179.813 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -67.11 155.06 72.41 Favored 'Trans proline' 0 C--N 1.305 -1.739 0 C-N-CA 122.722 2.281 . . . . 0.0 112.027 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 75.6 m-20 53.99 44.34 29.48 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.448 -0.782 . . . . 0.0 109.432 -179.865 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' THR . . . . . 0.546 ' O ' ' ND2' ' A' ' 115' ' ' ASN . 93.3 m -134.64 127.59 31.45 Favored 'General case' 0 N--CA 1.485 1.322 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 179.832 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 121' ' ' ASN . . . . . 0.413 ' OD1' ' SD ' ' A' ' 113' ' ' MET . 52.2 t30 -98.22 106.43 18.72 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.421 -0.8 . . . . 0.0 109.318 179.794 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -80.96 136.61 16.6 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 83.4 p -64.38 -23.73 67.39 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.268 -1.136 . . . . 0.0 109.442 179.853 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.2 mt-30 -103.73 150.89 23.63 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.267 -0.896 . . . . 0.0 109.675 -179.825 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 51.5 p90 -136.23 162.4 33.08 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.431 -0.793 . . . . 0.0 109.292 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.403 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 48.5 p90 -136.34 156.64 48.35 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.193 -0.942 . . . . 0.0 109.636 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 64.9 mt -122.53 133.1 69.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.449 -0.782 . . . . 0.0 109.189 179.812 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 128' ' ' CYS . . . . . 0.45 ' SG ' ' O ' ' A' ' 130' ' ' ALA . 5.7 t -99.82 118.46 36.33 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.154 -0.966 . . . . 0.0 109.499 179.938 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 64.9 p -95.05 4.12 54.1 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.294 -0.879 . . . . 0.0 109.489 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . 0.45 ' O ' ' SG ' ' A' ' 128' ' ' CYS . . . -147.41 155.82 42.31 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.271 -0.893 . . . . 0.0 109.684 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 51.4 tttp -72.9 137.17 45.45 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.204 -0.935 . . . . 0.0 109.423 179.918 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 7.2 p -122.46 161.49 23.45 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.47 -0.769 . . . . 0.0 109.542 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -104.88 -74.98 0.63 Allowed 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.336 -0.853 . . . . 0.0 109.666 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 134' ' ' TRP . . . . . 0.672 ' CD1' ' N ' ' A' ' 135' ' ' LEU . 45.9 p90 -61.65 -45.8 92.48 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.333 -0.854 . . . . 0.0 110.198 -179.56 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . 0.672 ' N ' ' CD1' ' A' ' 134' ' ' TRP . 13.5 tp -61.28 -32.3 72.13 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.336 -0.852 . . . . 0.0 109.72 -179.348 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 60.4 t0 -56.5 136.61 54.1 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.231 -0.918 . . . . 0.0 109.924 -179.38 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . 0.716 ' H ' ' CD2' ' A' ' 139' ' ' HIS . . . -162.65 -161.15 11.84 Favored Glycine 0 N--CA 1.486 2.009 0 N-CA-C 108.664 -1.774 . . . . 0.0 108.664 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . 0.464 ' O ' ' O ' ' A' ' 139' ' ' HIS . 92.1 mttt -57.21 -41.14 78.86 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.055 -1.262 . . . . 0.0 109.582 179.887 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 139' ' ' HIS . . . . . 0.716 ' CD2' ' H ' ' A' ' 137' ' ' GLY . 66.2 m-70 37.4 94.66 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.58 -0.7 . . . . 0.0 110.428 179.738 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.401 ' O ' ' OG ' ' A' ' 112' ' ' SER . 39.0 t -61.61 132.43 27.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 120.99 -1.069 . . . . 0.0 108.791 179.579 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 82.3 t -111.38 129.0 67.51 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 O-C-N 121.376 -0.828 . . . . 0.0 109.824 -179.45 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 41.9 p90 -116.19 -1.55 12.37 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.511 -0.743 . . . . 0.0 109.505 179.449 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -168.47 172.73 43.08 Favored Glycine 0 N--CA 1.493 2.479 0 N-CA-C 109.861 -1.296 . . . . 0.0 109.861 179.447 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 55.2 tt0 -139.99 160.33 40.18 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.31 -1.112 . . . . 0.0 109.347 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . 0.438 HG23 HD21 ' A' ' 111' ' ' LEU . 54.4 t -96.75 131.22 44.04 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.182 0 O-C-N 121.047 -1.033 . . . . 0.0 109.56 -179.759 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 16.4 m -111.0 -28.75 2.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.444 -0.785 . . . . 0.0 109.32 179.472 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -144.42 169.35 18.11 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.326 -0.859 . . . . 0.0 109.448 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 96.2 6.36 58.94 Favored Glycine 0 N--CA 1.494 2.511 0 N-CA-C 109.946 -1.262 . . . . 0.0 109.946 179.519 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 149' ' ' MET . . . . . 0.524 ' O ' HG12 ' A' ' 152' ' ' VAL . 89.0 mtp -59.89 -32.24 70.55 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.165 -1.197 . . . . 0.0 109.8 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -66.67 -42.66 86.2 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.868 -1.145 . . . . 0.0 109.994 -179.542 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 6.2 p -81.36 -34.86 13.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.167 -0.958 . . . . 0.0 110.555 -179.479 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 152' ' ' VAL . . . . . 0.556 ' O ' ' OE1' ' A' ' 156' ' ' GLU . 1.2 p -50.85 -42.39 23.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 120.843 -1.161 . . . . 0.0 108.772 -179.078 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 153' ' ' LYS . . . . . 0.445 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 61.5 mttp -67.39 -32.91 74.14 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.28 -0.887 . . . . 0.0 109.274 179.094 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -61.03 -30.89 70.58 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.469 -0.769 . . . . 0.0 110.396 -179.244 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 89.8 mt -68.54 -37.31 77.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.035 -1.041 . . . . 0.0 110.616 -179.384 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . 0.556 ' OE1' ' O ' ' A' ' 152' ' ' VAL . 42.0 mp0 -80.35 -39.13 29.13 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 120.815 -1.178 . . . . 0.0 111.743 -178.849 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 19.2 pttp -58.3 -37.4 74.97 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 120.455 -1.403 . . . . 0.0 109.161 -178.91 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 32.1 m -77.99 -15.05 14.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.273 -0.892 . . . . 0.0 108.82 179.163 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -78.9 176.52 54.6 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.719 -1.353 . . . . 0.0 109.719 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 22.7 t -156.46 171.75 19.73 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.31 -1.112 . . . . 0.0 109.288 -179.769 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 22.6 t -54.71 -30.78 56.88 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.13 -0.981 . . . . 0.0 109.224 179.84 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 86.8 p -59.98 -26.56 66.12 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.175 -0.953 . . . . 0.0 109.56 179.958 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 90.21 17.07 54.5 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 109.828 -1.309 . . . . 0.0 109.828 179.804 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 28.4 ttm180 -119.12 142.56 47.81 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.311 -1.111 . . . . 0.0 109.221 -180.0 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 165' ' ' THR . . . . . 0.71 HG22 HG21 ' A' ' 69' ' ' VAL . 82.2 p -79.36 149.14 31.78 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.165 -0.959 . . . . 0.0 109.761 -179.911 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -67.25 -35.62 79.93 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.314 -0.866 . . . . 0.0 109.153 179.686 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 96.6 mttt -117.27 156.93 26.92 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.515 -0.74 . . . . 0.0 109.138 179.918 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 63.9 mttp -68.69 130.74 43.71 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.096 -1.003 . . . . 0.0 109.333 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 34.4 t -122.42 123.36 68.45 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 121.409 -0.807 . . . . 0.0 109.392 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 42.1 t -144.41 141.03 24.27 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.34 -0.85 . . . . 0.0 109.23 179.762 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.877 HG22 ' H ' ' A' ' 64' ' ' SER . 4.8 m -65.65 119.29 10.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.103 -0.998 . . . . 0.0 109.296 179.912 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 -70.92 -36.94 72.87 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.033 -1.042 . . . . 0.0 110.621 -179.638 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 173' ' ' ASP . . . . . 0.482 ' OD1' ' N ' ' A' ' 174' ' ' CYS . 52.1 t0 -155.09 161.72 41.21 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.952 -1.092 . . . . 0.0 110.276 -179.184 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 174' ' ' CYS . . . . . 0.482 ' N ' ' OD1' ' A' ' 173' ' ' ASP . 14.8 p -147.36 152.56 38.4 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.398 -0.814 . . . . 0.0 109.224 179.788 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . 178.41 170.81 41.01 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 179.702 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 64.1 tt0 -105.17 119.35 38.82 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.365 -1.08 . . . . 0.0 109.474 179.925 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 30.8 tp -61.68 -37.97 86.07 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.213 -0.929 . . . . 0.0 109.422 179.87 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 38.7 m . . . . . 0 N--CA 1.489 1.513 0 CA-C-O 118.027 -0.987 . . . . 0.0 109.498 179.988 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.528 4.812 0 N-CA-C 119.393 2.517 . . . . 0.0 119.393 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 45.5 m -62.7 153.92 31.04 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.266 -1.138 . . . . 0.0 109.529 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 99.2 m-85 -112.89 125.24 54.16 Favored 'General case' 0 C--N 1.308 -1.198 0 O-C-N 121.357 -0.839 . . . . 0.0 108.911 179.72 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 11.2 t -135.12 153.3 52.05 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.502 -0.749 . . . . 0.0 109.538 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -61.12 -38.81 96.19 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.838 -1.305 . . . . 0.0 109.838 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 28.4 t -147.45 149.94 33.66 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.178 -1.189 . . . . 0.0 109.58 -179.816 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' MET . . . . . 0.44 ' N ' ' SD ' ' A' ' 7' ' ' MET . 0.2 OUTLIER -60.64 153.48 61.96 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.345 -0.847 . . . . 0.0 109.235 179.841 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -65.02 172.34 7.45 Favored 'Trans proline' 0 C--N 1.308 -1.575 0 C-N-CA 122.686 2.257 . . . . 0.0 112.054 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 16.3 m-80 -63.61 149.01 93.26 Favored Pre-proline 0 N--CA 1.49 1.567 0 O-C-N 121.353 -0.842 . . . . 0.0 109.437 -179.707 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -68.1 140.76 50.54 Favored 'Trans proline' 0 N--CA 1.496 1.627 0 C-N-CA 122.787 2.325 . . . . 0.0 112.501 -179.802 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.557 ' NH2' HG11 ' A' ' 27' ' ' VAL . 55.2 ttt85 -133.0 129.91 38.78 Favored 'General case' 0 N--CA 1.489 1.524 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 179.027 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.7 p -135.22 144.75 33.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.18 -0.95 . . . . 0.0 110.133 -179.006 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 48.6 p90 -136.79 154.47 50.54 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.447 -0.783 . . . . 0.0 109.1 179.752 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.568 ' CE2' ' SG ' ' A' ' 174' ' ' CYS . 86.9 m-85 -121.42 137.49 54.69 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.437 -0.79 . . . . 0.0 109.934 -179.848 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.2 t0 -94.71 115.06 27.06 Favored 'General case' 0 N--CA 1.494 1.748 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 178.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' MET . . . . . 0.569 ' SD ' HD11 ' A' ' 155' ' ' ILE . 77.7 mtp -108.35 146.58 32.77 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.198 -0.939 . . . . 0.0 110.826 -178.824 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.415 ' OG ' ' O ' ' A' ' 21' ' ' GLN . 46.8 t -134.25 149.58 50.96 Favored 'General case' 0 N--CA 1.491 1.605 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 179.61 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.418 ' C ' ' N ' ' A' ' 20' ' ' GLY . 35.5 m -112.2 133.96 56.23 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 121.178 -0.951 . . . . 0.0 109.721 -179.664 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 52.95 12.88 1.94 Allowed Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.418 ' N ' ' C ' ' A' ' 18' ' ' VAL . . . 97.11 -10.22 65.62 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.45 -1.46 . . . . 0.0 109.45 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' GLN . . . . . 0.415 ' O ' ' OG ' ' A' ' 17' ' ' SER . 81.4 mt-30 -88.99 149.37 43.19 Favored Pre-proline 0 N--CA 1.49 1.53 0 O-C-N 121.243 -1.151 . . . . 0.0 109.084 179.733 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -62.38 133.89 45.51 Favored 'Trans proline' 0 C--N 1.309 -1.527 0 C-N-CA 122.288 1.992 . . . . 0.0 112.014 -179.772 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -112.33 -65.21 1.2 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.438 -0.789 . . . . 0.0 109.339 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 179.92 -172.28 43.84 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 61.0 ttp180 -119.1 143.08 47.35 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.422 -1.046 . . . . 0.0 109.198 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 82.7 mt -119.8 128.9 75.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.384 -0.823 . . . . 0.0 109.03 179.779 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.557 HG11 ' NH2' ' A' ' 11' ' ' ARG . 39.0 t -116.59 133.78 62.15 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.406 -0.809 . . . . 0.0 109.272 -179.947 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 72.6 mtm -122.5 152.07 40.7 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.422 -0.798 . . . . 0.0 109.277 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -100.58 131.58 46.41 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.271 -0.893 . . . . 0.0 109.825 -179.626 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.41 ' N ' ' CD2' ' A' ' 30' ' ' LEU . 2.6 mm? -106.12 133.16 51.26 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 179.487 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -96.57 120.81 37.57 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.025 -1.047 . . . . 0.0 109.054 179.459 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -88.02 -41.51 13.06 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.269 -0.895 . . . . 0.0 109.657 -179.809 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -65.28 -42.42 93.2 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.347 -0.846 . . . . 0.0 110.519 -179.214 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 54.6 m -66.32 -44.61 82.88 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.031 -1.043 . . . . 0.0 110.208 -179.324 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.454 ' OG1' ' OG1' ' A' ' 38' ' ' THR . 0.1 OUTLIER -155.67 84.48 3.45 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.261 -0.899 . . . . 0.0 109.301 -179.72 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 1.7 Cg_endo -62.14 -42.07 31.61 Favored 'Trans proline' 0 C--N 1.307 -1.638 0 C-N-CA 122.078 1.852 . . . . 0.0 112.412 -179.245 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 50.1 mtt180 -63.21 -39.54 94.94 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.426 -0.796 . . . . 0.0 110.81 -179.028 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.454 ' OG1' ' OG1' ' A' ' 35' ' ' THR . 75.6 m -63.27 -40.14 96.55 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 120.834 -1.167 . . . . 0.0 109.947 -179.666 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -61.33 -31.56 71.43 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.137 -0.977 . . . . 0.0 109.216 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -67.55 -36.53 81.14 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.303 -0.873 . . . . 0.0 109.885 -179.898 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 45.2 t-20 -57.88 -41.79 83.26 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.219 -0.926 . . . . 0.0 109.85 -179.622 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 98.8 m-85 -87.0 -46.98 9.33 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.106 -0.996 . . . . 0.0 109.804 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.658 ' CZ ' HE22 ' A' ' 176' ' ' GLN . 78.5 ttt180 -57.07 -39.27 74.6 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.363 -0.836 . . . . 0.0 110.147 -179.623 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -63.96 -48.24 77.25 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.02 -1.05 . . . . 0.0 110.214 -179.292 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.74 HD12 ' CD1' ' A' ' 61' ' ' TYR . 4.3 mm? -65.78 -38.93 90.35 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.092 -1.005 . . . . 0.0 109.663 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' CYS . . . . . 0.56 ' SG ' ' SG ' ' A' ' 174' ' ' CYS . 77.7 m -66.01 -47.97 72.73 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.12 -0.988 . . . . 0.0 109.469 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 63.9 p -76.78 -30.78 56.62 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.259 -0.901 . . . . 0.0 109.697 179.733 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 76.25 31.64 54.32 Favored Glycine 0 N--CA 1.492 2.379 0 N-CA-C 110.214 -1.154 . . . . 0.0 110.214 179.521 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 77.8 mm-40 -62.25 -36.07 80.91 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.944 -1.327 . . . . 0.0 109.573 179.798 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 61.1 mmtt -60.43 -34.03 73.38 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.17 -0.956 . . . . 0.0 109.494 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 76.4 -94.54 1.04 Allowed Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.475 -1.45 . . . . 0.0 109.475 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 31.8 m -118.01 142.46 47.35 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.372 -1.075 . . . . 0.0 109.296 -179.798 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -54.53 -42.43 76.15 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.838 -1.305 . . . . 0.0 109.838 -179.828 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 82.0 mtp180 -147.05 -113.06 0.08 Allowed 'General case' 0 N--CA 1.486 1.364 0 O-C-N 121.172 -1.193 . . . . 0.0 109.265 179.871 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 3.4 m -107.08 -24.72 11.86 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.401 -0.812 . . . . 0.0 109.521 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -144.31 73.23 0.34 Allowed Glycine 0 N--CA 1.493 2.461 0 N-CA-C 109.471 -1.452 . . . . 0.0 109.471 -179.722 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 46.6 tttm -171.46 74.21 0.51 Allowed Pre-proline 0 N--CA 1.489 1.496 0 O-C-N 121.383 -1.069 . . . . 0.0 108.833 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_exo -50.06 128.75 23.08 Favored 'Trans proline' 0 C--N 1.305 -1.76 0 C-N-CA 122.646 2.231 . . . . 0.0 111.977 -179.4 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.525 ' O ' ' CG ' ' A' ' 60' ' ' HIS . 11.5 tp -112.24 118.38 35.14 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.531 -0.731 . . . . 0.0 109.186 -179.593 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . 0.533 ' O ' ' CE1' ' A' ' 80' ' ' PHE . 95.6 m-70 -158.52 140.73 14.07 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.128 -0.983 . . . . 0.0 109.904 -179.952 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . 0.74 ' CD1' HD12 ' A' ' 45' ' ' LEU . 2.4 m-85 -102.17 12.26 37.01 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.254 -0.904 . . . . 0.0 108.851 179.211 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 83.7 mttt -86.73 156.64 19.86 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.383 -0.823 . . . . 0.0 109.619 -179.709 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 54.6 t0 55.8 46.78 21.65 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.401 -0.812 . . . . 0.0 109.454 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 99.4 p -116.85 155.3 29.25 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.411 -0.806 . . . . 0.0 109.301 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 28.6 t -113.16 147.43 37.4 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.362 -0.836 . . . . 0.0 109.323 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.7 m-30 -61.11 142.43 56.7 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.213 -0.929 . . . . 0.0 108.864 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 80.5 t60 -57.29 -50.72 72.03 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.127 -0.983 . . . . 0.0 109.934 -179.206 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.692 HH21 ' NE2' ' A' ' 76' ' ' GLN . 30.1 ptt180 -169.42 160.95 9.61 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.115 -0.99 . . . . 0.0 109.843 179.834 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.474 HG21 HG21 ' A' ' 165' ' ' THR . 0.0 OUTLIER -136.1 135.37 50.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 179.548 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 75.1 mt -136.61 128.25 16.92 Favored Pre-proline 0 N--CA 1.492 1.667 0 O-C-N 121.309 -0.87 . . . . 0.0 109.349 -179.699 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -75.41 136.74 19.97 Favored 'Trans proline' 0 C--N 1.312 -1.39 0 C-N-CA 122.091 1.86 . . . . 0.0 111.888 179.672 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 94.5 -5.23 70.34 Favored Glycine 0 N--CA 1.492 2.432 0 N-CA-C 109.821 -1.312 . . . . 0.0 109.821 179.705 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 77.6 m-85 -135.13 -94.96 0.27 Allowed 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.211 -1.17 . . . . 0.0 109.677 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' MET . . . . . 0.506 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 6.9 ptt? -170.81 -165.88 0.46 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.172 -0.955 . . . . 0.0 109.464 -179.653 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 15.4 p -132.7 151.61 51.93 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.423 -0.798 . . . . 0.0 109.054 179.741 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' GLN . . . . . 0.692 ' NE2' HH21 ' A' ' 68' ' ' ARG . 94.1 mt-30 -115.72 158.71 22.39 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.372 -0.83 . . . . 0.0 109.63 -179.703 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -140.28 -172.68 12.97 Favored Glycine 0 N--CA 1.494 2.516 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 -179.898 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 95.59 6.33 59.69 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.475 -1.45 . . . . 0.0 109.475 -179.771 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 56.0 t0 -57.44 -25.75 60.13 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.278 -1.131 . . . . 0.0 109.444 179.912 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.533 ' CE1' ' O ' ' A' ' 60' ' ' HIS . 91.3 t80 -49.19 -44.81 43.38 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.378 -0.826 . . . . 0.0 110.151 -179.483 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.688 ' CB ' ' H ' ' A' ' 88' ' ' GLY . 65.0 p -69.85 -29.52 66.78 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 120.989 -1.069 . . . . 0.0 109.487 179.874 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . 0.684 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 163.3 -55.53 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.344 -0.847 . . . . 0.0 109.244 179.724 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 91.02 1.46 72.84 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 179.884 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . 0.478 ' ND2' ' OG1' ' A' ' 86' ' ' THR . 39.9 p-10 -89.8 7.64 35.96 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.21 -1.171 . . . . 0.0 109.482 -179.931 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 95.8 -38.45 3.11 Favored Glycine 0 N--CA 1.492 2.389 0 N-CA-C 109.246 -1.541 . . . . 0.0 109.246 -179.793 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . 0.478 ' OG1' ' ND2' ' A' ' 84' ' ' ASN . 56.7 p -73.16 -17.54 61.37 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.235 -1.156 . . . . 0.0 109.027 179.529 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -82.75 -164.82 36.02 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.589 -1.405 . . . . 0.0 109.589 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.688 ' H ' ' CB ' ' A' ' 81' ' ' THR . . . 81.94 47.76 6.07 Favored Glycine 0 N--CA 1.488 2.16 0 N-CA-C 109.264 -1.534 . . . . 0.0 109.264 -179.808 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -83.45 147.0 28.09 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.421 -1.046 . . . . 0.0 109.521 -179.722 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 50.5 m -107.84 150.12 27.41 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.485 -0.759 . . . . 0.0 109.275 -179.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 5.1 pt -59.6 -40.69 82.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.196 -0.94 . . . . 0.0 109.898 -179.759 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 3.4 m-30 -63.71 -41.42 98.09 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.013 -1.054 . . . . 0.0 109.321 179.733 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 72.58 24.53 76.04 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.719 -1.352 . . . . 0.0 109.719 179.725 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -147.28 153.82 40.22 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.135 -1.214 . . . . 0.0 109.698 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 94.6 mttt -96.73 142.08 29.19 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.361 -0.837 . . . . 0.0 109.552 179.88 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.533 ' CZ ' ' OD1' ' A' ' 121' ' ' ASN . 38.1 p90 -141.07 156.25 46.03 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.322 -0.861 . . . . 0.0 109.42 179.705 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -70.91 145.44 50.16 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.29 -0.881 . . . . 0.0 109.748 -179.699 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.539 ' OD2' HG21 ' A' ' 140' ' ' VAL . 87.8 m-20 -64.16 139.02 58.72 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.17 -0.957 . . . . 0.0 109.153 179.92 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . 0.482 ' O ' ' OD1' ' A' ' 100' ' ' ASN . 97.2 mt-10 -66.06 -41.13 91.21 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.178 -0.951 . . . . 0.0 110.56 -179.093 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . 0.482 ' OD1' ' O ' ' A' ' 99' ' ' GLU . 83.2 m-20 -149.96 149.16 29.99 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 120.948 -1.095 . . . . 0.0 110.466 -179.582 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -110.75 9.93 22.67 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.849 -0.797 . . . . 0.0 108.849 179.152 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 91.2 mt -54.97 -37.5 42.16 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.408 -0.807 . . . . 0.0 110.583 -179.069 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 57.0 mttm -76.52 134.46 39.46 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 120.899 -1.125 . . . . 0.0 109.63 -179.495 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 39.8 tttp -138.43 159.14 42.82 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.471 -0.768 . . . . 0.0 109.308 -179.735 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' HIS . . . . . 0.491 ' C ' ' ND1' ' A' ' 105' ' ' HIS . 6.8 t-80 -85.46 108.94 18.13 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.195 -0.941 . . . . 0.0 109.282 179.936 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 68.2 p -123.49 2.42 9.01 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.22 -0.925 . . . . 0.0 109.91 -179.888 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -155.05 175.06 33.19 Favored Glycine 0 N--CA 1.492 2.416 0 N-CA-C 109.818 -1.313 . . . . 0.0 109.818 -179.834 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -79.78 157.62 24.48 Favored 'Trans proline' 0 C--N 1.307 -1.617 0 C-N-CA 123.112 2.541 . . . . 0.0 112.142 179.714 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 78.11 45.17 10.5 Favored Glycine 0 N--CA 1.493 2.47 0 N-CA-C 109.678 -1.369 . . . . 0.0 109.678 179.604 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.72 137.33 50.92 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.378 -1.072 . . . . 0.0 109.754 -179.825 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.541 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 2.8 mm? -91.11 129.76 37.07 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.283 -0.886 . . . . 0.0 109.097 179.439 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 29.1 t -142.43 143.6 32.71 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.188 -0.945 . . . . 0.0 109.486 179.954 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 72.2 mtm -89.33 133.31 34.54 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.161 -0.962 . . . . 0.0 109.334 179.839 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -64.98 142.35 58.47 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.18 -0.95 . . . . 0.0 109.311 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . 0.525 ' ND2' ' O ' ' A' ' 117' ' ' GLY . 53.2 t-20 -143.04 153.16 42.67 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.204 -0.935 . . . . 0.0 109.85 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . 0.471 ' N ' ' OD1' ' A' ' 115' ' ' ASN . . . -123.91 -12.31 7.54 Favored 'General case' 0 N--CA 1.493 1.688 0 N-CA-C 108.836 -0.802 . . . . 0.0 108.836 179.624 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . 0.525 ' O ' ' ND2' ' A' ' 115' ' ' ASN . . . -145.52 166.34 27.75 Favored Glycine 0 N--CA 1.493 2.472 0 N-CA-C 109.236 -1.545 . . . . 0.0 109.236 179.934 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -70.74 152.28 64.1 Favored 'Trans proline' 0 C--N 1.306 -1.696 0 C-N-CA 122.72 2.28 . . . . 0.0 112.108 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 76.2 m-20 52.98 41.62 32.14 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.473 -0.767 . . . . 0.0 109.502 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' THR . . . . . 0.52 ' O ' ' ND2' ' A' ' 115' ' ' ASN . 62.2 m -138.75 125.79 21.27 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.339 -0.851 . . . . 0.0 109.223 179.771 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 121' ' ' ASN . . . . . 0.533 ' OD1' ' CZ ' ' A' ' 96' ' ' PHE . 28.7 m120 -106.32 121.89 45.13 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.532 -0.73 . . . . 0.0 109.383 179.844 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -93.6 132.85 11.4 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.669 -1.372 . . . . 0.0 109.669 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 18.8 m -58.83 -33.66 70.65 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.29 -1.123 . . . . 0.0 109.399 179.773 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.3 mt-30 -68.97 145.29 53.73 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.372 -0.83 . . . . 0.0 109.636 -179.793 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 48.8 p90 -135.66 162.54 32.45 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.408 -0.808 . . . . 0.0 109.133 179.83 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.506 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 48.9 p90 -136.51 157.1 47.57 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.176 -0.953 . . . . 0.0 109.775 -179.927 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 68.3 mt -120.9 136.54 57.56 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.506 -0.746 . . . . 0.0 109.288 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 23.0 t -115.95 126.74 54.27 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.269 -0.894 . . . . 0.0 109.416 179.881 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 28.0 p -102.51 11.17 38.27 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.353 -0.842 . . . . 0.0 109.511 -179.891 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -140.39 163.29 33.2 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.306 -0.871 . . . . 0.0 109.431 -179.775 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 71.9 mmtt -67.51 138.29 56.44 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.252 -0.905 . . . . 0.0 109.205 -179.946 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 61.6 p -150.18 85.29 1.4 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.295 -0.878 . . . . 0.0 109.534 -179.868 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -62.82 -36.09 82.05 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.278 -0.889 . . . . 0.0 109.85 -179.895 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 0.9 OUTLIER -64.76 -46.3 82.74 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.125 -0.984 . . . . 0.0 109.515 -179.892 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 18.1 mt -65.83 -32.4 73.9 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.232 -0.918 . . . . 0.0 109.611 179.266 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . 0.445 ' OD2' ' O ' ' A' ' 105' ' ' HIS . 60.9 t0 -79.71 119.65 22.93 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.308 -0.87 . . . . 0.0 109.71 -179.816 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 165.57 -100.54 0.17 Allowed Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 62.5 mttp -57.45 -36.16 71.05 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.294 -1.121 . . . . 0.0 109.825 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 78.0 m80 -65.04 150.22 48.48 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.338 -0.851 . . . . 0.0 109.705 -179.501 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.539 HG21 ' OD2' ' A' ' 98' ' ' ASP . 49.8 t -123.33 144.7 32.02 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 121.542 -0.724 . . . . 0.0 109.423 -179.739 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 61.7 t -92.45 130.58 41.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.293 -0.879 . . . . 0.0 109.857 -179.548 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 40.2 p90 -112.98 -3.11 14.1 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.445 -0.784 . . . . 0.0 109.328 179.624 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -168.19 177.35 42.37 Favored Glycine 0 N--CA 1.492 2.402 0 N-CA-C 109.169 -1.572 . . . . 0.0 109.169 179.796 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.2 pt20 -146.61 166.94 25.0 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.075 -1.25 . . . . 0.0 109.741 -179.744 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 75.0 t -96.45 129.7 46.14 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.283 0 O-C-N 121.266 -0.896 . . . . 0.0 109.389 -179.843 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 15.8 m -105.65 -33.92 2.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.339 -0.851 . . . . 0.0 109.723 179.756 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -142.45 169.17 18.08 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.274 -0.891 . . . . 0.0 109.689 -179.75 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 95.89 7.97 58.36 Favored Glycine 0 N--CA 1.493 2.47 0 N-CA-C 109.929 -1.269 . . . . 0.0 109.929 179.612 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 149' ' ' MET . . . . . 0.493 ' O ' HG12 ' A' ' 152' ' ' VAL . 64.9 mtt -60.34 -34.05 73.29 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.155 -1.203 . . . . 0.0 109.776 179.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 89.1 m-20 -65.03 -42.33 94.46 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 120.865 -1.147 . . . . 0.0 110.03 -179.553 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.6 p -82.44 -32.09 10.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.21 -0.932 . . . . 0.0 110.653 -179.263 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 152' ' ' VAL . . . . . 0.493 HG12 ' O ' ' A' ' 149' ' ' MET . 0.8 OUTLIER -55.58 -40.67 60.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 120.833 -1.167 . . . . 0.0 109.008 -179.332 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 153' ' ' LYS . . . . . 0.43 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 67.0 mttm -62.92 -36.46 83.46 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.132 -0.98 . . . . 0.0 108.999 179.396 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -62.45 -35.08 78.16 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.305 -0.872 . . . . 0.0 109.414 179.825 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.569 HD11 ' SD ' ' A' ' 16' ' ' MET . 93.6 mt -67.35 -12.79 15.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.513 -0.742 . . . . 0.0 109.808 179.9 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -118.55 -19.48 8.76 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 -179.617 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . 0.403 ' N ' ' O ' ' A' ' 153' ' ' LYS . 38.9 tttm -58.83 -42.18 88.63 Favored 'General case' 0 C--N 1.299 -1.597 0 CA-C-O 121.376 0.608 . . . . 0.0 109.743 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 16.5 m -83.75 -12.56 11.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.533 -0.729 . . . . 0.0 109.25 179.449 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . 0.648 ' HA2' HG22 ' A' ' 165' ' ' THR . . . -59.97 151.98 37.0 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.941 -1.264 . . . . 0.0 109.941 -179.729 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 27.0 t -143.27 158.31 43.73 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.505 -0.997 . . . . 0.0 109.255 179.917 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 22.9 t -54.1 -33.85 58.73 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.151 -0.968 . . . . 0.0 109.307 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 24.5 m -57.75 -29.47 64.82 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.321 -0.862 . . . . 0.0 109.401 179.682 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 100.52 1.05 55.48 Favored Glycine 0 N--CA 1.493 2.45 0 N-CA-C 109.263 -1.535 . . . . 0.0 109.263 -179.656 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 72.2 ttt-85 -108.16 149.98 27.83 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.477 -1.013 . . . . 0.0 108.933 179.666 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 165' ' ' THR . . . . . 0.648 HG22 ' HA2' ' A' ' 159' ' ' GLY . 69.8 p -117.05 155.51 29.12 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.272 -0.892 . . . . 0.0 110.104 -179.582 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -70.14 -37.29 75.23 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.578 -0.702 . . . . 0.0 109.694 179.776 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 53.9 mttm -109.56 152.6 25.28 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.359 -0.838 . . . . 0.0 109.928 -179.392 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 63.7 mttm -87.95 151.33 22.88 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.404 -0.81 . . . . 0.0 109.43 179.911 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . 0.436 ' O ' HG23 ' A' ' 169' ' ' VAL . 34.5 m -125.7 127.61 71.59 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 121.247 -0.908 . . . . 0.0 109.744 -179.988 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 43.4 t -146.63 145.91 19.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.245 -0.909 . . . . 0.0 109.196 179.722 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -88.15 120.95 37.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.111 -0.993 . . . . 0.0 109.479 -179.727 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -62.69 -28.59 70.04 Favored 'General case' 0 C--N 1.3 -1.586 0 N-CA-C 108.901 -0.777 . . . . 0.0 108.901 179.489 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 52.0 p30 -178.67 170.15 1.62 Allowed 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.383 -0.823 . . . . 0.0 110.202 -179.881 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 174' ' ' CYS . . . . . 0.568 ' SG ' ' CE2' ' A' ' 14' ' ' PHE . 54.1 t -139.43 134.98 33.12 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.529 -0.732 . . . . 0.0 109.062 179.356 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -150.67 169.25 30.52 Favored Glycine 0 N--CA 1.493 2.496 0 N-CA-C 109.738 -1.345 . . . . 0.0 109.738 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 176' ' ' GLN . . . . . 0.658 HE22 ' CZ ' ' A' ' 43' ' ' ARG . 63.9 tt0 -108.52 122.75 47.71 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.453 -1.028 . . . . 0.0 109.497 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 177' ' ' LEU . . . . . 0.605 HD13 ' O ' ' A' ' 177' ' ' LEU . 0.2 OUTLIER -63.72 -38.59 91.67 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.23 -0.919 . . . . 0.0 108.908 179.714 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 27.0 t . . . . . 0 N--CA 1.49 1.526 0 O-C-N 121.027 -1.046 . . . . 0.0 109.455 179.872 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.529 4.837 0 N-CA-C 119.426 2.53 . . . . 0.0 119.426 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 29.5 t -118.91 142.41 47.78 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.351 -1.088 . . . . 0.0 109.414 179.966 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 73.2 t80 -107.86 116.52 32.1 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.444 -0.785 . . . . 0.0 109.018 179.634 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 66.1 p -112.18 10.71 20.22 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.674 -0.641 . . . . 0.0 109.769 -179.801 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.55 12.36 62.85 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 -179.779 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 24.2 m -58.18 -32.98 68.75 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.337 -1.096 . . . . 0.0 109.642 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 12.5 mmt -122.07 79.83 42.99 Favored Pre-proline 0 N--CA 1.493 1.702 0 O-C-N 121.316 -0.865 . . . . 0.0 109.619 -179.732 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 89.6 Cg_endo -80.79 168.28 17.74 Favored 'Trans proline' 0 C--N 1.308 -1.557 0 C-N-CA 122.837 2.358 . . . . 0.0 112.115 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -66.9 149.39 98.46 Favored Pre-proline 0 N--CA 1.492 1.632 0 O-C-N 121.254 -0.904 . . . . 0.0 109.332 -179.843 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -68.1 139.69 47.35 Favored 'Trans proline' 0 N--CA 1.497 1.706 0 C-N-CA 122.713 2.276 . . . . 0.0 112.464 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 82.3 mtp180 -132.28 134.47 45.31 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.419 -0.8 . . . . 0.0 108.869 179.071 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.8 p -135.29 143.49 36.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 O-C-N 121.256 -0.903 . . . . 0.0 109.539 -179.652 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 42.8 p90 -138.95 155.61 47.9 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.321 -0.862 . . . . 0.0 109.459 179.948 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.593 ' CE2' ' SG ' ' A' ' 174' ' ' CYS . 76.4 m-85 -122.13 137.87 54.67 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.451 -0.781 . . . . 0.0 109.697 179.883 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 22.8 t70 -88.04 117.02 26.63 Favored 'General case' 0 N--CA 1.493 1.719 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 179.123 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' MET . . . . . 0.412 ' SD ' HD12 ' A' ' 26' ' ' ILE . 83.3 mtp -104.63 143.87 32.48 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.342 -0.849 . . . . 0.0 110.713 -179.044 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.463 ' OG ' ' OE2' ' A' ' 172' ' ' GLU . 61.9 m -141.43 159.3 42.51 Favored 'General case' 0 N--CA 1.49 1.551 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 179.383 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.47 HG13 ' HB2' ' A' ' 23' ' ' ALA . 33.1 m -123.58 147.95 27.77 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.179 -0.95 . . . . 0.0 109.756 -179.759 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 49.09 -107.75 0.33 Allowed Glycine 0 N--CA 1.488 2.113 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.925 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -128.83 25.83 4.62 Favored Glycine 0 N--CA 1.494 2.53 0 N-CA-C 109.631 -1.387 . . . . 0.0 109.631 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 10.7 pt20 -141.58 149.5 54.15 Favored Pre-proline 0 N--CA 1.493 1.714 0 O-C-N 121.3 -1.118 . . . . 0.0 109.29 179.846 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -67.57 138.43 45.64 Favored 'Trans proline' 0 N--CA 1.494 1.544 0 C-N-CA 122.504 2.136 . . . . 0.0 112.108 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.47 ' HB2' HG13 ' A' ' 18' ' ' VAL . . . -101.72 -54.29 2.77 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.411 -0.806 . . . . 0.0 109.216 179.713 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -176.02 -171.25 39.67 Favored Glycine 0 N--CA 1.488 2.156 0 N-CA-C 109.317 -1.513 . . . . 0.0 109.317 -179.916 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 33.0 ptt180 -131.1 148.57 52.75 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.482 -1.011 . . . . 0.0 109.138 179.73 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.412 HD12 ' SD ' ' A' ' 16' ' ' MET . 82.8 mt -122.91 130.11 74.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.318 -0.864 . . . . 0.0 109.248 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 42.0 t -111.0 132.63 58.97 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.491 -0.756 . . . . 0.0 109.222 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 74.1 mtm -120.88 146.93 46.08 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.439 -0.788 . . . . 0.0 109.18 -179.894 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -101.13 131.12 47.23 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.294 -0.879 . . . . 0.0 109.794 -179.718 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.418 ' N ' ' CD2' ' A' ' 30' ' ' LEU . 2.5 mm? -106.2 131.67 53.17 Favored 'General case' 0 N--CA 1.493 1.693 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 179.512 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 95.4 m-85 -98.4 118.29 34.74 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.215 -0.928 . . . . 0.0 109.024 179.572 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -80.68 -42.82 21.38 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.341 -0.85 . . . . 0.0 109.771 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -64.7 -45.89 84.67 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.293 -0.879 . . . . 0.0 110.311 -179.328 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . 0.409 HG21 ' CE ' ' A' ' 103' ' ' LYS . 26.4 m -67.8 -45.13 75.67 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.121 -0.987 . . . . 0.0 109.835 -179.57 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.472 ' O ' ' OG1' ' A' ' 35' ' ' THR . 4.6 p -142.67 81.4 13.37 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 121.282 -0.886 . . . . 0.0 109.325 -179.75 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -64.27 -58.29 0.26 Allowed 'Trans proline' 0 N--CA 1.494 1.537 0 C-N-CA 122.283 1.989 . . . . 0.0 112.582 -179.347 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 78.4 mtp180 -62.03 -37.11 83.68 Favored 'General case' 0 C--N 1.299 -1.602 0 O-C-N 121.428 -0.795 . . . . 0.0 110.647 -179.132 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 28.1 m -61.91 -41.34 97.81 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.87 -1.144 . . . . 0.0 109.981 -179.542 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -61.3 -31.23 71.07 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.11 -0.994 . . . . 0.0 109.311 -179.739 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.592 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 97.0 mt-10 -66.69 -35.34 79.91 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.351 -0.843 . . . . 0.0 109.885 -179.862 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 88.6 m-20 -55.98 -37.29 68.87 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.256 -0.903 . . . . 0.0 109.85 -179.688 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -97.67 -53.29 3.47 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.221 -0.925 . . . . 0.0 110.024 -179.852 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 59.7 ttp180 -57.94 -42.74 85.54 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.329 -0.857 . . . . 0.0 110.605 -179.179 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.592 ' HB3' ' O ' ' A' ' 40' ' ' GLU . . . -67.73 -44.67 77.05 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.904 -1.123 . . . . 0.0 110.305 -179.181 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.5 ' N ' ' CD2' ' A' ' 45' ' ' LEU . 2.5 mm? -65.74 -40.51 92.19 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.004 -1.06 . . . . 0.0 109.7 -179.801 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' CYS . . . . . . . . . . . . . 72.0 m -67.63 -49.54 62.47 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.067 -1.02 . . . . 0.0 109.334 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 57.5 p -74.46 -32.0 62.43 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.397 -0.814 . . . . 0.0 109.38 179.755 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.459 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 75.85 33.63 50.46 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 110.217 -1.153 . . . . 0.0 110.217 179.457 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -62.23 -37.66 86.22 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.99 -1.3 . . . . 0.0 109.423 179.78 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 54.6 mmtt -61.94 -34.12 75.52 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.275 -0.89 . . . . 0.0 109.349 179.934 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 92.53 172.48 41.27 Favored Glycine 0 N--CA 1.486 2.012 0 N-CA-C 109.239 -1.544 . . . . 0.0 109.239 -179.677 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.536 HG23 ' HA ' ' A' ' 58' ' ' PRO . 89.3 m -73.85 140.73 45.95 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.322 -1.105 . . . . 0.0 109.833 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -57.62 136.17 50.99 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.284 -1.527 . . . . 0.0 109.284 179.829 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 75.6 mtm180 -59.25 -34.11 71.85 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.243 -1.151 . . . . 0.0 110.017 -179.647 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 86.6 p -61.0 -24.82 66.44 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.102 -0.999 . . . . 0.0 109.942 -179.699 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 112.74 90.45 1.89 Allowed Glycine 0 N--CA 1.494 2.507 0 N-CA-C 109.109 -1.596 . . . . 0.0 109.109 -179.696 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . 0.531 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 3.0 ttmp? -175.25 80.73 0.31 Allowed Pre-proline 0 N--CA 1.489 1.502 0 O-C-N 121.479 -1.012 . . . . 0.0 108.448 -179.708 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.536 ' HA ' HG23 ' A' ' 52' ' ' THR . 69.7 Cg_exo -51.18 132.33 38.5 Favored 'Trans proline' 0 C--N 1.303 -1.847 0 C-N-CA 122.942 2.428 . . . . 0.0 112.848 -179.05 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.531 ' CD1' ' O ' ' A' ' 57' ' ' LYS . 7.6 mp -101.09 127.39 47.64 Favored 'General case' 0 N--CA 1.493 1.7 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 179.811 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 6.1 p80 -176.14 132.4 0.24 Allowed 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.094 -1.004 . . . . 0.0 109.86 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 4.4 m-85 -96.95 13.34 29.23 Favored 'General case' 0 N--CA 1.492 1.65 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 179.091 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 85.8 mttt -77.46 149.77 35.01 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.416 -0.802 . . . . 0.0 109.639 -179.765 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . 0.408 ' N ' HG23 ' A' ' 171' ' ' VAL . 46.4 t0 61.4 35.03 17.99 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.581 -0.699 . . . . 0.0 109.618 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.814 ' H ' ' CG2' ' A' ' 171' ' ' VAL . 55.3 p -83.94 160.08 21.15 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.278 -0.889 . . . . 0.0 108.808 179.094 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 31.3 t -128.58 147.96 50.75 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.168 -0.957 . . . . 0.0 109.57 -179.776 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 22.3 m-85 -72.25 130.12 40.06 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.258 -0.901 . . . . 0.0 109.296 179.86 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 79.4 t60 -61.79 -48.99 78.12 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.16 -0.962 . . . . 0.0 109.481 -179.88 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 37.1 ptt180 -164.71 159.74 19.08 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.27 -0.894 . . . . 0.0 109.678 179.671 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.575 HG21 HG22 ' A' ' 165' ' ' THR . 23.0 m -132.51 148.46 31.8 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 179.539 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 11.5 mt -146.79 125.07 6.17 Favored Pre-proline 0 N--CA 1.494 1.735 0 O-C-N 120.956 -1.09 . . . . 0.0 109.576 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -75.34 135.36 18.37 Favored 'Trans proline' 0 N--CA 1.491 1.34 0 C-N-CA 122.264 1.976 . . . . 0.0 112.117 179.667 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 89.67 1.56 77.19 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.686 -1.365 . . . . 0.0 109.686 179.795 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 95.3 m-85 -134.25 -96.09 0.28 Allowed 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.359 -1.083 . . . . 0.0 109.558 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' MET . . . . . 0.6 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 5.9 ptt? -166.67 158.85 13.5 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.047 -1.033 . . . . 0.0 109.686 -179.659 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 1.7 m -98.45 123.35 42.54 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.417 -0.802 . . . . 0.0 109.008 179.402 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 63.6 tt0 -98.87 125.91 44.39 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.276 -0.89 . . . . 0.0 109.811 -179.584 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -84.85 -174.06 50.16 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 179.599 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -137.59 155.52 23.1 Favored Glycine 0 N--CA 1.494 2.513 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 87.7 m-20 -77.02 150.5 35.8 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.226 -1.161 . . . . 0.0 109.502 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 40.8 p90 -64.85 -22.87 67.07 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.142 -0.974 . . . . 0.0 109.443 -179.856 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.468 ' O ' ' HB2' ' A' ' 82' ' ' ALA . 58.9 p -67.11 -30.98 71.15 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.294 -0.879 . . . . 0.0 109.52 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . 0.468 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 176.77 -56.44 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.314 -0.866 . . . . 0.0 109.328 179.953 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 96.12 -10.69 67.76 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 78.7 m-20 -89.15 3.22 52.61 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.177 -1.19 . . . . 0.0 109.323 179.813 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 95.19 -5.54 68.26 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.404 -1.479 . . . . 0.0 109.404 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 64.5 p -72.79 -21.98 60.9 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.245 -1.15 . . . . 0.0 109.41 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -125.32 -123.5 2.71 Favored Glycine 0 N--CA 1.494 2.53 0 N-CA-C 109.384 -1.486 . . . . 0.0 109.384 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 75.6 42.01 27.9 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 179.896 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -79.7 146.55 32.36 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.369 -1.077 . . . . 0.0 109.439 -179.883 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 50.8 m -108.86 148.61 30.35 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.384 -0.822 . . . . 0.0 109.265 -179.83 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.405 HG13 ' N ' ' A' ' 92' ' ' TYR . 15.8 pt -62.6 -39.42 84.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.295 -0.878 . . . . 0.0 109.948 -179.62 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . 0.405 ' N ' HG13 ' A' ' 91' ' ' ILE . 73.6 m-85 -68.0 -37.26 81.24 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.112 -0.993 . . . . 0.0 109.578 179.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 78.14 14.66 82.03 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 -179.932 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -148.87 158.48 44.2 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.238 -1.154 . . . . 0.0 109.588 -179.825 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . 0.466 ' HD3' HG23 ' A' ' 120' ' ' THR . 42.7 mttm -85.3 149.51 25.41 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.238 -0.914 . . . . 0.0 109.596 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.538 ' CE1' ' OD1' ' A' ' 121' ' ' ASN . 55.1 p90 -137.12 161.21 36.76 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.268 -0.895 . . . . 0.0 109.453 179.696 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -102.78 148.33 25.75 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.295 -0.878 . . . . 0.0 109.394 -179.785 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 89.3 m-20 -68.41 133.13 48.19 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.264 -0.897 . . . . 0.0 109.352 -179.897 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -66.26 -37.49 85.59 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.235 -0.916 . . . . 0.0 110.134 -179.731 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 86.9 m-20 -126.68 125.15 41.37 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.224 -0.922 . . . . 0.0 110.098 -179.477 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' PHE . . . . . 0.536 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 69.3 t80 -103.11 5.3 37.84 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.318 -0.864 . . . . 0.0 108.886 179.351 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 91.0 mt -57.19 -34.69 46.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.397 -0.814 . . . . 0.0 110.545 -179.187 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . 0.409 ' CE ' HG21 ' A' ' 34' ' ' THR . 91.7 mttt -72.55 135.08 45.52 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.808 -1.182 . . . . 0.0 109.951 -179.358 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 10.4 ptpp? -139.89 -179.05 5.72 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.435 -0.791 . . . . 0.0 109.382 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' HIS . . . . . 0.523 ' CE1' ' O ' ' A' ' 107' ' ' GLY . 82.3 t60 -84.33 77.6 9.96 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.149 -0.969 . . . . 0.0 109.165 179.872 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 54.6 p -75.5 -27.83 58.94 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.324 -0.86 . . . . 0.0 110.154 -179.581 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.523 ' O ' ' CE1' ' A' ' 105' ' ' HIS . . . -149.14 177.78 27.12 Favored Glycine 0 N--CA 1.494 2.517 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 -179.581 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -72.74 155.18 54.17 Favored 'Trans proline' 0 C--N 1.307 -1.65 0 C-N-CA 122.991 2.461 . . . . 0.0 112.314 179.792 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 82.6 47.0 6.15 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 110.138 -1.185 . . . . 0.0 110.138 179.588 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.417 HG12 ' O ' ' A' ' 107' ' ' GLY . 41.8 mm -115.7 138.09 47.24 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.819 0 O-C-N 121.302 -1.116 . . . . 0.0 109.628 179.857 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.418 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 3.7 mm? -89.15 126.72 35.59 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.267 -0.895 . . . . 0.0 109.216 179.627 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . 0.4 ' OG ' ' O ' ' A' ' 140' ' ' VAL . 38.9 t -142.72 142.15 31.91 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.334 -0.854 . . . . 0.0 109.509 179.863 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER -91.55 141.27 28.9 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.319 -0.863 . . . . 0.0 109.174 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . 0.521 ' O ' ' N ' ' A' ' 122' ' ' GLY . . . -63.49 147.31 51.7 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.267 -0.896 . . . . 0.0 109.594 179.986 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . 0.42 ' OD1' ' O ' ' A' ' 114' ' ' ALA . 65.6 m-20 -137.23 112.72 9.35 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.332 -0.855 . . . . 0.0 109.002 179.612 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -72.23 -32.03 66.37 Favored 'General case' 0 C--N 1.294 -1.811 0 O-C-N 121.466 -0.771 . . . . 0.0 109.432 179.807 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -148.49 176.08 27.46 Favored Glycine 0 N--CA 1.492 2.393 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 179.848 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . 0.43 ' O ' ' CG ' ' A' ' 119' ' ' ASN . 71.6 Cg_exo -50.31 148.03 15.17 Favored 'Trans proline' 0 C--N 1.304 -1.786 0 C-N-CA 122.604 2.203 . . . . 0.0 112.903 179.855 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 119' ' ' ASN . . . . . 0.43 ' CG ' ' O ' ' A' ' 118' ' ' PRO . 7.0 p-10 41.83 49.04 3.9 Favored 'General case' 0 N--CA 1.494 1.751 0 CA-C-O 121.135 0.493 . . . . 0.0 110.11 179.451 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 120' ' ' THR . . . . . 0.466 HG23 ' HD3' ' A' ' 95' ' ' LYS . 87.9 m -131.38 124.9 31.31 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.308 -0.87 . . . . 0.0 109.004 179.55 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 121' ' ' ASN . . . . . 0.538 ' OD1' ' CE1' ' A' ' 96' ' ' PHE . 25.4 m120 -101.93 119.1 38.25 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.535 -0.728 . . . . 0.0 109.237 179.768 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . 0.521 ' N ' ' O ' ' A' ' 114' ' ' ALA . . . -84.41 142.2 20.21 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.719 -1.352 . . . . 0.0 109.719 -179.751 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 88.1 p -64.26 -22.83 67.09 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.367 -1.078 . . . . 0.0 109.337 179.739 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 92.9 mt-30 -95.12 151.61 19.06 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.296 -0.878 . . . . 0.0 109.511 -179.873 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 49.3 p90 -134.79 161.57 34.83 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.364 -0.835 . . . . 0.0 109.428 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.6 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 54.1 p90 -138.94 158.88 43.41 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.33 -0.856 . . . . 0.0 109.547 -179.955 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 72.6 mt -121.31 130.75 74.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.435 -0.791 . . . . 0.0 109.486 179.758 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 1.6 m -93.25 105.74 17.78 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.273 -0.892 . . . . 0.0 108.89 179.663 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 60.0 p -75.49 -7.05 53.14 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.379 -0.826 . . . . 0.0 109.711 -179.713 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -149.21 156.28 41.9 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.158 -0.964 . . . . 0.0 109.741 -179.769 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 55.7 tttp -69.38 141.27 54.18 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.212 -0.93 . . . . 0.0 109.236 179.808 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 20.7 p -114.66 153.95 29.28 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.397 -0.814 . . . . 0.0 109.604 -179.858 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . 0.423 ' O ' ' CG ' ' A' ' 136' ' ' ASP . 92.6 mt-10 -106.23 -73.49 0.68 Allowed 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.385 -0.822 . . . . 0.0 109.925 -179.925 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 134' ' ' TRP . . . . . 0.524 ' CD1' ' N ' ' A' ' 135' ' ' LEU . 42.8 p90 -56.03 -36.74 68.32 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.265 -0.897 . . . . 0.0 110.109 -179.535 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . 0.524 ' N ' ' CD1' ' A' ' 134' ' ' TRP . 6.9 tp -74.6 4.04 6.79 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.251 -0.906 . . . . 0.0 109.559 -179.327 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . 0.452 ' C ' ' OD1' ' A' ' 136' ' ' ASP . 53.5 p30 -67.36 167.29 12.77 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.99 -1.069 . . . . 0.0 109.569 -179.941 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 148.96 -134.0 4.77 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.17 -1.572 . . . . 0.0 109.17 -179.909 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 13.7 mptt -91.76 128.84 37.75 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.208 -1.172 . . . . 0.0 109.018 179.647 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 139' ' ' HIS . . . . . 0.459 ' O ' ' CE1' ' A' ' 101' ' ' PHE . 98.4 m-70 -135.72 152.61 51.32 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.287 -0.883 . . . . 0.0 109.647 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.4 ' O ' ' OG ' ' A' ' 112' ' ' SER . 24.5 m -127.73 149.82 33.02 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 121.351 -0.843 . . . . 0.0 109.022 179.573 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 46.1 t -132.08 125.81 55.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.272 -0.892 . . . . 0.0 109.763 -180.0 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 47.1 p90 -109.64 3.01 20.61 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.446 -0.784 . . . . 0.0 108.932 178.932 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -178.11 178.6 48.55 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.024 -1.63 . . . . 0.0 109.024 179.562 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.3 pt20 -145.95 166.68 25.3 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.09 -1.241 . . . . 0.0 109.614 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 69.7 t -97.04 128.37 48.33 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.245 0 O-C-N 121.21 -0.931 . . . . 0.0 109.4 -179.719 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 15.9 m -103.83 -32.01 2.91 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 O-C-N 121.421 -0.799 . . . . 0.0 109.395 179.588 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -143.45 170.07 16.49 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.329 -0.857 . . . . 0.0 109.407 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 96.55 5.13 59.08 Favored Glycine 0 N--CA 1.493 2.475 0 N-CA-C 109.909 -1.276 . . . . 0.0 109.909 179.61 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 149' ' ' MET . . . . . 0.545 ' O ' HG12 ' A' ' 152' ' ' VAL . 97.0 mmm -60.18 -32.22 70.86 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.144 -1.209 . . . . 0.0 109.458 179.778 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -65.36 -41.71 93.52 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.899 -1.125 . . . . 0.0 110.106 -179.548 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 6.7 p -80.96 -33.26 13.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 120.987 -1.07 . . . . 0.0 110.707 -179.279 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 152' ' ' VAL . . . . . 0.545 HG12 ' O ' ' A' ' 149' ' ' MET . 1.0 OUTLIER -51.92 -41.08 29.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 120.84 -1.162 . . . . 0.0 108.998 -179.264 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 153' ' ' LYS . . . . . 0.439 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 66.8 mttm -65.68 -33.38 75.75 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.214 -0.929 . . . . 0.0 109.214 179.213 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -60.63 -37.23 80.79 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.489 -0.757 . . . . 0.0 109.942 -179.42 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 88.4 mt -70.52 -37.63 70.75 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.524 0 O-C-N 121.156 -0.965 . . . . 0.0 110.066 -179.687 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -77.06 -41.16 43.53 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.196 -0.94 . . . . 0.0 111.556 -178.39 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 16.7 pttm -59.91 -35.4 74.8 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 120.57 -1.331 . . . . 0.0 109.735 -178.763 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 31.5 m -81.1 -10.39 12.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.041 -1.037 . . . . 0.0 109.017 179.395 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -71.95 165.61 53.84 Favored Glycine 0 N--CA 1.488 2.16 0 N-CA-C 110.056 -1.217 . . . . 0.0 110.056 -179.623 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 24.1 t -154.52 167.87 28.63 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.506 -0.996 . . . . 0.0 109.482 -179.858 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 24.8 m -54.46 -29.89 51.17 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.292 -0.88 . . . . 0.0 109.194 179.827 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 22.8 t -54.26 -30.79 51.8 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.307 -0.871 . . . . 0.0 109.506 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 95.41 12.22 54.5 Favored Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.817 -1.313 . . . . 0.0 109.817 179.916 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 42.1 ttp180 -125.78 143.67 50.96 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.298 -1.119 . . . . 0.0 109.467 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 165' ' ' THR . . . . . 0.575 HG22 HG21 ' A' ' 69' ' ' VAL . 71.5 p -74.63 151.28 39.35 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.094 -1.004 . . . . 0.0 109.326 179.936 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -66.31 -37.93 86.53 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.154 -0.967 . . . . 0.0 109.52 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 67.1 mttm -108.94 156.96 19.1 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.432 -0.792 . . . . 0.0 109.4 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 48.1 mtmt -72.53 130.61 41.04 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.205 -0.934 . . . . 0.0 109.268 179.816 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 25.0 t -124.75 124.14 67.35 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 O-C-N 121.434 -0.791 . . . . 0.0 109.427 -179.888 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 57.5 t -144.33 137.05 22.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.271 -0.893 . . . . 0.0 109.499 179.668 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.814 ' CG2' ' H ' ' A' ' 64' ' ' SER . 27.0 m -71.31 126.32 31.44 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.251 -0.905 . . . . 0.0 109.487 179.746 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 172' ' ' GLU . . . . . 0.49 ' O ' ' OD1' ' A' ' 173' ' ' ASP . 96.3 mt-10 -69.84 -40.72 75.65 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.077 -1.014 . . . . 0.0 109.901 179.855 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 173' ' ' ASP . . . . . 0.49 ' OD1' ' O ' ' A' ' 172' ' ' GLU . 49.7 m-20 -163.91 167.67 20.36 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.219 -0.925 . . . . 0.0 110.218 -179.641 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 174' ' ' CYS . . . . . 0.593 ' SG ' ' CE2' ' A' ' 14' ' ' PHE . 43.7 t -136.51 140.82 43.29 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.581 -0.7 . . . . 0.0 109.306 179.597 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -154.94 173.34 33.29 Favored Glycine 0 N--CA 1.493 2.491 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 179.907 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 63.8 tt0 -104.48 119.25 38.56 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.343 -1.092 . . . . 0.0 109.526 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 34.5 tp -61.83 -38.24 87.45 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.203 -0.936 . . . . 0.0 109.575 179.897 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 8.7 t . . . . . 0 N--CA 1.488 1.454 0 O-C-N 121.094 -1.004 . . . . 0.0 109.454 -179.964 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.528 4.785 0 N-CA-C 119.379 2.512 . . . . 0.0 119.379 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 89.5 p -62.53 -23.5 67.0 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.236 -1.155 . . . . 0.0 109.537 179.91 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 46.7 p90 -140.27 164.43 30.1 Favored 'General case' 0 C--N 1.308 -1.23 0 N-CA-C 108.515 -0.92 . . . . 0.0 108.515 179.683 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 49.5 m -110.65 138.15 47.41 Favored 'General case' 0 C--N 1.295 -1.77 0 O-C-N 121.689 -0.632 . . . . 0.0 109.444 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 179.69 -174.04 45.72 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.413 -1.475 . . . . 0.0 109.413 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 29.8 t -117.66 139.09 51.48 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.337 -1.096 . . . . 0.0 109.395 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' MET . . . . . 0.586 ' N ' ' SD ' ' A' ' 7' ' ' MET . 2.4 mpp? -75.4 152.13 85.6 Favored Pre-proline 0 N--CA 1.491 1.604 0 O-C-N 121.361 -0.837 . . . . 0.0 109.191 179.908 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -69.49 168.64 20.62 Favored 'Trans proline' 0 C--N 1.311 -1.446 0 C-N-CA 122.636 2.224 . . . . 0.0 111.961 179.816 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 16.4 m120 -69.78 148.05 96.44 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.274 -0.891 . . . . 0.0 109.443 -179.873 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -70.21 141.68 44.03 Favored 'Trans proline' 0 N--CA 1.496 1.634 0 C-N-CA 122.769 2.313 . . . . 0.0 112.244 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 59.2 mtm180 -127.89 134.52 49.38 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.376 -0.827 . . . . 0.0 108.902 179.294 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 9.6 p -136.21 144.36 33.31 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.389 -0.819 . . . . 0.0 109.309 -179.701 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 48.3 p90 -138.1 153.89 49.26 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.342 -0.849 . . . . 0.0 109.477 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 88.7 m-85 -121.28 136.36 54.98 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.568 -0.707 . . . . 0.0 109.735 179.755 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -93.62 131.4 38.94 Favored 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 179.228 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' MET . . . . . 0.424 ' SD ' ' CD1' ' A' ' 26' ' ' ILE . 74.2 mtp -125.45 153.24 43.79 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.118 -0.989 . . . . 0.0 110.282 -179.386 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 85.2 p -143.78 161.05 39.62 Favored 'General case' 0 N--CA 1.488 1.463 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 179.718 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.422 ' C ' ' N ' ' A' ' 20' ' ' GLY . 33.0 m -126.32 137.49 57.62 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.105 -0.997 . . . . 0.0 109.534 -179.925 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 53.43 11.62 1.84 Allowed Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 179.848 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.422 ' N ' ' C ' ' A' ' 18' ' ' VAL . . . 95.6 -1.39 63.89 Favored Glycine 0 N--CA 1.493 2.465 0 N-CA-C 109.779 -1.328 . . . . 0.0 109.779 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 2.6 mp0 -99.93 152.09 37.7 Favored Pre-proline 0 N--CA 1.495 1.806 0 O-C-N 121.229 -1.159 . . . . 0.0 109.149 179.876 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -61.66 138.52 75.58 Favored 'Trans proline' 0 C--N 1.308 -1.558 0 C-N-CA 122.581 2.187 . . . . 0.0 112.15 -179.83 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -111.69 -64.18 1.32 Allowed 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.441 -0.787 . . . . 0.0 109.471 179.893 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -179.9 -168.75 39.12 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.414 -1.475 . . . . 0.0 109.414 -179.882 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 79.7 mtm180 -114.37 142.18 46.67 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.381 -1.07 . . . . 0.0 109.759 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.424 ' CD1' ' SD ' ' A' ' 16' ' ' MET . 80.2 mt -122.93 121.1 62.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 179.11 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 40.2 t -120.85 134.6 63.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.469 -0.769 . . . . 0.0 109.27 -179.808 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 72.6 mtm -122.44 154.81 37.28 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.405 -0.809 . . . . 0.0 109.349 -179.845 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -100.85 132.0 46.47 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.347 -0.845 . . . . 0.0 109.968 -179.611 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -107.48 128.93 54.93 Favored 'General case' 0 N--CA 1.493 1.717 0 N-CA-C 108.914 -0.772 . . . . 0.0 108.914 179.318 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -98.04 119.66 37.08 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.189 -0.944 . . . . 0.0 109.058 179.661 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -78.84 -40.16 33.47 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.318 -0.864 . . . . 0.0 110.047 -179.623 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.531 ' OD1' ' N ' ' A' ' 34' ' ' THR . 31.6 p-10 -68.72 -40.79 79.75 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.258 -0.902 . . . . 0.0 110.859 -179.093 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . 0.531 ' N ' ' OD1' ' A' ' 33' ' ' ASP . 17.4 m -67.51 -44.56 78.15 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.018 -1.051 . . . . 0.0 109.834 -179.4 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 38.2 p -154.03 83.99 4.16 Favored Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.385 -0.822 . . . . 0.0 109.018 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -70.53 -40.84 3.75 Favored 'Trans proline' 0 C--N 1.309 -1.544 0 C-N-CA 122.085 1.856 . . . . 0.0 112.333 -179.212 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.423 ' HD2' ' H ' ' A' ' 37' ' ' ARG . 1.5 mpt_? -63.71 -40.95 98.04 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.168 -0.958 . . . . 0.0 109.667 -179.973 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 38.3 m -66.16 -41.52 90.24 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.19 -0.944 . . . . 0.0 110.004 -179.755 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -60.66 -32.39 71.58 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.174 -0.953 . . . . 0.0 109.032 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -68.05 -38.23 82.24 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.433 -0.792 . . . . 0.0 109.735 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 46.4 t30 -58.23 -41.41 84.07 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.248 -0.908 . . . . 0.0 109.935 -179.436 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.494 ' O ' ' SG ' ' A' ' 46' ' ' CYS . 97.4 m-85 -86.15 -41.08 15.02 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.047 -1.033 . . . . 0.0 110.108 -179.664 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 61.3 ttp180 -59.14 -44.42 92.05 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.229 -0.919 . . . . 0.0 110.937 -178.925 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -71.17 -46.09 62.11 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 120.945 -1.097 . . . . 0.0 110.259 -179.271 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.498 ' N ' ' CD2' ' A' ' 45' ' ' LEU . 2.3 mm? -65.3 -38.13 89.26 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.164 -0.96 . . . . 0.0 109.69 -179.711 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' CYS . . . . . 0.494 ' SG ' ' O ' ' A' ' 42' ' ' PHE . 73.8 m -71.12 -50.5 32.82 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.098 -1.001 . . . . 0.0 109.576 -179.895 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 30.9 m -63.92 -36.72 84.89 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.329 -0.857 . . . . 0.0 109.589 -179.933 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 95.59 8.24 58.52 Favored Glycine 0 N--CA 1.493 2.46 0 N-CA-C 109.838 -1.305 . . . . 0.0 109.838 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 78.1 mm-40 -61.25 -32.24 72.04 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.238 -1.154 . . . . 0.0 109.526 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 20.9 tptp -58.25 -38.97 77.94 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.255 -0.903 . . . . 0.0 109.482 -179.11 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 90.65 171.45 43.75 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 110.018 -1.233 . . . . 0.0 110.018 179.558 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.555 ' O ' ' O ' ' A' ' 53' ' ' GLY . 81.7 m -79.08 148.44 32.42 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.585 -0.95 . . . . 0.0 109.479 179.925 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.555 ' O ' ' O ' ' A' ' 52' ' ' THR . . . -54.93 -122.36 0.01 OUTLIER Glycine 0 N--CA 1.492 2.389 0 N-CA-C 110.036 -1.226 . . . . 0.0 110.036 -179.839 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . 0.537 ' O ' ' CB ' ' A' ' 55' ' ' SER . 93.0 mtt180 -57.5 -41.15 80.2 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 120.971 -1.311 . . . . 0.0 109.766 -179.498 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . 0.537 ' CB ' ' O ' ' A' ' 54' ' ' ARG . 1.1 t 157.72 -26.86 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.724 0 N-CA-C 108.574 -0.898 . . . . 0.0 108.574 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -119.06 59.94 0.51 Allowed Glycine 0 N--CA 1.493 2.442 0 N-CA-C 109.169 -1.572 . . . . 0.0 109.169 179.926 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 36.4 tptt -172.05 70.97 0.45 Allowed Pre-proline 0 C--N 1.302 -1.474 0 O-C-N 121.447 -1.031 . . . . 0.0 108.56 -179.768 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 92.1 Cg_exo -42.9 94.8 0.02 OUTLIER 'Trans proline' 0 C--N 1.304 -1.766 0 C-N-CA 122.743 2.295 . . . . 0.0 112.202 -179.405 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.484 ' O ' ' CD1' ' A' ' 45' ' ' LEU . 8.2 tp -73.65 54.61 0.48 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.581 -0.699 . . . . 0.0 109.276 -179.731 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 40.5 m80 -138.39 150.63 46.72 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.252 -0.905 . . . . 0.0 109.603 -179.753 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 -67.28 -9.1 37.4 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.233 -0.917 . . . . 0.0 109.26 179.369 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 64.0 tttt -49.18 151.3 1.41 Allowed 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.319 -0.863 . . . . 0.0 109.841 -179.881 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 59.67 47.76 10.18 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.616 -0.677 . . . . 0.0 110.03 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.414 ' HB2' ' H ' ' A' ' 79' ' ' ASP . 62.2 p -115.78 151.06 35.91 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.353 -0.842 . . . . 0.0 109.01 179.202 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 29.4 t -126.46 148.61 49.64 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.346 -0.846 . . . . 0.0 109.594 -179.694 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.8 m-85 -70.99 135.34 47.79 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.252 -0.905 . . . . 0.0 109.084 179.958 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 95.8 m-70 -97.02 -29.99 13.33 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.243 -0.911 . . . . 0.0 110.425 -179.58 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 98.6 mtt180 -134.35 139.95 46.0 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.092 -1.005 . . . . 0.0 110.254 -179.457 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.728 HG21 HG22 ' A' ' 165' ' ' THR . 14.5 m -148.4 42.35 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.497 -0.752 . . . . 0.0 108.973 179.401 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 25.7 mt -76.94 132.84 70.38 Favored Pre-proline 0 C--N 1.301 -1.53 0 O-C-N 121.227 -0.921 . . . . 0.0 109.692 -178.926 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -69.93 145.6 56.66 Favored 'Trans proline' 0 N--CA 1.491 1.363 0 C-N-CA 122.213 1.942 . . . . 0.0 112.154 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 84.63 -54.44 4.92 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.636 -1.386 . . . . 0.0 109.636 179.905 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 83.7 m-85 -69.67 -80.6 0.05 OUTLIER 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.201 -1.176 . . . . 0.0 109.763 -179.905 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 12.9 ptt? 179.37 -179.04 0.38 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.092 -1.005 . . . . 0.0 109.741 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' CYS . . . . . 0.443 ' SG ' ' O ' ' A' ' 127' ' ' ILE . 0.8 OUTLIER -131.8 126.79 35.24 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.499 -0.751 . . . . 0.0 109.068 179.689 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 49.5 tt0 -98.14 137.57 36.71 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.342 -0.849 . . . . 0.0 109.331 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -151.94 -177.72 25.94 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.726 -1.35 . . . . 0.0 109.726 -179.887 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 78.6 56.92 3.46 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.639 -1.384 . . . . 0.0 109.639 -179.925 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.414 ' H ' ' HB2' ' A' ' 64' ' ' SER . 59.2 t0 -69.46 90.63 0.54 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.147 -1.208 . . . . 0.0 108.983 -179.96 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 68.3 t80 -61.19 -49.4 77.33 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.371 -0.83 . . . . 0.0 109.803 -179.623 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 6.6 p -153.2 -98.78 0.05 OUTLIER 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.164 -0.96 . . . . 0.0 109.418 179.828 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -86.37 -64.08 1.21 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.326 -0.859 . . . . 0.0 109.664 -179.899 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 98.48 -15.11 61.54 Favored Glycine 0 N--CA 1.493 2.438 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 -179.857 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 86.5 m-20 -63.5 -31.82 73.1 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.27 -1.135 . . . . 0.0 108.858 179.477 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 152.61 -33.3 0.83 Allowed Glycine 0 N--CA 1.489 2.216 0 N-CA-C 108.7 -1.76 . . . . 0.0 108.7 -179.691 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 55.0 p -78.1 -28.75 48.73 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.393 -1.063 . . . . 0.0 109.102 179.532 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -88.18 -171.07 46.33 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 179.854 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.449 ' CA ' ' OG ' ' A' ' 123' ' ' SER . . . 78.77 46.3 8.67 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 179.905 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -88.73 141.1 28.79 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.205 -1.173 . . . . 0.0 109.451 -179.82 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 92.9 p -107.13 159.32 16.41 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.471 -0.768 . . . . 0.0 109.395 -179.931 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 19.5 pt -59.55 -32.11 48.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.268 -0.895 . . . . 0.0 109.51 -179.805 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 76.5 m-85 -66.33 -24.08 66.47 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.165 -0.959 . . . . 0.0 109.436 179.903 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 76.05 -97.79 1.17 Allowed Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.089 -1.604 . . . . 0.0 109.089 -179.614 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -59.74 147.85 36.37 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.319 -1.106 . . . . 0.0 109.019 179.643 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 9.2 mtmp? -72.27 156.33 39.24 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.417 -0.802 . . . . 0.0 109.418 -179.744 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 36.2 p90 -128.6 160.7 31.57 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.437 -0.789 . . . . 0.0 109.484 -179.818 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -61.52 142.59 56.96 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.292 -0.88 . . . . 0.0 110.123 -179.23 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.425 ' H ' ' HA ' ' A' ' 119' ' ' ASN . 88.5 m-20 -70.24 151.42 45.36 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.226 -0.921 . . . . 0.0 109.615 179.772 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -94.93 164.73 12.78 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.324 -0.86 . . . . 0.0 109.185 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 81.5 m-20 -58.26 153.23 15.65 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.226 -0.922 . . . . 0.0 109.444 -179.765 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' PHE . . . . . 0.584 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 21.9 p90 -132.43 80.79 1.92 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.293 -0.879 . . . . 0.0 109.451 -179.853 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 87.4 mt -59.47 -34.38 54.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.248 -0.908 . . . . 0.0 109.378 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 63.3 mttp -85.77 145.21 27.34 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.232 -0.917 . . . . 0.0 109.385 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . 0.482 ' O ' ' N ' ' A' ' 106' ' ' THR . 19.8 pttm -134.66 -178.91 5.28 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.374 -0.829 . . . . 0.0 109.501 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' HIS . . . . . . . . . . . . . 96.5 m-70 -65.02 72.45 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.25 -0.906 . . . . 0.0 109.667 -179.971 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . 0.545 ' O ' ' NZ ' ' A' ' 131' ' ' LYS . 68.7 p -70.82 -27.45 63.89 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.141 -0.974 . . . . 0.0 109.682 179.946 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.421 ' O ' HG12 ' A' ' 110' ' ' ILE . . . -152.97 176.56 31.04 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 109.342 -1.503 . . . . 0.0 109.342 -179.885 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -72.64 153.97 54.49 Favored 'Trans proline' 0 C--N 1.307 -1.638 0 C-N-CA 122.889 2.393 . . . . 0.0 112.095 179.821 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 82.28 49.27 5.31 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 179.632 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.421 HG12 ' O ' ' A' ' 107' ' ' GLY . 39.1 mm -115.2 138.4 45.63 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 121.333 -1.098 . . . . 0.0 109.498 179.938 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.508 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 2.9 mm? -89.57 126.93 35.8 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.297 -0.877 . . . . 0.0 109.595 179.84 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 37.4 t -143.61 139.0 29.42 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.365 -0.835 . . . . 0.0 109.098 179.624 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' MET . . . . . 0.403 ' CE ' HD21 ' A' ' 121' ' ' ASN . 88.5 mtp -81.13 137.13 35.96 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.117 -0.989 . . . . 0.0 109.499 -179.821 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . 0.459 ' O ' ' OD1' ' A' ' 115' ' ' ASN . . . -64.14 142.44 58.41 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.281 -0.887 . . . . 0.0 109.604 -179.865 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . 0.459 ' OD1' ' O ' ' A' ' 114' ' ' ALA . 73.6 m-20 -146.84 114.0 6.22 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.313 -0.867 . . . . 0.0 108.854 179.569 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -68.2 -35.6 78.25 Favored 'General case' 0 C--N 1.298 -1.641 0 O-C-N 121.312 -0.867 . . . . 0.0 109.559 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -150.89 165.59 30.22 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.263 -1.535 . . . . 0.0 109.263 179.823 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_exo -47.14 153.13 1.72 Allowed 'Trans proline' 0 C--N 1.308 -1.585 0 C-N-CA 122.611 2.207 . . . . 0.0 112.826 179.831 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 119' ' ' ASN . . . . . 0.425 ' HA ' ' H ' ' A' ' 98' ' ' ASP . 18.9 m120 54.89 46.46 24.37 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.73 -0.606 . . . . 0.0 109.635 179.695 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 120' ' ' THR . . . . . 0.43 ' O ' ' OD1' ' A' ' 115' ' ' ASN . 58.5 m -135.39 124.45 24.32 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.316 -0.865 . . . . 0.0 109.099 179.857 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 121' ' ' ASN . . . . . 0.403 HD21 ' CE ' ' A' ' 113' ' ' MET . 23.1 t-20 -104.38 107.94 19.11 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.511 -0.743 . . . . 0.0 109.123 179.646 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -87.84 128.39 9.01 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.772 -1.331 . . . . 0.0 109.772 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 123' ' ' SER . . . . . 0.449 ' OG ' ' CA ' ' A' ' 88' ' ' GLY . 87.3 p -64.32 -23.43 67.29 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.366 -1.079 . . . . 0.0 109.343 179.719 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.4 mt-30 -92.65 153.25 19.09 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.302 -0.874 . . . . 0.0 109.562 -179.869 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 54.4 p90 -134.3 161.62 34.45 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.368 -0.832 . . . . 0.0 109.185 179.881 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 49.0 p90 -134.45 156.41 48.62 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.335 -0.853 . . . . 0.0 109.649 -179.854 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.443 ' O ' ' SG ' ' A' ' 75' ' ' CYS . 77.1 mt -122.2 134.11 66.46 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.453 -0.779 . . . . 0.0 109.556 179.928 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 128' ' ' CYS . . . . . 0.444 ' SG ' ' O ' ' A' ' 130' ' ' ALA . 3.9 t -97.92 112.92 24.66 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.177 -0.952 . . . . 0.0 109.087 179.346 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 41.3 p -80.36 -5.1 55.85 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.308 -0.87 . . . . 0.0 109.856 -179.469 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . 0.444 ' O ' ' SG ' ' A' ' 128' ' ' CYS . . . -147.5 161.64 40.67 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.19 -0.944 . . . . 0.0 109.669 -179.626 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.545 ' NZ ' ' O ' ' A' ' 106' ' ' THR . 63.6 mttm -76.56 140.8 41.23 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.194 -0.941 . . . . 0.0 109.299 179.898 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 6.3 p -125.11 158.93 32.64 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.437 -0.789 . . . . 0.0 109.258 -179.918 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -101.98 -74.92 0.61 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.204 -0.935 . . . . 0.0 109.956 -179.81 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 134' ' ' TRP . . . . . 0.581 ' CD1' ' N ' ' A' ' 135' ' ' LEU . 41.7 p90 -61.13 -46.93 88.57 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.21 -0.931 . . . . 0.0 109.999 -179.452 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . 0.581 ' N ' ' CD1' ' A' ' 134' ' ' TRP . 32.9 tp -61.63 -33.83 74.61 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.252 -0.905 . . . . 0.0 109.446 -179.819 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 23.5 t70 -76.5 119.03 19.78 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.258 -0.901 . . . . 0.0 109.645 -179.812 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . 0.438 ' H ' ' CD2' ' A' ' 139' ' ' HIS . . . -153.18 -129.87 1.44 Allowed Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.075 -1.61 . . . . 0.0 109.075 179.879 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 47.3 mmtm -86.99 114.43 23.59 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.212 -1.17 . . . . 0.0 108.966 179.659 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 139' ' ' HIS . . . . . 0.438 ' CD2' ' H ' ' A' ' 137' ' ' GLY . 98.0 m-70 -138.25 165.69 26.07 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.427 -0.795 . . . . 0.0 109.474 -179.858 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 48.1 t -113.58 132.6 62.04 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 121.356 -0.84 . . . . 0.0 109.274 179.845 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 61.4 t -112.69 129.07 68.95 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 121.272 -0.893 . . . . 0.0 109.308 179.826 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 40.0 p90 -115.76 2.2 13.6 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.334 -0.854 . . . . 0.0 109.725 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -176.26 179.69 47.2 Favored Glycine 0 N--CA 1.493 2.447 0 N-CA-C 109.771 -1.332 . . . . 0.0 109.771 179.64 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 2.6 pt20 -145.21 167.83 21.85 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.309 -1.112 . . . . 0.0 109.449 -179.89 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 55.4 t -96.34 130.16 45.39 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 O-C-N 121.157 -0.964 . . . . 0.0 109.576 -179.866 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 15.6 m -109.29 -33.25 2.43 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 121.323 -0.861 . . . . 0.0 109.409 179.558 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -142.14 171.1 14.52 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.324 -0.86 . . . . 0.0 109.483 179.914 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 98.71 1.96 57.46 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 109.858 -1.297 . . . . 0.0 109.858 179.674 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 149' ' ' MET . . . . . 0.431 ' O ' HG12 ' A' ' 152' ' ' VAL . 72.0 mtm -61.09 -33.76 73.85 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.049 -1.265 . . . . 0.0 109.539 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 56.2 t0 -63.85 -42.6 97.54 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 120.945 -1.097 . . . . 0.0 109.993 -179.713 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.4 p -82.98 -34.49 11.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.152 -0.968 . . . . 0.0 110.547 -179.532 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 152' ' ' VAL . . . . . 0.459 ' CG1' ' N ' ' A' ' 153' ' ' LYS . 0.6 OUTLIER -56.83 -41.93 76.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 120.896 -1.127 . . . . 0.0 109.289 -179.301 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 153' ' ' LYS . . . . . 0.459 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 46.6 mtpt -63.02 -34.28 77.23 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.186 -0.946 . . . . 0.0 109.424 179.459 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -62.13 -39.47 92.66 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.345 -0.847 . . . . 0.0 109.935 -179.559 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 89.2 mt -72.5 -34.86 49.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.162 -0.962 . . . . 0.0 110.042 -179.824 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -76.71 -41.44 45.24 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.153 -0.967 . . . . 0.0 111.182 -178.881 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 16.9 pttp -62.31 -33.59 74.97 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 120.824 -1.173 . . . . 0.0 109.931 -178.846 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 35.1 m -78.3 -10.41 12.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.023 -1.048 . . . . 0.0 109.262 179.662 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -75.52 174.46 52.36 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.743 -1.343 . . . . 0.0 109.743 -179.772 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 22.6 t -161.7 174.54 13.11 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.328 -1.101 . . . . 0.0 109.448 -179.802 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 23.6 m -54.83 -32.03 60.04 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.205 -0.934 . . . . 0.0 109.233 179.813 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 23.5 m -55.72 -33.18 64.0 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.263 -0.898 . . . . 0.0 109.577 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 94.61 10.09 58.23 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.726 -1.35 . . . . 0.0 109.726 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 16.3 tpt180 -116.98 142.69 46.63 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.426 -1.043 . . . . 0.0 109.058 179.833 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 165' ' ' THR . . . . . 0.728 HG22 HG21 ' A' ' 69' ' ' VAL . 68.0 p -80.21 151.52 29.63 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.229 -0.92 . . . . 0.0 109.579 -179.808 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -68.39 -35.69 78.05 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.337 -0.852 . . . . 0.0 109.104 179.476 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 93.6 mttt -112.0 159.31 18.56 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.531 -0.731 . . . . 0.0 109.283 179.925 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -72.7 132.74 44.06 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.31 -0.869 . . . . 0.0 109.411 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 42.7 t -121.35 126.14 74.58 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.233 -0.917 . . . . 0.0 109.634 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 43.2 t -147.56 151.22 13.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.334 -0.854 . . . . 0.0 109.302 179.769 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 2.7 t -87.93 125.57 41.43 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 C-N-CA 119.708 -0.797 . . . . 0.0 109.854 -179.271 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 172' ' ' GLU . . . . . 0.423 ' O ' ' HB3' ' A' ' 173' ' ' ASP . 97.3 mt-10 -65.62 -30.82 71.58 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.379 -0.826 . . . . 0.0 109.097 179.509 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 173' ' ' ASP . . . . . 0.425 ' C ' ' OD1' ' A' ' 173' ' ' ASP . 53.0 p30 177.73 -177.78 0.21 Allowed 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.335 -0.853 . . . . 0.0 110.093 -179.864 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 28.5 p -154.04 150.4 28.19 Favored 'General case' 0 N--CA 1.49 1.571 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 179.476 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -172.17 178.46 44.33 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 176' ' ' GLN . . . . . 0.436 ' OE1' ' OG ' ' A' ' 178' ' ' SER . 7.0 tt0 -106.04 124.17 49.15 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.463 -1.022 . . . . 0.0 109.75 -179.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 28.9 tp -62.29 -37.97 87.57 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.202 -0.936 . . . . 0.0 109.382 179.604 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 178' ' ' SER . . . . . 0.436 ' OG ' ' OE1' ' A' ' 176' ' ' GLN . 4.5 p . . . . . 0 N--CA 1.491 1.596 0 CA-C-O 117.994 -1.003 . . . . 0.0 109.497 -179.91 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.527 4.751 0 N-CA-C 119.449 2.539 . . . . 0.0 119.449 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . 0.47 ' OG ' ' CD2' ' A' ' 3' ' ' PHE . 87.3 p -62.18 -25.82 67.99 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.255 -1.144 . . . . 0.0 109.453 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.47 ' CD2' ' OG ' ' A' ' 2' ' ' SER . 99.5 m-85 -124.62 154.29 40.94 Favored 'General case' 0 C--N 1.308 -1.23 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 179.712 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 57.6 p -66.66 -16.82 64.48 Favored 'General case' 0 C--N 1.291 -1.939 0 O-C-N 121.605 -0.684 . . . . 0.0 109.525 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 68.19 -122.09 14.89 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.611 -1.396 . . . . 0.0 109.611 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 54.7 p -66.24 162.14 20.64 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.233 -1.157 . . . . 0.0 109.573 -179.916 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' MET . . . . . 0.518 ' N ' ' SD ' ' A' ' 7' ' ' MET . 1.3 mpt? -63.85 154.37 81.28 Favored Pre-proline 0 N--CA 1.489 1.517 0 O-C-N 121.37 -0.831 . . . . 0.0 109.275 -179.933 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -49.36 -26.15 11.29 Favored 'Trans proline' 0 C--N 1.311 -1.427 0 C-N-CA 122.237 1.958 . . . . 0.0 112.205 179.841 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 11.1 m120 -142.32 152.38 60.64 Favored Pre-proline 0 N--CA 1.492 1.671 0 O-C-N 121.312 -0.867 . . . . 0.0 109.389 -179.948 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -65.93 141.85 66.4 Favored 'Trans proline' 0 N--CA 1.496 1.663 0 C-N-CA 122.822 2.348 . . . . 0.0 112.206 179.828 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 98.5 mtt180 -128.73 133.22 48.06 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.373 -0.829 . . . . 0.0 108.887 179.237 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.0 p -136.52 142.97 36.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.725 0 O-C-N 121.333 -0.854 . . . . 0.0 109.626 -179.783 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' PHE . . . . . 0.462 ' CZ ' ' NH2' ' A' ' 25' ' ' ARG . 43.0 p90 -140.41 154.28 46.63 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.285 -0.884 . . . . 0.0 109.468 -179.998 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -127.83 140.06 52.26 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.424 -0.797 . . . . 0.0 109.584 179.836 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.417 ' O ' HG13 ' A' ' 171' ' ' VAL . 87.9 m-20 -91.44 132.94 35.89 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.263 -0.898 . . . . 0.0 108.91 179.368 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' MET . . . . . 0.424 ' SD ' HD12 ' A' ' 26' ' ' ILE . 65.6 mtp -124.72 153.53 42.25 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.198 -0.939 . . . . 0.0 110.259 -179.459 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 63.2 p -149.4 165.99 30.42 Favored 'General case' 0 N--CA 1.49 1.538 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 179.741 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.422 HG23 ' O ' ' A' ' 18' ' ' VAL . 24.0 m -125.54 133.88 68.11 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 121.25 -0.906 . . . . 0.0 109.544 179.975 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 54.75 17.08 8.37 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 179.797 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 92.33 4.55 66.22 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 33.7 mt-30 -105.58 111.57 64.77 Favored Pre-proline 0 N--CA 1.493 1.711 0 O-C-N 121.349 -1.089 . . . . 0.0 109.255 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 65.8 Cg_exo -48.35 135.23 25.84 Favored 'Trans proline' 0 N--CA 1.493 1.47 0 C-N-CA 122.171 1.914 . . . . 0.0 112.173 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -104.82 -57.73 1.99 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.42 -0.8 . . . . 0.0 109.417 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -171.55 -171.68 36.89 Favored Glycine 0 N--CA 1.488 2.118 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 -179.856 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . 0.462 ' NH2' ' CZ ' ' A' ' 13' ' ' PHE . 77.6 ttt180 -114.35 143.93 44.09 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.377 -1.072 . . . . 0.0 109.367 179.947 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.424 HD12 ' SD ' ' A' ' 16' ' ' MET . 83.2 mt -119.62 127.95 75.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.4 -0.812 . . . . 0.0 109.029 179.819 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 43.5 t -117.44 133.45 64.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.444 -0.785 . . . . 0.0 109.571 -179.773 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 73.2 mtm -121.35 150.49 41.38 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.423 -0.798 . . . . 0.0 109.03 179.699 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.424 ' C ' HD22 ' A' ' 30' ' ' LEU . 84.3 tt0 -101.89 131.15 48.42 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.253 -0.904 . . . . 0.0 109.997 -179.512 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.424 HD22 ' C ' ' A' ' 29' ' ' GLU . 2.8 mm? -109.59 130.15 55.53 Favored 'General case' 0 N--CA 1.493 1.701 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 179.357 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -97.77 118.26 33.91 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.039 -1.038 . . . . 0.0 108.981 179.427 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -79.6 -43.18 23.4 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.403 -0.811 . . . . 0.0 109.844 -179.739 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 57.6 t0 -65.25 -51.6 59.8 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.196 -0.94 . . . . 0.0 110.037 -179.301 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 49.4 m -67.86 -42.1 81.86 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.196 -0.94 . . . . 0.0 109.712 -179.871 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -137.34 80.37 33.84 Favored Pre-proline 0 N--CA 1.492 1.666 0 O-C-N 121.437 -0.789 . . . . 0.0 109.19 -179.73 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -70.83 -65.82 0.03 OUTLIER 'Trans proline' 0 C--N 1.308 -1.577 0 C-N-CA 122.579 2.186 . . . . 0.0 112.93 -179.601 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 62.7 mtp180 -61.5 -38.39 87.17 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.393 -0.817 . . . . 0.0 110.708 -179.036 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 36.9 m -62.49 -42.41 99.48 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 120.972 -1.08 . . . . 0.0 109.881 -179.691 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -62.65 -30.9 71.71 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.198 -0.939 . . . . 0.0 108.771 179.566 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.429 ' OE1' ' OH ' ' A' ' 92' ' ' TYR . 84.6 tt0 -65.65 -36.23 83.07 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.461 -0.774 . . . . 0.0 109.492 179.784 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 48.7 t-20 -58.59 -42.98 89.33 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.317 -0.864 . . . . 0.0 109.414 -179.794 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.42 ' CE2' ' CE2' ' A' ' 142' ' ' PHE . 90.6 m-85 -80.63 -45.34 17.41 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.31 -0.869 . . . . 0.0 109.625 179.886 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.424 ' HD2' HE22 ' A' ' 176' ' ' GLN . 61.9 ttp180 -57.31 -42.37 81.68 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.261 -0.899 . . . . 0.0 109.533 -179.769 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.505 ' O ' ' N ' ' A' ' 48' ' ' GLY . . . -68.41 -36.35 78.98 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.262 -0.899 . . . . 0.0 109.528 179.975 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.54 HD23 ' CD2' ' A' ' 61' ' ' TYR . 51.7 tp -60.36 -36.18 77.43 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.176 -0.953 . . . . 0.0 109.529 -179.702 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' CYS . . . . . . . . . . . . . 96.8 m -65.83 -59.73 3.58 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.212 -0.93 . . . . 0.0 110.068 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 57.3 p -74.97 -38.71 61.61 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.12 -0.988 . . . . 0.0 109.987 -179.761 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.505 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 71.98 7.3 66.14 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.183 -1.567 . . . . 0.0 109.183 -179.842 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 22.4 pt-20 -72.63 -16.91 61.71 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.451 -1.029 . . . . 0.0 110.033 -179.726 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 44.7 tptt -56.22 -38.61 71.26 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.166 -0.959 . . . . 0.0 109.739 -179.393 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 173.23 -173.23 45.62 Favored Glycine 0 N--CA 1.49 2.245 0 C-N-CA 119.664 -1.255 . . . . 0.0 110.03 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.53 ' O ' ' C ' ' A' ' 53' ' ' GLY . 82.5 m -120.57 145.89 46.88 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.673 -0.899 . . . . 0.0 109.266 179.946 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.53 ' C ' ' O ' ' A' ' 52' ' ' THR . . . -30.74 -73.9 0.05 OUTLIER Glycine 0 N--CA 1.495 2.608 0 N-CA-C 110.513 -1.035 . . . . 0.0 110.513 -179.827 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 93.7 mtt180 -139.86 -112.69 0.15 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.061 -1.258 . . . . 0.0 109.606 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 80.0 p -86.03 -23.64 26.7 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.313 -0.867 . . . . 0.0 110.112 -179.485 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -164.36 93.58 0.11 Allowed Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.377 -1.489 . . . . 0.0 109.377 -179.838 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 11.4 ttmm -174.4 75.31 0.34 Allowed Pre-proline 0 C--N 1.301 -1.506 0 O-C-N 121.484 -1.009 . . . . 0.0 108.629 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_exo -47.89 129.18 17.44 Favored 'Trans proline' 0 C--N 1.303 -1.832 0 C-N-CA 122.539 2.159 . . . . 0.0 111.897 -179.422 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 12.6 tp -106.48 119.96 40.67 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.522 -0.736 . . . . 0.0 109.333 -179.371 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -150.43 140.57 22.13 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.169 -0.957 . . . . 0.0 109.719 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . 0.54 ' CD2' HD23 ' A' ' 45' ' ' LEU . 2.9 t80 -62.25 -35.75 79.9 Favored 'General case' 0 N--CA 1.492 1.657 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 179.431 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 42.6 tttm -50.47 152.66 1.82 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.501 -0.75 . . . . 0.0 109.868 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 34.8 t0 71.24 43.07 0.66 Allowed 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.645 -0.659 . . . . 0.0 109.501 -179.835 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 90.8 p -119.23 152.67 36.24 Favored 'General case' 0 N--CA 1.492 1.659 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 179.503 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 30.3 t -145.85 154.6 42.16 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.198 -0.938 . . . . 0.0 109.778 -179.611 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 47.3 m-85 -89.99 127.58 36.07 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.335 -0.853 . . . . 0.0 109.253 179.651 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' HIS . . . . . 0.403 ' O ' ' O ' ' A' ' 163' ' ' GLY . 97.3 m-70 -99.04 -18.47 17.74 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.319 -0.863 . . . . 0.0 110.291 -179.279 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 58.5 mtp85 -127.31 137.07 52.73 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.11 -0.994 . . . . 0.0 110.126 -179.693 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.668 HG21 HG22 ' A' ' 165' ' ' THR . 3.1 m -153.34 81.33 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 121.428 -0.795 . . . . 0.0 108.98 179.474 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 22.0 mt -95.96 126.04 46.24 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.097 -1.002 . . . . 0.0 109.452 -179.501 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -71.64 138.25 31.72 Favored 'Trans proline' 0 N--CA 1.493 1.491 0 C-N-CA 122.157 1.905 . . . . 0.0 112.332 -179.664 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 92.67 -30.04 7.32 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.684 -1.366 . . . . 0.0 109.684 179.623 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -102.7 -89.73 0.37 Allowed 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.301 -1.117 . . . . 0.0 109.741 -179.884 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' MET . . . . . 0.452 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 7.6 ptt? -171.86 -175.42 1.51 Allowed 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.22 -0.925 . . . . 0.0 109.716 -179.678 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -127.27 141.94 51.59 Favored 'General case' 0 N--CA 1.494 1.748 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 179.699 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 48.1 tt0 -105.85 143.53 33.86 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.209 -0.932 . . . . 0.0 109.843 -179.589 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -156.11 -173.55 24.84 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 96.32 2.34 60.49 Favored Glycine 0 N--CA 1.494 2.516 0 N-CA-C 109.676 -1.37 . . . . 0.0 109.676 -179.969 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.574 ' O ' ' N ' ' A' ' 83' ' ' GLY . 89.9 m-20 -92.42 14.72 15.77 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.339 -1.095 . . . . 0.0 109.203 179.848 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.541 ' CD1' ' N ' ' A' ' 81' ' ' THR . 42.4 p90 -44.27 -31.56 1.05 Allowed 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.351 -0.843 . . . . 0.0 110.292 -179.815 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.541 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 18.5 m -58.0 -37.46 74.31 Favored 'General case' 0 C--N 1.303 -1.445 0 O-C-N 121.169 -0.957 . . . . 0.0 109.666 -178.993 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -145.48 -32.89 0.37 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.191 -0.943 . . . . 0.0 110.048 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.574 ' N ' ' O ' ' A' ' 79' ' ' ASP . . . 100.16 -37.14 3.69 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.424 -1.471 . . . . 0.0 109.424 -180.0 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 78.4 m-20 -89.7 1.51 55.97 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.316 -1.108 . . . . 0.0 109.376 179.873 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 88.67 2.33 79.13 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.446 -1.462 . . . . 0.0 109.446 -179.934 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 49.5 m -59.71 -38.72 82.4 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.366 -1.079 . . . . 0.0 109.633 -179.919 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -96.31 -115.21 3.09 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.859 -1.296 . . . . 0.0 109.859 -179.706 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.446 ' O ' ' CB ' ' A' ' 123' ' ' SER . . . 81.97 27.71 44.52 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.193 -1.563 . . . . 0.0 109.193 -179.636 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -59.51 142.84 51.69 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.329 -1.1 . . . . 0.0 109.869 -179.83 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 32.9 t -141.93 146.81 36.12 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.353 -0.842 . . . . 0.0 109.278 179.738 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 14.1 pt -69.53 -11.34 14.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.136 -0.977 . . . . 0.0 109.468 -179.887 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . 0.429 ' OH ' ' OE1' ' A' ' 40' ' ' GLU . 80.9 m-85 -107.47 29.51 7.1 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.393 -0.817 . . . . 0.0 109.778 -179.988 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -46.98 -31.26 5.57 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.382 -1.487 . . . . 0.0 109.382 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -63.26 145.16 56.11 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.139 -1.212 . . . . 0.0 108.992 179.625 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 93.8 mttt -87.77 135.51 33.35 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.368 -0.832 . . . . 0.0 109.631 -179.637 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.531 ' CE1' ' ND2' ' A' ' 121' ' ' ASN . 54.4 p90 -144.49 163.26 34.37 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.351 -0.843 . . . . 0.0 109.361 179.672 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -97.6 144.82 26.89 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.281 -0.887 . . . . 0.0 109.324 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 -67.93 135.34 52.27 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.213 -0.929 . . . . 0.0 109.345 -179.883 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . 0.525 ' O ' ' ND2' ' A' ' 100' ' ' ASN . 84.4 tt0 -63.55 -38.21 90.27 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.275 -0.89 . . . . 0.0 110.117 -179.653 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . 0.525 ' ND2' ' O ' ' A' ' 99' ' ' GLU . 24.0 m120 -144.18 171.04 14.84 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.996 -1.065 . . . . 0.0 110.041 -179.539 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' PHE . . . . . 0.43 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 38.3 p90 -151.17 37.85 0.63 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.471 -0.768 . . . . 0.0 109.094 179.772 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 90.3 mt -57.86 -34.13 47.51 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.318 -0.864 . . . . 0.0 109.936 -179.792 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 44.1 mtmt -75.63 144.27 41.8 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.992 -1.068 . . . . 0.0 109.511 -179.895 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 45.2 tttp -130.16 157.77 41.53 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.421 -0.799 . . . . 0.0 109.411 -179.872 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' HIS . . . . . 0.402 ' O ' ' OD2' ' A' ' 136' ' ' ASP . 85.5 t60 -98.93 127.09 44.77 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.328 -0.857 . . . . 0.0 109.39 -179.92 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -160.7 -6.66 0.05 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.229 -0.919 . . . . 0.0 109.698 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -127.72 171.48 19.07 Favored Glycine 0 N--CA 1.494 2.513 0 N-CA-C 109.456 -1.458 . . . . 0.0 109.456 -179.878 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 97.0 Cg_endo -80.61 154.72 20.84 Favored 'Trans proline' 0 C--N 1.306 -1.677 0 C-N-CA 123.023 2.482 . . . . 0.0 112.287 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 77.75 47.55 8.6 Favored Glycine 0 N--CA 1.494 2.536 0 N-CA-C 109.967 -1.253 . . . . 0.0 109.967 179.49 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 40.9 mm -115.29 134.74 57.49 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 O-C-N 121.437 -1.037 . . . . 0.0 109.511 -179.903 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.454 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 3.5 mm? -93.45 112.74 24.72 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.203 -0.936 . . . . 0.0 109.317 179.681 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 47.2 m -131.01 147.95 52.69 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.265 -0.897 . . . . 0.0 109.494 179.737 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 88.5 mtp -94.33 141.2 28.84 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.177 -0.952 . . . . 0.0 109.391 179.892 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . 0.55 ' O ' ' ND2' ' A' ' 115' ' ' ASN . . . -63.3 142.77 58.26 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.295 -0.878 . . . . 0.0 109.338 179.916 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . 0.55 ' ND2' ' O ' ' A' ' 114' ' ' ALA . 16.0 m120 -144.7 113.26 6.65 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.21 -0.931 . . . . 0.0 109.057 179.885 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -68.22 -27.8 66.68 Favored 'General case' 0 C--N 1.297 -1.712 0 O-C-N 121.35 -0.844 . . . . 0.0 109.169 179.795 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . 0.441 ' H ' ' HB ' ' A' ' 120' ' ' THR . . . -132.55 167.7 23.01 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.254 -1.539 . . . . 0.0 109.254 179.86 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 14.3 Cg_endo -58.44 -25.51 73.95 Favored 'Trans proline' 0 C--N 1.305 -1.76 0 C-N-CA 122.809 2.339 . . . . 0.0 111.929 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 42.5 p-10 -128.38 42.5 3.31 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.354 -0.841 . . . . 0.0 109.489 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 120' ' ' THR . . . . . 0.441 ' HB ' ' H ' ' A' ' 117' ' ' GLY . 89.1 m -128.87 124.47 35.34 Favored 'General case' 0 N--CA 1.486 1.329 0 O-C-N 121.445 -0.785 . . . . 0.0 108.896 179.77 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 121' ' ' ASN . . . . . 0.531 ' ND2' ' CE1' ' A' ' 96' ' ' PHE . 83.0 m-20 -108.9 149.57 28.96 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.59 -0.694 . . . . 0.0 109.438 -179.842 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -133.78 166.93 23.81 Favored Glycine 0 N--CA 1.494 2.518 0 N-CA-C 109.544 -1.422 . . . . 0.0 109.544 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 123' ' ' SER . . . . . 0.446 ' CB ' ' O ' ' A' ' 88' ' ' GLY . 46.4 p -82.41 -2.08 52.02 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.248 -1.148 . . . . 0.0 109.674 -179.907 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.4 mt-30 -100.5 144.91 28.93 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.253 -0.904 . . . . 0.0 109.752 -179.836 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 50.9 p90 -139.12 163.6 31.98 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.504 -0.747 . . . . 0.0 109.171 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.452 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 50.8 p90 -135.86 154.46 51.16 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.214 -0.928 . . . . 0.0 109.76 -179.89 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 64.5 mt -124.16 134.02 67.72 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.754 0 O-C-N 121.509 -0.745 . . . . 0.0 109.422 179.781 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 3.3 m -114.23 113.07 24.13 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.274 -0.891 . . . . 0.0 109.342 179.855 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . 0.45 ' OG1' ' OE1' ' A' ' 156' ' ' GLU . 7.3 p -94.39 -0.9 54.52 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.257 -0.902 . . . . 0.0 109.406 -179.905 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -109.97 152.74 25.49 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.383 -0.823 . . . . 0.0 109.338 -179.746 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 49.3 mtpt -77.39 115.29 17.04 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.18 -0.95 . . . . 0.0 109.228 179.84 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 50.0 p -129.23 158.18 39.76 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.445 -0.784 . . . . 0.0 109.366 -179.938 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -110.39 -40.83 4.53 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.368 -0.833 . . . . 0.0 109.683 179.857 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 0.6 OUTLIER -62.58 -34.21 76.52 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.195 -0.941 . . . . 0.0 109.748 -179.602 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 12.5 mt -62.22 -33.09 73.9 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.984 -1.072 . . . . 0.0 109.668 179.648 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . 0.402 ' OD2' ' O ' ' A' ' 105' ' ' HIS . 61.7 t0 -79.33 119.12 21.92 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.2 -0.938 . . . . 0.0 109.517 -179.731 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -165.05 -117.4 0.4 Allowed Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 3.3 mppt? -86.53 7.39 26.3 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.403 -1.057 . . . . 0.0 109.769 -179.853 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 77.3 m80 -70.52 151.24 45.29 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.149 -0.97 . . . . 0.0 109.571 -179.667 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 41.2 t -118.69 140.78 41.18 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.489 -0.757 . . . . 0.0 109.459 -179.776 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . 0.412 HG12 ' H ' ' A' ' 143' ' ' GLY . 50.6 t -100.2 133.32 43.63 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.416 -0.802 . . . . 0.0 109.565 -179.844 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . 0.42 ' CE2' ' CE2' ' A' ' 42' ' ' PHE . 38.0 p90 -109.12 1.09 20.17 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.277 -0.889 . . . . 0.0 109.823 179.873 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . 0.412 ' H ' HG12 ' A' ' 141' ' ' VAL . . . -174.4 -179.42 45.0 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 179.663 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.3 pt20 -146.22 167.39 23.61 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.26 -1.141 . . . . 0.0 109.561 -179.644 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 54.0 t -97.84 131.39 44.91 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.187 0 O-C-N 121.178 -0.952 . . . . 0.0 109.473 -179.885 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 16.6 m -107.76 -34.81 2.81 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.357 -0.839 . . . . 0.0 109.664 179.685 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 94.4 mt-10 -144.32 166.92 23.72 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.212 -0.93 . . . . 0.0 109.705 -179.827 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 96.79 4.15 59.12 Favored Glycine 0 N--CA 1.495 2.583 0 N-CA-C 110.194 -1.162 . . . . 0.0 110.194 179.395 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 149' ' ' MET . . . . . 0.483 ' O ' HG12 ' A' ' 152' ' ' VAL . 71.8 mtm -60.79 -33.22 72.65 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.002 -1.293 . . . . 0.0 109.722 179.923 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 89.3 m-20 -65.11 -41.96 94.4 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.833 -1.167 . . . . 0.0 110.07 -179.541 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.2 p -82.04 -34.29 12.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.216 -0.928 . . . . 0.0 110.696 -179.406 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 152' ' ' VAL . . . . . 0.483 HG12 ' O ' ' A' ' 149' ' ' MET . 0.8 OUTLIER -55.63 -42.49 69.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 120.873 -1.142 . . . . 0.0 109.399 -179.248 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 153' ' ' LYS . . . . . 0.454 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 99.2 mttt -65.53 -33.3 75.6 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.137 -0.977 . . . . 0.0 109.757 179.5 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -60.25 -40.15 89.3 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.312 -0.867 . . . . 0.0 110.284 -179.154 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 91.9 mt -71.56 -36.21 59.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.029 -1.044 . . . . 0.0 110.466 -179.508 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . 0.45 ' OE1' ' OG1' ' A' ' 129' ' ' THR . 84.4 tt0 -78.49 -40.35 35.58 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.929 -1.107 . . . . 0.0 111.36 -178.587 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 39.8 pttt -61.05 -34.42 74.86 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 120.793 -1.192 . . . . 0.0 110.005 -178.806 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 28.3 m -73.36 -12.65 15.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.101 -0.999 . . . . 0.0 109.377 179.884 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -77.82 173.4 55.08 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.757 -1.337 . . . . 0.0 109.757 -179.891 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 21.4 t -154.62 178.72 9.79 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.41 -1.053 . . . . 0.0 109.395 -179.741 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 23.7 t -54.3 -30.45 51.08 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.233 -0.917 . . . . 0.0 109.262 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 86.6 p -59.3 -26.61 65.13 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.255 -0.903 . . . . 0.0 109.4 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 163' ' ' GLY . . . . . 0.403 ' O ' ' O ' ' A' ' 67' ' ' HIS . . . 87.16 20.31 53.13 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.713 -1.355 . . . . 0.0 109.713 179.794 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 87.7 mtt180 -122.38 145.39 48.32 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.195 -1.18 . . . . 0.0 109.364 179.911 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 165' ' ' THR . . . . . 0.668 HG22 HG21 ' A' ' 69' ' ' VAL . 72.6 p -82.19 151.52 26.85 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.153 -0.967 . . . . 0.0 109.647 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -67.06 -36.44 82.05 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.287 -0.883 . . . . 0.0 109.302 179.692 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 62.4 mttp -117.6 156.57 27.89 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.576 -0.702 . . . . 0.0 109.248 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 94.2 mttt -69.22 131.62 45.2 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.11 -0.994 . . . . 0.0 109.225 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 41.1 t -122.14 125.08 72.49 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.725 0 O-C-N 121.325 -0.859 . . . . 0.0 109.644 -179.896 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 43.7 t -144.94 144.88 21.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.386 -0.821 . . . . 0.0 109.17 179.63 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.417 HG13 ' O ' ' A' ' 15' ' ' ASP . 2.7 t -74.54 124.17 31.57 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.677 0 C-N-CA 119.722 -0.791 . . . . 0.0 109.787 -179.284 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -67.85 -27.91 67.1 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.363 -0.836 . . . . 0.0 109.593 179.471 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 44.3 t0 -174.38 174.76 2.73 Favored 'General case' 0 N--CA 1.494 1.754 0 C-N-CA 119.29 -0.964 . . . . 0.0 110.321 -179.286 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 26.4 p -146.42 150.25 35.28 Favored 'General case' 0 N--CA 1.491 1.622 0 N-CA-C 109.063 -0.718 . . . . 0.0 109.063 179.638 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -172.64 173.16 45.38 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.804 -1.318 . . . . 0.0 109.804 179.913 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 176' ' ' GLN . . . . . 0.513 ' NE2' ' OXT' ' A' ' 178' ' ' SER . 62.6 tt0 -114.23 118.89 35.24 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.413 -1.051 . . . . 0.0 109.637 -179.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 37.1 tp -63.39 -37.42 87.2 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.124 -0.985 . . . . 0.0 109.217 179.403 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 178' ' ' SER . . . . . 0.513 ' OXT' ' NE2' ' A' ' 176' ' ' GLN . 61.2 m . . . . . 0 N--CA 1.491 1.582 0 CA-C-O 118.0 -1.0 . . . . 0.0 109.441 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.53 4.925 0 N-CA-C 119.364 2.506 . . . . 0.0 119.364 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 23.0 m -57.69 -35.26 70.37 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.194 -1.18 . . . . 0.0 109.502 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 99.2 m-85 -111.07 122.57 48.24 Favored 'General case' 0 N--CA 1.485 1.298 0 O-C-N 121.399 -0.813 . . . . 0.0 108.93 179.702 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 51.2 m -81.95 136.34 35.3 Favored 'General case' 0 C--N 1.296 -1.724 0 O-C-N 121.483 -0.76 . . . . 0.0 109.547 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 144.93 154.77 6.23 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 179.905 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 49.9 m -122.88 147.64 46.34 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.42 -1.047 . . . . 0.0 109.356 179.949 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 10.2 mmt -67.18 150.21 98.03 Favored Pre-proline 0 N--CA 1.489 1.48 0 O-C-N 121.23 -0.919 . . . . 0.0 109.28 179.882 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -71.7 166.75 28.5 Favored 'Trans proline' 0 C--N 1.309 -1.531 0 C-N-CA 122.606 2.204 . . . . 0.0 112.149 -179.881 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 2.3 m-80 -73.55 152.6 89.66 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.343 -0.848 . . . . 0.0 109.231 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 38.7 Cg_endo -64.85 141.65 72.36 Favored 'Trans proline' 0 N--CA 1.496 1.663 0 C-N-CA 122.616 2.211 . . . . 0.0 112.07 179.775 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 96.4 mtt180 -126.79 131.62 51.24 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.459 -0.776 . . . . 0.0 109.061 179.497 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.4 p -136.09 142.38 38.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.314 -0.866 . . . . 0.0 109.243 -179.905 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 41.2 p90 -142.3 154.01 44.36 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.297 -0.877 . . . . 0.0 109.572 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.58 ' CE2' ' SG ' ' A' ' 174' ' ' CYS . 44.3 m-85 -120.07 135.78 54.82 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.468 -0.77 . . . . 0.0 109.091 179.643 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.1 t0 -88.55 114.47 25.2 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.078 -1.013 . . . . 0.0 108.509 179.489 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 83.7 mtp -104.53 136.17 44.58 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.453 -0.779 . . . . 0.0 110.532 -179.08 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 44.5 m -135.1 154.23 51.74 Favored 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 179.195 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.405 ' O ' ' C ' ' A' ' 19' ' ' GLY . 34.3 m -125.98 141.45 45.61 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.148 -0.97 . . . . 0.0 109.891 -179.886 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.405 ' C ' ' O ' ' A' ' 18' ' ' VAL . . . 41.05 -114.7 0.61 Allowed Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.936 -1.266 . . . . 0.0 109.936 179.77 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -120.94 15.46 9.52 Favored Glycine 0 N--CA 1.496 2.644 0 N-CA-C 109.416 -1.474 . . . . 0.0 109.416 179.858 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 39.6 tt0 -124.12 88.03 53.0 Favored Pre-proline 0 N--CA 1.494 1.756 0 O-C-N 121.459 -1.024 . . . . 0.0 109.078 -179.826 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 75.7 Cg_exo -47.05 132.86 18.24 Favored 'Trans proline' 0 C--N 1.309 -1.548 0 C-N-CA 122.336 2.024 . . . . 0.0 112.294 -179.561 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -85.07 -63.25 1.36 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.313 -0.867 . . . . 0.0 109.834 -179.688 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 172.62 -167.08 39.91 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 -179.756 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 28.7 ptt180 -116.53 151.18 36.67 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.534 -0.98 . . . . 0.0 108.952 179.735 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 83.4 mt -120.1 129.11 75.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.377 -0.827 . . . . 0.0 109.06 -179.854 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 39.5 t -107.7 134.6 48.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.4 -0.813 . . . . 0.0 109.436 -179.599 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 76.3 mtm -120.86 148.9 43.4 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.557 -0.714 . . . . 0.0 109.215 179.932 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -95.77 133.7 39.58 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.277 -0.889 . . . . 0.0 109.731 -179.593 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -108.35 133.42 52.57 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.572 -0.705 . . . . 0.0 109.357 179.895 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -96.37 119.56 35.08 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.23 -0.919 . . . . 0.0 108.656 179.187 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -89.61 -42.48 11.37 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.295 -0.878 . . . . 0.0 109.835 -179.65 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.2 m-20 -64.58 -48.63 74.27 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.218 -0.926 . . . . 0.0 110.24 -179.263 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 33.3 m -70.91 -43.47 68.21 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.075 -1.016 . . . . 0.0 109.966 -179.652 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.469 ' O ' ' OG1' ' A' ' 35' ' ' THR . 5.1 p -136.38 79.85 41.21 Favored Pre-proline 0 N--CA 1.493 1.678 0 O-C-N 121.351 -0.843 . . . . 0.0 109.404 -179.604 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 27.2 Cg_endo -67.05 -60.88 0.09 OUTLIER 'Trans proline' 0 C--N 1.309 -1.525 0 C-N-CA 122.479 2.12 . . . . 0.0 112.849 -179.401 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.476 ' NH2' ' CG ' ' A' ' 92' ' ' TYR . 17.2 mtp-105 -60.8 -37.78 83.12 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.405 -0.809 . . . . 0.0 110.811 -178.878 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 26.3 m -61.8 -43.16 99.4 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.883 -1.136 . . . . 0.0 109.835 -179.764 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -64.81 -28.48 69.59 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.175 -0.953 . . . . 0.0 109.307 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -65.18 -37.72 88.22 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.341 -0.849 . . . . 0.0 109.687 -179.833 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 86.7 m-20 -59.59 -41.63 90.7 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.244 -0.91 . . . . 0.0 109.745 -179.652 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.489 ' O ' ' SG ' ' A' ' 46' ' ' CYS . 95.5 m-85 -81.37 -46.68 14.3 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.239 -0.913 . . . . 0.0 109.705 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.713 ' HE ' ' NE2' ' A' ' 176' ' ' GLN . 76.1 ttt180 -58.15 -43.09 87.21 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.346 -0.846 . . . . 0.0 110.019 -179.522 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -78.11 -47.9 17.2 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.141 -0.975 . . . . 0.0 110.165 -179.578 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.661 HD23 ' CZ ' ' A' ' 61' ' ' TYR . 58.4 tp -60.59 -38.83 85.93 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.254 -0.904 . . . . 0.0 109.838 -179.518 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' CYS . . . . . 0.489 ' SG ' ' O ' ' A' ' 42' ' ' PHE . 71.2 m -68.56 -58.74 3.84 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.032 -1.042 . . . . 0.0 109.417 -179.908 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 31.6 m -64.11 -37.45 87.5 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.135 -0.978 . . . . 0.0 109.278 179.703 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 81.53 34.27 25.9 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 179.648 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -61.1 -34.36 74.83 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.018 -1.283 . . . . 0.0 109.338 179.61 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 69.4 mmtt -59.57 -33.58 71.61 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.317 -0.864 . . . . 0.0 109.331 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 94.3 168.87 37.44 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.329 -1.508 . . . . 0.0 109.329 -179.771 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 91.7 m -77.79 139.18 39.31 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.413 -1.051 . . . . 0.0 109.737 -179.933 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -60.78 141.19 48.09 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.521 -1.432 . . . . 0.0 109.521 179.94 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 67.4 mtm180 -59.19 -37.12 76.65 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.277 -1.131 . . . . 0.0 109.765 -179.799 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 23.6 m -58.7 -33.75 70.53 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.273 -0.892 . . . . 0.0 109.709 -179.784 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . 0.427 ' O ' ' CB ' ' A' ' 57' ' ' LYS . . . 120.58 109.53 2.2 Favored Glycine 0 N--CA 1.495 2.577 0 N-CA-C 108.996 -1.642 . . . . 0.0 108.996 -179.645 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . 0.455 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 3.2 mmtp 166.14 85.93 0.02 OUTLIER Pre-proline 0 N--CA 1.492 1.628 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 -179.669 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 71.3 Cg_exo -50.96 133.73 40.98 Favored 'Trans proline' 0 C--N 1.304 -1.773 0 C-N-CA 122.559 2.173 . . . . 0.0 112.383 -179.308 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.455 ' CD1' ' O ' ' A' ' 57' ' ' LYS . 8.9 mp -99.65 44.77 1.01 Allowed 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.558 -0.714 . . . . 0.0 109.378 -179.793 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 88.4 m-70 -123.82 133.31 53.82 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.413 -0.804 . . . . 0.0 109.672 -179.828 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . 0.661 ' CZ ' HD23 ' A' ' 45' ' ' LEU . 20.8 m-85 -69.12 -12.11 61.39 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.158 -0.964 . . . . 0.0 108.907 178.789 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 61.2 tttt -49.93 138.62 14.97 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.345 -0.847 . . . . 0.0 109.898 -179.703 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . 0.406 ' N ' HG23 ' A' ' 171' ' ' VAL . 41.0 t0 67.77 42.53 1.96 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.782 -0.574 . . . . 0.0 110.141 179.67 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.818 ' H ' ' CG2' ' A' ' 171' ' ' VAL . 83.2 p -110.47 149.76 29.84 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.233 -0.917 . . . . 0.0 108.595 178.807 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 28.7 t -117.45 144.23 45.22 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.172 -0.955 . . . . 0.0 109.697 -179.353 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -69.61 138.87 53.47 Favored 'General case' 0 N--CA 1.491 1.595 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 179.66 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' HIS . . . . . 0.717 ' CD2' ' HE ' ' A' ' 68' ' ' ARG . 77.8 t60 -59.59 -50.95 71.91 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.108 -0.995 . . . . 0.0 109.932 -179.416 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.717 ' HE ' ' CD2' ' A' ' 67' ' ' HIS . 20.2 ptp180 -172.81 163.05 4.98 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.213 -0.929 . . . . 0.0 109.684 179.669 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.403 HG11 HG22 ' A' ' 155' ' ' ILE . 0.1 OUTLIER -134.05 127.0 50.97 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.418 -0.802 . . . . 0.0 109.035 179.53 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 39.5 mt -121.9 118.38 29.36 Favored Pre-proline 0 N--CA 1.493 1.719 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 179.86 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -71.58 136.13 27.67 Favored 'Trans proline' 0 C--N 1.31 -1.473 0 C-N-CA 121.853 1.702 . . . . 0.0 111.894 -179.803 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 94.25 -1.07 66.79 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.731 -1.348 . . . . 0.0 109.731 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 85.7 m-85 -137.1 -96.13 0.21 Allowed 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.22 -1.164 . . . . 0.0 109.81 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' MET . . . . . 0.595 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 5.6 ptt? -163.95 160.86 22.46 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.157 -0.964 . . . . 0.0 109.896 -179.491 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' CYS . . . . . 0.492 ' O ' ' SG ' ' A' ' 75' ' ' CYS . 12.1 p -97.38 130.59 44.51 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.417 -0.802 . . . . 0.0 108.966 179.241 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 93.8 mt-30 -105.79 149.82 26.12 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.27 -0.894 . . . . 0.0 109.648 -179.712 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -143.91 126.24 2.69 Favored Glycine 0 N--CA 1.492 2.425 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 179.85 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -86.05 178.48 49.58 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.77 -1.332 . . . . 0.0 109.77 -179.76 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 88.1 m-20 -72.13 149.38 44.79 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.357 -1.084 . . . . 0.0 109.554 179.842 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 43.6 p90 -61.53 -22.97 65.62 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.201 -0.937 . . . . 0.0 109.571 -179.907 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.56 ' O ' ' HB2' ' A' ' 82' ' ' ALA . 61.6 p -65.98 -30.17 70.68 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.133 -0.979 . . . . 0.0 109.424 -179.926 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . 0.56 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 171.4 -55.7 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.339 -0.851 . . . . 0.0 109.284 179.809 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 94.79 -10.3 70.53 Favored Glycine 0 N--CA 1.493 2.462 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 179.889 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 50.4 t30 -86.18 1.71 49.66 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.176 -1.191 . . . . 0.0 109.345 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 97.21 -8.83 65.02 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.311 -1.516 . . . . 0.0 109.311 -179.865 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 68.0 p -73.34 -20.0 60.89 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.311 -1.111 . . . . 0.0 109.273 179.675 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -127.68 -130.51 3.35 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 109.334 -1.507 . . . . 0.0 109.334 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 72.48 55.02 7.06 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.175 -1.57 . . . . 0.0 109.175 -179.948 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -84.77 140.73 31.03 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.368 -1.077 . . . . 0.0 109.808 -179.506 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 27.8 t -111.65 143.07 43.14 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.453 -0.779 . . . . 0.0 109.111 179.773 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 15.4 pt -65.12 -38.64 83.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.18 -0.95 . . . . 0.0 110.061 -179.529 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . 0.476 ' CG ' ' NH2' ' A' ' 37' ' ' ARG . 50.7 m-85 -67.83 -38.5 83.3 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.09 -1.006 . . . . 0.0 109.677 -179.906 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 76.09 22.05 74.7 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.342 -1.503 . . . . 0.0 109.342 -179.8 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -147.28 162.69 38.42 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.283 -1.128 . . . . 0.0 109.592 -179.708 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 61.0 mttp -77.19 154.16 33.38 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.269 -0.895 . . . . 0.0 109.527 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.463 ' CD1' ' N ' ' A' ' 96' ' ' PHE . 2.1 m-85 -100.37 133.19 45.16 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.303 -0.873 . . . . 0.0 109.059 179.969 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -91.44 130.45 37.27 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.092 -1.005 . . . . 0.0 109.582 -179.874 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 88.2 m-20 -72.05 143.4 49.11 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.269 -0.894 . . . . 0.0 109.362 179.76 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -141.0 -47.44 0.4 Allowed 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.242 -0.911 . . . . 0.0 109.734 -179.848 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 86.0 m-20 -105.0 122.08 45.11 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.242 -0.911 . . . . 0.0 109.905 -179.585 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' PHE . . . . . 0.553 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 71.7 t80 -120.43 14.48 11.98 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.461 -0.774 . . . . 0.0 108.965 179.549 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 89.7 mt -55.11 -38.31 46.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.417 -0.802 . . . . 0.0 110.237 -179.434 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 67.4 mttm -84.54 136.98 33.58 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.991 -1.068 . . . . 0.0 109.782 -179.528 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . 0.516 ' HZ3' ' CG2' ' A' ' 106' ' ' THR . 21.3 pttm -139.58 -177.12 4.81 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.457 -0.777 . . . . 0.0 109.274 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' HIS . . . . . 0.533 ' CE1' ' O ' ' A' ' 107' ' ' GLY . 8.5 t-80 -86.52 107.01 17.92 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.121 -0.987 . . . . 0.0 109.491 -179.881 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . 0.516 ' CG2' ' HZ3' ' A' ' 104' ' ' LYS . 46.6 p -114.43 -1.31 13.51 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.348 -0.845 . . . . 0.0 109.779 179.955 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.533 ' O ' ' CE1' ' A' ' 105' ' ' HIS . . . -154.31 170.54 32.8 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 -179.756 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -77.01 153.7 32.68 Favored 'Trans proline' 0 C--N 1.307 -1.656 0 C-N-CA 122.909 2.406 . . . . 0.0 112.264 179.804 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 78.53 52.4 5.13 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 110.032 -1.227 . . . . 0.0 110.032 179.491 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 35.3 mm -114.27 137.31 47.99 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 O-C-N 121.27 -1.135 . . . . 0.0 109.825 -179.86 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.535 ' N ' ' CD2' ' A' ' 111' ' ' LEU . 2.5 mm? -89.42 125.61 35.23 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.308 -0.87 . . . . 0.0 109.021 179.564 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 36.8 t -147.74 142.83 27.07 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.027 -1.046 . . . . 0.0 109.794 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 64.9 mtt -88.45 135.96 33.22 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.185 -0.947 . . . . 0.0 109.411 179.606 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . 0.535 ' O ' ' ND2' ' A' ' 115' ' ' ASN . . . -72.22 135.59 46.12 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.137 -0.977 . . . . 0.0 109.34 179.808 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . 0.535 ' ND2' ' O ' ' A' ' 114' ' ' ALA . 17.6 m120 -145.37 113.32 6.45 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.162 -0.962 . . . . 0.0 109.336 179.77 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -70.15 -28.7 65.56 Favored 'General case' 0 C--N 1.297 -1.68 0 O-C-N 121.457 -0.777 . . . . 0.0 109.362 179.796 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -134.46 165.25 24.5 Favored Glycine 0 N--CA 1.493 2.484 0 N-CA-C 109.279 -1.528 . . . . 0.0 109.279 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -70.17 154.91 65.67 Favored 'Trans proline' 0 C--N 1.306 -1.667 0 C-N-CA 122.776 2.317 . . . . 0.0 112.199 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 77.5 m-20 54.72 46.9 23.67 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.467 -0.77 . . . . 0.0 109.559 179.841 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 87.3 m -132.27 129.75 40.0 Favored 'General case' 0 C--N 1.306 -1.312 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 179.709 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 121' ' ' ASN . . . . . 0.402 ' OD1' ' CE2' ' A' ' 96' ' ' PHE . 50.8 t30 -74.69 123.15 24.38 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 121.442 -0.786 . . . . 0.0 109.329 -179.855 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -90.74 103.64 3.06 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.839 -1.304 . . . . 0.0 109.839 -179.84 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 85.5 p -65.03 -23.63 67.25 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.248 -1.148 . . . . 0.0 109.245 179.596 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.0 mt-30 -109.19 151.83 25.96 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.434 -0.791 . . . . 0.0 109.622 -179.805 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 49.2 p90 -136.63 160.85 37.56 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.377 -0.827 . . . . 0.0 109.108 179.75 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.595 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 50.2 p90 -140.58 158.5 43.9 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.224 -0.923 . . . . 0.0 109.724 -179.895 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 65.1 mt -120.98 133.6 67.1 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 O-C-N 121.593 -0.692 . . . . 0.0 109.325 179.674 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 6.7 m -97.48 108.64 21.4 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.169 -0.957 . . . . 0.0 109.305 179.779 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 60.2 p -76.39 -10.07 59.12 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.182 -0.949 . . . . 0.0 109.528 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -137.89 161.55 36.34 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.309 -0.87 . . . . 0.0 109.302 -179.818 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 49.0 tttp -62.22 133.21 54.87 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.226 -0.921 . . . . 0.0 109.433 -179.806 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 29.4 p -140.37 91.93 2.48 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.313 -0.867 . . . . 0.0 109.281 -179.898 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -63.57 -34.9 78.84 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.255 -0.903 . . . . 0.0 109.73 -179.813 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 0.9 OUTLIER -67.76 -47.9 67.93 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.068 -1.02 . . . . 0.0 109.646 -179.876 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 15.3 mt -66.79 -31.73 72.55 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.111 -0.993 . . . . 0.0 109.701 179.511 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 60.0 t0 -78.18 121.48 24.4 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.109 -0.994 . . . . 0.0 109.767 -179.566 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 179.88 -114.94 0.46 Allowed Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . 0.437 ' O ' ' C ' ' A' ' 139' ' ' HIS . 66.4 mttm -57.64 -36.24 71.57 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.297 -1.12 . . . . 0.0 109.748 179.886 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 139' ' ' HIS . . . . . 0.437 ' C ' ' O ' ' A' ' 138' ' ' LYS . 53.7 m170 -40.94 144.69 0.25 Allowed 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.543 -0.723 . . . . 0.0 109.816 -179.683 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 42.4 t -115.11 138.84 44.11 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 121.359 -0.838 . . . . 0.0 109.601 -179.678 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 91.8 t -97.97 129.06 48.72 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.341 -0.85 . . . . 0.0 109.441 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 39.1 p90 -115.15 0.54 13.61 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.348 -0.845 . . . . 0.0 109.492 179.844 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -176.19 175.6 47.48 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.349 -1.5 . . . . 0.0 109.349 179.558 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.4 pt20 -147.86 168.21 22.78 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.125 -1.221 . . . . 0.0 110.045 -179.837 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 82.1 t -94.61 131.28 41.9 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.245 0 O-C-N 121.333 -0.854 . . . . 0.0 109.363 -179.814 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 10.9 m -112.43 -30.71 2.2 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.325 -0.859 . . . . 0.0 109.853 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 92.9 mt-10 -141.91 169.45 17.56 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.152 -0.968 . . . . 0.0 109.611 -179.881 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 95.57 6.85 59.43 Favored Glycine 0 N--CA 1.493 2.452 0 N-CA-C 109.984 -1.246 . . . . 0.0 109.984 179.597 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 149' ' ' MET . . . . . 0.447 ' O ' HG12 ' A' ' 152' ' ' VAL . 65.0 mtt -60.14 -31.92 70.53 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.058 -1.26 . . . . 0.0 109.543 -179.978 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . 0.54 ' OD1' ' N ' ' A' ' 151' ' ' VAL . 31.8 p-10 -65.0 -36.96 86.08 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.812 -1.18 . . . . 0.0 109.821 -179.64 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.54 ' N ' ' OD1' ' A' ' 150' ' ' ASP . 3.5 p -87.08 -34.19 7.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.148 -0.97 . . . . 0.0 110.385 -179.64 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 152' ' ' VAL . . . . . 0.46 ' CG1' ' N ' ' A' ' 153' ' ' LYS . 0.9 OUTLIER -56.67 -41.87 75.32 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 120.991 -1.068 . . . . 0.0 109.188 -179.478 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 153' ' ' LYS . . . . . 0.46 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 66.8 mttm -63.99 -34.72 78.65 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.274 -0.891 . . . . 0.0 109.406 179.583 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -62.17 -36.81 83.01 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.29 -0.881 . . . . 0.0 109.934 -179.477 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.403 HG22 HG11 ' A' ' 69' ' ' VAL . 62.5 mt -74.36 -37.56 45.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.136 -0.977 . . . . 0.0 109.84 -179.786 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -73.73 -40.61 63.43 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.129 -0.982 . . . . 0.0 111.399 -178.493 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 18.1 pttp -59.86 -35.61 75.16 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.679 -1.263 . . . . 0.0 109.696 -178.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 27.1 m -77.04 -17.52 14.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.08 -1.012 . . . . 0.0 108.952 179.389 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -64.43 150.21 50.93 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 49.7 m -136.28 161.23 36.35 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.454 -1.027 . . . . 0.0 109.175 179.914 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 23.8 m -51.35 -33.12 28.17 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.187 -0.946 . . . . 0.0 108.966 179.875 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 22.6 t -57.89 -29.02 64.73 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.36 -0.837 . . . . 0.0 109.334 179.643 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.22 10.14 52.08 Favored Glycine 0 N--CA 1.493 2.465 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 -179.806 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 83.7 mtp180 -117.04 155.28 29.49 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.384 -1.068 . . . . 0.0 109.175 179.909 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 165' ' ' THR . . . . . 0.403 ' OG1' ' O ' ' A' ' 167' ' ' LYS . 44.8 p -110.71 156.43 21.04 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.243 -0.911 . . . . 0.0 109.62 -179.759 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -68.19 -37.28 80.76 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.414 -0.804 . . . . 0.0 109.435 179.676 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 167' ' ' LYS . . . . . 0.403 ' O ' ' OG1' ' A' ' 165' ' ' THR . 3.7 mptp? -105.18 158.67 16.43 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.405 -0.809 . . . . 0.0 109.597 -179.834 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 61.3 mttp -81.34 151.99 27.73 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.346 -0.846 . . . . 0.0 109.475 179.83 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . 0.476 ' O ' HG23 ' A' ' 169' ' ' VAL . 30.9 m -131.14 124.37 55.45 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.301 -0.874 . . . . 0.0 109.649 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 46.3 t -148.59 147.08 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.296 -0.877 . . . . 0.0 108.988 179.602 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.818 ' CG2' ' H ' ' A' ' 64' ' ' SER . 2.8 m -87.81 123.16 40.25 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.838 0 O-C-N 120.952 -1.093 . . . . 0.0 109.944 -179.9 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -74.29 -36.72 63.78 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.327 -0.858 . . . . 0.0 110.367 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 173' ' ' ASP . . . . . 0.465 ' OD1' ' N ' ' A' ' 174' ' ' CYS . 54.3 t0 -155.08 153.65 31.22 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 120.914 -1.116 . . . . 0.0 110.662 -179.1 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 174' ' ' CYS . . . . . 0.58 ' SG ' ' CE2' ' A' ' 14' ' ' PHE . 45.4 t -142.15 141.49 32.64 Favored 'General case' 0 N--CA 1.492 1.63 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.48 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -169.52 -178.86 40.99 Favored Glycine 0 N--CA 1.493 2.441 0 N-CA-C 109.806 -1.318 . . . . 0.0 109.806 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 176' ' ' GLN . . . . . 0.713 ' NE2' ' HE ' ' A' ' 43' ' ' ARG . 6.8 tt0 -105.22 120.49 41.67 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.406 -1.055 . . . . 0.0 109.66 -179.875 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 32.1 tp -63.59 -37.81 88.75 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.156 -0.965 . . . . 0.0 109.321 179.414 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 10.9 t . . . . . 0 N--CA 1.49 1.533 0 CA-C-O 118.001 -0.999 . . . . 0.0 109.432 -179.952 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.529 4.859 0 N-CA-C 119.357 2.503 . . . . 0.0 119.357 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 55.1 p -69.89 161.73 29.36 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.273 -1.133 . . . . 0.0 109.518 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 99.1 m-85 -111.39 122.89 49.04 Favored 'General case' 0 N--CA 1.487 1.379 0 O-C-N 121.479 -0.763 . . . . 0.0 108.956 179.766 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 75.4 m -81.01 139.38 35.8 Favored 'General case' 0 C--N 1.299 -1.625 0 O-C-N 121.565 -0.709 . . . . 0.0 109.507 179.824 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 165.91 40.06 0.02 OUTLIER Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.631 -1.387 . . . . 0.0 109.631 -179.92 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 28.6 t -113.75 142.98 45.38 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.412 -1.052 . . . . 0.0 109.308 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 63.0 mtt -125.48 67.14 56.7 Favored Pre-proline 0 N--CA 1.493 1.714 0 O-C-N 121.371 -0.831 . . . . 0.0 109.521 -179.951 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_endo -66.79 -15.46 47.33 Favored 'Trans proline' 0 C--N 1.308 -1.6 0 C-N-CA 122.587 2.191 . . . . 0.0 112.138 179.926 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 14.9 m-80 -124.19 72.23 55.94 Favored Pre-proline 0 N--CA 1.494 1.73 0 O-C-N 121.342 -0.849 . . . . 0.0 109.675 -179.768 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -68.22 141.67 52.9 Favored 'Trans proline' 0 N--CA 1.496 1.67 0 C-N-CA 122.62 2.213 . . . . 0.0 112.144 179.877 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 78.4 mtm180 -128.08 133.43 49.04 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.463 -0.773 . . . . 0.0 108.981 179.428 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.2 p -135.57 143.38 36.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.329 -0.857 . . . . 0.0 109.576 -179.822 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 39.2 p90 -137.22 152.83 50.3 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.418 -0.801 . . . . 0.0 109.34 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.459 ' CE1' ' CE1' ' A' ' 61' ' ' TYR . 98.1 m-85 -124.08 132.84 53.71 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.563 -0.711 . . . . 0.0 109.399 179.8 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.6 t0 -91.29 114.56 27.12 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.224 -0.923 . . . . 0.0 108.776 179.485 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 79.7 mtp -107.26 137.33 45.52 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.255 -0.903 . . . . 0.0 110.031 -179.392 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 19.8 m -130.41 152.93 49.28 Favored 'General case' 0 N--CA 1.492 1.639 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 179.636 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.411 ' O ' ' N ' ' A' ' 21' ' ' GLN . 29.8 m -119.05 134.85 61.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.227 -0.921 . . . . 0.0 109.442 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 49.26 25.03 5.47 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 84.24 20.67 58.52 Favored Glycine 0 N--CA 1.492 2.398 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 -179.914 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' GLN . . . . . 0.411 ' N ' ' O ' ' A' ' 18' ' ' VAL . 40.6 mt-30 -120.11 99.19 48.79 Favored Pre-proline 0 N--CA 1.495 1.778 0 O-C-N 121.377 -1.072 . . . . 0.0 109.414 -179.904 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 75.2 Cg_exo -46.53 99.1 0.03 OUTLIER 'Trans proline' 0 N--CA 1.491 1.382 0 C-N-CA 122.353 2.035 . . . . 0.0 112.237 -179.883 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -65.27 -39.85 93.14 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.355 -0.841 . . . . 0.0 109.806 -179.799 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 167.36 -169.11 40.89 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.677 -1.369 . . . . 0.0 109.677 -179.798 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 97.1 mtt180 -115.26 147.05 40.86 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.5 -1.0 . . . . 0.0 109.45 179.812 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 77.2 mt -119.71 123.29 70.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 N-CA-C 108.463 -0.94 . . . . 0.0 108.463 179.118 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 24.8 t -114.26 132.95 61.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.373 -0.829 . . . . 0.0 109.423 -179.488 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . 0.78 ' SD ' HD11 ' A' ' 111' ' ' LEU . 73.2 mtm -125.66 152.71 44.86 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.382 -0.824 . . . . 0.0 109.196 -179.84 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -99.01 133.26 43.53 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.259 -0.901 . . . . 0.0 109.761 179.877 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -108.85 131.16 55.27 Favored 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 179.794 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 98.2 m-85 -96.36 120.3 36.41 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.095 -1.003 . . . . 0.0 109.063 179.764 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -84.06 -41.1 17.54 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.338 -0.851 . . . . 0.0 109.865 -179.729 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -65.81 -44.71 84.83 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.275 -0.891 . . . . 0.0 110.624 -179.185 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 52.9 m -67.05 -44.87 79.06 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.09 -1.006 . . . . 0.0 110.241 -179.291 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 2.0 m -150.68 82.89 5.98 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.155 -0.966 . . . . 0.0 109.269 -179.666 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 39.9 Cg_endo -71.37 -38.32 4.79 Favored 'Trans proline' 0 C--N 1.308 -1.592 0 C-N-CA 122.19 1.927 . . . . 0.0 112.361 -179.361 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 35.2 mmt180 -64.5 -41.81 96.22 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.126 -0.983 . . . . 0.0 109.691 -179.858 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.48 HG23 ' SD ' ' A' ' 113' ' ' MET . 80.8 m -67.55 -42.66 82.32 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.194 -0.941 . . . . 0.0 110.034 -179.715 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -61.31 -31.81 71.66 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.11 -0.994 . . . . 0.0 108.962 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -70.33 -38.07 74.8 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.422 -0.799 . . . . 0.0 109.999 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 20.4 t-20 -57.91 -43.92 86.49 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.265 -0.897 . . . . 0.0 109.865 -179.534 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -85.3 -46.71 10.74 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.247 -0.908 . . . . 0.0 109.606 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 71.2 ttp85 -57.24 -42.88 82.32 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.312 -0.867 . . . . 0.0 109.663 -179.894 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.5 ' O ' ' N ' ' A' ' 48' ' ' GLY . . . -72.13 -46.27 57.22 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.288 -0.883 . . . . 0.0 109.899 -179.691 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 38.2 tp -61.97 -37.68 85.69 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.095 -1.003 . . . . 0.0 109.438 -179.817 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' CYS . . . . . . . . . . . . . 98.7 m -67.19 -65.93 0.62 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.305 -0.872 . . . . 0.0 109.579 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 31.0 m -64.6 -37.17 86.65 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.374 -0.829 . . . . 0.0 109.404 179.656 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.5 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 80.94 37.8 17.86 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 110.037 -1.225 . . . . 0.0 110.037 179.831 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -61.72 -37.85 85.72 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.089 -1.242 . . . . 0.0 109.51 179.913 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 70.4 mmtt -61.37 -35.49 77.62 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.295 -0.878 . . . . 0.0 109.42 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 88.16 -174.89 44.25 Favored Glycine 0 N--CA 1.484 1.875 0 N-CA-C 108.979 -1.648 . . . . 0.0 108.979 -179.574 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.548 HG23 ' HA ' ' A' ' 58' ' ' PRO . 89.6 m -71.36 139.19 49.73 Favored 'General case' 0 C--N 1.295 -1.78 0 O-C-N 121.537 -0.978 . . . . 0.0 109.603 179.893 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -56.8 136.37 50.09 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.176 -1.57 . . . . 0.0 109.176 179.795 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 86.4 mtt-85 -58.77 -36.94 75.22 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.222 -1.164 . . . . 0.0 109.857 -179.617 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 24.8 m -59.59 -33.94 72.11 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.21 -0.931 . . . . 0.0 109.802 -179.825 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 124.96 91.92 0.91 Allowed Glycine 0 N--CA 1.494 2.514 0 N-CA-C 108.953 -1.659 . . . . 0.0 108.953 -179.658 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . 0.494 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 28.0 tttp -175.69 79.76 0.3 Allowed Pre-proline 0 N--CA 1.489 1.478 0 O-C-N 121.447 -1.031 . . . . 0.0 108.406 -179.709 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.548 ' HA ' HG23 ' A' ' 52' ' ' THR . 73.7 Cg_exo -49.65 131.8 29.38 Favored 'Trans proline' 0 C--N 1.303 -1.848 0 C-N-CA 122.923 2.415 . . . . 0.0 112.845 -178.927 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.494 ' CD1' ' O ' ' A' ' 57' ' ' LYS . 8.7 mp -103.35 113.09 26.3 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.591 -0.693 . . . . 0.0 109.365 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . 0.507 ' O ' ' CE1' ' A' ' 80' ' ' PHE . 70.8 m80 -141.1 126.25 18.43 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.203 -0.936 . . . . 0.0 109.544 179.473 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . 0.459 ' CE1' ' CE1' ' A' ' 14' ' ' PHE . 13.7 t80 -94.42 -11.67 29.36 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.359 -0.838 . . . . 0.0 108.936 179.743 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -78.68 160.52 27.46 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.451 -0.78 . . . . 0.0 109.775 -179.485 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 50.1 t0 60.44 45.8 10.48 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.513 -0.742 . . . . 0.0 109.932 179.647 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 92.5 p -116.25 150.9 36.82 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.328 -0.858 . . . . 0.0 108.841 179.291 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . 0.408 ' O ' ' OD2' ' A' ' 79' ' ' ASP . 29.4 t -121.17 147.33 45.73 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.257 -0.902 . . . . 0.0 109.716 -179.514 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.3 m-30 -68.18 138.34 55.56 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.351 -0.843 . . . . 0.0 108.907 179.825 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 80.0 t60 -60.51 -51.2 70.48 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.218 -0.926 . . . . 0.0 110.138 -179.327 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.689 HH21 ' NE2' ' A' ' 76' ' ' GLN . 38.5 ptt180 -162.85 162.78 26.58 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.073 -1.017 . . . . 0.0 109.873 179.946 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.577 HG21 HG22 ' A' ' 165' ' ' THR . 18.4 m -131.52 150.01 33.68 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.725 0 O-C-N 121.445 -0.785 . . . . 0.0 109.052 179.761 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 14.3 mt -147.29 119.43 4.71 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.024 -1.047 . . . . 0.0 109.433 179.714 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -73.95 134.48 19.79 Favored 'Trans proline' 0 C--N 1.313 -1.316 0 C-N-CA 122.022 1.815 . . . . 0.0 111.868 179.948 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 89.54 2.58 76.04 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.456 ' C ' ' SD ' ' A' ' 74' ' ' MET . 80.2 m-85 -137.22 -94.32 0.22 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.312 -1.11 . . . . 0.0 109.711 179.9 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' MET . . . . . 0.456 ' SD ' ' C ' ' A' ' 73' ' ' PHE . 0.0 OUTLIER -162.98 172.71 14.62 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.161 -0.962 . . . . 0.0 109.81 -179.688 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 1.9 m -119.49 135.16 54.89 Favored 'General case' 0 N--CA 1.494 1.728 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 179.543 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' GLN . . . . . 0.689 ' NE2' HH21 ' A' ' 68' ' ' ARG . 93.8 mt-30 -104.06 153.75 20.51 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.286 -0.884 . . . . 0.0 109.816 -179.638 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -158.99 -170.89 24.08 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.329 -1.509 . . . . 0.0 109.329 -179.958 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 80.02 37.94 20.61 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.504 -1.439 . . . . 0.0 109.504 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.437 ' C ' ' OD1' ' A' ' 79' ' ' ASP . 54.2 p30 -85.24 12.16 8.6 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.291 -1.123 . . . . 0.0 109.46 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.507 ' CE1' ' O ' ' A' ' 60' ' ' HIS . 76.3 t80 -52.88 -44.9 67.2 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.348 -0.845 . . . . 0.0 109.937 -179.902 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.668 ' O ' ' HB2' ' A' ' 82' ' ' ALA . 69.0 p -69.45 -29.25 66.9 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.149 -0.969 . . . . 0.0 109.513 -179.928 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . 0.668 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 165.76 -55.88 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.229 -0.919 . . . . 0.0 109.365 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 92.28 0.29 70.76 Favored Glycine 0 N--CA 1.492 2.389 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 -179.928 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 77.7 m-20 -87.57 5.51 38.98 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.213 -1.169 . . . . 0.0 109.474 179.931 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 96.04 -36.81 3.67 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.329 -1.508 . . . . 0.0 109.329 -179.903 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 56.2 p -73.53 -18.9 61.03 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.271 -1.134 . . . . 0.0 109.164 179.638 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -83.34 -164.04 35.62 Favored Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.611 -1.395 . . . . 0.0 109.611 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.647 ' H ' ' CB ' ' A' ' 81' ' ' THR . . . 92.28 24.09 25.24 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.314 -1.514 . . . . 0.0 109.314 -179.785 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -57.3 145.59 31.6 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.432 -1.04 . . . . 0.0 109.687 -179.864 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 28.8 t -107.03 146.14 31.49 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.328 -0.858 . . . . 0.0 109.263 179.941 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 20.3 pt -61.26 -33.24 55.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.131 -0.98 . . . . 0.0 109.746 -179.812 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 91.7 m-85 -65.51 -36.15 82.98 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.285 -0.884 . . . . 0.0 109.653 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.09 15.24 70.12 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.319 -1.513 . . . . 0.0 109.319 -179.654 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -143.64 155.92 44.4 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.309 -1.113 . . . . 0.0 109.545 -179.859 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 63.1 mttp -94.03 137.89 32.72 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.287 -0.883 . . . . 0.0 109.586 -179.846 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -123.9 154.23 40.0 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.309 -0.869 . . . . 0.0 109.768 179.901 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -107.1 154.65 20.85 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.469 -0.769 . . . . 0.0 109.06 179.536 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 60.0 t0 -76.68 105.48 7.77 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.032 -1.042 . . . . 0.0 109.378 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -67.22 -34.15 76.88 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.284 -0.885 . . . . 0.0 110.062 -179.809 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 86.5 m-20 -105.0 124.71 50.0 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.251 -0.906 . . . . 0.0 110.052 -179.35 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 99.2 m-85 -108.13 12.78 26.46 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.462 -0.774 . . . . 0.0 109.067 179.556 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 92.6 mt -53.36 -39.25 34.86 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.326 -0.859 . . . . 0.0 110.048 -179.319 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 58.0 mttm -82.25 132.9 35.23 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.983 -1.073 . . . . 0.0 109.592 -179.849 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 80.7 tttt -138.65 158.85 43.46 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.41 -0.806 . . . . 0.0 109.335 -179.891 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' HIS . . . . . 0.611 ' CE1' ' SG ' ' A' ' 128' ' ' CYS . 85.2 t60 -86.07 99.17 11.29 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.233 -0.917 . . . . 0.0 109.431 179.886 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 65.9 p -115.78 -1.62 12.59 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.352 -0.842 . . . . 0.0 109.607 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.539 ' O ' ' CE1' ' A' ' 105' ' ' HIS . . . -153.84 169.92 32.47 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -73.88 158.86 45.92 Favored 'Trans proline' 0 C--N 1.306 -1.671 0 C-N-CA 122.935 2.424 . . . . 0.0 112.25 179.811 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . 0.468 ' O ' HG12 ' A' ' 145' ' ' VAL . . . 81.9 43.21 8.38 Favored Glycine 0 N--CA 1.493 2.459 0 N-CA-C 109.885 -1.286 . . . . 0.0 109.885 179.694 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 44.3 mm -117.0 132.7 66.0 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.725 0 O-C-N 121.287 -1.125 . . . . 0.0 109.598 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.78 HD11 ' SD ' ' A' ' 28' ' ' MET . 1.7 mm? -89.23 133.63 34.36 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.214 -0.929 . . . . 0.0 108.756 179.452 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . 0.552 ' OG ' ' CZ ' ' A' ' 126' ' ' PHE . 99.0 p -143.38 154.26 43.54 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.109 -0.994 . . . . 0.0 109.628 -179.907 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' MET . . . . . 0.48 ' SD ' HG23 ' A' ' 38' ' ' THR . 72.1 mtm -93.64 136.66 33.7 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.305 -0.872 . . . . 0.0 109.213 179.556 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -65.09 138.09 58.08 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.215 -0.928 . . . . 0.0 109.185 179.815 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 70.6 m-20 -135.19 115.29 13.2 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.257 -0.902 . . . . 0.0 109.441 179.88 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -85.1 -9.89 57.43 Favored 'General case' 0 C--N 1.297 -1.675 0 O-C-N 121.501 -0.749 . . . . 0.0 109.096 179.501 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . 0.43 ' H ' HG21 ' A' ' 120' ' ' THR . . . -136.12 173.76 21.76 Favored Glycine 0 N--CA 1.492 2.367 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 -179.746 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -57.09 -25.4 63.41 Favored 'Trans proline' 0 C--N 1.307 -1.648 0 C-N-CA 122.747 2.298 . . . . 0.0 112.196 -179.905 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 119' ' ' ASN . . . . . 0.441 ' O ' ' OD1' ' A' ' 119' ' ' ASN . 42.4 p-10 -153.19 96.18 2.03 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.17 -0.956 . . . . 0.0 109.908 179.836 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 120' ' ' THR . . . . . 0.43 HG21 ' H ' ' A' ' 117' ' ' GLY . 0.5 OUTLIER -148.74 123.81 10.09 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 121.327 -0.858 . . . . 0.0 109.338 179.774 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 51.3 t-20 -100.38 121.84 42.18 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.355 -0.84 . . . . 0.0 109.449 -179.861 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -137.08 158.99 24.52 Favored Glycine 0 N--CA 1.493 2.473 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 78.5 p -69.06 -19.08 64.08 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.345 -1.091 . . . . 0.0 109.645 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.9 mt-30 -66.5 137.44 56.8 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.134 -0.978 . . . . 0.0 109.613 -179.593 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 44.5 p90 -146.49 161.68 39.91 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.33 -0.857 . . . . 0.0 109.323 179.892 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.552 ' CZ ' ' OG ' ' A' ' 112' ' ' SER . 51.9 p90 -141.16 159.05 43.04 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.166 -0.959 . . . . 0.0 109.577 179.716 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 77.7 mt -116.43 135.1 57.77 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.354 -0.841 . . . . 0.0 109.425 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 128' ' ' CYS . . . . . 0.611 ' SG ' ' CE1' ' A' ' 105' ' ' HIS . 0.2 OUTLIER -99.23 99.79 10.81 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.388 -0.82 . . . . 0.0 109.423 -179.871 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 61.9 p -76.3 -6.86 53.37 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.322 -0.861 . . . . 0.0 109.321 179.812 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -139.91 162.76 34.41 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.369 -0.832 . . . . 0.0 109.316 -179.897 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.525 ' O ' ' CZ3' ' A' ' 134' ' ' TRP . 99.2 mttt -71.56 131.99 44.04 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.19 -0.944 . . . . 0.0 109.563 -179.654 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . 0.408 HG22 ' CZ2' ' A' ' 134' ' ' TRP . 74.0 p -122.97 37.99 4.29 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.538 -0.726 . . . . 0.0 109.318 179.936 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 78.3 mm-40 -57.65 -31.12 65.99 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.272 -0.893 . . . . 0.0 109.733 -179.504 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 134' ' ' TRP . . . . . 0.525 ' CZ3' ' O ' ' A' ' 131' ' ' LYS . 12.7 p90 -55.24 -28.44 53.26 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.047 -1.033 . . . . 0.0 109.64 -179.805 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . 0.503 ' N ' ' CD1' ' A' ' 134' ' ' TRP . 69.0 mt -58.11 -35.93 72.18 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.055 -1.028 . . . . 0.0 109.473 179.3 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 57.2 t0 53.81 69.92 0.66 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.436 -0.79 . . . . 0.0 109.705 179.569 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -138.4 176.36 20.83 Favored Glycine 0 N--CA 1.484 1.857 0 N-CA-C 108.915 -1.674 . . . . 0.0 108.915 179.712 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . 0.427 ' O ' ' O ' ' A' ' 139' ' ' HIS . 63.0 mttp -59.21 -40.12 84.8 Favored 'General case' 0 C--N 1.296 -1.727 0 O-C-N 121.39 -1.065 . . . . 0.0 109.968 -179.768 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 139' ' ' HIS . . . . . 0.427 ' O ' ' O ' ' A' ' 138' ' ' LYS . 61.3 m170 51.75 98.89 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.414 -0.804 . . . . 0.0 109.542 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 52.1 t -105.49 135.18 44.69 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.751 0 O-C-N 121.461 -0.774 . . . . 0.0 109.395 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 48.5 t -117.04 128.71 74.38 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.485 -0.76 . . . . 0.0 109.691 -179.726 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 37.5 p90 -113.31 -1.21 14.32 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.376 -0.828 . . . . 0.0 109.539 179.458 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -173.84 -177.36 42.98 Favored Glycine 0 N--CA 1.493 2.438 0 N-CA-C 109.818 -1.313 . . . . 0.0 109.818 179.842 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.4 pt20 -144.22 171.39 14.37 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.311 -1.111 . . . . 0.0 109.475 -179.763 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . 0.468 HG12 ' O ' ' A' ' 109' ' ' GLY . 8.3 p -111.08 138.29 40.0 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.902 0 O-C-N 121.268 -0.895 . . . . 0.0 109.281 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 10.5 m -119.32 -28.16 2.05 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.483 -0.761 . . . . 0.0 109.679 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -138.06 167.16 22.37 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.249 -0.907 . . . . 0.0 109.567 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 97.49 3.23 58.6 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.779 -1.329 . . . . 0.0 109.779 179.652 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 149' ' ' MET . . . . . 0.432 ' O ' HG12 ' A' ' 152' ' ' VAL . 89.2 mtp -60.65 -32.56 71.73 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.183 -1.186 . . . . 0.0 109.771 179.951 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . 0.549 ' OD1' ' N ' ' A' ' 151' ' ' VAL . 32.9 p-10 -65.46 -37.44 86.86 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 120.85 -1.156 . . . . 0.0 109.902 -179.565 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.549 ' N ' ' OD1' ' A' ' 150' ' ' ASP . 5.2 p -87.31 -34.31 7.39 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.711 0 O-C-N 121.101 -0.999 . . . . 0.0 110.243 -179.672 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 152' ' ' VAL . . . . . 0.461 ' CG1' ' N ' ' A' ' 153' ' ' LYS . 0.9 OUTLIER -56.04 -42.35 71.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 120.996 -1.065 . . . . 0.0 109.101 -179.513 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 153' ' ' LYS . . . . . 0.461 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 98.7 mttt -64.42 -33.77 76.64 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.172 -0.955 . . . . 0.0 109.433 179.471 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -61.24 -38.8 87.95 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.351 -0.843 . . . . 0.0 110.132 -179.4 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 86.8 mt -72.3 -36.64 56.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.045 -1.034 . . . . 0.0 110.159 -179.728 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -76.29 -41.69 47.89 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.178 -0.951 . . . . 0.0 111.402 -178.784 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 16.8 pttp -60.45 -35.23 75.36 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 120.744 -1.223 . . . . 0.0 109.734 -178.845 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 32.7 m -82.46 -10.9 12.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.166 -0.958 . . . . 0.0 109.061 179.581 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -70.97 165.1 53.31 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.981 -1.248 . . . . 0.0 109.981 -179.565 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 24.1 t -154.08 168.55 26.1 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.421 -1.046 . . . . 0.0 109.439 -179.82 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 25.1 m -54.32 -29.6 48.33 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.279 -0.888 . . . . 0.0 109.341 179.808 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 24.7 m -53.31 -31.27 43.25 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.287 -0.883 . . . . 0.0 109.589 -179.882 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 96.05 8.98 57.55 Favored Glycine 0 N--CA 1.493 2.472 0 N-CA-C 109.766 -1.333 . . . . 0.0 109.766 179.896 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 82.3 mtm180 -122.93 145.56 48.36 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.209 -1.171 . . . . 0.0 109.471 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 165' ' ' THR . . . . . 0.577 HG22 HG21 ' A' ' 69' ' ' VAL . 80.9 p -80.57 153.52 28.01 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.189 -0.945 . . . . 0.0 109.36 179.79 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -66.0 -34.6 78.46 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.293 -0.879 . . . . 0.0 109.158 179.714 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 62.9 mttp -112.38 157.49 20.96 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.466 -0.771 . . . . 0.0 109.262 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 63.0 mttp -69.87 141.69 53.16 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.245 -0.91 . . . . 0.0 109.144 179.912 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 18.2 m -128.05 125.33 64.39 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 121.315 -0.866 . . . . 0.0 109.683 -179.819 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 46.5 t -148.33 152.13 12.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.43 -0.794 . . . . 0.0 109.114 179.766 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.401 HG23 ' H ' ' A' ' 171' ' ' VAL . 0.2 OUTLIER -91.15 114.94 29.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.23 -0.919 . . . . 0.0 109.374 -179.753 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -75.68 -11.47 60.01 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.521 -0.737 . . . . 0.0 110.072 -179.882 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 173' ' ' ASP . . . . . 0.475 ' OD1' ' N ' ' A' ' 174' ' ' CYS . 51.8 t0 -164.85 157.79 16.69 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 120.76 -1.212 . . . . 0.0 110.848 -179.31 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 174' ' ' CYS . . . . . 0.475 ' N ' ' OD1' ' A' ' 173' ' ' ASP . 16.7 t -154.85 141.64 19.05 Favored 'General case' 0 N--CA 1.492 1.657 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 179.372 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -178.05 178.08 48.46 Favored Glycine 0 N--CA 1.493 2.48 0 N-CA-C 109.749 -1.34 . . . . 0.0 109.749 179.776 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 176' ' ' GLN . . . . . 0.416 HE21 ' HB2' ' A' ' 178' ' ' SER . 60.9 tt0 -106.93 124.06 49.07 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.367 -1.078 . . . . 0.0 109.732 -179.981 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 30.6 tp -62.92 -37.99 89.22 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.132 -0.98 . . . . 0.0 109.264 179.509 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 178' ' ' SER . . . . . 0.416 ' HB2' HE21 ' A' ' 176' ' ' GLN . 33.1 m . . . . . 0 N--CA 1.49 1.549 0 CA-C-O 118.066 -0.969 . . . . 0.0 109.501 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.529 4.881 0 N-CA-C 119.318 2.487 . . . . 0.0 119.318 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 28.8 t -115.9 141.7 47.76 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.295 -1.121 . . . . 0.0 109.35 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 49.0 p90 -148.12 164.34 34.17 Favored 'General case' 0 C--N 1.306 -1.309 0 O-C-N 121.291 -0.88 . . . . 0.0 108.75 179.837 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 18.8 p -118.53 162.36 18.49 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.593 -0.692 . . . . 0.0 109.285 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -139.13 56.15 0.65 Allowed Glycine 0 N--CA 1.493 2.449 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 -179.761 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 54.5 p -67.2 159.36 29.2 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.089 -1.242 . . . . 0.0 109.257 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 55.1 mtt -74.67 149.78 86.17 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.194 -0.941 . . . . 0.0 109.518 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -71.53 169.67 20.38 Favored 'Trans proline' 0 C--N 1.31 -1.491 0 C-N-CA 122.648 2.232 . . . . 0.0 111.921 179.881 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 13.4 m-20 -64.18 146.62 97.5 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.254 -0.904 . . . . 0.0 109.088 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_endo -67.73 140.81 52.43 Favored 'Trans proline' 0 N--CA 1.494 1.556 0 C-N-CA 122.492 2.128 . . . . 0.0 112.07 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 80.9 mtm180 -126.58 139.18 53.39 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.316 -0.865 . . . . 0.0 109.166 179.614 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 15.0 p -133.71 142.81 40.47 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 121.327 -0.858 . . . . 0.0 109.519 -179.878 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' PHE . . . . . 0.483 ' CE2' ' NH2' ' A' ' 25' ' ' ARG . 28.6 p90 -141.85 155.94 45.54 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.304 -0.872 . . . . 0.0 109.683 -179.598 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -130.46 139.27 50.55 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.484 -0.76 . . . . 0.0 109.777 179.628 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -95.35 117.24 29.97 Favored 'General case' 0 N--CA 1.491 1.601 0 N-CA-C 108.188 -1.041 . . . . 0.0 108.188 178.788 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' MET . . . . . 0.414 ' SD ' HD12 ' A' ' 26' ' ' ILE . 76.9 mtp -107.74 147.44 30.79 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.121 -0.987 . . . . 0.0 110.443 -178.816 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.407 ' HA ' ' H ' ' A' ' 23' ' ' ALA . 88.4 p -143.3 163.25 33.51 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 179.574 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.401 ' O ' ' C ' ' A' ' 19' ' ' GLY . 29.1 m -122.97 140.55 46.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.218 -0.927 . . . . 0.0 109.476 179.921 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.401 ' C ' ' O ' ' A' ' 18' ' ' VAL . . . 44.46 -102.68 0.04 OUTLIER Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.636 -1.386 . . . . 0.0 109.636 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -130.38 38.15 2.01 Favored Glycine 0 N--CA 1.493 2.475 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 8.4 tt0 -147.18 133.49 9.68 Favored Pre-proline 0 N--CA 1.492 1.656 0 O-C-N 121.125 -1.221 . . . . 0.0 109.181 179.974 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 43.0 Cg_endo -69.9 126.7 13.52 Favored 'Trans proline' 0 N--CA 1.493 1.494 0 C-N-CA 122.193 1.929 . . . . 0.0 112.218 -179.788 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.407 ' H ' ' HA ' ' A' ' 17' ' ' SER . . . -80.39 -48.21 13.26 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.288 -0.883 . . . . 0.0 109.432 179.849 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 170.94 -169.41 42.42 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.37 -1.492 . . . . 0.0 109.37 -179.788 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . 0.483 ' NH2' ' CE2' ' A' ' 13' ' ' PHE . 66.4 ttt180 -116.93 142.47 46.9 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.413 -1.051 . . . . 0.0 109.291 179.942 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.414 HD12 ' SD ' ' A' ' 16' ' ' MET . 86.9 mt -120.68 128.03 75.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.424 -0.797 . . . . 0.0 108.998 179.804 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 46.1 t -116.99 133.81 62.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.508 -0.745 . . . . 0.0 109.311 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 71.3 mtm -125.38 147.37 49.19 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.343 -0.848 . . . . 0.0 109.251 179.91 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -112.56 132.6 55.03 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.267 -0.896 . . . . 0.0 109.84 -179.686 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.501 HD13 ' HA ' ' A' ' 39' ' ' ALA . 11.8 mt -103.09 139.66 38.33 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.416 -0.802 . . . . 0.0 109.36 179.262 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -95.6 113.32 24.95 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 108.342 -0.985 . . . . 0.0 108.342 178.795 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -73.96 -42.8 59.97 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 121.232 -0.917 . . . . 0.0 109.94 -179.376 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 56.6 t0 -61.33 -46.58 89.66 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.191 -0.943 . . . . 0.0 110.163 -179.36 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . 0.487 HG21 ' HE2' ' A' ' 103' ' ' LYS . 24.0 m -72.41 -45.77 58.18 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.16 -0.962 . . . . 0.0 110.215 -179.596 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.553 HG22 ' OE1' ' A' ' 99' ' ' GLU . 6.4 p -137.87 80.66 29.95 Favored Pre-proline 0 N--CA 1.494 1.774 0 O-C-N 121.162 -0.962 . . . . 0.0 110.069 -179.224 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -77.24 -6.18 16.29 Favored 'Trans proline' 0 C--N 1.307 -1.645 0 C-N-CA 122.507 2.138 . . . . 0.0 111.642 179.546 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 4.5 tpt180 -94.29 -67.03 0.88 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.375 -0.828 . . . . 0.0 110.151 -178.797 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 46.4 m -56.46 -43.32 79.43 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.191 -0.943 . . . . 0.0 110.231 -179.058 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.501 ' HA ' HD13 ' A' ' 30' ' ' LEU . . . -61.77 -31.71 71.93 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.146 -0.971 . . . . 0.0 108.968 179.747 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -75.51 -51.18 13.55 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.272 -0.893 . . . . 0.0 109.9 -179.898 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 54.2 t-20 -60.39 -46.71 88.99 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.177 -0.952 . . . . 0.0 109.605 -179.707 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.51 ' CE2' ' SG ' ' A' ' 46' ' ' CYS . 71.8 t80 -61.28 -43.23 99.22 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.3 -0.875 . . . . 0.0 109.215 179.637 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 60.1 ttp180 -56.63 -38.37 72.02 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.466 -0.771 . . . . 0.0 109.844 179.825 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -62.85 -44.21 96.74 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.137 -0.977 . . . . 0.0 109.915 -179.507 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.652 HD13 ' O ' ' A' ' 59' ' ' LEU . 3.7 mm? -62.96 -39.06 93.52 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.097 -1.002 . . . . 0.0 109.131 179.729 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' CYS . . . . . 0.51 ' SG ' ' CE2' ' A' ' 42' ' ' PHE . 3.4 m -69.52 -62.4 1.4 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.259 -0.901 . . . . 0.0 109.473 -179.875 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 35.5 m -63.13 -38.57 91.71 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.398 -0.814 . . . . 0.0 109.272 179.889 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 80.83 35.33 25.18 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 110.197 -1.161 . . . . 0.0 110.197 179.555 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -62.52 -38.13 88.75 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.046 -1.267 . . . . 0.0 109.544 179.89 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 69.3 mmtt -62.56 -37.18 85.14 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.178 -0.951 . . . . 0.0 109.777 -179.83 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 89.34 170.01 44.58 Favored Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.297 -1.521 . . . . 0.0 109.297 -179.646 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.521 HG23 ' HA ' ' A' ' 58' ' ' PRO . 91.3 m -77.66 139.52 39.47 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.355 -1.085 . . . . 0.0 109.706 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -63.25 139.41 44.18 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 31.6 mmt180 -59.68 -34.37 72.78 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.33 -1.1 . . . . 0.0 109.767 -179.72 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 85.9 p -61.55 -25.58 67.39 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.222 -0.924 . . . . 0.0 109.902 -179.667 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 113.78 93.1 1.99 Allowed Glycine 0 N--CA 1.495 2.596 0 N-CA-C 109.063 -1.615 . . . . 0.0 109.063 -179.64 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . 0.477 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 30.3 ttmt -177.64 80.43 0.24 Allowed Pre-proline 0 N--CA 1.49 1.543 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 -179.769 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.523 ' O ' ' CE2' ' A' ' 80' ' ' PHE . 74.6 Cg_exo -49.64 127.23 18.07 Favored 'Trans proline' 0 C--N 1.304 -1.812 0 C-N-CA 122.847 2.365 . . . . 0.0 112.768 -178.898 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.652 ' O ' HD13 ' A' ' 45' ' ' LEU . 8.7 mp -96.97 19.68 12.39 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.57 -0.707 . . . . 0.0 109.263 179.808 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 27.2 m170 -112.44 132.01 55.27 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.354 -0.841 . . . . 0.0 109.759 -179.441 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 46.4 m-85 -71.93 -1.92 16.18 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.217 -0.927 . . . . 0.0 108.838 178.953 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 43.6 tttm -54.85 144.23 23.34 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.411 -0.805 . . . . 0.0 109.712 -179.88 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 51.1 t0 58.99 45.57 14.72 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.549 -0.719 . . . . 0.0 109.623 179.853 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 87.7 p -116.52 152.12 34.74 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.394 -0.817 . . . . 0.0 109.131 179.547 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 29.4 t -120.95 146.73 46.35 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.395 -0.816 . . . . 0.0 109.506 -179.725 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.449 ' HE2' ' HG ' ' A' ' 75' ' ' CYS . 3.8 m-30 -65.7 134.02 52.31 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.247 -0.908 . . . . 0.0 108.992 179.763 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 78.5 t60 -62.1 -50.73 70.74 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.265 -0.897 . . . . 0.0 110.1 -179.36 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 29.1 ptt180 -164.61 160.41 20.09 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.062 -1.024 . . . . 0.0 109.471 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -141.05 130.08 24.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.217 -0.927 . . . . 0.0 109.585 179.588 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 21.9 mt -121.93 110.11 33.39 Favored Pre-proline 0 N--CA 1.491 1.6 0 N-CA-C 108.874 -0.788 . . . . 0.0 108.874 179.443 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_exo -50.39 140.69 34.29 Favored 'Trans proline' 0 C--N 1.311 -1.438 0 C-N-CA 122.341 2.028 . . . . 0.0 112.758 -179.478 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 86.09 -56.29 4.8 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 110.407 -1.077 . . . . 0.0 110.407 179.038 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 81.2 m-85 -66.51 -75.18 0.1 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.005 -1.291 . . . . 0.0 110.178 -179.303 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 12.9 ptt? 179.63 -168.07 0.09 Allowed 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.01 -1.056 . . . . 0.0 109.912 -179.788 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' CYS . . . . . 0.449 ' HG ' ' HE2' ' A' ' 66' ' ' PHE . 7.7 t -128.76 129.34 45.57 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.544 -0.723 . . . . 0.0 109.276 179.743 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 63.7 tt0 -100.12 112.96 25.27 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.148 -0.97 . . . . 0.0 109.321 179.816 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -63.17 -37.32 94.71 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.772 -1.331 . . . . 0.0 109.772 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 82.23 -164.88 44.4 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.22 -1.552 . . . . 0.0 109.22 -179.671 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.523 ' OD2' HG23 ' A' ' 81' ' ' THR . 18.0 t70 -143.82 147.5 34.2 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.203 -1.175 . . . . 0.0 109.385 179.938 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.523 ' CE2' ' O ' ' A' ' 58' ' ' PRO . 50.5 p90 -70.89 -20.58 62.49 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.228 -0.92 . . . . 0.0 109.943 -179.79 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.523 HG23 ' OD2' ' A' ' 79' ' ' ASP . 59.0 p -69.26 -28.42 66.3 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.129 -0.982 . . . . 0.0 109.703 -179.817 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . 0.482 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 176.57 -58.13 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.277 -0.89 . . . . 0.0 109.47 179.904 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 90.7 2.54 72.32 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 109.413 -1.475 . . . . 0.0 109.413 -179.854 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . 0.63 ' ND2' ' H ' ' A' ' 86' ' ' THR . 0.0 OUTLIER -88.55 7.26 34.03 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.279 -1.13 . . . . 0.0 109.589 179.919 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . 0.538 ' N ' HD22 ' A' ' 84' ' ' ASN . . . 98.29 -37.87 3.31 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 -179.88 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . 0.63 ' H ' ' ND2' ' A' ' 84' ' ' ASN . 49.4 p -71.38 -25.24 62.28 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.196 -1.179 . . . . 0.0 109.047 179.661 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -86.52 -165.92 41.69 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 179.96 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 85.44 37.08 9.97 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -60.17 148.4 36.33 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.249 -1.148 . . . . 0.0 109.421 179.925 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 50.3 m -108.01 149.13 28.79 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.402 -0.811 . . . . 0.0 109.391 -179.886 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 21.6 pt -66.24 -32.24 57.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.211 -0.931 . . . . 0.0 110.047 -179.534 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 49.1 m-85 -64.3 -37.4 87.35 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.012 -1.055 . . . . 0.0 109.448 -179.912 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 81.51 8.27 87.22 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.157 -1.577 . . . . 0.0 109.157 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -150.35 155.69 40.09 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.272 -1.134 . . . . 0.0 109.525 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 62.6 mttt -92.95 154.84 17.93 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.241 -0.912 . . . . 0.0 109.641 179.927 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.621 ' CG ' ' ND2' ' A' ' 121' ' ' ASN . 38.6 p90 -128.65 156.17 43.85 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.387 -0.82 . . . . 0.0 109.281 179.563 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -65.0 147.31 53.7 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.216 -0.927 . . . . 0.0 110.358 -179.139 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -62.48 154.33 28.86 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.315 -0.866 . . . . 0.0 109.609 179.912 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . 0.553 ' OE1' HG22 ' A' ' 35' ' ' THR . 94.6 mt-10 -85.35 -175.41 5.68 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.283 -0.886 . . . . 0.0 109.755 -179.833 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 18.5 m120 -60.3 162.78 5.67 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.416 -0.803 . . . . 0.0 109.94 -179.422 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 -98.67 23.63 8.46 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.43 -0.794 . . . . 0.0 109.585 -179.817 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 97.0 mt -48.38 -42.94 12.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.138 -0.977 . . . . 0.0 109.937 -179.327 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . 0.487 ' HE2' HG21 ' A' ' 34' ' ' THR . 59.0 mttm -89.47 139.29 30.67 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 120.931 -1.106 . . . . 0.0 109.689 179.972 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 87.5 mttt -127.28 -172.35 2.64 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.492 -0.755 . . . . 0.0 109.489 -179.898 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' HIS . . . . . 0.428 ' C ' ' ND1' ' A' ' 105' ' ' HIS . 12.3 t-80 -113.77 111.67 22.16 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.531 -0.73 . . . . 0.0 109.189 179.752 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 60.6 p -131.16 4.82 4.43 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.276 -0.89 . . . . 0.0 109.922 -179.862 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -149.37 169.46 29.66 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.825 -1.31 . . . . 0.0 109.825 -179.824 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 76.6 Cg_endo -79.54 155.39 24.48 Favored 'Trans proline' 0 C--N 1.309 -1.543 0 C-N-CA 122.942 2.428 . . . . 0.0 112.083 179.783 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 76.89 52.61 5.72 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.894 -1.282 . . . . 0.0 109.894 179.628 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 38.1 mm -115.21 136.38 52.14 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.403 -1.057 . . . . 0.0 109.51 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.657 ' N ' HD22 ' A' ' 111' ' ' LEU . 3.3 mm? -88.27 134.37 33.82 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.227 -0.921 . . . . 0.0 109.537 179.786 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 28.9 t -146.3 142.79 28.65 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.255 -0.903 . . . . 0.0 109.374 179.729 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 87.6 mmm -87.64 132.06 34.22 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.231 -0.918 . . . . 0.0 109.284 179.902 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . 0.463 ' O ' ' OD1' ' A' ' 115' ' ' ASN . . . -68.23 139.69 56.04 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.123 -0.986 . . . . 0.0 109.405 -179.948 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . 0.463 ' OD1' ' O ' ' A' ' 114' ' ' ALA . 70.3 m-20 -145.94 113.44 6.31 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.247 -0.908 . . . . 0.0 109.01 179.642 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -69.15 -30.04 68.19 Favored 'General case' 0 C--N 1.297 -1.687 0 O-C-N 121.393 -0.817 . . . . 0.0 109.442 179.816 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -136.11 170.28 23.29 Favored Glycine 0 N--CA 1.494 2.525 0 N-CA-C 109.146 -1.582 . . . . 0.0 109.146 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -67.61 151.99 78.73 Favored 'Trans proline' 0 C--N 1.305 -1.719 0 C-N-CA 122.77 2.314 . . . . 0.0 111.847 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 16.9 m120 53.34 44.26 30.32 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.33 -0.856 . . . . 0.0 109.143 -179.769 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 120' ' ' THR . . . . . 0.451 ' O ' ' OD1' ' A' ' 115' ' ' ASN . 58.3 m -132.26 123.83 27.69 Favored 'General case' 0 N--CA 1.486 1.373 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 179.924 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 121' ' ' ASN . . . . . 0.621 ' ND2' ' CG ' ' A' ' 96' ' ' PHE . 81.0 m-20 -113.39 138.62 49.8 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.506 -0.746 . . . . 0.0 109.537 -179.832 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -138.54 148.09 19.69 Favored Glycine 0 N--CA 1.493 2.489 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 23.3 m -61.23 -32.55 72.34 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.227 -1.16 . . . . 0.0 109.822 179.978 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.5 mt-30 -64.24 143.26 58.02 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.207 -0.933 . . . . 0.0 109.879 -179.481 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 48.7 p90 -141.42 163.9 31.68 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.346 -0.846 . . . . 0.0 109.028 179.858 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 45.3 p90 -136.91 158.14 45.14 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.299 -0.876 . . . . 0.0 109.696 -179.968 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 68.5 mt -120.39 136.53 57.13 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.519 -0.738 . . . . 0.0 109.273 179.799 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -108.5 120.82 43.54 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.457 -0.777 . . . . 0.0 109.358 -179.796 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . 0.404 HG22 ' H ' ' A' ' 129' ' ' THR . 1.4 t -88.72 0.98 55.94 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.199 -0.938 . . . . 0.0 109.236 179.816 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -148.19 155.48 41.44 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.271 -0.893 . . . . 0.0 109.176 179.937 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 7.7 ttpm? -75.64 127.91 34.09 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.184 -0.947 . . . . 0.0 109.516 179.996 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 22.6 p -126.98 126.69 43.62 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.37 -0.831 . . . . 0.0 109.247 179.882 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -72.23 -36.56 69.16 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.28 -0.887 . . . . 0.0 110.366 -179.582 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 0.4 OUTLIER -65.03 -41.76 94.99 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.135 -0.978 . . . . 0.0 110.043 -179.157 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . 0.44 ' O ' ' CD2' ' A' ' 139' ' ' HIS . 12.9 mt -66.59 -33.83 76.53 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.985 -1.072 . . . . 0.0 109.8 179.701 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -68.46 140.85 55.75 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.15 -0.969 . . . . 0.0 109.522 -179.824 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 134.59 -86.19 0.26 Allowed Glycine 0 N--CA 1.492 2.417 0 N-CA-C 109.684 -1.366 . . . . 0.0 109.684 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 31.6 mmtp -85.97 5.32 33.79 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.132 -1.216 . . . . 0.0 109.507 -179.835 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 139' ' ' HIS . . . . . 0.44 ' CD2' ' O ' ' A' ' 135' ' ' LEU . 54.4 m-70 -103.26 138.19 40.38 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.286 -0.884 . . . . 0.0 109.477 -179.955 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 43.2 t -120.48 141.54 40.38 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 O-C-N 121.415 -0.803 . . . . 0.0 109.684 -179.565 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 96.1 t -94.8 128.96 45.61 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.361 -0.837 . . . . 0.0 109.245 179.821 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . 0.434 ' CE2' HD21 ' A' ' 30' ' ' LEU . 38.0 p90 -116.18 0.42 12.92 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.429 -0.794 . . . . 0.0 109.757 -179.77 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -169.42 178.04 42.71 Favored Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.676 -1.37 . . . . 0.0 109.676 179.684 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.2 pt20 -145.13 165.8 27.25 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.21 -1.171 . . . . 0.0 109.479 -179.865 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 77.7 t -96.54 127.28 48.82 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.265 0 O-C-N 121.193 -0.942 . . . . 0.0 109.274 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 22.2 m -94.7 -33.77 5.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.134 -0.979 . . . . 0.0 109.746 179.916 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -144.94 171.92 13.77 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.248 -0.907 . . . . 0.0 109.663 -179.797 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 96.68 4.93 58.99 Favored Glycine 0 N--CA 1.493 2.435 0 N-CA-C 109.915 -1.274 . . . . 0.0 109.915 179.642 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 149' ' ' MET . . . . . 0.491 ' O ' HG12 ' A' ' 152' ' ' VAL . 71.9 mtm -60.31 -33.05 71.82 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.071 -1.252 . . . . 0.0 109.809 179.888 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -65.63 -42.49 91.44 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 120.87 -1.144 . . . . 0.0 110.085 -179.586 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 6.5 p -81.73 -34.33 12.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.149 -0.969 . . . . 0.0 110.522 -179.484 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 152' ' ' VAL . . . . . 0.596 ' O ' ' OE1' ' A' ' 156' ' ' GLU . 0.8 OUTLIER -52.55 -43.07 41.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 120.816 -1.178 . . . . 0.0 109.0 -179.13 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 153' ' ' LYS . . . . . 0.454 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 48.5 mttp -63.12 -34.41 77.54 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.192 -0.942 . . . . 0.0 109.317 179.251 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -63.27 -32.11 73.43 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.429 -0.795 . . . . 0.0 110.176 -179.558 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.419 ' O ' HG22 ' A' ' 158' ' ' VAL . 69.1 mt -68.79 -43.14 82.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.124 -0.985 . . . . 0.0 110.836 -179.179 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . 0.596 ' OE1' ' O ' ' A' ' 152' ' ' VAL . 32.4 mp0 -77.21 -37.98 52.32 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 120.768 -1.207 . . . . 0.0 112.025 -178.683 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 12.1 pttm -57.48 -35.55 70.33 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 120.523 -1.36 . . . . 0.0 109.731 -178.516 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.419 HG22 ' O ' ' A' ' 155' ' ' ILE . 26.9 m -75.11 -19.8 16.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 120.969 -1.082 . . . . 0.0 109.013 179.042 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -67.33 167.46 40.04 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 -179.911 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 89.4 p -148.74 168.22 23.48 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.316 -1.108 . . . . 0.0 109.42 -179.798 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 22.9 m -54.55 -34.21 61.45 Favored 'General case' 0 N--CA 1.487 1.406 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 179.425 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 23.9 m -58.39 -30.77 67.07 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.472 -0.767 . . . . 0.0 109.063 179.438 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.69 7.49 55.52 Favored Glycine 0 N--CA 1.492 2.431 0 N-CA-C 109.814 -1.315 . . . . 0.0 109.814 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 75.3 ttt-85 -114.74 139.5 49.65 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.31 -1.112 . . . . 0.0 109.084 179.781 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 165' ' ' THR . . . . . . . . . . . . . 51.1 p -87.47 156.24 19.64 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.214 -0.929 . . . . 0.0 109.879 -179.768 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -66.8 -37.22 84.13 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.531 -0.731 . . . . 0.0 109.433 179.765 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 67.2 mttm -111.25 156.82 20.89 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.411 -0.805 . . . . 0.0 109.606 -179.835 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 94.3 mttt -76.24 139.77 41.31 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.287 -0.883 . . . . 0.0 109.331 179.871 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 43.1 t -118.02 126.35 74.84 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.265 -0.897 . . . . 0.0 109.636 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 42.6 t -146.0 150.3 15.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.345 -0.847 . . . . 0.0 109.294 179.608 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -88.54 122.12 39.62 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 O-C-N 121.288 -0.882 . . . . 0.0 109.691 -179.446 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -67.0 -25.61 66.39 Favored 'General case' 0 C--N 1.3 -1.565 0 O-C-N 121.438 -0.789 . . . . 0.0 109.536 179.56 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 173' ' ' ASP . . . . . 0.413 ' OD1' ' N ' ' A' ' 174' ' ' CYS . 44.9 t0 -173.06 169.96 4.52 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.01 -1.056 . . . . 0.0 110.542 -179.383 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 174' ' ' CYS . . . . . 0.413 ' N ' ' OD1' ' A' ' 173' ' ' ASP . 30.4 p -152.61 150.35 29.42 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.501 -0.749 . . . . 0.0 109.014 179.416 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . 179.71 -177.07 47.99 Favored Glycine 0 N--CA 1.494 2.528 0 N-CA-C 110.044 -1.222 . . . . 0.0 110.044 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 58.9 tt0 -105.33 122.39 45.86 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.529 -0.983 . . . . 0.0 109.632 -179.868 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 177' ' ' LEU . . . . . 0.591 HD13 ' O ' ' A' ' 177' ' ' LEU . 0.2 OUTLIER -65.2 -40.82 94.71 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.171 -0.956 . . . . 0.0 108.566 179.485 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 178' ' ' SER . . . . . 0.464 ' C ' ' O ' ' A' ' 177' ' ' LEU . 1.2 t . . . . . 0 N--CA 1.493 1.702 0 CA-C-O 118.022 -0.99 . . . . 0.0 109.935 179.859 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.528 4.781 0 N-CA-C 119.433 2.533 . . . . 0.0 119.433 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 44.0 m -62.68 154.13 30.27 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.187 -1.184 . . . . 0.0 109.445 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 99.2 m-85 -111.42 121.88 46.37 Favored 'General case' 0 N--CA 1.486 1.34 0 O-C-N 121.43 -0.794 . . . . 0.0 108.957 179.722 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -135.05 -6.65 2.35 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.515 -0.741 . . . . 0.0 109.489 179.856 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 86.97 9.64 73.57 Favored Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 85.9 p -63.19 -23.94 67.66 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.21 -1.171 . . . . 0.0 109.651 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 30.7 ttm -124.44 77.42 62.31 Favored Pre-proline 0 N--CA 1.494 1.746 0 O-C-N 121.323 -0.861 . . . . 0.0 109.587 -179.784 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -79.9 -61.14 0.03 OUTLIER 'Trans proline' 0 C--N 1.308 -1.555 0 C-N-CA 122.643 2.229 . . . . 0.0 112.239 179.897 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -123.26 153.91 65.23 Favored Pre-proline 0 N--CA 1.494 1.738 0 O-C-N 121.529 -0.732 . . . . 0.0 109.243 179.877 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -69.18 138.53 39.92 Favored 'Trans proline' 0 N--CA 1.496 1.627 0 C-N-CA 122.744 2.296 . . . . 0.0 112.306 179.913 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.701 HH21 HD23 ' A' ' 177' ' ' LEU . 50.8 ttp180 -133.69 126.53 30.96 Favored 'General case' 0 N--CA 1.49 1.568 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 179.143 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.5 p -131.88 141.83 44.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.29 -0.881 . . . . 0.0 109.521 -179.139 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 40.5 p90 -140.28 157.87 44.9 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.379 -0.826 . . . . 0.0 109.524 -179.602 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 95.2 m-85 -126.93 142.58 51.51 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.472 -0.768 . . . . 0.0 109.808 179.902 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 19.1 t70 -93.74 113.51 25.59 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.412 -0.958 . . . . 0.0 108.412 178.931 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 96.8 mmm -97.13 146.54 24.95 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.452 -0.78 . . . . 0.0 110.112 -179.164 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 41.8 t -149.58 162.07 40.91 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.457 -0.777 . . . . 0.0 109.036 179.628 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.536 HG22 ' O ' ' A' ' 21' ' ' GLN . 25.6 m -124.27 159.9 29.36 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.314 -0.867 . . . . 0.0 109.562 179.894 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -49.18 -30.45 10.64 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.822 -1.311 . . . . 0.0 109.822 -179.475 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -73.93 -79.65 0.52 Allowed Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.674 -1.37 . . . . 0.0 109.674 -179.837 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' GLN . . . . . 0.536 ' O ' HG22 ' A' ' 18' ' ' VAL . 4.2 pt20 -146.35 157.15 49.43 Favored Pre-proline 0 N--CA 1.494 1.727 0 O-C-N 121.177 -1.19 . . . . 0.0 109.129 -179.968 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 75.6 Cg_exo -45.78 130.31 12.51 Favored 'Trans proline' 0 C--N 1.31 -1.455 0 C-N-CA 122.25 1.967 . . . . 0.0 112.138 179.792 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -80.05 -56.42 4.25 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.28 -0.888 . . . . 0.0 109.703 -179.891 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 168.82 -170.74 42.54 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 -179.898 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 56.9 ttp180 -114.48 142.01 46.95 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.392 -1.063 . . . . 0.0 109.338 179.818 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 81.5 mt -120.04 130.5 74.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.429 -0.795 . . . . 0.0 109.012 179.877 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 43.6 t -110.56 134.63 52.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.386 -0.821 . . . . 0.0 109.717 -179.792 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 72.1 mtm -121.71 151.89 40.0 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.447 -0.783 . . . . 0.0 109.082 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -105.54 132.86 51.17 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.265 -0.897 . . . . 0.0 110.053 -179.517 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -105.18 129.52 53.55 Favored 'General case' 0 N--CA 1.494 1.767 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 179.143 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -97.7 119.0 35.5 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.207 -0.933 . . . . 0.0 109.131 179.716 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -81.39 -42.21 20.78 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.383 -0.823 . . . . 0.0 109.638 179.847 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -64.8 -46.11 83.42 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.281 -0.887 . . . . 0.0 110.215 -179.388 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 28.4 m -65.99 -45.4 81.74 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.163 -0.961 . . . . 0.0 109.589 -179.766 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.445 ' O ' ' OG1' ' A' ' 35' ' ' THR . 4.1 p -141.38 80.58 16.33 Favored Pre-proline 0 N--CA 1.492 1.668 0 N-CA-C 108.798 -0.816 . . . . 0.0 108.798 179.912 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_endo -59.49 -65.1 0.09 OUTLIER 'Trans proline' 0 N--CA 1.496 1.622 0 C-N-CA 122.419 2.079 . . . . 0.0 113.018 -178.843 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 94.8 mtt180 -60.62 -36.88 79.7 Favored 'General case' 0 C--N 1.298 -1.668 0 O-C-N 121.596 -0.69 . . . . 0.0 110.965 -178.769 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 23.0 m -60.85 -43.32 98.48 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 120.928 -1.107 . . . . 0.0 109.954 -179.423 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -61.94 -31.58 71.91 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.176 -0.952 . . . . 0.0 108.87 179.769 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -70.52 -41.73 72.21 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.352 -0.842 . . . . 0.0 109.937 -179.862 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . 0.439 ' O ' HD23 ' A' ' 45' ' ' LEU . 81.5 m-20 -60.71 -45.31 94.69 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.137 -0.977 . . . . 0.0 109.75 -179.585 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 56.3 t80 -71.76 -48.24 48.2 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.202 -0.936 . . . . 0.0 109.225 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.509 ' CD ' ' NE2' ' A' ' 176' ' ' GLN . 61.8 ttp180 -58.24 -38.92 77.82 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.47 -0.768 . . . . 0.0 109.887 179.917 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.489 ' O ' ' N ' ' A' ' 48' ' ' GLY . . . -60.99 -40.59 94.09 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.289 -0.882 . . . . 0.0 110.22 -178.925 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.439 HD23 ' O ' ' A' ' 41' ' ' ASN . 3.8 mm? -61.61 -39.38 91.03 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.056 -1.027 . . . . 0.0 109.473 179.946 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' CYS . . . . . . . . . . . . . 20.1 m -80.87 -53.13 6.74 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.015 -1.053 . . . . 0.0 109.71 -179.832 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 68.8 p -69.17 -36.74 77.67 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.336 -0.853 . . . . 0.0 109.855 -179.821 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.489 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 73.6 32.79 59.09 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.815 -1.314 . . . . 0.0 109.815 179.636 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 78.1 mm-40 -60.91 -37.43 82.21 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.081 -1.246 . . . . 0.0 109.262 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 32.5 mmtm -61.39 -31.38 71.29 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.311 -0.868 . . . . 0.0 109.303 179.649 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 97.59 169.2 32.7 Favored Glycine 0 N--CA 1.489 2.168 0 N-CA-C 109.323 -1.511 . . . . 0.0 109.323 -179.773 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.493 HG23 ' HA ' ' A' ' 58' ' ' PRO . 98.1 m -75.32 141.68 43.33 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.289 -1.124 . . . . 0.0 109.749 -179.84 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -56.78 140.3 44.25 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.254 -1.538 . . . . 0.0 109.254 179.87 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 93.5 mtt-85 -59.04 -33.39 70.71 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.189 -1.183 . . . . 0.0 109.998 -179.787 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 86.6 p -60.55 -25.46 66.18 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.161 -0.962 . . . . 0.0 109.902 -179.397 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 108.8 90.45 2.11 Favored Glycine 0 N--CA 1.495 2.578 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 -179.756 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . 0.431 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 17.7 tttm -176.26 78.62 0.28 Allowed Pre-proline 0 N--CA 1.489 1.493 0 O-C-N 121.397 -1.06 . . . . 0.0 108.46 -179.683 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.493 ' HA ' HG23 ' A' ' 52' ' ' THR . 87.0 Cg_exo -47.31 128.9 15.26 Favored 'Trans proline' 0 C--N 1.304 -1.793 0 C-N-CA 122.66 2.24 . . . . 0.0 112.174 -179.046 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.537 ' O ' ' CG ' ' A' ' 60' ' ' HIS . 7.2 mp -91.62 94.78 9.57 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.684 -0.635 . . . . 0.0 109.753 -179.348 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . 0.537 ' CG ' ' O ' ' A' ' 59' ' ' LEU . 93.7 m-70 -159.75 125.39 4.17 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.358 -0.839 . . . . 0.0 109.531 179.685 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . 0.42 ' O ' ' OG ' ' A' ' 64' ' ' SER . 55.5 m-85 -68.59 -5.05 17.7 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.104 -0.997 . . . . 0.0 108.986 179.269 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 35.2 ttmt -54.74 144.9 20.8 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.463 -0.773 . . . . 0.0 109.743 -179.866 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 84.1 m-20 56.25 45.41 23.17 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.612 -0.68 . . . . 0.0 109.793 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.42 ' OG ' ' O ' ' A' ' 61' ' ' TYR . 39.3 m -120.23 147.91 44.35 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.413 -0.804 . . . . 0.0 108.996 179.528 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 30.0 t -113.12 147.04 38.15 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.424 -0.798 . . . . 0.0 109.554 -179.699 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 4.2 m-30 -64.79 136.31 56.77 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.279 -0.888 . . . . 0.0 108.959 179.951 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 53.3 t-80 -61.5 -50.53 72.34 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.274 -0.891 . . . . 0.0 110.285 -179.193 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.696 HH21 ' NE2' ' A' ' 76' ' ' GLN . 36.8 ptt180 -161.47 160.71 29.56 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.117 -0.989 . . . . 0.0 110.136 -179.757 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.585 HG21 HG22 ' A' ' 165' ' ' THR . 24.0 m -132.91 151.34 34.14 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.509 -0.744 . . . . 0.0 108.993 179.716 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 11.6 mt -146.92 119.83 4.91 Favored Pre-proline 0 N--CA 1.492 1.657 0 O-C-N 121.038 -1.039 . . . . 0.0 109.436 179.78 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -74.68 135.35 19.59 Favored 'Trans proline' 0 C--N 1.312 -1.368 0 C-N-CA 122.161 1.907 . . . . 0.0 111.997 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 90.39 1.1 75.47 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 93.1 m-85 -135.81 -90.76 0.29 Allowed 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.376 -1.073 . . . . 0.0 109.632 179.963 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 9.6 ptp -170.28 172.62 6.13 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.109 -0.994 . . . . 0.0 109.618 -179.946 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 1.7 m -116.14 138.9 50.86 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.403 -0.811 . . . . 0.0 108.877 179.748 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' GLN . . . . . 0.696 ' NE2' HH21 ' A' ' 68' ' ' ARG . 94.6 mt-30 -108.54 154.87 21.32 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.269 -0.894 . . . . 0.0 109.707 -179.683 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -147.04 -165.79 11.96 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 -179.816 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.47 ' O ' ' N ' ' A' ' 80' ' ' PHE . . . 94.37 11.59 57.03 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 109.459 -1.457 . . . . 0.0 109.459 -179.737 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -48.15 -15.4 0.07 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.391 -1.064 . . . . 0.0 109.594 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.47 ' N ' ' O ' ' A' ' 78' ' ' GLY . 81.2 t80 -48.21 -47.96 35.21 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.229 -0.919 . . . . 0.0 110.2 -179.535 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.808 ' CB ' ' H ' ' A' ' 88' ' ' GLY . 54.4 p -71.15 -32.18 68.62 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.916 -1.115 . . . . 0.0 109.49 -179.929 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . 0.694 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 163.21 -54.64 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.426 -0.796 . . . . 0.0 109.14 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 91.77 1.04 71.23 Favored Glycine 0 N--CA 1.492 2.42 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 179.947 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 78.6 m-20 -87.63 5.91 37.18 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.225 -1.162 . . . . 0.0 109.474 179.923 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 95.53 -39.82 2.78 Favored Glycine 0 N--CA 1.493 2.45 0 N-CA-C 109.263 -1.535 . . . . 0.0 109.263 -179.79 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 56.3 p -73.85 -14.2 61.05 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.418 -1.048 . . . . 0.0 108.944 179.665 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -80.66 -160.76 24.0 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 -179.881 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.808 ' H ' ' CB ' ' A' ' 81' ' ' THR . . . 89.54 23.18 34.54 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.426 -1.47 . . . . 0.0 109.426 -179.819 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -55.69 148.89 15.27 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.293 -1.122 . . . . 0.0 109.529 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 49.8 m -105.14 151.12 24.43 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.394 -0.816 . . . . 0.0 109.384 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.411 HD13 HG21 ' A' ' 91' ' ' ILE . 27.6 pt -62.78 -32.48 55.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.247 -0.908 . . . . 0.0 109.974 -179.549 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 89.6 m-85 -65.08 -35.19 80.36 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.155 -0.965 . . . . 0.0 109.606 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 87.1 7.43 77.23 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.391 -1.483 . . . . 0.0 109.391 -179.862 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -147.53 155.89 42.3 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.32 -1.106 . . . . 0.0 109.376 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 64.1 mttp -89.89 143.65 26.61 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.255 -0.903 . . . . 0.0 109.82 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 41.4 p90 -138.15 160.38 39.55 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.543 -0.723 . . . . 0.0 109.067 179.779 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -67.35 132.79 48.38 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.04 -1.037 . . . . 0.0 109.596 -179.599 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -75.27 140.02 42.91 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.4 -0.813 . . . . 0.0 109.799 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -59.83 149.06 32.41 Favored 'General case' 0 C--N 1.305 -1.35 0 O-C-N 121.309 -0.87 . . . . 0.0 109.093 179.581 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . 0.425 ' N ' HD22 ' A' ' 100' ' ' ASN . 2.8 m120 -53.36 162.56 0.73 Allowed 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.409 -0.807 . . . . 0.0 109.309 -179.942 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' PHE . . . . . 0.584 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 22.3 p90 -130.63 82.15 2.04 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.462 -0.774 . . . . 0.0 109.372 -179.787 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 87.8 mt -60.31 -33.97 55.79 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.18 -0.95 . . . . 0.0 109.478 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 91.6 mttt -84.45 136.29 33.9 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.311 -0.868 . . . . 0.0 109.342 179.932 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 61.9 mttp -116.31 -178.62 3.46 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.485 -0.759 . . . . 0.0 109.986 -179.877 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' HIS . . . . . 0.526 ' O ' ' CG ' ' A' ' 105' ' ' HIS . 49.9 p-80 -99.79 101.39 12.53 Favored 'General case' 0 N--CA 1.493 1.694 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 179.692 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 66.5 p -101.19 -2.16 32.01 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.273 -0.892 . . . . 0.0 109.768 -179.743 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -149.8 171.91 29.79 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -74.24 157.81 45.61 Favored 'Trans proline' 0 C--N 1.304 -1.785 0 C-N-CA 122.899 2.399 . . . . 0.0 112.027 179.784 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 84.91 40.47 8.1 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 110.158 -1.177 . . . . 0.0 110.158 179.663 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 43.0 mm -113.66 133.55 59.26 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.382 -1.07 . . . . 0.0 109.183 179.677 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.537 ' N ' HD22 ' A' ' 111' ' ' LEU . 3.4 mm? -90.61 133.15 35.31 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.145 -0.972 . . . . 0.0 109.825 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 42.9 t -144.8 142.6 30.1 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.353 -0.842 . . . . 0.0 109.197 179.744 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 113' ' ' MET . . . . . 0.586 ' SD ' ' CE1' ' A' ' 142' ' ' PHE . 83.8 mmm -83.97 129.79 34.91 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.12 -0.988 . . . . 0.0 109.288 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . 0.531 ' O ' ' ND2' ' A' ' 115' ' ' ASN . . . -69.6 143.94 53.16 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.283 -0.886 . . . . 0.0 109.462 -179.951 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . 0.531 ' ND2' ' O ' ' A' ' 114' ' ' ALA . 14.6 m120 -142.94 112.72 6.96 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.363 -0.836 . . . . 0.0 108.961 179.463 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -69.45 -29.51 67.22 Favored 'General case' 0 C--N 1.298 -1.66 0 O-C-N 121.471 -0.768 . . . . 0.0 109.657 -179.872 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -134.43 166.73 24.09 Favored Glycine 0 N--CA 1.493 2.477 0 N-CA-C 109.406 -1.477 . . . . 0.0 109.406 179.888 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -68.88 153.82 72.08 Favored 'Trans proline' 0 C--N 1.305 -1.721 0 C-N-CA 122.81 2.34 . . . . 0.0 111.94 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 17.9 m120 54.19 43.17 31.01 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.483 -0.761 . . . . 0.0 109.441 -179.925 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 92.8 m -134.91 125.07 25.98 Favored 'General case' 0 N--CA 1.485 1.324 0 O-C-N 121.42 -0.8 . . . . 0.0 108.929 179.928 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 22.6 t-20 -103.05 102.6 12.63 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.469 -0.77 . . . . 0.0 109.391 179.828 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -92.93 133.93 11.95 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.414 -1.474 . . . . 0.0 109.414 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 83.3 p -63.77 -23.46 67.37 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.191 -1.182 . . . . 0.0 109.296 179.83 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 92.6 mt-30 -68.66 144.57 54.41 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.335 -0.853 . . . . 0.0 109.505 -179.882 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 49.7 p90 -137.53 163.07 32.06 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.396 -0.815 . . . . 0.0 109.166 179.773 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 48.9 p90 -135.81 160.93 37.05 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.271 -0.893 . . . . 0.0 109.776 -179.937 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 70.2 mt -117.61 132.68 66.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.444 -0.785 . . . . 0.0 109.568 -179.918 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 1.9 p -100.72 106.6 18.05 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.325 -0.859 . . . . 0.0 109.255 179.555 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . 0.431 ' OG1' ' OE1' ' A' ' 156' ' ' GLU . 68.5 p -90.93 3.03 55.68 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.189 -0.945 . . . . 0.0 109.809 -179.765 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -146.0 154.63 42.1 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.12 -0.987 . . . . 0.0 109.674 -179.726 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 78.9 tttt -81.16 131.06 35.28 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.336 -0.853 . . . . 0.0 109.362 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 9.4 p -125.29 161.65 26.49 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.358 -0.839 . . . . 0.0 109.418 179.933 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -127.52 -28.79 2.73 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.236 -0.915 . . . . 0.0 109.642 -179.891 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 2.0 p90 -75.8 -6.53 51.11 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.159 -0.963 . . . . 0.0 109.777 -179.841 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 8.2 mt -90.78 7.69 38.47 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.242 -0.911 . . . . 0.0 109.548 179.486 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . 0.472 ' O ' ' OD1' ' A' ' 136' ' ' ASP . 52.2 p30 -53.63 153.34 4.43 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.301 -0.874 . . . . 0.0 109.724 -179.755 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 144.48 -129.6 3.64 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.012 -1.635 . . . . 0.0 109.012 -179.685 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 2.0 mptp? -90.4 127.55 36.23 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.214 -1.168 . . . . 0.0 108.91 179.643 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 139' ' ' HIS . . . . . . . . . . . . . 85.6 t60 -140.57 127.58 20.75 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.375 -0.828 . . . . 0.0 109.694 -179.85 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 44.7 t -123.11 132.76 70.81 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 121.458 -0.776 . . . . 0.0 109.048 179.595 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 38.8 t -116.5 129.36 73.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.321 -0.862 . . . . 0.0 109.211 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . 0.586 ' CE1' ' SD ' ' A' ' 113' ' ' MET . 38.3 p90 -119.93 5.89 10.89 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.323 -0.861 . . . . 0.0 109.734 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -179.43 177.66 48.37 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 179.655 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.2 pt20 -146.17 167.13 24.2 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.265 -1.138 . . . . 0.0 109.453 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 55.2 t -95.33 130.24 44.36 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 O-C-N 121.232 -0.918 . . . . 0.0 109.326 -179.886 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 13.3 m -108.51 -36.63 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.308 -0.87 . . . . 0.0 109.653 179.812 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 94.4 mt-10 -139.75 161.89 36.46 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.26 -0.9 . . . . 0.0 109.575 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . 0.43 ' O ' HG12 ' A' ' 151' ' ' VAL . . . 95.02 5.64 60.78 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 110.102 -1.199 . . . . 0.0 110.102 179.578 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 149' ' ' MET . . . . . 0.593 ' O ' HG12 ' A' ' 152' ' ' VAL . 65.0 mtt -60.0 -32.58 71.0 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.049 -1.266 . . . . 0.0 109.319 179.859 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 56.1 t0 -64.85 -41.89 95.33 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.954 -1.091 . . . . 0.0 110.291 -179.563 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.43 HG12 ' O ' ' A' ' 148' ' ' GLY . 7.6 p -78.15 -32.32 17.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.06 -1.025 . . . . 0.0 110.911 -179.266 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 152' ' ' VAL . . . . . 0.593 HG12 ' O ' ' A' ' 149' ' ' MET . 0.9 OUTLIER -51.62 -40.57 26.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 120.962 -1.087 . . . . 0.0 109.011 -179.18 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 153' ' ' LYS . . . . . 0.439 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 59.1 mttp -65.69 -32.63 74.3 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.242 -0.911 . . . . 0.0 109.441 179.09 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -60.11 -39.37 85.97 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.341 -0.849 . . . . 0.0 110.113 -179.28 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 90.0 mt -72.31 -33.95 47.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.048 -1.033 . . . . 0.0 109.757 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . 0.431 ' OE1' ' OG1' ' A' ' 129' ' ' THR . 84.5 tt0 -77.63 -41.72 37.43 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.231 -0.918 . . . . 0.0 111.34 -178.859 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . 0.431 ' HG2' ' HZ2' ' A' ' 157' ' ' LYS . 17.5 pttm -59.65 -35.57 74.66 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 120.682 -1.261 . . . . 0.0 109.579 -178.838 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 35.3 m -77.15 -10.34 13.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.155 -0.966 . . . . 0.0 108.798 179.228 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -73.89 163.45 54.63 Favored Glycine 0 N--CA 1.488 2.124 0 N-CA-C 110.178 -1.169 . . . . 0.0 110.178 -179.596 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 54.2 m -148.07 165.77 29.8 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.598 -0.942 . . . . 0.0 109.276 -179.895 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 23.9 t -55.08 -26.56 38.71 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.217 -0.927 . . . . 0.0 109.293 179.849 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 86.8 p -57.64 -25.65 60.48 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.243 -0.911 . . . . 0.0 109.639 -179.749 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 92.48 12.98 57.77 Favored Glycine 0 N--CA 1.492 2.414 0 N-CA-C 109.941 -1.264 . . . . 0.0 109.941 179.87 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 24.2 ttm180 -127.14 143.09 51.35 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.204 -1.174 . . . . 0.0 109.491 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 165' ' ' THR . . . . . 0.585 HG22 HG21 ' A' ' 69' ' ' VAL . 79.1 p -76.9 154.81 33.35 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.255 -0.903 . . . . 0.0 109.344 179.851 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -63.93 -35.88 82.13 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.24 -0.912 . . . . 0.0 109.231 179.813 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -116.78 154.69 30.23 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.571 -0.706 . . . . 0.0 109.151 179.794 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -66.44 142.43 57.57 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.121 -0.987 . . . . 0.0 109.095 -179.949 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . 0.465 ' O ' HG23 ' A' ' 169' ' ' VAL . 33.0 m -123.99 128.38 74.09 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.363 -0.836 . . . . 0.0 109.707 -179.716 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 40.7 t -144.16 147.76 19.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.395 -0.816 . . . . 0.0 109.011 179.649 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.407 HG23 ' H ' ' A' ' 171' ' ' VAL . 0.2 OUTLIER -83.86 115.53 26.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 120.935 -1.103 . . . . 0.0 109.464 -179.787 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -66.08 -22.39 66.41 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.364 -0.835 . . . . 0.0 109.213 179.469 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 173' ' ' ASP . . . . . 0.454 ' OD1' ' N ' ' A' ' 174' ' ' CYS . 48.0 t0 -167.38 163.39 15.07 Favored 'General case' 0 N--CA 1.492 1.654 0 C-N-CA 119.035 -1.066 . . . . 0.0 110.564 -179.493 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 174' ' ' CYS . . . . . 0.454 ' N ' ' OD1' ' A' ' 173' ' ' ASP . 18.5 p -161.78 146.62 13.06 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.592 -0.693 . . . . 0.0 109.325 179.535 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . 170.45 175.08 38.97 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 179.829 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 176' ' ' GLN . . . . . 0.509 ' NE2' ' CD ' ' A' ' 43' ' ' ARG . 47.9 tt0 -102.58 121.02 41.55 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.228 -1.16 . . . . 0.0 109.779 179.925 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 177' ' ' LEU . . . . . 0.701 HD23 HH21 ' A' ' 11' ' ' ARG . 46.2 tp -64.74 -36.58 84.75 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.33 -0.856 . . . . 0.0 109.371 179.408 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 7.9 t . . . . . 0 N--CA 1.49 1.565 0 CA-C-O 118.025 -0.988 . . . . 0.0 109.368 179.999 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.757 ' O ' HG23 ' A' ' 4' ' ' THR . . . . . . . . 1 N--CA 1.528 4.821 0 N-CA-C 119.397 2.519 . . . . 0.0 119.397 . . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 85.1 p -64.64 -23.5 67.28 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.179 -1.189 . . . . 0.0 109.958 -179.806 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 98.8 m-85 -95.34 18.74 11.92 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.175 -0.953 . . . . 0.0 110.229 -179.323 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.757 HG23 ' O ' ' A' ' 1' ' ' GLY . 60.2 p -68.58 -30.61 69.4 Favored 'General case' 0 C--N 1.297 -1.68 0 O-C-N 121.37 -0.831 . . . . 0.0 109.459 179.644 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 75.67 31.67 55.8 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.73 -1.348 . . . . 0.0 109.73 179.682 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 23.2 t -60.71 -37.97 83.49 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.2 -1.177 . . . . 0.0 109.709 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 1.4 ptm -132.36 80.12 63.96 Favored Pre-proline 0 N--CA 1.496 1.855 0 O-C-N 121.329 -0.857 . . . . 0.0 109.303 -179.884 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -80.82 -24.18 5.11 Favored 'Trans proline' 0 C--N 1.308 -1.596 0 C-N-CA 122.77 2.313 . . . . 0.0 112.488 -179.486 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -141.74 157.55 64.61 Favored Pre-proline 0 N--CA 1.493 1.686 0 O-C-N 121.263 -0.898 . . . . 0.0 109.322 -179.922 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -69.42 139.67 41.97 Favored 'Trans proline' 0 N--CA 1.496 1.65 0 C-N-CA 122.686 2.257 . . . . 0.0 112.152 179.887 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 75.1 mtt85 -128.93 132.87 47.69 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.387 -0.82 . . . . 0.0 109.077 179.092 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.7 p -135.06 142.68 39.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.488 -0.757 . . . . 0.0 109.223 -179.859 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 41.6 p90 -139.55 153.81 47.51 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.296 -0.878 . . . . 0.0 109.505 -179.786 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 93.4 m-85 -122.15 135.23 54.76 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.516 -0.74 . . . . 0.0 109.446 179.699 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.6 t0 -90.3 113.4 25.25 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.111 -0.993 . . . . 0.0 108.374 179.212 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 71.6 mtp -105.24 147.38 28.11 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.072 -1.017 . . . . 0.0 110.389 -179.168 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.435 ' HA ' ' H ' ' A' ' 23' ' ' ALA . 84.2 p -144.9 165.2 28.81 Favored 'General case' 0 N--CA 1.489 1.501 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 179.724 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 33.5 m -125.37 151.16 31.01 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.28 -0.888 . . . . 0.0 109.43 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -51.17 102.49 0.07 OUTLIER Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 140.43 -75.13 0.35 Allowed Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.714 -1.354 . . . . 0.0 109.714 179.873 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -138.41 158.78 70.0 Favored Pre-proline 0 N--CA 1.492 1.663 0 O-C-N 121.337 -1.096 . . . . 0.0 109.264 -179.763 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -58.63 138.77 87.64 Favored 'Trans proline' 0 N--CA 1.494 1.524 0 C-N-CA 122.581 2.187 . . . . 0.0 111.887 179.78 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.435 ' H ' ' HA ' ' A' ' 17' ' ' SER . . . -84.27 -62.47 1.55 Allowed 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.223 -0.923 . . . . 0.0 109.568 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 168.9 -169.69 41.96 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 -179.836 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 58.9 ttp180 -115.72 141.81 47.59 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.338 -1.095 . . . . 0.0 109.265 179.936 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 82.8 mt -121.24 128.96 76.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.331 -0.855 . . . . 0.0 109.237 179.831 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 46.5 t -114.18 134.09 58.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.335 -0.853 . . . . 0.0 109.26 179.908 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . 0.421 ' HG2' HG22 ' A' ' 145' ' ' VAL . 73.9 mtm -119.93 151.74 38.47 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.384 -0.822 . . . . 0.0 109.318 -179.928 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -98.68 131.98 44.43 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.339 -0.851 . . . . 0.0 109.763 -179.57 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -107.34 132.62 52.93 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.494 -0.754 . . . . 0.0 109.143 179.681 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 95.7 m-85 -98.6 125.41 43.85 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.223 -0.923 . . . . 0.0 109.176 179.66 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -94.47 1.25 55.76 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.255 -0.903 . . . . 0.0 109.997 -179.692 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -95.45 -75.17 0.53 Allowed 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.046 -1.034 . . . . 0.0 110.581 -179.342 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 47.0 m -64.67 -40.65 95.79 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.354 -0.841 . . . . 0.0 111.017 -178.646 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.569 HG21 ' HA ' ' A' ' 142' ' ' PHE . 43.3 p -126.46 76.18 73.7 Favored Pre-proline 0 N--CA 1.496 1.829 0 O-C-N 121.089 -1.007 . . . . 0.0 110.149 -178.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 63.7 Cg_endo -78.21 -57.42 0.04 OUTLIER 'Trans proline' 0 C--N 1.308 -1.601 0 C-N-CA 122.764 2.31 . . . . 0.0 112.729 179.724 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 24.1 mmt85 -57.39 -38.47 74.32 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.247 -0.908 . . . . 0.0 110.151 -179.249 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.555 HG23 ' SD ' ' A' ' 113' ' ' MET . 41.5 m -61.41 -40.85 95.9 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.039 -1.038 . . . . 0.0 109.915 -179.581 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -61.89 -31.1 71.36 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.203 -0.936 . . . . 0.0 109.216 179.842 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -67.57 -37.19 82.29 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.389 -0.819 . . . . 0.0 109.766 -179.846 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 49.6 t-20 -58.64 -43.05 89.62 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.24 -0.912 . . . . 0.0 109.841 -179.678 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.495 ' O ' ' SG ' ' A' ' 46' ' ' CYS . 96.9 m-85 -83.31 -46.63 12.38 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.165 -0.96 . . . . 0.0 109.756 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.651 ' NE ' HE22 ' A' ' 176' ' ' GLN . 76.5 ttt180 -57.19 -42.06 80.53 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.295 -0.878 . . . . 0.0 109.901 -179.697 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.482 ' O ' ' N ' ' A' ' 48' ' ' GLY . . . -76.63 -48.54 18.76 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.132 -0.98 . . . . 0.0 110.29 -179.612 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.401 HD12 ' HA ' ' A' ' 45' ' ' LEU . 40.8 tp -58.1 -37.92 75.45 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.112 -0.993 . . . . 0.0 109.795 -179.4 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' CYS . . . . . 0.495 ' SG ' ' O ' ' A' ' 42' ' ' PHE . 39.8 m -77.32 -63.97 1.25 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.113 -0.992 . . . . 0.0 109.929 -179.795 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 26.0 m -63.17 -38.39 91.0 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.117 -0.989 . . . . 0.0 109.678 -179.813 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.482 ' N ' ' O ' ' A' ' 44' ' ' ALA . . . 80.58 37.16 21.1 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 110.043 -1.223 . . . . 0.0 110.043 179.744 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -61.4 -37.57 83.94 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.058 -1.26 . . . . 0.0 109.367 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 42.2 mmtm -61.52 -32.56 72.61 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.287 -0.883 . . . . 0.0 109.458 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 95.71 172.4 36.21 Favored Glycine 0 N--CA 1.487 2.097 0 N-CA-C 109.173 -1.571 . . . . 0.0 109.173 -179.62 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.54 HG23 ' HA ' ' A' ' 58' ' ' PRO . 94.1 m -72.36 141.19 48.77 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.315 -1.109 . . . . 0.0 109.871 -179.824 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -58.5 137.84 49.75 Favored Glycine 0 N--CA 1.489 2.169 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 179.804 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 94.1 mtt180 -59.72 -34.14 72.53 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.397 -1.061 . . . . 0.0 109.983 -179.68 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 86.2 p -61.32 -24.95 66.8 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.312 -0.867 . . . . 0.0 109.952 -179.564 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 112.58 89.83 1.85 Allowed Glycine 0 N--CA 1.495 2.572 0 N-CA-C 109.094 -1.603 . . . . 0.0 109.094 -179.595 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . 0.51 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 15.4 tptp -175.98 81.0 0.29 Allowed Pre-proline 0 N--CA 1.488 1.461 0 O-C-N 121.438 -1.036 . . . . 0.0 108.444 -179.659 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.54 ' HA ' HG23 ' A' ' 52' ' ' THR . 75.2 Cg_exo -51.01 131.48 35.04 Favored 'Trans proline' 0 C--N 1.304 -1.808 0 C-N-CA 122.799 2.333 . . . . 0.0 112.728 -179.168 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.51 ' CD1' ' O ' ' A' ' 57' ' ' LYS . 8.8 mp -101.13 89.13 3.7 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.487 -0.758 . . . . 0.0 109.224 -179.919 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . 0.515 ' O ' ' CE1' ' A' ' 80' ' ' PHE . 77.2 m80 -138.78 136.25 35.49 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.362 -0.836 . . . . 0.0 109.531 179.778 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -87.31 -7.95 57.25 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.289 -0.882 . . . . 0.0 108.771 179.529 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 34.2 ttmt -64.15 151.33 43.6 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.524 -0.735 . . . . 0.0 109.958 -179.729 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 59.93 46.61 10.89 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.628 -0.67 . . . . 0.0 109.965 179.896 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 20.8 t -115.83 141.61 47.87 Favored 'General case' 0 N--CA 1.494 1.728 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.323 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 28.7 t -114.97 145.73 41.95 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.386 -0.821 . . . . 0.0 109.682 -179.64 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.5 m-30 -69.41 137.76 53.02 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.243 -0.91 . . . . 0.0 108.996 179.791 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 58.5 t-80 -60.76 -50.75 72.21 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.242 -0.912 . . . . 0.0 110.249 -179.378 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 37.7 ptt180 -163.72 162.21 23.87 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.061 -1.024 . . . . 0.0 109.939 -179.677 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.564 HG21 HG22 ' A' ' 165' ' ' THR . 15.1 m -131.65 142.81 42.19 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.424 -0.798 . . . . 0.0 108.946 179.615 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 10.3 mt -148.03 109.85 3.75 Favored Pre-proline 0 N--CA 1.494 1.739 0 O-C-N 120.907 -1.121 . . . . 0.0 109.83 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -53.36 145.89 43.4 Favored 'Trans proline' 0 N--CA 1.494 1.524 0 C-N-CA 122.347 2.031 . . . . 0.0 112.489 179.524 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 82.01 -57.52 4.96 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 110.161 -1.175 . . . . 0.0 110.161 179.428 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -70.46 -88.68 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.137 -1.214 . . . . 0.0 109.828 -179.544 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 11.3 ptt? -178.31 176.4 1.08 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.221 -0.925 . . . . 0.0 109.57 -179.753 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -111.1 131.58 54.96 Favored 'General case' 0 N--CA 1.493 1.69 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 179.54 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 63.5 tt0 -98.26 150.14 21.85 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.239 -0.913 . . . . 0.0 109.958 -179.439 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -140.66 -170.1 11.97 Favored Glycine 0 N--CA 1.493 2.487 0 N-CA-C 109.287 -1.525 . . . . 0.0 109.287 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 96.52 6.33 58.57 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.861 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 54.8 t0 -58.33 -24.98 61.37 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.35 -1.088 . . . . 0.0 109.728 179.906 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.515 ' CE1' ' O ' ' A' ' 60' ' ' HIS . 76.4 t80 -48.21 -46.37 35.07 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.359 -0.838 . . . . 0.0 110.068 -179.38 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.737 ' CB ' ' H ' ' A' ' 88' ' ' GLY . 69.1 p -70.95 -29.93 66.09 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 120.96 -1.088 . . . . 0.0 109.493 179.896 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . 0.672 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 163.85 -55.84 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.412 -0.805 . . . . 0.0 109.225 179.822 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 92.37 0.41 70.33 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.529 -1.429 . . . . 0.0 109.529 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 78.7 m-20 -87.81 5.88 38.0 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.27 -1.135 . . . . 0.0 109.459 -179.962 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 96.12 -38.55 3.07 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 109.253 -1.539 . . . . 0.0 109.253 -179.895 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 61.7 p -73.82 -15.7 61.16 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.242 -1.152 . . . . 0.0 109.092 179.526 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -81.39 -163.9 31.83 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 -179.919 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.737 ' H ' ' CB ' ' A' ' 81' ' ' THR . . . 81.86 50.82 4.76 Favored Glycine 0 N--CA 1.487 2.099 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 -179.896 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -90.31 147.32 23.57 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.342 -1.093 . . . . 0.0 109.665 -179.728 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 50.5 m -112.17 149.71 31.84 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.461 -0.774 . . . . 0.0 109.403 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 5.1 pt -60.8 -42.13 91.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.277 -0.89 . . . . 0.0 110.106 -179.584 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 3.9 m-30 -66.65 -38.82 87.66 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.113 -0.992 . . . . 0.0 109.582 179.915 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 74.29 26.04 69.23 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.118 -1.593 . . . . 0.0 109.118 -179.742 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -143.64 161.29 38.9 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.421 -1.046 . . . . 0.0 109.569 -179.708 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 83.6 mttt -83.24 148.32 27.48 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.405 -0.81 . . . . 0.0 109.74 -179.736 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 88.6 m-85 -104.1 131.85 50.95 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.376 -0.828 . . . . 0.0 108.865 179.618 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -77.27 136.12 38.48 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.139 -0.976 . . . . 0.0 109.573 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.53 ' OD2' ' CE1' ' A' ' 101' ' ' PHE . 32.3 p-10 -87.86 128.22 35.35 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.215 -0.928 . . . . 0.0 109.279 179.714 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . 0.491 ' O ' ' OD1' ' A' ' 100' ' ' ASN . 84.6 tt0 -61.41 -43.15 99.36 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.155 -0.966 . . . . 0.0 109.989 -179.481 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . 0.491 ' OD1' ' O ' ' A' ' 99' ' ' GLU . 84.0 m-20 -155.24 165.4 36.77 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.145 -0.972 . . . . 0.0 110.071 -179.829 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' PHE . . . . . 0.53 ' CE1' ' OD2' ' A' ' 98' ' ' ASP . 98.6 m-85 -102.62 8.17 39.77 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.429 -0.794 . . . . 0.0 109.156 179.358 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 97.4 mt -53.79 -36.47 29.89 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.344 -0.847 . . . . 0.0 110.404 -179.404 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 33.3 mmtp -73.68 124.91 26.89 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.022 -1.049 . . . . 0.0 109.661 -179.512 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 12.9 pttm -142.77 -177.6 5.39 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.321 -0.862 . . . . 0.0 109.246 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' HIS . . . . . . . . . . . . . 93.6 m-70 -74.99 88.33 2.37 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.144 -0.973 . . . . 0.0 109.209 179.723 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 54.9 p -71.06 -26.81 63.24 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.188 -0.945 . . . . 0.0 109.572 -179.79 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -162.08 -168.45 24.0 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.305 -1.518 . . . . 0.0 109.305 -179.855 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -80.58 154.83 20.99 Favored 'Trans proline' 0 C--N 1.306 -1.705 0 C-N-CA 122.935 2.423 . . . . 0.0 112.175 179.783 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 80.33 43.45 9.49 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.944 -1.262 . . . . 0.0 109.944 179.667 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 41.7 mm -115.55 135.5 55.41 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.863 0 O-C-N 121.364 -1.08 . . . . 0.0 109.628 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.432 ' N ' HD22 ' A' ' 111' ' ' LEU . 4.3 mm? -91.25 124.4 35.42 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.25 -0.906 . . . . 0.0 109.272 179.654 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 30.9 t -140.72 141.07 34.95 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.176 -0.952 . . . . 0.0 109.501 179.867 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 113' ' ' MET . . . . . 0.555 ' SD ' HG23 ' A' ' 38' ' ' THR . 88.9 mtp -89.92 137.89 31.96 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.264 -0.897 . . . . 0.0 109.215 179.75 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . 0.531 ' O ' ' ND2' ' A' ' 115' ' ' ASN . . . -60.9 144.57 52.7 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.121 -0.987 . . . . 0.0 109.381 -179.955 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . 0.531 ' ND2' ' O ' ' A' ' 114' ' ' ALA . 5.0 m120 -137.05 110.78 8.1 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.216 -0.928 . . . . 0.0 109.275 179.848 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -73.57 -29.46 62.44 Favored 'General case' 0 C--N 1.297 -1.677 0 O-C-N 121.406 -0.809 . . . . 0.0 109.4 179.684 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -140.6 175.39 22.08 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 179.926 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -68.17 151.89 76.63 Favored 'Trans proline' 0 C--N 1.305 -1.717 0 C-N-CA 122.746 2.297 . . . . 0.0 111.822 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 119' ' ' ASN . . . . . 0.429 ' OD1' ' OD1' ' A' ' 98' ' ' ASP . 71.8 m-20 52.84 40.52 30.87 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.453 -0.779 . . . . 0.0 109.278 -179.781 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 94.6 m -140.78 124.17 16.76 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.406 -0.809 . . . . 0.0 109.248 179.904 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 87.9 m-20 -109.86 114.81 28.67 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.568 -0.708 . . . . 0.0 109.16 179.503 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -78.05 135.52 16.26 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 179.947 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 22.8 t -55.83 -32.72 63.84 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.212 -1.169 . . . . 0.0 109.195 179.793 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 94.2 mt-30 -72.47 146.6 46.78 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.348 -0.845 . . . . 0.0 109.28 179.729 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 41.2 p90 -133.16 163.3 29.57 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.351 -0.843 . . . . 0.0 109.088 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 49.2 p90 -135.65 156.33 49.02 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.222 -0.923 . . . . 0.0 109.699 -179.931 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 76.2 mt -121.62 134.61 64.41 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 179.804 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 128' ' ' CYS . . . . . 0.435 ' SG ' ' O ' ' A' ' 130' ' ' ALA . 5.5 t -116.22 124.66 50.8 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.288 -0.883 . . . . 0.0 109.368 179.968 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 44.1 p -89.26 -2.1 58.34 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.448 -0.782 . . . . 0.0 109.766 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . 0.435 ' O ' ' SG ' ' A' ' 128' ' ' CYS . . . -149.0 156.96 43.02 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.18 -0.95 . . . . 0.0 109.691 -179.857 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 63.6 tttm -72.84 136.78 45.4 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.31 -0.869 . . . . 0.0 109.34 179.813 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 17.1 p -121.48 158.8 27.63 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.43 -0.794 . . . . 0.0 109.537 -179.846 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -103.05 -74.65 0.63 Allowed 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.246 -0.909 . . . . 0.0 109.915 -179.829 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 134' ' ' TRP . . . . . 0.605 ' CD1' ' N ' ' A' ' 135' ' ' LEU . 42.0 p90 -58.73 -47.76 83.52 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.291 -0.881 . . . . 0.0 110.08 -179.419 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . 0.605 ' N ' ' CD1' ' A' ' 134' ' ' TRP . 31.5 tp -60.98 -35.08 75.87 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.203 -0.936 . . . . 0.0 109.332 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 62.1 t0 -80.05 118.16 21.52 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.202 -0.936 . . . . 0.0 109.541 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . 0.544 ' H ' ' CE1' ' A' ' 139' ' ' HIS . . . -144.24 -126.58 1.95 Allowed Glycine 0 N--CA 1.492 2.4 0 N-CA-C 109.096 -1.602 . . . . 0.0 109.096 179.844 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 2.0 mptm? -84.71 105.5 15.55 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.112 -1.228 . . . . 0.0 108.959 179.629 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 139' ' ' HIS . . . . . 0.544 ' CE1' ' H ' ' A' ' 137' ' ' GLY . 76.9 m80 -138.16 161.07 37.76 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.353 -0.842 . . . . 0.0 109.483 -179.862 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 45.0 t -119.58 136.04 58.0 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 O-C-N 121.399 -0.813 . . . . 0.0 109.404 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 59.2 t -105.31 130.25 56.85 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 O-C-N 121.395 -0.816 . . . . 0.0 109.144 179.82 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . 0.569 ' HA ' HG21 ' A' ' 35' ' ' THR . 39.9 p90 -114.33 -0.81 13.72 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.306 -0.871 . . . . 0.0 109.766 -179.865 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -174.71 174.79 46.8 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.589 -1.405 . . . . 0.0 109.589 179.546 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 2.6 pt20 -146.72 167.23 24.34 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.213 -1.169 . . . . 0.0 109.665 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . 0.421 HG22 ' HG2' ' A' ' 28' ' ' MET . 9.5 t -96.73 132.63 40.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 O-C-N 121.218 -0.926 . . . . 0.0 109.529 -179.95 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 15.9 m -111.43 -30.19 2.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.541 -0.724 . . . . 0.0 109.145 179.577 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 78.6 mm-40 -140.02 166.0 25.83 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.342 -0.849 . . . . 0.0 109.344 179.876 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 96.69 4.9 58.98 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.889 -1.285 . . . . 0.0 109.889 179.649 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 149' ' ' MET . . . . . 0.493 ' O ' HG12 ' A' ' 152' ' ' VAL . 65.1 mtt -60.2 -32.24 70.91 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 121.056 -1.261 . . . . 0.0 109.467 179.932 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 89.0 m-20 -64.38 -40.35 95.65 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 120.894 -1.129 . . . . 0.0 109.805 -179.807 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.402 ' H ' HG12 ' A' ' 151' ' ' VAL . 4.4 p -83.69 -35.09 11.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.251 -0.906 . . . . 0.0 110.502 -179.504 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 152' ' ' VAL . . . . . 0.493 HG12 ' O ' ' A' ' 149' ' ' MET . 0.9 OUTLIER -53.9 -42.0 51.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 120.835 -1.166 . . . . 0.0 108.871 -179.336 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 153' ' ' LYS . . . . . 0.455 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 60.0 mttm -65.68 -32.94 74.77 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.12 -0.987 . . . . 0.0 109.123 179.064 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -60.08 -36.96 78.55 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.423 -0.798 . . . . 0.0 109.751 -179.512 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 98.5 mt -71.2 -34.74 55.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.092 -1.005 . . . . 0.0 109.945 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 83.0 tt0 -76.63 -42.17 43.19 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.246 -0.908 . . . . 0.0 111.324 -178.823 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 33.3 pttt -62.13 -33.38 74.38 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 120.798 -1.189 . . . . 0.0 109.822 -178.921 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 33.0 m -83.5 -0.59 5.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.036 -1.04 . . . . 0.0 108.828 179.523 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -75.32 173.01 53.34 Favored Glycine 0 N--CA 1.488 2.115 0 N-CA-C 110.048 -1.221 . . . . 0.0 110.048 -179.53 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 89.7 p -153.22 164.02 38.84 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.462 -1.022 . . . . 0.0 109.764 -179.711 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 23.3 m -58.69 -32.82 69.49 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.309 -0.869 . . . . 0.0 108.834 179.31 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 25.4 m -55.84 -31.57 62.84 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.386 -0.821 . . . . 0.0 109.172 179.86 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 101.08 9.08 46.18 Favored Glycine 0 N--CA 1.495 2.574 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 179.893 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 35.8 ttp180 -116.48 141.12 48.59 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.238 -1.154 . . . . 0.0 109.293 179.898 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 165' ' ' THR . . . . . 0.564 HG22 HG21 ' A' ' 69' ' ' VAL . 80.6 p -76.5 155.87 33.44 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.292 -0.88 . . . . 0.0 109.304 179.932 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -62.37 -35.83 80.37 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.231 -0.918 . . . . 0.0 109.298 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 62.5 mttp -118.93 152.98 35.34 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.475 -0.766 . . . . 0.0 109.157 179.764 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -64.67 141.55 58.74 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.021 -1.049 . . . . 0.0 108.957 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . 0.48 ' O ' HG23 ' A' ' 169' ' ' VAL . 33.9 m -121.66 126.63 74.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.226 -0.921 . . . . 0.0 109.8 -179.748 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 44.5 t -145.03 148.81 17.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 N-CA-C 108.839 -0.801 . . . . 0.0 108.839 179.704 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.454 ' H ' HG23 ' A' ' 171' ' ' VAL . 0.1 OUTLIER -80.91 115.7 23.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.119 -0.988 . . . . 0.0 109.463 -179.798 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 78.4 mm-40 -67.9 -20.31 65.09 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.396 -0.815 . . . . 0.0 109.505 179.629 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 20.2 t70 -167.66 162.18 13.93 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.015 -1.053 . . . . 0.0 110.364 -179.456 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 30.6 p -155.89 144.52 20.26 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.459 -0.776 . . . . 0.0 109.294 179.604 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . 177.25 179.98 47.8 Favored Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 176' ' ' GLN . . . . . 0.651 HE22 ' NE ' ' A' ' 43' ' ' ARG . 63.6 tt0 -105.62 124.0 48.83 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.41 -1.053 . . . . 0.0 109.77 -179.905 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 35.5 tp -61.23 -37.8 84.34 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.187 -0.946 . . . . 0.0 109.395 179.658 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 7.9 t . . . . . 0 N--CA 1.489 1.522 0 CA-C-O 117.994 -1.003 . . . . 0.0 109.475 -179.967 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.529 4.839 0 N-CA-C 119.402 2.521 . . . . 0.0 119.402 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 29.8 t -119.66 143.62 47.61 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.295 -1.12 . . . . 0.0 109.455 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 49.6 p90 -145.52 158.28 43.86 Favored 'General case' 0 C--N 1.306 -1.29 0 O-C-N 121.183 -0.948 . . . . 0.0 108.647 179.721 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.551 HG22 ' H ' ' A' ' 6' ' ' SER . 45.1 m -86.23 132.36 34.02 Favored 'General case' 0 C--N 1.297 -1.694 0 O-C-N 121.398 -0.814 . . . . 0.0 109.596 -179.819 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -60.79 -31.92 77.4 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.774 -1.33 . . . . 0.0 109.774 179.88 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.551 ' H ' HG22 ' A' ' 4' ' ' THR . 29.5 t -89.44 146.09 24.88 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.304 -1.115 . . . . 0.0 109.701 -179.536 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' MET . . . . . 0.418 ' HB2' HH22 ' A' ' 11' ' ' ARG . 44.3 mtt -66.88 151.67 96.63 Favored Pre-proline 0 N--CA 1.489 1.517 0 O-C-N 121.265 -0.897 . . . . 0.0 109.318 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 26.0 Cg_endo -63.32 -20.17 69.82 Favored 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 122.723 2.282 . . . . 0.0 112.377 -179.878 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.446 ' ND2' ' O ' ' A' ' 10' ' ' PRO . 0.5 OUTLIER -62.13 136.67 95.47 Favored Pre-proline 0 N--CA 1.491 1.615 0 O-C-N 121.102 -0.999 . . . . 0.0 109.342 -179.736 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.446 ' O ' ' ND2' ' A' ' 9' ' ' ASN . 82.8 Cg_endo -75.29 140.15 24.37 Favored 'Trans proline' 0 N--CA 1.495 1.612 0 C-N-CA 122.473 2.116 . . . . 0.0 112.599 -179.833 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.418 HH22 ' HB2' ' A' ' 7' ' ' MET . 71.0 mtt85 -132.74 132.58 42.45 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.35 -0.844 . . . . 0.0 108.834 178.996 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.0 p -135.62 143.21 37.22 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.327 -0.858 . . . . 0.0 109.707 -179.764 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 42.7 p90 -138.21 154.21 49.12 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.523 -0.736 . . . . 0.0 109.183 179.941 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.415 ' CE1' ' CE1' ' A' ' 61' ' ' TYR . 97.5 m-85 -124.18 137.54 54.52 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.481 -0.762 . . . . 0.0 109.788 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 60.4 t0 -93.39 117.94 30.7 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.359 -0.838 . . . . 0.0 108.801 179.425 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' MET . . . . . 0.454 ' SD ' HD12 ' A' ' 26' ' ' ILE . 77.1 mtp -112.12 151.21 29.71 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.151 -0.968 . . . . 0.0 110.457 -179.174 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 84.5 p -142.91 163.09 33.73 Favored 'General case' 0 N--CA 1.489 1.519 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 179.804 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.534 ' O ' ' N ' ' A' ' 20' ' ' GLY . 26.2 m -125.96 143.01 40.94 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.201 -0.937 . . . . 0.0 109.706 -179.87 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 47.89 11.5 0.11 Allowed Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.817 -1.313 . . . . 0.0 109.817 179.833 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.534 ' N ' ' O ' ' A' ' 18' ' ' VAL . . . 97.43 -13.98 63.82 Favored Glycine 0 N--CA 1.493 2.499 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 -179.927 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' GLN . . . . . 0.608 ' NE2' ' N ' ' A' ' 21' ' ' GLN . 2.1 mp0 -84.62 150.85 57.54 Favored Pre-proline 0 N--CA 1.492 1.675 0 O-C-N 121.26 -1.141 . . . . 0.0 109.112 179.757 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_endo -62.15 136.93 63.33 Favored 'Trans proline' 0 C--N 1.308 -1.584 0 C-N-CA 122.453 2.102 . . . . 0.0 112.012 -179.893 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -111.72 -65.59 1.16 Allowed 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.439 -0.788 . . . . 0.0 109.359 179.886 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 178.98 -170.1 41.75 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.348 -1.501 . . . . 0.0 109.348 -179.924 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 92.2 mtt180 -116.72 143.72 45.31 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.358 -1.083 . . . . 0.0 109.526 179.792 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.454 HD12 ' SD ' ' A' ' 16' ' ' MET . 84.7 mt -121.06 122.77 68.49 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 179.304 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 38.8 t -118.47 132.75 67.43 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.434 0 O-C-N 121.376 -0.828 . . . . 0.0 109.154 -179.984 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 73.6 mtm -122.32 151.54 41.03 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.408 -0.807 . . . . 0.0 109.122 -179.886 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -99.32 130.79 45.63 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.298 -0.877 . . . . 0.0 109.847 -179.629 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.404 ' N ' ' CD2' ' A' ' 30' ' ' LEU . 2.7 mm? -107.07 129.12 54.86 Favored 'General case' 0 N--CA 1.491 1.575 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 179.535 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -99.63 120.23 39.36 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.244 -0.91 . . . . 0.0 109.082 179.572 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -78.95 -40.52 31.63 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.337 -0.852 . . . . 0.0 110.01 -179.753 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.537 ' OD1' ' N ' ' A' ' 34' ' ' THR . 31.9 p-10 -68.23 -41.22 81.54 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.228 -0.92 . . . . 0.0 110.72 -179.082 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . 0.537 ' N ' ' OD1' ' A' ' 33' ' ' ASP . 17.1 m -67.66 -44.52 77.66 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.005 -1.06 . . . . 0.0 109.997 -179.375 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.414 HG23 ' O ' ' A' ' 34' ' ' THR . 28.5 p -155.23 83.62 3.73 Favored Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.226 -0.921 . . . . 0.0 109.217 -179.903 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 13.4 Cg_endo -70.55 -35.77 9.79 Favored 'Trans proline' 0 C--N 1.307 -1.654 0 C-N-CA 121.987 1.791 . . . . 0.0 112.088 -179.537 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.424 ' HD2' ' H ' ' A' ' 37' ' ' ARG . 1.6 mpt_? -66.51 -41.93 88.07 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.077 -1.014 . . . . 0.0 109.702 179.771 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.552 HG23 ' SD ' ' A' ' 113' ' ' MET . 56.1 m -65.16 -42.06 94.11 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.203 -0.936 . . . . 0.0 110.008 -179.519 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -61.88 -31.37 71.65 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.135 -0.978 . . . . 0.0 109.083 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -69.84 -37.99 76.37 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.397 -0.814 . . . . 0.0 110.052 -179.742 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 3.3 m120 -58.42 -41.99 86.25 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.026 -1.046 . . . . 0.0 109.965 -179.345 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 -87.13 -48.41 8.08 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.114 -0.991 . . . . 0.0 109.554 179.878 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.47 ' O ' HG23 ' A' ' 47' ' ' THR . 66.8 ttp85 -57.63 -42.27 83.01 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.208 -0.933 . . . . 0.0 109.563 -179.853 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -69.74 -46.4 65.98 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.267 -0.896 . . . . 0.0 109.829 -179.674 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 44.9 tp -63.64 -37.78 88.65 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.29 -0.881 . . . . 0.0 109.701 -179.594 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' CYS . . . . . . . . . . . . . 81.7 m -72.99 -48.76 33.69 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.171 -0.956 . . . . 0.0 109.782 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . 0.47 HG23 ' O ' ' A' ' 43' ' ' ARG . 69.8 p -70.93 -35.58 72.28 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.164 -0.96 . . . . 0.0 109.687 -179.93 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 73.46 25.26 73.13 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 179.906 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 22.7 pt-20 -64.77 -33.1 75.18 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.225 -1.162 . . . . 0.0 109.622 -179.768 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 47.2 mmtm -60.14 -33.81 72.68 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.305 -0.872 . . . . 0.0 109.362 179.771 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 92.24 174.84 42.12 Favored Glycine 0 N--CA 1.486 2.032 0 N-CA-C 109.283 -1.527 . . . . 0.0 109.283 -179.753 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.502 HG23 ' HA ' ' A' ' 58' ' ' PRO . 65.5 m -70.57 139.22 51.44 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.387 -1.067 . . . . 0.0 109.705 -179.971 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -57.72 135.35 51.82 Favored Glycine 0 N--CA 1.488 2.137 0 N-CA-C 109.219 -1.552 . . . . 0.0 109.219 179.766 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 73.4 mtp180 -59.0 -33.88 71.22 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.178 -1.19 . . . . 0.0 109.958 -179.678 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 87.0 p -60.55 -24.46 65.41 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.18 -0.95 . . . . 0.0 109.684 -179.621 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 112.66 90.92 1.93 Allowed Glycine 0 N--CA 1.494 2.562 0 N-CA-C 109.049 -1.621 . . . . 0.0 109.049 -179.714 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . 0.509 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 33.0 tttm -174.72 78.61 0.33 Allowed Pre-proline 0 N--CA 1.488 1.437 0 O-C-N 121.425 -1.044 . . . . 0.0 108.365 -179.73 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.502 ' HA ' HG23 ' A' ' 52' ' ' THR . 75.8 Cg_exo -49.47 130.75 26.3 Favored 'Trans proline' 0 C--N 1.304 -1.783 0 C-N-CA 122.787 2.325 . . . . 0.0 112.77 -179.087 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.509 ' CD1' ' O ' ' A' ' 57' ' ' LYS . 7.1 mp -97.48 120.38 37.74 Favored 'General case' 0 N--CA 1.49 1.572 0 N-CA-C 109.195 -0.669 . . . . 0.0 109.195 179.854 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 58.7 m80 -149.79 93.84 2.09 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.273 -0.892 . . . . 0.0 109.448 179.679 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . 0.415 ' CE1' ' CE1' ' A' ' 14' ' ' PHE . 24.3 t80 -60.65 -34.38 74.21 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 179.831 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . 0.425 ' HE2' ' H ' ' A' ' 174' ' ' CYS . 92.8 mttt -54.77 167.9 0.33 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.495 -0.753 . . . . 0.0 109.794 -179.686 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 83.0 m-20 57.24 47.16 17.44 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.5 -0.75 . . . . 0.0 110.02 179.609 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 96.3 p -114.12 154.03 28.49 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.383 -0.823 . . . . 0.0 108.918 179.366 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 28.2 t -131.66 149.04 52.63 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.255 -0.903 . . . . 0.0 109.668 -179.552 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 28.6 m-85 -77.51 125.0 28.65 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.306 -0.871 . . . . 0.0 109.369 179.852 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 62.0 t60 -67.93 -46.4 71.6 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.598 -0.689 . . . . 0.0 110.782 -179.176 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 94.5 mtt180 -132.39 150.05 52.23 Favored 'General case' 0 N--CA 1.498 1.925 0 O-C-N 121.041 -1.037 . . . . 0.0 110.739 -178.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.714 HG21 HG22 ' A' ' 165' ' ' THR . 7.7 m -144.19 52.26 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 N-CA-C 108.744 -0.836 . . . . 0.0 108.744 179.471 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 14.4 mt -76.69 133.44 70.31 Favored Pre-proline 0 C--N 1.301 -1.537 0 O-C-N 121.193 -0.942 . . . . 0.0 110.07 -178.702 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_endo -70.09 149.95 65.53 Favored 'Trans proline' 0 N--CA 1.492 1.405 0 C-N-CA 122.408 2.072 . . . . 0.0 112.283 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 79.42 -55.19 4.38 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 179.864 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 90.9 m-85 -71.35 -87.7 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.249 -1.147 . . . . 0.0 109.702 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' MET . . . . . 0.602 ' SD ' ' CD2' ' A' ' 126' ' ' PHE . 12.1 ptt? 179.15 -178.83 0.35 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.184 -0.948 . . . . 0.0 109.763 -179.926 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 1.1 m -117.46 131.9 56.65 Favored 'General case' 0 N--CA 1.492 1.67 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 179.255 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 63.5 tt0 -95.04 146.16 24.46 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.161 -0.962 . . . . 0.0 110.222 -179.013 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -143.55 -175.07 16.31 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.186 -1.566 . . . . 0.0 109.186 179.841 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 93.24 10.55 59.43 Favored Glycine 0 N--CA 1.494 2.528 0 N-CA-C 109.426 -1.47 . . . . 0.0 109.426 -179.905 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.438 ' OD1' ' O ' ' A' ' 82' ' ' ALA . 62.4 t0 -56.18 -15.52 3.91 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.341 -1.094 . . . . 0.0 109.681 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 73.5 t80 -50.07 -47.86 53.37 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.174 -0.954 . . . . 0.0 110.17 -179.291 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.756 ' CB ' ' H ' ' A' ' 88' ' ' GLY . 65.6 p -71.53 -31.96 67.63 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.892 -1.13 . . . . 0.0 109.606 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . 0.685 ' HB2' ' O ' ' A' ' 81' ' ' THR . . . 164.51 -54.63 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.302 -0.874 . . . . 0.0 109.334 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 92.46 1.09 69.2 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.629 -1.388 . . . . 0.0 109.629 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 22.1 m120 -87.3 5.4 38.61 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.256 -1.144 . . . . 0.0 109.511 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 95.41 -39.61 2.82 Favored Glycine 0 N--CA 1.494 2.503 0 N-CA-C 109.243 -1.543 . . . . 0.0 109.243 -179.866 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 60.8 p -73.12 -16.92 61.44 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.24 -1.153 . . . . 0.0 109.085 179.634 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -81.77 -162.37 29.77 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.756 ' H ' ' CB ' ' A' ' 81' ' ' THR . . . 84.19 37.97 10.59 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 -179.951 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 78.1 mm-40 -58.02 149.7 22.65 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.266 -1.137 . . . . 0.0 109.808 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 50.8 m -115.57 147.08 41.15 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.666 -0.646 . . . . 0.0 109.273 179.925 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 18.1 pt -67.82 -35.53 72.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.264 -0.897 . . . . 0.0 110.037 -179.624 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . . . . . . . . . 49.2 m-85 -67.43 -38.67 84.92 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.03 -1.044 . . . . 0.0 109.64 -179.809 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 77.87 13.74 83.09 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.342 -1.503 . . . . 0.0 109.342 -179.701 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -147.0 155.9 42.62 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.275 -1.132 . . . . 0.0 109.429 -179.838 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 53.5 mttp -95.08 148.65 22.13 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.339 -0.851 . . . . 0.0 109.807 -179.976 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 54.9 p90 -134.33 160.23 38.58 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.403 -0.811 . . . . 0.0 109.141 179.453 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -104.53 150.88 24.23 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.302 -0.874 . . . . 0.0 109.788 -179.633 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 60.1 t0 -137.77 81.58 1.87 Allowed 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.314 -0.866 . . . . 0.0 109.246 179.763 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -63.78 -29.03 70.28 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.429 -0.794 . . . . 0.0 109.956 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . 0.421 HD22 ' N ' ' A' ' 100' ' ' ASN . 2.7 m120 -56.58 141.34 43.52 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.134 -0.979 . . . . 0.0 110.075 -179.244 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' PHE . . . . . 0.537 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 74.4 t80 -150.33 46.51 0.89 Allowed 'General case' 0 N--CA 1.491 1.615 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.824 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 90.9 mt -59.03 -34.82 54.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.416 -0.803 . . . . 0.0 110.228 -179.492 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 71.8 mmtt -80.78 139.85 35.82 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.112 -0.993 . . . . 0.0 109.765 -179.393 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 35.5 tttm -93.32 156.0 17.07 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.394 -0.816 . . . . 0.0 109.571 -179.961 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' HIS . . . . . . . . . . . . . 85.2 t60 -96.36 78.48 3.05 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.334 -0.854 . . . . 0.0 108.77 179.356 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 14.9 m -56.56 -40.03 74.49 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.3 -0.875 . . . . 0.0 109.436 -179.42 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.456 ' H ' HG13 ' A' ' 110' ' ' ILE . . . 130.09 -95.74 0.35 Allowed Glycine 0 N--CA 1.493 2.498 0 N-CA-C 110.044 -1.223 . . . . 0.0 110.044 179.575 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -68.81 141.24 48.65 Favored 'Trans proline' 0 N--CA 1.496 1.621 0 C-N-CA 122.694 2.263 . . . . 0.0 113.131 -179.233 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 75.95 22.65 73.85 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 110.241 -1.143 . . . . 0.0 110.241 179.033 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.456 HG13 ' H ' ' A' ' 107' ' ' GLY . 33.5 mm -115.54 134.41 58.83 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 121.315 -1.109 . . . . 0.0 110.076 -179.782 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.678 ' N ' HD22 ' A' ' 111' ' ' LEU . 3.1 mm? -93.78 137.03 33.46 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.289 -0.882 . . . . 0.0 108.894 179.148 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 34.0 t -146.05 141.17 27.35 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.226 -0.921 . . . . 0.0 109.691 179.781 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 113' ' ' MET . . . . . 0.552 ' SD ' HG23 ' A' ' 38' ' ' THR . 72.0 mtm -85.53 137.04 33.15 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.245 -0.91 . . . . 0.0 109.181 179.715 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . 0.452 ' O ' ' OD1' ' A' ' 115' ' ' ASN . . . -61.83 138.32 58.33 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.148 -0.97 . . . . 0.0 109.333 -179.879 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . 0.452 ' OD1' ' O ' ' A' ' 114' ' ' ALA . 77.2 m-20 -148.51 114.01 5.62 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.328 -0.858 . . . . 0.0 109.206 179.828 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -69.21 -29.77 67.8 Favored 'General case' 0 C--N 1.297 -1.713 0 O-C-N 121.43 -0.794 . . . . 0.0 109.179 179.613 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -137.84 168.42 24.52 Favored Glycine 0 N--CA 1.494 2.503 0 N-CA-C 109.085 -1.606 . . . . 0.0 109.085 179.783 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -67.4 155.6 69.68 Favored 'Trans proline' 0 C--N 1.306 -1.666 0 C-N-CA 122.758 2.305 . . . . 0.0 111.946 -179.858 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 75.9 m-20 54.92 45.3 26.78 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.425 -0.797 . . . . 0.0 109.498 -179.907 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 94.1 m -130.27 125.93 36.02 Favored 'General case' 0 N--CA 1.485 1.314 0 O-C-N 121.386 -0.821 . . . . 0.0 108.79 179.725 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 25.1 t-20 -99.09 110.62 23.18 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.449 -0.782 . . . . 0.0 109.621 -179.838 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -106.61 121.27 6.55 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.271 -1.532 . . . . 0.0 109.271 179.646 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 20.1 m -56.84 -34.43 67.76 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.209 -1.171 . . . . 0.0 109.187 179.971 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 93.6 mt-30 -71.62 144.94 49.27 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.263 -0.898 . . . . 0.0 109.148 179.81 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 44.9 p90 -135.59 163.53 29.91 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.317 -0.865 . . . . 0.0 109.297 -179.961 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.602 ' CD2' ' SD ' ' A' ' 74' ' ' MET . 52.8 p90 -132.15 157.38 44.41 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.405 -0.81 . . . . 0.0 109.503 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 67.1 mt -119.08 133.25 66.54 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.49 -0.756 . . . . 0.0 109.338 179.849 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 128' ' ' CYS . . . . . 0.402 ' SG ' ' O ' ' A' ' 130' ' ' ALA . 7.1 t -115.84 126.35 53.86 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.355 -0.841 . . . . 0.0 109.15 179.847 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 30.1 p -97.18 0.53 48.5 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.276 -0.89 . . . . 0.0 109.702 -179.708 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . 0.402 ' O ' ' SG ' ' A' ' 128' ' ' CYS . . . -148.86 164.26 35.0 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.235 -0.915 . . . . 0.0 109.429 -179.8 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -70.07 137.48 51.26 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.118 -0.989 . . . . 0.0 109.177 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 3.6 p -113.53 101.12 9.05 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.495 -0.753 . . . . 0.0 109.45 -179.737 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -64.35 -36.52 84.4 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.296 -0.878 . . . . 0.0 109.596 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 1.2 p90 -67.55 -33.29 74.74 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.15 -0.969 . . . . 0.0 109.59 -179.835 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . 0.546 ' O ' ' NE2' ' A' ' 139' ' ' HIS . 8.6 mt -93.11 12.15 25.23 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.102 -0.998 . . . . 0.0 109.322 179.358 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 60.1 t0 -57.05 124.18 17.82 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.137 -0.977 . . . . 0.0 109.616 -179.577 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -176.11 -159.29 21.56 Favored Glycine 0 N--CA 1.486 1.987 0 N-CA-C 109.009 -1.636 . . . . 0.0 109.009 -179.852 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 87.6 mttt -57.24 -38.51 73.92 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.317 -1.107 . . . . 0.0 109.646 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 139' ' ' HIS . . . . . 0.546 ' NE2' ' O ' ' A' ' 135' ' ' LEU . 63.3 m-70 53.57 71.51 0.5 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.318 -0.864 . . . . 0.0 109.957 179.766 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 39.3 t -69.0 135.44 28.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.14 -0.975 . . . . 0.0 108.879 179.295 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 17.4 m -126.94 148.23 31.78 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 121.222 -0.924 . . . . 0.0 109.74 -179.489 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . 0.454 ' CB ' HG21 ' A' ' 38' ' ' THR . 43.3 p90 -120.06 -6.01 9.99 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.382 -0.824 . . . . 0.0 110.019 179.831 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -164.74 -179.77 38.97 Favored Glycine 0 N--CA 1.495 2.618 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 179.692 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 14.4 pt20 -143.85 166.53 24.65 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.23 -1.159 . . . . 0.0 109.566 -179.769 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 44.7 t -97.21 132.18 42.36 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.13 0 O-C-N 121.096 -1.002 . . . . 0.0 109.54 -179.742 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 17.2 m -110.45 -32.74 2.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 O-C-N 121.413 -0.805 . . . . 0.0 109.3 179.321 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -145.35 170.25 16.68 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.308 -0.87 . . . . 0.0 109.46 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 97.35 2.47 58.96 Favored Glycine 0 N--CA 1.494 2.539 0 N-CA-C 109.977 -1.249 . . . . 0.0 109.977 179.531 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 149' ' ' MET . . . . . 0.477 ' O ' HG12 ' A' ' 152' ' ' VAL . 88.3 mtp -61.06 -33.07 72.74 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.189 -1.183 . . . . 0.0 109.685 179.925 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -64.78 -42.43 95.1 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 120.876 -1.14 . . . . 0.0 109.987 -179.547 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.4 p -82.53 -34.01 11.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.128 -0.983 . . . . 0.0 110.591 -179.341 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 152' ' ' VAL . . . . . 0.477 HG12 ' O ' ' A' ' 149' ' ' MET . 0.8 OUTLIER -53.74 -40.88 45.21 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 120.957 -1.09 . . . . 0.0 109.067 -179.408 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 153' ' ' LYS . . . . . 0.445 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 99.0 mttt -63.53 -34.12 77.08 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.113 -0.992 . . . . 0.0 109.292 179.201 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -61.51 -37.11 82.49 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.322 -0.861 . . . . 0.0 109.937 -179.638 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 97.9 mt -71.99 -35.05 52.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.173 -0.955 . . . . 0.0 109.981 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -75.93 -42.0 50.05 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.177 -0.952 . . . . 0.0 111.209 -178.894 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . 0.422 ' HG2' ' HZ2' ' A' ' 157' ' ' LYS . 15.4 pttm -61.81 -34.2 75.49 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 120.769 -1.207 . . . . 0.0 109.719 -178.924 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.425 ' HB ' ' H ' ' A' ' 166' ' ' ALA . 34.0 m -79.91 -13.79 13.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.152 -0.968 . . . . 0.0 109.082 179.562 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -76.88 170.43 55.09 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.836 -1.306 . . . . 0.0 109.836 -179.826 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 23.1 t -159.02 173.95 15.69 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.409 -1.054 . . . . 0.0 109.315 -179.841 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 23.6 m -53.84 -32.47 53.01 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.236 -0.915 . . . . 0.0 109.121 179.663 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 24.0 m -56.45 -32.57 65.05 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.393 -0.817 . . . . 0.0 109.412 179.842 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 95.1 13.23 53.38 Favored Glycine 0 N--CA 1.493 2.465 0 N-CA-C 109.791 -1.323 . . . . 0.0 109.791 179.954 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 98.0 mtt180 -119.24 144.82 46.54 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.283 -1.128 . . . . 0.0 109.379 179.862 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 165' ' ' THR . . . . . 0.714 HG22 HG21 ' A' ' 69' ' ' VAL . 80.1 p -82.39 150.46 27.11 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.25 -0.906 . . . . 0.0 109.563 179.867 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 166' ' ' ALA . . . . . 0.425 ' H ' ' HB ' ' A' ' 158' ' ' VAL . . . -65.95 -35.5 80.78 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.339 -0.851 . . . . 0.0 108.896 179.523 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 66.6 mttm -112.58 157.68 20.89 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.524 -0.735 . . . . 0.0 109.07 179.731 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -69.7 130.75 43.21 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.134 -0.979 . . . . 0.0 109.324 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 43.0 t -123.2 125.32 71.77 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 121.201 -0.937 . . . . 0.0 109.575 -179.949 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . 0.43 HG12 ' N ' ' A' ' 171' ' ' VAL . 60.7 t -150.33 157.17 6.15 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 O-C-N 121.486 -0.758 . . . . 0.0 108.972 179.582 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.43 ' N ' HG12 ' A' ' 170' ' ' VAL . 0.2 OUTLIER -87.98 119.41 35.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.104 -0.998 . . . . 0.0 109.529 -179.727 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -65.91 -24.62 66.88 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.361 -0.837 . . . . 0.0 109.414 179.407 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 19.9 t70 -173.81 171.16 3.8 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.127 -0.983 . . . . 0.0 110.301 -179.51 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 174' ' ' CYS . . . . . 0.425 ' H ' ' HE2' ' A' ' 62' ' ' LYS . 11.0 p -151.84 153.15 33.65 Favored 'General case' 0 N--CA 1.492 1.66 0 N-CA-C 109.052 -0.721 . . . . 0.0 109.052 179.499 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -175.75 174.55 46.94 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 109.702 -1.359 . . . . 0.0 109.702 179.784 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 62.2 tt0 -107.89 120.67 42.94 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.3 -1.118 . . . . 0.0 109.652 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 177' ' ' LEU . . . . . . . . . . . . . 32.4 tp -61.71 -37.03 82.66 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.135 -0.978 . . . . 0.0 109.032 179.434 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 25.0 t . . . . . 0 N--CA 1.49 1.559 0 CA-C-O 118.087 -0.959 . . . . 0.0 109.466 179.972 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.529 4.882 0 N-CA-C 119.38 2.512 . . . . 0.0 119.38 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 54.5 p -70.38 160.99 31.29 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.219 -1.165 . . . . 0.0 109.573 179.96 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 98.6 m-85 -96.87 20.56 10.86 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.252 -0.905 . . . . 0.0 109.396 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 18.2 p -121.49 162.77 19.93 Favored 'General case' 0 N--CA 1.494 1.745 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -152.37 -118.7 0.77 Allowed Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 -179.907 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 86.7 p -61.26 -29.28 69.75 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.204 -1.174 . . . . 0.0 109.836 -179.812 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 25.6 ttp 49.88 70.05 2.28 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.06 -1.025 . . . . 0.0 109.229 -179.924 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -50.73 -33.19 39.33 Favored 'Trans proline' 0 C--N 1.306 -1.694 0 C-N-CA 122.833 2.355 . . . . 0.0 112.378 -179.457 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 8.2 p-10 -158.94 146.35 13.21 Favored Pre-proline 0 N--CA 1.489 1.489 0 O-C-N 121.131 -0.981 . . . . 0.0 109.555 179.782 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -73.76 145.87 37.32 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 122.803 2.335 . . . . 0.0 112.047 179.763 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.482 ' NH2' ' CB ' ' A' ' 178' ' ' SER . 95.5 mtm-85 -119.16 132.49 55.97 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.271 -0.893 . . . . 0.0 108.783 179.222 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.6 p -135.04 142.39 40.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.269 -0.895 . . . . 0.0 109.772 -179.192 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' PHE . . . . . . . . . . . . . 42.8 p90 -141.12 155.61 46.09 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.434 -0.791 . . . . 0.0 109.506 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -128.18 142.32 51.21 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.421 -0.799 . . . . 0.0 109.887 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 59.4 t0 -94.6 124.26 38.52 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.227 -0.92 . . . . 0.0 108.734 179.151 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' MET . . . . . . . . . . . . . 39.1 mtp -119.66 147.51 44.47 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.136 -0.978 . . . . 0.0 110.279 -179.312 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.43 ' OG ' ' CD ' ' A' ' 172' ' ' GLU . 59.7 m -128.57 153.67 46.98 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.604 -0.685 . . . . 0.0 109.355 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.406 HG23 ' O ' ' A' ' 18' ' ' VAL . 34.7 m -114.93 131.93 65.66 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.835 0 O-C-N 121.388 -0.82 . . . . 0.0 109.426 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 63.59 9.65 32.99 Favored Glycine 0 N--CA 1.492 2.398 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 179.858 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 94.67 -1.67 66.31 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 -179.895 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 75.0 mt-30 -103.69 151.2 38.74 Favored Pre-proline 0 N--CA 1.493 1.717 0 O-C-N 121.295 -1.121 . . . . 0.0 109.073 179.756 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 14.3 Cg_endo -58.36 134.23 60.08 Favored 'Trans proline' 0 C--N 1.309 -1.507 0 C-N-CA 122.412 2.074 . . . . 0.0 112.266 -179.532 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -114.23 -65.06 1.23 Allowed 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.514 -0.741 . . . . 0.0 109.274 179.775 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -176.77 -170.48 39.34 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.456 -1.457 . . . . 0.0 109.456 179.943 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . 0.419 HH12 HG21 ' A' ' 27' ' ' VAL . 46.6 ptt85 -120.06 148.55 43.45 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.318 -1.107 . . . . 0.0 109.11 179.851 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 83.3 mt -122.57 129.15 75.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.496 -0.753 . . . . 0.0 109.32 -179.863 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.419 HG21 HH12 ' A' ' 25' ' ' ARG . 46.3 t -113.14 133.26 59.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.539 -0.725 . . . . 0.0 109.062 179.673 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 74.5 mtm -121.12 149.69 42.38 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.391 -0.818 . . . . 0.0 109.52 -179.753 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -97.57 132.51 43.17 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.388 -0.82 . . . . 0.0 109.542 -179.858 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -109.36 130.57 55.49 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.533 -0.729 . . . . 0.0 109.425 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 86.5 m-85 -94.55 118.41 31.63 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.126 -0.984 . . . . 0.0 108.483 178.89 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -93.38 -42.06 9.49 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.299 -0.875 . . . . 0.0 109.68 -179.683 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 90.6 m-20 -62.26 -49.23 76.53 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.09 -1.006 . . . . 0.0 109.764 -179.498 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . 0.493 HG21 ' HD3' ' A' ' 103' ' ' LYS . 61.9 m -73.52 -42.03 62.28 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.069 -1.02 . . . . 0.0 109.72 179.8 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.529 ' O ' ' OG1' ' A' ' 35' ' ' THR . 1.8 p -132.24 79.02 67.21 Favored Pre-proline 0 N--CA 1.492 1.657 0 O-C-N 121.3 -0.875 . . . . 0.0 109.439 -179.69 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 21.2 Cg_endo -66.77 -61.79 0.08 OUTLIER 'Trans proline' 0 C--N 1.31 -1.468 0 C-N-CA 122.376 2.051 . . . . 0.0 112.603 -179.48 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.623 ' NH2' ' CE1' ' A' ' 92' ' ' TYR . 68.7 mtp85 -60.9 -34.98 75.49 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.415 -0.803 . . . . 0.0 110.4 -179.308 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 25.7 m -59.98 -41.47 92.07 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.953 -1.092 . . . . 0.0 109.859 -179.559 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -62.62 -30.18 71.17 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.089 -1.007 . . . . 0.0 109.35 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.401 ' O ' ' HB3' ' A' ' 44' ' ' ALA . 96.6 mt-10 -67.59 -34.91 77.98 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.284 -0.885 . . . . 0.0 109.761 -179.983 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . 0.437 ' O ' HD23 ' A' ' 45' ' ' LEU . 26.2 m120 -56.82 -39.08 73.54 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.149 -0.97 . . . . 0.0 109.768 -179.767 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.4 ' O ' ' SG ' ' A' ' 46' ' ' CYS . 98.8 m-85 -94.16 -50.45 5.28 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.121 -0.987 . . . . 0.0 109.512 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.91 ' HE ' HE22 ' A' ' 176' ' ' GLN . 75.8 ttt-85 -57.19 -42.01 80.43 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.41 -0.806 . . . . 0.0 110.491 -179.392 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.401 ' HB3' ' O ' ' A' ' 40' ' ' GLU . . . -63.72 -44.87 92.29 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.999 -1.063 . . . . 0.0 110.077 -179.121 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.515 ' N ' ' CD2' ' A' ' 45' ' ' LEU . 2.7 mm? -67.64 -37.2 82.1 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.19 -0.944 . . . . 0.0 109.637 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' CYS . . . . . 0.4 ' SG ' ' O ' ' A' ' 42' ' ' PHE . 64.1 m -66.69 -48.99 67.57 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.136 -0.977 . . . . 0.0 110.108 -179.533 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 60.6 p -72.65 -30.71 64.52 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.192 -0.943 . . . . 0.0 109.694 -179.844 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 74.03 27.34 66.68 Favored Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 179.778 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 23.0 pt-20 -62.25 -35.59 79.41 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.212 -1.169 . . . . 0.0 109.381 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 43.6 mmtm -61.19 -33.2 73.07 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.289 -0.882 . . . . 0.0 109.128 179.588 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 93.64 168.4 38.29 Favored Glycine 0 N--CA 1.488 2.136 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 -179.793 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.541 HG23 ' HA ' ' A' ' 58' ' ' PRO . 68.4 m -76.45 139.9 41.05 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.306 -1.114 . . . . 0.0 109.686 -179.947 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -53.9 135.15 43.27 Favored Glycine 0 N--CA 1.488 2.165 0 N-CA-C 109.224 -1.551 . . . . 0.0 109.224 179.753 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 91.9 mtm-85 -58.92 -35.99 74.0 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.192 -1.181 . . . . 0.0 109.917 -179.551 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 22.7 t -59.14 -31.21 68.75 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.18 -0.95 . . . . 0.0 109.919 -179.587 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . 0.449 ' O ' ' CG ' ' A' ' 57' ' ' LYS . . . 117.91 81.05 0.77 Allowed Glycine 0 N--CA 1.495 2.614 0 N-CA-C 108.749 -1.74 . . . . 0.0 108.749 -179.381 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . 0.547 ' O ' ' CD1' ' A' ' 59' ' ' LEU . 57.4 mttm -161.69 79.87 2.03 Favored Pre-proline 0 C--N 1.303 -1.434 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 -179.576 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.541 ' HA ' HG23 ' A' ' 52' ' ' THR . 71.3 Cg_exo -50.9 133.02 39.19 Favored 'Trans proline' 0 C--N 1.301 -1.964 0 C-N-CA 122.894 2.396 . . . . 0.0 112.809 -178.734 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.571 ' O ' ' CG ' ' A' ' 60' ' ' HIS . 7.0 mp -100.19 98.32 9.03 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.613 -0.679 . . . . 0.0 109.524 -179.47 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . 0.571 ' CG ' ' O ' ' A' ' 59' ' ' LEU . 93.5 m-70 -160.45 125.91 3.93 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.167 -0.958 . . . . 0.0 109.948 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 9.5 m-85 -71.95 -5.98 38.73 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.136 -0.978 . . . . 0.0 108.811 178.889 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . 0.561 ' O ' ' O ' ' A' ' 171' ' ' VAL . 48.7 tttt -53.39 -25.88 17.34 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.527 -0.733 . . . . 0.0 109.57 179.891 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 89.3 m-20 -103.6 4.85 36.1 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.467 -0.771 . . . . 0.0 110.071 -179.402 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 63.8 p -82.04 162.35 22.62 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.069 -1.019 . . . . 0.0 109.856 -179.754 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 29.2 t -147.31 159.34 43.78 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.473 -0.767 . . . . 0.0 109.083 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.5 m-85 -64.18 123.5 19.26 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.079 -1.013 . . . . 0.0 108.929 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 61.7 t60 -66.62 -50.26 63.6 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.304 -0.872 . . . . 0.0 110.548 -179.112 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 93.2 mtt180 -141.47 150.47 42.29 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 120.951 -1.093 . . . . 0.0 110.287 -179.658 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.642 HG21 HG22 ' A' ' 165' ' ' THR . 4.9 m -137.09 130.92 45.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 179.096 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 19.1 mt -149.33 128.39 6.2 Favored Pre-proline 0 N--CA 1.492 1.646 0 O-C-N 120.94 -1.1 . . . . 0.0 109.41 -179.785 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 65.3 Cg_endo -76.0 133.44 15.13 Favored 'Trans proline' 0 C--N 1.311 -1.429 0 C-N-CA 122.148 1.899 . . . . 0.0 112.014 179.707 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 90.49 3.88 71.27 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.793 -1.323 . . . . 0.0 109.793 179.662 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 82.6 m-85 -138.77 -94.37 0.18 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.129 -1.218 . . . . 0.0 109.811 179.845 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 7.3 ptt? -171.45 175.79 4.01 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.168 -0.957 . . . . 0.0 109.839 -179.655 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -122.28 136.28 54.88 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 108.231 -1.026 . . . . 0.0 108.231 179.363 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 92.4 mt-30 -94.56 136.0 35.37 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.88 -1.138 . . . . 0.0 110.198 -179.262 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -90.03 -173.52 45.15 Favored Glycine 0 N--CA 1.492 2.379 0 N-CA-C 108.941 -1.664 . . . . 0.0 108.941 179.395 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -155.63 174.3 33.67 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.779 -1.329 . . . . 0.0 109.779 179.84 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.547 ' OD1' ' N ' ' A' ' 83' ' ' GLY . 48.5 p30 -106.37 165.59 11.15 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.415 -1.05 . . . . 0.0 109.56 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 46.4 p90 -75.2 -19.95 59.54 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.309 -0.87 . . . . 0.0 109.66 -179.884 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.557 ' OG1' ' N ' ' A' ' 88' ' ' GLY . 71.2 p -65.93 -37.06 85.06 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.281 -0.887 . . . . 0.0 109.989 -179.629 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -174.46 -51.32 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.267 -0.896 . . . . 0.0 109.539 -179.934 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.547 ' N ' ' OD1' ' A' ' 79' ' ' ASP . . . 94.71 2.2 63.23 Favored Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 78.7 m-20 -86.02 4.15 39.17 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.189 -1.183 . . . . 0.0 109.448 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 93.71 -37.47 3.39 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 51.6 p -69.99 -29.11 66.11 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.185 -1.185 . . . . 0.0 109.231 179.842 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -87.85 -168.23 44.24 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.983 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.557 ' N ' ' OG1' ' A' ' 81' ' ' THR . . . 84.03 45.07 6.43 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.571 -1.412 . . . . 0.0 109.571 179.879 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -56.37 144.37 30.94 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.344 -1.092 . . . . 0.0 109.43 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 27.4 t -78.24 144.57 36.1 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.159 -0.963 . . . . 0.0 109.552 -179.913 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 17.0 pt -66.34 -36.29 77.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.291 -0.881 . . . . 0.0 109.849 -179.871 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . 0.623 ' CE1' ' NH2' ' A' ' 37' ' ' ARG . 96.4 m-85 -66.21 -36.44 83.04 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.175 -0.953 . . . . 0.0 109.566 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 84.21 5.74 87.03 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.202 -1.559 . . . . 0.0 109.202 -179.752 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -150.97 158.0 43.6 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.348 -1.09 . . . . 0.0 109.381 -179.911 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -85.17 148.29 26.18 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.178 -0.951 . . . . 0.0 109.484 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 45.6 p90 -135.39 159.13 42.56 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.327 -0.858 . . . . 0.0 109.392 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -73.25 135.68 44.51 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.262 -0.899 . . . . 0.0 109.932 -179.678 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.438 ' C ' ' OD1' ' A' ' 98' ' ' ASP . 54.4 p30 -99.84 -163.87 1.07 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.313 -0.867 . . . . 0.0 109.549 179.774 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . 0.442 ' OE1' ' O ' ' A' ' 34' ' ' THR . 94.5 mt-10 -108.02 163.01 13.52 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.371 -0.831 . . . . 0.0 109.455 179.77 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 82.9 m-20 -64.76 165.95 9.66 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.257 -0.902 . . . . 0.0 109.566 -179.809 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' PHE . . . . . 0.489 ' CD2' ' O ' ' A' ' 101' ' ' PHE . 33.3 p90 -80.7 51.43 1.5 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.27 -0.894 . . . . 0.0 109.718 -179.811 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 90.7 mt -56.22 -41.08 68.96 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.101 -0.999 . . . . 0.0 109.547 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . 0.493 ' HD3' HG21 ' A' ' 34' ' ' THR . 43.6 mtpt -89.33 146.14 24.9 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.178 -0.951 . . . . 0.0 109.693 -179.939 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 49.3 pttt -134.85 179.98 5.97 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.42 -0.8 . . . . 0.0 109.356 179.804 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' HIS . . . . . 0.532 ' O ' ' CG ' ' A' ' 105' ' ' HIS . 48.4 p-80 -92.64 100.75 13.2 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.292 -0.88 . . . . 0.0 109.407 -179.872 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 51.2 p -76.54 -22.46 54.34 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.331 -0.856 . . . . 0.0 109.628 -179.903 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.409 ' O ' HG12 ' A' ' 110' ' ' ILE . . . -151.15 -179.46 26.89 Favored Glycine 0 N--CA 1.492 2.406 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 -179.688 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -72.65 158.87 49.94 Favored 'Trans proline' 0 C--N 1.307 -1.626 0 C-N-CA 122.951 2.434 . . . . 0.0 112.178 179.83 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 84.95 38.25 9.47 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 110.233 -1.147 . . . . 0.0 110.233 179.532 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.409 HG12 ' O ' ' A' ' 107' ' ' GLY . 34.4 mm -113.38 138.39 43.13 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.29 -1.123 . . . . 0.0 108.979 179.598 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.827 ' N ' HD22 ' A' ' 111' ' ' LEU . 2.4 mm? -87.58 139.75 30.22 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.246 -0.909 . . . . 0.0 109.658 -179.754 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 23.1 t -128.16 143.54 51.06 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.54 -0.725 . . . . 0.0 109.27 179.85 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 58.3 ttp -96.71 127.08 42.35 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.305 -0.872 . . . . 0.0 109.533 -179.9 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -66.16 146.5 54.58 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.236 -0.915 . . . . 0.0 109.633 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . 0.502 ' N ' ' OD1' ' A' ' 115' ' ' ASN . 9.1 p-10 -168.25 115.73 0.7 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.272 -0.893 . . . . 0.0 109.668 179.818 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -66.18 -33.95 76.92 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.379 -0.825 . . . . 0.0 109.347 179.806 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -145.52 166.92 27.65 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.352 -1.499 . . . . 0.0 109.352 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -66.59 158.58 55.04 Favored 'Trans proline' 0 C--N 1.306 -1.678 0 C-N-CA 122.822 2.348 . . . . 0.0 111.963 179.919 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 119' ' ' ASN . . . . . . . . . . . . . 73.7 m-20 55.03 44.07 28.74 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.467 -0.771 . . . . 0.0 109.392 -179.886 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 87.2 m -137.28 129.33 29.22 Favored 'General case' 0 C--N 1.305 -1.359 0 O-C-N 121.405 -0.81 . . . . 0.0 109.113 179.943 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 121' ' ' ASN . . . . . . . . . . . . . 22.4 t-20 -79.94 116.24 19.97 Favored 'General case' 0 C--N 1.298 -1.65 0 O-C-N 121.489 -0.757 . . . . 0.0 109.33 179.859 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -85.32 -179.54 50.69 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.736 -1.346 . . . . 0.0 109.736 -179.82 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 123' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -130.64 -14.25 3.66 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.367 -1.079 . . . . 0.0 109.749 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 94.3 mt-30 -121.89 159.42 26.89 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.299 -0.876 . . . . 0.0 109.622 -179.876 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 43.6 p90 -130.83 158.74 39.35 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.489 -0.757 . . . . 0.0 109.474 -179.898 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -117.47 143.84 45.63 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.49 -0.757 . . . . 0.0 110.02 -179.766 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 84.2 mt -120.77 134.27 64.75 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 121.613 -0.679 . . . . 0.0 109.224 179.246 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 128' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -125.27 126.36 45.01 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.293 -0.879 . . . . 0.0 109.376 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 30.3 p -98.32 3.39 48.64 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.348 -0.845 . . . . 0.0 109.301 179.868 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -153.62 159.63 42.16 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.243 -0.911 . . . . 0.0 109.428 -179.795 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 7.9 ttpm? -66.44 130.05 41.89 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.165 -0.959 . . . . 0.0 109.081 179.8 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 16.6 p -109.09 95.86 5.92 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.395 -0.816 . . . . 0.0 109.633 -179.658 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -65.74 -35.72 81.55 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.213 -0.929 . . . . 0.0 109.581 179.844 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 1.0 OUTLIER -66.47 -33.86 76.64 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.245 -0.91 . . . . 0.0 109.55 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 9.7 mt -90.06 7.17 39.09 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.166 -0.959 . . . . 0.0 109.201 179.295 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . 0.533 ' O ' ' OD1' ' A' ' 136' ' ' ASP . 47.2 p30 -46.79 138.45 6.22 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.184 -0.948 . . . . 0.0 109.783 -179.617 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 174.21 -161.88 32.12 Favored Glycine 0 N--CA 1.484 1.885 0 N-CA-C 108.873 -1.691 . . . . 0.0 108.873 -179.708 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . 0.477 ' O ' ' O ' ' A' ' 139' ' ' HIS . 88.8 mttt -57.36 -39.55 76.21 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 121.276 -1.132 . . . . 0.0 109.432 179.86 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 139' ' ' HIS . . . . . 0.477 ' O ' ' O ' ' A' ' 138' ' ' LYS . 66.3 m-70 53.18 109.22 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.51 -0.744 . . . . 0.0 110.049 179.63 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 40.6 t -107.42 136.54 42.27 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.36 -0.837 . . . . 0.0 108.825 179.435 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 141' ' ' VAL . . . . . . . . . . . . . 23.5 m -125.09 142.47 41.87 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.307 -0.871 . . . . 0.0 109.587 -179.464 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 42.8 p90 -126.46 -9.89 6.29 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.5 -0.75 . . . . 0.0 109.751 179.73 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -156.52 175.72 34.07 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 179.631 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . . . . . . . . . 58.6 tt0 -141.43 159.44 42.22 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.238 -1.154 . . . . 0.0 109.675 -179.614 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . 0.483 HG23 HD21 ' A' ' 111' ' ' LEU . 9.8 t -97.83 134.39 36.24 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.22 0 O-C-N 121.124 -0.985 . . . . 0.0 109.126 179.904 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . . . . . . . . . 11.6 m -113.62 -35.45 2.26 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.493 -0.754 . . . . 0.0 109.535 179.653 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 91.9 mt-10 -142.83 167.86 21.08 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.227 -0.92 . . . . 0.0 109.627 -179.849 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 97.78 4.36 57.95 Favored Glycine 0 N--CA 1.494 2.553 0 N-CA-C 110.079 -1.209 . . . . 0.0 110.079 179.534 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 149' ' ' MET . . . . . 0.458 ' O ' HG12 ' A' ' 152' ' ' VAL . 88.0 mtp -60.84 -33.22 72.72 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.062 -1.258 . . . . 0.0 109.741 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . 0.54 ' OD1' ' N ' ' A' ' 151' ' ' VAL . 30.9 p-10 -65.67 -38.26 88.8 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.9 -1.125 . . . . 0.0 110.107 -179.441 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.54 ' N ' ' OD1' ' A' ' 150' ' ' ASP . 7.6 p -86.52 -33.9 7.51 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.066 -1.021 . . . . 0.0 110.262 -179.593 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 152' ' ' VAL . . . . . 0.469 ' CG1' ' N ' ' A' ' 153' ' ' LYS . 1.0 OUTLIER -56.1 -42.65 73.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 120.943 -1.098 . . . . 0.0 109.175 -179.503 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 153' ' ' LYS . . . . . 0.469 ' N ' ' CG1' ' A' ' 152' ' ' VAL . 98.7 mttt -64.87 -33.88 77.06 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.189 -0.944 . . . . 0.0 109.537 179.431 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -62.33 -40.4 96.22 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.287 -0.883 . . . . 0.0 110.11 -179.321 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 75.4 mt -71.19 -36.79 63.81 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.228 -0.92 . . . . 0.0 110.394 -179.481 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -79.57 -41.45 27.15 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.085 -1.009 . . . . 0.0 111.406 -178.725 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 23.5 pttt -61.02 -34.0 74.15 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.705 -1.247 . . . . 0.0 110.193 -178.591 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.425 ' HB ' ' H ' ' A' ' 166' ' ' ALA . 35.1 m -73.37 -10.44 13.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.027 -1.046 . . . . 0.0 109.2 179.906 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -76.38 176.36 52.11 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 -179.822 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 83.2 p -155.31 176.07 13.05 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.425 -1.044 . . . . 0.0 109.039 -179.641 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 22.7 m -52.28 -36.01 51.77 Favored 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 179.429 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 23.8 m -60.71 -33.19 72.52 Favored 'General case' 0 N--CA 1.487 1.387 0 O-C-N 121.377 -0.827 . . . . 0.0 108.93 179.164 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 96.31 8.94 57.29 Favored Glycine 0 N--CA 1.493 2.437 0 N-CA-C 109.805 -1.318 . . . . 0.0 109.805 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 69.6 ttp85 -101.74 138.69 38.39 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.348 -1.089 . . . . 0.0 109.521 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 165' ' ' THR . . . . . 0.642 HG22 HG21 ' A' ' 69' ' ' VAL . 65.2 p -84.12 151.85 24.67 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.175 -0.953 . . . . 0.0 109.544 179.81 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 166' ' ' ALA . . . . . 0.425 ' H ' ' HB ' ' A' ' 158' ' ' VAL . . . -67.28 -34.8 78.15 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.245 -0.909 . . . . 0.0 109.063 179.557 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 167' ' ' LYS . . . . . . . . . . . . . 63.2 mttp -114.52 158.43 21.65 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.563 -0.711 . . . . 0.0 109.34 -179.994 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 168' ' ' LYS . . . . . . . . . . . . . 63.1 mttp -73.79 137.81 44.12 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.148 -0.97 . . . . 0.0 109.353 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 2.7 m -132.65 119.71 39.23 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.35 -0.844 . . . . 0.0 109.843 -179.758 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 39.2 t -145.67 141.58 22.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 CA-C-O 121.898 0.856 . . . . 0.0 109.424 179.41 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.561 ' O ' ' O ' ' A' ' 62' ' ' LYS . 22.1 t -61.36 132.36 26.89 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.783 0 C-N-CA 120.333 -0.547 . . . . 0.0 109.762 -179.608 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 172' ' ' GLU . . . . . 0.452 ' O ' ' OD1' ' A' ' 173' ' ' ASP . 95.6 mt-10 -105.87 -7.08 18.44 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.335 -0.853 . . . . 0.0 109.808 179.61 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 173' ' ' ASP . . . . . 0.452 ' OD1' ' O ' ' A' ' 172' ' ' GLU . 30.5 m-20 -158.44 168.22 27.55 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.082 -1.011 . . . . 0.0 110.007 -179.734 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 20.4 p -170.32 126.25 0.78 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.474 -0.766 . . . . 0.0 109.539 179.565 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -173.55 173.86 45.92 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 179.8 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 176' ' ' GLN . . . . . 0.91 HE22 ' HE ' ' A' ' 43' ' ' ARG . 58.7 tt0 -105.2 121.35 43.66 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.383 -1.069 . . . . 0.0 109.853 -179.787 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 177' ' ' LEU . . . . . 0.473 HD23 ' HE ' ' A' ' 11' ' ' ARG . 36.8 tp -62.41 -36.57 82.77 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.239 -0.913 . . . . 0.0 108.95 179.125 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 178' ' ' SER . . . . . 0.513 ' OXT' ' NE2' ' A' ' 176' ' ' GLN . 7.2 t . . . . . 0 N--CA 1.491 1.589 0 CA-C-O 117.977 -1.011 . . . . 0.0 109.428 179.976 . . . . . . . . 1 1 . 1 stop_ save_